<SEC-DOCUMENT>0001213900-21-025389.txt : 20210510
<SEC-HEADER>0001213900-21-025389.hdr.sgml : 20210510
<ACCEPTANCE-DATETIME>20210510165541
ACCESSION NUMBER:		0001213900-21-025389
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		91
CONFORMED PERIOD OF REPORT:	20210331
FILED AS OF DATE:		20210510
DATE AS OF CHANGE:		20210510

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ABVC BIOPHARMA, INC.
		CENTRAL INDEX KEY:			0001173313
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				260014658
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	333-91436
		FILM NUMBER:		21908084

	BUSINESS ADDRESS:	
		STREET 1:		44370 OLD WARM SPRINGS BLVD.
		CITY:			FREMONT
		STATE:			CA
		ZIP:			94538
		BUSINESS PHONE:		510-668-0881

	MAIL ADDRESS:	
		STREET 1:		44370 OLD WARM SPRINGS BLVD.
		CITY:			FREMONT
		STATE:			CA
		ZIP:			94538

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	American BriVision (Holding) Corp
		DATE OF NAME CHANGE:	20160111

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	METU BRANDS, INC.
		DATE OF NAME CHANGE:	20150908

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ECOLOGY COATINGS, INC.
		DATE OF NAME CHANGE:	20080821
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>f10q0321_abvcbio.htm
<DESCRIPTION>QUARTERLY REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE
COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM 10-Q</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;
</FONT>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">For the quarterly period
ended <B><U>March 31, 2021</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;
</FONT>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">For the transition period
from ____________ to ____________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Commission file number <B><U>333-91436</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><I><U>ABVC BioPharma,
Inc.</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of Registrant
as specified in its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; width: 49%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Nevada</B></FONT></TD>
    <TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 49%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>26-0014658</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">State or jurisdiction of</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">incorporation or organization</P></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">IRS Employer</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Identification Number</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>44370 Old Warm Springs
Blvd.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Fremont, CA 94538</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Tel: (510) 668-0881</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address and telephone number
of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><I><U>American BriVision
(Holding) Corporation</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Former name, if changed
since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Title of each class</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Trading Symbol(s)</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Name of each exchange<BR>
    on which registered</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">None</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the issuer (1)
filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period
that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the last 90 days. Yes&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT>&nbsp;No&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Indicate by check mark
whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation
S-T (&sect; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit
such files). Yes&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT>&nbsp;No&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company.
See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; &ldquo;smaller reporting company,&rdquo;
and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 23%"><FONT STYLE="font-size: 10pt">Large accelerated filer</FONT></TD>
    <TD STYLE="width: 37%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="width: 30%"><FONT STYLE="font-size: 10pt">Accelerated filer</FONT></TD>
    <TD STYLE="width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Non-accelerated filer</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Smaller reporting company</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Emerging growth company</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT>&nbsp;No&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of May 10, 2021, there were 24,420,526 shares of common stock, par value per share $0.001, issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 8%; text-align: justify"><FONT STYLE="font-size: 10pt"><B>PART I</B></FONT></TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; width: 83%"><A HREF="#a_001"><FONT STYLE="font-size: 10pt"><B>FINANCIAL INFORMATION</B></FONT></A></TD>
    <TD STYLE="width: 9%; text-align: center"><FONT STYLE="font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Item 1.</B></FONT></TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in"><A HREF="#a_002"><FONT STYLE="font-size: 10pt">Financial Statements (Unaudited)</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in"><A HREF="#a_003"><FONT STYLE="font-size: 10pt">Unaudited Consolidated Balance Sheets as of March 31, 2021 and December 31, 2020</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in"><A HREF="#a_004"><FONT STYLE="font-size: 10pt">Unaudited Consolidated Statements of Operations and Comprehensive Loss for the Three M</FONT>o<FONT STYLE="font-size: 10pt">nths Ended March 31, 2021 and 2020</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">2</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in"><A HREF="#a_005"><FONT STYLE="font-size: 10pt">Unaudited Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2021 and 2020</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">3</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in"><A HREF="#a_006"><FONT STYLE="font-size: 10pt">Unaudited Consolidated Statement of Changes in Equity (Deficit) for the Three Months Ended March 31, 2021 and 2020</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">4</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in"><A HREF="#a_007"><FONT STYLE="font-size: 10pt">Notes to Unaudited Consolidated Financial Statements</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">5</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Item 2.</B></FONT></TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in"><A HREF="#a_008"><FONT STYLE="font-size: 10pt">Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">41</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Item 3.</B></FONT></TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in"><A HREF="#a_009"><FONT STYLE="font-size: 10pt">Quantitative and Qualitative Disclosures About Market Risk</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">63</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Item 4.</B></FONT></TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in"><A HREF="#a_010"><FONT STYLE="font-size: 10pt">Controls and Procedures</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">63</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>PART II</B></FONT></TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in"><A HREF="#a_011"><FONT STYLE="font-size: 10pt"><B>OTHER INFORMATION</B></FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">64</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Item 1.</B></FONT></TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in"><A HREF="#a_012"><FONT STYLE="font-size: 10pt">Legal Proceedings</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">64</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Item 1A.</B></FONT></TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in"><A HREF="#a_013"><FONT STYLE="font-size: 10pt">Risk Factors</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">64</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Item 2.</B></FONT></TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in"><A HREF="#a_014"><FONT STYLE="font-size: 10pt">Unregistered Sales of Equity Securities and Use of Proceeds</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">64</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Item 3.</B></FONT></TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in"><A HREF="#a_015"><FONT STYLE="font-size: 10pt">Defaults Upon Senior Securities</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">64</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Item 4.</B></FONT></TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in"><A HREF="#a_016"><FONT STYLE="font-size: 10pt">Mine Safety Disclosures</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">64</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Item 5.</B></FONT></TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in"><A HREF="#a_017"><FONT STYLE="font-size: 10pt">Other Information</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">64</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Item 6.</B></FONT></TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in"><A HREF="#a_018"><FONT STYLE="font-size: 10pt">Exhibits</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">65</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="2" STYLE="text-align: justify"><A HREF="#a_019"><FONT STYLE="font-size: 10pt">Signatures</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">67</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CAUTIONARY NOTE ON FORWARD
LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Quarterly Report on Form 10-Q (this &ldquo;Report&rdquo;)
contains &ldquo;forward-looking statements&rdquo; which discuss matters that are not historical facts. Because they discuss future events
or conditions, forward-looking statements may include words such as &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo;
&ldquo;intend,&rdquo; &ldquo;could,&rdquo; &ldquo;should,&rdquo; &ldquo;would,&rdquo; &ldquo;may,&rdquo; &ldquo;seek,&rdquo; &ldquo;plan,&rdquo;
&ldquo;might,&rdquo; &ldquo;will,&rdquo; &ldquo;expect,&rdquo; &ldquo;predict,&rdquo; &ldquo;project,&rdquo; &ldquo;forecast,&rdquo;
&ldquo;potential,&rdquo; &ldquo;continue&rdquo; and negatives thereof or similar expressions. Forward-looking statements speak only as
of the date they are made, are based on various underlying assumptions and current expectations about the future and are not guarantees.
Such statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, level of activity,
performance or achievement to be materially different from the results of operations or plans expressed or implied by such forward-looking
statements. We cannot predict all of the risks and uncertainties. Accordingly, such information should not be regarded as representations
that the results or conditions described in such statements or that our objectives and plans will be achieved and we do not assume any
responsibility for the accuracy or completeness of any of these forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These forward-looking statements represent our
intentions, plans, expectations, assumptions and beliefs about future events and are subject to risks, uncertainties and other factors.
Many of those factors are outside of our control and could cause actual results to differ materially from the results expressed or implied
by those forward-looking statements. Factors that could cause or contribute to such differences in results and outcomes include, without
limitation, those specifically addressed under the headings &ldquo;Risks Factors&rdquo; and &ldquo;Management&rsquo;s Discussion and
Analysis of Financial Condition and Results of Operations&rdquo; in our annual report on Form 10-K and its amendment filed with the Securities
and Exchange Commission (the &ldquo;SEC&rdquo; OR &ldquo;Commission&rdquo;); in &ldquo;Management&rsquo;s Discussion and Analysis of
Financial Condition and Results of Operations&rdquo; in this Report, and information contained in other reports that we file with the
SEC. In light of these risks, uncertainties and assumptions, the events described in the forward-looking statements might not occur or
might occur to a different extent or at a different time than we have described. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this Report. All subsequent written and oral forward-looking statements
concerning other matters addressed in this Report and attributable to us or any person acting on our behalf are expressly qualified in
their entirety by the cautionary statements contained or referred to in this Report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are important factors that could cause
actual results to vary materially from those described in this report as anticipated, estimated or expected, including, but not limited
to: the effects of the COVID-19 outbreak, including on the demand for our products&#894; the duration of the COVID-19 outbreak and severity
of such outbreak in regions where we operate&#894; the pace of recovery following the COVID-19 outbreak&#894; our ability to implement
cost containment and business recovery strategies&#894; the adverse effects of the COVID-19 outbreak on our business or the market price
of our ordinary shares; competition in the industry in which we operate and the impact of such competition on pricing, revenues and margins,
volatility in the securities market due to the general economic downturn; SEC regulations which affect trading in the securities of &ldquo;penny
stocks,&rdquo; and other risks and uncertainties. Except as required by law, we assume no obligation to update any forward-looking statements
publicly, or to update the reasons actual results could differ materially from those anticipated in any forward- looking statements,
even if new information becomes available in the future. Depending on the market for our stock and other conditional tests, a specific
safe harbor under the Private Securities Litigation Reform Act of 1995 may be available. Notwithstanding the above, Section 27A of the
Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;) and Section 21E of the Securities Exchange Act of 1934, as amended
(the &ldquo;Exchange Act&rdquo;) expressly state that the safe harbor for forward-looking statements does not apply to companies that
issue penny stock. Because we may from time to time be considered to be an issuer of penny stock, the safe harbor for forward-looking
statements may not apply to us at certain times.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As used in this Report, the terms &ldquo;we&rdquo;,
&ldquo;us&rdquo;, &ldquo;our&rdquo;, and &ldquo;our Company&rdquo; and &ldquo;the Company&rdquo; refer to ABVC BioPharma, Inc. and its
subsidiaries, unless otherwise indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="a_001"></A>PART I - FINANCIAL INFORMATION</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><A NAME="a_002"></A><FONT STYLE="font-size: 10pt"><B>Item 1.</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><B>Financial Statements.</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="a_003"></A><B>ABVC BIOPHARMA, INC.
AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><B>CONSOLIDATED
BALANCE SHEETS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 7pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March&nbsp;31, <BR> 2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&nbsp;31,<BR> 2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">(Unaudited)</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">ASSETS</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Current Assets</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; text-indent: -9pt; padding-left: 0.25in">Cash and cash equivalents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2,615,073</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">4,273,208</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Restricted cash and cash equivalents</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">718,163</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">728,163</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Accounts receivable, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">392,532</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">159,712</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Accounts receivable - related parties, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">145,075</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">143,435</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Due from related parties</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">702,889</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">696,255</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Inventory, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Prepaid expense and other current assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">631,721</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">172,193</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Total Current Assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,205,453</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">6,172,966</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Property and equipment, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">504,952</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">514,834</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Operating lease right-of-use assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,714,740</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,772,747</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Goodwill, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Long-term investments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,126,884</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,190,727</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Deferred tax assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,815,755</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,790,597</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Prepaid expenses &ndash; noncurrent</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">117,639</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">119,315</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Security deposits</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">40,639</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">45,519</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.5in">Total Assets</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">10,526,062</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">11,606,705</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">LIABILITIES AND EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Current Liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">10,334</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">23,044</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Short-term bank loans</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,615,250</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,629,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Short-term loan</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Notes payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">105,300</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">106,800</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Accrued expenses and other current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,135,912</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,118,854</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Advance from customers</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,070</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,070</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Operating lease liabilities &ndash; current portion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">331,179</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">316,178</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Other payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">44,103</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Due to related parties</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">312,152</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">288,445</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Convertible notes payable - related parties, current portion</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">250,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.5in">Total Current Liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,666,300</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,844,391</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Paycheck Protection Program loan payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">236,498</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">124,400</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Tenant security deposit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,080</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">19,280</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Operating lease liability &ndash; noncurrent portion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,383,560</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,456,567</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Convertible notes payable &ndash; noncurrent portion</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,500,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,500,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Total Liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">8,797,438</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">8,944,638</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">Equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Preferred stock, $0.001 par value, 20,000,000 authorized, nil shares issued and outstanding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Common stock, $0.001 par value, 100,000,000 authorized, 24,420,526 and 24,420,526 shares issued and outstanding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24,420</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24,420</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">40,751,807</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">40,751,807</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Stock subscription receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,934,620</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,160,360</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Accumulated deficit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(26,770,892</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(25,642,387</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Accumulated other comprehensive income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">601,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">564,860</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Treasury stock</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(9,100,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(9,100,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Total Stockholders&rsquo; Equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,571,715</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,438,340</TD><TD STYLE="text-align: left"></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Noncontrolling interest</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(843,091</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(776,273</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Total Equity</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,728,624</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,662,067</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total Liabilities and Equity</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">10,526,062</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">11,606,705</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>The accompanying notes are an integral part
of these consolidated financial statements.</I></P>


<!-- Field: Page; Sequence: 4; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="a_004"></A>ABVC
BIOPHARMA, INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CONSOLIDATED STATEMENTS
OF OPERATIONS AND COMPREHENSIVE LOSS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FOR THE THREE MONTHS
ENDED MARCH 31, 2021 AND 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(UNAUDITED)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March&nbsp;31, <BR> 2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March&nbsp;31, <BR> 2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font-weight: bold; text-indent: -9pt; padding-left: 9pt">Revenues</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">263,150</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">78,786</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Cost of revenues</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,245</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,959</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Gross profit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">261,905</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">74,827</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Operating expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Selling, general and administrative expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,167,595</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,152,889</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Research and development expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">121,315</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">92,790</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Stock-based compensation</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">225,740</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">525</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,514,650</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,246,204</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Loss from operations</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,252,745</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,171,377</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Other income (expense)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Interest income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">52,529</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,720</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(130,229</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(131,517</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Rental income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,867</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,231</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Rental income &ndash; related parties</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,600</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,200</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Gain/Loss on foreign exchange changes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">951</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Gain/Loss on investment in equity securities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(47,791</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(70,411</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Other income (expense)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">71</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,322</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Government grant income</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">124,400</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Total other income (expenses)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">6,398</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(178,453</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Loss before provision income tax</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,246,347</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,349,830</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Provision for income tax</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(51,024</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(40,568</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Net loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,195,323</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,309,262</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Net loss attributable to noncontrolling interests</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(66,818</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(61,724</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Net loss attributed to ABVC and subsidiaries</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,128,505</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,247,538</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Foreign currency translation adjustment</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">36,140</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(6,451</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Comprehensive loss</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(1,092,365</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(1,253,989</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">Net loss per share:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in">Basic and diluted</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(0.05</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(0.06</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">Weighted average number of common shares outstanding:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in">Basic and diluted</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">24,420,526</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">19,484,542</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>The accompanying notes
are an integral part of these consolidated financial statements.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="a_005"></A>ABVC
BIOPHARMA, INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CONSOLIDATED STATEMENTS
OF CASH FLOWS</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FOR THE THREE MONTHS ENDED
MARCH 31, 2021 AND 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(UNAUDITED)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Cash flows from operating activities</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; padding-left: 9pt">Net loss</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(1,195,323</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(1,309,262</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Adjustments to reconcile net loss to net cash used in operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in">Depreciation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,928</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,174</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">Stock based compensation for nonemployees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">225,740</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">525</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Gain/Loss on investment in equity securities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">47,791</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">70,411</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">Government grant income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(124,400</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Other non-cash income and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,333</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">Deferred tax</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(51,024</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(40,568</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Changes in operating assets and liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 27pt">Decrease (increase) in accounts receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(238,484</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">52,950</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 27pt">Decrease (increase) in prepaid expenses and deposits</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(187,723</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,834</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 27pt">Decrease (increase) in due from related parties</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(18,229</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,536</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 27pt">Increase (decrease) in accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(12,710</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,632</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 27pt">Increase (decrease) in accrued expenses and other current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">136,519</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">500,743</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 27pt">Increase (decrease) in due to related parties</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,841</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">68,750</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 0.5in">Net cash used in operating activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,413,074</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(630,944</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Cash flows from investing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Prepayment for equity investment</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(281,952</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 0.5in">Net cash used in investing activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(281,952</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Cash flows from financing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Issuance of common stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">40,448</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">267,740</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Proceeds from short-term borrowing from third parties</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">280,940</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Repayment of convertible notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(250,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Proceeds from long-term loans</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">236,498</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Borrowings from related parties</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,280</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">71,688</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Repayment of long-term bank loans</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(9,981</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 0.5in">Net cash provided by financing activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">42,226</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">610,387</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Effect of exchange rate changes on cash and cash equivalents and restricted cash</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(15,335</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(93</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net increase (decrease) in cash and cash equivalents and restricted cash</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,668,135</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(20,650</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Cash and cash equivalents and restricted cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 9pt">Beginning</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,001,371</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">160,443</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt; padding-left: 9pt">Ending</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">3,333,236</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">139,793</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Supplemental disclosure of cash flows</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Cash paid during the year for:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 0.25in">Interest expense paid</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">21,666</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">10,446</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 0.25in">Income taxes paid</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>The accompanying notes
are an integral part of these consolidated financial statements.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_006"></A><B>ABVC BIOPHARMA, INC. AND
SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSOLIDATED STATEMENTS OF STOCKHOLDERS&rsquo;
EQUITY (DEFICIT)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FOR THE THREE MONTHS ENDED MARCH 31, 2021 AND
2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(UNAUDITED)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Common
    Stock</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Stock</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Additional</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Treasury
    Stock</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Non</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Stockholders&rsquo;</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Number
    of <BR> shares</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Amounts</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 8pt"><B>Subscription
                                            </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 8pt"><B>Receivable</B></FONT></P></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Paid-in
    <BR> Capital</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Accumulated<BR>
    Deficit</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Comprehensive<BR>
    Income</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Number&nbsp;of
    <BR> shares</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Amounts</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">controlling<BR>
    Interest</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Equity
    <BR> (Deficit)</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; width: 25%"><FONT STYLE="font-size: 8pt">Balance at December 31, 2019</FONT></TD><TD STYLE="width: 0.5%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 8pt">19,478,168</FONT></TD><TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 0.5%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 8pt">19,478</FONT></TD><TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 0.5%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 8pt">(4,063,320</FONT></TD><TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="width: 0.5%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 8pt">28,180,348</FONT></TD><TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 0.5%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 8pt">(15,851,223</FONT></TD><TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="width: 0.5%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 8pt">663,753</FONT></TD><TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 0.5%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 8pt">(275,347</FONT></TD><TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="width: 0.5%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 8pt">(9,100,000</FONT></TD><TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="width: 0.5%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 8pt">26,147</FONT></TD><TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 0.5%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 8pt">(124,817</FONT></TD><TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-indent: -0.125in"><FONT STYLE="font-size: 8pt">Issuance of common shares</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">10,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">10</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">225,740</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">41,989</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">267,739</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-indent: -0.125in; text-align: left"><FONT STYLE="font-size: 8pt">Stock based compensation</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">525</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">525</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-indent: -0.125in; text-align: left"><FONT STYLE="font-size: 8pt">Net loss for the period</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(1,247,538</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(61,724</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(1,309,262</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">Cumulative
    transaction adjustments</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8pt">(6,451</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8pt">(6,451</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 4pt"><FONT STYLE="font-size: 8pt">Balance at March 31, 2020</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-size: 8pt">19,488,168</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-size: 8pt">19,488</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-size: 8pt">(3,837,580</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-size: 8pt">28,222,862</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-size: 8pt">(17,098,761</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-size: 8pt">657,302</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-size: 8pt">(275,347</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-size: 8pt">(9,100,000</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-size: 8pt">(35,577</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-size: 8pt">(1,172,266</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Common
    Stock</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Stock</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Additional</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Treasury
    Stock</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Non</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Stockholders&rsquo;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Number
    of <BR> shares</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Amounts</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Subscription
                                            </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Receivable</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Paid-in
    <BR> Capital</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Accumulated<BR>
    Deficit</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Comprehensive<BR>
    Income</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Number&nbsp;of
    <BR> shares</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Amounts</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">controlling<BR>
    Interest</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Equity
    <BR> (Deficit)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 25%; text-indent: -9pt; padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Balance
    at December 31, 2020</FONT></TD><TD STYLE="width: 0.5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">24,420,526</FONT></TD><TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 0.5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">24,420</FONT></TD><TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 0.5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(3,160,360</FONT></TD><TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD><TD STYLE="width: 0.5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">40,751,807</FONT></TD><TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 0.5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(25,642,387</FONT></TD><TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD><TD STYLE="width: 0.5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">564,860</FONT></TD><TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 0.5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(275,347</FONT></TD><TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD><TD STYLE="width: 0.5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(9,100,000</FONT></TD><TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD><TD STYLE="width: 0.5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(776,273</FONT></TD><TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD><TD STYLE="width: 0.5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">2,662,067</FONT></TD><TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Stock
    based compensation</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">225,740</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">225,740</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Net
    loss for the period</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(1,128,505</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(66,818</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(1,195,323</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Cumulative
    transaction adjustments</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">36,140</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">36,140</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Balance
    at March 31, 2021</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">24,420,526</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">24,420</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(2,934,620</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">40,751,807</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(26,770,892</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">601,000</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(275,347</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(9,100,000</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(843,091</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">1,728,624</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>The accompanying notes
are an integral part of these consolidated financial statements.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_007"></A><B>ABVC BIOPHARMA, INC. AND
SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(UNAUDITED)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>1. ORGANIZATION AND DESCRIPTION OF BUSINESS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ABVC BioPharma, Inc. (the
&ldquo;Company&rdquo;), formerly known as American BriVision (Holding) Corporation, a Nevada corporation, through the Company&rsquo;s operating entity, American BriVision Corporation
(&ldquo;BriVision&rdquo;), which was incorporated in July 2015 in the State of Delaware, engages in biotechnology to fulfill unmet
medical needs and focuses on the development of new drugs and medical devices derived from plants. &nbsp;BriVision develops its
pipeline by carefully tracking new medical discoveries or medical device technologies in research institutions in the Asia-Pacific
region. Pre-clinical, disease animal model and Phase I safety studies are examined closely by the Company to identify drugs that
BriVision believes demonstrate efficacy and safety. Once a drug appears to be a good candidate for development and ultimately
commercialization, BriVision licenses the drug or medical device from the original researchers and begins to introduce the drugs
clinical plan to highly respected principal investigators in the United States, Australia and Taiwan to conduct a Phase II clinical
trial. At present, clinical trials for the Company&rsquo;s drugs and medical devices are being conducted at such world-famous
institutions as Memorial Sloan Kettering Cancer Center (&ldquo;MSKCC&rdquo;) and MD Anderson Cancer Center. BriVision had no
predecessor operations prior to its formation on July 21, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Name Change</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s shareholders approved an amendment to the Company&rsquo;s
Articles of Incorporation to change the Company&rsquo;s corporate name from American BriVision (Holding) Corporation to ABVC BioPharma,
Inc. and approved and adopted the Certificate of Amendment to affect same at the 2020 annual meeting of shareholders (the &ldquo;Annual
Meeting&rdquo;). The name change amendment to the Company&rsquo;s Articles of Incorporation was filed with Nevada&rsquo;s Secretary of
State and became effective on March 8, 2021 and FINRA processed our request to change our name on April 30, 2021, which became effective
as of May 3, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s stock symbol remains ABVC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Reverse Merger</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 8, 2016, a Share Exchange
Agreement (the &ldquo;Share Exchange Agreement&rdquo;) was entered into by and among the Company, BriVision, and Euro-Asia Investment
&amp; Finance Corp. Limited, a company incorporated under the laws of Hong Kong Special Administrative Region of the People&rsquo;s
Republic of China (&ldquo;Euro-Asia&rdquo;), being the owners of record of 164,387,376 (52,336,000 pre-stock split) shares of Common
Stock of the Company, and the owners of record of all of the issued share capital of BriVision (the &ldquo;BriVision
Stock&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Share Exchange Agreement, upon
surrender by the BriVision Shareholders and the cancellation by BriVision of the certificates evidencing the BriVision Stock as registered
in the name of each BriVision Shareholder, and pursuant to the registration of the Company in the register of members maintained by BriVision
as the new holder of the BriVision Stock and the issuance of the certificates evidencing the aforementioned registration of the BriVision
Stock in the name of the Company, the Company issued 166,273,921 (52,936,583 pre-stock split) shares (the &ldquo;Acquisition Stock&rdquo;)
(subject to adjustment for fractionalized shares as set forth below) of the Company&rsquo;s Common Stock to the BriVision Shareholders
(or their designees), and 163,159,952 (51,945,225 pre-stock split) shares of the Company&rsquo;s Common Stock owned by Euro-Asia were
cancelled and retired to treasury. The Acquisition Stock collectively represented 79.70% of the issued and outstanding Common Stock of
the Company immediately after the Closing, in exchange for the BriVision Stock, representing 100% of the issued share capital of BriVision
in a reverse merger (the &ldquo;Merger&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Merger, all of the issued and
outstanding common shares of BriVision were converted, at an exchange ratio of 0.2536-for-1, into an aggregate of 166,273,921 (52,936,583pre-stock
split) common shares of the Company and BriVision had become a wholly owned subsidiary of the Company. The holders of Company&rsquo;s
Common Stock as of immediately prior to the Merger held an aggregate of 205,519,223(65,431,144 pre-stock split) shares of Company&rsquo;s
Common Stock. Because of the exchange of the BriVision Stock for the Acquisition Stock (the &ldquo;Share Exchange&rdquo;), BriVision
had become a wholly owned subsidiary (the &ldquo;Subsidiary&rdquo;) of the Company and there was a change of control of the Company following
the closing. There were no warrants, options or other equity instruments issued in connection with the share exchange agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon the consummation of the Share Exchange,
BriVision became a wholly owned subsidiary of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Following the Share Exchange, the Company has
abandoned prior business plan and is now pursuing BriVision&rsquo;s historically proposed businesses, which focus on the development
of new drugs and innovative medical devices to fulfill unmet medical needs. The business model of the Company is to integrate research
achievements from world-famous institutions, conduct clinical trials of translational medicine for Proof of Concept (&ldquo;POC&rdquo;),
out-license to international pharmaceutical companies, and explore global markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.2pt">&nbsp;</P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Accounting Treatment of the Reverse Merger</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For financial reporting purposes, the Share Exchange
represents a &ldquo;reverse merger&rdquo;&nbsp;rather than a business combination and&nbsp;BriVision&nbsp;is deemed the accounting acquirer
in the transaction. The&nbsp;Share Exchange is being accounted for as a reverse-merger and recapitalization. BriVision&nbsp;is the acquirer
for financial reporting purposes and the&nbsp;Company&nbsp;is the acquired company. Consequently, the assets and liabilities and the
operations reflected in the historical financial statements prior to the Share Exchange will be those of&nbsp;BriVision&nbsp;and recorded
at the historical cost basis of&nbsp;BriVision. In addition, the consolidated financial statements after completion of the Share Exchange
will include the assets and liabilities of the Company and BriVision, and the historical operations of&nbsp;BriVision&nbsp;and operations
of the Combined Company from the closing date of the Share Exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Merger</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 8, 2019, the Company, BioLite Holding,
Inc. (&ldquo;BioLite&rdquo;), BioKey, Inc. (&ldquo;BioKey&rdquo;), BioLite Acquisition Corp., a direct wholly-owned subsidiary of Parent
(&ldquo;Merger Sub 1&rdquo;), and BioKey Acquisition Corp., a direct wholly-owned subsidiary of Parent (&ldquo;Merger Sub 2&rdquo;) (collectively
referred to as the &ldquo;Parties&rdquo;) completed the business combination pursuant to the Agreement and Plan of Merger (the &ldquo;Merger
Agreement&rdquo;) dated as of January 31, 2018 where ABVC acquired BioLite and BioKey via issuing additional Common Stock of ABVC to
the shareholders of BioLite and BioKey.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the terms of the Merger Agreement,
BioLite and BioKey became two wholly-owned subsidiaries of the Company on February 8, 2019. ABVC issued an aggregate of 104,558,777 shares
(prior to the reverse stock split in 2019) to the shareholders of both BioLite and BioKey under a registration statement on Form S-4
(file number 333-226285), which became effective by operation of law on or about February 5, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BioLite Holding, Inc. (the &ldquo;BioLite Holding&rdquo;)
was incorporated under the laws of the State of Nevada on July 27, 2016. BioLite BVI, Inc. (the &ldquo;BioLite BVI&rdquo;), a wholly
owned subsidiary of BioLite Holding, was incorporated in the British Virgin Islands on September 13, 2016. BioLite Holding and BioLite
BVI are holding companies and have not carried out substantive business operations of their own.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BioLite, Inc., (the &ldquo;BioLite Taiwan&rdquo;)
was incorporated on February 13, 2006 under the laws of Taiwan. BioLite is in the business of developing and commercialization of new
botanical drugs with application in central nervous system, autoimmunity, inflammation, hematology, and oncology. In addition, BioLite
Taiwan distributes dietary supplements made from extracts of Chinese herbs and Maitake mushroom.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In January 2017, BioLite Holding, BioLite BVI,
BioLite Taiwan, and certain shareholders of BioLite Taiwan entered into a share purchase / exchange agreement (the &ldquo;BioLite Share
Purchase / Exchange Agreement&rdquo;). Pursuant to the BioLite Share Purchase / Exchange Agreement, the shareholder participants to the
BioLite Share Purchase / Exchange Agreement have sold their equity in BioLite Taiwan and were using the proceeds from such sales to purchase
shares of Common Stock of BioLite Holding at the same price per share, resulting in their owning the same number of shares of Common
Stock as they owned in the BioLite Taiwan. Upon closing of the Share Purchase/ Exchange Agreement in August 2017, BioLite Holding ultimately
owns via BioLite BVI approximately 73% of BioLite Taiwan. The other shareholders who did not enter this Share Purchase/ Exchange Agreement
retain their equity ownership in BioLite Taiwan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BioKey, Inc. was incorporated on August 9, 2000
in the State of California. BioKey provides a wide range of services, including, API characterization, pre-formulation studies, formulation
development, analytical method development, stability studies, IND/NDA/ANDA/510K submissions, and manufacturing clinical trial materials
(Phase I through phase III) and commercial manufacturing. It also licenses out its technologies and initiates joint research and development
processes with other biotechnology, pharmaceutical, and nutraceutical companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Accounting Treatment of the Merger</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company adopted ASC 805, &ldquo;Business
Combination&rdquo; to record the merger transactions of BioKey. Since the Company and BioLite Holding are the entities under Dr. Tsung-Shann
Jiang&rsquo;s common control, the transaction is accounted for as a restructuring transaction.&nbsp;All the assets and liabilities of
BioLite Holding, BioLite BVI, and BioLite Taiwan were transferred to the Company at their respective carrying amounts on the closing
date of the Merger. The Company has recast prior period financial statements to reflect the conveyance of BioLite Holding&rsquo;s common
shares as if the restructuring transaction had occurred as of the earliest date of the financial statements. All material intercompany
accounts, transactions, and profits have been eliminated in consolidation. The nature of and effects on earnings per share (EPS) of nonrecurring
intra-entity transactions involving long-term assets and liabilities is not required to be eliminated and EPS amounts have been recast
to include the earnings (or losses) of the transferred net assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Basis of Presentation</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
have been prepared in accordance with the generally accepted accounting principles in the United States of America (the &ldquo;U.S. GAAP&rdquo;).
All significant intercompany transactions and account balances have been eliminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This basis of accounting involves the application
of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred.
The Company&rsquo;s financial statements are expressed in U.S. dollars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Fiscal Year</U>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company changed its fiscal year from the
period beginning on October 1st and ending on September 30th to the period beginning on January 1st and ending on December 31st, beginning
January 1, 2018. All references herein to a fiscal year prior to December 31, 2017 refer to the twelve months ended September 30th of
such year.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Use of Estimates</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity
with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated
financial statements and the amount of revenues and expenses during the reporting periods. Actual results could differ materially from
those results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Inventory</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inventory consists of raw materials, work-in-process,
finished goods, and merchandise. Inventories are stated at the lower of cost or market and valued on a moving weighted average cost basis.
Market is determined based on net realizable value. The Company periodically reviews the age and turnover of its inventory to determine
whether any inventory has become obsolete or has declined in value, and incurs a charge to operations for known and anticipated inventory
obsolescence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Reclassifications</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain classifications have been made to the
prior year financial statements to conform to the current year presentation. The reclassification had no impact on previously reported
net loss or accumulated deficit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Forward Stock Split</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 21, 2016, the Board of Directors of
the Company approved an amendment to Articles of Incorporation to effect a forward split at a ratio of 1 to 3.141 and increase the number
of our authorized shares of Common Stock, par value $0.001 per share, to 360,000,000, which was effective on April 8, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Stock Reverse Split</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 12, 2019, the Board of Directors of
the Company by unanimous written consent in lieu of a meeting approved to i) effect a stock reverse split at the ratio of 1-for-18 (the
&ldquo;Reverse Split&rdquo;) of both the authorized common stock of the Company (the &ldquo;Common Stock&rdquo;) and the issued and outstanding
Common Stock and ii) to amend the articles of incorporation of the Company to reflect the Reverse Split. The Board approved and authorized
the Reverse Split without obtaining approval of the Company&rsquo;s shareholders pursuant to Section 78.207 of Nevada Revised Statutes.
On May 3, 2019, the Company filed a certificate of amendment to the Company&rsquo;s articles of incorporation (the &ldquo;Amendment&rdquo;)
to effect the Reverse Split with the Secretary of State of Nevada. The Financial Industry Regulatory Authority (&ldquo;FINRA&rdquo;)
informed the Company that the Reverse Split was effective on May 8, 2019. All shares and related financial information in this Form 10-K
reflect this 1-for-18 reverse stock split.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Fair Value Measurements</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FASB ASC 820, &ldquo;Fair Value Measurements&rdquo;
defines fair value for certain financial and nonfinancial assets and liabilities that are recorded at fair value, establishes a framework
for measuring fair value and expands disclosures about fair value measurements. It requires that an entity measure its financial instruments
to base fair value on exit price, maximize the use of observable units and minimize the use of unobservable inputs to determine the exit
price. It establishes a hierarchy which prioritizes the inputs to valuation techniques used to measure fair value. This hierarchy increases
the consistency and comparability of fair value measurements and related disclosures by maximizing the use of observable inputs and minimizing
the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that reflect
the assumptions market participants would use in pricing the assets or liabilities based on market data obtained from sources independent
of the Company. Unobservable inputs are inputs that reflect the Company&rsquo;s own assumptions about the assumptions market participants
would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy prioritizes
the inputs into three broad levels based on the reliability of the inputs as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Level 1 - Inputs are quoted prices in active markets for identical
    assets or liabilities that the Company has the ability to access at the measurement date. Valuation of these instruments does not
    require a high degree of judgment as the valuations are based on quoted prices in active markets that are readily and regularly available.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Level 2 - Inputs other than quoted prices in active markets that are
    either directly or indirectly observable as of the measurement date, such as quoted prices for similar assets or liabilities; quoted
    prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially
    the full term of the assets or liabilities.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Level 3 - Valuations based on inputs that are unobservable and not
    corroborated by market data. The fair value for such assets and liabilities is generally determined using pricing models, discounted
    cash flow methodologies, or similar techniques that incorporate the assumptions a market participant would use in pricing the asset
    or liability.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The carrying values of certain assets and liabilities
of the Company, such as cash and cash equivalents, restricted cash, accounts receivable, due from related parties, inventory, prepaid
expenses and other current assets, accounts payable, accrued liabilities, and due to related parties approximate fair value due to their
relatively short maturities. The carrying value of the Company&rsquo;s short-term bank loan, convertible notes payable, and accrued interest
approximates their fair value as the terms of the borrowing are consistent with current market rates and the duration to maturity is
short. The carrying value of the Company&rsquo;s long-term bank loan approximates fair value because the interest rates approximate market
rates that the Company could obtain for debt with similar terms and maturities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Cash and Cash Equivalents</U>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers highly liquid investments
with maturities of three months or less, when purchased, to be cash equivalents. As of March 31, 2021 and December 31, 2020, the Company&rsquo;s
cash and cash equivalents amounted $2,615,073 and $4,273,208, respectively. Some&nbsp;of the Company&rsquo;s cash deposits are held in
financial institutions located in Taiwan where there is currently regulation mandated on obligatory insurance of bank accounts. The Company
believes this financial institution is of high credit quality.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Restricted Cash Equivalents</U>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Restricted cash equivalents primarily consist
of cash held in a reserve bank account in Taiwan. As of March 31, 2021 and December 31, 2020, the Company&rsquo;s restricted cash equivalents
amounted $718,163 and $728,163, respectively.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Concentration of Credit Risk</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s financial instruments that
are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash and temporary
cash investments in high quality credit institutions, but these investments may be in excess of Taiwan Central Deposit Insurance Corporation
and the U.S. Federal Deposit Insurance Corporation&rsquo;s insurance limits. The Company does not enter into financial instruments for
hedging, trading or speculative purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Revenue Recognition</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the fiscal year 2018, the Company adopted
Accounting Standards Codification (&ldquo;ASC&rdquo;), Topic 606 (ASC 606), Revenue from Contracts with Customers, using the modified
retrospective method to all contracts that were not completed as of January 1, 2018, and applying the new revenue standard as an adjustment
to the opening balance of accumulated deficit at the beginning of 2018 for the cumulative effect. The results for the Company&rsquo;s
reporting periods beginning on and after January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and
continue to be reported under the accounting standards in effect for the prior period. Based on the Company&rsquo;s review of existing
collaborative agreements as of January 1, 2018, the Company concluded that the adoption of the new guidance did not have a significant
change on the Company&rsquo;s revenue during all periods presented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to ASC 606, the Company recognizes revenue
when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the Company expects
to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines is
within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify
the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance
obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only
applies the five-step model to contracts when it is probable that the Company will collect the consideration the Company is entitled
to in exchange for the goods or services the Company transfers to the customers. At inception of the contract, once the contract is determined
to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are
performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount
of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following are examples of when the Company
recognizes revenue based on the types of payments the Company receives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Collaborative Revenues &mdash; </B>The Company
recognizes collaborative revenues generated through collaborative research, development and/or commercialization agreements. The terms
of these agreements typically include payment to the Company related to one or more of the following: non-refundable upfront license
fees, development and commercial milestones, partial or complete reimbursement of research and development costs, and royalties on net
sales of licensed products. Each type of payments results in collaborative revenues except for revenues from royalties on net sales of
licensed products, which are classified as royalty revenues. To date, the Company has not received any royalty revenues. Revenue is recognized
upon satisfaction of a performance obligation by transferring control of a good or service to the collaboration partners.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As part of the accounting for these arrangements,
the Company applies judgment to determine whether the performance obligations are distinct, and develop assumptions in determining the
stand-alone selling price for each distinct performance obligation identified in the collaboration agreements. To determine the stand-alone
selling price, the Company relies on assumptions which may include forecasted revenues, development timelines, reimbursement rates for
R&amp;D personnel costs, discount rates and probabilities of technical and regulatory success.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company had multiple deliverables under the
collaborative agreements, including deliverables relating to grants of technology licenses, regulatory and clinical development, and
marketing activities. Estimation of the performance periods of the Company&rsquo;s deliverables requires the use of management&rsquo;s
judgment. Significant factors considered in management&rsquo;s evaluation of the estimated performance periods include, but are not limited
to, the Company&rsquo;s experience in conducting clinical development, regulatory and manufacturing activities. The Company reviews the
estimated duration of its performance periods under its collaborative agreements on an annually basis, and makes any appropriate adjustments
on a prospective basis. Future changes in estimates of the performance period under its collaborative agreements could impact the timing
of future revenue recognition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(i) Non-refundable upfront payments</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If a license to the Company&rsquo;s intellectual
property is determined to be distinct from the other performance obligations identified in an arrangement, the Company recognizes revenue
from the related non-refundable upfront payments based on the relative standalone selling price prescribed to the license compared to
the total selling price of the arrangement. The revenue is recognized when the license is transferred to the collaboration partners and
the collaboration partners are able to use and benefit from the license. To date, the receipt of non-refundable upfront fees was solely
for the compensation of past research efforts and contributions made by the Company before the collaborative agreements entered into
and it does not relate to any future obligations and commitments made between the Company and the collaboration partners in the collaborative
agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(ii) Milestone payments</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is eligible to receive milestone
payments under the collaborative agreement with collaboration partners based on achievement of specified development, regulatory and
commercial events. Management evaluated the nature of the events triggering these contingent payments, and concluded that these events
fall into two categories: (a) events which involve the performance of the Company&rsquo;s obligations under the collaborative agreement
with collaboration partners, and (b) events which do not involve the performance of the Company&rsquo;s obligations under the collaborative
agreement with collaboration partners.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The former category of milestone payments consists
of those triggered by development and regulatory activities in the territories specified in the collaborative agreements. Management
concluded that each of these payments constitute substantive milestone payments. This conclusion was based primarily on the facts that
(i) each triggering event represents a specific outcome that can be achieved only through successful performance by the Company of one
or more of its deliverables, (ii) achievement of each triggering event was subject to inherent risk and uncertainty and would result
in additional payments becoming due to the Company, (iii) each of the milestone payments is non-refundable, (iv) substantial effort is
required to complete each milestone, (v) the amount of each milestone payment is reasonable in relation to the value created in achieving
the milestone, (vi) a substantial amount of time is expected to pass between the upfront payment and the potential milestone payments,
and (vii) the milestone payments relate solely to past performance. Based on the foregoing, the Company recognizes any revenue from these
milestone payments in the period in which the underlying triggering event occurs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(iii) Multiple Element Arrangements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company evaluates multiple element arrangements
to determine (1) the deliverables included in the arrangement and (2) whether the individual deliverables represent separate units of
accounting or whether they must be accounted for as a combined unit of accounting. This evaluation involves subjective determinations
and requires management to make judgments about the individual deliverables and whether such deliverables are separate from other aspects
of the contractual relationship. Deliverables are considered separate units of accounting provided that: (i) the delivered item(s) has
value to the customer on a standalone basis and (ii) if the arrangement includes a general right of return relative to the delivered
item(s), delivery or performance of the undelivered item(s) is considered probable and substantially within its control. In assessing
whether an item under a collaboration has standalone value, the Company considers factors such as the research, manufacturing, and commercialization
capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. The Company also
considers whether its collaboration partners can use the other deliverable(s) for their intended purpose without the receipt of the remaining
element(s), whether the value of the deliverable is dependent on the undelivered item(s), and whether there are other vendors that can
provide the undelivered element(s).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognizes arrangement consideration
allocated to each unit of accounting when all of the revenue recognition criteria in ASC 606 are satisfied for that particular unit of
accounting. In the event that a deliverable does not represent a separate unit of accounting, the Company recognizes revenue from the
combined unit of accounting over the Company&rsquo;s contractual or estimated performance period for the undelivered elements, which
is typically the term of the Company&rsquo;s research and development obligations. If there is no discernible pattern of performance
or objectively measurable performance measures do not exist, then the Company recognizes revenue under the arrangement on a straight-line
basis over the period the Company is expected to complete its performance obligations. Conversely, if the pattern of performance in which
the service is provided to the customer can be determined and objectively measurable performance measures exist, then the Company recognizes
revenue under the arrangement using the proportional performance method. Revenue recognized is limited to the lesser of the cumulative
amount of payments received or the cumulative amount of revenue earned, as determined using the straight-line method or proportional
performance method, as applicable, as of the period ending date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the inception of an arrangement that includes
milestone payments, the Company evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent
nature of the milestone. This evaluation includes an assessment of whether: (1) the consideration is commensurate with either the Company&rsquo;s
performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting
from its performance to achieve the milestone, (2) the consideration relates solely to past performance and (3) the consideration is
reasonable relative to all of the deliverables and payment terms within the arrangement. The Company evaluates factors such as the scientific,
clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone and the level of effort and
investment required to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining
whether a milestone satisfies all of the criteria required to conclude that a milestone is substantive. Milestones that are not considered
substantive are recognized as earned if there are no remaining performance obligations or over the remaining period of performance, assuming
all other revenue recognition criteria are met.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(iv) Royalties and Profit Sharing Payments</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the collaborative agreement with the collaboration
partners, the Company is entitled to receive royalties on sales of products, which is at certain percentage of the net sales. The Company
recognizes revenue from these events based on the revenue recognition criteria set forth in ASC 606. Based on those criteria, the Company
considers these payments to be contingent revenues, and recognizes them as revenue in the period in which the applicable contingency
is resolved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenues Derived from Research and Development
Activities Services &mdash; Revenues related to research and development and regulatory activities are recognized when the related services
or activities are performed, in accordance with the contract terms. The Company typically has only one performance obligation at the
inception of a contract, which is to perform research and development services. The Company may also provide its customers with an option
to request that the Company provides additional goods or services in the future, such as active pharmaceutical ingredient, API, or IND/NDA/ANDA/510K
submissions. The Company evaluates whether these options are material rights at the inception of the contract. If the Company determines
an option is a material right, the Company will consider the option a separate performance obligation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the Company is entitled to reimbursement from
its customers for specified research and development expenses, the Company accounts for the related services that it provides as separate
performance obligations if it determines that these services represent a material right. The Company also determines whether the reimbursement
of research and development expenses should be accounted for as revenues or an offset to research and development expenses in accordance
with provisions of gross or net revenue presentation. The Company recognizes the corresponding revenues or records the corresponding
offset to research and development expenses as it satisfies the related performance obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company then determines the transaction price
by reviewing the amount of consideration the Company is eligible to earn under the contracts, including any variable consideration. Under
the outstanding contracts, consideration typically includes fixed consideration and variable consideration in the form of potential milestone
payments. At the start of an agreement, the Company&rsquo;s transaction price usually consists of the payments made to or by the Company
based on the number of full-time equivalent researchers assigned to the project and the related research and development expenses incurred.
The Company does not typically include any payments that the Company may receive in the future in its initial transaction price because
the payments are not probable. The Company would reassess the total transaction price at each reporting period to determine if the Company
should include additional payments in the transaction price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company receives payments from its customers
based on billing schedules established in each contract. Upfront payments and fees may be recorded as advance from customers upon receipt
or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under these
arrangements. Amounts are recorded as accounts receivable when the right of the Company to consideration is unconditional. The Company
does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period
between payment by the customers and the transfer of the promised goods or services to the customers will be one year or less.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Property and Equipment</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property and equipment is carried at cost net
of accumulated depreciation. Repairs and maintenance are expensed as incurred. Expenditures that improve the functionality of the related
asset or extend the useful life are capitalized. When property and equipment is retired or otherwise disposed of, the related gain or
loss is included in operating income. Leasehold improvements are depreciated on the straight-line method over the shorter of the remaining
lease term or estimated useful life of the asset. Depreciation is calculated on the straight-line method, including property and equipment
under capital leases, generally based on the following useful lives:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="width: 91%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 8%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Estimated&nbsp;Life<BR>
    in Years</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Buildings and leasehold improvements</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">5 ~ 50</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Machinery and equipment</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">5 ~ 10</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Office equipment</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">3 ~ 6</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Impairment of Long-Lived Assets</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has adopted Accounting Standards
Codification subtopic 360-10, Property, Plant and Equipment (&ldquo;ASC 360-10&rdquo;). ASC 360-10 requires that long-lived assets and
certain identifiable intangibles held and used by the Company be reviewed for impairment whenever events or changes in circumstances
indicate that the carrying amount of an asset may not be recoverable. The Company evaluates its long-lived assets for impairment annually
or more often if events and circumstances warrant. Events relating to recoverability may include significant unfavorable changes in business
conditions, recurring losses, or a forecasted inability to achieve break-even operating results over an extended period. Should impairment
in value be indicated, the carrying value of intangible assets will be adjusted, based on estimates of future discounted cash flows resulting
from the use and ultimate disposition of the asset. ASC 360-10 also requires assets to be disposed of be reported at the lower of the
carrying amount or the fair value less costs to sell.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Long-term Equity Investment</U>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company acquires the equity investments to
promote business and strategic objectives. The Company accounts for non-marketable equity and other equity investments for which the
Company does not have control over the investees as:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Equity method investments when the Company has the ability to exercise
    significant influence, but not control, over the investee. Its proportionate share of the income or loss is recognized monthly and
    is recorded in gains (losses) on equity investments.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Non-marketable cost method investments when the equity method does
    not apply.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Significant judgment is required to identify
whether an impairment exists in the valuation of the Company&rsquo;s non-marketable equity investments, and therefore the Company considers
this a critical accounting estimate. Its yearly analysis considers both qualitative and quantitative factors that may have a significant
impact on the investee&rsquo;s fair value. Qualitative analysis of its investments involves understanding the financial performance and
near-term prospects of the investee, changes in general market conditions in the investee&rsquo;s industry or geographic area, and the
management and governance structure of the investee. Quantitative assessments of the fair value of its investments are developed using
the market and income approaches. The market approach includes the use of comparable financial metrics of private and public companies
and recent financing rounds. The income approach includes the use of a discounted cash flow model, which requires significant estimates
regarding the investees&rsquo; revenue, costs, and discount rates. The Company&rsquo;s assessment of these factors in determining whether
an impairment exists could change in the future due to new developments or changes in applied assumptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Other-Than-Temporary Impairment</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s long-term equity investments
are subject to a periodic impairment review. Impairments affect earnings as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Marketable equity securities include the consideration of general market
    conditions, the duration and extent to which the fair value is below cost, and our ability and intent to hold the investment for
    a sufficient period of time to allow for recovery of value in the foreseeable future. The Company also considers specific adverse
    conditions related to the financial health of, and the business outlook for, the investee, which may include industry and sector
    performance, changes in technology, operational and financing cash flow factors, and changes in the investee&rsquo;s credit rating.
    The Company records other-than-temporary impairments on marketable equity securities and marketable equity method investments in
    gains (losses) on equity investments.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Non-marketable equity investments based on the Company&rsquo;s assessment
    of the severity and duration of the impairment, and qualitative and quantitative analysis of the operating performance of the investee;
    adverse changes in market conditions and the regulatory or economic environment; changes in operating structure or management of
    the investee; additional funding requirements; and the investee&rsquo;s ability to remain in business. A series of operating losses
    of an investee or other factors may indicate that a decrease in value of the investment has occurred that is other than temporary
    and that shall be recognized even though the decrease in value is in excess of what would otherwise be recognized by application
    of the equity method. A loss in value of an investment that is other than a temporary decline shall be recognized. Evidence of a
    loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the
    investment or inability of the investee to sustain an earnings capacity that would justify the carrying amount of the investment.
    The Company records other-than-temporary impairments for non-marketable cost method investments and equity method investments in
    gains (losses) on equity investments. Other-than-temporary impairments of equity investments were $0 and $0 for the three months
    ended March 31, 2021 and 2020, respectively.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Goodwill</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company evaluates goodwill for impairment
annually or more frequently when an event occurs or circumstances change that indicate the carrying value may not be recoverable. In
testing goodwill for impairment, the Company may elect to utilize a qualitative assessment to evaluate whether it is more likely than
not that the fair value of a reporting unit is less than its carrying amount. If the qualitative assessment indicates that goodwill impairment
is more likely than not, the Company performs a two-step impairment test. The Company tests goodwill for impairment under the two-step
impairment test by first comparing the book value of net assets to the fair value of the reporting units. If the fair value is determined
to be less than the book value or qualitative factors indicate that it is more likely than not that goodwill is impaired, a second step
is performed to compute the amount of impairment as the difference between the estimated fair value of goodwill and the carrying value.
The Company estimates the fair value of the reporting units using discounted cash flows. Forecasts of future cash flows are based on
our best estimate of future net sales and operating expenses, based primarily on expected category expansion, pricing, market segment
share, and general economic conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company completed the required testing of
goodwill for impairment as of March 31, 2021, and determined that goodwill was impaired because of the current financial condition of
the Company and the Company&rsquo;s inability to generate future operating income without substantial sales volume increases, which are
highly uncertain. Furthermore, the Company anticipates future cash flows indicate that the recoverability of goodwill is not reasonably
assured.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Research and Development Expenses</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for the cost of using licensing
rights in research and development cost according to ASC Topic 730-10-25-1. This guidance provides that absent alternative future uses
the acquisition of product rights to be used in research and development activities must be charged to research and development expenses
when incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For CDMO business unit, the Company accounts
for R&amp;D costs in accordance with Accounting Standards Codification (&ldquo;ASC&rdquo;) 730, Research and Development (&ldquo;ASC
730&rdquo;). Research and development expenses are charged to expense as incurred unless there is an alternative future use in other
research and development projects or otherwise. Research and development expenses are comprised of costs incurred in performing research
and development activities, including personnel-related costs, facilities-related overhead, and outside contracted services including
clinical trial costs, manufacturing and process development costs for both clinical and preclinical materials, research costs, and other
consulting services. Non-refundable advance payment for goods and services that will be used in future research and development activities
are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. In instances
where the Company enters into agreements with third parties to provide research and development services, costs are expensed as services
are performed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Post-retirement and post-employment benefits</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s subsidiaries in Taiwan adopted
the government mandated defined contribution plan pursuant to the Labor Pension Act (the &ldquo;Act&rdquo;) in Taiwan. Such labor regulations
require that the rate of contribution made by an employer to the Labor Pension Fund per month shall not be less than 6% of the worker&rsquo;s
monthly salaries. Pursuant to the Act, the Company makes monthly contribution equal to 6% of employees&rsquo; salaries to the employees&rsquo;
pension fund. The Company has no legal obligation for the benefits beyond the contributions made. The total amounts for such employee
benefits, which were expensed as incurred, were $2,503 and $3,598 for the three months ended March 31, 2021 and 2020, respectively. Other
than the above, the Company does not provide any other post-retirement or post-employment benefits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Stock-based Compensation</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company measures expense associated with
all employee stock-based compensation awards using a fair value method and recognizes such expense in the consolidated financial statements
on a straight-line basis over the requisite service period in accordance with FASB ASC Topic 718 &ldquo;Compensation-Stock Compensation&rdquo;.
Total employee stock-based compensation expenses were $0 and $0 for the three months ended March 31, 2021 and 2020, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounted for stock-based compensation
to non-employees in accordance with FASB ASC Topic 718 &ldquo;Compensation-Stock Compensation&rdquo; and FASB ASC Topic 505-50 &ldquo;Equity-Based
Payments to Non-Employees&rdquo; which requires that the cost of services received from non-employees is measured at fair value at the
earlier of the performance commitment date or the date service is completed and recognized over the period the service is provided. Total
non-employee stock-based compensation expenses were $225,740 and $525 for the three months ended March 31, 2021 and 2020, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Beneficial Conversion Feature</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, the Company may issue convertible
notes that may contain an imbedded beneficial conversion feature. A beneficial conversion feature exists on the date a convertible note
is issued when the fair value of the underlying common stock to which the note is convertible into is in excess of the remaining unallocated
proceeds of the note after first considering the allocation of a portion of the note proceeds to the fair value of the warrants, if related
warrants have been granted. The intrinsic value of the beneficial conversion feature is recorded as a debt discount with a corresponding
amount to additional paid in capital. The debt discount is amortized to interest expense over the life of the note using the effective
interest method.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Income Taxes</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for income taxes using the
asset and liability approach which allows the recognition and measurement of deferred tax assets to be based upon the likelihood of realization
of tax benefits in future years. Under the asset and liability approach, deferred taxes are provided for the net tax effects of temporary
differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax
purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not these items will expire before the
Company is able to realize their benefits, or future deductibility is uncertain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under ASC 740, a tax position is recognized as
a benefit only if it is&nbsp;&ldquo;more likely than not&rdquo;&nbsp;that the tax position would be sustained in a tax examination, with
a tax examination being presumed to occur. The evaluation of a tax position is a two-step process. The first step is to determine whether
it is more-likely-than-not that a tax position will be sustained upon examination, including the resolution of any related appeals or
litigations based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not
threshold to determine the amount of benefits recognized in the financial statements. A tax position is measured at the largest amount
of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. Tax positions that previously failed to
meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which the threshold is met.
Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent
financial reporting period in which the threshold is no longer satisfied. Penalties and interest incurred related to underpayment of income
tax are classified as income tax expense in the year incurred. No significant penalty or interest relating to income taxes has been incurred
for the three months ended March 31, 2021 and 2020. GAAP also provides guidance on de-recognition, classification, interest and penalties,
accounting in interim periods, disclosures and transition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 22, 2017, the SEC issued Staff Accounting
Bulletin (&ldquo;SAB 118&rdquo;), which provides guidance on accounting for tax effects of the Tax Act. SAB 118 provides a measurement
period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740.
In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the Act for which the accounting under
ASC 740 is complete. To the extent that a company&rsquo;s accounting for certain income tax effects of the Tax Act is incomplete but
it is able to determine a reasonable estimate, it must record a provisional estimate to be included in the financial statements. If a
company cannot determine a provisional estimate to be included in the financial statements, it should continue to apply ASC 740 on the
basis of the provision of the tax laws that were in effect immediately before the enactment of the Tax Act. While the Company is able
to make reasonable estimates of the impact of the reduction in corporate rate and the deemed repatriation transition tax, the final impact
of the Tax Act may differ from these estimates, due to, among other things, changes in our interpretations and assumptions, additional
guidance that may be issued by the I.R.S., and actions the Company may take. The Company is continuing to gather additional information
to determine the final impact.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Valuation of Deferred Tax Assets</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A valuation allowance is recorded to reduce the
Company&rsquo;s deferred tax assets to the amount that is more likely than not to be realized. In assessing the need for the valuation
allowance, management considers, among other things, projections of future taxable income and ongoing prudent and feasible tax planning
strategies. If the Company determines that sufficient negative evidence exists, then it will consider recording a valuation allowance
against a portion or all of the deferred tax assets in that jurisdiction. If, after recording a valuation allowance, the Company&rsquo;s
projections of future taxable income and other positive evidence considered in evaluating the need for a valuation allowance prove, with
the benefit of hindsight, to be inaccurate, it could prove to be more difficult to support the realization of its deferred tax assets.
As a result, an additional valuation allowance could be required, which would have an adverse impact on its effective income tax rate
and results. Conversely, if, after recording a valuation allowance, the Company determines that sufficient positive evidence exists in
the jurisdiction in which the valuation allowance was recorded, it may reverse a portion or all of the valuation allowance in that jurisdiction.
In such situations, the adjustment made to the deferred tax asset would have a favorable impact on its effective income tax rate and
results in the period such determination was made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Loss Per Share of Common Stock</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company calculates net loss per share in
accordance with ASC Topic 260, &ldquo;Earnings per Share&rdquo;. Basic loss per share is computed by dividing the net loss by the weighted
average number of common shares outstanding during the period. Diluted loss per share is computed similar to basic loss per share except
that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential
common stock equivalents had been issued and if the additional common shares were dilutive. Diluted earnings per share excludes all dilutive
potential shares if their effect is anti-dilutive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Commitments and Contingencies</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has adopted ASC Topic 450 &ldquo;Contingencies&rdquo;
subtopic 20, in determining its accruals and disclosures with respect to loss contingencies. Accordingly, estimated losses from loss
contingencies are accrued by a charge to income when information available before financial statements are issued or are available to
be issued indicates that it is probable that an assets had been impaired or a liability had been incurred at the date of the financial
statements and the amount of the loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred.
If a loss contingency is not probable or reasonably estimable, disclosure of the loss contingency is made in the financial statements
when it is at least reasonably possible that a material loss could be incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Foreign-currency Transactions</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the Company&rsquo;s subsidiaries in Taiwan,
the foreign-currency transactions are recorded in New Taiwan dollars (&ldquo;NTD&rdquo;) at the rates of exchange in effect when the
transactions occur. Gains or losses resulting from the application of different foreign exchange rates when cash in foreign currency
is converted into New Taiwan dollars, or when foreign-currency receivables or payables are settled, are credited or charged to income
in the year of conversion or settlement. On the balance sheet dates, the balances of foreign-currency assets and liabilities are restated
at the prevailing exchange rates and the resulting differences are charged to current income except for those foreign currencies denominated
investments in shares of stock where such differences are accounted for as translation adjustments under the Statements of Stockholders&rsquo;
Equity (Deficit).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Translation Adjustment</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accounts of the Company&rsquo;s subsidiaries
in Taiwan were maintained, and their financial statements were expressed, in New Taiwan Dollar (&ldquo;NT$&rdquo;). Such financial statements
were translated into U.S. Dollars (&ldquo;$&rdquo; or &ldquo;USD&rdquo;) in accordance ASC 830, &ldquo;Foreign Currency Matters&rdquo;,
with the NT$ as the functional currency. According to the Statement, all assets and liabilities are translated at the current exchange
rate, stockholder&rsquo;s deficit are translated at the historical rates and income statement items are translated at an average exchange
rate for the period. The resulting translation adjustments are reported under other comprehensive income (loss) as a component of stockholders&rsquo;
equity (deficit).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Recent Accounting Pronouncements</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2019, the FASB issued ASU 2019-12,&nbsp;<I>Income
Taxes (Topic 740): Simplifying the Accounting for Income Taxes</I>, as part of its overall simplification initiative to reduce costs
and complexity of applying accounting standards while maintaining or improving the usefulness of the information provided to users of
financial statements. The FASB&rsquo;s amendments primarily impact ASC 740,&nbsp;<I>Income Taxes</I>, and may impact both interim and
annual reporting periods. ASU 2019-12 will be effective for fiscal years beginning after December 15, 2020, and interim periods within
those fiscal years and early adoption is permitted. The Company is currently evaluating the impact of adopting ASU 2019-12.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In August 2020, the
FASB issued ASU 2020-06,&nbsp;<I>Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging- Contracts in Entity&rsquo;s
Own Equity (Subtopic 815-40)</I>, to reduce the complexity associated with applying U.S. GAAP principles for certain financial instruments
with characteristics of liabilities and equity. The amendments in this ASU reduce the number of accounting models for convertible instruments
and expand the existing disclosure requirements over earnings per share as it relates to convertible instruments. This ASU will be effective
for the fiscal year beginning January 1, 2022 and interim periods therein. Early adoption is permitted, but no earlier than fiscal years
beginning after December 15, 2020. The amendments may be adopted through either a modified retrospective method, or a fully retrospective
method. The Company is currently evaluating the impact of adopting ASU 2020-06.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3. COLLABORATIVE AGREEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Collaborative agreements with BHK</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(i) On February 24, 2015, BioLite Taiwan and
BioHopeKing Corporation (the &ldquo;BHK&rdquo;) entered into a co-development agreement, (the &ldquo;BHK Co-Development Agreement&rdquo;),
pursuant to which it is collaborative with BHK to develop and commercialize BLI-1401-2 (Botanical Drug) Triple Negative Breast Cancer
(TNBC) Combination Therapy (BLI-1401-2 Products) in Asian countries excluding Japan for all related intellectual property rights, and
has developed it for medicinal use in collaboration with outside researchers. The development costs shall be shared 50/50 between BHK
and the Company. The BHK Co-Development Agreement will remain in effect for fifteen years from the date of first commercial sale of the
Product in in Asia excluding Japan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 27, 2016, BioLite Taiwan and BHK agreed
to amend the payment terms of the milestone payment in an aggregate amount of $10 million based on the following schedule:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Upon the signing of the BHK Co-Development Agreement: $1 million, or
    10% of total payment</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Upon the first Investigational New Drug (IND) submission and BioLite
    Taiwan will deliver all data to BHK according to FDA Reviewing requirement: $1 million, or 10% of total payment</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">At the completion of first phase II clinical trial: $1 million, or 10% of total payment</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">At the initiation of phase III of clinical trial research: $3 million, or 30% of total payment</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Upon the New Drug Application (NDA) submission: $4 million, or 40% of total payment</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2015, BHK has paid a non-refundable
upfront cash payment of $1 million, or 10% of $10,000,000, upon the signing of BHK Co-Development Agreement. The Company concluded that
the deliverables are considered separate units of accounting as the delivered items have value to the customer on a standalone basis
and recognized this cash receipt as collaboration revenue when all research, technical, and development data was delivered to BHK in
2015. The receipt is for the compensation of past research efforts and contributions made by BioLite Taiwan before this collaborative
agreement was signed and it does not relate to any future commitments made by BioLite Taiwan and BHK in this collaborative agreement.
In August 2016, the Company has received the second milestone payment of NT$31,649,000, approximately equivalent to $1 million, and recognized
collaboration revenue for the year ended December 31, 2016. As of the date of this report, the Company has not completed the first phase
II clinical trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to the milestone payments, BioLite
Taiwan is entitled to receive royalty on 12% of BHK&rsquo;s net sales related to BLI-1401-2 Products. As of March 31, 2021 and December
31, 2020, the Company has not earned the royalty under the BHK Co-Development Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(ii) On December 9, 2015, BioLite Taiwan entered
into another two collaborative agreements (the &ldquo;BHK Collaborative Agreements&rdquo;), pursuant to which it is collaborative with
BHK to co-develop and commercialize BLI-1005 for &ldquo;Targeting Major Depressive Disorder&rdquo; (BLI-1005 Products) and BLI-1006 for
&ldquo;Targeting Inflammatory Bowel Disease&rdquo; (BLI-1006 Products) in Asia excluding Japan for all related intellectual property
rights, and has developed it for medicinal use in collaboration with outside researchers. The development costs shall be shared 50/50
between BHK and the Company. The BHK Co-Development Agreement will remain in effect for fifteen years from the date of first commercial
sale of the Product in in Asia excluding Japan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In 2015, the Company recognized the cash receipt
in a total of NT$50 million, approximately equivalent to $1.6 million, as collaboration revenue when all research, technical, and development
data was delivered to BHK. The Company concluded that the deliverables are considered separate units of accounting as the delivered items
have value to the customer on a standalone basis and recognized this payment as collaboration revenue when all research, technical, data
and development data was delivered to BHK. The cash receipt is for the compensation of past research efforts and contributions made by
BioLite Taiwan before this BHK Collaborative Agreements was signed and it does not relate to any future commitments made by BioLite Taiwan
and BHK in this BHK Collaborative Agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to the total of NT$50 million, approximately
equivalent to $1.60 million, BioLite Taiwan is entitled to receive 50% of the future net licensing income or net sales profit. As of
March 31, 2021 and December 31, 2020, the Company has not earned the royalty under the BHK Collaborative Agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Co-Development agreement with Rgene Corporation,
a related party</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 26, 2017, BriVision entered into a
co-development agreement (the &ldquo;Co-Dev Agreement&rdquo;) with Rgene Corporation (the &ldquo;Rgene&rdquo;), a related party
under common control by controlling beneficiary shareholder of YuanGene Corporation and the Company (See Note 12). Pursuant to
Co-Dev Agreement, BriVision and Rgene agreed to co-develop and commercialize ABV-1507 HER2/neu Positive Breast Cancer Combination
Therapy, ABV-1511 Pancreatic Cancer Combination Therapy and ABV-1527 Ovary Cancer Combination Therapy. Under the terms of the Co-Dev
Agreement, Rgene is required to&nbsp;pay the Company $3,000,000 in cash or stock of Rgene with equivalent value by August 15, 2017.
The payment is for the compensation of BriVision&rsquo;s past research efforts and contributions made by BriVision before the Co-Dev
Agreement was signed and it does not relate to any future commitments made by BriVision and Rgene in this Co-Dev Agreement. In
addition to $3,000,000, the Company is entitled to receive 50% of the future net licensing income or net sales profit earned by
Rgene, if any, and any development costs shall be equally shared by both BriVision and Rgene.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 1, 2017, the Company has delivered all
research, technical, data and development data to Rgene. Since both Rgene and the Company are related parties and under common control
by a controlling beneficiary shareholder of YuanGene Corporation and the Company, the Company has recorded the full amount of $3,000,000
in connection with the Co-Dev Agreement as additional paid-in capital during the year ended December 31, 2017. During the year ended
December 31, 2017, the Company has received $450,000 in cash. On December 24, 2018, the Company received the remaining balance of $2,550,000
in the form of newly issued shares of Rgene&rsquo;s Common Stock, at the price of NT$50 (approximately equivalent to $1.60 per share),
for an aggregate number of 1,530,000 shares, which accounted for equity method long-term investment as of December 31, 2018. During the
year ended December 31, 2018, the Company has recognized investment loss of $549. On December 31, 2018, the Company determined to fully
write off this investment based on the Company&rsquo;s assessment of the severity and duration of the impairment, and qualitative and
quantitative analysis of the operating performance of the investee, adverse changes in market conditions and the regulatory or economic
environment, changes in operating structure of Rgene, additional funding requirements, and Rgene&rsquo;s ability to remain in business.
All projects that have been initiated will be managed and supported by the Company and Rgene.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company and Rgene signed an amendment to
the Co-Dev Agreement on November 10, 2020, pursuant to which both parties agreed to delete AB-1507 HER2/neu Positive Breast Cancer Combination
Therapy and AB 1527 Ovary Cancer Combination Therapy and add ABV-1519 EGFR Positive Non-Small Cell Lung Cancer Combination Therapy and
ABV-1526 Large Intestine / Colon / Rectal Cancer Combination Therapy to the products to be co-developed and commercialized. Other provisions
of the Co-Dev Agreement remain in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Collaborative agreement with BioFirst Corporation,
a related party</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 24, 2017, BriVision entered into a
collaborative agreement (the &ldquo;BioFirst Collaborative Agreement&rdquo;) with BioFirst Corporation (&ldquo;BioFirst&rdquo;),
pursuant to which BioFirst granted the Company the global licensing right for medical use of the product (the
&ldquo;Product&rdquo;): BFC-1401 Vitreous Substitute for Vitrectomy. BioFirst is a related party to the Company because a
controlling beneficiary shareholder of YuanGene Corporation and the Company is one of the directors and Common Stock shareholders of
BioFirst (See Note 12).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the BioFirst Collaborative Agreement,
the Company will co-develop and commercialize the Product with BioFirst and pay BioFirst in a total amount of $3,000,000 in cash or stock
of the Company before December 31, 2018. The amount of $3,000,000 is in connection with the compensation for BioFirst&rsquo;s past research
efforts and contributions made by BioFirst before the BioFirst Collaborative Agreement was signed and it does not relate to any future
commitments made by BioFirst and BriVision in this BioFirst Collaborative Agreement. In addition, the Company is entitled to receive
50% of the future net licensing income or net sales profit, if any, and any development cost shall be equally shared by both BriVision
and BioFirst.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 25, 2017, BioFirst has delivered
all research, technical, data and development data to BriVision. The Company determined to fully expense the entire amount of $3,000,000
since currently the related licensing rights do not have alternative future uses. According to ASC 730-10-25-1, absent alternative future
uses the acquisition of product rights to be used in research and development activities must be charged to research and development
expenses immediately. Hence, the entire amount of $3,000,000 is fully expensed as research and development expense during the year ended
December 31, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 30, 2019, BriVision entered into a Stock
Purchase Agreement (the &ldquo;Purchase Agreement&rdquo;) with BioFirst Corporation (&ldquo;BioFirst&rdquo;). Pursuant to the Purchase
Agreement, the Company issued 428,571 shares of the Company&rsquo;s common stock (the &ldquo;Shares&rdquo;) to BioFirst in consideration
for $3,000,000 owed by the Company to BioFirst (the &ldquo;Total Payment&rdquo;) in connection with a certain collaborative agreement
between the Company and BioFirst dated July 24, 2017 (the &ldquo;Collaborative Agreement&rdquo;). Pursuant to the Collaborative Agreement,
BioFirst granted the Company the global licensing right to co-develop BFC-1401 or ABV-1701 Vitreous Substitute for Vitrectomy for medical
purposes in consideration for the Total Payment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 5, 2019, BriVision entered into a second
Stock Purchase Agreement (&ldquo;Purchase Agreement 2&rdquo;) with BioFirst Corporation (&ldquo;BioFirst&rdquo;). Pursuant to Purchase
Agreement 2, the Company issued 414,702 shares of the Company&rsquo;s common stock (the &ldquo;Shares&rdquo;) to BioFirst in consideration
for $2,902,911 owed by the Company to BioFirst (the &ldquo;Total Payment&rdquo;) in connection with a loan provided to BriVision from
BioFirst.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>4. INVENTORY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Inventory consists of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.9pt; text-align: justify; text-indent: -22.9pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,<BR> 2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,<BR> 2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">(Unaudited)</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Finished goods</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">99,549</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">100,967</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Work-in-process</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21,729</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22,038</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Raw materials</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">60,851</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">61,718</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Allowance for inventory valuation and obsolescence loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(182,129</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(184,723</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Inventory, net</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.9pt; text-align: justify; text-indent: -22.9pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>5. PROPERTY AND EQUIPMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-indent: -23.75pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-align: justify; text-indent: -23.75pt">Property and
equipment as of March 31, 2021 and December 31, 2020 are summarized as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-align: justify; text-indent: -23.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">March 31,<BR>
    2021</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">December&nbsp;31,<BR>
    2020</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold">(Unaudited)</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: justify">Land</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">390,088</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">395,645</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Buildings and leasehold improvements</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,231,712</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,233,573</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Machinery and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">992,882</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">994,544</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Office equipment</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">187,181</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">189,760</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,801,863</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,813,522</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Less: accumulated depreciation</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(3,296,911</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(3,298,688</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 4pt">Property and equipment, net</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">504,952</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">514,834</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Depreciation expenses were $2,928 and $11,174
for three months ended March 31, 2021 and 2020, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-indent: -23.75pt"><B>6. LONG-TERM INVESTMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-indent: -23.75pt"><B>&nbsp;&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">The ownership percentages of each investee are listed as follows:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 331.3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Ownership percentage</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center">March 31,</TD><TD STYLE="white-space: nowrap; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center">December&nbsp;31,</TD><TD STYLE="white-space: nowrap; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-weight: bold; text-align: center">Accounting</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold">Name of related party</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">treatments</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left">Braingenesis Biotechnology Co., Ltd.</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">0.17</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">0.17</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 11%; text-align: center">Cost Method</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Genepharm Biotech Corporation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.70</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.70</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Cost Method</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">BioHopeKing Corporation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.90</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.90</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Cost Method</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">BioFirst Corporation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15.99</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15.99</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Equity Method</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Rgene Corporation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">31.62</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">31.62</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Equity Method</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">The extent the investee relies on the company for its business are summarized as follows:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="border-bottom: black 1.5pt solid; width: 30%"><FONT STYLE="font-size: 10pt"><B>Name of related party</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 69%"><FONT STYLE="font-size: 10pt"><B>The extent the investee relies on the Company
    for its business &nbsp;</B></FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Braingenesis Biotechnology Co., Ltd.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">No specific business relationship</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Genepharm Biotech Corporation</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">No specific business relationship</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">BioHopeKing Corporation</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Collaborating with the Company to develop and commercialize drugs</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD><FONT STYLE="font-size: 10pt">BioFirst Corporation</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Loaned from the investee and provides research and development support service</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Rgene Corporation</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Collaborating with the Company to develop and commercialize drugs</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><B>&nbsp;&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(3)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Long-term investment mainly consists of the following:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March&nbsp;31,<BR> 2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&nbsp;31,<BR> 2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Non-marketable Cost Method Investments, net</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; padding-left: 9pt">Braingenesis Biotechnology Co., Ltd.</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">7,742</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">7,853</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Genepharm Biotech Corporation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23,638</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23,974</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">BioHopeKing Corporation</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">878,056</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">890,564</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">Sub total</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">909,436</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">922,391</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Equity Method Investments, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">BioFirst Corporation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">217,448</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">268,336</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Rgene Corporation</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt; padding-left: 0.25in">Total</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,126,884</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,190,727</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">BioFirst
                                            Corporation (the &ldquo;BioFirst&rdquo;):</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company holds an equity interest
in BioFirst Corporation, accounting for its equity interest using the equity method to accounts for its equity investment as prescribed
in ASC 323, Investments&mdash;Equity Method and Joint Ventures (&ldquo;ASC 323&rdquo;). Equity method adjustments include the Company&rsquo;s
proportionate share of investee&rsquo;s income or loss and other adjustments required by the equity method. As of March 31, 2021 and December
31, 2020, the Company owns 15.99% and 15.99% common stock shares of BioFirst, respectively. During the three months ended March 31, 2021,
the Company made prepayment for equity investment in BioFirst to purchase additional 132,000 shares issued by BioFirst in the aggregate
amount of $281,952.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Summarized financial information for the Company&rsquo;s
equity method investee, BioFirst, is as follows:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Balance Sheet</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,<BR> 2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&nbsp;31,<BR> 2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Current Assets</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,216,963</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,299,822</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Non-current Assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,633,925</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,540,041</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Current Liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,959,919</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,986,340</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Non-current Liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">76,082</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">73,197</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Stockholders&rsquo; Equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,814,887</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,780,326</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Statement of operation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended<BR> March 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="6">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Net sales</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">12,239</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">12,110</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Gross profit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,080</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,578</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(220,855</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(325,652</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Share of losses from investments accounted for using the equity method</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(47,791</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(70,411</TD><TD STYLE="text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Rgene
                                            Corporation (the &ldquo;Rgene&rdquo;)</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Both Rgene and the Company are under
common control by Dr. Tsung-Shann Jiang, the CEO and chairman of the BioLite Inc. Since Dr. Tsung-Shann Jiang is able to exercise significant
influence, but not control, over the Rgene, the Company determined to use the equity method to accounts for its equity investment as
prescribed in ASC 323, Investments&mdash;Equity Method and Joint Ventures (&ldquo;ASC 323&rdquo;). Equity method adjustments include
the Company&rsquo;s proportionate share of investee&rsquo;s income or loss and other adjustments required by the equity method. As of
March 31, 2021 and December 31, 2020, the Company owns 31.62% and 31.62% Common Stock shares of Rgene, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Summarized financial information for the Company&rsquo;s
equity method investee, Rgene, is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Balance Sheets</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">March 31,<BR>
    2021</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">December&nbsp;31,<BR>
    2020</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Current Assets</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">107,682</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">123,958</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Noncurrent Assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">395,665</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">412,342</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Current Liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,451,387</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,392,756</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Noncurrent Liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">28,877</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">38,953</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Shareholders&rsquo; Deficit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(976,917</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(895,409</TD><TD STYLE="text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Statement of operations</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Three Months Ended<BR>
    March 31,</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2021</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2020</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="6">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 76.98%"><FONT STYLE="font-size: 10pt">Net sales</FONT></TD>
    <TD STYLE="width: 0.98%">&nbsp;</TD>
    <TD STYLE="width: 1.06%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 8.98%; text-align: right">-</TD>
    <TD STYLE="width: 0.98%">&nbsp;</TD>
    <TD STYLE="width: 0.98%">&nbsp;</TD>
    <TD STYLE="width: 1.06%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 7.98%; text-align: right">-</TD>
    <TD STYLE="width: 0.98%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Gross Profit</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Net loss</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(95,395</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(21,889</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Share of loss from investments accounted for using the equity method</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(4)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Disposition
                                            of long-term investment</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">During the year ended December 31,
2020, the Company sold 218,000 shares of common stock of BioHopeKing Corporation at price of NT$24, equivalent $0.85, to several individuals,
and the percentage of ownership decreased to 5.90% as of December 31, 2020. As a result of the transactions, the Company recognized investment
loss of $40,589 and impairment loss of $961,217 for the same period. As of March 31. 2021, there is no disposition of long-term investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(5)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Losses
                                            on Equity Investments</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The components of losses on equity investments
for each period were as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended<BR> March 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Share of equity method investee losses</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(47,791</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(70,411</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>7. CONVERTIBLE NOTES PAYABLE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 9, 2018, the Company issued an eighteen-month
term unsecured convertible promissory note (the &ldquo;Yu and Wei Note&rdquo;) in an aggregate principal amount of $300,000 to Guoliang
Yu and Yingfei Wei Family Trust (the &ldquo;Yu and Wei&rdquo;), pursuant to which the Company received $300,000. The Yu and Wei Note bears
interest at 8% per annum. The Company shall pay to the Yu and Wei an amount in cash representing all outstanding principal and accrued
and unpaid interest on the Eighteenth (18) month anniversary of the issuance date of the Yu and Wei Note, which is on November 8, 2019.
In the event that the Company raises gross proceeds from the sale of its common stock of at least $5,000,000 (an &ldquo;Equity Offering&rdquo;)
then within five days of the closing for such offering, the Company must repay the outstanding amount of this Yu and Wei Note. At any
time from the date hereof until this Yu and Wei Note has been satisfied, the Yu and Wei may convert the unpaid and outstanding principal
plus any accrued and unpaid interest and or default interest, if any, into shares of the Company&rsquo;s common stock at a conversion
price (the &ldquo;Conversion Price&rdquo;) equal to the lower of (i) $2.00 per share (the &ldquo;Fixed Conversion Price&rdquo;), subject
to adjustment or (ii) 80% of the per share offering price (the &ldquo;Alternative Conversion Price&rdquo;) of any completed equity offering
of the Company in an amount exceeding $500,000 that occurs when any part of the Yu and Wei Note is outstanding, subject to adjustments
set forth in the Yu and Wei Note. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial
conversion feature present in the Yu and Wei Note. On January 21, 2020, Yu and Wei entered into a new agreement that the new Note bears
interest at 20% per annum. The Company shall pay to the Yu and Wei an amount in cash representing all outstanding principal and accrued
and unpaid interest on the Twelve (12) month anniversary of the issuance date of the new &ldquo;Yu and Wei&rdquo; Note, which is on January
20, 2021. On April 5, 2020, the Company entered into an exchange agreement with &ldquo;Yu and Wei&rdquo;. The aggregate principal amount
plus accrued interest expenses were $354,722, and the Company agreed to issue to the Holders an aggregate of 192,784 shares of the Company&rsquo;s
common stock, and warrants to purchase 192,784 shares of the Company&rsquo;s common stock. As of March 31, 2021, these common shares have
been issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 27, 2018, the Company issued an eighteen-month
term unsecured convertible promissory note (the &ldquo;Keypoint Note&rdquo;) in the aggregate principal amount of $250,000 to Keypoint
Technology Ltd. (&ldquo;Keypoint&rdquo;), a related party, pursuant to which the Company received $250,000. The Keypoint Note bears interest
at 8% per annum. The Company shall pay to the Keypoint an amount in cash representing all outstanding principal and accrued and unpaid
interest on the Eighteenth (18) month anniversary of the issuance date of the Keypoint Note, which is on December 26, 2019. In the event
that the Company raises gross proceeds from the sale of its common stock of at least $5,000,000 (an &ldquo;Equity Offering&rdquo;) then
within five days of the closing for such offering, the Company must repay the outstanding amount of this Keypoint Note. At any time from
the date hereof until this Keypoint Note has been satisfied, Keypoint may convert the unpaid and outstanding principal plus any accrued
and unpaid interest and or default interest, if any, into shares of the Company&rsquo;s common stock at a conversion price (the &ldquo;Conversion
Price&rdquo;) equal to the lower of (i) $2.00 per share (the &ldquo;Fixed Conversion Price&rdquo;), subject to adjustment or (ii) 80%
of the per share offering price (the &ldquo;Alternative Conversion Price&rdquo;) of any completed equity offering of the Company in an
amount exceeding $500,000 that occurs when any part of the Keypoint Note is outstanding, subject to adjustments set forth in the Keypoint
Note. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature
present in the Keypoint Note. On January 21, 2020, Keypoint entered into a new agreement that the new Note bears interest at 20% per annum.
The Company shall pay to the Keypoint an amount in cash representing all outstanding principal and accrued and unpaid interest on the
Twelve (12) month anniversary of the issuance date of the new &ldquo;Keypoint&rdquo; Note, which is on January 20, 2021. On April 5, 2020,
the Company entered into an exchange agreement with &ldquo;Keypoint&rdquo;. The aggregate principal amount plus accrued interest expenses
were $292,826, and the Company agreed to issue to the Holders an aggregate of 159,145 shares of the Company&rsquo;s common stock, and
warrants to purchase 159,145 shares of the Company&rsquo;s common stock. As of March 31, 2021, these common shares have been issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 25, 2018, the Company issued an eighteen-month
term unsecured convertible promissory notes (the &ldquo;Odaira Note&rdquo;) in the aggregate principal amount of $250,000 to Yoshinobu
Odaira. (&ldquo;Odaira&rdquo;), pursuant to which the Company received $250,000. The Odaira Note bears interest at 8% per annum. The Company
shall pay to the Odaira an amount in cash representing all outstanding principal and accrued and unpaid interest on the Eighteenth (18)
month anniversary of the issuance date of the Odaira Note, which is on February 24, 2020. In the event that the Company raises gross proceeds
from the sale of its common stock of at least $5,000,000 (an &ldquo;Equity Offering&rdquo;) then within five days of the closing for such
offering, the Company must repay the outstanding amount of this Odaira Note. At any time from the date hereof until this Odaira Note has
been satisfied, Odaira may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default interest,
if any, into shares of the Company&rsquo;s common stock at a conversion price (the &ldquo;Conversion Price&rdquo;) equal to the lower
of (i) $2.00 per share (the &ldquo;Fixed Conversion Price&rdquo;), subject to adjustment or (ii) 80% of the per share offering price (the
&ldquo;Alternative Conversion Price&rdquo;) of any completed equity offering of the Company in an amount exceeding $500,000 that occurs
when any part of the Odaira Note is outstanding, subject to adjustments set forth in the Odaira Note. In accordance with FASB ASC 470-20,
the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the Odaira Note. On January 21,
2020, Odaira entered into a new agreement that the new Note bears interest at 20% per annum. The Company shall pay to the Odaira an amount
in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date
of the new &ldquo;Odaira&rdquo; Note, which is on January 20, 2021. On April 5, 2020, the Company entered into an exchange agreement with
&ldquo;Odaira&rdquo;. The aggregate principal amount plus accrued interest expenses were $284,036, and the Company agreed to issue to
the Holders an aggregate of 154,368 shares of the Company&rsquo;s common stock, and warrants to purchase 154,368 shares of the Company&rsquo;s
common stock. As of March 31, 2021, these common shares have been issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 30 and July 10, 2019, the Company issued
two (2) twelve-month term unsecured convertible promissory notes (the &ldquo;KSL Note&rdquo;) in an aggregate principal amount of $250,000
to Kuo Sheng Lung (the &ldquo;KSL&rdquo;), pursuant to which the Company received $160,000 and $90,000, respectively. The KSL Note bears
interest at 20% per annum. The Company shall pay to KSL an amount in cash representing all outstanding principal and accrued and unpaid
interest on the Twelve (12) month anniversary of the issuance date of the KSL Note, which is on May 29, 2020 and July 9, 2020. At any
time from the issuance date until the KSL Note has been satisfied, the KSL may convert the unpaid and outstanding principal plus any accrued
and unpaid interest and or default interest, if any, into shares of the Company&rsquo;s common stock at a conversion price (the &ldquo;Conversion
Price&rdquo;) equal to the lower of (i) $0.50 per share (the &ldquo;Fixed Conversion Price&rdquo;), subject to adjustment, or (ii) 70%
of the per share offering price (the &ldquo;Alternative Conversion Price&rdquo;) of the completed public equity offering of the Company
in an amount exceeding $10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission
on November 14, 2018 (the &ldquo;Public Offering&rdquo;), as amended from time to time. In accordance with FASB ASC 470-20, the Company
recognized none of the intrinsic value of the embedded beneficial conversion feature present in the KSL Note. On May 13, 2020, the Company
received an acknowledgement letter from KSL that they will not claim the repayment of loan for 12 months. On November 9, 2020, the Company
entered into an agreement with &ldquo;KSL&rdquo;. The aggregate principal amount plus accrued interest expenses are $270,272, and KSL
agreed to use the full amount to purchase certain securities pursuant to a securities purchase agreement; KSL agreed to purchase and the
Company agreed to issue 120,121 shares of the Company&rsquo;s common stock and warrants for a purchase price of $270,272.&nbsp;As of March
31, 2021, the Company issued to the Holders an aggregate of 120,121 shares of the Company&rsquo;s common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 10, 2019, the Company issued a twelve-month
term unsecured convertible promissory note (the &ldquo;NEA Note&rdquo;) in an aggregate principal amount of $250,000 to New Eastern Asia
(the &ldquo;NEA&rdquo;), a related party, pursuant to which the Company received $250,000 on July 10, 2019. The NEA Note bears interest
at 20% per annum. The Company shall pay to the NEA an amount in cash representing all outstanding principal and accrued and unpaid interest
on the Twelve (12) month anniversary of the issuance date of the NEA Note, which is on July 9, 2020. At any time from the date hereof
until this NEA Note has been satisfied, the NEA may convert the unpaid and outstanding principal plus any accrued and unpaid interest
and or default interest, if any, into shares of the Company&rsquo;s common stock at a conversion price (the &ldquo;Conversion Price&rdquo;)
equal to the lower of (i) $.50 per share (the &ldquo;Fixed Conversion Price&rdquo;), subject to adjustment, or (ii) 70% of the per share
offering price (the &ldquo;Alternative Conversion Price&rdquo;) of the completed public equity offering of the Company in an amount exceeding
$10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018
(the &ldquo;Public Offering&rdquo;), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of
the intrinsic value of embedded beneficial conversion feature present in the NEA Note. As of March 31, 2021, the Company paid off the convertible
promissory note of $306,667, including principal and accrued and unpaid interest expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 28, 2019, the Company issued a twelve-month
term unsecured convertible promissory note (the &ldquo;KLS Note&rdquo;) in an aggregate principal amount of $200,000 to Kuo Li Shen (the
&ldquo;KLS&rdquo;), pursuant to which the Company received $200,000 on August 28, 2019. The KLS Note bears interest at 20% per annum.
The Company shall pay to the KLS an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve
(12) month anniversary of the issuance date of the KLS Note, which is on August 27, 2020. At any time from the date hereof until this
KLS Note has been satisfied, the KLS may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default
interest, if any, into shares of the Company&rsquo;s common stock at a conversion price (the &ldquo;Conversion Price&rdquo;) equal to
the lower of (i) $.50 per share (the &ldquo;Fixed Conversion Price&rdquo;), subject to adjustment, or (ii) 70% of the per share offering
price (the &ldquo;Alternative Conversion Price&rdquo;) of the completed public equity offering of the Company in an amount exceeding $10,000,000
as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the &ldquo;Public
Offering&rdquo;), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value
of embedded beneficial conversion feature present in the KLS Note. On April 20, 2020, the Company entered into an exchange agreement with
KLS. The aggregate principal amount plus accrued interest expenses were $225,222, and the Company agreed to issue to the Holders an aggregate
of 126,530 shares of the Company&rsquo;s common stock, and warrants to purchase 126,530 shares of common stock. As of March 31, 2021,
these common shares have been issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 4, 2019, the Company issued 3 twelve-month
term unsecured convertible promissory note (the &ldquo;C.L.L. Note&rdquo;) in an aggregate principal amount of $257,500 to Chang Ping
Shan, Lin Shan Tyan, and Liu Ching Hsuan (together the &ldquo;C.L.L.&rdquo;), pursuant to which the Company received $257,500 on September
4, 2019. Chang Ping Shan and Liu Ching Hsuan are related parties to the Company. The C.L.L. Note bears interest at 20% per annum. The
Company shall pay to the C.L.L. an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve
(12) month anniversary of the issuance date of the C.L.L. Note, which is on September 3, 2020. At any time from the date hereof until
this C.L.L. Note has been satisfied, the C.L.L. may convert the unpaid and outstanding principal plus any accrued and unpaid interest
and or default interest, if any, into shares of the Company&rsquo;s common stock at a conversion price (the &ldquo;Conversion Price&rdquo;)
equal to the lower of (i) $.50 per share (the &ldquo;Fixed Conversion Price&rdquo;), subject to adjustment, or (ii) 70% of the per share
offering price (the &ldquo;Alternative Conversion Price&rdquo;) of the completed public equity offering of the Company in an amount exceeding
$10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018
(the &ldquo;Public Offering&rdquo;), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of
the intrinsic value of embedded beneficial conversion feature present in the C.L.L. Note. On April 20, 2020, the Company entered into
an exchange agreement with C.L.L.. The aggregate principal amount plus accrued interest expenses were $289,974, and the Company agreed
to issue to the Holders an aggregate of 162,908 shares of the Company&rsquo;s common stock, and warrants to purchase 162,908 shares of
common stock. As of March 31, 2021, these common shares have been issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 29, 2019, the Company issued a twelve-month
term unsecured convertible promissory note (the &ldquo;Lee Note&rdquo;) in an aggregate principal amount of $250,000 to Hwalin Lee (the
&ldquo;Lee&rdquo;), a related party, pursuant to which the Company received $250,000 on October 29, 2019. The Lee Note bears interest
at 20% per annum. The Company shall pay to the Lee an amount in cash representing all outstanding principal and accrued and unpaid interest
on the Twelve (12) month anniversary of the issuance date of the Lee Note, which is on October 28, 2020. At any time from the date hereof
until this Lee Note has been satisfied, the Lee may convert the unpaid and outstanding principal plus any accrued and unpaid interest
and or default interest, if any, into shares of the Company&rsquo;s common stock at a conversion price (the &ldquo;Conversion Price&rdquo;)
equal to the lower of (i) $.50 per share (the &ldquo;Fixed Conversion Price&rdquo;), subject to adjustment, or (ii) 70% of the per share
offering price (the &ldquo;Alternative Conversion Price&rdquo;) of the completed public equity offering of the Company in an amount exceeding
$10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018
(the &ldquo;Public Offering&rdquo;), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of
the intrinsic value of embedded beneficial conversion feature present in the Lee Note. As of March 31, 2021, the Company paid off the
convertible promissory note of $311,233, including principal and accrued and unpaid interest expense.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 23, 2020, the Company entered
into a Securities Purchase Agreement (the &ldquo;October SPA&rdquo;) with one accredited investor. Pursuant to the October SPA, the Company
sold and issued a convertible promissory note (the &ldquo;October Note&rdquo;) in the principal amount of $2,500,000 to the investor and
received the payment from such investor on October 30, 2020. The October Note was issued on October 23, 2020 and the maturity date of
the October Note is the twenty-four (24) month anniversary from the issuance date (the &ldquo;Maturity Date&rdquo;). Upon the Maturity
Date, the Company shall pay to the holder, in cash, an amount representing all outstanding principal amount and accrued and unpaid interest
under the October Note. The October Note bears an interest rate of ten percent (10%) per annum and may be convertible into shares of the
Company&rsquo;s common stock at a fixed conversion price of $2.25 per share. The holder of the October Note may elect to convert part
or all of the outstanding balance of the October Note from the issuance date until the Maturity Date. The Company may prepay the outstanding
amount at any time, in whole or in part, without any penalty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2021 and December 31, 2020, the
aggregate carrying values of the convertible debentures were $2,500,000 and $2,750,000, respectively; and accrued convertible interest
was $110,215 and $104,551, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Total interest expenses in connection with the above convertible note
payable were $66,897 and $95,214 for the three months ended March 31, 2021 and 2020, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>8. BANK LOANS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Short-term bank loan consists of the following:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: bottom; white-space: nowrap; text-align: center">&nbsp;</TD><TD STYLE="vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap">March 31,</TD><TD STYLE="vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center">&nbsp;</TD><TD STYLE="vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap">December&nbsp;31,</TD><TD STYLE="vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: bottom; white-space: nowrap; text-align: center">&nbsp;</TD><TD STYLE="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap">2021</TD><TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap; text-align: center">&nbsp;</TD><TD STYLE="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap">2020</TD><TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: justify">Cathay United Bank</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">263,250</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">267,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">CTBC Bank</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">702,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">712,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Cathay Bank</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">650,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">650,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 4pt">Total</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,615,250</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,629,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Cathay United Bank</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 28, 2016, BioLite Taiwan and Cathay United
Bank entered into a one-year bank loan agreement (the &ldquo;Cathay United Loan Agreement&rdquo;) in an amount of NT$7,500,000, equivalent
to $263,250. The term started June 28, 2016 with maturity date at June 28, 2017. The loan balance bears interest at a floating rate of
prime rate plus 1.15%. The prime rate is based on term deposit saving interest rate of Cathay United Bank. On September 6, 2017, BioLite
Taiwan extended the Cathay United Loan Agreement for one year, which was due on September 6, 2018, with the principal amount of NT$7,500,000,
equivalent to $263,250. On October 1, 2018, BioLite Taiwan extended the Cathay United Loan Agreement with the same principal amount of
NT$7,500,000, equivalent to $263,250 for one year, which was due on September 6, 2019. On September 6, 2019, BioLite Taiwan extended the
Cathay United Loan Agreement with the same principal amount of NT$7,500,000, equivalent to $263,250 for one year, which is due on September
6, 2020. On September 6, 2020, BioLite Taiwan extended the Cathay United Loan Agreement with the same principal amount of NT$7,500,000,
equivalent to $263,250 for one year, which is due on September 6, 2021. As of March 31, 2021 and December 31, 2020, the effective interest
rates per annum was 2.1%. The loan is collateralized by the building and improvement of BioLite Taiwan, and is also personal guaranteed
by the Company&rsquo;s chairman.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Interest expenses were $1,383 and $1,378 for the
three months ended March 31, 2021 and 2020, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>CTBC Bank</U>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 12, 2017 and July 19, 2017, BioLite Taiwan
and CTBC Bank entered into short-term saving secured bank loan agreements (the &ldquo;CTBC Loan Agreements&rdquo;) in an amount of NT$10,000,000,
equivalent to $351,000, and NT$10,000,000, equivalent to $351,000, respectively. Both two loans with the same maturity date at January
19, 2018. In February 2018, BioLite Taiwan combined two loans and extended the loan contract with CTBC for one year. On January 18, 2019,
BioLite Taiwan and CTBC Bank agreed to extend the loan with a new maturity date, which was July 18, 2019. On July 18, 2019, BioLite Taiwan
extended the CTBC Loan Agreement with the same principal amount of NT$20,000,000, equivalent to $702,000 for six months, which is due
on January 17, 2020. On January 19, 2020, BioLite Taiwan extended the CTBC Loan Agreement with the same principal amount of NT$20,000,000,
equivalent to $702,000 for six months, which is due on July 19, 2020. On July 17, 2020, BioLite Taiwan extended the CTBC Loan Agreement
with the same principal amount of NT$20,000,000, equivalent to $702,000 for six months, which is due on January 15, 2021. On January 15,
2021, BioLite Taiwan extended the CTBC Loan Agreement with the same principal amount of NT$20,000,000, equivalent to $702,000 for six
months, which is due on July 15, 2021. The loan balances bear interest at a fixed rate of 1.68% per annum. The loan is secured by the
money deposited in a savings account with the CTBC Bank. This loan was also personal guaranteed by the Company&rsquo;s chairman and BioFirst.
During the year ended December 31, 2020, BioLite Taiwan has opened a TCD account with CTBC bank to guarantee the loan going forward.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Interest expenses were $2,949 and $2,755 for the
three months ended March 31, 2021 and 2020, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Cathay Bank</U>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 21, 2019, the Company received a loan
in the amount of $500,000 from Cathay Bank (the &ldquo;Bank&rdquo;) pursuant to a business loan agreement (the &ldquo;Loan Agreement&rdquo;)
entered by and between the Company and Bank on January 8, 2019 and a promissory note (the &ldquo;Note&rdquo;) executed by the Company
on the same day. The Loan Agreement provides for a revolving line of credit in the principal amount of $1,000,000 with a maturity date
(the &ldquo;Maturity Date&rdquo;) of January 1, 2020. The Note executed in connection with the Loan Agreement bears an interest rate (the
&ldquo;Regular Interest Rate&rdquo;) equal to the sum of one percent (1%) and the prime rate as published in the Wall Street Journal (the
&ldquo;Index&rdquo;) and the accrued interest shall become payable each month from February 1, 2019. Pursuant to the Note, the Company
shall pay the entire outstanding principal plus accrued unpaid interest on the Maturity Date and may prepay portion or all of the Note
before the Maturity Date without penalty. If the Company defaults on the Note, the default interest rate shall become five percent (5%)
plus the Regular Interest Rate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Note and Loan Agreement,
on January 8, 2019, each of Dr. Tsung Shann Jiang and Dr. George Lee, executed a commercial guaranty (the &ldquo;Guaranty&rdquo;) to guaranty
the loans for the Company pursuant to the Loan Agreement and Note, severally and individually, in the amount not exceeding $500,000 each
until the entire Note plus interest are fully paid and satisfied. Dr. Tsung Shann Jiang is the Chairman and Chief Executive Officer of
BioLite Holding, Inc. and Dr. George Lee serves as the Chairman of the board of directors of BioKey, Inc, which became a wholly-owned
subsidiary of the Company effective by operation of law on or about February 5, 2019. On December 29, 2020, the Company entered into a
new loan extension agreement and assignment of deposit account with the Bank, which allowed Dr. Tsung Shann Jiang and Dr. George Lee to
be removed as guarantees from the list of Guaranty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, on January 8, 2019, each of the
Company and BioKey, a wholly-owned subsidiary of the Company, signed a commercial security agreement (the &ldquo;Security Agreement&rdquo;)
to secure the loans under the Loan Agreement and the Note. Pursuant to the Security Agreements, each of the Company and BioKey (each,
a &ldquo;Grantor&rdquo;, and collectively, the &ldquo;Grantors&rdquo;) granted security interest in the collaterals as defined therein,
comprised of almost all of the assets of each Grantor, to secure such loans for the benefit of the Bank. On March 31, 2020, the Company
extended the Loan Agreement with the same term for seven months, which is due on October 31, 2020. On April 8, 2020 and October 3, 2020,
the Company repaid an aggregated principal amount of $350,000. On December 3, 2020, The Company renewed the Loan Agreement with the principal
amount of $650,000 for ten months, which is due on October 31, 2021. The outstanding loan balance was $650,000 as of March 31, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Interest expenses were $3,927 and $13,740 for
the three months ended March 31, 2021 and 2020, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>9. PAYCHECK PROTECTION PROGRAM LOAN PAYABLE</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 14, 2020, the Company received a loan
in the amount of $124,400 under the Paycheck Protection Program (&ldquo;PPP&rdquo;) administered by the United States Small Business
Administration (the &ldquo;SBA&rdquo;) from East West Bank. According to the Coronavirus Aid, Relief, and Economic Security Act (the
&ldquo;Cares Act&rdquo;), PPP loan provides for forgiveness of up to the full principal amount and accrued interest if the funds are
used for payroll costs, interest on mortgages, rent, and utilities. However, at least 60% of the forgiven amount must have been used
for payroll.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The loan was granted pursuant to a promissory
note dated April 14, 2020 issued by the Company, which matures on April 13, 2022 and bears interest at a rate of 1.00% per annum. The
Company will pay the principal in one payment of all outstanding principal plus all accrued unpaid interest on that date that is two years
after the date of the promissory note. In addition, the Company will pay regular monthly payments in an amount equal to one month&rsquo;s
accrued interest commencing on the date that is seven months after the date of the promissory note, with all subsequent interest payments
to be due on the same day of each month after that. No collateral or personal guarantees are required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 29, 2021, the entity of BioKey received
a loan in the amount of $132,331 under the Paycheck Protection Program administered by the United States Small Business Administration
from East West Bank. According to the Coronavirus Aid, Relief, and Economic Security Act (the &ldquo;Cares Act&rdquo;), PPP loan provides
for forgiveness of up to the full principal amount and accrued interest if the funds are used for payroll costs, interest on mortgages,
rent, and utilities. However, at least 60% of the forgiven amount must have been used for payroll. The loan was granted pursuant to a
promissory note dated January 27, 2021 issued by the Company, which matures on January 28, 2026 and bears interest at a rate of 1.00%
per annum. The Company will pay the principal in one payment of all outstanding principal plus all accrued unpaid interest on that date
that is five years after the date of the promissory note. In addition, the Company will start the application with the US Government regarding
the loan forgiveness program as soon as the US Government allows. No collateral or personal guarantees are required.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 7, 2021, the entity of ABVC received
a loan in the amount of $104,167 under the Paycheck Protection Program administered by the United States Small Business Administration
from Cathay Bank. According to the Coronavirus Aid, Relief, and Economic Security Act (the &ldquo;Cares Act&rdquo;), PPP loan provides
for forgiveness of up to the full principal amount and accrued interest if the funds are used for payroll costs, interest on mortgages,
rent, and utilities. However, at least 60% of the forgiven amount must have been used for payroll. The loan was granted pursuant to a
promissory note dated February 7, 2021 issued by the Company, which matures on February 6, 2026 and bears interest at a rate of 1.00%
per annum. The Company will pay the principal in one payment of all outstanding principal plus all accrued unpaid interest on that date
that is five years after the date of the promissory note. In addition, the Company will start the application with the US Government regarding
the loan forgiveness program as soon as the US Government allows. No collateral or personal guarantees are required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>PPP loan Forgiveness&nbsp;</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 27, 2021, the Company submitted all
required to East West Bank for the application of forgiveness. During 2021, the PPP loan from East West Bank of $124,400 was waived by
the SBA as a gesture of supporting the operation of the Company. The Company recorded the forgiveness of the PPP loan as government grant
income during the three months ended March 31, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>10. NOTES PAYABLE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In January, 2019, BioLite Taiwan entered an unsecured
loan agreement with one individual bearing interest at fixed rates at 12% per annum of NT$3,000,000, equivalent to $105,300, for working
capital purpose. As of the date of this report, BioLite Taiwan is still in discussion with the individual with respect to the terms of
the unsecured loans.&nbsp;As of March 31, 2021 and 2020, the balance due to this individual amounted to $105,300 and $106,800, respectively.&nbsp;Interest
expense was $3,204 and $2,988 for the three months ended March 31, 2021 and 2020, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>11. SHORT-TERM LOAN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 18, 2020, the Company entered an unsecured
loan agreement with a third-party in the amount of $100,000. This loan bears the interest rate of 1.5% per annum and will be matured on
August 17, 2020. On August 18, 2020, the Company extended the contract for six months under the same term. Accrued interest expense was
$375 and $1,302 as of March 31, 2021 and December 31, 2020, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>12. RELATED PARTIES TRANSACTIONS</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The related parties of the company with whom transactions
are reported in these financial statements are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="background-color: white">
    <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: top; width: 36%"><FONT STYLE="font-size: 10pt"><B>Name of entity or Individual</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 62%; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Relationship with the Company and its subsidiaries</B></FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">BioFirst Corporation (the &ldquo;BioFirst&rdquo;)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Entity controlled by controlling beneficiary shareholder of YuanGene</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">BioFirst (Australia) Pty Ltd. (the &ldquo;BioFirst (Australia)&rdquo;)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Rgene Corporation (the &ldquo;Rgene&rdquo;)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Shareholder of the Company; entity controlled by controlling beneficiary shareholder of YuanGene</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">YuanGene Corporation (the &ldquo;YuanGene&rdquo;)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Controlling beneficiary shareholder of the Company</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">AsiaGene Corporation (the &ldquo;AsiaGene&rdquo;)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Shareholder; entity controlled by controlling beneficiary shareholder of YuanGene</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Eugene Jiang</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Former President and Chairman</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Keypoint Technology Ltd. (the &ldquo;Keypoint&rsquo;)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">The Chairman of Keypoint is Eugene Jiang&rsquo;s mother.</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Lion Arts Promotion Inc. (the &ldquo;Lion Arts&rdquo;)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Shareholder of the Company</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Yoshinobu Odaira (the &ldquo;Odaira&rdquo;)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Director of the Company</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">GenePharm Inc. (the &ldquo;GenePharm&rdquo;)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Dr. George Lee, Board Director of Biokey, is the Chairman of GenePharm.</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Euro-Asia Investment &amp; Finance Corp Ltd. (the &ldquo;Euro-Asia&rdquo;)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Shareholder of the Company</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">LBG USA, Inc. (the &ldquo;LBG USA&rdquo;)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">LionGene Corporation (the &ldquo;LionGene&rdquo;)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Shareholder of the Company; Entity controlled by controlling beneficiary shareholder of YuanGene</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Kimho Consultants Co., Ltd. (the &ldquo;Kimho&rdquo;)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Shareholder of the Company</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Mr. Tsung-Shann Jiang, the controlling beneficiary shareholder of the Company and Rgene, the Chairman and CEO of the BioLite Holding Inc. and BioLite Inc. and the President and a member of board of directors of BioFirst<BR>
&nbsp;<BR>
Ms. Shu-Ling Jiang, Mr. Tsung-Shann Jiang&rsquo;s wife, is the Chairman of Keypoint; and a member of board of directors of BioLite Inc.<BR>
&nbsp;<BR>
Mr. Eugene Jiang is Mr. and Ms. Jiang&rsquo;s son. Mr. Eugene Jiang is the chairman, and majority shareholder of the Company and a member of board of directors of BioLite Inc.<BR>
&nbsp;<BR>
Mr. Chang-Jen Jiang is Mr. Tsung-Shann Jiang&rsquo;s sibling and the director of the Company.<BR>
&nbsp;<BR>
Ms. Mei-Ling Jiang is Ms. Shu-Ling Jiang&rsquo;s sibling.</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Amkey Ventures, LLC (&ldquo;Amkey&rdquo;)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">An entity controlled by Dr. George Lee, who serves as one of the board directors of BioKey, Inc</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">BioLite Japan</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Entity controlled by controlling beneficiary shareholder of ABVC</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Accounts receivable - related parties</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounts receivable due from related parties consisted
of the following as of the periods indicated:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: bottom; text-align: center; white-space: nowrap">&nbsp;</TD><TD STYLE="vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap">March 31,</TD><TD STYLE="vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center">&nbsp;</TD><TD STYLE="vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap">December 31,</TD><TD STYLE="vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: bottom; text-align: center; white-space: nowrap">&nbsp;</TD><TD STYLE="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap">2021</TD><TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap; text-align: center">&nbsp;</TD><TD STYLE="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap">2020</TD><TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">GenePharm Inc.</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">142,225</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">142,225</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">Amkey</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,850</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,210</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt; padding-left: 9pt">Total</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">145,075</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">143,435</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Due from related parties</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Amount due from related parties consisted of the
following as of the periods indicated:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">March 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">December 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%">Rgene</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">43,266</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">42,911</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>AsiaGene</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,287</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,241</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">BioFirst (Australia)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">379,110</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">373,235</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">BioHopeKing Corporation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">121,848</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">123,583</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">LBG USA</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">675</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">675</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">BioLite Japan</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">150,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">150,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Keypoint</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,610</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,610</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">The Jiangs</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,093</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt; padding-left: 9pt">Total</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">702,889</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">696,255</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">As of March 31, 2021, and December 31, 2020,
    the Company has advanced an aggregate amount of $43,266 and $42,911 to Rgene for working capital purpose. Under the terms of the
    loan agreement, the loan bears interest at 1% per month (or equivalent to 12% per annum) and the maturity date was December 31, 2020.
    As of March 31, 2021, and December 31, 2020, the outstanding loan balance was $31,239 and $31,684; and accrued interest was $12,027
    and $11,227, respectively.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">On May 27, 2019, the Company entered into
    loan agreements with AsiaGene for NT $100,000, equivalent to $3,510, to meet its working capital needs.&nbsp;&nbsp;Under the terms
    of the loan agreement, the loan bears interest at 1% per month (or equivalent to 12% per annum) and the loan maturity date was December
    31, 2020. As of March 31, 2021, and December 31, 2020, the outstanding loan balance was $3,510 and $3,560, and accrued interest was
    $777 and $681, respectively.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 11, 2018, the Company and BioFirst (Australia) entered into a loan agreement for a total amount of $40,000 to meet its working capital needs. The advances bear 0% interest rate and are due on demand prior to June 30, 2020. Afterwards, all outstanding load will bear interest rate at 12% per annum. On July 1, 2020, the Company entered into a loan agreement with BioFirst (Australia) for $321,487 to properly record R&amp;D cost and tax refund allocation based on co-development contract executed on July 24, 2017. The loan will be matured on June 30, 2021 with an interest rate of 12% per annum. As of March 31, 2021 and December 31, 2020, the aggregate amount of outstanding loan and accrued interest was $379,110 and $373,235, respectively.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">On February 24, 2015, BioLite Taiwan and
    BioHopeKing Corporation (the &ldquo;BHK&rdquo;) entered into a co-development agreement, (the &ldquo;BHK Co-Development Agreement&rdquo;,
    see Note 3). The development costs shall be shared 50/50 between BHK and the Company. Under the term of the agreement, BioLite issued
    relevant development cost to BHK. As of March 31, 2021 and 2020, due from BHK was $121,848 and $123,583, respectively.&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -24.1pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 27, 2019, the
    Company has advanced funds to LBG USA for working capital purpose. The advances bear 0% interest rate and are due on demand. As of
    March 31, 2021 and 2020, the outstanding advance balances was $675 and $675, respectively.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">On May 8, 2020, the Company and Lucidaim
    entered into a Letter of Intent (LOI) in regard to a potential joint venture of BioLite Japan. Based on the LOI, each party will
    advance an aggregated amount of $150,000 to meet BioLite Japan&rsquo;s working capital needs, which the Company advanced an amount
    of $150,000 and the advance bear 0% interest rate. As of March 31, 2021 and December 31, 2020, the outstanding advance balances was
    $150,000 and $150,000, respectively.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 31, 2020, the
    Company has advanced an aggregate amount of $1,610 to Keypoint for working capital purpose. Under the terms of the loan agreement,
    the loan bears interest at 6.5% per annum and the loan will be matured on October 30, 2021. As of March 31, 2021 and December 31, 2020, the outstanding
    loan balance was $1,610.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8) </FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2021, the Company has advanced funds to the Jiangs. The advances bear 0% interest rate and are due on demand. As of March 31, 2021 and December 31, 2020, the outstanding advance balances was $2,093 and $0, respectively</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Due to related parties</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Amount due to related parties consisted of the
following as of the periods indicated:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">March&nbsp;31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">December&nbsp;31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">BioFirst Corporation</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">23,647</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">23,647</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>AsiaGene</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24,017</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>YuanGene</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,205</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,205</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">The Jiangs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,750</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,627</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Due to shareholders</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">163,566</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">166,261</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Due to employee</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">72,967</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">72,704</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt; padding-left: 9pt">Total</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">312,152</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">288,445</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify">
    Since 2019, BioFirst has advanced funds to the Company for working
capital purpose. The advances bear interest 1% per month (or equivalent to 12% per annum). As of March 31, 2021 and December 31, 2020,
the aggregate amount of outstanding balance and accrued interest is $23,647 and $23,647, respectively.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2021, and December 31, 2020, AsiaGene
    has advanced the Company an aggregate amount of $24,017 and $0, respectively for working capital purpose. This advance bears 0% interest
    rate and is due on demand.</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">(3)</FONT></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2021, and December 31, 2020, YuanGene
    has advanced the Company an aggregate amount of $9,205 for working capital purpose. This advance bears 0% interest rate and is due on
    demand.</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">(4)</FONT></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since 2019, the Jiangs advanced funds to the Company
    for working capital purpose. As of March 31, 2021, and December 31, 2020, the outstanding balance due to the Jiangs amounted to $18,750
    and $16,627, respectively. These loans bear interest rate of 0% to 1% per month, and are due on demand.</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -24.1pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Since 2018, the Company&rsquo;s shareholders
    have advanced funds to the Company for working capital purpose. The advances bear interest rate from 12% to 13.6224% per annum. As
    of March 31, 2021 and December 31, 2020, the outstanding principal and accrued interest was $163,566 and $166,261, respectively.
    Interest expenses in connection with these loans were $5,298 and $5,269 for the three months ended March 31, 2021 and 2020, respectively.&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -24.1pt"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Commencing January, 2020, the Company had
    advances from one employee for working capital purpose. The outstanding balance including accrued interest due to this employee amounted
    to $72,967 and $72,704 as of March 31, 2021 and December 31, 2020, respectively. This loan bears interest rate of 1.5% per annum,
    and is due on demand.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -24.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -24.1pt"></P>

<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -24.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>13. EQUITY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 8, 2016, a Share Exchange
Agreement (&ldquo;Share Exchange Agreement&rdquo;) was entered into by and among the&nbsp;Company, BriVision, Euro-Asia Investment
&amp; Finance Corp. Limited, a company incorporated under the laws of Hong Kong Special Administrative Region of People&rsquo;s
Republic of China (&ldquo;Euro-Asia&rdquo;), being the owners of record of 164,387,376 (52,336,000 pre-stock split) shares of Common
Stock of the Company, and the owners of record of all of the issued share capital of BriVision (the&nbsp;&ldquo;BriVision
Stock&rdquo;). Pursuant to the Share Exchange Agreement, upon surrender by the BriVision Shareholders and the cancellation by
BriVision of the certificates evidencing the BriVision Stock as registered in the name of each BriVision Shareholder, and pursuant
to the registration of the Company in the register of members maintained by BriVision as the new holder of the BriVision Stock and
the issuance of the certificates evidencing the aforementioned registration of the BriVision Stock in the name of the Company, the
Company should issue 166,273,921(52,936,583 pre-stock split) shares (the&nbsp;&ldquo;Acquisition Stock&rdquo;) (subject to
adjustment for fractionalized shares as set forth below) of the Company&rsquo;s Common Stock to the BriVision Shareholders (or their
designees), and 163,159,952 (51,945,225 pre-stock split) shares of the Company&rsquo;s Common Stock owned by Euro-Asia should be
cancelled and retired to treasury. The Acquisition Stock collectively should represent 79.70% of the issued and outstanding Common
Stock of the Company immediately after the Closing, in exchange for the BriVision Stock, representing 100% of the issued share
capital of BriVision in a reverse merger, or the Merger. Pursuant to the Merger, all of the issued and outstanding shares of
BriVision&rsquo;s Common Stock were converted, at an exchange ratio of 0.2536-for-1, into an aggregate of 166,273,921(52,936,583
pre-stock split) shares of Company&rsquo;s Common Stock and BriVision became a wholly owned subsidiary, of the Company. The holders
of Company&rsquo;s Common Stock as of immediately prior to the Merger held an aggregate of 205,519,223 (65,431,144 pre-stock split)
shares of Company&rsquo;s Common Stock,&nbsp;Because of the exchange of the BriVision Stock for the Acquisition Stock
(the&nbsp;&ldquo;Share Exchange&rdquo;), BriVision became a wholly owned subsidiary (the &ldquo;Subsidiary&rdquo;) of the Company
and there was a change of control of the Company following the closing.&nbsp;&nbsp;There were no warrants, options or other equity
instruments issued in connection with the share exchange agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 17, 2016, pursuant to the 2016 Equity
Incentive Plan (the &ldquo;2016 Plan&rdquo;), 157,050 (50,000 pre-stock split) shares were granted to the employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 21, 2016, the Board of Directors of the
Company approved an amendment to Articles of Incorporation to effect a forward split at a ratio of 1 to 3:141 (the &ldquo;Forward&nbsp;Stock&nbsp;Split&rdquo;)
and increase the number of our authorized shares of Common Stock, par value $0.001 per share, to 360,000,000, which was effective on April
8, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 6, 2016, the Company and BioLite Taiwan
agreed to amend the BioLite Collaborative Agreement, through entry into the Milestone Payment Agreement, whereby the Company has agreed
to issue shares of Common Stock of the Company, at the price of $1.60 per share, for an aggregate number of 562,500 shares, as part of
the Company&rsquo;s first installation of payment pursuant to the Milestone Payment. The shares issuance was completed in June 2016. On
August 26, 2016, the Company issued 1,468,750 shares (&ldquo;Shares&rdquo;) of the Company&rsquo;s Common Stock, par value $0.001 (the
&ldquo;Offering&rdquo;) to BioLite Taiwan pursuant to a certain Stock Purchase Agreement dated August 26, 2016 (the &ldquo;SPA&rdquo;).
The Shares are exempt from the registration requirements of the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;),
pursuant to Regulation S of the Securities Act promulgated thereunder. The purchase price per share of the Offering is $1.60. The net
proceeds to the Company from the Offering are approximately $2,350,000. Pursuant to the BioLite Collaborative Agreement, BriVision should
pay a total of $100,000,000 in cash or stock of the Company with equivalent value according to the milestone achieved. The agreement requires
that 6.5% of total payment, $6,500,000 shall be made upon the first IND submission which was submitted in March 2016. In February 2017,
the Company remitted this amount to BioLite with $650,000 in cash and $5,850,000 in the form of newly issued shares of the Company&rsquo;s
Common Stock, at the price of $2.0 per share, for an aggregate number of 2,925,000 shares. Upon the consummation of the restructuring
transaction between the Company and BioLite on February 8, 2019, the Company&rsquo;s Common Stock held by BioLite Taiwan was accounted
for treasury stocks in the statement of equity (deficit). On February 8, 2019, after the Merger, the Company issued 74,997,546 shares
to the shareholders of BioLite and 29,561,231 shares to the shareholders of BioKey.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 3, 2019, the Company filed a Certificate
of Amendment with the Secretary of State of Nevada, which was effective May 8, 2019 upon its receipt of the written notice from Financial
Industry Regulatory Authority (&ldquo;FINRA&rdquo;). Pursuant to the Certificate of Amendment, the Company effectuated a 1-for-18 reverse
stock split of its issued and outstanding shares of common stock, $0.001 par value, whereby 318,485,252 outstanding shares of the Company&rsquo;s
common stock were exchanged for 17,693,625 shares of the Company&rsquo;s Common Stock. All shares and related financial information in
this Form 10-K reflect this 1-for-18 reverse stock split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 1, 2016, the Company entered into a
consulting agreement with Kazunori Kameyama (&ldquo;Kameyama&rdquo;) for the provision of services related to the clinical trials and
other administrative work, public relation work, capital raising, trip coordination, In consideration for providing such services, the
Company agreed to indemnify the consultant in an amount of $150 per hour in cash up to $3,000 per month, and issue to Kameyama the Company&rsquo;s
Common Stock at $1.00 per share for any amount exceeding $3,000. The Company&rsquo;s stocks shall be calculated and issued in December
every year. On November 21, 2020, the Company entered into an agreement with Kameyama, pursuant to which the Company granted and issued
24,694 stock options to Kameyama related to unpaid consulting fees of $49,388 (see Note 14).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2019, the Company
entered into service agreements with Euro-Asia Investment &amp; Finance Corp Ltd. (a related party), Ever Adventure inv. (Formosa) Consultant
Co., Ltd., New Eastern Asia (a related party), and Kimho Consultants Co., Ltd. (a related party) for the maintenance of the listing in
the U.S. stock exchange market, investor relations, and business development. Pursuant to the agreements, the Company issued 644,972 shares
of the Company&rsquo;s common stock for the consulting service from July 2019 to July 2024 for the service fee of $4,514,800 in aggregate,
and recorded as stock subscription receivable. As of March 31, 2021 and December 31, 2020, stock subscription receivable was $2,934,620
and $3,160,360, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 24, 2017, BriVision entered into a collaborative agreement
(the &ldquo;BioFirst Collaborative Agreement&rdquo;) with BioFirst (See Note 3). On September 25, 2017, BioFirst has delivered all research,
technical, data and development data to BriVision, and the Company has recorded the full amount of $3,000,000 due to BioFirst. On June
30, 2019, the Company entered into a Stock Purchase Agreement with BioFirst, pursuant to which the Company agreed to issue 428,571 shares
of the Company&rsquo;s common stock to BioFirst in consideration for $3,000,000 owed by the Company to BioFirst. These common shares were
issued during the year ended December 31, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August, 2019, the Company entered into several
Conversion Agreements to all creditors that are listed under below table of &ldquo;due to related parties&rdquo; in consideration for
a total of $4,872,340 owed by the Company to various creditors based on outstanding loan agreements. Under the Conversion Agreements,
creditor agrees to convert the amount of debt into the Company&rsquo;s common stock at a price of $7.00 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; vertical-align: bottom; text-align: center">&nbsp;</TD><TD STYLE="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Amount of<BR> Debt<BR> Converted</TD><TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Number of<BR> Shares<BR> Issued</TD><TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left">Lion Arts Promotion Inc</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">97,864</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">13,981</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">LionGene Corporation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">428,099</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">61,157</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">BioFirst Corporation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,902,911</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">414,702</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">AsiaGene Corporation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">160,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22,858</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">YuanGene Corporation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">92,690</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,242</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">The Jiangs</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,190,776</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">170,111</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-bottom: 4pt; padding-left: 0.25in">Total</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">4,872,340</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">696,051</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 12, 2020, the board of directors of the
Company approved and adopted an amendment to the Company&rsquo;s Articles of Incorporation, to increase the authorized shares of its common
stock, par value $0.001 per share, from 20,000,000 to 100,000,000 shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 8, 2020, the Company entered an agreement
with View Trade Securities Inc. (&ldquo;ViewTrade&rdquo;) to engage ViewTrade as the placement agent&nbsp;and the Company&rsquo;s advisor
with respect to its ongoing capital events. Pursuant to the agreement, the Company agreed to pay View Trade 60,000 restricted common shares
of the Company and 60,000 warrants to purchase common shares of the Company at an exercise price of $6 per share for a period of 5 years
with cashless exercise provision. As of December 31, 2020, the Company has issued 60,000 shares of common stock to ViewTrade for the consulting
fee with an estimated value of $135,000. The warrants were never issued and the parties mutually agreed to terminate the agreement on
November 19, 2020. As a termination fee, the Company agreed to issue ViewTrade 50,000 restricted common shares of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Also on November 19,
2020, the Company and ViewTrade agreed to a new Advisory agreement under which ViewTrade was engaged to provide advisory services only.
In addition to a retainer fee, the Company agreed to issue 200,000 warrants, with an exercise price of $2.25, an industry standard cashless
exercise provision, and a term of 5 years from November 19, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year&nbsp;ended December 31, 2020,
the Company entered into a consulting agreement with a service provider for consulting and advisory services, pursuant to which the Company
agreed to pay the service fee by issuing 50,000 shares of unrestricted common shares, valued at the closing price of $2.9 per share on
the grant date. As of December 31, 2020, these shares have been issued.&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2020, the Company
received aggregated capital contributions of $7,615,331 in cash from 45 investors through private placements of the sale of the Company&rsquo;s
common stock for the purchase price of&nbsp;$2.25 per share and a free warrant attached with each common stock purchased. As of March
31, 2021, 3,384,615 shares of the Company&rsquo;s common stock have been issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2020, the Company
entered into consulting agreements with four service providers for consulting and advisory services, pursuant to which the Company agreed
to pay the service fee by issuing 521,887 shares of unrestricted common shares, valued at the closing price from $2 to $3.68 per share
on the grant date. As of March 31, 2021, these shares have been issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2021, the Company issued aggregated
common shares of 915,856 &nbsp;to six previous note holders, who had converted their outstanding principals and accrued and unpaid interests,
including the debt conversion to the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">a.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Keypoint converted the aggregated amount of $292,826 at the conversion price of $1.84 on April 5, 2020, in exchange for 159,145 shares of the Company&rsquo;s common stock, and warrants to purchase 159,145 shares of the Company&rsquo;s common stock.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">b.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Odaira converted the aggregated amount of $284,036 at the conversion price of $1.84 on April 5, 2020, in exchange for 154,368 shares of the Company&rsquo;s common stock, and warrants to purchase 154,368 shares of the Company&rsquo;s common stock.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">c.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">C.L.L. converted the aggregated amount of $289,974 at the conversion price of $1.78 on April 20, 2020, in exchange for 162,908 shares of the Company&rsquo;s common stock, and warrants to purchase 162,908 shares of the Company&rsquo;s common stock.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">d.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">KLS converted the aggregated amount of $225,222 at the conversion price of $1.78 on April 20, 2020, in exchange for 126,530 shares of the Company&rsquo;s common stock, and warrants to purchase 126,530 shares of the Company&rsquo;s common stock.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">e.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Yu and Wei converted the aggregated amount of $354,722 at the conversion price of $1.84 on April 5, 2020, in exchange for 192,784 shares of the Company&rsquo;s common stock, and warrants to purchase 192,784 shares of the Company&rsquo;s common stock.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">f.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">KSL converted the aggregated amount of $270,272 at the conversion price of $2.25 on November 9, 2020, in exchange for 120,121 shares of the Company&rsquo;s common stock, and warrants to purchase 120,121 shares of the Company&rsquo;s common stock.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">See Note 7 for more details in connection with the above debt conversion.&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>14. STOCK OPTIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 30, 2020, the Company issued an aggregate
of 545,182 shares of common stock in lieu of unpaid salaries of certain employees and unpaid consulting fees under the 2016 Equity Incentive
Plan, as amended, at a conversion price of $2 per share; the total amount of converted salaries and consulting fees was $1,090,361. On
November 21, 2020, the Company has entered&nbsp;into&nbsp;acknowledgement&nbsp;agreements and stock option purchase agreements with these
employees and consultant; pursuant to which the Company granted stock options to purchase 545,182 shares of the Company&rsquo;s common
stock in lieu of common stock. The options were vested at the grant date and become exercisable for 10 years from the grant date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Options issued and outstanding as of December
31, 2020, and their activities during the year then ended are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD><TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD><TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD><TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD><TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD><TD STYLE="vertical-align: bottom; font-weight: bold; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center">Weighted-</TD><TD STYLE="vertical-align: bottom; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD><TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD><TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD><TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD><TD STYLE="vertical-align: bottom; font-weight: bold; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center">Weighted-</TD><TD STYLE="vertical-align: bottom; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="vertical-align: bottom; font-weight: bold; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center">Average</TD><TD STYLE="vertical-align: bottom; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD><TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD><TD STYLE="vertical-align: bottom; font-weight: bold; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center"></TD><TD STYLE="vertical-align: bottom; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="vertical-align: bottom; font-weight: bold; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center">Average</TD><TD STYLE="vertical-align: bottom; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="vertical-align: bottom; font-weight: bold; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center">Contractual</TD><TD STYLE="vertical-align: bottom; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD><TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD><TD STYLE="vertical-align: bottom; font-weight: bold; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center">Number&nbsp;of</TD><TD STYLE="vertical-align: bottom; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="vertical-align: bottom; font-weight: bold; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center">Exercise </TD><TD STYLE="vertical-align: bottom; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="vertical-align: bottom; font-weight: bold; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center">Life </TD><TD STYLE="vertical-align: bottom; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="vertical-align: bottom; font-weight: bold; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center">Aggregate</TD><TD STYLE="vertical-align: bottom; font-weight: bold; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD><TD STYLE="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Underlying<BR>
Shares</TD><TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Price<BR>
Per&nbsp;Share</TD><TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Remaining<BR>
in Years</TD><TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Intrinsic<BR>
 Value</TD><TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Outstanding as of January 1, 2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#8239;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 52%">Granted</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">545,182</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">2.00</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">9.89</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">616,056</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">Forfeited</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt">Outstanding as of December 31, 2020</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">545,182</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right">2.00</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right">9.89</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">616,056</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">Exercisable as of December 31, 2020</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">545,182</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right">2.00</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right">9.89</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">616,056</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Vested and expected to vest</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">545,182</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">$</TD><TD STYLE="padding-bottom: 4pt; text-align: right">2.00</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right">9.89</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">616,056</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of stock options granted for the
year ended December 31, 2020 was calculated using the Black-Scholes option-pricing model applying the following assumptions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 0pt; vertical-align: bottom; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 0pt; vertical-align: bottom; font-weight: bold; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 0pt; vertical-align: bottom; font-weight: bold; text-align: center">Year ended</TD><TD STYLE="padding-bottom: 0pt; vertical-align: bottom; font-weight: bold; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; padding-bottom: 0pt; vertical-align: bottom; text-align: center">&nbsp;</TD><TD STYLE="white-space: nowrap; vertical-align: bottom; font-weight: bold; padding-bottom: 0pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1.5pt solid; padding-bottom: 0pt; vertical-align: bottom; font-weight: bold; text-align: center">December&nbsp;31,<BR>
2020</TD><TD STYLE="white-space: nowrap; vertical-align: bottom; padding-bottom: 0pt; font-weight: bold; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 0pt; width: 88%; text-align: left">Risk free interest rate</TD><TD STYLE="padding-bottom: 0pt; width: 1%">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 0pt; width: 9%; text-align: right">0.38</TD><TD STYLE="padding-bottom: 0pt; width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 0pt; text-align: left">Expected term (in years)</TD><TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 0pt; text-align: right">5.00</TD><TD STYLE="padding-bottom: 0pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 0pt; text-align: left">Dividend yield</TD><TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 0pt; text-align: right">0</TD><TD STYLE="padding-bottom: 0pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 0pt; text-align: left">Expected volatility</TD><TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 0pt; text-align: right">89.01</TD><TD STYLE="padding-bottom: 0pt; text-align: left">%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The weighted average grant date fair value of
options granted during 2020 was $3.13. There are 2,812,949 options available for grant under the 2016 Equity Incentive Plan as of December
31, 2020. Compensation costs associated with the Company&rsquo;s stock options are recognized, based on the grant-date fair values of
these options over vesting period. Accordingly, the Company recognized stock-based compensation expense of $0 and $0 for the three months
ended March 31, 2021 and 2020, respectively. As of March 31, 2021, there were no unvested options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>15. LOSS PER SHARE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic loss per share is computed by dividing net
loss by the weighted-average number of common shares outstanding during the year. Diluted loss per share is computed by dividing net loss
by the weighted-average number of common shares and dilutive potential common shares outstanding during the three months ended March 31,
2021 and 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD><TD STYLE="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">For the Three Months Ended</TD><TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD><TD STYLE="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">March&nbsp;31,<BR> 2021</TD><TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">March&nbsp;31,<BR> 2020</TD><TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Numerator:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Net loss attributable to ABVC&rsquo;s common stockholders</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(1,128,505</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(1,247,538</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Denominator:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Weighted-average shares outstanding:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Weighted-average shares outstanding - Basic</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">24,420,526</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">19,484,542</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Stock options</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Weighted-average shares outstanding - Diluted</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">24,420,526</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">19,484,542</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Loss per share</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt">-Basic</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(0.05</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(0.06</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">-Diluted</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(0.05</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(0.06</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Diluted loss per share takes into account the
potential dilution that could occur if securities or other contracts to issue Common Stock were exercised and converted into Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>16. LEASE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company adopted FASB Accounting Standards
Codification, Topic 842, Leases (&ldquo;ASC 842&rdquo;) using the modified retrospective approach, electing the practical expedient that
allows the Company not to restate its comparative periods prior to the adoption of the standard on January 1, 2019. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company applied the following practical expedients in the transition
to the new standard and allowed under ASC 842:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Reassessment of expired or existing contracts: The Company elected not to reassess, at the application date, whether any expired or existing contracts contained leases, the lease classification for any expired or existing leases, and the accounting for initial direct costs for any existing leases.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Use of hindsight: The Company elected to use hindsight in determining the lease term (that is, when considering options to extend or terminate the lease and to purchase the underlying asset) and in assessing impairment of right-to-use assets.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Reassessment of existing or expired land easements: The Company elected not to evaluate existing or expired land easements that were not previously accounted for as leases under ASC 840, as allowed under the transition practical expedient. Going forward, new or modified land easements will be evaluated under ASU No. 2016-02.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Separation of lease and non- lease components: Lease agreements that contain both lease and non-lease components are generally accounted for separately.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Short-term lease recognition exemption: The Company also elected the short-term lease recognition exemption and will not recognize ROU assets or lease liabilities for leases with a term less than 12 months.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The new leasing standard requires recognition
of leases on the consolidated balance sheets as right-of-use (&ldquo;ROU&rdquo;) assets and lease liabilities. ROU assets represent the
Company&rsquo;s right to use underlying assets for the lease terms and lease liabilities represent the Company&rsquo;s obligation to make
lease payments arising from the leases. Operating lease ROU assets and operating lease liabilities are recognized based on the present
value and future minimum lease payments over the lease term at commencement date. The Company&rsquo;s future minimum based payments used
to determine the Company&rsquo;s lease liabilities mainly include minimum based rent payments. As most of Company&rsquo;s leases do not
provide an implicit rate, the Company uses its estimated incremental borrowing rate based on the information available at commencement
date in determining the present value of lease payments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognized lease liabilities, with
corresponding ROU assets, based on the present value of unpaid lease payments for existing operating leases longer than twelve months.
The ROU assets were adjusted per ASC 842 transition guidance for existing lease-related balances of accrued and prepaid rent, unamortized
lease incentives provided by lessors, and restructuring liabilities. Operating lease cost is recognized as a single lease cost on a straight-line
basis over the lease term and is recorded in Selling, general and administrative expenses. Variable lease payments for common area maintenance,
property taxes and other operating expenses are recognized as expense in the period when the changes in facts and circumstances on which
the variable lease payments are based occur.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has no finance leases. The Company&rsquo;s
leases primarily include various office and laboratory spaces, copy machine, and vehicles under various operating lease arrangements.
The Company&rsquo;s operating leases have remaining lease terms of up to approximately five years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD><TD STYLE="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">March&nbsp;31, <BR> 2021</TD><TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">December&nbsp;31, <BR> 2020</TD><TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">ASSETS</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Operating lease right-of-use assets</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,714,740</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,772,747</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">LIABILITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Operating lease liabilities (current)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">331,179</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">316,178</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Operating lease liabilities (noncurrent)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,383,560</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,456,567</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Supplemental Information</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following provides details of the Company&rsquo;s
lease expenses:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD><TD STYLE="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Three Months Ended<BR> March 31,</TD><TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD><TD STYLE="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2021</TD><TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2020</TD><TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Operating lease expenses</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">78,847</P></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">77,527</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other information related to leases is presented
below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD><TD STYLE="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Three Months Ended <BR> March&nbsp;31,</TD><TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD><TD STYLE="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2021</TD><TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2020</TD><TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Cash paid for amounts included in the measurement of operating lease liabilities</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">78,847</P></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">77,527</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD><TD STYLE="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">March&nbsp;31, <BR> 2021</TD><TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">December&nbsp;31, <BR> 2020</TD><TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Weighted Average Remaining Lease Term:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Operating leases</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;3.58 years </FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;3.08 years</FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Weighted Average Discount Rate:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Operating leases</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.45</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.55</TD><TD STYLE="text-align: left">%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The minimum future annual payments under non-cancellable
leases during the next five years and thereafter, at rates now in force, are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Operating leases</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 90%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021(excluding three months ended March 31, 2021)</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">253,618</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">352,248</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">359,591</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">374,584</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">338,676</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thereafter</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">56,916</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total future minimum lease payments, undiscounted</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,735,633</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less: Imputed interest</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20,893</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Present value of future minimum lease payments</FONT></TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,714,740</FONT></TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>17. BUSINESS COMBINATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 8, 2019, the Company consummated the
Merger transactions of BioLite and BioKey (See Note 1). Pursuant to the terms of the Merger Agreement, BioLite and BioKey became two wholly-owned
subsidiaries of the Company on February 8, 2019. The Company adopted ASC 805, &ldquo;Business Combination&rdquo; to record the merger
transactions of BioKey. The acquisition was accounted for as a business combination under the purchase method of accounting. BioKey&rsquo;s
results of operations were included in the Company&rsquo;s results beginning February 8, 2019. The purchase price has been allocated to
the assets acquired and the liabilities assumed based on their fair value at the acquisition date as summarized in the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>Purchase consideration:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left">Common Stock (*)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">44,341,847</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Allocation of the purchase price:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Cash and cash equivalents</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">531,147</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accounts receivable, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">188,550</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Property and equipment, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">56,075</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Operating lease right-of-use assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">485,684</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Security deposits</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">10,440</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total assets acquired</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,271,896</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(56,204</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accrued expenses and other current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(251,335</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Operating lease liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(267,256</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Tenant security deposit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,880</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Total liabilities assumed</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(577,675</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Total net assets acquired</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">694,221</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Goodwill as a result of the Merger</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">43,647,626</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">29,561,231 shares (1,642,291 after stock reverse split) of common stock of the Company was issued to BioKey in connection with the Merger. Those shares were valued at $1.50 per share, based on the bid-and-ask share price of common stock of the Company on the final day of trading, February 8, 2019.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 8, 2019, the Company has recorded
a 100% goodwill write-down of $43,647,626. Goodwill was determined to have been impaired because of the current financial condition of
the Company and the Company&rsquo;s inability to generate future operating income without substantial sales volume increases, which are
highly uncertain. Furthermore, the Company&rsquo;s anticipated future cash flows indicate that the recoverability of goodwill is not reasonably
assured. The goodwill write-down was reflected as a decrease in additional paid-in capital in the statement of equity upon the consummation
of the Merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>18. SUBSEQUENT EVENTS</B>&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has evaluated subsequent events through the date which
the financial statements were available to be issued. All subsequent events requiring recognition as of March 31, 2021 have been incorporated
into these financial statements and there are no subsequent events that require disclosure in accordance with FASB ASC Topic 855, &ldquo;Subsequent
Events.&rdquo;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><A NAME="a_008"></A><B>ITEM 2. MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS&nbsp;OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>The following discussion and analysis should
be read together with our financial statements and the related notes appearing elsewhere in this prospectus. This discussion contains
forward-looking statements reflecting our current expectations that involve risks and uncertainties. See &ldquo;Cautionary Note Regarding
Forward-Looking Statements and Industry Data&rdquo; for a discussion of the uncertainties, risks and assumptions associated with these
statements. Actual results and the timing of events could differ materially from those discussed in our forward-looking statements as
a result of many factors, including those set forth under &ldquo;Risk Factors&rdquo; and elsewhere in this prospectus.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From its inception, the Company has not generated
substantial revenue from its medical device and new drug development. For the three months ended March 31, 2021, the Company generated
$263,150 in revenue, mainly from the sale of Contract Development &amp; Manufacturing Organization (&ldquo;CDMO&rdquo;) services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Business Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company operates through American BriVision
Corporation (&ldquo;BriVision&rdquo;), which was incorporated in July 2015 in the State of Delaware, is a clinical stage biopharmaceutical
company focused on development of new drugs and medical devices, all of which are derived from plants.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Medicines derived from plants have a long history
of relieving or preventing many diseases and, typically, have exhibited fewer side effects than drugs developed from animals or chemical
ingredients. Perhaps the most famous example is aspirin, which evolved from a compound found in the bark and leaves of the willow tree
and was later marketed by Bayer starting in 1899. Aspirin has very few serious side effects and has proven to be one of the most successful
drugs in medical history. Some 50 years later, scientists identified anticancer compounds in the rosy periwinkle, which Eli Lilly subsequently
produced for the treatment of leukemia and Hodgkins disease. Other well-known examples of successful botanical drugs include the cancer-fighting
Taxol, isolated from the Pacific yew tree.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company develops its pipeline by carefully
tracking new medical discoveries or medical device technologies in research institutions in the Asia-Pacific region. Pre-clinical, disease
animal model and Phase I safety studies are examined closely by the Company&rsquo;s scientists and other specialists known to the Company
to identify drugs that it believes demonstrate efficacy and safety based on the Company&rsquo;s internal qualifications. Once a drug is
shown to be a good candidate for further development and ultimately commercialization, BriVision licenses the drug or medical device from
the original researchers and begins to introduce the drugs clinical plan to highly respected principal investigators in the United States,
Australia and Taiwan. In almost all cases, we have found that research institutions in each of those countries are eager to work with
the Company to move forward with Phase II clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Currently, institutions that have or are now conducting
phase II clinical trials in partnership with ABVC include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; width: 0.2in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Drug: ABV-1504, Major Depressive Disorder (MDD), Phase II completed. NCE drug Principal Investigators: Charles DeBattista M.D. and Alan F. Schatzberg, MD,&nbsp;Stanford University Medical Center, Cheng-Ta Li, MD, Ph.D &ndash;&nbsp;Taipei Veterans General Hospital</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.2in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Drug: ABV-1505, Adult Attention-Deficit Hyperactivity Disorder (ADHD), Phase II Part 1 completed. NCE drug Principal Investigators: Keith McBurnett, Ph.D. and Linda Pfiffner, Ph.D.,&nbsp;University of California San Francisco (UCSF), School of Medicine</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.2in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Drug: ABV-1601, Major Depression in Cancer Patients, Phase I/II, NCE drug Principal Investigator: Scott Irwin, MD, Ph.D. &ndash;&nbsp;Cedars Sinai Medical Center (CSMC)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.2in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Drug: ABV-1703, Advanced Inoperable or Metastatic Pancreatic Cancer, Phase II, NCE drug Principal Investigator: Andrew E. Hendifar, MD &ndash;&nbsp;Cedars Sinai Medical Center (CSMC)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 44 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">The following trials
are expected to begin in</FONT><FONT STYLE="font-size: 8pt">&nbsp;</FONT> <FONT STYLE="font-size: 10pt">the second or third quarter of
2021:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.2in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Medical Device: ABV-1701, Vitargus&reg; in vitrectomy surgery, Pivotal Study in Australia, Principal Investigator: Andrew Chang, MD, Ph.D., Sydney Eye Hospital, Australia</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.2in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Drug: ABV-1501, A Phase I/II, Open Label Study to Evaluate the Safety and Efficacy of BLEX 404 Oral Liquid Combined with Docetaxel Monotherapy in Patients with Stage IV or Recurrent Breast Cancer Patients</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon successful completion of the Phase II trial,
the Company will seek a partner &ndash; a large pharmaceutical company &ndash; to complete a Phase III study, submit the New Drug Application
(NDA), and commercialize the drug upon approval by the FDA and Taiwan FDAs. The Company expects to seek its first commercialization partner
in 2021 for Vitargus, its vitreous substitute that helps to maintain a round shape and retinal location during vitrectomy surgery.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Another part of the Company&rsquo;s business is
conducted by BioKey, a wholly owned subsidiary, that is engaged in a wide range of services, including, API characterization, pre-formulation
studies, formulation development, analytical method development, stability studies, IND/NDA/ANDA/510K submissions, and manufacturing clinical
trial materials (phase I through phase III) and commercial manufacturing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 8, 2019, the Company, BioLite Holding,
Inc. (&ldquo;BioLite&rdquo;), BioKey, Inc. (&ldquo;BioKey&rdquo;), BioLite Acquisition Corp., a direct wholly-owned subsidiary of the
Company and BioKey Acquisition Corp., a direct wholly-owned subsidiary of the Company completed the business combination pursuant to that
certain Agreement and Plan of Merger dated January 31, 2018, pursuant to which the Company acquired BioLite and BioKey via issuing shares
of the Company&rsquo;s Common Stock to the shareholders of BioLite and BioKey. As a result, BioLite and BioKey became two wholly-owned
subsidiaries of the Company on February 8, 2019. The Company issued an aggregate of 104,558,777 shares of Common Stock (prior to the reverse
stock split in 2019) to the shareholders of both BioLite and BioKey under a registration statement on Form S-4 (file number 333-226285),
which became effective by operation of law on or about February 5, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BioLite was incorporated under the laws of the
State of Nevada on July 27, 2016, with 500,000,000 shares authorized, par value $0.0001. BioLite&rsquo;s key subsidiaries include BioLite
BVI, Inc. (&ldquo;BioLite BVI&rdquo;) that was incorporated in the British Virgin Islands on September 13, 2016 and BioLite, Inc. (&ldquo;BioLite
Taiwan&rdquo;), a Taiwanese corporation that was founded in February 2006. BioLite Taiwan has been in the business of developing new drugs
for over ten years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BioLite and BioLite BVI are holding companies
and have not carried out substantive business operations of their own.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In January 2017, BioLite, BioLite BVI, BioLite
Taiwan, and certain shareholders of BioLite Taiwan entered into a share purchase / exchange agreement (the &ldquo;BioLite Share Purchase
/ Exchange Agreement&rdquo;). Pursuant to the BioLite Share Purchase / Exchange Agreement, the shareholder participants to the BioLite
Share Purchase / Exchange Agreement sold their equity in BioLite Taiwan and used the proceeds from such sales to purchase shares of Common
Stock of BioLite at the same price per share, resulting in their owning the same number of shares of Common Stock as they owned in BioLite
Taiwan. Upon closing of the Share Purchase/ Exchange Agreement in August 2017, BioLite owns, via BioLite BVI, approximately 73% of BioLite
Taiwan. The other shareholders who did not enter this Share Purchase/ Exchange Agreement retain their equity ownership in BioLite Taiwan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BioKey was incorporated on August 9, 2000 in the
State of California. It is engaged primarily in research and development, manufacturing, and distribution of generic drugs and nutraceuticals
with strategic partners. BioKey provides a wide range of services, including, API characterization, pre-formulation studies, formulation
development, analytical method development, stability studies, IND/NDA/ANDA/510K submissions, and manufacturing clinical trial materials
(phase 1 through phase 3) and commercial manufacturing. It also licenses out its technologies and initiates joint research and development
processes with other biotechnology, pharmaceutical, and nutraceutical companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 45 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Common Stock Reverse Split</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 12, 2019, the Board by unanimous written
consent in lieu of a meeting approved to i) effect a stock reverse split at the ratio of 1-for-18 (the &ldquo;Reverse Split&rdquo;) of
both the authorized common stock of the Company and the issued and outstanding common stock and ii) to amend the articles of incorporation
of the Company to reflect the Reverse Split. The Board approved and authorized the Reverse Split without obtaining approval of the Company&rsquo;s
shareholders pursuant to Section 78.207 of Nevada Revised Statutes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 3, 2019, the Company filed a certificate
of amendment to the Company&rsquo;s articles of incorporation (the &ldquo;Amendment&rdquo;) to effect the Reverse Split with the Secretary
of State of the State of Nevada. The Reverse Split took effect on May 8, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Series A Convertible Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 28, 2019, the Company filed a certificate
of designation (the &ldquo;Series A COD&rdquo;) of Series A Convertible Preferred Stock (the &ldquo;Series A Stock&rdquo;) with the Secretary
of the State of Nevada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Series A COD, the Company designated
3,500,000 shares of preferred stock as Series A Stock, par value of $0.001 per share. Subject to the laws of Nevada, the Company will
pay cumulative dividends on the Series A Stock on each anniversary from the date of original issue for a period of four calendar years.
The Series A Stock will rank senior to the outstanding common stock of the Company, par value $0.001 (the &ldquo;Common Stock&rdquo;)
with respect to dividend rights, rights upon liquidation, dissolution or winding up in the amount of accrued but unpaid dividend. Holders
of the Series A Stock will have the same voting rights as the Company&rsquo;s Common Stock holders. Each share of Series A Stock is initially
convertible at any time at the option of the holder into one share of Common Stock and automatically converts into one share of Common
Stock on the four-year anniversary of its issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2021, no Series A Convertible
Preferred Stock has been issued by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Increasing the Authorized Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 12, 2020, our board of directors approved
and adopted an amendment to the Company&rsquo;s Articles of Incorporation, to increase the authorized shares of the common stock, par
value $0.001 per share, from 20,000,000 to 100,000,000, such that, after including the previously authorized 20,000,000 shares of preferred
stock, par value $0.001 per share, the aggregate number of shares of stock that the Company has authority to issue is 120,000,000 shares.
The amendment became effective on April 2, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Financings</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Financing in November 2020</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 11, 2020, we conducted a closing with
regard to certain securities purchase agreements (the &ldquo;<B>SPAs</B>&rdquo;) dated October 23, 2020, separately with two non-U.S.
investors (the &ldquo;<B>Investors</B>&rdquo;). Each of the Investors agreed to purchase and the Company agreed to sell to each of the
Investors 1,111,112 shares of the Company&rsquo;s Common Stock, and warrants (the &ldquo;<B>November Warrants</B>&rdquo;) to purchase
1,111,112 shares of Common Stock, for a purchase price of $2,500,000. The November Warrants are exercisable upon issuance and will expire
three years from the date of issuance. The initial exercise price of the November Warrants is $6.00, subject to stock, splits, stock dividend
and other similar events. In addition, when the closing price of the Common Stock equals or exceeds $9.00 per share for twenty Trading
Days (as defined in the SPAs) during any thirty-day period, the Company shall have the right to require the Investors to exercise all
or any portion of the November Warrants for a cash exercise. The aggregate net proceeds were $5,000,000. The Company and the Investors
further agreed to amend the terms of the SPA to permit the closing of the offering to occur on a rolling basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company paid the following fees to a FINRA
member firm in connection with such offering: (i) a cash&nbsp;success fee of $175,000 and (ii) warrants to purchase a number of shares
of Common Stock equal to 7% of the number of shares of Common Stock sold in the Offering, at an exercise price per share equal to $6.00
subject to adjustment (the &ldquo;<B>Comp Warrants</B>&rdquo;). The Comp Warrants are exercisable on a cashless basis, at the holder&rsquo;s
discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 46 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Financing in October 2020</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 23, 2020, we entered into a Securities
Purchase Agreement (the &ldquo;<B>October SPA</B>&rdquo;) with one accredited investor. Pursuant to the October SPA, the Company sold
and issued a convertible promissory note (the &ldquo;<B>October Note</B>&rdquo;) in the principal amount of $2,500,000 to the investor
and received the payment from such investor on October 30, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The October Note was issued on October 23, 2020
and the maturity date of the October Note is the twenty-four (24) month anniversary from the issuance date (the &ldquo;<B>Maturity Date</B>&rdquo;).
Upon the Maturity Date, the Company shall pay to the holder, in cash, an amount representing all outstanding principal amount and accrued
and unpaid interest under the October Note. The October Note bears an interest rate of ten percent (10%) per annum and may be convertible
into shares of the Company&rsquo;s common stock at a fixed conversion price of $2.25 per share. The holder of the October Note may elect
to convert part or all of the outstanding balance of the October Note from the issuance date until the Maturity Date. The Company may
prepay the outstanding amount at any time, in whole or in part, without any penalty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the October Note and pursuant
to the terms of an agreement entered into between the Company and a FINRA member firm, such firm shall receive (i) a cash success fee
of $78,750 and (ii) upon conversion of the October Note, warrants equal to 7.0% of the number of shares of Common Stock received by the
investor at the time of conversion (&ldquo;<B>Note Warrants</B>&rdquo;). The warrants are exercisable on a cashless basis, at the holder&rsquo;s
discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The issuance and sale of the Common Stock, the
Investor Warrants, Comp Warrants, Note Warrants and the shares of Common Stock underlying the Investor Warrants, the Comp Warrants and
the October Note were made in reliance on an exemption from registration contained in either&nbsp;Regulation D&nbsp;or&nbsp;Regulation
S&nbsp;of the&nbsp;Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Financing in May 2020</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May 2020, the Company received capital contributions
of approximately $1,602,040 in cash from 40 investors through private placements with the term of $2.25 per share and a free warrant attaches
with each Common stock that was purchased. The exercise price of the warrant will be at $6.00 with a mandatory exercise price of $9.00.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the terms of an agreement entered
into between the Company and a FINRA member firm, such firm shall receive (i) a cash success fee of $60,831.65 (ii) a warrant to purchase
37,852 shares of Common Stock with an exercise price of $2.25 per share, and (iii) a warrant to purchase 37,852 shares of Common Stock
with an exercise price of $6.00 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Financing in April 2020</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 21, 2020, the Company entered into
three note agreements with existing note investors who executed the agreements in 2018. These three investors are Guoliang Yu and Yingfei
Wei Family Trust, Keypoint Technology Ltd., and Yoshinobu Odaira. The new agreements bear the same term as other notes investors who executed
the contract in 2019. On April 5, 2020, the Company entered into exchange agreements with such note holders. Pursuant to the exchange
agreements, the Holders agreed to deliver the Notes to the Company for cancellation, of which the aggregate principal amount plus accrued
interest expenses are $931,584, and the Company agreed to issue to the Holders an aggregate of 506,297 shares of the Company&rsquo;s common
stock and warrants to purchase 506,297 shares of the Company&rsquo;s common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 28, 2019 and September 4, 2019, the
Company issued convertible promissory notes in the aggregate principal amount plus accrued interest expenses are $515,196 to Kuo, Li Shen,
Chang, Ping Shan, Lin, Shan Tyan, and Liu, Ching Hsuan. On April 20, 2020, the Company entered into separate exchange agreements with
each note holder. Pursuant to the exchange agreements, the note holders agreed to cancel the notes and the Company agreed to issue to
the holders an aggregate of 289,438 shares of the Company&rsquo;s common stock and warrants to purchase 289,438 shares of the Company&rsquo;s
common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 47 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Recent PPP Loan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 14, 2020, the Company received a loan
in the amount of $124,400 under the Paycheck Protection Program (&ldquo;PPP&rdquo;) administered by the United States Small Business Administration
(the &ldquo;SBA&rdquo;) from East West Bank. According to the Coronavirus Aid, Relief, and Economic Security Act (the &ldquo;Cares Act&rdquo;),
PPP loan provides for forgiveness of up to the full principal amount and accrued interest if the funds are used for payroll costs, interest
on mortgages, rent, and utilities. However, at least 60% of the forgiven amount must have been used for payroll. The loan was granted
pursuant to a promissory note dated April 14, 2020 issued by the Company, which matures on April 13, 2022 and bears interest at a rate
of 1.00% per annum. The Company will pay the principal in one payment of all outstanding principal plus all accrued unpaid interest on
that date that is two years after the date of the promissory note. On October 23, ABVC BioPharma, Inc.(the &ldquo;Company&rdquo;) has
started the application with the US Government regarding the loan forgiveness program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 29, 2021, BioKey&nbsp;received a loan
in the amount of $132,331 under the Paycheck Protection Program (&ldquo;PPP&rdquo;) administered by the United States Small Business Administration
(the &ldquo;SBA&rdquo;) from East West Bank. According to the Coronavirus Aid, Relief, and Economic Security Act (the &ldquo;Cares Act&rdquo;),
PPP loan provides for forgiveness of up to the full principal amount and accrued interest if the funds are used for payroll costs, interest
on mortgages, rent, and utilities. However, at least 60% of the forgiven amount must have been used for payroll. The loan was granted
pursuant to a promissory note dated January 27, 2021 issued by the Company, which matures on January 28, 2026 and bears interest at a
rate of 1.00% per annum. The Company will pay the principal in one payment of all outstanding principal plus all accrued unpaid interest
on that date that is five years after the date of the promissory note. In addition, the Company will start the application with the US
Government regarding the loan forgiveness program as soon as the US Government allows. No collateral or personal guarantees are required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 7, 2021, the Company received a loan
in the amount of $104,167 under the Paycheck Protection Program (&ldquo;PPP&rdquo;) administered by the United States Small Business Administration
(the &ldquo;SBA&rdquo;) from Cathay Bank. According to the Coronavirus Aid, Relief, and Economic Security Act (the &ldquo;Cares Act&rdquo;),
PPP loan provides for forgiveness of up to the full principal amount and accrued interest if the funds are used for payroll costs, interest
on mortgages, rent, and utilities. However, at least 60% of the forgiven amount must have been used for payroll. The loan was granted
pursuant to a promissory note dated February 7, 2021 issued by the Company, which matures on February 6, 2026 and bears interest at a
rate of 1.00% per annum. The Company will pay the principal in one payment of all outstanding principal plus all accrued unpaid interest
on that date that is five years after the date of the promissory note. In addition, the Company will start the application with the US
Government regarding the loan forgiveness program as soon as the US Government allows. No collateral or personal guarantees are required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Recent Research
Results</B></FONT><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 23, 2019, the Company announced its internal
Phase II clinical study results of ABV-1504 for Major Depression Disorder (&ldquo;MDD&rdquo;). The clinical study results showed that
PDC-1421, the active pharmaceutical ingredient of ABV-1504, met the pre-specified primary endpoint of the Phase II clinical trial and
significantly improved the symptoms of MDD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Phase II clinical study was a randomized,
double-blind, placebo-controlled, multi-center trial, in which 60 adult patients with confirmed moderate to severe MDD were treated with
PDC-1421 in either low dose (380 mg) or high dose (2 x 380 mg) compared with placebo administration, three times a day for six weeks.
PDC-1421 high dose (2 x 380 mg) met the pre-specified primary endpoint by demonstrating a highly significant 13.2-point reduction in the
Montgomery-&Aring;sberg Depression Rating Scale (MADRS) total score by Intention-To-Treat (ITT) analysis, averaged over the 6-week treatment
period (overall treatment effect) from baseline, as compared to 9.2-point reduction of the placebo group. By Per-Protocol (PP) analysis,
PDC-1421 showed a dose dependent efficacy toward MDD in which high dose (2 x 380 mg) gave 13.4-point reduction in MADRS total score from
baseline and low dose (380 mg) gave 10.4-point reduction as compared to a 8.6-point in the placebo group. The Company has decided to use
the high dose formula in the Phase III clinical trial of ABV-1504.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 9, 2020, the Company issued a full
clinical study report (CSR) of Vitargus&reg; First-in-Human Phase I Clinical Trial<I>.&nbsp;</I>The safety and preliminary efficacy findings
from this study, combined with the unique properties of Vitargus&reg; (BFC-1401), are supportive of further development for its use during
vitrectomy surgery in patients requiring vitreous replacement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 48 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The study was an open label, Phase I study undertaken
at a single study center in Sydney, Australia. A total of 11&nbsp;participants were enrolled for the study in which each participant had
been diagnosed with either (1) a complex or rhegmatogenous retinal detachment or chronic retinal detachment with failure of gas or silicone
oil treatment or (2) a vitreous hemorrhage that requires vitrectomy surgery. The study found that Vitargus&reg; was well-tolerated as
a vitreous substitute without any apparent toxicity to ocular tissues. Further, there was no indication of an increased overall safety
risk with Vitargus&reg;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 9, 2020 the Company issued a full
clinical study report (CSR) of its ABV-1505 Phase II Part I clinical trial conducted at the University of California, San Francisco (UCSF)
for the treatment of Adult Attention-Deficit Hyperactivity Disorder (ADHD). The Phase II Part I clinical study for treating ADHD found
that the active ingredient of ABV-1505, PDC-1421, was safe, well tolerated and efficacious during its treatment and the follow-up period
with six adult patients. For the primary endpoints, the percentages of improvement in Adult Attention-Deficit/Hyperactivity Disorder Rating
Scale-Investigator Rated-IV (ADHD-RS-IV) score from baseline to 8 weeks treatment were 83.3% (N=5) in the Intention-To-Treat (ITT) population
and 80.0% (N=4) in the Per-Protocol (PP) population. Both low and high doses of PDC-1421 Capsule met the primary end points by passing
the required 40% population in ADHD-RS-IV test scores. Overall, the results from this study, which demonstrate the therapeutic value of
PDC-1421, support further clinical development of ABV-1505 for the treatment of adult ADHD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 4, 2020, the Company executed an amendment
to its collaboration agreement with BioFirst to add BFC-1403 Intraocular Irrigation Solution and BFC-1404 Corneal Storage Solution to
our agreement. BFC-1404 is utilized during a corneal transplant procedure to replace a damaged or diseased cornea while BFC-1403 has broader
utilization during a variety of ocular procedures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Initially the Company will focus on BFC-1404,
a solution utilized to store a donor cornea prior to either penetrating keratoplasty (full thickness cornea transplant) or endothelial
keratoplasty (back layer cornea transplant). Designated ABV-2002 under the Company&rsquo;s product identification system, the solution
is comprised of a specific poly amino acid that protects ocular tissue from damage caused by external osmolarity exposure during pre-surgery
storage. The specific polymer in ABV 2002 can adjust osmolarity to maintain a range of 330 to 390 mOsM thereby permitting hydration within
the corneal stroma during the storage period. Stromal hydration results in (a) maintaining acceptable corneal transparency and (b) prevents
donor cornea swelling. ABV-2002 also contains an abundant phenolic phytochemical found in plant cell walls that provides antioxidant antibacterial
properties and neuroprotection.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Early testing by BioFirst indicates that ABV-2002
may be more effective for protecting the cornea and retina during long-term storage than other storage media available today and can be
manufactured at lower cost. Categorized as a Class I Medical Device which has the lowest risk to patients, the Company intends to submit
a Premarket Notification 510(K) submission to the FDA before the end of 2021 to demonstrate the device is at least as safe and effective
as current products on the market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Strategy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Key elements of our business strategy include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.2in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Advancing to the pivotal trial phase of ABV-1701 Vitargus for the treatments of Retinal Detachment or Vitreous Hemorrhage, which we expect to generate revenues in the future.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.2in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Focusing on licensing ABV-1504 for the treatment of major depressive disorder, MDD, after the successful completion of its Phase II clinical trials.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.2in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Completing Phase II, Part 2 clinical trial for ABV-1505 for the treatment of attention deficit hyperactivity disorder, ADHD.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.2in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Out licensing drug candidates and medical device candidates to major pharmaceutical companies for phase III and pivotal clinical trials, as applicable, and further marketing if approved by the FDA.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We plan to augment our core research and development
capability and assets by conducting Phase I and II clinical trials for investigational new drugs and medical devices in the fields of
CNS, Hematology/Oncology and Ophthalmology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 49 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our management team has extensive experiences
across a wide range of new drug and medical device development and we have in-licensed new drug and medical device candidates from large
research institutes and universities in both the U.S. and Taiwan. Through an assertive product development approach, we expect that we
will build a substantial portfolio of Oncology/ Hematology, CNS and Ophthalmology products. We primarily focus on Phase I and II research
of new drug candidates and out license the post-Phase-II products to pharmaceutical companies; we do not expect to devote substantial
efforts and resources to building the disease-specific distribution channels.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Business Objectives</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is operating its core business based
on collaborative activities that can generate current and future revenues through research, development and/or commercialization joint
venture agreements. The terms of these agreements typically include payment to the Company related to one or more of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.2in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">nonrefundable upfront license fees,</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.2in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">development and commercial milestones,</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.2in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">partial or complete reimbursement of research and development costs and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.2in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">royalties on net sales of licensed products.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each type of payments results in revenue except
for revenue from royalties on net sales of licensed products, which are classified as royalty revenues. To date, we have not received
any royalty revenues. Revenue is recognized upon satisfaction of a performance obligation by transferring control of a good or service
to the joint venture partner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As part of the accounting for these arrangements,
the Company applies judgment to determine whether the performance obligations are distinct and develop assumptions in determining the
stand-alone selling price for each distinct performance obligation identified in the collaboration agreements. To determine the stand-alone
selling price, the Company relies on assumptions which may include forecasted revenues, development timelines, reimbursement rates for
R&amp;D personnel costs, discount rates and probabilities of technical and regulatory success.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company had multiple deliverables under the
collaborative agreements, including deliverables relating to grants of technology licenses, regulatory and clinical development, and marketing
activities. Estimation of the performance periods of the Company&rsquo;s deliverables requires the use of management&rsquo;s judgment.
Significant factors considered in management&rsquo;s evaluation of the estimated performance periods include, but are not limited to,
the Company&rsquo;s experience in conducting clinical development, regulatory and manufacturing activities. The Company reviews the estimated
duration of its performance periods under its collaborative agreements on an annually basis, and makes any appropriate adjustments on
a prospective basis. Future changes in estimates of the performance period under its collaborative agreements could impact the timing
of future revenue recognition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(i) Nonrefundable upfront payments</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If a license to the Company&rsquo;s intellectual
property is determined to be distinct from the other performance obligations identified in an arrangement, the Company recognizes revenue
from the related nonrefundable upfront payments based on the relative standalone selling price prescribed to the license compared to the
total selling price of the arrangement. The revenue is recognized when the license is transferred to the collaboration partners and the
collaboration partners are able to use and benefit from the license. To date, the receipt of nonrefundable upfront fees was solely for
the compensation of past research efforts and contributions made by the Company before the collaborative agreements entered into and it
does not relate to any future obligations and commitments made between the Company and the collaboration partners in the collaborative
agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 50 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(ii) Milestone payments</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is eligible to receive milestone payments
under the collaborative agreement with collaboration partners based on achievement of specified development, regulatory and commercial
events. Management evaluated the nature of the events triggering these contingent payments, and concluded that these events fall into
two categories: (a) events which involve the performance of the Company&rsquo;s obligations under the collaborative agreement with collaboration
partners, and (b) events which do not involve the performance of the Company&rsquo;s obligations under the collaborative agreement with
collaboration partners.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The former category of milestone payments consists
of those triggered by development and regulatory activities in the territories specified in the collaborative agreements. Management concluded
that each of these payments constitute substantive milestone payments. This conclusion was based primarily on the facts that (i) each
triggering event represents a specific outcome that can be achieved only through successful performance by the Company of one or more
of its deliverables, (ii) achievement of each triggering event was subject to inherent risk and uncertainty and would result in additional
payments becoming due to the Company, (iii) each of the milestone payments is nonrefundable, (iv) substantial effort is required to complete
each milestone, (v) the amount of each milestone payment is reasonable in relation to the value created in achieving the milestone, (vi)
a substantial amount of time is expected to pass between the upfront payment and the potential milestone payments, and (vii) the milestone
payments relate solely to past performance. Based on the foregoing, the Company recognizes any revenue from these milestone payments in
the period in which the underlying triggering event occurs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(iii) Multiple Element Arrangements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company evaluates multiple element arrangements
to determine (1) the deliverables included in the arrangement and (2) whether the individual deliverables represent separate units of
accounting or whether they must be accounted for as a combined unit of accounting. This evaluation involves subjective determinations
and requires management to make judgments about the individual deliverables and whether such deliverables are separate from other aspects
of the contractual relationship. Deliverables are considered separate units of accounting provided that: (i) the delivered item(s) has
value to the customer on a standalone basis and (ii) if the arrangement includes a general right of return relative to the delivered item(s),
delivery or performance of the undelivered item(s) is considered probable and substantially within its control. In assessing whether an
item under a collaboration has standalone value, the Company considers factors such as the research, manufacturing, and commercialization
capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. The Company also
considers whether its collaboration partners can use the other deliverable(s) for their intended purpose without the receipt of the remaining
element(s), whether the value of the deliverable is dependent on the undelivered item(s), and whether there are other vendors that can
provide the undelivered element(s).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognizes arrangement consideration
allocated to each unit of accounting when all of the revenue recognition criteria in ASC 606 are satisfied for that particular unit of
accounting. In the event that a deliverable does not represent a separate unit of accounting, the Company recognizes revenue from the
combined unit of accounting over the Company&rsquo;s contractual or estimated performance period for the undelivered elements, which is
typically the term of the Company&rsquo;s research and development obligations. If there is no discernible pattern of performance or objectively
measurable performance measures do not exist, then the Company recognizes revenue under the arrangement on a straight-line basis over
the period the Company is expected to complete its performance obligations. Conversely, if the pattern of performance in which the service
is provided to the customer can be determined and objectively measurable performance measures exist, then the Company recognizes revenue
under the arrangement using the proportional performance method. Revenue recognized is limited to the lesser of the cumulative amount
of payments received or the cumulative amount of revenue earned, as determined using the straight-line method or proportional performance
method, as applicable, as of the period ending date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the inception of an arrangement that includes
milestone payments, the Company evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent
nature of the milestone. This evaluation includes an assessment of whether: (1) the consideration is commensurate with either the Company&rsquo;s
performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting
from its performance to achieve the milestone, (2) the consideration relates solely to past performance and (3) the consideration is reasonable
relative to all of the deliverables and payment terms within the arrangement. The Company evaluates factors such as the scientific, clinical,
regulatory, commercial, and other risks that must be overcome to achieve the particular milestone and the level of effort and investment
required to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether
a milestone satisfies all of the criteria required to conclude that a milestone is substantive. Milestones that are not considered substantive
are recognized as earned if there are no remaining performance obligations or over the remaining period of performance, assuming all other
revenue recognition criteria are met.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 51 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(iv) Royalties and Profit Sharing Payments</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the collaborative agreement with the collaboration
partners, the Company is entitled to receive royalties on sales of products, which is at certain percentage of the net sales. The Company
recognizes revenue from these events based on the revenue recognition criteria set forth in ASC 606. Based on those criteria, the Company
considers these payments to be contingent revenues, and recognizes them as revenue in the period in which the applicable contingency is
resolved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenues Derived from Research and Development
Activities Services &mdash; Revenues related to research and development and regulatory activities are recognized when the related services
or activities are performed, in accordance with the contract terms. The Company typically has only one performance obligation at the inception
of a contract, which is to perform research and development services. The Company may also provide its customers with an option to request
that the Company provides additional goods or services in the future, such as active pharmaceutical ingredient, API, or IND/NDA/ANDA/510K
submissions. The Company evaluates whether these options are material rights at the inception of the contract. If the Company determines
an option is a material right, the Company will consider the option a separate performance obligation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the Company is entitled to reimbursement from
its customers for specified research and development expenses, the Company accounts for the related services that it provides as separate
performance obligations if it determines that these services represent a material right. The Company also determines whether the reimbursement
of research and development expenses should be accounted for as revenues or an offset to research and development expenses in accordance
with provisions of gross or net revenue presentation. The Company recognizes the corresponding revenues or records the corresponding offset
to research and development expenses as it satisfies the related performance obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company then determines the transaction price
by reviewing the amount of consideration the Company is eligible to earn under the contracts, including any variable consideration. Under
the outstanding contracts, consideration typically includes fixed consideration and variable consideration in the form of potential milestone
payments. At the start of an agreement, the Company&rsquo;s transaction price usually consists of the payments made to or by the Company
based on the number of full-time equivalent researchers assigned to the project and the related research and development expenses incurred.
The Company does not typically include any payments that the Company may receive in the future in its initial transaction price because
the payments are not probable. The Company would reassess the total transaction price at each reporting period to determine if the Company
should include additional payments in the transaction price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company receives payments from its customers
based on billing schedules established in each contract. Upfront payments and fees may be recorded as advance from customers upon receipt
or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under these
arrangements. Amounts are recorded as accounts receivable when the right of the Company to consideration is unconditional. The Company
does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period
between payment by the customers and the transfer of the promised goods or services to the customers will be one year or less.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Examples of collaborative agreements the Company
has entered into are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Collaborative agreements with BHK</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">In February and December of 2015, BioLite, Inc. entered into a total of three joint venture agreements with BioHopeKing to jointly develop ABV-1501 for Triple Negative Breast Cancer (TNBC), ABV-1504 for MDD and ABV-1505 for ADHD. The agreements granted marketing rights to BioHopeKing for certain Asian countries in return for a series of milestone payments totaling $10 million in cash and equity of BioHopeKing or equity securities owned by BioHopeKing.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 52 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The milestone payments are determined
by a schedule of BioLite development achievements as shown below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold">Milestone</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Payment</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left; text-indent: -9pt; padding-left: 9.25pt">Execution of BHK Co-Development Agreement</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,000,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9.25pt">Investigational New Drug (IND) Submission</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9.25pt">Phase II Clinical Trial Complete</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9.25pt">Initiation of Phase III Clinical Trial</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; text-indent: -9pt; padding-left: 9.25pt">New Drug Application (NDA) Submission</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,000,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt; text-indent: -9pt; padding-left: 18.25pt">Total</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">10,000,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">In December of 2015, BHK paid the initial cash payment of $1 million upon the execution of the BHK Agreement. The Company concluded that certain deliverables are considered separate units of accounting as the delivered items have value to the customer on a standalone basis and recognized this cash payment as collaboration revenue when all research, technical, and development data was delivered to BHK in 2015. The payment included compensation for past research efforts and contributions made by BioLite Taiwan before the BHK agreement was signed and does not relate to any future commitments made by BioLite Taiwan and BHK in the BHK Agreement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">In August 2016, the Company received the second milestone payment of
$1 million, and recognized collaboration revenue for the year ended December 31, 2016. As of March 31, 2021, the Company had not completed
the first phase II clinical trial.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">(iv)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">In addition to the milestone payments, BioLite Taiwan is entitled to
receive a royalty equal to 12% of BHK&rsquo;s net sales related to ABV-1501, ABV-1504 and ABV-1505 Products. As of March 31, 2021, the
Company has not earned royalties under the BHK Co-Development Agreement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">(v)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The BHK Co-Development Agreement will remain in effect for fifteen years from the date of first commercial sale of the Product in in Asia excluding Japan.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Co-Development agreement with Rgene Corporation,
a related party</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 26, 2017, BriVision entered into a co-development agreement
(the &ldquo;Rgene Agreement&rdquo;) with Rgene Corporation (the &ldquo;Rgene&rdquo;), a related party under common control by the controlling
beneficiary shareholder of YuanGene Corporation and the Company (See Note 12). Pursuant to the Rgene Agreement, BriVision and Rgene agreed
to co-develop and commercialize ABV-1507 HER2/neu Positive Breast Cancer Combination Therapy, ABV-1703 Pancreatic Cancer Combination Therapy
and ABV-1527 Ovary Cancer Combination Therapy. Under the terms of the Rgene Agreement, Rgene is required to&nbsp;pay the Company $3,000,000
in cash or stock of Rgene with equivalent value by August 15, 2017 as compensation of BriVision&rsquo;s past research efforts and contributions
made by BriVision before the Rgene Agreement was executed. The payment does not relate to any future milestones attained by BriVision.
In addition to $3,000,000, the Company is entitled to receive 50% of the future net licensing income or net sales profit earned by Rgene.
All development costs shall be equally shared by both BriVision and Rgene.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 1, 2017, the Company delivered all research,
technical data and development data to Rgene pursuant to the Rgene Agreement in return for a cash payment of $450,000 and 1,530,000 common
shares of Rgene stock valued at $2,550,000, which in 2018 was accounted for using the equity method long-term investment. On December
31, 2018, the Company determined to fully write off this investment based on the Company&rsquo;s assessment of the severity and duration
of the impairment, and qualitative and quantitative analysis of the operating performance of the investee, adverse changes in market conditions,
the regulatory or economic environment, changes in operating structure of Rgene, additional funding requirements and Rgene&rsquo;s ability
to remain in business. All research projects that were initiated will be managed and funded equally by the Company and Rgene.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company and Rgene signed an amendment to the
Rgene Agreement on November 10, 2020, pursuant to which both parties agreed to delete AB-1507 HER2/neu Positive Breast Cancer Combination
Therapy and AB-1527 Ovary Cancer Combination Therapy and add ABV-1519 EGFR Positive Non-Small Cell Lung Cancer Combination Therapy and
ABV-1526 Large Intestine / Colon / Rectal Cancer Combination Therapy to the products to be co-developed and commercialized. Other provisions
of the Rgene Agreement remain in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 53 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Collaborative agreement with BioFirst Corporation,
a related party</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 24, 2017, BriVision entered into a collaborative agreement
(the &ldquo;BioFirst Agreement&rdquo;) with BioFirst Corporation, a corporation incorporated under the laws of Taiwan (&ldquo;BioFirst&rdquo;),
pursuant to which BioFirst granted the Company global licensing rights to medical use of ABV-1701 Vitreous Substitute for Vitrectomy.
BioFirst is a related party to the Company because a controlling beneficiary shareholder of YuanGene Corporation and the Company is a
Director and shareholders of BioFirst (See Note 12).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the BioFirst Agreement, the Company
and BioFirst will co-develop and commercialize BFC-1401. The Company will pay BioFirst a total amount of $3,000,000 in cash or stock of
the Company before September 30, 2018 as payment in full for BioFirst&rsquo;s past research efforts and contributions made by BioFirst
before the BioFirst Agreement was executed. The Company is entitled to receive 50% of any future net licensing revenue or net profit associated
with Vitargus. All development cost will be equally shared by both BriVision and BioFirst.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 25, 2017, BioFirst delivered all
research, technical, data and development data to BriVision. For the year ended September 30, 2017, the Company determined to fully expense
the entire amount of $3,000,000 since the related licensing rights do not have alternative future uses. According to ASC 730-10-25-1,
absent alternative future uses the acquisition of product rights to be used in research and development activities must be charged to
research and development expenses immediately. Hence, the entire amount of $3,000,000 is fully expensed as research and development expense
during the year ended September 30, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 30, 2019, BriVision entered into a Stock
Purchase Agreement (the &ldquo;Purchase Agreement&rdquo;) with BioFirst. Pursuant to the Purchase Agreement, the Company issued 428,571
shares of the Company&rsquo;s common stock to BioFirst as payment for $3,000,000 owed by the Company to BioFirst in connection with the
BioFirst Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 5, 2019, BriVision entered into a second
Stock Purchase Agreement with BioFirst whereby the Company issued 414,702 shares of the Company&rsquo;s common stock to BioFirst as repayment
in full for a loan in the amount of $2,902,911 provided to BriVision from BioFirst.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 4, 2020, the Company executed an amendment
to the BioFirst Agreement with BioFirst to add ABV-2001 Intraocular Irrigation Solution and ABV-2002 Corneal Storage Solution to the agreement.
ABV-2002 is utilized during a corneal transplant procedure to replace a damaged or diseased cornea while ABV-2001 has broader utilization
during a variety of ocular procedures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Initially the Company will focus on ABV-2002,
a solution utilized to store a donor cornea prior to either penetrating keratoplasty (full thickness cornea transplant) or endothelial
keratoplasty (back layer cornea transplant). ABV-2002 is a solution comprised of a specific poly amino acid that protects ocular tissue
from damage caused by external osmolarity exposure during pre-surgery storage. The specific polymer in ABV-2002 can adjust osmolarity
to maintain a range of 330 to 390 mOsM thereby permitting hydration within the corneal stroma during the storage period. Stromal hydration
results in (a) maintaining acceptable corneal transparency and (b) prevents donor cornea swelling. ABV-2002 also contains an abundant
phenolic phytochemical found in plant cell walls that provides antioxidant antibacterial properties and neuroprotection.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Early testing by BioFirst indicates that ABV-2002
may be more effective for protecting the cornea and retina during long-term storage than other storage media available today and can be
manufactured at lower cost. Categorized as a lower risk Class I Medical Device, the Company intends to submit a Premarket Notification
510(K) submission to the FDA before the end of 2021 to demonstrate the device is at least as safe and effective as current products on
the market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 54 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>BioKey Revenues</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to collaborative agreements, ABVC
earns revenue through its wholly owned BioKey subsidiary which provides a wide range of Contract Development &amp; Manufacturing Organization
(&ldquo;CDMO&rdquo;) services including API characterization, pre-formulation studies, formulation development, analytical method development,
stability studies, IND/NDA/ANDA/510K submissions, and manufacturing clinical trial materials (from Phase I through Phase III) and commercial
manufacturing of pharmaceutical products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, BioKey provides a variety of regulatory
services tailored to the needs of its customers, which include proofreading and regulatory review of submission documents related to formulation
development, clinical trials, marketed products, generics, nutraceuticals and OTC products and training presentations. In addition to
supporting ABVC&rsquo;s new drug development, BioKey submits INDs, NDAs, ANDAs, and DMFs to the FDA, on ABVC&rsquo;s behalf in compliance
with new electronic submission guidelines of the FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Impact of COVID-19 Outbreak</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 30, 2020, the World Health Organization
declared the coronavirus outbreak a &ldquo;Public Health Emergency of International Concern&rdquo; and on March 10, 2020, declared it
to be a pandemic. Actions taken around the world to help mitigate the spread of the coronavirus include restrictions on travel, and quarantines
in certain areas, and forced closures for certain types of public places and businesses. The coronavirus and actions taken to mitigate
it have had and are expected to continue to have an adverse impact on the economies and financial markets of many countries, including
the geographical area in which the Company operates. While the closures and limitations on movement, domestically and internationally,
are expected to be temporary, if the outbreak continues on its current trajectory the duration of the supply chain disruption could reduce
the availability, or result in delays, of materials or supplies to and from the Company, which in turn could materially interrupt the
Company&rsquo;s business operations. Given the speed and frequency of the continuously evolving developments with respect to this pandemic,
the Company cannot reasonably estimate the magnitude of the impact to its consolidated results of operations. We have taken every precaution
possible to ensure the safety of our employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Due to the COVID-19, our revenue for the first
half of fiscal 2020 was significantly impacted. As we have not seen a stronger signal to indicate that overall global economic will be
back to normal in the third quarter, our business&rsquo;s overall revenue stream may be impacted further until the restrictions of COVID-19
can be released, then the company can start operating normally.&nbsp;The global pandemic of COVID-19 continues to evolve rapidly, and
we will continue to monitor the situation closely, including its potential effect on our plans and timelines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, it is reasonably possible that estimates
made in the financial statements have been, or will be, materially and adversely impacted in the near term as a result of these conditions,
including losses on inventory; impairment losses related to goodwill and other long-lived assets and current obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Summary of Critical Accounting Policies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Basis of Presentation</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
have been prepared in accordance with the generally accepted accounting principles in the United States of America (the &ldquo;U.S. GAAP&rdquo;).
All significant intercompany transactions and account balances have been eliminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This basis of accounting involves the application
of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred.
The Company&rsquo;s financial statements are expressed in U.S. dollars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Fiscal Year</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company changed its fiscal year from the period
beginning on October 1st and ending on September 30th to the period beginning on January 1st and ending on December 31st, beginning January
1, 2018. All references herein to a fiscal year prior to December 31, 2017 refer to the twelve months ended September 30th of such year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 55 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Use of Estimates</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity
with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated
financial statements and the amount of revenues and expenses during the reporting periods. Actual results could differ materially from
those results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Inventory</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inventory consists of raw materials, work-in-process,
finished goods, and merchandise. Inventories are stated at the lower of cost or market and valued on a moving weighted average cost basis.
Market is determined based on net realizable value. The Company periodically reviews the age and turnover of its inventory to determine
whether any inventory has become obsolete or has declined in value, and incurs a charge to operations for known and anticipated inventory
obsolescence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Reclassifications</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain classifications have been made to the
prior year financial statements to conform to the current year presentation. The reclassification had no impact on previously reported
net loss or accumulated deficit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Forward Stock Split</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 21, 2016, the Board of Directors of the
Company approved an amendment to Articles of Incorporation to effect a forward split at a ratio of 1 to 3.141 and increase the number
of our authorized shares of Common Stock, par value $0.001 per share, to 360,000,000, which was effective on April 8, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Stock Reverse Split</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 12, 2019, the Board of Directors of the
Company by unanimous written consent in lieu of a meeting approved to i) effect a stock reverse split at the ratio of 1-for-18 (the &ldquo;Reverse
Split&rdquo;) of both the authorized common stock of the Company (the &ldquo;Common Stock&rdquo;) and the issued and outstanding Common
Stock and ii) to amend the articles of incorporation of the Company to reflect the Reverse Split. The Board approved and authorized the
Reverse Split without obtaining approval of the Company&rsquo;s shareholders pursuant to Section 78.207 of Nevada Revised Statutes. On
May 3, 2019, the Company filed a certificate of amendment to the Company&rsquo;s articles of incorporation (the &ldquo;Amendment&rdquo;)
to effect the Reverse Split with the Secretary of State of Nevada. The Financial Industry Regulatory Authority (&ldquo;FINRA&rdquo;) informed
the Company that the Reverse Split was effective on May 8, 2019. All shares and related financial information in this Form 10-Q reflect
this 1-for-18 reverse stock split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Fair Value Measurements</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FASB ASC 820, &ldquo;Fair Value Measurements&rdquo;
defines fair value for certain financial and nonfinancial assets and liabilities that are recorded at fair value, establishes a framework
for measuring fair value and expands disclosures about fair value measurements. It requires that an entity measure its financial instruments
to base fair value on exit price, maximize the use of observable units and minimize the use of unobservable inputs to determine the exit
price. It establishes a hierarchy which prioritizes the inputs to valuation techniques used to measure fair value. This hierarchy increases
the consistency and comparability of fair value measurements and related disclosures by maximizing the use of observable inputs and minimizing
the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that reflect the
assumptions market participants would use in pricing the assets or liabilities based on market data obtained from sources independent
of the Company. Unobservable inputs are inputs that reflect the Company&rsquo;s own assumptions about the assumptions market participants
would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy prioritizes
the inputs into three broad levels based on the reliability of the inputs as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt; width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; width: 0.2in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; text-align: justify"><FONT STYLE="font-size: 10pt">Level 1 - Inputs are quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Valuation of these instruments does not require a high degree of judgment as the valuations are based on quoted prices in active markets that are readily and regularly available.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 56 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt; width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; width: 0.2in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; text-align: justify"><FONT STYLE="font-size: 10pt">Level 2 - Inputs other than quoted prices in active markets that are either directly or indirectly observable as of the measurement date, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt; width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; width: 0.2in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; text-align: justify"><FONT STYLE="font-size: 10pt">Level 3 - Valuations based on inputs that are unobservable and not corroborated by market data. The fair value for such assets and liabilities is generally determined using pricing models, discounted cash flow methodologies, or similar techniques that incorporate the assumptions a market participant would use in pricing the asset or liability.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The carrying values of certain assets and liabilities
of the Company, such as cash and cash equivalents, restricted cash, accounts receivable, due from related parties, inventory, prepaid
expenses and other current assets, accounts payable, accrued liabilities, and due to related parties approximate fair value due to their
relatively short maturities. The carrying value of the Company&rsquo;s short-term bank loan, convertible notes payable, and accrued interest
approximates their fair value as the terms of the borrowing are consistent with current market rates and the duration to maturity is short.
The carrying value of the Company&rsquo;s long-term bank loan approximates fair value because the interest rates approximate market rates
that the Company could obtain for debt with similar terms and maturities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Cash and Cash Equivalents</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers highly liquid investments
with maturities of three months or less, when purchased, to be cash equivalents. As of March 31, 2021 and December 31, 2020, the Company&rsquo;s
cash and cash equivalents amounted $2,615,073 and $4,273,208, respectively. Some of the Company&rsquo;s cash deposits are held in financial
institutions located in Taiwan where there is currently regulation mandated on obligatory insurance of bank accounts. The Company believes
this financial institution is of high credit quality.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Restricted Cash Equivalents</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Restricted cash equivalents primarily consist
of cash held in a reserve bank account in Taiwan. As of March 31, 2021 and December 31, 2020, the Company&rsquo;s restricted cash equivalents
amounted $718,163 and $728,163, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Concentration of Credit Risk</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s financial instruments that
are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash and temporary
cash investments in high quality credit institutions, but these investments may be in excess of Taiwan Central Deposit Insurance Corporation
and the U.S. Federal Deposit Insurance Corporation&rsquo;s insurance limits. The Company does not enter into financial instruments for
hedging, trading or speculative purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Revenue Recognition</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the fiscal year 2018, the Company adopted
Accounting Standards Codification (&ldquo;ASC&rdquo;), Topic 606 (ASC 606), Revenue from Contracts with Customers, using the modified
retrospective method to all contracts that were not completed as of January 1, 2018, and applying the new revenue standard as an adjustment
to the opening balance of accumulated deficit at the beginning of 2018 for the cumulative effect. The results for the Company&rsquo;s
reporting periods beginning on and after January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and
continue to be reported under the accounting standards in effect for the prior period. Based on the Company&rsquo;s review of existing
collaborative agreements as of January 1, 2018, the Company concluded that the adoption of the new guidance did not have a significant
change on the Company&rsquo;s revenue during all periods presented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 57 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to ASC 606, the Company recognizes revenue
when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the Company expects
to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines is within
the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance
obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations
in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step
model to contracts when it is probable that the Company will collect the consideration the Company is entitled to in exchange for the
goods or services the Company transfers to the customers. At inception of the contract, once the contract is determined to be within the
scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations,
and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price
that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Property and Equipment</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property and equipment is carried at cost net
of accumulated depreciation. Repairs and maintenance are expensed as incurred. Expenditures that improve the functionality of the related
asset or extend the useful life are capitalized. When property and equipment is retired or otherwise disposed of, the related gain or
loss is included in operating income. Leasehold improvements are depreciated on the straight-line method over the shorter of the remaining
lease term or estimated useful life of the asset. Depreciation is calculated on the straight-line method, including property and equipment
under capital leases, generally based on the following useful lives:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-left: 0; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0.25pt 0.25pt 0.25pt 9.25pt; text-indent: -9pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0.25pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; padding: 0.25pt 0.25pt 0.75pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Estimated&nbsp;Life<BR>
    in Years</B></FONT></TD>
    <TD STYLE="padding: 0.25pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="padding: 0.25pt 0.25pt 0.25pt 9.25pt; vertical-align: bottom; width: 86%; text-indent: -9pt"><FONT STYLE="font-size: 10pt">Buildings
    and leasehold improvements</FONT></TD>
    <TD STYLE="padding: 0.25pt; vertical-align: bottom; width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0.25pt; vertical-align: top; width: 12%; text-align: center"><FONT STYLE="font-size: 10pt">5 ~ 50</FONT></TD>
    <TD STYLE="padding: 0.25pt; vertical-align: bottom; width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="padding: 0.25pt 0.25pt 0.25pt 9.25pt; vertical-align: bottom; text-indent: -9pt"><FONT STYLE="font-size: 10pt">Machinery
    and equipment</FONT></TD>
    <TD STYLE="padding: 0.25pt; vertical-align: bottom"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0.25pt; vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">5 ~ 10</FONT></TD>
    <TD STYLE="padding: 0.25pt; vertical-align: bottom"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="padding: 0.25pt 0.25pt 0.25pt 9.25pt; vertical-align: bottom; text-indent: -9pt"><FONT STYLE="font-size: 10pt">Office
    equipment</FONT></TD>
    <TD STYLE="padding: 0.25pt; vertical-align: bottom"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0.25pt; vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">3 ~ 6</FONT></TD>
    <TD STYLE="padding: 0.25pt; vertical-align: bottom"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Impairment of Long-Lived Assets</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has adopted Accounting Standards Codification
subtopic 360-10, Property, Plant and Equipment (&ldquo;ASC 360-10&rdquo;). ASC 360-10 requires that long-lived assets and certain identifiable
intangibles held and used by the Company be reviewed for impairment whenever events or changes in circumstances indicate that the carrying
amount of an asset may not be recoverable. The Company evaluates its long-lived assets for impairment annually or more often if events
and circumstances warrant. Events relating to recoverability may include significant unfavorable changes in business conditions, recurring
losses, or a forecasted inability to achieve break-even operating results over an extended period. Should impairment in value be indicated,
the carrying value of intangible assets will be adjusted, based on estimates of future discounted cash flows resulting from the use and
ultimate disposition of the asset. ASC 360-10 also requires assets to be disposed of be reported at the lower of the carrying amount or
the fair value less costs to sell.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Long-term Equity Investment</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company acquires the equity investments to
promote business and strategic objectives. The Company accounts for non-marketable equity and other equity investments for which the Company
does not have control over the investees as:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt; width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; width: 0.2in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; text-align: justify"><FONT STYLE="font-size: 10pt">Equity method investments when the Company has the ability to exercise significant influence, but not control, over the investee. Its proportionate share of the income or loss is recognized monthly and is recorded in gains (losses) on equity investments.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt; width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; width: 0.2in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; text-align: justify"><FONT STYLE="font-size: 10pt">Non-marketable cost method investments when the equity method does not apply.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 58 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Significant judgment is required to identify whether
an impairment exists in the valuation of the Company&rsquo;s non-marketable equity investments, and therefore the Company considers this
a critical accounting estimate. Its yearly analysis considers both qualitative and quantitative factors that may have a significant impact
on the investee&rsquo;s fair value. Qualitative analysis of its investments involves understanding the financial performance and near-term
prospects of the investee, changes in general market conditions in the investee&rsquo;s industry or geographic area, and the management
and governance structure of the investee. Quantitative assessments of the fair value of its investments are developed using the market
and income approaches. The market approach includes the use of comparable financial metrics of private and public companies and recent
financing rounds. The income approach includes the use of a discounted cash flow model, which requires significant estimates regarding
the investees&rsquo; revenue, costs, and discount rates. The Company&rsquo;s assessment of these factors in determining whether an impairment
exists could change in the future due to new developments or changes in applied assumptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Other-Than-Temporary Impairment</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s long-term equity investments
are subject to a periodic impairment review. Impairments affect earnings as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt; width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; width: 0.2in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; text-align: justify"><FONT STYLE="font-size: 10pt">Marketable equity securities include the consideration of general market conditions, the duration and extent to which the fair value is below cost, and our ability and intent to hold the investment for a sufficient period of time to allow for recovery of value in the foreseeable future. The Company also considers specific adverse conditions related to the financial health of, and the business outlook for, the investee, which may include industry and sector performance, changes in technology, operational and financing cash flow factors, and changes in the investee&rsquo;s credit rating. The Company records other-than-temporary impairments on marketable equity securities and marketable equity method investments in gains (losses) on equity investments.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt; width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; width: 0.2in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; text-align: justify"><FONT STYLE="font-size: 10pt">Non-marketable equity investments based on the Company&rsquo;s assessment of the severity and duration of the impairment, and qualitative and quantitative analysis of the operating performance of the investee; adverse changes in market conditions and the regulatory or economic environment; changes in operating structure or management of the investee; additional funding requirements; and the investee&rsquo;s ability to remain in business. A series of operating losses of an investee or other factors may indicate that a decrease in value of the investment has occurred that is other than temporary and that shall be recognized even though the decrease in value is in excess of what would otherwise be recognized by application of the equity method. A loss in value of an investment that is other than a temporary decline shall be recognized. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity that would justify the carrying amount of the investment. The Company records other-than-temporary impairments for non-marketable cost method investments and equity method investments in gains (losses) on equity investments. Other-than-temporary impairments of equity investments were $0 and $0 for the three months ended March 31, 2021 and 2020, respectively.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Goodwill</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company evaluates goodwill for impairment
annually or more frequently when an event occurs or circumstances change that indicate the carrying value may not be recoverable. In testing
goodwill for impairment, the Company may elect to utilize a qualitative assessment to evaluate whether it is more likely than not that
the fair value of a reporting unit is less than its carrying amount. If the qualitative assessment indicates that goodwill impairment
is more likely than not, the Company performs a two-step impairment test. The Company tests goodwill for impairment under the two-step
impairment test by first comparing the book value of net assets to the fair value of the reporting units. If the fair value is determined
to be less than the book value or qualitative factors indicate that it is more likely than not that goodwill is impaired, a second step
is performed to compute the amount of impairment as the difference between the estimated fair value of goodwill and the carrying value.
The Company estimates the fair value of the reporting units using discounted cash flows. Forecasts of future cash flows are based on our
best estimate of future net sales and operating expenses, based primarily on expected category expansion, pricing, market segment share,
and general economic conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 59 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">The Company completed
the required testing of goodwill for impairment as of March 31, 2021, and determined that goodwill was impaired because of the current financial condition of the Company and the Company&rsquo;s inability
to generate future operating income without substantial sales volume increases, which are highly uncertain. Furthermore, the Company anticipates
future cash flows indicate that the recoverability of goodwill is not reasonably assured.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Research and Development Expenses</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for the cost of using licensing
rights in research and development cost according to ASC Topic 730-10-25-1. This guidance provides that absent alternative future uses
the acquisition of product rights to be used in research and development activities must be charged to research and development expenses
when incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For CDMO business unit, the Company accounts for
R&amp;D costs in accordance with Accounting Standards Codification (&ldquo;ASC&rdquo;) 730, Research and Development (&ldquo;ASC 730&rdquo;).
Research and development expenses are charged to expense as incurred unless there is an alternative future use in other research and development
projects or otherwise. Research and development expenses are comprised of costs incurred in performing research and development activities,
including personnel-related costs, facilities-related overhead, and outside contracted services including clinical trial costs, manufacturing
and process development costs for both clinical and preclinical materials, research costs, and other consulting services. Non-refundable
advance payment for goods and services that will be used in future research and development activities are expensed when the activity
has been performed or when the goods have been received rather than when the payment is made. In instances where the Company enters into
agreements with third parties to provide research and development services, costs are expensed as services are performed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Post-retirement and post-employment benefits</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s subsidiaries in Taiwan adopted
the government mandated defined contribution plan pursuant to the Labor Pension Act (the &ldquo;Act&rdquo;) in Taiwan. Such labor regulations
require that the rate of contribution made by an employer to the Labor Pension Fund per month shall not be less than 6% of the worker&rsquo;s
monthly salaries. Pursuant to the Act, the Company makes monthly contribution equal to 6% of employees&rsquo; salaries to the employees&rsquo;
pension fund. The Company has no legal obligation for the benefits beyond the contributions made. The total amounts for such employee
benefits, which were expensed as incurred, were $2,503 and $3,598 for the three months ended March 31, 2021 and 2020, respectively. Other
than the above, the Company does not provide any other post-retirement or post-employment benefits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Stock-based Compensation</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company measures expense associated with all
employee stock-based compensation awards using a fair value method and recognizes such expense in the consolidated financial statements
on a straight-line basis over the requisite service period in accordance with FASB ASC Topic 718 &ldquo;Compensation-Stock Compensation&rdquo;.
Total employee stock-based compensation expenses were $0 and $0 for the three months ended March 31, 2021 and 2020, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounted for stock-based compensation
to non-employees in accordance with FASB ASC Topic 718 &ldquo;Compensation-Stock Compensation&rdquo; and FASB ASC Topic 505-50 &ldquo;Equity-Based
Payments to Non-Employees&rdquo; which requires that the cost of services received from non-employees is measured at fair value at the
earlier of the performance commitment date or the date service is completed and recognized over the period the service is provided. Total
non-employee stock-based compensation expenses were $225,740 and $525 for the three months ended March 31, 2021 and 2020, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Beneficial Conversion Feature</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, the Company may issue convertible
notes that may contain an imbedded beneficial conversion feature. A beneficial conversion feature exists on the date a convertible note
is issued when the fair value of the underlying common stock to which the note is convertible into is in excess of the remaining unallocated
proceeds of the note after first considering the allocation of a portion of the note proceeds to the fair value of the warrants, if related
warrants have been granted. The intrinsic value of the beneficial conversion feature is recorded as a debt discount with a corresponding
amount to additional paid in capital. The debt discount is amortized to interest expense over the life of the note using the effective
interest method.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Income Taxes</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for income taxes using the
asset and liability approach which allows the recognition and measurement of deferred tax assets to be based upon the likelihood of realization
of tax benefits in future years. Under the asset and liability approach, deferred taxes are provided for the net tax effects of temporary
differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax
purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not these items will expire before the Company
is able to realize their benefits, or future deductibility is uncertain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Under ASC 740, a
tax position is recognized as a benefit only if it is&nbsp;&ldquo;more likely than not&rdquo;&nbsp;that the tax position would be sustained
in a tax examination, with a tax examination being presumed to occur. The evaluation of a tax position is a two-step process. The first
step is to determine whether it is more-likely-than-not that a tax position will be sustained upon examination, including the resolution
of any related appeals or litigations based on the technical merits of that position. The second step is to measure a tax position that
meets the more-likely-than-not threshold to determine the amount of benefits recognized in the financial statements. A tax position is
measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. Tax positions
that previously failed to meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which
the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized
in the first subsequent financial reporting period in which the threshold is no longer satisfied. Penalties and interest incurred related
to underpayment of income tax are classified as income tax expense in the year incurred. No significant penalty or interest relating to
income taxes has been incurred for the three months ended March 31, 2021 and 2020. GAAP </FONT><FONT STYLE="font-size: 8pt">&nbsp;</FONT><FONT STYLE="font-size: 10pt">also
provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosures and transition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 22, 2017, the SEC issued Staff Accounting
Bulletin (&ldquo;SAB 118&rdquo;), which provides guidance on accounting for tax effects of the Tax Act. SAB 118 provides a measurement
period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740.
In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the Act for which the accounting under ASC
740 is complete. To the extent that a company&rsquo;s accounting for certain income tax effects of the Tax Act is incomplete but it is
able to determine a reasonable estimate, it must record a provisional estimate to be included in the financial statements. If a company
cannot determine a provisional estimate to be included in the financial statements, it should continue to apply ASC 740 on the basis of
the provision of the tax laws that were in effect immediately before the enactment of the Tax Act. While the Company is able to make reasonable
estimates of the impact of the reduction in corporate rate and the deemed repatriation transition tax, the final impact of the Tax Act
may differ from these estimates, due to, among other things, changes in our interpretations and assumptions, additional guidance that
may be issued by the I.R.S., and actions the Company may take. The Company is continuing to gather additional information to determine
the final impact.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Valuation of Deferred Tax Assets</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A valuation allowance is recorded to reduce the
Company&rsquo;s deferred tax assets to the amount that is more likely than not to be realized. In assessing the need for the valuation
allowance, management considers, among other things, projections of future taxable income and ongoing prudent and feasible tax planning
strategies. If the Company determines that sufficient negative evidence exists, then it will consider recording a valuation allowance
against a portion or all of the deferred tax assets in that jurisdiction. If, after recording a valuation allowance, the Company&rsquo;s
projections of future taxable income and other positive evidence considered in evaluating the need for a valuation allowance prove, with
the benefit of hindsight, to be inaccurate, it could prove to be more difficult to support the realization of its deferred tax assets.
As a result, an additional valuation allowance could be required, which would have an adverse impact on its effective income tax rate
and results. Conversely, if, after recording a valuation allowance, the Company determines that sufficient positive evidence exists in
the jurisdiction in which the valuation allowance was recorded, it may reverse a portion or all of the valuation allowance in that jurisdiction.
In such situations, the adjustment made to the deferred tax asset would have a favorable impact on its effective income tax rate and results
in the period such determination was made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 61 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Loss Per Share of Common Stock</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company calculates net loss per share in accordance
with ASC Topic 260, &ldquo;Earnings per Share&rdquo;. Basic loss per share is computed by dividing the net loss by the weighted average
number of common shares outstanding during the period. Diluted loss per share is computed similar to basic loss per share except that
the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common
stock equivalents had been issued and if the additional common shares were dilutive. Diluted earnings per share excludes all dilutive
potential shares if their effect is anti-dilutive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Commitments and Contingencies</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has adopted ASC Topic 450 &ldquo;Contingencies&rdquo;
subtopic 20, in determining its accruals and disclosures with respect to loss contingencies. Accordingly, estimated losses from loss contingencies
are accrued by a charge to income when information available before financial statements are issued or are available to be issued indicates
that it is probable that an assets had been impaired or a liability had been incurred at the date of the financial statements and the
amount of the loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred. If a loss contingency
is not probable or reasonably estimable, disclosure of the loss contingency is made in the financial statements when it is at least reasonably
possible that a material loss could be incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Foreign-currency Transactions</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the Company&rsquo;s subsidiaries in Taiwan,
the foreign-currency transactions are recorded in New Taiwan dollars (&ldquo;NTD&rdquo;) at the rates of exchange in effect when the transactions
occur. Gains or losses resulting from the application of different foreign exchange rates when cash in foreign currency is converted into
New Taiwan dollars, or when foreign-currency receivables or payables are settled, are credited or charged to income in the year of conversion
or settlement. On the balance sheet dates, the balances of foreign-currency assets and liabilities are restated at the prevailing exchange
rates and the resulting differences are charged to current income except for those foreign currencies denominated investments in shares
of stock where such differences are accounted for as translation adjustments under the Statements of Stockholders&rsquo; Equity (Deficit).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Translation Adjustment</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accounts of the Company&rsquo;s subsidiaries
in Taiwan were maintained, and their financial statements were expressed, in New Taiwan Dollar (&ldquo;NT$&rdquo;). Such financial statements
were translated into U.S. Dollars (&ldquo;$&rdquo; or &ldquo;USD&rdquo;) in accordance ASC 830, &ldquo;Foreign Currency Matters&rdquo;,
with the NT$ as the functional currency. According to the Statement, all assets and liabilities are translated at the current exchange
rate, shareholder&rsquo;s deficit are translated at the historical rates and income statement items are translated at an average exchange
rate for the period. The resulting translation adjustments are reported under other comprehensive income (loss) as a component of shareholders&rsquo;
equity (deficit).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Recent Accounting Pronouncements</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2019, the FASB issued ASU 2019-12,&nbsp;<I>Income
Taxes (Topic 740): Simplifying the Accounting for Income Taxes</I>, as part of its overall simplification initiative to reduce costs and
complexity of applying accounting standards while maintaining or improving the usefulness of the information provided to users of financial
statements. The FASB&rsquo;s amendments primarily impact ASC 740,&nbsp;<I>Income Taxes</I>, and may impact both interim and annual reporting
periods. ASU 2019-12 will be effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years
and early adoption is permitted. The Company is currently evaluating the impact of adopting ASU 2019-12.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August 2020, the FASB issued ASU 2020-06,&nbsp;<I>Debt
with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging- Contracts in Entity&rsquo;s Own Equity (Subtopic 815-40)</I>,
to reduce the complexity associated with applying U.S. GAAP principles for certain financial instruments with characteristics of liabilities
and equity. The amendments in this ASU reduce the number of accounting models for convertible instruments and expand the existing disclosure
requirements over earnings per share as it relates to convertible instruments. This ASU will be effective for the fiscal year beginning
January 1, 2022 and interim periods therein. Early adoption is permitted, but no earlier than fiscal years beginning after December 15,
2020. The amendments may be adopted through either a modified retrospective method, or a fully retrospective method. The Company is currently
evaluating the impact of adopting ASU 2020-06.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 62 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Estimates and Assumptions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In preparing our consolidated financial statements,
we use estimates and assumptions that affect the reported amounts and disclosures. Our estimates are often based on complex judgments,
probabilities and assumptions that we believe to be reasonable, but that are inherently uncertain and unpredictable. We are also subject
to other risks and uncertainties that may cause actual results to differ from estimated amounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Results of Operations
&mdash; Three Months Ended March 31, 2021 Compared to Three Months Ended March 31, 2020.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table presents, for the three months
indicated, our consolidated statements of operations information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, <BR> 2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,<BR> 2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font-weight: bold">Revenues</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">263,150</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">78,786</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">Cost of revenues</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,245</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,959</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Gross profit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">261,905</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">74,827</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Operating expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Selling, general and administrative expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,167,595</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,152,889</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Research and development expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">121,315</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">92,790</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Stock-based compensation</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">225,740</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">525</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Total operating expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,514,650</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,246,204</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Loss from operations</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,252,745</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,171,377</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Other income (expense)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Interest income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">52,529</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,720</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(130,229</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(131,517</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Rent income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,867</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,231</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Rent income &ndash; related parties</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,600</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,200</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Gain/Loss on foreign exchange changes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">951</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Gain/Loss on investment in equity securities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(47,791</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(70,411</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Other income (expense)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">71</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,322</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Government grant income</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">124,400</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Total other income (expenses)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">6,398</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(178,453</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Loss before provision income tax</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,246,347</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,349,830</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Provision for income tax</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(51,024</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(40,568</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Net loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,195,323</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,309,262</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Net loss attributable to noncontrolling interests</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(66,818</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(61,724</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net loss attributed to ABVC and subsidiaries</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,128,505</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,247,538</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Foreign currency translation adjustment</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">36,140</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(6,451</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Comprehensive Loss</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(1,092,365</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(1,253,989</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Net loss per share:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 9pt">Basic and diluted</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(0.05</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(0.06</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Weighted average number of common shares outstanding:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 9pt">Basic and diluted</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">24,420,526</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">19,484,542</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 63 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Revenues.</I></B>&nbsp;We generated $263,150
and $78,786 in revenues for the three months ended March 31, 2021 and 2020, respectively; and incurred $1,245 and $3,959 in cost of sales
for the three months ended March 31, 2021 and 2020, respectively. The increase in revenues was mainly due to the recovery from the impact
of COVID-19 onto our CDMO business sector. &nbsp;&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Operating Expenses.</I></B>&nbsp;&nbsp;Our
operating expenses have increased by $268,446, or 22%, to $1,514,650 for the three months ended March 31, 2021 from $1,246,204 for the
three months ended March 31, 2020. Such increase in operating expenses was mainly due to the increase in selling, general and administrative
expenses and research and development expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our selling, general and administrative expenses
and stock-based compensation increased by $239,921, or 21%, mainly due to the increase in company&rsquo;s marketing and up-list related
expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our research and development expenses increased
by $28,525 or approximately 31% primarily because of new service agreements signed with vendors during the three months ended March 31,
2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Other Income (Expense). </I></B>Our other
income was $6,398 for the three months ended March 31, 2021 as compared to other expense $178,453 for the three months ended March 31,
2020. The change was principally caused by the increase&nbsp;in government grant income of $124,400 during the quarter, due to the grant
of the PPP loan, as well as increase in interest income and decreasing loss on investment in equity securities.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Interest income was $52,529 for the three months
ended March 31, 2021 as compared to $10,720 for the three months ended March 31, 2020. The increase of $41,809, or approximately 390%,
was primarily due to the interest income for various related-party loans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Loss on investment in equity securities was $47,791
for the three months ended March 31, 2021 as compared to $70,411 for the three months ended March 31, 2020. The decrease of $22,620,
or approximately 32%, was primarily due to the loss on investment in BioFirst.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other income and government grant income totaled
$124,471 for the three months ended March 31, 2021 as compared to $6,322 for the three months ended March 31, 2020. The increase of $118,149,
or approximately 1,869%, was primarily due to the grant of the PPP loans.&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><B><I>Net Loss.</I></B>&nbsp;As a result of the above factors, our
net loss was $1,195,323 for the three months ended March 31, 2021 compared to $1,309,262 for the three months ended March 31, 2020, representing
a decrease of $113,939, or 9%.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 64 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Liquidity and Capital Resources</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Working Capital</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of&nbsp;<BR> March 31,<BR> 2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of <BR> December&nbsp;31,<BR> 2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">(Unaudited)</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Current Assets</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">5,205,453</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">6,172,966</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Current Liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4,666,300</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4,844,391</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Working Capital (deficit)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">539,153</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,328,575</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Cash Flow from Operating Activities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three months ended March 31, 2021 and
2020, the net cash used in operating activities were $1,413,074 and $630,944, respectively. The increase in the amount used in operating
activities of $782,130 was primarily due to the increased accounts receivables, prepaid expenses and deposits, and accrued expenses and
other current liabilities, partially offset by the decrease in net loss during the three months ended March 31, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Cash Flow from Investing Activities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three months ended March 31, 2021,
the net cash used in investing activities was $281,952, compared to the net cash used in investing activities was $0 for the three months
ended March 31, 2020.&nbsp;The increase was due to the prepayment for equity investment during the first quarter of 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Cash Flow from Financing Activities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three months ended March 31, 2021 and
2020, the net cash provided by financing activities were $42,226 and $610,387, respectively. The decrease in net cash provided by financing
activities were primarily due to proceeds from long-term loan and issuance of common stock for cash, partially offset by the repayment
of convertible notes during the three months ended March 31, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Off-Balance Sheet Arrangements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2021, we did not have any off-balance
sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial
condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources that is material to investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 65 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25pt"><A NAME="a_009"></A><B>ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT
MARKET RISK.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a smaller reporting company, we are not required
to provide the information required by this item.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25pt"><A NAME="a_010"></A><B>ITEM 4. CONTROLS AND PROCEDURES.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Disclosure Controls and Procedures</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We maintain disclosure controls and procedures
designed to provide reasonable assurance that material information required to be disclosed by us in the reports we file or submit under
the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the SEC&rsquo;s
rules and forms, and that the information is accumulated and communicated to our management, including our Chief Executive Officer and
Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. We performed an evaluation, under the
supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness
of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based on their evaluation, our management, including
our Chief Executive Officer and Chief Financial Officer, concluded that our disclosure controls and procedures were not effective as of
March 31, 2021.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We do not expect that our disclosure controls
and procedures will prevent all errors and all instances of fraud. Disclosure controls and procedures, no matter how well conceived and
operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met.
Further, the design of disclosure controls and procedures must reflect the fact that there are resource constraints, and the benefits
must be considered relative to their costs. Because of the inherent limitations in all disclosure controls and procedures, no evaluation
of disclosure controls and procedures can provide absolute assurance that we have detected all our control deficiencies and instances
of fraud, if any. The design of disclosure controls and procedures is also based partly on certain assumptions about the likelihood of
future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Management Plan to Remediate Material Weaknesses</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We expect to implement the following measures
in 2021 to continue to remediate the material weaknesses identified:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.2in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">To continue providing applicable training for our financial and accounting staff to enhance their understanding of U.S. GAAP and internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.2in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">To expand involvement of qualified external consultants to supervise and review our financial reporting process.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Changes in Internal Control Over Financial Reporting</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There have been no changes in our internal controls
over financial reporting that occurred during our last fiscal quarter to which this Quarterly Report on Form 10-Q relates that have materially
affected, or are reasonably likely to materially affect our internal controls over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 66 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_011"></A>PART II. - OTHER INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><A NAME="a_012"></A><B>ITEM 1. LEGAL PROCEEDINGS.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">From time to time
ABVC and its Subsidiaries may become involved in legal proceedings and claims, or be threatened with other legal actions and claims,
arising in the ordinary course of business relating to its intellectual property, product liability, regulatory compliance and/or marketing
and advertising of its products. As of the date of this report, ABVC and its Subsidiaries were not involved or threatened with any legal
actions and regulatory proceedings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><A NAME="a_013"></A><B>ITEM 1A. RISK FACTORS.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a smaller reporting company as defined by Rule 12b-2 of the
Securities Exchange Act of 1934 and, as such, are not required to provide the information under this item.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><A NAME="a_014"></A><B>ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES
AND USE OF PROCEEDS.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">There were no sales
of</FONT><FONT STYLE="font-size: 8pt">&nbsp;</FONT> <FONT STYLE="font-size: 10pt">equity securities during the three months ended March
31, 2021. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><A NAME="a_015"></A><B>ITEM 3. DEFAULTS UPON SENIOR SECURITIES.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">None. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><A NAME="a_016"></A><B>ITEM 4. MINE SAFETY DISCLOSURES.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><A NAME="a_017"></A><FONT STYLE="font-size: 10pt"><B>ITEM
5. OTHER INFORMATION.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 21, 2021 we terminated our service agreement
with Olde Monmouth Stock Transfer Co., Inc to serve as our transfer agent and appointed Vstock Transfer, LLC to serve as our new transfer
agent. Vstock&rsquo;s address is 18 Lafayette Place, Woodmere, NY 11598, phone number (212) 828 &ndash; 8436.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 67 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><A NAME="a_018"></A><B>ITEM 6. EXHIBITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following exhibits are filed herewith:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; border-bottom: black 1.5pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit&nbsp;No.</B></FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1173313/000101489716000457/exhibit101.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share Exchange Agreement, dated February 8, 2016 (1)</FONT></A></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1173313/000113789202000063/fex301ai.txt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Articles of Incorporation of the Company (2)</FONT></A></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1173313/000113789202000063/fex302bl.txt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bylaws of the Company (3)</FONT></A></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1173313/000161577416004635/s102891_4-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment to Articles of Incorporation filed on March 21, 2016 (4)</FONT></A></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1173313/000161577416007154/s104086_ex3-4.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment to Articles of Incorporation filed on December 21, 2016 (5)</FONT></A></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1173313/000121390020008785/ea120454ex3-1_americanbri.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment to Articles of Incorporation filed on March 30, 2020 (6)</FONT></A></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font-size: 10pt">3.6</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><A HREF="f10q0321ex3-6_abvcbio.htm">Certificate of Amendment to Articles of Incorporation filed on February 17, 2021 +</A></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1173313/000121390020010040/ea121013ex4-1_american.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Warrant (7)</FONT></A></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1173313/000101489716000457/exhibit102.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collaboration Agreement dated December 29, 2015 (8)</FONT></A></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1173313/000161577416005823/s103448_ex99-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collaborative Agreement and Milestone Payment Agreement dated June 9, 2016 (9)</FONT></A></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1173313/000121390017000304/f10k2016ex10iii_american.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement with Kira Huang (10)</FONT></A></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1173313/000121390017001707/f8k0217ex99i_americanbri.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Addendum to the Collaboration Agreement dated January 12, 2017 (11)</FONT></A></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1173313/000121390017007869/f8k072417ex10i_americanbri.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collaboration Agreement with BioFirst dated July 24, 2017 (12)</FONT></A></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1173313/000121390017005978/f8k052617ex99i_american.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Co-Deve Agreement with Rgene dated May 26, 2017 (13)</FONT></A></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1173313/000121390017009853/f8k091517ex10-1_americanbriv.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement with Dr. Howard Doong (14)</FONT></A></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1173313/000121390017009853/f8k091517ex10-3_americanbriv.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement with Dr. Chi-Hsin Richard King (15)</FONT></A></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1173313/000121390020012685/f10k2019ex10-9_americanbriv.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement with Chihliang An (25)</FONT></A></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1173313/000121390019001553/f8k012119ex10-1_americanbri.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business Loan Agreement entered by and between Cathay Bank and American BriVision (Holding) Corporation (16)</FONT></A></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1173313/000121390019001553/f8k012119ex10-2_americanbri.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Promissory Note entered by American BriVision (Holding) Corporation (17)</FONT></A></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1173313/000121390019001553/f8k012119ex10-3_americanbri.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Commercial Security Agreement (18)</FONT></A></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1173313/000121390020010040/ea121013ex10-1_american.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Exchange Agreement entered into by and between the Company and non-US person (19)</FONT></A></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1173313/000121390020009167/ea120625ex10-2_americanbri.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Exchange Agreement entered into by and between the Company and non-US person (20)</FONT></A></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1173313/000121390020012685/f10k2019ex10-15_americanbriv.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Securities Purchase Agreement entered into by and between the Company and U.S. investors (21)</FONT></A></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1173313/000121390020012685/f10k2019ex10-16_americanbriv.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Securities Purchase Agreement entered into by and between the Company and non-U.S. investors (22)</FONT></A></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1173313/000121390021015729/f10k2020ex10-17_americanbriv.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Amercian BriVision (Holding) Corporation 2016 Equity Incentive (26)</FONT></A></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><A HREF="f10q0321ex31-1_abvcbio.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certifications pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*+</FONT></A></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><A HREF="f10q0321ex31-2_abvcbio.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certifications pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*+</FONT></A></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><A HREF="f10q0321ex32-1_abvcbio.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certifications pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.+</FONT></A></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><A HREF="f10q0321ex32-2_abvcbio.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certifications pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.+</FONT></A></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; width: 10%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 89%">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Instance Document+</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Taxonomy Extension Schema Document+</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Taxonomy Extension Calculation Linkbase Document+</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Taxonomy Extension Definition Linkbase Document+</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Taxonomy Extension Label Linkbase Document+</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Taxonomy Extension Presentation Linkbase Document+</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">In accordance with SEC Release 33-8238, Exhibits 32.1 and 32.2 are being furnished and not filed.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">+</TD><TD STYLE="text-align: justify">Filed herewith</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify">Incorporated by reference to Exhibit 10.1 to the Company&rsquo;s
Current Report on Form 8-K, filed on February 16, 2016.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Incorporated by reference to Exhibit 3.01 to the Company&rsquo;s Form SB-2 filed on June 28, 2002</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Incorporated by reference to Exhibit 3.02 to the Company&rsquo;s Form SB-2, filed on June 28, 2002</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Incorporated by reference to Exhibit 4.1 to the Company&rsquo;s Current Report on Form 8-K, filed on March 28, 2016.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Incorporated by reference to Exhibit 3.4 to the Company&rsquo;s Form S-1, filed on September 13, 2016. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">(6)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Incorporated by reference to Exhibit 3.1 to the Company&rsquo;s Form 8-K, filed on April 7, 2020</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">(7)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Incorporated by reference to Exhibit 4.1 the Company&rsquo;s Current Report on Form 8-K, filed on April 24, 2020</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">(8)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Incorporated by reference to Exhibit 10.2 the Company&rsquo;s Current Report on Form 8-K, filed on February 16, 2016.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 68; Options: NewSection; Value: 65 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">(9)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Incorporated by reference to Exhibit 99.1 to the Company&rsquo;s Current Report on Form 8-K, filed on June 9, 2016.</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">(10)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Incorporated by reference to Exhibit 10.3 to the Company&rsquo;s Annual Report on Form 10-K, filed on January 12, 2017.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">(11)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Incorporated by reference to Exhibit 99.1 to the Company&rsquo;s Current Report on Form 8-K, filed on February 22, 2017.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">(12)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Incorporated by reference to Exhibit 10.1 to the Company&rsquo;s Current Report on Form 8-K, filed on July 24, 2017.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">(13)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Incorporated by reference to Exhibit 99.1 to the Company&rsquo;s Current Report on Form 8-K, filed on May 30, 2017.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">(14)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Incorporated by reference to Exhibit 10.1 to the Company&rsquo;s Current Report on Form 8-K, filed on September 20, 2017.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">(15)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Incorporated by reference to Exhibit 10.3 to the Company&rsquo;s Current Report on Form 8-K, filed on September 20, 2017.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">(16)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Incorporated by reference to Exhibit 10.1 to the Company&rsquo;s Current Report on Form 8-K, filed on February 1, 2019.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">(17)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Incorporated by reference to Exhibit 10.2 to the Company&rsquo;s Current Report on Form 8-K, filed on February 1, 2019.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">(18)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Incorporated by reference to Exhibit 10.3 to the Company&rsquo;s Current Report on Form 8-K, filed on February 1, 2019.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">(19)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Incorporated by reference to Exhibit 10.1 to the Company&rsquo;s Current Report on Form 8-K, filed on April 24, 2020.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">(20)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Incorporated by reference to Exhibit 10.3 to the Company&rsquo;s Current Report on Form 8-K, filed April 14, 2020.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">(21)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Incorporated by reference to Exhibit 10.15 to the Company&rsquo;s Annual Report on Form 10-K, filed May 15, 2020.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">(22)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Incorporated by reference to Exhibit 10.16 to the Company&rsquo;s Annual Report on Form 10-K, filed May 15, 2020</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">(23)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Incorporated by reference to Exhibit 14.1 to the Company&rsquo;s Amendment No.1 to Form S-1, filed on November 14, 2016.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">(24)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Incorporated by reference to 21.1 to the Company&rsquo;s Form S-1, filed on September 13, 2016.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">(25)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Incorporated by reference to Exhibit 10.9 to the Company&rsquo;s Annual Report on Form 10-K, filed May 15, 2020.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">(26)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Incorporated by reference to Exhibit 10.17 to the Company&rsquo;s Annual Report on Form 10-K, filed March 16, 2021.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 69; Value: 65 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_019"></A>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>ABVC BioPharma, Inc.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 36%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Dated: May 10, 2021</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Howard Doong</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Howard Doong</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Executive Officer<BR>
(Principal Executive Officer)</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>ABVC BioPharma, Inc.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 36%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Dated: May 10, 2021</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Chihliang An</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chihliang An</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Financial Officer<BR>
(Principal Financial Officer)</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">67</P>



<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>






























































































































































































































</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.6
<SEQUENCE>2
<FILENAME>f10q0321ex3-6_abvcbio.htm
<DESCRIPTION>CERTIFICATE OF AMENDMENT TO ARTICLES OF INCORPORATION FILED ON FEBRUARY 17, 2021
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0"><B>Exhibit 3.6</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex10a_001.jpg" ALT="" STYLE="width: 811px; height: 1050px"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; text-align: center; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="text-align: center; break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex10a_002.jpg" ALT="" STYLE="width: 811px; height: 1050px">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>f10q0321ex31-1_abvcbio.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>E<FONT STYLE="text-transform: lowercase">XHIBIT
</FONT>31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER
PURSUANT TO<BR>
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Howard Doong, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">I have reviewed this Quarterly Report on Form 10-Q for the three months ended&nbsp;March 31, 2021 of <B>ABVC BioPharma, Inc.</B>;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">2</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.2in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.2in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">3</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">4</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">a.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">b.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">c.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">d.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">5</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">a.&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">b.&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 60%"><FONT STYLE="font-size: 10pt">Date: May 10, 2021</FONT></TD>
<TD STYLE="width: 4%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
<TD STYLE="width: 36%; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Howard Doong</FONT></TD></TR>
<TR>
<TD STYLE="vertical-align: top">&nbsp;</TD>
<TD STYLE="vertical-align: top">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">Howard Doong<BR>
Chief Executive Officer<BR>
(Principal Executive Officer)</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>f10q0321ex31-2_abvcbio.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>E<FONT STYLE="text-transform: lowercase">XHIBIT
</FONT>31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF THE CHIEF FINANCIAL OFFICER
PURSUANT TO<BR>
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Chihliang An, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">I have reviewed this Quarterly Report on Form 10-Q for the three months ended&nbsp;March 31, 2021 of <B>ABVC BioPharma, Inc.</B>;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">2</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.2in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.2in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">3</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">4</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">a.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">b.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">c.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">d.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">5</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">a.&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">b.&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 60%"><FONT STYLE="font-size: 10pt">Date: May 10, 2021</FONT></TD>
<TD STYLE="width: 4%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
<TD STYLE="width: 36%; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Chihliang An</FONT></TD></TR>
<TR>
<TD STYLE="vertical-align: top">&nbsp;</TD>
<TD STYLE="vertical-align: top">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">Chihliang An<BR>
Chief Financial Officer<BR>
(Principal Financial and Accounting Officer)</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>f10q0321ex32-1_abvcbio.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>E<FONT STYLE="text-transform: lowercase">XHIBIT
</FONT>32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION 906 OF SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Howard Doong, certify, pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002, 18 U.S.C. Section 1350, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.2in; font: 12pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 0.2in; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">The Quarterly Report on Form 10-Q for the three months ended&nbsp;March 31, 2021 of <B>ABVC BioPharma, Inc.</B> (the &ldquo;Report&rdquo;) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (U.S.C. 78m or 78o(d)); and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.2in">&nbsp;</TD>
    <TD STYLE="width: 0.2in"><FONT STYLE="font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
<TD STYLE="vertical-align: top; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: May 10,
2021</FONT></TD>
<TD STYLE="vertical-align: top; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
<TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 36%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Howard Doong</FONT></TD></TR>
<TR>
<TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Howard Doong</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
Executive Officer<BR>
(Principal Executive Officer)</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing certification is being furnished
solely pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United
States Code) and is not being filed as part of a separate disclosure document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>f10q0321ex32-2_abvcbio.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>E<FONT STYLE="text-transform: lowercase">XHIBIT
</FONT>32.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Certification Pursuant To</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Section 906 of Sarbanes-Oxley Act of 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Chihliang An, certify, pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002, 18 U.S.C. Section 1350, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.2in; font: 12pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 0.2in; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">The Quarterly Report on Form 10-Q for the three months ended&nbsp;March 31, 2021 of <B>ABVC BioPharma, Inc.</B> (the &ldquo;Report&rdquo;) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (U.S.C. 78m or 78o(d)); and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.2in">&nbsp;</TD>
    <TD STYLE="width: 0.2in"><FONT STYLE="font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%">Date: May 10, 2021</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%">By:</TD>
<TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 36%">/s/ Chihliang An</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">Chihliang An</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">Chief Financial Officer<BR>
(Principal Financial and Accounting Officer)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing certification is being furnished
solely pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United
States Code) and is not being filed as part of a separate disclosure document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>ex10a_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10a_001.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP"$  8&!@8'!@<(" <*"PH+"@\.# P.
M#Q80$1 1$!8B%1D5%1D5(AXD'AP>)!XV*B8F*C8^-#(T/DQ$1$Q?6E]\?*<!
M!@8&!@<&!P@(!PH+"@L*#PX,# X/%A 1$!$0%B(5&145&14B'B0>'!XD'C8J
M)B8J-CXT,C0^3$1$3%]:7WQ\I__  !$(")@&I ,!(0 "$0$#$0'_Q #   $
M 04! 0$             !@(#! 4' 0@)$  !! (! @,#!0D&$ T"  \!  (#
M! 4&$0<2$R$Q%$%1%2)A<9,(%A<R4E61DK(C-$)35G0D)3,V5&)R<W6!@I2Q
ML]'3&#5#1%=C9(.5H<+2U"8G-T4XHH2CP</A1N(H1V6T 0$! 0$
M         0(#$0$! 0 ! P0" @(!!0$! 0   1$A A(Q05%QL2)288$3<@,C
M8F.1P4)3H?_:  P# 0 "$0,1 #\ ^8VMY< OM6#H3HD]*L\PV@\Q-+G-G*E%
M#ON>-, _?5_[4*P?N>=-]UK(?:-4_*> 'W/6F^^YD?UVJ@_<\:@?2[D/UVIO
M5Z"D_<\:C[KV0_7:G_!WU/WW\A^LQ-ZP_P"#QJ?YPR'Z6([[GG4>/*_D/UV)
MW48L'W/>KF>9C\E?(;]+%E#[GC4O?>R'ZS5KKXL^(UU3+_4^E#_N=]6/IDKX
M_P ;$_X.VK?G._\ I8L;ULG_  =]5_.-_P#2Q4C[G76/SI?_ $L3>L/^#KJ_
MYTO_ *6*D_<Z:U^=[_\ ^8F]8?\ !SUK\[W_ /\ ,5;_ +FW7C^)E[P_45Y]
M19/W.&O?GN[^AB'[G# ?GN]^ABT!^YLP@]<]<_48A^YKPOH,[=_58@LG[G'"
M?GV[^HQ/^#;A?4YZY^HQ!7_P:L/^?[?ZC$/W-F&_/US]1B"V?N:\7[MBM?9-
M1GW-6.]^PV?LFJ"P?N;L?_**Q]BU4.^YOH^[8IQ]< 05O^YKICTV.;[$(?N:
MZ@]=BG^P"F!_P:(#Z;+)]@J#]S3"/79)/L$ ?<T0_P I'_8*@_<UQ>[9G_8(
M ^YIC(/&RO\ L%;/W-)_E/\ IK*P#]S1-[]G'^;)_P &H^?.S'_-E1X/N:)>
MWEVSC_-D_P"#//\ RF'^;(+8^YKG=Z;,/\V0_<TV?Y3L_P V3<%;_N:9AZ;-
M^FLL?_@W6OY2L_S9-T#]S9>;Z[+']@@^YNN>_98OL$W /W-ET>NRQ?8+W_@U
M7P 3LL7V"G=0=]S5D1Z;)#]@G_!HR'\I(OL%0/W-&2Y\MDA^P5)^YJR0X/WQ
MP_8*=U%H_<VY0$<[%!]@4=]S9E_4;#7^Q*=U _<W98>NPP?8E4#[F[-\NYSU
M7[)R=U _<W9<>N?K?8E'_<W9MO'&>J_9%.ZA_P &_,^IS];[(JAWW.&:;_\
MCZK]DY.ZB@_<Y9WS[<[3/UL>J?\ @Y9_WYRE^H].ZA_P<L]W?\>4^W^X>A^Y
MSS_ XSE+]1Z=U%!^YSV3W9FC^AZ'[G38_=F:/Z'IW44#[G39_P [T/T/3_@Z
M;.3P,Q0_0]4)/N<]I9_^-Z"I/W.NT>[+4/\ \] /W.NU?G7'I_P=MJ_.N/\
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MW<T/J\5 _ %O7GYT?M4/0+??A1^V0&= M[=ZF@/^^58Z ;QY\OH?:E9VB@]
M][_[!]LGX ]\^%'[9):*&]!=\][*7VR#H)OGPH_;*]U%?X ]Z_[#]L@Z!;U_
MV'[5.ZB@]!=\_(I?;*T>A&_>Z&G]N@#H3OW('@T_MT_ 1O\ WD""G]NFA^ ?
M?OXBG]NJ#T+Z@?V+5^W"H'H7U ]U6K]N$_ 5U!_L6K]N$'OX">H']CT_MT_
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M3\%'4+^3L_Z6(!Z4]0@3SKUG]+%:=TNW]OKKMI316.E?4'^3MG]+51^"[?\
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M5O?9/_WB?@NZF?\ 2K>^R?\ [Q _!=U,_P"E6]]D_P#WB?@NZF?]*M[[)_\
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MUFMX)BF@F?"1W3,:?Q$$8VK+T<?'A'ZCL$UK+R7H&,HLOOO,GC/X_B,>]_:
M/5ZZM%L%,Y^QA/ L"[%1]L#>&]KX>_L!:>?4E!B4]VQ%S%P7X([!$]]]*& M
M:V5\["06#D@?P2M'LVPZ\_5,N_,T\I%5BLLKVHV-<R8/!8]O#HCY DCSY0;O
M(;IBL=FQA#6ORW34-AD<4#G=[00WAA]Y5=#=,+?P8RT1G:PV#6\!\9$XL!_9
MX)9^7R@L1[QA(WYB"XRQ1GQD GLP3M;W^"[TD88R\/!64[:Z-5F1-ZI;I-I5
M&V93,UA!C<2!VF)SP3RU!EX[,,M7IZ<E"W6FB@CE(F#.TLD) +71N>#Z*'=2
M<;F)Z>*FP>0GIY0Y"-D!$[VQ/X:YW9*P'M(/"#6/VR+9^GF?E/CT,KCJTS;E
M9DKX9:UF-OQ80>U3N+-4*>;KZ^8K(L/J/L0%Q[VOCC(#OGN<3SR?>@U5GJ-@
M:N#RN7FANM@Q]Y].RT0]SVS1D CR)'')5V3?L1%E3C)*>29.^!TU4&L[^BPT
M\$0H(1OVR4<]TZS-^FZ[5FH9&O!-%(70212">-KV2!IX([7*=XW>\/?SWR*:
M]^I;?$9:XMUW0"S&WU=%W($^]X:NZE)+#:;2M6Q6AR'8WV=TI/:!Z]P!(X#B
M.U8PZA88Y6SC(*.4FGK6X:\XCJ/(C,_H]_P8@EJ("("("("("("("("XE1__
M "B,K_@ ?^A!VU$!$!$!$!$!'(/AOKE)W]0;@_(K0-1!R.(@/9S\0OT\Q4K7
M8ZH6^^%A_2$%Q$!$!$!>%!8B_?,WU-60K6NKS/B?0BC(B B B B B B B B
MB B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
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M(,A$!$!$!>%!:@)%F;ZFJ\K5OI\3Z$401 1 1 1 1 1 1 1 1 1 1 1 1 1
M1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0<H"("("("("("
M("("("("("("("("("("("("("("("XEU]_XNU#_  _"@[:B C7L>.6N#A\0
M>4!$!$!$!$!$!$!$!$!$!$!$!$!$&KG_ *\,9_@F[_K8%M$!$!$!$!$!$!$!
M$!$!$!$!$!$!$!$!$!$!$!<2H_\ Y1&5_P  #_T(.VH@(@(@(@(@+P\\GE!\
M,]<!QU#O_.)Y@@_81!R6$\2,/P<%^G- CV*L0.!X+/\ 0K1D(H"("("\*"U
M ;4O)]S5>5K75YGQ/H11D1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M 1 1 1 1 1 1 1 1 7$NOO\ Q=J'^'X4';40<YV&?);'GSJN.L25JD$;)<O;
MC/#^'_B0,/N+EA]+JD&-O[O2IOD-*OEQ' Q[R_M(C'>.2@ZDB B B B B B
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MVA%-0#Y6TW"+OL>A?(?>P$>34&-T*NYVSI4DF5M2V(VWI64II"2Y\#5UM 1
M1 1 1 1 1 1 1 1 1 7$J/\ ^41E?\ #_P!"#MJ("("("("(".0?#'6TA_4+
M(_1# #]FB#DL7]49Q^4%^H&-\J-;GCGPF<_X@@]1 1 1 7A06(?WS+]35D*U
MKJ\_U/H11D1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
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MM:L>:C<Z8W8+-.>>?6)I1'9KRN[S1+_21A_(0=;MWJ%&F^];LQ15F1][I7N
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M*A6HQ>^2:0$,:$&ZU>_8Q>U8G3ZUF)\5+"F>_P"]YL/<H_U5VR$9&#6XK<X
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M5K75YGQ/H11D1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
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MH'LNW_GC$_\ ATO_ ,E/9=O_ #QB?_#I?_DH'LNW_GC$_P#ATO\ \E/9=O\
MSQB?_#I?_DH'LNW_ )XQ/_ATO_R4]EV_\\8G_P .E_\ DH'LNW_GC$_^'2__
M "4]EV_\\8G_ ,.E_P#DH'LNW_GC$_\ ATO_ ,E/9=O_ #QB?_#I?_DH'LNW
M_GC$_P#ATO\ \E/9=O\ SQB?_#I?_DH'LNW_ )XQ/_ATO_R4]EV_\\8G_P .
ME_\ DH'LNW_GC$_^'2__ "4]EV_\\8G_ ,.E_P#DH'LNW_GC$_\ ATO_ ,E/
M9=O_ #QB?_#I?_DH'LNW_GC$_P#ATO\ \E/9=O\ SQB?_#I?_DH'LNW_ )XQ
M/_ATO_R4]EV_\\8G_P .E_\ DH'LNW_GC$_^'2__ "4]EV_\\8G_ ,.E_P#D
MH'LNW_GC$_\ ATO_ ,E/9=O_ #QB?_#I?_DH'LNW_GC$_P#ATO\ \E/9=O\
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M,K$9*1B@D>)6]G>."!ZD>C?548G><-D<C2QL,%Z*Q9JFS$R>NZ+F)I[23W?
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M;GB@>]C3-$X%Q+?B]R"2ZE%9CW;?)Y*=J*"W/2?6EDA>QD@A@$;NTN"GB B
MB B B B B B B B B B B N)4?\ \HC*_P" !_Z$';40$0$0$0$0%22@^#.L
M0/X1L[]</^I:B#G= <W:O]^9_I7Z<P?U)G]R$!$!$!$!>%6"Q#^^9?J:LA*U
MU>?ZGT(HR(@(@(@(@(@(@$\+DN[]5<7KP?6I@7;OH8VGYL?TO*L@^6MAV?+;
M!;=/D[KI."3'$WRC8/H"P8<+:M576I7>'4A> ]X'F.3[@K:*[N/K5;,;(+(F
M8X-\^.T_4>?1278<'%[)%?Q\);%PV.1GY#FCU^HH*\Y%9O-P+H(2]\T CY'O
M>"HT8!'=;'.[CMD#7\>[M/TI@FUB!WWZU6QN#:P#"#ZL\'A6<(RG'/L%UCV,
M@!,44A'=P'GCRY2P1K(FM[,RL(HG313.+K#>1X@6%3P\EUKVP3 2.>UD,9\R
M\_1RF#&LU)Z<XCLQECV\D.'()^D%=+U#JYF<"65KSWY"F&#U/$L:2P?5NO;%
MB,_5%JA<CE9P"X _.:3[B%NEF\4$0$0$0%Q_<.J\NM;&S#0X26Y,^%CV=C_,
M]R<>HU$/6PP9&K6R^MW,=%._M$TB[L'CL#@>01SRG XUA>L>-RFX.P'L98#/
M)%%9[^0\L4KWW=F:=B8,@^F;(?.(NT.[4X'.CUOMQP"W-I^095]3,IRWJ-CI
M](L[13@?+%"T]\!/#@X'@M5R>@@E;KC:LP">+3[[X?XQAY"Z7I&\XW;Z$EFH
MU\3X7=LT+_5A*9T\V"WOF]TM-H5[4\+IG32]C(FD K:ZGLU79L'5RM9I8R7D
M&,^K2T\$*9P.:7NM+(,OD,9!KMVS)5F<QYB6RUOK!B,SF8L1/0M4;4A(8)E<
MF#J.1OPX^A:N3NXB@B=(\_0T*!=/^J&-W"U=@AJOKR0,#N'D'N!4'2U 9M]J
MQ[O%JQIRF=\?>)N1V<=O<@PMLZFXO7,E5QC*\MV],0!!#ZMY70J-BQ/4ADF@
M,+WL#GQ$\EI/N)5LS!DKF6Y]4L+JUN*B89;=QXY\"'U:I.1@:KU?PV=R3<98
MJST+C_*..;T>4VWJU0UC.G$RXRU/+X3'@Q^_O5P8&.ZTT\AD:5%F R+'SS,C
MY>W@-[E.-NWG!ZG59+D)CWR<^%"P<O>I,M'-JG7O#&VR.]B+E2"3\29R[K5N
M5[=6&>O*)(96A[7CT<"E@YOL?5; :_L,6&LQS.E=V=\C>.UG>I)MNV5M7Q'R
MG8KS30![6N\+U'<KG@;C#YJKE,/5R58\0SPB0$^H"A>O=4,-F9,P^&":.OCF
M%T]B3@,3!$)^O. 8\OAQ5^6J'<&P&<-71_OTP\FK3;%7>Z:I'"9"&_C>7J$P
M5X/<,9E]<;G>XUZA#R3+P.T,/"TVL]1\?LMFZW'4;9@K!W?9<T",\((G'U_U
MOE[68R^>WU(8I9IO4K%;7?GJU*5N,Q0^(3,W@)G Z*B@(@(@(@(@(@(@(@(@
M(@(@(@(@(@(@(@(@(@(@(@(@(@+B77W_ (NU#_#\*#KV<LW*>$R=RI 9IX*L
MLD,0')D>UI(:!])7(-WQ>+V$T<C@,9>J;2VS 8)15EKO9\\=_M)(#>P-095_
MLP>Y['\LZW=OT<J^&:G9K5W60"V(1/@D#5<L>V:IM.%S0UVPW$S80T'UJ4/C
M.I/$QF;RR-!F;?+:O4-3GBP5Z-@VBG;,$=61\C*["2Z69L0/:57NHGQVVX?/
M6,+:R.*?CI*=AD$1EEKO+Q(V7L0:[8J#'ZM2OXO6IZD#=EI7WP,KD67Q1O'?
M,^)O)[E?S][)9#,9RI+A\K'!/AF_)_L]=[3:D>U_(L2M_$[/<QQ"#38SVT0=
M'^_$9-HH,<RUS3F/A?T-X/+^ >!W*=]2:=J&CCMCQS _(86R)HV<\&>&7ADL
M'^6$$OU[&RX[$UX)W!UEW=-:>/1T\Q+Y"/H[B>% ZYMZ]U%V:Y>@LOH9BM3?
M6LQPOF;')488S"X1@D$\\A!#\K@,I4Z6;E W'7'SYC*6K=6E% ^65D<\P+&%
MK >/(+NE.=DU6*9K9&AS1PV1CHW?XVO (0<[S4VNYZKD\;M6"LED%N=E>7V.
M9_>P.X:^!\0/#E#FXC8\?H6F>W5K\YQVS5;)C[#-9BI,D=V=[&<DD H-ILUO
M*Y*[MU&;#Y5D<V&;\G-K5WM%I[X7<^T2L]\9/ 82K4)OP?@DR+L/DC%1ISU[
M+!6>962/J-B'<SU +@@LUQ!B<SLN*SVHWL@+V3GM49X:YGBGBLGGPGGT:6+M
ME"(5Z-6$01PB.!C/"C_$9VCCM9] 05(@(@(@(@(@U<_]>&,_P3=_UL"VB B
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MN/JL$3VX[EHKB6(\M>?+D\'S0;Y$!$!$!$!$!$!$!$!$!$&JG_KPQG^";O\
MK8%1LNOC.T6T),A:K5W.YL>S.\.21O'DSO\ <WXH.3=&:&4Q>?WC&,O3V<-2
MNB"L^8]W[J">X!2K&1V,I@=MSL=ZS6?D+-E]::$@/%>HTP1<<@\ ]A>@C_1:
M3)Y3IG:>;CWW9K-P,L3.+R)'#@.*B&;Z2U,/D-8IP[+F;-J_DF1O8^;AG@1
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MQG^UB#0/?<N=<=;]N?*8<C5-M]20GL:PLE,3"SZ&M"^I$!$!$!$!$!<2H_\
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MF[N7Q6P:Y&/E"!X$H!#>0/0J1RW.H\F>UUT5-D-!\+#D6<L)8_W@%!U-?/\
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MF"4RCEPK>;^71M5O"FQ2W/1VP1305K^(MB4R3%TML0L8YLT[/0/0=E1 1 1
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MC6J35L3:@Q3&B"$LL,+I9CP[P^!Y-);Z+8US&-Q^,,WB-E@MC@1\D'O9[S]
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M>WS78>B>V"ADY,#/)^X6>7U@?X#U/6P?5810$0%\R]5L;DJ&Z4-BDPQR>-9
M&/A]6M(3<&%KE_IYL6X8J]2\?#9&)WE &@1S%3G;>H6?&TG6=;K5WVF1]\T\
MQ^:Q7)/'@;'0^HEK+29C'9N"*O?QK2^4L/+',"A<?4KJ)G67\E@,-7=C:[W
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MSV)IC+">06O[W'E4U.GFIU)L5/'2E,N/[A5?)9FD+&N '9R]QY9\&H),B B
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MU&];K5UW6),K7DAEDD %0$\MD)6;H.RP;!K].T;D<]D1-]I#/+LD/N(4$R1
M1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 7$NOO_%VH?X?A0=M
M1 1 1 1 1 1 1 1 1 1 1 1 1 1 1!JI_P"O#&?X)N_ZV!4;+KXSM%M"3(6J
MU=SN;'LSO#DD;QY,[_<WXH.3=&:&4Q>?WC&,O3V<-2NB"L^8]W[J">X!=Q0$
M0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0%Q*C_ /E$97_  _\ 0@[:B B B B
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MM#&PRU8WRE@ +W*43M% 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
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M!_;#_?H'R_\ =#?R/P?VP_WZ?+_W0W\C\']L/]^@P'7^OYR,%[[T<*)(J\L
M F';VRN8[^/^+%G_ "_]T-_(_!_;#_?H'R_]T-_(_!_;#_?I\O\ W0W\C\']
ML/\ ?H'R_P#=#?R/P?VP_P!^GR_]T-_(_!_;#_?H'R_]T-_(_!_;#_?I\O\
MW0W\C\']L/\ ?H'R_P#=#?R/P?VP_P!^GR_]T-_(_!_;#_?H'R_]T-_(_!_;
M#_?I\O\ W0W\C\']L/\ ?H'R_P#=#?R/P?VP_P!^GR_]T-_(_!_;#_?H'R_]
MT-_(_!_;#_?I\O\ W0W\C\']L/\ ?H'R_P#=#?R/P?VP_P!^GR_]T-_(_!_;
M#_?H'R_]T-_(_!_;#_?I\O\ W0W\C\']L/\ ?H'R_P#=#?R/P?VP_P!^GR_]
MT-_(_!_;#_?H'R_]T-_(_!_;#_?I\O\ W0W\C\']L/\ ?H'R_P#=#?R/P?VP
M_P!^GR_]T-_(_!_;#_?H'R_]T-_(_!_;#_?I\O\ W0W\C\']L/\ ?H'R_P#=
M#?R/P?VP_P!^GR_]T-_(_!_;#_?H'R_]T-_(_!_;#_?I\O\ W0W\C\']L/\
M?H'R_P#=#?R/P?VP_P!^GR_]T-_(_!_;#_?H'R_]T-_(_!_;#_?I\O\ W0W\
MC\']L/\ ?H'R_P#=#?R/P?VP_P!^K6CZ[U#EZDVMFV;#U:8EQAK_ +A*PMY!
M9QY![R@[DB B B B B J2@_/KJ?()-^V(_\ :R$013#.+<MCB/46HOV@OTO8
M1V GX(*T0$0$0%X4&/"?Z)F^IJR5:UU>9\3Z$49$0$0$0$0<XZP5O%T#+M'J
MQC7_ *'!?&.,%<9*+QHW/B(^>!Y'CZ%1,Z\6"\-KX,/8L?/X)<3RW]50RT;D
M&28Z &*:*QPWR[7-<3Y!63!O:L%^IL#VYV)SI96AS^\^9!^D+99]MJJ<?3QG
M;XEON+7?0%?31U#IQF<G/$_'Y(]TD7IW#A[.SW+I5B>"M''8M.#8^\ .X]_^
MP<*SD8,IP>X8NU@I[C)'F/Q(',]6<>A7%<CJNQXN6&I:J1>A$<W/#'<+/BP8
MV1UN[#BYS&^ $ %_:?3ZU?@UFY9J08^Q>BBHR</:#YN)=])5&KBT"\QC6LR<
M1(D<?@./<5/-:@R^'RM&D7UIHA$6QN#@'L'JXN0<TV:][1GG/K=CC%?#&$<_
M \^:Z5!H=$XTSWK,XL>]C3QVH,[%].,'9B?WW;!>.?H] H;?UIU::=E2<GL)
M[6.'EY(-.(8'=L[W]Q9RUS2"T@\<*)Q,V&+'Y22EXGR>Y[A-V^GP\PGK PU&
MMV6)K+97Q0M!$;3QR3]*W4S\%>@L"I4?6G:SN;W/[FN#?4+/D1G$L RV*(''
M==AX_2%^B;/Q0@(H"AVW;U@M3KQR9&8]\G]3A8.7N00O!];-8RF1CHSPV*3Y
M"!&^<#M*[*'<M!Y2@BG(<IRFT.40$5&IS><QV#Q\U[(6&Q01CS)7*X.O&F2V
M1 1;CC<X 3.C5P3_ #VYX;!8:/+697/J2.:&/B'?SWK-M;-AZE.C:LVVQ,M]
M@@:[\9Y?Z !3*-\#R$0%J<[FJ.#Q=G(W7N;!  7D#D^9X06=>V/%[#C(\ACI
M_$A>2/@01[B%CZ_M>*SMK)P4G/+Z,_@S][>T!Z8)(B B K5F=D$,DKSPR-A<
M[Z@.2@TFN;-BMDH&]C9G20AY9R6EI[@I EW04/V/>M:UJ2*/*7Q%)(.6Q@%S
MB$DMHSM=VS!;'5DL8NZV9C#P_P!Q:?I!4>FZIZ1#D74),S&)6N[2>#V<_6K.
MF[?X&_S>V8'!5J]G(WF0PSGB)_FX._0H^SJOH;WL8S.1%SB !VO3!O\ /[A@
M-=ABDRE^. 2_B @ESOJ 67@MCP^>J&UC+D=B'G@EOJ#\""IEP6LWM&&PCZ;<
MC<;$;,HBA;P27.*W[3R$R\!R?-1V;:<)!G*^%?=8+\S2YD !)XX)231;S^X:
M[KPC^5<C%7+_ ,1IY+B/J"R\)L>&SU4V<9>CL1 \$M]Q^D%.VYHT][J+IU"^
M:%C-5X[ /#F_ J8LF;*UKV.#FN'+2/0@IE&C@V7#6,U/AX;K'W86=\D(YY:%
MODNP$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0
M$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$*
M#\]^II;]_NQ]O]F.1!%\( [,XP'T-N$']<+]+F#YH05(@(@(@+PI!8A_?,OU
M-60K6NKS_4^A%&1$!$!$!$$8W2C\H:MF:O:TE]63@.].0%\'TKDE6Q3G9\TM
M(([ASYCR5@F=W/[!#*V+D,D($@9"QO\ Z5&<U#D8I'RVF/;.XME'EP5:+UIF
M=A]@SN08^6"7RCDY]>!Z+IOR=+E=>9:C[*[_  W>&!R>T^[S3S!J\!D,Q1MB
M.&S"RTT=KY'@.<0L^WL&QW+<,<]^%KX0]\8# (WN'EPX*C)P%7+8L5\ECYH6
M3W']EAI8.8VM/J.5TS$2YK(Y>[B,U?AEKM@ A(C )D_&Y_Q*YQR(7AF"GMNS
MU<I6[ _@!G!+7M#>.1]#EJL/K>Q6]1R%&?'ACN7>ROF?V/80[N' 4T;S[U=A
MF;K[WFK6GJ/>)YN>[N81Y<A9^1;B-:Q%VV'L-N=G[O.?FF5WP;^2$G(XIJTE
M>&>::P\M:]SY*G(':9&?6NF8#=WWX<;#<?WW9^\<-: WL;[C]*#J;+F+CBB#
M<A#&6Q\'EPY ^D%0;-SXNM-*^.[&]TH!'#@5O.(.=9TXX!]VM<87EO$C!R>X
MKGTC,_C\:&2]\5.[('#AWS7<+%XL&^P%#*@R7J+(GL:0WL)\Y!]1]RN9"S>;
M#,'8F&B"#WN:SM\C[EF4:_2:CLEMF"J#C@V@_GU\H_-??S?0* B OFQ]>OGN
MNEF#(@/AI5P88G?0Q!U?9M#UC832=>KM:Z"3EI9\PN'Y)6BZD/VJ"KC8,+DJ
MU"L3Q8LRR!KF@?#N2<"!=.]USAWE^OV<XW+5)(GEE@#T<T=RP8,OU+V;:=DQ
M.)S(A@IW#\]P [&AQ#6J]UGH&[;IL]':X<%/FWXNI# SFZ(N\S/[ >]=(Z?9
MK.G"9*UF<K3O5Z_+HK,3N7%C/7O3;?00#$Y+JGN<%W.8S*QTJD<CQ5K]H/?V
MK?4^I&6R73O/WAQ7RV,'9*0 1W)ZY1$YL_U6N:;'L\>4A@K0Q@^$Q@[Y0#P7
ME?0>G9>?-:SB<C.T"6>N'OX^*7!Q;K477]CU##2/+:T\W,GT\N 74\OT^UC)
MX08Q]&**,, 8]C0'L^D%2^((5U C.E].Z]?$D=D$\3&F8"7U/TJ =5(L_8R.
MC31W(P)XXA6'''9-Y<N3P)UL.Q;CJ>2U(Y'(QSU++Q#>+8P 7K9YW:\W-U%P
M>O8F<,A[/&O<-#N6*RS!V-OHN<]7>#T[SW][9^V%!P+IEF+VDY7&PY)W&,S<
M#)(Y/<QZGG3S*U\3+U*R,O)B@R#Y2KYDHC#.H?46SC9]FAMT&4(Y211/;WE@
M*G>W;]FV:5A=IP78V"1X]JB>P/X#D&1N?4&_'CM79@'L]LS#V&/D!_#"L?;\
MMU(BRPK4)Z="C# ";TY9Q*[A7B"C0.I>1R>%V6?+>#++BF]_?$.&R-4:QVT=
M4\U@[^PMCJ'&]DH%3CASF#D$L3C1LND-K(U>FF0GQ]3VBTVS,8H?3DJ.9+J#
MU)UT4[F4MX]XGD'?2';XC FP?4=.<6:D$X' EC:\#X=PY7S/U(N8_!]2L?E)
M*S,D9*W:^EZOCX' <L!TOA=?I;W?H=E>Q:#F14F^L*AE(Z5'TQR=>ZR%F;9(
M\%K_ "G\0.6QVKIGCL=LO3K#,RU1EH0/D:SQ?/CL<H1A]3P>R=2K;J6-BAQ.
M((8[L' FF"S).<HVF7H5L]UO@H7H6S5JE#GPG^G/;RJ] K,P?5/;\+5'96,0
ME9'[FI;1"]XU3/X[*Z_ELUE3:M6LNQC6#\2)@=R %]7W,E0QT+)+EJ*!A(:'
M2.#03\/--M$7V'>\%B<#<RD=N&P(N&,9&\.+Y7>C%\\ZOC,[5ZJZW?S4G-O)
M1367,_(!8\!JN4=NS6@:_:V=VSY:T9(XH.#!-QX+.T+EO3TQ,SN^YS$L,6(B
M@D$ 'DUS@H(YJVKX[+=+MHRUN!LMTRRR,G/XX,:Z1I[MHS?2;'PX>Z(;O>8?
M&?[HVO5$;Z9X27"=5<Y0FN&S)%2Y?,[U>7<%?4"ET$0$0$0$0$0$0$0$0$0$
M0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$
M0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$/H@_/CJ:\R;[L1_[8X(@B^#<
M&9G&.(YXMPGC_+"_2YA(: .$'H1 1 1 7A068A_1,OU-5]6M=7F?$^A%&1$!
M$!$!$%,[&O8YCAR"""/K7Y\9_'/QF?R=-_D(+CNW@<<!QY""36L[.RG7DALP
M!_8&O;X0[VGXERBMR[9N'Q9I7R.[>WEWJ>5ON@HKP;!EZ$D+)'R5Z [BQS^
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MW #GXKU 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M1 0H/SRZD<??UL?F#_1TB((_@/\ CS%?SR']L+]+6<=H0$0$0$0%X4*M0$BS
M-]05Y6K?3X@BB"("("("("@_4'6?ODUNY2;Y3@>) ?@]B#X=,<L%B1LD?9(U
MQ8\>G:X>JE^-N8FKB;T%FH9)I>!%+[F?20%J".6&=T':""..">%:QE+$RB[\
MIVI(BV#NJO\ 7N</<4'2M(V!QQ'LF1[VPQN'@S\\<@_P5UB_?;)AZ3W/F;'6
M)=W]W)<%N4<@RF7M7,W V7(3N:/Q&1\CM8NAXV&W?CGY#A,1PSMY:>0?4()-
MK^SB''P06)&RF-[HWO=Y'EIX\^5T.$XBU R=]2,_3V ^BS1BVQCXQS V.+D=
MQ' ;R1Y\KCV4RN2RT$\5:6O[+6F[))>_M>[^U;^C@%6>!7)6S-AU:,X%S(N_
METC@3Y$#@\'E3:O3[,9!!:G:WC\5@':&@#D>JFC3V\0'.!%R -:#Y M[EP+9
MA$_/PT[5JR:GB\22O'FQI]P5HA]J*K7R-EE&R9*S7CPWGRY6RQKJWML+K9/A
MA_+@UO)X^A9&RV&7$F_W8Z/PX3'SV>G"UFO8F3-9O'8UH<XVIFA_;ZA@]4O@
M??V.I5Z%.O4KL#(H8PQC?@ LQ9!$ KA6WW[6?ZCX/5X9'LJU>+=LM)'?P.0%
M8*]RZ>=\^5SDVVWZ=< S.C:3V, 6AZ5:UG\EB,Q?O9>Z(+U=\%,O>2X,_C5)
M:(MO.H9K6(J#*NWY*U<MS"*O5[B'/4RW5^6U'I)5IS9*9^0EE8Q\W>>_E[C(
MX J]U&CTK"T;^1QACZBV;%IA;+)4#SPXCS+1RIP_)V-;ZL-JR3/-'.0@L822
M&3L5W@=J+O)?)>4S&0W+8<\)MJ&(H493%6;W]@D<%F#J6*L[AB^F^2GGO07K
MD,#W5)XG=_+ N%C)9FCAL1L-7<I[.3LV0'T>\N_Q=JH^K<YLU; :X[*Y#YA$
M+3X?O=(X?B!<.Z1[!G,SO6=FR<TH>^MWB!Q/:Q!]-<^2^5-JS=W)]1,Q1.W/
MQ%.M&U@/>0TO 4G ZKKVMY";4+M2';Y;DEL\Q7VGN,?T-7(=QP^XZ]:Q5"MN
M=ZW?NS=D4 Y'#?BK;=$VW_+['BZ.J:M0R+AD+_;'-;_A+'T3([+K^^6=2R^3
M?=B?6\6"1Z:-+F;VQ[#NVQ8^?:'8:#'-+H(P[L[P%TGHWL.9S6LOER4AF?!9
M?"R<^LC0G.#K"* B B B B B B B B B B B B B B B B B B B B B B B
M B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
M B B B B B B B B B B B B B B B B A0?GCU&B\+>=C9_VZ1$&@U\M&<Q
M1>TN;[9#R/\ +"_2V/\ %"H(H"("("\*"Q#^^9?J:LA6M=7F?$^A%&1$!$!$
M!$!"@^1^K^IRXC-_+$<8-*Z0'_"*5<C@,C0X.!Y!Y]W"UTT;_&X/*Y:M/[+&
M7"$=TGH%';53AX$G! < 1Z<<'Z$&REFFG>^A&[P8O#[HSV\EQY]/)=LOZ/GX
MM8QQ@=(Z40,,U;NY>P_$)SX$:HZU9F@9+0=^[5HCX[9/5Y]P^@\A26AL.?J0
MFYDJK*\;6&-D3?.0D?PRM>HC4-ZP^];F]E>YMCAPB:T-:PGR[G$KI.+W&7%P
MQP,K.D8P<.;R/)!C[?MU.]A+4T7CPV/#';"XM]YXY7-\*S'U_9I+,DK8F$$"
M/\9[Q\[D_4E'8*>TZ[6X,-W(1G@^4@+FC@$>?*U^4W2>].<=4@,[I^T,+&?'
MX\^B8(1MF$O8['Q7HYA))'9 G;$>?!8X<!<BDM3WI<@VXXO/IW/]>0EHQ\50
MM7+D=2LWOE>2 /[E9ENG9J69*T[3WM]1Z*#16;;CV!P9Y>17U7T6TL8W''.6
MV?T7<;^Y@C^IQ+%'=T0$0%PG"QB/KCL)F'SGX]AA_0U6>HKZZ7;/R1A\+ >'
M9.ZUCOJ:NR8RC%0QU.I$T!D$+(VCZ&CA0</I]^?ZVW9)/G086IVQ#X/(4SZF
M6]5JXFH_8<;+;J^U -[!R&/^)0<<WINKR9_33J!K^VFR/WK^1Y<=W"F_4\"3
M=.GD3/ZO[:X\_1RU:'=".YCA]"^0-/P^IU]MVZELPA#V/D\ 3G@<$DDA2#;Z
MCD,O1Z4[;-2,ABBM2"F?A&3P2%$+^.T^CT^Q&7QUX?+HF8\D/YD[^?,%JL]1
M/-NCWS,7]7M' OO5(:D4[H.0&.G(Y/<M'HV<V>;JED9AA6MGL<,N0^Z!@38)
MT<?UL^6G<9& 4?:?C'R(NY*4?2;(;!L(M50RZTN]I-P\ GWEG<IY\"QT'$P&
MRB!SSC1; J\K(U.,[)U7V/+S^<>+ KU@GK19ZJO;B][TG,SCBLR4LD?[@K<-
MFOF>ND,]*5LL-3'_ #Y&'D<]BGH(S3QN V[=]N?M%X02UWF*M$7^%PQO([E.
MN@V2LR8G,4"[Q:E*V659?BUR<CNR("("("("("("("("("("("("("("("("
M("("("("("("("("("("("("("("("("("('*("("("("("("("("("("("(
M"("("("("("("("("("("("("("("("("("("("("("("("("(/SMZ@OD?N^
MQ%_K[?*B#3ZX6C8,1W>GML'/ZX7Z5-] @(@(@(@%4E6"U#^^9?J:KZ5KJ\_U
M/H11D1 1 1 1 1!K,YAJ.7QMG'W(Q)#,PM>%\-;5K-[6\I/B[320#W5YO=+&
MK!K\7FK-6&:*O9?%WMX> >.X+#D#_P!T<?/U"ULS!(M5R];#9*"W:HMF8T@E
MK_QF\>7+5WF"Z<E=;D,7D7OJR^$RQ,U_,T<;#W<=I].2K++!)*L>)S]6YEYO
MZ%$3W%DL9+).UGOD"A&0U7-WKILU,C#<@D8T-C<>QX'";<HT]"/*X.:[\JX6
MP^(R=D,C07A@]Q+0H/LF:RT.4F?5QY#(R.]S(SP\J=TR"3]+L#6S^2OYS/Q>
M499'! YI#2>/52F_K=]VP9 XVF[P'L88.&AC&AH:TM\U,OD+&K"O4;-G,R8V
M.^:6P\D>O'FX>BVD;7UVF#%0LA\2(35N.'&R&_-<TO\ <0%<HP+>5QFLPSV[
MLL;K,\'#\:UW<"?<X_!<$R-@7KLML5VP,<>1'&TAHX5LS!9J7Y\=,)H)'1R\
MCM</(@*Q?OV;$LUB2=[W$DD^]0=!Z6:$_9,F;]R,_)U=WVKPOLJ*..)C(V-[
M6M   ]  L"XB B N3;7A,G6W77=CQM1T_:35NL9Z^$_T<K!/\C@,-E+-*S>I
MLFFJ/[Z[W>K"MU[E!I<?KF&Q^1R&0J5&QV;C@9Y!ZO69E<11R=":I>@;+#,W
MM<P^\((KKO3O4]=L&SC\<UL_NE<2]P48APN0S74Z?*7:DD5+$0B*F7#RED?Z
MO"0=?X4&V+IYJFPW&VK^/#YAP.\$M) ]QX4HDU+#XRCCF8^O5C95:PL$0'S>
M"H+!TDT>#*B_'C!WA_>(R26<IR.FAC0T !:*KK6$IYBYEJ]-K+EEH$TO)Y<
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MLNPS XZA+X3NWFQ*.Q@Y7TGJ'1O!89[+>1/M]T'D/D_$8LT=C9&&,#6@ #T
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M)C61L#&CT \E4J"("("("("("("("<("('"(' 10$0.$5!$!$#A$ <(@<!.
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MB#^?QK Z9=/=0R>D8B[=P\,T\H>Y\C_4\/03>3I-H#R3\APJN/I1H#&%OR#
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M#J75MOK5RWVRJ&L]7QV_N&7^V*?Y!0<!U<9R/ S/VKEY\D]7&]Q[,W]H]/\
M(*W8WJ^T=W9F_M'JH4.L0'E'G?UGI_D%!J]8& /+,Z!]<B!G6$$CC/?ID5_R
M?Q!YQUA^&?\ _P ]#-U@;R.[.^G_ %B=_P#$%(N]73QP_.G[15&[U>_C,[^B
M1/\ )_$%'RMU:#2[Q\WQ]3T9FNK4GXEG-G_$]3O_ (@?+_5H/[/:\UW?#M>J
MALG5L _T5F>!_:/3_)_$ ;1U:Y_?>8_4<@VGJVWGBWF/U')_D_B -TZKN'E>
MROV950W/JTWR%W*_9)_D_B!]_/5@>M[)_9(=YZLL];F4^Q5_R?Q ^_[JN/\
MG^2^Q5!ZC=4AZY*]]DIW_P 05?A&ZJ?G&]]@K<W5'J77X$V8M1_W<30G?OH/
MLG0\M;S.I8;(6W SS5@9#\7*6* B B B B B B 240$*#\Z-\_KTV+_"$W[2
M(+&FDMVO D#D^WP?MK]'F'R0$0$0$0%X4%F+]\R_4U7U:O5Z?$^A%$$0</\
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MVC=<OG[<.:M6I(&5>6B6/M'=ROI)*"* B B B B B B B B B B B B B B
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M0X!!Q+HQMVXYW/WH<S>FEA95[FA\88.Y?1Z B B B B B B B B B B B B
MB B B B B B B B B B B B B B B B B B OGS[HG^MK$_S_P#]"#IG2H Z
M!KOT4PIN@(@(@(@(@(@(@)R@(4'YP;FXNVS/GMXYR$_[91!7I/(V[ <.X_H^
M']I?HRP\A!6B B B J2@L1?OF;ZFK)5OI\1KJ\SXGT(HR(@X;]T(6G3*? _Y
M^Q3'I#&3T]U_^\._;*#H*("("("("("("("("("("("("("("("("("("("(
M"("("("("("("("("("("("("A>W;3<UYE1]? W,B)BX.%?UC[?B@A8ZK9?^
M0>:_50=5\H?31,W^JKP*CU7RC3P[0\Y^HJ#U=N?R'S?ZB<"G\,$K>/%TS-L/
M][57X7+/\BLW]FG 'JW/V\NTG-_9(WJ^2WD:=FOLD[8*CU>> '.T[.!GQ\)!
MU?\ >=/SG;\1"F3W#\,4?NU+-_8JO\+P'KI^=^P3.GW%!ZPP>_4\W]@J'=9J
MC!YZOFA]<"=O3[BH=9J?OU?-_8)^&G'\'C6<U]@F3W ]:,;_ ";S7V"-ZT8[
MWZSFOL$[9[@.M&,]VN9O[!#UIQ/)#M>S7V"9/<4#K+@V#N&O9D?565T=:<,0
M3\@YK_-DR>X?AJP1'/R)F?\ -E5^&G!_F3-?YLK.F>XX5U8S4NXY3'VL;ALD
MV."L6.\2!P75=?ZJ87%X#%4+F%RWC5Z[(WCV;D<M3)@WK.M6LM' Q.6'T"LJ
MW=:]=_-.8_S9)TSW%H]9=3F_'Q64=]=5&=;-38.!C\J/JJIV3?,%S\-NJ^^E
ME?\ -D/7#4&G@U<GW?S9.R>\%1ZWZEQR:V3'UUE8=UHT=[PY]._W?$U4[)[P
M7SUNTKM_$R'^;%5#K?I0'I?_ ,V<G9/>"Q)UIT%[FF6.YS\752KPZV:/V@=U
MW_-G)V3W@KCZV:)_&7/\V>AZVZ&[TGM_YL],E]8,4]7^FI?W@R]_Q%1RR_PW
M: !YW+/V#T[?Y@'K3T\?ZW9C]==ZK'6SI]_9T_V$B=O\P/PT]/?7VZ;_ #:1
M5?AIZ>N'GDI?L)4P&=:.G3'?O^3_ !5Y%U;'W8+U."S7<3%,P/:XCCEKAR%,
M%:* B B B B B B B B B B B B B B B B B B B B B B B B B B B B
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MX ] J"*@B B B B B B B B B B B B B B B B B B B B B B B B B B
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MC?1[?RFKKBGJ'<$0$Y""&[KNF,U'%B[=;(\O=V0QL]7O5G0-HGVG7F966NR
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MAJL,N..,=8]KM,(>']O:IP/MQIY 10$0$4!$!$!%010$0$_QH"("(") 1 1
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M(\^YH4'-*G57'2R5))\/D:U"U*(X+TC!X;B5O]CW6IA;U+'1T+-V]:87Q5X
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MHFW2O/W]@HSWY\#5H0<AD,D0X,J^<][X/6"W_A&M_H8G&C[9R+><9<_F[_\
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M#A'7R]=I:WC)*EN6%YN<$QO+5M^B5VY=TL3V[$LTAMRCO>XN*NS,'8.4#@5
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M,9%]/8OI%0<+Z\['\G:Q'C8G\2WW\'^]L7"-4Z1;/L6)BRE2>""*0D,[R02
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M*T;F]P.:D<1]#7ER^]0$H^%LL>>LDO\ AMG[:^SMD_K>R_\ ,IOV2E]!\F=
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MZS;)BGXZ_@H/!>YKCV=@*=TDS!+>F&O;)KNI;+7R5(P.+7R0<D'D]BY5T'9
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M?VNX/*-Y;PV-7;?([*$0?/N]]$Y=@SUG*T,E' ^;@R1O"FO3?1[^J8R[6O9
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MR]C.\&9[WB21Z^N:\,<$,<4;0UD; UH'H /()NB\B B!PB!PG 0$X"!P$0.
MG:$#@)VA X3M"!PG:$#A.$#A.$!.$#@(@)VA X"(':$X"!V@)P@=K?@B!VA$
M#M:G:$!.T(':$0$X0.QOP3M"!VA$!.$#@(@$ IVA X"<! X3M" 0"J700GU8
MTGZ0H*@QH' '"%H*H  (6-/J$#M"\FIU96<3PLD'P< 4 11@!K6  >@X\@O0
MT!!Y+!!+&6RQM>T^YPY"MU\91B/=%5BC^EK0$%W@)8H5+,9CGA;(WWAPY""B
M*G5@9V0PLC9^2T !5-BB8.&M ^H<*#U"T%4:U^O8#QQ.,96,H=SW^&WGE9[J
ML#N"^)I(].0/)!488BTL+&EO'H1Y+R.O#&#V1M;SZ\#A!Y/3JS -FA9)Q^4
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MM/\ ] :[_,V()BB B B B B B B B B B B B B B B B B B B B B B B
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MAOIO']A=5Z7D#0=<_F3$$P1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
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MQ7>\O;%SVR,6>8(='M?4W3960V)KD+!Z166]["OJ;ICOAW+$3330"*U6>&3
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M =I0?F9F1QE\D"..+<W[9142SI@6#?==[B /:POT';Z* B B B J3ZH,>O\
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M$!$!$!$!$!$!$!$!?-'W1W[SUS^_3H.Z:1Y:C@/\'P?L!2- 1 1 1 1 1 1
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MU%X=FO',/R7M#A_YJQ0PN,H@BI3A@:?7L8&\H+XHTHY3(RO&'^]P:.56YK7
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MB:[XAB:*Y<+?R>[PW[</91QD/%3_ *R:4?.?_B"G[?1 1 1 1 1 1 1 1 1
M1 1 1 1 1 1 1 1 1 1 1 1 1 1 7S-]T=^]=<_OMA!W;3//4L!_@^#]A2-
M1 1 1 1 1 1 1 7DGXKOJ0?F3D@?E&[Y<?T1)Y?Y11!-NE+RSJ#KWTV"/TL*
M_0%OH@(@(@(@*DI1CU_WW/\ 4U92UU>9\1OK\S_6?0BRP(@^=/NB_P#B+!?3
M<?\ L+K_ $W>&:'KO\QC02Q$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$
M!$!$!$!$!$!%-!%01 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
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M*Q_?VKZ!QN2IY*E#<J3ME@E:'1O;Z$)8-+L&W8'7VQ_*-YD;Y"!'$/-[B?@
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MS_7I^A%ED1!\Y?=&\C#8'Z;<B[+T^/&CZYR?^81()0B B B B B B B B B
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MQ"3X!(.A:=&R?<]\M2@&9MR" ?1&R)4=-&""_NU6,CP8LV\Q_1WCDA3D>['
M+/4[3HY>.R&I;F8#[W\ *Q-1K_A4L0",&&[@C[6WX\/X2#1=2\=?QFN18_'X
MJ!N A,1LO8>9F-#^26A;B$U<EU.Q+Q('P08'Q:H/_6'CE495&I'%U2ST+&@P
MVL1"^=GN[N>U7^E\\S*6;QCR2S'96:"'Z(_4!!U)% 1 1 1 1 1 1 1 1 1
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M]D]/\=]Q=/6OI\6\#*'[-Z-ZS]/?SK_^K>G^.^XN?AKZ?_G7_P#,>C>L_3X
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M &L: %[X+?R0@]$ /'('"H?5A?P7QM)^I!;-.N[\:)A^L*L58&L $3>!Z>2
M:T7''AM^KA>^SQ_D-_0@.IQ.(+HV<CXA6_8JY !B9Y>GD@J-2 \\Q,\_H"H=
M2K'CF"/]4('R;4/G[/%^J$9CZK00((QSZ^2"S)B:$KFN?5B):?+EH51QE'D$
MUHN1_:A!3\E4. !5B_5"MQ87&0EQCIPM+CR2&A!E.H5G%I,$?E]"]]@K'@>!
M'P/[4(!I53ZP1_JA>"A59Z01C_)"#PT*8=W"O%W<>O8%Y\GT_P"QHO7\D*9!
M2[&T3ZU8?U AQU%W!-6+R_M F0>#%X\?\T@\SR?F!#B\>01['!^H$P'8O'\
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MG 7-$("ZYTKVZ?-09.A/=%Q^/F#&6_3QXSZ.2X)'U#V.WK^M6;E-@=:<]D4
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MAF\CEH)ZS[,;)Z;(@!&)%]!Q/[V-<.>' %0?/6TX;9)^KN*%7-F$RU7R0.[
M?!C;ZL399-F;U4-? ^$+<V)8Q\T@Y$;>?-Z:)!JV?W3&[H[6]@NQVQ-5,]>=
MC ST6NR6V[7G\]D:."RM'&TJ,OA/L3]I?(\>O *OQ-&_T7<,Q8S5G7<[)7EN
MPQ^+%9@([)HUTO+D?)60)_L:7]E9RRCX^U>AD]6P^'W;'E[X#-+%D8?C%W]J
MZWOF2K9'+]-KM5XE@FR7>QP5&SV[;]A?L?WNZ])5@FCA;):M3D<1A_H "L/
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M,[F1ZOI!RBZSI8<%/8.7OY3)30'PV.=)W^*0I! Z4],-)S,4!E9B+WBSL'Y
M>6DJ[[T;;J?U$US,:B^CBK(M36#$7!K#^Y,#@27K(W_+213ZIC+V1LX[#SU
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M9W?[$_$&W-PY=W8JE] $Y_V*ZZYM?/S,54XY/K.?I^A/Q W-J#O+%52/[_\
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M_?!EOY.7/UX_]J9!0=CRX=Q][-WCX]\:J^^+)@#_ .G+OZS/]J"@;-DRUO\
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M=UUX-:XVG 'CC]S?[TR!]^FNAX9[;YG^T>@W;6SZ7QP"!^([Z/\ :H,B+<<
M\-[+K3SQQ\UWOX^CZ5;^_+7?(^WM\R /FN]_'_N"!]^6N^7],6>?'N=[^/\
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M"!Z&E+W+[5'HI[ B B B O"@L0_OF7ZFK(5K75YGQ/H11D1 1 1 1 1 1 1
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M':LYR[_Z1O\ VD:9/<#M69_DGD/UF*K[Z\KV@_>KD?TL3)[BU]^&6_DED_\
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M,@[<B B B B B B B M#M7/WM9OM]?8)^/U"@_-H^J(.U]!"!O/IZTI5]L!
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M^].Z"HTMS\N,Q0^G^A7?^]4MI[P.><MCG>G_ #9P_P#4G<*O9=V_.6-^P?\
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M\,GO+>//O6^,K&\<O:/AR4LOH*^0?>O/%;SV]PY0>]P^*\$C7>C@@]+VCU<
M@<"F4:78\G+BL%D[\30Y]>L^1H=Z$M"UNC[!9V'6,=E;4;(Y;#7%S&<\#AQ"
M>@V&R967%X+)WX0Q\E:L^1K7>A+0FM96;+8'&9"9K6/LUF2.:/0%P3T&[#F^
MYR<A.0+P?0J)0[4R;;[6OM@\X*;9WREWY9\F@(,VM=SIS>1@L48X\='$PU[
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MP%,$9V%X99P/)XYR3?V'*3!4$04R<AKOJ*XGT+_K>S!^.6F0=N1 1 1 1 1
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M^*[ZBN*=#O\ B3.?X7F0=L1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
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M4Y3D.4Y3D.4Y3D.4Y4Y!%>01.01.01 14$0$0$4V B; 1-@(FP$38")L!$V
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MGUIC[].[![16GCFCY(#V.#FH+BPSD*0N"F;$7M!;WB'N'>1\>$&8B B B B
MX\!8\%NM,7"*5DG:?/M<#P@R$0$0$0$04L<USRP$<JKA X7A'""ACF2 .:01
M\0KG:@.:'#@@+P1M XX " & >@ 3M\D%![>0O1&WS/""D%@^"\+(BX'M!(]"
MG(N]@X5MU:)W'+ >/1!7X#?@%X86?DA [6JDPQ_D!!4&-'GP%Z&-/N"F0>F!
MCO,M"MFM"[UC;^A,@H?5@/K$P_XE6(8^..P<?4F04F"'D.,;>1]"\\"#GGPV
M\_4F!['6!)$+.3]"\=4KN'!A9^A,%1K5_+]R9^A4OIUG\\P,_0$P4MI56GD0
M,_0K+\5CW^1JQ'_)3!D1XZI$ &01C@<>31Z(^G6<"TPL((X_%"#'^1\;Y<TX
M?(<#E@5QN(H>1]EA\AQ^($P8LFNX=SG.-&#N=[^P<JB'7,+!_4\?7'F3^(/>
MJ*K.M86=S734('._N LAF$Q3&@"C  /0=@04?(F*X</88.#Z_,"L,U[$1MD:
M*,/#_P 8=@\T%Z+!8F/\2A /\@*ENO8=A+ACZX)]_8$%QV!Q,@'=0@/'IRP*
MV[ X<\<X^OY>G[F%!2[7,*XGG'5O/U_<PK1U? 'UQE;]0*BO[UL"UG;\F5A]
M'AA4_>M@#Y_)57[,(/1JF 8"!C*OGZ@QA6/O/UL@ 8JJ #[HP@N,U;7FC@8J
MK]F$.JZ\7AYQ53D#^*:I@NC6L"/3%U/LFJLZY@^WSQ=3Z!X34P8]O!8<U)V_
M)U;CPW>7A-^"YAT#X^\J?_",JH[:B B B B B B B HIO30_3MA#OS?-^R@_
M.9$'>?N>SQN-O^8._;"^RT!$!$!$!>%!8A_?,OU-60K6NKS_ %/H11D1!SW9
M^GF&V/.8W*7Y97"H./ Y_<WA<9OU<;F^L&'9KM=@AH&,W)H1Q'S&>2@^J$0?
M';-EP.O=4MKM9>F^>)\KVL#6!_!6'N>7US=YJ-35M>F%\R<ND;&&<-5D@[=N
M>XW=)UO"4X6-GRD\;(8^[TY8 "Y1(;YONKW\6_9W5)Z%QW#G0@!\1*LP9>]]
M3L]3V:'!85U2 NB8\VK'H>\<K;Z=L'4M^;93S%*O:I/:>;D!;VM3@<JL-W<]
M8IFP2U/E,-/87?U(0]B[7N>:Z@5GX^C@<6Q\DD8,]Q_!B8Y9$=TO?]HFVV?6
M<Z*DL_@N?'/!Z<@+F^".\OZLY0P^R?*([O:._P#J7A+5P=9W+J#G:^PU]:UR
MK%/D2SOF?)^)&FG=0\Y+L<NL[+5BAO=G?#)%^)(I@U>1ZB;CE-LO875<? ]E
M(\333*(:IE[^8ZV13Y&@*MJ.J^*:'GD!S(T'U63P%PC+]2MCRNQSX33L?%9=
M5)%BQ+^(D&VTSJ/DK^<GU[8J(I95G)C Y[)0%%,MU@V*KL^:P=3#,M2Q2&*H
M&<\EP][TD'<-8O96_A*-O*517N21<S0_DE;Q0$0$0$0$0$0>2_B.^HKBG0L\
MZWE/IRLR#MBCM]P&Q83R_@6>#]30@D2((_-V_?-6/=Y_)\OES_;M4@0<9ZOS
M3V8M=P3)"R/*9!L<Q^+&KIE+ 8BECF4(*43:[6=O9VC@A!'=<U#%:B_-6ZT\
MH@L/,SH3^)$&_DJ!0;9U V43W\$_'TL>'$5A/YR3@*B4X'>;N1UK.368(XLG
MBVR-GC![F=[6\AP^@J#4-BZM;+A7Y.JW'UJ<E9P'>"7/X]7!!F=))-BIZ1;M
MVIX'TV0SOJ1]OSPYI)/<HOO&7V;.=.,#=$=-E6U(P6&-'!\3OX9P@Z);S&QZ
M[AM7BNP4#8LY.*N\1M/8V-WIV_2FQ[EMEG8Y\!JE*%\M5C76[,WXC"[S#4&?
MJ6U;7+/EZ.QXAT4]*/Q1- TF.4?!OTJ+??=U7RT#KN-P-2I5Y/8VP?W1X4X&
M#F=JSVT=)LK=BBA@GB?)#?9\6,]>Q2/ ;'D]8Z<5<GG?"E(BA;3B@]7M>T!C
M"@US]OZI4J1S-O#T/8F#OEK,>1.V-=DPV5K9?%T\A6),5B)LC.?@4'#NJPVK
M[\-0%'V;L]JYJ!_\?[^]3':MWR^&&*Q%*DR[G;<0=X321$SXN0:RAO.W8G,8
MW'[7BH(8KSQ'#;@<2P2>YKEV9*.']5)WYG+:]J$#O.Y.)K7T11JK186:GN>9
MU=IXJV8VVZ0/Z'M5YP2+==YOX?(T</A\;[=D[32]L9/#&,'O*UVM[GM_WPMP
MVR8)L#YHR^&Q!RZ-0:V?J'N&7R%^+5,%'/5IR.8^S,_@/<WW-6^PW4ADFJW\
MQFJ,M*6D\QSQ$'S?Z ,3@14=1^H;:9S+M3:,4/GD"3]V$7Q4GV?J3#BM8P^>
MI5O:8+L\;>.>"&N5$3=U>S^+GJ6<YK;JV-M]P@>Q_=*LV#JIL-;(XTYG6G4\
M;>F$4,W?W/!=Z=P09^V]4+6"V9^#KX=]R=]9CZP:[@N>]9.K=1<S9V%N"V'#
M_)UR:(OJD/[FR! V'J#FHLW/A]?UZ6_8@X\:5Y[(F$K(T_?\CE\U<P>9Q)H9
M""(2]@?WM>Q,$;BZL9_(SWZF'UAUJS5L2L>?%XC#&+>XKJ-=R>I9C*1X@MOX
MUQ;8IN=[VI1+F[=2.GMV(_U#V/Q^W_TK-U/,V\S@:.2L517DL1]_A ]W:T^B
M@Y1UD;C3E=)&1[!5.0=XW?Z=BRLI^!4X^9LK\2&=OK&1W_XNU6"CHYWXW5LM
M/,Z6/&BW+)5=+_$A(^J.RY%LUW#:?/:QD;B/',O8^0?%C4]1*CU(POWGR[&!
M)X<9['0>D@F].Q1:#JGG*]FA\LZG/5JW)&LBG9)W\=_IW!7.!']PS&T0=5L*
M:F'$YBK2"JPR\"9CO5ZZ'M'4(X;(UL31Q,^1R4L7>8(O(,'TE0:_7NH^2MY^
M#"9O7IL;9GC>ZN7/[FO[0H;HN:V>;J7M/C84-$TL#;A\7][!C2&)@EV3ZHSG
M*V:& U^SEC6?V33,/;&'*4ZONM+/4[CWPR5+-/RMUIO)\28((WK!-9=/:J:Q
M>FQ$3RQ]YO[0:MGT5G;/JMV9A/9+E;+V_42@ZS:GBKUY9I'!K(VESB?< OD*
MSC<A?I9'J1$^03QY425V?]GC/8D@^K:F9AMX*')0GNB?6$S0/>.WNX7(:'6*
MWEP'8G4[]M@;P]P(X:]0:WI'GLQ;;GX[6(E]F?;GFDL.?Z/]\2F>N[9J^-T@
MYB&H:%!DLO[EZGO[^%1IHNL<+;%9U[7LA4Q\[@([L@^:K%IK'];L3*T\AV'>
M4&ZS75*"GEY\9BL-<RD\!XG, ^8PJ1ZUO.*S]*Y.T25I:G/M5>8=LD28(1+U
MHIL[[3,!DGXP/+?;@SYB[%A\G4R="M?JO+X9XP^-WIR')8--LVT8K6L:Z[D)
M2&\]K&-'+Y'_  :% L=U>QTV1JU,EB;V-;:=Q7FG;PQZ2"0;=U"QFJVJ=:W!
M/+)9A>^$1#DN+"!VK?ZKL,N=Q0NOQUBF7/<WPIQP_P":F#5=0=A^0-4R-QKO
MW8L\* ?&23R"XOHN,NZ)MV'JW)W&#.41WD^C; \^U/0=RVS;L=JU.M;OB3PI
M9VQ L'/:3[RH-7ZUZQ+>CAF@N5ZTKB(KDK.(GI(+L/6;7),A! :UUE::3LCN
M/CXB<5,=JW7#:O7AENO>Y\QXAAC'<^3Z@F#1Z[U.PV:R3<<^O;I6GCF*.RSL
M[UDYOJ5@,)E;.,M^T>TQQ,>UC&=YD[_0,3MHJU/J+A]FMVJ4,5BM;A'<Z"=G
M8_M6)L'5+7,)DI,>19M68OZJRO&7]B8(SHF<I9OJ+M.0H3E]>2C4[5O<MU;U
MS'Y&:E%%;NOA/$SJT?>UB8)IA=FP^;Q(R=.T#6X)<YWS2SM]0Y0"7K'ITTTL
M#9;'@GE@M^$1#W*#+Z+ES]#HO+RXF>Q_K"I_F\WCL)0FOY"P(:\7'<XH.:,Z
MW::9XXWFY'&\\"=\)#%-\]N&#P Q[LA9\-EQ_9$_CEOISR2K@CF*ZKZGD\K#
MCH9IV23'B!TL18R7ZB5OMFW;7M89&<E<['R F.)K2][_ *@$P<QJ[AB]EZDZ
MO+B[DCH6T[0EB/+.'<>C@N^*#YHP.JMVK;-S%S+9")E2_P!L389RP#O5&ZZ]
MDM$J5\OB-FO'LG8QU:>7O[P5K1WR[G\?B\-'DLE8;7B\)CGEWQ</11G"]4=0
MS-Z.E7O/9-(>(A+&Z/O^HE9&WV7=]=UD1#)W.Q\O)9&UI>]P'T!6\3O6MYC'
MW+M"\)F5F%\S "'M ^+2K@Y_TQZ@Q9W)9JI8M3R327)9:P<P]K8 I7D^JVCX
MRT^M/E@9&'AXC8Z0-^LM06MGZ@XB#2;>:QU\2"1CHJTK&EW$RO=/-NJ9W6*\
MYMODFK0L;<DD!;\_MY*F SJMHK[@JC-1]Y?V=W:[L_64UOY;'XVC)>N6HX:[
M&]SI7'R 3!Q;>^I&"R>G908+-\6XWP$=O,;^#* >%W6B\^Q5SSRXQ-+C_B5$
M7WC/C :OD\B'</CA(B^E[O)JX_TOSNRTMB&(V"[-.<C19:JF0IZ4=VRF;Q>(
M9 ^_<C@;+)V,+SP"Y<HW7JW@8,!9.$S4+[Q>&1AH)4D&]R&<QF=US$7JNS.I
M1NMQ-\=H/[J\>L2G&6SV(PU<39*_#79[B]W'*#$Q6T8/.U)Y<5D(K'8T]W8?
M-I4-Z39?(Y+6K=K(W'S/%Z<![SZ,:@DT._:?->]BCSM0S]W:&=_O4CNY*E0J
MR6;=F.&%@Y=(\\-"8-9B-JUW-%S<=E:]AS?5K' E;] 1 1 1 1 1 1 1 1 1
M 1!:M?O>;^]N_P!"XOT"\M*G^G(RH.VH@(@(@(@(@(@(@**[\'C3=@[?Q_8)
M?V4'YRE$'>?N>PS[\+9/J*#B/UPOLL("("("("\*#'A\[,P^AJR5:UU>?ZGT
M(HR(@^>NMF[9/&P1X3&"5DD\?=9F8/1A]&!1WIEOF"Q QN%IZ[;;-:F8R:TX
MCE[S[RG [$>H=4;V-4]@E,I'/C\CL_$[UT7W(/FO1J,%WJMNXMU&RL/?Y2,Y
M'XZQ=[UZYH&QU=JUZ'MJ/?V6J[/Q$@M]6Q'L6%U?9JT4LM)A(G8W\=H>M#8D
MZ99"[BJ>&P60R$T[P'L,TK!$M<"6=19M/&>IXS8L%/!!'6 AR43B3P!Z*&:2
MTTNHE*MJ.2MV\:2#9[VD,#$$HS^8JZSUM&3R1,=62H!W\$^K.%C]2-A?<W'&
M4LED+=/ 2UV2!\/(\3O"G T.C2:[5ZLT!AA,*+X9(XI)>>9'EGJI&S/4-:ZU
M9VQE9/!AGA[62<?$ A-@TNX4L=0ZI2WLZ^W#C+S ^*S"2SU8%O=*JZ7?W^-^
M&@R=HU&%XO23%T:9*,;4-AQ^D;YM]/-R&!EF?OCE<WZ2Y6M2SU78.M\N2K,<
M('P/#.1P2UD8;RGH/JQPY7RSH&9I:)MFT8O/D5#9F$D,SP>T@$J#:XZ=FY]7
MJ^9Q8+L=C8.'V>. ]W:4T&&.7K'N4KO6/Q>W_&]!])(@(@(@(@(@(@HG/[E)
M]#"N+=!R#J^0_P *3(.V*(YR[6HYS!6+,C8X0VRTR/\ 0.+00.4&R.U8#\Y5
M_P!=4/VK7F<]V4JC_+"#6U\G2O[1%[+99*(\?)W%CN0"7M4Q0<MZLX;(6L/1
MOX^+Q+>,MLM-8/5P'J%ATNM6D38[QK-I]>=K?GP.8[OY3R,74;VT[=2V6W>+
MX<?;8^+'0N: 0"..Y<JUK'],J%1^.VB*>KE*Q>)A(^1H?]+.U43K58L =/W&
MWA,79JUI()6LEF>7>,&L]0"NA:,PGIUB8V-\W8Y007ISF\?-H&3Q#7D7:5>W
MX\)!! )*CUOC\"^KCXW:W^M5$\ZG'STL?'-P+4XS8,?J>^;75S4@K19&=EFK
M.\?,>.W@MY0;<=3?E0[$<%0-J#'T3*VU[GS>Y@"Y70M:OE<(,ILFZW9[$G)?
M2B>8^QWY 8U6R#)TWB;I#NL$$3^6S6>V/W@=H*V^ROJ;)TFQ,F,F-@8YU0VF
M1?C@1MX>ID&BLP=(QAG6QGLE+RS]["P_Q7._)[2OH31JU2KJN(BJ03PP>!W,
MCF/,C0X\\.2B$=3[=:AG-'OVW]E:#)N,LON:"U:K.YK'83J/B<_<<#C+^-\&
M*WZL8Y04;YLF%V3(:W@\3:CMV'9.&9YB/<(V,7=Y'MCB<]QX:T$D_ !!\U:]
MKQZA[/GMCER-NK##.*]-T!['=K0FXZA/I5S$[36REVV*MIC)A._O(B>FT2++
M96EBNI.*S=YXCQ]_%>%%9/XC7^JF)W_#W\_4PF*XNR3,>9IHG L@:!ZDJB']
M--APN Q>1PN5N0U+E2].7B4]A>USN0Y8NX9[[\=+S%G&4)75J&0B>'^ZRR(\
MN+4R"6V^HVF#4I+C<A7<QU4M;7Y^>7EO'86KF<N-=6Z?=/JUN,@RYF)Y8?<)
M'ER"?]68(WT]8C,8(.=K!5=8@T:_AOHS5-2",9/-8C$=;&2Y![6,EQ+(V2O]
M&/*V&?R-'/\ 4K3JV*ECL.Q[II[4T?F(V$>A*HUC\WF]EVO/T?OGCPM:A.8A
M$UK!-(!ZO[GK5:$,:SJK?93S$V2:,:X&S*[N+WJB=]'XH1C,_*T#O=FK/<G3
MMD<^7Z@QN8"Q^7<URE'*IY+S2.FK0_DYGU']AG]U7UC4K15J\4$30&1L#6CX
M !0<7ZLTX+N?T*K/$)(I<@\/85E;OTIPM[&FSAZ,-3(5OW2 L;PUY;Y]K@@Q
M:&R/V[IGFH(HQ'DH*<D-B!HX(>U0K3L+1NZS6F9U#NU!%!^[5Q(U@A(]1P51
MLL5!I5'0,V9[E^_C+5_MFG,7:1)^6U:3*,SVG5*V4PVXQ9+'][ RI,0][@3Z
M-5@GN?OP0=3].LVWMA9)C)P"\\ /<J=ASV>O[S-@L3>I8WP*K'OMS,#Y) \<
M\1\H((UKX.JVJ0S[0_+SL?)XCCP&Q$L]!VKH>J6JK.I/4"O),UDTKZAC83P7
M<1J#G/3? W[-2_29N5G&6H+DHL4PUOZ_SE(L9A*@DWOV'9+&5R+L8Z*<F/@<
M\?-'</(E!-M"SFOLZ>4'^/ R*M3+++"0"U[?Q@Y8G0]\+M,E=$.&')6"Q!=Z
MQ9V2CK(QM9W]%Y245HA]!]5H*O37>(, S$LV^-M7P#&8/9FEH#DE%WIGD+,&
MK[!KEYW]%8@S1_7&02%(^CU:*+0,4YC #)XKW_2>\H-9TRGB&&VAG>WO&4N$
MM7,9F-_!5KDTC2ZM%G2ZP/BSQ"@[_L6>U7&X)MG)&"2H0SLCX$G?\.UJ@1FC
MGZR8I\8(:<$2T>G *"%:#AMCN2YZ.AMHQTT>1F\:L8&O=_=$N4IU?#UJ.S['
M;R>TQY.5F/[+L;(>WAGQ=VJ\B,#$;-CL)+>U//5KN!(?(*=D-/:SU+3WKO.@
MYQF<U/&Y!M9L!DCX\)HX:TL):>$H@'44U8]WT.;)<?)XGG!+OQ!,0.SE9'6B
M7%_>5.R7L=9?+$*8'X_?WCT4P8^<JB;J1T[CGX>Z.C9<?I<UB[8P<!!\[]3#
ME-GW/"ZSB9(@^H/;)B_S8UWN[U@;[KW4I^*9DK^0Q\XQD@LL$$98\%B0;CJ#
MD*NR:?I]H &.YDZO</K\G!;'K%B,?]Z=!@KL:UF0KL8&CC@./">!>ZKXNC4T
M&..&%K6PVJHCX'IP\!17<JV:M=2<%'2N5:TOR7S6DL,[V<^_A45Y_6MO??P;
M\SL^(:8[K'P'PNQY?\ I30J5['6+,2RQASX,5#V'X%R<BN:K!!UCJ/BC#728
M:0O6'TEAHR/VJ65K3?.5F;.7?C]JD&HP,5>#=>I3<2&CMHL+.SW2=I6GZ=8_
M?9M7AFP]_$1PO>_N9)$3+W@^?>5? 28K,8C4>H9DR5*>:;L?+'4_Y)Q/#^0N
MHXK&ZV_IQ7C$4/L)Q?+G$#\CDE!C=%./P?8S^^V/]:5F=4,EAZ>,IQ7L7\H3
MSVF-I5?0/F"GJ.3=0OOZLZ?9FRF.Q6/I-+/W!I[YO4< *0[E2JY&/I96G DA
MELPAX^(\,())U+QU1DFH3MB:U\6:KL80..&E86.J5;W5W/G),9)+6I0&BQ_F
M P^I"08EO'8VKUJPKZD;&22T)G3M:/H(!7=D'S%K.H#8MMWF23*7JOA9#M'L
MTACYY6"-8K:KOF/CV>6;(4;+A[#:FD)$<OP>$$IZMMR=S9M/H5(H)6R.E>R*
M<\1/D;Z=RUFTX'J'DL= R[0P-9L,S'Q3LD,;HR"DT;[<,%G)-AQF9P\U&UDJ
MU ,EHS$'EOY351H><J2[7<J9+5QBLS/ 27-Y[)F-6O09G33V.#';I+.UK8FY
M:UXI^# HMK5I\].Q%JFA12TY'OXN79 !(H,+4F2'I]U%@L10@Q3S_N;/.-CN
MS^ M]M,LM3HC1]C'9XM:HR0L\OFO4&)%A=O9KYQ[-%PQK20@<B8<^8_'6!?Q
MF4&N=.L%GI!X<N5,<_$G>',:>6-)"HD/6C5<##J4=Z"G#!/5GA9$6 -Y:X@%
MJ[U3#6T8/>3$W_0I1\]=8;]_*9K!ZWCJ;K;V.]KL0,/'<&K2[OEMK\; YR?4
M9* Q,X<9A*'_ +F> 6D!6>!,.JXJ9[#ZDQC^8+N3@_5>$ZGZK@,7HMGV/&5H
MB):X[@P=WXZG(O\ 4>K7JZSK$5>%C&#*4^ P<!8UC$4=EZL7X,HP2PX_'0F"
M!_FTE_J5<HEM/2-:PF?FR-!_LT\M5[#5:X!C_I[5Q&M?N4^C>4]E<X/FR[XG
M%OD>U[T&RDPN1. &/9TP !AY$XG:9>[W/Y6^R>M[7ENGF 9<KF6_0G[Y*4S_
M -\L:> "IE&GU[):J_<\*;NMVL#D8R61-;Y13.(XX*^GV^B@(@(@(@(@(@(@
M(@(@(@(@LW/WK8_O3_\ 0N,= ^?O)G_PC*@[:B B B B B B B HQO7GI^P?
MS";]A!^<91!W?[GP$[G9/N%%Z^S$!$!$!$!>%!CP?OJ?ZFK)6NKS/B-=7G^I
M]"++(B"U)7@E'$D37#^V *\]EJM<"R%C>/3AH4P&XZG[1[4ZO%XH''B=H[_T
MJ\J*6P0-D<]L;0YWJX  E>R012L+9&-<T^H<.0@"G6\(Q&%G9^1P.%BPXK&U
MI7RP4X8WN]7-8 2I@R+F.H6(>RU7CF!]SVAP_P#-8E3%XZB9/8Z<4(<>7=C
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M_A*9!VQ>/BCD'SV CZ1R@&K7]\3/T!6C2JGGF"/]4(*V5H(C\R)C2?4@ *M
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M0$0$0$0%%M][!IFPND/#?8)OV4'YR%$'>_N>FC[\+K^?,4'?MA?9* B B B
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M('*('(^*>7Q4T.1\408V2=_0-L_"!_\ H7'^@Q)T?ZK\ZH[2B B B B B B
MB H?U&9SHVQAA^=[!*@_.SR1!WG[GHO&YVO@:#N?UPOLI 1 1 1 7A08]=W%
MJ?ZFK)6NKS/B-=?F?$^A%ED1!\M;YC[V\]3:F"XFBI4V%KY@WZ.Y[EF['T*A
MBPMV>IF;L\\$1?#%+Y@\(,FIE[>7Z&Y*.>&7VFK7-9P(/)#'#A;;!0RMZ%2,
M\%W><;9'9Q\7N30T2O*SHQ;B,3@\UKOS2%#M>UO)9CHG>H01.]H%QTK(R."[
ML(*NB)4[_3NKK5>"QK%BQG& 1O@=XK0Y_/KR%TK>,8*71J&"'&>QETD,CJS2
M9.PN>G D&Q,>.B79V$GY*@4!S."O9'HEKTE:)SI*;C,YGO[>XIHJV7JGC<OT
M\.+JUK#[\E=D<[.P\1]GJY9=O7K^8Z&XF*K$]\]?]V\/WD!Y4V"$MM]-W:]C
MH68:]9RQ[(Y*@DD;\Y3;J?@9L;@],R-7'.96QCAXU<GO,8)#E1J>JG4?$;-K
M5>EBHII?W:.2=YC($:^D]0X&I8-O'F*,/[ 2X.,]<,ED:MK7JYN3UL7.]XM2
M0KDF0CU&MMNKOU_QY*L=J(V+<G<>]_?]*FP=5W<-EZSZ8".0&,_TN5?6$\[C
MH'T6C_K&(,#J)8.M=5-?V.S$\TC$&/>!SQP"TJ/=3MQPVR[)JC,7(9HJ]@=T
MW:0"7O;Y*\#ZZ9Y\(H"("("("("(+-L$5IS[O#=_H7'>A']9<OTY&=!VA$!$
M!$!$!$!$!$&GO. S&)'Q$_/ZH6X0%'8_ZZY^"./DV/G[1R"1+Y^W;!Q9WJW@
MZ4EN>!AQ;W]\+^Q_D2@C&^Z*=;MX_(VKV0R.#\<-N0/F<2P%33JO/"SIK5;A
M^P4YI:[&]AX8(2DVT:B? ;_/KSJ PVNLIO@]Q] 1^,J\EI^1OZ!J^-FRM'Y1
MJS]U8/>'13\$\,5VBU3S%JIL>%;M^H0U[ G$52_!^('E2W%QQ_A?SQX;Y8J!
M,&AL9.H_;,W][>G_ "E>;*UMJY,\"-KP/0=RP-)AR4753*LR52G5GDQG)@K'
MEB8-OHKG5L!OD\#!XK,C=+/\040T"EN7WL0SX[ 8BS#9+B^6:3]TD))Y[T\>
MFA/C]DU_1MV;9CKUF3SQ%L->3O$(D(#UTW+:EJYZ=S0,IP""/&F2.4 <]P9S
MW\J7WS!NNDOET]P'GZ0%:GJ]G)J&JR4JG)N9*058&#U/?ZH.59G'[]/HT. ^
M\UL455D;V3,G!>#$>2X!=&?L8S_1V_?Y'B_)<K)OHD8.TJBO6=7PM/IG"YM&
M RR8B21\I8"XF1G<5IL1#%%T+D=&QC2_$S%Q">HU&3J0Y)O2;$7?WE/"7RL]
MSW1Q@M:5U+,:9I[[>+O6(8JDU6=G@/C(AY(]&)=T0 6)ZO4;J!9@\Y8L(Q[/
MK#5#=%AV9NO,GJ:-2OMM]SI+<T[>^;DJ[@DVNZIL1U3;\3=ACQ4-I_=4C\8/
M;$7>K%#K$]?#T*F-VS1O"KP.9QD*?Q'OY"3D?5N/L06:%6>N[NADB:Z,_P!J
M1Y+GNR]2+FOY>2E'J]^XUK&D3Q#EAY6>!--=S#\SB:M^2E+4=*"3!+^.W@KF
M740!^\]/F$<@VYD&GO=W3C=1<8",#F'\3@>D$ZCV'RDU'I]U"O4I#WG*3"-[
M?A(0WD*P=,PG3;47:I6JRX^&4S5FNEG(Y>YSASW=RHZ,7+$NISUI9C*RI>FK
MQ//O8PJ71D]5#KGWOPC-S61 ;;"V&#\>=X]&+AV\^S3ZMXN/T&7&UX'1EEZ3
MB-[.7!!T3><'7V'?=%H6N3"^I/)-P>.X-'*UNYZ+@F;UIE&G7%:"\R=EED)[
M ]D #T&[V' 8S ;[HMG%5F538FE@F$8[0]G8H&9[>7W79+UK59\V*UPUX!W@
M1P!GT)HDVC5LQ5WR62#6+.)Q]FJX68G.[HN]OHX)T[TO"9?)[9?R5=MKC*SQ
M11O\V-5RP6<%/+K.*ZGUJ)+8Z$_=6'Y!D:M]A.F>K6]'@?/69)<LU/'?<))D
M\1XYY!4Y$*I,[.@>29W<D3R#]$RV^S].\!C>FDMUD/\ 3"*M%.;9),A>@O97
MI]@H>ETU]\0?D13;:-PDF4R>JT>YYB_=QNA8N2"U;@MT6SVH(3P^?M"L&GRM
M.6%M&77]!RF-R%29CF3@\\CWAZGNYX9FP=1]1I6^]L3\;*^=@)!('JU!7E=8
MQ6M]1]*EQ$ JLN&Q%.QGH_L8KNL:[@QU6V[BA#_0L=22#R_$>]O)<$Y$$V3'
M0X?<,]>V?7+.1I6IN8+<;B1&Q=>Z:1:S9U:U3Q5^:Y2=+(U\4WDZ(2>L:OH.
MB8G$T<10@I4HA%7B!#&*)=38*,FLSQW<T_'5^]AFE9ZO'Y 61\U[0S0&X![\
M#@LH)X^"R^6O8SZW%RZ3O]6;,87IU5?(\/M6(6O>/7SC5HQ>HW3O4\+A\4ZG
MC@Q\N4@C>_N))8]2CJ)CJ>,Q^FTZ4#88(\W &,:@U=K P[YO^:@R<TAH8@11
M,K EH<]XYY4RP>@P:O=R<V.ORBC-6(]B/+FA_P"6"4Y''*.P7,+TB)JROCEL
MY:6#O8.7AKG^?:M5;@TUF)_H# ;!#DHQW17.QW>9/BY68)MN,FQYO0-6N35+
M;V"1IR<$?+)7@+%T(Z(_:*,V R-K&S!CF3XZ?G]W4\CZ8<?)?-^UU-*.T9";
M:-AGNOY @Q\ ?^XM^!#$@\Z66Z<6\9NAB3=CQAHME9!9YY#P5C]-]&I9^7)9
M;*36)&5LI**D0D(:PL?W$I1HI\]@-AS^:L[-%D[,4%E\%2M78\Q,8P\<GM]Z
MEW2W+B#:LEB,?[>[$/K^-"VTP@PR#U"O&#Z(O\BI.1[HW<?H7S1TKTNE=P53
M9LG9M2SP32OK-\0]C&1%2"#TLQKNRSW,IM%S+R3OD>(HJ['^%"P>G!:NA]/L
MYF[.!VS&8Z6S/[(PG&33M(>0\>AY5'.<%%K<S(VVMBR6*V)LO+YK!<(R_E=-
MZG:UC[]S2IK4KIYK%J*K-*QW D8E$CW?#P5<?AJ1V3Y(P\ +)FAY$LH'H Y<
M?-_7,/L>"?JN=R,KI+L<<[9"\Q/8X\'S<D$WR>EX>]U@BCF$O;+1-MX#R/W0
M%:3<-DQN5W:_C\WEKE;&8\M8RO6:\F5W')+BQ)Y&;H^RX[';E7QN&RMVWBKD
M+RZ*RUW,$C!R.TN6=@M=N]1)\EGLEEK<%;VB2*C!!)V",1GCE*-GT>JY"AL&
MZ07K!GL0V8HW2N]7\ \%=8VO,G!Z]E,FU@<ZO Y[1\7*4<?Q'3C+YW$19C)[
M-D&9*U&)H_">0R'O\P.%0=DS-WI5LPN6'C)8U[ZTD[#VEQC>.'(,"_IVPOTM
MFR2;+>^5(:++# U_;&&!H/9PL[?LE-E= TN_-_5)[])[T$NI7;V(ZFVZ%F=[
MZF6I">JU[N0R6'R>UJM:[<MYWJ)G[S+$OR?C8VU(H^3V/F]7E!U.XZP*TQKA
MIE#'>&'>0[N/+E?-%['SB*:WLO4=U6_R7""M)RR/X#AJ0;BCLV8M]&<M???D
M?;@,L3+33VO(:\<%8M[7=S.GQ[/)M%QN1BJMG$#3Q$(P.>U!)<_MV;MZUJ=7
M&2>%D,Z&-\;WQ#MY>Y0/?]3V+7L-5)V&S?I37(!99/Y\/[O)S5!]20<""+^X
M:N5[[7VFYD:M:MFX<3B_#+I[/>!(7_!! <#G+F%W?"8JIN!S5.X7LF8\]QB*
MV=L[=L6_;'@:F<FIT8/"E=(SS>SYODUBHHV;9L@<ZS5V[.S&14JT9MWY./%G
M>X>C5YJVT6L-M^/PYVAF;HW^0Q_/,D,@2CZ'>OE>+.;+L6?S3'[HS$3U;;XJ
MM)P#00$@Z;ELKM=#I?D+M^6.+*PP']UA((_'X#EK-FV799H-1P6%G$>2RE1D
MTUEP_$8& ER",YV3J+J64P%278GW:5V_"PS&,!X//FPJ2[7F=Q?U"J8'"W61
M,GQQ>>]H<V/XR)HHPE[;L!OM/7\KESDJMZL^6.5[ QS7,"P,QMV;SFSY+%X_
M8:N&HT'B)\[^TR2O^@.5E&STC=,I%G;.O9G(5[[A Z>M=A(X>QOJ'<+74;W4
MC;G6\WB,I#1H1RO;4K.8'>,(_BI?<;3HE:MV*>R6+489/)EGF4?!ZD_5GC\'
MF?\ [TW]H*#G%-_5H:Y7S=>[4CACK->S'F,'F)@6ZRW4#+##ZCL50AE"S8;%
M?B+0>.X\*^=$DWW9,I1GU[&8>4-N9*V!W]H?VPM\W%=- (C')Y("@Y#G;W4C
M(;#;H8>.#'T(&C^C9V]W>3^2K&G;1LK-MLZWG;=2V\5?&AL0#](*HT6(V+J1
ML]S/4\98IP14[\L?M<C/</1@"FG37:,UFH<M3S$3!=QMOP)7L' >@Z'E?/'7
M0/['D_9*Y+T('&B-^F[.H.S(@(@(@(@(@(@(@*'=1>6Z+LC_ /L$J#\[$0=]
M^YY/&VW_ *:!_;"^QT!$!$!$!4GU08]?]]S_ %-64M=7F?$;Z_,_UGT(LL"(
M BC[BX-'<?4IP$%(AA#2T,;VGW<>2]$3 WM#0&_ #R0/#;QP  $;&QHX  'P
M"E&/)C,<9A+[+"9!Y]_8.>5D/ACD86/8' ^H(Y"F#UU>%T?ANC:6<<=O'DJ1
M#"R/PVL:& << >2HPH,5C8"_PJ4#._\ &[6 <K.$<;&AC6 -'H /)3!A#$XI
MECVB.A V7^,#!W++FKP3Q/CFC:]CAPYK@""%1K*^ PL$3HHL=69&YP<6B-O!
M(6U8QC&AK6@- X "08M['T+\/@VJK)F<\]LC0X*B'#XJ*&*&*C V*,\M:&#@
M%,%V6A1DL13OJQNFC'#)"T%S?J*KM4:%B6*22M%(^(\L>YH):?H08^1Q6/R,
M!@NU(IXC_!D:'!8<&NX.NR".+&5FLA<71@1M^:?B%,&Z16 BH(@(@(@(@L7"
M/9;'P\)W^A<AZ#NXTIW\_G0=E1 1 1 1 1 1 1!'\S%DFV\=;J4Q8\+Q0YG>
M(_QQZ@E679381Z8'GZK#$#Y3V#AQ^0?J'M#$QC<K-F;-RW2]GC]E9$P>*'DD
M/<3Z(),H=9U*.?=*>QFR>ZO3?7$/;Y'N]_*"0Y3&5,IC[5&W'WP3QECV_05"
ML7T^J5-5MZY<N2W:4A/A]XX=$WU "G@0YO2C8Q3;C!NEOY,]'0=GGV?#E2_.
M].<7DM>Q^)JRR4S0(=4G9YOC<%KNHU%#IOE9<I0N;!L<V2;2?WUX2P,8'CT)
M6YS.BRW=HJY^CEIJ4[6,CG8P<B9C3SVJ;HT-OIMGJ^8R%W [/+CX;LIDGA[
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M]E^+?@2IILO3W'9BMCA5GDH6J#.VI8A]6#X)HTM+IID9LE2N9_9+.2%1X?#
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MM8N;%KDE*G*T3LE9*UCOQ'EAY[2GJ.;SX[JCG<1/AY,3CL9 Z$L?*T\E_P!
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M*0S1S1,DC>U['#D.:>01]"#U$!$!8[[M9EF*L^9C99 2R,GYS@WUX"#(1 1
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M("("("("("("("@W5",-T#8B[WU"@_/0H@^A/N=>X[/E6_&A_P"M?8" B B
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M0$0$0"L3'<>S#X=[_P!HH,M$!$!$!$!$!$!$!$!$!$!$&FV7@:_F/YC/^P5
MNAYXZ>8_^_3_ +90=61 1 1 1 1 1 1 4"ZHNXT#8R/[$0?GN40?2'W.0_IQ
MG?YK'^VOK5 1 1 1 7A06(?WS+]35D*UKJ\_U/H11D1 1 1 1 1 1 1 1 1
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MXX/T$\GV,G^SZ4^^[!D@>T.^RD_V)@'<,"!R;3OLG_[$^^_7^WGVS_\ ,?\
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M 3%;;@,Q1GNT,A'-#"TND+?5@ Y\PK@Y]T\ZC5]@S><IS7RYYMN-&/LX'L[
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MB&3QFTQ9,G\'@GCA2E4$0:3:_+6LU_,)_P!@J"]%/_P=8D_]98_UI0=51 1
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ME<UO:QN>7T:#%Y%M3VV&Y 6ECOFF*(JRB;;SA+F:T[)8REV>TS1,:P./ \G
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MH:SL6&0F1I!<P$+Z#4!$&FW%H9J></PH3_L%03HN..G6'^N?_6N0=41 1 1
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M1/\ _!]C?[]/_K2@ZPB B B B B B B B B O \=X;R.2.>$'J("I\4$'S'
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MZ?JQ29CJ]26:'&AT++1X9])"HR^ WNWLF OWZN&J/@N-/C0R=CGCWM0?1_\
M 7#^FU"E;SVZW;<;);ORH^,]X!+8PIZ!NM+7\+K>[/PIC9>FAC-N*-_FP.('
M/:M#AJN^S:O6JU]:P3Z4E5OJ_P#&:0KS@UN1PV4QG1NUC\C)"2+\8C\*3Q U
MCY%U#;L+C*'3?+0P5(6MCQA#>&A2B*[3$R/H=&&-#>:%/]MJR]UHU9,QTV[X
M(W%USM<2T'D"-(,[*1MCZO:\V-@:&X6?@+6]*,5CLC6V+)W:\<]Z?*V(YG2
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M(Y6?C,>ST*#0G19)H-6;;RTT\V(L&;QG@<S?05N]MUB'8ZM"%]A\/LUV*SR
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MQRE1U#/[?++4#>UD<+.TO_NRKM&^L]-G6=&H:[)DB)J3P^"TUO'#FDD*_G-
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M)'13PGS[)6>H3;]AFP.,\>O1DMV)96Q00L][W_'X!*(CBMQVNIFL9CMEQ$$
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M#PE@D2* B B B B B B B B B B B B B B B B B B B B B B B B B B
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MQO/H7P!?3* B B B O"@L0_OF7ZFK(5K75YGQ/H11D1 1 1 1 1 1 1 1 1
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M^<!&[QU(X)/3Y_\ G34_$/O\ZBL?Q^#V7GZ++4&_=01Z].Y_\Y";T?R*?O\
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M':QC7@  +#N;1TRNM<RUDL3,'N#G!Y:[DIV]0SX-VT2"%L4.<QT<;?)K&R-
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M[ )WWV@H.D]3P/+J ?L ATSJE[M^'V 3OOM ^\SJG[M_'^;!/O1ZL#TWN/\
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MZ2\?@_P']X=^V4$XOWJ]"NZ>=Q# 0/(%Q)<>  !YDE:YF?J.:"*U[_-I ?\
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M_EO8"5N:E.M3@C@KPLBB8.&,8   IVP9+FAP((Y!46^\K5!;]K&$IB;GGO\
M#"8-]<Q]2Y"(;->.6,.:X,>T.'+3R"LM46+-6O:A?#8A;+&\$.8\ @J'P=-]
M(@FCFCP%3O8>6GM03":K!- ^"2)CXG-[7,(!:1\.%@U,'B*5)U&M0@BK.Y[H
M6L 8>?7D(-/0T+4,=;%NIA:L<X/(>&\D*19/&8[(UW5;=6.>%WXS'CN!0:;#
M:AKF#DDEQF+@KR/'#GL'F0MK4QM&F^R^M5CB=/)XDQ8..]_Q*#19:M'A,?E\
MAB,0)+\S>>R)O#I9/0%RL:)KLF P$->P0ZW,]T]M_P 9I3R4$S1 1 1 1 1
M1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
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M2O?1??\ L!=X0$0$0$0%X4%F+]\R_4U7U:O5Z?$^A%$$0$0$0$0 B B B B
MB B B B B B B B B B"!]6CSH&?_FP_;"S]"_K-U[^81():B B B B B B
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ME8.2RE'&57VKMAL,+2 7N^+CP J,T.:0""O>5 6HRN<Q^*?2;<E+/:K#8(N
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M<KUCG&;]M.):.()V17HA\'/\GKJB@(@(@YMU?_\ P>YW^XC_ -8%)-,Y^]3
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M\83Q;YQC(XWUF3DMEC#@2KS@FO1G 4\?JE:]$^4S7&DR=SR6CM>5B]9]<I9
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M6MABBE='6\IH#\V1C@>"TI@BTO6".$5[;]>OMQ4T@8+SN U=DA>U[&O:>0X
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M7YGQ/H199$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0<TZUL Z=Y;ZX?\
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M1-!$T$3014$0$4@>?**@B B B B B B B B B B B B B B B B B B B B
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M("("("("("("("^9?NCGGV37&_&6=!\J(@^Y^A\?;T^QY^,T_P"VNO)01 1
M1 7A08T')MS_ %-64M=7F?$:Z_,^)]"++(B B B B B B B B B B B B B
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M)W4>-TCJ3QP=^?\ 8!#I74_W;YY?3 %= Z;U3 <?OY;]', 3[S^JO'(WAGV
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MICJNRT=CP53)52.)6_/;ZECQZM*8(WK&TY'*;3N&-F;'X.,EB; 6C@GO!]5
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M;9XJD0DBR\L43NT<L9\ E$(&3NX[0ML-20Q2S["^ RCU:)'@%3^;I#J(UET
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MWR"("("("I<@LPC^B9?J:LA6^GQ&NKS/B?0BC(B B B B B B B B B B B
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MI6:LDP+O+B,GE3C<\+D<QK]FGCKKZMH=KXI&DM^<SSX*#D.3PW4?::M?%9;
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MUWJ"%-<%E8,QB:.1KG]SLPMD;]'(]$&U1 1 1 1 1 1 1 1 1 1 1 1 1 1
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M6WD"-CV\DL"WNG8O8:.]WIK=3'48K%+F6K6F[N]X=Y2=BHZ?LV%ASN"R.,F
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MYI6/&0NB:,#W-# W@I<$)M8#J/CK&1@Q=VA=HV9G21B[RY\/?ZA3;1M9?K>
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M@+>0X<?%.12)XB_L#VEW'/;R.5<)04":-QX#FD_ %5.D:!YD )@]:X'S"$H
M>WGCE \?% +VCU*<A Y1 1 1 1!Q+KKR,%@_\+PKML?XC?J" B B B B B B
M B OE'[HX/\ ;]=^'@3H/FE$'WUTCY.@8'DD_N+OVRNE<\("("("("\*"S 3
M[5-]35?5K75YGQ/H11D1 1 1 1 1 1 1 1 1 1 1 0H"("("("("("(.,=<O
M+6<9].5@79H?ZC'_ '(0>H@(@(@(@(@(@BV\6\I1U;+6<:PFVR F( <E?+N1
M=J66UJ;V9V:RF:,/<_O,I$3O4EP]$GS@ZKLU^#&XSIUEIVR>R596&=X:3V!T
M/:NVU+=>Y5ALP/[XI6!['>G+7#D(/G"UA;N6PO4V"O"]\HS8F:ST+Q%PX@+1
MV[G2N7"-,+\M->>SL^3_ !Y^\R? J^GG!+]RO2XMFGXVU:N8C#NJD3RPDOD;
M(UH B+U&M>?@8.I6M3X5V0LU96V(GW+1>0^0L/ 87J[,%W8I^GV1RV5DR;[F
MOYJ"5P+XBX^+V^CQVC@\K=WK68GZ+239/QI91*PA[QP]\+9QVN<@[GA,QCLS
MC8+M"PV:![?)X^(]0N*;UFY#N?R9E-AM8?%MJ-DB?""#.\^H[PI/(U?3-^+'
M4*^<?->FKRXT=D]OGOF+7>;AW+L748]NC9\_]D<E\B([M#&.EE=G  $5+]IJ
MSNHX:,/KH ],O261%]USD_WZC%Y#8IL+CF5&R1RQ#AT[CZCO6DT5^*^_O,G'
M7;MN"3$'LLVB2Z8@^9:7+>"^*UG\%FN7HH72MH9!MJ:(#DF-DIY6XWO=-?V+
M7Z^(Q%D7+F1GA#(XP2Z,!X)<Y3)>?8;VI"T=6"".3%@& '_+69&0>K%CZ,"W
M_P Y$X&DZ=RXO)8?9-?G>#.+]T3P'\;LE?ZJ$:4,AF<[A-9NQGPM8FGDG)])
M"#VPI[CZAX':N&Z3L6&UW(;3A\Q:CJ6VY.>SWR_-$L4GF""H*M)G9D!U!S5>
M(MHW9C[,[CCO$49#GJ;=,6C[P]>_F@0:+J/;JTLUH]BS*(X694][W'@#EBJK
M>S6NJSYV.9(!@6.8\'D<&1!@9*LZ;J%G88!Q+-K? ^EQ<0N;:HRH-;:+/4.Y
MCGU0Z.>D2QOA$'T *W!V#I1!CX=6!H3VIJ\EF5['V&AKG)U3HS#"U<W7_?.)
MLLLM^EGH\+'J(WI9?MEW9]G:T@3PFG0Y]S&-5[I[M.N8O3&4[UR"M/0\6.W#
M(X!_>"5=$0[.SI!9MF(QUY<L+$3#_ A-A3_.VJUS<^GDU:5DL3C<+7M/(_J0
M5%S0(HOOCWV7M'><OP3] 8H-?HV;F"ZFQUHC(]N;;(Z,>KV1EKG!3@;;?-UT
MZ[TXM1UK<$K[,#&05@1WM>NQZXT# XGZ*4'[ 0<IAR>)H]9<LR[(R.6?%P,K
M/>>!SZD*T]T>9ZA9ZSAWAS*V"?7GEC]'SO\ -K4P9O3O/ZU4Z=UFS6((?9(7
MLMQ/(!#P3SR% :E*6#IKB\_!&\?)^7DNUV?"!TO!">!C22DU)>HT;'EXSG<W
MZ:8_<>%LK^/R,_2G-YAP(LY2Z+LOT0B0<)HV&:IY*;4W2WNHM0XZ6 #]YQ'N
M'P :MV^G"[8.F4+IC8;%4G<V1S>PN[8APX@I9U#M?B1M<UI< 7>0!/JJRH./
M]-[5"";::UF6-E]F5F?8#SP2PGEKE">^M+KO52WCW<T)9^(2/0O '>0M#O.L
M5(JNO8F&-@#65(AP/[E1;J50PMZACZM[*>P676FNH6.#PV=JQZB#8FYMN$W3
M"4\^_'Y(6Q)#7N1M GC''<I1H=VM7SN\U)9 R9N6=,6N/!['M'#EK! )K#[^
MD=3K6/<7"7+2'D>^,%O<NH3V=)9HD,UEM9^'%5A[. 0>/</I3*--4AH7>J52
MRR+EC-<8^ %O':'/6XH00P=3LMX; WQ<- ^3C^$X2$<J<RBCJVR=VB9/PP\M
M#H3,&^^(2 N6BZAV-8_!E.6& P/K,]C#>/-WN[59!BY*I!<S72R&9C7,%=[^
M/I9""L?>&9C\(>O08_V%I]@F-<6F\Q=_/SN /X22"AV-V<;KK5G+Y'"0SM>\
M,9 '-ED80>YB4[V8OYW8W:O@\=$P6BRW=MO),DC/@U:&ITR%XU'J&R=T$CA8
MG[C"/W,N[/5B;&RR-"T*&JVN(Y9ZXD$OE"7=OD)$&3M6%W6>G3&0EUZK%#9A
M=%987,<QW/D&J3,QU:[U8<^U$R4U\)&6]PY'<YREVP=A9$V-@:UH#0.  N)Z
M;2PT_4+>9IV1/N,M,#.X EL9"S(,2&M5J9GJ=%0 %7Y.8Z1K?Q&SF-W<LO&X
MR#%]'W3T(&BR<.^0R!H[RY[4L&VQ&"U(]-H6N@KFH_'"264@<]W;R7$_%<Y,
M4&0P722++O#H9++P_O\ 1P ^8"KR)UU!Q>-JY'4+M*"./(-RT$478."Z(_C!
M7=7J4K^\[K9OQ,EMP6(8862 .,<'9R"U7-@C[Z]6AF^I-/'!K*AP[998V?BL
MG+"M_K>KX.'IM4)QM=\CL6Z1TCHP7%SVDK-@BEFK4AZ*XLPQ,89#3<\@ =Q\
M92BS2IY;JBR#)1,EBJ8ADE2*3S87//#G<*YP,>3&T,1U7Q0QC&PBYCYS;BC'
M /9Z.(5GIMJ&O7<3F+ENA#9EL9"TQSI&AW#6O023H["V+6)86<^%#D+;&?0T
M/6NZFUHLAF=-QEMW%&SD'^.WW/[&\AI4&MWO 8C"W=9RF*@CJWFY*"!@B'8)
M(W>1:0LR/!XF;JU<>_'P.(Q$<WFP']T+_P =71U7.4ZUO$W:\T+98GPO[PX<
MM/DOG>/%T*_0VW-!6BCEL0CQ9 /-_$Z0;?<]$U_#]._:*=.-ENF()F60/W0O
M[PK&W/O97?:%-^!.6@JXMDS*IF$4??(?.0]R#-UK'YRMO-.U!J0PU.6"6*XT
M3L<R3@<L<&M7:<KC*^5Q=VA8;S%8@?&[_*"FZ.#_ 'S76]/'8 /YS(N?(X'^
M/@/_ %%M+.M8Z[M^"UFV.[&XW#B:.OSP)I.>WERL%<N#QNL=0\%7Q3!%7RT%
MF.W4'XA$;>0Y8>FZ[AJL&^68*43)X+EN")_Y$?9^*$&BMXUN4UCI51D>\1SS
M\/X/!X[5)<SJ>#UG;=+GPU3V5TUQ\,O8X\/9V)M#"ZKC=IV?:[V=9[5[/<-6
M"%Y/;&P!5=+L37Q&W;K0K3.D@@? V/EW/:.">U!)NLC2=&M-:_M+YX!S\.7A
M0O:>G6!PFI/R^.[X<C28R=MKO/+WA):,W)4X]PW#$XS*/>:<&(9<?5[BT22R
M*FUK%+";?!AL=S%C\WC[+)ZO)+6O8/)X2VB*/OWLEH.*U&*;MOR9&2C)\0RN
M2];&ADY]AP>DZV7N\8VGB_\ $1T2KGN-5D;-+/[3G7YK$9C(04[1KUH:K3X,
M;6?'@CYRD&JSY"MA]VH,IY*#&QT7RT?;&D/87,/>P%.!)NF.E8VMB<-GI3--
MDI:@+IGR./D\>BEV^M[M5R3'988YA8 ^R03VLY\P/I*@^<,I/J=*/&W-7@S,
M=J&W#W77B012![@"'EZGG4JE89LM3(Y>E?O8,5.WPJCR/"E][G@)ME@E'2&U
MAI,?DXL;F)[4#;/<R"<$25FG^"LOJ\;@U:$59G12RY"LQCVG@@EZ@@.T:1;P
M5[79L7G+[+M^X*UF=\I<7]X\W*38[6QJF]8:*G?N2PY"M8$[)Y3)RZ(=P>KM
M$<VYFN_?'DCL>S6Y22WV6A3,G,3./X08KVF&]GM*VNA5R%TB"PX4'S$B=@:.
M\ J\X,_,;=:S&CX"M3F?'D<K/'5<6GA[#&?W4KNM.$05H80XGL8UO)/)/ X4
MHN(H"("(.)=<P/D3 _3F(5VUGXH^I 1 1 1 1 1 1 1 7R5]T9W?+&!^'LLB
M#YO1!^@G2IH;H.O?35704!$!$!$!>%!9A']$R_4U7U:UU>9\3Z$49$0$0$0$
M0$0$0$0$0$0$0$0$0$0$0$0$0$0$0<9ZZ?UN8H#\ZP+LT/\ 4F?W(0$0$0$0
M$0$0$0" 1P5CQ5*L/=X4,;.[U[6@<J"Y+7AEC,<D;7L/JUP!"K;&UH#0. !P
M $%+86-)(:!R>3Q[RL/Y+QWC^/['!XO\9V#N_2I9N"]9IUK4?AV(&2LYY[7M
M#@JF58&!H9"QH;^+P ./J3(,>?$8VS,V:>E!)(WT>]C7$++D@C?$8WL:YA'!
M:1R.$SR+=6I6J0MAKPLBB;Z,8 T!6+V(QEY\9M5(9S'YL,C0[M/T<J^@R658
M(RTLB8"!P" !P%7-#'+&Z.1C7L<.'-(Y!"2"U)5KRP^#)"Q\?E\QPY'EZ*N2
MO#*&B2-KNUP<T$<\$>\*C"R&%P^3#!?HPV/#/+!(P.X/T<K2[/2R<>%G& I5
M77O#\.(/X8&L=Y'@I!=T_!OPVM8S&3$.DAAXE/N+CYE;&G@,-1GDGJXZM#+(
M>7O9&&N*EW1G^RUA8-@0L\8L[#)P.[M]>.?@O?9:_CF<1,\4M[/$X'=V^O'*
MHCV3QOR?%DLGA\56?E)(O> PS$?P7.6@T'7,ECCE\IEV1#)92QXLS(SRV-H\
MFL4'1EH,OJNOYE['Y+&5[#F^CGM!*M&UKT:E:JRK! QD+&=C8VCAH;\.%=J5
M:]2"."")L<3!PQC1P&CX !(,#+8/%YJJ:N1IQ6(>X'M>.1R%=JXK'U"QU>I%
M&60MB:YK0"(V^C>?@@O.QU%MXW&P,]H,8C,O'SBT'GCE1G)Z!J.4MFW=PM:6
M<GDO(X)6>1*H*T-:&.&&-K(V- :QHX  7MNI!9KR03L;)'(TM>P^8(/N*T,;
M'XVCC:K*M.M'!"W\6-@[0%H,CHFI92\+US#5I;'/)>0@WUK&4;5%]&>M&^L]
MG8Z(@=O:M?C]7P&.CHLJX^&,5._V?@><?B?C<?6I-&RK8RE3ELR5Z[(WV)/$
MF<T<=[^..2M#EL38JXS+.P$<$&0L.,W<YO+9)?[?ZU1P:[@]ESL4M-G3RGCK
M5KB.SD.YG:T<^;F!?35&NVK4KUV_BQ1-8/J:.$W1R^QI$&9W;8+.8Q;9J$M.
MHRN]Q]7LY[N%/\+K^)P=-M/&5&00@D]K?>3[R4$;N],=)O9-V0GQ$;IW/[W^
M9#7.^):%+Y<71FH/H/@8:SHO",7HWLXXX4Y&#][&#^1/D7V"(4.SL]G_ (/!
M/*V#,=39292$#?9VQB,1_P 'L XX5$('2;0V7A;;AX^\.[@SN=X?/T,4PGPF
M-EOT;TE<&Q4:]L#OR \<%3D:;-X*?(9S7;D98UE&>620DGN(<SM "EH3T$%V
M+ISJFQ6VV[](F<#@R1O+"X?!W"W$>J8&/!286.BQE%[.UT3?($)R)!6KQ5X8
MXHV]L<;0UH^ "U6Q:]B=AHOHY&N)8"0>.2""/>"$$9UGIQK&N6C;IP2/L\<"
M:5Y>YH^ 3/\ 3;5,]DAD+E1_CG@/<R1S.\#W/X3D;[$ZOA,/5M5:-)D4%B1S
MY8_5I+AP?(J&0=']+@R++;:TI8R0R-JND+H [^Y*"=LP6.9FG9=K#[4ZL*_=
MR>/#!YXX5[Y'H,R\F38QWM+Z[8'.Y\NQI[@.%1C;2+T.OWY*=&.Y.(_*L_TD
M'O:OE6;%:[FH#0PFFY2')S.#7"<O\"KR?G$<JP?4 UG&OL82W(UQGQL)9 0>
M  YG8>5;V?4<1LU6."^Q_,;N^*6-W8^-WT%9&@UKIIA,#DCDO'LV[G!:R:P_
MO+ L7)])M=O9F?(B>Y![0[FQ!#*61RE6"18;2<!A8,E7I5RR"[_58BXEOIV^
M2U='IO@JN#O8622S9I3O[@R9_=X7P[$T:O&]),)4R$%JS?OWA 08(;,O>R,A
M3F/7J,6?FS0,GM,E5L!'/S>QIY31OG>B^?J>@19[8]OO23WJ-EF2[8)XB8R8
MRQ!U+&:9A\9@;6(KAXCL,>)Y2>99"\<%SBMUB\15QV(JXR,%\$, B'?YDM X
M\U!R]_1K$F5\+,MD&8UTO>['B3]R3?M;I9'+Z+B#5?[$)K#7^&"!&UL7DM:-
M_@^F^.QN3@R5K(7LA9@Y%9UF3O$(^A5[/T^IYF^,E5R%O'7_  ^QUBN[CO;\
M'!07<+H&)Q.#R>.CEFD??8\6K3SS*\N'"E6+PL%3"U\6'N?##6$'<[U+0./-
M!SZGTOJU<+<PYS%R2G)9BEAC=QQ!X;^_M:M[M.D4]@EJ6F7+%*]5!$-J \/
M*46-5T2M@K,]^Q?L9#(S,['VYSR0SX-"WNLZ]#@,;+2BG?*U]B68N< #S*[N
M0-7UZ'7Z$M.&9\C7V99B7?&5W<L?;M3H;/CA4LO?&^.02031GA\;Q[PI1%\+
MTYG@RU7)9K/6LK+4_>@E\FQJ7C7(8]IFS@G<7OI-K&/W -/=RJ)#*QKV.8X<
MAP(/U%<FK=,[46 RV"ES\LE&=[36C,8_< ']Z":;)KC,[KL^'=8,+9&L'B <
MD=A!6EVC2I<M/C[^/RDN/R--A9%88T$.8?5KPFC#US1,C3S?RUG<[+DKK&.9
M!Y=D<37?!JZ:/1-M'-OP=4#O8VCQSSV<FOQY>-V]GB++V_3K&:GH9#&Y%U#)
MT^X0V0WN!8_U8X)HP=9T?(5,T<[GLN<ADA$8XB&=D<33Z]@5JGHV6HY_/V*^
M68,;DQ(Z2L8^7"5[>.04T7X-%FBJZ;";P)PLG<X]G]5^;PM]G===ELK@+HL"
M,8ZTZ8M+>>_EO:@Y1G[.+9M>6^3ML?@+WS1<CFC!BG 'E(SN69T8HMBL;/>@
MMS68)[3&QVI!P9RP'O>KZ"4]98@_29HN2/%M0,)^MX6@9T^VR^:F-RVQB?"0
M%KO"#.V:4-]&O*F]68)#MNF9*YDL?F,#D&T\C5B,7+F]S)(_R7!-:T_-1YAV
M>V+),MY#P?"A9$WLBA8?4!/2"S5Z=LK]09]E%H>"]A+:_'I*YO:7*[K/3^+!
M[9GLWXK7-N']PC_B@X\O31A935MNQN>O9/5[M1L=XAUJM9!+!(!QWMX61A]/
MV*/$["<MF/:\ADX'1^\0Q#M( :%=$VUG'3XK 8O'S/:Z2M69&XM]"6A:/J!J
M]K9L ^I5G$5B*>.>$N_$+X_0.4'-\OI?4O9L2*N2R6.JB)[',@@8>)',/J\J
M6Y_#;U!EH,C@KL$S'UVQ6:5DGPN6C\=B;!D:)J&2Q%[,9;*2UO;<@6=\==O;
M$P,6YW3 V\YCJE>L]C7Q7Z\Y+_3MB?R4%.TX&[E;NN35RP-I9$3R]QX/:&D>
M2NY7"W+6T8#)QEG@TV6!*">'?NK>!P@YRW6-ZP>P9>7#UL;:@R-@RBS9_JD)
M*D?3W5L[KLVP/RMF";VRR)FR,00?2];BFZF9RU!-XN.QLSS!^0R><<N 7T4$
M!$!$!$'$^N31\C:]_AB%=L;^*$!$!$!$!$!$!$!$!?)?W1C.,M@'?&K*@^;C
MPB#]!^EK7,T+7@\DGV13Y 1 1 1 7A06H7$69N/@U7E:UU>9\3Z$49$0$0$0
M$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0<6ZY_\08;_  M NT1?U*/^Y"#U$!$!
M$!$!$!$$8W7-6,%K>1R5=C7RP1@L:[TY+@%LJF6J3^!$ZS#[2^)KS%WCO\Q\
M%<X&SDGCC87.<&M'J2> %15N5K,?B03,D:?1S'!P_2%!=) "QQ;K>(V,3,+W
M#N:T.!)'Q 05.MP"5L;I6!Y]&%PY/^)7G/ !)/ 3!999AD:"R5C@?>""KH>"
M[CD<\(/'R =P;QW<<\+58:UDYJ#)<G!#!8+W@LB?WM !X'FF4;1L\;Q\QX(]
M_!Y1LT;^0U[3QZ\'E,'KY&M')< /B5%(=DDDV^;!BN.QE%ECQN?,ESN.%<&]
MR4UR"C9EIUQ/8;&3%$7=H>[W#E7:DL[ZL#[,8CE=&TR1@\AKN/,<J#(;(P^A
M!5;W<-Y00./=ZUG5LMGJU9QCIF<!CB!W^">%*L1D!?QM&YV]GCUV2]GP[QSP
MF<#8]P0$*#U"]O/JJ'<$[@H!<$Y" ' H@=P"L6K$<$$T[SPR-A>X_0T<JP0G
M3MON[/XM@8.:K0(YK69)&GQO/CT"GJ6!W!.5,!><A,#D+3T\[0MY3)8V%Y=/
M1$7C^7D#*.X %6#<=R]01VSL-:OL=#"NB>9K5>69CQ^*!%Z@J1<A*'(0$('<
MK4\HCBDE<#PQA<>/@%/4:36=AI[%BH,E5CD9%(YP >.#RT\*0=R4.X("@ A"
M4#D)R"@(2@=R<A.05/#>?)!5R$04O>UC'./H 25@8K*TLM1BN5'/,,A/:7-+
M#\T\'R*#8\H2 4Y!%0*>2@<A$#D)Y%4$0$0$0$08,^5H5K=6K-98R>QW"&,G
MS?VCD\+.0$0$0$0$08]RY5HP/L6IXX8F\=TCW!K1R>!R2LAI:YH<#R#Z("(!
M/'FK,%JO8C\2&5DC>2.YA#AR/J01[-8'5LI:K#*4:DUC@B(2@%Q \R M]4J5
MJD$<%:%D43!PUC &M ^@!3!5?H5+M?P+=>.6,N#NQXY +?,*^  %0/ X5KQH
MC(8A(WOXY[>?/CX\(+J* B BH(@)R.>$!/) 6/DL95OXZU4M-[HIXRQS>2/(
MH-5K>MXG7* I8V#PH>XN/)+B2?>25O4!$!$!$'$>N/ QFM_X9A7;F_BA 1 1
M 1 1 1 1 1 7RA]T=P,EKWQ\"9!\TE$'Z$=+/ZP]>^FH%/4!$!$!$!>%!9B_
M?,OU-5]6KU>GQ/H11!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$'&.N+1\
MB8/_  O NSQ_B-^H("("("("("("((#U9:T:!G03Y^ /V@N=W>FF%K:7\JP3
MS,RT-/VH7_$/<9 .Y6:-)LV=NY^?4L?=H7[=6;&-N6JE3R?,];33H[.+W6HW
M$:[F,=CK4<C;D4[?W(. Y8\)LP=\ON_H"V?A"_\ 97SQI&L8[%Z1]^,S9)\G
M#5GF@<]Y(C#06M "DT1O%U,3D,(+V3UG8KF4LM,IR+&GR?Z@Q\'T"EL^0V3.
M:YI>"R,UBE/E+4T-R0CLE=%!_P"]:#:=&QVLY74I\1)-#!)EX(YX#(2QY]SU
M.ZCB>K&2')X&#B_UBG(MQ2A_53+@/_%P4?</@2]<VM,L3](\?'%8D9++F.QL
MC20?G3D*C;[5BZ6BZ_0QV+=<8<I;9'<FB)DG>T#EW9\"5%9'TL%;QUW5\/L-
M>RV=C9V3Q/,<[#Y.[^25)<$ZMXAV\[OEJF0LV&8W&11,%9CRSODE'=RY4:-K
MTN ZD9N@;DUB)N-C= Z5_<YL9=^*FVCIN_\ ='IF>>U[F/%*0@CU"Y7LU3(9
M0]-Z%;(3UC8A?XLD;R#V",$I!FQ:U#J74'7&8N>R*V1BG98A?*Z0%T;>0[S7
M9<G1BOT+-24O#)HG,<6$M=P1[B%+;1\X:QKM"CTTVR_&Z=TKX[L)#I#V]L;T
ML:)<IZ S8G9V_P#*D%)D[")2&,8 .(P%=N#<;OM!M3:OC+5J[!4LT1;NOIL<
MZ5_P8.Q6-2S=7&;?CL?A)LM-C;P>V>&[%)^X/:WEKF.>G&#OF4O"AC+MQPY$
M$$DI'Q[&\KA&%TC+[9@6Y_(;'>CR=MOBU3%(6Q0#^".T)MD$CVF+)U<!@X,[
MMK*$3&\9">'ELM@@>0C4*TO-XRIOV.H8'+Y*W0N03"9EOOX#V#N#F=Z31KLO
M>C=M&9CV?8,SBK LD8^2+N;6;%[CY*;;7M-_#Z5@81G63S7WB%^3A87?,][V
M )MH@+=AQVMW<;;P.Q9>Z\S-9;J6XI2R5CO4CN X*^KF/[F!WQ'*4<,JXO,;
MWE<W;GSMZE1J6WUJL%9W9YQ^KW*BG\LW]:W'6\MDYW6,9SV6V'A\D1;WM[DV
M\P2?I)A/DW4J$_MUF;VJ!C_#D?RR/Z&*[U(?D!!C@S8HL11,I]LG[NV4CW-C
M4FCFVFYNM6Z@T,=A]HNY.A:@E\=MGN(8]OP)7T/EJDES&W*\4SX9)87M9(P\
M.:XCR(5OD<CPV[VZ?36_<OREV2QQEJ2=WFYTX/:Q:Z[+MTD6IZI6RTT-VY4=
M:R%TGND8SX!!FUJV?TW;\)2=FK5_%Y4OA(LGO?%,UO<""M/J^$LXS>=WORYN
MZ^/'&.61A(XG#H2_B3^Y3? C3-K;DZ+LM/U&DIY*3E[*3 1!#\(R%WO0-E?L
MVK4<E*QK9G=T<H'IWQG@D)9P.?=0*V:M]0-9K8BU[-/-1LM?/QR8X^1W$+)H
M'9=3VK%XJ[F9LEC<IWQPRS?U6&5@Y31G:YM5G'8W:JN9LF6SA9I"9'^KX7CO
MC*DG3J7,6=5IW,K9?+9METY[OX#'GEK4HT>ZY79)\_B-<P5ME26S%)/8LEH<
M8XF? %6,5BMZPU^]!>RORGBI*<CA/+P)8Y %-O$$<U>?/P]*,><++!%8?,\/
MGE(#86&0]S_G+2-V3*839,%%!O;,RVW:9#:K$-/;W^\=JT-AM^R9=VZVL58V
MHX&I%$QU4B+D3DCU+U*),[N..Z=Y&_--5N7X ?!L0$/:^/GCQ" IHCFEY?9;
M61QDM3=:N8AE=_1M65K8GQ#XL69L^Y7;VUW,)6V6MA*M(,\:P_M,DKW>YG<E
M\C,T[=,F^UFL/8R,&9FJU#9JVH. 9A^0X-4(P6S[OEP+]/<*3\@9>'869C8@
M!SP6@N5\#Z@87&-A> '%H[N/BN0[%F-MS.WR:W@+C*$52!DURX6"1P[_ $:
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MW8RZQI ^,?FN@G)G+97IM?=7\$SQV'^%^3S$@=.+-"G<VRI<?%%?&5EDF[R
MYT;O-KE$":\V#ZJ6J!'L$DO$7'XI>&_/+4]=$UV;'THND=F"*%K8V8N-S0M3
MG<=CLG/JK*N=.,SL>.#JDA9W,D80.6GE/(R]&RF=@VW)8?-U:#[IJLG==K
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MMMEN2E ZPT<"8L!>/\:#*]BK>$Z+P(_#)Y+.T=I/KSPO37@\9LQC9X@;VA_
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M[<3),W0+^#VP3$#EWKRWX>2#;^SQ?D!#7B_(":*35@_BPGLD'']3'*:'L<'
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MM&QO576G- #G8JYR?J(6KZ6.H,&UMG+!?&7L&UW\=W9S\U!%]EM:?-7PWR;
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M@(@(@(@(?1!HZC0,UDG >9B@!/:WZ??ZK>(.&];>.S3_ /#4:[D/1 1 1 1
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MM;;(:7N/$K/0K-V/3<!LL<3,K2$WA'ECP2Q[?\806:FCZQ4PMC#P8YC:<_\
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MKFL?2W.S1P8W([9/9PT3@14[ '/#?1KGH.@SZO&_8L+E8YO#;CZTL+80/42
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MR2\C]S\RYS$$Z6GL<MSM1O/_ #6;RX=\6_XD&X1 1 1 1 1 1 1 1 1 1 1
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M0$0$0$*#1TQ_3C)GCCED/![6CGR/O'F5O$'#>M!_=M*^G-1KN05]("* B B
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MZ1=/SZX.'_$YZ9_(LGI#T^[N?D1GZ[UC/Z.=/)2'#$\?5*]3!5^!KI]^:/\
M]:]!T9Z??FD_:O5S^1:=T:Z>CDG&'[5ZIAZ.=.23QCB__OGI@]?T6Z?$\C'/
M^U>JQT7Z>#TQ3_MGIE]Q3^!;I]PW^E;_ +9Z?@6Z??FQ_P!L],ON*!T2T $G
MY/E^V>GX$= [23CY?MGIR/#T1Z?_ -@3?;/5'X#]!_L.?[9R >B&@\<"G/\
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M-,K TN+@&@<\K"KY;&67^'!>@E?^2Q[7%!L%:GLP0-+Y96L;\7$ (*8;,$[
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M;XYC&'@")S_(I)S@W^N[%B]BQ[+^-F,D#G.:'%I;YM^@K=J6901 1 1 1 1
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M.XO?W!Q)4LSV!?E=7N89DP89JO@B0CD!!&-AT";*ZMA<7#DC7MXTPO@L!O\
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MK(OTZ-2E$(:U>.&,<D,8T-'Z LE 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
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MH'<6\.8>1Z(-L&   >X(T('"("<("<('"<('"(' 3@("<! X3A X"<! 3M"
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M0^Z+_&MM=V7!XZ>2M;R,$,K(?&>U[N"(_3N06-?W+6L[+*S&9**P^,<N:WU
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M**[CL8UK 6\K[/X_@E@\/GMY[W!J"159C-6@F+>WOC:[CX=PY60'#A Y1 1
M1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1!Q#J\.S8>GP/YU_\
MVL7;P@(@(@(@(@(@(@(@+XLZ_1/9NL3R?)]&)!PTH@_2#2W!VIX!P/KCX/V
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M9CLVV0SUWGNX!3G!]%/QF2=L$5\91[:C:QC=2[1VN>?1_*D 601 1 1 1 1
M1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1!PWJWR-DZ>#W_ "H?]+%W) 1
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M>1<H#F+6&ORX237=/L5:=7)0OFMF$AQ\_10?4(V*!FPQ8?V:?Q7U3.)NW]S
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MT':7B'#DOM_YQ(J3IF-+0T6+S1\!9>FT#IF-<?WU?'KZ67JG[R\?QQ[9D/\
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M5K_!X_J?[84PI-;[- 3[HV^7^)!6B B B B B B B B B B B B B B B B
MB B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
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M0$0$0$0$0$0$0</ZJ$??ITXX_L]_^EB[@@(@(@(@(@(@AV^Q^)K=IG'JZ/\
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M:")H(F@B B B BH(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(5!!@">H+O\$_\
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M_P!B\.\:^"1[1+Y>O[B],!V]:XW@&X[[)_\ L1V]:V#PZZ?LWI@.WO6&D@Y
M<C^T>JQN^M<?O\?J/3M#[^-8Y(^4V<CU^:Y!N^L'_P#&<?TCAR=HTV+R5/)[
MM//2E\6)F-#"\<\!W>NBJ B B B B#AO4[RZA=-P/[+?^TQ=R3V!$!$!$!$!
M$!$!$!?$/7?^OV7^9P(.,(@_2G7'<Z_AR&@<TH/V MX@(@(@(@*ER"Q#^^9O
MJ:LE6^GQ&NKS/B?0BC(B B B B B B B B B B B B B B B B B B#B?4D\
M[_TY_G<J[8@(@(@(@(@(@*B>>*%CGR/:QC?5SCP @KC>U[0YI!!'((1 5J2Q
M"Q[&O>UI>>&@D D_0@NH@*S[3!V.D\1G8/5W(X""ZUP< 000O4%(>.2$;*Q_
M(:X'@\'@\J"I%01 1!1)-'&.7O#1])X5;7M<T$'D)@MR311_CR-'UD!7 >4!
M$!$!$ D!.0@(@(@*F>5D,;Y'N#6,:7./P 01=FXXF1@?&RV]A'(<*\A!50V_
M%%KCV6_(_P!C2?[%< ;=BB >RW_CK2?[%Y]^.'Y  M?YM)_L4P5#<\,/?9]>
M"?9Y/]BH.Z8)OD9)_L)/]B8#=RP3F!XEGX_O$G^Q5??C@PWDS2_82?[%<#[\
M<%W!HGEYX'K#)_L7C-TP#G "Q)]C)_L3!5]^. \N;3OLI/\ 8KAV[!]P!M.Y
MX_BW_P"Q,%H;IKI<&BX?LGJX-NP)/[[/V;_]BF"C[\]=) ]N\S_:/53=OUYS
MNT7V\_#M<G:/1N&O'TOM_5<GWWZYSQ\H,Y^IR8/!N&N'TR4?Z"@W#7">!DHO
M_-,'IV[70X-.2BY*]^^W7/SG"F =NUOR'RI!^E&[?K1/ RL!/UIVT>C;-<(!
M&5K_ *RJ9M6NR<=N5K'GCCYX3LH].SZ^ TG*5@#P >\(-IUUW/&6JGC^W"=E
M!NTZZ?3*U?3G^J!5??-KQ/ RM;]<)V4/ODP//'RI5^T".V; -')RE7[0)V4>
M_?+K_'/RK5^T"N#8,&1R,G6X_OC4[*/?E[#?G&M]HU&Y_".'EDZI_P"\:G;1
M5\MX<^F1K?:-3Y<PX(!R-;[1J=M%7RSBO+^CZ_G_ -8U/EG$\@>WU_M&I@#,
MX@^F0K?:-50RV+(/%ZN?^\:F#UN6Q;QR+T'VC54,GC^.1<@_7:F#T9+'GCBY
M">?3YX7HOT3Z6H?UPF#T7J/NM0_KA/;J9(XL1?KA,%7M=3^/C_6"]%NK_'Q_
MK!,#VJK_ !S/U@GM5;T\9GZP3!5[17_CF?K!/'@/I*W](3![XT)_AM_2%Z)8
MC_#;^E7 $L9_A#]*][V?E!,#O9\0G>SXH'<WXH',/O4'O<U.6I@<M3EJ!R$Y
M"!Y+WR0/)>?-0>]@^ 7IC;\ @=@^"\\-I]P0.QOP"&)OO:$'GA-_):J#!&2>
M6-_0@>SQ_P 6W] 0UXN/.-OZ H*?98"2?"9R?7R"&G7]3#'S_<A,%;((V$EK
M&M)]X"N*@B B B B#A_4H@]1NF_\ZD_::NX("("("("("("("(/.5\0==O+?
MI_IJ0(.,\H@_2W78?#P.(CXX[*4(_0P+<H"("("("I*"S#^^IOJ:LA7J\SXC
M77Y_J?0BC(B B B B B B B B B B B B B B B B B B#B?41A_")TZ!_CY
M5VQ 1 1 1 1 1 7.^KPXZ>9W^X9^V$]17#L=7 :]JK;,<CS<%:LSM]SGM6_V
M78ZFNXYEVTR1\9GCBX9Z\R'@(-%M74/#ZQ;JUKD4[Y;$!DA;&WN[B#QVK3OS
M^ S-K4+>1Q5V"U-;F;19(.PQO:/,N5P96Q=3<;A<M+BX<=<O686!\[:[.X1\
M_%;[6-TP^R8R>_3>YC(7%LS)1VNC(^*8(<>LVMNE/95ONIB0L==$)\$*-:A-
MB3TJSUG*.E?0?>M.>8R>\L+QQP@Z9D]MP&KZ[CK4[WB%\,;:L('?+(.T< +5
M:]U2P.<R H>!:J6G-+HHIV=AD^I!!]#W:2]U!V6&2C?XMS1-C#AR*XB:0>]=
M%U6WKD)V>>B^9@BR$INNF)X$@]>WZ$$>=UMU(3/ BO/@:[@V1">Q3?)[E@\;
M@&9R2QWTGEG;)&.[GO/ 2S,$0?UGTUEED7?:\(O[!9\$^$NKPRME8U[' M<T
M$$>\%01S9]NPFL5&6<G8[&O/;&T#N>\_0%'=?ZI:OG;T=&&6:&Q(.8V3QEG>
MD@XWOVPXC.[_ $L9=M7XJ%5KHY61,<"^5?3U.""G1@AA!$,436L!\R&M"#Y9
M&6U[;>I]LW[.0]D)ABJ0M#VCO]#W? +M.;ZIZA@;QQTUF62>/R>R&,R=BHDV
M(V_!9G$S9.C<$M>%KC*>""SL')!"CU#JEJ.1R5.A3MR2RV .TMB<6CRYX)3!
MB6^K^CUJT$YOOD$I=PUD9+@&'@EP5^[U9TFG6JSNR7B">/O8V)A>X#Z0KVB5
MT-GPM_##,078S2[2XRGR#>WUY4'=UGT43=GMLQ9_&B%_8IF#3=6-YAQN$Q/L
M-N4&[/'*V6+T= T\N4EOY? YNIJ]YV4MU63W0:S6@L,SQY=CP@WNR;OKFM&)
MN3O".23\2, O>?\ $%7KNZZ[L@D&,O-E?'YOC(+7C_$4P8&2ZE:?C);45G*L
M;)7E\*2,-)?WK<:]M>$V.J^SB[@F8P\/'!!:?I!4&7A\[C<S%/)1G$K(IG1/
M/!'#V^H\U=S7EBL@>>.*TO[*#S"M9\CXW@>E:/S_ ,2V?:/@I@=K4[0F#SL"
M&-I]P3 $3?@GAM^ 3 \)GO 7@B9^2$P>F)OP"!C?R0F#SP6?DA>^$SX!!28(
MB/-C?T)X$7KV-Y^I4/ C_(;^A>>SP_Q;?T('L\7/]3;^A>BO$!_4V_H04FM!
MR#X3.0/@%Y[+!_$L_5"@\-2L?6&/]4)['4[N6UXQ_DA.13[%5_B(_P!4)[!3
M\OZ&B_5"8*3C:)'SJD/U=@3Y-H <"I#^H$#Y-H #^A(?3C\0)\F4/,>R0\?W
M 3D4?)6-_L*#]0)\CXQHX]A@^S:F?R*?D;%_V!7^S".PN(/S?8*_']P%>12<
M)B?S?7^S"?(>'!Y^3JO/][:G(\^0<,/_ ,75N?[VU4_(&&)Y^3:WV;4 X##$
M@_)M;[-J\^]_"?FVK]FU-% UK AW(Q=7[-J].N8,MX=C*OIQ_4VIH.UG ,#1
M\EU?J$80:U@1_P#BRM] [ FA][&!:WSQ=;ZO#"L#5==;SVXFL.?7Y@30^]/7
M/S36^CY@7K-5UYHX&*K#_(":#M1USGDXN#GZE0-0UD<\8J#]""XS2=:Y8\XJ
M %JM'3];[N1BX/T(*/O,UDGDXN%4?>5K/YLB_25= Z5K1X_I<SR].'.7HTS6
MPT 8]O 'Y;DT5LTK6V'YE!HX]_>Y4G3->/'%,_:/316W3-? Y%,_:/5MFEZZ
MS\6FX?\ >O30.EX$.:?9Y.1_UTG^U>#2L![H)?MY/]J:/?O-P3"0V.?C^_R?
M[51]Y>#!\FV?\XE_VIH#2L'PT=MGR^%F7_:O1IV&:3V^U<?38D_VIH?>=B>[
MD27!Y_V3)_M3[S\4WTEN_P"<R?[4T4G3\62#XU[_ #F3_:JW:EC2SCVB\/I%
MF1-% U*@#R+=_GCCGVF14ZF)(V96!TTDC8+\D;#(YSG=H ][E!+40$0$0$0$
M0$0$0$0$0$0$0<.ZCCCJ3TY_O\B[B@(@(@(@(@(@(@(@+X@Z[GG?Y_HJ0(.-
M(@_2_ EYPV,+_4U(>?U MJ@(@(@(@*ER"S#^^9OJ:LA6^GQ&NKS_ %/H11D1
M 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1!Q7J)Y]1^G0_ZZ4KM2 B B B B
M B#6YG*UL3C;=^P'F*O&7O[1R> N5]2-CQV7Z66;M:3F.ZR(0M/KR7H,'>0*
M>$T 3GM$61J=[C[N&K/ZRWJHUK'5C*WOFR=;L'/F0'(&PUH+'573&RL#NRA.
M]9>^?UX]//Y_/^P@C.2P64GW/.9'3]C@;>Y8+].5O(! 6'5SN2N:WO\ B[.'
M@IY6I4+YWUO27O"#H&GC 'IOC>\0>Q?)P\?GT]/G]RY1A6,_ -G.PGL,TY9]
MH$P2B_#6.\=.!=(-;Y*>(0[\7Q@Q=)SAU&OE<-+DVP"Z9NRB2.7]Y^'"HB6C
M]@W[J(/^T5?V% )GSMTWJD8>[DYB0'C\DD<H.S86G@':928(X#2-!I<>!QQV
M^9*X"UG?T:O1>9K'-AL'][,RGBCK'4S#XZ+II>C9 QK8*\1BX'H00NC:\[^D
M6*Y]34B_9"#F6R05;75?6X<@&N@&/F? Q_FTRJQU>J8^'&X6>"-C,@W)P"J6
M#A_JF:,LP1/ZP4R^)G/R(2>1[^Y=@X\D''=9@B;U-WWMB;RV&F1]?8L/H[0Q
MT^%OWIXF27Y<A.+)>T%S3W)@T\,%.GN746OC0&U/D3OF8SR8V?M4OZ4XFE5T
M#%3,A8))H'RN?QY]SD&@Z0:SB)]&\>>G%*^Y//XI<WU#7EBIZ,:YBFZYD)WU
M8WODOSQ$O )[&)@T>LOP5'IUML>6B>_'Q9>=GA,/!/SP&M"HOR;C/JEF*OIV
M.HXP5#QXSP7AG"UD&',!/T?TUTK0\C)0M'VI71NH\;6W]%:P!H&:8H-9@\=2
MR?5;;)\BQDLU2.!M2-_GPPM]0FQ8ZEB^IVH3XR-D,]LS,M,9Y!\8'J4[>19T
M3 8R[NF\9"U6CEEBR(CC[QSVK8Z-2KT>H6]05XQ'%S6<&#T!<$P==KUJU8.;
M!"R,.<7.#0 "3[UBYO\ XHR YX_H67]E07<(0W#8X ^?LT?[*SD!$!$!$!$!
M$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$
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M[4@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@<)P%,#A.
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M@B B B O"@LP_OF7ZFJ^K6NKS/B?0BC(B B B B B B B B B B B B B B
MB B B B#B>]D?A4Z?@?"9=L0$0$0$0$0$0%SG:^H$&%NPXRC1ER.2E'(JP^K
M1\7E!'H^JEW'Y&M6V36Y\9'.X!E@O[XU.-BVF/#3X.,5S,,C<; US7<=O/\
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M(K@?1W%YZO/G[<V5=+#'>GCDKAO]5F'J]!F>-U)RC+5ZQGZF#C[WB&I(QI<
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MEZ<!ML,]29D%A\19&]_;[BNG=/)"=)U][R72&C$EF02M% 1 1 1 1 1 1 1
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MN1L=5ZVN-V>3,P,$<3)G4&Q#CPD'=\!D3E,/C\AV=GM%=DA;\.X<K:J B B
MB B B B B B B B B A0<-V?SZV:5_,I?V7KN2 B B B B B B B >5\$]8R
M3U$SGUP_ZIJ#EZ(/U"@'S& _DA7$]01 1 1 7A068OWS+]35?5J]7I\3Z$40
M1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1!Q'9Q_P#>73/YG/\ Z'KMR B
MB B B B B B L6^"ZG:#02?!?QQ]2"*X?9\+#BJ44MP-DB@8U["'<@M'!"V3
M]JP+6]QOL ^IR#2[%L6(M86]7@N,?-+'V1L <27$\<*>,_%" 5K<9AL;BHYF
M4:D<#9972R!@X[GN]2@]LX?'6KU.]/68^S5[O E/JSO'!X2]B<=>FIS6:K)'
MU9/$A<[S+'_$(,7.:O@L_ R/*4(K#6?B%X\Q]1"QL!J.OZ\V1N+QT4'?^.X>
M;C_C*"2<*&Y_IYJ6=LBSD,7')/[Y!RUQ^LA!NL;KN'Q>+-"G3CBJEI:8V_PN
MX<'E9.,Q-#%T(J-.!L5>($,C'H 4&-3UW#4L9+C:]*-E20O+XO4'Q/-RT]?0
M]5KXFQBHL8P5)Y1))'R>"YJ#-S^IX'/U8*V2I-FCA/,8/(+5S/J18R%^*+3,
M;A9S[4(1[5Q^XQQ H.P8?&5\9C*=& =L5>%L;/J:%E68(YX9896\LD86.'Q#
MAP4&#BL-0Q&-@QU*$1UHFEK&<D\ K65]1P-?"3X9E-II2EY?$XD@F0\E!&,=
MTBT6B]SVXL2_ 3/<\-6_;HVMLH8VBRCQ7HV?'K,[W<,?SR@VV;U_%YN*M#>A
M\1L$[)F<.(X>ST7F<P&,SE,5,A#XD(E9(&\EOSF'D>B#"V/4<%LE1E;)U!(U
MAYC<"6N;]1"U.N=-]4UZV;5*F3/[I97F1S?JY03PCR6CQ>O8W&7LI<JQN;+?
ME$DY+B07-'"!7U_&5LOD,I%"19N1L9.XDD.$?IY*!2=&M*EORVG5IN)'][H1
M(1$@E>&TC7,*<@*-$1LN ">+DEA#1QZ%1!G132A<,QBLF(O[A6,I\(%!UJ&%
MD,+(XVAK&M#6M'D  HAL&B:[L5V*YDZIFDC@="SYQ #7(-=J_337-;OR7JS9
MI;!;VLDF?WF-OP:L_;= P&S&&2Y&]EF(<1V87=DC$&/J73S ZL^::HV6:U*.
M'V9G=SR%KMBZ6Z_F\D_)"2S3MO'$DM9_9WH-YJ^D8/6:<\%")W=/_5IGGND>
MMGKN HZ]B(<92[_ C<\M[SR>7GDH&OZ]1P%>S!3[^V>R^=_>>3WR'DJK9]<Q
M>QXV7'7XN^%_!!!X<UP]'!!S:MT3UAL3F7;5ZX.WA@EE/#%*QH6'%77ZP?/V
M8B;Q*W+N2?H<KM&WS^MTLZ<=[4Z0>QVV6(^P\<N9\4V+7*6?K5H+;I R&RR=
MO8>#W,4&IVW0L/LXKR6#+!:@_J-J$]LC5JM8Z88K!Y/Y4FNVK]T#B.:P[GL0
M2C&:S2QV;S&6BDD,V1,9E:3\T>&.!PD.LTX=GMYYLDAGGJL@<P\=O:Q!"LMT
MFQUO*3WJ&4NX_P!I?S:A@=PR52;5=&P^L5\C7I>(Z&W+WO9(>0/+CA71"K'1
MNNV>P,9G\A0J3O[I*D3OF*=T-)P%'7)<#'5YIRL+90?5Y=ZN)^*:.?-Z+4S%
M+3L9_(RXX ^!4+_FL*FM_2_'PN$Q=;*6:K<>^(A\9X,C8QQVN4$['H$0$0$0
M$0$0$0$0$0$0$0$01O(_UPX/^YL_LA20%*'*CD_=]]-0@>7L$G[80<DVN_D<
M'U/KYAN%NW*PQGA$P,Y\RJ\QU#V;-4I\=A-1R,<]B/L$TX[&L#T&1G=1LX;H
M_9PL$;Y[(9&7A@Y+I'2ASEG;G<RF/H8,SX-F2PQKAEZ 1]TS'\< A-$(TS%4
MKN]X_(:UA;V,H012>V&?D-E[AP&@%7-GO8TY?(5-SU22Q()":5NG$?GQ>X$A
M78+NKZ5ELCTYV7'^%/!'<LF7'03GY[!&01RMQ#U;G@Q0H2:[D/EJ-@A\ 1GL
M,@''/<H-'L.KY3%=(HJ<L+Y+T^198GC8.XA\C^Y2C>K-[ ;-J^S&A+8I5JTD
M%@1CE[/$"L&BGV>QM/4'2[=3%W(\?!+-V32Q\=[BU;FYE'X'J[//9HV709&C
M!!#+&PN'>"@M.UZUF[75*@&%ALRUQ"]PX#G")6L5U;IXO",Q^2QEV/*5(A#X
M#8B1(YGD""@U$N$RM#I'G9+M=[;5^U[280.2WO>%U';0X]-+X[27'% <#U_%
M2C?:.7,U#!#MX/L,/[*DJ@(@(@(@(@(@(@(@(@(@(@(@(4'#=AX/6_4/HH3?
MLR+N2 B B B B B B B O@7J\Y[NH>?+OXV/_5A!S-$'ZB0 AH\_(-"J0$0$
M0$0%X4%F+]\R_4U7U:UU>9\3Z$49$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0
M$0$*#B.R<?AGT_\ F,_^AZ[<@(@(@(@(@(@(@(@(4%'@L_)"\\%A]6M0!!'S
M^(WZ^%<0$4!%01 1 1 1 7G:.>>$'J("("("("("("("("("("("("("("("
M("("("("("("("("("("("("("("("(--E<,W(/JRBW/!+ 7%CXB ?G#@CS!
M6$,!?#>/O@O'Z?W/_P!J"G[W<D1S]\=\#ZH__:LG'X,U;9M39&S9D\/L;XI'
M#1ZGCM 0;\L3M^ "!PO"T>A0&L#?14NC:3YM!05=JI,$0?W=C>[X\(*RT%4N
MC#@0X CX)!XV%C0T!K0!Z<#T7IB:2"X D>A0 P D\!6GU:SY?$,$?=\>!R@N
MF/EO! (^!7OA-<TM(!!'H@]8P,     X "("("("("("("("("("("("("(.
M'9_RZX:G]..F_8>NXH"("("("("("("("^">L3N>HN=^A\/^J:@Y@B#]0X?)
MK?H 52 B B B O"@L0_OF7ZFK(5K75Y_J?0BC(B B B B B B B B B B B
MB B B B B B B#A^P_\ X:=3_F$W^AZ[@@(@(@(@(@(@(@(@*S:F;!!-,[\6
M-CG'ZFCE!&X<UFIX(YH<&7L>T.8?'8.6D<@JLY3/CG^D!/U6&(+%C/9>I$9K
M6#>R%O'>]LS'%H)XYX4M\R.4'-L]U MX?*6:;=5RMMD(!\>%G,;N1RHQ1ZT#
M(L>^EJ>6G8Q_8\QM!X*"=Q;I"<GKV/EH6(9\K!)*QK^ 8O#'):]38% 1 3E
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MR!UF:LY[W<<>800>GNF??TIOY]\S#?A=*&R=@X\I>Q8E;+]1H];R>R7[M2.
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M,OU-5]6M=7F?$^A%&1$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$'%,V?\
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MF0IOGC#:$C@\N8Y?54#R^&-Y!:7-!(^'(6*.!G-8O%];<H;TS(1-0BCBD>>
M'<!;/*7Z6:ZJ:RS&RLG-&O.^S+&>X-#AP 2%9/4<^P>(@EVC:J-[;;>*M_*+
MW-B9((Q*UWF'<E2;!X3$LVK)QT]FO9/)1XJ5O<>'QM#QP 7IS[B,=.L!!D,(
M^$;K?QUJ"603TVO$8C(*E^L8W#T\?O\ )2S5K)3&L]EF>4#M+FL=QVN'JF6"
M;=-((H^F^&:&CA])Q=]/<L7HF?\ [?4/HGL?ZTH,CJ?L=S!X:F*<<!GN78X&
M23CF./GS[BN,]1J.R5=:GGS>[,M.D<P148&AK)%9X$XMPQ3[=TH9*WN Q\KO
M\;8@5NM\J5I]ZZ?]\;''VJ?U^AH*F05]1&M^^;I\>//Y5*@;<;D[G4W;((=F
MDQ-A[HG1- !,S.Q!OL=K+*N^89]_=);^1ACD<R Q?P/?R6K=],J\'RWO<X:.
M\Y<MY5NX-5CH'G8NJC*S.)'0,[>/B8EO.EU_#,Z=T29(F,ABD%H$^C@3W=RF
M;!R3%\3=*=Y=C@?!.2>6?WKN"F6!P&U6=>JSU.H<3*GLS?FBM&6L;QZ%7G.!
M$[E"KCM*ULG*-R&+9L/?9E9&6,[2Y=-ZQ3XH]/;7>^,]YA]FX^/<E'3<&6C#
M8S^:Q?LA;59!$!$!$!$$7OD_?1A0#_S:S_Z5* @*.2%OWV, /ICS^V@XWL^)
MCS/4O-X]PY\772&_6L"#:99>CL=0//MSY1C /?W=_"HVNG8Z'#]3<S5C\F5\
M)7;^AK5SR'-ZOLE[)9/:/E>R]T[V5X:['F*!@^EJ:)]TJS9-O/X>M-=EQL,'
MC4GV6%KV?%BUW2W3ZM[#5MER=JU++5GF=59XI#&,B)2WV&7K.E'>\=-LF<R5
MOQ[<LAJ,BD[&P,82T<)H&1R.O8'J%8NSOLSX^Y)RYYY[G,8DMHY]5M:9E<>+
MV<SN9.6FYD=,QC^R(_!BFE?;,GEND.Q&:Q*^>D_P66>"Q\C.X=KE1T/0M)./
M]DSMO*7;-^S4:9N]Y[/G@'T75F^BR"("("("("("("("("("("("("("("(.
M(9;RZYX#Z,5+_H>NWH"("("("("("("("^!.KO\ ^$//_P!^9^P$'-"B#]16
MKU 1 1 1 7A068OWS+]05]6K?3XGT(H@B G'F@(@(@(@(@(@(@(@(@(@(@(@
M(@(@(@(@(4'$LTSCK?KW^"Y5VU 1 1 1 1 1 1 1 6+D*QLTK, /!EB>SGX=
MPX01VO\ ?56KQ0-IT'AC T'QGCR:.!_!609MH#CQ1H<>X^.__P!B;TC R=39
M<G6FI25J$<4CFAS_ !'/(:'<^G:%,P@*F.".,$-8UHYYX X\R@.B8YX>6MY'
MH>/,*EU>-[F.<QKBP\M)'/:?H06[%.O9C#)X8Y&_![0X?^:5J56JTB"".('U
M#&AJ@R) 3&YH]2%S71=-.,P+Z>7J5I9O;9YF^D@ >[D(.CQ0QQ1AD;&L:!P
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M2R/'X<</]&(>NVH"("("("("("("("U6?(;A,H2?2I+^R4&7CCS1J<_Q+/\
M0LI!'MI'.&G_ +Y#[@?^5:I"/1!;F\HI/[DKD71'@ZG;/QREE!H^HE#+9#J-
MJ]/&775)I*4X=.WU9'_"55+'9G3=[P--N;N7:&4;,R1EA_?P]@5&AV?;:^9V
M[)8S([3)A\;0>(PR$.$D[_>20MGH>V1U=R&"I[%)E\?:@<^"27DR0/9[B2H/
MH1Q=VGCCGCR7SCDZ-^:>[/M'4,8Z42D15*LP C:@R]'V?*7=/W")^5DM_)XE
M%6[YA[FEI(*Z5J-RU/H&-MSV'R3NQY>Z0GEQ/"HXSGF7<UT6@R-O)67S02N>
M>7<B7F7LX>MQO6)FPG2ZA7AN6+4OMM5['SGN/<4T8^RXG>=8PL>SOVRU/9B?
M$ZS5(X@[7GCM 4RW3/Y^[D,'KF"G%:UD(3//9]3#"$&BNP[)T_OXF_-L%K)X
M^U:96M16/5AD]'M5[:)-KRW4/Y QF;FHU7XQDTKVCDMX=ZL0;*>7.83;- PC
M\Q/99+!=]J>_UG+&=P+E']TI;+K>-MY"??[H[Y2*U=L327N=Z,:@W&&R^S:I
MT]O9S9+3[5L@210R>K._AK&%0B/+9:S1=E)>J%:&^6=[*;"WP&^_L02RYU-R
M4W3W&9*C&SY4O6!39[V-FYX+E%=^PW4+#:G<LV]C.1KV&-9=@?& (^X^L:@^
MC-</;K>'X_L*+]D+D/5+9\WC\UA<9!F/DFE98]TM[L[_ #'N0;703MC,G<99
MS]?,XDQ P6PYO>'_  ("@.MT]TRF?W"EA\HS'U6Y:1\UKL[Y"\^C&JCH73_.
M;1*[9<3EYF6[F+F#&2@!GBAPY"BLT'4RY#-?RNX5,%R]QBJ<,X:!\2@S\%N^
M<N]-,_?DN,??QYFB%IC00_L]'J[K-G=H\:-LSF=:ZC[ ^8T&1 #@-Y:>Y!&J
M.<V[/U#EG;YC<6Y_+Z]#]S(#?A(I(.I64FZ>9;*PP1')4)?9YNSY\7?R!XH0
M:+"7]_L3XW(8O;J><8^9HN4P&1]C"OHUJE'SUL<^Q,ZO6ZF!$(MV,/&PS2^;
M8FAW)>M_J^;W3&[H=:V&[#=9+3=8KV&,##P"J*\Q/U/RF9R,&-FK8?'UW!C)
MY@'OF^D+7:IM&WV[NS:]<R-6S?IU/$JW80TM)02_0]OES&G_ "AD7@6JIE9<
M\NWA\2A\/4?-T]).<NL9+9OWGQXV'@,:&$\,[D&!-GNI>&H',6\[B+<;!WSX
M]G8"&?!C@NZ8C(P93&U+\!/A6(6R,^IP0<2ZBV\S3ZBZL_#UV37I*<\<39/Q
M!W^\K8Q;-O6LY[$U-HEJ6Z61?X3+,+.PQR*096T;=LUG8Y,!K1J125XVOMV[
M)':SO]  F V_8\?L5; [++3G=<:34MUO0EGJUX6LF##L;;N.Q9O(5-;EHTZ%
M*4Q/N6!W%\@]0 M[IVW9JSD\G@<XRN,C4B$K)H#S'-&4R8(9KVV=4-MQ\\F+
M90K"O+*QUF5O(F<#Y-8%T;IOM&2V+ SR9*)K+E:V^O/V>32Z-2X))L>5GQ.%
MNWH*4MN6&/N9!&.7/*X]=SO62OC9,Q+5Q,,$<?BFJ>>_L22#<;#U(NU='P.P
MT*K"^[/"Q\+_ (.Y[@%J<KON_P"L35;N?P]1V/M/[&PUG<RQ//H"5>![?W;J
M'@[.,OYK%TF8NW.V-T<9)EA[_3N*E6W;IEJF4K8+7J4=K)RQ^*\RGB*&/XN3
M(-?C-PVW%YZAB=IIU.R\2RM;JD]O?^2X%6LOO6VC=+VMX7%5IWL@8]DLA(#.
M1R2]+(,S3=PV*SL&2P&QU((;D$0FC?#^*]BU$F];OF\C?^]7#UIJ%*0L=-.[
M@S/;ZABG Q.F&;-[,[WE+D!JGQHC-$X\F/L:00LJINW43/B:_@,#3^3FN(B-
MF3MDF 02>CU%I3:ID,S:KN@FH=S+=4^K)1Y=J@61WCJ"=>MY._J\+,58KO'[
MG)S/$QXX#RG$'1NE0[= U_Z:ZZ I?((@(@(@(@(@BN1@9-LV+9*QCX_9)R6N
M\QSRWSX*W9PV&?R?DVKR?7]S:@/P6$!';C:OU^$U:2M3JU=ILMKP1Q--!G=V
M-[03WE!#-RV;89]AJZMK;XXK<D/BV;3QR((U'\KK_4G6:AR]/:9LF8!WSTY8
M^0\>_M3<P=AP68^4L)2R,L#ZWC0A[XY1VEBQ:VY:M;N>Q5\W3DL<\",2@DE,
M&YN9*C2\'VFU%#XK^R/O<&]SO@.5K*FUZ[<O&E6R]26S_%-D!<@VE?)X^6[/
M49;B?/" 9(0X%[>?B%[/>J5YH(9;,3))R1$QS@'/(]0T>]!A9'/X7%N8R_DJ
MU=S_ ,422-:2MC#;K35VSQ31OB+>X2-<"TCX\A!K6[#A'SP5VY2J99F]T3!*
MTEX^A>6-CP5:U[+/E:D<_P#%NE:')E&%L[LB['P''9:O1D-B/]VF +7-Y\VC
MGWE;Z>W7J0&6Q/'%&W\9[R&M_24%NCE,?D(S)3N0SL!X+HWAX_\ )527Z,7C
M=]N%OA &3EX'8#^5\$P54KU.['XM6S%-'SQWQN#A^D+)0$0$0$0$0$0$0$0$
M0$0$0$0$0</LGCKOC?\  [EW! 1 1 1 1 1 1 1 )7Y^=4^?O_V'G^RD'/2B
M#]16IR@(@(@(@*DH+,0_HF7ZFK(5K75Y_J?0BC(B B B B B B B B B B B
M B B B B B B B#B5\<]<<5]&'>NVH"("("("("("("("T^R<_(.5\^/Z#F_
M9*#,QY:*-4 @@0L_T++#T$<VD_TFF_OL'D./XUOQ4D'H@M6 3%* .26$<+F'
M1[&Y#&:I)#=JR5YC?G?V/':>"@R,O1OR=4->N,JO-:/'6&OE ^8TE4[=C[UC
M=-(L0U))(8)YS-(T<A@+?>@AV8J6=/VS*9-^NG*XS*.;(XQQB22"4+;:9D\O
MG=B=;AU>'%XJ&)P#Y80V>1Y5'7[<<\E.PR%W;*Z)X8[X.(\BOE'6IZV 9:J9
M/0+F0S G<'3EGB-E)/(/+E!->GN$S#JF]4LAB'T)+IYC9QQ&.]A\FE:? ;AL
M]+6)-59K%V3)UH9(!)Z1!OY1*UL&ZK8'+6.A[L<*<@N>"7^"1P\]LO<J]CR&
M1V30,4]F%NP2QY.HU\+XSW$1GS<%D3;JI3M7- RL-:"265PA[6,'+CP\*-;?
M2S6'R6M[9CJ+[7L=3V>[6;^.8GH-)E-BGZCWL/B<9BKD%6"Y'9NSSL[ T1>?
M:IK7JVQU:M6#7D\#Y#8P2\'LY[_3E!C[=!:/4?2;,=>5\<$%]SW-:2!S&N18
M_;A?VZ?.;/A<H\P'C'U(X"Z.$?$K4'6,M;BZCZ5G*5&C<KO'9X?M,9C[WL/>
M.%S.OM6CX_%0T\AH[SF*T8B=#[,.'R#RY[E!*,U@<])H&(O5\+#4O4;PO"C
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MLR)D?4@CKN= 'D,D<1Y=Z<C;Z=A:VN=3,WBL:7QT9,?'/X')+6O)7;U 1 1
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M00:;6>HNJ6;C-5?4LXV>9\K*T_DZ$O4JU37-JK4LQ9SV5-F_>C+1$"?!A''
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M!$!$!$'A9RO!&/@%,#P6GS[0O0P-]  D'J*@B B B B B B B B B B B B
MB B B B B B B B#ACO/KTWZ,*NYH"("("("("("("(#@OSVZF\_?YL7\\<J
M(&44'ZBH@(@(@(@+PH+,/G9E^IJOJUKJ]/B?0BC(B B B B B B B B B B
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MV<ZLW*L6,9JL%>U^(^^][71C^W 4BV'6L]/+HX#G7'T;P?;GX:SW>O";T_\
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M/R76^,_VS_\ :@P,I0BCHS/CDG:YK>0?%D]?\1*D#/Q&H"("(.(4N?PZY+_
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M!$!$&KS9XQED_P!K]/Q^A;1GXH0$0$0<.Q8'X=,WS^:6+N* B B B B B B
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M3N0.X)W! Y3E [@B!RB!RB!RG*!RB B A*!RG*!RG*!RG*!RB B B B B B
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MW=J;!J,UN'4S7(Z,^3I8Z6*W/%%S'S^XEY]"N],)+&D_!2@B#AFLCGK=N/\
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MT(S\QQ*GFHZQ4U?"Q8NK-))%&][@Y_K\]W*"WN>GTMJPIQUR1T33*V1CV?C
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MORC6=/++$6"/A_DU?2T?XC?J"M@(5!PO5?/K7NG/]AQ_Z&+NB B B B B B
MB B 2OS<VTD[1G"1P3?G_;*".(@_49$!$!$!$!4N068?WS-]35D*WT^(UU>9
M\3Z$49$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0</P/'X<-I_P?'_ *&+
MN"!RG<$$7V_9H-:PTF0DA?,>]D<4+/61[SP LK7,GD\EC([&0QKJ,KG.Y@<X
M.( ]"F#?=P3N'Q0.0G(0.0B"Q9LM@@FE/I'&YY'T-'*UFNYR+.86GD8HG1LL
M-+@QWJ@W7</BG(0.0B G(0.0G*!RG(0:IF9H29>;%LFYM10MF>SCT8X\!;5
M3E Y3N"!R$Y0.4Y0.0M/5SV.GS-W$M<XV:T+))!QY!LGH@W'(6%D,G1H11RV
MK#8F/E9&PN][WG@ (,T'R3D('(3E 3E 3E 1!B7+U2C$);,[(F%[6ASCP.YQ
MX 6)/FL?!DZF-DL<6K+'OBCX/SFL]4&V!"<H"("HGG9%$^1[NUC&ESC\ /,E
M!8H9"I?I5[=2820S,#V/'HYI64@(@)R@+PD!!@X_*T<E&^6G99,QDAC<YAY
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M& >0 4 MX"YWA].R<>SS9O,9877Q,?'28&!@B8\JCHJ.:'#@H*6QM:.&@ ?
M*H-4!4&%A=W=C>[X\>:HK,0<"' $'U!5+8FMXX:!P/)![V*AT$3R"]C2?B0@
MK[!QQP.$[5!X(P!P $\/@< #CX*BET#'QECVM+"..TCD*F*M# TMBB8P?!H
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M/^AQ3@5?A!ZI<\'0_P#\\H>H?5 <DZ&?UDX%7W_]4OY!']=4?A'ZFM]=#?\
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MXET?""$W<1CLIT\TJL_*QT;XCADQTC_0S!JUT.8W#!;%@(]MQ=.XQ]D05;S
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M3NT,[4SUW8,K<U[#UQ;EC;AXK,K(;(@?*YWQ>4X'1NELV?BJ9.IEN[^AI^(
M^9LTH8X<]KR%>ZD:SC<M@KUVV'O=3J3.B9W$,[B/4A9HE&J MUK# ^HI0_LK
MG.0JY'9MXS6,ES%JG3QT$/9% _L=(Z4<]Y*" 9*IE,_C\#5OY29QJ[&ZBV=A
M_JK1Z2?W07TN:,3L>:<I?(PP^$XD_.<..#R5:.+W*&.S62Q&!UZA&REB;D<U
MJZ!\UAC/]28?>XKNH0$4!$!$!$!$!$!$!$"5P:QQ/H OS'R3Q)D+C^0>Z>0_
MI<@P>$0?J*T+U 1 1 1 5)]4&/7_ 'W/]35E+75YGQ&^OS/]9]"++ B B B
MB B B B B B B B B B B B B B B B# OXFA?=5?:KLE->82PEW\%X]'!9X
M" B B B B G" HCEM(UW,9FIE;U(2V*[0&<D]OQ'(02Y@ "('"PLOBZ64QUG
M'VF=\$\99( >.04%RC3@IU8*T+.V*&-K&-^#6C@!8&>P..SM TK\1? 9&/X!
M+3RP\A!N&M' 3@("<!!HLIKV.RE[%V[+'&6A,98""0 XCA;T! X1 X3A 3A
M1 3@("=H0. G"!PB B B B B B B B B B B B B B B B B B B B B B B
M B B B B B B B B B B B B B B B B B B B B B M2S#48\S/E6L=[1+
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M@AJ/UN7'Y+/""[[6]DM 4@^R9._R(=ZE=7VS(6M,RL&2B$DSLGB?8R>/-UN
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M$H-3B]/US$WK%VECH8IYN>]X"DJH(@(@(@(@(@(@(@(@\E_$=]17YBW0!;L
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M"("("("I/J@QZ_[[G^IJREKJ\SXC?7YG^O3]"++ B B B B B B B B B B
MB B B B B B B A< @!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$! @(@(@(@(@(
M@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(
M@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@Q
M[G[VG_O;O]"_,:7^J/\ [HH+7FB#]1D0$0$0$0%2?5!CU_WW/]35E+75YGQ&
M^OS/]9]"++ B B B B B B B B B B B B B B B B B A:"@(@(@(@(@(@(
M@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(
M@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(
M@(@(@(@(@(@(@(@(@(@(@(@(@(@(@P<K((<?<E//#()''CZ&DK\RY#R]WUE!
M;1!^HR("("("("I*#'K_ +[G^IJREKJ\SXC?7YG^O3]"++ B B B B B B B
M B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
M B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
M B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
M J>2@P,H!\F7A(>![-+R?H[2OS.?^,[ZR@MH@_49$!$!$!$!>%#U8]?@6YS]
M#5DK75YGQ&NOS/B?0BRR(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@
M(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@
M(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@
M(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@P\AYT;?ES^X/\OC\U?F5)^.[
MZR@M%$'ZC(@(@(@(@+PI1C0?OJ?ZFK*6NKS/B-=7G^I]"++(B B B B B B
MB B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
MB B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
MB B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
MB B#!RK.['76\GSKR#D?2TK\RW_C'ZT%LH@_49$!$!$!$!>%*,>#]]3?4U9*
MUU>GQ&NOS_4^A%ED1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1!K<M)V8O(.].*TO[)7YG/_&=]:"A$
M'ZC(@(@(@(@*ER"Q#^^9OJ:LE7J]/B-=?G^I]"*,B("("("("("("("("("(
M"("("("("("("("("("("("("("("("("("("("("("("("("("("("("("(
M"("("("("("("("("("("("("("("("("("("("("("("("("("("("("("(
M"("("("("("("("("("("("("("("("("("("("("("("("("("("("(-)LY
M_I!F#\*4W[!7YKN]4%"(/U&1 D9WL<WN(Y'J#P0@' 0$0$0%X4%BL0;<_(]
MU9"UU>GQ&NOS_4^A%ED1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 3E!JLYVG#9/GT]DFY_4*_-%WJ?K
M04(@_48(@(@(@(@+PH,:O^^Y_J:LI:ZO,^(UU^9\3Z$661$!$!$!$!$!$!$!
M$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!
M$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!
M$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!
M/<@TFR2-BU_,2'T;2G_8*_-=WJ@H*(/U&:B B B B O"B,>J.;<_/N#5DK75
MYGQ&^OS/B?0BRR(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(IR"*@B
MB B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
MB B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
MB B B B B B B B B B B B 40$0$0$*#2;"1\@Y;^93_L%?FN?>@I1!V.+K
MMU 8>?:JI^N *_\ A[WW@CQ*7V"NP5MZ_;\'<E](_P#=*H]?]Z^%'[$IL%__
M (0>[>^"A]F54?NA-R]U3'_9N4X%8^Z%V_\ L''_ *CD=]T+N!]*6/\ U'H
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5@C^UN[-8S9_[!/\ L%?F\4%*(/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>ex10a_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10a_002.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP"$  8&!@8'!@<(" <*"PH+"@\.# P.
M#Q80$1 1$!8B%1D5%1D5(AXD'AP>)!XV*B8F*C8^-#(T/DQ$1$Q?6E]\?*<!
M!@8&!@<&!P@(!PH+"@L*#PX,# X/%A 1$!$0%B(5&145&14B'B0>'!XD'C8J
M)B8J-CXT,C0^3$1$3%]:7WQ\I__  !$(")@&I ,!(0 "$0$#$0'_Q "U  $
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MV)9]O&.:BC\#'4?^I4^WB*5Z,]1?+^1D^VC*"]&>HR=O\BHOU31!>C/45/\
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MWY&O<_\  >.?A&4W2]K>BJF!O_8O*7Z?M+%X=@K_ -@\<_"'WF[5WJSY!O\
M<GJG@/+"ZOL:.5OR+>Y1>%3P'CGX16S4MG?)X;<'?5WP\!Y0NK;(BHGR+?\
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M170D5-,U].55?88O7ZBB8(B*. '     ,6^WBL_XE]/1#5\9]:OA/M5@RR<
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M08' [4&0%:BCL:,@=J#L:,@=B#L09 [4"QM1!D'QL;5]?0(U.%*"-0^]J$R
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MD'AX_1/IZ]9-+UYRHG*T8C7H3$$     %G(?.KO*T+?&?6KX3[58(R
M                              !V^?(
M
M                               !0          .<;?9BAR<+5F5.:[5
M_P#J4%T> D/T3Z?=R:5K_<J*OL,8]"8M5>/,$     %K(+S XJ:6^,^M7PGV
MJP1D
M
M                                                !QCJ%'W9N!>Y
MB?Q1GKS_ #W :/$9^BV@M5NEX!O_ .8Q%]"6@@     M7UY@<5-+?&?6KXS[
M58(R
M                                                        $3@
M                                                  .0./[_  UY
M,S LBO1?9&>G/\YP+U_:S7AQ#](-&A1-1P2+Y*E&']TC21@     "U>7F%Q4
MA;XSZU?&?:K!&0
M
M                                                         /B\
M^0'!.ITMYN?KI#%$YOL3/-WQ[W@<]'C=#]']%G1VG8%45?.C#^Z424$
M%F]^8<5H7TU?&?:K!&0
M
M
M  *7(!PKJ9=MP9ZLR)Z(WV)G[[P!XR0_1O2&>'J."9\*,/[I?0E((     +=
M]>87%2%]+?&?:J!$                            #CSY
M
M
M   #D\E5 /.W55EQ=C@6.JDC?88_/OX_3>"CR(A^C>DHB:C@D157^(0_NCT)
M2"     "U<\H7%:>XOI;XSZJ!$
M
M
M          *!YVZL9*>OLE:-C.4]@C_?> /(B>I^C&B*JZ?@55/^X0_NE]"6
M @     MWEYA<5)[B^EOC/JH$0
M                             $50
M                                            !%Y
M               >;NKF19!L]=B]GE0C_?> /)B'Z0Z(]$T[ JOK[##^Z7T)
M&"     "W?7F%Q]0OI;XS[58(@
M
M                                       #D
M           #SGU<GJ,V>NDU1CW>P1_OO R#R.A^CVDKQJ.!:B^7L$/[@]"3
M      "S<_,/*T+Z:OC/M5@C(
M
M
M        'P#@W5"I%-L%9SUX7V%B>G]MX \:IZGZ1Z8Y&:E@D;_L,/ZNQ"^A
M(00     6KOYEQ6A?2WQGVJ@1
M
M
M        H!/,/<G 'FWJW;ILV:NDO?W>P1^B_P!MX \FIZGZ2:>C?O5P?GS_
M !&#]Q"^A( 0     6KOYEQ6A?2WQGVJ@1
M
M
M                  *7>@'FSJ\L+=GK)(Q%7Y/C_?>"CR@A^D&F/>_4L&JI
MQS1A_='H20$     %J[^9<5H7TM\9]JH$0
M
M
M                 /4I7S0#S1U=CO/V>NL,;E9[!'^^\%'E0_2317(FGX+A
M?^XP_N(/0D (     +5U?Q+BM"^EOC/M5 B
M
M
M                   ?%\TX \^]5FJNQ5>&O_S!GHG]MX \?(?H_I#VII^
M[/\ 88?W1Z$E      %BY^8>5H7U/K5\9]JX",@
M
M
M                      % \\]5XI7['65KN$]@C]Z_SW@U.<>04/TATIG^
M2.!Y\E]@A_<0SZ$C      %F]^8<5H7TU?&?:K!&0
M
M
M      >8                 . X#SYU6>[[XJO#'?YA'Z<_SW@#Q\T_2+2Y
M7)J6"3W^P0^?_(A?0D0(     +-U.VN_DK0M\9]:OC/M5@C(
M
M
M                               !0//'5KN^^6KQ*B)[!'^^\ >0FGZ.
M:3Q]Z.!\^4]@A_=+Z$H"D     %FZG$#BMI;XS[6KXS[58(R
M
M
M                                 \U=7X;K]GK+$Q5;[!'^^\ >4$/T
METN3_)+!JC.SFC#Y?\B#T-^      +-W\PXK0OIJ^,^U6",@
M
M
M                                .!]47R-V&LC53CV%G[[P71XW0_2/
M3'HNH8+SYYHP?N(3T)"      +%W\P\N(6^,^M7QGVJP1D
M
M
M                              !P3JA86/8*R)&B_P 19^^\&AXV3U/T
MDTE[OO0P/*<.]@A_<0SZ$@      %BZGXAY<0M\9]:OC/M5@C(
M
M
M                                 !P'G3JS*C-DK)Q_W"/W_P!MX+H\
MC)ZGZ3:HO^3.%X553V&#]Q"#?      "W?\ *!R!"WQGUK_F?:N C(
M
M
M                                     %*KQR!YDZQ.1-IK<O\ _#X_
MWW@#RPA^D>FR=VJ8/X+0@_<0"0@     "S>7\0XJ0M\9]:OC/M7 1D
M
M
M                                     #XJ >9NL,]9FT5D? CE^3X_
MWW@#RJGJ?I-J7A?>K@E1O"K0A\OA\Q -\      +-U>8'E:%OC/K5\9]JL$9
M
M
M                                             >7.LK[+=L@1C/+Y
M/C_?> /+R'Z.:0B+J& 5/]@A_= E       L7%_$/+B%]-7QGVJP1D
M
M
M                                      !YYZKR5V['621&\^P,]4_M
MO 'D%#]&](_U0P']QA_='H2D      6+GYAY6A?35\9]JX",@
M       .0"N1/54+3K$*?E2M3_%!@^LL1/\ -LC53Z%+B*B@
M
M
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MB9!UNGD:-N-)*UB.5JIRBM<BF:9P
M
M                                              'E;K0O&VP>O^CX
MOT^/TW@#S(?H]ICG.U' \IY^P0_N@28      6+OYAY<0M\9]:OA/M5@C(
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MX<GUD@(
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M5/O$J7^Q'-]I?"KED\QF#UKI*Q2ZUC+$>,BH>/$DCZT;>Q&.<2PF
M
M                                  /+W66>5NUP(V-JI\GQ_OO 'EQ#
M])].5&:G@VM_V&#]Q -Z      +-[S@<5H6^,^M7PGVJP1D
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MYS//A5'-!WG1\GLN2PWCY[')3M>,YJ1(G'S$]%)D
M
M                      'FOK#;CBVFNSPD=QCX_P!]X \GIZGZ3:2[MU#
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M7N10
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MZF;G@LIBK68RT-RE>7F2)CV/?&B_5Z&<'KJ"5LT3)&NY:YJ.1?BBE9
M
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MI$=W*AK,!HFWW+>-IRZI3I01/8MFS(Q'J]&_6JBT>OHF(QC6HB(B)PB(5D
M
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ME;Y8HH^^1[6I\57A"H   5[6IRJHB .4
M
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M9T%&Q,J32(]>]DT:^3"]AW#IM?V&]K59^:I>SS,X9$GHKXD:G#CH1D
M
M                                    "@>0.M\MI-T8C%9V^P0\<N^E
MP \]M]4/TMUN-C-?Q+4]$IPHG[" ;8      6[R\PN^"%2%]+?&?:J!$
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ML3U0FP
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M1K&-:U/<B<(7>XH<CE  50'([D =P[@'(
M
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M6S<BF]F>QGJ^0;!$^F.\;1G.H,L&1M2I YDSEJKZ,/4@H @
M
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MQ21ZG:LS1\MM6U<Q')Y<,)>HAVB^76W.?79/51
M
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M$EHT*E&K%5JPLBAC;PQC4X1$ U%75M?IY6;*08Z%ER555\R(O<O<2
M
M                           4#XJ<<!.% \B]<6,^_.+\0COY/A_ZN 'G
MB/\ *;]:'Z9XGSQE%?\ \WC_ '2^AG@@     M7?.%Q4A?35\9]JL$9
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M'4YD21GDKN%4]'ZEG4V#7\?E?!\+VB/N6/GGA47@E$C!
M
M                                     ^<@>+>NTTK=Z5$<[RHP #B#
M/RD/TRPRM3$T$;Z>S1\?LH/T;       6KOYEQ6A?2WQGVJ@1
M  !KLOC8<CC[5*9.631N8Y/K/!F<PMK [#:QTD:POB>O@\^CV^Y2SN+TEJ:>
MOW<?C>$1S4^'EYF7>QN3J5:UVQ3[8)6=K)%7\OW<H41VJ](GR3RIXJ1_D,5>
MY$Y.W=,Y]DOV[$E>9O@.B^'DQ1.+IM&%>P>;SF:R%>\]S'\M9$KD\N$]Y-L)
M;R.M.IXEV%61\?G/8]S&%VT5Y_;*S\E7GIS*C%3B=6$VPNT4XJC%GL.<K^.U
M"C+S&QU6XV:U%:1J,:OK\3ANM7Y+F6N>)=<D,ST61%\T49D'=:F1P51C6I9C
M\D1&IVHAKKNXT;CI*%)ZNLJO#2WAZCF.YYO-Z]'"EI[G)88Y>.[E$//SI)+4
MTUGO<Q7JO*(O')FV#9TL??L-E?!&KT8G+U0L0<\O=XBHJL7GSX553W$E##4,
MCE\I4J54[K%AW;]#$^*GO' 8>'$XNK29Y^$Q$5WQ44;H&0 'G[:W.FZTZC#)
MYQQP*]A(>L^0L0:HRE6G2.:_;B@^E6J()SJ.!CU_7,=C45'+!"B/<B<<N7S5
M3A&(FAW;K#/:?&Y:N+8J1HOQB7@L$DZJ8K5<OG\!4S&;DJ/5'(V-&>3D=[U<
M0G3JT6!ZL_)>"NNGH21?CO/O3CLY+E$LT95AZN[G!#Y0JWN<Q#=]=T>NCNX:
MJ\6HB#@]6I4PN-U3.X_,ROOS6&MFJH_SX1?3R);O=)NT]25Q[[46/\"FWF=?
M5_ER7!'M0VS+8;7]FQ./H^.]O/98B;RO+E[552"6%BHQX7QL;/#<CLNEG>].
M/%3N141HN#T;G.I6\0357XW69'U9ZS9(^^-RO1>/-%X(_G,5@=RV3%OS.<=1
MO/Q[/&I=G:L:\=WJHZ>A8Z*VLG4VS-8:&=T^.B23E_JSECN$4V5:9^W=9962
MR*^GB>7,B=Z=\:=I/T9.](E+K!J5VU(V.JZ-J(YRD8]JXZTY:_45LK(8)Y55
MOFUR-@ Y[2P7WS4]DS?MU:DV%[I4J^G>OY7"(>M>EF53*:5B9DKI"D;%B[6I
MPB^'Y<H!T,$
M
M   %*5 \7]=H%7>E7Q43FA  .'M_*13]+\*Y5Q-!53A5K1\I_P J#T-F
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MOJL.QXG$T<-CZ]&E"D<$+>UC$$T;,%
M
M                       YO'O \7==G*F]?G43^(0@#AS/RD^L_3'$_P"C
M*/GS_%X_/X_-03L-B      +5U?Q+BI"^FKXS[58(R              <U.
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MVO:O'KPI5W)\1U!%104
M
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M=SX3&)SW<?$G:#TGHG22*!E3(YI.;7'>D"?DM._0QHQJ-1J-1/)$0Q!6"@
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M+ Z5ZJGFGBM1$4FVB2=#ESV1BS6;R-N:2.S,C(6O553EJJKE0[^3>H
M
M                                  !RIY >*NNW*[V[\4G^8P #B3/)
MR?6?ICBF_P ET>555]GCY7_E0#8CS\@     +-U>8'E2%OBU?&?5P$9
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M6\ H     @'4726[CA64FSI!-%*DD<BIR6&:#7;H"ZJLZ.3P%9XW;^FKN_N
MQNG'3YVH8O(5+%EEE;4O+E1G"=O'! [W1&\VWD68G/K4Q]QWXVMVJ)W$IV#I
M3!?U'&Z_1M)795E1[I%:KE>I%ZO0^VW+X];V<?:QM1W,<#AHWNV=)YK^:9F<
M%DUH6_\ M/56J-<Z2KA\+GH),CXU[)0.B?+PJ,:+=%$'21[>GTVMOOM\=]CQ
MTG[?)'FO7H[D+.HIB[N8\6W!/XE.;S[8D].T2X-CJW2O)4]BBS>=RZW;$#4;
M B(J(G"<$CQNEY*IU R>Q/OM6M8A1B0#FP=,1"#]0M3?M6M3XZ.5(Y5D8^)Z
M^B.:!S2YT8EET:CA8;D3;L-I9WS<+V/5QUC$:O6H:I!@7\/C2HL,BHG'=W)Y
MJ31QO6^AKZ5?/09&[#*ENMX4"L9YQKSSWDYZ8=/%TZE>2>9DUJS)YO;Z=C?1
M!*-5BNEDM'J!?SZV874YDE[8.WSYE0HTCI.NM;;>R[K+'P*DB58T]6(\#?PZ
MIL3>H-G-.RJ_)KXN$J]R^O9VF-J'3VW@L9LT$MMCY<E)(K5:GDQ%140NATTT
M"YJN&R5&_/%-[5+S\SX<<$>TCI!+KFVSY:6XR2!B/]F8B>:=XT:[-])MG;E\
MI9PN9C2M>1ROBG17<=Y(L)T@H4=1R.&GMO?+>1BS2IZ->ST[!H@\'1C;YFU\
M7?V!%Q$4O*1-529;9THFMRXZY@+ZU+-2..-K7JJQJD8YK18TKI?F,7G+^=RM
M^)]Z2-[8O!3AJ*]..Y313ZIL.%UK9W;3=FR5*=C.UD+U>^-4?SW^9=P< NSS
M/P4=>//NGA;*B14>'<ISSY\>AZ+DZ6S9O0M:B27V;*4H$6-Z_P!M>[M<.87-
M<Z5;"_9:N8VC+);6HC/9T:OO:;WJQTYM[;%C)\<L3+4#W->K_+F-QG1TO7,+
M6P>%H8R!J(RO$C?K=[U-T4
M
M  #XH'BCKKW??V_S?_F4  XJS\IOUGZ;XJ1BXRBJ+RWV>/M^I6CT,L
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M<.0 5> '(           #N0    #N    "*
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MSCH"XG7S:?=BX!S<'X'X>]I7G^2X O7W9?T<7!R3FX?P4IU_VA/7&UBO\/\
MLO\ 5<!=X:*U^Z"S_NQ, _A [#[L5 -X07[H/8/=BH!_""V#^JH!O""?=!;#
MZ_)4 _A"9_\ JF ;PA_"#S_]4URM/NA,W_5, WA!?NAL\OG\DP!?NA,U[L/
M-X03[H3,(OGAX"XOW0N7]V&A&\(H7[H3,HJ?R/ /X0F7_J> ;!4OW0N7]V&A
M"?=#9;CSPT EX!3_  A<M_4T 3[H7*(Y?Y'A%O"*_P"$/E.[RPT!7_"'O_U-
M%^V)R"Y_"(M^_"L_;"?=#6?/G"Q_MFOX#^$1;_J2/]L)]T/:Y\\)'^V2\@K_
M (0TOOPC/VRP[[H>]SY86+]L2\ ?PB,@OIA8_P!LM?PALI_4\)=X 3[H;)_U
M/"5+]T-DOZFA_;4EO '\(;)>_#PA?NALG[L1"-X 3[H;)>_#P\_6I4GW0V2]
M^&B_;4;P@OW0]_W86+]L-^Z'R'OP\7[:C^!7_"'N\I_(T?[:C^$1=[_]#1]O
M^^3>$/X1%WWX9G[9<_A$V_ZDC_;+_ ?PBK'OPK/VPGW1-GWX6/\ ;'\!_")L
M\_Z$9^V/X1,_NPC?M!O #?NA[/OPZ?MES^$3)[L*G[9/X!/NB943SPB?:#^$
M3)_4:?:#^ 3[HAR)_H3_ .X$^Z)D3TPJ?:%_@5I]T4OOPO\ ]TJ3[HE/?AE^
MT'\!_"']/Y'7[0?PAV?U,OV@MX 3[HB/^I'?:E:_=#P<JGR.[[0?Q^A_"(B_
MJ5?M GW0\'OPS_M"_P "^GW0U+U^2)/VQ_"'I<(OR/)]H3^ _A#T^W_1$G/^
M^5+]T/C_ .J)?VRYP OW0]#W8B3]L?PAZ'OP\GVA+.$/X0^._J>7[0K3[H?'
M?U1+^V,X?T/X0V,1?+%3?ME:?=#8KWXJ?]L9P?\ H4M^Z%QO*JN+F_;"?=#X
MU/3%3?MC('\(?&=R<8J?]L?PA\7_ %7/^V,X?T/X0N+]^*G*'?=#8[W8F?\
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M03K_ *POK3MA.O\ JW^RW!RS]%Q.OVJ<>=:V$Z^ZI_06QRS]%:=?-1_HK?[
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MK!&0      #Y)^0[Z@/*72KSZG[#]<_[YZN0
M                         !_H!^?L./@R74=:5AG,,V7<Q[?BU9#T/L71
M#475+MFDZ>I(V)7L1'<L16H+*..=$\C8K;S4KL?PRQ%*R1/BB-5QW_/]8<+@
M]CEPL]2=SXGQH^7E$:G>:P8+>N&O2YR+&15;#T?92%)TX[29[CO^!U.LU]V5
M7S/\V5X_-[B<HYJS[H/ +*U%QMI$53L=#9,7DL5)D:%EEB!C'*JL7WM3G@O+
M!X@ZA[=!M6Q_*$<+XX6QLC1CO7A#N&J9'I[D=:V.2A@WUTK4%;95%3Q9&*@Y
M1K^E64T:E9RD^*Q][QX:<DLDDST5>QOZ*''=MVN'-[H_-1Q2I#XL2MC>OFB1
MC,'L?1MYH;?4LS5()8D@>UCD>3LR/$_5O.Y'/[N[$L=^)K3I!!&GO<X[E@NB
MNHT\7X-VLMN=[/GS/545/J%WH.';%TEVC%[.RO@JT]B#RD@G].P]?8EUV##5
M'91[&V&5VK8=S\U'(GFO(ZV#E&R]<M=Q-J:M3@?>>SM^>QR)&;/5^L>LY^ZV
MFO?4E<WEOC*B->OP137+,@F>V[72U;$+DK<<DD22-9Q'YKRXYC8Z]ZPRBL\5
M2R^7O5J1>2"<,&TBZS8)=;AS,E*RUCK"P*Q/-4>B<F/-UTU2/'PVT9.Y7OD;
MX*<=Z=A>6#.U3K'KFPW(J2H^I/(GDDBIVJIU>>S!7A?--*UD;&JYSW+PB(GO
M4SQ3K!PS,=>]=HVI(:E.>VC'*BR(J,:234NK>M[)994175;*M149+Z*OP:I>
M68)=M>U8_5\7\H7FR.B\1K.&)RO+CF][KIK,&-KVX()YG2R.;X/DCF]A.642
M_$]1\!DM<FSBO?!7B<K%23R57)[D.?6ON@]=CF8D&.M2L7U?RC2SA'0M1ZC:
M]M<TT%"5Z31L[EC>G"JAYCZQ[A7V'-P0U73)%31\3V/\D\1'"9+1V3I#N^)N
M8K%Z]&DB6H*KE?Y>2\*1K76=-?PAQ+33(IDUNS=B/_-I)Y\B\,O;T/1>3RV/
MQ5-]J]9C@B:GFYRG'9NO>IQVHV,@M2Q>^1$).&71TK6=QP&S0^+C;:/5.>Z-
M?)[?K0P]NWS!:FZDF265/:>_L[&\^3!R]1&\IUEU''P0/\2:5\T'BLC:TWNJ
M]1=;V>5T-*PK9VM15BD3M<+!M-HVS%:O1CN9)[TB?*D;>QO<O*E.J[AA]IK3
MSXUTBLB?V/[V\>9,F:)6
M        '(NMK>=!O_1-$!C= U>S2/-B(BVI.%.S                #XH'
MASKE+W]0KJ)^A7@: .11\][>/BA^FF-5[J557IPY86*J?!>"^AF@@     MW
M_P P[X'U"WQGVM7QGVJP1D       ^2?D.^H#RITH\^IVQ_7-^^>K$
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M>NLDJ)[WJX4=SZ3ZOA*>L8C*PTF)=FJ?/F]ZG -+Y_#%7\O3)6?^CQ!(.O\
MG%LY^GBHWO\ XK#R]/<KI3HFJ]&=8?K-9<C#X]NS CWS(JIV*]/1HHX-4]LT
MGJ'[)7MJQ(+K8W/^,3E]''3_ +HM?]6_JG+^#*Z;=*,%EM6K9++1/EFM,<L?
M*JG8B*J(<9Q<<VO=18(*D[NZME$A;)\6]_8)WH]E;_I#-OP<=%UM8'-E21C^
M.XQ>GFALTW&V:J75LK/,DCG*WM,CH(
M                  <BZV_ZAW?HFB M=!UC^\>'Z+,IV(            'J
M   *'KY?0!X>ZZ=R;]/_ '2  <?C3E[4^E#]-<>WLHU$YYXA8G/Q\B^AF @
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MJ&+BOV:\LS'S)$C6%&C[Q2W"A9MU:TL+894C5'C.FB;@@
M                                <CZU,1VAW_HEB M]#$1FBP+\;$IV
M                 J'Q4 \3==D_R]D^?_W*  <8C_.,^M#]-,>[FA57G_LF
M?]"^AF@@     LW/S#RM"WQC5\9]JL$9       /DB<L=]2@>5.DR]G4O9$[
M/?-^^>K&KY%O< 0
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MM6,;2R7>D39$D:K'=JHJ%C4],Q&J4YJF-23LDD[WJ]W<JJ2:)6"@
M                                      !R'K=_J'=_XT0%CH/_ *C,
M_O4IV4                ' >'.N*.3J#=_N\'[H Y%"BK*Q$][D/TWIM5*M
M=%]T;?\ H!D@     "WD%YA<B'U"WQBWQGVJP1       #Y+^0_ZE \H])FN
M7J9L2\*G'C?OGJ]OH6]P!                              30!0
M       <J             ^/>U%\U ^H        C.SZGA=GIQU,I LD;).]
MG#E:J*9.N:YB]<QJ8_&Q+'71ZO[5<KE[G ;T
M                                         Y!UO_U"N?\ &B L="FJ
MFC0_39D.S                 H'A_KJ[G?['T5( !R.HG-F!.>.9&^?^)^G
M53M;7C\^>&H!4      +5WSA<5I[B^EOC/JH$0       IE_-O\ ]U0/*_2/
M_P#&-LO_ ,7]\]5-]                     !S?>>I6$U.)\3W)->[$5E9
M!(.0+]T/9\5J_(421\>:>*=1T7JMA=J>RH]OLU]>52%?-'(GP<7^<Z#JP(
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M#KO/D6S !        ^/7M3E0.+X;K)0RNW,P,6*F1'SOB297^]GQ:=I+0!
M    ,#)Y?&XJ!;%ZW%7C_GR.1H&OUS:<7L5.6UC)5?"R9T2O5..5:;\
M                                                           '
M'>N'^HEO_CQ 4="_+18/[S*=E                >:AR >&^N3^[J#<^BM
M .2UT5T\2(OJ]#].J3/XM$U5]&-1?U 7      !1>=S$X^H7TM\9]JH$0
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M6;<[U[WJQKT1ON1I<@B6IY*+'[UC[=%\D=;VY$8JIYI$Y>.%.K_=$?Y]@/\
M@3$V#H72[2<&NCTY;F+@?/<C<Z5[VHY515.!:;#+A.JE:K$J<19%\/T=J\H2
M2#;=<[CK.ZI71[U;#7C;]"*X]"8[I[J_WGP47XV!ZOIM[Y>Q.]7JWGNY%@\O
M=,X%K=2<9#[H[4C?U(I+?N@O/::']R0#I]71,#C^ETZR8V!]EV-6:2943N[U
M;SZG#>CN QV;VY(K\*30P0ND2-?1509!)>O.NT,7D\3:I5HH&3Q/1S8V=OFQ
M3>;;FITZ*Z]&^;B2TD3/K;&!SG0-FU' QWW9C#/NSRKPQW#7-:SZG$<R&9QS
M-P3)8&&2E7]HC?$Q?)6*AK^8.T_=$2MDBU-Z*BHYEI?UI&2/HUI&%ET]M_(8
MZ">6W*]461J/XC;Y&1PNE#\B=4X8*K%B;!F.R-J^YBOX.J_=#4:<+<-9B@8R
M>5\J2R(B(KT1!@E70G$XW[UFW_9H%M>TRIXW;R]#O('-MXV',4\A@<1ANU+E
M^S\]ZM1W9 SS<XAEW,]2<IN.?Q>"R%.*"@L?E-&GH]I1EXG>=EJ1;1B\TR!^
M3QE)UEDT7Y#T5#I6MY.W?U7'9&RK5GEIME?PG"=RH*.(R=2ML?I+,G%-72W)
MF5JM^8G",,_*9GJ_K=3Y5OKCKE.+A9V,1$5&E&]V7J+D7XO6F8&!K;^:1'0K
M-YMB:7]8V+>JFPQXC9:L4T=F-75[E9OS$5GJCN"#?:;L>5RV9VNI=:Q&4+R1
M0]B>C2NELN0GZA9;!/2-*M>A%,SR^=W.)[$6R_4_V'?*^.:B+BXG)6N3]O/9
M8D\VFXZH;GD-2QV+NU&,>DEQ&3-<G/+.TH;=O2U- 78\,YCUE2'PE>G*)WO1
M%Y0C^[['U#P]),W0=07&)5@>]CF\O[Y!,&^TFYU+M7()\['CTQ\M?O9X7Y:*
M[S0V>VS]0H;U;[WJE&2OX2^,L[N%[QL'/-2W+J=L:JD%+&I'5N>#;E<JM7R]
M41#8YG?-MR>R6L-J%&"5*?E9LS?D=XV#;:KON7^7_O=V>A'5R*M[H9(_..8D
MG438;^O:K=R=)&+/$K.WO3E/-P]P8VK;O!L6I29:#M2Q#"_QHOYDC$.9OZG;
M?:P^J+CZE7V_)RS1JCT7M58U*-G;WCJ)K#ZDVR8>D^E-.V-TU=_G'R2/;=QS
M\.9J8/7*$4]V6O[0KYG<,2,=!=TO;MDM9RU@MAQ;(+D4'C-EA7\6YA)MOM;7
M6I0.UZC7LSK*B2-E?VHC"=J.;X?>-^DW+'X+(XFG'RCI+*PN[U9&8M[JCLZR
M9/)8["P287'65BGD>_ME<7IH[I4MQ6ZM>S$O,<L;7M7XHY.4.';!U'W*.YFY
M</@X5Q^*D5EB6=51SU;ZJTDS:-WG>I5N' :W9Q6/26]F>$@AD7AK"_K?4"\_
MY:I[%294NXR#QY?#7NC=$7((Q5ZE;E W%9;*8:O%A;ME&)*BKXC&/7AJJ>@&
M.3MY0@\\6>KV<@S4C?DZHN/;D_8^._BQ]?:>AV+\T4<9VW;.HN%LY&:MK]-^
M-@3N;9?-^@8%+JKEFZ;#FK^(8EFW:\"C"Q5:V4"0ZINNP3[)+@]@QL%2TM9)
MX/!?WHYI)-VVINKX&?)>S+.]'-9'&B^KWCIHBFJ[WL-O/0XC/X5E.:S66>LZ
M-W<BHWU1QI<IU,VF*3,VZ& KRXS&VEAFD=-Q)\WU4O0;;9>HV1JX[6I\+CH[
M,V615C@E7M=Z<DAT[.;9DF79<]A8Z#(VM6%6O1_?\29@AD/4+=\G76YA-9CM
MU5LS,8Y9.U>R-41%+^H]1]AS-O,LO8.*"''0/?/(R3GAZ)RC!+!J\;U<S4L.
M.R=[ 118FW<]F9,R7F3N.[S6&05I9G(Y6L8KU1$Y7A$Y\A1PY_5?.LJLR\FN
M)'A7W$A2P^3B1$YX[NPDV?WO+P9^+#X##)D9TJI/.JR>&C&N]!T&)'U4@34<
MEF+&/?#;HS>!-35?255X0P\=U(S\&0Q+-AP+*5/)NXK3LD[NU53R1XZ"8XS9
M;3-QR>"OOB[EA98H]B<*L2^3D7Z4)R0                   XWUR=QHECZ
M;$0%[H6_MT.O],\IUX    #@           %0#PKUL8C>H>2^F&!5^S '*8$
MYECY].Y#].Z?#:T*)Z(QO'Z@+H      IO,1*KCXWU+?&+?&?:K!$
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MXQVI=*+:LC8ZS[!+/-WIW=TDB<JBD'"F:S/B=/UW9%S*6H$NQ2_)J^;.7/\
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MO5A*\1@,7A*JU<=597A5ZO5C/3EPE%<N$QTV5K9.2!%M5XW1Q2^]K7^I;S.
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MM#&-9.Q%['J]SU;]7<HEHU.)PM^_O^4SUNN^"*I$E.FUWK(GJZ0Z<4
M             XSUT5/O&F^FS$!D]#UXT*G_ ,:4ZZ                "@
M>$NM*HO43+>?/#(/_P $@ Y?48C[,#5\NZ1J?K4_3RJB)"Q/@U$ ^@     "
MS<_,O*T+?%;XS[58(@      !3/^;D_W5 \J]&?+?=D3C^D]W]L]6)Z
M     <H Y0      !Y?$@* '(*
M                '  #@   ( *
M  '"                    '&.NG^HTO]YB RNB*?Y!TO\ BRG70
M         4#PGUK9V=1,JO'Y<<"I]F@ Y9"O$T:_VD/T^J(BUXU]W:@'T
M   6;J_B'%:%OC&KXS[58(R       4S^44B_P!E0/*W1E/\O-D7CC\OW<?I
MGJMOH         %7@X?O763&8*2>CC&)9NL7ASE_-,4LFCD:===S2SX[HJRP
M_P!%X?#3LN@=7,?LDU;'7(O9\A(CN/Z)_ Z4=G1>00  .8[EU0PVM6TH)&ZS
M?56?B47M1J/^+A.HF6<RDF/P%[(QQHY\%5TJ,=Z*J)SPIR;IGU2RFWYFS2M4
M:\+(H%DYC5PZ#9=2^I[M2L5J56HV6S*SO59/)B,(7JG5K;<@N06WCH'Q04I9
MTE1JL1.Q#4Y9.HD?3;JKDMOS<]"QCX(6,K++WL53NAF@   Q[ERO3K36;$B1
MPQ,5[WKZ(U/52$:QU&P>SY:W1QB2N2"+O65R=K5$G31/P  &NS&8H8?'SW[T
MR15X6\O<1O3MWQ^W0WIJ,$K(H)DC1TGDKQ@FJ   !!-^W:#4,0RZ^%DTTDJ,
MB@5_8KP(?H/6!FTYOY-FQC:KEB<^-?$[^Y6G:Q0  $T - %           $@
M H<>8<O" <!N=?L-5NV*LF'M<PRN9RCV&*OW1&"]V%M_ML+D_1,=+ZQ8+9,D
MM!('U)%3F/Q7(OB'5R4   !2#97J!KV.S='#K.LUVS.D7A1>:QJOO>)U$Y1>
M40 #3YW8\-@:R3Y*Y'!&O*-[E\W*GN1 +&M;%3V+%0Y.FV1(97/1O>G"KV+P
M;\  ! NH>\QZ72IVI*+K/CRJQ&H]&""[H6\UMPQ\UR"G) L4G8]KU1Q.!04Y
M/LW5[7M=S<N+M06'OB:BR/CX5$52R";:MLV/V7$PY.CW)$]SF]K_ "<BM7CS
M)$0#X]Z-3E?)/B!$:.]:[=V)N$IV4L6/"?(]T?#HVHSW*IA[CU#P6H34XLDV
M=5LM<YGAL[O)I<ZC>:OM&.V3%,R6/23PG/<Q.].%Y:;\@$;VS9JNLX:;)V87
MRQQN8BM9Z_/7@3K<%C3]UP^UUK%C')+VPN1CN]O;YJ2L7I0          4Y'
MLG6/7L!G9L78K3R^$Q%?+%PJ([X%D'0-;V'';%BX,C1>JPR\^3O)S53R5%-X
M0 -       "-;;LD.M8*WE9H'RLA[4[&KPJJYR- U6C]0L3MZ7%HP3L=6[>]
M)/[9.A>E  "#[YNT&GXV&]-3?8229(^UCD:)W&=I.V5]KPL>4AJOA:LCV=CU
MY\VDJ      &ISN7APV)O9*>-[XZT2R.:S\I40")Z1U&Q6Y/NLHU9XEK-8KU
MEX\^\Z$6S !      .,==?\ 4:7Z+40&;T0<J:#2\O664ZT
M   "@>$.M#^_J)ET[U7M; GU?BD '+X.5FCXXY[DX/T[J\^SQ<^O8WG]0%P
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MV;(THG>CYXVK_BY$/TT@X2)J?0@%0      LW5_$/*T+?&?6KXS[58(R
M )R !;L>4,O^ZH'E7HO_ *\[#_S^Y$_3/5R"@        MRQ,EC<R1B.:Y%1
MS53E%1?<IXZWWIIG];R]G.8A'/J>/XL:P^4D*J-P:6WU9Z@S8^2A-.]KW)VN
M>D7;+PI)NE'33+V<Y5S65JNAJP+XL:/]9'EO%+.@Z%UKT.]G*M?*X]G?/3C<
MDD:>KV')L;U?V7%ZXN&=2[I61K%%8=RCV()<'2>D-/J#/;9=RMRTS&,A5&0S
M>:RJ\YIU79(O5![.QR_.K"V#VA!^99_NH>+^M-&Y1WM]Y*RLBE2)\4GN>K$$
MN#H^O]0,EMNG[=#;J,C?!07L\)%\T5I#/N?6_P"4V2Y9Z4AL%GKXG&WT_+R]
MC8>B<OY=.+7'E_)"_N >>ON?6.^^J^O:O'L*FTZRZ?FJ6PIM&/C?)$_L616>
M:POC)V$4S76/9<SKTF'?78R29O9+,SGO>AT3IOI>SLU78)[R2MEOT%AIPR/+
M;!QG4\U/H^U^U9'&RJ^%LD;XE3M7E?(V'4?;LOM<E2_+C9*U!BN97Y3E%4:/
M0N*EGS_1WPZD:OF=C7PHSXNC\CS/I.[7M,R-Z6.DV226/PG-D56]JHI1UKJ_
MIUS+U:6U8Z/Q4=58MEC$_4\T-'K;>JZHF,6HJWF1+$RSSZ-)+!.^D%_J'DK*
MS92>5<8R+R6=GSGJOIV*>B4]":.6=8Z5N[HF196B=(YCHWN:GKVM4X!TAW]^
M MLPSJ?B,O6V)W\\*Q5\BRC/ZOZ3D\7L2YRA!(^"T_Q7*QO/A2()>O.:?@O8
MFT&);6/L6RB__/L)+.HSNB^DY>?._+]^!\,$"*L7>G"R/>>M4 \W_= ["R&A
MCL+%(G?*_P >5OP:PU'3+I/@,[K,&3RL<SY9I55G#^U.QI*)QENB&GK2MOHU
M)FV$KO\ !3QEX[S@O2K,)K6]119+OA1_?5D:J>CW%@D/635<EB-I78:D;UK3
MO9(LJ>D<K1G.N65R>M/QL=/P+<K>R6RQQJ8)OT6QFV6&7;^4L6?8GUO!KLE<
MOG]*(IQR2#.=-]U2S)75R02N6-RHJ,EC<3=HD6Y=7,IM<5&EBZ<U1Z2H[YCU
M5[GG4Z.@;%D>FE^AEKD\F0LN\>)CW\JQS/-K .':9N.8Z>Y>U%9HR*U_S)Z[
MU[#,W;>LQU"NU*-'&O;#&_F*!GSWJY1<P=0S.J2:MT8O5)7JL\JQRSHON>YR
M>1'ON=E_EC-_W9@&HZ_JGWX5OHI,.VL56]&N??\ (:_N#T.'= E_RSF_N4A8
MZZ.XWMZ_"I"!(:'6VSB]8BQDV)<EZ&%L,;G>3.SCR53 Z%:S<O;$_.NY97J(
MJ)_;?(BH*(;NT;\=U+R$M^HJQ?*7BJQZ>3XE=R2KJ5U#P>PXFOC<+C7LAA>V
M21ZL1B((.A] 98EUC+L1R=Z6N7)];#E72GA>JD'_ !;?[K@.]]<>$T&U_>(2
M*?<[<?(^:^/M+ -#U_P"P9#&YV%>._\ %/\ CW,\T4TG1+#29G;+.5M,29M5
MBN5[OZ5X'L9/3@/Y1JD'@G!<OZIU/_6%_?/;&R:]0V'#VL=;B:YDK/)?>UWN
M<@'AZ%^:Z=[IP[EDE:7AR^Z6)3N'5VA-MVIX3.XB!9XHD?(_CU1CR^ASS1NJ
M=/7,"_&W\3[2^)ZK6=Y>_P!RDHZ5[-M^?V>3FM ^CWJ^=ZPM3PD]R,4NS!7U
M2VK?\!L+V*J?)4DC7P(L358]&IYL52*;IN^BY_!*V#7UAR;_ #25J(WL4"<_
M<[XVY'%GK\L3V0RK"R+X/5O)R;8,A-KO5"]D):CE6#)OG2-W+.]O</8Z'OVS
M6]VT%F2I5I(X*N15+,'/<J)V^3E(STTZA:[JV/O,OXQ\MI\O='*QJ*!!9,K+
ME-U9D5A\!T]YDG8GNY5/B=[^Z'J/=C<%:]S)9&*2C6]'NHJ=F-U2:HG#WRHR
M8YME:5_1=\6>[CTFB;8>^/N3B.6-Q:)'N75.C?6E'@,5#!V+W2K+ QRO4[3B
ML+FMCZ:6:N4J5Z]JW$Y\3(XTC^EBN06\,]#SOHVW7NGV?N17Z4O:_P#%V(?1
MR<%_J;U'7<'U8J]=\5.!55._U>]0.T?<]^>L9'^_'?GKPBKSPB(9'AKJGGG[
M1O"UJ,B31Q/;6KHTZW%]SWAUBC5^8MH_M3N\FEHYMU,Z6U=0QE6]4O3SM?/X
M3TD.A=+=DER/3K/T)E3NQ]65L?N7PWL52SL(;]SXO.W9#Z:#SU+LS'OU_+M:
MU55:4Z(G_(I*/$?3/;,=JNPOOW6/='[.]G#4\^5)[UUR=;*PZG?@Y6.Q4ED9
M]2JTHZ)TXQK\MTCFQ\;D:^=EF-#A>B[98T'8;;;U296<+%-%SV^B^I()/NG6
M;+9:]49KDEFG&Q/H5TKE)_NJ;"O1^23.3^)=D?"]_DC>Q%<79T@P>A59+FI;
M#51W"RR=GZV'$J,4&F[G)#F\>VW'6D>Q\2IY/14\G)R-ZB8[GO>I2/JQZY@:
M7"><KY:Z?._LHAU5,EMF*Z;PY7$X:A4F5?%F@BC7\TOZ:-'\P<WP'4'5<RMM
MFZ8ZL^1Z>5ED/G]2]ARS+PXNSL<D.N0SOK2RM]G8O/>+/<'Z$XN*:+'TXY>>
M]L#$?RO/FB>93EZ;KN.O56KPLU=\:+\%<G!D>%L#D<CTZW17W*?>Z!71RQ^G
M<QWO:I-^H_5Z'8\*S&8R">%DRL6=7<?/3U[#4'1.A6NVL;@+N1LP>&MYZ+%\
M>QAQ_ITK%ZN5_IMV_P!UX'MX*J(AD>&=]RL^W=07U&/YA2PVK!V>?DB\*IU=
MGW/&)[?/-V?V&FMZ#E'4OINW2_D^:"V^Q%.KD57-XX<ATS![$[+]%\U#(K/$
MIP+#\5[0(U]SRSG8LH_EOE4'W0G<FRXSE/+V,E'>=<;_ .S*EQ_4Z_N'G;H)
MY[G/_<Y -%U(P;M8WJ:=U9):TDS;$;7(O8]%7E6$LS'4C0EQ3?DW4J_MBJU5
M2:%G8TL'6.D-FY?Q%V_+@Z-&"142%8&=BR=IPKI2O/5*#Z7V?W5)D@[_ -<^
MU.G]GZ;,!&N@"=^IY9OQNK^X@'"L;;LZ#OZOL1R,;5LO:]GO=$XGG4KJUCMB
MPJ8O%0RMCE<CIWRMX7YBHJ(TU!F= JJVX=J@YX22")GU=_<<J?7L:1NG9<@9
M86I/YLD;RR5BF;1U/9^J>G>QP_(6!J+.LC?%2>JWCL.FZW6L;7T\OMFP]2@M
MZ-Z1,B9PUR)^2]4+<D'GSIYM"Z%LUQF3K/;&Y%ALIVKWL5IL>J_4:IM;Z57'
M>)[' BO57MX5SU'K1W3H;_J)!_>9CL:\F:/!G46:;\(N17+(]8VVD143R7P?
MH)CN^Y]/;.J+B\!BV>,_M3Q%A[%C1I>E$E^YWLPK5S]?S[^Z)YS'0E>O5.FL
M<R,YOR_XIY\H4>D^M:HG3Z_],L7[QSG[G9J+!LGUP$@Y.KI-%ZD+--77LIWG
M.1J>^)YU'J?U6U_-:L_%XN1\LEE[?%56JSL1CD<7-#[G+RL;%_N0'J4R
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M@#G6,1KLC21WDU;$:+]7<A^FL7YMOU ?0     !9O_F'%:%OC/K5\9]JL$9
M      *;"HV*3C^:H'E7HQ_KUL?_ #_OGJM.2WN/H(
M           H      #E   #S     )H H&BR.L8#)V66+N+K32M]'O8BJ!O
M6M1J(B>B     %N>&*Q%)%*QKV/:K7-7S147W*!%J>BZC2LLL5\'49(U>6N1
MB>1+41$
M                         <3Z]+QI/UW(P-WT65/P?XGZY?WSJ(
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M?-$ YUTRZGW-RR-ZI/CXH/ A21',55.S"@
M                                          '$>O7EI2?WR,#>]&./
MP?XKZY?WSJ(                *GD!X(ZP*OX1<_P#[\/\ ^": (!BT:[)4
M4?SVK8C1?J[D/TVBX1C?J       "Q=1%@>7$+?&?6KXS[58(R       46/
M*&3_ '5 \L]%7\[KLOGZJ_\ ?/5*
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M!>/B.40:'*!%0 /\0'*?$(J?$!R@*
M    !Q+KS_J5_P#K<8&\Z)KSH&+55]%E_?.H@                J@>".L'
M;^$7/<*OY</_ .": (#B45<G01/5;,?[R'Z:Q_D)]0       6;GYAQ6B%OB
MM\9]JL$0       MV/S,O^XH'EGHG_KGLO\ S_OGJI/0
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M*OL. I9*#R;,SYZ>]'IY*A!OP0
MXAU[?QIC$^-Q@&[Z+MXT#%?7+^^=4           =H     4#P-U?1&]1<^B
M>G?%_P#.)H @N(<K<KCW)PBI9B5.?3\I#],8E3PVJOP J      %JZOXEQ6A
M?2WQGVJ@1       "FTW^+R_[B@>6>B/^M^RK]?[YZH0
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M QJHB]S_ "[E53/TO7&Z]KU+&I*KUB172.7WO?YN*)*
M                  <.Z^>6F1?3=8!(.C2]W3[$K\/$_?.H@
M     Y/(#P#U8C1G4+8$1$\YV+^MB "&X/GY9QG'^UP_OH?I>Q?) /H
M LWN%@<A6A;XSZU?&?:K!&0      "BTO$$OQ[% \L]$>Y=PV5?K_?/5*
M                                     $T!Y( !0
M             .$                          #@
M                   #AG7UW&G0I\;K )5T85$Z?XE5^#_WU.D@
M        H'@#JR_GJ'L'_'9^X@ A^"1JYK%HY%5/:X>4_P"=#]+&_DIY 5H
M     +-Y?Q#RM"WQGUJ^,^U6",@      %JS^8F_W% \M]$.5V_9/\?WSU2
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M<51OLC5C;,+9$:OJB.-D
M                       X7U^_U/@_OK )3T;>J=/L1]4G[ZG2P
M         =Y(!^?_ %7\^H6P_P!X3]Q !$<$G.:Q:?&W#^^A^ET?",0
M  +-U>8'E:%OC/JWQX?M5@B       %NS^8G_P!Q0/+/0UW^5NR?X_OGJI
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MBAW(.4 =R#E '<@Y0 " .4 <CE"@.0'(Y  !R@Y0!W(.0
M                   <+Z_+_DA73XW6 2KH^Y%T##K]#_WSI0
M      *!X!ZL\_A#V#RX_'L_<0 0[ NXS>+7X7(?WT/TM8G+4 J      %FY
M^8>5H6^,^K?&?:K!$       +5K_ #>;_<4#RUT,7G;=C_Q_?/52%O< 0
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M_@2191G;#)$WM\*5$_(4E^O9V\_/YK!Y.5C[-=4F@>QO:CH)/3_%""=@@
M                             <+Z^JB:?!]-Q@$IZ0>>@8;ZG_OG2P
M              =Z ?G[U565>H.P^)Z^TI^KL3@ 1/ KQF\7Y\+[9#Y_\Z'Z
M71_DH       %J[_ )LY?U(5-+?&?6KXS[58(R       6K/^;R_[B@>6.A_
M=]^&PKSY?/\ WSU8CD):'*?$^<I\0/O*?$<I\1H<I\1Y?$!R@ <I\1_B '*
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MA@T-%_TM_P#;<.4$ZPZ%_6R?9N'X9=!]/E7_ .V\G*"=8] XY^5_UQO'X9-
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M&]^)8%Z2:)_4[!@MOZ0Z,[_PM!^"+1/ZG83 7I#HKG*OR4TMKT>T7M5$Q?\
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M?0       +-S\P\K0M\9]6^,^JP1
M  #O0#C73MR_?EOZ=O")<B.R@
M B  H#@*@ <   X':    .!P  #A  [1P X"M <(. '  <#@ C$'   .
M    #@ !VH ' #L0< !P   <  C40!P   =H <!                !AY#E
M:5GC^B?_ - .-=#FHF%RZ(WTR,AW$M $              #O0#\^>J"N7?\
M8N?]K4 :#5>S[Y,+W^GMT//[:'Z2LY[0       LW%YA<7$+Z6^,^U4"(
M     ,6SD*55T+;%F.-97]D:/<B=SO@AE #5V<]AZEGV:QD:T4W'/AOD1KN
M,>/:=>E>R./+TW/<Y&M:DK5554V%S)4:,;7V[44+7+PCI'(U%7_$9Q>X+$V:
MQ,%>*S+D*[(9/)DBO1&N^I3.JVZMJ%L\$S)8U_)<Q4<U1F"Z !2^9L;'/<Y&
MM1/-5\D0"J.5DC4<UR*GQ1>0  !5*%GB]?$;Q]8R^A6CF\<\@ .0      Y0
M '^@'%NG'GN74%??[=&=I         "KPG) EZG:*U[V+GH.6KPODX9HD6#V
M?!9UDS\9?BLI$J(_L]RJ;L9@?XF+2R%*VDRUK$<WA2+&_M7E$<GJB@97(
M                                         ,'-9'Y,Q=J[[/+,D+.Y
M8XDY>[ZCC\_7'"5G1LGPV3C<]?)'QHA9(-]0ZEP7X,E)%@LHWV2NLRH^+CO^
MA"<X#,,R^)J9!M>6#QV=WARIP]I!M^Y!RA.H<I\1R@T.4!0
M                             Q;W*5+'IYQ/_P"@'&>AWEA,O_ZC(=P%
M                *!^?'4__ %^V/^^* -!JSD;L>%5?1+T/[Z'Z3-]
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MGTVW7\AK%#,:_C%N.L2,YA5W:K&JO#A<$^8JJB*J>9](
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M&_X7'-_8\@!I]/A2;:<'&OOO0_O'Z0,]        M7?S+BM"^EOC/JH$0
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M>QL3^97HZ1262CKD:\HBGT
M    !QWJI@,OEMBTV2E5D?'!<YFD9^@G* 3#J/C;N1T;,5*<*S3RPHC&)ZJ<
MCIZOGV5NE['8^5/8II%M?^5RO*=Q8)CN.%R=S?\ 2KD%1[ZU9\JSRIZ,*]@P
MN3GZG:Q?CIO=5AJS)+-[FJHT<VIX.36=DSL.3TUV3ISSK+6GAA1_;W>:-)WH
M>/R]1F>S$FOUZ"/8J5:+(T9+PQ/>Y"VB=:5G,KG,6MO)8E]"7Q7-2%WO1/?Y
MDN,T                                          ,;(<>QV?\ @O\
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MEX[VI[G&?KO3G5]<OK>QM1T<RQ>'RKU7R)!.3X]$5"CB_3;A-NW]/_S]AVD
M        *A@.Q&,?W*M&!5<O+E[$\P+U>E5K-5M>".-JKRJ,:C44QK^#Q.1D
MADN48)G1.[HUD8CE:H&7%3KP_FH6,\N/FHB>1\93KQO<]D+&O=^4Y&HBJ!JI
M=6U^:XRY)BJJV&+RV58T[C;RTH)XT9+$Q[45%1'(BIRGHH%Y$X
M                                  J !V@.U!V@.T=H!$X
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M=J
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M-#Q$0<@ 4                 ,').XHV_\ @O\ ^@''NA:JNN9'X>WR';P
M               5>0/SRZD*Y=[V/G_;I !@Z3W_ 'W8'M3E?;X?WC]&V^@
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M-/J,1.:L<]E[D\U1...%.PIZ&0       ^*!Q;IFB??5O_\ Z@P[4
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MXUNY'O.<WGP+EME:>M D"<JQT3T.A]+<Y=R>NK7OO5;N/G?6GY]5[!:.E@@
M                8>07BE:_X3_^@''^A:)][F1_O\IVP
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M.'*2CL((                 &#DU5*-OC^A?_T X_T+Y36\A_?Y#MPH
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M;D@7M8SR5[ATYUB?7=9KUK7G;E>Z:PO]MY1/       '(  !R  #E  Y0
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M+:0L3YDW;^6ITK4MKQ^U8KY0HQRLB\5T?$J<+RT9!*"EQ!Q?I>SC8M\7L_\
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M$_Q6;Q67CF?0MQSMBE6*16>:->WU0VA
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M.K8+7<1@H[,6.K^$R>=TTB=RNY>[U7S-\
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MQ'>C$)*0
M               -=EE1,==Y]/ ?_P! .5="D[=4L<-XYNRG9@
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MKU:]>-(X8F1L3T:U$1 +P
M                                   !K<NO&-N_\"3_ * <NZ&=J:G-
M_?)3L8                . _.+=72+MV?5[.U5R$_*?\X RNGS%DW77FI_M
MT1^B:>@       6+B?B7EU"^EOC/M5 B       $%ZD7Y:&E9R>)%[_9U;Y+
MPJ=_D! .BNM8=VH,O35H)I[,LG>Y6HY41%X[288/IQKF RN0RE'Q$GE1Z=G?
M\QB.]R(/8\SZ)4VJUL><9K]QE:=$>KY'HGHC_1#L'2C==GS"YZADI6V+%-G,
M?<B-=WFMH@V9VSJ9CHK.1OYRM4<R=$91YC<YWU(WDFFU=1,S^#;#YS'6? LS
MSHR1R,+THA^3W#JQCL'B]CLWH6U)W,1(48S];R<]1^I&6Q6!P"8UJ1WLE"R7
MO]>Q";.@@^R;IU7U>"A!D;4'%GA[+",:KOI:2SJ#U)S=7+8_ 8-[&VY&Q+-*
MO'K)Y]OF)=%[2=]V>';4UG8I8)Y)&*Z*>/CX=WJPCLW43?MDVFY1UA&,AK]_
MDJ-5%:Q?5RO%R#$Z3SY*WU+SMF_$D=M8)O'9QZ/[CJ.B9#J);V/+QY^!8Z,7
M<D/S&HBN[O+A4)LHZAE[T>.QMRY(J(V"%\B\^GS4Y."T()['37:=EM_Y]EH)
M)7JGHC&>3$:)VHM:GT>US*ZKC+EM9VVYX$D61DAM-"V677\;M-#+W'S,PD_#
M/?(L:B=1>9UAO1Q07;NJVX,;(]$]KYY1&.]'&[V+J<N,R]/'4,/+D9+55L\"
MQ/X[D<,&EAZNY6>W-0BT^XZ_"JK-!W_D,1"1Q=4<8NEKL,U5[.V18?9D7E_B
M\\=HZ#5TNJMMMFC\LZW:Q]6R_M99>O<WE3)R?4^6'8;V&QF LWYJK.Z56.1H
MR"%;_ON1RFD4KN-I6:R27DCL*KNQT;XU\F$IJ97Q=RU>7)T9ZU^3#SN<U)46
M-K4^*#I@L7.LC&ON24-=NW:4"KS;9Y,\CJVOYZIG</3R-3N\&=G<G/DJ+Z*B
MD&X  I>!QCI:SMSN]?3E#M(
M
M            -;F/]&7O^!)_T Y5T(X^]2?G_;93LX                .4
M#\W]Q>U^UYYS?-%R$_[Z@#/Z>R^'NNON]/X[&A^AR\]O* 5@     "U=_,N*
MT+Z6^,^U4"(       :O.XB'+XF]CY7*UEB%T;E3U3D#RCC\UOG39;F&3%K/
M Z5SH'JQ7)]:*TG73'";I:R^3V',RSP1V8W]M=5\I'.+S3(--T4H7H-JV1\]
M25C.QR<O9V^?>6](I9-,UU&;CZ<D$[F/2NU?<[N42CE]+%W)L9EJ,FKVY\HW
MO<ZR]7(D3$\U\OB2_,Q6W]&,-%[+-W19!R/1443B@F'4"M/^!W7XO!?WI[-R
MSM,3J)@LA+KFDY2FQ%LTJL?,*\(]41$=Y-$P<[W?<=BVF'"R7L:E:O'/VQN\
MT[WDGZIZ;=H;%!GFT)+./F9$Z=&*J*US4X4MXN$9G2BA0O[FMRG@)X*L$4BQ
MSRO<Y47CL1%,"OE,ITQW3.(_#/EJW%<L7GSRWE58J.)L&RZ1V<C>ZBYK(6ZK
MXY)ZTDCT5BIQWN.IZ'U%N[/GLQCI\8D#:O*L>BJOH_MX<2\HZ!M-5MO7<M75
M53Q*DK>?^4XUB+26^A4Z(WSCHS1?XL<6"QK75K7<;J6.I,CGEOP5FQI6;&OS
MWFF9I^R7])W&_:I+#=R<[++(/5_9&O/:78+N5WO&;#HL.N4*T\N5G@B@6!(E
M3L<PE6$HOH]2,14F:BN@UQC%7X*@HOZVW_VN;@JL_P"Z0',\WC)9-'SRPQ2+
M%6V61\C(_P"C122P6)%U3)KBH,5=S64M>TPN6I)(]&M:B\JOFGN-IM-O75VW
M*.RZW,%>B:B06JRN<EA/<YW"%_D,S?S=SI3%:R3'/2/+QNCD\/L5\".\GJA+
M'Y.KGM\URWC^9(IL!::Q514\_-!L&ATK?<3J6M9#"YB)\>0JSS]M96*OBJ]>
M4.Z:=>L9#7J%N?&I1?*Q7+63R1B*HL]B4 R!2[T XMTH15R^\K_^E3M8
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MNB9.U51CEY5.%X)#WH 54(7/N56#<JVM.KR>--669LJ*G:6":
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M&C'JJO;VIPY7>JJ!8KX?&U9%D@I01/5.%<QB-4^7,+C+ZM6W2@F5$\E>Q'<
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M:CE194140C&#QFQX[K#C(<Y?]LE]BD\&?CUC1 /3X,@
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MLE"5&)*_\F7E5\T)B
M             -7G%1,5?\N?XO)Y?X <OZ%\,U%_EZVY3L@
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M7\*()_B\K)M74M9H)E6AB*R]JL]'R3(9.NQK0ZN;-%"].RQ3BG<WX/ [*#(
M    !WHH'%NE2]V4W=>$_P!+':0       AF8T/"96[8MSK99-,UB/6*=[$5
M&?0AKXNE&GQ2+*RI.V5?5Z3R(XET5R=,=4D[T=%9<U?5%LRJA/X(&0Q,C8G#
M&-1K4^"(4?1P X' #M'  < .U  X0<(!'-JUYFPX2WC76I*_B=O$K/5%:O)@
M:5IM+4\8^I7FDF?*_OFF?ZO>31,AVE#M'83H':.TH=H[4 < !VCM =@[4 #@
M!V(@X =H[0':%;R ':@#M'8 X0=J .P< .!V( [1VH X':B$!&ISR"@
M                                                  :G.=OR1D.[
M_9Y/^@'-.A?":>OTVI3L(                +Z ?G!N+N=LSZHG'\H3_OJ
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MEE.V           %4<I\2=0[D0%      =R  3 !0  $#E 4     !R Y
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M>1/]L8I^AC0       LWW?B'?!"M"WQGUK_B?:K!&0
M               *7@<?Z6-1+^Z*JHJKEW'8@          !R7$JB=8]@_\
M1X1^_!I>M5&.[;TRD]?F391&/-1UOH5,9C]>N4Z\<,T-Y$8]B(A9W$;EK;3>
MZJ9-]62BRY%78Z'VKS;X2L3S82?5<;G*G4WQ<A>Q:6'TW)-!6\E<SXJ@_P#T
M.Q[EQ]Z.=^/L,W[IQ+ X&I6Z.2Y+'U8F9!]*5[I^/G^I((7HN V>[J%E].##
M/IRJ]97V4YD14,3)5+E/I]@:4U^&:B_,.19(%5Z=I9.(=+ZL8;!U<#K\M.G
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M94@1SWO7E>7_ #B42H$ U&P^6%R7]VD_Z <ZZ&M1FFMY]]B13K@
M       .] /S8VAZ3;)FI$;VHMZ?R_YU $@Z81,FWS7F.]/:D7]2'Z#H
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ML)!U,T#)[#>Q%S&2=KV<P6O/MY@>-T:G:.EUJ]N6#M4XF_)R11,N)SV^4!Z
M8UK6HB)PB)PA+0!0-/L"_P B9+X^S2?] .=]#U1--9S[IY3K@
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MVECZZ5ZE>."%OHR-J-0#,   #597!8K*25'VZ;)75I4EA<[U8] -J
M < !P@                 #1YS6L+GHZT>2J-G2"5)(T553AQO&M1$1
M        X < !P.      !I-C\\%E/[K)^Z!SWH;PW2XO[Q*==
M     1/, '(!^:VR)_E#F?[]/^^H D'3*1\>^:\YC>5]K0_0=CU\P*@
M!9O+^(>5H6^,^MWPGVJP1@                                  _P#)
M4#CW2GN6QN*N]^8>=A        @    '(Y <D>P>SXS-SY.&FLBNI3K#-W-5
MJ=X$A-79S="GD<?1FDXGMN>D+./7L3E0-IR": Y&AR:C/Y['X'&39&\]65XN
M.]417+YKP6#9U;,5FM#/$O+)6(]J_0[S0N !R   <@:RMF\==ENPUK+)7U'=
ML[6>?8[X&+KVQXW/TWVJ+W*UDCHWM<G:YCV^J*@&]
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MJV0I,M-9[G2L\E5!+H[ GH"
M                                        !I-E1?D'*_W27_H! NAZ
M]ND0?\>4ZP                "@?FQLZ_Y29K^_S_OJ )/TGX_"!@/IF=^X
MI[^[2BI$!     !8OK_%WEU/0M\9]K5\)]JH$9
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MEBFVD?+D.M4*1I\S'8M>]R?&0#MB @
M                                               :+:.?D#+?W23_
M * 0+HD[C2:WQ2:4ZT                #O0#\U=CX38,Q_?I_WU $GZ5]J
M[_@.?]H7]Q3] FH!]      %C(?YN\N)Z%OC/M:OA/M__BL$9
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M]T:>3&@="
M                           #1[7\W7<OS_LDG_0"!]$43[R*W*^DTIU@
M                %] /S6V3_6+,\IQ_'I_WU $EZ6<_?]@/[PO[JGZ"-]
M      L7O\W>A<0M\9]:OA/M5@C(
M %,GHJI\ ..](EYCVC_UB4[(           '(#D
M
M               "/[4B?>[E^?\ 8Y?^@$'Z)<)HU3_C2G6!0
M    #_) /S2V!?Y=RW*_]]G_ 'U $NZ3,<_J#@./=,]?U,4]_M]        L
MW5Y@<5H6^,^M7QGVJP1D                                 !)QVK]0
M''ND?'9M*HJ+SF93L(          $-VW#;/DV5?D3.)CW1JOB\Q]Z/13D6-C
MZFW-IS."3;F(^C#"]9EA14>DA=&\S^9V;5+6F5;^<9,D]R1MV=6(Q'1^1/\
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M,D1S@-A9N5JL2R6)F1,3U<]4:ASJUNTSM\PF&IOKRTK=225\C?->6@=-
M                                           T&V\)K685R>7L<O\
MT @_13M9H]3Z)93JXH#D              !_Y*@?F;F>SY7R/9^3[5+Q]7>H
M FG29'+U!P/'],_]78I[^;Z       !9O+^(<5H6^,^M7QGVJP1D
M                         #Y)^2[Z@.2=)_S>T+SZYF;WHIUPM[@"
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M@DI2/2-55>Q>U11Z3!D
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MRY9^2DK+BU_S-K?RT)F0
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M1VEJ>NT<G9R5;'0LMS.5SYN.7<N D0                *G( !4X <
M                                             $;W+_5?-?W.0"*=
M%U1-$H?7(=/                !_':OU ?F5E48W)WTC_(2S*C?J[E $\Z/
M]R]0\%V_SY?W%/? 'T      6[R\PN*D+Z6^,^U4"(
M               !3+^0[Z@.1=(7=]'8EY]<S/[T4Z^6@"         C&Q[E
MKVM)7^5KJ0>/W>&G:KE7M^HC?X7= ]4S*?9O+.&T;VMONKVDQG@Y!')D)'QU
M?F.3O<Q>%)<+, $   !C.OU6VF573L2=S%>V+GYRM3U5$-?BMCPV7FN0T+K)
MGUG]DR-Y^8X#<@ :O+9W%XB.&2_;9 R65(HU=[WKZ(!M$7E   &INYW$T;M.
MG:NQ13VEX@C<O"O5/@;8 :O+9_$8AL+K]Z&LV1W;&LB\=S@-HUR.1%1?)0
M $ %&KQF>Q62GO0U;"2OJ2^%.U$5.Q_P-H    #!R>7Q^+BCENV&PL?*R)BN
M][WKPB 9P       @ H D %%BOD*<\UB&*=CY(7(V1C5158JISPXO@#'NWZ=
M*-)+-B.&-7(U'/<C455]$ R
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MB)RI*//L?5#=\LF3MX/ 5)Z=698_-ZK*[@T/57-V<MINK9*Q1DK3NNJJP/\
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M)T<@67J#B%[>>SQ7_J8I[S9Q\0*@     !9N?F'%Q"^EOC/M5 B
M                         4S_ )M_^ZH').CST=BLZO**ORQ.==%
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MS[%AZ5^CC+5V-ERRW\3$O/+S>H9
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M3(V)Z-:B(A,%]\;7M5KD145.%13!BQ.-A5ZQTH&*_P#*[6(G/EQYE%YU&K)
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MN15Y545H$@N:SA+N6IY2Q3:^W53B"557EIO4
M                        1?=^/O4S?/\ L<@G>".='EXT3%_4XZ6+W
M             HG5$CD55X^:H'YC6G=UF=W//,CEY^/*@#JG1!W'4"A],$Q[
MH3T'J       +-WS@>5(6]HU?&?:N C(
M     %,R?BI/]T#DG1QR.PN957=W.7L'72WN (        !R.0'(
M            Y              !\ ^@
M                               $6WI.-1SGQ]CD$[B-='>4T/%_\YTX
M4               "W/VK#)W)Y*Q>0/S%L]OM$W;^3WNX^KD =1Z*H]>H&.5
M/=%,J_5V'NU/0OJ "     "U>7F%Q4A;VGUK_F?58(R
M                !1/^:DX_FJ!R3HV]7X++*YW<JY:Q^EW'7BT 0
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MG">J\C!@/V? -?"Q^7I(Z1$5B+,WYR+\#:R68H8GRR2-8QJ<J]RHB(GQY&#
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MY\\D0S&O+@\AFVYW5K&0KOG5\62KR/18HU(/2'39^*74J"8N_8M54[D:^?\
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M-MW?#58Y%5[.>TQL'J,NL=7<9 EN>>M)CIEKNE7E6M1..PF]X/20(
M               $3WU5^]#.\*B+[(\#0]'T;]X>)^IYTH
M  I;FX\-_/IVKR!^8MA6K8F5OIWNX '3^BR.7J#B^.?)DW[BGNUH]"H
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M,@BUC5;+M_@V'QF>%'CG5UB\^[N5>37T-,N5.H64V3VICH+55L?A<+W(J(B
M:A>F]BQL6WWK%UGLV7JI"Q&HO>PBD73KJ2F#^0/ODILQW"L\HU[^PLHRY.D6
M2FTS#81V2@2:I>6=[T:O:J.)QONG7-DQ6+J5K,<;JMR*55?[VL&B.YO1-H@V
MN7.ZQDJU:2S"C++)V]R<M*=<T38<1L=O/Y?*Q7EGHO9::C%1WU,0;1S;#.2E
MCLN_7-RK4\9))(Z>O;C1MB%?[!)=#U*':.E;\=/*^/Q;DLD<O9Y]R.+HS6Z'
MU*R%:KB,KL-9,;&YO>^%%29S&$X^\NRS?,=G8IV>S08Y:RQKSW\DMHP=TTC/
M7\[2S^!RK*]Z"'PO"E;S&]I1J6E9V'8[6Q[%<@EON@2"-D"<,1@T3_9=>I[#
M@;N,M]R1SLX[D]45/-%0XFFD]4TQRZY\NU/DK\CVKA?'\(2X))/TSDKLT>KC
M[+?9\-;?-.Y_Y4BN5''8VD'GG?OD1^]U'U,P_$9R&)G9/+$JP3H[T:JFCH8S
M(WNL6.==R\5^:"!9YG0,XCA[4\F%VX)I:T?;<!F<A?U"U42"^_NFJSIY,?\
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MKY,AF5?J[3W,GH@]05      "U?7\2XJ0M\9]:_YGU6",@
M                   43HO@R\?S% Y9T??_ "#DU:_O5<K8\^[N.K"@
M                  ]X  6+%2O/V)-"R1&/1[>]$7AR>BIS[T+X    ''
M*B*!SG(]*M'R.06]/B6)*KE5Z,>YC7_6B$]I4JU*M%6KQ-CAB:C6,:G"(B 9
M(      BVRZ;K^S11,RE))ECY['HJM>WGX*A1K6E:]K,;TQE-(WO1$?*JJY[
M_K50)8      !H=DU?"[%[(F1K^+[-,DL2HY6JUR ;Y&HB(@X < !P$3@!P"
M8 *    !    . 3 X'!0          '! X P. B%
M  "(;]RFG9U4_P!D<)W@UG2./G1<-Z(GAJ="                %N9.(97?
M!J@?F),O,TBJJ\JY0!U;HEW_ (0<?V\?F9^?J[#W2B>1;Z $     %B\G$#B
MXA;XSZU?"?:K!&0                                 *+7:D$W*^78O
M*@<GZ-OC=KN0>Q_?SE+"]W?W'6RT 0        &AV'9</KM5EK*6D@A?(C&N
M[5=RY?J,#.[MK>O^RID[Z0K88KX4['.[D3ZD&:-53ZJ:)=?V1YR%%_MHZ/\
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MU2TR5L4JQR*SW/;ZM SP!K9LQC*U^M2GN1,L3\K%$KD1[T3X(;(
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MF9RV8ZLZI\IX=^-FB\O#<_O[CU6@H @
M                            0[J"J?>9G?+UK.]Z(!B=)^UFB895_HB>
M                "U:_S>;_ (;O^@'YAO3Y[OK4 =<Z&HB[_3^BO.>Y4
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M18D:ODWCGU)1) 0
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MK5(88%556-C41OF01FKT]T^ID5R$&&KML=_>C^/1?BU"093$8_+4Y*=ZK'/
M]/-CT'4:K%:3K.)]F=2Q-:)\'/A2=O+T[OI-DF"Q*91<HE*%+JL[/'[?G]I1
MM@
MAO43_4S._P!U4#5])DXT3#?\-QT8              (@ &'DWI'0N.7T2!ZK
M_@T#\R7_ )3OK '9>@Z,7>X_->4IS'MU        LW/S#RM"^FKXS[58(R
M                               !8N<^S3_\-W_0#F/1]475'\+Z9"S[
MU7],ZJ6]P!         !R            #@   "M0       '(10
M
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M)EQD]>5\^1BAD;RC_F..GQ^:<@?0
M                                    @O4A>-*SG]W =,>QND83L_H"
M=                # RSNS&7W<JG;6D7R3E?R5 _,QZ_.4 =EZ$2(S>F(J(
MO=3F/;J>@]0      !9O+^(<5H6^,:OC/JL$9
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M[%X1#(^@
M               !!NI*<Z3G?[N Z82(NCX1?_()R                -;E
MT>N+R",_*]FEX^OM4#\SW?E* .R]!VJN^Q+\*<Y[=0       +-U>8'E:%]1
MJ^,^U6",@                                 8U_CV.US_1._Z <VZ+
MJBZ=SRG^>V/WSJ0H          YGL6D6LUO. S,D\:TJ$:\PKZK(3W(X^#(4
M+5*9/Q<\3HWHGEY.3@@X96Z3Y^'%XO'.R\+X:.92U#RB^4)TK?\ 4$VO7)L>
MV5(YD>V2%Z^B/:40N#1=OM6]2L9;)5978JR]SE8U458^$1#,S6E;-3V.QFM5
MNP027&<7(Y_-JN3T5!HQ)^FV7GU?8(;%]DV7RTD;YI?2-.Q?)J&TS^AY2S!@
MKV+R"09;&0-BC<OG&]..%11;V&)B-*VRYGZF8V3,-5:GE#7K<M8OTN+=_5=]
MQN6R#]?R==].ZY7NCM\R+&[X-+S"4Z!I[]7Q4T4TZ2VK,RS3N;Y,[U]S2QO>
MJ9/-W]9GJNB1M&^D\R/7S[2#%ZEZ9?VRAC*U2:*/P+B2R*_X$=R&B[9BMGM9
MK6[55[K<*-F9:\^U6_S1M&1K.A[-2W=^P97)065EJ.8_L3M[7+Z-:6=NZ97,
MWO>*S$<D24T\);;%]56$HE&_Z9-L5.C/1F2'(X^7Q:CU].?@I%:6N=1<WFJ$
MNPVH:M*HY)$95?PLKT)*.W^C3@T.L=2L%F,_;PSZ$D&0NNE\.5?-OP4L&YQ7
M3!BZCE<;E+'?=RDOCVIF>C9>>4[2+KK'5>7&5L#X]*"G&K8_;(UXE\)@WN)9
MMW3Z[<QN%GQ=^1<IB&_Q:65>?%^/>:ZA@.I.:R^.L9Z]%2J5.'+'4?YS+\'"
M42'4M1R.(VS:\I9DC6&_*Q8$:6M<U#)8_?\ 9\W.L:UKC&)"02/>M7=L^M7<
M8V5(WOX=&_W(]J\H<HGTSJ)F=3EPMZ6A4BAB1L;(DY=.L?IW*64;C(].,V_$
M:I:Q]R*#+XBNC&H_SC<8%32-ZS.W8?8<[-2A2FY$\"+E?)!HS\EK&YZ_LE_+
M:OX-F'(.[[-:=>.U_P 3*U7I_E(X=J9L4\4ZYA6J]8QHT$&L=4<12EU_&VJC
MZ"_,@NJO$L,:DBR/3&U:U?$44S<RY+'2.F@NN\U[U&B.973NH^T.H/R]FG R
MA;A<R%GFDO:J=\BJ=8LU=E7::$\-N-N(;6>D\/Z;I?/@@EB
M                                                       !!>I/
M^I.<_NXG<4=,$5-'PG_ )Z                -7G'JF&R;FJJ.2I,J?7V*!
M^:#ORE ';.@3$7>N_P"%&4]KH       %J^O,+BI"^EOC/M5@B
M                        8N17^(VO^"__ * <UZ,JGWFL_OEG]\ZH
M              <   ' #@*@'P^@  ' #@< .$'  =J   X' #@ .
M
M   ""=2U1-)SG_  KZ9)V:1A6HOK 3@                :G8$XP>5X:YR^
MQS>3?7\A0/S1=ZJ .T=!^/O\9]%*8]N(       %FY^9<7$+Z6^,^U4"(
M                              !C9%.*-I?A"[_H!S3HR_C2XU^-NS[U
M7U>=4           &GH;#ALA=M4ZF0@EL5U5)8FNY<Q4 W!;MW:]:)99Y611
M-]7/5&H!@6\YC*=FG6L6XXYK:\5V*OG(J? V8&%D<G1QE22W=L,AA9QW2/7A
M$Y,F">.>*.6)Z.8]J.:Y/147T4"X !@V\KCZ,E:.U9CB=._LB1R\*]WP0#.
M    +-:]6LI(M>9DG8]6/[51>UR>J+](%X     Q<AD:>.J2VKD[(88TY?(Y
M>$1"#(KSPSPQS1/1['M1S7)Z*B^BE2J48=/*4+<]F*"Q'*^N_LE:U>>QWP4S
M *72L9QW.1/<G*\%2* "J!B4LG0N/G2M8CF6&18Y$8J+V/3U1QE@
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MN
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M$S@V'3/8L37Q^\YZ1ZQ4ERSYN51?)BH=PQ&<J9G&5LA2?W06&=['+Y+P09@
M
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MUHA?QV-IXVE!3IPMB@A8C8V-]$1 ,L%
M                                     YWU47C1<U_PD V/3O\ U-PB
M_&LTF8                U6>1BX3*H[R1:<R*OP3L4#\T5]5 ';N@2Q)N[T
M5%[EHR]A[5       "S?_,/*T+?&?6KX3[58(R
M           !K\PO&,O>7/XA_P#T @?1EJ)HE%?_ #9_WU.F           !
MR ! !0
M                                       #G759W;HF:_X: ;;I]Y:A
MA?[JTEX                TVRM[M?S#?C1G_<4#\U5]5 '<_N?NQ=UG1R^:
MT).T]H       !;R"\P.3W'U"WQGUJ^$^U6",@
M           :[-+_ "5?7CG^+R>7^ $"Z/(J:+C_ "XYEG_?4Z<
M ! .H.[PZGBV2,C2:[8=V58/YSCF\3>N:L3)>)5\W=WL*]OH79()SJ/4.+,X
M3*6+T+:MO&JYMN)5\D5"'R]2LCDNFN6S,$\%:_%*G9'$O*L9WHGFBCH.J8/8
M\?-B\7[3D:WM4E:)SV*]J.5[VHI)9[,,$2R2RLC8GJYR\(A+*,:IDZ%WN]EM
MPS<>O8]'<?J+<V9Q4#WLEOUV.:O#FND:BHH&QBD9(Q',<CFJG**GFBH?0
M
M                           !SCJNG.B9G_<:!N]!3MU+#?W5A+
M          !IMED\+7LS+Z]E&9?_ *% _-5>>0!W3[GU$7=9W<^E"0]G@
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M^/B)JJG*O8+:/1F.H5L;2K4JS5;#!&C&)SSPB&:8 %   J@
M
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M3M&T9221CH\C)$Z)J>K>QHW1]FCW#[^('LD9\AI57O;Y<K(3@
M                                          5?,
M                      !S;JP]4T7,_P"X@$@T9RKJF'5??582D
M         1O<?/5,^B_U?/\ N ?G H [M]SXB+NDZK[J#SV:       %J^O,
M#BI"WQGUK_F?:K!&0                                 -9GO/#Y%/_
M ,VD\N.?<!".D*(FB8KRX\YOWU.E
M
M                  YKU97C1<Q_N(!(=(\]6PW]U82D
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MKD%    Y0 !RA   <^90     .9]6G<:+E_]Q )=IK576L2GN]EC5?U&^
M             $=W!ZLU7/N^&/G_ ' /S>4 =_\ N=W(FW7_ (^P+^^A[$
M     "W?X\!R(?4+?&?6O^9]JL$9
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MDY+^0ZKZ]2@QKT@MS2W(/&9!''R]K/BXO*)!J&]8+:$F]C>])8?SL$B</:3
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M'(JI+B)U1ZJY/+M1%&3N/46E7,E=U;$6<C"D5F2NU7M1.#DE9>_K_;^C'_\
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M]@F_= _.-0!Z!^YU:J[9DOHH+^^A["       "Q=3\0\N(6^,^M7PGVJP1D
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MIXVJV&)/7XN7XN4#8WJ-:_4GJV8FR0RL5CV+Z*BD/@Z9Z56NP6X\+ DL2)V
M2R_C*>0IRU+<#)8)&]KF.3E%0T."T;6, O=CL9#$_E5\14[G_K4"[L6FZ_LD
M3&92DR;L_(?Z.0RL7K6&Q6+7&TJ<<596JUS$_21WKRH&1CL)CL9C&8ZI7;'5
M8U6I&GP=ZES$8>CAZ,5*C"D4$?/:Q/=RO(&+F]<PV>KK!DJ44[./+N3S3ZE-
M53Z?ZA2;72#"U46%_?&Y6\N1WQY W53!8RED+U^O69'9N=BSR)ZO[$X0JH83
M&XZ6W+4J1POM2^).YJ>;W_%0+-#7L/CF76U*44:6Y%DG1$\I'.]54CE;IEI-
M:])<CPE?O=[E3EB?4U0)%9US#6LC2R$U*)]JHG$$BIYL0KR&OXG)6Z5JW3CE
MFJ/[X)'>K% U&P:)K.Q2QS9/'LEE9Z2(JM=Q\%5#/PNJX#!K*N,Q\-=9&M:]
M6)ZHT#36NFNEV,I\H2XB!TZJJN_F.7XJA)9L'BYL;\FR4X5I]G9X/:G9P!#*
MO2?1*[NY,-&YW?WHKG.7@Z,QO:G">B 0/.]--1SN12_=H(L_Z;F.5G?_ +W!
MM<3IFMX>>:QC\9#!)+&D<BM3U:!H)^D^C3Y'VUV*8CO?$U52)5^*M.BUX(H8
MF1QL1K&(B-:GDB(@&EFUS%3YNMF9(.;D$3HHY.5\FN--M&@:WL\D4V0K+XS$
MX26-RL?P!ML-K&$P=62OC:,<$;_R^/5_UJI'4Z:ZRW7I,&D,J4WV_:7)WKRK
M^0,O:=!U_9X8F7H%;)$U$BGC7MD8A?UG1]>UIB_)]1$E5O#YW+W2/^M5)M%Z
M/3<#'L;]@96XOO9VND1R\*G''H6JNCZ[2V*QGH*G%Z;GN?RO'+O540HQ-IZ<
M:[L<C;-Z%\=GCM2:)RL?P9NMZ7@M;I3U<=7[6S?G7.7N>_ZU(-AKNO8_7\>V
MA1:YL*/>_AR\KR]>5-?O.MQ;)KUW'^:/5O?"[X2,\VJ4<7VM,OL'3S 038Z=
M;4.2B@M1]B\_,Y8KCH.*Z1Z?0R,=YM>61T:HL,<DBN9&J%T3*#5\7#L4^=8Q
MR7)8$A<[N7M[4,3:]*P&T,A3(0*KX>?"E8Y6O808NK=/\!K,DDM.)[[,B</L
M2N[WJ9.Q:5@MBN8ZUD8.^2F_F/A>/\% S=CU3&;#0@K7T<L<4[)6(QW:O<PP
MMETO [+7BBR-?E8OS<K%5LC/J5"4:S6^FNLZWD5OXZ&5LZP+$JND5Y8S72S4
MLQE%R$M9\<SEYF\)ZL20;1+\#@,7@*#*..KI# U57M]555]ZJI:V36\5L5%]
M')0)+"KD=\%14]Z*A1!H.C&BQPNC?1DE5?TWRN5290:IAJ^6K92*NJ68*B5H
MW=R\)$GN Q=GT;7=G=6?E*RR/@Y\-S7*Q2_CM/PF.REC(UH52Q-79 ]RO5R*
MQB<(!#+O1?2;EV6TM::-)/-T4<BM9R2>_H^'N6<#+\^-,4_NKL9Y(!@[+TTU
MC9+S;MV"1)T9V]\3U8JH;;5M,P>K5I8<775B2*BR.<JN<XDM$@V'#TLWB;6-
MN(Y89V]KNU>%-+D=4Q>0UOY!F1_LGA1QIPOSD;&48NPZ1@M@Q=:A>A<K(./"
M>U>'MX^"D7Q'1S4L5D:E^)++YJ\J21J^52;1,\+J^-PUW+6ZG?XF0G\:;N7E
M.[Z"C :KC<!)E'T_$YO65GE[EY^<OP*-;6T#!UL)F,0SQEKY&5\D_+O/E_P(
M?%T,U!EB.3ON.C8J+X*R\L4EM@G^SZ?AMEQ28Z]"OAM5%B<SR=&J>]I%=>Z0
MZMA+[+J)-:EC_-K.[O1A9TE@EF,U6ACL_ELS$^19[Z,25JK\U.Q.$X-3MG3G
M [1/'9M>+!98G"3P.['JWX*3M8*M9T'#:O7N>Q-DEGG1>Z>5>Z1?HY'3K7LA
MK^NI2O*WQELRR\-=W<(]>40#9[/JE'8V8Y+4LC$J6FSL[/>K3'ETVC+M];9%
MGE2Q#76%(_T.%*)A/$R6-T;VHYKD5'-7T5%.-+T2UGVZ:5+5Q*DBJJU&R*D9
M-L$\U;4Z&LXIV-J/>^!97O\ G^?Y?N-7J/3_ !>K7\O;I2R+[:]%[%](T157
MA"C2;+TGQV9S:Y2#(3T7RHB66P>7BES%=)<!A\O)>H33QI)4? ^+N547O3A7
M$VZ,MW3>FNJXG ^W2^'2MLG23A.7=KU?P6=MZ8T<]?9DJU^QC[_:C'3PKYO:
M.:C7XKH_B,3FL;EJF0MI/7[O&5Z]WC=R<&C7H=!757XW8KU65[W>,]OZ;5+S
M43M.GN+ATNUK55ZQ,GB5))^.7N>OJ]2C8>G>-SFOX_&2SO9+1C8E:RWR>QS$
M1.2:-+@NDU2GDJ^1R^7MY2S J+ LR\-88.?C79NI6&H0Q*D6$YL6953R5S^%
M1B%T=L1     #E_5[_47*?\ (!--83C XM$=S_%H_/U]QO
M  "JG)$]Z5&Z;L+E5>/8)O3Z6@?G0H ] ?<[JQ-LR**Y45:"_OH>PP
M M7EYA<5(6^,^M7QGVJP1D                                 #2[+Y
MX'*IV\_Q27RXY_1 BO2=.-!P:?\ E/\ WU.B #XYRHB@>8DP<'4?<-IN3,_B
ME.NM6L__ ,U/1Q)>A&21<)D<5)+S-3MN\O@U1U&GV+>-SBWS+Z]B(F6ED2/V
M9CT3B)43N5Q#M^PW4%SM93.9"K--+96.#MX3L>Y?>642C>[N;PV7T>M/[-+8
M699)7QPI\YZO1/+DD'4?9\[9SM#6M?IMDO(C)UF7S6(#0X_9=RPVVX[$[A4C
MMI=_%03-1/+Q%X\E0S]9IT9^I^^16HD= V%BJU?@T2ST-?5SNY[)?M+I%:&E
MCJ?,:2RHGXW]LF?3?9[5S,9G$YFA'6S4/#YW,])6B\6].4=BF@AF:SO;W*UZ
M/3Z%0\_ZFG'6W;/GH[^+_P#]!(._358)O#61G=V\JG^*<'EO:=(^^3==N93>
MK+5&I5?53W*J(6";ZIF:^TZ7;DR#4=D\=7FAE3E45.U/)5-'T6GKT-#SMZ2)
M[T9/(]Z)ZJC&%%C#[)U0V.K?RF#BK5J22N6."5.5?]2J2?2+-;:L!<M9''>!
M:IRR1.:R9Z)RWYQ='+,%E]ZS^,MT\/03B.=[YK+WNX5&K\UC548W;MMS[4Q^
M)PW.3@^;/-XCN$8WR]%4<_".C=,[<MZ3*83/0*S(T7*K^)7^;'D5DR>>R&Q7
MJ&DU'NCJ][)K,T[Y6NY^"O4;.M$NTC.RY+(6];V/'35LDUKG^3WHDC3NE6O%
M7ACBC148QO"<JJKPGTJ9HN @
M  -++0R#EA\+)OC:USED3PV.5Z*OIS[N#-K5YHN.ZS)(B1HWYW'*JGZ2\>]0
M,T    !WH8=&O8@B<V>W).Y7N7O<C4X1?T4[40#,                  %3
MD$ %      $P 4  +;8(F/>]K&HYZ\N5$\U^L"X     <MZP.5NC9+ZV 375
M_P#0.+\^>:L:\^O/D;T               !P17>F,73L^USN$6A-^Z!^<R@#
MT/\ <Z]B[#F>6^?L2<+_ ,YZ\       "S<_,/*T+ZGUJ^,^U6",@
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MIC5AL\31/@1ZJY1U]"6Z]A+$752!V3V5+]^&HYRHR+L1$^"GHXEWV
M
M                    '+.L/^HV2^M@$XUI.,%C/[M'[^?<;L
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MV4;W3>G^&U1LKZROGM2^4EF7S>I/2== %
M                                                           Y
M5UB\M(OK]+!.XGNN+SA<:JK_ -VC7UY]QN!0               (EU 5J:5L
M7/\ 5\P'YT@#T9]SAV+LN7^*43UN       %N\GXAQ4A?2WQGVJ@1
M                           -#MWEK681$[OXI)[N[W? ".]*N5T/ _\
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MT^WQXT1>6=_FALP    'O1B*J^B(!H=?V;$[#7GGQLZRQQ3.B>JM5OSFF^
M"/TMKPEZ]DJ=:XU\U#_.4X5.PRL+L>'SD#Y\;=CL1L?VN5GHB_!1E%[+9:EB
M,=8OW9/#KPM[I'\*O"&5C[U6[3@MP/\ $CE8CXU^+53E% O   !KLIF<9B(6
MRW[D5>-R]J/D=VHJB#*KVX+4$4\$C9(I&HYCVKRBHOHJ&GR.T:_B["5[V4K5
MY5:BHR1Z-7A1.&T8GW[ZC_7]#[9IO+62HTZBV[-F**!$15E>Y$;Y^GF.6C*K
M3PV(HYH9&OC>WN8]J\HJ+[T,/(Y?&XN-DEZY#78Y>&ND<C$51!?FOUH:RV99
MXV0(WN617(C4;\>2#3=5=$ANMJNS<*O7]-$56)];D$EHG%*_4NPLGJSLFB<G
M+7L<CD4RB8(?)OVG16'029VHV5)%8K5?Z.0V%#;=;R"L;3R]25SW=K6MD3N5
M2\M@SK^:QF.=7;<N10+._LB1[D;WN^"&R1>0!JLIF\5AX62Y&Y#68]W:UTCN
M$51)HTZ;YIW*)\O4?M4)-!<KSP)/#,R2)454>Q4<B\?2A<L&'A\YC,U52WC[
M"30*]S.]$5/-B\*GF;,@        ,'*9;'XJHZU>LQP0-5$5[UX1%4S*MF"S
M7CG@D;)'(U',>U>45%]Z 5                           <JZQ^6CWUY]
M)8@)[KR+\CX_E?\ N[/^AN                !"^HGEH^QKVJY?8)0/SO7C
MD >B?N<45=HRJ\>24#UV       %BY^8<B%U/<7TM\9]5 B
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MMQBV<%:AQ[UX;9/05&U#:J0V87=T<K&O8OQ:Y.44@K
M     #E76-W;HUW_ (T/[X'0<$JKB:*K[X&+Z\^J?$V@
MB/4%532MB_N$P'YTJ /1GW.'/WRY?X>PGK@       +%SRA<74+Z6^,^J@1
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M]?\ *'-MX]:;3UH       %BY^8>7$+Z6^,^U6"(
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M#U2       %J^O,#BI"WQC5\9]5@C(
M   $4WUJ-T_/<_[%(!B]-DXTG ?W1I-47S
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MR"!'-:KW^2<N7A"C8,D:]C7M5%1R(J+[N%,5V1I)<2G[3$EA6=Z0]R=_;\>
M-;4V; V\J_&5\E!+;8BJ^)CNY41#>\@ 30  <@.1R@T.1R@T.4'(&NKY;'V+
MUJE#9C?8K=OC1(OSF=_FAL2@                                 ')N
MLO\ J=*O'I:@_? Z5BD_B%3RX3PFF>                (+U0[4T'8^?]C4
M#\]0!Z5^YR3B_L+O_(A/5Z*       %FZOXEY6A?46^,^U6"(
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M(K$R"#W>(_U%Y?0TNR>TX+?M5S$2)&N41*E]OZ"J=S;Z&;V@
M                     !R3K*O&G2?3;@_> Z9B?]'U/^$TSP
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M5H8&S+9KL;YM[Y?-B*IGU1..H\K+>W:+B5X>UUY9WM3U3L.UM\D)Z@
M                           !R'K0G.H?5=@ Z?BTXH54^$33/
M         $#ZI*B:!L?G_P!S4#\^ !Z6^YL5ORSGTX\UJQ'JT       +5YW
M,#BII;XSZU?&?:K!&0      6;5NO5A=-/(UD;4Y5SO)$-4W9,$YJ.;DZJI_
MQ&C+0^^/!?UI5^U:5MV#"NYXR59>/_,:.6CZN=PR>N1K?:-'R]A?+^4JWVC1
MRT7/EO%+_P!_K_:-*US&-3G^.P?MH7**OE7'_P"V0?MH%R^._P!L@_;:,H?*
M=#_:X?VT*_E"IQ_G$7[2#EXOP/E*GPJI9B_:0J2Y6]T\?[2#.+\#VVM_3Q_M
M(/;JR)SX\?U]R#EXOP5>UP>OBL_6@=9A1/.5J?XH.7B_!\]K@YX\5G[2%U+,
M:)Y.;^L9?P/:(U_3;^L^+.S^<@RBKVAGQ0),SXH,H^+,U%]4/J3-3WH3EH>,
MU?>A]\9OQ090\1I\\1OQ091]61I\65"Y0\5OQ(5U%D1=*S_"IS[(\2717T^<
MK=,P7=PB^QL)GXB#+H>(T=Z#*'<.]"91S#JVR.34)N_T2>%>?APXG^,>QU"F
MZ->6+"U47GU\BY1L>]!WDRC R,SHZ5B1CD:]L3G-5?1%1#F_23,Y;+Z_8LY&
MPDK_ &R5K%+EP=6[D^ [D)U#N0=R? 90Y0=R#*'<@[D'4?>4'*#J'*#N3X#J
M'/T#E!U!5*7.)U'.M&LV+&0VE9+'B,;DE:Q%55[41/0Z/R:XNX=P[C(=Q2JH
MH$.SVHX_(R-NPL2"_%RL-AGDJ.^DP]6V>Q:L38K+1)!DH/5/=(G\YI8)]W)\
M!W)R [N!W(3J'<GP/O* ?%<G!%LGJU'(9K&9=))(;=-51'Q^7>QWJQXZB4>X
M>0 ^KP /O"%#R #A J(@%/D?41 /H('!\ ^\!4\P':?%9R 5/(C&N:M1U]F1
M;6?(]+=M]A_?[G/]R%$HX/B-1/<0<ORG3=TV4O7\7GKN/==>CK;(U[D>2_6-
M9Q^N8MM&HKW)WJ^25Z\OD>[U<XO-HD2-1"'[IJ,>PQ4UAL^S7*<[9JUCCN['
M(!+6-5&M1R\JB)ROQ4C>WZZ_8<0_&I<=79))&LJM3E7,:O*M WM*E!2K05H&
M(R**-&,:B<(B(92M -1$"MY =J!6(J^B ./(I1B)Z< %8U?<A][.0/GAM:O*
M(B#PVJO/" %C:[R<B*A]\- ,*_5EL4;,$-ET$DD3FLF:G*L54\G(1C2M036:
M-EDEU]NU9F66S8?Y*]P%=73X(]NN[%/:=/-)"V*!BIY0L3UX)D
M                        #D769534D^B[!^\!U#&\>QU^$_[-IF@
M          %0YWU75GX/]A[_ /9D_>0#\_P4>DON<FN^5<^_X5HCUD0
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MY^"4U\1U?9'V+FZ#OF>JQ^9'<MH/4Z[:AR3LY46W69^*[6]JJ.?_  8>'O\
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MKG*)!O.0   $V@"@  *   @ H$)ZBHBZ3GT7_9'"=Q?T%.--P7]SC)>+W
M!J\U"V;%WHW)RCH'HJ?X$4Z:9%E_4Z*M]8NZ)?K8H]"?@#4;!&DN%R4?'/=6
MD3CU]Q'NG"<:7@_+C^+(!.     #26<IX.7I4>WCQXI'=_TL5/(#=M3R]0
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M"1<IZ(0?%A;Z\)R<AZR^6KPNX3E+\'"ED'5L=S['7Y]?#;S^HS
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MG(Q"?T;#+-6"PW\F2-KT_P"9.2^AD @
M                                 <AZS?ZKP?W^ #J>/Y]D@_X;3+
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MX=PZAWA%11E#E!W(.H
M     <:ZTNXUNM_ZA"!UG'?YG7_X3?\ H9@                YQU<7CIYL
M'_!9^^@'@( >I/N;4B1VR*J^?\6/4        6+B?B'EQ"WQGUJ^,^U6",@
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MUL\[(THG(^=C_-407O(.^ZQG:V?PM')P?DSQ]RMYY[7>BM-X0
M                                  #B_6UO.MTO_480.OX_RIU_^$W_
M *&2                .=]7N%Z>9_\ X3/WT _/Y?4 >I/N;O-=D;_=CU"
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M4@<JM6OS_BJJJDAVEL3M>RZ2HWL]CEY[O3\DGL<JZ /F^]"SRJ\)>>C#N8
M                                            XOUL_P!7<?\ ^HP@
M=?H_YK7\_P#LV_\ 0R0               !SCK$QJ].<\CO<R+]?B(!X"4 >
MI_N:_79/BOLQZ=       "S=X\!R%:%OC/K5\9]5@C(      !Q'J0^?[^]!
MC5B>$EQR]X@N]1:&1R.Y:C6QV16E86.TK9D3GA$1" [#BLAB=AQ-?=,S9OX:
M9>6/3EK$E3T21$+.+!D]3'SV-XP./K8QM^%*/,-17*QBFGP\V?QVS9OP<4W$
MJF'FDDJQ2=[5<C?FNX$HV<.I:Q9Z26,NZNV2^M9\S["N57I+R;2\G;:Z0(J^
M79__ &-*)/;DB?U5R7#_ ,C77',H**VNC^/@;([FUG49RONYE5A.HL=2L)3P
M.6P&$QF,D6K.B2R0,D5/:94\B[B)LOBM]PDM369,2EI?#E@\7ELK"\VB3ZQI
M^$V_%;/D<GXBW9LA.Q)'NX?72->6H;GHG5B33,Q!(J2-2].QR^YR(U$)1NNA
M\SW:2U%5>QEV=K/H;W'72>P             "$=2_P#4?/?#V50,S1?+4,"G
MPI1$9ZH;S6U;"/C14?=M,<R!G_5R@>/<0_)8*_B<_-1?X*SJ^)SV_-D5OKP>
M^\%EZ>:QE7(57]T4S$<GT?% -P !".HE&6WJ>2;"Q721HV5J)Z_,7N WNO7_
M )1PN.N<=OC0,>;H <NLP)C^IU"WXO8R]0DB5/<Y\?':!TN9%=#(B)SRU3FG
M2>UXNK^$K>U\%N>)Z?3WJX#2];Y%FUVGCF/XDM6TX^IA-NG-B.73,&L:HO;3
MC8O'N5$ FIQ?K5%VX"A>1.'UKT:M?[T[@.NX[M]BK*WT6)JI_BAEO] .7]/(
M$AL[8Q$X3Y6?[N##1T>5ZHRQ/XDAQM!O#5\T25Z^I;W$^V#$5\UA[E&5C7)+
M&J-Y]SO<I#^G.?EL8^SA[RJE_%O\&9J^KF^YQ!M]_H/R&IY2)KU1S8O%3A.?
M./YQEZ=DF9+6,5:;)W]U=J/=_:;Y*!I,N],_F8L*DKDKPHDUE[/TE:ODSE#3
M:VR*KU)V>!&*Q'U:[VI[E1$*)ANUED.L9%'R-9XK/!15^,J]I#>E$U['P7]=
MO^4U%R+%],+P.Q<@@'R157C@#D\-JMB.ILU2+MXR=5'R)SZ/C.LHJ"@ !IL\
MV*7"Y)CU3M6M(B_J \\=!W/BRV4CG<O,L#71HOP1QZ@Y4"V]R(G*GF;J_C9L
M)9CM8Z3PXL@O%J!/1RL\^XL'H+7K,-C"XZ2)Z/8ZM'PJ+S[C=]J$'+]T<[!9
M/'[#$K^SQ&5[3$5.'L<O"*1[JE9L81V+VFA$BS0+X,_EZQ2&OP=9P*POQ-&2
M-O:DD+9./I>G<IM^$,#CV?US+X#/6-DU]K9&R1JMRAZ=_;[X_I)!@NH^O9.!
MB36&T[7"))5F7M>UQJ00O9<CCL-ON'SC<A!X-N/P)T1?-&\<HXWF3Z@SW',J
M:U3==F>O"S<*D3$+@E6IZRF%K2OGD6:]9=WVIU]7+\$^A"8$H @        (
M!U)U*;:=:EI02]EB.1)H%^+V'(<#UARN"J+BM@PME]JJSL1[$\W=OIW%@OZM
MB=AWS;X-GR\$E:A45%J0_%4-%U5O6\-U/QN7CIOF2O#"]$]SN!:-\WKOE'L:
MYNJ3*BN[4\W$\U_-KU$UO-5+^(DI^L*H_P!%51D',<#N.S=-N_"9S%36:<2K
M[/+&7\UO^S;Y7FPNO8&:.&=.V>:0O3-'?-3U^#7<#0QD*)^)C3O5/TGKYN4D
MAD                                #N>/(            !Q?K6BNP&
M-1$1><E"!V&DJ^R5T^$;2^                .;]76.7IWG_+R\)G[Z > U
MY 'JC[FY>V/8W?3 >G        M7?.%Q6A?2WQGVJ@1       #EG5+"W;.-
MIYC'IS=Q,Z6(F\<]Z>] )3'AZ^5N8+.V&21V:U9RLC]R+,U.[DS=@U[';!C)
M\?>C[HI$]4]6JGHK0(GFNF>+RF+QM=;EB*S2C[(+K7?CN#+U/0<?KRVIWV);
MMVRG$UF?S<J$VCG6Y]+ZF/P>P6Z&1NM@6)TR4&K^+\0D,VA-V?2]7[K<M.[2
MJQN@E3U:[M0MMR#8ZOTSK8/)6LE-E;-RS9KNAF=)[^XS:_3K'5]>HX9EN;P:
MV0;::[R[E5']_ &?N.DT-HKUDEFD@LUG]]:Q'Y.8XT&!Z:^S96IE\UEY\E>K
M(J0N?Y,8@EP:_+]*99LC8?B\[8H4KKE=>K,55[U7S54+K<3!TVTC)Q4GRVY9
M9E\%')YK+-PQJ#;1+] P#]?U;&X^1>96L5\O^_(O<I,               0G
MJ:C$T7/<K_W90,K1>?O/P/\ <HCC&U=*]LVC='W[UF!,?XJ(SAWFV% .L[1I
M&-SFKNPK8V1)%&GLKOZ)S"+]*-2VS5HKU/*3P.IJO,#6+W*C@.HY+,8[%P^-
M=M1P1JO'<]>$-4NZZLG:BYFHG/\ ;0N NY:OQ_IFI]HA:L[1JMF"6%^7J=LD
M:HJ>(GHHRB#=/=GP5?&W:#\M%Q4MRHQ7O3SC5?(Z$S;=<D9RS+553GCRD08*
MTVG7VM55RM7[1"#[ILNOPPXG)-R-=RUKK%3M>BN[7>3A@G$6S8"1B*W*U5:J
M<HOB(<MUK8L#@-LS>+=>K)7OS>V5I$<G8BN\E8)!J_OAP^S]2V,EO,]CQ59Z
M1JJHULDSR0=-]CPU.OEL2_(0HE2]*D/+D1%B<OEP!TC[Z\ JJB9:IS_Q$.8=
M6<]@+>E7(VY"&1[I8^Q(Y$5>YJC*)SKNSX67!XV1<E!RM=B+W/1%Y1.%-K:V
MC!PPK-)DJR,1.?SB"2T<XZ<['B)F9ZVMR"-+&2>YJ.<C?FEC7L_B8NH.QL6[
M&J6$C=&]7)VKVH+!U/Y<Q/DORA6_;0Y5M<^-@RK=BPMZNMRGQ[9"QZ<3PJ,'
M0,;M&!R^,9-%=@[)F\.8KTY3GU0XIC=]I:I6RVO,<DUR*V]E16^3%21>455+
M@ZEJ5+'8O&QLFRD,EJ9RS6G]Z+W/=[D^"(1W:LA2Q.Q8_9J]R%\#6+!<CC>B
MN>GN4=1J;>VXS>-DQ..IR-=C*TGM%N1_S.59YL0VVY2U<9G\+LM.]"G:]*ME
MB/14?$]1@ZG!E\;-$R1EN%6N3R7O0R?E&C_M,/[:&<H+D:/^TP_MH?'Y"FC5
M7VB)/K<@RCS'U3UC-,V6QLF/OQQL9'%PK9.'M4E^-WS8L!3IKG*C+E9\*N2W
M ].4^'<BFO\ !T/$]1-2RB,\'*0H]4Y['KVJ2CY9QB)_GM?[1I.6C3Y+<=;Q
ML3I+.4KMX]W<BG(<EN%_=YDQF'XJ8R1W;8N2*B*YOO1"X)#GJ%# 1X;)X=:O
M..;X<R=Z<N@]Y/\ ";=A<S2CLU[D7"HBJQSD1S>?B,&1D=@Q%&!\\^0@8UOQ
M>A VQXW9[LV1N2Q>S) L55'N1/FRIYJ)!KM)V"MKTKM;R,T;'0O<M:3N3M?&
MJ^1UY,G25.[VJ'C_ 'T%X1R[:<M2S^6IX&&2-\,=B.:XY7(B(QGSDX*^JF.=
MFM0L5*%J)9$>QW9W(O=VC!.L%-%!B,='-/%XL=:-K_G>]&FW6_5;ZSQI_P R
M$RBA;-55_/1_M(13*ZGJ&7D<ZW4KN>[GER+VJOZA)1SS=.FNHQZSD):4")9@
M@5\;O%^!,NFV3Q%G3\7+52*)&Q)&]$X14<SR7DMEP= 2W7]TL?[2%:7(%])6
M?K0G+0]IA7_M&_K0)8B_GL_6A,HK2S&OH]OZT'M,7/Y3?UC*/GC1_P YI4MA
MGO<B?XC*/K)$=Z*?0  * "E*4J\CN]\+%^E6IRH'U&(U$1J(B%#Z\,GF^-KN
M/3E$4![-#Q^;8B<\IY(5MC:U%X:B 6Y:T,R<21L>GP<B*(JT,*<1QL8GP:B(
M!=                                               XOUJ\\)B4^.
M4A [#4\H(O\ <0O@               #G'5Z1&].L^O]B-/UR(!X#4 >I_N<
MOS&Q+S^G >G.0       M7?S+BM"^EOC/M5 B       !410    YK7)PJ(J
M?!0B(B     I?&Q_DYJ.3U\TY J               (%U/Y^\3/?W<#9Z(G&
MH8'^XQ$J <#@"-;-JN*V:@M+)0J^/N1S5:O#D5"%.Z*Z(OG[#+]JX=07HKHB
M_P#<9?M7%IW1+1_5*LZ?5*I/Z$(O]+=1J;G0I2Q3)5MUWJQB/7S>PFJ=$](]
MU>?[52_UT"3HCI;_ $BLM^J52S/T0T_V:1L<4_?VKVJLBD_H135NC^NV*TB9
M%EQ+,3W,<SQ"5+T-TKV98TCL]_\ 2+(O<7^@_ 9I7$7#+35:GNE(!MW2?$87
M)T\BQEI,2OE:1J\NA_MB"8U^C^@7H%NUIIWPRM1[5;-Y(A%L1TIU;,YZ^M9U
MA<;5XCY[_*24MT1Z/0,!@LS?QNQ/MMK+P^K>:Y48C/@I8W73]13V&OK5J:W>
MN3(QD3).]B-&#J.,Z%ZTRA1;;?.MAD?X]S'\(]RFAV3H532!D^%GG29KT[XY
M'>K1HA$FIZWX*0K5S<=]\G8R#U3N)UKO0S&SXV"7)SVHYU5RN:Q_JP=1N+'0
M777V>^O?MP1+ZQHX?@"U;AG?;N.>GJ_N&C)3H7K'?W);O_:"3H7J[U;_ !FZ
MC?>SOY12;19=T(UE'RK!;MPHY/+AQ0_H+@'1M9\IW_VR[1HZO0N".X^";+W?
M"7SB>PWOX",1S_IK(?M$V@G0G$>_-Y'Z^X.Z%8MS%;\NY$;10[H1B%C_ !V:
MR+U(?A>DD%N_EL1?RMR.2J]CH>%14?$OZ2(6:)(_[GK!*BJS*7#,9T%P/8B2
M9.\JC:+J] ]55>5LW"XWH7K3&<1V[C/J>-HI?T*U]T?9\H7OVRW'T%UR-K_"
MOW6C:*9N@NO2+Y9"[_BXO?@*U[L1JY&_PG]L;1:EZ"Z]))W.OW2A_07#+Y)E
M[R(-HK9T&P#%?V9*\G<%Z%85.>S+7T&T/P$XSE5^7+XDZ$XI>>W-7T1?BX;0
M7H9C?/MSN00)T-HHB?R]?Y'-15)T.QCN4=FKZHY%Y3DYO)TSJXG:X<-<S%F&
MC<C[JSVKV\N^#AMM'1%Z%XW]#.Y!O_.69^B>+AB?(NR7X^/5[G#>*T0N_K&C
MXYS8EW+(RRO]$A7O(^_4,W?DDCPD68E3GYDLSNQ@ZP;*ATCZDSR?C;WLS%7U
M68G.+Z*YA.7W]IL]WPB51S4;%_1>SRBLVN^A0G1.;O15VS(#FHZ?J.L)KF/;
M46]/:7GE9)26D
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MNXZE>A?!:@9+&[U:].4-3B=2U[$2/DHXZ&)ZO5_<B>:*XHVE[*XW'1]]RY#
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M$Z;KF)8C:>-A9[^53E23MC:U/1$)H^@@
M 4#CEGKCJ].S/&^I>XBE<Q9/"\E5IGXCJ]@<KE*M&M1OKX[^&2NA5&%P23 ;
M]A,S6RLT#WQ1T)598?*G9QP9&5W+"XO%4LK)(Z6K9FCCC?&G/*R>@P2AKN41
M?B@(                         !Q?K3YXC"^7/\JP@=BK?F8_]U"\
M            .9=9FJO3K.?5!_\ A6@>"%50!ZI^YQY]FV+_ (L!Z;
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M$])@      !9N?F7%Q"^EOC/M5 B
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M[:]&GC<E+/PGB=_S$A<I(>G=9=-W')X/)R\OM,8M.95\G(W]$:/1S>"HP
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M9]>Y>?'B/20       6;R_B'%:%O:-7QGVJP1D
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MT>Y:I!L&/2-K49;B7OJS^^-Z#L-9H>W291MC%Y*-8,K2=V3,=Y=Z)Z/0Z4A
M                               ![&O;VN:BH$3A *4AC3N3L;Y^I8KT
M*=:-8X*T4;%=W=K6HB<_$"Y/6@G9V31,>WX.1%0K9#'&U$:QK43T1$X)@J!0
M                       #BO67SI:ZGQRT0'9X/*-OU(5@
M   #EO6MB?@YS'T/@_\ PJ >#5]0!ZQ^YOE1M#843U\:$])HH       6KR\
MPN*D+?&+?&?58(@                                 '/>JO":%G/\
MA)^\!O\ 3N/O7P?]QA_=)&        $H H  1/+;MB,3G,7B)N]]NZ_B-C&\
M]J?%P$L10                          ! +,\$4[%CE8U[5]6N3E%*.?9
M+0*RV'6L1;FQUA&NX\%?F*Y?BAJXK/47#IV6JD63C:O*21N2-W"%V8.;9?9\
MMD]QPT]#7[5>W%82.:16>K%\E/4<:<IYDH^@                .
M                                      <6ZQPI+5USZ,M&!V:!4\-G
M'\U"L              #@ <JZW=S>G65^E\'/VJ >#U 'K#[F]&I1V)59ZS0
MGI7@       +%M/Q+RZA?2WQGVJ@1
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M9V=R<^2HJ+PJ*6P;@$               #@=J /#9SSVIS\0
M                                                   XKUB3N35F
M_'+, [3 GS4^"(A]                '*^N3.>GF3[/=+!W?:(!X/Y 'K7[
MG-O&'SKOC;C/1X       6KOYEQ6A?2WQGVJ@1
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M(4^#)%5> .Q
M                                 <5ZO^?WJI\<NP#M,7Y*?4?0
M           !R;K?Q^#O)_\ &@_?0#PFH ]8?<Y]_P FY_U[/:8CTIR/P?0
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M1!ZFPF(JX?$T\?78C8X(D8G"<<JGJIRG7(H,5U?VFHB\>W4XK#43T10.V)Z
M                            )0  %#E 30!0
M                         .+]7O-^II\<NP#M$/Y/(
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M=1RQ.LVUQ]UN;3YDH_'AYU[3=]PFU57249.V=J)XD#_)[!W@F@(
M                                    !QGJNG=:U!.SUS$0'96'T
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M6^:C8V3&0I4L>!<JRI+7E]R/02]='*-DZ=]1]IAJP9.]0[8/1Z(O*FSQ_2S
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M&)D=:[%YQM7T[VF8/3@
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MCC8C&-3T1&IPB$')\G@-@M]5\/E4K-^3:E1R>+RGJY%14.N@
M           %+O=]94!Y<N6V=.>J]N_:8[Y,RK'+WHWT[SLV0ZD:?5Q\]IN:
MJO[(U5K&/[G.4LZB!=.K^UYG6MAS&8NR2068Y4J1NXX1$1>50U70*K2MX++)
M-4B>K+WDYZ(HT>@XZ%&!_B15HF._G-8B*>9UM/Z<]3KL]Y7KC,KR]94;Z=Y)
M>H[K)ONGLJ+87.T_#[>?*1%4XKHJ_?CU/RFRI"]*=9G$"_%>.Q"Y@],@@
M                                          '%.K//RGI2(OKE4\A.
MX[6ST0                #D/7+RZ?7_ /CP?O@>&5 'KK[G:!68+,S>Y]Q$
M_4P]%       !9MHO@.*T0OI;XSZK!$
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MW<]BRN[3IV,Q..Q51E6C4C@A9Z,8G""VT;
M                     #B'5Q.<EI2?_I43N.W,/H                X_
MUV5C>G]E%3E5M0(@'AO@ >O?N=V*FNY9>_R6]Z?4P]#@      !;O+S"XJ3W
M%]+?&?50(@                                 ',.KW:F@YA57W1_OH
M!-]9?S@,2J+ZTX?/GG]!#<   5IR'+=&]?R>0M77WKS'SO[GM9)Y#K.PTLG0
M?!N1W9E[[?@O>:V3H!454[-AMCFX_P#T"] ,?[L]<+3ON?H?=L-D;Q_^@7H
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MC2>IT&4K2W-L1]9DJ.D9YKWH=T9RB<%MT5 @+Z!
M                    "             !Q'JRWOS&D-]><F)W';8_0^@
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M=R_! +GD6);M&%R)-8BC_P!YR)_U J66%K%>KVHQ$Y5RKY<%UJL5.45%1?>
M3@<( '"* X0<(0.U!PA=#A!VD#A 4                           Y0=R
M .4'<@                           #BW53A<QI"?'*"=QVEB
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MD=VN5.45%^"HO"H0;L                         XIU58K\UI#?5/E/T
M[6Q0                .0]<G?\ L^N_38@_? \,*H ]A?<[J[[VLJBIY)>\
MOV#T'Y_        +5Y>8'GU"WQGUJ^,^U<!&0
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M4OOY\G7U.^       !8M\>"\N(7U/JWQGU6"(
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MU%-'"XK']WL=&O!W>JQL1O)!D5<=3I^+[-7BB\1ZO?V-1O<Y?>O!E" "@
M                          "%;SJ$>V8J"B^TL"1V62]Z-[OR25/JL?2=
M655[%B6/GW\<< <RQG2NA3T[)Z[)=?(ER9TBS=J(K5+,732\_'Z[4N[!)/\
M)5[QV.6/\MB>C +VR=-[%K-?+F!S4N+OR>4[D3O9(AEZ9TXKZ]?LY:WD);V4
ML(J2SO\ )//S7A .F@                        '#^JOGLFBM]?Y07RX[
M@.X,7R     "HBHJ*           4XAU]3_(5GTY"(#Q2H ]E_<ZNXU?)<^Z
M\O[B'>@       LW5YA<7$+Z6^,^U4"(
M     !R?K.O&AW_IFA_? G6.E?!K].1K'3.928J,:OF]49Z(J\'(]1ZNVLYM
M\^*?C)4BFE[8$\D6%&(O>KP)&F]3U=AW"K>G@BJ8V&%T"N\OG/;Z*I3TRV_8
M=K9>O7Y*'@>210P*OBL7^V6P=(R68Q>+B2:_=AK1J[M1TCT:BJ,=G,+DXGR4
M<A!8:Q?GK&]'<$RC%?O&HQJQ'YVBWGXS-,_Y9P[;5:L^[ DTS>Z*-7IW/3XM
M3WH,HO3Y;'16H*DEN*.:;GPHU<B/?QZ]J%NY?H48O&N68X(^43O>Y&IRONY4
M"Q4V' RV_9(<E6DL_P!$V5JO_4BGRWM&O5+#JUG+5(96^L;Y6-<GUHJC*+EC
M.X:FD3K.1K0I)^0KY&MY^KDORYK&MI)<]M@2LJ(J3J]$9Y_!PP:^KL. MS-B
MKY6K+([T8R5KE4SK63QM+L6W;A@:Y>&^(]&\_K&476Y"G-!XD,\;HD3E7HY%
M;Q\>4+$.Q8&Q(V*+)U)'N]&-E:Y5&"Y;RE"KV^T6H84=^3WO1O/'UEZ&W5EA
M26&9CXU3R>U45%_Q0#FV^;[!@,&MS'6*5F?QV,2)9$=Y.7X-.@TY7358)7(B
M*^)KE3X*J<C!\ER>/K.[9K<,;N/1[T:I<]MIK!X_M$?A>Y_<G;^L91:CR%&5
M[F1VHGN3U:CT52J&]3F>YL5B-[D]4:]'*,HN.OT89.V:S$QW'*-<Y$4N268&
M-:Y\C6HJ^7*\(H%->_2D56QV(W.X]&N12W/;K1^3YF,7CGA7(@P1'3ML78*%
M^W- RNR"]+ GS^>4C]ZDT2Y6>JHV9B\>Y%08$<\3^>Q[7?4O(6S CNUTC4^A
M5 .FC;^4Y$0H]HB?SV2-7CX*!#=5W:ALES,5Z\3XW4+*PO[E14?]*$U61B.1
MJN3E?1 'B,Y[>Y.>.>!XK.%X<GEZ@?4GB7\EZ*H1[5YX<B\ 0G?]JGUC79LG
M7@9,]DT;.QR^7SE)55MLFJ03N5&>)$U_"KZ<IR!%<#N467V7/X9*JL7&N8GB
M]_<DB/)JKD H66-6KP].3DF!ZH)>@VZS<H^%%AY?+L=RZ1H'4,3DJ^1QM*_&
MBHRQ R5K7>J=Z<F>DC%\T5% >(WXCN: [V<\<IR%>U/50'*'Q'M1?-0(K>VF
M"GL^)P:Q=\EV*63O1WY"1H2MKV_% '>U%]1W( [T7T4(]$]5 =R#N3X@!WM
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M3LE1KU8Y6.1R(Y/5/("[R@   <1ZI<+LFBL5$=SD%\@.W1IY
M     <+Z_I_D77^B_$!XO4 >R_N=O+5K_P#?W'>0       M7UY@<5(6^,^M
M7QGVJP1D                                 #DO6OG[Q+?_ !X0.AX-
M.<+CD7WU(OI_10Q,?J6NXV:*>IC88I8W2JQZ)YHLOY8')J]2K<W#J;%:@9*S
MV2%>UZ<^D9)^CM*G!HN-GA@8R6;O65Z(B*_AZ@1/J<F(L[7AZMBG=RDZ5GJW
M%QKVQK\'JXB^D4[6.ZAY*LN)3%L?B9'+4259?J5REFBG3>G> S&B9/)6H56V
MY]I8Y45>8^P303Q:3I&WL=WS8IR,E1_GWQJ_M'7]$MU>-^V=2<GG)N'T\;&V
M*D].>WO<AM.NR(NFQ<N[4]NA((-O&I:]K.JX3+X9ZQ7XIX%CF:JJZ=7BIJV.
MVWJIGTRK%?%%3@E6)%5O+W,:7K!1HVDZYM>2V2;+,D=)6M+!'4[W-\"-ODTB
MN1]KHZGO6$@MK9Q="]6;6D7S[%=)YM0=:)/O.BX37-(Q>:Q??!D(%@7QDD7E
MZR%_6Z-;>-ZS3-F8]SZE:)8*3WN1K.41'EZC$BQJ8N?J3K>-O*VFRDR6-RO\
MHG^^-7.(CA,5C:DN"AR^,NXFS',QT>2B7Q(YU>O*(X;>@WN:O3YKJ%GF6L#9
MS,5-JQ0UF2+&D3?17%JGEMCP.L;E6;%)3J1^$RO6?,CWUUG=YD&PW'0-8Q&@
MXO+4F*ZVJUN9^]51_B'J:EYTJO\ P6?]!1Y4SM+!Y/:]B?;K9?-V63*R)D#%
M8V!&_HJIK\:]R](=I8^26)D62:D,3U[E9YHO87J*<QH$.,BTE*5N>#)9-R-G
M<CUX^<B*JDCFUJ'3>HN APL\[G25I)+3'.]6-0;1 (E?GH\MF,EKN3R$\\DO
M99AD5(H>WZ$^!+LU)E+O2[4:5WO2U8R+8X%1>Y5C151% V&7TZ#1=CTZ;"6Y
M_:K=I8I6R.Y1Z>7)G8#3:^^Y+:,IG;4TKHKDE6!C5[4B1@VB/UUBH=%MAK+)
MYKEEAC^*JDC2SENG+L/E-,@QUZ[%-EV>%<1'^B(U%DX4;8-[!09HF^NJXBQ8
MGKQ8:>S;BDD\N4:JMY.7NG;D,;>RMVGFY;T_?*VS'RD$2]WEQ\402B5;-:S.
M<Q/3B"_+-5DL*^%4Y7N>SEK$F)74U:/4^I>&Q-*[9?4R-.5)V2.YY1&J+1G]
M(-5QE39MJLL5ROHW'5H&JO/:Q22=4UGP^3UC9HY.&4[20V$^,<H@YGC=OL,Z
MHRYVS.YN*GGEJ,E[OQ?#&&+?DOQ:Q42.[8B38LZ]Z\*O*P=W""B3YS74T'8]
M4L8;(V42[92O8CE=WHYI+.C\TLJ[<LDKG<99X]#GN=6TO2W8)7N<]K\^_A7/
M[N&I(7Z-";J'MEO'W\C-!3QE2)D<,3NUSN4(-UT<Q2XC<]SH+(LG@+&Q'N\U
M5.5)KU>F[,%5A?G5QT4UA$D[6.=),W^8SL)-]C@^/L_(VZ:V_$1Y>O7GG:Q5
MN<]LZ.\E5$4NXNA#<USJDZ5'<Q64D:J+QYL>XU1E;;:N8;5M/P>*6TC,C RS
M8['JLLCE1/FM*-7RN5Q.XX9,;B\U#5F<D-F"TYST<B^2N0@D^FZK:V7;-BOS
MYN]"F.S*I'$Q_D[SY.N]3<W9P>F9.Y5D5DZHV*)_P=(J-(.-;)I5K5=3J[+4
MV'(K?B\!\O,O>QZR*AM<Q0GW7?Z=)F5M05F8:*>=(G*Q45Q8.^4ZB8K#Q5TF
MDE2M71.^1>Y[NQ/5RGGC5M+R6YXBYG[FQWXI[$\RUFQR*C(N% M;+K&9N;'H
M.+M9=TEE:LL<]B!>UW8SU5'&\UJC8U;J/>P;,E:GJS8Q98W3R*_PQOH<XR60
MQK*.0E?F<UD<GXSU]MJ*]*T1.<[8SF4TS0%JY6Q#<MSLA?,QZMY[D+O87&4,
MEH^^Z[69FKEVOD(Y$G;.]53N:AJM7Q&<W^;.Y279K]5(K;V011.5$0=<T:.#
M=\_A= R<3[L\UV;*/K-G<]7.C:U$Y5#2TMCRN.RN#L4,CG97K.Q+3;35\.3N
M7W)RI1[5D<[P%<WA'=G*=WQ^D\>9K+31Q7[5K=K\^521ZM@H=RUXC,$KV#.;
M/?T#29X,M+%>NVDB=(Q58Y_=RU.>#93UM@TK<]4B78K>0@RLCH9HK#O10,W7
M=QNZ]8W7'[#9FDGI/?:@5R]W="[T1A/^F<&;CU2K-E[LEBQ:59^7KRK&2>;6
MBCE^PLVW/=4;N$Q^>LT:L->.23L<J(U.TR,5FMEP-_;=>RF5EMRQ8U]NI;7\
MM$1I1J,/:V_#ZH_<;^SRSLDIKX-1Z*Y.]Z]K#G,._9N.)F2^^S)R7>]'K56)
M? 7^QSW%Z#HNQ8U<WN.CV9<E;AGR$*S*Q%14@1&\\1$7S/4'*6]GR%639+]&
MA6<L47@Q]SW=GERX=!EUNH^S6-'S,<>3F=<JW86Q6NWA[XY7<$JRV1V_1=2E
MM9#/OM7<C)$V'O3N]F\N7\#L(9AM\S%3+X7V7:KF26Q::RU7GA5K.'+ZM.@/
MJ[SG][V3'0;1/2I5.Q4\-J>7>G+6H.@UF-W78L;IVY^VY19[N.MI7@G>GFJN
M\C?8W7^IK*V'RL&V+<658I+%69J-9X;B:()F>I=K);7DX'[)9Q6/K*L<*01+
M(LCFG3ND&Z7]AIY*G<G6R^C(G%OCM\5D@N8+?4G9<\F>P.L8*VM:U>=W23_!
MAIUFVK2=QP&.L9JQD\;DN86)-QW,>/4%&DKNNRV[5[[[98JM/*21NK+$CN]&
MN].3LFR392+!7WXQ\++:1+X3YEX8U?BJB]QY8GW*?'4FWZ6]WK665T?C5W1<
MP.\^'(WN3@Z%G<AN63ZA5L#0SDM2M8QT4TJL8Q>Q.WS5!HHP.6W-K-ZP+\K+
M8LXR+FI8X:LAL[6^9"WHFONH7FIELE-%5\5$3YDO/#U5% [*QD]?&(V299)H
MX/G2*GFYR)ZGGC2<CN>;K7=AR6R3QU,;+(K84C:C9D8G*HXD$9K;[D\I2LY:
MWO,M"Y&Z18*$=?NC^A%-MN>?M9_1=)R-IB)-)DD23CR15:+8-KG]@R2[#E:N
M4W%,1# Q/8X:WSE?RGDKU0T\F=R>V=+=ADR>1574+"(V5K$3Q_@CT D^;ES&
M I=/:<.3?*Z>PC'/D8SGM<C2_K6]Y3&8K;J.>F>^[A^]S)G>KVO\F%$>M;MN
M&)U[5Z=W(-K7,F^666[.U'>%#SY%_6-TR5+=,7BW;4W-U+S>)'^$K?!>-@[E
MN6:EPFL97)Q,1SZ\"N8B^G<ODAQ6.?J(FEIM[MG19.Q+7L7A(D2Q?S#(;!NN
MX7]CU?'8>ZRFF4QT4CD5B/1BR<JJG>,'6R5/$UX,E?2Y:C:OB3HQ(^_S54\D
M+1Q"E;W;J!D,TZCFW8K&4YW0P>&SY\CV_%34W<_L.3U3=\#E;[%N8EB=T[&\
M+/&!K64<O^#[1V0Y#\;/E8EK=S$X@]2:T[NSZENV+Q.2SLN2IWX)7M5[4[VO
M:@T0&?J%ELW=REN3;$Q"5'N2G4:Q5\56^G>2B?J%M60Z;5<M2GA9?7(-K2N:
MP6P=>TO%;'C*DS,QFOE!SU1T3E9VN8BIYHJG.]RR&VV]_@U[#9CV)EF@DCG*
MWN1JL55$&D;MF?U[*[LMNRRY+0H5E:JL:Q'2+PWDL927J=5U)=K?LR(KX&O6
MDV%.UC)%1$5"#:;C#F,CLG3ME.]X%R2M*[QU9W=O+/-2K&Y;<J>?SNI9/+^T
M2/QKYZE[L:BM\BC/Z$5<BS5Y9Y;J/K/L2)%!V>;%1?->21]0MFR^.N83"8=6
M-O965T:3.\_!8GJ_@E[B+8[);YA=ZP. R^7CN5;;9Y/&2-&*_B-?F$:K[?L>
M/P>SY>FM5J4=C5)XTB:GB0N7LX+@Z'L6ZWGY?4,;AY(T=DWI/-+Y/1(&>;D(
M'<ZBY_.Y?*-Q&>QN+K4']L23\+[5Y_%P%^7J]F9M4JVZE:!<DS)-J68U15C>
MJ^]AOGY_J#@<[A'9J6E/5RDZ0>S1)PM=R@=>S+;3L7=]E>ULW@/[%=YHB\'F
M_IWL.9UGI[E<Q(V&Q599<D,'H_QG.1JJKB"6KM74/7W8[(YZ.E/CKTS&*R'R
M?!XAW=J\M12@" <2ZHHU^S:(W_\ 2"^0';&*?0               !PWK_Q]
MY,7]_B \6JH ]E?<^/1=2NM^%]YWH       +5]WXAQ4TM\9]:_YGVJP1D
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ME\4U6QX\$[_)DR]_=VH!N+UO:]U9A\&_7IZ"UIXI;EF;\A/!_F'HIB<-1
M'#.J4+I-MT3WI[:OS0.Y,\D/H               !3AG7]O^1,"_#(1 >+@!
M[.^YZ8]NHW'?&\\[L       %F]YP.0K0M\8U?&?:K!&0
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MHO: *??P!]5.#X45)P4\>?(%78   '#NIDB+N.ALX[E]K?Y =P8?0
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M?IM:3WLOQ@>,%Y 'L_[GU>=-MI\,@\[L       %FYY0N+B%]+?&?:J!$
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M3GX^0%B[B,9=1_M-&"57Q]CE<Q%56_#E2_2H4Z-:.O6KQPPL3AK&(B(@&"_
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M1C*$DLE2E# Z1&H]8V(WE&^GH09%VG2N0^#9@CF9W([M>B*G+?-%X4U./U?
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M4Q27L)?K596LC]K>G,9*MCZF8S#9&/&05+%^ZYG>L-=.5:T8-WJ6[4=EK6/
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MJQ(.6CI]2Y!=J0VJ\J/BE8CV.3WM<G**:'%;CC<EF\MAX%>EFAV^-RG"+W?
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M5TNS_?Y#N8       6;B)X+RM"WQGUJ^,^JP1D
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MQO2G; '/*      "U=7\2XK0OI;XS[50(@
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MY'O^3+WM$\DGFK_H:6<0Z\GH<.WIJ+U-T/X]\P'<6@                <
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MH'CP >VN@G*Z+]5V8[4       %J[^9<5H7TM\9]JH$0
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M4KZ2W[>1VO=+ENLZO-))#WPKZL [^"  !Q+=?/JIHWU3"#MK$\@
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MJ6L1J6OX2627'8Z&"1[4:YS4\U0@D/ * X <#@!P. '  <#@ . ' 5. ' X
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M)ZC[+BLOC:NQ6*%B"^[LCEK/3F%?IX*(MMZDY7;\YC<,E5U:E<X<Z1B(B,^
MO3T+&2ZD;5D\S?APEO'5*]29(.+3DYFD-]^%=[=0]K2!),M[5[$V%/-C[ S8
M-7-N_4/5[N*FVBO56A;D['+"GG&1/"X[9LGU;R3Y&T99(7QOG>]B*U(/+M5B
M?$EH]9-3A 0
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MMLY_Y5[\9+4;5M+"Q7_]HB>]"7D
M
M .([:CEZN:4B>Z&8#MR                 OJ>??NB/+6L2BIZWOU?, \>*
M /</0A.-"@^FU.=D       "U=\X7%:>XOI;XSZJ!$      !\D54;R>?,SU
MUK8S+6Z*XF1W@N[.5<68-6GW0]?CSPK_ -LOQ?="XU47OQ$R?4\=!?;]T+A?
M?B[!7_"#P7/^C;(R"M/N@L![Z%D+]T%KR+Y4+(Y8+J=?]97G^*6BZG7W5_\
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M!4DK!XK?B [V^X>(GH [FCN;\0'<WWJ.]OQ *]#B&U*OX7=,_P"!,4=O0$
M              \[_=%?Z PW]^7]P#R( /<?0YR_>!2Y;Z3S_OG8"WN (
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MY\O\V OLW3K"Y&N2*TJ?W8S-#R^QY;J9AI<TLOBL9+VI(WMX16@>QV^@(
M            !YV^Z*;S@,*OPNN_< \B*H ]R]#7M?H-'Z)IT7]LZ^6]P!
M   !9OK^(<5M+?&?6KXS[58(R               #A           ")Y  $:
MG/*@    +QP!XLV;'WLUU8R>+BNN@2:UY/5?).(T4Q\Q5SG3K8<>^GGVVEF1
M?-J\_0J.::@Z#N]RTG5;4%9+(Q)&0*J<_%3J&U=4=7UJRM2S+)+83\J*).>T
M@WVN;EK^PX^6[1M(L<2?C4?\U8_K(%9ZY:7!<6!JV9&(O"S-9Y#!.)MXUF'
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M:^7"W'@>1P![DZ%(S[P:G'K[3/R=@%       6L@O,#D*FEOC/K5\)]JL$9
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ME!@T73>&:MU66!])E-S63=]9CNYK%["6=)47\).X?7)^^9O:#K?51>- S_\
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MD5SQ1.P9                        " #BFP\_ACU3^XS"#M:
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MK>IV\!HRXBM)S;2M+^,3R3QGEGIMA=IQ.)G9L%U9[$DW<Q%?W]C1HZ.
M                    $14 '$]@\NL>J?31F [8                !YQ^
MZ+:SY%P:^]+;_P!P#R0 /=70R7GI]01$])IT_P#K.M@      !9OKW0/*T+?
M&?6KX3[58(R
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M_K5#K@       6KZ\P.*D+?&?6KX3[58(R
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MUMD]7;=<PM1D<J74D?8]ZLC1.44BF,5=?ZKW,9$KDJ9:HMED7HQDK2#M@(
M                                             '%\UY=:=;1?=CY0
M.T                 >:_NC//&8#S]+,H'DX >Z>B3)&]/<9W>BRSJW[13K
MB      /,>?P M7UY@<5(6^,^M7PGVJP1D       $N@     "@     ":
M H                              %#_G(J <$Z<U5K,W?7%E]GO+:E=$
MWT7LD3A'H15NB[G4U>UA:VLTEM3*YDN129.]\:J!)\OIVWLP^C6L?6B=D<.G
M:^N]Z=AL[]#?F;M#EZN,@?!/CHJ\Z>(B+%SYN^M6J71 <7IVVXB+,UFZG!<R
M#Y'NAR<DC?1_O1'&^=I>U-TK3[-2KQF</9D>D+W)YL5XT;FG'U'V+++=R%5V
M,H0T96MIH]%6>1[5;PXNT=<S471>;#OJ/2\M*9$@]_+GJY$ ZGK5:Q3US$5I
MV=LL5.)CV_!R-."Y'4,_5W?.Y.?5F9J.RO?5>^5$2,@S]5T?:9<7N=/,58JZ
M91B/A:BHYK9#1YJ+JYD\!5UZ7 -9%'V,DGC>WF1D1=@EFP8';<#LE;8\!02\
M^:DR"S6<O';V(4:-B-NFV#:\QF,1[&^_41L;.Y%3N&C6YG4MJKZOI$]/'^+>
MQ,W?)51240:[F<SFM@LY"A[*S(X."'S5'HR7A>6C1"XF]3(];74TU=CJZPNJ
MI<63W+Y=Y)Z.FYFAN^IS)%XM2AB5@EL)PB=Z(78,G,:UF[74BS?A@<VL["/A
M2?GR21R*AS+&:WM=3 3X6OI$:79VR,FR4KVN\E V%+4-N?E.G4EG$R-2@SLL
M+RU48C)%5.3OVY^>IYW^X3?ND'G+!7-_R.B5M>AP'B5;<7A17E=Y-A>I)MTT
MO,4[>IS18Z3,T*%5():B.[55[4_++:+6"P&?L;/E;>2P#,71O822NB,5JQPH
MB>K^"+KM&WXK2+N!AQL5FK V6!,DQZ+&L)>E&U31<L_6-*S]"FRW:I5D6:G)
MPJ2Q.<KR5:WB=FR^T5<G/K];"T:S%18NQCI)7DT.FWMN/FW#5WSI!?CL23P/
MXYY;+Z/('G,%M]ZHN'MZ7')DEE3MR\/#$7SY[E[1HZ/U)BGAT/$8*27ONV9J
ML"-1?.16JG<=FI5V5:=>NQ.&QQ-8B?0U."#SDFN9_P"]OJ5 F,G\2U?[X&JW
MSD;W^K3T+@8WPX;'1R-5KV5HVN:ON5&@<SQ&*R3.KFP7WU)$JR48FLF5/FJI
M&\EJ68S.<ZB5/971U[D,#Z\CDX8^9@T0_'PYFQC:> 9T^AAR+5;$_(R0M5B(
MU?-Z\H3G:<;F=7VS%;)CL8^[7912K8AA1$7R3A.$+HHFI[IO6&V1;M5:-2>!
MJ4*<B)W^)'Y\J0^DRYDL?1PM3I[%6O\ #(Y+T\*+$SM\G/'\T23=H+]/+Q5L
MEK"9;$K2;'62O$B/B>U$[O-/-#0X#"[I7T;85I8YW@2W&NK4+2>(]8$Y[TX4
M;PC!Q>/R66V[!SX+7+F';"]'W%=RV%>"Q'2R%++9MFSZU?R]V2?FJ]G/@*78
M%.KE?P=U:#L-;9*FQ,>]GA+PC57D]);AAOEK5\G0Y1KI:Z]JJGHYOFAFCDW1
MJE<RMO(;-=[>Y8HZ4*>OE"B(Y39VW_+O6*C' _F+#5'+,Y/=(\#N((
M                                         '%\MS^&G7_HQLH@[0
M              !YH^Z.:OL6O+W>7CS@>40![LZ)O5>GF*^A\Z)]JIUD
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M\M\F_P 8RI-%ZB,X[=[D^S'/?R W1>HB/_UXD[>/56%"Z-U*3GC>7_L#GOY
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M@_H9)^^ITT       +-S\P\K0M\9]:_YGU6",@
M                                                           *
MT                  '   !P@#A!P@#M3X#@      .   <( '"#A  X <#
MM3X .!P@#A!VI\ ':GP':GP =J#@!VH%: 1HX <#M =OF..% <#A ' X0 .
M'"!4\P*%8B^X^HQ/@!4K4.)Y!/\ VW8?Z,7((.V                 >9ON
MCI%]CUQG*<++.H'E, >].B\79T]PWT^,[]<JG410      %BY^8>7$+?&?6K
MXS[58(R
M
M                                '%+_ !^&_%?#Y*D [6
M      !YC^Z.>GLVN,X3E9)U \K #WUT?1K.GN"X3CF.1?UR*=++0!     !
M9O+^(>5M+?&?6KXS[58(R
M
M                                              '$+RK^'#%_^E/
M[>                !YC^Z/5/!UI.Q/6P!Y6 'O?H_W?@]P?<J+PR7]7B*=
M.%       47U18'(@0M\9]:OC/M5@C(
M                                        !RO(
M                                                          !Q
M&YQ^'#'?3B7B#MP                'F#[H[SBUOZ[('ED >\NC/8G3S#<?
M^=^OQ5.IEH @     LWOS#BM"WQGUJ^,^U6",@
M
M
M  !Q6TB?APH\N],0X0=J                 \N?='/\]:C^BRH'ET >]ND'
M'X/L'Y?H2?OJ=/0M $     %F]^8<5H6^,^M7QGVJP1D
M
M
M         .)SJJ]<*?\ 9Q+@.V                 >7?ND$1/O9\O/BT!Y
M< 'OGI$CTZ?X/O=ROAOX^KO4Z86@"     "S>_,.*VEOC/K7_,^U6",@
M
M
M                    !Q?O:O6UB?\ Z'+!V@$                \O_=(
M>FL_7: \M #] .E#4;H&O\+SS!_U<IT44      !9N_F'%:%O:?5OC/M5@B
M
M
M                        !Q9C_P#VVN3W?) ':0                /+
M/W1Z+XVM+\660/,  _0#I5S^#_7^4X_BZ_O*=%+0!     !:N_F7%:%]+?&?
M:J!$
M
M                             #BT7<[K9(G?Y)B .T@
M   O/)Y8^Z0Y\76?/R[+('F%0!^A/3%%30]=15_[FTG@H      "W>7F)2I"
M^FKX3[50(R
M                                   <
M                                    *<7K>?6JWYHG;B$ [0
M          "GEG[I!4\764_L60/,"@#]!^F/EH6N_P!T0GP       6;J_B'
ME:%]-?\ ,^U6",@
M
M                                       !Q:AS^&C)_P#I3 .T@
M             >4_NC>?;-<^B*<#S, /T*Z8-XT/74\E_B;2=@      !9N?
MF'E:%OC/K7_,^JP1D
M
M                                          .*T%_]M.4\_P#PI@':
M@                /*WW2'E:UMOPCL >8U 'Z&=,N/O$US^Y,)R       %
MJ^OXEQ4TM\9]:_YGVJP1D
M            #D
M                                               4XMC')^&C,_\
MI; .T@                >4/NC>[V_7OAX$X'FA0!^AG3#E=#USG_8VDZ%
M      6KR\PN*FEOC/K7_,^U6",@
M                   )Y@
M                                                      !QG&,X
MZS9E>/3%Q@=F                !4/)WW1B_P I:^G'I7F \U@#]$>G,;8M
M)UYK/3V&-2:"@      +-Y?Q#BM"WQGUJ^,^U6",@
M
M
M     !Q;%*[\,N=\O+Y,B$':0                /)_W1KN<CKS?A!,!YI4
M ?H?TV23[Q]>[_7V)A-Q0      %F\OXAY6A;XSZU?&?:K!&0
M
M
M             !3C>'8B]8]A54]<;"(.R                 >2_NBV<97
MO\_.M*!YM4 ?HATX:K-&UQ%3A?88R;"@      +-[\PXK0M\9]:OC/M5@C(
M
M
M                        IQG"NYZQ[%]&.A [,                !Y.
M^Z-5?E3 -^%:4#S6 /T9T+RT[7D__,(?W26"@      +-[S@<5H6^,^M7PGV
MJP1D
M
M                             4XO@V?^V+9EX7_1\)8.T @
M      'DS[HZ-69K!<O]:D@'FU0!^B73E9/O(UWO147V&,F8]@      +-Y?
MQ#BM"WQGUK_F?58(R
M
M                                          '%L#Y]8MG_ +A"4=I!
M                /)?W1O;\M8+^YO \W* /T6T)95TW7N_\KV"$EX
M 6;WYAQ6A;XSZU_S/M5@C(
M                                                     "@
M                                               "G$==<J]8-J^;
MZTHBP=N!                /)7W1B_RQ@D^%23]\#S>J@#]%="8C=,U[Z*$
M),!>X      "U?7F%Q4A;XSZU_S/M5@C(
M
M                                                          IQ
M?647\+&W.5O_ '6 L': 0               #R1]T7VKF\'\?8W_ +X'G!0!
M^CNC1HFHZ^W_ /1\/[I*0       MWEYA<?4+Z6^,^JP1
M
M
M           XWJR<]5-R<B>D$"<@=D                 \A?=$JS[X<-\?
M85_? \[J@ _1K1%5=/U]5\U^3X?W25@      !:NK^)<5H7TM\9]JH$0
M
M
M                     4XWJGGU2W+X^# !V0                #R!]T0
MO^4F(3X4/^KP//*@#]&M$E274-?<C5:BT(?+ZFDK%[@      +%Y.('EQI;X
MSZU?"?:K!&0
M
M                                   !3C.I>?5+='?^5 !V8
M         #Q_]T0Y%V;$I\*'_5Z@>>P!^CNE\)J> _N$'[B$G%       6;R
M\P/*T+?&?6KX3[58(R
M
M                                           '']1:B=3-W7W=E<#L
M                 'C_ .Z)7G9\5_</_P"]0//0 _2#3TXU7!?W"#]Q"2H*
M       L7/S#RXA;XK?&?:K!$
M
M                                                  #C^GK_ .TC
M>$_NX'8                 /'OW0_\ K/B_[A__ 'J!Y\4 ?I)IJ?Y+8).?
M),?!^XA(0       M7?S+BM"^EOC/JH$0
M
M                                                          .-
MZ=Y]2]X7Z( .R                 >.ONA^?OIQG]P3]]0.  #](-.3LU;!
M-_\ S"#]Q"2       !:N_F7%:%]+?&?:J!$
M
M
M %.-:._OZA[TOP?"GJ@'90                /''W0O^M>._N"?OJ!P%5 '
MZ0Z>COO6P7<GG[!!^XA)!>X      "S>7\0XK0OJ-7QGU6",@
M                                         !Y\@
M
M                IQC07(N^[WQ_30@=G                 \;_="]GWW4
M$1?3'M_?4#@0 _2/4%5VL8-5=RJT(/W$)$/8      "S=7F!Y6A?35\9]JL$
M9
M
M                          ''%] _U[WI>?\ MXDX[BCM (
M     ')XU^Z$_P!<*?TT&@<& 'Z2:HBLUK"-7U2A B_L(;\>P      %N\O,
M+CZA?2WQGU6"(
M
M                                      /.,]/I._=M[^=_WF+WB>QV
M8                #Q=U_2%-S@5BKWK0C[P.%J /TEU=%;KF&1>/*C#^XA(
M"T 0     6KOYEQ6A?2WQGVJ@1
M
M                                                   'QYQ?IHO^
M5.]?.[OX^WWE':00               #Q5U^14WAG]PB X> /TLU]O;@\4GE
MY4X?3T_)0W*       !:M_F7%:%]+?&?:J!$
M
M
M ?'H<8Z;/1VU;SYIS[:SR[@.T                 >*NOJJN[Q_W"(#B  _
M2W7T3Y$Q2(JJGL</[B&W       "U=7\2XJ0OI;XSZK!$
M
M
M          ?)#BO2Z;OV+>$^%]OEW*!VL   'FH            #Q1U\_P!>
MD_N$('$5 'Z6Z]RW"8M%1$7V.'G]A#<       !:O+S"[@J0OJ?6KXSZK!&0
M                    $ %
M                           Y\P
M0 4                         ?).#B'2IZ/S^[JGDGMZ>7*@=P    C5Y
M            !P>*>OB(F\,^FA"!Q!0!^F.$B\/$8V-5Y[:L2*OU-0V@
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M$D!                /$?7CA-]D^FE"!Q50!^F.!C\+#XV+^94B;^IJ&U
M     "U>1?9W? ^H6^,:OC/M7 1D      !3C.R9CJS2O9&6CB\>_'P\OC>Y
M>7*Q!T]B+ZWO/5G8((;=+$4'UG2<=Z^1T7$;G?GWC-8.TRM'7J5HWL?[U5QK
MI1.[=IZ4;$U5&2R-B<Z-$7E'.1/)#4ZEELS=U^M9R]=E:T_N\1C?1.%,X)##
M8AEY[)6.1/7M5%*W.1$557R0>QQS"]1\]G]MGI8?$Q28JK-X5FVYW#OK0["C
MTY1.Y.?@+!4.Y '<G( #D!R   ^*O!']?VC%Y]EQ^/E<]*UA89%5JM^>T8,7
M<]L@U3"NR<]=\S$E8SL8J(OSE)/2NMM4Z\[$5$EC:]$7U1')R3!<      H#
MD !0!   C$VW4(-GJZ^YDWM4\"RM>C?F(U"B3@#3Y_.TL#B[62NN<D$#45_:
MG*^:\&7CLE!D:%6[7<JPSQ-D8JIPO:X8-#+NN(AVF'7%?)[=)"LB<-^:B<<D
MKY%Z8    "   +E  %(O@=TP^9RN6QU)[W3T%1LRN8J(,Z"4&'D\I1QE5]J[
M9C@@9ZO>O"(49<4C9&-<U45KDY1?BBGT@*02+J5JDN?3!Q9!'VU?V)V,56=_
MP[BP3M%!- %                                    $    !0  $ %
M$    !0            $   4!P      '                    4\1=>&=
MF^RKW*J.IPJ@'%U 'Z;XSYV/H\+ZUV?]$,X       +5WSA<5(7TM\9]5@B
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MR:%GL$+/)[I'F)=VSJK@L;2SN4BH2X]58LT,;>'HQXL@V.X]0=EBS6N4M<;
M],G521B2,Y\W&5C-PW+#[?2PNTMJNAO-5*]B!O:G>.@T-;=.I^;SV<Q^%AH+
M%2MN9WR)QPTS^GFV9.?);G[=CZJS4N'/]DB[7RO;R@OY.XUMW<^JD&$ES<D.
M,K5E57103>4O8:7JGG<UFM!UK(+' RK;[73)Y]WC#MZRB=9C=-EPU'7,%7K0
M3YZY U>?2!K$+N#W[9*.SUL%M=6K"ZVU?9;,"_,<[X"Y@ZIG5RR8BZN+;$ZX
MD:^"DOY"N^D\S=+9[."QV;V/)4*B4H%F5;'K.Z;E$[&D&^_"+U/?B%SD6#H_
M)WY?'=R_L)AL?5BCCM1Q67IPI-8R*<5X7+PB.3U52V=9T&A?U#WS V,7-LF)
MI-H6Y4C5\+_GL5QD[7U$V-NVOUS Q4F/2%'K/97A%54Y\A>4370M@V;+)D(<
M_BEJSUI4:U[4XCD3^R=$,@
M                              =R       .Y '(
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MS+?*C&=DU%CW,_&&[W34K4FB:CDH,=/#!5C>D]?O61[&2O[D<6Y)O,,'(U-
MN38FK@Y<KE;4TK46!9G-1GTKW-)OOJZE8VQ<;LV/?28E6+V7)1*O*_0\>Z-E
MTFR60CR.?BCR%J[@*D?XBS/\6>O:=IUC9\9LN.3(8]7K!XCF)WM[556DHD (
M
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M,L4      !:N^<+BM"^EOC/M5 B             @  "@     %3D B<#CS
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M5:R05Z\<4*)PD;&HUOZD/E#&T\?!X%2M'#%RJ]C&]J<J(,P
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M/22"@                "GB#KORN_3?W. #C( _3F@C6TZJ-]$A8B?J,P
M     +5WA(7%2%]+?&?58(@
M
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MGSW58% XV /T]HL1E6NU/-&Q-3]2&0       %F]^8<5H6^,^M?\SZK!&0
M
M
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MZOA214431L]3O:S^$G'PZY4ECA^3'LL^2L3E/BCCTFAF@
M !XBZ\?Z^R?W* #BZ@#]/**K['6Y3A4B;Y?X&2       %J^O,+BI"WQC5\9
M]5@C(
M
M               17;M8@V7'P4Y;#X4CMQS]S4Y55C4"SMNIU]CH5X'69*\U
M>9DL$[/-S'M(CF^F$UZ]:MT,]/1=<A8RXC(T5)E3U>!N=DZ?4LWJE/!K:>SV
M;P_"G7YSD["O(Z'5N7]:G2T^./%02Q(Q$\WI)'V"413'])[L%W'>U[+/9HT[
M7CPUW,3GE/3EY9GZ06EMY!M78I8,=<LK++52-/TEY5$<-HV6<Z97Y\C+;P>?
MEQJ35(Z\[$;W][8DX:;K%Z9E<3C=8H5,TK(\=*Y;/#/*PQRJO!-OL=&.97=
MFDBVY*^02-^9EC=SV^4;6)PJ%$[;CH8\5[!$B,8E?P6\)Y(G;VG.V].'_(6K
MXE][F+&VTFFX1427A54#6[!T^VJYML^=Q^;K1JK$9"R:'O\ "0SLOIVY7%P]
MRML4,.2K020SS)#\V1KU'-1)]0U9V P+Z$MGQYYGR23S\<=[Y#4T]#='I"Z]
M+=<DB.D>R>/EO:]7J]J@86D:'E,1E9\OF<HEV\L7A1N:G:C&'5P
M        'B'KNO._3_14@ XN /U!KHC(8D^#$0N@ @     %J[^9<5H7TM\9
M]5 B
M
M                                                IX<ZZ?Z_VO[M
M !QT ?I_"JK#%[U[4+P       6KR_B7%2%]3ZM\9]5@B
M
M
M                            !Y\'A7K=/XO4+))_,B@;_P#0!R0 ?I]7
M^;!$G=SPQOF7T       "Q<_,/+B%OC/K5\9]JL$9
M                          #YVN1R+SY? #Z
M                             %
M                                    'A?K@B)U"R'TPP?N <B 'Z?5
MU588E5/5B%]        LWE_$.*VEOC/K5\9]JL$9
M
M
M                       !3PIUMY_"%D^5_P"S@_<0#DB@#]0H$5(V(J?H
MH7![       6;WYAQ6A;XSZU?&?:K!&0
M
M
M               5#PMUNE[^H>3;V\=D4#?K^8!R)0!^H<*JK(_+A>U.2M0
M      M7UY@<5(6^,^M7QGU6",@
M$7D
M
M            'A;K>JKU#R7*>D,'[B <B4 ?J(SS:GE[BK@ %10     +%U?
MQ#RXA;XSZU?&?:K!&0
M
M
M /"'6E>>HF8^J#_\$@'*% 'Z@Q<I''ROGVH70       L7?S#BXA;XSZU_S/
MM5@C(
M
M                                              !\5>$ >:^IX-ZS
M*J]1<W_\#_\ !- Y8 /U$9RC6_45       !9O?F'%:%OC/K5\9]JL$9
M
M
M                                       !3P7UEY_"+F__ ('_ .":
M!RT ?J*SS8T^@      !9O?F'%:%OC/K5\)]JL$9
M
M
M            X           !3P7UF>KNHN;^CP$_5$T#EP _41OHA]
M  "U?7\0XJ0M\9]:_P"9]O\ _%8(R
M
M
M            "\*>"NL;T?U$S?UPI^J)H'+P!^H:>34^HJ       "U?7F!Y
M4TM\9]:OA/M5@C(
M
M                                                         ]0"
MG@/JX]7]0L^JHB?C6)^J- .; #]16^B        +%]?XN\N)Z%OC/K5\)]JL
M$9
M
M                                            "H!\5%/ O5[_ /&'
MGO\ B1_N- YJ /U%]P       "Q?\Z[RXGH6^,^M7PGVJP1D
M
M
M                               ''@;J^YCNH>=[?<^+]:1H!S)0!^HW
M        "Q?_ ,W>7$+?"?:U?"?:K!&0
M
M
M               4\#=8$XZB9[R_3B__  30.9 #]1N>4        6+R\P/+
MB%OA/K5\)]JL$9
M      \^0
M
M4\ ]6Y%DZAY]53TF8GZF(@'-P!^HP       #'N_YN\NH6^,^M7PGVJP1D
M
M
M                                         %/S_P"K'?\ A!S_ 'IY
M^.G[B <Y4 ?J,B@       ,>]_F[RZA;XS[6KX3[58(R
M
M
M                           #C\_NJ[N[J!L"]JI_&$_^34 YT /U&;Y>
M0       "QD/.N\N)Z%OC/M:OA/M5@C(
M
M
M              4"WPI^?O5)ZOW_ &)5_P!J @  _44       !C7>/97EY/
M0M\9]:OA/M5@C(                      (    "@"   * 50
M                                             %
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M5UZ#[90GW1U[WZ[!]NHR"C^$;E.S_0%;N_XSBG^$9EO?@*OVKAD%[^$=>_\
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MCQ&_%!!2Z>+C\MJ)]82:/C\I%3X\ERBM'M"O;\2#YR.] /O<.0".1/54'<@
M .1R  #N0<H    %4(H         '(       .0             +Y>8'SD_
3/CJA(C]^V)>SM_CBH40$$'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>9
<FILENAME>abvcd-20210331.xml
<DESCRIPTION>XBRL INSTANCE FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon May 10 19:51:10 UTC 2021 -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:compsci="http://compsciresources.com" xmlns:abvcd="http://metuboutique.com/20210331" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance">
  <link:schemaRef xlink:type="simple" xlink:href="abvcd-20210331.xsd"/>
  <context id="c0_From1Jan2021To31Mar2021">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c1_AsOf10May2021">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
    </entity>
    <period>
      <instant>2021-05-10</instant>
    </period>
  </context>
  <context id="c2_AsOf31Mar2021">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c3_AsOf31Dec2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c4_From1Jan2020To31Mar2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-03-31</endDate>
    </period>
  </context>
  <context id="c5_AsOf31Dec2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c6_AsOf31Mar2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
    </entity>
    <period>
      <instant>2020-03-31</instant>
    </period>
  </context>
  <context id="c7_AsOf31Dec2019_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c8_AsOf31Dec2019_StockSubscriptionReceivableMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abvcd:StockSubscriptionReceivableMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c9_AsOf31Dec2019_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c10_AsOf31Dec2019_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c11_AsOf31Dec2019_ComprehensiveIncomeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c12_AsOf31Dec2019_TreasuryStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c13_AsOf31Dec2019_NoncontrollingInterestMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c14_From1Jan2020To31Mar2020_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-03-31</endDate>
    </period>
  </context>
  <context id="c15_From1Jan2020To31Mar2020_StockSubscriptionReceivableMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abvcd:StockSubscriptionReceivableMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-03-31</endDate>
    </period>
  </context>
  <context id="c16_From1Jan2020To31Mar2020_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-03-31</endDate>
    </period>
  </context>
  <context id="c17_From1Jan2020To31Mar2020_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-03-31</endDate>
    </period>
  </context>
  <context id="c18_From1Jan2020To31Mar2020_NoncontrollingInterestMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-03-31</endDate>
    </period>
  </context>
  <context id="c19_From1Jan2020To31Mar2020_ComprehensiveIncomeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-03-31</endDate>
    </period>
  </context>
  <context id="c20_AsOf31Mar2020_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-03-31</instant>
    </period>
  </context>
  <context id="c21_AsOf31Mar2020_StockSubscriptionReceivableMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abvcd:StockSubscriptionReceivableMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-03-31</instant>
    </period>
  </context>
  <context id="c22_AsOf31Mar2020_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-03-31</instant>
    </period>
  </context>
  <context id="c23_AsOf31Mar2020_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-03-31</instant>
    </period>
  </context>
  <context id="c24_AsOf31Mar2020_ComprehensiveIncomeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-03-31</instant>
    </period>
  </context>
  <context id="c25_AsOf31Mar2020_TreasuryStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-03-31</instant>
    </period>
  </context>
  <context id="c26_AsOf31Mar2020_NoncontrollingInterestMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-03-31</instant>
    </period>
  </context>
  <context id="c27_AsOf31Dec2020_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c28_AsOf31Dec2020_StockSubscriptionReceivableMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abvcd:StockSubscriptionReceivableMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c29_AsOf31Dec2020_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c30_AsOf31Dec2020_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c31_AsOf31Dec2020_ComprehensiveIncomeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c32_AsOf31Dec2020_TreasuryStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c33_AsOf31Dec2020_NoncontrollingInterestMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c34_From1Jan2021To31Mar2021_StockSubscriptionReceivableMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abvcd:StockSubscriptionReceivableMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c35_From1Jan2021To31Mar2021_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c36_From1Jan2021To31Mar2021_NoncontrollingInterestMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c37_From1Jan2021To31Mar2021_ComprehensiveIncomeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c38_AsOf31Mar2021_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c39_AsOf31Mar2021_StockSubscriptionReceivableMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abvcd:StockSubscriptionReceivableMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c40_AsOf31Mar2021_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c41_AsOf31Mar2021_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c42_AsOf31Mar2021_ComprehensiveIncomeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c43_AsOf31Mar2021_TreasuryStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c44_AsOf31Mar2021_NoncontrollingInterestMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c45_From2Feb2016To8Feb2016_ShareExchangeAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvcd:ShareExchangeAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-02-02</startDate>
      <endDate>2016-02-08</endDate>
    </period>
  </context>
  <context id="c46_From2Feb2016To8Feb2016_ShareExchangeAgreementOneMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvcd:ShareExchangeAgreementOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-02-02</startDate>
      <endDate>2016-02-08</endDate>
    </period>
  </context>
  <context id="c47_From2Feb2016To8Feb2016_ShareExchangeAgreementTwoMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvcd:ShareExchangeAgreementTwoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-02-02</startDate>
      <endDate>2016-02-08</endDate>
    </period>
  </context>
  <context id="c48_AsOf8Feb2016_ShareExchangeAgreementTwoMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvcd:ShareExchangeAgreementTwoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-02-08</instant>
    </period>
  </context>
  <context id="c49_From2Feb2016To8Feb2016_ShareExchangeAgreementThreeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvcd:ShareExchangeAgreementThreeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-02-02</startDate>
      <endDate>2016-02-08</endDate>
    </period>
  </context>
  <context id="c50_From2Feb2016To8Feb2016_ShareExchangeAgreementFourMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvcd:ShareExchangeAgreementFourMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-02-02</startDate>
      <endDate>2016-02-08</endDate>
    </period>
  </context>
  <context id="c51_From2Feb2019To8Feb2019_MergerAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvcd:MergerAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-02-02</startDate>
      <endDate>2019-02-08</endDate>
    </period>
  </context>
  <context id="c52_AsOf31Aug2017">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
    </entity>
    <period>
      <instant>2017-08-31</instant>
    </period>
  </context>
  <context id="c53_From1Jan2021To31Mar2021_MinimumMember_BuildingsAndLeaseholdImprovementsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">abvcd:BuildingsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c54_From1Jan2021To31Mar2021_MaximumMember_BuildingsAndLeaseholdImprovementsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">abvcd:BuildingsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c55_From1Jan2021To31Mar2021_MinimumMember_MachineryAndEquipmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c56_From1Jan2021To31Mar2021_MaximumMember_MachineryAndEquipmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c57_From1Jan2021To31Mar2021_MinimumMember_OfficeEquipmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c58_From1Jan2021To31Mar2021_MaximumMember_OfficeEquipmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c59_From2Jul2016To27Jul2016_BHKCoDevelopmentAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvcd:BHKCoDevelopmentAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-07-02</startDate>
      <endDate>2016-07-27</endDate>
    </period>
  </context>
  <context id="c60_AsOf27Jul2016_BHKCoDevelopmentAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvcd:BHKCoDevelopmentAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-07-27</instant>
    </period>
  </context>
  <context id="c61_From2Apr2016To30Apr2016_BHKCoDevelopmentAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvcd:BHKCoDevelopmentAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-04-02</startDate>
      <endDate>2016-04-30</endDate>
    </period>
  </context>
  <context id="c62_From1Jan2015To31Dec2015_BHKCoDevelopmentAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvcd:BHKCoDevelopmentAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="c63_From1Jan2021To31Mar2021_BHKCoDevelopmentAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvcd:BHKCoDevelopmentAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c64_From2Aug2017To15Aug2017_CodevelopmentagreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvcd:CodevelopmentagreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-08-02</startDate>
      <endDate>2017-08-15</endDate>
    </period>
  </context>
  <context id="c65_From2May2017To26May2017_CodevelopmentagreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvcd:CodevelopmentagreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-05-02</startDate>
      <endDate>2017-05-26</endDate>
    </period>
  </context>
  <context id="c66_AsOf31Dec2017_CodevelopmentagreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvcd:CodevelopmentagreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="c67_From2Dec2018To24Dec2018">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
    </entity>
    <period>
      <startDate>2018-12-02</startDate>
      <endDate>2018-12-24</endDate>
    </period>
  </context>
  <context id="c68_From2Dec2018To31Dec2018_CollaborativeArrangementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-12-02</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="c69_From2Sep2017To25Sep2017_CollaborativeArrangementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-09-02</startDate>
      <endDate>2017-09-25</endDate>
    </period>
  </context>
  <context id="c70_From1Jan2017To31Dec2017_CollaborativeArrangementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="c71_AsOf30Jun2019_BioFirstStockPurchaseAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvcd:BioFirstStockPurchaseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-06-30</instant>
    </period>
  </context>
  <context id="c72_AsOf5Aug2019_BioFirstStockPurchaseAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvcd:BioFirstStockPurchaseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-08-05</instant>
    </period>
  </context>
  <context id="c73_AsOf31Mar2021_LandMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c74_AsOf31Dec2020_LandMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c75_AsOf31Mar2021_BuildingsAndLeaseholdImprovementsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">abvcd:BuildingsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c76_AsOf31Dec2020_BuildingsAndLeaseholdImprovementsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">abvcd:BuildingsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c77_AsOf31Mar2021_MachineryAndEquipmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c78_AsOf31Dec2020_MachineryAndEquipmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c79_AsOf31Mar2021_OfficeEquipmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c80_AsOf31Dec2020_OfficeEquipmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c81_From1Jan2021To31Mar2021_BioFirstCorporationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvcd:BioFirstCorporationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c82_From1Jan2020To31Dec2020_BioFirstCorporationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvcd:BioFirstCorporationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c83_From1Jan2021To31Mar2021_RgeneCorporationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvcd:RgeneCorporationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c84_From1Jan2020To31Dec2020_RgeneCorporationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvcd:RgeneCorporationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c85_AsOf31Mar2021_BraingenesisBiotechnologyCoLtdMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvcd:BraingenesisBiotechnologyCoLtdMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c86_AsOf31Dec2020_BraingenesisBiotechnologyCoLtdMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvcd:BraingenesisBiotechnologyCoLtdMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c87_From1Jan2021To31Mar2021_BraingenesisBiotechnologyCoLtdMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvcd:BraingenesisBiotechnologyCoLtdMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c88_AsOf31Mar2021_GenepharmBiotechCorporationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvcd:GenepharmBiotechCorporationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c89_AsOf31Dec2020_GenepharmBiotechCorporationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvcd:GenepharmBiotechCorporationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c90_From1Jan2021To31Mar2021_GenepharmBiotechCorporationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvcd:GenepharmBiotechCorporationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c91_AsOf31Mar2021_BioHopeKingCorporationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvcd:BioHopeKingCorporationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c92_AsOf31Dec2020_BioHopeKingCorporationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvcd:BioHopeKingCorporationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c93_From1Jan2021To31Mar2021_BioHopeKingCorporationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvcd:BioHopeKingCorporationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c94_AsOf31Mar2021_BioFirstCorporationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvcd:BioFirstCorporationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c95_AsOf31Dec2020_BioFirstCorporationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvcd:BioFirstCorporationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c96_AsOf31Mar2021_RgeneCorporationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvcd:RgeneCorporationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c97_AsOf31Dec2020_RgeneCorporationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvcd:RgeneCorporationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c98_AsOf31Mar2021_BraingenesisBiotechnologyCoLtdMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:BraingenesisBiotechnologyCoLtdMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c99_AsOf31Dec2020_BraingenesisBiotechnologyCoLtdMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:BraingenesisBiotechnologyCoLtdMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c100_AsOf31Mar2021_GenepharmBiotechCorporationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:GenepharmBiotechCorporationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c101_AsOf31Dec2020_GenepharmBiotechCorporationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:GenepharmBiotechCorporationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c102_AsOf31Mar2021_BioHopeKingCorporationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:BioHopeKingCorporationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c103_AsOf31Dec2020_BioHopeKingCorporationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:BioHopeKingCorporationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c104_AsOf31Mar2021_BioFirstCorporationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:BioFirstCorporationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c105_AsOf31Dec2020_BioFirstCorporationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:BioFirstCorporationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c106_AsOf31Mar2021_RgeneCorporationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:RgeneCorporationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c107_AsOf31Dec2020_RgeneCorporationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:RgeneCorporationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c108_AsOf31Mar2021_BioFirstMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:BioFirstMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c109_AsOf31Dec2020_BioFirstMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:BioFirstMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c110_AsOf31Mar2021_RgeneMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:RgeneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c111_AsOf31Dec2020_RgeneMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:RgeneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c112_From1Jan2021To31Mar2021_BioFirstMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:BioFirstMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c113_From1Jan2020To31Mar2020_BioFirstMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:BioFirstMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-03-31</endDate>
    </period>
  </context>
  <context id="c114_From1Jan2021To31Mar2021_RgeneMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:RgeneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c115_From1Jan2020To31Mar2020_RgeneMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:RgeneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-03-31</endDate>
    </period>
  </context>
  <context id="c116_AsOf9May2018_UnsecuredConvertiblePromissoryNoteMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-05-09</instant>
    </period>
  </context>
  <context id="c117_From25Apr2018To9May2018_UnsecuredConvertiblePromissoryNoteMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-04-25</startDate>
      <endDate>2018-05-09</endDate>
    </period>
  </context>
  <context id="c118_AsOf27Jun2018_UnsecuredConvertiblePromissoryNoteMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-06-27</instant>
    </period>
  </context>
  <context id="c119_From2Jun2018To27Jun2018_UnsecuredConvertiblePromissoryNoteMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-06-02</startDate>
      <endDate>2018-06-27</endDate>
    </period>
  </context>
  <context id="c120_AsOf25Aug2018_UnsecuredConvertiblePromissoryNoteMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-08-25</instant>
    </period>
  </context>
  <context id="c121_From2Aug2018To25Aug2018_UnsecuredConvertiblePromissoryNoteMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-08-02</startDate>
      <endDate>2018-08-25</endDate>
    </period>
  </context>
  <context id="c122_AsOf30May2018_UnsecuredConvertiblePromissoryNoteMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-05-30</instant>
    </period>
  </context>
  <context id="c123_From1May2018To30May2018_UnsecuredConvertiblePromissoryNoteMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-05-01</startDate>
      <endDate>2018-05-30</endDate>
    </period>
  </context>
  <context id="c124_AsOf10Jul2019_UnsecuredConvertiblePromissoryNoteMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-07-10</instant>
    </period>
  </context>
  <context id="c125_From26Jun2019To10Jul2019_UnsecuredConvertiblePromissoryNoteMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-26</startDate>
      <endDate>2019-07-10</endDate>
    </period>
  </context>
  <context id="c126_AsOf28Aug2019_UnsecuredConvertiblePromissoryNoteMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-08-28</instant>
    </period>
  </context>
  <context id="c127_From1Aug2019To28Aug2019_UnsecuredConvertiblePromissoryNoteMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-08-01</startDate>
      <endDate>2019-08-28</endDate>
    </period>
  </context>
  <context id="c128_AsOf4Sep2019_UnsecuredConvertiblePromissoryNoteMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-09-04</instant>
    </period>
  </context>
  <context id="c129_From20Aug2019To4Sep2019_UnsecuredConvertiblePromissoryNoteMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-08-20</startDate>
      <endDate>2019-09-04</endDate>
    </period>
  </context>
  <context id="c130_AsOf29Oct2019_UnsecuredConvertiblePromissoryNoteMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-10-29</instant>
    </period>
  </context>
  <context id="c131_From1Oct2019To29Oct2019_UnsecuredConvertiblePromissoryNoteMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-10-01</startDate>
      <endDate>2019-10-29</endDate>
    </period>
  </context>
  <context id="c132_From1Oct2020To23Oct2020_SecuritiesPurchaseAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-10-01</startDate>
      <endDate>2020-10-23</endDate>
    </period>
  </context>
  <context id="c133_AsOf31Mar2021_UnsecuredConvertiblePromissoryNoteMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c134_AsOf31Dec2020_UnsecuredConvertiblePromissoryNoteMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c135_From1Jan2021To31Mar2021_UnsecuredConvertiblePromissoryNoteMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c136_From1Jan2020To31Dec2020_UnsecuredConvertiblePromissoryNoteMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c137_AsOf28Jun2016_NTMember_CathayUnitedLoanAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="abvcd:TypeOfCurrencyAxis">abvcd:NTMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-06-28</instant>
    </period>
  </context>
  <context id="c138_AsOf28Jun2016_CathayUnitedLoanAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-06-28</instant>
    </period>
  </context>
  <context id="c139_From1Jun2016To28Jun2016_CathayUnitedLoanAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-06-01</startDate>
      <endDate>2016-06-28</endDate>
    </period>
  </context>
  <context id="c140_From1Sep2017To6Sep2017_CathayUnitedLoanAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-09-01</startDate>
      <endDate>2017-09-06</endDate>
    </period>
  </context>
  <context id="c141_AsOf6Sep2017_NTMember_CathayUnitedLoanAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="abvcd:TypeOfCurrencyAxis">abvcd:NTMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-09-06</instant>
    </period>
  </context>
  <context id="c142_AsOf6Sep2017_CathayUnitedLoanAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-09-06</instant>
    </period>
  </context>
  <context id="c143_AsOf1Oct2018_NTMember_CathayUnitedLoanAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="abvcd:TypeOfCurrencyAxis">abvcd:NTMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-10-01</instant>
    </period>
  </context>
  <context id="c144_AsOf1Oct2018_CathayUnitedLoanAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-10-01</instant>
    </period>
  </context>
  <context id="c145_From25Sep2018To1Oct2018_CathayUnitedLoanAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-09-25</startDate>
      <endDate>2018-10-01</endDate>
    </period>
  </context>
  <context id="c146_AsOf6Sep2019_NTMember_CathayUnitedLoanAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="abvcd:TypeOfCurrencyAxis">abvcd:NTMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-09-06</instant>
    </period>
  </context>
  <context id="c147_AsOf6Sep2019_CathayUnitedLoanAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-09-06</instant>
    </period>
  </context>
  <context id="c148_From1Sep2019To6Sep2019_CathayUnitedLoanAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-09-01</startDate>
      <endDate>2019-09-06</endDate>
    </period>
  </context>
  <context id="c149_AsOf6Sep2020_NTMember_CathayUnitedLoanAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="abvcd:TypeOfCurrencyAxis">abvcd:NTMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-09-06</instant>
    </period>
  </context>
  <context id="c150_AsOf6Sep2020_CathayUnitedLoanAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-09-06</instant>
    </period>
  </context>
  <context id="c151_From1Sep2020To6Sep2020_CathayUnitedLoanAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-09-01</startDate>
      <endDate>2020-09-06</endDate>
    </period>
  </context>
  <context id="c152_From1Jan2021To31Mar2021_CathayUnitedLoanAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c153_From1Jan2020To31Mar2020_CathayUnitedLoanAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-03-31</endDate>
    </period>
  </context>
  <context id="c154_AsOf12Jun2017_NTMember_CTBCBankMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="abvcd:TypeOfCurrencyAxis">abvcd:NTMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:CTBCBankMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-06-12</instant>
    </period>
  </context>
  <context id="c155_AsOf12Jun2017_CTBCBankMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:CTBCBankMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-06-12</instant>
    </period>
  </context>
  <context id="c156_AsOf19Jun2017_NTMember_CTBCBankMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="abvcd:TypeOfCurrencyAxis">abvcd:NTMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:CTBCBankMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-06-19</instant>
    </period>
  </context>
  <context id="c157_AsOf19Jun2017_CTBCBankMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:CTBCBankMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-06-19</instant>
    </period>
  </context>
  <context id="c158_From1Jun2017To12Jun2017_CTBCBankMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:CTBCBankMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-06-01</startDate>
      <endDate>2017-06-12</endDate>
    </period>
  </context>
  <context id="c159_From1Jun2017To19Jun2017_CTBCBankMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:CTBCBankMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-06-01</startDate>
      <endDate>2017-06-19</endDate>
    </period>
  </context>
  <context id="c160_AsOf18Jul2019_NTMember_CTBCBankMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="abvcd:TypeOfCurrencyAxis">abvcd:NTMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:CTBCBankMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-07-18</instant>
    </period>
  </context>
  <context id="c161_AsOf18Jul2019_CTBCBankMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:CTBCBankMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-07-18</instant>
    </period>
  </context>
  <context id="c162_From1Jul2019To18Jul2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
    </entity>
    <period>
      <startDate>2019-07-01</startDate>
      <endDate>2019-07-18</endDate>
    </period>
  </context>
  <context id="c163_AsOf19Jan2020_NTMember_CTBCBankMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="abvcd:TypeOfCurrencyAxis">abvcd:NTMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:CTBCBankMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-01-19</instant>
    </period>
  </context>
  <context id="c164_AsOf19Jan2020_CTBCBankMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:CTBCBankMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-01-19</instant>
    </period>
  </context>
  <context id="c165_From1Jan2020To19Jan2020_CTBCBankMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:CTBCBankMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-01-19</endDate>
    </period>
  </context>
  <context id="c166_AsOf17Jul2020_NTMember_CTBCBankMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="abvcd:TypeOfCurrencyAxis">abvcd:NTMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:CTBCBankMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-07-17</instant>
    </period>
  </context>
  <context id="c167_AsOf17Jul2020_CTBCBankMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:CTBCBankMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-07-17</instant>
    </period>
  </context>
  <context id="c168_From1Jul2020To17Jul2020_CTBCBankMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:CTBCBankMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-07-01</startDate>
      <endDate>2020-07-17</endDate>
    </period>
  </context>
  <context id="c169_AsOf15Jan2021_NTMember_CTBCBankMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="abvcd:TypeOfCurrencyAxis">abvcd:NTMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:CTBCBankMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-01-15</instant>
    </period>
  </context>
  <context id="c170_AsOf15Jan2021_CTBCBankMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:CTBCBankMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-01-15</instant>
    </period>
  </context>
  <context id="c171_From1Jan2021To15Jan2021_CTBCBankMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:CTBCBankMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-01-15</endDate>
    </period>
  </context>
  <context id="c172_AsOf31Mar2021_CTBCBankMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:CTBCBankMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c173_From1Jan2021To31Mar2021_CTBCBankMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:CTBCBankMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c174_From1Jan2020To31Mar2020_CTBCBankMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:CTBCBankMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-03-31</endDate>
    </period>
  </context>
  <context id="c175_AsOf21Jan2019_LoanAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:LoanAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-01-21</instant>
    </period>
  </context>
  <context id="c176_AsOf21Jan2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
    </entity>
    <period>
      <instant>2019-01-21</instant>
    </period>
  </context>
  <context id="c177_From1Jan2019To21Jan2019_LoanAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:LoanAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-01-21</endDate>
    </period>
  </context>
  <context id="c178_From1Jan2019To8Jan2019_LoanAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:LoanAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-01-08</endDate>
    </period>
  </context>
  <context id="c179_From1Jan2020To31Mar2020_LoanAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:LoanAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-03-31</endDate>
    </period>
  </context>
  <context id="c180_AsOf8Apr2020_CathayBnakMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:CathayBnakMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-04-08</instant>
    </period>
  </context>
  <context id="c181_AsOf3Oct2020_CathayBnakMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:CathayBnakMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-10-03</instant>
    </period>
  </context>
  <context id="c182_AsOf3Dec2020_CathayBnakMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:CathayBnakMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-03</instant>
    </period>
  </context>
  <context id="c183_From1Dec2020To3Dec2020_CathayBnakMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:CathayBnakMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-12-01</startDate>
      <endDate>2020-12-03</endDate>
    </period>
  </context>
  <context id="c184_AsOf31Mar2021_CathayBnakMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:CathayBnakMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c185_From1Jan2021To31Mar2021_CathayBnakMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:CathayBnakMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c186_From1Jan2020To31Mar2020_CathayBnakMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:CathayBnakMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-03-31</endDate>
    </period>
  </context>
  <context id="c187_AsOf31Mar2021_CathayUnitedBankMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:CathayUnitedBankMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c188_AsOf31Dec2020_CathayUnitedBankMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:CathayUnitedBankMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c189_AsOf31Dec2020_CTBCBankMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:CTBCBankMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c190_AsOf31Dec2020_CathayBnakMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvcd:CathayBnakMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c191_From1Apr2020To14Apr2020_PAYCHECKPROTECTIONPROGRAMMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:PAYCHECKPROTECTIONPROGRAMMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-04-01</startDate>
      <endDate>2020-04-14</endDate>
    </period>
  </context>
  <context id="c192_AsOf29Jan2021">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
    </entity>
    <period>
      <instant>2021-01-29</instant>
    </period>
  </context>
  <context id="c193_From2Jan2021To29Jan2021">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
    </entity>
    <period>
      <startDate>2021-01-02</startDate>
      <endDate>2021-01-29</endDate>
    </period>
  </context>
  <context id="c194_AsOf7Feb2021">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
    </entity>
    <period>
      <instant>2021-02-07</instant>
    </period>
  </context>
  <context id="c195_From27Jan2021To7Feb2021">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
    </entity>
    <period>
      <startDate>2021-01-27</startDate>
      <endDate>2021-02-07</endDate>
    </period>
  </context>
  <context id="c196_AsOf31Mar2021_PAYCHECKPROTECTIONPROGRAMMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:PAYCHECKPROTECTIONPROGRAMMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c197_From1Jan2019To31Jan2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-01-31</endDate>
    </period>
  </context>
  <context id="c198_AsOf31Dec2021">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
    </entity>
    <period>
      <instant>2021-12-31</instant>
    </period>
  </context>
  <context id="c199_From1Jan2021To31Dec2021">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-12-31</endDate>
    </period>
  </context>
  <context id="c200_AsOf18Feb2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
    </entity>
    <period>
      <instant>2020-02-18</instant>
    </period>
  </context>
  <context id="c201_From1Jan2021To31Mar2021_RgeneCorporationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:RgeneCorporationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c202_From1Jan2020To31Dec2020_RgeneCorporationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:RgeneCorporationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c203_From25Jan2019To3Feb2019_ConversionAgreementsOneMember_BioFirstMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="abvcd:AgreemnetAxis">abvcd:ConversionAgreementsOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:BioFirstMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-25</startDate>
      <endDate>2019-02-03</endDate>
    </period>
  </context>
  <context id="c204_From1May2019To27May2019_NTMember_AsiangeneCorporationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="abvcd:TypeOfCurrencyAxis">abvcd:NTMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:AsiangeneCorporationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-05-01</startDate>
      <endDate>2019-05-27</endDate>
    </period>
  </context>
  <context id="c205_From1May2019To27May2019_AsiangeneCorporationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:AsiangeneCorporationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-05-01</startDate>
      <endDate>2019-05-27</endDate>
    </period>
  </context>
  <context id="c206_From1Jan2020To31Dec2020_AsiangeneCorporationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:AsiangeneCorporationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c207_From1Jan2021To31Mar2021_AsiangeneCorporationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:AsiangeneCorporationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c208_AsOf31Mar2021_AsiangeneCorporationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:AsiangeneCorporationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c209_AsOf31Dec2020_AsiangeneCorporationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:AsiangeneCorporationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c210_AsOf11May2018_BioFirstAustraliaMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:BioFirstAustraliaMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-05-11</instant>
    </period>
  </context>
  <context id="c211_From1May2018To11May2018_BioFirstAustraliaMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:BioFirstAustraliaMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-05-01</startDate>
      <endDate>2018-05-11</endDate>
    </period>
  </context>
  <context id="c212_AsOf1Jul2020_BioFirstAustraliaMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:BioFirstAustraliaMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-07-01</instant>
    </period>
  </context>
  <context id="c213_From1Jan2021To31Mar2021_BioFirstAustraliaMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:BioFirstAustraliaMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c214_From1Jan2020To31Dec2020_BioFirstAustraliaMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:BioFirstAustraliaMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c215_From1Jan2021To31Mar2021_BioLiteTaiwanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:BioLiteTaiwanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c216_AsOf31Mar2021_BioLiteTaiwanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:BioLiteTaiwanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c217_AsOf31Dec2020_BioLiteTaiwanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:BioLiteTaiwanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c218_From1Jan2021To31Mar2021_LbgUsaIncMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:LbgUsaIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c219_From1Jan2020To31Mar2020_LbgUsaIncMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:LbgUsaIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-03-31</endDate>
    </period>
  </context>
  <context id="c220_From1May2020To8May2020_BioLiteJapanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:BioLiteJapanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-05-01</startDate>
      <endDate>2020-05-08</endDate>
    </period>
  </context>
  <context id="c221_From1Jan2021To31Mar2021_BioLiteJapanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:BioLiteJapanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c222_From1Jan2020To31Dec2020_BioLiteJapanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:BioLiteJapanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c223_From1Oct2020To31Oct2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
    </entity>
    <period>
      <startDate>2020-10-01</startDate>
      <endDate>2020-10-31</endDate>
    </period>
  </context>
  <context id="c224_From1Jan2020To31Dec2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c225_From1Jan2021To31Jan2021">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-01-31</endDate>
    </period>
  </context>
  <context id="c226_From1Jan2021To31Mar2021_ConversionAgreementsOneMember_YuanGeneMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="abvcd:AgreemnetAxis">abvcd:ConversionAgreementsOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:YuanGeneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c227_From1Jan2020To31Dec2020_ConversionAgreementsOneMember_YuanGeneMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="abvcd:AgreemnetAxis">abvcd:ConversionAgreementsOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:YuanGeneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c228_From1Jan2021To31Mar2021_JIANGSMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:JIANGSMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c229_From1Jan2020To31Dec2020_JIANGSMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:JIANGSMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c230_From1Jan2018To31Dec2018">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="c231_From1Jan2020To31Mar2020_JIANGSMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:JIANGSMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-03-31</endDate>
    </period>
  </context>
  <context id="c232_From1Jan2021To31Mar2021_BioFirstCorporationtheBioFirstMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:BioFirstCorporationtheBioFirstMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c233_From1Jan2021To31Mar2021_BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c234_From1Jan2021To31Mar2021_RgeneCorporationtheRgeneMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:RgeneCorporationtheRgeneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c235_From1Jan2021To31Mar2021_YuanGeneCorporationtheYuanGeneMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:YuanGeneCorporationtheYuanGeneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c236_From1Jan2021To31Mar2021_AsiaGeneCorporationtheAsiaGeneMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:AsiaGeneCorporationtheAsiaGeneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c237_From1Jan2021To31Mar2021_EugeneJiangMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:EugeneJiangMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c238_From1Jan2021To31Mar2021_KeypointTechnologyLtdtheKeypointMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:KeypointTechnologyLtdtheKeypointMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c239_From1Jan2021To31Mar2021_LionArtsPromotionInctheLionArtsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:LionArtsPromotionInctheLionArtsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c240_From1Jan2021To31Mar2021_YoshinobuOdairatheOdairaMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:YoshinobuOdairatheOdairaMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c241_From1Jan2021To31Mar2021_GenePharmInctheGenePharmMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:GenePharmInctheGenePharmMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c242_From1Jan2021To31Mar2021_EuroAsiaInvestmentFinanceCorpLtdtheEuroAsiaMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:EuroAsiaInvestmentFinanceCorpLtdtheEuroAsiaMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c243_From1Jan2021To31Mar2021_LBGUSAInctheLBGUSAMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:LBGUSAInctheLBGUSAMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c244_From1Jan2021To31Mar2021_LionGeneCorporationtheLionGeneMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:LionGeneCorporationtheLionGeneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c245_From1Jan2021To31Mar2021_KimhoConsultantsCoLtdtheKimhoMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:KimhoConsultantsCoLtdtheKimhoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c246_From1Jan2021To31Mar2021_MrTsungShannJiangMsShuLingJiangMrChangJenJiangMsMeiLingJiangAndMrEugeneJiangcollectivelyTheJiangsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:MrTsungShannJiangMsShuLingJiangMrChangJenJiangMsMeiLingJiangAndMrEugeneJiangcollectivelyTheJiangsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c247_From1Jan2021To31Mar2021_AmkeyVenturesLLCAmkeyMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:AmkeyVenturesLLCAmkeyMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c248_AsOf31Mar2021_GenePharmIncMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:GenePharmIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c249_AsOf31Dec2020_GenePharmIncMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:GenePharmIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c250_AsOf31Mar2021_AmkeyMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:AmkeyMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c251_AsOf31Dec2020_AmkeyMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:AmkeyMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c252_AsOf31Mar2021_AsiaGeneMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:AsiaGeneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c253_AsOf31Dec2020_AsiaGeneMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:AsiaGeneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c254_AsOf31Mar2021_BioFirstAustraliaMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:BioFirstAustraliaMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c255_AsOf31Dec2020_BioFirstAustraliaMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:BioFirstAustraliaMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c256_AsOf31Mar2021_LBGUSAMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:LBGUSAMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c257_AsOf31Dec2020_LBGUSAMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:LBGUSAMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c258_AsOf31Mar2021_BioLiteJapanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:BioLiteJapanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c259_AsOf31Dec2020_BioLiteJapanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:BioLiteJapanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c260_AsOf31Mar2021_KeypointMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:KeypointMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c261_AsOf31Dec2020_KeypointMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:KeypointMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c262_AsOf31Mar2021_TheJiangsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:TheJiangsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c263_AsOf31Dec2020_TheJiangsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:TheJiangsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c264_AsOf31Mar2021_YuanGeneMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:YuanGeneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c265_AsOf31Dec2020_YuanGeneMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:YuanGeneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c266_AsOf31Mar2021_DueToshareholdersMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:DueToshareholdersMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c267_AsOf31Dec2020_DueToshareholdersMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:DueToshareholdersMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c268_AsOf31Mar2021_DueToEmployeesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:DueToEmployeesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c269_AsOf31Dec2020_DueToEmployeesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:DueToEmployeesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c270_From1Feb2016To8Feb2016_ShareExchangeAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvcd:ShareExchangeAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-02-01</startDate>
      <endDate>2016-02-08</endDate>
    </period>
  </context>
  <context id="c271_From1Feb2016To8Feb2016_ShareExchangeAgreementOneMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvcd:ShareExchangeAgreementOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-02-01</startDate>
      <endDate>2016-02-08</endDate>
    </period>
  </context>
  <context id="c272_From1Feb2016To8Feb2016_ShareExchangeAgreementTwoMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvcd:ShareExchangeAgreementTwoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-02-01</startDate>
      <endDate>2016-02-08</endDate>
    </period>
  </context>
  <context id="c273_From1Feb2016To8Feb2016_ShareExchangeAgreementThreeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvcd:ShareExchangeAgreementThreeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-02-01</startDate>
      <endDate>2016-02-08</endDate>
    </period>
  </context>
  <context id="c274_From1Feb2016To8Feb2016_ShareExchangeAgreementFourMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvcd:ShareExchangeAgreementFourMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-02-01</startDate>
      <endDate>2016-02-08</endDate>
    </period>
  </context>
  <context id="c275_From1Feb2016To17Feb2016_TwoThousandSixteenEquityIncentivePlanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abvcd:TwoThousandSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-02-01</startDate>
      <endDate>2016-02-17</endDate>
    </period>
  </context>
  <context id="c276_From1Mar2016To21Mar2016">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
    </entity>
    <period>
      <startDate>2016-03-01</startDate>
      <endDate>2016-03-21</endDate>
    </period>
  </context>
  <context id="c277_AsOf21Mar2016">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
    </entity>
    <period>
      <instant>2016-03-21</instant>
    </period>
  </context>
  <context id="c278_From1May2016To6May2016">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
    </entity>
    <period>
      <startDate>2016-05-01</startDate>
      <endDate>2016-05-06</endDate>
    </period>
  </context>
  <context id="c279_From1Aug2016To26Aug2016">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
    </entity>
    <period>
      <startDate>2016-08-01</startDate>
      <endDate>2016-08-26</endDate>
    </period>
  </context>
  <context id="c280_From1Feb2017To28Feb2017">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
    </entity>
    <period>
      <startDate>2017-02-01</startDate>
      <endDate>2017-02-28</endDate>
    </period>
  </context>
  <context id="c281_From1Feb2019To8Feb2019_BioLiteMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">abvcd:BioLiteMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-02-01</startDate>
      <endDate>2019-02-08</endDate>
    </period>
  </context>
  <context id="c282_From1Feb2019To8Feb2019_BioKeyMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">abvcd:BioKeyMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-02-01</startDate>
      <endDate>2019-02-08</endDate>
    </period>
  </context>
  <context id="c283_From1May2019To3May2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
    </entity>
    <period>
      <startDate>2019-05-01</startDate>
      <endDate>2019-05-03</endDate>
    </period>
  </context>
  <context id="c284_From24Sep2016To1Oct2016_CollaborativeArrangementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-09-24</startDate>
      <endDate>2016-10-01</endDate>
    </period>
  </context>
  <context id="c285_From1Nov2020To21Nov2020_KameyamaMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:KameyamaMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-11-01</startDate>
      <endDate>2020-11-21</endDate>
    </period>
  </context>
  <context id="c286_AsOf31Dec2019_EuroAsiaInvestmentAndFinanceCorpLtdMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvcd:EuroAsiaInvestmentAndFinanceCorpLtdMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c287_From1Jan2019To31Dec2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c288_AsOf24Jun2017_CodevelopmentagreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvcd:CodevelopmentagreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-06-24</instant>
    </period>
  </context>
  <context id="c289_From1Jun2019To30Jun2019_CollaborativeArrangementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2019-06-30</endDate>
    </period>
  </context>
  <context id="c290_From1Aug2019To31Aug2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
    </entity>
    <period>
      <startDate>2019-08-01</startDate>
      <endDate>2019-08-31</endDate>
    </period>
  </context>
  <context id="c291_AsOf31Aug2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
    </entity>
    <period>
      <instant>2019-08-31</instant>
    </period>
  </context>
  <context id="c292_AsOf12Mar2020_ArticlesOfIncorporationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:ArticlesOfIncorporationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-03-12</instant>
    </period>
  </context>
  <context id="c293_AsOf12Mar2020_MinimumMember_ArticlesOfIncorporationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:ArticlesOfIncorporationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-03-12</instant>
    </period>
  </context>
  <context id="c294_AsOf12Mar2020_MaximumMember_ArticlesOfIncorporationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:ArticlesOfIncorporationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-03-12</instant>
    </period>
  </context>
  <context id="c295_From1Jul2020To8Jul2020_ViewTradeSecuritiesIncMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:ViewTradeSecuritiesIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-07-01</startDate>
      <endDate>2020-07-08</endDate>
    </period>
  </context>
  <context id="c296_AsOf31Dec2020_ViewTradeSecuritiesIncMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:ViewTradeSecuritiesIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c297_From1Jan2020To31Dec2020_ViewTradeSecuritiesIncMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:ViewTradeSecuritiesIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c298_From1Nov2020To19Nov2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
    </entity>
    <period>
      <startDate>2020-11-01</startDate>
      <endDate>2020-11-19</endDate>
    </period>
  </context>
  <context id="c299_AsOf19Nov2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
    </entity>
    <period>
      <instant>2020-11-19</instant>
    </period>
  </context>
  <context id="c300_AsOf19Nov2020_ConsultingAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:ConsultingAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-11-19</instant>
    </period>
  </context>
  <context id="c301_From1Jan2020To31Dec2020_PrivatePlacementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c302_AsOf31Dec2020_PrivatePlacementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c303_AsOf31Dec2020_ConsultingAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvcd:ConsultingAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c304_AsOf31Dec2020_MinimumMember_ConsultingAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvcd:ConsultingAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c305_From1Jan2020To31Dec2020_MaximumMember_ConsultingAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvcd:ConsultingAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c306_From1Jan2021To31Mar2021_NonRelatedPartiesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvcd:NonRelatedPartiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c307_From1Aug2019To31Aug2019_LionArtsPromotionInctheLIONMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvcd:LionArtsPromotionInctheLIONMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-08-01</startDate>
      <endDate>2019-08-31</endDate>
    </period>
  </context>
  <context id="c308_From1Aug2019To31Aug2019_LionGeneCorporationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvcd:LionGeneCorporationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-08-01</startDate>
      <endDate>2019-08-31</endDate>
    </period>
  </context>
  <context id="c309_From1Aug2019To31Aug2019_BioFirstCorporationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvcd:BioFirstCorporationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-08-01</startDate>
      <endDate>2019-08-31</endDate>
    </period>
  </context>
  <context id="c310_From1Aug2019To31Aug2019_AsiangeneCorporationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvcd:AsiangeneCorporationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-08-01</startDate>
      <endDate>2019-08-31</endDate>
    </period>
  </context>
  <context id="c311_From1Aug2019To31Aug2019_YuangeneCorporationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvcd:YuangeneCorporationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-08-01</startDate>
      <endDate>2019-08-31</endDate>
    </period>
  </context>
  <context id="c312_From1Aug2019To31Aug2019_TheJiangsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvcd:TheJiangsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-08-01</startDate>
      <endDate>2019-08-31</endDate>
    </period>
  </context>
  <context id="c313_From1Oct2020To30Oct2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
    </entity>
    <period>
      <startDate>2020-10-01</startDate>
      <endDate>2020-10-30</endDate>
    </period>
  </context>
  <context id="c314_AsOf30Oct2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
    </entity>
    <period>
      <instant>2020-10-30</instant>
    </period>
  </context>
  <context id="c315_AsOf21Nov2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
    </entity>
    <period>
      <instant>2020-11-21</instant>
    </period>
  </context>
  <context id="c316_AsOf31Dec2020_TwoThousandSixteenEquityIncentivePlanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abvcd:TwoThousandSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c317_AsOf31Dec2019_EmployeeStockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c318_From1Jan2020To31Dec2020_EmployeeStockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c319_AsOf31Dec2020_EmployeeStockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c320_AsOf8Feb2019_BioKeyMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">abvcd:BioKeyMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-02-08</instant>
    </period>
  </context>
  <context id="c321_From1Feb2019To8Feb2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
    </entity>
    <period>
      <startDate>2019-02-01</startDate>
      <endDate>2019-02-08</endDate>
    </period>
  </context>
  <context id="c322_AsOf8Feb2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
    </entity>
    <period>
      <instant>2019-02-08</instant>
    </period>
  </context>
  <unit id="shares">
    <measure>xbrli:shares</measure>
  </unit>
  <unit id="usd">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="usdPershares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>xbrli:shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="pure">
    <measure>xbrli:pure</measure>
  </unit>
  <unit id="twd">
    <measure>iso4217:TWD</measure>
  </unit>
  <link:footnoteLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:label="_BusinessCombinationConsiderationTransferredOther1-c321_From1Feb2019To8Feb2019_usd" xlink:href="#_BusinessCombinationConsiderationTransferredOther1-c321_From1Feb2019To8Feb2019_usd"/>
    <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="ftnt_0" xml:lang="en-US">29,561,231 shares (1,642,291 after stock reverse split) of common stock of the Company was issued to BioKey in connection with the Merger. Those shares were valued at $1.50 per share, based on the bid-and-ask share price of common stock of the Company on the final day of trading, February 8, 2019.</link:footnote>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_BusinessCombinationConsiderationTransferredOther1-c321_From1Feb2019To8Feb2019_usd" xlink:to="ftnt_0" order="1"/>
  </link:footnoteLink>
  <dei:AmendmentFlag contextRef="c0_From1Jan2021To31Mar2021">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate contextRef="c0_From1Jan2021To31Mar2021">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus contextRef="c0_From1Jan2021To31Mar2021">Q1</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus contextRef="c0_From1Jan2021To31Mar2021">2021</dei:DocumentFiscalYearFocus>
  <dei:DocumentPeriodEndDate contextRef="c0_From1Jan2021To31Mar2021">2021-03-31</dei:DocumentPeriodEndDate>
  <dei:DocumentType contextRef="c0_From1Jan2021To31Mar2021">10-Q</dei:DocumentType>
  <dei:EntityCentralIndexKey contextRef="c0_From1Jan2021To31Mar2021">0001173313</dei:EntityCentralIndexKey>
  <dei:EntityCurrentReportingStatus contextRef="c0_From1Jan2021To31Mar2021">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityEmergingGrowthCompany contextRef="c0_From1Jan2021To31Mar2021">false</dei:EntityEmergingGrowthCompany>
  <dei:EntityFileNumber contextRef="c0_From1Jan2021To31Mar2021">333-91436</dei:EntityFileNumber>
  <dei:EntityFilerCategory contextRef="c0_From1Jan2021To31Mar2021">Non-accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityIncorporationStateCountryCode contextRef="c0_From1Jan2021To31Mar2021">NV</dei:EntityIncorporationStateCountryCode>
  <dei:EntityInteractiveDataCurrent contextRef="c0_From1Jan2021To31Mar2021">Yes</dei:EntityInteractiveDataCurrent>
  <dei:EntityRegistrantName contextRef="c0_From1Jan2021To31Mar2021">ABVC BioPharma, Inc.</dei:EntityRegistrantName>
  <dei:EntityShellCompany contextRef="c0_From1Jan2021To31Mar2021">false</dei:EntityShellCompany>
  <dei:EntitySmallBusiness contextRef="c0_From1Jan2021To31Mar2021">true</dei:EntitySmallBusiness>
  <dei:EntityCommonStockSharesOutstanding unitRef="shares" contextRef="c1_AsOf10May2021" decimals="INF">24420526</dei:EntityCommonStockSharesOutstanding>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">2615073</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">4273208</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">718163</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">728163</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:AccountsReceivableNetCurrent unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">392532</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccountsReceivableNetCurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">159712</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccountsReceivableRelatedPartiesCurrent unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">145075</us-gaap:AccountsReceivableRelatedPartiesCurrent>
  <us-gaap:AccountsReceivableRelatedPartiesCurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">143435</us-gaap:AccountsReceivableRelatedPartiesCurrent>
  <us-gaap:DueFromOtherRelatedPartiesCurrent unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">702889</us-gaap:DueFromOtherRelatedPartiesCurrent>
  <us-gaap:DueFromOtherRelatedPartiesCurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">696255</us-gaap:DueFromOtherRelatedPartiesCurrent>
  <us-gaap:InventoryNet unitRef="usd" contextRef="c2_AsOf31Mar2021" xs:nil="true"/>
  <us-gaap:InventoryNet unitRef="usd" contextRef="c3_AsOf31Dec2020" xs:nil="true"/>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">631721</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">172193</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:AssetsCurrent unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">5205453</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">6172966</us-gaap:AssetsCurrent>
  <us-gaap:PropertyPlantAndEquipmentNet unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">504952</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">514834</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:OperatingLeaseRightOfUseAsset unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">1714740</us-gaap:OperatingLeaseRightOfUseAsset>
  <us-gaap:OperatingLeaseRightOfUseAsset unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">1772747</us-gaap:OperatingLeaseRightOfUseAsset>
  <us-gaap:Goodwill unitRef="usd" contextRef="c2_AsOf31Mar2021" xs:nil="true"/>
  <us-gaap:Goodwill unitRef="usd" contextRef="c3_AsOf31Dec2020" xs:nil="true"/>
  <us-gaap:LongTermInvestments unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">1126884</us-gaap:LongTermInvestments>
  <us-gaap:LongTermInvestments unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">1190727</us-gaap:LongTermInvestments>
  <us-gaap:DeferredIncomeTaxAssetsNet unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">1815755</us-gaap:DeferredIncomeTaxAssetsNet>
  <us-gaap:DeferredIncomeTaxAssetsNet unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">1790597</us-gaap:DeferredIncomeTaxAssetsNet>
  <us-gaap:PrepaidExpenseNoncurrent unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">117639</us-gaap:PrepaidExpenseNoncurrent>
  <us-gaap:PrepaidExpenseNoncurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">119315</us-gaap:PrepaidExpenseNoncurrent>
  <us-gaap:SecurityDeposit unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">40639</us-gaap:SecurityDeposit>
  <us-gaap:SecurityDeposit unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">45519</us-gaap:SecurityDeposit>
  <us-gaap:Assets unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">10526062</us-gaap:Assets>
  <us-gaap:Assets unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">11606705</us-gaap:Assets>
  <us-gaap:AccountsPayableCurrent unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">10334</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">23044</us-gaap:AccountsPayableCurrent>
  <us-gaap:ShortTermBankLoansAndNotesPayable unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">1615250</us-gaap:ShortTermBankLoansAndNotesPayable>
  <us-gaap:ShortTermBankLoansAndNotesPayable unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">1629000</us-gaap:ShortTermBankLoansAndNotesPayable>
  <us-gaap:OtherShortTermBorrowings unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">100000</us-gaap:OtherShortTermBorrowings>
  <us-gaap:OtherShortTermBorrowings unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">100000</us-gaap:OtherShortTermBorrowings>
  <us-gaap:NotesPayableToBankCurrent unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">105300</us-gaap:NotesPayableToBankCurrent>
  <us-gaap:NotesPayableToBankCurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">106800</us-gaap:NotesPayableToBankCurrent>
  <us-gaap:AccruedLiabilitiesCurrent unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">2135912</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">2118854</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:CustomerAdvancesForConstruction unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">12070</us-gaap:CustomerAdvancesForConstruction>
  <us-gaap:CustomerAdvancesForConstruction unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">12070</us-gaap:CustomerAdvancesForConstruction>
  <us-gaap:OperatingLeaseLiabilityCurrent unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">331179</us-gaap:OperatingLeaseLiabilityCurrent>
  <us-gaap:OperatingLeaseLiabilityCurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">316178</us-gaap:OperatingLeaseLiabilityCurrent>
  <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">44103</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
  <us-gaap:DueToRelatedPartiesCurrent unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">312152</us-gaap:DueToRelatedPartiesCurrent>
  <us-gaap:DueToRelatedPartiesCurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">288445</us-gaap:DueToRelatedPartiesCurrent>
  <us-gaap:OtherNotesPayableCurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">250000</us-gaap:OtherNotesPayableCurrent>
  <us-gaap:LiabilitiesCurrent unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">4666300</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">4844391</us-gaap:LiabilitiesCurrent>
  <us-gaap:LoansPayable unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">236498</us-gaap:LoansPayable>
  <us-gaap:LoansPayable unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">124400</us-gaap:LoansPayable>
  <us-gaap:SecurityDepositLiability unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">11080</us-gaap:SecurityDepositLiability>
  <us-gaap:SecurityDepositLiability unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">19280</us-gaap:SecurityDepositLiability>
  <us-gaap:OperatingLeaseLiabilityNoncurrent unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">1383560</us-gaap:OperatingLeaseLiabilityNoncurrent>
  <us-gaap:OperatingLeaseLiabilityNoncurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">1456567</us-gaap:OperatingLeaseLiabilityNoncurrent>
  <us-gaap:ConvertibleLongTermNotesPayable unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">2500000</us-gaap:ConvertibleLongTermNotesPayable>
  <us-gaap:ConvertibleLongTermNotesPayable unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">2500000</us-gaap:ConvertibleLongTermNotesPayable>
  <us-gaap:Liabilities unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">8797438</us-gaap:Liabilities>
  <us-gaap:Liabilities unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">8944638</us-gaap:Liabilities>
  <us-gaap:PreferredStockValue unitRef="usd" contextRef="c2_AsOf31Mar2021" xs:nil="true"/>
  <us-gaap:PreferredStockValue unitRef="usd" contextRef="c3_AsOf31Dec2020" xs:nil="true"/>
  <us-gaap:PreferredStockParOrStatedValuePerShare unitRef="usdPershares" contextRef="c2_AsOf31Mar2021" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare unitRef="usdPershares" contextRef="c3_AsOf31Dec2020" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized unitRef="shares" contextRef="c2_AsOf31Mar2021" decimals="INF">20000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized unitRef="shares" contextRef="c3_AsOf31Dec2020" decimals="INF">20000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued unitRef="shares" contextRef="c2_AsOf31Mar2021" xs:nil="true"/>
  <us-gaap:PreferredStockSharesIssued unitRef="shares" contextRef="c3_AsOf31Dec2020" xs:nil="true"/>
  <us-gaap:PreferredStockSharesOutstanding unitRef="shares" contextRef="c2_AsOf31Mar2021" xs:nil="true"/>
  <us-gaap:PreferredStockSharesOutstanding unitRef="shares" contextRef="c3_AsOf31Dec2020" xs:nil="true"/>
  <us-gaap:CommonStockValue unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">24420</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">24420</us-gaap:CommonStockValue>
  <us-gaap:CommonStockParOrStatedValuePerShare unitRef="usdPershares" contextRef="c2_AsOf31Mar2021" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare unitRef="usdPershares" contextRef="c3_AsOf31Dec2020" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized unitRef="shares" contextRef="c2_AsOf31Mar2021" decimals="INF">100000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized unitRef="shares" contextRef="c3_AsOf31Dec2020" decimals="INF">100000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued unitRef="shares" contextRef="c2_AsOf31Mar2021" decimals="INF">24420526</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued unitRef="shares" contextRef="c3_AsOf31Dec2020" decimals="INF">24420526</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding unitRef="shares" contextRef="c2_AsOf31Mar2021" decimals="INF">24420526</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding unitRef="shares" contextRef="c3_AsOf31Dec2020" decimals="INF">24420526</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:AdditionalPaidInCapital unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">40751807</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AdditionalPaidInCapital unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">40751807</us-gaap:AdditionalPaidInCapital>
  <us-gaap:StockholdersEquityNoteSubscriptionsReceivable unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">2934620</us-gaap:StockholdersEquityNoteSubscriptionsReceivable>
  <us-gaap:StockholdersEquityNoteSubscriptionsReceivable unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">3160360</us-gaap:StockholdersEquityNoteSubscriptionsReceivable>
  <us-gaap:RetainedEarningsAccumulatedDeficit unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">-26770892</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">-25642387</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">601000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">564860</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:TreasuryStockValue unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">9100000</us-gaap:TreasuryStockValue>
  <us-gaap:TreasuryStockValue unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">9100000</us-gaap:TreasuryStockValue>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">2571715</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">3438340</us-gaap:StockholdersEquity>
  <us-gaap:MinorityInterest unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">-843091</us-gaap:MinorityInterest>
  <us-gaap:MinorityInterest unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">-776273</us-gaap:MinorityInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">1728624</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">2662067</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:LiabilitiesAndStockholdersEquity unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">10526062</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">11606705</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:Revenues unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">263150</us-gaap:Revenues>
  <us-gaap:Revenues unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">78786</us-gaap:Revenues>
  <us-gaap:CostOfRevenue unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">1245</us-gaap:CostOfRevenue>
  <us-gaap:CostOfRevenue unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">3959</us-gaap:CostOfRevenue>
  <us-gaap:GrossProfit unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">261905</us-gaap:GrossProfit>
  <us-gaap:GrossProfit unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">74827</us-gaap:GrossProfit>
  <us-gaap:SellingGeneralAndAdministrativeExpense unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">1167595</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">1152889</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">121315</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">92790</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ShareBasedCompensation unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">225740</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">525</us-gaap:ShareBasedCompensation>
  <us-gaap:OperatingExpenses unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">1514650</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">1246204</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">-1252745</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">-1171377</us-gaap:OperatingIncomeLoss>
  <us-gaap:InvestmentIncomeInterest unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">52529</us-gaap:InvestmentIncomeInterest>
  <us-gaap:InvestmentIncomeInterest unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">10720</us-gaap:InvestmentIncomeInterest>
  <us-gaap:InterestExpense unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">130229</us-gaap:InterestExpense>
  <us-gaap:InterestExpense unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">131517</us-gaap:InterestExpense>
  <us-gaap:RentalIncomeNonoperating unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">4867</us-gaap:RentalIncomeNonoperating>
  <us-gaap:RentalIncomeNonoperating unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">5231</us-gaap:RentalIncomeNonoperating>
  <abvcd:RentalIncomeRelatedParties unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">1600</abvcd:RentalIncomeRelatedParties>
  <abvcd:RentalIncomeRelatedParties unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">1200</abvcd:RentalIncomeRelatedParties>
  <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">951</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
  <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">2</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
  <us-gaap:EquitySecuritiesFvNiRealizedGainLoss unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">-47791</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
  <us-gaap:EquitySecuritiesFvNiRealizedGainLoss unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">-70411</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
  <us-gaap:OtherNonoperatingIncomeExpense unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">71</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">6322</us-gaap:OtherNonoperatingIncomeExpense>
  <abvcd:GovernmentGrantIncome unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">124400</abvcd:GovernmentGrantIncome>
  <us-gaap:NonoperatingIncomeExpense unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">6398</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">-178453</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">-1246347</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">-1349830</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeTaxExpenseBenefit unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">-51024</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxExpenseBenefit unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">-40568</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">-1195323</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">-1309262</us-gaap:NetIncomeLoss>
  <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">-66818</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
  <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">-61724</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
  <abvcd:NetLossAttributableToAbvcAndSubsidiaries unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">-1128505</abvcd:NetLossAttributableToAbvcAndSubsidiaries>
  <abvcd:NetLossAttributableToAbvcAndSubsidiaries unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">-1247538</abvcd:NetLossAttributableToAbvcAndSubsidiaries>
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">36140</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">-6451</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">-1092365</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">-1253989</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:EarningsPerShareBasicAndDiluted unitRef="usdPershares" contextRef="c0_From1Jan2021To31Mar2021" decimals="2">-0.05</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted unitRef="usdPershares" contextRef="c4_From1Jan2020To31Mar2020" decimals="2">-0.06</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted unitRef="shares" contextRef="c0_From1Jan2021To31Mar2021" decimals="INF">24420526</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted unitRef="shares" contextRef="c4_From1Jan2020To31Mar2020" decimals="INF">19484542</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:Depreciation unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">2928</us-gaap:Depreciation>
  <us-gaap:Depreciation unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">11174</us-gaap:Depreciation>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">225740</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">525</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:UnrealizedGainLossOnInvestments unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">-47791</us-gaap:UnrealizedGainLossOnInvestments>
  <us-gaap:UnrealizedGainLossOnInvestments unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">-70411</us-gaap:UnrealizedGainLossOnInvestments>
  <abvcd:IncreaseDecreaseInGovernmentGrantIncome unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">124400</abvcd:IncreaseDecreaseInGovernmentGrantIncome>
  <abvcd:IncreaseDecreaseInGovernmentGrantIncome unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" xs:nil="true"/>
  <us-gaap:OtherNoncashIncomeExpense unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" xs:nil="true"/>
  <us-gaap:OtherNoncashIncomeExpense unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">2333</us-gaap:OtherNoncashIncomeExpense>
  <us-gaap:DeferredIncomeTaxExpenseBenefit unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">-51024</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <us-gaap:DeferredIncomeTaxExpenseBenefit unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">-40568</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <us-gaap:IncreaseDecreaseInAccountsReceivable unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">238484</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInAccountsReceivable unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">-52950</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">187723</us-gaap:IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets>
  <us-gaap:IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">-27834</us-gaap:IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets>
  <us-gaap:IncreaseDecreaseDueFromOtherRelatedParties unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">18229</us-gaap:IncreaseDecreaseDueFromOtherRelatedParties>
  <us-gaap:IncreaseDecreaseDueFromOtherRelatedParties unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">7536</us-gaap:IncreaseDecreaseDueFromOtherRelatedParties>
  <us-gaap:IncreaseDecreaseInAccountsPayableTrade unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">-12710</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
  <us-gaap:IncreaseDecreaseInAccountsPayableTrade unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">-3632</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
  <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">136519</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
  <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">500743</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
  <us-gaap:IncreaseDecreaseInDueToRelatedParties unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">1841</us-gaap:IncreaseDecreaseInDueToRelatedParties>
  <us-gaap:IncreaseDecreaseInDueToRelatedParties unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">68750</us-gaap:IncreaseDecreaseInDueToRelatedParties>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">-1413074</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">-630944</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:PaymentsToAcquireOtherInvestments unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">281952</us-gaap:PaymentsToAcquireOtherInvestments>
  <us-gaap:PaymentsToAcquireOtherInvestments unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" xs:nil="true"/>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">-281952</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" xs:nil="true"/>
  <us-gaap:ProceedsFromIssuanceOfCommonStock unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">40448</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">267740</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <abvcd:NetProceedsFromShortTermBorrowingsFromThirdParties unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" xs:nil="true"/>
  <abvcd:NetProceedsFromShortTermBorrowingsFromThirdParties unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">280940</abvcd:NetProceedsFromShortTermBorrowingsFromThirdParties>
  <us-gaap:RepaymentsOfNotesPayable unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">250000</us-gaap:RepaymentsOfNotesPayable>
  <us-gaap:RepaymentsOfNotesPayable unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" xs:nil="true"/>
  <us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">236498</us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt>
  <us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" xs:nil="true"/>
  <us-gaap:ProceedsFromRelatedPartyDebt unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">15280</us-gaap:ProceedsFromRelatedPartyDebt>
  <us-gaap:ProceedsFromRelatedPartyDebt unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">71688</us-gaap:ProceedsFromRelatedPartyDebt>
  <us-gaap:RepaymentsOfLongTermDebt unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" xs:nil="true"/>
  <us-gaap:RepaymentsOfLongTermDebt unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">9981</us-gaap:RepaymentsOfLongTermDebt>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">42226</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">610387</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">-15335</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">-93</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">-1668135</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">-20650</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">5001371</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents unitRef="usd" contextRef="c5_AsOf31Dec2019" decimals="0">160443</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">3333236</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents unitRef="usd" contextRef="c6_AsOf31Mar2020" decimals="0">139793</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:InterestPaidNet unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">21666</us-gaap:InterestPaidNet>
  <us-gaap:InterestPaidNet unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">10446</us-gaap:InterestPaidNet>
  <us-gaap:IncomeTaxesPaid unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" xs:nil="true"/>
  <us-gaap:IncomeTaxesPaid unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" xs:nil="true"/>
  <us-gaap:SharesOutstanding unitRef="shares" contextRef="c7_AsOf31Dec2019_CommonStockMember" decimals="INF">19478168</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest unitRef="usd" contextRef="c7_AsOf31Dec2019_CommonStockMember" decimals="0">19478</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest unitRef="usd" contextRef="c8_AsOf31Dec2019_StockSubscriptionReceivableMember" decimals="0">-4063320</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest unitRef="usd" contextRef="c9_AsOf31Dec2019_AdditionalPaidInCapitalMember" decimals="0">28180348</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest unitRef="usd" contextRef="c10_AsOf31Dec2019_RetainedEarningsMember" decimals="0">-15851223</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest unitRef="usd" contextRef="c11_AsOf31Dec2019_ComprehensiveIncomeMember" decimals="0">663753</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:SharesOutstanding unitRef="shares" contextRef="c12_AsOf31Dec2019_TreasuryStockMember" decimals="INF">-275347</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest unitRef="usd" contextRef="c12_AsOf31Dec2019_TreasuryStockMember" decimals="0">-9100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest unitRef="usd" contextRef="c13_AsOf31Dec2019_NoncontrollingInterestMember" decimals="0">26147</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest unitRef="usd" contextRef="c5_AsOf31Dec2019" decimals="0">-124817</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues unitRef="shares" contextRef="c14_From1Jan2020To31Mar2020_CommonStockMember" decimals="INF">10000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues unitRef="usd" contextRef="c14_From1Jan2020To31Mar2020_CommonStockMember" decimals="0">10</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues unitRef="usd" contextRef="c15_From1Jan2020To31Mar2020_StockSubscriptionReceivableMember" decimals="0">225740</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues unitRef="usd" contextRef="c16_From1Jan2020To31Mar2020_AdditionalPaidInCapitalMember" decimals="0">41989</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">267739</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation unitRef="usd" contextRef="c16_From1Jan2020To31Mar2020_AdditionalPaidInCapitalMember" decimals="0">525</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">525</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c17_From1Jan2020To31Mar2020_RetainedEarningsMember" decimals="0">-1247538</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c18_From1Jan2020To31Mar2020_NoncontrollingInterestMember" decimals="0">-61724</us-gaap:NetIncomeLoss>
  <abvcd:CumulativeTransactionAdjustments unitRef="usd" contextRef="c19_From1Jan2020To31Mar2020_ComprehensiveIncomeMember" decimals="0">-6451</abvcd:CumulativeTransactionAdjustments>
  <abvcd:CumulativeTransactionAdjustments unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">-6451</abvcd:CumulativeTransactionAdjustments>
  <us-gaap:SharesOutstanding unitRef="shares" contextRef="c20_AsOf31Mar2020_CommonStockMember" decimals="INF">19488168</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest unitRef="usd" contextRef="c20_AsOf31Mar2020_CommonStockMember" decimals="0">19488</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest unitRef="usd" contextRef="c21_AsOf31Mar2020_StockSubscriptionReceivableMember" decimals="0">-3837580</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest unitRef="usd" contextRef="c22_AsOf31Mar2020_AdditionalPaidInCapitalMember" decimals="0">28222862</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest unitRef="usd" contextRef="c23_AsOf31Mar2020_RetainedEarningsMember" decimals="0">-17098761</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest unitRef="usd" contextRef="c24_AsOf31Mar2020_ComprehensiveIncomeMember" decimals="0">657302</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:SharesOutstanding unitRef="shares" contextRef="c25_AsOf31Mar2020_TreasuryStockMember" decimals="INF">-275347</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest unitRef="usd" contextRef="c25_AsOf31Mar2020_TreasuryStockMember" decimals="0">-9100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest unitRef="usd" contextRef="c26_AsOf31Mar2020_NoncontrollingInterestMember" decimals="0">-35577</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest unitRef="usd" contextRef="c6_AsOf31Mar2020" decimals="0">-1172266</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:SharesOutstanding unitRef="shares" contextRef="c27_AsOf31Dec2020_CommonStockMember" decimals="INF">24420526</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest unitRef="usd" contextRef="c27_AsOf31Dec2020_CommonStockMember" decimals="0">24420</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest unitRef="usd" contextRef="c28_AsOf31Dec2020_StockSubscriptionReceivableMember" decimals="0">-3160360</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest unitRef="usd" contextRef="c29_AsOf31Dec2020_AdditionalPaidInCapitalMember" decimals="0">40751807</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest unitRef="usd" contextRef="c30_AsOf31Dec2020_RetainedEarningsMember" decimals="0">-25642387</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest unitRef="usd" contextRef="c31_AsOf31Dec2020_ComprehensiveIncomeMember" decimals="0">564860</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:SharesOutstanding unitRef="shares" contextRef="c32_AsOf31Dec2020_TreasuryStockMember" decimals="INF">-275347</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest unitRef="usd" contextRef="c32_AsOf31Dec2020_TreasuryStockMember" decimals="0">-9100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest unitRef="usd" contextRef="c33_AsOf31Dec2020_NoncontrollingInterestMember" decimals="0">-776273</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation unitRef="usd" contextRef="c34_From1Jan2021To31Mar2021_StockSubscriptionReceivableMember" decimals="0">225740</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">225740</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c35_From1Jan2021To31Mar2021_RetainedEarningsMember" decimals="0">-1128505</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c36_From1Jan2021To31Mar2021_NoncontrollingInterestMember" decimals="0">-66818</us-gaap:NetIncomeLoss>
  <abvcd:CumulativeTransactionAdjustments unitRef="usd" contextRef="c37_From1Jan2021To31Mar2021_ComprehensiveIncomeMember" decimals="0">36140</abvcd:CumulativeTransactionAdjustments>
  <abvcd:CumulativeTransactionAdjustments unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">36140</abvcd:CumulativeTransactionAdjustments>
  <us-gaap:SharesOutstanding unitRef="shares" contextRef="c38_AsOf31Mar2021_CommonStockMember" decimals="INF">24420526</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest unitRef="usd" contextRef="c38_AsOf31Mar2021_CommonStockMember" decimals="0">24420</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest unitRef="usd" contextRef="c39_AsOf31Mar2021_StockSubscriptionReceivableMember" decimals="0">-2934620</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest unitRef="usd" contextRef="c40_AsOf31Mar2021_AdditionalPaidInCapitalMember" decimals="0">40751807</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest unitRef="usd" contextRef="c41_AsOf31Mar2021_RetainedEarningsMember" decimals="0">-26770892</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest unitRef="usd" contextRef="c42_AsOf31Mar2021_ComprehensiveIncomeMember" decimals="0">601000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:SharesOutstanding unitRef="shares" contextRef="c43_AsOf31Mar2021_TreasuryStockMember" decimals="INF">-275347</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest unitRef="usd" contextRef="c43_AsOf31Mar2021_TreasuryStockMember" decimals="0">-9100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest unitRef="usd" contextRef="c44_AsOf31Mar2021_NoncontrollingInterestMember" decimals="0">-843091</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb+OcBO0cz/DPQtq8WT+vHGytpy5eqldqmljvYMs+ffK0hVJun/LoadZRO6MVQWNprQnn57cflcp0+RqqLVbNVtuKFz5+pgq1gL8cjM8xFnzOUdEjZ0sDSJzg18XsOaa9RO4cDdhaiGpwVK1skYTQsz6wjLPW7PJKd/ex+Rw6OhX8y162iyhal66ZGdonDoY3lgzlpDE9OdpA==] CSR-->
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;&lt;b&gt;1. ORGANIZATION AND DESCRIPTION OF BUSINESS&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;ABVC BioPharma, Inc. (the
&amp;#x201c;Company&amp;#x201d;), formerly known as American BriVision (Holding) Corporation, a Nevada corporation, through the Company&amp;#x2019;s operating entity, American BriVision Corporation
(&amp;#x201c;BriVision&amp;#x201d;), which was incorporated in July 2015 in the State of Delaware, engages in biotechnology to fulfill unmet
medical needs and focuses on the development of new drugs and medical devices derived from plants. &amp;#xa0;BriVision develops its
pipeline by carefully tracking new medical discoveries or medical device technologies in research institutions in the Asia-Pacific
region. Pre-clinical, disease animal model and Phase I safety studies are examined closely by the Company to identify drugs that
BriVision believes demonstrate efficacy and safety. Once a drug appears to be a good candidate for development and ultimately
commercialization, BriVision licenses the drug or medical device from the original researchers and begins to introduce the drugs
clinical plan to highly respected principal investigators in the United States, Australia and Taiwan to conduct a Phase II clinical
trial. At present, clinical trials for the Company&amp;#x2019;s drugs and medical devices are being conducted at such world-famous
institutions as Memorial Sloan Kettering Cancer Center (&amp;#x201c;MSKCC&amp;#x201d;) and MD Anderson Cancer Center. BriVision had no
predecessor operations prior to its formation on July 21, 2015.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;Name Change&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The Company&amp;#x2019;s shareholders approved an amendment to the Company&amp;#x2019;s
Articles of Incorporation to change the Company&amp;#x2019;s corporate name from American BriVision (Holding) Corporation to ABVC BioPharma,
Inc. and approved and adopted the Certificate of Amendment to affect same at the 2020 annual meeting of shareholders (the &amp;#x201c;Annual
Meeting&amp;#x201d;). The name change amendment to the Company&amp;#x2019;s Articles of Incorporation was filed with Nevada&amp;#x2019;s Secretary of
State and became effective on March 8, 2021 and FINRA processed our request to change our name on April 30, 2021, which became effective
as of May 3, 2021.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The Company&amp;#x2019;s stock symbol remains ABVC.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;Reverse Merger&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;On February 8, 2016, a Share Exchange
Agreement (the &amp;#x201c;Share Exchange Agreement&amp;#x201d;) was entered into by and among the Company, BriVision, and Euro-Asia Investment
&amp;amp; Finance Corp. Limited, a company incorporated under the laws of Hong Kong Special Administrative Region of the People&amp;#x2019;s
Republic of China (&amp;#x201c;Euro-Asia&amp;#x201d;), being the owners of record of 164,387,376 (52,336,000 pre-stock split) shares of Common
Stock of the Company, and the owners of record of all of the issued share capital of BriVision (the &amp;#x201c;BriVision
Stock&amp;#x201d;).&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;Pursuant to the Share Exchange Agreement, upon
surrender by the BriVision Shareholders and the cancellation by BriVision of the certificates evidencing the BriVision Stock as registered
in the name of each BriVision Shareholder, and pursuant to the registration of the Company in the register of members maintained by BriVision
as the new holder of the BriVision Stock and the issuance of the certificates evidencing the aforementioned registration of the BriVision
Stock in the name of the Company, the Company issued 166,273,921 (52,936,583 pre-stock split) shares (the &amp;#x201c;Acquisition Stock&amp;#x201d;)
(subject to adjustment for fractionalized shares as set forth below) of the Company&amp;#x2019;s Common Stock to the BriVision Shareholders
(or their designees), and 163,159,952 (51,945,225 pre-stock split) shares of the Company&amp;#x2019;s Common Stock owned by Euro-Asia were
cancelled and retired to treasury. The Acquisition Stock collectively represented 79.70% of the issued and outstanding Common Stock of
the Company immediately after the Closing, in exchange for the BriVision Stock, representing 100% of the issued share capital of BriVision
in a reverse merger (the &amp;#x201c;Merger&amp;#x201d;).&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;Pursuant to the Merger, all of the issued and
outstanding common shares of BriVision were converted, at an exchange ratio of 0.2536-for-1, into an aggregate of 166,273,921 (52,936,583pre-stock
split) common shares of the Company and BriVision had become a wholly owned subsidiary of the Company. The holders of Company&amp;#x2019;s
Common Stock as of immediately prior to the Merger held an aggregate of 205,519,223(65,431,144 pre-stock split) shares of Company&amp;#x2019;s
Common Stock. Because of the exchange of the BriVision Stock for the Acquisition Stock (the &amp;#x201c;Share Exchange&amp;#x201d;), BriVision
had become a wholly owned subsidiary (the &amp;#x201c;Subsidiary&amp;#x201d;) of the Company and there was a change of control of the Company following
the closing. There were no warrants, options or other equity instruments issued in connection with the share exchange agreement.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;Upon the consummation of the Share Exchange,
BriVision became a wholly owned subsidiary of the Company.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;Following the Share Exchange, the Company has
abandoned prior business plan and is now pursuing BriVision&amp;#x2019;s historically proposed businesses, which focus on the development
of new drugs and innovative medical devices to fulfill unmet medical needs. The business model of the Company is to integrate research
achievements from world-famous institutions, conduct clinical trials of translational medicine for Proof of Concept (&amp;#x201c;POC&amp;#x201d;),
out-license to international pharmaceutical companies, and explore global markets.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;Accounting Treatment of the Reverse Merger&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;For financial reporting purposes, the Share Exchange
represents a &amp;#x201c;reverse merger&amp;#x201d;&amp;#xa0;rather than a business combination and&amp;#xa0;BriVision&amp;#xa0;is deemed the accounting acquirer
in the transaction. The&amp;#xa0;Share Exchange is being accounted for as a reverse-merger and recapitalization. BriVision&amp;#xa0;is the acquirer
for financial reporting purposes and the&amp;#xa0;Company&amp;#xa0;is the acquired company. Consequently, the assets and liabilities and the
operations reflected in the historical financial statements prior to the Share Exchange will be those of&amp;#xa0;BriVision&amp;#xa0;and recorded
at the historical cost basis of&amp;#xa0;BriVision. In addition, the consolidated financial statements after completion of the Share Exchange
will include the assets and liabilities of the Company and BriVision, and the historical operations of&amp;#xa0;BriVision&amp;#xa0;and operations
of the Combined Company from the closing date of the Share Exchange.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;Merger&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;On February 8, 2019, the Company, BioLite Holding,
Inc. (&amp;#x201c;BioLite&amp;#x201d;), BioKey, Inc. (&amp;#x201c;BioKey&amp;#x201d;), BioLite Acquisition Corp., a direct wholly-owned subsidiary of Parent
(&amp;#x201c;Merger Sub 1&amp;#x201d;), and BioKey Acquisition Corp., a direct wholly-owned subsidiary of Parent (&amp;#x201c;Merger Sub 2&amp;#x201d;) (collectively
referred to as the &amp;#x201c;Parties&amp;#x201d;) completed the business combination pursuant to the Agreement and Plan of Merger (the &amp;#x201c;Merger
Agreement&amp;#x201d;) dated as of January 31, 2018 where ABVC acquired BioLite and BioKey via issuing additional Common Stock of ABVC to
the shareholders of BioLite and BioKey.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;Pursuant to the terms of the Merger Agreement,
BioLite and BioKey became two wholly-owned subsidiaries of the Company on February 8, 2019. ABVC issued an aggregate of 104,558,777 shares
(prior to the reverse stock split in 2019) to the shareholders of both BioLite and BioKey under a registration statement on Form S-4
(file number 333-226285), which became effective by operation of law on or about February 5, 2019.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;BioLite Holding, Inc. (the &amp;#x201c;BioLite Holding&amp;#x201d;)
was incorporated under the laws of the State of Nevada on July 27, 2016. BioLite BVI, Inc. (the &amp;#x201c;BioLite BVI&amp;#x201d;), a wholly
owned subsidiary of BioLite Holding, was incorporated in the British Virgin Islands on September 13, 2016. BioLite Holding and BioLite
BVI are holding companies and have not carried out substantive business operations of their own.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;BioLite, Inc., (the &amp;#x201c;BioLite Taiwan&amp;#x201d;)
was incorporated on February 13, 2006 under the laws of Taiwan. BioLite is in the business of developing and commercialization of new
botanical drugs with application in central nervous system, autoimmunity, inflammation, hematology, and oncology. In addition, BioLite
Taiwan distributes dietary supplements made from extracts of Chinese herbs and Maitake mushroom.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;In January 2017, BioLite Holding, BioLite BVI,
BioLite Taiwan, and certain shareholders of BioLite Taiwan entered into a share purchase / exchange agreement (the &amp;#x201c;BioLite Share
Purchase / Exchange Agreement&amp;#x201d;). Pursuant to the BioLite Share Purchase / Exchange Agreement, the shareholder participants to the
BioLite Share Purchase / Exchange Agreement have sold their equity in BioLite Taiwan and were using the proceeds from such sales to purchase
shares of Common Stock of BioLite Holding at the same price per share, resulting in their owning the same number of shares of Common
Stock as they owned in the BioLite Taiwan. Upon closing of the Share Purchase/ Exchange Agreement in August 2017, BioLite Holding ultimately
owns via BioLite BVI approximately 73% of BioLite Taiwan. The other shareholders who did not enter this Share Purchase/ Exchange Agreement
retain their equity ownership in BioLite Taiwan.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;BioKey, Inc. was incorporated on August 9, 2000
in the State of California. BioKey provides a wide range of services, including, API characterization, pre-formulation studies, formulation
development, analytical method development, stability studies, IND/NDA/ANDA/510K submissions, and manufacturing clinical trial materials
(Phase I through phase III) and commercial manufacturing. It also licenses out its technologies and initiates joint research and development
processes with other biotechnology, pharmaceutical, and nutraceutical companies.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;Accounting Treatment of the Merger&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The Company adopted ASC 805, &amp;#x201c;Business
Combination&amp;#x201d; to record the merger transactions of BioKey. Since the Company and BioLite Holding are the entities under Dr. Tsung-Shann
Jiang&amp;#x2019;s common control, the transaction is accounted for as a restructuring transaction.&amp;#xa0;All the assets and liabilities of
BioLite Holding, BioLite BVI, and BioLite Taiwan were transferred to the Company at their respective carrying amounts on the closing
date of the Merger. The Company has recast prior period financial statements to reflect the conveyance of BioLite Holding&amp;#x2019;s common
shares as if the restructuring transaction had occurred as of the earliest date of the financial statements. All material intercompany
accounts, transactions, and profits have been eliminated in consolidation. The nature of and effects on earnings per share (EPS) of nonrecurring
intra-entity transactions involving long-term assets and liabilities is not required to be eliminated and EPS amounts have been recast
to include the earnings (or losses) of the transferred net assets.&lt;/p&gt;&lt;br/&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
  <abvcd:CommonStockIssuedAfterStockSplit unitRef="shares" contextRef="c45_From2Feb2016To8Feb2016_ShareExchangeAgreementMember" decimals="INF">164387376</abvcd:CommonStockIssuedAfterStockSplit>
  <abvcd:CommonStockIssuedBeforeStockSplit unitRef="shares" contextRef="c45_From2Feb2016To8Feb2016_ShareExchangeAgreementMember" decimals="INF">52336000</abvcd:CommonStockIssuedBeforeStockSplit>
  <abvcd:CommonStockIssuedAfterStockSplit unitRef="shares" contextRef="c46_From2Feb2016To8Feb2016_ShareExchangeAgreementOneMember" decimals="INF">166273921</abvcd:CommonStockIssuedAfterStockSplit>
  <abvcd:CommonStockIssuedBeforeStockSplit unitRef="shares" contextRef="c46_From2Feb2016To8Feb2016_ShareExchangeAgreementOneMember" decimals="INF">52936583</abvcd:CommonStockIssuedBeforeStockSplit>
  <abvcd:CommonStockIssuedAfterStockSplit unitRef="shares" contextRef="c47_From2Feb2016To8Feb2016_ShareExchangeAgreementTwoMember" decimals="INF">163159952</abvcd:CommonStockIssuedAfterStockSplit>
  <abvcd:CommonStockIssuedBeforeStockSplit unitRef="shares" contextRef="c47_From2Feb2016To8Feb2016_ShareExchangeAgreementTwoMember" decimals="INF">51945225</abvcd:CommonStockIssuedBeforeStockSplit>
  <abvcd:PercentageOfCommonSharesIssuedAndOutstanding unitRef="pure" contextRef="c48_AsOf8Feb2016_ShareExchangeAgreementTwoMember" decimals="4">0.7970</abvcd:PercentageOfCommonSharesIssuedAndOutstanding>
  <abvcd:PercentageOfIssuedShareCapital unitRef="pure" contextRef="c48_AsOf8Feb2016_ShareExchangeAgreementTwoMember" decimals="2">1.00</abvcd:PercentageOfIssuedShareCapital>
  <abvcd:CommonStockIssuedAfterStockSplit unitRef="shares" contextRef="c49_From2Feb2016To8Feb2016_ShareExchangeAgreementThreeMember" decimals="INF">166273921</abvcd:CommonStockIssuedAfterStockSplit>
  <abvcd:CommonStockIssuedBeforeStockSplit unitRef="shares" contextRef="c49_From2Feb2016To8Feb2016_ShareExchangeAgreementThreeMember" decimals="INF">52936</abvcd:CommonStockIssuedBeforeStockSplit>
  <abvcd:CommonStockIssuedAfterStockSplit unitRef="shares" contextRef="c50_From2Feb2016To8Feb2016_ShareExchangeAgreementFourMember" decimals="INF">205519223</abvcd:CommonStockIssuedAfterStockSplit>
  <abvcd:CommonStockIssuedBeforeStockSplit unitRef="shares" contextRef="c50_From2Feb2016To8Feb2016_ShareExchangeAgreementFourMember" decimals="INF">65431144</abvcd:CommonStockIssuedBeforeStockSplit>
  <abvcd:CommonStockIssuedBeforeStockSplit unitRef="shares" contextRef="c51_From2Feb2019To8Feb2019_MergerAgreementMember" decimals="INF">104558777</abvcd:CommonStockIssuedBeforeStockSplit>
  <abvcd:PercentageOfCommonSharesIssuedAndOutstanding unitRef="pure" contextRef="c52_AsOf31Aug2017" decimals="2">0.73</abvcd:PercentageOfCommonSharesIssuedAndOutstanding>
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;Basis of Presentation&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The accompanying consolidated financial statements
have been prepared in accordance with the generally accepted accounting principles in the United States of America (the &amp;#x201c;U.S. GAAP&amp;#x201d;).
All significant intercompany transactions and account balances have been eliminated.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;This basis of accounting involves the application
of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred.
The Company&amp;#x2019;s financial statements are expressed in U.S. dollars.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;Fiscal Year&lt;/font&gt;&amp;#xa0;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The Company changed its fiscal year from the
period beginning on October 1st and ending on September 30th to the period beginning on January 1st and ending on December 31st, beginning
January 1, 2018. All references herein to a fiscal year prior to December 31, 2017 refer to the twelve months ended September 30th of
such year.&amp;#xa0;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;Use of Estimates&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The preparation of financial statements in conformity
with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated
financial statements and the amount of revenues and expenses during the reporting periods. Actual results could differ materially from
those results.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;Inventory&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;Inventory consists of raw materials, work-in-process,
finished goods, and merchandise. Inventories are stated at the lower of cost or market and valued on a moving weighted average cost basis.
Market is determined based on net realizable value. The Company periodically reviews the age and turnover of its inventory to determine
whether any inventory has become obsolete or has declined in value, and incurs a charge to operations for known and anticipated inventory
obsolescence.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;Reclassifications&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;Certain classifications have been made to the
prior year financial statements to conform to the current year presentation. The reclassification had no impact on previously reported
net loss or accumulated deficit.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;Forward Stock Split&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;On March 21, 2016, the Board of Directors of
the Company approved an amendment to Articles of Incorporation to effect a forward split at a ratio of 1 to 3.141 and increase the number
of our authorized shares of Common Stock, par value $0.001 per share, to 360,000,000, which was effective on April 8, 2016.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;Stock Reverse Split&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;On March 12, 2019, the Board of Directors of
the Company by unanimous written consent in lieu of a meeting approved to i) effect a stock reverse split at the ratio of 1-for-18 (the
&amp;#x201c;Reverse Split&amp;#x201d;) of both the authorized common stock of the Company (the &amp;#x201c;Common Stock&amp;#x201d;) and the issued and outstanding
Common Stock and ii) to amend the articles of incorporation of the Company to reflect the Reverse Split. The Board approved and authorized
the Reverse Split without obtaining approval of the Company&amp;#x2019;s shareholders pursuant to Section 78.207 of Nevada Revised Statutes.
On May 3, 2019, the Company filed a certificate of amendment to the Company&amp;#x2019;s articles of incorporation (the &amp;#x201c;Amendment&amp;#x201d;)
to effect the Reverse Split with the Secretary of State of Nevada. The Financial Industry Regulatory Authority (&amp;#x201c;FINRA&amp;#x201d;)
informed the Company that the Reverse Split was effective on May 8, 2019. All shares and related financial information in this Form 10-K
reflect this 1-for-18 reverse stock split.&amp;#xa0;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;Fair Value Measurements&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;FASB ASC 820, &amp;#x201c;Fair Value Measurements&amp;#x201d;
defines fair value for certain financial and nonfinancial assets and liabilities that are recorded at fair value, establishes a framework
for measuring fair value and expands disclosures about fair value measurements. It requires that an entity measure its financial instruments
to base fair value on exit price, maximize the use of observable units and minimize the use of unobservable inputs to determine the exit
price. It establishes a hierarchy which prioritizes the inputs to valuation techniques used to measure fair value. This hierarchy increases
the consistency and comparability of fair value measurements and related disclosures by maximizing the use of observable inputs and minimizing
the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that reflect
the assumptions market participants would use in pricing the assets or liabilities based on market data obtained from sources independent
of the Company. Unobservable inputs are inputs that reflect the Company&amp;#x2019;s own assumptions about the assumptions market participants
would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy prioritizes
the inputs into three broad levels based on the reliability of the inputs as follows:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse&quot;&gt;
  &lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 0.25in; text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 0.25in; text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;&amp;#x25cf;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Level 1 - Inputs are quoted prices in active markets for identical
    assets or liabilities that the Company has the ability to access at the measurement date. Valuation of these instruments does not
    require a high degree of judgment as the valuations are based on quoted prices in active markets that are readily and regularly available.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;&amp;#x25cf;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Level 2 - Inputs other than quoted prices in active markets that are
    either directly or indirectly observable as of the measurement date, such as quoted prices for similar assets or liabilities; quoted
    prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially
    the full term of the assets or liabilities.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;&amp;#x25cf;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Level 3 - Valuations based on inputs that are unobservable and not
    corroborated by market data. The fair value for such assets and liabilities is generally determined using pricing models, discounted
    cash flow methodologies, or similar techniques that incorporate the assumptions a market participant would use in pricing the asset
    or liability.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The carrying values of certain assets and liabilities
of the Company, such as cash and cash equivalents, restricted cash, accounts receivable, due from related parties, inventory, prepaid
expenses and other current assets, accounts payable, accrued liabilities, and due to related parties approximate fair value due to their
relatively short maturities. The carrying value of the Company&amp;#x2019;s short-term bank loan, convertible notes payable, and accrued interest
approximates their fair value as the terms of the borrowing are consistent with current market rates and the duration to maturity is
short. The carrying value of the Company&amp;#x2019;s long-term bank loan approximates fair value because the interest rates approximate market
rates that the Company could obtain for debt with similar terms and maturities.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;Cash and Cash Equivalents&lt;/font&gt;&amp;#xa0;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The Company considers highly liquid investments
with maturities of three months or less, when purchased, to be cash equivalents. As of March 31, 2021 and December 31, 2020, the Company&amp;#x2019;s
cash and cash equivalents amounted $2,615,073 and $4,273,208, respectively. Some&amp;#xa0;of the Company&amp;#x2019;s cash deposits are held in
financial institutions located in Taiwan where there is currently regulation mandated on obligatory insurance of bank accounts. The Company
believes this financial institution is of high credit quality.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;Restricted Cash Equivalents&lt;/font&gt;&amp;#xa0;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;Restricted cash equivalents primarily consist
of cash held in a reserve bank account in Taiwan. As of March 31, 2021 and December 31, 2020, the Company&amp;#x2019;s restricted cash equivalents
amounted $718,163 and $728,163, respectively.&amp;#xa0;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;Concentration of Credit Risk&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The Company&amp;#x2019;s financial instruments that
are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash and temporary
cash investments in high quality credit institutions, but these investments may be in excess of Taiwan Central Deposit Insurance Corporation
and the U.S. Federal Deposit Insurance Corporation&amp;#x2019;s insurance limits. The Company does not enter into financial instruments for
hedging, trading or speculative purposes.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;Revenue Recognition&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;During the fiscal year 2018, the Company adopted
Accounting Standards Codification (&amp;#x201c;ASC&amp;#x201d;), Topic 606 (ASC 606), Revenue from Contracts with Customers, using the modified
retrospective method to all contracts that were not completed as of January 1, 2018, and applying the new revenue standard as an adjustment
to the opening balance of accumulated deficit at the beginning of 2018 for the cumulative effect. The results for the Company&amp;#x2019;s
reporting periods beginning on and after January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and
continue to be reported under the accounting standards in effect for the prior period. Based on the Company&amp;#x2019;s review of existing
collaborative agreements as of January 1, 2018, the Company concluded that the adoption of the new guidance did not have a significant
change on the Company&amp;#x2019;s revenue during all periods presented.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;Pursuant to ASC 606, the Company recognizes revenue
when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the Company expects
to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines is
within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify
the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance
obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only
applies the five-step model to contracts when it is probable that the Company will collect the consideration the Company is entitled
to in exchange for the goods or services the Company transfers to the customers. At inception of the contract, once the contract is determined
to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are
performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount
of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The following are examples of when the Company
recognizes revenue based on the types of payments the Company receives.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;Collaborative Revenues &amp;#x2014; &lt;/b&gt;The Company
recognizes collaborative revenues generated through collaborative research, development and/or commercialization agreements. The terms
of these agreements typically include payment to the Company related to one or more of the following: non-refundable upfront license
fees, development and commercial milestones, partial or complete reimbursement of research and development costs, and royalties on net
sales of licensed products. Each type of payments results in collaborative revenues except for revenues from royalties on net sales of
licensed products, which are classified as royalty revenues. To date, the Company has not received any royalty revenues. Revenue is recognized
upon satisfaction of a performance obligation by transferring control of a good or service to the collaboration partners.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;As part of the accounting for these arrangements,
the Company applies judgment to determine whether the performance obligations are distinct, and develop assumptions in determining the
stand-alone selling price for each distinct performance obligation identified in the collaboration agreements. To determine the stand-alone
selling price, the Company relies on assumptions which may include forecasted revenues, development timelines, reimbursement rates for
R&amp;amp;D personnel costs, discount rates and probabilities of technical and regulatory success.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The Company had multiple deliverables under the
collaborative agreements, including deliverables relating to grants of technology licenses, regulatory and clinical development, and
marketing activities. Estimation of the performance periods of the Company&amp;#x2019;s deliverables requires the use of management&amp;#x2019;s
judgment. Significant factors considered in management&amp;#x2019;s evaluation of the estimated performance periods include, but are not limited
to, the Company&amp;#x2019;s experience in conducting clinical development, regulatory and manufacturing activities. The Company reviews the
estimated duration of its performance periods under its collaborative agreements on an annually basis, and makes any appropriate adjustments
on a prospective basis. Future changes in estimates of the performance period under its collaborative agreements could impact the timing
of future revenue recognition.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;(i) Non-refundable upfront payments&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;If a license to the Company&amp;#x2019;s intellectual
property is determined to be distinct from the other performance obligations identified in an arrangement, the Company recognizes revenue
from the related non-refundable upfront payments based on the relative standalone selling price prescribed to the license compared to
the total selling price of the arrangement. The revenue is recognized when the license is transferred to the collaboration partners and
the collaboration partners are able to use and benefit from the license. To date, the receipt of non-refundable upfront fees was solely
for the compensation of past research efforts and contributions made by the Company before the collaborative agreements entered into
and it does not relate to any future obligations and commitments made between the Company and the collaboration partners in the collaborative
agreements.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;(ii) Milestone payments&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The Company is eligible to receive milestone
payments under the collaborative agreement with collaboration partners based on achievement of specified development, regulatory and
commercial events. Management evaluated the nature of the events triggering these contingent payments, and concluded that these events
fall into two categories: (a) events which involve the performance of the Company&amp;#x2019;s obligations under the collaborative agreement
with collaboration partners, and (b) events which do not involve the performance of the Company&amp;#x2019;s obligations under the collaborative
agreement with collaboration partners.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The former category of milestone payments consists
of those triggered by development and regulatory activities in the territories specified in the collaborative agreements. Management
concluded that each of these payments constitute substantive milestone payments. This conclusion was based primarily on the facts that
(i) each triggering event represents a specific outcome that can be achieved only through successful performance by the Company of one
or more of its deliverables, (ii) achievement of each triggering event was subject to inherent risk and uncertainty and would result
in additional payments becoming due to the Company, (iii) each of the milestone payments is non-refundable, (iv) substantial effort is
required to complete each milestone, (v) the amount of each milestone payment is reasonable in relation to the value created in achieving
the milestone, (vi) a substantial amount of time is expected to pass between the upfront payment and the potential milestone payments,
and (vii) the milestone payments relate solely to past performance. Based on the foregoing, the Company recognizes any revenue from these
milestone payments in the period in which the underlying triggering event occurs.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;(iii) Multiple Element Arrangements&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The Company evaluates multiple element arrangements
to determine (1) the deliverables included in the arrangement and (2) whether the individual deliverables represent separate units of
accounting or whether they must be accounted for as a combined unit of accounting. This evaluation involves subjective determinations
and requires management to make judgments about the individual deliverables and whether such deliverables are separate from other aspects
of the contractual relationship. Deliverables are considered separate units of accounting provided that: (i) the delivered item(s) has
value to the customer on a standalone basis and (ii) if the arrangement includes a general right of return relative to the delivered
item(s), delivery or performance of the undelivered item(s) is considered probable and substantially within its control. In assessing
whether an item under a collaboration has standalone value, the Company considers factors such as the research, manufacturing, and commercialization
capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. The Company also
considers whether its collaboration partners can use the other deliverable(s) for their intended purpose without the receipt of the remaining
element(s), whether the value of the deliverable is dependent on the undelivered item(s), and whether there are other vendors that can
provide the undelivered element(s).&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The Company recognizes arrangement consideration
allocated to each unit of accounting when all of the revenue recognition criteria in ASC 606 are satisfied for that particular unit of
accounting. In the event that a deliverable does not represent a separate unit of accounting, the Company recognizes revenue from the
combined unit of accounting over the Company&amp;#x2019;s contractual or estimated performance period for the undelivered elements, which
is typically the term of the Company&amp;#x2019;s research and development obligations. If there is no discernible pattern of performance
or objectively measurable performance measures do not exist, then the Company recognizes revenue under the arrangement on a straight-line
basis over the period the Company is expected to complete its performance obligations. Conversely, if the pattern of performance in which
the service is provided to the customer can be determined and objectively measurable performance measures exist, then the Company recognizes
revenue under the arrangement using the proportional performance method. Revenue recognized is limited to the lesser of the cumulative
amount of payments received or the cumulative amount of revenue earned, as determined using the straight-line method or proportional
performance method, as applicable, as of the period ending date.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;At the inception of an arrangement that includes
milestone payments, the Company evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent
nature of the milestone. This evaluation includes an assessment of whether: (1) the consideration is commensurate with either the Company&amp;#x2019;s
performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting
from its performance to achieve the milestone, (2) the consideration relates solely to past performance and (3) the consideration is
reasonable relative to all of the deliverables and payment terms within the arrangement. The Company evaluates factors such as the scientific,
clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone and the level of effort and
investment required to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining
whether a milestone satisfies all of the criteria required to conclude that a milestone is substantive. Milestones that are not considered
substantive are recognized as earned if there are no remaining performance obligations or over the remaining period of performance, assuming
all other revenue recognition criteria are met.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;(iv) Royalties and Profit Sharing Payments&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;Under the collaborative agreement with the collaboration
partners, the Company is entitled to receive royalties on sales of products, which is at certain percentage of the net sales. The Company
recognizes revenue from these events based on the revenue recognition criteria set forth in ASC 606. Based on those criteria, the Company
considers these payments to be contingent revenues, and recognizes them as revenue in the period in which the applicable contingency
is resolved.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;Revenues Derived from Research and Development
Activities Services &amp;#x2014; Revenues related to research and development and regulatory activities are recognized when the related services
or activities are performed, in accordance with the contract terms. The Company typically has only one performance obligation at the
inception of a contract, which is to perform research and development services. The Company may also provide its customers with an option
to request that the Company provides additional goods or services in the future, such as active pharmaceutical ingredient, API, or IND/NDA/ANDA/510K
submissions. The Company evaluates whether these options are material rights at the inception of the contract. If the Company determines
an option is a material right, the Company will consider the option a separate performance obligation.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;If the Company is entitled to reimbursement from
its customers for specified research and development expenses, the Company accounts for the related services that it provides as separate
performance obligations if it determines that these services represent a material right. The Company also determines whether the reimbursement
of research and development expenses should be accounted for as revenues or an offset to research and development expenses in accordance
with provisions of gross or net revenue presentation. The Company recognizes the corresponding revenues or records the corresponding
offset to research and development expenses as it satisfies the related performance obligations.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The Company then determines the transaction price
by reviewing the amount of consideration the Company is eligible to earn under the contracts, including any variable consideration. Under
the outstanding contracts, consideration typically includes fixed consideration and variable consideration in the form of potential milestone
payments. At the start of an agreement, the Company&amp;#x2019;s transaction price usually consists of the payments made to or by the Company
based on the number of full-time equivalent researchers assigned to the project and the related research and development expenses incurred.
The Company does not typically include any payments that the Company may receive in the future in its initial transaction price because
the payments are not probable. The Company would reassess the total transaction price at each reporting period to determine if the Company
should include additional payments in the transaction price.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The Company receives payments from its customers
based on billing schedules established in each contract. Upfront payments and fees may be recorded as advance from customers upon receipt
or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under these
arrangements. Amounts are recorded as accounts receivable when the right of the Company to consideration is unconditional. The Company
does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period
between payment by the customers and the transfer of the promised goods or services to the customers will be one year or less.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;Property and Equipment&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;Property and equipment is carried at cost net
of accumulated depreciation. Repairs and maintenance are expensed as incurred. Expenditures that improve the functionality of the related
asset or extend the useful life are capitalized. When property and equipment is retired or otherwise disposed of, the related gain or
loss is included in operating income. Leasehold improvements are depreciated on the straight-line method over the shorter of the remaining
lease term or estimated useful life of the asset. Depreciation is calculated on the straight-line method, including property and equipment
under capital leases, generally based on the following useful lives:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;width: 91%; text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: black 1.5pt solid; width: 8%; text-align: center&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;&lt;b&gt;Estimated&amp;#xa0;Life&lt;br/&gt;
    in Years&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: #CCEEFF&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Buildings and leasehold improvements&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;5 ~ 50&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Machinery and equipment&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;5 ~ 10&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: #CCEEFF&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Office equipment&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;3 ~ 6&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;Impairment of Long-Lived Assets&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The Company has adopted Accounting Standards
Codification subtopic 360-10, Property, Plant and Equipment (&amp;#x201c;ASC 360-10&amp;#x201d;). ASC 360-10 requires that long-lived assets and
certain identifiable intangibles held and used by the Company be reviewed for impairment whenever events or changes in circumstances
indicate that the carrying amount of an asset may not be recoverable. The Company evaluates its long-lived assets for impairment annually
or more often if events and circumstances warrant. Events relating to recoverability may include significant unfavorable changes in business
conditions, recurring losses, or a forecasted inability to achieve break-even operating results over an extended period. Should impairment
in value be indicated, the carrying value of intangible assets will be adjusted, based on estimates of future discounted cash flows resulting
from the use and ultimate disposition of the asset. ASC 360-10 also requires assets to be disposed of be reported at the lower of the
carrying amount or the fair value less costs to sell.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;Long-term Equity Investment&lt;/font&gt;&amp;#xa0;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The Company acquires the equity investments to
promote business and strategic objectives. The Company accounts for non-marketable equity and other equity investments for which the
Company does not have control over the investees as:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse&quot;&gt;
  &lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 0.25in&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 0.25in&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;&amp;#x25cf;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Equity method investments when the Company has the ability to exercise
    significant influence, but not control, over the investee. Its proportionate share of the income or loss is recognized monthly and
    is recorded in gains (losses) on equity investments.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse&quot;&gt;
  &lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 0.25in&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 0.25in&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;&amp;#x25cf;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Non-marketable cost method investments when the equity method does
    not apply.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;Significant judgment is required to identify
whether an impairment exists in the valuation of the Company&amp;#x2019;s non-marketable equity investments, and therefore the Company considers
this a critical accounting estimate. Its yearly analysis considers both qualitative and quantitative factors that may have a significant
impact on the investee&amp;#x2019;s fair value. Qualitative analysis of its investments involves understanding the financial performance and
near-term prospects of the investee, changes in general market conditions in the investee&amp;#x2019;s industry or geographic area, and the
management and governance structure of the investee. Quantitative assessments of the fair value of its investments are developed using
the market and income approaches. The market approach includes the use of comparable financial metrics of private and public companies
and recent financing rounds. The income approach includes the use of a discounted cash flow model, which requires significant estimates
regarding the investees&amp;#x2019; revenue, costs, and discount rates. The Company&amp;#x2019;s assessment of these factors in determining whether
an impairment exists could change in the future due to new developments or changes in applied assumptions.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;Other-Than-Temporary Impairment&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The Company&amp;#x2019;s long-term equity investments
are subject to a periodic impairment review. Impairments affect earnings as follows:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse&quot;&gt;
  &lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 0.25in&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 0.25in&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;&amp;#x25cf;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Marketable equity securities include the consideration of general market
    conditions, the duration and extent to which the fair value is below cost, and our ability and intent to hold the investment for
    a sufficient period of time to allow for recovery of value in the foreseeable future. The Company also considers specific adverse
    conditions related to the financial health of, and the business outlook for, the investee, which may include industry and sector
    performance, changes in technology, operational and financing cash flow factors, and changes in the investee&amp;#x2019;s credit rating.
    The Company records other-than-temporary impairments on marketable equity securities and marketable equity method investments in
    gains (losses) on equity investments.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse&quot;&gt;
  &lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 0.25in&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 0.25in&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;&amp;#x25cf;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Non-marketable equity investments based on the Company&amp;#x2019;s assessment
    of the severity and duration of the impairment, and qualitative and quantitative analysis of the operating performance of the investee;
    adverse changes in market conditions and the regulatory or economic environment; changes in operating structure or management of
    the investee; additional funding requirements; and the investee&amp;#x2019;s ability to remain in business. A series of operating losses
    of an investee or other factors may indicate that a decrease in value of the investment has occurred that is other than temporary
    and that shall be recognized even though the decrease in value is in excess of what would otherwise be recognized by application
    of the equity method. A loss in value of an investment that is other than a temporary decline shall be recognized. Evidence of a
    loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the
    investment or inability of the investee to sustain an earnings capacity that would justify the carrying amount of the investment.
    The Company records other-than-temporary impairments for non-marketable cost method investments and equity method investments in
    gains (losses) on equity investments. Other-than-temporary impairments of equity investments were $0 and $0 for the three months
    ended March 31, 2021 and 2020, respectively.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;Goodwill&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The Company evaluates goodwill for impairment
annually or more frequently when an event occurs or circumstances change that indicate the carrying value may not be recoverable. In
testing goodwill for impairment, the Company may elect to utilize a qualitative assessment to evaluate whether it is more likely than
not that the fair value of a reporting unit is less than its carrying amount. If the qualitative assessment indicates that goodwill impairment
is more likely than not, the Company performs a two-step impairment test. The Company tests goodwill for impairment under the two-step
impairment test by first comparing the book value of net assets to the fair value of the reporting units. If the fair value is determined
to be less than the book value or qualitative factors indicate that it is more likely than not that goodwill is impaired, a second step
is performed to compute the amount of impairment as the difference between the estimated fair value of goodwill and the carrying value.
The Company estimates the fair value of the reporting units using discounted cash flows. Forecasts of future cash flows are based on
our best estimate of future net sales and operating expenses, based primarily on expected category expansion, pricing, market segment
share, and general economic conditions.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The Company completed the required testing of
goodwill for impairment as of March 31, 2021, and determined that goodwill was impaired because of the current financial condition of
the Company and the Company&amp;#x2019;s inability to generate future operating income without substantial sales volume increases, which are
highly uncertain. Furthermore, the Company anticipates future cash flows indicate that the recoverability of goodwill is not reasonably
assured.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;Research and Development Expenses&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The Company accounts for the cost of using licensing
rights in research and development cost according to ASC Topic 730-10-25-1. This guidance provides that absent alternative future uses
the acquisition of product rights to be used in research and development activities must be charged to research and development expenses
when incurred.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;For CDMO business unit, the Company accounts
for R&amp;amp;D costs in accordance with Accounting Standards Codification (&amp;#x201c;ASC&amp;#x201d;) 730, Research and Development (&amp;#x201c;ASC
730&amp;#x201d;). Research and development expenses are charged to expense as incurred unless there is an alternative future use in other
research and development projects or otherwise. Research and development expenses are comprised of costs incurred in performing research
and development activities, including personnel-related costs, facilities-related overhead, and outside contracted services including
clinical trial costs, manufacturing and process development costs for both clinical and preclinical materials, research costs, and other
consulting services. Non-refundable advance payment for goods and services that will be used in future research and development activities
are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. In instances
where the Company enters into agreements with third parties to provide research and development services, costs are expensed as services
are performed.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;Post-retirement and post-employment benefits&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The Company&amp;#x2019;s subsidiaries in Taiwan adopted
the government mandated defined contribution plan pursuant to the Labor Pension Act (the &amp;#x201c;Act&amp;#x201d;) in Taiwan. Such labor regulations
require that the rate of contribution made by an employer to the Labor Pension Fund per month shall not be less than 6% of the worker&amp;#x2019;s
monthly salaries. Pursuant to the Act, the Company makes monthly contribution equal to 6% of employees&amp;#x2019; salaries to the employees&amp;#x2019;
pension fund. The Company has no legal obligation for the benefits beyond the contributions made. The total amounts for such employee
benefits, which were expensed as incurred, were $2,503 and $3,598 for the three months ended March 31, 2021 and 2020, respectively. Other
than the above, the Company does not provide any other post-retirement or post-employment benefits.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;Stock-based Compensation&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The Company measures expense associated with
all employee stock-based compensation awards using a fair value method and recognizes such expense in the consolidated financial statements
on a straight-line basis over the requisite service period in accordance with FASB ASC Topic 718 &amp;#x201c;Compensation-Stock Compensation&amp;#x201d;.
Total employee stock-based compensation expenses were $0 and $0 for the three months ended March 31, 2021 and 2020, respectively.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The Company accounted for stock-based compensation
to non-employees in accordance with FASB ASC Topic 718 &amp;#x201c;Compensation-Stock Compensation&amp;#x201d; and FASB ASC Topic 505-50 &amp;#x201c;Equity-Based
Payments to Non-Employees&amp;#x201d; which requires that the cost of services received from non-employees is measured at fair value at the
earlier of the performance commitment date or the date service is completed and recognized over the period the service is provided. Total
non-employee stock-based compensation expenses were $225,740 and $525 for the three months ended March 31, 2021 and 2020, respectively.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;Beneficial Conversion Feature&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;From time to time, the Company may issue convertible
notes that may contain an imbedded beneficial conversion feature. A beneficial conversion feature exists on the date a convertible note
is issued when the fair value of the underlying common stock to which the note is convertible into is in excess of the remaining unallocated
proceeds of the note after first considering the allocation of a portion of the note proceeds to the fair value of the warrants, if related
warrants have been granted. The intrinsic value of the beneficial conversion feature is recorded as a debt discount with a corresponding
amount to additional paid in capital. The debt discount is amortized to interest expense over the life of the note using the effective
interest method.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;Income Taxes&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The Company accounts for income taxes using the
asset and liability approach which allows the recognition and measurement of deferred tax assets to be based upon the likelihood of realization
of tax benefits in future years. Under the asset and liability approach, deferred taxes are provided for the net tax effects of temporary
differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax
purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not these items will expire before the
Company is able to realize their benefits, or future deductibility is uncertain.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;Under ASC 740, a tax position is recognized as
a benefit only if it is&amp;#xa0;&amp;#x201c;more likely than not&amp;#x201d;&amp;#xa0;that the tax position would be sustained in a tax examination, with
a tax examination being presumed to occur. The evaluation of a tax position is a two-step process. The first step is to determine whether
it is more-likely-than-not that a tax position will be sustained upon examination, including the resolution of any related appeals or
litigations based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not
threshold to determine the amount of benefits recognized in the financial statements. A tax position is measured at the largest amount
of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. Tax positions that previously failed to
meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which the threshold is met.
Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent
financial reporting period in which the threshold is no longer satisfied. Penalties and interest incurred related to underpayment of income
tax are classified as income tax expense in the year incurred. No significant penalty or interest relating to income taxes has been incurred
for the three months ended March 31, 2021 and 2020. GAAP also provides guidance on de-recognition, classification, interest and penalties,
accounting in interim periods, disclosures and transition.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;On December 22, 2017, the SEC issued Staff Accounting
Bulletin (&amp;#x201c;SAB 118&amp;#x201d;), which provides guidance on accounting for tax effects of the Tax Act. SAB 118 provides a measurement
period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740.
In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the Act for which the accounting under
ASC 740 is complete. To the extent that a company&amp;#x2019;s accounting for certain income tax effects of the Tax Act is incomplete but
it is able to determine a reasonable estimate, it must record a provisional estimate to be included in the financial statements. If a
company cannot determine a provisional estimate to be included in the financial statements, it should continue to apply ASC 740 on the
basis of the provision of the tax laws that were in effect immediately before the enactment of the Tax Act. While the Company is able
to make reasonable estimates of the impact of the reduction in corporate rate and the deemed repatriation transition tax, the final impact
of the Tax Act may differ from these estimates, due to, among other things, changes in our interpretations and assumptions, additional
guidance that may be issued by the I.R.S., and actions the Company may take. The Company is continuing to gather additional information
to determine the final impact.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;Valuation of Deferred Tax Assets&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;A valuation allowance is recorded to reduce the
Company&amp;#x2019;s deferred tax assets to the amount that is more likely than not to be realized. In assessing the need for the valuation
allowance, management considers, among other things, projections of future taxable income and ongoing prudent and feasible tax planning
strategies. If the Company determines that sufficient negative evidence exists, then it will consider recording a valuation allowance
against a portion or all of the deferred tax assets in that jurisdiction. If, after recording a valuation allowance, the Company&amp;#x2019;s
projections of future taxable income and other positive evidence considered in evaluating the need for a valuation allowance prove, with
the benefit of hindsight, to be inaccurate, it could prove to be more difficult to support the realization of its deferred tax assets.
As a result, an additional valuation allowance could be required, which would have an adverse impact on its effective income tax rate
and results. Conversely, if, after recording a valuation allowance, the Company determines that sufficient positive evidence exists in
the jurisdiction in which the valuation allowance was recorded, it may reverse a portion or all of the valuation allowance in that jurisdiction.
In such situations, the adjustment made to the deferred tax asset would have a favorable impact on its effective income tax rate and
results in the period such determination was made.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;Loss Per Share of Common Stock&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The Company calculates net loss per share in
accordance with ASC Topic 260, &amp;#x201c;Earnings per Share&amp;#x201d;. Basic loss per share is computed by dividing the net loss by the weighted
average number of common shares outstanding during the period. Diluted loss per share is computed similar to basic loss per share except
that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential
common stock equivalents had been issued and if the additional common shares were dilutive. Diluted earnings per share excludes all dilutive
potential shares if their effect is anti-dilutive.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;Commitments and Contingencies&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The Company has adopted ASC Topic 450 &amp;#x201c;Contingencies&amp;#x201d;
subtopic 20, in determining its accruals and disclosures with respect to loss contingencies. Accordingly, estimated losses from loss
contingencies are accrued by a charge to income when information available before financial statements are issued or are available to
be issued indicates that it is probable that an assets had been impaired or a liability had been incurred at the date of the financial
statements and the amount of the loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred.
If a loss contingency is not probable or reasonably estimable, disclosure of the loss contingency is made in the financial statements
when it is at least reasonably possible that a material loss could be incurred.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;Foreign-currency Transactions&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;For the Company&amp;#x2019;s subsidiaries in Taiwan,
the foreign-currency transactions are recorded in New Taiwan dollars (&amp;#x201c;NTD&amp;#x201d;) at the rates of exchange in effect when the
transactions occur. Gains or losses resulting from the application of different foreign exchange rates when cash in foreign currency
is converted into New Taiwan dollars, or when foreign-currency receivables or payables are settled, are credited or charged to income
in the year of conversion or settlement. On the balance sheet dates, the balances of foreign-currency assets and liabilities are restated
at the prevailing exchange rates and the resulting differences are charged to current income except for those foreign currencies denominated
investments in shares of stock where such differences are accounted for as translation adjustments under the Statements of Stockholders&amp;#x2019;
Equity (Deficit).&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;Translation Adjustment&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The accounts of the Company&amp;#x2019;s subsidiaries
in Taiwan were maintained, and their financial statements were expressed, in New Taiwan Dollar (&amp;#x201c;NT$&amp;#x201d;). Such financial statements
were translated into U.S. Dollars (&amp;#x201c;$&amp;#x201d; or &amp;#x201c;USD&amp;#x201d;) in accordance ASC 830, &amp;#x201c;Foreign Currency Matters&amp;#x201d;,
with the NT$ as the functional currency. According to the Statement, all assets and liabilities are translated at the current exchange
rate, stockholder&amp;#x2019;s deficit are translated at the historical rates and income statement items are translated at an average exchange
rate for the period. The resulting translation adjustments are reported under other comprehensive income (loss) as a component of stockholders&amp;#x2019;
equity (deficit).&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;Recent Accounting Pronouncements&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;In December 2019, the FASB issued ASU 2019-12,&amp;#xa0;&lt;i&gt;Income
Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/i&gt;, as part of its overall simplification initiative to reduce costs
and complexity of applying accounting standards while maintaining or improving the usefulness of the information provided to users of
financial statements. The FASB&amp;#x2019;s amendments primarily impact ASC 740,&amp;#xa0;&lt;i&gt;Income Taxes&lt;/i&gt;, and may impact both interim and
annual reporting periods. ASU 2019-12 will be effective for fiscal years beginning after December 15, 2020, and interim periods within
those fiscal years and early adoption is permitted. The Company is currently evaluating the impact of adopting ASU 2019-12.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; &quot;&gt;In August 2020, the
FASB issued ASU 2020-06,&amp;#xa0;&lt;i&gt;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging- Contracts in Entity&amp;#x2019;s
Own Equity (Subtopic 815-40)&lt;/i&gt;, to reduce the complexity associated with applying U.S. GAAP principles for certain financial instruments
with characteristics of liabilities and equity. The amendments in this ASU reduce the number of accounting models for convertible instruments
and expand the existing disclosure requirements over earnings per share as it relates to convertible instruments. This ASU will be effective
for the fiscal year beginning January 1, 2022 and interim periods therein. Early adoption is permitted, but no earlier than fiscal years
beginning after December 15, 2020. The amendments may be adopted through either a modified retrospective method, or a fully retrospective
method. The Company is currently evaluating the impact of adopting ASU 2020-06.&lt;/p&gt;&lt;br/&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;Basis of Presentation&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The accompanying consolidated financial statements
have been prepared in accordance with the generally accepted accounting principles in the United States of America (the &amp;#x201c;U.S. GAAP&amp;#x201d;).
All significant intercompany transactions and account balances have been eliminated.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;This basis of accounting involves the application
of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred.
The Company&amp;#x2019;s financial statements are expressed in U.S. dollars.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:FiscalPeriod contextRef="c0_From1Jan2021To31Mar2021">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;Fiscal Year&lt;/font&gt;&amp;#xa0;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The Company changed its fiscal year from the
period beginning on October 1st and ending on September 30th to the period beginning on January 1st and ending on December 31st, beginning
January 1, 2018. All references herein to a fiscal year prior to December 31, 2017 refer to the twelve months ended September 30th of
such year.&lt;/p&gt;</us-gaap:FiscalPeriod>
  <us-gaap:UseOfEstimates contextRef="c0_From1Jan2021To31Mar2021">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;Use of Estimates&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The preparation of financial statements in conformity
with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated
financial statements and the amount of revenues and expenses during the reporting periods. Actual results could differ materially from
those results.&lt;/p&gt;</us-gaap:UseOfEstimates>
  <us-gaap:InventoryPolicyTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;Inventory&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;Inventory consists of raw materials, work-in-process,
finished goods, and merchandise. Inventories are stated at the lower of cost or market and valued on a moving weighted average cost basis.
Market is determined based on net realizable value. The Company periodically reviews the age and turnover of its inventory to determine
whether any inventory has become obsolete or has declined in value, and incurs a charge to operations for known and anticipated inventory
obsolescence.&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
  <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="c0_From1Jan2021To31Mar2021">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;Reclassifications&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;Certain classifications have been made to the
prior year financial statements to conform to the current year presentation. The reclassification had no impact on previously reported
net loss or accumulated deficit.&lt;/p&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
  <abvcd:ForwardStockSplitsPolicyTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;Forward Stock Split&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;On March 21, 2016, the Board of Directors of
the Company approved an amendment to Articles of Incorporation to effect a forward split at a ratio of 1 to 3.141 and increase the number
of our authorized shares of Common Stock, par value $0.001 per share, to 360,000,000, which was effective on April 8, 2016.&lt;/p&gt;</abvcd:ForwardStockSplitsPolicyTextBlock>
  <abvcd:StockReverseSplitPolicyTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;Stock Reverse Split&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;On March 12, 2019, the Board of Directors of
the Company by unanimous written consent in lieu of a meeting approved to i) effect a stock reverse split at the ratio of 1-for-18 (the
&amp;#x201c;Reverse Split&amp;#x201d;) of both the authorized common stock of the Company (the &amp;#x201c;Common Stock&amp;#x201d;) and the issued and outstanding
Common Stock and ii) to amend the articles of incorporation of the Company to reflect the Reverse Split. The Board approved and authorized
the Reverse Split without obtaining approval of the Company&amp;#x2019;s shareholders pursuant to Section 78.207 of Nevada Revised Statutes.
On May 3, 2019, the Company filed a certificate of amendment to the Company&amp;#x2019;s articles of incorporation (the &amp;#x201c;Amendment&amp;#x201d;)
to effect the Reverse Split with the Secretary of State of Nevada. The Financial Industry Regulatory Authority (&amp;#x201c;FINRA&amp;#x201d;)
informed the Company that the Reverse Split was effective on May 8, 2019. All shares and related financial information in this Form 10-K
reflect this 1-for-18 reverse stock split.&lt;/p&gt;</abvcd:StockReverseSplitPolicyTextBlock>
  <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;Fair Value Measurements&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;FASB ASC 820, &amp;#x201c;Fair Value Measurements&amp;#x201d;
defines fair value for certain financial and nonfinancial assets and liabilities that are recorded at fair value, establishes a framework
for measuring fair value and expands disclosures about fair value measurements. It requires that an entity measure its financial instruments
to base fair value on exit price, maximize the use of observable units and minimize the use of unobservable inputs to determine the exit
price. It establishes a hierarchy which prioritizes the inputs to valuation techniques used to measure fair value. This hierarchy increases
the consistency and comparability of fair value measurements and related disclosures by maximizing the use of observable inputs and minimizing
the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that reflect
the assumptions market participants would use in pricing the assets or liabilities based on market data obtained from sources independent
of the Company. Unobservable inputs are inputs that reflect the Company&amp;#x2019;s own assumptions about the assumptions market participants
would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy prioritizes
the inputs into three broad levels based on the reliability of the inputs as follows:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse&quot;&gt;
  &lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 0.25in; text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 0.25in; text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;&amp;#x25cf;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Level 1 - Inputs are quoted prices in active markets for identical
    assets or liabilities that the Company has the ability to access at the measurement date. Valuation of these instruments does not
    require a high degree of judgment as the valuations are based on quoted prices in active markets that are readily and regularly available.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;&amp;#x25cf;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Level 2 - Inputs other than quoted prices in active markets that are
    either directly or indirectly observable as of the measurement date, such as quoted prices for similar assets or liabilities; quoted
    prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially
    the full term of the assets or liabilities.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;&amp;#x25cf;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Level 3 - Valuations based on inputs that are unobservable and not
    corroborated by market data. The fair value for such assets and liabilities is generally determined using pricing models, discounted
    cash flow methodologies, or similar techniques that incorporate the assumptions a market participant would use in pricing the asset
    or liability.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The carrying values of certain assets and liabilities
of the Company, such as cash and cash equivalents, restricted cash, accounts receivable, due from related parties, inventory, prepaid
expenses and other current assets, accounts payable, accrued liabilities, and due to related parties approximate fair value due to their
relatively short maturities. The carrying value of the Company&amp;#x2019;s short-term bank loan, convertible notes payable, and accrued interest
approximates their fair value as the terms of the borrowing are consistent with current market rates and the duration to maturity is
short. The carrying value of the Company&amp;#x2019;s long-term bank loan approximates fair value because the interest rates approximate market
rates that the Company could obtain for debt with similar terms and maturities.&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;Cash and Cash Equivalents&lt;/font&gt;&amp;#xa0;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The Company considers highly liquid investments
with maturities of three months or less, when purchased, to be cash equivalents. As of March 31, 2021 and December 31, 2020, the Company&amp;#x2019;s
cash and cash equivalents amounted $2,615,073 and $4,273,208, respectively. Some&amp;#xa0;of the Company&amp;#x2019;s cash deposits are held in
financial institutions located in Taiwan where there is currently regulation mandated on obligatory insurance of bank accounts. The Company
believes this financial institution is of high credit quality.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <us-gaap:Cash unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">2615073</us-gaap:Cash>
  <us-gaap:Cash unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">4273208</us-gaap:Cash>
  <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="c0_From1Jan2021To31Mar2021">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;Restricted Cash Equivalents&lt;/font&gt;&amp;#xa0;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;Restricted cash equivalents primarily consist
of cash held in a reserve bank account in Taiwan. As of March 31, 2021 and December 31, 2020, the Company&amp;#x2019;s restricted cash equivalents
amounted $718,163 and $728,163, respectively.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
  <us-gaap:RestrictedCashAndCashEquivalents unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">718163</us-gaap:RestrictedCashAndCashEquivalents>
  <us-gaap:RestrictedCashAndCashEquivalents unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">728163</us-gaap:RestrictedCashAndCashEquivalents>
  <us-gaap:ConcentrationRiskCreditRisk contextRef="c0_From1Jan2021To31Mar2021">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;Concentration of Credit Risk&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The Company&amp;#x2019;s financial instruments that
are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash and temporary
cash investments in high quality credit institutions, but these investments may be in excess of Taiwan Central Deposit Insurance Corporation
and the U.S. Federal Deposit Insurance Corporation&amp;#x2019;s insurance limits. The Company does not enter into financial instruments for
hedging, trading or speculative purposes.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
  <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;Revenue Recognition&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;During the fiscal year 2018, the Company adopted
Accounting Standards Codification (&amp;#x201c;ASC&amp;#x201d;), Topic 606 (ASC 606), Revenue from Contracts with Customers, using the modified
retrospective method to all contracts that were not completed as of January 1, 2018, and applying the new revenue standard as an adjustment
to the opening balance of accumulated deficit at the beginning of 2018 for the cumulative effect. The results for the Company&amp;#x2019;s
reporting periods beginning on and after January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and
continue to be reported under the accounting standards in effect for the prior period. Based on the Company&amp;#x2019;s review of existing
collaborative agreements as of January 1, 2018, the Company concluded that the adoption of the new guidance did not have a significant
change on the Company&amp;#x2019;s revenue during all periods presented.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;Pursuant to ASC 606, the Company recognizes revenue
when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the Company expects
to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines is
within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify
the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance
obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only
applies the five-step model to contracts when it is probable that the Company will collect the consideration the Company is entitled
to in exchange for the goods or services the Company transfers to the customers. At inception of the contract, once the contract is determined
to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are
performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount
of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The following are examples of when the Company
recognizes revenue based on the types of payments the Company receives.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;Collaborative Revenues &amp;#x2014; &lt;/b&gt;The Company
recognizes collaborative revenues generated through collaborative research, development and/or commercialization agreements. The terms
of these agreements typically include payment to the Company related to one or more of the following: non-refundable upfront license
fees, development and commercial milestones, partial or complete reimbursement of research and development costs, and royalties on net
sales of licensed products. Each type of payments results in collaborative revenues except for revenues from royalties on net sales of
licensed products, which are classified as royalty revenues. To date, the Company has not received any royalty revenues. Revenue is recognized
upon satisfaction of a performance obligation by transferring control of a good or service to the collaboration partners.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;As part of the accounting for these arrangements,
the Company applies judgment to determine whether the performance obligations are distinct, and develop assumptions in determining the
stand-alone selling price for each distinct performance obligation identified in the collaboration agreements. To determine the stand-alone
selling price, the Company relies on assumptions which may include forecasted revenues, development timelines, reimbursement rates for
R&amp;amp;D personnel costs, discount rates and probabilities of technical and regulatory success.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The Company had multiple deliverables under the
collaborative agreements, including deliverables relating to grants of technology licenses, regulatory and clinical development, and
marketing activities. Estimation of the performance periods of the Company&amp;#x2019;s deliverables requires the use of management&amp;#x2019;s
judgment. Significant factors considered in management&amp;#x2019;s evaluation of the estimated performance periods include, but are not limited
to, the Company&amp;#x2019;s experience in conducting clinical development, regulatory and manufacturing activities. The Company reviews the
estimated duration of its performance periods under its collaborative agreements on an annually basis, and makes any appropriate adjustments
on a prospective basis. Future changes in estimates of the performance period under its collaborative agreements could impact the timing
of future revenue recognition.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;(i) Non-refundable upfront payments&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;If a license to the Company&amp;#x2019;s intellectual
property is determined to be distinct from the other performance obligations identified in an arrangement, the Company recognizes revenue
from the related non-refundable upfront payments based on the relative standalone selling price prescribed to the license compared to
the total selling price of the arrangement. The revenue is recognized when the license is transferred to the collaboration partners and
the collaboration partners are able to use and benefit from the license. To date, the receipt of non-refundable upfront fees was solely
for the compensation of past research efforts and contributions made by the Company before the collaborative agreements entered into
and it does not relate to any future obligations and commitments made between the Company and the collaboration partners in the collaborative
agreements.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;(ii) Milestone payments&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The Company is eligible to receive milestone
payments under the collaborative agreement with collaboration partners based on achievement of specified development, regulatory and
commercial events. Management evaluated the nature of the events triggering these contingent payments, and concluded that these events
fall into two categories: (a) events which involve the performance of the Company&amp;#x2019;s obligations under the collaborative agreement
with collaboration partners, and (b) events which do not involve the performance of the Company&amp;#x2019;s obligations under the collaborative
agreement with collaboration partners.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The former category of milestone payments consists
of those triggered by development and regulatory activities in the territories specified in the collaborative agreements. Management
concluded that each of these payments constitute substantive milestone payments. This conclusion was based primarily on the facts that
(i) each triggering event represents a specific outcome that can be achieved only through successful performance by the Company of one
or more of its deliverables, (ii) achievement of each triggering event was subject to inherent risk and uncertainty and would result
in additional payments becoming due to the Company, (iii) each of the milestone payments is non-refundable, (iv) substantial effort is
required to complete each milestone, (v) the amount of each milestone payment is reasonable in relation to the value created in achieving
the milestone, (vi) a substantial amount of time is expected to pass between the upfront payment and the potential milestone payments,
and (vii) the milestone payments relate solely to past performance. Based on the foregoing, the Company recognizes any revenue from these
milestone payments in the period in which the underlying triggering event occurs.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;(iii) Multiple Element Arrangements&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The Company evaluates multiple element arrangements
to determine (1) the deliverables included in the arrangement and (2) whether the individual deliverables represent separate units of
accounting or whether they must be accounted for as a combined unit of accounting. This evaluation involves subjective determinations
and requires management to make judgments about the individual deliverables and whether such deliverables are separate from other aspects
of the contractual relationship. Deliverables are considered separate units of accounting provided that: (i) the delivered item(s) has
value to the customer on a standalone basis and (ii) if the arrangement includes a general right of return relative to the delivered
item(s), delivery or performance of the undelivered item(s) is considered probable and substantially within its control. In assessing
whether an item under a collaboration has standalone value, the Company considers factors such as the research, manufacturing, and commercialization
capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. The Company also
considers whether its collaboration partners can use the other deliverable(s) for their intended purpose without the receipt of the remaining
element(s), whether the value of the deliverable is dependent on the undelivered item(s), and whether there are other vendors that can
provide the undelivered element(s).&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The Company recognizes arrangement consideration
allocated to each unit of accounting when all of the revenue recognition criteria in ASC 606 are satisfied for that particular unit of
accounting. In the event that a deliverable does not represent a separate unit of accounting, the Company recognizes revenue from the
combined unit of accounting over the Company&amp;#x2019;s contractual or estimated performance period for the undelivered elements, which
is typically the term of the Company&amp;#x2019;s research and development obligations. If there is no discernible pattern of performance
or objectively measurable performance measures do not exist, then the Company recognizes revenue under the arrangement on a straight-line
basis over the period the Company is expected to complete its performance obligations. Conversely, if the pattern of performance in which
the service is provided to the customer can be determined and objectively measurable performance measures exist, then the Company recognizes
revenue under the arrangement using the proportional performance method. Revenue recognized is limited to the lesser of the cumulative
amount of payments received or the cumulative amount of revenue earned, as determined using the straight-line method or proportional
performance method, as applicable, as of the period ending date.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;At the inception of an arrangement that includes
milestone payments, the Company evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent
nature of the milestone. This evaluation includes an assessment of whether: (1) the consideration is commensurate with either the Company&amp;#x2019;s
performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting
from its performance to achieve the milestone, (2) the consideration relates solely to past performance and (3) the consideration is
reasonable relative to all of the deliverables and payment terms within the arrangement. The Company evaluates factors such as the scientific,
clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone and the level of effort and
investment required to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining
whether a milestone satisfies all of the criteria required to conclude that a milestone is substantive. Milestones that are not considered
substantive are recognized as earned if there are no remaining performance obligations or over the remaining period of performance, assuming
all other revenue recognition criteria are met.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;(iv) Royalties and Profit Sharing Payments&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;Under the collaborative agreement with the collaboration
partners, the Company is entitled to receive royalties on sales of products, which is at certain percentage of the net sales. The Company
recognizes revenue from these events based on the revenue recognition criteria set forth in ASC 606. Based on those criteria, the Company
considers these payments to be contingent revenues, and recognizes them as revenue in the period in which the applicable contingency
is resolved.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;Revenues Derived from Research and Development
Activities Services &amp;#x2014; Revenues related to research and development and regulatory activities are recognized when the related services
or activities are performed, in accordance with the contract terms. The Company typically has only one performance obligation at the
inception of a contract, which is to perform research and development services. The Company may also provide its customers with an option
to request that the Company provides additional goods or services in the future, such as active pharmaceutical ingredient, API, or IND/NDA/ANDA/510K
submissions. The Company evaluates whether these options are material rights at the inception of the contract. If the Company determines
an option is a material right, the Company will consider the option a separate performance obligation.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;If the Company is entitled to reimbursement from
its customers for specified research and development expenses, the Company accounts for the related services that it provides as separate
performance obligations if it determines that these services represent a material right. The Company also determines whether the reimbursement
of research and development expenses should be accounted for as revenues or an offset to research and development expenses in accordance
with provisions of gross or net revenue presentation. The Company recognizes the corresponding revenues or records the corresponding
offset to research and development expenses as it satisfies the related performance obligations.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The Company then determines the transaction price
by reviewing the amount of consideration the Company is eligible to earn under the contracts, including any variable consideration. Under
the outstanding contracts, consideration typically includes fixed consideration and variable consideration in the form of potential milestone
payments. At the start of an agreement, the Company&amp;#x2019;s transaction price usually consists of the payments made to or by the Company
based on the number of full-time equivalent researchers assigned to the project and the related research and development expenses incurred.
The Company does not typically include any payments that the Company may receive in the future in its initial transaction price because
the payments are not probable. The Company would reassess the total transaction price at each reporting period to determine if the Company
should include additional payments in the transaction price.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The Company receives payments from its customers
based on billing schedules established in each contract. Upfront payments and fees may be recorded as advance from customers upon receipt
or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under these
arrangements. Amounts are recorded as accounts receivable when the right of the Company to consideration is unconditional. The Company
does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period
between payment by the customers and the transfer of the promised goods or services to the customers will be one year or less.&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;Property and Equipment&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;Property and equipment is carried at cost net
of accumulated depreciation. Repairs and maintenance are expensed as incurred. Expenditures that improve the functionality of the related
asset or extend the useful life are capitalized. When property and equipment is retired or otherwise disposed of, the related gain or
loss is included in operating income. Leasehold improvements are depreciated on the straight-line method over the shorter of the remaining
lease term or estimated useful life of the asset. Depreciation is calculated on the straight-line method, including property and equipment
under capital leases, generally based on the following useful lives:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;width: 91%; text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: black 1.5pt solid; width: 8%; text-align: center&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;&lt;b&gt;Estimated&amp;#xa0;Life&lt;br/&gt;
    in Years&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: #CCEEFF&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Buildings and leasehold improvements&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;5 ~ 50&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Machinery and equipment&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;5 ~ 10&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: #CCEEFF&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Office equipment&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;3 ~ 6&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;Impairment of Long-Lived Assets&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The Company has adopted Accounting Standards
Codification subtopic 360-10, Property, Plant and Equipment (&amp;#x201c;ASC 360-10&amp;#x201d;). ASC 360-10 requires that long-lived assets and
certain identifiable intangibles held and used by the Company be reviewed for impairment whenever events or changes in circumstances
indicate that the carrying amount of an asset may not be recoverable. The Company evaluates its long-lived assets for impairment annually
or more often if events and circumstances warrant. Events relating to recoverability may include significant unfavorable changes in business
conditions, recurring losses, or a forecasted inability to achieve break-even operating results over an extended period. Should impairment
in value be indicated, the carrying value of intangible assets will be adjusted, based on estimates of future discounted cash flows resulting
from the use and ultimate disposition of the asset. ASC 360-10 also requires assets to be disposed of be reported at the lower of the
carrying amount or the fair value less costs to sell.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
  <abvcd:LongTermEquityInvestmentPolicy contextRef="c0_From1Jan2021To31Mar2021">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;Long-term Equity Investment&lt;/font&gt;&amp;#xa0;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The Company acquires the equity investments to
promote business and strategic objectives. The Company accounts for non-marketable equity and other equity investments for which the
Company does not have control over the investees as:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse&quot;&gt;
  &lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 0.25in&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 0.25in&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;&amp;#x25cf;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Equity method investments when the Company has the ability to exercise
    significant influence, but not control, over the investee. Its proportionate share of the income or loss is recognized monthly and
    is recorded in gains (losses) on equity investments.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse&quot;&gt;
  &lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 0.25in&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 0.25in&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;&amp;#x25cf;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Non-marketable cost method investments when the equity method does
    not apply.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;Significant judgment is required to identify
whether an impairment exists in the valuation of the Company&amp;#x2019;s non-marketable equity investments, and therefore the Company considers
this a critical accounting estimate. Its yearly analysis considers both qualitative and quantitative factors that may have a significant
impact on the investee&amp;#x2019;s fair value. Qualitative analysis of its investments involves understanding the financial performance and
near-term prospects of the investee, changes in general market conditions in the investee&amp;#x2019;s industry or geographic area, and the
management and governance structure of the investee. Quantitative assessments of the fair value of its investments are developed using
the market and income approaches. The market approach includes the use of comparable financial metrics of private and public companies
and recent financing rounds. The income approach includes the use of a discounted cash flow model, which requires significant estimates
regarding the investees&amp;#x2019; revenue, costs, and discount rates. The Company&amp;#x2019;s assessment of these factors in determining whether
an impairment exists could change in the future due to new developments or changes in applied assumptions.&lt;/p&gt;</abvcd:LongTermEquityInvestmentPolicy>
  <abvcd:OtherThanTemporaryImpairmentPolicyTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;Other-Than-Temporary Impairment&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The Company&amp;#x2019;s long-term equity investments
are subject to a periodic impairment review. Impairments affect earnings as follows:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse&quot;&gt;
  &lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 0.25in&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 0.25in&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;&amp;#x25cf;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Marketable equity securities include the consideration of general market
    conditions, the duration and extent to which the fair value is below cost, and our ability and intent to hold the investment for
    a sufficient period of time to allow for recovery of value in the foreseeable future. The Company also considers specific adverse
    conditions related to the financial health of, and the business outlook for, the investee, which may include industry and sector
    performance, changes in technology, operational and financing cash flow factors, and changes in the investee&amp;#x2019;s credit rating.
    The Company records other-than-temporary impairments on marketable equity securities and marketable equity method investments in
    gains (losses) on equity investments.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse&quot;&gt;
  &lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 0.25in&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 0.25in&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;&amp;#x25cf;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Non-marketable equity investments based on the Company&amp;#x2019;s assessment
    of the severity and duration of the impairment, and qualitative and quantitative analysis of the operating performance of the investee;
    adverse changes in market conditions and the regulatory or economic environment; changes in operating structure or management of
    the investee; additional funding requirements; and the investee&amp;#x2019;s ability to remain in business. A series of operating losses
    of an investee or other factors may indicate that a decrease in value of the investment has occurred that is other than temporary
    and that shall be recognized even though the decrease in value is in excess of what would otherwise be recognized by application
    of the equity method. A loss in value of an investment that is other than a temporary decline shall be recognized. Evidence of a
    loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the
    investment or inability of the investee to sustain an earnings capacity that would justify the carrying amount of the investment.
    The Company records other-than-temporary impairments for non-marketable cost method investments and equity method investments in
    gains (losses) on equity investments. Other-than-temporary impairments of equity investments were $0 and $0 for the three months
    ended March 31, 2021 and 2020, respectively.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</abvcd:OtherThanTemporaryImpairmentPolicyTextBlock>
  <abvcd:MarketableSecuritiesRealizedGainLossOtherThanTemporaryImpairmentsAmounts unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">0</abvcd:MarketableSecuritiesRealizedGainLossOtherThanTemporaryImpairmentsAmounts>
  <abvcd:MarketableSecuritiesRealizedGainLossOtherThanTemporaryImpairmentsAmounts unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">0</abvcd:MarketableSecuritiesRealizedGainLossOtherThanTemporaryImpairmentsAmounts>
  <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;Goodwill&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The Company evaluates goodwill for impairment
annually or more frequently when an event occurs or circumstances change that indicate the carrying value may not be recoverable. In
testing goodwill for impairment, the Company may elect to utilize a qualitative assessment to evaluate whether it is more likely than
not that the fair value of a reporting unit is less than its carrying amount. If the qualitative assessment indicates that goodwill impairment
is more likely than not, the Company performs a two-step impairment test. The Company tests goodwill for impairment under the two-step
impairment test by first comparing the book value of net assets to the fair value of the reporting units. If the fair value is determined
to be less than the book value or qualitative factors indicate that it is more likely than not that goodwill is impaired, a second step
is performed to compute the amount of impairment as the difference between the estimated fair value of goodwill and the carrying value.
The Company estimates the fair value of the reporting units using discounted cash flows. Forecasts of future cash flows are based on
our best estimate of future net sales and operating expenses, based primarily on expected category expansion, pricing, market segment
share, and general economic conditions.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The Company completed the required testing of
goodwill for impairment as of March 31, 2021, and determined that goodwill was impaired because of the current financial condition of
the Company and the Company&amp;#x2019;s inability to generate future operating income without substantial sales volume increases, which are
highly uncertain. Furthermore, the Company anticipates future cash flows indicate that the recoverability of goodwill is not reasonably
assured.&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c0_From1Jan2021To31Mar2021">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;Research and Development Expenses&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The Company accounts for the cost of using licensing
rights in research and development cost according to ASC Topic 730-10-25-1. This guidance provides that absent alternative future uses
the acquisition of product rights to be used in research and development activities must be charged to research and development expenses
when incurred.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;For CDMO business unit, the Company accounts
for R&amp;amp;D costs in accordance with Accounting Standards Codification (&amp;#x201c;ASC&amp;#x201d;) 730, Research and Development (&amp;#x201c;ASC
730&amp;#x201d;). Research and development expenses are charged to expense as incurred unless there is an alternative future use in other
research and development projects or otherwise. Research and development expenses are comprised of costs incurred in performing research
and development activities, including personnel-related costs, facilities-related overhead, and outside contracted services including
clinical trial costs, manufacturing and process development costs for both clinical and preclinical materials, research costs, and other
consulting services. Non-refundable advance payment for goods and services that will be used in future research and development activities
are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. In instances
where the Company enters into agreements with third parties to provide research and development services, costs are expensed as services
are performed.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy contextRef="c0_From1Jan2021To31Mar2021">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;Post-retirement and post-employment benefits&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The Company&amp;#x2019;s subsidiaries in Taiwan adopted
the government mandated defined contribution plan pursuant to the Labor Pension Act (the &amp;#x201c;Act&amp;#x201d;) in Taiwan. Such labor regulations
require that the rate of contribution made by an employer to the Labor Pension Fund per month shall not be less than 6% of the worker&amp;#x2019;s
monthly salaries. Pursuant to the Act, the Company makes monthly contribution equal to 6% of employees&amp;#x2019; salaries to the employees&amp;#x2019;
pension fund. The Company has no legal obligation for the benefits beyond the contributions made. The total amounts for such employee
benefits, which were expensed as incurred, were $2,503 and $3,598 for the three months ended March 31, 2021 and 2020, respectively. Other
than the above, the Company does not provide any other post-retirement or post-employment benefits.&lt;/p&gt;</us-gaap:PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy>
  <abvcd:PercentageOfMonthlyContribution unitRef="pure" contextRef="c2_AsOf31Mar2021" decimals="2">0.06</abvcd:PercentageOfMonthlyContribution>
  <us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">2503</us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash>
  <us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">3598</us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash>
  <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;Stock-based Compensation&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The Company measures expense associated with
all employee stock-based compensation awards using a fair value method and recognizes such expense in the consolidated financial statements
on a straight-line basis over the requisite service period in accordance with FASB ASC Topic 718 &amp;#x201c;Compensation-Stock Compensation&amp;#x201d;.
Total employee stock-based compensation expenses were $0 and $0 for the three months ended March 31, 2021 and 2020, respectively.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The Company accounted for stock-based compensation
to non-employees in accordance with FASB ASC Topic 718 &amp;#x201c;Compensation-Stock Compensation&amp;#x201d; and FASB ASC Topic 505-50 &amp;#x201c;Equity-Based
Payments to Non-Employees&amp;#x201d; which requires that the cost of services received from non-employees is measured at fair value at the
earlier of the performance commitment date or the date service is completed and recognized over the period the service is provided. Total
non-employee stock-based compensation expenses were $225,740 and $525 for the three months ended March 31, 2021 and 2020, respectively.&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
  <us-gaap:EmployeeBenefitsAndShareBasedCompensation unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">0</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
  <us-gaap:EmployeeBenefitsAndShareBasedCompensation unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">0</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
  <abvcd:StockBasedCompensationForNonemployees unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">225740</abvcd:StockBasedCompensationForNonemployees>
  <abvcd:StockBasedCompensationForNonemployees unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">525</abvcd:StockBasedCompensationForNonemployees>
  <abvcd:BeneficialConversionFeature contextRef="c0_From1Jan2021To31Mar2021">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;Beneficial Conversion Feature&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;From time to time, the Company may issue convertible
notes that may contain an imbedded beneficial conversion feature. A beneficial conversion feature exists on the date a convertible note
is issued when the fair value of the underlying common stock to which the note is convertible into is in excess of the remaining unallocated
proceeds of the note after first considering the allocation of a portion of the note proceeds to the fair value of the warrants, if related
warrants have been granted. The intrinsic value of the beneficial conversion feature is recorded as a debt discount with a corresponding
amount to additional paid in capital. The debt discount is amortized to interest expense over the life of the note using the effective
interest method.&lt;/p&gt;</abvcd:BeneficialConversionFeature>
  <us-gaap:IncomeTaxPolicyTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;Income Taxes&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The Company accounts for income taxes using the
asset and liability approach which allows the recognition and measurement of deferred tax assets to be based upon the likelihood of realization
of tax benefits in future years. Under the asset and liability approach, deferred taxes are provided for the net tax effects of temporary
differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax
purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not these items will expire before the
Company is able to realize their benefits, or future deductibility is uncertain.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;Under ASC 740, a tax position is recognized as
a benefit only if it is&amp;#xa0;&amp;#x201c;more likely than not&amp;#x201d;&amp;#xa0;that the tax position would be sustained in a tax examination, with
a tax examination being presumed to occur. The evaluation of a tax position is a two-step process. The first step is to determine whether
it is more-likely-than-not that a tax position will be sustained upon examination, including the resolution of any related appeals or
litigations based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not
threshold to determine the amount of benefits recognized in the financial statements. A tax position is measured at the largest amount
of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. Tax positions that previously failed to
meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which the threshold is met.
Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent
financial reporting period in which the threshold is no longer satisfied. Penalties and interest incurred related to underpayment of income
tax are classified as income tax expense in the year incurred. No significant penalty or interest relating to income taxes has been incurred
for the three months ended March 31, 2021 and 2020. GAAP also provides guidance on de-recognition, classification, interest and penalties,
accounting in interim periods, disclosures and transition.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;On December 22, 2017, the SEC issued Staff Accounting
Bulletin (&amp;#x201c;SAB 118&amp;#x201d;), which provides guidance on accounting for tax effects of the Tax Act. SAB 118 provides a measurement
period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740.
In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the Act for which the accounting under
ASC 740 is complete. To the extent that a company&amp;#x2019;s accounting for certain income tax effects of the Tax Act is incomplete but
it is able to determine a reasonable estimate, it must record a provisional estimate to be included in the financial statements. If a
company cannot determine a provisional estimate to be included in the financial statements, it should continue to apply ASC 740 on the
basis of the provision of the tax laws that were in effect immediately before the enactment of the Tax Act. While the Company is able
to make reasonable estimates of the impact of the reduction in corporate rate and the deemed repatriation transition tax, the final impact
of the Tax Act may differ from these estimates, due to, among other things, changes in our interpretations and assumptions, additional
guidance that may be issued by the I.R.S., and actions the Company may take. The Company is continuing to gather additional information
to determine the final impact.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <abvcd:ValuationOfDeferredTaxAssetsPolicyTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;Valuation of Deferred Tax Assets&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;A valuation allowance is recorded to reduce the
Company&amp;#x2019;s deferred tax assets to the amount that is more likely than not to be realized. In assessing the need for the valuation
allowance, management considers, among other things, projections of future taxable income and ongoing prudent and feasible tax planning
strategies. If the Company determines that sufficient negative evidence exists, then it will consider recording a valuation allowance
against a portion or all of the deferred tax assets in that jurisdiction. If, after recording a valuation allowance, the Company&amp;#x2019;s
projections of future taxable income and other positive evidence considered in evaluating the need for a valuation allowance prove, with
the benefit of hindsight, to be inaccurate, it could prove to be more difficult to support the realization of its deferred tax assets.
As a result, an additional valuation allowance could be required, which would have an adverse impact on its effective income tax rate
and results. Conversely, if, after recording a valuation allowance, the Company determines that sufficient positive evidence exists in
the jurisdiction in which the valuation allowance was recorded, it may reverse a portion or all of the valuation allowance in that jurisdiction.
In such situations, the adjustment made to the deferred tax asset would have a favorable impact on its effective income tax rate and
results in the period such determination was made.&lt;/p&gt;</abvcd:ValuationOfDeferredTaxAssetsPolicyTextBlock>
  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;Loss Per Share of Common Stock&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The Company calculates net loss per share in
accordance with ASC Topic 260, &amp;#x201c;Earnings per Share&amp;#x201d;. Basic loss per share is computed by dividing the net loss by the weighted
average number of common shares outstanding during the period. Diluted loss per share is computed similar to basic loss per share except
that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential
common stock equivalents had been issued and if the additional common shares were dilutive. Diluted earnings per share excludes all dilutive
potential shares if their effect is anti-dilutive.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:CommitmentsAndContingenciesPolicyTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;Commitments and Contingencies&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The Company has adopted ASC Topic 450 &amp;#x201c;Contingencies&amp;#x201d;
subtopic 20, in determining its accruals and disclosures with respect to loss contingencies. Accordingly, estimated losses from loss
contingencies are accrued by a charge to income when information available before financial statements are issued or are available to
be issued indicates that it is probable that an assets had been impaired or a liability had been incurred at the date of the financial
statements and the amount of the loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred.
If a loss contingency is not probable or reasonably estimable, disclosure of the loss contingency is made in the financial statements
when it is at least reasonably possible that a material loss could be incurred.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
  <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;Foreign-currency Transactions&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;For the Company&amp;#x2019;s subsidiaries in Taiwan,
the foreign-currency transactions are recorded in New Taiwan dollars (&amp;#x201c;NTD&amp;#x201d;) at the rates of exchange in effect when the
transactions occur. Gains or losses resulting from the application of different foreign exchange rates when cash in foreign currency
is converted into New Taiwan dollars, or when foreign-currency receivables or payables are settled, are credited or charged to income
in the year of conversion or settlement. On the balance sheet dates, the balances of foreign-currency assets and liabilities are restated
at the prevailing exchange rates and the resulting differences are charged to current income except for those foreign currencies denominated
investments in shares of stock where such differences are accounted for as translation adjustments under the Statements of Stockholders&amp;#x2019;
Equity (Deficit).&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
  <abvcd:TranslationAdjustmentPolicyTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;Translation Adjustment&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The accounts of the Company&amp;#x2019;s subsidiaries
in Taiwan were maintained, and their financial statements were expressed, in New Taiwan Dollar (&amp;#x201c;NT$&amp;#x201d;). Such financial statements
were translated into U.S. Dollars (&amp;#x201c;$&amp;#x201d; or &amp;#x201c;USD&amp;#x201d;) in accordance ASC 830, &amp;#x201c;Foreign Currency Matters&amp;#x201d;,
with the NT$ as the functional currency. According to the Statement, all assets and liabilities are translated at the current exchange
rate, stockholder&amp;#x2019;s deficit are translated at the historical rates and income statement items are translated at an average exchange
rate for the period. The resulting translation adjustments are reported under other comprehensive income (loss) as a component of stockholders&amp;#x2019;
equity (deficit).&lt;/p&gt;</abvcd:TranslationAdjustmentPolicyTextBlock>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;Recent Accounting Pronouncements&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;In December 2019, the FASB issued ASU 2019-12,&amp;#xa0;&lt;i&gt;Income
Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/i&gt;, as part of its overall simplification initiative to reduce costs
and complexity of applying accounting standards while maintaining or improving the usefulness of the information provided to users of
financial statements. The FASB&amp;#x2019;s amendments primarily impact ASC 740,&amp;#xa0;&lt;i&gt;Income Taxes&lt;/i&gt;, and may impact both interim and
annual reporting periods. ASU 2019-12 will be effective for fiscal years beginning after December 15, 2020, and interim periods within
those fiscal years and early adoption is permitted. The Company is currently evaluating the impact of adopting ASU 2019-12.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; &quot;&gt;In August 2020, the
FASB issued ASU 2020-06,&amp;#xa0;&lt;i&gt;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging- Contracts in Entity&amp;#x2019;s
Own Equity (Subtopic 815-40)&lt;/i&gt;, to reduce the complexity associated with applying U.S. GAAP principles for certain financial instruments
with characteristics of liabilities and equity. The amendments in this ASU reduce the number of accounting models for convertible instruments
and expand the existing disclosure requirements over earnings per share as it relates to convertible instruments. This ASU will be effective
for the fiscal year beginning January 1, 2022 and interim periods therein. Early adoption is permitted, but no earlier than fiscal years
beginning after December 15, 2020. The amendments may be adopted through either a modified retrospective method, or a fully retrospective
method. The Company is currently evaluating the impact of adopting ASU 2020-06.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <abvcd:ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;width: 91%; text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: black 1.5pt solid; width: 8%; text-align: center&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;&lt;b&gt;Estimated&amp;#xa0;Life&lt;br/&gt;
    in Years&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: #CCEEFF&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Buildings and leasehold improvements&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;5 ~ 50&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Machinery and equipment&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;5 ~ 10&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: #CCEEFF&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Office equipment&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;3 ~ 6&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</abvcd:ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock>
  <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="c53_From1Jan2021To31Mar2021_MinimumMember_BuildingsAndLeaseholdImprovementsMember">5</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
  <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="c54_From1Jan2021To31Mar2021_MaximumMember_BuildingsAndLeaseholdImprovementsMember">50</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
  <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="c55_From1Jan2021To31Mar2021_MinimumMember_MachineryAndEquipmentMember">5</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
  <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="c56_From1Jan2021To31Mar2021_MaximumMember_MachineryAndEquipmentMember">10</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
  <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="c57_From1Jan2021To31Mar2021_MinimumMember_OfficeEquipmentMember">3</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
  <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="c58_From1Jan2021To31Mar2021_MaximumMember_OfficeEquipmentMember">6</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
  <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;3. COLLABORATIVE AGREEMENTS&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;Collaborative agreements with BHK&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;(i) On February 24, 2015, BioLite Taiwan and
BioHopeKing Corporation (the &amp;#x201c;BHK&amp;#x201d;) entered into a co-development agreement, (the &amp;#x201c;BHK Co-Development Agreement&amp;#x201d;),
pursuant to which it is collaborative with BHK to develop and commercialize BLI-1401-2 (Botanical Drug) Triple Negative Breast Cancer
(TNBC) Combination Therapy (BLI-1401-2 Products) in Asian countries excluding Japan for all related intellectual property rights, and
has developed it for medicinal use in collaboration with outside researchers. The development costs shall be shared 50/50 between BHK
and the Company. The BHK Co-Development Agreement will remain in effect for fifteen years from the date of first commercial sale of the
Product in in Asia excluding Japan.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;On July 27, 2016, BioLite Taiwan and BHK agreed
to amend the payment terms of the milestone payment in an aggregate amount of $10 million based on the following schedule:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%&quot;&gt;
  &lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 0.25in&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 0.25in&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;&amp;#x25cf;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Upon the signing of the BHK Co-Development Agreement: $1 million, or
    10% of total payment&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%&quot;&gt;
  &lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 0.25in&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 0.25in&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;&amp;#x25cf;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Upon the first Investigational New Drug (IND) submission and BioLite
    Taiwan will deliver all data to BHK according to FDA Reviewing requirement: $1 million, or 10% of total payment&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%&quot;&gt;
  &lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 0.25in&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 0.25in&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;&amp;#x25cf;&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;At the completion of first phase II clinical trial: $1 million, or 10% of total payment&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%&quot;&gt;
  &lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 0.25in&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 0.25in&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;&amp;#x25cf;&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;At the initiation of phase III of clinical trial research: $3 million, or 30% of total payment&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%&quot;&gt;
  &lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 0.25in&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 0.25in&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;&amp;#x25cf;&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Upon the New Drug Application (NDA) submission: $4 million, or 40% of total payment&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;In December 2015, BHK has paid a non-refundable
upfront cash payment of $1 million, or 10% of $10,000,000, upon the signing of BHK Co-Development Agreement. The Company concluded that
the deliverables are considered separate units of accounting as the delivered items have value to the customer on a standalone basis
and recognized this cash receipt as collaboration revenue when all research, technical, and development data was delivered to BHK in
2015. The receipt is for the compensation of past research efforts and contributions made by BioLite Taiwan before this collaborative
agreement was signed and it does not relate to any future commitments made by BioLite Taiwan and BHK in this collaborative agreement.
In August 2016, the Company has received the second milestone payment of NT$31,649,000, approximately equivalent to $1 million, and recognized
collaboration revenue for the year ended December 31, 2016. As of the date of this report, the Company has not completed the first phase
II clinical trial.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;In addition to the milestone payments, BioLite
Taiwan is entitled to receive royalty on 12% of BHK&amp;#x2019;s net sales related to BLI-1401-2 Products. As of March 31, 2021 and December
31, 2020, the Company has not earned the royalty under the BHK Co-Development Agreement.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;(ii) On December 9, 2015, BioLite Taiwan entered
into another two collaborative agreements (the &amp;#x201c;BHK Collaborative Agreements&amp;#x201d;), pursuant to which it is collaborative with
BHK to co-develop and commercialize BLI-1005 for &amp;#x201c;Targeting Major Depressive Disorder&amp;#x201d; (BLI-1005 Products) and BLI-1006 for
&amp;#x201c;Targeting Inflammatory Bowel Disease&amp;#x201d; (BLI-1006 Products) in Asia excluding Japan for all related intellectual property
rights, and has developed it for medicinal use in collaboration with outside researchers. The development costs shall be shared 50/50
between BHK and the Company. The BHK Co-Development Agreement will remain in effect for fifteen years from the date of first commercial
sale of the Product in in Asia excluding Japan.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;In 2015, the Company recognized the cash receipt
in a total of NT$50 million, approximately equivalent to $1.6 million, as collaboration revenue when all research, technical, and development
data was delivered to BHK. The Company concluded that the deliverables are considered separate units of accounting as the delivered items
have value to the customer on a standalone basis and recognized this payment as collaboration revenue when all research, technical, data
and development data was delivered to BHK. The cash receipt is for the compensation of past research efforts and contributions made by
BioLite Taiwan before this BHK Collaborative Agreements was signed and it does not relate to any future commitments made by BioLite Taiwan
and BHK in this BHK Collaborative Agreements.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;In addition to the total of NT$50 million, approximately
equivalent to $1.60 million, BioLite Taiwan is entitled to receive 50% of the future net licensing income or net sales profit. As of
March 31, 2021 and December 31, 2020, the Company has not earned the royalty under the BHK Collaborative Agreements.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;Co-Development agreement with Rgene Corporation,
a related party&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;On May 26, 2017, BriVision entered into a
co-development agreement (the &amp;#x201c;Co-Dev Agreement&amp;#x201d;) with Rgene Corporation (the &amp;#x201c;Rgene&amp;#x201d;), a related party
under common control by controlling beneficiary shareholder of YuanGene Corporation and the Company (See Note 12). Pursuant to
Co-Dev Agreement, BriVision and Rgene agreed to co-develop and commercialize ABV-1507 HER2/neu Positive Breast Cancer Combination
Therapy, ABV-1511 Pancreatic Cancer Combination Therapy and ABV-1527 Ovary Cancer Combination Therapy. Under the terms of the Co-Dev
Agreement, Rgene is required to&amp;#xa0;pay the Company $3,000,000 in cash or stock of Rgene with equivalent value by August 15, 2017.
The payment is for the compensation of BriVision&amp;#x2019;s past research efforts and contributions made by BriVision before the Co-Dev
Agreement was signed and it does not relate to any future commitments made by BriVision and Rgene in this Co-Dev Agreement. In
addition to $3,000,000, the Company is entitled to receive 50% of the future net licensing income or net sales profit earned by
Rgene, if any, and any development costs shall be equally shared by both BriVision and Rgene.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;On June 1, 2017, the Company has delivered all
research, technical, data and development data to Rgene. Since both Rgene and the Company are related parties and under common control
by a controlling beneficiary shareholder of YuanGene Corporation and the Company, the Company has recorded the full amount of $3,000,000
in connection with the Co-Dev Agreement as additional paid-in capital during the year ended December 31, 2017. During the year ended
December 31, 2017, the Company has received $450,000 in cash. On December 24, 2018, the Company received the remaining balance of $2,550,000
in the form of newly issued shares of Rgene&amp;#x2019;s Common Stock, at the price of NT$50 (approximately equivalent to $1.60 per share),
for an aggregate number of 1,530,000 shares, which accounted for equity method long-term investment as of December 31, 2018. During the
year ended December 31, 2018, the Company has recognized investment loss of $549. On December 31, 2018, the Company determined to fully
write off this investment based on the Company&amp;#x2019;s assessment of the severity and duration of the impairment, and qualitative and
quantitative analysis of the operating performance of the investee, adverse changes in market conditions and the regulatory or economic
environment, changes in operating structure of Rgene, additional funding requirements, and Rgene&amp;#x2019;s ability to remain in business.
All projects that have been initiated will be managed and supported by the Company and Rgene.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The Company and Rgene signed an amendment to
the Co-Dev Agreement on November 10, 2020, pursuant to which both parties agreed to delete AB-1507 HER2/neu Positive Breast Cancer Combination
Therapy and AB 1527 Ovary Cancer Combination Therapy and add ABV-1519 EGFR Positive Non-Small Cell Lung Cancer Combination Therapy and
ABV-1526 Large Intestine / Colon / Rectal Cancer Combination Therapy to the products to be co-developed and commercialized. Other provisions
of the Co-Dev Agreement remain in full force and effect.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;Collaborative agreement with BioFirst Corporation,
a related party&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;On July 24, 2017, BriVision entered into a
collaborative agreement (the &amp;#x201c;BioFirst Collaborative Agreement&amp;#x201d;) with BioFirst Corporation (&amp;#x201c;BioFirst&amp;#x201d;),
pursuant to which BioFirst granted the Company the global licensing right for medical use of the product (the
&amp;#x201c;Product&amp;#x201d;): BFC-1401 Vitreous Substitute for Vitrectomy. BioFirst is a related party to the Company because a
controlling beneficiary shareholder of YuanGene Corporation and the Company is one of the directors and Common Stock shareholders of
BioFirst (See Note 12).&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;Pursuant to the BioFirst Collaborative Agreement,
the Company will co-develop and commercialize the Product with BioFirst and pay BioFirst in a total amount of $3,000,000 in cash or stock
of the Company before December 31, 2018. The amount of $3,000,000 is in connection with the compensation for BioFirst&amp;#x2019;s past research
efforts and contributions made by BioFirst before the BioFirst Collaborative Agreement was signed and it does not relate to any future
commitments made by BioFirst and BriVision in this BioFirst Collaborative Agreement. In addition, the Company is entitled to receive
50% of the future net licensing income or net sales profit, if any, and any development cost shall be equally shared by both BriVision
and BioFirst.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;On September 25, 2017, BioFirst has delivered
all research, technical, data and development data to BriVision. The Company determined to fully expense the entire amount of $3,000,000
since currently the related licensing rights do not have alternative future uses. According to ASC 730-10-25-1, absent alternative future
uses the acquisition of product rights to be used in research and development activities must be charged to research and development
expenses immediately. Hence, the entire amount of $3,000,000 is fully expensed as research and development expense during the year ended
December 31, 2017.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;On June 30, 2019, BriVision entered into a Stock
Purchase Agreement (the &amp;#x201c;Purchase Agreement&amp;#x201d;) with BioFirst Corporation (&amp;#x201c;BioFirst&amp;#x201d;). Pursuant to the Purchase
Agreement, the Company issued 428,571 shares of the Company&amp;#x2019;s common stock (the &amp;#x201c;Shares&amp;#x201d;) to BioFirst in consideration
for $3,000,000 owed by the Company to BioFirst (the &amp;#x201c;Total Payment&amp;#x201d;) in connection with a certain collaborative agreement
between the Company and BioFirst dated July 24, 2017 (the &amp;#x201c;Collaborative Agreement&amp;#x201d;). Pursuant to the Collaborative Agreement,
BioFirst granted the Company the global licensing right to co-develop BFC-1401 or ABV-1701 Vitreous Substitute for Vitrectomy for medical
purposes in consideration for the Total Payment.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;On August 5, 2019, BriVision entered into a second
Stock Purchase Agreement (&amp;#x201c;Purchase Agreement 2&amp;#x201d;) with BioFirst Corporation (&amp;#x201c;BioFirst&amp;#x201d;). Pursuant to Purchase
Agreement 2, the Company issued 414,702 shares of the Company&amp;#x2019;s common stock (the &amp;#x201c;Shares&amp;#x201d;) to BioFirst in consideration
for $2,902,911 owed by the Company to BioFirst (the &amp;#x201c;Total Payment&amp;#x201d;) in connection with a loan provided to BriVision from
BioFirst.&lt;/p&gt;&lt;br/&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
  <abvcd:MilestonePayments unitRef="usd" contextRef="c59_From2Jul2016To27Jul2016_BHKCoDevelopmentAgreementMember" decimals="-6">10000000</abvcd:MilestonePayments>
  <us-gaap:RelatedPartyTransactionTermsAndMannerOfSettlement contextRef="c59_From2Jul2016To27Jul2016_BHKCoDevelopmentAgreementMember">&amp;#x25cf; Upon the signing of the BHK Co-Development Agreement: $1 million, or 10% of total payment &amp;#x25cf; Upon the first Investigational New Drug (IND) submission and BioLite Taiwan will deliver all data to BHK according to FDA Reviewing requirement: $1 million, or 10% of total payment &amp;#x25cf; At the completion of first phase II clinical trial: $1 million, or 10% of total payment &amp;#x25cf; At the initiation of phase III of clinical trial research: $3 million, or 30% of total payment &amp;#x25cf; Upon the New Drug Application (NDA) submission: $4 million, or 40% of total payment</us-gaap:RelatedPartyTransactionTermsAndMannerOfSettlement>
  <abvcd:UpfrontCashPayment unitRef="usd" contextRef="c60_AsOf27Jul2016_BHKCoDevelopmentAgreementMember" decimals="-6">1000000</abvcd:UpfrontCashPayment>
  <abvcd:PercentageOfPaymentsUnderCodevelopmentAgreement unitRef="pure" contextRef="c59_From2Jul2016To27Jul2016_BHKCoDevelopmentAgreementMember" decimals="2">0.10</abvcd:PercentageOfPaymentsUnderCodevelopmentAgreement>
  <abvcd:IssuanceOfStockValue unitRef="usd" contextRef="c59_From2Jul2016To27Jul2016_BHKCoDevelopmentAgreementMember" decimals="0">10000000</abvcd:IssuanceOfStockValue>
  <abvcd:MilestonePayments unitRef="twd" contextRef="c61_From2Apr2016To30Apr2016_BHKCoDevelopmentAgreementMember" decimals="0">31649000</abvcd:MilestonePayments>
  <abvcd:IssuanceOfStockValue unitRef="usd" contextRef="c61_From2Apr2016To30Apr2016_BHKCoDevelopmentAgreementMember" decimals="-6">1000000</abvcd:IssuanceOfStockValue>
  <abvcd:MilestonePaymentsRoyaltyPercentage unitRef="pure" contextRef="c0_From1Jan2021To31Mar2021" decimals="2">0.12</abvcd:MilestonePaymentsRoyaltyPercentage>
  <abvcd:CollaborativeAgreementsDescription contextRef="c62_From1Jan2015To31Dec2015_BHKCoDevelopmentAgreementMember">In 2015, the Company recognized the cash receipt in a total of NT$50 million, approximately equivalent to $1.6 million, as collaboration revenue when all research, technical, and development data was delivered to BHK.</abvcd:CollaborativeAgreementsDescription>
  <abvcd:CollaborativeAgreementsDescription contextRef="c63_From1Jan2021To31Mar2021_BHKCoDevelopmentAgreementMember">In addition to the total of NT$50 million, approximately equivalent to $1.60 million, BioLite Taiwan is entitled to receive 50% of the future net licensing income or net sales profit. As of March 31, 2021 and December 31, 2020, the Company has not earned the royalty under the BHK Collaborative Agreements.</abvcd:CollaborativeAgreementsDescription>
  <us-gaap:PaymentsForParticipationLiabilities unitRef="usd" contextRef="c64_From2Aug2017To15Aug2017_CodevelopmentagreementMember" decimals="0">3000000</us-gaap:PaymentsForParticipationLiabilities>
  <abvcd:AdditionCashPayment unitRef="usd" contextRef="c65_From2May2017To26May2017_CodevelopmentagreementMember" decimals="0">3000000</abvcd:AdditionCashPayment>
  <abvcd:PercentageOfPaymentsUnderCodevelopmentAgreement unitRef="pure" contextRef="c65_From2May2017To26May2017_CodevelopmentagreementMember" decimals="2">0.50</abvcd:PercentageOfPaymentsUnderCodevelopmentAgreement>
  <us-gaap:AdditionalPaidInCapital unitRef="usd" contextRef="c66_AsOf31Dec2017_CodevelopmentagreementMember" decimals="0">3000000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent unitRef="usd" contextRef="c66_AsOf31Dec2017_CodevelopmentagreementMember" decimals="0">450000</us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent>
  <abvcd:CoDevAgreementDescription contextRef="c67_From2Dec2018To24Dec2018">the Company received the remaining balance of $2,550,000 in the form of newly issued shares of Rgene&amp;#x2019;s Common Stock, at the price of NT$50 (approximately equivalent to $1.60 per share), for an aggregate number of 1,530,000 shares, which accounted for equity method long-term investment as of December 31, 2018. During the year ended December 31, 2018, the Company has recognized investment loss of $549.</abvcd:CoDevAgreementDescription>
  <abvcd:IssuanceOfStockValue unitRef="usd" contextRef="c68_From2Dec2018To31Dec2018_CollaborativeArrangementMember" decimals="0">3000000</abvcd:IssuanceOfStockValue>
  <us-gaap:PaymentsForParticipationLiabilities unitRef="usd" contextRef="c68_From2Dec2018To31Dec2018_CollaborativeArrangementMember" decimals="0">3000000</us-gaap:PaymentsForParticipationLiabilities>
  <abvcd:PercentageOfPaymentsUnderCodevelopmentAgreement unitRef="pure" contextRef="c68_From2Dec2018To31Dec2018_CollaborativeArrangementMember" decimals="2">0.50</abvcd:PercentageOfPaymentsUnderCodevelopmentAgreement>
  <us-gaap:CostOfGoodsAndServicesSold unitRef="usd" contextRef="c69_From2Sep2017To25Sep2017_CollaborativeArrangementMember" decimals="0">3000000</us-gaap:CostOfGoodsAndServicesSold>
  <us-gaap:OtherResearchAndDevelopmentExpense unitRef="usd" contextRef="c70_From1Jan2017To31Dec2017_CollaborativeArrangementMember" decimals="0">3000000</us-gaap:OtherResearchAndDevelopmentExpense>
  <us-gaap:SharesIssued unitRef="shares" contextRef="c71_AsOf30Jun2019_BioFirstStockPurchaseAgreementMember" decimals="INF">428571</us-gaap:SharesIssued>
  <us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent unitRef="usd" contextRef="c71_AsOf30Jun2019_BioFirstStockPurchaseAgreementMember" decimals="0">3000000</us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent>
  <us-gaap:SharesIssued unitRef="shares" contextRef="c72_AsOf5Aug2019_BioFirstStockPurchaseAgreementMember" decimals="INF">414702</us-gaap:SharesIssued>
  <us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent unitRef="usd" contextRef="c72_AsOf5Aug2019_BioFirstStockPurchaseAgreementMember" decimals="0">2902911</us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent>
  <us-gaap:InventoryDisclosureTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;&lt;b&gt;4. INVENTORY&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;Inventory consists of the following:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;March 31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;December 31,&lt;br/&gt; 2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;(Unaudited)&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: left&quot;&gt;Finished goods&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;99,549&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;100,967&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td&gt;Work-in-process&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;21,729&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;22,038&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Raw materials&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;60,851&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;61,718&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt&quot;&gt;Allowance for inventory valuation and obsolescence loss&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(182,129&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(184,723&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt&quot;&gt;Inventory, net&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;</us-gaap:InventoryDisclosureTextBlock>
  <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;March 31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;December 31,&lt;br/&gt; 2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;(Unaudited)&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: left&quot;&gt;Finished goods&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;99,549&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;100,967&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td&gt;Work-in-process&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;21,729&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;22,038&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Raw materials&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;60,851&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;61,718&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt&quot;&gt;Allowance for inventory valuation and obsolescence loss&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(182,129&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(184,723&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt&quot;&gt;Inventory, net&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
  <us-gaap:InventoryFinishedGoods unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">99549</us-gaap:InventoryFinishedGoods>
  <us-gaap:InventoryFinishedGoods unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">100967</us-gaap:InventoryFinishedGoods>
  <us-gaap:InventoryWorkInProcess unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">21729</us-gaap:InventoryWorkInProcess>
  <us-gaap:InventoryWorkInProcess unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">22038</us-gaap:InventoryWorkInProcess>
  <us-gaap:InventoryRawMaterials unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">60851</us-gaap:InventoryRawMaterials>
  <us-gaap:InventoryRawMaterials unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">61718</us-gaap:InventoryRawMaterials>
  <abvcd:AllowanceForInventoryValuationAndObsolescenceLoss unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">-182129</abvcd:AllowanceForInventoryValuationAndObsolescenceLoss>
  <abvcd:AllowanceForInventoryValuationAndObsolescenceLoss unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">-184723</abvcd:AllowanceForInventoryValuationAndObsolescenceLoss>
  <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;&lt;b&gt;5. PROPERTY AND EQUIPMENT&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-align: justify; text-indent: -23.75pt&quot;&gt;Property and
equipment as of March 31, 2021 and December 31, 2020 are summarized as follows:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center&quot;&gt;March 31,&lt;br/&gt;
    2021&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center&quot;&gt;December&amp;#xa0;31,&lt;br/&gt;
    2020&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; font-weight: bold&quot;&gt;(Unaudited)&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: justify&quot;&gt;Land&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;390,088&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;395,645&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;Buildings and leasehold improvements&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;2,231,712&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;2,233,573&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;Machinery and equipment&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;992,882&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;994,544&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-bottom: 1.5pt&quot;&gt;Office equipment&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;187,181&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;189,760&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;3,801,863&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;3,813,522&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-bottom: 1.5pt&quot;&gt;Less: accumulated depreciation&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(3,296,911&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(3,298,688&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-bottom: 4pt&quot;&gt;Property and equipment, net&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;504,952&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;514,834&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;Depreciation expenses were $2,928 and $11,174
for three months ended March 31, 2021 and 2020, respectively.&lt;/p&gt;&lt;br/&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
  <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center&quot;&gt;March 31,&lt;br/&gt;
    2021&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center&quot;&gt;December&amp;#xa0;31,&lt;br/&gt;
    2020&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; font-weight: bold&quot;&gt;(Unaudited)&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: justify&quot;&gt;Land&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;390,088&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;395,645&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;Buildings and leasehold improvements&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;2,231,712&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;2,233,573&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;Machinery and equipment&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;992,882&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;994,544&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-bottom: 1.5pt&quot;&gt;Office equipment&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;187,181&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;189,760&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;3,801,863&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;3,813,522&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-bottom: 1.5pt&quot;&gt;Less: accumulated depreciation&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(3,296,911&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(3,298,688&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-bottom: 4pt&quot;&gt;Property and equipment, net&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;504,952&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;514,834&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
  <us-gaap:PropertyPlantAndEquipmentGross unitRef="usd" contextRef="c73_AsOf31Mar2021_LandMember" decimals="0">390088</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross unitRef="usd" contextRef="c74_AsOf31Dec2020_LandMember" decimals="0">395645</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross unitRef="usd" contextRef="c75_AsOf31Mar2021_BuildingsAndLeaseholdImprovementsMember" decimals="0">2231712</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross unitRef="usd" contextRef="c76_AsOf31Dec2020_BuildingsAndLeaseholdImprovementsMember" decimals="0">2233573</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross unitRef="usd" contextRef="c77_AsOf31Mar2021_MachineryAndEquipmentMember" decimals="0">992882</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross unitRef="usd" contextRef="c78_AsOf31Dec2020_MachineryAndEquipmentMember" decimals="0">994544</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross unitRef="usd" contextRef="c79_AsOf31Mar2021_OfficeEquipmentMember" decimals="0">187181</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross unitRef="usd" contextRef="c80_AsOf31Dec2020_OfficeEquipmentMember" decimals="0">189760</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">3801863</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">3813522</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">3296911</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">3298688</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <abvcd:LongTermInvestmentTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-indent: -23.75pt&quot;&gt;&lt;b&gt;6. LONG-TERM INVESTMENTS&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%&quot;&gt;
  &lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 0.25in&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;(1)&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;The ownership percentages of each investee are listed as follows:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;Ownership percentage&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;white-space: nowrap; font-weight: bold; text-align: center&quot;&gt;March 31,&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;white-space: nowrap; font-weight: bold; text-align: center&quot;&gt;December&amp;#xa0;31,&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;white-space: nowrap; font-weight: bold; text-align: center&quot;&gt;Accounting&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold&quot;&gt;Name of related party&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;2021&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;treatments&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 64%; text-align: left&quot;&gt;Braingenesis Biotechnology Co., Ltd.&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;0.17&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;%&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;0.17&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;%&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 11%; text-align: center&quot;&gt;Cost Method&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Genepharm Biotech Corporation&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;0.70&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;0.70&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;Cost Method&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;BioHopeKing Corporation&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5.90&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5.90&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;Cost Method&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;BioFirst Corporation&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;15.99&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;15.99&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;Equity Method&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Rgene Corporation&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;31.62&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;31.62&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;Equity Method&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%&quot;&gt;
  &lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 0.25in&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;(2)&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;The extent the investee relies on the company for its business are summarized as follows:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;border-bottom: black 1.5pt solid; width: 30%&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;&lt;b&gt;Name of related party&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: black 1.5pt solid; width: 69%&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;&lt;b&gt;The extent the investee relies on the Company
    for its business &amp;#xa0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;background-color: rgb(204,238,255)&quot;&gt;
    &lt;td&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Braingenesis Biotechnology Co., Ltd.&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;No specific business relationship&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Genepharm Biotech Corporation&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;No specific business relationship&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;background-color: rgb(204,238,255)&quot;&gt;
    &lt;td&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;BioHopeKing Corporation&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Collaborating with the Company to develop and commercialize drugs&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;BioFirst Corporation&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Loaned from the investee and provides research and development support service&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;background-color: rgb(204,238,255)&quot;&gt;
    &lt;td&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Rgene Corporation&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Collaborating with the Company to develop and commercialize drugs&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%&quot;&gt;
  &lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 0.25in&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;(3)&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Long-term investment mainly consists of the following:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;March&amp;#xa0;31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;December&amp;#xa0;31,&lt;br/&gt; 2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;Non-marketable Cost Method Investments, net&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: left; padding-left: 9pt&quot;&gt;Braingenesis Biotechnology Co., Ltd.&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;7,742&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;7,853&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 9pt&quot;&gt;Genepharm Biotech Corporation&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;23,638&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;23,974&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt; padding-left: 9pt&quot;&gt;BioHopeKing Corporation&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;878,056&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;890,564&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 0.25in&quot;&gt;Sub total&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;909,436&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;922,391&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Equity Method Investments, net&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 9pt&quot;&gt;BioFirst Corporation&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;217,448&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;268,336&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt; padding-left: 9pt&quot;&gt;Rgene Corporation&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 4pt; padding-left: 0.25in&quot;&gt;Total&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;1,126,884&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;1,190,727&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%&quot;&gt;&lt;tr style=&quot;vertical-align: top; text-align: justify&quot;&gt;
&lt;td style=&quot;width: 0&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.25in; text-align: left&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;(a)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;BioFirst
                                            Corporation (the &amp;#x201c;BioFirst&amp;#x201d;):&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify&quot;&gt;The Company holds an equity interest
in BioFirst Corporation, accounting for its equity interest using the equity method to accounts for its equity investment as prescribed
in ASC 323, Investments&amp;#x2014;Equity Method and Joint Ventures (&amp;#x201c;ASC 323&amp;#x201d;). Equity method adjustments include the Company&amp;#x2019;s
proportionate share of investee&amp;#x2019;s income or loss and other adjustments required by the equity method. As of March 31, 2021 and December
31, 2020, the Company owns 15.99% and 15.99% common stock shares of BioFirst, respectively. During the three months ended March 31, 2021,
the Company made prepayment for equity investment in BioFirst to purchase additional 132,000 shares issued by BioFirst in the aggregate
amount of $281,952.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;Summarized financial information for the Company&amp;#x2019;s
equity method investee, BioFirst, is as follows:&amp;#xa0;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;&lt;i&gt;Balance Sheet&lt;/i&gt;&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;March 31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;December&amp;#xa0;31,&lt;br/&gt; 2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: left&quot;&gt;Current Assets&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;1,216,963&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;1,299,822&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Non-current Assets&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;2,633,925&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;2,540,041&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Current Liabilities&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,959,919&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,986,340&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Non-current Liabilities&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;76,082&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;73,197&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Stockholders&amp;#x2019; Equity&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,814,887&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,780,326&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;&lt;i&gt;Statement of operation&lt;/i&gt;&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;Three Months Ended&lt;br/&gt; March 31,&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;2021&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: left&quot;&gt;Net sales&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;12,239&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;12,110&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Gross profit&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;7,080&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,578&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Net loss&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(220,855&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(325,652&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Share of losses from investments accounted for using the equity method&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(47,791&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(70,411&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%&quot;&gt;&lt;tr style=&quot;vertical-align: top; text-align: justify&quot;&gt;
&lt;td style=&quot;width: 0&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.25in; text-align: left&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;(b)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Rgene
                                            Corporation (the &amp;#x201c;Rgene&amp;#x201d;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify&quot;&gt;Both Rgene and the Company are under
common control by Dr. Tsung-Shann Jiang, the CEO and chairman of the BioLite Inc. Since Dr. Tsung-Shann Jiang is able to exercise significant
influence, but not control, over the Rgene, the Company determined to use the equity method to accounts for its equity investment as
prescribed in ASC 323, Investments&amp;#x2014;Equity Method and Joint Ventures (&amp;#x201c;ASC 323&amp;#x201d;). Equity method adjustments include
the Company&amp;#x2019;s proportionate share of investee&amp;#x2019;s income or loss and other adjustments required by the equity method. As of
March 31, 2021 and December 31, 2020, the Company owns 31.62% and 31.62% Common Stock shares of Rgene, respectively.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;Summarized financial information for the Company&amp;#x2019;s
equity method investee, Rgene, is as follows:&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;i&gt;Balance Sheets&lt;/i&gt;&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center&quot;&gt;March 31,&lt;br/&gt;
    2021&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center&quot;&gt;December&amp;#xa0;31,&lt;br/&gt;
    2020&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: left&quot;&gt;Current Assets&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;107,682&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;123,958&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Noncurrent Assets&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;395,665&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;412,342&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Current Liabilities&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,451,387&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,392,756&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Noncurrent Liabilities&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;28,877&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;38,953&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Shareholders&amp;#x2019; Deficit&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(976,917&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(895,409&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;&lt;i&gt;Statement of operations&lt;/i&gt;&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;border-bottom: black 1.5pt solid; text-align: center&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;&lt;b&gt;Three Months Ended&lt;br/&gt;
    March 31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: black 1.5pt solid; text-align: center&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: black 1.5pt solid; text-align: center&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: #CCEEFF&quot;&gt;
    &lt;td style=&quot;width: 76.98%&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Net sales&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 0.98%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1.06%&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;$&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 8.98%; text-align: right&quot;&gt;-&lt;/td&gt;
    &lt;td style=&quot;width: 0.98%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 0.98%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1.06%&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;$&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 7.98%; text-align: right&quot;&gt;-&lt;/td&gt;
    &lt;td style=&quot;width: 0.98%&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Gross Profit&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: #CCEEFF&quot;&gt;
    &lt;td&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Net loss&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;(95,395&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;)&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;(21,889&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Share of loss from investments accounted for using the equity method&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;-&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;-&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%&quot;&gt;&lt;tr style=&quot;vertical-align: top; text-align: justify&quot;&gt;
&lt;td style=&quot;width: 0&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.25in; text-align: left&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;(4)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Disposition
                                            of long-term investment&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify&quot;&gt;During the year ended December 31,
2020, the Company sold 218,000 shares of common stock of BioHopeKing Corporation at price of NT$24, equivalent $0.85, to several individuals,
and the percentage of ownership decreased to 5.90% as of December 31, 2020. As a result of the transactions, the Company recognized investment
loss of $40,589 and impairment loss of $961,217 for the same period. As of March 31. 2021, there is no disposition of long-term investment.&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%&quot;&gt;&lt;tr style=&quot;vertical-align: top; text-align: justify&quot;&gt;
&lt;td style=&quot;width: 0&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.25in; text-align: left&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;(5)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Losses
                                            on Equity Investments&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The components of losses on equity investments
for each period were as follows:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;Three Months Ended&lt;br/&gt; March 31,&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;2021&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: left&quot;&gt;Share of equity method investee losses&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;(47,791&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;(70,411&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;</abvcd:LongTermInvestmentTextBlock>
  <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger unitRef="pure" contextRef="c81_From1Jan2021To31Mar2021_BioFirstCorporationMember" decimals="4">0.1599</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
  <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger unitRef="pure" contextRef="c82_From1Jan2020To31Dec2020_BioFirstCorporationMember" decimals="4">0.1599</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
  <us-gaap:IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements unitRef="shares" contextRef="c0_From1Jan2021To31Mar2021" decimals="INF">132000</us-gaap:IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements>
  <abvcd:AggregateAmount unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">281952</abvcd:AggregateAmount>
  <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger unitRef="pure" contextRef="c83_From1Jan2021To31Mar2021_RgeneCorporationMember" decimals="4">0.3162</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
  <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger unitRef="pure" contextRef="c84_From1Jan2020To31Dec2020_RgeneCorporationMember" decimals="4">0.3162</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
  <us-gaap:SaleOfStockDescriptionOfTransaction contextRef="c82_From1Jan2020To31Dec2020_BioFirstCorporationMember">the Company sold 218,000 shares of common stock of BioHopeKing Corporation at price of NT$24, equivalent $0.85, to several individuals, and the percentage of ownership decreased to 5.90% as of December 31, 2020. As a result of the transactions, the Company recognized investment loss of $40,589 and impairment loss of $961,217 for the same period.</us-gaap:SaleOfStockDescriptionOfTransaction>
  <abvcd:ScheduleOfOwnershipPercentagesOfInvesteeTableTextBlocks contextRef="c0_From1Jan2021To31Mar2021">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;Ownership percentage&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;white-space: nowrap; font-weight: bold; text-align: center&quot;&gt;March 31,&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;white-space: nowrap; font-weight: bold; text-align: center&quot;&gt;December&amp;#xa0;31,&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;white-space: nowrap; font-weight: bold; text-align: center&quot;&gt;Accounting&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold&quot;&gt;Name of related party&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;2021&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;treatments&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 64%; text-align: left&quot;&gt;Braingenesis Biotechnology Co., Ltd.&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;0.17&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;%&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;0.17&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;%&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 11%; text-align: center&quot;&gt;Cost Method&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Genepharm Biotech Corporation&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;0.70&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;0.70&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;Cost Method&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;BioHopeKing Corporation&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5.90&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5.90&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;Cost Method&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;BioFirst Corporation&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;15.99&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;15.99&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;Equity Method&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Rgene Corporation&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;31.62&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;31.62&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;Equity Method&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</abvcd:ScheduleOfOwnershipPercentagesOfInvesteeTableTextBlocks>
  <us-gaap:EquityMethodInvestmentOwnershipPercentage unitRef="pure" contextRef="c85_AsOf31Mar2021_BraingenesisBiotechnologyCoLtdMember" decimals="4">0.0017</us-gaap:EquityMethodInvestmentOwnershipPercentage>
  <us-gaap:EquityMethodInvestmentOwnershipPercentage unitRef="pure" contextRef="c86_AsOf31Dec2020_BraingenesisBiotechnologyCoLtdMember" decimals="4">0.0017</us-gaap:EquityMethodInvestmentOwnershipPercentage>
  <abvcd:AccountingTreatmentDescription contextRef="c87_From1Jan2021To31Mar2021_BraingenesisBiotechnologyCoLtdMember">Cost Method</abvcd:AccountingTreatmentDescription>
  <us-gaap:EquityMethodInvestmentOwnershipPercentage unitRef="pure" contextRef="c88_AsOf31Mar2021_GenepharmBiotechCorporationMember" decimals="4">0.0070</us-gaap:EquityMethodInvestmentOwnershipPercentage>
  <us-gaap:EquityMethodInvestmentOwnershipPercentage unitRef="pure" contextRef="c89_AsOf31Dec2020_GenepharmBiotechCorporationMember" decimals="4">0.0070</us-gaap:EquityMethodInvestmentOwnershipPercentage>
  <abvcd:AccountingTreatmentDescription contextRef="c90_From1Jan2021To31Mar2021_GenepharmBiotechCorporationMember">Cost Method</abvcd:AccountingTreatmentDescription>
  <us-gaap:EquityMethodInvestmentOwnershipPercentage unitRef="pure" contextRef="c91_AsOf31Mar2021_BioHopeKingCorporationMember" decimals="4">0.0590</us-gaap:EquityMethodInvestmentOwnershipPercentage>
  <us-gaap:EquityMethodInvestmentOwnershipPercentage unitRef="pure" contextRef="c92_AsOf31Dec2020_BioHopeKingCorporationMember" decimals="4">0.0590</us-gaap:EquityMethodInvestmentOwnershipPercentage>
  <abvcd:AccountingTreatmentDescription contextRef="c93_From1Jan2021To31Mar2021_BioHopeKingCorporationMember">Cost Method</abvcd:AccountingTreatmentDescription>
  <us-gaap:EquityMethodInvestmentOwnershipPercentage unitRef="pure" contextRef="c94_AsOf31Mar2021_BioFirstCorporationMember" decimals="4">0.1599</us-gaap:EquityMethodInvestmentOwnershipPercentage>
  <us-gaap:EquityMethodInvestmentOwnershipPercentage unitRef="pure" contextRef="c95_AsOf31Dec2020_BioFirstCorporationMember" decimals="4">0.1599</us-gaap:EquityMethodInvestmentOwnershipPercentage>
  <abvcd:AccountingTreatmentDescription contextRef="c81_From1Jan2021To31Mar2021_BioFirstCorporationMember">Equity Method</abvcd:AccountingTreatmentDescription>
  <us-gaap:EquityMethodInvestmentOwnershipPercentage unitRef="pure" contextRef="c96_AsOf31Mar2021_RgeneCorporationMember" decimals="4">0.3162</us-gaap:EquityMethodInvestmentOwnershipPercentage>
  <us-gaap:EquityMethodInvestmentOwnershipPercentage unitRef="pure" contextRef="c97_AsOf31Dec2020_RgeneCorporationMember" decimals="4">0.3162</us-gaap:EquityMethodInvestmentOwnershipPercentage>
  <abvcd:AccountingTreatmentDescription contextRef="c83_From1Jan2021To31Mar2021_RgeneCorporationMember">Equity Method</abvcd:AccountingTreatmentDescription>
  <abvcd:ScheduleOfExtentInvesteeReliesTableTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;border-bottom: black 1.5pt solid; width: 30%&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;&lt;b&gt;Name of related party&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: black 1.5pt solid; width: 69%&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;&lt;b&gt;The extent the investee relies on the Company
    for its business &amp;#xa0;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;background-color: rgb(204,238,255)&quot;&gt;
    &lt;td&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Braingenesis Biotechnology Co., Ltd.&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;No specific business relationship&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Genepharm Biotech Corporation&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;No specific business relationship&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;background-color: rgb(204,238,255)&quot;&gt;
    &lt;td&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;BioHopeKing Corporation&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Collaborating with the Company to develop and commercialize drugs&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;BioFirst Corporation&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Loaned from the investee and provides research and development support service&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;background-color: rgb(204,238,255)&quot;&gt;
    &lt;td&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Rgene Corporation&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Collaborating with the Company to develop and commercialize drugs&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</abvcd:ScheduleOfExtentInvesteeReliesTableTextBlock>
  <abvcd:RelatedPartyTransactionDescriptionOfTransactions contextRef="c87_From1Jan2021To31Mar2021_BraingenesisBiotechnologyCoLtdMember">No specific business relationship</abvcd:RelatedPartyTransactionDescriptionOfTransactions>
  <abvcd:RelatedPartyTransactionDescriptionOfTransactions contextRef="c90_From1Jan2021To31Mar2021_GenepharmBiotechCorporationMember">No specific business relationship</abvcd:RelatedPartyTransactionDescriptionOfTransactions>
  <abvcd:RelatedPartyTransactionDescriptionOfTransactions contextRef="c93_From1Jan2021To31Mar2021_BioHopeKingCorporationMember">Collaborating with the Company to develop and commercialize drugs</abvcd:RelatedPartyTransactionDescriptionOfTransactions>
  <abvcd:RelatedPartyTransactionDescriptionOfTransactions contextRef="c81_From1Jan2021To31Mar2021_BioFirstCorporationMember">Loaned from the investee and provides research and development support service</abvcd:RelatedPartyTransactionDescriptionOfTransactions>
  <abvcd:RelatedPartyTransactionDescriptionOfTransactions contextRef="c83_From1Jan2021To31Mar2021_RgeneCorporationMember">Collaborating with the Company to develop and commercialize drugs</abvcd:RelatedPartyTransactionDescriptionOfTransactions>
  <abvcd:ScheduleOfLongTermInvestmentTableTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;March&amp;#xa0;31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;December&amp;#xa0;31,&lt;br/&gt; 2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;Non-marketable Cost Method Investments, net&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: left; padding-left: 9pt&quot;&gt;Braingenesis Biotechnology Co., Ltd.&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;7,742&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;7,853&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 9pt&quot;&gt;Genepharm Biotech Corporation&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;23,638&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;23,974&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt; padding-left: 9pt&quot;&gt;BioHopeKing Corporation&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;878,056&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;890,564&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 0.25in&quot;&gt;Sub total&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;909,436&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;922,391&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Equity Method Investments, net&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 9pt&quot;&gt;BioFirst Corporation&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;217,448&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;268,336&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt; padding-left: 9pt&quot;&gt;Rgene Corporation&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 4pt; padding-left: 0.25in&quot;&gt;Total&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;1,126,884&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;1,190,727&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</abvcd:ScheduleOfLongTermInvestmentTableTextBlock>
  <abvcd:NonmarketableCostMethodInvestmentsNet unitRef="usd" contextRef="c98_AsOf31Mar2021_BraingenesisBiotechnologyCoLtdMember" decimals="0">7742</abvcd:NonmarketableCostMethodInvestmentsNet>
  <abvcd:NonmarketableCostMethodInvestmentsNet unitRef="usd" contextRef="c99_AsOf31Dec2020_BraingenesisBiotechnologyCoLtdMember" decimals="0">7853</abvcd:NonmarketableCostMethodInvestmentsNet>
  <abvcd:NonmarketableCostMethodInvestmentsNet unitRef="usd" contextRef="c100_AsOf31Mar2021_GenepharmBiotechCorporationMember" decimals="0">23638</abvcd:NonmarketableCostMethodInvestmentsNet>
  <abvcd:NonmarketableCostMethodInvestmentsNet unitRef="usd" contextRef="c101_AsOf31Dec2020_GenepharmBiotechCorporationMember" decimals="0">23974</abvcd:NonmarketableCostMethodInvestmentsNet>
  <abvcd:NonmarketableCostMethodInvestmentsNet unitRef="usd" contextRef="c102_AsOf31Mar2021_BioHopeKingCorporationMember" decimals="0">878056</abvcd:NonmarketableCostMethodInvestmentsNet>
  <abvcd:NonmarketableCostMethodInvestmentsNet unitRef="usd" contextRef="c103_AsOf31Dec2020_BioHopeKingCorporationMember" decimals="0">890564</abvcd:NonmarketableCostMethodInvestmentsNet>
  <abvcd:NonmarketableCostMethodInvestmentsNet unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">909436</abvcd:NonmarketableCostMethodInvestmentsNet>
  <abvcd:NonmarketableCostMethodInvestmentsNet unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">922391</abvcd:NonmarketableCostMethodInvestmentsNet>
  <us-gaap:EquityMethodInvestments unitRef="usd" contextRef="c104_AsOf31Mar2021_BioFirstCorporationMember" decimals="0">217448</us-gaap:EquityMethodInvestments>
  <us-gaap:EquityMethodInvestments unitRef="usd" contextRef="c105_AsOf31Dec2020_BioFirstCorporationMember" decimals="0">268336</us-gaap:EquityMethodInvestments>
  <us-gaap:EquityMethodInvestments unitRef="usd" contextRef="c106_AsOf31Mar2021_RgeneCorporationMember" xs:nil="true"/>
  <us-gaap:EquityMethodInvestments unitRef="usd" contextRef="c107_AsOf31Dec2020_RgeneCorporationMember" xs:nil="true"/>
  <us-gaap:EquityMethodInvestments unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">1126884</us-gaap:EquityMethodInvestments>
  <us-gaap:EquityMethodInvestments unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">1190727</us-gaap:EquityMethodInvestments>
  <srt:ScheduleOfCondensedBalanceSheetTableTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;March 31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;December&amp;#xa0;31,&lt;br/&gt; 2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: left&quot;&gt;Current Assets&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;1,216,963&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;1,299,822&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Non-current Assets&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;2,633,925&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;2,540,041&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Current Liabilities&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,959,919&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,986,340&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Non-current Liabilities&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;76,082&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;73,197&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Stockholders&amp;#x2019; Equity&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,814,887&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,780,326&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center&quot;&gt;March 31,&lt;br/&gt;
    2021&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center&quot;&gt;December&amp;#xa0;31,&lt;br/&gt;
    2020&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: left&quot;&gt;Current Assets&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;107,682&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;123,958&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Noncurrent Assets&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;395,665&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;412,342&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Current Liabilities&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,451,387&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,392,756&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Noncurrent Liabilities&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;28,877&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;38,953&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Shareholders&amp;#x2019; Deficit&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(976,917&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(895,409&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</srt:ScheduleOfCondensedBalanceSheetTableTextBlock>
  <us-gaap:AssetsCurrent unitRef="usd" contextRef="c108_AsOf31Mar2021_BioFirstMember" decimals="0">1216963</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent unitRef="usd" contextRef="c109_AsOf31Dec2020_BioFirstMember" decimals="0">1299822</us-gaap:AssetsCurrent>
  <us-gaap:AssetsNoncurrent unitRef="usd" contextRef="c108_AsOf31Mar2021_BioFirstMember" decimals="0">2633925</us-gaap:AssetsNoncurrent>
  <us-gaap:AssetsNoncurrent unitRef="usd" contextRef="c109_AsOf31Dec2020_BioFirstMember" decimals="0">2540041</us-gaap:AssetsNoncurrent>
  <us-gaap:LiabilitiesCurrent unitRef="usd" contextRef="c108_AsOf31Mar2021_BioFirstMember" decimals="0">1959919</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent unitRef="usd" contextRef="c109_AsOf31Dec2020_BioFirstMember" decimals="0">1986340</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesNoncurrent unitRef="usd" contextRef="c108_AsOf31Mar2021_BioFirstMember" decimals="0">76082</us-gaap:LiabilitiesNoncurrent>
  <us-gaap:LiabilitiesNoncurrent unitRef="usd" contextRef="c109_AsOf31Dec2020_BioFirstMember" decimals="0">73197</us-gaap:LiabilitiesNoncurrent>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c108_AsOf31Mar2021_BioFirstMember" decimals="0">1814887</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c109_AsOf31Dec2020_BioFirstMember" decimals="0">1780326</us-gaap:StockholdersEquity>
  <us-gaap:AssetsCurrent unitRef="usd" contextRef="c110_AsOf31Mar2021_RgeneMember" decimals="0">107682</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent unitRef="usd" contextRef="c111_AsOf31Dec2020_RgeneMember" decimals="0">123958</us-gaap:AssetsCurrent>
  <us-gaap:AssetsNoncurrent unitRef="usd" contextRef="c110_AsOf31Mar2021_RgeneMember" decimals="0">395665</us-gaap:AssetsNoncurrent>
  <us-gaap:AssetsNoncurrent unitRef="usd" contextRef="c111_AsOf31Dec2020_RgeneMember" decimals="0">412342</us-gaap:AssetsNoncurrent>
  <us-gaap:LiabilitiesCurrent unitRef="usd" contextRef="c110_AsOf31Mar2021_RgeneMember" decimals="0">1451387</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent unitRef="usd" contextRef="c111_AsOf31Dec2020_RgeneMember" decimals="0">1392756</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesNoncurrent unitRef="usd" contextRef="c110_AsOf31Mar2021_RgeneMember" decimals="0">28877</us-gaap:LiabilitiesNoncurrent>
  <us-gaap:LiabilitiesNoncurrent unitRef="usd" contextRef="c111_AsOf31Dec2020_RgeneMember" decimals="0">38953</us-gaap:LiabilitiesNoncurrent>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c110_AsOf31Mar2021_RgeneMember" decimals="0">-976917</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c111_AsOf31Dec2020_RgeneMember" decimals="0">-895409</us-gaap:StockholdersEquity>
  <srt:ScheduleOfCondensedIncomeStatementTableTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;Three Months Ended&lt;br/&gt; March 31,&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;2021&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: left&quot;&gt;Net sales&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;12,239&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;12,110&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Gross profit&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;7,080&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,578&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Net loss&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(220,855&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(325,652&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Share of losses from investments accounted for using the equity method&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(47,791&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(70,411&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;border-bottom: black 1.5pt solid; text-align: center&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;&lt;b&gt;Three Months Ended&lt;br/&gt;
    March 31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: black 1.5pt solid; text-align: center&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: black 1.5pt solid; text-align: center&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: #CCEEFF&quot;&gt;
    &lt;td style=&quot;width: 76.98%&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Net sales&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 0.98%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1.06%&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;$&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 8.98%; text-align: right&quot;&gt;-&lt;/td&gt;
    &lt;td style=&quot;width: 0.98%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 0.98%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1.06%&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;$&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 7.98%; text-align: right&quot;&gt;-&lt;/td&gt;
    &lt;td style=&quot;width: 0.98%&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Gross Profit&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: #CCEEFF&quot;&gt;
    &lt;td&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Net loss&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;(95,395&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;)&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;(21,889&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Share of loss from investments accounted for using the equity method&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;-&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;-&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</srt:ScheduleOfCondensedIncomeStatementTableTextBlock>
  <us-gaap:Revenues unitRef="usd" contextRef="c112_From1Jan2021To31Mar2021_BioFirstMember" decimals="0">12239</us-gaap:Revenues>
  <us-gaap:Revenues unitRef="usd" contextRef="c113_From1Jan2020To31Mar2020_BioFirstMember" decimals="0">12110</us-gaap:Revenues>
  <us-gaap:GrossProfit unitRef="usd" contextRef="c112_From1Jan2021To31Mar2021_BioFirstMember" decimals="0">7080</us-gaap:GrossProfit>
  <us-gaap:GrossProfit unitRef="usd" contextRef="c113_From1Jan2020To31Mar2020_BioFirstMember" decimals="0">1578</us-gaap:GrossProfit>
  <abvcd:LongTermInvestmentNetLoss unitRef="usd" contextRef="c112_From1Jan2021To31Mar2021_BioFirstMember" decimals="0">-220855</abvcd:LongTermInvestmentNetLoss>
  <abvcd:LongTermInvestmentNetLoss unitRef="usd" contextRef="c113_From1Jan2020To31Mar2020_BioFirstMember" decimals="0">-325652</abvcd:LongTermInvestmentNetLoss>
  <us-gaap:GainLossOnInvestments unitRef="usd" contextRef="c112_From1Jan2021To31Mar2021_BioFirstMember" decimals="0">-47791</us-gaap:GainLossOnInvestments>
  <us-gaap:GainLossOnInvestments unitRef="usd" contextRef="c113_From1Jan2020To31Mar2020_BioFirstMember" decimals="0">-70411</us-gaap:GainLossOnInvestments>
  <us-gaap:Revenues unitRef="usd" contextRef="c114_From1Jan2021To31Mar2021_RgeneMember" xs:nil="true"/>
  <us-gaap:Revenues unitRef="usd" contextRef="c115_From1Jan2020To31Mar2020_RgeneMember" xs:nil="true"/>
  <us-gaap:GrossProfit unitRef="usd" contextRef="c114_From1Jan2021To31Mar2021_RgeneMember" xs:nil="true"/>
  <us-gaap:GrossProfit unitRef="usd" contextRef="c115_From1Jan2020To31Mar2020_RgeneMember" xs:nil="true"/>
  <abvcd:LongTermInvestmentNetLoss unitRef="usd" contextRef="c114_From1Jan2021To31Mar2021_RgeneMember" decimals="0">-95395</abvcd:LongTermInvestmentNetLoss>
  <abvcd:LongTermInvestmentNetLoss unitRef="usd" contextRef="c115_From1Jan2020To31Mar2020_RgeneMember" decimals="0">-21889</abvcd:LongTermInvestmentNetLoss>
  <us-gaap:GainLossOnInvestments unitRef="usd" contextRef="c114_From1Jan2021To31Mar2021_RgeneMember" xs:nil="true"/>
  <us-gaap:GainLossOnInvestments unitRef="usd" contextRef="c115_From1Jan2020To31Mar2020_RgeneMember" xs:nil="true"/>
  <us-gaap:EquityMethodInvestmentsTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;Three Months Ended&lt;br/&gt; March 31,&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;2021&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: left&quot;&gt;Share of equity method investee losses&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;(47,791&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;(70,411&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:EquityMethodInvestmentsTextBlock>
  <abvcd:ShareOfEquityMethodInvesteeLosses unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">-47791</abvcd:ShareOfEquityMethodInvesteeLosses>
  <abvcd:ShareOfEquityMethodInvesteeLosses unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">-70411</abvcd:ShareOfEquityMethodInvesteeLosses>
  <abvcd:ConvertibleNotesPayableDisclosureTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;7. CONVERTIBLE NOTES PAYABLE&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;On May 9, 2018, the Company issued an eighteen-month
term unsecured convertible promissory note (the &amp;#x201c;Yu and Wei Note&amp;#x201d;) in an aggregate principal amount of $300,000 to Guoliang
Yu and Yingfei Wei Family Trust (the &amp;#x201c;Yu and Wei&amp;#x201d;), pursuant to which the Company received $300,000. The Yu and Wei Note bears
interest at 8% per annum. The Company shall pay to the Yu and Wei an amount in cash representing all outstanding principal and accrued
and unpaid interest on the Eighteenth (18) month anniversary of the issuance date of the Yu and Wei Note, which is on November 8, 2019.
In the event that the Company raises gross proceeds from the sale of its common stock of at least $5,000,000 (an &amp;#x201c;Equity Offering&amp;#x201d;)
then within five days of the closing for such offering, the Company must repay the outstanding amount of this Yu and Wei Note. At any
time from the date hereof until this Yu and Wei Note has been satisfied, the Yu and Wei may convert the unpaid and outstanding principal
plus any accrued and unpaid interest and or default interest, if any, into shares of the Company&amp;#x2019;s common stock at a conversion
price (the &amp;#x201c;Conversion Price&amp;#x201d;) equal to the lower of (i) $2.00 per share (the &amp;#x201c;Fixed Conversion Price&amp;#x201d;), subject
to adjustment or (ii) 80% of the per share offering price (the &amp;#x201c;Alternative Conversion Price&amp;#x201d;) of any completed equity offering
of the Company in an amount exceeding $500,000 that occurs when any part of the Yu and Wei Note is outstanding, subject to adjustments
set forth in the Yu and Wei Note. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial
conversion feature present in the Yu and Wei Note. On January 21, 2020, Yu and Wei entered into a new agreement that the new Note bears
interest at 20% per annum. The Company shall pay to the Yu and Wei an amount in cash representing all outstanding principal and accrued
and unpaid interest on the Twelve (12) month anniversary of the issuance date of the new &amp;#x201c;Yu and Wei&amp;#x201d; Note, which is on January
20, 2021. On April 5, 2020, the Company entered into an exchange agreement with &amp;#x201c;Yu and Wei&amp;#x201d;. The aggregate principal amount
plus accrued interest expenses were $354,722, and the Company agreed to issue to the Holders an aggregate of 192,784 shares of the Company&amp;#x2019;s
common stock, and warrants to purchase 192,784 shares of the Company&amp;#x2019;s common stock. As of March 31, 2021, these common shares have
been issued.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;On June 27, 2018, the Company issued an eighteen-month
term unsecured convertible promissory note (the &amp;#x201c;Keypoint Note&amp;#x201d;) in the aggregate principal amount of $250,000 to Keypoint
Technology Ltd. (&amp;#x201c;Keypoint&amp;#x201d;), a related party, pursuant to which the Company received $250,000. The Keypoint Note bears interest
at 8% per annum. The Company shall pay to the Keypoint an amount in cash representing all outstanding principal and accrued and unpaid
interest on the Eighteenth (18) month anniversary of the issuance date of the Keypoint Note, which is on December 26, 2019. In the event
that the Company raises gross proceeds from the sale of its common stock of at least $5,000,000 (an &amp;#x201c;Equity Offering&amp;#x201d;) then
within five days of the closing for such offering, the Company must repay the outstanding amount of this Keypoint Note. At any time from
the date hereof until this Keypoint Note has been satisfied, Keypoint may convert the unpaid and outstanding principal plus any accrued
and unpaid interest and or default interest, if any, into shares of the Company&amp;#x2019;s common stock at a conversion price (the &amp;#x201c;Conversion
Price&amp;#x201d;) equal to the lower of (i) $2.00 per share (the &amp;#x201c;Fixed Conversion Price&amp;#x201d;), subject to adjustment or (ii) 80%
of the per share offering price (the &amp;#x201c;Alternative Conversion Price&amp;#x201d;) of any completed equity offering of the Company in an
amount exceeding $500,000 that occurs when any part of the Keypoint Note is outstanding, subject to adjustments set forth in the Keypoint
Note. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature
present in the Keypoint Note. On January 21, 2020, Keypoint entered into a new agreement that the new Note bears interest at 20% per annum.
The Company shall pay to the Keypoint an amount in cash representing all outstanding principal and accrued and unpaid interest on the
Twelve (12) month anniversary of the issuance date of the new &amp;#x201c;Keypoint&amp;#x201d; Note, which is on January 20, 2021. On April 5, 2020,
the Company entered into an exchange agreement with &amp;#x201c;Keypoint&amp;#x201d;. The aggregate principal amount plus accrued interest expenses
were $292,826, and the Company agreed to issue to the Holders an aggregate of 159,145 shares of the Company&amp;#x2019;s common stock, and
warrants to purchase 159,145 shares of the Company&amp;#x2019;s common stock. As of March 31, 2021, these common shares have been issued.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;On August 25, 2018, the Company issued an eighteen-month
term unsecured convertible promissory notes (the &amp;#x201c;Odaira Note&amp;#x201d;) in the aggregate principal amount of $250,000 to Yoshinobu
Odaira. (&amp;#x201c;Odaira&amp;#x201d;), pursuant to which the Company received $250,000. The Odaira Note bears interest at 8% per annum. The Company
shall pay to the Odaira an amount in cash representing all outstanding principal and accrued and unpaid interest on the Eighteenth (18)
month anniversary of the issuance date of the Odaira Note, which is on February 24, 2020. In the event that the Company raises gross proceeds
from the sale of its common stock of at least $5,000,000 (an &amp;#x201c;Equity Offering&amp;#x201d;) then within five days of the closing for such
offering, the Company must repay the outstanding amount of this Odaira Note. At any time from the date hereof until this Odaira Note has
been satisfied, Odaira may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default interest,
if any, into shares of the Company&amp;#x2019;s common stock at a conversion price (the &amp;#x201c;Conversion Price&amp;#x201d;) equal to the lower
of (i) $2.00 per share (the &amp;#x201c;Fixed Conversion Price&amp;#x201d;), subject to adjustment or (ii) 80% of the per share offering price (the
&amp;#x201c;Alternative Conversion Price&amp;#x201d;) of any completed equity offering of the Company in an amount exceeding $500,000 that occurs
when any part of the Odaira Note is outstanding, subject to adjustments set forth in the Odaira Note. In accordance with FASB ASC 470-20,
the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the Odaira Note. On January 21,
2020, Odaira entered into a new agreement that the new Note bears interest at 20% per annum. The Company shall pay to the Odaira an amount
in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date
of the new &amp;#x201c;Odaira&amp;#x201d; Note, which is on January 20, 2021. On April 5, 2020, the Company entered into an exchange agreement with
&amp;#x201c;Odaira&amp;#x201d;. The aggregate principal amount plus accrued interest expenses were $284,036, and the Company agreed to issue to
the Holders an aggregate of 154,368 shares of the Company&amp;#x2019;s common stock, and warrants to purchase 154,368 shares of the Company&amp;#x2019;s
common stock. As of March 31, 2021, these common shares have been issued.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;On May 30 and July 10, 2019, the Company issued
two (2) twelve-month term unsecured convertible promissory notes (the &amp;#x201c;KSL Note&amp;#x201d;) in an aggregate principal amount of $250,000
to Kuo Sheng Lung (the &amp;#x201c;KSL&amp;#x201d;), pursuant to which the Company received $160,000 and $90,000, respectively. The KSL Note bears
interest at 20% per annum. The Company shall pay to KSL an amount in cash representing all outstanding principal and accrued and unpaid
interest on the Twelve (12) month anniversary of the issuance date of the KSL Note, which is on May 29, 2020 and July 9, 2020. At any
time from the issuance date until the KSL Note has been satisfied, the KSL may convert the unpaid and outstanding principal plus any accrued
and unpaid interest and or default interest, if any, into shares of the Company&amp;#x2019;s common stock at a conversion price (the &amp;#x201c;Conversion
Price&amp;#x201d;) equal to the lower of (i) $0.50 per share (the &amp;#x201c;Fixed Conversion Price&amp;#x201d;), subject to adjustment, or (ii) 70%
of the per share offering price (the &amp;#x201c;Alternative Conversion Price&amp;#x201d;) of the completed public equity offering of the Company
in an amount exceeding $10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission
on November 14, 2018 (the &amp;#x201c;Public Offering&amp;#x201d;), as amended from time to time. In accordance with FASB ASC 470-20, the Company
recognized none of the intrinsic value of the embedded beneficial conversion feature present in the KSL Note. On May 13, 2020, the Company
received an acknowledgement letter from KSL that they will not claim the repayment of loan for 12 months. On November 9, 2020, the Company
entered into an agreement with &amp;#x201c;KSL&amp;#x201d;. The aggregate principal amount plus accrued interest expenses are $270,272, and KSL
agreed to use the full amount to purchase certain securities pursuant to a securities purchase agreement; KSL agreed to purchase and the
Company agreed to issue 120,121 shares of the Company&amp;#x2019;s common stock and warrants for a purchase price of $270,272.&amp;#xa0;As of March
31, 2021, the Company issued to the Holders an aggregate of 120,121 shares of the Company&amp;#x2019;s common stock.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;On July 10, 2019, the Company issued a twelve-month
term unsecured convertible promissory note (the &amp;#x201c;NEA Note&amp;#x201d;) in an aggregate principal amount of $250,000 to New Eastern Asia
(the &amp;#x201c;NEA&amp;#x201d;), a related party, pursuant to which the Company received $250,000 on July 10, 2019. The NEA Note bears interest
at 20% per annum. The Company shall pay to the NEA an amount in cash representing all outstanding principal and accrued and unpaid interest
on the Twelve (12) month anniversary of the issuance date of the NEA Note, which is on July 9, 2020. At any time from the date hereof
until this NEA Note has been satisfied, the NEA may convert the unpaid and outstanding principal plus any accrued and unpaid interest
and or default interest, if any, into shares of the Company&amp;#x2019;s common stock at a conversion price (the &amp;#x201c;Conversion Price&amp;#x201d;)
equal to the lower of (i) $.50 per share (the &amp;#x201c;Fixed Conversion Price&amp;#x201d;), subject to adjustment, or (ii) 70% of the per share
offering price (the &amp;#x201c;Alternative Conversion Price&amp;#x201d;) of the completed public equity offering of the Company in an amount exceeding
$10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018
(the &amp;#x201c;Public Offering&amp;#x201d;), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of
the intrinsic value of embedded beneficial conversion feature present in the NEA Note. As of March 31, 2021, the Company paid off the convertible
promissory note of $306,667, including principal and accrued and unpaid interest expense.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;On August 28, 2019, the Company issued a twelve-month
term unsecured convertible promissory note (the &amp;#x201c;KLS Note&amp;#x201d;) in an aggregate principal amount of $200,000 to Kuo Li Shen (the
&amp;#x201c;KLS&amp;#x201d;), pursuant to which the Company received $200,000 on August 28, 2019. The KLS Note bears interest at 20% per annum.
The Company shall pay to the KLS an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve
(12) month anniversary of the issuance date of the KLS Note, which is on August 27, 2020. At any time from the date hereof until this
KLS Note has been satisfied, the KLS may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default
interest, if any, into shares of the Company&amp;#x2019;s common stock at a conversion price (the &amp;#x201c;Conversion Price&amp;#x201d;) equal to
the lower of (i) $.50 per share (the &amp;#x201c;Fixed Conversion Price&amp;#x201d;), subject to adjustment, or (ii) 70% of the per share offering
price (the &amp;#x201c;Alternative Conversion Price&amp;#x201d;) of the completed public equity offering of the Company in an amount exceeding $10,000,000
as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the &amp;#x201c;Public
Offering&amp;#x201d;), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value
of embedded beneficial conversion feature present in the KLS Note. On April 20, 2020, the Company entered into an exchange agreement with
KLS. The aggregate principal amount plus accrued interest expenses were $225,222, and the Company agreed to issue to the Holders an aggregate
of 126,530 shares of the Company&amp;#x2019;s common stock, and warrants to purchase 126,530 shares of common stock. As of March 31, 2021,
these common shares have been issued.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;On September 4, 2019, the Company issued 3 twelve-month
term unsecured convertible promissory note (the &amp;#x201c;C.L.L. Note&amp;#x201d;) in an aggregate principal amount of $257,500 to Chang Ping
Shan, Lin Shan Tyan, and Liu Ching Hsuan (together the &amp;#x201c;C.L.L.&amp;#x201d;), pursuant to which the Company received $257,500 on September
4, 2019. Chang Ping Shan and Liu Ching Hsuan are related parties to the Company. The C.L.L. Note bears interest at 20% per annum. The
Company shall pay to the C.L.L. an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve
(12) month anniversary of the issuance date of the C.L.L. Note, which is on September 3, 2020. At any time from the date hereof until
this C.L.L. Note has been satisfied, the C.L.L. may convert the unpaid and outstanding principal plus any accrued and unpaid interest
and or default interest, if any, into shares of the Company&amp;#x2019;s common stock at a conversion price (the &amp;#x201c;Conversion Price&amp;#x201d;)
equal to the lower of (i) $.50 per share (the &amp;#x201c;Fixed Conversion Price&amp;#x201d;), subject to adjustment, or (ii) 70% of the per share
offering price (the &amp;#x201c;Alternative Conversion Price&amp;#x201d;) of the completed public equity offering of the Company in an amount exceeding
$10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018
(the &amp;#x201c;Public Offering&amp;#x201d;), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of
the intrinsic value of embedded beneficial conversion feature present in the C.L.L. Note. On April 20, 2020, the Company entered into
an exchange agreement with C.L.L.. The aggregate principal amount plus accrued interest expenses were $289,974, and the Company agreed
to issue to the Holders an aggregate of 162,908 shares of the Company&amp;#x2019;s common stock, and warrants to purchase 162,908 shares of
common stock. As of March 31, 2021, these common shares have been issued.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;On October 29, 2019, the Company issued a twelve-month
term unsecured convertible promissory note (the &amp;#x201c;Lee Note&amp;#x201d;) in an aggregate principal amount of $250,000 to Hwalin Lee (the
&amp;#x201c;Lee&amp;#x201d;), a related party, pursuant to which the Company received $250,000 on October 29, 2019. The Lee Note bears interest
at 20% per annum. The Company shall pay to the Lee an amount in cash representing all outstanding principal and accrued and unpaid interest
on the Twelve (12) month anniversary of the issuance date of the Lee Note, which is on October 28, 2020. At any time from the date hereof
until this Lee Note has been satisfied, the Lee may convert the unpaid and outstanding principal plus any accrued and unpaid interest
and or default interest, if any, into shares of the Company&amp;#x2019;s common stock at a conversion price (the &amp;#x201c;Conversion Price&amp;#x201d;)
equal to the lower of (i) $.50 per share (the &amp;#x201c;Fixed Conversion Price&amp;#x201d;), subject to adjustment, or (ii) 70% of the per share
offering price (the &amp;#x201c;Alternative Conversion Price&amp;#x201d;) of the completed public equity offering of the Company in an amount exceeding
$10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018
(the &amp;#x201c;Public Offering&amp;#x201d;), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of
the intrinsic value of embedded beneficial conversion feature present in the Lee Note. As of March 31, 2021, the Company paid off the
convertible promissory note of $311,233, including principal and accrued and unpaid interest expense.&amp;#xa0;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;On October 23, 2020, the Company entered
into a Securities Purchase Agreement (the &amp;#x201c;October SPA&amp;#x201d;) with one accredited investor. Pursuant to the October SPA, the Company
sold and issued a convertible promissory note (the &amp;#x201c;October Note&amp;#x201d;) in the principal amount of $2,500,000 to the investor and
received the payment from such investor on October 30, 2020. The October Note was issued on October 23, 2020 and the maturity date of
the October Note is the twenty-four (24) month anniversary from the issuance date (the &amp;#x201c;Maturity Date&amp;#x201d;). Upon the Maturity
Date, the Company shall pay to the holder, in cash, an amount representing all outstanding principal amount and accrued and unpaid interest
under the October Note. The October Note bears an interest rate of ten percent (10%) per annum and may be convertible into shares of the
Company&amp;#x2019;s common stock at a fixed conversion price of $2.25 per share. The holder of the October Note may elect to convert part
or all of the outstanding balance of the October Note from the issuance date until the Maturity Date. The Company may prepay the outstanding
amount at any time, in whole or in part, without any penalty.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;As of March 31, 2021 and December 31, 2020, the
aggregate carrying values of the convertible debentures were $2,500,000 and $2,750,000, respectively; and accrued convertible interest
was $110,215 and $104,551, respectively.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;Total interest expenses in connection with the above convertible note
payable were $66,897 and $95,214 for the three months ended March 31, 2021 and 2020, respectively.&lt;/p&gt;&lt;br/&gt;</abvcd:ConvertibleNotesPayableDisclosureTextBlock>
  <us-gaap:DebtInstrumentFaceAmount unitRef="usd" contextRef="c116_AsOf9May2018_UnsecuredConvertiblePromissoryNoteMember" decimals="0">300000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:PaymentsToAcquireNotesReceivable unitRef="usd" contextRef="c117_From25Apr2018To9May2018_UnsecuredConvertiblePromissoryNoteMember" decimals="0">300000</us-gaap:PaymentsToAcquireNotesReceivable>
  <us-gaap:DebtInstrumentInterestRateDuringPeriod unitRef="pure" contextRef="c117_From25Apr2018To9May2018_UnsecuredConvertiblePromissoryNoteMember" decimals="2">0.08</us-gaap:DebtInstrumentInterestRateDuringPeriod>
  <us-gaap:SaleOfStockDescriptionOfTransaction contextRef="c117_From25Apr2018To9May2018_UnsecuredConvertiblePromissoryNoteMember">In the event that the Company raises gross proceeds from the sale of its common stock of at least $5,000,000 (an &amp;#x201c;Equity Offering&amp;#x201d;) then within five days of the closing for such offering, the Company must repay the outstanding amount of this Yu and Wei Note.</us-gaap:SaleOfStockDescriptionOfTransaction>
  <us-gaap:ConversionOfStockDescription contextRef="c117_From25Apr2018To9May2018_UnsecuredConvertiblePromissoryNoteMember">(i) $2.00 per share (the &amp;#x201c;Fixed Conversion Price&amp;#x201d;), subject to adjustment or (ii) 80% of the per share offering price (the &amp;#x201c;Alternative Conversion Price&amp;#x201d;) of any completed equity offering of the Company in an amount exceeding $500,000 that occurs when any part of the Yu and Wei Note is outstanding, subject to adjustments set forth in the Yu and Wei Note. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the Yu and Wei Note. On January 21, 2020, Yu and Wei entered into a new agreement that the new Note bears interest at 20% per annum. The Company shall pay to the Yu and Wei an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the new &amp;#x201c;Yu and Wei&amp;#x201d; Note, which is on January 20, 2021. On April 5, 2020, the Company entered into an exchange agreement with &amp;#x201c;Yu and Wei&amp;#x201d;. The aggregate principal amount plus accrued interest expenses were $354,722, and the Company agreed to issue to the Holders an aggregate of 192,784 shares of the Company&amp;#x2019;s common stock, and warrants to purchase 192,784 shares of the Company&amp;#x2019;s common stock. As of March 31, 2021, these common shares have been issued.</us-gaap:ConversionOfStockDescription>
  <us-gaap:DebtInstrumentFaceAmount unitRef="usd" contextRef="c118_AsOf27Jun2018_UnsecuredConvertiblePromissoryNoteMember" decimals="0">250000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:PaymentsToAcquireNotesReceivable unitRef="usd" contextRef="c119_From2Jun2018To27Jun2018_UnsecuredConvertiblePromissoryNoteMember" decimals="0">250000</us-gaap:PaymentsToAcquireNotesReceivable>
  <us-gaap:DebtInstrumentInterestRateDuringPeriod unitRef="pure" contextRef="c119_From2Jun2018To27Jun2018_UnsecuredConvertiblePromissoryNoteMember" decimals="2">0.08</us-gaap:DebtInstrumentInterestRateDuringPeriod>
  <us-gaap:ConversionOfStockDescription contextRef="c119_From2Jun2018To27Jun2018_UnsecuredConvertiblePromissoryNoteMember">In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the Keypoint Note. On January 21, 2020, Keypoint entered into a new agreement that the new Note bears interest at 20% per annum. The Company shall pay to the Keypoint an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the new &amp;#x201c;Keypoint&amp;#x201d; Note, which is on January 20, 2021. On April 5, 2020, the Company entered into an exchange agreement with &amp;#x201c;Keypoint&amp;#x201d;. The aggregate principal amount plus accrued interest expenses were $292,826, and the Company agreed to issue to the Holders an aggregate of 159,145 shares of the Company&amp;#x2019;s common stock, and warrants to purchase 159,145 shares of the Company&amp;#x2019;s common stock. As of March 31, 2021, these common shares have been issued.</us-gaap:ConversionOfStockDescription>
  <us-gaap:DebtInstrumentFaceAmount unitRef="usd" contextRef="c120_AsOf25Aug2018_UnsecuredConvertiblePromissoryNoteMember" decimals="0">250000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:PaymentsToAcquireNotesReceivable unitRef="usd" contextRef="c121_From2Aug2018To25Aug2018_UnsecuredConvertiblePromissoryNoteMember" decimals="0">250000</us-gaap:PaymentsToAcquireNotesReceivable>
  <us-gaap:DebtInstrumentInterestRateDuringPeriod unitRef="pure" contextRef="c121_From2Aug2018To25Aug2018_UnsecuredConvertiblePromissoryNoteMember" decimals="2">0.08</us-gaap:DebtInstrumentInterestRateDuringPeriod>
  <us-gaap:ConversionOfStockDescription contextRef="c121_From2Aug2018To25Aug2018_UnsecuredConvertiblePromissoryNoteMember">In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the Odaira Note. On January 21, 2020, Odaira entered into a new agreement that the new Note bears interest at 20% per annum. The Company shall pay to the Odaira an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the new &amp;#x201c;Odaira&amp;#x201d; Note, which is on January 20, 2021. On April 5, 2020, the Company entered into an exchange agreement with &amp;#x201c;Odaira&amp;#x201d;. The aggregate principal amount plus accrued interest expenses were $284,036, and the Company agreed to issue to the Holders an aggregate of 154,368 shares of the Company&amp;#x2019;s common stock, and warrants to purchase 154,368 shares of the Company&amp;#x2019;s common stock. As of March 31, 2021, these common shares have been issued.</us-gaap:ConversionOfStockDescription>
  <us-gaap:DebtInstrumentFaceAmount unitRef="usd" contextRef="c122_AsOf30May2018_UnsecuredConvertiblePromissoryNoteMember" decimals="0">250000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:PaymentsToAcquireNotesReceivable unitRef="usd" contextRef="c123_From1May2018To30May2018_UnsecuredConvertiblePromissoryNoteMember" decimals="0">160000</us-gaap:PaymentsToAcquireNotesReceivable>
  <us-gaap:SaleOfStockDescriptionOfTransaction contextRef="c123_From1May2018To30May2018_UnsecuredConvertiblePromissoryNoteMember">The KSL Note bears interest at 20% per annum. The Company shall pay to KSL an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the KSL Note, which is on May 29, 2020 and July 9, 2020.</us-gaap:SaleOfStockDescriptionOfTransaction>
  <us-gaap:DebtInstrumentInterestRateDuringPeriod unitRef="pure" contextRef="c123_From1May2018To30May2018_UnsecuredConvertiblePromissoryNoteMember" decimals="2">0.20</us-gaap:DebtInstrumentInterestRateDuringPeriod>
  <us-gaap:ConversionOfStockDescription contextRef="c123_From1May2018To30May2018_UnsecuredConvertiblePromissoryNoteMember">In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of the embedded beneficial conversion feature present in the KSL Note. On May 13, 2020, the Company received an acknowledgement letter from KSL that they will not claim the repayment of loan for 12 months. On November 9, 2020, the Company entered into an agreement with &amp;#x201c;KSL&amp;#x201d;. The aggregate principal amount plus accrued interest expenses are $270,272, and KSL agreed to use the full amount to purchase certain securities pursuant to a securities purchase agreement; KSL agreed to purchase and the Company agreed to issue 120,121 shares of the Company&amp;#x2019;s common stock and warrants for a purchase price of $270,272. As of March 31, 2021, the Company issued to the Holders an aggregate of 120,121 shares of the Company&amp;#x2019;s common stock.</us-gaap:ConversionOfStockDescription>
  <us-gaap:DebtInstrumentFaceAmount unitRef="usd" contextRef="c124_AsOf10Jul2019_UnsecuredConvertiblePromissoryNoteMember" decimals="0">250000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:PaymentsToAcquireNotesReceivable unitRef="usd" contextRef="c125_From26Jun2019To10Jul2019_UnsecuredConvertiblePromissoryNoteMember" decimals="0">250000</us-gaap:PaymentsToAcquireNotesReceivable>
  <us-gaap:DebtInstrumentInterestRateDuringPeriod unitRef="pure" contextRef="c125_From26Jun2019To10Jul2019_UnsecuredConvertiblePromissoryNoteMember" decimals="2">0.20</us-gaap:DebtInstrumentInterestRateDuringPeriod>
  <us-gaap:ConversionOfStockDescription contextRef="c125_From26Jun2019To10Jul2019_UnsecuredConvertiblePromissoryNoteMember">(i) $.50 per share (the &amp;#x201c;Fixed Conversion Price&amp;#x201d;), subject to adjustment, or (ii) 70% of the per share offering price (the &amp;#x201c;Alternative Conversion Price&amp;#x201d;) of the completed public equity offering of the Company in an amount exceeding $10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the &amp;#x201c;Public Offering&amp;#x201d;), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the NEA Note. As of March 31, 2021, the Company paid off the convertible promissory note of $306,667, including principal and accrued and unpaid interest expense.</us-gaap:ConversionOfStockDescription>
  <us-gaap:DebtInstrumentFaceAmount unitRef="usd" contextRef="c126_AsOf28Aug2019_UnsecuredConvertiblePromissoryNoteMember" decimals="0">200000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:PaymentsToAcquireNotesReceivable unitRef="usd" contextRef="c127_From1Aug2019To28Aug2019_UnsecuredConvertiblePromissoryNoteMember" decimals="0">200000</us-gaap:PaymentsToAcquireNotesReceivable>
  <us-gaap:DebtInstrumentInterestRateDuringPeriod unitRef="pure" contextRef="c127_From1Aug2019To28Aug2019_UnsecuredConvertiblePromissoryNoteMember" decimals="2">0.20</us-gaap:DebtInstrumentInterestRateDuringPeriod>
  <us-gaap:ConversionOfStockDescription contextRef="c127_From1Aug2019To28Aug2019_UnsecuredConvertiblePromissoryNoteMember">(i) $.50 per share (the &amp;#x201c;Fixed Conversion Price&amp;#x201d;), subject to adjustment, or (ii) 70% of the per share offering price (the &amp;#x201c;Alternative Conversion Price&amp;#x201d;) of the completed public equity offering of the Company in an amount exceeding $10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the &amp;#x201c;Public Offering&amp;#x201d;), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the KLS Note. On April 20, 2020, the Company entered into an exchange agreement with KLS. The aggregate principal amount plus accrued interest expenses were $225,222, and the Company agreed to issue to the Holders an aggregate of 126,530 shares of the Company&amp;#x2019;s common stock, and warrants to purchase 126,530 shares of common stock. As of March 31, 2021, these common shares have been issued.</us-gaap:ConversionOfStockDescription>
  <us-gaap:DebtInstrumentFaceAmount unitRef="usd" contextRef="c128_AsOf4Sep2019_UnsecuredConvertiblePromissoryNoteMember" decimals="0">257500</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:PaymentsToAcquireNotesReceivable unitRef="usd" contextRef="c129_From20Aug2019To4Sep2019_UnsecuredConvertiblePromissoryNoteMember" decimals="0">257500</us-gaap:PaymentsToAcquireNotesReceivable>
  <us-gaap:DebtInstrumentInterestRateDuringPeriod unitRef="pure" contextRef="c129_From20Aug2019To4Sep2019_UnsecuredConvertiblePromissoryNoteMember" decimals="2">0.20</us-gaap:DebtInstrumentInterestRateDuringPeriod>
  <us-gaap:ConversionOfStockDescription contextRef="c129_From20Aug2019To4Sep2019_UnsecuredConvertiblePromissoryNoteMember">(i) $.50 per share (the &amp;#x201c;Fixed Conversion Price&amp;#x201d;), subject to adjustment, or (ii) 70% of the per share offering price (the &amp;#x201c;Alternative Conversion Price&amp;#x201d;) of the completed public equity offering of the Company in an amount exceeding $10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the &amp;#x201c;Public Offering&amp;#x201d;), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the C.L.L. Note. On April 20, 2020, the Company entered into an exchange agreement with C.L.L.. The aggregate principal amount plus accrued interest expenses were $289,974, and the Company agreed to issue to the Holders an aggregate of 162,908 shares of the Company&amp;#x2019;s common stock, and warrants to purchase 162,908 shares of common stock. As of March 31, 2021, these common shares have been issued.</us-gaap:ConversionOfStockDescription>
  <us-gaap:DebtInstrumentFaceAmount unitRef="usd" contextRef="c130_AsOf29Oct2019_UnsecuredConvertiblePromissoryNoteMember" decimals="0">250000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:PaymentsToAcquireNotesReceivable unitRef="usd" contextRef="c131_From1Oct2019To29Oct2019_UnsecuredConvertiblePromissoryNoteMember" decimals="0">250000</us-gaap:PaymentsToAcquireNotesReceivable>
  <us-gaap:DebtInstrumentInterestRateDuringPeriod unitRef="pure" contextRef="c131_From1Oct2019To29Oct2019_UnsecuredConvertiblePromissoryNoteMember" decimals="2">0.20</us-gaap:DebtInstrumentInterestRateDuringPeriod>
  <us-gaap:ConversionOfStockDescription contextRef="c131_From1Oct2019To29Oct2019_UnsecuredConvertiblePromissoryNoteMember">(i) $.50 per share (the &amp;#x201c;Fixed Conversion Price&amp;#x201d;), subject to adjustment, or (ii) 70% of the per share offering price (the &amp;#x201c;Alternative Conversion Price&amp;#x201d;) of the completed public equity offering of the Company in an amount exceeding $10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the &amp;#x201c;Public Offering&amp;#x201d;), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the Lee Note. As of March 31, 2021, the Company paid off the convertible promissory note of $311,233, including principal and accrued and unpaid interest expense.</us-gaap:ConversionOfStockDescription>
  <us-gaap:ConversionOfStockDescription contextRef="c132_From1Oct2020To23Oct2020_SecuritiesPurchaseAgreementMember">Pursuant to the October SPA, the Company sold and issued a convertible promissory note (the &amp;#x201c;October Note&amp;#x201d;) in the principal amount of $2,500,000 to the investor and received the payment from such investor on October 30, 2020. The October Note was issued on October 23, 2020 and the maturity date of the October Note is the twenty-four (24) month anniversary from the issuance date (the &amp;#x201c;Maturity Date&amp;#x201d;). Upon the Maturity Date, the Company shall pay to the holder, in cash, an amount representing all outstanding principal amount and accrued and unpaid interest under the October Note. The October Note bears an interest rate of ten percent (10%) per annum and may be convertible into shares of the Company&amp;#x2019;s common stock at a fixed conversion price of $2.25 per share.</us-gaap:ConversionOfStockDescription>
  <us-gaap:ConvertibleDebt unitRef="usd" contextRef="c133_AsOf31Mar2021_UnsecuredConvertiblePromissoryNoteMember" decimals="0">2500000</us-gaap:ConvertibleDebt>
  <us-gaap:ConvertibleDebt unitRef="usd" contextRef="c134_AsOf31Dec2020_UnsecuredConvertiblePromissoryNoteMember" decimals="0">2750000</us-gaap:ConvertibleDebt>
  <us-gaap:DebtInstrumentIncreaseAccruedInterest unitRef="usd" contextRef="c135_From1Jan2021To31Mar2021_UnsecuredConvertiblePromissoryNoteMember" decimals="0">110215</us-gaap:DebtInstrumentIncreaseAccruedInterest>
  <us-gaap:DebtInstrumentIncreaseAccruedInterest unitRef="usd" contextRef="c136_From1Jan2020To31Dec2020_UnsecuredConvertiblePromissoryNoteMember" decimals="0">104551</us-gaap:DebtInstrumentIncreaseAccruedInterest>
  <abvcd:TotalInterestExpenses unitRef="usd" contextRef="c135_From1Jan2021To31Mar2021_UnsecuredConvertiblePromissoryNoteMember" decimals="0">66897</abvcd:TotalInterestExpenses>
  <abvcd:TotalInterestExpenses unitRef="usd" contextRef="c136_From1Jan2020To31Dec2020_UnsecuredConvertiblePromissoryNoteMember" decimals="0">95214</abvcd:TotalInterestExpenses>
  <abvcd:BankLoansAbstract contextRef="c0_From1Jan2021To31Mar2021">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;8. BANK LOANS&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%&quot;&gt;
  &lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 24px; font-size: 10pt&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;(1)&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;font-size: 10pt&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Short-term bank loan consists of the following:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;vertical-align: bottom; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;March 31,&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;December&amp;#xa0;31,&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;vertical-align: bottom; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;2021&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: justify&quot;&gt;Cathay United Bank&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;263,250&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;267,000&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;CTBC Bank&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;702,000&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;712,000&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-bottom: 1.5pt&quot;&gt;Cathay Bank&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;650,000&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;650,000&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-bottom: 4pt&quot;&gt;Total&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;1,615,250&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;1,629,000&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;Cathay United Bank&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;On June 28, 2016, BioLite Taiwan and Cathay United
Bank entered into a one-year bank loan agreement (the &amp;#x201c;Cathay United Loan Agreement&amp;#x201d;) in an amount of NT$7,500,000, equivalent
to $263,250. The term started June 28, 2016 with maturity date at June 28, 2017. The loan balance bears interest at a floating rate of
prime rate plus 1.15%. The prime rate is based on term deposit saving interest rate of Cathay United Bank. On September 6, 2017, BioLite
Taiwan extended the Cathay United Loan Agreement for one year, which was due on September 6, 2018, with the principal amount of NT$7,500,000,
equivalent to $263,250. On October 1, 2018, BioLite Taiwan extended the Cathay United Loan Agreement with the same principal amount of
NT$7,500,000, equivalent to $263,250 for one year, which was due on September 6, 2019. On September 6, 2019, BioLite Taiwan extended the
Cathay United Loan Agreement with the same principal amount of NT$7,500,000, equivalent to $263,250 for one year, which is due on September
6, 2020. On September 6, 2020, BioLite Taiwan extended the Cathay United Loan Agreement with the same principal amount of NT$7,500,000,
equivalent to $263,250 for one year, which is due on September 6, 2021. As of March 31, 2021 and December 31, 2020, the effective interest
rates per annum was 2.1%. The loan is collateralized by the building and improvement of BioLite Taiwan, and is also personal guaranteed
by the Company&amp;#x2019;s chairman.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;Interest expenses were $1,383 and $1,378 for the
three months ended March 31, 2021 and 2020, respectively.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;CTBC Bank&lt;/font&gt;&amp;#xa0;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;On June 12, 2017 and July 19, 2017, BioLite Taiwan
and CTBC Bank entered into short-term saving secured bank loan agreements (the &amp;#x201c;CTBC Loan Agreements&amp;#x201d;) in an amount of NT$10,000,000,
equivalent to $351,000, and NT$10,000,000, equivalent to $351,000, respectively. Both two loans with the same maturity date at January
19, 2018. In February 2018, BioLite Taiwan combined two loans and extended the loan contract with CTBC for one year. On January 18, 2019,
BioLite Taiwan and CTBC Bank agreed to extend the loan with a new maturity date, which was July 18, 2019. On July 18, 2019, BioLite Taiwan
extended the CTBC Loan Agreement with the same principal amount of NT$20,000,000, equivalent to $702,000 for six months, which is due
on January 17, 2020. On January 19, 2020, BioLite Taiwan extended the CTBC Loan Agreement with the same principal amount of NT$20,000,000,
equivalent to $702,000 for six months, which is due on July 19, 2020. On July 17, 2020, BioLite Taiwan extended the CTBC Loan Agreement
with the same principal amount of NT$20,000,000, equivalent to $702,000 for six months, which is due on January 15, 2021. On January 15,
2021, BioLite Taiwan extended the CTBC Loan Agreement with the same principal amount of NT$20,000,000, equivalent to $702,000 for six
months, which is due on July 15, 2021. The loan balances bear interest at a fixed rate of 1.68% per annum. The loan is secured by the
money deposited in a savings account with the CTBC Bank. This loan was also personal guaranteed by the Company&amp;#x2019;s chairman and BioFirst.
During the year ended December 31, 2020, BioLite Taiwan has opened a TCD account with CTBC bank to guarantee the loan going forward.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;Interest expenses were $2,949 and $2,755 for the
three months ended March 31, 2021 and 2020, respectively.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;Cathay Bank&lt;/font&gt;&amp;#xa0;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;On January 21, 2019, the Company received a loan
in the amount of $500,000 from Cathay Bank (the &amp;#x201c;Bank&amp;#x201d;) pursuant to a business loan agreement (the &amp;#x201c;Loan Agreement&amp;#x201d;)
entered by and between the Company and Bank on January 8, 2019 and a promissory note (the &amp;#x201c;Note&amp;#x201d;) executed by the Company
on the same day. The Loan Agreement provides for a revolving line of credit in the principal amount of $1,000,000 with a maturity date
(the &amp;#x201c;Maturity Date&amp;#x201d;) of January 1, 2020. The Note executed in connection with the Loan Agreement bears an interest rate (the
&amp;#x201c;Regular Interest Rate&amp;#x201d;) equal to the sum of one percent (1%) and the prime rate as published in the Wall Street Journal (the
&amp;#x201c;Index&amp;#x201d;) and the accrued interest shall become payable each month from February 1, 2019. Pursuant to the Note, the Company
shall pay the entire outstanding principal plus accrued unpaid interest on the Maturity Date and may prepay portion or all of the Note
before the Maturity Date without penalty. If the Company defaults on the Note, the default interest rate shall become five percent (5%)
plus the Regular Interest Rate.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;In connection with the Note and Loan Agreement,
on January 8, 2019, each of Dr. Tsung Shann Jiang and Dr. George Lee, executed a commercial guaranty (the &amp;#x201c;Guaranty&amp;#x201d;) to guaranty
the loans for the Company pursuant to the Loan Agreement and Note, severally and individually, in the amount not exceeding $500,000 each
until the entire Note plus interest are fully paid and satisfied. Dr. Tsung Shann Jiang is the Chairman and Chief Executive Officer of
BioLite Holding, Inc. and Dr. George Lee serves as the Chairman of the board of directors of BioKey, Inc, which became a wholly-owned
subsidiary of the Company effective by operation of law on or about February 5, 2019. On December 29, 2020, the Company entered into a
new loan extension agreement and assignment of deposit account with the Bank, which allowed Dr. Tsung Shann Jiang and Dr. George Lee to
be removed as guarantees from the list of Guaranty.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;In addition, on January 8, 2019, each of the
Company and BioKey, a wholly-owned subsidiary of the Company, signed a commercial security agreement (the &amp;#x201c;Security Agreement&amp;#x201d;)
to secure the loans under the Loan Agreement and the Note. Pursuant to the Security Agreements, each of the Company and BioKey (each,
a &amp;#x201c;Grantor&amp;#x201d;, and collectively, the &amp;#x201c;Grantors&amp;#x201d;) granted security interest in the collaterals as defined therein,
comprised of almost all of the assets of each Grantor, to secure such loans for the benefit of the Bank. On March 31, 2020, the Company
extended the Loan Agreement with the same term for seven months, which is due on October 31, 2020. On April 8, 2020 and October 3, 2020,
the Company repaid an aggregated principal amount of $350,000. On December 3, 2020, The Company renewed the Loan Agreement with the principal
amount of $650,000 for ten months, which is due on October 31, 2021. The outstanding loan balance was $650,000 as of March 31, 2021.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;Interest expenses were $3,927 and $13,740 for
the three months ended March 31, 2021 and 2020, respectively.&lt;/p&gt;&lt;br/&gt;</abvcd:BankLoansAbstract>
  <us-gaap:DebtInstrumentFaceAmount unitRef="usd" contextRef="c137_AsOf28Jun2016_NTMember_CathayUnitedLoanAgreementMember" decimals="0">7500000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentFaceAmount unitRef="usd" contextRef="c138_AsOf28Jun2016_CathayUnitedLoanAgreementMember" decimals="0">263250</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentMaturityDate contextRef="c139_From1Jun2016To28Jun2016_CathayUnitedLoanAgreementMember">2017-06-28</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:DebtInstrumentInterestRateEffectivePercentage unitRef="pure" contextRef="c138_AsOf28Jun2016_CathayUnitedLoanAgreementMember" decimals="4">0.0115</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
  <us-gaap:DebtInstrumentTerm contextRef="c140_From1Sep2017To6Sep2017_CathayUnitedLoanAgreementMember">P1Y</us-gaap:DebtInstrumentTerm>
  <us-gaap:DebtInstrumentFaceAmount unitRef="usd" contextRef="c141_AsOf6Sep2017_NTMember_CathayUnitedLoanAgreementMember" decimals="0">7500000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentFaceAmount unitRef="usd" contextRef="c142_AsOf6Sep2017_CathayUnitedLoanAgreementMember" decimals="0">263250</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentFaceAmount unitRef="usd" contextRef="c143_AsOf1Oct2018_NTMember_CathayUnitedLoanAgreementMember" decimals="0">7500000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentFaceAmount unitRef="usd" contextRef="c144_AsOf1Oct2018_CathayUnitedLoanAgreementMember" decimals="0">263250</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentTerm contextRef="c145_From25Sep2018To1Oct2018_CathayUnitedLoanAgreementMember">P1Y</us-gaap:DebtInstrumentTerm>
  <us-gaap:DebtInstrumentFaceAmount unitRef="usd" contextRef="c146_AsOf6Sep2019_NTMember_CathayUnitedLoanAgreementMember" decimals="0">7500000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentFaceAmount unitRef="usd" contextRef="c147_AsOf6Sep2019_CathayUnitedLoanAgreementMember" decimals="0">263250</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentTerm contextRef="c148_From1Sep2019To6Sep2019_CathayUnitedLoanAgreementMember">P1Y</us-gaap:DebtInstrumentTerm>
  <us-gaap:DebtInstrumentFaceAmount unitRef="usd" contextRef="c149_AsOf6Sep2020_NTMember_CathayUnitedLoanAgreementMember" decimals="0">7500000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentFaceAmount unitRef="usd" contextRef="c150_AsOf6Sep2020_CathayUnitedLoanAgreementMember" decimals="0">263250</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentTerm contextRef="c151_From1Sep2020To6Sep2020_CathayUnitedLoanAgreementMember">P1Y</us-gaap:DebtInstrumentTerm>
  <us-gaap:DebtInstrumentInterestRateEffectivePercentage unitRef="pure" contextRef="c3_AsOf31Dec2020" decimals="3">0.021</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
  <us-gaap:InterestAndDebtExpense unitRef="usd" contextRef="c152_From1Jan2021To31Mar2021_CathayUnitedLoanAgreementMember" decimals="0">1383</us-gaap:InterestAndDebtExpense>
  <us-gaap:InterestAndDebtExpense unitRef="usd" contextRef="c153_From1Jan2020To31Mar2020_CathayUnitedLoanAgreementMember" decimals="0">1378</us-gaap:InterestAndDebtExpense>
  <us-gaap:DebtInstrumentFaceAmount unitRef="usd" contextRef="c154_AsOf12Jun2017_NTMember_CTBCBankMember" decimals="0">10000000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentFaceAmount unitRef="usd" contextRef="c155_AsOf12Jun2017_CTBCBankMember" decimals="0">351000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentFaceAmount unitRef="usd" contextRef="c156_AsOf19Jun2017_NTMember_CTBCBankMember" decimals="0">10000000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentFaceAmount unitRef="usd" contextRef="c157_AsOf19Jun2017_CTBCBankMember" decimals="0">351000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentMaturityDate contextRef="c158_From1Jun2017To12Jun2017_CTBCBankMember">2018-01-19</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:DebtInstrumentTerm contextRef="c159_From1Jun2017To19Jun2017_CTBCBankMember">P1Y</us-gaap:DebtInstrumentTerm>
  <us-gaap:DebtInstrumentTerm contextRef="c158_From1Jun2017To12Jun2017_CTBCBankMember">P1Y</us-gaap:DebtInstrumentTerm>
  <us-gaap:DebtInstrumentFaceAmount unitRef="usd" contextRef="c160_AsOf18Jul2019_NTMember_CTBCBankMember" decimals="0">20000000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentFaceAmount unitRef="usd" contextRef="c161_AsOf18Jul2019_CTBCBankMember" decimals="0">702000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentTerm contextRef="c162_From1Jul2019To18Jul2019">P6Y</us-gaap:DebtInstrumentTerm>
  <us-gaap:DebtInstrumentFaceAmount unitRef="usd" contextRef="c163_AsOf19Jan2020_NTMember_CTBCBankMember" decimals="0">20000000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentFaceAmount unitRef="usd" contextRef="c164_AsOf19Jan2020_CTBCBankMember" decimals="0">702000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentTerm contextRef="c165_From1Jan2020To19Jan2020_CTBCBankMember">P6Y</us-gaap:DebtInstrumentTerm>
  <us-gaap:DebtInstrumentFaceAmount unitRef="usd" contextRef="c166_AsOf17Jul2020_NTMember_CTBCBankMember" decimals="0">20000000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentFaceAmount unitRef="usd" contextRef="c167_AsOf17Jul2020_CTBCBankMember" decimals="0">702000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentTerm contextRef="c168_From1Jul2020To17Jul2020_CTBCBankMember">P6Y</us-gaap:DebtInstrumentTerm>
  <us-gaap:DebtInstrumentFaceAmount unitRef="usd" contextRef="c169_AsOf15Jan2021_NTMember_CTBCBankMember" decimals="0">20000000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentFaceAmount unitRef="usd" contextRef="c170_AsOf15Jan2021_CTBCBankMember" decimals="0">702000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentTerm contextRef="c171_From1Jan2021To15Jan2021_CTBCBankMember">P6Y</us-gaap:DebtInstrumentTerm>
  <us-gaap:DebtInstrumentInterestRateEffectivePercentage unitRef="pure" contextRef="c172_AsOf31Mar2021_CTBCBankMember" decimals="4">0.0168</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
  <us-gaap:InterestAndDebtExpense unitRef="usd" contextRef="c173_From1Jan2021To31Mar2021_CTBCBankMember" decimals="0">2949</us-gaap:InterestAndDebtExpense>
  <us-gaap:InterestAndDebtExpense unitRef="usd" contextRef="c174_From1Jan2020To31Mar2020_CTBCBankMember" decimals="0">2755</us-gaap:InterestAndDebtExpense>
  <abvcd:ReceivedLoanAmount unitRef="usd" contextRef="c175_AsOf21Jan2019_LoanAgreementMember" decimals="0">500000</abvcd:ReceivedLoanAmount>
  <us-gaap:DebtInstrumentFaceAmount unitRef="usd" contextRef="c176_AsOf21Jan2019" decimals="0">1000000</us-gaap:DebtInstrumentFaceAmount>
  <abvcd:RegularInterestRateDescription contextRef="c177_From1Jan2019To21Jan2019_LoanAgreementMember">The Note executed in connection with the Loan Agreement bears an interest rate (the &amp;#x201c;Regular Interest Rate&amp;#x201d;) equal to the sum of one percent (1%) and the prime rate as published in the Wall Street Journal (the &amp;#x201c;Index&amp;#x201d;) and the accrued interest shall become payable each month from February 1, 2019. Pursuant to the Note, the Company shall pay the entire outstanding principal plus accrued unpaid interest on the Maturity Date and may prepay portion or all of the Note before the Maturity Date without penalty. If the Company defaults on the Note, the default interest rate shall become five percent (5%) plus the Regular Interest Rate.</abvcd:RegularInterestRateDescription>
  <abvcd:ExceedingAmount unitRef="usd" contextRef="c178_From1Jan2019To8Jan2019_LoanAgreementMember" decimals="0">500000</abvcd:ExceedingAmount>
  <abvcd:RegularInterestRateDescription contextRef="c179_From1Jan2020To31Mar2020_LoanAgreementMember">On March 31, 2020, the Company extended the Loan Agreement with the same term for seven months, which is due on October 31, 2020.</abvcd:RegularInterestRateDescription>
  <abvcd:ReceivedLoanAmount unitRef="usd" contextRef="c180_AsOf8Apr2020_CathayBnakMember" decimals="0">350000</abvcd:ReceivedLoanAmount>
  <abvcd:ReceivedLoanAmount unitRef="usd" contextRef="c181_AsOf3Oct2020_CathayBnakMember" decimals="0">350000</abvcd:ReceivedLoanAmount>
  <us-gaap:DebtInstrumentFaceAmount unitRef="usd" contextRef="c182_AsOf3Dec2020_CathayBnakMember" decimals="0">650000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentTerm contextRef="c183_From1Dec2020To3Dec2020_CathayBnakMember">P10Y</us-gaap:DebtInstrumentTerm>
  <us-gaap:LoansPayable unitRef="usd" contextRef="c184_AsOf31Mar2021_CathayBnakMember" decimals="0">650000</us-gaap:LoansPayable>
  <us-gaap:InterestAndDebtExpense unitRef="usd" contextRef="c185_From1Jan2021To31Mar2021_CathayBnakMember" decimals="0">3927</us-gaap:InterestAndDebtExpense>
  <us-gaap:InterestAndDebtExpense unitRef="usd" contextRef="c186_From1Jan2020To31Mar2020_CathayBnakMember" decimals="0">13740</us-gaap:InterestAndDebtExpense>
  <us-gaap:ScheduleOfShortTermDebtTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;vertical-align: bottom; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;March 31,&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;December&amp;#xa0;31,&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;vertical-align: bottom; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;2021&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: justify&quot;&gt;Cathay United Bank&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;263,250&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;267,000&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;CTBC Bank&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;702,000&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;712,000&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-bottom: 1.5pt&quot;&gt;Cathay Bank&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;650,000&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;650,000&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-bottom: 4pt&quot;&gt;Total&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;1,615,250&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;1,629,000&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfShortTermDebtTextBlock>
  <us-gaap:ShortTermBorrowings unitRef="usd" contextRef="c187_AsOf31Mar2021_CathayUnitedBankMember" decimals="0">263250</us-gaap:ShortTermBorrowings>
  <us-gaap:ShortTermBorrowings unitRef="usd" contextRef="c188_AsOf31Dec2020_CathayUnitedBankMember" decimals="0">267000</us-gaap:ShortTermBorrowings>
  <us-gaap:ShortTermBorrowings unitRef="usd" contextRef="c172_AsOf31Mar2021_CTBCBankMember" decimals="0">702000</us-gaap:ShortTermBorrowings>
  <us-gaap:ShortTermBorrowings unitRef="usd" contextRef="c189_AsOf31Dec2020_CTBCBankMember" decimals="0">712000</us-gaap:ShortTermBorrowings>
  <us-gaap:ShortTermBorrowings unitRef="usd" contextRef="c184_AsOf31Mar2021_CathayBnakMember" decimals="0">650000</us-gaap:ShortTermBorrowings>
  <us-gaap:ShortTermBorrowings unitRef="usd" contextRef="c190_AsOf31Dec2020_CathayBnakMember" decimals="0">650000</us-gaap:ShortTermBorrowings>
  <us-gaap:ShortTermBorrowings unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">1615250</us-gaap:ShortTermBorrowings>
  <us-gaap:ShortTermBorrowings unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">1629000</us-gaap:ShortTermBorrowings>
  <abvcd:PaycheckProtectionProgramLoanPayableTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;9. PAYCHECK PROTECTION PROGRAM LOAN PAYABLE&lt;/b&gt;&amp;#xa0;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;On April 14, 2020, the Company received a loan
in the amount of $124,400 under the Paycheck Protection Program (&amp;#x201c;PPP&amp;#x201d;) administered by the United States Small Business
Administration (the &amp;#x201c;SBA&amp;#x201d;) from East West Bank. According to the Coronavirus Aid, Relief, and Economic Security Act (the
&amp;#x201c;Cares Act&amp;#x201d;), PPP loan provides for forgiveness of up to the full principal amount and accrued interest if the funds are
used for payroll costs, interest on mortgages, rent, and utilities. However, at least 60% of the forgiven amount must have been used
for payroll.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The loan was granted pursuant to a promissory
note dated April 14, 2020 issued by the Company, which matures on April 13, 2022 and bears interest at a rate of 1.00% per annum. The
Company will pay the principal in one payment of all outstanding principal plus all accrued unpaid interest on that date that is two years
after the date of the promissory note. In addition, the Company will pay regular monthly payments in an amount equal to one month&amp;#x2019;s
accrued interest commencing on the date that is seven months after the date of the promissory note, with all subsequent interest payments
to be due on the same day of each month after that. No collateral or personal guarantees are required.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;On January 29, 2021, the entity of BioKey received
a loan in the amount of $132,331 under the Paycheck Protection Program administered by the United States Small Business Administration
from East West Bank. According to the Coronavirus Aid, Relief, and Economic Security Act (the &amp;#x201c;Cares Act&amp;#x201d;), PPP loan provides
for forgiveness of up to the full principal amount and accrued interest if the funds are used for payroll costs, interest on mortgages,
rent, and utilities. However, at least 60% of the forgiven amount must have been used for payroll. The loan was granted pursuant to a
promissory note dated January 27, 2021 issued by the Company, which matures on January 28, 2026 and bears interest at a rate of 1.00%
per annum. The Company will pay the principal in one payment of all outstanding principal plus all accrued unpaid interest on that date
that is five years after the date of the promissory note. In addition, the Company will start the application with the US Government regarding
the loan forgiveness program as soon as the US Government allows. No collateral or personal guarantees are required.&amp;#xa0;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;On February 7, 2021, the entity of ABVC received
a loan in the amount of $104,167 under the Paycheck Protection Program administered by the United States Small Business Administration
from Cathay Bank. According to the Coronavirus Aid, Relief, and Economic Security Act (the &amp;#x201c;Cares Act&amp;#x201d;), PPP loan provides
for forgiveness of up to the full principal amount and accrued interest if the funds are used for payroll costs, interest on mortgages,
rent, and utilities. However, at least 60% of the forgiven amount must have been used for payroll. The loan was granted pursuant to a
promissory note dated February 7, 2021 issued by the Company, which matures on February 6, 2026 and bears interest at a rate of 1.00%
per annum. The Company will pay the principal in one payment of all outstanding principal plus all accrued unpaid interest on that date
that is five years after the date of the promissory note. In addition, the Company will start the application with the US Government regarding
the loan forgiveness program as soon as the US Government allows. No collateral or personal guarantees are required.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;PPP loan Forgiveness&amp;#xa0;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;On February 27, 2021, the Company submitted all
required to East West Bank for the application of forgiveness. During 2021, the PPP loan from East West Bank of $124,400 was waived by
the SBA as a gesture of supporting the operation of the Company. The Company recorded the forgiveness of the PPP loan as government grant
income during the three months ended March 31, 2021.&lt;/p&gt;&lt;br/&gt;</abvcd:PaycheckProtectionProgramLoanPayableTextBlock>
  <abvcd:PaycheckProtectionProgramDescription contextRef="c191_From1Apr2020To14Apr2020_PAYCHECKPROTECTIONPROGRAMMember">the Company received a loan in the amount of $124,400 under the Paycheck Protection Program (&amp;#x201c;PPP&amp;#x201d;) administered by the United States Small Business Administration (the &amp;#x201c;SBA&amp;#x201d;) from East West Bank. According to the Coronavirus Aid, Relief, and Economic Security Act (the &amp;#x201c;Cares Act&amp;#x201d;), PPP loan provides for forgiveness of up to the full principal amount and accrued interest if the funds are used for payroll costs, interest on mortgages, rent, and utilities. However, at least 60% of the forgiven amount must have been used for payroll. The loan was granted pursuant to a promissory note dated April 14, 2020 issued by the Company, which matures on April 13, 2022 and bears interest at a rate of 1.00% per annum. The Company will pay the principal in one payment of all outstanding principal plus all accrued unpaid interest on that date that is two years after the date of the promissory note. In addition, the Company will pay regular monthly payments in an amount equal to one month&amp;#x2019;s accrued interest commencing on the date that is seven months after the date of the promissory note, with all subsequent interest payments to be due on the same day of each month after that. No collateral or personal guarantees are required. On January 29, 2021, the entity of BioKey received a loan in the amount of $132,331 under the Paycheck Protection Program administered by the United States Small Business Administration from East West Bank. According to the Coronavirus Aid, Relief, and Economic Security Act (the &amp;#x201c;Cares Act&amp;#x201d;), PPP loan provides for forgiveness of up to the full principal amount and accrued interest if the funds are used for payroll costs, interest on mortgages, rent, and utilities. However, at least 60% of the forgiven amount must have been used for payroll. The loan was granted pursuant to a promissory note dated January 27, 2021 issued by the Company, which matures on January 28, 2026 and bears interest at a rate of 1.00% per annum. The Company will pay the principal in one payment of all outstanding principal plus all accrued unpaid interest on that date that is five years after the date of the promissory note. In addition, the Company will start the application with the US Government regarding the loan forgiveness program as soon as the US Government allows. No collateral or personal guarantees are required. On February 7, 2021, the entity of ABVC received a loan in the amount of $104,167 under the Paycheck Protection Program administered by the United States Small Business Administration from Cathay Bank. According to the Coronavirus Aid, Relief, and Economic Security Act (the &amp;#x201c;Cares Act&amp;#x201d;), PPP loan provides for forgiveness of up to the full principal amount and accrued interest if the funds are used for payroll costs, interest on mortgages, rent, and utilities. However, at least 60% of the forgiven amount must have been used for payroll. The loan was granted pursuant to a promissory note dated February 7, 2021 issued by the Company, which matures on February 6, 2026 and bears interest at a rate of 1.00% per annum. The Company will pay the principal in one payment of all outstanding principal plus all accrued unpaid interest on that date that is five years after the date of the promissory note. In addition, the Company will start the application with the US Government regarding the loan forgiveness program as soon as the US Government allows. No collateral or personal guarantees are required.</abvcd:PaycheckProtectionProgramDescription>
  <us-gaap:DebtInstrumentFaceAmount unitRef="usd" contextRef="c192_AsOf29Jan2021" decimals="0">132331</us-gaap:DebtInstrumentFaceAmount>
  <abvcd:PercentageOfForgivenAmount unitRef="pure" contextRef="c192_AsOf29Jan2021" decimals="2">0.60</abvcd:PercentageOfForgivenAmount>
  <abvcd:InterestRate unitRef="pure" contextRef="c192_AsOf29Jan2021" decimals="4">0.0100</abvcd:InterestRate>
  <abvcd:PromissoryNoteTerm contextRef="c193_From2Jan2021To29Jan2021">P5Y</abvcd:PromissoryNoteTerm>
  <us-gaap:DebtInstrumentFaceAmount unitRef="usd" contextRef="c194_AsOf7Feb2021" decimals="0">104167</us-gaap:DebtInstrumentFaceAmount>
  <abvcd:PercentageOfForgivenAmount unitRef="pure" contextRef="c194_AsOf7Feb2021" decimals="2">0.60</abvcd:PercentageOfForgivenAmount>
  <abvcd:InterestRate unitRef="pure" contextRef="c194_AsOf7Feb2021" decimals="4">0.0100</abvcd:InterestRate>
  <abvcd:PromissoryNoteTerm contextRef="c195_From27Jan2021To7Feb2021">P5Y</abvcd:PromissoryNoteTerm>
  <abvcd:LoanAmout unitRef="usd" contextRef="c196_AsOf31Mar2021_PAYCHECKPROTECTIONPROGRAMMember" decimals="0">124400</abvcd:LoanAmout>
  <us-gaap:MembersEquityNotesDisclosureTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;&lt;b&gt;10. NOTES PAYABLE&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;In January, 2019, BioLite Taiwan entered an unsecured
loan agreement with one individual bearing interest at fixed rates at 12% per annum of NT$3,000,000, equivalent to $105,300, for working
capital purpose. As of the date of this report, BioLite Taiwan is still in discussion with the individual with respect to the terms of
the unsecured loans.&amp;#xa0;As of March 31, 2021 and 2020, the balance due to this individual amounted to $105,300 and $106,800, respectively.&amp;#xa0;Interest
expense was $3,204 and $2,988 for the three months ended March 31, 2021 and 2020, respectively.&lt;/p&gt;&lt;br/&gt;</us-gaap:MembersEquityNotesDisclosureTextBlock>
  <abvcd:UnsecuredLoanAgreementsDescription contextRef="c197_From1Jan2019To31Jan2019">In January, 2019, BioLite Taiwan entered an unsecured loan agreement with one individual bearing interest at fixed rates at 12% per annum of NT$3,000,000, equivalent to $105,300, for working capital purpose.</abvcd:UnsecuredLoanAgreementsDescription>
  <us-gaap:OtherNotesPayable unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">105300</us-gaap:OtherNotesPayable>
  <us-gaap:OtherNotesPayable unitRef="usd" contextRef="c198_AsOf31Dec2021" decimals="0">106800</us-gaap:OtherNotesPayable>
  <us-gaap:InterestExpenseOther unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">3204</us-gaap:InterestExpenseOther>
  <us-gaap:InterestExpenseOther unitRef="usd" contextRef="c199_From1Jan2021To31Dec2021" decimals="0">2988</us-gaap:InterestExpenseOther>
  <us-gaap:ShortTermDebtTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;11. SHORT-TERM LOAN&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;On February 18, 2020, the Company entered an unsecured
loan agreement with a third-party in the amount of $100,000. This loan bears the interest rate of 1.5% per annum and will be matured on
August 17, 2020. On August 18, 2020, the Company extended the contract for six months under the same term. Accrued interest expense was
$375 and $1,302 as of March 31, 2021 and December 31, 2020, respectively.&lt;/p&gt;&lt;br/&gt;</us-gaap:ShortTermDebtTextBlock>
  <us-gaap:UnsecuredDebt unitRef="usd" contextRef="c200_AsOf18Feb2020" decimals="0">100000</us-gaap:UnsecuredDebt>
  <us-gaap:ShortTermDebtInterestRateIncrease unitRef="pure" contextRef="c0_From1Jan2021To31Mar2021" decimals="3">0.015</us-gaap:ShortTermDebtInterestRateIncrease>
  <us-gaap:DebtInstrumentIncreaseAccruedInterest unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">375</us-gaap:DebtInstrumentIncreaseAccruedInterest>
  <us-gaap:DebtInstrumentIncreaseAccruedInterest unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">1302</us-gaap:DebtInstrumentIncreaseAccruedInterest>
  <us-gaap:DebtInstrumentMaturityDate contextRef="c0_From1Jan2021To31Mar2021">2020-08-17</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;12. RELATED PARTIES TRANSACTIONS&lt;/b&gt;&amp;#xa0;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The related parties of the company with whom transactions
are reported in these financial statements are as follows:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse&quot;&gt;
  &lt;tr&gt;
    &lt;td style=&quot;border-bottom: black 1.5pt solid; vertical-align: top; width: 36%&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;&lt;b&gt;Name of entity or Individual&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; width: 2%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: black 1.5pt solid; vertical-align: bottom; width: 62%; text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;&lt;b&gt;Relationship with the Company and its subsidiaries&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style=&quot;vertical-align: top&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;BioFirst Corporation (the &amp;#x201c;BioFirst&amp;#x201d;)&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Entity controlled by controlling beneficiary shareholder of YuanGene&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style=&quot;vertical-align: top&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;BioFirst (Australia) Pty Ltd. (the &amp;#x201c;BioFirst (Australia)&amp;#x201d;)&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style=&quot;vertical-align: top&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Rgene Corporation (the &amp;#x201c;Rgene&amp;#x201d;)&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Shareholder of the Company; entity controlled by controlling beneficiary shareholder of YuanGene&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style=&quot;vertical-align: top&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;YuanGene Corporation (the &amp;#x201c;YuanGene&amp;#x201d;)&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Controlling beneficiary shareholder of the Company&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style=&quot;vertical-align: top&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;AsiaGene Corporation (the &amp;#x201c;AsiaGene&amp;#x201d;)&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Shareholder; entity controlled by controlling beneficiary shareholder of YuanGene&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style=&quot;vertical-align: top&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Eugene Jiang&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Former President and Chairman&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style=&quot;vertical-align: top&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Keypoint Technology Ltd. (the &amp;#x201c;Keypoint&amp;#x2019;)&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;The Chairman of Keypoint is Eugene Jiang&amp;#x2019;s mother.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style=&quot;vertical-align: top&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Lion Arts Promotion Inc. (the &amp;#x201c;Lion Arts&amp;#x201d;)&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Shareholder of the Company&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style=&quot;vertical-align: top&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Yoshinobu Odaira (the &amp;#x201c;Odaira&amp;#x201d;)&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Director of the Company&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style=&quot;vertical-align: top&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;GenePharm Inc. (the &amp;#x201c;GenePharm&amp;#x201d;)&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Dr. George Lee, Board Director of Biokey, is the Chairman of GenePharm.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style=&quot;vertical-align: top&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Euro-Asia Investment &amp;amp; Finance Corp Ltd. (the &amp;#x201c;Euro-Asia&amp;#x201d;)&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Shareholder of the Company&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style=&quot;vertical-align: top&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;LBG USA, Inc. (the &amp;#x201c;LBG USA&amp;#x201d;)&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style=&quot;vertical-align: top&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;LionGene Corporation (the &amp;#x201c;LionGene&amp;#x201d;)&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Shareholder of the Company; Entity controlled by controlling beneficiary shareholder of YuanGene&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style=&quot;vertical-align: top&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Kimho Consultants Co., Ltd. (the &amp;#x201c;Kimho&amp;#x201d;)&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Shareholder of the Company&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style=&quot;vertical-align: top&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Mr. Tsung-Shann Jiang, the controlling beneficiary shareholder of the Company and Rgene, the Chairman and CEO of the BioLite Holding Inc. and BioLite Inc. and the President and a member of board of directors of BioFirst&lt;br/&gt;
&amp;#xa0;&lt;br/&gt;
Ms. Shu-Ling Jiang, Mr. Tsung-Shann Jiang&amp;#x2019;s wife, is the Chairman of Keypoint; and a member of board of directors of BioLite Inc.&lt;br/&gt;
&amp;#xa0;&lt;br/&gt;
Mr. Eugene Jiang is Mr. and Ms. Jiang&amp;#x2019;s son. Mr. Eugene Jiang is the chairman, and majority shareholder of the Company and a member of board of directors of BioLite Inc.&lt;br/&gt;
&amp;#xa0;&lt;br/&gt;
Mr. Chang-Jen Jiang is Mr. Tsung-Shann Jiang&amp;#x2019;s sibling and the director of the Company.&lt;br/&gt;
&amp;#xa0;&lt;br/&gt;
Ms. Mei-Ling Jiang is Ms. Shu-Ling Jiang&amp;#x2019;s sibling.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style=&quot;vertical-align: top&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Amkey Ventures, LLC (&amp;#x201c;Amkey&amp;#x201d;)&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;An entity controlled by Dr. George Lee, who serves as one of the board directors of BioKey, Inc&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style=&quot;vertical-align: top&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;BioLite Japan&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Entity controlled by controlling beneficiary shareholder of ABVC&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;Accounts receivable - related parties&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;Accounts receivable due from related parties consisted
of the following as of the periods indicated:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;March 31,&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;December 31,&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;2021&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: left&quot;&gt;GenePharm Inc.&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;142,225&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;142,225&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;Amkey&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;2,850&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;1,210&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 4pt; padding-left: 9pt&quot;&gt;Total&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font-weight: bold; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font-weight: bold; text-align: right&quot;&gt;145,075&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font-weight: bold; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font-weight: bold; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font-weight: bold; text-align: right&quot;&gt;143,435&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font-weight: bold; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;Due from related parties&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;Amount due from related parties consisted of the
following as of the periods indicated:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;March 31,&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;December 31,&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2021&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%&quot;&gt;Rgene&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;43,266&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;42,911&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td&gt;AsiaGene&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;4,287&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;4,241&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;BioFirst (Australia)&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;379,110&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;373,235&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;BioHopeKing Corporation&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;121,848&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;123,583&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;LBG USA&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;675&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;675&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;BioLite Japan&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;150,000&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;150,000&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td&gt;Keypoint&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,610&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,610&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt&quot;&gt;The Jiangs&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;2,093&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 4pt; padding-left: 9pt&quot;&gt;Total&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;702,889&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;696,255&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%&quot;&gt;
  &lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 24px&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;(1)&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;As of March 31, 2021, and December 31, 2020,
    the Company has advanced an aggregate amount of $43,266 and $42,911 to Rgene for working capital purpose. Under the terms of the
    loan agreement, the loan bears interest at 1% per month (or equivalent to 12% per annum) and the maturity date was December 31, 2020.
    As of March 31, 2021, and December 31, 2020, the outstanding loan balance was $31,239 and $31,684; and accrued interest was $12,027
    and $11,227, respectively.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%&quot;&gt;
  &lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 24px&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;(2)&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;On May 27, 2019, the Company entered into
    loan agreements with AsiaGene for NT $100,000, equivalent to $3,510, to meet its working capital needs.&amp;#xa0;&amp;#xa0;Under the terms
    of the loan agreement, the loan bears interest at 1% per month (or equivalent to 12% per annum) and the loan maturity date was December
    31, 2020. As of March 31, 2021, and December 31, 2020, the outstanding loan balance was $3,510 and $3,560, and accrued interest was
    $777 and $681, respectively.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%&quot;&gt;
  &lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 24px; font-size: 10pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;(3)&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify; font-size: 10pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;On May 11, 2018, the Company and BioFirst (Australia) entered into a loan agreement for a total amount of $40,000 to meet its working capital needs. The advances bear 0% interest rate and are due on demand prior to June 30, 2020. Afterwards, all outstanding load will bear interest rate at 12% per annum. On July 1, 2020, the Company entered into a loan agreement with BioFirst (Australia) for $321,487 to properly record R&amp;amp;D cost and tax refund allocation based on co-development contract executed on July 24, 2017. The loan will be matured on June 30, 2021 with an interest rate of 12% per annum. As of March 31, 2021 and December 31, 2020, the aggregate amount of outstanding loan and accrued interest was $379,110 and $373,235, respectively.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%&quot;&gt;
  &lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 24px&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;(4)&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;On February 24, 2015, BioLite Taiwan and
    BioHopeKing Corporation (the &amp;#x201c;BHK&amp;#x201d;) entered into a co-development agreement, (the &amp;#x201c;BHK Co-Development Agreement&amp;#x201d;,
    see Note 3). The development costs shall be shared 50/50 between BHK and the Company. Under the term of the agreement, BioLite issued
    relevant development cost to BHK. As of March 31, 2021 and 2020, due from BHK was $121,848 and $123,583, respectively.&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%&quot;&gt;
  &lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 24px&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;(5)&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;On February 27, 2019, the
    Company has advanced funds to LBG USA for working capital purpose. The advances bear 0% interest rate and are due on demand. As of
    March 31, 2021 and 2020, the outstanding advance balances was $675 and $675, respectively.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%&quot;&gt;
  &lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 24px&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;(6)&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;On May 8, 2020, the Company and Lucidaim
    entered into a Letter of Intent (LOI) in regard to a potential joint venture of BioLite Japan. Based on the LOI, each party will
    advance an aggregated amount of $150,000 to meet BioLite Japan&amp;#x2019;s working capital needs, which the Company advanced an amount
    of $150,000 and the advance bear 0% interest rate. As of March 31, 2021 and December 31, 2020, the outstanding advance balances was
    $150,000 and $150,000, respectively.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;(7)&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;On October 31, 2020, the
    Company has advanced an aggregate amount of $1,610 to Keypoint for working capital purpose. Under the terms of the loan agreement,
    the loan bears interest at 6.5% per annum and the loan will be matured on October 30, 2021. As of March 31, 2021 and December 31, 2020, the outstanding
    loan balance was $1,610.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%&quot;&gt;
  &lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 24px; font-size: 10pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;(8) &lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify; font-size: 10pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;In January 2021, the Company has advanced funds to the Jiangs. The advances bear 0% interest rate and are due on demand. As of March 31, 2021 and December 31, 2020, the outstanding advance balances was $2,093 and $0, respectively&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;Due to related parties&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;Amount due to related parties consisted of the
following as of the periods indicated:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;March&amp;#xa0;31,&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;December&amp;#xa0;31,&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2021&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: left&quot;&gt;BioFirst Corporation&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;23,647&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;23,647&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td&gt;AsiaGene&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;24,017&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td&gt;YuanGene&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;9,205&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;9,205&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;The Jiangs&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;18,750&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;16,627&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Due to shareholders&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;163,566&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;166,261&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt&quot;&gt;Due to employee&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;72,967&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;72,704&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 4pt; padding-left: 9pt&quot;&gt;Total&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font-weight: bold; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font-weight: bold; text-align: right&quot;&gt;312,152&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font-weight: bold; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font-weight: bold; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font-weight: bold; text-align: right&quot;&gt;288,445&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font-weight: bold; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%&quot;&gt;
  &lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 24px&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;(1)&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;
    Since 2019, BioFirst has advanced funds to the Company for working
capital purpose. The advances bear interest 1% per month (or equivalent to 12% per annum). As of March 31, 2021 and December 31, 2020,
the aggregate amount of outstanding balance and accrued interest is $23,647 and $23,647, respectively.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%&quot;&gt;
  &lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 24px&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;(2)&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;
    &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;/p&gt;
    &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;As of March 31, 2021, and December 31, 2020, AsiaGene
    has advanced the Company an aggregate amount of $24,017 and $0, respectively for working capital purpose. This advance bears 0% interest
    rate and is due on demand.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%&quot;&gt;
  &lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 24px&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;(3)&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;
    &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;/p&gt;
    &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;As of March 31, 2021, and December 31, 2020, YuanGene
    has advanced the Company an aggregate amount of $9,205 for working capital purpose. This advance bears 0% interest rate and is due on
    demand.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%&quot;&gt;
  &lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 24px&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;(4)&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;
    &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;/p&gt;
    &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;Since 2019, the Jiangs advanced funds to the Company
    for working capital purpose. As of March 31, 2021, and December 31, 2020, the outstanding balance due to the Jiangs amounted to $18,750
    and $16,627, respectively. These loans bear interest rate of 0% to 1% per month, and are due on demand.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%&quot;&gt;
  &lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 24px&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;(5)&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Since 2018, the Company&amp;#x2019;s shareholders
    have advanced funds to the Company for working capital purpose. The advances bear interest rate from 12% to 13.6224% per annum. As
    of March 31, 2021 and December 31, 2020, the outstanding principal and accrued interest was $163,566 and $166,261, respectively.
    Interest expenses in connection with these loans were $5,298 and $5,269 for the three months ended March 31, 2021 and 2020, respectively.&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%&quot;&gt;
  &lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 24px&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;(6)&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Commencing January, 2020, the Company had
    advances from one employee for working capital purpose. The outstanding balance including accrued interest due to this employee amounted
    to $72,967 and $72,704 as of March 31, 2021 and December 31, 2020, respectively. This loan bears interest rate of 1.5% per annum,
    and is due on demand.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <us-gaap:DebtInstrumentFaceAmount unitRef="usd" contextRef="c106_AsOf31Mar2021_RgeneCorporationMember" decimals="0">43266</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentFaceAmount unitRef="usd" contextRef="c107_AsOf31Dec2020_RgeneCorporationMember" decimals="0">42911</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentInterestRateTerms contextRef="c201_From1Jan2021To31Mar2021_RgeneCorporationMember">the loan bears interest at 1% per month (or equivalent to 12% per annum) and the maturity date was December 31, 2020.</us-gaap:DebtInstrumentInterestRateTerms>
  <us-gaap:ShorttermDebtAverageOutstandingAmount unitRef="usd" contextRef="c202_From1Jan2020To31Dec2020_RgeneCorporationMember" decimals="0">31239</us-gaap:ShorttermDebtAverageOutstandingAmount>
  <us-gaap:ShorttermDebtAverageOutstandingAmount unitRef="usd" contextRef="c201_From1Jan2021To31Mar2021_RgeneCorporationMember" decimals="0">31684</us-gaap:ShorttermDebtAverageOutstandingAmount>
  <abvcd:AccruedInterest unitRef="usd" contextRef="c106_AsOf31Mar2021_RgeneCorporationMember" decimals="0">12027</abvcd:AccruedInterest>
  <abvcd:AccruedInterest unitRef="usd" contextRef="c107_AsOf31Dec2020_RgeneCorporationMember" decimals="0">11227</abvcd:AccruedInterest>
  <abvcd:StockPurchaseAgreementDescription contextRef="c203_From25Jan2019To3Feb2019_ConversionAgreementsOneMember_BioFirstMember">On May 27, 2019, the Company entered into loan agreements with AsiaGene for NT $100,000, equivalent to $3,510, to meet its working capital needs. Under the terms of the loan agreement, the loan bears interest at 1% per month (or equivalent to 12% per annum) and the loan maturity date was December 31, 2020.</abvcd:StockPurchaseAgreementDescription>
  <abvcd:AggregateWorkingcapital unitRef="usd" contextRef="c204_From1May2019To27May2019_NTMember_AsiangeneCorporationMember" decimals="0">100000</abvcd:AggregateWorkingcapital>
  <abvcd:AggregateWorkingcapital unitRef="usd" contextRef="c205_From1May2019To27May2019_AsiangeneCorporationMember" decimals="0">3510</abvcd:AggregateWorkingcapital>
  <us-gaap:ShorttermDebtAverageOutstandingAmount unitRef="usd" contextRef="c206_From1Jan2020To31Dec2020_AsiangeneCorporationMember" decimals="0">3510</us-gaap:ShorttermDebtAverageOutstandingAmount>
  <us-gaap:ShorttermDebtAverageOutstandingAmount unitRef="usd" contextRef="c207_From1Jan2021To31Mar2021_AsiangeneCorporationMember" decimals="0">3560</us-gaap:ShorttermDebtAverageOutstandingAmount>
  <abvcd:AccruedInterest unitRef="usd" contextRef="c208_AsOf31Mar2021_AsiangeneCorporationMember" decimals="0">777</abvcd:AccruedInterest>
  <abvcd:AccruedInterest unitRef="usd" contextRef="c209_AsOf31Dec2020_AsiangeneCorporationMember" decimals="0">681</abvcd:AccruedInterest>
  <us-gaap:DebtInstrumentFaceAmount unitRef="usd" contextRef="c210_AsOf11May2018_BioFirstAustraliaMember" decimals="0">40000</us-gaap:DebtInstrumentFaceAmount>
  <abvcd:AdvancesBearInterestDescription contextRef="c211_From1May2018To11May2018_BioFirstAustraliaMember">The advances bear 0% interest rate and are due on demand prior to June 30, 2020.</abvcd:AdvancesBearInterestDescription>
  <us-gaap:RelatedPartyTransactionRate unitRef="pure" contextRef="c211_From1May2018To11May2018_BioFirstAustraliaMember" decimals="2">0.12</us-gaap:RelatedPartyTransactionRate>
  <us-gaap:DebtInstrumentFaceAmount unitRef="usd" contextRef="c212_AsOf1Jul2020_BioFirstAustraliaMember" decimals="0">321487</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentMaturityDate contextRef="c112_From1Jan2021To31Mar2021_BioFirstMember">2021-06-30</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:RelatedPartyTransactionRate unitRef="pure" contextRef="c213_From1Jan2021To31Mar2021_BioFirstAustraliaMember" decimals="2">0.12</us-gaap:RelatedPartyTransactionRate>
  <us-gaap:ShorttermDebtAverageOutstandingAmount unitRef="usd" contextRef="c213_From1Jan2021To31Mar2021_BioFirstAustraliaMember" decimals="0">379110</us-gaap:ShorttermDebtAverageOutstandingAmount>
  <us-gaap:ShorttermDebtAverageOutstandingAmount unitRef="usd" contextRef="c214_From1Jan2020To31Dec2020_BioFirstAustraliaMember" decimals="0">373235</us-gaap:ShorttermDebtAverageOutstandingAmount>
  <us-gaap:DebtInstrumentInterestRateTerms contextRef="c215_From1Jan2021To31Mar2021_BioLiteTaiwanMember">The development costs shall be shared 50/50 between BHK and the Company. Under the term of the agreement, BioLite issued relevant development cost to BHK.</us-gaap:DebtInstrumentInterestRateTerms>
  <us-gaap:DueFromOtherRelatedParties unitRef="usd" contextRef="c216_AsOf31Mar2021_BioLiteTaiwanMember" decimals="0">121848</us-gaap:DueFromOtherRelatedParties>
  <us-gaap:DueFromOtherRelatedParties unitRef="usd" contextRef="c217_AsOf31Dec2020_BioLiteTaiwanMember" decimals="0">123583</us-gaap:DueFromOtherRelatedParties>
  <us-gaap:ShorttermDebtAverageOutstandingAmount unitRef="usd" contextRef="c218_From1Jan2021To31Mar2021_LbgUsaIncMember" decimals="0">675</us-gaap:ShorttermDebtAverageOutstandingAmount>
  <us-gaap:ShorttermDebtAverageOutstandingAmount unitRef="usd" contextRef="c219_From1Jan2020To31Mar2020_LbgUsaIncMember" decimals="0">675</us-gaap:ShorttermDebtAverageOutstandingAmount>
  <abvcd:AggregateWorkingcapital unitRef="usd" contextRef="c220_From1May2020To8May2020_BioLiteJapanMember" decimals="0">150000</abvcd:AggregateWorkingcapital>
  <us-gaap:DebtInstrumentInterestRateTerms contextRef="c220_From1May2020To8May2020_BioLiteJapanMember">the Company advanced an amount of $150,000 and the advance bear 0% interest rate.</us-gaap:DebtInstrumentInterestRateTerms>
  <abvcd:AdvancesBearInterestDescription contextRef="c0_From1Jan2021To31Mar2021">0%</abvcd:AdvancesBearInterestDescription>
  <us-gaap:ShorttermDebtAverageOutstandingAmount unitRef="usd" contextRef="c221_From1Jan2021To31Mar2021_BioLiteJapanMember" decimals="0">150000</us-gaap:ShorttermDebtAverageOutstandingAmount>
  <us-gaap:ShorttermDebtAverageOutstandingAmount unitRef="usd" contextRef="c222_From1Jan2020To31Dec2020_BioLiteJapanMember" decimals="0">150000</us-gaap:ShorttermDebtAverageOutstandingAmount>
  <abvcd:AggregateWorkingcapital unitRef="usd" contextRef="c223_From1Oct2020To31Oct2020" decimals="0">1610</abvcd:AggregateWorkingcapital>
  <us-gaap:RelatedPartyTransactionRate unitRef="pure" contextRef="c223_From1Oct2020To31Oct2020" decimals="3">0.065</us-gaap:RelatedPartyTransactionRate>
  <us-gaap:DebtInstrumentMaturityDate contextRef="c223_From1Oct2020To31Oct2020">2021-10-30</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:PaymentsOfLoanCosts unitRef="usd" contextRef="c224_From1Jan2020To31Dec2020" decimals="0">1610</us-gaap:PaymentsOfLoanCosts>
  <us-gaap:PaymentsOfLoanCosts unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">1610</us-gaap:PaymentsOfLoanCosts>
  <us-gaap:RelatedPartyTransactionRate unitRef="pure" contextRef="c225_From1Jan2021To31Jan2021" decimals="2">0.00</us-gaap:RelatedPartyTransactionRate>
  <us-gaap:ShorttermDebtAverageOutstandingAmount unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">2093</us-gaap:ShorttermDebtAverageOutstandingAmount>
  <us-gaap:ShorttermDebtAverageOutstandingAmount unitRef="usd" contextRef="c224_From1Jan2020To31Dec2020" decimals="0">0</us-gaap:ShorttermDebtAverageOutstandingAmount>
  <us-gaap:DebtInstrumentInterestRateTerms contextRef="c112_From1Jan2021To31Mar2021_BioFirstMember">The advances bear interest 1% per month (or equivalent to 12% per annum).</us-gaap:DebtInstrumentInterestRateTerms>
  <us-gaap:DueToRelatedPartiesCurrent unitRef="usd" contextRef="c108_AsOf31Mar2021_BioFirstMember" decimals="0">23647</us-gaap:DueToRelatedPartiesCurrent>
  <us-gaap:DueToRelatedPartiesCurrent unitRef="usd" contextRef="c109_AsOf31Dec2020_BioFirstMember" decimals="0">23647</us-gaap:DueToRelatedPartiesCurrent>
  <abvcd:AggregateWorkingcapital unitRef="usd" contextRef="c207_From1Jan2021To31Mar2021_AsiangeneCorporationMember" decimals="0">24017</abvcd:AggregateWorkingcapital>
  <abvcd:AggregateWorkingcapital unitRef="usd" contextRef="c206_From1Jan2020To31Dec2020_AsiangeneCorporationMember" decimals="0">0</abvcd:AggregateWorkingcapital>
  <us-gaap:RelatedPartyTransactionRate unitRef="pure" contextRef="c207_From1Jan2021To31Mar2021_AsiangeneCorporationMember" decimals="2">0.00</us-gaap:RelatedPartyTransactionRate>
  <abvcd:AggregateWorkingcapital unitRef="usd" contextRef="c226_From1Jan2021To31Mar2021_ConversionAgreementsOneMember_YuanGeneMember" decimals="0">9205</abvcd:AggregateWorkingcapital>
  <us-gaap:RelatedPartyTransactionRate unitRef="pure" contextRef="c227_From1Jan2020To31Dec2020_ConversionAgreementsOneMember_YuanGeneMember" decimals="2">0.00</us-gaap:RelatedPartyTransactionRate>
  <abvcd:AggregateWorkingcapital unitRef="usd" contextRef="c228_From1Jan2021To31Mar2021_JIANGSMember" decimals="0">18750</abvcd:AggregateWorkingcapital>
  <abvcd:AggregateWorkingcapital unitRef="usd" contextRef="c229_From1Jan2020To31Dec2020_JIANGSMember" decimals="0">16627</abvcd:AggregateWorkingcapital>
  <us-gaap:RelatedPartyTransactionRate unitRef="pure" contextRef="c228_From1Jan2021To31Mar2021_JIANGSMember" decimals="2">0.00</us-gaap:RelatedPartyTransactionRate>
  <us-gaap:RelatedPartyTransactionRate unitRef="pure" contextRef="c229_From1Jan2020To31Dec2020_JIANGSMember" decimals="2">0.01</us-gaap:RelatedPartyTransactionRate>
  <us-gaap:DebtInstrumentInterestRateTerms contextRef="c230_From1Jan2018To31Dec2018">The advances bear interest rate from 12% to 13.6224% per annum.</us-gaap:DebtInstrumentInterestRateTerms>
  <abvcd:AccruedInterest unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">163566</abvcd:AccruedInterest>
  <abvcd:AccruedInterest unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">166261</abvcd:AccruedInterest>
  <us-gaap:InterestExpense unitRef="usd" contextRef="c228_From1Jan2021To31Mar2021_JIANGSMember" decimals="0">5298</us-gaap:InterestExpense>
  <us-gaap:InterestExpense unitRef="usd" contextRef="c231_From1Jan2020To31Mar2020_JIANGSMember" decimals="0">5269</us-gaap:InterestExpense>
  <abvcd:NumberOfEmployees unitRef="pure" contextRef="c3_AsOf31Dec2020" decimals="INF">1</abvcd:NumberOfEmployees>
  <us-gaap:AccruedEmployeeBenefitsCurrent unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">72967</us-gaap:AccruedEmployeeBenefitsCurrent>
  <us-gaap:AccruedEmployeeBenefitsCurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">72704</us-gaap:AccruedEmployeeBenefitsCurrent>
  <us-gaap:RelatedPartyTransactionRate unitRef="pure" contextRef="c0_From1Jan2021To31Mar2021" decimals="3">0.015</us-gaap:RelatedPartyTransactionRate>
  <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse&quot;&gt;
  &lt;tr&gt;
    &lt;td style=&quot;border-bottom: black 1.5pt solid; vertical-align: top; width: 36%&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;&lt;b&gt;Name of entity or Individual&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; width: 2%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: black 1.5pt solid; vertical-align: bottom; width: 62%; text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;&lt;b&gt;Relationship with the Company and its subsidiaries&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style=&quot;vertical-align: top&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;BioFirst Corporation (the &amp;#x201c;BioFirst&amp;#x201d;)&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Entity controlled by controlling beneficiary shareholder of YuanGene&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style=&quot;vertical-align: top&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;BioFirst (Australia) Pty Ltd. (the &amp;#x201c;BioFirst (Australia)&amp;#x201d;)&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style=&quot;vertical-align: top&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Rgene Corporation (the &amp;#x201c;Rgene&amp;#x201d;)&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Shareholder of the Company; entity controlled by controlling beneficiary shareholder of YuanGene&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style=&quot;vertical-align: top&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;YuanGene Corporation (the &amp;#x201c;YuanGene&amp;#x201d;)&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Controlling beneficiary shareholder of the Company&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style=&quot;vertical-align: top&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;AsiaGene Corporation (the &amp;#x201c;AsiaGene&amp;#x201d;)&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Shareholder; entity controlled by controlling beneficiary shareholder of YuanGene&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style=&quot;vertical-align: top&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Eugene Jiang&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Former President and Chairman&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style=&quot;vertical-align: top&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Keypoint Technology Ltd. (the &amp;#x201c;Keypoint&amp;#x2019;)&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;The Chairman of Keypoint is Eugene Jiang&amp;#x2019;s mother.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style=&quot;vertical-align: top&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Lion Arts Promotion Inc. (the &amp;#x201c;Lion Arts&amp;#x201d;)&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Shareholder of the Company&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style=&quot;vertical-align: top&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Yoshinobu Odaira (the &amp;#x201c;Odaira&amp;#x201d;)&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Director of the Company&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style=&quot;vertical-align: top&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;GenePharm Inc. (the &amp;#x201c;GenePharm&amp;#x201d;)&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Dr. George Lee, Board Director of Biokey, is the Chairman of GenePharm.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style=&quot;vertical-align: top&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Euro-Asia Investment &amp;amp; Finance Corp Ltd. (the &amp;#x201c;Euro-Asia&amp;#x201d;)&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Shareholder of the Company&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style=&quot;vertical-align: top&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;LBG USA, Inc. (the &amp;#x201c;LBG USA&amp;#x201d;)&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style=&quot;vertical-align: top&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;LionGene Corporation (the &amp;#x201c;LionGene&amp;#x201d;)&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Shareholder of the Company; Entity controlled by controlling beneficiary shareholder of YuanGene&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style=&quot;vertical-align: top&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Kimho Consultants Co., Ltd. (the &amp;#x201c;Kimho&amp;#x201d;)&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Shareholder of the Company&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style=&quot;vertical-align: top&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Mr. Tsung-Shann Jiang, the controlling beneficiary shareholder of the Company and Rgene, the Chairman and CEO of the BioLite Holding Inc. and BioLite Inc. and the President and a member of board of directors of BioFirst&lt;br/&gt;
&amp;#xa0;&lt;br/&gt;
Ms. Shu-Ling Jiang, Mr. Tsung-Shann Jiang&amp;#x2019;s wife, is the Chairman of Keypoint; and a member of board of directors of BioLite Inc.&lt;br/&gt;
&amp;#xa0;&lt;br/&gt;
Mr. Eugene Jiang is Mr. and Ms. Jiang&amp;#x2019;s son. Mr. Eugene Jiang is the chairman, and majority shareholder of the Company and a member of board of directors of BioLite Inc.&lt;br/&gt;
&amp;#xa0;&lt;br/&gt;
Mr. Chang-Jen Jiang is Mr. Tsung-Shann Jiang&amp;#x2019;s sibling and the director of the Company.&lt;br/&gt;
&amp;#xa0;&lt;br/&gt;
Ms. Mei-Ling Jiang is Ms. Shu-Ling Jiang&amp;#x2019;s sibling.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style=&quot;vertical-align: top&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Amkey Ventures, LLC (&amp;#x201c;Amkey&amp;#x201d;)&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;An entity controlled by Dr. George Lee, who serves as one of the board directors of BioKey, Inc&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style=&quot;vertical-align: top&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;BioLite Japan&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Entity controlled by controlling beneficiary shareholder of ABVC&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
  <abvcd:RelatedPartyTransactionDescriptionOfTransactions contextRef="c232_From1Jan2021To31Mar2021_BioFirstCorporationtheBioFirstMember">Entity controlled by controlling beneficiary shareholder of YuanGene</abvcd:RelatedPartyTransactionDescriptionOfTransactions>
  <abvcd:RelatedPartyTransactionDescriptionOfTransactions contextRef="c233_From1Jan2021To31Mar2021_BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember">100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene</abvcd:RelatedPartyTransactionDescriptionOfTransactions>
  <abvcd:RelatedPartyTransactionDescriptionOfTransactions contextRef="c234_From1Jan2021To31Mar2021_RgeneCorporationtheRgeneMember">Shareholder of the Company; entity controlled by controlling beneficiary shareholder of YuanGene</abvcd:RelatedPartyTransactionDescriptionOfTransactions>
  <abvcd:RelatedPartyTransactionDescriptionOfTransactions contextRef="c235_From1Jan2021To31Mar2021_YuanGeneCorporationtheYuanGeneMember">Controlling beneficiary shareholder of the Company</abvcd:RelatedPartyTransactionDescriptionOfTransactions>
  <abvcd:RelatedPartyTransactionDescriptionOfTransactions contextRef="c236_From1Jan2021To31Mar2021_AsiaGeneCorporationtheAsiaGeneMember">Shareholder; entity controlled by controlling beneficiary shareholder of YuanGene</abvcd:RelatedPartyTransactionDescriptionOfTransactions>
  <abvcd:RelatedPartyTransactionDescriptionOfTransactions contextRef="c237_From1Jan2021To31Mar2021_EugeneJiangMember">Former President and Chairman</abvcd:RelatedPartyTransactionDescriptionOfTransactions>
  <abvcd:RelatedPartyTransactionDescriptionOfTransactions contextRef="c238_From1Jan2021To31Mar2021_KeypointTechnologyLtdtheKeypointMember">The Chairman of Keypoint is Eugene Jiang&apos;s mother.</abvcd:RelatedPartyTransactionDescriptionOfTransactions>
  <abvcd:RelatedPartyTransactionDescriptionOfTransactions contextRef="c239_From1Jan2021To31Mar2021_LionArtsPromotionInctheLionArtsMember">Shareholder of the Company</abvcd:RelatedPartyTransactionDescriptionOfTransactions>
  <abvcd:RelatedPartyTransactionDescriptionOfTransactions contextRef="c240_From1Jan2021To31Mar2021_YoshinobuOdairatheOdairaMember">Director of the Company</abvcd:RelatedPartyTransactionDescriptionOfTransactions>
  <abvcd:RelatedPartyTransactionDescriptionOfTransactions contextRef="c241_From1Jan2021To31Mar2021_GenePharmInctheGenePharmMember">Dr. George Lee, Board Director of Biokey, is the Chairman of GenePharm.</abvcd:RelatedPartyTransactionDescriptionOfTransactions>
  <abvcd:RelatedPartyTransactionDescriptionOfTransactions contextRef="c242_From1Jan2021To31Mar2021_EuroAsiaInvestmentFinanceCorpLtdtheEuroAsiaMember">Shareholder of the Company</abvcd:RelatedPartyTransactionDescriptionOfTransactions>
  <abvcd:RelatedPartyTransactionDescriptionOfTransactions contextRef="c243_From1Jan2021To31Mar2021_LBGUSAInctheLBGUSAMember">100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene</abvcd:RelatedPartyTransactionDescriptionOfTransactions>
  <abvcd:RelatedPartyTransactionDescriptionOfTransactions contextRef="c244_From1Jan2021To31Mar2021_LionGeneCorporationtheLionGeneMember">Shareholder of the Company; Entity controlled by controlling beneficiary shareholder of YuanGene</abvcd:RelatedPartyTransactionDescriptionOfTransactions>
  <abvcd:RelatedPartyTransactionDescriptionOfTransactions contextRef="c245_From1Jan2021To31Mar2021_KimhoConsultantsCoLtdtheKimhoMember">Shareholder of the Company</abvcd:RelatedPartyTransactionDescriptionOfTransactions>
  <abvcd:RelatedPartyTransactionDescriptionOfTransactions contextRef="c246_From1Jan2021To31Mar2021_MrTsungShannJiangMsShuLingJiangMrChangJenJiangMsMeiLingJiangAndMrEugeneJiangcollectivelyTheJiangsMember">Mr. Tsung-Shann Jiang, the controlling beneficiary shareholder of the Company and Rgene, the Chairman and CEO of the BioLite Holding Inc. and BioLite Inc. and the President and a member of board of directors of BioFirst Ms. Shu-Ling Jiang, Mr. Tsung-Shann Jiang&apos;s wife, is the Chairman of Keypoint; and a member of board of directors of BioLite Inc. Mr. Eugene Jiang is Mr. and Ms. Jiang&apos;s son. Mr. Eugene Jiang is the chairman, and majority shareholder of the Company and a member of board of directors of BioLite Inc. Mr. Chang-Jen Jiang is Mr. Tsung-Shann Jiang&apos;s sibling and the director of the Company. Ms. Mei-Ling Jiang is Ms. Shu-Ling Jiang&apos;s sibling.</abvcd:RelatedPartyTransactionDescriptionOfTransactions>
  <abvcd:RelatedPartyTransactionDescriptionOfTransactions contextRef="c247_From1Jan2021To31Mar2021_AmkeyVenturesLLCAmkeyMember">An entity controlled by Dr. George Lee, who serves as one of the board directors of BioKey, Inc</abvcd:RelatedPartyTransactionDescriptionOfTransactions>
  <abvcd:RelatedPartyTransactionDescriptionOfTransactions contextRef="c221_From1Jan2021To31Mar2021_BioLiteJapanMember">Entity controlled by controlling beneficiary shareholder of ABVC</abvcd:RelatedPartyTransactionDescriptionOfTransactions>
  <abvcd:ScheduleOfAccountReceivableDueFromRelatedPartiesTableTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;March 31,&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;December 31,&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;2021&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: left&quot;&gt;GenePharm Inc.&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;142,225&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;142,225&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;Amkey&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;2,850&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;1,210&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 4pt; padding-left: 9pt&quot;&gt;Total&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font-weight: bold; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font-weight: bold; text-align: right&quot;&gt;145,075&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font-weight: bold; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font-weight: bold; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font-weight: bold; text-align: right&quot;&gt;143,435&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font-weight: bold; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</abvcd:ScheduleOfAccountReceivableDueFromRelatedPartiesTableTextBlock>
  <us-gaap:AccountsReceivableRelatedParties unitRef="usd" contextRef="c248_AsOf31Mar2021_GenePharmIncMember" decimals="0">142225</us-gaap:AccountsReceivableRelatedParties>
  <us-gaap:AccountsReceivableRelatedParties unitRef="usd" contextRef="c249_AsOf31Dec2020_GenePharmIncMember" decimals="0">142225</us-gaap:AccountsReceivableRelatedParties>
  <us-gaap:AccountsReceivableRelatedParties unitRef="usd" contextRef="c250_AsOf31Mar2021_AmkeyMember" decimals="0">2850</us-gaap:AccountsReceivableRelatedParties>
  <us-gaap:AccountsReceivableRelatedParties unitRef="usd" contextRef="c251_AsOf31Dec2020_AmkeyMember" decimals="0">1210</us-gaap:AccountsReceivableRelatedParties>
  <us-gaap:AccountsReceivableRelatedParties unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">145075</us-gaap:AccountsReceivableRelatedParties>
  <us-gaap:AccountsReceivableRelatedParties unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">143435</us-gaap:AccountsReceivableRelatedParties>
  <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;March 31,&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;December 31,&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2021&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%&quot;&gt;Rgene&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;43,266&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;42,911&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td&gt;AsiaGene&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;4,287&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;4,241&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;BioFirst (Australia)&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;379,110&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;373,235&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;BioHopeKing Corporation&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;121,848&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;123,583&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;LBG USA&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;675&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;675&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;BioLite Japan&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;150,000&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;150,000&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td&gt;Keypoint&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,610&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,610&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt&quot;&gt;The Jiangs&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;2,093&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 4pt; padding-left: 9pt&quot;&gt;Total&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;702,889&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;696,255&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
  <us-gaap:DueFromRelatedPartiesCurrent unitRef="usd" contextRef="c110_AsOf31Mar2021_RgeneMember" decimals="0">43266</us-gaap:DueFromRelatedPartiesCurrent>
  <us-gaap:DueFromRelatedPartiesCurrent unitRef="usd" contextRef="c111_AsOf31Dec2020_RgeneMember" decimals="0">42911</us-gaap:DueFromRelatedPartiesCurrent>
  <us-gaap:DueFromRelatedPartiesCurrent unitRef="usd" contextRef="c252_AsOf31Mar2021_AsiaGeneMember" decimals="0">4287</us-gaap:DueFromRelatedPartiesCurrent>
  <us-gaap:DueFromRelatedPartiesCurrent unitRef="usd" contextRef="c253_AsOf31Dec2020_AsiaGeneMember" decimals="0">4241</us-gaap:DueFromRelatedPartiesCurrent>
  <us-gaap:DueFromRelatedPartiesCurrent unitRef="usd" contextRef="c254_AsOf31Mar2021_BioFirstAustraliaMember" decimals="0">379110</us-gaap:DueFromRelatedPartiesCurrent>
  <us-gaap:DueFromRelatedPartiesCurrent unitRef="usd" contextRef="c255_AsOf31Dec2020_BioFirstAustraliaMember" decimals="0">373235</us-gaap:DueFromRelatedPartiesCurrent>
  <us-gaap:DueFromRelatedPartiesCurrent unitRef="usd" contextRef="c102_AsOf31Mar2021_BioHopeKingCorporationMember" decimals="0">121848</us-gaap:DueFromRelatedPartiesCurrent>
  <us-gaap:DueFromRelatedPartiesCurrent unitRef="usd" contextRef="c103_AsOf31Dec2020_BioHopeKingCorporationMember" decimals="0">123583</us-gaap:DueFromRelatedPartiesCurrent>
  <us-gaap:DueFromRelatedPartiesCurrent unitRef="usd" contextRef="c256_AsOf31Mar2021_LBGUSAMember" decimals="0">675</us-gaap:DueFromRelatedPartiesCurrent>
  <us-gaap:DueFromRelatedPartiesCurrent unitRef="usd" contextRef="c257_AsOf31Dec2020_LBGUSAMember" decimals="0">675</us-gaap:DueFromRelatedPartiesCurrent>
  <us-gaap:DueFromRelatedPartiesCurrent unitRef="usd" contextRef="c258_AsOf31Mar2021_BioLiteJapanMember" decimals="0">150000</us-gaap:DueFromRelatedPartiesCurrent>
  <us-gaap:DueFromRelatedPartiesCurrent unitRef="usd" contextRef="c259_AsOf31Dec2020_BioLiteJapanMember" decimals="0">150000</us-gaap:DueFromRelatedPartiesCurrent>
  <us-gaap:DueFromRelatedPartiesCurrent unitRef="usd" contextRef="c260_AsOf31Mar2021_KeypointMember" decimals="0">1610</us-gaap:DueFromRelatedPartiesCurrent>
  <us-gaap:DueFromRelatedPartiesCurrent unitRef="usd" contextRef="c261_AsOf31Dec2020_KeypointMember" decimals="0">1610</us-gaap:DueFromRelatedPartiesCurrent>
  <us-gaap:DueFromRelatedPartiesCurrent unitRef="usd" contextRef="c262_AsOf31Mar2021_TheJiangsMember" decimals="0">2093</us-gaap:DueFromRelatedPartiesCurrent>
  <us-gaap:DueFromRelatedPartiesCurrent unitRef="usd" contextRef="c263_AsOf31Dec2020_TheJiangsMember" xs:nil="true"/>
  <us-gaap:DueFromRelatedPartiesCurrent unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">702889</us-gaap:DueFromRelatedPartiesCurrent>
  <us-gaap:DueFromRelatedPartiesCurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">696255</us-gaap:DueFromRelatedPartiesCurrent>
  <abvcd:ScheduleOfRelatedPartyTransactionsAmountDueToRelatedParty contextRef="c0_From1Jan2021To31Mar2021">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;March&amp;#xa0;31,&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;December&amp;#xa0;31,&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2021&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: left&quot;&gt;BioFirst Corporation&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;23,647&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;23,647&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td&gt;AsiaGene&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;24,017&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td&gt;YuanGene&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;9,205&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;9,205&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;The Jiangs&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;18,750&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;16,627&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Due to shareholders&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;163,566&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;166,261&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt&quot;&gt;Due to employee&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;72,967&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;72,704&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 4pt; padding-left: 9pt&quot;&gt;Total&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font-weight: bold; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font-weight: bold; text-align: right&quot;&gt;312,152&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font-weight: bold; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font-weight: bold; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font-weight: bold; text-align: right&quot;&gt;288,445&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font-weight: bold; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</abvcd:ScheduleOfRelatedPartyTransactionsAmountDueToRelatedParty>
  <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent unitRef="usd" contextRef="c104_AsOf31Mar2021_BioFirstCorporationMember" decimals="0">23647</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
  <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent unitRef="usd" contextRef="c105_AsOf31Dec2020_BioFirstCorporationMember" decimals="0">23647</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
  <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent unitRef="usd" contextRef="c252_AsOf31Mar2021_AsiaGeneMember" decimals="0">24017</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
  <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent unitRef="usd" contextRef="c264_AsOf31Mar2021_YuanGeneMember" decimals="0">9205</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
  <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent unitRef="usd" contextRef="c265_AsOf31Dec2020_YuanGeneMember" decimals="0">9205</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
  <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent unitRef="usd" contextRef="c262_AsOf31Mar2021_TheJiangsMember" decimals="0">18750</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
  <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent unitRef="usd" contextRef="c263_AsOf31Dec2020_TheJiangsMember" decimals="0">16627</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
  <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent unitRef="usd" contextRef="c266_AsOf31Mar2021_DueToshareholdersMember" decimals="0">163566</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
  <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent unitRef="usd" contextRef="c267_AsOf31Dec2020_DueToshareholdersMember" decimals="0">166261</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
  <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent unitRef="usd" contextRef="c268_AsOf31Mar2021_DueToEmployeesMember" decimals="0">72967</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
  <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent unitRef="usd" contextRef="c269_AsOf31Dec2020_DueToEmployeesMember" decimals="0">72704</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
  <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">312152</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
  <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">288445</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;&lt;b&gt;13. EQUITY&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;On February 8, 2016, a Share Exchange
Agreement (&amp;#x201c;Share Exchange Agreement&amp;#x201d;) was entered into by and among the&amp;#xa0;Company, BriVision, Euro-Asia Investment
&amp;amp; Finance Corp. Limited, a company incorporated under the laws of Hong Kong Special Administrative Region of People&amp;#x2019;s
Republic of China (&amp;#x201c;Euro-Asia&amp;#x201d;), being the owners of record of 164,387,376 (52,336,000 pre-stock split) shares of Common
Stock of the Company, and the owners of record of all of the issued share capital of BriVision (the&amp;#xa0;&amp;#x201c;BriVision
Stock&amp;#x201d;). Pursuant to the Share Exchange Agreement, upon surrender by the BriVision Shareholders and the cancellation by
BriVision of the certificates evidencing the BriVision Stock as registered in the name of each BriVision Shareholder, and pursuant
to the registration of the Company in the register of members maintained by BriVision as the new holder of the BriVision Stock and
the issuance of the certificates evidencing the aforementioned registration of the BriVision Stock in the name of the Company, the
Company should issue 166,273,921(52,936,583 pre-stock split) shares (the&amp;#xa0;&amp;#x201c;Acquisition Stock&amp;#x201d;) (subject to
adjustment for fractionalized shares as set forth below) of the Company&amp;#x2019;s Common Stock to the BriVision Shareholders (or their
designees), and 163,159,952 (51,945,225 pre-stock split) shares of the Company&amp;#x2019;s Common Stock owned by Euro-Asia should be
cancelled and retired to treasury. The Acquisition Stock collectively should represent 79.70% of the issued and outstanding Common
Stock of the Company immediately after the Closing, in exchange for the BriVision Stock, representing 100% of the issued share
capital of BriVision in a reverse merger, or the Merger. Pursuant to the Merger, all of the issued and outstanding shares of
BriVision&amp;#x2019;s Common Stock were converted, at an exchange ratio of 0.2536-for-1, into an aggregate of 166,273,921(52,936,583
pre-stock split) shares of Company&amp;#x2019;s Common Stock and BriVision became a wholly owned subsidiary, of the Company. The holders
of Company&amp;#x2019;s Common Stock as of immediately prior to the Merger held an aggregate of 205,519,223 (65,431,144 pre-stock split)
shares of Company&amp;#x2019;s Common Stock,&amp;#xa0;Because of the exchange of the BriVision Stock for the Acquisition Stock
(the&amp;#xa0;&amp;#x201c;Share Exchange&amp;#x201d;), BriVision became a wholly owned subsidiary (the &amp;#x201c;Subsidiary&amp;#x201d;) of the Company
and there was a change of control of the Company following the closing.&amp;#xa0;&amp;#xa0;There were no warrants, options or other equity
instruments issued in connection with the share exchange agreement.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;On February 17, 2016, pursuant to the 2016 Equity
Incentive Plan (the &amp;#x201c;2016 Plan&amp;#x201d;), 157,050 (50,000 pre-stock split) shares were granted to the employees.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;On March 21, 2016, the Board of Directors of the
Company approved an amendment to Articles of Incorporation to effect a forward split at a ratio of 1 to 3:141 (the &amp;#x201c;Forward&amp;#xa0;Stock&amp;#xa0;Split&amp;#x201d;)
and increase the number of our authorized shares of Common Stock, par value $0.001 per share, to 360,000,000, which was effective on April
8, 2016.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;On May 6, 2016, the Company and BioLite Taiwan
agreed to amend the BioLite Collaborative Agreement, through entry into the Milestone Payment Agreement, whereby the Company has agreed
to issue shares of Common Stock of the Company, at the price of $1.60 per share, for an aggregate number of 562,500 shares, as part of
the Company&amp;#x2019;s first installation of payment pursuant to the Milestone Payment. The shares issuance was completed in June 2016. On
August 26, 2016, the Company issued 1,468,750 shares (&amp;#x201c;Shares&amp;#x201d;) of the Company&amp;#x2019;s Common Stock, par value $0.001 (the
&amp;#x201c;Offering&amp;#x201d;) to BioLite Taiwan pursuant to a certain Stock Purchase Agreement dated August 26, 2016 (the &amp;#x201c;SPA&amp;#x201d;).
The Shares are exempt from the registration requirements of the Securities Act of 1933, as amended (the &amp;#x201c;Securities Act&amp;#x201d;),
pursuant to Regulation S of the Securities Act promulgated thereunder. The purchase price per share of the Offering is $1.60. The net
proceeds to the Company from the Offering are approximately $2,350,000. Pursuant to the BioLite Collaborative Agreement, BriVision should
pay a total of $100,000,000 in cash or stock of the Company with equivalent value according to the milestone achieved. The agreement requires
that 6.5% of total payment, $6,500,000 shall be made upon the first IND submission which was submitted in March 2016. In February 2017,
the Company remitted this amount to BioLite with $650,000 in cash and $5,850,000 in the form of newly issued shares of the Company&amp;#x2019;s
Common Stock, at the price of $2.0 per share, for an aggregate number of 2,925,000 shares. Upon the consummation of the restructuring
transaction between the Company and BioLite on February 8, 2019, the Company&amp;#x2019;s Common Stock held by BioLite Taiwan was accounted
for treasury stocks in the statement of equity (deficit). On February 8, 2019, after the Merger, the Company issued 74,997,546 shares
to the shareholders of BioLite and 29,561,231 shares to the shareholders of BioKey.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;On May 3, 2019, the Company filed a Certificate
of Amendment with the Secretary of State of Nevada, which was effective May 8, 2019 upon its receipt of the written notice from Financial
Industry Regulatory Authority (&amp;#x201c;FINRA&amp;#x201d;). Pursuant to the Certificate of Amendment, the Company effectuated a 1-for-18 reverse
stock split of its issued and outstanding shares of common stock, $0.001 par value, whereby 318,485,252 outstanding shares of the Company&amp;#x2019;s
common stock were exchanged for 17,693,625 shares of the Company&amp;#x2019;s Common Stock. All shares and related financial information in
this Form 10-K reflect this 1-for-18 reverse stock split.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;On October 1, 2016, the Company entered into a
consulting agreement with Kazunori Kameyama (&amp;#x201c;Kameyama&amp;#x201d;) for the provision of services related to the clinical trials and
other administrative work, public relation work, capital raising, trip coordination, In consideration for providing such services, the
Company agreed to indemnify the consultant in an amount of $150 per hour in cash up to $3,000 per month, and issue to Kameyama the Company&amp;#x2019;s
Common Stock at $1.00 per share for any amount exceeding $3,000. The Company&amp;#x2019;s stocks shall be calculated and issued in December
every year. On November 21, 2020, the Company entered into an agreement with Kameyama, pursuant to which the Company granted and issued
24,694 stock options to Kameyama related to unpaid consulting fees of $49,388 (see Note 14).&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;During the year ended December 31, 2019, the Company
entered into service agreements with Euro-Asia Investment &amp;amp; Finance Corp Ltd. (a related party), Ever Adventure inv. (Formosa) Consultant
Co., Ltd., New Eastern Asia (a related party), and Kimho Consultants Co., Ltd. (a related party) for the maintenance of the listing in
the U.S. stock exchange market, investor relations, and business development. Pursuant to the agreements, the Company issued 644,972 shares
of the Company&amp;#x2019;s common stock for the consulting service from July 2019 to July 2024 for the service fee of $4,514,800 in aggregate,
and recorded as stock subscription receivable. As of March 31, 2021 and December 31, 2020, stock subscription receivable was $2,934,620
and $3,160,360, respectively.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;On July 24, 2017, BriVision entered into a collaborative agreement
(the &amp;#x201c;BioFirst Collaborative Agreement&amp;#x201d;) with BioFirst (See Note 3). On September 25, 2017, BioFirst has delivered all research,
technical, data and development data to BriVision, and the Company has recorded the full amount of $3,000,000 due to BioFirst. On June
30, 2019, the Company entered into a Stock Purchase Agreement with BioFirst, pursuant to which the Company agreed to issue 428,571 shares
of the Company&amp;#x2019;s common stock to BioFirst in consideration for $3,000,000 owed by the Company to BioFirst. These common shares were
issued during the year ended December 31, 2019.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;In August, 2019, the Company entered into several
Conversion Agreements to all creditors that are listed under below table of &amp;#x201c;due to related parties&amp;#x201d; in consideration for
a total of $4,872,340 owed by the Company to various creditors based on outstanding loan agreements. Under the Conversion Agreements,
creditor agrees to convert the amount of debt into the Company&amp;#x2019;s common stock at a price of $7.00 per share.&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; vertical-align: bottom; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;Amount of&lt;br/&gt; Debt&lt;br/&gt; Converted&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;Number of&lt;br/&gt; Shares&lt;br/&gt; Issued&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left&quot;&gt;Lion Arts Promotion Inc&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;97,864&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;13,981&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;LionGene Corporation&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;428,099&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;61,157&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;BioFirst Corporation&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;2,902,911&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;414,702&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;AsiaGene Corporation&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;160,000&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;22,858&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;YuanGene Corporation&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;92,690&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;13,242&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt&quot;&gt;The Jiangs&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;1,190,776&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;170,111&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-bottom: 4pt; padding-left: 0.25in&quot;&gt;Total&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font-weight: bold; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font-weight: bold; text-align: right&quot;&gt;4,872,340&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font-weight: bold; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font-weight: bold; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font-weight: bold; text-align: right&quot;&gt;696,051&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font-weight: bold; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;On March 12, 2020, the board of directors of the
Company approved and adopted an amendment to the Company&amp;#x2019;s Articles of Incorporation, to increase the authorized shares of its common
stock, par value $0.001 per share, from 20,000,000 to 100,000,000 shares.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;On July 8, 2020, the Company entered an agreement
with View Trade Securities Inc. (&amp;#x201c;ViewTrade&amp;#x201d;) to engage ViewTrade as the placement agent&amp;#xa0;and the Company&amp;#x2019;s advisor
with respect to its ongoing capital events. Pursuant to the agreement, the Company agreed to pay View Trade 60,000 restricted common shares
of the Company and 60,000 warrants to purchase common shares of the Company at an exercise price of $6 per share for a period of 5 years
with cashless exercise provision. As of December 31, 2020, the Company has issued 60,000 shares of common stock to ViewTrade for the consulting
fee with an estimated value of $135,000. The warrants were never issued and the parties mutually agreed to terminate the agreement on
November 19, 2020. As a termination fee, the Company agreed to issue ViewTrade 50,000 restricted common shares of the Company.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; &quot;&gt;Also on November 19,
2020, the Company and ViewTrade agreed to a new Advisory agreement under which ViewTrade was engaged to provide advisory services only.
In addition to a retainer fee, the Company agreed to issue 200,000 warrants, with an exercise price of $2.25, an industry standard cashless
exercise provision, and a term of 5 years from November 19, 2020.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;During the year&amp;#xa0;ended December 31, 2020,
the Company entered into a consulting agreement with a service provider for consulting and advisory services, pursuant to which the Company
agreed to pay the service fee by issuing 50,000 shares of unrestricted common shares, valued at the closing price of $2.9 per share on
the grant date. As of December 31, 2020, these shares have been issued.&amp;#xa0;&amp;#xa0;&amp;#xa0;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;During the year ended December 31, 2020, the Company
received aggregated capital contributions of $7,615,331 in cash from 45 investors through private placements of the sale of the Company&amp;#x2019;s
common stock for the purchase price of&amp;#xa0;$2.25 per share and a free warrant attached with each common stock purchased. As of March
31, 2021, 3,384,615 shares of the Company&amp;#x2019;s common stock have been issued.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;During the year ended December 31, 2020, the Company
entered into consulting agreements with four service providers for consulting and advisory services, pursuant to which the Company agreed
to pay the service fee by issuing 521,887 shares of unrestricted common shares, valued at the closing price from $2 to $3.68 per share
on the grant date. As of March 31, 2021, these shares have been issued.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;As of March 31, 2021, the Company issued aggregated
common shares of 915,856 &amp;#xa0;to six previous note holders, who had converted their outstanding principals and accrued and unpaid interests,
including the debt conversion to the following:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%&quot;&gt;
  &lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 0.25in&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 0.25in&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;a.&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Keypoint converted the aggregated amount of $292,826 at the conversion price of $1.84 on April 5, 2020, in exchange for 159,145 shares of the Company&amp;#x2019;s common stock, and warrants to purchase 159,145 shares of the Company&amp;#x2019;s common stock.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%&quot;&gt;
  &lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 0.25in&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 0.25in&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;b.&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Odaira converted the aggregated amount of $284,036 at the conversion price of $1.84 on April 5, 2020, in exchange for 154,368 shares of the Company&amp;#x2019;s common stock, and warrants to purchase 154,368 shares of the Company&amp;#x2019;s common stock.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%&quot;&gt;
  &lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 0.25in&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 0.25in&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;c.&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;C.L.L. converted the aggregated amount of $289,974 at the conversion price of $1.78 on April 20, 2020, in exchange for 162,908 shares of the Company&amp;#x2019;s common stock, and warrants to purchase 162,908 shares of the Company&amp;#x2019;s common stock.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%&quot;&gt;
  &lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 0.25in&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 0.25in&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;d.&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;KLS converted the aggregated amount of $225,222 at the conversion price of $1.78 on April 20, 2020, in exchange for 126,530 shares of the Company&amp;#x2019;s common stock, and warrants to purchase 126,530 shares of the Company&amp;#x2019;s common stock.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%&quot;&gt;
  &lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 0.25in&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 0.25in&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;e.&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Yu and Wei converted the aggregated amount of $354,722 at the conversion price of $1.84 on April 5, 2020, in exchange for 192,784 shares of the Company&amp;#x2019;s common stock, and warrants to purchase 192,784 shares of the Company&amp;#x2019;s common stock.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%&quot;&gt;
  &lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 0.25in&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 0.25in&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;f.&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;KSL converted the aggregated amount of $270,272 at the conversion price of $2.25 on November 9, 2020, in exchange for 120,121 shares of the Company&amp;#x2019;s common stock, and warrants to purchase 120,121 shares of the Company&amp;#x2019;s common stock.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;See Note 7 for more details in connection with the above debt conversion.&amp;#xa0;&amp;#xa0;&lt;/p&gt;&lt;br/&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <abvcd:CommonStockIssuedAfterStockSplit unitRef="shares" contextRef="c270_From1Feb2016To8Feb2016_ShareExchangeAgreementMember" decimals="INF">164387376</abvcd:CommonStockIssuedAfterStockSplit>
  <abvcd:CommonStockIssuedBeforeStockSplit unitRef="shares" contextRef="c270_From1Feb2016To8Feb2016_ShareExchangeAgreementMember" decimals="INF">52336000</abvcd:CommonStockIssuedBeforeStockSplit>
  <abvcd:CommonStockIssuedAfterStockSplit unitRef="shares" contextRef="c271_From1Feb2016To8Feb2016_ShareExchangeAgreementOneMember" decimals="INF">166273921</abvcd:CommonStockIssuedAfterStockSplit>
  <abvcd:CommonStockIssuedBeforeStockSplit unitRef="shares" contextRef="c271_From1Feb2016To8Feb2016_ShareExchangeAgreementOneMember" decimals="INF">52936583</abvcd:CommonStockIssuedBeforeStockSplit>
  <abvcd:CommonStockIssuedAfterStockSplit unitRef="shares" contextRef="c272_From1Feb2016To8Feb2016_ShareExchangeAgreementTwoMember" decimals="INF">163159952</abvcd:CommonStockIssuedAfterStockSplit>
  <abvcd:CommonStockIssuedBeforeStockSplit unitRef="shares" contextRef="c272_From1Feb2016To8Feb2016_ShareExchangeAgreementTwoMember" decimals="INF">51945225</abvcd:CommonStockIssuedBeforeStockSplit>
  <us-gaap:EquityMethodInvestmentOwnershipPercentage unitRef="pure" contextRef="c48_AsOf8Feb2016_ShareExchangeAgreementTwoMember" decimals="4">0.7970</us-gaap:EquityMethodInvestmentOwnershipPercentage>
  <abvcd:CommonStockIssuedAfterStockSplit unitRef="shares" contextRef="c273_From1Feb2016To8Feb2016_ShareExchangeAgreementThreeMember" decimals="INF">166273921</abvcd:CommonStockIssuedAfterStockSplit>
  <abvcd:CommonStockIssuedBeforeStockSplit unitRef="shares" contextRef="c273_From1Feb2016To8Feb2016_ShareExchangeAgreementThreeMember" decimals="INF">52936583</abvcd:CommonStockIssuedBeforeStockSplit>
  <abvcd:CommonStockIssuedAfterStockSplit unitRef="shares" contextRef="c274_From1Feb2016To8Feb2016_ShareExchangeAgreementFourMember" decimals="INF">205519223</abvcd:CommonStockIssuedAfterStockSplit>
  <abvcd:CommonStockIssuedBeforeStockSplit unitRef="shares" contextRef="c274_From1Feb2016To8Feb2016_ShareExchangeAgreementFourMember" decimals="INF">65431144</abvcd:CommonStockIssuedBeforeStockSplit>
  <abvcd:CommonStockIssuedAfterStockSplit unitRef="shares" contextRef="c275_From1Feb2016To17Feb2016_TwoThousandSixteenEquityIncentivePlanMember" decimals="INF">157050</abvcd:CommonStockIssuedAfterStockSplit>
  <abvcd:CommonStockIssuedBeforeStockSplit unitRef="shares" contextRef="c275_From1Feb2016To17Feb2016_TwoThousandSixteenEquityIncentivePlanMember" decimals="INF">50000</abvcd:CommonStockIssuedBeforeStockSplit>
  <abvcd:StockholderEquityReverseStockSplit contextRef="c276_From1Mar2016To21Mar2016">On March 21, 2016, the Board of Directors of the Company approved an amendment to Articles of Incorporation to effect a forward split at a ratio of 1 to 3:141 (the &amp;#x201c;Forward Stock Split&amp;#x201d;) and increase the number of our authorized shares of Common Stock, par value $0.001 per share, to 360,000,000, which was effective on April 8, 2016.</abvcd:StockholderEquityReverseStockSplit>
  <us-gaap:CommonStockParOrStatedValuePerShare unitRef="usdPershares" contextRef="c277_AsOf21Mar2016" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized unitRef="shares" contextRef="c277_AsOf21Mar2016" decimals="INF">360000000</us-gaap:CommonStockSharesAuthorized>
  <abvcd:AgreementDescription contextRef="c278_From1May2016To6May2016">the Company and BioLite Taiwan agreed to amend the BioLite Collaborative Agreement, through entry into the Milestone Payment Agreement, whereby the Company has agreed to issue shares of Common Stock of the Company, at the price of $1.60 per share, for an aggregate number of 562,500 shares, as part of the Company&amp;#x2019;s first installation of payment pursuant to the Milestone Payment. The shares issuance was completed in June 2016.</abvcd:AgreementDescription>
  <abvcd:AgreementDescription contextRef="c279_From1Aug2016To26Aug2016">the Company issued 1,468,750 shares (&amp;#x201c;Shares&amp;#x201d;) of the Company&amp;#x2019;s Common Stock, par value $0.001 (the &amp;#x201c;Offering&amp;#x201d;) to BioLite Taiwan pursuant to a certain Stock Purchase Agreement dated August 26, 2016 (the &amp;#x201c;SPA&amp;#x201d;). The Shares are exempt from the registration requirements of the Securities Act of 1933, as amended (the &amp;#x201c;Securities Act&amp;#x201d;), pursuant to Regulation S of the Securities Act promulgated thereunder. The purchase price per share of the Offering is $1.60. The net proceeds to the Company from the Offering are approximately $2,350,000. Pursuant to the BioLite Collaborative Agreement, BriVision should pay a total of $100,000,000 in cash or stock of the Company with equivalent value according to the milestone achieved. The agreement requires that 6.5% of total payment, $6,500,000 shall be made upon the first IND submission which was submitted in March 2016.</abvcd:AgreementDescription>
  <abvcd:AgreementDescription contextRef="c280_From1Feb2017To28Feb2017">the Company remitted this amount to BioLite with $650,000 in cash and $5,850,000 in the form of newly issued shares of the Company&amp;#x2019;s Common Stock, at the price of $2.0 per share, for an aggregate number of 2,925,000 shares. Upon the consummation of the restructuring transaction between the Company and BioLite on February 8, 2019, the Company&amp;#x2019;s Common Stock held by BioLite Taiwan was accounted for treasury stocks in the statement of equity (deficit).</abvcd:AgreementDescription>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues unitRef="shares" contextRef="c281_From1Feb2019To8Feb2019_BioLiteMember" decimals="INF">74997546</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues unitRef="shares" contextRef="c282_From1Feb2019To8Feb2019_BioKeyMember" decimals="INF">29561231</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <abvcd:FinancialAmendmentDescription contextRef="c283_From1May2019To3May2019">the Company filed a Certificate of Amendment with the Secretary of State of Nevada, which was effective May 8, 2019 upon its receipt of the written notice from Financial Industry Regulatory Authority (&amp;#x201c;FINRA&amp;#x201d;). Pursuant to the Certificate of Amendment, the Company effectuated a 1-for-18 reverse stock split of its issued and outstanding shares of common stock, $0.001 par value, whereby 318,485,252 outstanding shares of the Company&amp;#x2019;s common stock were exchanged for 17,693,625 shares of the Company&amp;#x2019;s Common Stock. All shares and related financial information in this Form 10-K reflect this 1-for-18 reverse stock split.</abvcd:FinancialAmendmentDescription>
  <abvcd:Consultingagreementdescription contextRef="c284_From24Sep2016To1Oct2016_CollaborativeArrangementMember">On October 1, 2016, the Company entered into a consulting agreement with Kazunori Kameyama (&amp;#x201c;Kameyama&amp;#x201d;) for the provision of services related to the clinical trials and other administrative work, public relation work, capital raising, trip coordination, In consideration for providing such services, the Company agreed to indemnify the consultant in an amount of $150 per hour in cash up to $3,000 per month, and issue to Kameyama the Company&amp;#x2019;s Common Stock at $1.00 per share for any amount exceeding $3,000.</abvcd:Consultingagreementdescription>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues unitRef="shares" contextRef="c285_From1Nov2020To21Nov2020_KameyamaMember" decimals="INF">24694</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <abvcd:UnpaidConsultingFees unitRef="usd" contextRef="c285_From1Nov2020To21Nov2020_KameyamaMember" decimals="0">49388</abvcd:UnpaidConsultingFees>
  <us-gaap:CommonStockSharesIssued unitRef="shares" contextRef="c286_AsOf31Dec2019_EuroAsiaInvestmentAndFinanceCorpLtdMember" decimals="INF">644972</us-gaap:CommonStockSharesIssued>
  <us-gaap:ProfessionalFees unitRef="usd" contextRef="c287_From1Jan2019To31Dec2019" decimals="0">4514800</us-gaap:ProfessionalFees>
  <abvcd:StockSubscriptionReceivable unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">2934620</abvcd:StockSubscriptionReceivable>
  <abvcd:StockSubscriptionReceivable unitRef="usd" contextRef="c5_AsOf31Dec2019" decimals="0">3160360</abvcd:StockSubscriptionReceivable>
  <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent unitRef="usd" contextRef="c288_AsOf24Jun2017_CodevelopmentagreementMember" decimals="0">3000000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues unitRef="shares" contextRef="c289_From1Jun2019To30Jun2019_CollaborativeArrangementMember" decimals="INF">428571</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <abvcd:StockIssuedValue unitRef="usd" contextRef="c289_From1Jun2019To30Jun2019_CollaborativeArrangementMember" decimals="0">3000000</abvcd:StockIssuedValue>
  <us-gaap:DebtConversionConvertedInstrumentAmount1 unitRef="usd" contextRef="c290_From1Aug2019To31Aug2019" decimals="0">4872340</us-gaap:DebtConversionConvertedInstrumentAmount1>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 unitRef="usdPershares" contextRef="c291_AsOf31Aug2019" decimals="2">7.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <us-gaap:CommonStockParOrStatedValuePerShare unitRef="usdPershares" contextRef="c292_AsOf12Mar2020_ArticlesOfIncorporationMember" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized unitRef="shares" contextRef="c293_AsOf12Mar2020_MinimumMember_ArticlesOfIncorporationMember" decimals="INF">20000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized unitRef="shares" contextRef="c294_AsOf12Mar2020_MaximumMember_ArticlesOfIncorporationMember" decimals="INF">100000000</us-gaap:CommonStockSharesAuthorized>
  <abvcd:PlacementAgentAgreementDescription contextRef="c295_From1Jul2020To8Jul2020_ViewTradeSecuritiesIncMember">Pursuant to the agreement, the Company agreed to pay View Trade 60,000 restricted common shares of the Company and 60,000 warrants to purchase common shares of the Company at an exercise price of $6 per share for a period of 5 years with cashless exercise provision.</abvcd:PlacementAgentAgreementDescription>
  <us-gaap:CommonStockSharesIssued unitRef="shares" contextRef="c296_AsOf31Dec2020_ViewTradeSecuritiesIncMember" decimals="INF">60000</us-gaap:CommonStockSharesIssued>
  <us-gaap:ProfessionalFees unitRef="usd" contextRef="c297_From1Jan2020To31Dec2020_ViewTradeSecuritiesIncMember" decimals="0">135000</us-gaap:ProfessionalFees>
  <abvcd:RestrictedCommonShares unitRef="shares" contextRef="c296_AsOf31Dec2020_ViewTradeSecuritiesIncMember" decimals="INF">50000</abvcd:RestrictedCommonShares>
  <abvcd:WarrantIssued unitRef="shares" contextRef="c298_From1Nov2020To19Nov2020" decimals="INF">200000</abvcd:WarrantIssued>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 unitRef="usdPershares" contextRef="c299_AsOf19Nov2020" decimals="2">2.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <abvcd:WarrantTerm contextRef="c298_From1Nov2020To19Nov2020">P5Y</abvcd:WarrantTerm>
  <abvcd:UnrestrictedCommonShares unitRef="shares" contextRef="c300_AsOf19Nov2020_ConsultingAgreementMember" decimals="INF">50000</abvcd:UnrestrictedCommonShares>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 unitRef="usdPershares" contextRef="c300_AsOf19Nov2020_ConsultingAgreementMember" decimals="1">2.9</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <us-gaap:ProceedsFromContributionsFromAffiliates unitRef="usd" contextRef="c301_From1Jan2020To31Dec2020_PrivatePlacementMember" decimals="0">7615331</us-gaap:ProceedsFromContributionsFromAffiliates>
  <abvcd:NumberOfInvestors unitRef="pure" contextRef="c302_AsOf31Dec2020_PrivatePlacementMember" decimals="INF">45</abvcd:NumberOfInvestors>
  <us-gaap:SharesIssuedPricePerShare unitRef="usdPershares" contextRef="c302_AsOf31Dec2020_PrivatePlacementMember" decimals="2">2.25</us-gaap:SharesIssuedPricePerShare>
  <abvcd:IssuanceOfCommonStock unitRef="shares" contextRef="c2_AsOf31Mar2021" decimals="INF">3384615</abvcd:IssuanceOfCommonStock>
  <us-gaap:SharesIssued unitRef="shares" contextRef="c303_AsOf31Dec2020_ConsultingAgreementMember" decimals="INF">521887</us-gaap:SharesIssued>
  <us-gaap:SaleOfStockPricePerShare unitRef="usdPershares" contextRef="c304_AsOf31Dec2020_MinimumMember_ConsultingAgreementMember" decimals="0">2</us-gaap:SaleOfStockPricePerShare>
  <abvcd:StockIssuedDuringPeriodShareBasedCompensationServicesforShares unitRef="shares" contextRef="c305_From1Jan2020To31Dec2020_MaximumMember_ConsultingAgreementMember" decimals="INF">3.68</abvcd:StockIssuedDuringPeriodShareBasedCompensationServicesforShares>
  <abvcd:AggregateCommonStockShares unitRef="shares" contextRef="c224_From1Jan2020To31Dec2020" decimals="INF">915856</abvcd:AggregateCommonStockShares>
  <us-gaap:DebtInstrumentConvertibleTermsOfConversionFeature contextRef="c306_From1Jan2021To31Mar2021_NonRelatedPartiesMember">a. Keypoint converted the aggregated amount of $292,826 at the conversion price of $1.84 on April 5, 2020, in exchange for 159,145 shares of the Company&amp;#x2019;s common stock, and warrants to purchase 159,145 shares of the Company&amp;#x2019;s common stock. b. Odaira converted the aggregated amount of $284,036 at the conversion price of $1.84 on April 5, 2020, in exchange for 154,368 shares of the Company&amp;#x2019;s common stock, and warrants to purchase 154,368 shares of the Company&amp;#x2019;s common stock. c. C.L.L. converted the aggregated amount of $289,974 at the conversion price of $1.78 on April 20, 2020, in exchange for 162,908 shares of the Company&amp;#x2019;s common stock, and warrants to purchase 162,908 shares of the Company&amp;#x2019;s common stock. d. KLS converted the aggregated amount of $225,222 at the conversion price of $1.78 on April 20, 2020, in exchange for 126,530 shares of the Company&amp;#x2019;s common stock, and warrants to purchase 126,530 shares of the Company&amp;#x2019;s common stock. e. Yu and Wei converted the aggregated amount of $354,722 at the conversion price of $1.84 on April 5, 2020, in exchange for 192,784 shares of the Company&amp;#x2019;s common stock, and warrants to purchase 192,784 shares of the Company&amp;#x2019;s common stock. f. KSL converted the aggregated amount of $270,272 at the conversion price of $2.25 on November 9, 2020, in exchange for 120,121 shares of the Company&amp;#x2019;s common stock, and warrants to purchase 120,121 shares of the Company&amp;#x2019;s common stock.</us-gaap:DebtInstrumentConvertibleTermsOfConversionFeature>
  <us-gaap:ScheduleOfDebtConversionsTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; vertical-align: bottom; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;Amount of&lt;br/&gt; Debt&lt;br/&gt; Converted&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;Number of&lt;br/&gt; Shares&lt;br/&gt; Issued&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left&quot;&gt;Lion Arts Promotion Inc&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;97,864&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;13,981&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;LionGene Corporation&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;428,099&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;61,157&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;BioFirst Corporation&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;2,902,911&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;414,702&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;AsiaGene Corporation&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;160,000&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;22,858&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;YuanGene Corporation&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;92,690&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;13,242&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt&quot;&gt;The Jiangs&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;1,190,776&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;170,111&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-indent: -0.125in; padding-bottom: 4pt; padding-left: 0.25in&quot;&gt;Total&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font-weight: bold; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font-weight: bold; text-align: right&quot;&gt;4,872,340&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font-weight: bold; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font-weight: bold; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font-weight: bold; text-align: right&quot;&gt;696,051&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font-weight: bold; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfDebtConversionsTextBlock>
  <us-gaap:DebtConversionConvertedInstrumentAmount1 unitRef="usd" contextRef="c307_From1Aug2019To31Aug2019_LionArtsPromotionInctheLIONMember" decimals="0">97864</us-gaap:DebtConversionConvertedInstrumentAmount1>
  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 unitRef="shares" contextRef="c307_From1Aug2019To31Aug2019_LionArtsPromotionInctheLIONMember" decimals="INF">13981</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
  <us-gaap:DebtConversionConvertedInstrumentAmount1 unitRef="usd" contextRef="c308_From1Aug2019To31Aug2019_LionGeneCorporationMember" decimals="0">428099</us-gaap:DebtConversionConvertedInstrumentAmount1>
  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 unitRef="shares" contextRef="c308_From1Aug2019To31Aug2019_LionGeneCorporationMember" decimals="INF">61157</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
  <us-gaap:DebtConversionConvertedInstrumentAmount1 unitRef="usd" contextRef="c309_From1Aug2019To31Aug2019_BioFirstCorporationMember" decimals="0">2902911</us-gaap:DebtConversionConvertedInstrumentAmount1>
  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 unitRef="shares" contextRef="c309_From1Aug2019To31Aug2019_BioFirstCorporationMember" decimals="INF">414702</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
  <us-gaap:DebtConversionConvertedInstrumentAmount1 unitRef="usd" contextRef="c310_From1Aug2019To31Aug2019_AsiangeneCorporationMember" decimals="0">160000</us-gaap:DebtConversionConvertedInstrumentAmount1>
  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 unitRef="shares" contextRef="c310_From1Aug2019To31Aug2019_AsiangeneCorporationMember" decimals="INF">22858</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
  <us-gaap:DebtConversionConvertedInstrumentAmount1 unitRef="usd" contextRef="c311_From1Aug2019To31Aug2019_YuangeneCorporationMember" decimals="0">92690</us-gaap:DebtConversionConvertedInstrumentAmount1>
  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 unitRef="shares" contextRef="c311_From1Aug2019To31Aug2019_YuangeneCorporationMember" decimals="INF">13242</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
  <us-gaap:DebtConversionConvertedInstrumentAmount1 unitRef="usd" contextRef="c312_From1Aug2019To31Aug2019_TheJiangsMember" decimals="0">1190776</us-gaap:DebtConversionConvertedInstrumentAmount1>
  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 unitRef="shares" contextRef="c312_From1Aug2019To31Aug2019_TheJiangsMember" decimals="INF">170111</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 unitRef="shares" contextRef="c290_From1Aug2019To31Aug2019" decimals="INF">696051</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
  <abvcd:StockOptionsTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;&lt;b&gt;14. STOCK OPTIONS&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;On October 30, 2020, the Company issued an aggregate
of 545,182 shares of common stock in lieu of unpaid salaries of certain employees and unpaid consulting fees under the 2016 Equity Incentive
Plan, as amended, at a conversion price of $2 per share; the total amount of converted salaries and consulting fees was $1,090,361. On
November 21, 2020, the Company has entered&amp;#xa0;into&amp;#xa0;acknowledgement&amp;#xa0;agreements and stock option purchase agreements with these
employees and consultant; pursuant to which the Company granted stock options to purchase 545,182 shares of the Company&amp;#x2019;s common
stock in lieu of common stock. The options were vested at the grant date and become exercisable for 10 years from the grant date.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;Options issued and outstanding as of December
31, 2020, and their activities during the year then ended are as follows:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;Weighted-&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;Weighted-&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;Average&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;Average&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;Contractual&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;Number&amp;#xa0;of&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;Exercise &lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;Life &lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;Aggregate&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;Underlying&lt;br/&gt;
Shares&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;Price&lt;br/&gt;
Per&amp;#xa0;Share&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;Remaining&lt;br/&gt;
in Years&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;Intrinsic&lt;br/&gt;
 Value&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td&gt;Outstanding as of January 1, 2020&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&lt;font style=&quot;font-size: 10pt&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#x202f;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;width: 52%&quot;&gt;Granted&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;545,182&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;2.00&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;9.89&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;616,056&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;Forfeited&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 4pt&quot;&gt;Outstanding as of December 31, 2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;545,182&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;2.00&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;9.89&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;616,056&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 4pt&quot;&gt;Exercisable as of December 31, 2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;545,182&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;2.00&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;9.89&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;616,056&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt&quot;&gt;Vested and expected to vest&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;545,182&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;2.00&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;9.89&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;616,056&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The fair value of stock options granted for the
year ended December 31, 2020 was calculated using the Black-Scholes option-pricing model applying the following assumptions:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-bottom: 0pt; vertical-align: bottom; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 0pt; vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;padding-bottom: 0pt; vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;Year ended&lt;/td&gt;&lt;td style=&quot;padding-bottom: 0pt; vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;white-space: nowrap; padding-bottom: 0pt; vertical-align: bottom; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; vertical-align: bottom; font-weight: bold; padding-bottom: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;white-space: nowrap; border-bottom: Black 1.5pt solid; padding-bottom: 0pt; vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;December&amp;#xa0;31,&lt;br/&gt;
2020&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; vertical-align: bottom; padding-bottom: 0pt; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-bottom: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;padding-bottom: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 0pt; width: 88%; text-align: left&quot;&gt;Risk free interest rate&lt;/td&gt;&lt;td style=&quot;padding-bottom: 0pt; width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 0pt; width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 0pt; width: 9%; text-align: right&quot;&gt;0.38&lt;/td&gt;&lt;td style=&quot;padding-bottom: 0pt; width: 1%; text-align: left&quot;&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 0pt; text-align: left&quot;&gt;Expected term (in years)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 0pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 0pt; text-align: right&quot;&gt;5.00&lt;/td&gt;&lt;td style=&quot;padding-bottom: 0pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 0pt; text-align: left&quot;&gt;Dividend yield&lt;/td&gt;&lt;td style=&quot;padding-bottom: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 0pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 0pt; text-align: right&quot;&gt;0&lt;/td&gt;&lt;td style=&quot;padding-bottom: 0pt; text-align: left&quot;&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 0pt; text-align: left&quot;&gt;Expected volatility&lt;/td&gt;&lt;td style=&quot;padding-bottom: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 0pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 0pt; text-align: right&quot;&gt;89.01&lt;/td&gt;&lt;td style=&quot;padding-bottom: 0pt; text-align: left&quot;&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The weighted average grant date fair value of
options granted during 2020 was $3.13. There are 2,812,949 options available for grant under the 2016 Equity Incentive Plan as of December
31, 2020. Compensation costs associated with the Company&amp;#x2019;s stock options are recognized, based on the grant-date fair values of
these options over vesting period. Accordingly, the Company recognized stock-based compensation expense of $0 and $0 for the three months
ended March 31, 2021 and 2020, respectively. As of March 31, 2021, there were no unvested options.&lt;/p&gt;&lt;br/&gt;</abvcd:StockOptionsTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod unitRef="shares" contextRef="c313_From1Oct2020To30Oct2020" decimals="INF">545182</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:SharePrice unitRef="usdPershares" contextRef="c314_AsOf30Oct2020" decimals="0">2</us-gaap:SharePrice>
  <abvcd:ConsultingFees unitRef="usd" contextRef="c314_AsOf30Oct2020" decimals="0">1090361</abvcd:ConsultingFees>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber unitRef="shares" contextRef="c315_AsOf21Nov2020" decimals="INF">545182</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="c0_From1Jan2021To31Mar2021">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue unitRef="usdPershares" contextRef="c0_From1Jan2021To31Mar2021" decimals="2">3.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant unitRef="shares" contextRef="c316_AsOf31Dec2020_TwoThousandSixteenEquityIncentivePlanMember" decimals="INF">2812949</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <abvcd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">0</abvcd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants>
  <abvcd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">0</abvcd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;Weighted-&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;Weighted-&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;Average&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;Average&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;Contractual&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;Number&amp;#xa0;of&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;Exercise &lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;Life &lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;Aggregate&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;Underlying&lt;br/&gt;
Shares&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;Price&lt;br/&gt;
Per&amp;#xa0;Share&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;Remaining&lt;br/&gt;
in Years&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;Intrinsic&lt;br/&gt;
 Value&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td&gt;Outstanding as of January 1, 2020&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&lt;font style=&quot;font-size: 10pt&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#x202f;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;width: 52%&quot;&gt;Granted&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;545,182&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;2.00&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;9.89&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;616,056&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;Forfeited&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 4pt&quot;&gt;Outstanding as of December 31, 2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;545,182&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;2.00&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;9.89&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;616,056&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 4pt&quot;&gt;Exercisable as of December 31, 2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;545,182&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;2.00&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;9.89&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;616,056&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt&quot;&gt;Vested and expected to vest&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;545,182&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;2.00&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: right&quot;&gt;9.89&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;616,056&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber unitRef="shares" contextRef="c317_AsOf31Dec2019_EmployeeStockOptionMember" xs:nil="true"/>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c317_AsOf31Dec2019_EmployeeStockOptionMember" xs:nil="true"/>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod unitRef="shares" contextRef="c318_From1Jan2020To31Dec2020_EmployeeStockOptionMember" decimals="INF">545182</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c318_From1Jan2020To31Dec2020_EmployeeStockOptionMember" decimals="2">2.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <abvcd:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm contextRef="c318_From1Jan2020To31Dec2020_EmployeeStockOptionMember">P9Y324D</abvcd:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm>
  <abvcd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue unitRef="usd" contextRef="c318_From1Jan2020To31Dec2020_EmployeeStockOptionMember" decimals="0">616056</abvcd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod unitRef="shares" contextRef="c318_From1Jan2020To31Dec2020_EmployeeStockOptionMember" xs:nil="true"/>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c318_From1Jan2020To31Dec2020_EmployeeStockOptionMember" xs:nil="true"/>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber unitRef="shares" contextRef="c319_AsOf31Dec2020_EmployeeStockOptionMember" decimals="INF">545182</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c319_AsOf31Dec2020_EmployeeStockOptionMember" decimals="2">2.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c318_From1Jan2020To31Dec2020_EmployeeStockOptionMember">P9Y324D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue unitRef="usd" contextRef="c319_AsOf31Dec2020_EmployeeStockOptionMember" decimals="0">616056</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber unitRef="shares" contextRef="c319_AsOf31Dec2020_EmployeeStockOptionMember" decimals="INF">545182</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c319_AsOf31Dec2020_EmployeeStockOptionMember" decimals="2">2.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c318_From1Jan2020To31Dec2020_EmployeeStockOptionMember">P9Y324D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 unitRef="usd" contextRef="c319_AsOf31Dec2020_EmployeeStockOptionMember" decimals="0">616056</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber unitRef="shares" contextRef="c319_AsOf31Dec2020_EmployeeStockOptionMember" decimals="INF">545182</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c319_AsOf31Dec2020_EmployeeStockOptionMember" decimals="2">2.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c318_From1Jan2020To31Dec2020_EmployeeStockOptionMember">P9Y324D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue unitRef="usd" contextRef="c319_AsOf31Dec2020_EmployeeStockOptionMember" decimals="0">616056</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-bottom: 0pt; vertical-align: bottom; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 0pt; vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;padding-bottom: 0pt; vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;Year ended&lt;/td&gt;&lt;td style=&quot;padding-bottom: 0pt; vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;white-space: nowrap; padding-bottom: 0pt; vertical-align: bottom; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; vertical-align: bottom; font-weight: bold; padding-bottom: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;white-space: nowrap; border-bottom: Black 1.5pt solid; padding-bottom: 0pt; vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;December&amp;#xa0;31,&lt;br/&gt;
2020&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; vertical-align: bottom; padding-bottom: 0pt; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-bottom: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;padding-bottom: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 0pt; width: 88%; text-align: left&quot;&gt;Risk free interest rate&lt;/td&gt;&lt;td style=&quot;padding-bottom: 0pt; width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 0pt; width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 0pt; width: 9%; text-align: right&quot;&gt;0.38&lt;/td&gt;&lt;td style=&quot;padding-bottom: 0pt; width: 1%; text-align: left&quot;&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 0pt; text-align: left&quot;&gt;Expected term (in years)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 0pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 0pt; text-align: right&quot;&gt;5.00&lt;/td&gt;&lt;td style=&quot;padding-bottom: 0pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 0pt; text-align: left&quot;&gt;Dividend yield&lt;/td&gt;&lt;td style=&quot;padding-bottom: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 0pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 0pt; text-align: right&quot;&gt;0&lt;/td&gt;&lt;td style=&quot;padding-bottom: 0pt; text-align: left&quot;&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 0pt; text-align: left&quot;&gt;Expected volatility&lt;/td&gt;&lt;td style=&quot;padding-bottom: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 0pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 0pt; text-align: right&quot;&gt;89.01&lt;/td&gt;&lt;td style=&quot;padding-bottom: 0pt; text-align: left&quot;&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate unitRef="pure" contextRef="c287_From1Jan2019To31Dec2019" decimals="4">0.0038</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c287_From1Jan2019To31Dec2019">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate unitRef="pure" contextRef="c287_From1Jan2019To31Dec2019" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate unitRef="pure" contextRef="c287_From1Jan2019To31Dec2019" decimals="4">0.8901</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:EarningsPerShareTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;&lt;b&gt;15. LOSS PER SHARE&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;Basic loss per share is computed by dividing net
loss by the weighted-average number of common shares outstanding during the year. Diluted loss per share is computed by dividing net loss
by the weighted-average number of common shares and dilutive potential common shares outstanding during the three months ended March 31,
2021 and 2020.&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;For the Three Months Ended&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;March&amp;#xa0;31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;March&amp;#xa0;31,&lt;br/&gt; 2020&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;Numerator:&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: left&quot;&gt;Net loss attributable to ABVC&amp;#x2019;s common stockholders&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;(1,128,505&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;(1,247,538&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td&gt;Denominator:&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td&gt;Weighted-average shares outstanding:&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt&quot;&gt;Weighted-average shares outstanding - Basic&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;24,420,526&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;19,484,542&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt&quot;&gt;Stock options&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;&amp;#x2013;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt&quot;&gt;Weighted-average shares outstanding - Diluted&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;24,420,526&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;19,484,542&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td&gt;Loss per share&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 4pt&quot;&gt;-Basic&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;(0.05&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;(0.06&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 4pt&quot;&gt;-Diluted&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;(0.05&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;(0.06&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;Diluted loss per share takes into account the
potential dilution that could occur if securities or other contracts to issue Common Stock were exercised and converted into Common Stock.&lt;/p&gt;&lt;br/&gt;</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;For the Three Months Ended&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;March&amp;#xa0;31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;March&amp;#xa0;31,&lt;br/&gt; 2020&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;Numerator:&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: left&quot;&gt;Net loss attributable to ABVC&amp;#x2019;s common stockholders&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;(1,128,505&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;(1,247,538&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td&gt;Denominator:&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td&gt;Weighted-average shares outstanding:&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt&quot;&gt;Weighted-average shares outstanding - Basic&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;24,420,526&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;19,484,542&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt&quot;&gt;Stock options&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;&amp;#x2013;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt&quot;&gt;Weighted-average shares outstanding - Diluted&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;24,420,526&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;19,484,542&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td&gt;Loss per share&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 4pt&quot;&gt;-Basic&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;(0.05&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;(0.06&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 4pt&quot;&gt;-Diluted&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;(0.05&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;(0.06&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
  <abvcd:NetLoss unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">-1128505</abvcd:NetLoss>
  <abvcd:NetLoss unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">-1247538</abvcd:NetLoss>
  <abvcd:StockOptions unitRef="shares" contextRef="c4_From1Jan2020To31Mar2020" xs:nil="true"/>
  <us-gaap:EarningsPerShareBasic unitRef="usdPershares" contextRef="c0_From1Jan2021To31Mar2021" decimals="2">-0.05</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareBasic unitRef="usdPershares" contextRef="c4_From1Jan2020To31Mar2020" decimals="2">-0.06</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareDiluted unitRef="usdPershares" contextRef="c0_From1Jan2021To31Mar2021" decimals="2">-0.05</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareDiluted unitRef="usdPershares" contextRef="c4_From1Jan2020To31Mar2020" decimals="2">-0.06</us-gaap:EarningsPerShareDiluted>
  <us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;&lt;b&gt;16. LEASE&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The Company adopted FASB Accounting Standards
Codification, Topic 842, Leases (&amp;#x201c;ASC 842&amp;#x201d;) using the modified retrospective approach, electing the practical expedient that
allows the Company not to restate its comparative periods prior to the adoption of the standard on January 1, 2019. &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;The Company applied the following practical expedients in the transition
to the new standard and allowed under ASC 842:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%&quot;&gt;
  &lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 0.25in&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 0.25in&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;&amp;#x25cf;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Reassessment of expired or existing contracts: The Company elected not to reassess, at the application date, whether any expired or existing contracts contained leases, the lease classification for any expired or existing leases, and the accounting for initial direct costs for any existing leases.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%&quot;&gt;
  &lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 0.25in&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 0.25in&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;&amp;#x25cf;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Use of hindsight: The Company elected to use hindsight in determining the lease term (that is, when considering options to extend or terminate the lease and to purchase the underlying asset) and in assessing impairment of right-to-use assets.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%&quot;&gt;
  &lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 0.25in&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 0.25in&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;&amp;#x25cf;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Reassessment of existing or expired land easements: The Company elected not to evaluate existing or expired land easements that were not previously accounted for as leases under ASC 840, as allowed under the transition practical expedient. Going forward, new or modified land easements will be evaluated under ASU No. 2016-02.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%&quot;&gt;
  &lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 0.25in&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 0.25in&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;&amp;#x25cf;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Separation of lease and non- lease components: Lease agreements that contain both lease and non-lease components are generally accounted for separately.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%&quot;&gt;
  &lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 0.25in&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 0.25in&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;&amp;#x25cf;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Short-term lease recognition exemption: The Company also elected the short-term lease recognition exemption and will not recognize ROU assets or lease liabilities for leases with a term less than 12 months.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The new leasing standard requires recognition
of leases on the consolidated balance sheets as right-of-use (&amp;#x201c;ROU&amp;#x201d;) assets and lease liabilities. ROU assets represent the
Company&amp;#x2019;s right to use underlying assets for the lease terms and lease liabilities represent the Company&amp;#x2019;s obligation to make
lease payments arising from the leases. Operating lease ROU assets and operating lease liabilities are recognized based on the present
value and future minimum lease payments over the lease term at commencement date. The Company&amp;#x2019;s future minimum based payments used
to determine the Company&amp;#x2019;s lease liabilities mainly include minimum based rent payments. As most of Company&amp;#x2019;s leases do not
provide an implicit rate, the Company uses its estimated incremental borrowing rate based on the information available at commencement
date in determining the present value of lease payments.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The Company recognized lease liabilities, with
corresponding ROU assets, based on the present value of unpaid lease payments for existing operating leases longer than twelve months.
The ROU assets were adjusted per ASC 842 transition guidance for existing lease-related balances of accrued and prepaid rent, unamortized
lease incentives provided by lessors, and restructuring liabilities. Operating lease cost is recognized as a single lease cost on a straight-line
basis over the lease term and is recorded in Selling, general and administrative expenses. Variable lease payments for common area maintenance,
property taxes and other operating expenses are recognized as expense in the period when the changes in facts and circumstances on which
the variable lease payments are based occur.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The Company has no finance leases. The Company&amp;#x2019;s
leases primarily include various office and laboratory spaces, copy machine, and vehicles under various operating lease arrangements.
The Company&amp;#x2019;s operating leases have remaining lease terms of up to approximately five years.&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;March&amp;#xa0;31, &lt;br/&gt; 2021&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;December&amp;#xa0;31, &lt;br/&gt; 2020&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;font-weight: bold&quot;&gt;ASSETS&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: left&quot;&gt;Operating lease right-of-use assets&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;1,714,740&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;1,772,747&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;font-weight: bold&quot;&gt;LIABILITIES&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Operating lease liabilities (current)&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;331,179&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;316,178&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Operating lease liabilities (noncurrent)&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,383,560&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,456,567&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;&lt;b&gt;&lt;i&gt;Supplemental Information&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The following provides details of the Company&amp;#x2019;s
lease expenses:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;Three Months Ended&lt;br/&gt; March 31,&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;2021&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: left&quot;&gt;Operating lease expenses&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;&lt;p style=&quot;margin: 0pt 0; font: 10pt Times New Roman, Times, Serif&quot;&gt;78,847&lt;/p&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;77,527&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;Other information related to leases is presented
below:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;Three Months Ended &lt;br/&gt; March&amp;#xa0;31,&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;2021&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: left&quot;&gt;Cash paid for amounts included in the measurement of operating lease liabilities&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;&lt;p style=&quot;margin: 0pt 0; font: 10pt Times New Roman, Times, Serif&quot;&gt;78,847&lt;/p&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;77,527&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;March&amp;#xa0;31, &lt;br/&gt; 2021&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;December&amp;#xa0;31, &lt;br/&gt; 2020&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;Weighted Average Remaining Lease Term:&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: left&quot;&gt;Operating leases&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;&amp;#xa0;3.58 years &lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;&amp;#xa0;3.08 years&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td&gt;Weighted Average Discount Rate:&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Operating leases&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1.45&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;0.55&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The minimum future annual payments under non-cancellable
leases during the next five years and thereafter, at rates now in force, are as follows:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: black 1.5pt solid; text-align: center&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;Operating leases&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: #CCEEFF&quot;&gt;
    &lt;td style=&quot;width: 90%&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;2021(excluding three months ended March 31, 2021)&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;$&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 7%; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;253,618&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;2022&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;352,248&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: #CCEEFF&quot;&gt;
    &lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;2023&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;359,591&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;2024&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;374,584&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: #CCEEFF&quot;&gt;
    &lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;2025&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;338,676&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Thereafter&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;56,916&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: #CCEEFF&quot;&gt;
    &lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Total future minimum lease payments, undiscounted&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;1,735,633&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Less: Imputed interest&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;20,893&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: #CCEEFF&quot;&gt;
    &lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Present value of future minimum lease payments&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;$&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;1,714,740&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;</us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock>
  <abvcd:ScheduleOfOperatingLeaseArrangementsTableTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;March&amp;#xa0;31, &lt;br/&gt; 2021&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;December&amp;#xa0;31, &lt;br/&gt; 2020&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;font-weight: bold&quot;&gt;ASSETS&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: left&quot;&gt;Operating lease right-of-use assets&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;1,714,740&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;1,772,747&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;font-weight: bold&quot;&gt;LIABILITIES&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Operating lease liabilities (current)&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;331,179&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;316,178&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Operating lease liabilities (noncurrent)&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,383,560&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,456,567&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</abvcd:ScheduleOfOperatingLeaseArrangementsTableTextBlock>
  <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;Three Months Ended&lt;br/&gt; March 31,&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;2021&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: left&quot;&gt;Operating lease expenses&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;&lt;p style=&quot;margin: 0pt 0; font: 10pt Times New Roman, Times, Serif&quot;&gt;78,847&lt;/p&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;77,527&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;Three Months Ended &lt;br/&gt; March&amp;#xa0;31,&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;2021&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: left&quot;&gt;Cash paid for amounts included in the measurement of operating lease liabilities&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;&lt;p style=&quot;margin: 0pt 0; font: 10pt Times New Roman, Times, Serif&quot;&gt;78,847&lt;/p&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;77,527&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;vertical-align: bottom; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;March&amp;#xa0;31, &lt;br/&gt; 2021&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center&quot;&gt;December&amp;#xa0;31, &lt;br/&gt; 2020&lt;/td&gt;&lt;td style=&quot;vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;Weighted Average Remaining Lease Term:&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: left&quot;&gt;Operating leases&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;&amp;#xa0;3.58 years &lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;&amp;#xa0;3.08 years&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td&gt;Weighted Average Discount Rate:&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Operating leases&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1.45&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;0.55&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
  <us-gaap:OperatingLeaseCost unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">78847</us-gaap:OperatingLeaseCost>
  <us-gaap:OperatingLeaseCost unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">77527</us-gaap:OperatingLeaseCost>
  <us-gaap:OperatingLeaseLeaseIncomeLeasePayments unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">78847</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
  <us-gaap:OperatingLeaseLeaseIncomeLeasePayments unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">77527</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
  <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c2_AsOf31Mar2021">P3Y211D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
  <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c6_AsOf31Mar2020">P3Y29D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
  <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent unitRef="pure" contextRef="c2_AsOf31Mar2021" decimals="4">0.0145</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
  <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent unitRef="pure" contextRef="c6_AsOf31Mar2020" decimals="4">0.0055</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
  <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: black 1.5pt solid; text-align: center&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;Operating leases&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: #CCEEFF&quot;&gt;
    &lt;td style=&quot;width: 90%&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;2021(excluding three months ended March 31, 2021)&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;$&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 7%; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;253,618&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;2022&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;352,248&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: #CCEEFF&quot;&gt;
    &lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;2023&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;359,591&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;2024&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;374,584&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: #CCEEFF&quot;&gt;
    &lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;2025&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;338,676&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Thereafter&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;56,916&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: #CCEEFF&quot;&gt;
    &lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Total future minimum lease payments, undiscounted&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;1,735,633&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Less: Imputed interest&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;20,893&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: #CCEEFF&quot;&gt;
    &lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Present value of future minimum lease payments&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;$&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;1,714,740&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">253618</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">352248</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">359591</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">374584</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">338676</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">56916</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDue unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">1735633</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
  <us-gaap:InterestPortionOfMinimumLeasePaymentsSaleLeasebackTransactions unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">20893</us-gaap:InterestPortionOfMinimumLeasePaymentsSaleLeasebackTransactions>
  <us-gaap:PresentValueOfFutureMinimumLeasePaymentsSaleLeasebackTransactions unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">1714740</us-gaap:PresentValueOfFutureMinimumLeasePaymentsSaleLeasebackTransactions>
  <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;17. BUSINESS COMBINATION&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;On February 8, 2019, the Company consummated the
Merger transactions of BioLite and BioKey (See Note 1). Pursuant to the terms of the Merger Agreement, BioLite and BioKey became two wholly-owned
subsidiaries of the Company on February 8, 2019. The Company adopted ASC 805, &amp;#x201c;Business Combination&amp;#x201d; to record the merger
transactions of BioKey. The acquisition was accounted for as a business combination under the purchase method of accounting. BioKey&amp;#x2019;s
results of operations were included in the Company&amp;#x2019;s results beginning February 8, 2019. The purchase price has been allocated to
the assets acquired and the liabilities assumed based on their fair value at the acquisition date as summarized in the following:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;Purchase consideration:&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 88%; text-align: left&quot;&gt;Common Stock (*)&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;44,341,847&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td&gt;Allocation of the purchase price:&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Cash and cash equivalents&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;531,147&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Accounts receivable, net&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;188,550&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Property and equipment, net&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;56,075&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Operating lease right-of-use assets&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;485,684&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt&quot;&gt;Security deposits&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;10,440&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Total assets acquired&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,271,896&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Accounts payable&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(56,204&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Accrued expenses and other current liabilities&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(251,335&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Operating lease liability&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(267,256&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt&quot;&gt;Tenant security deposit&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(2,880&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt&quot;&gt;Total liabilities assumed&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(577,675&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt&quot;&gt;Total net assets acquired&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;694,221&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt&quot;&gt;Goodwill as a result of the Merger&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;43,647,626&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%&quot;&gt;
  &lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 0px&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 24px&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;*&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;29,561,231 shares (1,642,291 after stock reverse split) of common stock of the Company was issued to BioKey in connection with the Merger. Those shares were valued at $1.50 per share, based on the bid-and-ask share price of common stock of the Company on the final day of trading, February 8, 2019.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;On February 8, 2019, the Company has recorded
a 100% goodwill write-down of $43,647,626. Goodwill was determined to have been impaired because of the current financial condition of
the Company and the Company&amp;#x2019;s inability to generate future operating income without substantial sales volume increases, which are
highly uncertain. Furthermore, the Company&amp;#x2019;s anticipated future cash flows indicate that the recoverability of goodwill is not reasonably
assured. The goodwill write-down was reflected as a decrease in additional paid-in capital in the statement of equity upon the consummation
of the Merger.&lt;/p&gt;&lt;br/&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
  <abvcd:CommonStockIssuedAfterStockSplit unitRef="shares" contextRef="c282_From1Feb2019To8Feb2019_BioKeyMember" decimals="INF">1642291</abvcd:CommonStockIssuedAfterStockSplit>
  <us-gaap:SharesIssuedPricePerShare unitRef="usdPershares" contextRef="c320_AsOf8Feb2019_BioKeyMember" decimals="2">1.50</us-gaap:SharesIssuedPricePerShare>
  <abvcd:PercentageOfGoodwill unitRef="pure" contextRef="c321_From1Feb2019To8Feb2019" decimals="2">1.00</abvcd:PercentageOfGoodwill>
  <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill unitRef="usd" contextRef="c321_From1Feb2019To8Feb2019" decimals="0">43647626</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
  <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;Purchase consideration:&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 88%; text-align: left&quot;&gt;Common Stock (*)&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;44,341,847&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td&gt;Allocation of the purchase price:&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Cash and cash equivalents&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;531,147&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Accounts receivable, net&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;188,550&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Property and equipment, net&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;56,075&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Operating lease right-of-use assets&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;485,684&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt&quot;&gt;Security deposits&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;10,440&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Total assets acquired&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,271,896&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Accounts payable&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(56,204&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Accrued expenses and other current liabilities&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(251,335&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Operating lease liability&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(267,256&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt&quot;&gt;Tenant security deposit&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(2,880&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt&quot;&gt;Total liabilities assumed&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(577,675&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt&quot;&gt;Total net assets acquired&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;694,221&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt&quot;&gt;Goodwill as a result of the Merger&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;43,647,626&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%&quot;&gt;
  &lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 0px&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 24px&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;*&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;29,561,231 shares (1,642,291 after stock reverse split) of common stock of the Company was issued to BioKey in connection with the Merger. Those shares were valued at $1.50 per share, based on the bid-and-ask share price of common stock of the Company on the final day of trading, February 8, 2019.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
  <us-gaap:BusinessCombinationConsiderationTransferredOther1 id="_BusinessCombinationConsiderationTransferredOther1-c321_From1Feb2019To8Feb2019_usd" unitRef="usd" contextRef="c321_From1Feb2019To8Feb2019" decimals="0">44341847</us-gaap:BusinessCombinationConsiderationTransferredOther1>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents unitRef="usd" contextRef="c322_AsOf8Feb2019" decimals="0">531147</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables unitRef="usd" contextRef="c322_AsOf8Feb2019" decimals="0">188550</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment unitRef="usd" contextRef="c322_AsOf8Feb2019" decimals="0">56075</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
  <abvcd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets unitRef="usd" contextRef="c322_AsOf8Feb2019" decimals="0">485684</abvcd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets unitRef="usd" contextRef="c322_AsOf8Feb2019" decimals="0">10440</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets unitRef="usd" contextRef="c322_AsOf8Feb2019" decimals="0">1271896</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable unitRef="usd" contextRef="c322_AsOf8Feb2019" decimals="0">56204</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther unitRef="usd" contextRef="c322_AsOf8Feb2019" decimals="0">251335</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther>
  <abvcd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability unitRef="usd" contextRef="c322_AsOf8Feb2019" decimals="0">-267256</abvcd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther unitRef="usd" contextRef="c322_AsOf8Feb2019" decimals="0">2880</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities unitRef="usd" contextRef="c322_AsOf8Feb2019" decimals="0">577675</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet unitRef="usd" contextRef="c322_AsOf8Feb2019" decimals="0">694221</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet unitRef="usd" contextRef="c322_AsOf8Feb2019" decimals="0">43647626</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
  <us-gaap:SubsequentEventsTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;18. SUBSEQUENT EVENTS&lt;/b&gt;&amp;#xa0;&amp;#xa0;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The Company has evaluated subsequent events through the date which
the financial statements were available to be issued. All subsequent events requiring recognition as of March 31, 2021 have been incorporated
into these financial statements and there are no subsequent events that require disclosure in accordance with FASB ASC Topic 855, &amp;#x201c;Subsequent
Events.&amp;#x201d;&amp;#xa0;&amp;#xa0;&lt;/p&gt;&lt;br/&gt;</us-gaap:SubsequentEventsTextBlock>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>abvcd-20210331.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon May 10 19:51:10 UTC 2021 -->
<xs:schema elementFormDefault="qualified" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" targetNamespace="http://metuboutique.com/20210331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:abvcd="http://metuboutique.com/20210331" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="abvcd-20210331_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="abvcd-20210331_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="abvcd-20210331_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="abvcd-20210331_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://metuboutique.com/role/ConsolidatedBalanceSheet" id="abvcd_r_ConsolidatedBalanceSheet">
        <link:definition>001 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ConsolidatedBalanceSheet_Parentheticals" id="abvcd_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>002 - Statement - Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ConsolidatedIncomeStatement" id="abvcd_r_ConsolidatedIncomeStatement">
        <link:definition>003 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ConsolidatedCashFlow" id="abvcd_r_ConsolidatedCashFlow">
        <link:definition>004 - Statement - Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ShareholdersEquityType2or3" id="abvcd_r_ShareholdersEquityType2or3">
        <link:definition>005 - Statement - Consolidated Statements of Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/OrganizationandDescriptionofBusiness" id="abvcd_r_OrganizationandDescriptionofBusiness">
        <link:definition>006 - Disclosure - Organization and Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/SummaryofSignificantAccountingPolicies" id="abvcd_r_SummaryofSignificantAccountingPolicies">
        <link:definition>007 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/CollaborativeAgreements" id="abvcd_r_CollaborativeAgreements">
        <link:definition>008 - Disclosure - Collaborative Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/Inventory" id="abvcd_r_Inventory">
        <link:definition>009 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/PropertyandEquipment" id="abvcd_r_PropertyandEquipment">
        <link:definition>010 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/LongTermInvestments" id="abvcd_r_LongTermInvestments">
        <link:definition>011 - Disclosure - Long-Term Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ConvertibleNotesPayable" id="abvcd_r_ConvertibleNotesPayable">
        <link:definition>012 - Disclosure - Convertible Notes Payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/BankLoans" id="abvcd_r_BankLoans">
        <link:definition>013 - Disclosure - Bank Loans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/PaycheckProtectionProgramLoanPayable" id="abvcd_r_PaycheckProtectionProgramLoanPayable">
        <link:definition>014 - Disclosure - Paycheck Protection Program Loan Payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/NotesPayable" id="abvcd_r_NotesPayable">
        <link:definition>015 - Disclosure - Notes Payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ShorttermLoan" id="abvcd_r_ShorttermLoan">
        <link:definition>016 - Disclosure - Short-term Loan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/RelatedPartiesTransactions" id="abvcd_r_RelatedPartiesTransactions">
        <link:definition>017 - Disclosure - Related Parties Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/Equity" id="abvcd_r_Equity">
        <link:definition>018 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/StockOptions" id="abvcd_r_StockOptions">
        <link:definition>019 - Disclosure - Stock Options</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/LossperShare" id="abvcd_r_LossperShare">
        <link:definition>020 - Disclosure - Loss per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/Lease" id="abvcd_r_Lease">
        <link:definition>021 - Disclosure - Lease</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/BusinessCombination" id="abvcd_r_BusinessCombination">
        <link:definition>022 - Disclosure - Business Combination</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/SubsequentEvents" id="abvcd_r_SubsequentEvents">
        <link:definition>023 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/AccountingPoliciesByPolicy" id="abvcd_r_AccountingPoliciesByPolicy">
        <link:definition>024 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesTables" id="abvcd_r_SummaryofSignificantAccountingPoliciesTables">
        <link:definition>025 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/InventoryTables" id="abvcd_r_InventoryTables">
        <link:definition>026 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/PropertyandEquipmentTables" id="abvcd_r_PropertyandEquipmentTables">
        <link:definition>027 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/LongTermInvestmentsTables" id="abvcd_r_LongTermInvestmentsTables">
        <link:definition>028 - Disclosure - Long-Term Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/BankLoansTables" id="abvcd_r_BankLoansTables">
        <link:definition>029 - Disclosure - Bank Loans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/RelatedPartiesTransactionsTables" id="abvcd_r_RelatedPartiesTransactionsTables">
        <link:definition>030 - Disclosure - Related Parties Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/EquityTables" id="abvcd_r_EquityTables">
        <link:definition>031 - Disclosure - Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/StockOptionsTables" id="abvcd_r_StockOptionsTables">
        <link:definition>032 - Disclosure - Stock Options (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/LossperShareTables" id="abvcd_r_LossperShareTables">
        <link:definition>033 - Disclosure - Loss per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/LeaseTables" id="abvcd_r_LeaseTables">
        <link:definition>034 - Disclosure - Lease (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/BusinessCombinationTables" id="abvcd_r_BusinessCombinationTables">
        <link:definition>035 - Disclosure - Business Combination (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/OrganizationandDescriptionofBusinessDetails" id="abvcd_r_OrganizationandDescriptionofBusinessDetails">
        <link:definition>036 - Disclosure - Organization and Description of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails" id="abvcd_r_SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>037 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofpropertyandequipmentTable" id="abvcd_r_ScheduleofpropertyandequipmentTable">
        <link:definition>038 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of property and equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/CollaborativeAgreementsDetails" id="abvcd_r_CollaborativeAgreementsDetails">
        <link:definition>039 - Disclosure - Collaborative Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofinventoryTable" id="abvcd_r_ScheduleofinventoryTable">
        <link:definition>040 - Disclosure - Inventory (Details) - Schedule of inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/PropertyandEquipmentDetails" id="abvcd_r_PropertyandEquipmentDetails">
        <link:definition>041 - Disclosure - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofpropertyandequipmentTable0" id="abvcd_r_ScheduleofpropertyandequipmentTable0">
        <link:definition>042 - Disclosure - Property and Equipment (Details) - Schedule of property and equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/LongTermInvestmentsDetails" id="abvcd_r_LongTermInvestmentsDetails">
        <link:definition>043 - Disclosure - Long-Term Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofownershippercentagesofinvesteeTable" id="abvcd_r_ScheduleofownershippercentagesofinvesteeTable">
        <link:definition>044 - Disclosure - Long-Term Investments (Details) - Schedule of ownership percentages of investee</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofextenttheinvesteereliesTable" id="abvcd_r_ScheduleofextenttheinvesteereliesTable">
        <link:definition>045 - Disclosure - Long-Term Investments (Details) - Schedule of extent the investee relies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleoflongterminvestmentTable" id="abvcd_r_ScheduleoflongterminvestmentTable">
        <link:definition>046 - Disclosure - Long-Term Investments (Details) - Schedule of long-term investment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofbalancesheetsTable" id="abvcd_r_ScheduleofbalancesheetsTable">
        <link:definition>047 - Disclosure - Long-Term Investments (Details) - Schedule of balance sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofstatementsofoperationTable" id="abvcd_r_ScheduleofstatementsofoperationTable">
        <link:definition>048 - Disclosure - Long-Term Investments (Details) - Schedule of statements of operation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofequityinvestmentsTable" id="abvcd_r_ScheduleofequityinvestmentsTable">
        <link:definition>049 - Disclosure - Long-Term Investments (Details) - Schedule of equity investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ConvertibleNotesPayableDetails" id="abvcd_r_ConvertibleNotesPayableDetails">
        <link:definition>050 - Disclosure - Convertible Notes Payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/BankLoansDetails" id="abvcd_r_BankLoansDetails">
        <link:definition>051 - Disclosure - Bank Loans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofshorttermbankloanTable" id="abvcd_r_ScheduleofshorttermbankloanTable">
        <link:definition>052 - Disclosure - Bank Loans (Details) - Schedule of short-term bank loan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/PaycheckProtectionProgramLoanPayableDetails" id="abvcd_r_PaycheckProtectionProgramLoanPayableDetails">
        <link:definition>053 - Disclosure - Paycheck Protection Program Loan Payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/NotesPayableDetails" id="abvcd_r_NotesPayableDetails">
        <link:definition>054 - Disclosure - Notes Payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ShorttermLoanDetails" id="abvcd_r_ShorttermLoanDetails">
        <link:definition>055 - Disclosure - Short-term Loan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb+OcBO0cz/DPQtq8WT+vHGytpy5eqldqmljvYMs+ffK0hVJun/LoadZRO6MVQWNprQnn57cflcp0+RqqLVbNVtuKFz5+pgq1gL8cjM8xFnzOUdEjZ0sDSJzg18XsOaa9RO4cDdhaiGpwVK1skYTQsz6wjLPW7PJKd/ex+Rw6OhX8y162iyhal6uKXl3HZHtizJwyzq+BhZrw==] CSR-->
      <link:roleType roleURI="http://metuboutique.com/role/RelatedPartiesTransactionsDetails" id="abvcd_r_RelatedPartiesTransactionsDetails">
        <link:definition>056 - Disclosure - Related Parties Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofrelatedpartytransactionsTable" id="abvcd_r_ScheduleofrelatedpartytransactionsTable">
        <link:definition>057 - Disclosure - Related Parties Transactions (Details) - Schedule of related party transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofaccountsreceivableduefromrelatedpartiesTable" id="abvcd_r_ScheduleofaccountsreceivableduefromrelatedpartiesTable">
        <link:definition>058 - Disclosure - Related Parties Transactions (Details) - Schedule of accounts receivable due from related parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofamountduefromrelatedpartiesTable" id="abvcd_r_ScheduleofamountduefromrelatedpartiesTable">
        <link:definition>059 - Disclosure - Related Parties Transactions (Details) - Schedule of amount due from related parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofamountduetorelatedpartiesTable" id="abvcd_r_ScheduleofamountduetorelatedpartiesTable">
        <link:definition>060 - Disclosure - Related Parties Transactions (Details) - Schedule of amount due to related parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/EquityDetails" id="abvcd_r_EquityDetails">
        <link:definition>061 - Disclosure - Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofconvertedamountofdebtandsharesTable" id="abvcd_r_ScheduleofconvertedamountofdebtandsharesTable">
        <link:definition>062 - Disclosure - Equity (Details) - Schedule of converted amount of debt and shares</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/StockOptionsDetails" id="abvcd_r_StockOptionsDetails">
        <link:definition>063 - Disclosure - Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofoptionsissuedandoutstandingTable" id="abvcd_r_ScheduleofoptionsissuedandoutstandingTable">
        <link:definition>064 - Disclosure - Stock Options (Details) - Schedule of options issued and outstanding</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleoffairvalueofstockoptionsgrantedTable" id="abvcd_r_ScheduleoffairvalueofstockoptionsgrantedTable">
        <link:definition>065 - Disclosure - Stock Options (Details) - Schedule of fair value of stock options granted</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleoflosspershareTable" id="abvcd_r_ScheduleoflosspershareTable">
        <link:definition>066 - Disclosure - Loss per Share (Details) - Schedule of loss per share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofoperatingleasearrangementsTable" id="abvcd_r_ScheduleofoperatingleasearrangementsTable">
        <link:definition>067 - Disclosure - Lease (Details) - Schedule of operating lease arrangements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofsupplementalinformationrelatedtooperatingleasesTable" id="abvcd_r_ScheduleofsupplementalinformationrelatedtooperatingleasesTable">
        <link:definition>068 - Disclosure - Lease (Details) - Schedule of supplemental information related to operating leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofminimumfutureannualpaymentsundernoncancellableleasesTable" id="abvcd_r_ScheduleofminimumfutureannualpaymentsundernoncancellableleasesTable">
        <link:definition>069 - Disclosure - Lease (Details) - Schedule of minimum future annual payments under non-cancellable leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/BusinessCombinationDetails" id="abvcd_r_BusinessCombinationDetails">
        <link:definition>070 - Disclosure - Business Combination (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofassetsacquiredandliabilitiesassumedbasedonfairvalueTable" id="abvcd_r_ScheduleofassetsacquiredandliabilitiesassumedbasedonfairvalueTable">
        <link:definition>071 - Disclosure - Business Combination (Details) - Schedule of assets acquired and liabilities assumed based on fair value</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2020-01-31" schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd"/>
  <xs:element name="ScheduleOfPropertyAndEquipmentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_ScheduleOfPropertyAndEquipmentAbstract"/>
  <xs:element name="ScheduleOfInventoryAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_ScheduleOfInventoryAbstract"/>
  <xs:element name="LongTermInvestmentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_LongTermInvestmentAbstract"/>
  <xs:element name="ScheduleOfOwnershipPercentagesOfInvesteeAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_ScheduleOfOwnershipPercentagesOfInvesteeAbstract"/>
  <xs:element name="ScheduleOfExtentTheInvesteeReliesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_ScheduleOfExtentTheInvesteeReliesAbstract"/>
  <xs:element name="ScheduleOfLongTermInvestmentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_ScheduleOfLongTermInvestmentAbstract"/>
  <xs:element name="ScheduleOfBalanceSheetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_ScheduleOfBalanceSheetsAbstract"/>
  <xs:element name="ScheduleOfStatementsOfOperationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_ScheduleOfStatementsOfOperationAbstract"/>
  <xs:element name="ScheduleOfEquityInvestmentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_ScheduleOfEquityInvestmentsAbstract"/>
  <xs:element name="ConvertibleNotesPayableDisclosureAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_ConvertibleNotesPayableDisclosureAbstract"/>
  <xs:element name="BankLoansAbstractAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_BankLoansAbstractAbstract"/>
  <xs:element name="ScheduleOfShortTermBankLoanAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_ScheduleOfShortTermBankLoanAbstract"/>
  <xs:element name="PaycheckProtectionProgramLoanPayableAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_PaycheckProtectionProgramLoanPayableAbstract"/>
  <xs:element name="ScheduleOfRelatedPartyTransactionsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_ScheduleOfRelatedPartyTransactionsAbstract"/>
  <xs:element name="ScheduleOfAccountsReceivableDueFromRelatedPartiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_ScheduleOfAccountsReceivableDueFromRelatedPartiesAbstract"/>
  <xs:element name="ScheduleOfAmountDueFromRelatedPartiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_ScheduleOfAmountDueFromRelatedPartiesAbstract"/>
  <xs:element name="ScheduleOfAmountDueToRelatedPartiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_ScheduleOfAmountDueToRelatedPartiesAbstract"/>
  <xs:element name="ScheduleOfConvertedAmountOfDebtAndSharesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_ScheduleOfConvertedAmountOfDebtAndSharesAbstract"/>
  <xs:element name="StockOptionsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_StockOptionsAbstract"/>
  <xs:element name="ScheduleOfOptionsIssuedAndOutstandingAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_ScheduleOfOptionsIssuedAndOutstandingAbstract"/>
  <xs:element name="ScheduleOfFairValueOfStockOptionsGrantedAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_ScheduleOfFairValueOfStockOptionsGrantedAbstract"/>
  <xs:element name="ScheduleOfLossPerShareAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_ScheduleOfLossPerShareAbstract"/>
  <xs:element name="ScheduleOfOperatingLeaseArrangementsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_ScheduleOfOperatingLeaseArrangementsAbstract"/>
  <xs:element name="ScheduleOfSupplementalInformationRelatedToOperatingLeasesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_ScheduleOfSupplementalInformationRelatedToOperatingLeasesAbstract"/>
  <xs:element name="ScheduleOfMinimumFutureAnnualPaymentsUnderNonCancellableLeasesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_ScheduleOfMinimumFutureAnnualPaymentsUnderNonCancellableLeasesAbstract"/>
  <xs:element name="ScheduleOfAssetsAcquiredAndLiabilitiesAssumedBasedOnFairValueAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_ScheduleOfAssetsAcquiredAndLiabilitiesAssumedBasedOnFairValueAbstract"/>
  <xs:element name="CashPaidDuringTheYearForAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_CashPaidDuringTheYearForAbstract"/>
  <xs:element name="NonMarketableCostMethodInvestmentsNetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_NonMarketableCostMethodInvestmentsNetAbstract"/>
  <xs:element name="EquityMethodInvestmentsNetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_EquityMethodInvestmentsNetAbstract"/>
  <xs:element name="NumeratorAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_NumeratorAbstract"/>
  <xs:element name="DenominatorAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_DenominatorAbstract"/>
  <xs:element name="WeightedAverageRemainingLeaseTermAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_WeightedAverageRemainingLeaseTermAbstract"/>
  <xs:element name="WeightedAverageDiscountRateAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_WeightedAverageDiscountRateAbstract"/>
  <xs:element name="PurchaseConsiderationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_PurchaseConsiderationAbstract"/>
  <xs:element name="AllocationOfThePurchasePriceAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_AllocationOfThePurchasePriceAbstract"/>
  <xs:element name="RentalIncomeRelatedParties" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvcd_RentalIncomeRelatedParties"/>
  <xs:element name="GovernmentGrantIncome" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvcd_GovernmentGrantIncome"/>
  <xs:element name="NetLossAttributableToAbvcAndSubsidiaries" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvcd_NetLossAttributableToAbvcAndSubsidiaries"/>
  <xs:element name="IncreaseDecreaseInGovernmentGrantIncome" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvcd_IncreaseDecreaseInGovernmentGrantIncome"/>
  <xs:element name="NetProceedsFromShortTermBorrowingsFromThirdParties" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abvcd_NetProceedsFromShortTermBorrowingsFromThirdParties"/>
  <xs:element name="CumulativeTransactionAdjustments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvcd_CumulativeTransactionAdjustments"/>
  <xs:element name="CollaborativeAgreementsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abvcd_CollaborativeAgreementsTable"/>
  <xs:element name="CollaborativeAgreementsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_CollaborativeAgreementsLineItems"/>
  <xs:element name="LongTermInvestmentTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_LongTermInvestmentTextBlock"/>
  <xs:element name="ConvertibleNotesPayableDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_ConvertibleNotesPayableDisclosureTextBlock"/>
  <xs:element name="BankLoansAbstract" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_BankLoansAbstract"/>
  <xs:element name="PaycheckProtectionProgramLoanPayableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_PaycheckProtectionProgramLoanPayableTextBlock"/>
  <xs:element name="NotesPayableTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abvcd_NotesPayableTable"/>
  <xs:element name="NotesPayableLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_NotesPayableLineItems"/>
  <xs:element name="StockOptionsTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_StockOptionsTextBlock"/>
  <xs:element name="ForwardStockSplitsPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_ForwardStockSplitsPolicyTextBlock"/>
  <xs:element name="StockReverseSplitPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_StockReverseSplitPolicyTextBlock"/>
  <xs:element name="LongTermEquityInvestmentPolicy" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_LongTermEquityInvestmentPolicy"/>
  <xs:element name="OtherThanTemporaryImpairmentPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_OtherThanTemporaryImpairmentPolicyTextBlock"/>
  <xs:element name="BeneficialConversionFeature" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_BeneficialConversionFeature"/>
  <xs:element name="ValuationOfDeferredTaxAssetsPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_ValuationOfDeferredTaxAssetsPolicyTextBlock"/>
  <xs:element name="TranslationAdjustmentPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_TranslationAdjustmentPolicyTextBlock"/>
  <xs:element name="ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock"/>
  <xs:element name="ScheduleOfOwnershipPercentagesOfInvesteeTableTextBlocks" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_ScheduleOfOwnershipPercentagesOfInvesteeTableTextBlocks"/>
  <xs:element name="ScheduleOfExtentInvesteeReliesTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_ScheduleOfExtentInvesteeReliesTableTextBlock"/>
  <xs:element name="ScheduleOfLongTermInvestmentTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_ScheduleOfLongTermInvestmentTableTextBlock"/>
  <xs:element name="ScheduleOfAccountReceivableDueFromRelatedPartiesTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_ScheduleOfAccountReceivableDueFromRelatedPartiesTableTextBlock"/>
  <xs:element name="ScheduleOfRelatedPartyTransactionsAmountDueToRelatedParty" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_ScheduleOfRelatedPartyTransactionsAmountDueToRelatedParty"/>
  <xs:element name="ScheduleOfOperatingLeaseArrangementsTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_ScheduleOfOperatingLeaseArrangementsTableTextBlock"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abvcd_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentTable"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems"/>
  <xs:element name="AllowanceForInventoryValuationAndObsolescenceLoss" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvcd_AllowanceForInventoryValuationAndObsolescenceLoss"/>
  <xs:element name="LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abvcd_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeTable"/>
  <xs:element name="LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeLineItems"/>
  <xs:element name="AccountingTreatmentDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_AccountingTreatmentDescription"/>
  <xs:element name="LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abvcd_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesTable"/>
  <xs:element name="LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesLineItems"/>
  <xs:element name="RelatedPartyTransactionDescriptionOfTransactions" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_RelatedPartyTransactionDescriptionOfTransactions"/>
  <xs:element name="LongTermInvestmentsDetailsScheduleoflongterminvestmentTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abvcd_LongTermInvestmentsDetailsScheduleoflongterminvestmentTable"/>
  <xs:element name="LongTermInvestmentsDetailsScheduleoflongterminvestmentLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_LongTermInvestmentsDetailsScheduleoflongterminvestmentLineItems"/>
  <xs:element name="NonmarketableCostMethodInvestmentsNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abvcd_NonmarketableCostMethodInvestmentsNet"/>
  <xs:element name="LongTermInvestmentNetLoss" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abvcd_LongTermInvestmentNetLoss"/>
  <xs:element name="ShareOfEquityMethodInvesteeLosses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvcd_ShareOfEquityMethodInvesteeLosses"/>
  <xs:element name="RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abvcd_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesTable"/>
  <xs:element name="RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesLineItems"/>
  <xs:element name="RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abvcd_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesTable"/>
  <xs:element name="RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesLineItems"/>
  <xs:element name="StockOptionsDetailsScheduleofoptionsissuedandoutstandingTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abvcd_StockOptionsDetailsScheduleofoptionsissuedandoutstandingTable"/>
  <xs:element name="StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abvcd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue"/>
  <xs:element name="NetLoss" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abvcd_NetLoss"/>
  <xs:element name="StockOptions" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_StockOptions"/>
  <xs:element name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abvcd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets"/>
  <xs:element name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvcd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability"/>
  <xs:element name="OrganizationandDescriptionofBusinessDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abvcd_OrganizationandDescriptionofBusinessDetailsTable"/>
  <xs:element name="OrganizationandDescriptionofBusinessDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_OrganizationandDescriptionofBusinessDetailsLineItems"/>
  <xs:element name="CommonStockIssuedAfterStockSplit" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_CommonStockIssuedAfterStockSplit"/>
  <xs:element name="CommonStockIssuedBeforeStockSplit" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_CommonStockIssuedBeforeStockSplit"/>
  <xs:element name="PercentageOfCommonSharesIssuedAndOutstanding" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="abvcd_PercentageOfCommonSharesIssuedAndOutstanding"/>
  <xs:element name="PercentageOfIssuedShareCapital" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="abvcd_PercentageOfIssuedShareCapital"/>
  <xs:element name="MarketableSecuritiesRealizedGainLossOtherThanTemporaryImpairmentsAmounts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abvcd_MarketableSecuritiesRealizedGainLossOtherThanTemporaryImpairmentsAmounts"/>
  <xs:element name="PercentageOfMonthlyContribution" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="abvcd_PercentageOfMonthlyContribution"/>
  <xs:element name="StockBasedCompensationForNonemployees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abvcd_StockBasedCompensationForNonemployees"/>
  <xs:element name="CollaborativeAgreementsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abvcd_CollaborativeAgreementsDetailsTable"/>
  <xs:element name="CollaborativeAgreementsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_CollaborativeAgreementsDetailsLineItems"/>
  <xs:element name="MilestonePayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abvcd_MilestonePayments"/>
  <xs:element name="UpfrontCashPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abvcd_UpfrontCashPayment"/>
  <xs:element name="PercentageOfPaymentsUnderCodevelopmentAgreement" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_PercentageOfPaymentsUnderCodevelopmentAgreement"/>
  <xs:element name="IssuanceOfStockValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvcd_IssuanceOfStockValue"/>
  <xs:element name="MilestonePaymentsRoyaltyPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_MilestonePaymentsRoyaltyPercentage"/>
  <xs:element name="CollaborativeAgreementsDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_CollaborativeAgreementsDescription"/>
  <xs:element name="AdditionCashPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvcd_AdditionCashPayment"/>
  <xs:element name="CoDevAgreementDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_CoDevAgreementDescription"/>
  <xs:element name="LongTermInvestmentsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abvcd_LongTermInvestmentsDetailsTable"/>
  <xs:element name="LongTermInvestmentsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_LongTermInvestmentsDetailsLineItems"/>
  <xs:element name="AggregateAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvcd_AggregateAmount"/>
  <xs:element name="ConvertibleNotesPayableDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abvcd_ConvertibleNotesPayableDetailsTable"/>
  <xs:element name="ConvertibleNotesPayableDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_ConvertibleNotesPayableDetailsLineItems"/>
  <xs:element name="TotalInterestExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abvcd_TotalInterestExpenses"/>
  <xs:element name="TypeOfCurrencyDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_TypeOfCurrencyDomain"/>
  <xs:element name="BankLoansDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abvcd_BankLoansDetailsTable"/>
  <xs:element name="BankLoansDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_BankLoansDetailsLineItems"/>
  <xs:element name="ReceivedLoanAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abvcd_ReceivedLoanAmount"/>
  <xs:element name="RegularInterestRateDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_RegularInterestRateDescription"/>
  <xs:element name="ExceedingAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abvcd_ExceedingAmount"/>
  <xs:element name="PaycheckProtectionProgramLoanPayableDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abvcd_PaycheckProtectionProgramLoanPayableDetailsTable"/>
  <xs:element name="PaycheckProtectionProgramLoanPayableDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_PaycheckProtectionProgramLoanPayableDetailsLineItems"/>
  <xs:element name="PaycheckProtectionProgramDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_PaycheckProtectionProgramDescription"/>
  <xs:element name="PercentageOfForgivenAmount" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="abvcd_PercentageOfForgivenAmount"/>
  <xs:element name="InterestRate" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="abvcd_InterestRate"/>
  <xs:element name="PromissoryNoteTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_PromissoryNoteTerm"/>
  <xs:element name="LoanAmout" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvcd_LoanAmout"/>
  <xs:element name="UnsecuredLoanAgreementsDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_UnsecuredLoanAgreementsDescription"/>
  <xs:element name="AgreemnetDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_AgreemnetDomain"/>
  <xs:element name="RelatedPartiesTransactionsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abvcd_RelatedPartiesTransactionsDetailsTable"/>
  <xs:element name="RelatedPartiesTransactionsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_RelatedPartiesTransactionsDetailsLineItems"/>
  <xs:element name="AccruedInterest" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abvcd_AccruedInterest"/>
  <xs:element name="StockPurchaseAgreementDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_StockPurchaseAgreementDescription"/>
  <xs:element name="AggregateWorkingcapital" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abvcd_AggregateWorkingcapital"/>
  <xs:element name="AdvancesBearInterestDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_AdvancesBearInterestDescription"/>
  <xs:element name="NumberOfEmployees" type="xbrli:integerItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="abvcd_NumberOfEmployees"/>
  <xs:element name="EquityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abvcd_EquityDetailsTable"/>
  <xs:element name="EquityDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_EquityDetailsLineItems"/>
  <xs:element name="StockholderEquityReverseStockSplit" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_StockholderEquityReverseStockSplit"/>
  <xs:element name="AgreementDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_AgreementDescription"/>
  <xs:element name="FinancialAmendmentDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_FinancialAmendmentDescription"/>
  <xs:element name="Consultingagreementdescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_Consultingagreementdescription"/>
  <xs:element name="UnpaidConsultingFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abvcd_UnpaidConsultingFees"/>
  <xs:element name="StockSubscriptionReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvcd_StockSubscriptionReceivable"/>
  <xs:element name="StockIssuedValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvcd_StockIssuedValue"/>
  <xs:element name="PlacementAgentAgreementDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_PlacementAgentAgreementDescription"/>
  <xs:element name="RestrictedCommonShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="abvcd_RestrictedCommonShares"/>
  <xs:element name="WarrantIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_WarrantIssued"/>
  <xs:element name="WarrantTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_WarrantTerm"/>
  <xs:element name="UnrestrictedCommonShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="abvcd_UnrestrictedCommonShares"/>
  <xs:element name="NumberOfInvestors" type="xbrli:integerItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="abvcd_NumberOfInvestors"/>
  <xs:element name="IssuanceOfCommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="abvcd_IssuanceOfCommonStock"/>
  <xs:element name="StockIssuedDuringPeriodShareBasedCompensationServicesforShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_StockIssuedDuringPeriodShareBasedCompensationServicesforShares"/>
  <xs:element name="AggregateCommonStockShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_AggregateCommonStockShares"/>
  <xs:element name="StockOptionsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abvcd_StockOptionsDetailsTable"/>
  <xs:element name="StockOptionsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_StockOptionsDetailsLineItems"/>
  <xs:element name="ConsultingFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abvcd_ConsultingFees"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvcd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants"/>
  <xs:element name="BusinessCombinationDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abvcd_BusinessCombinationDetailsTable"/>
  <xs:element name="BusinessCombinationDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_BusinessCombinationDetailsLineItems"/>
  <xs:element name="PercentageOfGoodwill" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_PercentageOfGoodwill"/>
  <xs:element name="AgreemnetAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="abvcd_AgreemnetAxis"/>
  <xs:element name="TypeOfCurrencyAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="abvcd_TypeOfCurrencyAxis"/>
  <xs:element name="AmkeyMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_AmkeyMember"/>
  <xs:element name="AmkeyVenturesLLCAmkeyMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_AmkeyVenturesLLCAmkeyMember"/>
  <xs:element name="ArticlesOfIncorporationMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_ArticlesOfIncorporationMember"/>
  <xs:element name="AsiaGeneCorporationtheAsiaGeneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_AsiaGeneCorporationtheAsiaGeneMember"/>
  <xs:element name="AsiaGeneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_AsiaGeneMember"/>
  <xs:element name="AsiangeneCorporationMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_AsiangeneCorporationMember"/>
  <xs:element name="BHKCoDevelopmentAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_BHKCoDevelopmentAgreementMember"/>
  <xs:element name="BioFirstAustraliaMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_BioFirstAustraliaMember"/>
  <xs:element name="BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember"/>
  <xs:element name="BioFirstCorporationMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_BioFirstCorporationMember"/>
  <xs:element name="BioFirstCorporationtheBioFirstMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_BioFirstCorporationtheBioFirstMember"/>
  <xs:element name="BioFirstMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_BioFirstMember"/>
  <xs:element name="BioFirstStockPurchaseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_BioFirstStockPurchaseAgreementMember"/>
  <xs:element name="BioHopeKingCorporationMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_BioHopeKingCorporationMember"/>
  <xs:element name="BioKeyMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_BioKeyMember"/>
  <xs:element name="BioLiteJapanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_BioLiteJapanMember"/>
  <xs:element name="BioLiteMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_BioLiteMember"/>
  <xs:element name="BioLiteTaiwanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_BioLiteTaiwanMember"/>
  <xs:element name="BraingenesisBiotechnologyCoLtdMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_BraingenesisBiotechnologyCoLtdMember"/>
  <xs:element name="BuildingsAndLeaseholdImprovementsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_BuildingsAndLeaseholdImprovementsMember"/>
  <xs:element name="CTBCBankMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_CTBCBankMember"/>
  <xs:element name="CathayBnakMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_CathayBnakMember"/>
  <xs:element name="CathayUnitedBankMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_CathayUnitedBankMember"/>
  <xs:element name="CathayUnitedLoanAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_CathayUnitedLoanAgreementMember"/>
  <xs:element name="CodevelopmentagreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_CodevelopmentagreementMember"/>
  <xs:element name="ConsultingAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_ConsultingAgreementMember"/>
  <xs:element name="ConversionAgreementsOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_ConversionAgreementsOneMember"/>
  <xs:element name="DueToEmployeesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_DueToEmployeesMember"/>
  <xs:element name="DueToshareholdersMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_DueToshareholdersMember"/>
  <xs:element name="EugeneJiangMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_EugeneJiangMember"/>
  <xs:element name="EuroAsiaInvestmentAndFinanceCorpLtdMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_EuroAsiaInvestmentAndFinanceCorpLtdMember"/>
  <xs:element name="EuroAsiaInvestmentFinanceCorpLtdtheEuroAsiaMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_EuroAsiaInvestmentFinanceCorpLtdtheEuroAsiaMember"/>
  <xs:element name="GenePharmIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_GenePharmIncMember"/>
  <xs:element name="GenePharmInctheGenePharmMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_GenePharmInctheGenePharmMember"/>
  <xs:element name="GenepharmBiotechCorporationMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_GenepharmBiotechCorporationMember"/>
  <xs:element name="JIANGSMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_JIANGSMember"/>
  <xs:element name="KameyamaMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_KameyamaMember"/>
  <xs:element name="KeypointMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_KeypointMember"/>
  <xs:element name="KeypointTechnologyLtdtheKeypointMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_KeypointTechnologyLtdtheKeypointMember"/>
  <xs:element name="KimhoConsultantsCoLtdtheKimhoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_KimhoConsultantsCoLtdtheKimhoMember"/>
  <xs:element name="LBGUSAInctheLBGUSAMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_LBGUSAInctheLBGUSAMember"/>
  <xs:element name="LBGUSAMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_LBGUSAMember"/>
  <xs:element name="LbgUsaIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_LbgUsaIncMember"/>
  <xs:element name="LionArtsPromotionInctheLIONMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_LionArtsPromotionInctheLIONMember"/>
  <xs:element name="LionArtsPromotionInctheLionArtsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_LionArtsPromotionInctheLionArtsMember"/>
  <xs:element name="LionGeneCorporationMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_LionGeneCorporationMember"/>
  <xs:element name="LionGeneCorporationtheLionGeneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_LionGeneCorporationtheLionGeneMember"/>
  <xs:element name="LoanAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_LoanAgreementMember"/>
  <xs:element name="MergerAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_MergerAgreementMember"/>
  <xs:element name="MrTsungShannJiangMsShuLingJiangMrChangJenJiangMsMeiLingJiangAndMrEugeneJiangcollectivelyTheJiangsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_MrTsungShannJiangMsShuLingJiangMrChangJenJiangMsMeiLingJiangAndMrEugeneJiangcollectivelyTheJiangsMember"/>
  <xs:element name="NTMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_NTMember"/>
  <xs:element name="NonRelatedPartiesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_NonRelatedPartiesMember"/>
  <xs:element name="PAYCHECKPROTECTIONPROGRAMMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_PAYCHECKPROTECTIONPROGRAMMember"/>
  <xs:element name="RgeneCorporationMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_RgeneCorporationMember"/>
  <xs:element name="RgeneCorporationtheRgeneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_RgeneCorporationtheRgeneMember"/>
  <xs:element name="RgeneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_RgeneMember"/>
  <xs:element name="SecuritiesPurchaseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_SecuritiesPurchaseAgreementMember"/>
  <xs:element name="ShareExchangeAgreementFourMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_ShareExchangeAgreementFourMember"/>
  <xs:element name="ShareExchangeAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_ShareExchangeAgreementMember"/>
  <xs:element name="ShareExchangeAgreementOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_ShareExchangeAgreementOneMember"/>
  <xs:element name="ShareExchangeAgreementThreeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_ShareExchangeAgreementThreeMember"/>
  <xs:element name="ShareExchangeAgreementTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_ShareExchangeAgreementTwoMember"/>
  <xs:element name="StockSubscriptionReceivableMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_StockSubscriptionReceivableMember"/>
  <xs:element name="TheJiangsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_TheJiangsMember"/>
  <xs:element name="TwoThousandSixteenEquityIncentivePlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_TwoThousandSixteenEquityIncentivePlanMember"/>
  <xs:element name="UnsecuredConvertiblePromissoryNoteMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_UnsecuredConvertiblePromissoryNoteMember"/>
  <xs:element name="ViewTradeSecuritiesIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_ViewTradeSecuritiesIncMember"/>
  <xs:element name="YoshinobuOdairatheOdairaMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_YoshinobuOdairatheOdairaMember"/>
  <xs:element name="YuanGeneCorporationtheYuanGeneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_YuanGeneCorporationtheYuanGeneMember"/>
  <xs:element name="YuanGeneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_YuanGeneMember"/>
  <xs:element name="YuangeneCorporationMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_YuangeneCorporationMember"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvcd_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>abvcd-20210331_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon May 10 19:51:10 UTC 2021 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_ConsolidatedBalanceSheet" roleURI="http://metuboutique.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_ConsolidatedIncomeStatement" roleURI="http://metuboutique.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_ConsolidatedCashFlow" roleURI="http://metuboutique.com/role/ConsolidatedCashFlow"/>
  <calculationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableRelatedPartiesCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueFromOtherRelatedPartiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromOtherRelatedPartiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_DueFromOtherRelatedPartiesCurrent" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Goodwill" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_LongTermInvestments" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PrepaidExpenseNoncurrent" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDeposit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_SecurityDeposit" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermBankLoansAndNotesPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ShortTermBankLoansAndNotesPayable" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherShortTermBorrowings" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherShortTermBorrowings"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherShortTermBorrowings" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableToBankCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableToBankCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_NotesPayableToBankCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerAdvancesForConstruction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerAdvancesForConstruction"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_CustomerAdvancesForConstruction" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent" order="9" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNotesPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNotesPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherNotesPayableCurrent" order="10" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LoansPayable" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SecurityDepositLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDepositLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_SecurityDepositLiability" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleLongTermNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_ConvertibleLongTermNotesPayable" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteSubscriptionsReceivable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" order="6" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_TreasuryStockValue" order="7" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquity" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_MinorityInterest" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_Revenues" order="1" weight="1"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb+OcBO0cz/DPQtq8WT+vHGytpy5eqldqmljvYMs+ffK0hVJun/LoadZRO6MVQWNprQnn57cflcp0+RqqLVbNVtuKFz5+pgq1gL8cjM8xFnzOUdEjZ0sDSJzg18XsOaa9RO4cDdhaiGpwVK1skYTQsz6wjLPW7PJKd/ex+Rw6OhX8y162iyhal6RDNjyCS2logIkP1H5GkFfw==] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfRevenue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_CostOfRevenue" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ShareBasedCompensation" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GrossProfit" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RentalIncomeNonoperating" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RentalIncomeNonoperating"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_RentalIncomeNonoperating" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="abvcd_RentalIncomeRelatedParties" xlink:href="abvcd-20210331.xsd#abvcd_RentalIncomeRelatedParties"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="abvcd_RentalIncomeRelatedParties" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_EquitySecuritiesFvNiRealizedGainLoss" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="abvcd_GovernmentGrantIncome" xlink:href="abvcd-20210331.xsd#abvcd_GovernmentGrantIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="abvcd_GovernmentGrantIncome" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpense" order="8" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="abvcd_NetLossAttributableToAbvcAndSubsidiaries" xlink:href="abvcd-20210331.xsd#abvcd_NetLossAttributableToAbvcAndSubsidiaries"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="abvcd_NetLossAttributableToAbvcAndSubsidiaries" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="abvcd_NetLossAttributableToAbvcAndSubsidiaries" xlink:to="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="abvcd_NetLossAttributableToAbvcAndSubsidiaries" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrealizedGainLossOnInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" order="8" weight="-1"/>
    <loc xlink:type="locator" xlink:label="abvcd_IncreaseDecreaseInGovernmentGrantIncome" xlink:href="abvcd-20210331.xsd#abvcd_IncreaseDecreaseInGovernmentGrantIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="abvcd_IncreaseDecreaseInGovernmentGrantIncome" order="9" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="10" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="11" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets" order="12" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseDueFromOtherRelatedParties" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseDueFromOtherRelatedParties"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseDueFromOtherRelatedParties" order="13" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireOtherInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireOtherInvestments" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="abvcd_NetProceedsFromShortTermBorrowingsFromThirdParties" xlink:href="abvcd-20210331.xsd#abvcd_NetProceedsFromShortTermBorrowingsFromThirdParties"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="abvcd_NetProceedsFromShortTermBorrowingsFromThirdParties" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfNotesPayable" order="5" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfLongTermDebt" order="6" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" order="4" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>abvcd-20210331_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon May 10 19:51:10 UTC 2021 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_ConsolidatedBalanceSheet" roleURI="http://metuboutique.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://metuboutique.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_ConsolidatedIncomeStatement" roleURI="http://metuboutique.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_ConsolidatedCashFlow" roleURI="http://metuboutique.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_ShareholdersEquityType2or3" roleURI="http://metuboutique.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_OrganizationandDescriptionofBusiness" roleURI="http://metuboutique.com/role/OrganizationandDescriptionofBusiness"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_SummaryofSignificantAccountingPolicies" roleURI="http://metuboutique.com/role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_CollaborativeAgreements" roleURI="http://metuboutique.com/role/CollaborativeAgreements"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_Inventory" roleURI="http://metuboutique.com/role/Inventory"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_PropertyandEquipment" roleURI="http://metuboutique.com/role/PropertyandEquipment"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_LongTermInvestments" roleURI="http://metuboutique.com/role/LongTermInvestments"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_ConvertibleNotesPayable" roleURI="http://metuboutique.com/role/ConvertibleNotesPayable"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_BankLoans" roleURI="http://metuboutique.com/role/BankLoans"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_PaycheckProtectionProgramLoanPayable" roleURI="http://metuboutique.com/role/PaycheckProtectionProgramLoanPayable"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_NotesPayable" roleURI="http://metuboutique.com/role/NotesPayable"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_ShorttermLoan" roleURI="http://metuboutique.com/role/ShorttermLoan"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_RelatedPartiesTransactions" roleURI="http://metuboutique.com/role/RelatedPartiesTransactions"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_Equity" roleURI="http://metuboutique.com/role/Equity"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_StockOptions" roleURI="http://metuboutique.com/role/StockOptions"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_LossperShare" roleURI="http://metuboutique.com/role/LossperShare"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_Lease" roleURI="http://metuboutique.com/role/Lease"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_BusinessCombination" roleURI="http://metuboutique.com/role/BusinessCombination"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_SubsequentEvents" roleURI="http://metuboutique.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_AccountingPoliciesByPolicy" roleURI="http://metuboutique.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_SummaryofSignificantAccountingPoliciesTables" roleURI="http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_InventoryTables" roleURI="http://metuboutique.com/role/InventoryTables"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_PropertyandEquipmentTables" roleURI="http://metuboutique.com/role/PropertyandEquipmentTables"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_LongTermInvestmentsTables" roleURI="http://metuboutique.com/role/LongTermInvestmentsTables"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_BankLoansTables" roleURI="http://metuboutique.com/role/BankLoansTables"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_RelatedPartiesTransactionsTables" roleURI="http://metuboutique.com/role/RelatedPartiesTransactionsTables"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_EquityTables" roleURI="http://metuboutique.com/role/EquityTables"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_StockOptionsTables" roleURI="http://metuboutique.com/role/StockOptionsTables"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_LossperShareTables" roleURI="http://metuboutique.com/role/LossperShareTables"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_LeaseTables" roleURI="http://metuboutique.com/role/LeaseTables"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_BusinessCombinationTables" roleURI="http://metuboutique.com/role/BusinessCombinationTables"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_ScheduleofpropertyandequipmentTable" roleURI="http://metuboutique.com/role/ScheduleofpropertyandequipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_ScheduleofinventoryTable" roleURI="http://metuboutique.com/role/ScheduleofinventoryTable"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_ScheduleofpropertyandequipmentTable0" roleURI="http://metuboutique.com/role/ScheduleofpropertyandequipmentTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_ScheduleofownershippercentagesofinvesteeTable" roleURI="http://metuboutique.com/role/ScheduleofownershippercentagesofinvesteeTable"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_ScheduleofextenttheinvesteereliesTable" roleURI="http://metuboutique.com/role/ScheduleofextenttheinvesteereliesTable"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_ScheduleoflongterminvestmentTable" roleURI="http://metuboutique.com/role/ScheduleoflongterminvestmentTable"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_ScheduleofbalancesheetsTable" roleURI="http://metuboutique.com/role/ScheduleofbalancesheetsTable"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_ScheduleofstatementsofoperationTable" roleURI="http://metuboutique.com/role/ScheduleofstatementsofoperationTable"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_ScheduleofequityinvestmentsTable" roleURI="http://metuboutique.com/role/ScheduleofequityinvestmentsTable"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_ScheduleofshorttermbankloanTable" roleURI="http://metuboutique.com/role/ScheduleofshorttermbankloanTable"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_ScheduleofrelatedpartytransactionsTable" roleURI="http://metuboutique.com/role/ScheduleofrelatedpartytransactionsTable"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_ScheduleofaccountsreceivableduefromrelatedpartiesTable" roleURI="http://metuboutique.com/role/ScheduleofaccountsreceivableduefromrelatedpartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_ScheduleofamountduefromrelatedpartiesTable" roleURI="http://metuboutique.com/role/ScheduleofamountduefromrelatedpartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_ScheduleofamountduetorelatedpartiesTable" roleURI="http://metuboutique.com/role/ScheduleofamountduetorelatedpartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_ScheduleofconvertedamountofdebtandsharesTable" roleURI="http://metuboutique.com/role/ScheduleofconvertedamountofdebtandsharesTable"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_ScheduleofoptionsissuedandoutstandingTable" roleURI="http://metuboutique.com/role/ScheduleofoptionsissuedandoutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_ScheduleoffairvalueofstockoptionsgrantedTable" roleURI="http://metuboutique.com/role/ScheduleoffairvalueofstockoptionsgrantedTable"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_ScheduleoflosspershareTable" roleURI="http://metuboutique.com/role/ScheduleoflosspershareTable"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_ScheduleofoperatingleasearrangementsTable" roleURI="http://metuboutique.com/role/ScheduleofoperatingleasearrangementsTable"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_ScheduleofsupplementalinformationrelatedtooperatingleasesTable" roleURI="http://metuboutique.com/role/ScheduleofsupplementalinformationrelatedtooperatingleasesTable"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_ScheduleofminimumfutureannualpaymentsundernoncancellableleasesTable" roleURI="http://metuboutique.com/role/ScheduleofminimumfutureannualpaymentsundernoncancellableleasesTable"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_ScheduleofassetsacquiredandliabilitiesassumedbasedonfairvalueTable" roleURI="http://metuboutique.com/role/ScheduleofassetsacquiredandliabilitiesassumedbasedonfairvalueTable"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_OrganizationandDescriptionofBusinessDetails" roleURI="http://metuboutique.com/role/OrganizationandDescriptionofBusinessDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_CollaborativeAgreementsDetails" roleURI="http://metuboutique.com/role/CollaborativeAgreementsDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_PropertyandEquipmentDetails" roleURI="http://metuboutique.com/role/PropertyandEquipmentDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_LongTermInvestmentsDetails" roleURI="http://metuboutique.com/role/LongTermInvestmentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_ConvertibleNotesPayableDetails" roleURI="http://metuboutique.com/role/ConvertibleNotesPayableDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_BankLoansDetails" roleURI="http://metuboutique.com/role/BankLoansDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_PaycheckProtectionProgramLoanPayableDetails" roleURI="http://metuboutique.com/role/PaycheckProtectionProgramLoanPayableDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_NotesPayableDetails" roleURI="http://metuboutique.com/role/NotesPayableDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_ShorttermLoanDetails" roleURI="http://metuboutique.com/role/ShorttermLoanDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_RelatedPartiesTransactionsDetails" roleURI="http://metuboutique.com/role/RelatedPartiesTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_EquityDetails" roleURI="http://metuboutique.com/role/EquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_StockOptionsDetails" roleURI="http://metuboutique.com/role/StockOptionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_BusinessCombinationDetails" roleURI="http://metuboutique.com/role/BusinessCombinationDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#DocumentAndEntityInformation" roleURI="http://metuboutique.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableRelatedPartiesCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueFromOtherRelatedPartiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromOtherRelatedPartiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DueFromOtherRelatedPartiesCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_AssetsCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Goodwill" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_LongTermInvestments" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseNoncurrent" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDeposit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_SecurityDeposit" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_Assets" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermBankLoansAndNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ShortTermBankLoansAndNotesPayable" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherShortTermBorrowings" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherShortTermBorrowings"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherShortTermBorrowings" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableToBankCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableToBankCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_NotesPayableToBankCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerAdvancesForConstruction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerAdvancesForConstruction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_CustomerAdvancesForConstruction" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DueToRelatedPartiesCurrent" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNotesPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNotesPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherNotesPayableCurrent" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNotesPayableCurrent" xlink:to="us-gaap_LiabilitiesCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LoansPayable" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SecurityDepositLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDepositLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_SecurityDepositLiability" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleLongTermNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_ConvertibleLongTermNotesPayable" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConvertibleLongTermNotesPayable" xlink:to="us-gaap_Liabilities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_EquityAbstract" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteSubscriptionsReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_TreasuryStockValue" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_MinorityInterest" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MinorityInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostOfRevenue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GrossProfit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_OperatingExpenses" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RentalIncomeNonoperating" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RentalIncomeNonoperating"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_RentalIncomeNonoperating" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_RentalIncomeRelatedParties" xlink:href="abvcd-20210331.xsd#abvcd_RentalIncomeRelatedParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="abvcd_RentalIncomeRelatedParties" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_EquitySecuritiesFvNiRealizedGainLoss" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_GovernmentGrantIncome" xlink:href="abvcd-20210331.xsd#abvcd_GovernmentGrantIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="abvcd_GovernmentGrantIncome" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_GovernmentGrantIncome" xlink:to="us-gaap_NonoperatingIncomeExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_NetLossAttributableToAbvcAndSubsidiaries" xlink:href="abvcd-20210331.xsd#abvcd_NetLossAttributableToAbvcAndSubsidiaries"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetIncomeLoss" xlink:to="abvcd_NetLossAttributableToAbvcAndSubsidiaries" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrealizedGainLossOnInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_IncreaseDecreaseInGovernmentGrantIncome" xlink:href="abvcd-20210331.xsd#abvcd_IncreaseDecreaseInGovernmentGrantIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="abvcd_IncreaseDecreaseInGovernmentGrantIncome" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseDueFromOtherRelatedParties" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseDueFromOtherRelatedParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseDueFromOtherRelatedParties" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireOtherInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireOtherInvestments" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_NetProceedsFromShortTermBorrowingsFromThirdParties" xlink:href="abvcd-20210331.xsd#abvcd_NetProceedsFromShortTermBorrowingsFromThirdParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="abvcd_NetProceedsFromShortTermBorrowingsFromThirdParties" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfNotesPayable" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfLongTermDebt" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_StockSubscriptionReceivableMember" xlink:href="abvcd-20210331.xsd#abvcd_StockSubscriptionReceivableMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="abvcd_StockSubscriptionReceivableMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_ComprehensiveIncomeMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_TreasuryStockMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_NoncontrollingInterestMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_CumulativeTransactionAdjustments" xlink:href="abvcd-20210331.xsd#abvcd_CumulativeTransactionAdjustments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="abvcd_CumulativeTransactionAdjustments" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/OrganizationandDescriptionofBusiness">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/SummaryofSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/CollaborativeAgreements">
    <loc xlink:type="locator" xlink:label="abvcd_CollaborativeAgreementsLineItems" xlink:href="abvcd-20210331.xsd#abvcd_CollaborativeAgreementsLineItems"/>
    <loc xlink:type="locator" xlink:label="abvcd_CollaborativeAgreementsTable" xlink:href="abvcd-20210331.xsd#abvcd_CollaborativeAgreementsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abvcd_CollaborativeAgreementsLineItems" xlink:to="abvcd_CollaborativeAgreementsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_CollaborativeAgreementsLineItems" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/Inventory">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/PropertyandEquipment">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/LongTermInvestments">
    <loc xlink:type="locator" xlink:label="abvcd_LongTermInvestmentAbstract" xlink:href="abvcd-20210331.xsd#abvcd_LongTermInvestmentAbstract"/>
    <loc xlink:type="locator" xlink:label="abvcd_LongTermInvestmentTextBlock" xlink:href="abvcd-20210331.xsd#abvcd_LongTermInvestmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_LongTermInvestmentAbstract" xlink:to="abvcd_LongTermInvestmentTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ConvertibleNotesPayable">
    <loc xlink:type="locator" xlink:label="abvcd_ConvertibleNotesPayableDisclosureAbstract" xlink:href="abvcd-20210331.xsd#abvcd_ConvertibleNotesPayableDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="abvcd_ConvertibleNotesPayableDisclosureTextBlock" xlink:href="abvcd-20210331.xsd#abvcd_ConvertibleNotesPayableDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_ConvertibleNotesPayableDisclosureAbstract" xlink:to="abvcd_ConvertibleNotesPayableDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/BankLoans">
    <loc xlink:type="locator" xlink:label="abvcd_BankLoansAbstractAbstract" xlink:href="abvcd-20210331.xsd#abvcd_BankLoansAbstractAbstract"/>
    <loc xlink:type="locator" xlink:label="abvcd_BankLoansAbstract" xlink:href="abvcd-20210331.xsd#abvcd_BankLoansAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_BankLoansAbstractAbstract" xlink:to="abvcd_BankLoansAbstract" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/PaycheckProtectionProgramLoanPayable">
    <loc xlink:type="locator" xlink:label="abvcd_PaycheckProtectionProgramLoanPayableAbstract" xlink:href="abvcd-20210331.xsd#abvcd_PaycheckProtectionProgramLoanPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="abvcd_PaycheckProtectionProgramLoanPayableTextBlock" xlink:href="abvcd-20210331.xsd#abvcd_PaycheckProtectionProgramLoanPayableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_PaycheckProtectionProgramLoanPayableAbstract" xlink:to="abvcd_PaycheckProtectionProgramLoanPayableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/NotesPayable">
    <loc xlink:type="locator" xlink:label="abvcd_NotesPayableLineItems" xlink:href="abvcd-20210331.xsd#abvcd_NotesPayableLineItems"/>
    <loc xlink:type="locator" xlink:label="abvcd_NotesPayableTable" xlink:href="abvcd-20210331.xsd#abvcd_NotesPayableTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abvcd_NotesPayableLineItems" xlink:to="abvcd_NotesPayableTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MembersEquityNotesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MembersEquityNotesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_NotesPayableLineItems" xlink:to="us-gaap_MembersEquityNotesDisclosureTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ShorttermLoan">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ShortTermDebtTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/RelatedPartiesTransactions">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/Equity">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/StockOptions">
    <loc xlink:type="locator" xlink:label="abvcd_StockOptionsAbstract" xlink:href="abvcd-20210331.xsd#abvcd_StockOptionsAbstract"/>
    <loc xlink:type="locator" xlink:label="abvcd_StockOptionsTextBlock" xlink:href="abvcd-20210331.xsd#abvcd_StockOptionsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_StockOptionsAbstract" xlink:to="abvcd_StockOptionsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/LossperShare">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/Lease">
    <loc xlink:type="locator" xlink:label="us-gaap_ASU201602TransitionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ASU201602TransitionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ASU201602TransitionAbstract" xlink:to="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/BusinessCombination">
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiscalPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiscalPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FiscalPeriod" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_ForwardStockSplitsPolicyTextBlock" xlink:href="abvcd-20210331.xsd#abvcd_ForwardStockSplitsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="abvcd_ForwardStockSplitsPolicyTextBlock" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_StockReverseSplitPolicyTextBlock" xlink:href="abvcd-20210331.xsd#abvcd_StockReverseSplitPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="abvcd_StockReverseSplitPolicyTextBlock" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_LongTermEquityInvestmentPolicy" xlink:href="abvcd-20210331.xsd#abvcd_LongTermEquityInvestmentPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="abvcd_LongTermEquityInvestmentPolicy" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_OtherThanTemporaryImpairmentPolicyTextBlock" xlink:href="abvcd-20210331.xsd#abvcd_OtherThanTemporaryImpairmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="abvcd_OtherThanTemporaryImpairmentPolicyTextBlock" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_BeneficialConversionFeature" xlink:href="abvcd-20210331.xsd#abvcd_BeneficialConversionFeature"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="abvcd_BeneficialConversionFeature" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_ValuationOfDeferredTaxAssetsPolicyTextBlock" xlink:href="abvcd-20210331.xsd#abvcd_ValuationOfDeferredTaxAssetsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="abvcd_ValuationOfDeferredTaxAssetsPolicyTextBlock" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_TranslationAdjustmentPolicyTextBlock" xlink:href="abvcd-20210331.xsd#abvcd_TranslationAdjustmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="abvcd_TranslationAdjustmentPolicyTextBlock" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="27" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="abvcd_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:href="abvcd-20210331.xsd#abvcd_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="abvcd_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/InventoryTables">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/PropertyandEquipmentTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/LongTermInvestmentsTables">
    <loc xlink:type="locator" xlink:label="abvcd_LongTermInvestmentAbstract" xlink:href="abvcd-20210331.xsd#abvcd_LongTermInvestmentAbstract"/>
    <loc xlink:type="locator" xlink:label="abvcd_ScheduleOfOwnershipPercentagesOfInvesteeTableTextBlocks" xlink:href="abvcd-20210331.xsd#abvcd_ScheduleOfOwnershipPercentagesOfInvesteeTableTextBlocks"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_LongTermInvestmentAbstract" xlink:to="abvcd_ScheduleOfOwnershipPercentagesOfInvesteeTableTextBlocks" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_ScheduleOfExtentInvesteeReliesTableTextBlock" xlink:href="abvcd-20210331.xsd#abvcd_ScheduleOfExtentInvesteeReliesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_LongTermInvestmentAbstract" xlink:to="abvcd_ScheduleOfExtentInvesteeReliesTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_ScheduleOfLongTermInvestmentTableTextBlock" xlink:href="abvcd-20210331.xsd#abvcd_ScheduleOfLongTermInvestmentTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_LongTermInvestmentAbstract" xlink:to="abvcd_ScheduleOfLongTermInvestmentTableTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfCondensedBalanceSheetTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_LongTermInvestmentAbstract" xlink:to="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedIncomeStatementTableTextBlock" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfCondensedIncomeStatementTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_LongTermInvestmentAbstract" xlink:to="srt_ScheduleOfCondensedIncomeStatementTableTextBlock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_LongTermInvestmentAbstract" xlink:to="us-gaap_EquityMethodInvestmentsTextBlock" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/BankLoansTables">
    <loc xlink:type="locator" xlink:label="abvcd_BankLoansAbstractAbstract" xlink:href="abvcd-20210331.xsd#abvcd_BankLoansAbstractAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_BankLoansAbstractAbstract" xlink:to="us-gaap_ScheduleOfShortTermDebtTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/RelatedPartiesTransactionsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_ScheduleOfAccountReceivableDueFromRelatedPartiesTableTextBlock" xlink:href="abvcd-20210331.xsd#abvcd_ScheduleOfAccountReceivableDueFromRelatedPartiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="abvcd_ScheduleOfAccountReceivableDueFromRelatedPartiesTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_ScheduleOfRelatedPartyTransactionsAmountDueToRelatedParty" xlink:href="abvcd-20210331.xsd#abvcd_ScheduleOfRelatedPartyTransactionsAmountDueToRelatedParty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="abvcd_ScheduleOfRelatedPartyTransactionsAmountDueToRelatedParty" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/EquityTables">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDebtConversionsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtConversionsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfDebtConversionsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/StockOptionsTables">
    <loc xlink:type="locator" xlink:label="abvcd_StockOptionsAbstract" xlink:href="abvcd-20210331.xsd#abvcd_StockOptionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_StockOptionsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_StockOptionsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/LossperShareTables">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/LeaseTables">
    <loc xlink:type="locator" xlink:label="us-gaap_ASU201602TransitionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ASU201602TransitionAbstract"/>
    <loc xlink:type="locator" xlink:label="abvcd_ScheduleOfOperatingLeaseArrangementsTableTextBlock" xlink:href="abvcd-20210331.xsd#abvcd_ScheduleOfOperatingLeaseArrangementsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ASU201602TransitionAbstract" xlink:to="abvcd_ScheduleOfOperatingLeaseArrangementsTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ASU201602TransitionAbstract" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ASU201602TransitionAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/BusinessCombinationTables">
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofpropertyandequipmentTable">
    <loc xlink:type="locator" xlink:label="abvcd_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems" xlink:href="abvcd-20210331.xsd#abvcd_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="abvcd_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentTable" xlink:href="abvcd-20210331.xsd#abvcd_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abvcd_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems" xlink:to="abvcd_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvcd_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvcd_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentTable" xlink:to="srt_RangeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_BuildingsAndLeaseholdImprovementsMember" xlink:href="abvcd-20210331.xsd#abvcd_BuildingsAndLeaseholdImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="abvcd_BuildingsAndLeaseholdImprovementsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofinventoryTable">
    <loc xlink:type="locator" xlink:label="abvcd_ScheduleOfInventoryAbstract" xlink:href="abvcd-20210331.xsd#abvcd_ScheduleOfInventoryAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_ScheduleOfInventoryAbstract" xlink:to="us-gaap_InventoryFinishedGoods" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcess" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_ScheduleOfInventoryAbstract" xlink:to="us-gaap_InventoryWorkInProcess" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_ScheduleOfInventoryAbstract" xlink:to="us-gaap_InventoryRawMaterials" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_AllowanceForInventoryValuationAndObsolescenceLoss" xlink:href="abvcd-20210331.xsd#abvcd_AllowanceForInventoryValuationAndObsolescenceLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_ScheduleOfInventoryAbstract" xlink:to="abvcd_AllowanceForInventoryValuationAndObsolescenceLoss" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_ScheduleOfInventoryAbstract" xlink:to="us-gaap_InventoryNet" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofpropertyandequipmentTable0">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LandMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LandMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_BuildingsAndLeaseholdImprovementsMember" xlink:href="abvcd-20210331.xsd#abvcd_BuildingsAndLeaseholdImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="abvcd_BuildingsAndLeaseholdImprovementsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofownershippercentagesofinvesteeTable">
    <loc xlink:type="locator" xlink:label="abvcd_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeLineItems" xlink:href="abvcd-20210331.xsd#abvcd_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeLineItems"/>
    <loc xlink:type="locator" xlink:label="abvcd_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeTable" xlink:href="abvcd-20210331.xsd#abvcd_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abvcd_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeLineItems" xlink:to="abvcd_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvcd_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_BraingenesisBiotechnologyCoLtdMember" xlink:href="abvcd-20210331.xsd#abvcd_BraingenesisBiotechnologyCoLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvcd_BraingenesisBiotechnologyCoLtdMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_GenepharmBiotechCorporationMember" xlink:href="abvcd-20210331.xsd#abvcd_GenepharmBiotechCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvcd_GenepharmBiotechCorporationMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_BioHopeKingCorporationMember" xlink:href="abvcd-20210331.xsd#abvcd_BioHopeKingCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvcd_BioHopeKingCorporationMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_BioFirstCorporationMember" xlink:href="abvcd-20210331.xsd#abvcd_BioFirstCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvcd_BioFirstCorporationMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_RgeneCorporationMember" xlink:href="abvcd-20210331.xsd#abvcd_RgeneCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvcd_RgeneCorporationMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_AccountingTreatmentDescription" xlink:href="abvcd-20210331.xsd#abvcd_AccountingTreatmentDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeLineItems" xlink:to="abvcd_AccountingTreatmentDescription" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofextenttheinvesteereliesTable">
    <loc xlink:type="locator" xlink:label="abvcd_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesLineItems" xlink:href="abvcd-20210331.xsd#abvcd_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesLineItems"/>
    <loc xlink:type="locator" xlink:label="abvcd_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesTable" xlink:href="abvcd-20210331.xsd#abvcd_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abvcd_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesLineItems" xlink:to="abvcd_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvcd_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_BraingenesisBiotechnologyCoLtdMember" xlink:href="abvcd-20210331.xsd#abvcd_BraingenesisBiotechnologyCoLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvcd_BraingenesisBiotechnologyCoLtdMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_GenepharmBiotechCorporationMember" xlink:href="abvcd-20210331.xsd#abvcd_GenepharmBiotechCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvcd_GenepharmBiotechCorporationMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_BioHopeKingCorporationMember" xlink:href="abvcd-20210331.xsd#abvcd_BioHopeKingCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvcd_BioHopeKingCorporationMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_BioFirstCorporationMember" xlink:href="abvcd-20210331.xsd#abvcd_BioFirstCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvcd_BioFirstCorporationMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_RgeneCorporationMember" xlink:href="abvcd-20210331.xsd#abvcd_RgeneCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvcd_RgeneCorporationMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_RelatedPartyTransactionDescriptionOfTransactions" xlink:href="abvcd-20210331.xsd#abvcd_RelatedPartyTransactionDescriptionOfTransactions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesLineItems" xlink:to="abvcd_RelatedPartyTransactionDescriptionOfTransactions" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleoflongterminvestmentTable">
    <loc xlink:type="locator" xlink:label="abvcd_LongTermInvestmentsDetailsScheduleoflongterminvestmentLineItems" xlink:href="abvcd-20210331.xsd#abvcd_LongTermInvestmentsDetailsScheduleoflongterminvestmentLineItems"/>
    <loc xlink:type="locator" xlink:label="abvcd_LongTermInvestmentsDetailsScheduleoflongterminvestmentTable" xlink:href="abvcd-20210331.xsd#abvcd_LongTermInvestmentsDetailsScheduleoflongterminvestmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abvcd_LongTermInvestmentsDetailsScheduleoflongterminvestmentLineItems" xlink:to="abvcd_LongTermInvestmentsDetailsScheduleoflongterminvestmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvcd_LongTermInvestmentsDetailsScheduleoflongterminvestmentTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_BraingenesisBiotechnologyCoLtdMember" xlink:href="abvcd-20210331.xsd#abvcd_BraingenesisBiotechnologyCoLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvcd_BraingenesisBiotechnologyCoLtdMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_GenepharmBiotechCorporationMember" xlink:href="abvcd-20210331.xsd#abvcd_GenepharmBiotechCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvcd_GenepharmBiotechCorporationMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_BioHopeKingCorporationMember" xlink:href="abvcd-20210331.xsd#abvcd_BioHopeKingCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvcd_BioHopeKingCorporationMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_BioFirstCorporationMember" xlink:href="abvcd-20210331.xsd#abvcd_BioFirstCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvcd_BioFirstCorporationMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_RgeneCorporationMember" xlink:href="abvcd-20210331.xsd#abvcd_RgeneCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvcd_RgeneCorporationMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_NonMarketableCostMethodInvestmentsNetAbstract" xlink:href="abvcd-20210331.xsd#abvcd_NonMarketableCostMethodInvestmentsNetAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_LongTermInvestmentsDetailsScheduleoflongterminvestmentLineItems" xlink:to="abvcd_NonMarketableCostMethodInvestmentsNetAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_NonmarketableCostMethodInvestmentsNet" xlink:href="abvcd-20210331.xsd#abvcd_NonmarketableCostMethodInvestmentsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_NonMarketableCostMethodInvestmentsNetAbstract" xlink:to="abvcd_NonmarketableCostMethodInvestmentsNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_EquityMethodInvestmentsNetAbstract" xlink:href="abvcd-20210331.xsd#abvcd_EquityMethodInvestmentsNetAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_LongTermInvestmentsDetailsScheduleoflongterminvestmentLineItems" xlink:to="abvcd_EquityMethodInvestmentsNetAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_EquityMethodInvestmentsNetAbstract" xlink:to="us-gaap_EquityMethodInvestments" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofbalancesheetsTable">
    <loc xlink:type="locator" xlink:label="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CondensedBalanceSheetStatementsCaptionsLineItems"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedBalanceSheetStatementTable" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CondensedBalanceSheetStatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="srt_CondensedBalanceSheetStatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_CondensedBalanceSheetStatementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_BioFirstMember" xlink:href="abvcd-20210331.xsd#abvcd_BioFirstMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvcd_BioFirstMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_RgeneMember" xlink:href="abvcd-20210331.xsd#abvcd_RgeneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvcd_RgeneMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_AssetsCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_AssetsNoncurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_LiabilitiesCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_LiabilitiesNoncurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_StockholdersEquity" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofstatementsofoperationTable">
    <loc xlink:type="locator" xlink:label="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CondensedIncomeStatementsCaptionsLineItems"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedIncomeStatementTable" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CondensedIncomeStatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="srt_CondensedIncomeStatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_CondensedIncomeStatementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_BioFirstMember" xlink:href="abvcd-20210331.xsd#abvcd_BioFirstMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvcd_BioFirstMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_RgeneMember" xlink:href="abvcd-20210331.xsd#abvcd_RgeneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvcd_RgeneMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="us-gaap_Revenues" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="us-gaap_GrossProfit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_LongTermInvestmentNetLoss" xlink:href="abvcd-20210331.xsd#abvcd_LongTermInvestmentNetLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="abvcd_LongTermInvestmentNetLoss" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="us-gaap_GainLossOnInvestments" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofequityinvestmentsTable">
    <loc xlink:type="locator" xlink:label="abvcd_ScheduleOfEquityInvestmentsAbstract" xlink:href="abvcd-20210331.xsd#abvcd_ScheduleOfEquityInvestmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="abvcd_ShareOfEquityMethodInvesteeLosses" xlink:href="abvcd-20210331.xsd#abvcd_ShareOfEquityMethodInvesteeLosses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_ScheduleOfEquityInvestmentsAbstract" xlink:to="abvcd_ShareOfEquityMethodInvesteeLosses" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofshorttermbankloanTable">
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ScheduleOfShortTermDebtTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_CathayUnitedBankMember" xlink:href="abvcd-20210331.xsd#abvcd_CathayUnitedBankMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="abvcd_CathayUnitedBankMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_CTBCBankMember" xlink:href="abvcd-20210331.xsd#abvcd_CTBCBankMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="abvcd_CTBCBankMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_CathayBnakMember" xlink:href="abvcd-20210331.xsd#abvcd_CathayBnakMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="abvcd_CathayBnakMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowings" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermBorrowings"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermBorrowings" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofrelatedpartytransactionsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_BioFirstCorporationtheBioFirstMember" xlink:href="abvcd-20210331.xsd#abvcd_BioFirstCorporationtheBioFirstMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvcd_BioFirstCorporationtheBioFirstMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember" xlink:href="abvcd-20210331.xsd#abvcd_BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvcd_BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_RgeneCorporationtheRgeneMember" xlink:href="abvcd-20210331.xsd#abvcd_RgeneCorporationtheRgeneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvcd_RgeneCorporationtheRgeneMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_YuanGeneCorporationtheYuanGeneMember" xlink:href="abvcd-20210331.xsd#abvcd_YuanGeneCorporationtheYuanGeneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvcd_YuanGeneCorporationtheYuanGeneMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_AsiaGeneCorporationtheAsiaGeneMember" xlink:href="abvcd-20210331.xsd#abvcd_AsiaGeneCorporationtheAsiaGeneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvcd_AsiaGeneCorporationtheAsiaGeneMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_EugeneJiangMember" xlink:href="abvcd-20210331.xsd#abvcd_EugeneJiangMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvcd_EugeneJiangMember" order="5" xbrldt:closed="true"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb+OcBO0cz/DPQtq8WT+vHGytpy5eqldqmljvYMs+ffK0hVJun/LoadZRO6MVQWNprQnn57cflcp0+RqqLVbNVtuKFz5+pgq1gL8cjM8xFnzOUdEjZ0sDSJzg18XsOaa9RO4cDdhaiGpwVK1skYTQsz6wjLPW7PJKd/ex+Rw6OhX8y162iyhal64E3DMn0UJtn0HXBG8rQ15A==] CSR-->
    <loc xlink:type="locator" xlink:label="abvcd_KeypointTechnologyLtdtheKeypointMember" xlink:href="abvcd-20210331.xsd#abvcd_KeypointTechnologyLtdtheKeypointMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvcd_KeypointTechnologyLtdtheKeypointMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_LionArtsPromotionInctheLionArtsMember" xlink:href="abvcd-20210331.xsd#abvcd_LionArtsPromotionInctheLionArtsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvcd_LionArtsPromotionInctheLionArtsMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_YoshinobuOdairatheOdairaMember" xlink:href="abvcd-20210331.xsd#abvcd_YoshinobuOdairatheOdairaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvcd_YoshinobuOdairatheOdairaMember" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_GenePharmInctheGenePharmMember" xlink:href="abvcd-20210331.xsd#abvcd_GenePharmInctheGenePharmMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvcd_GenePharmInctheGenePharmMember" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_EuroAsiaInvestmentFinanceCorpLtdtheEuroAsiaMember" xlink:href="abvcd-20210331.xsd#abvcd_EuroAsiaInvestmentFinanceCorpLtdtheEuroAsiaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvcd_EuroAsiaInvestmentFinanceCorpLtdtheEuroAsiaMember" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_LBGUSAInctheLBGUSAMember" xlink:href="abvcd-20210331.xsd#abvcd_LBGUSAInctheLBGUSAMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvcd_LBGUSAInctheLBGUSAMember" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_LionGeneCorporationtheLionGeneMember" xlink:href="abvcd-20210331.xsd#abvcd_LionGeneCorporationtheLionGeneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvcd_LionGeneCorporationtheLionGeneMember" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_KimhoConsultantsCoLtdtheKimhoMember" xlink:href="abvcd-20210331.xsd#abvcd_KimhoConsultantsCoLtdtheKimhoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvcd_KimhoConsultantsCoLtdtheKimhoMember" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_MrTsungShannJiangMsShuLingJiangMrChangJenJiangMsMeiLingJiangAndMrEugeneJiangcollectivelyTheJiangsMember" xlink:href="abvcd-20210331.xsd#abvcd_MrTsungShannJiangMsShuLingJiangMrChangJenJiangMsMeiLingJiangAndMrEugeneJiangcollectivelyTheJiangsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvcd_MrTsungShannJiangMsShuLingJiangMrChangJenJiangMsMeiLingJiangAndMrEugeneJiangcollectivelyTheJiangsMember" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_AmkeyVenturesLLCAmkeyMember" xlink:href="abvcd-20210331.xsd#abvcd_AmkeyVenturesLLCAmkeyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvcd_AmkeyVenturesLLCAmkeyMember" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_BioLiteJapanMember" xlink:href="abvcd-20210331.xsd#abvcd_BioLiteJapanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvcd_BioLiteJapanMember" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_RelatedPartyTransactionDescriptionOfTransactions" xlink:href="abvcd-20210331.xsd#abvcd_RelatedPartyTransactionDescriptionOfTransactions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="abvcd_RelatedPartyTransactionDescriptionOfTransactions" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofaccountsreceivableduefromrelatedpartiesTable">
    <loc xlink:type="locator" xlink:label="abvcd_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesLineItems" xlink:href="abvcd-20210331.xsd#abvcd_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesLineItems"/>
    <loc xlink:type="locator" xlink:label="abvcd_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesTable" xlink:href="abvcd-20210331.xsd#abvcd_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abvcd_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesLineItems" xlink:to="abvcd_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvcd_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_GenePharmIncMember" xlink:href="abvcd-20210331.xsd#abvcd_GenePharmIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvcd_GenePharmIncMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_AmkeyMember" xlink:href="abvcd-20210331.xsd#abvcd_AmkeyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvcd_AmkeyMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableRelatedParties" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesLineItems" xlink:to="us-gaap_AccountsReceivableRelatedParties" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofamountduefromrelatedpartiesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_RgeneMember" xlink:href="abvcd-20210331.xsd#abvcd_RgeneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvcd_RgeneMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_AsiaGeneMember" xlink:href="abvcd-20210331.xsd#abvcd_AsiaGeneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvcd_AsiaGeneMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_BioFirstAustraliaMember" xlink:href="abvcd-20210331.xsd#abvcd_BioFirstAustraliaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvcd_BioFirstAustraliaMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_BioHopeKingCorporationMember" xlink:href="abvcd-20210331.xsd#abvcd_BioHopeKingCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvcd_BioHopeKingCorporationMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_LBGUSAMember" xlink:href="abvcd-20210331.xsd#abvcd_LBGUSAMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvcd_LBGUSAMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_BioLiteJapanMember" xlink:href="abvcd-20210331.xsd#abvcd_BioLiteJapanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvcd_BioLiteJapanMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_KeypointMember" xlink:href="abvcd-20210331.xsd#abvcd_KeypointMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvcd_KeypointMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_TheJiangsMember" xlink:href="abvcd-20210331.xsd#abvcd_TheJiangsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvcd_TheJiangsMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueFromRelatedPartiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_DueFromRelatedPartiesCurrent" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofamountduetorelatedpartiesTable">
    <loc xlink:type="locator" xlink:label="abvcd_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesLineItems" xlink:href="abvcd-20210331.xsd#abvcd_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesLineItems"/>
    <loc xlink:type="locator" xlink:label="abvcd_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesTable" xlink:href="abvcd-20210331.xsd#abvcd_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abvcd_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesLineItems" xlink:to="abvcd_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvcd_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_BioFirstCorporationMember" xlink:href="abvcd-20210331.xsd#abvcd_BioFirstCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvcd_BioFirstCorporationMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_AsiaGeneMember" xlink:href="abvcd-20210331.xsd#abvcd_AsiaGeneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvcd_AsiaGeneMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_YuanGeneMember" xlink:href="abvcd-20210331.xsd#abvcd_YuanGeneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvcd_YuanGeneMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_TheJiangsMember" xlink:href="abvcd-20210331.xsd#abvcd_TheJiangsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvcd_TheJiangsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_DueToshareholdersMember" xlink:href="abvcd-20210331.xsd#abvcd_DueToshareholdersMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvcd_DueToshareholdersMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_DueToEmployeesMember" xlink:href="abvcd-20210331.xsd#abvcd_DueToEmployeesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvcd_DueToEmployeesMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofconvertedamountofdebtandsharesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DebtConversionTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtConversionTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_LionArtsPromotionInctheLIONMember" xlink:href="abvcd-20210331.xsd#abvcd_LionArtsPromotionInctheLIONMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abvcd_LionArtsPromotionInctheLIONMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_LionGeneCorporationMember" xlink:href="abvcd-20210331.xsd#abvcd_LionGeneCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abvcd_LionGeneCorporationMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_BioFirstCorporationMember" xlink:href="abvcd-20210331.xsd#abvcd_BioFirstCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abvcd_BioFirstCorporationMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_AsiangeneCorporationMember" xlink:href="abvcd-20210331.xsd#abvcd_AsiangeneCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abvcd_AsiangeneCorporationMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_YuangeneCorporationMember" xlink:href="abvcd-20210331.xsd#abvcd_YuangeneCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abvcd_YuangeneCorporationMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_TheJiangsMember" xlink:href="abvcd-20210331.xsd#abvcd_TheJiangsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abvcd_TheJiangsMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofoptionsissuedandoutstandingTable">
    <loc xlink:type="locator" xlink:label="abvcd_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:href="abvcd-20210331.xsd#abvcd_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems"/>
    <loc xlink:type="locator" xlink:label="abvcd_StockOptionsDetailsScheduleofoptionsissuedandoutstandingTable" xlink:href="abvcd-20210331.xsd#abvcd_StockOptionsDetailsScheduleofoptionsissuedandoutstandingTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abvcd_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="abvcd_StockOptionsDetailsScheduleofoptionsissuedandoutstandingTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvcd_StockOptionsDetailsScheduleofoptionsissuedandoutstandingTable" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:to="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:to="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm" xlink:href="abvcd-20210331.xsd#abvcd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="abvcd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue" xlink:href="abvcd-20210331.xsd#abvcd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="abvcd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="18" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleoffairvalueofstockoptionsgrantedTable">
    <loc xlink:type="locator" xlink:label="abvcd_ScheduleOfFairValueOfStockOptionsGrantedAbstract" xlink:href="abvcd-20210331.xsd#abvcd_ScheduleOfFairValueOfStockOptionsGrantedAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_ScheduleOfFairValueOfStockOptionsGrantedAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_ScheduleOfFairValueOfStockOptionsGrantedAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_ScheduleOfFairValueOfStockOptionsGrantedAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_ScheduleOfFairValueOfStockOptionsGrantedAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleoflosspershareTable">
    <loc xlink:type="locator" xlink:label="abvcd_ScheduleOfLossPerShareAbstract" xlink:href="abvcd-20210331.xsd#abvcd_ScheduleOfLossPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="abvcd_NumeratorAbstract" xlink:href="abvcd-20210331.xsd#abvcd_NumeratorAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_ScheduleOfLossPerShareAbstract" xlink:to="abvcd_NumeratorAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_NetLoss" xlink:href="abvcd-20210331.xsd#abvcd_NetLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_NumeratorAbstract" xlink:to="abvcd_NetLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_ScheduleOfLossPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_StockOptions" xlink:href="abvcd-20210331.xsd#abvcd_StockOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="abvcd_StockOptions" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_ScheduleOfLossPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofoperatingleasearrangementsTable">
    <loc xlink:type="locator" xlink:label="abvcd_ScheduleOfOperatingLeaseArrangementsAbstract" xlink:href="abvcd-20210331.xsd#abvcd_ScheduleOfOperatingLeaseArrangementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_ScheduleOfOperatingLeaseArrangementsAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_ScheduleOfOperatingLeaseArrangementsAbstract" xlink:to="us-gaap_LiabilitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofsupplementalinformationrelatedtooperatingleasesTable">
    <loc xlink:type="locator" xlink:label="abvcd_ScheduleOfSupplementalInformationRelatedToOperatingLeasesAbstract" xlink:href="abvcd-20210331.xsd#abvcd_ScheduleOfSupplementalInformationRelatedToOperatingLeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_ScheduleOfSupplementalInformationRelatedToOperatingLeasesAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_ScheduleOfSupplementalInformationRelatedToOperatingLeasesAbstract" xlink:to="us-gaap_OperatingLeaseLeaseIncomeLeasePayments" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_ScheduleOfSupplementalInformationRelatedToOperatingLeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_ScheduleOfSupplementalInformationRelatedToOperatingLeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofminimumfutureannualpaymentsundernoncancellableleasesTable">
    <loc xlink:type="locator" xlink:label="abvcd_ScheduleOfMinimumFutureAnnualPaymentsUnderNonCancellableLeasesAbstract" xlink:href="abvcd-20210331.xsd#abvcd_ScheduleOfMinimumFutureAnnualPaymentsUnderNonCancellableLeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_ScheduleOfMinimumFutureAnnualPaymentsUnderNonCancellableLeasesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_ScheduleOfMinimumFutureAnnualPaymentsUnderNonCancellableLeasesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_ScheduleOfMinimumFutureAnnualPaymentsUnderNonCancellableLeasesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_ScheduleOfMinimumFutureAnnualPaymentsUnderNonCancellableLeasesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_ScheduleOfMinimumFutureAnnualPaymentsUnderNonCancellableLeasesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPortionOfMinimumLeasePaymentsSaleLeasebackTransactions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPortionOfMinimumLeasePaymentsSaleLeasebackTransactions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="us-gaap_InterestPortionOfMinimumLeasePaymentsSaleLeasebackTransactions" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PresentValueOfFutureMinimumLeasePaymentsSaleLeasebackTransactions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PresentValueOfFutureMinimumLeasePaymentsSaleLeasebackTransactions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="us-gaap_PresentValueOfFutureMinimumLeasePaymentsSaleLeasebackTransactions" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofassetsacquiredandliabilitiesassumedbasedonfairvalueTable">
    <loc xlink:type="locator" xlink:label="abvcd_ScheduleOfAssetsAcquiredAndLiabilitiesAssumedBasedOnFairValueAbstract" xlink:href="abvcd-20210331.xsd#abvcd_ScheduleOfAssetsAcquiredAndLiabilitiesAssumedBasedOnFairValueAbstract"/>
    <loc xlink:type="locator" xlink:label="abvcd_PurchaseConsiderationAbstract" xlink:href="abvcd-20210331.xsd#abvcd_PurchaseConsiderationAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_ScheduleOfAssetsAcquiredAndLiabilitiesAssumedBasedOnFairValueAbstract" xlink:to="abvcd_PurchaseConsiderationAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredOther1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_PurchaseConsiderationAbstract" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredOther1" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_AllocationOfThePurchasePriceAbstract" xlink:href="abvcd-20210331.xsd#abvcd_AllocationOfThePurchasePriceAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_ScheduleOfAssetsAcquiredAndLiabilitiesAssumedBasedOnFairValueAbstract" xlink:to="abvcd_AllocationOfThePurchasePriceAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_AllocationOfThePurchasePriceAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_AllocationOfThePurchasePriceAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_AllocationOfThePurchasePriceAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:href="abvcd-20210331.xsd#abvcd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_AllocationOfThePurchasePriceAbstract" xlink:to="abvcd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_AllocationOfThePurchasePriceAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_AllocationOfThePurchasePriceAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_AllocationOfThePurchasePriceAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_AllocationOfThePurchasePriceAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability" xlink:href="abvcd-20210331.xsd#abvcd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_AllocationOfThePurchasePriceAbstract" xlink:to="abvcd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_AllocationOfThePurchasePriceAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_AllocationOfThePurchasePriceAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_AllocationOfThePurchasePriceAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_AllocationOfThePurchasePriceAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" order="12" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/OrganizationandDescriptionofBusinessDetails">
    <loc xlink:type="locator" xlink:label="abvcd_OrganizationandDescriptionofBusinessDetailsLineItems" xlink:href="abvcd-20210331.xsd#abvcd_OrganizationandDescriptionofBusinessDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="abvcd_OrganizationandDescriptionofBusinessDetailsTable" xlink:href="abvcd-20210331.xsd#abvcd_OrganizationandDescriptionofBusinessDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abvcd_OrganizationandDescriptionofBusinessDetailsLineItems" xlink:to="abvcd_OrganizationandDescriptionofBusinessDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvcd_OrganizationandDescriptionofBusinessDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_ShareExchangeAgreementMember" xlink:href="abvcd-20210331.xsd#abvcd_ShareExchangeAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abvcd_ShareExchangeAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_ShareExchangeAgreementOneMember" xlink:href="abvcd-20210331.xsd#abvcd_ShareExchangeAgreementOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abvcd_ShareExchangeAgreementOneMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_ShareExchangeAgreementTwoMember" xlink:href="abvcd-20210331.xsd#abvcd_ShareExchangeAgreementTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abvcd_ShareExchangeAgreementTwoMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_ShareExchangeAgreementThreeMember" xlink:href="abvcd-20210331.xsd#abvcd_ShareExchangeAgreementThreeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abvcd_ShareExchangeAgreementThreeMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_ShareExchangeAgreementFourMember" xlink:href="abvcd-20210331.xsd#abvcd_ShareExchangeAgreementFourMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abvcd_ShareExchangeAgreementFourMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_MergerAgreementMember" xlink:href="abvcd-20210331.xsd#abvcd_MergerAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abvcd_MergerAgreementMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_CommonStockIssuedAfterStockSplit" xlink:href="abvcd-20210331.xsd#abvcd_CommonStockIssuedAfterStockSplit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_OrganizationandDescriptionofBusinessDetailsLineItems" xlink:to="abvcd_CommonStockIssuedAfterStockSplit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_CommonStockIssuedBeforeStockSplit" xlink:href="abvcd-20210331.xsd#abvcd_CommonStockIssuedBeforeStockSplit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_OrganizationandDescriptionofBusinessDetailsLineItems" xlink:to="abvcd_CommonStockIssuedBeforeStockSplit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_PercentageOfCommonSharesIssuedAndOutstanding" xlink:href="abvcd-20210331.xsd#abvcd_PercentageOfCommonSharesIssuedAndOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_OrganizationandDescriptionofBusinessDetailsLineItems" xlink:to="abvcd_PercentageOfCommonSharesIssuedAndOutstanding" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_PercentageOfIssuedShareCapital" xlink:href="abvcd-20210331.xsd#abvcd_PercentageOfIssuedShareCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_OrganizationandDescriptionofBusinessDetailsLineItems" xlink:to="abvcd_PercentageOfIssuedShareCapital" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_Cash" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalents" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_MarketableSecuritiesRealizedGainLossOtherThanTemporaryImpairmentsAmounts" xlink:href="abvcd-20210331.xsd#abvcd_MarketableSecuritiesRealizedGainLossOtherThanTemporaryImpairmentsAmounts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="abvcd_MarketableSecuritiesRealizedGainLossOtherThanTemporaryImpairmentsAmounts" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_PercentageOfMonthlyContribution" xlink:href="abvcd-20210331.xsd#abvcd_PercentageOfMonthlyContribution"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="abvcd_PercentageOfMonthlyContribution" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_StockBasedCompensationForNonemployees" xlink:href="abvcd-20210331.xsd#abvcd_StockBasedCompensationForNonemployees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="abvcd_StockBasedCompensationForNonemployees" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/CollaborativeAgreementsDetails">
    <loc xlink:type="locator" xlink:label="abvcd_CollaborativeAgreementsDetailsLineItems" xlink:href="abvcd-20210331.xsd#abvcd_CollaborativeAgreementsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="abvcd_CollaborativeAgreementsDetailsTable" xlink:href="abvcd-20210331.xsd#abvcd_CollaborativeAgreementsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abvcd_CollaborativeAgreementsDetailsLineItems" xlink:to="abvcd_CollaborativeAgreementsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvcd_CollaborativeAgreementsDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_BHKCoDevelopmentAgreementMember" xlink:href="abvcd-20210331.xsd#abvcd_BHKCoDevelopmentAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abvcd_BHKCoDevelopmentAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_CodevelopmentagreementMember" xlink:href="abvcd-20210331.xsd#abvcd_CodevelopmentagreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abvcd_CodevelopmentagreementMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_BioFirstStockPurchaseAgreementMember" xlink:href="abvcd-20210331.xsd#abvcd_BioFirstStockPurchaseAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abvcd_BioFirstStockPurchaseAgreementMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_MilestonePayments" xlink:href="abvcd-20210331.xsd#abvcd_MilestonePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_CollaborativeAgreementsDetailsLineItems" xlink:to="abvcd_MilestonePayments" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_CollaborativeAgreementsDetailsLineItems" xlink:to="us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_UpfrontCashPayment" xlink:href="abvcd-20210331.xsd#abvcd_UpfrontCashPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_CollaborativeAgreementsDetailsLineItems" xlink:to="abvcd_UpfrontCashPayment" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_PercentageOfPaymentsUnderCodevelopmentAgreement" xlink:href="abvcd-20210331.xsd#abvcd_PercentageOfPaymentsUnderCodevelopmentAgreement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_CollaborativeAgreementsDetailsLineItems" xlink:to="abvcd_PercentageOfPaymentsUnderCodevelopmentAgreement" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_IssuanceOfStockValue" xlink:href="abvcd-20210331.xsd#abvcd_IssuanceOfStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_CollaborativeAgreementsDetailsLineItems" xlink:to="abvcd_IssuanceOfStockValue" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_MilestonePaymentsRoyaltyPercentage" xlink:href="abvcd-20210331.xsd#abvcd_MilestonePaymentsRoyaltyPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_CollaborativeAgreementsDetailsLineItems" xlink:to="abvcd_MilestonePaymentsRoyaltyPercentage" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_CollaborativeAgreementsDescription" xlink:href="abvcd-20210331.xsd#abvcd_CollaborativeAgreementsDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_CollaborativeAgreementsDetailsLineItems" xlink:to="abvcd_CollaborativeAgreementsDescription" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForParticipationLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForParticipationLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_CollaborativeAgreementsDetailsLineItems" xlink:to="us-gaap_PaymentsForParticipationLiabilities" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_AdditionCashPayment" xlink:href="abvcd-20210331.xsd#abvcd_AdditionCashPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_CollaborativeAgreementsDetailsLineItems" xlink:to="abvcd_AdditionCashPayment" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_CollaborativeAgreementsDetailsLineItems" xlink:to="us-gaap_AdditionalPaidInCapital" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_CollaborativeAgreementsDetailsLineItems" xlink:to="us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_CoDevAgreementDescription" xlink:href="abvcd-20210331.xsd#abvcd_CoDevAgreementDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_CollaborativeAgreementsDetailsLineItems" xlink:to="abvcd_CoDevAgreementDescription" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_CollaborativeAgreementsDetailsLineItems" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_CollaborativeAgreementsDetailsLineItems" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_CollaborativeAgreementsDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="15" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/PropertyandEquipmentDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_Depreciation" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/LongTermInvestmentsDetails">
    <loc xlink:type="locator" xlink:label="abvcd_LongTermInvestmentsDetailsLineItems" xlink:href="abvcd-20210331.xsd#abvcd_LongTermInvestmentsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="abvcd_LongTermInvestmentsDetailsTable" xlink:href="abvcd-20210331.xsd#abvcd_LongTermInvestmentsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abvcd_LongTermInvestmentsDetailsLineItems" xlink:to="abvcd_LongTermInvestmentsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvcd_LongTermInvestmentsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_BioFirstCorporationMember" xlink:href="abvcd-20210331.xsd#abvcd_BioFirstCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvcd_BioFirstCorporationMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_RgeneCorporationMember" xlink:href="abvcd-20210331.xsd#abvcd_RgeneCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvcd_RgeneCorporationMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_LongTermInvestmentsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_LongTermInvestmentsDetailsLineItems" xlink:to="us-gaap_IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_AggregateAmount" xlink:href="abvcd-20210331.xsd#abvcd_AggregateAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_LongTermInvestmentsDetailsLineItems" xlink:to="abvcd_AggregateAmount" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockDescriptionOfTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockDescriptionOfTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_LongTermInvestmentsDetailsLineItems" xlink:to="us-gaap_SaleOfStockDescriptionOfTransaction" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ConvertibleNotesPayableDetails">
    <loc xlink:type="locator" xlink:label="abvcd_ConvertibleNotesPayableDetailsLineItems" xlink:href="abvcd-20210331.xsd#abvcd_ConvertibleNotesPayableDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="abvcd_ConvertibleNotesPayableDetailsTable" xlink:href="abvcd-20210331.xsd#abvcd_ConvertibleNotesPayableDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abvcd_ConvertibleNotesPayableDetailsLineItems" xlink:to="abvcd_ConvertibleNotesPayableDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvcd_ConvertibleNotesPayableDetailsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_UnsecuredConvertiblePromissoryNoteMember" xlink:href="abvcd-20210331.xsd#abvcd_UnsecuredConvertiblePromissoryNoteMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="abvcd_UnsecuredConvertiblePromissoryNoteMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_SecuritiesPurchaseAgreementMember" xlink:href="abvcd-20210331.xsd#abvcd_SecuritiesPurchaseAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="abvcd_SecuritiesPurchaseAgreementMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_ConvertibleNotesPayableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireNotesReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireNotesReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_ConvertibleNotesPayableDetailsLineItems" xlink:to="us-gaap_PaymentsToAcquireNotesReceivable" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_ConvertibleNotesPayableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockDescriptionOfTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockDescriptionOfTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_ConvertibleNotesPayableDetailsLineItems" xlink:to="us-gaap_SaleOfStockDescriptionOfTransaction" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_ConvertibleNotesPayableDetailsLineItems" xlink:to="us-gaap_ConversionOfStockDescription" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_ConvertibleNotesPayableDetailsLineItems" xlink:to="us-gaap_ConvertibleDebt" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_ConvertibleNotesPayableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_TotalInterestExpenses" xlink:href="abvcd-20210331.xsd#abvcd_TotalInterestExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_ConvertibleNotesPayableDetailsLineItems" xlink:to="abvcd_TotalInterestExpenses" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/BankLoansDetails">
    <loc xlink:type="locator" xlink:label="abvcd_BankLoansDetailsLineItems" xlink:href="abvcd-20210331.xsd#abvcd_BankLoansDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="abvcd_BankLoansDetailsTable" xlink:href="abvcd-20210331.xsd#abvcd_BankLoansDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abvcd_BankLoansDetailsLineItems" xlink:to="abvcd_BankLoansDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvcd_BankLoansDetailsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_TypeOfCurrencyAxis" xlink:href="abvcd-20210331.xsd#abvcd_TypeOfCurrencyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvcd_BankLoansDetailsTable" xlink:to="abvcd_TypeOfCurrencyAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_TypeOfCurrencyDomain" xlink:href="abvcd-20210331.xsd#abvcd_TypeOfCurrencyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="abvcd_TypeOfCurrencyAxis" xlink:to="abvcd_TypeOfCurrencyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_TypeOfCurrencyDomain_0" xlink:href="abvcd-20210331.xsd#abvcd_TypeOfCurrencyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="abvcd_TypeOfCurrencyAxis" xlink:to="abvcd_TypeOfCurrencyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_CathayUnitedLoanAgreementMember" xlink:href="abvcd-20210331.xsd#abvcd_CathayUnitedLoanAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="abvcd_CathayUnitedLoanAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_CTBCBankMember" xlink:href="abvcd-20210331.xsd#abvcd_CTBCBankMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="abvcd_CTBCBankMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_LoanAgreementMember" xlink:href="abvcd-20210331.xsd#abvcd_LoanAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="abvcd_LoanAgreementMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_CathayBnakMember" xlink:href="abvcd-20210331.xsd#abvcd_CathayBnakMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="abvcd_CathayBnakMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_NTMember" xlink:href="abvcd-20210331.xsd#abvcd_NTMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_TypeOfCurrencyDomain" xlink:to="abvcd_NTMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_BankLoansDetailsLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_BankLoansDetailsLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_BankLoansDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_BankLoansDetailsLineItems" xlink:to="us-gaap_DebtInstrumentTerm" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestAndDebtExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestAndDebtExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_BankLoansDetailsLineItems" xlink:to="us-gaap_InterestAndDebtExpense" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_ReceivedLoanAmount" xlink:href="abvcd-20210331.xsd#abvcd_ReceivedLoanAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_BankLoansDetailsLineItems" xlink:to="abvcd_ReceivedLoanAmount" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_RegularInterestRateDescription" xlink:href="abvcd-20210331.xsd#abvcd_RegularInterestRateDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_BankLoansDetailsLineItems" xlink:to="abvcd_RegularInterestRateDescription" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_ExceedingAmount" xlink:href="abvcd-20210331.xsd#abvcd_ExceedingAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_BankLoansDetailsLineItems" xlink:to="abvcd_ExceedingAmount" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_BankLoansDetailsLineItems" xlink:to="us-gaap_LoansPayable" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/PaycheckProtectionProgramLoanPayableDetails">
    <loc xlink:type="locator" xlink:label="abvcd_PaycheckProtectionProgramLoanPayableDetailsLineItems" xlink:href="abvcd-20210331.xsd#abvcd_PaycheckProtectionProgramLoanPayableDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="abvcd_PaycheckProtectionProgramLoanPayableDetailsTable" xlink:href="abvcd-20210331.xsd#abvcd_PaycheckProtectionProgramLoanPayableDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abvcd_PaycheckProtectionProgramLoanPayableDetailsLineItems" xlink:to="abvcd_PaycheckProtectionProgramLoanPayableDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvcd_PaycheckProtectionProgramLoanPayableDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_PAYCHECKPROTECTIONPROGRAMMember" xlink:href="abvcd-20210331.xsd#abvcd_PAYCHECKPROTECTIONPROGRAMMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvcd_PAYCHECKPROTECTIONPROGRAMMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_PaycheckProtectionProgramDescription" xlink:href="abvcd-20210331.xsd#abvcd_PaycheckProtectionProgramDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_PaycheckProtectionProgramLoanPayableDetailsLineItems" xlink:to="abvcd_PaycheckProtectionProgramDescription" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_PaycheckProtectionProgramLoanPayableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_PercentageOfForgivenAmount" xlink:href="abvcd-20210331.xsd#abvcd_PercentageOfForgivenAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_PaycheckProtectionProgramLoanPayableDetailsLineItems" xlink:to="abvcd_PercentageOfForgivenAmount" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_InterestRate" xlink:href="abvcd-20210331.xsd#abvcd_InterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_PaycheckProtectionProgramLoanPayableDetailsLineItems" xlink:to="abvcd_InterestRate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_PromissoryNoteTerm" xlink:href="abvcd-20210331.xsd#abvcd_PromissoryNoteTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_PaycheckProtectionProgramLoanPayableDetailsLineItems" xlink:to="abvcd_PromissoryNoteTerm" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_LoanAmout" xlink:href="abvcd-20210331.xsd#abvcd_LoanAmout"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_PaycheckProtectionProgramLoanPayableDetailsLineItems" xlink:to="abvcd_LoanAmout" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/NotesPayableDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <loc xlink:type="locator" xlink:label="abvcd_UnsecuredLoanAgreementsDescription" xlink:href="abvcd-20210331.xsd#abvcd_UnsecuredLoanAgreementsDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="abvcd_UnsecuredLoanAgreementsDescription" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_OtherNotesPayable" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_InterestExpenseOther" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ShorttermLoanDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnsecuredDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnsecuredDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_UnsecuredDebt" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtInterestRateIncrease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtInterestRateIncrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ShortTermDebtInterestRateIncrease" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/RelatedPartiesTransactionsDetails">
    <loc xlink:type="locator" xlink:label="abvcd_RelatedPartiesTransactionsDetailsLineItems" xlink:href="abvcd-20210331.xsd#abvcd_RelatedPartiesTransactionsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="abvcd_RelatedPartiesTransactionsDetailsTable" xlink:href="abvcd-20210331.xsd#abvcd_RelatedPartiesTransactionsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abvcd_RelatedPartiesTransactionsDetailsLineItems" xlink:to="abvcd_RelatedPartiesTransactionsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvcd_RelatedPartiesTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_AgreemnetAxis" xlink:href="abvcd-20210331.xsd#abvcd_AgreemnetAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvcd_RelatedPartiesTransactionsDetailsTable" xlink:to="abvcd_AgreemnetAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_AgreemnetDomain" xlink:href="abvcd-20210331.xsd#abvcd_AgreemnetDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="abvcd_AgreemnetAxis" xlink:to="abvcd_AgreemnetDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_AgreemnetDomain_0" xlink:href="abvcd-20210331.xsd#abvcd_AgreemnetDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="abvcd_AgreemnetAxis" xlink:to="abvcd_AgreemnetDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_TypeOfCurrencyAxis" xlink:href="abvcd-20210331.xsd#abvcd_TypeOfCurrencyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvcd_RelatedPartiesTransactionsDetailsTable" xlink:to="abvcd_TypeOfCurrencyAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_TypeOfCurrencyDomain" xlink:href="abvcd-20210331.xsd#abvcd_TypeOfCurrencyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="abvcd_TypeOfCurrencyAxis" xlink:to="abvcd_TypeOfCurrencyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_TypeOfCurrencyDomain_0" xlink:href="abvcd-20210331.xsd#abvcd_TypeOfCurrencyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="abvcd_TypeOfCurrencyAxis" xlink:to="abvcd_TypeOfCurrencyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_ConversionAgreementsOneMember" xlink:href="abvcd-20210331.xsd#abvcd_ConversionAgreementsOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_AgreemnetDomain" xlink:to="abvcd_ConversionAgreementsOneMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_RgeneCorporationMember" xlink:href="abvcd-20210331.xsd#abvcd_RgeneCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvcd_RgeneCorporationMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_BioFirstMember" xlink:href="abvcd-20210331.xsd#abvcd_BioFirstMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvcd_BioFirstMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_AsiangeneCorporationMember" xlink:href="abvcd-20210331.xsd#abvcd_AsiangeneCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvcd_AsiangeneCorporationMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_BioFirstAustraliaMember" xlink:href="abvcd-20210331.xsd#abvcd_BioFirstAustraliaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvcd_BioFirstAustraliaMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_BioLiteTaiwanMember" xlink:href="abvcd-20210331.xsd#abvcd_BioLiteTaiwanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvcd_BioLiteTaiwanMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_LbgUsaIncMember" xlink:href="abvcd-20210331.xsd#abvcd_LbgUsaIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvcd_LbgUsaIncMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_BioLiteJapanMember" xlink:href="abvcd-20210331.xsd#abvcd_BioLiteJapanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvcd_BioLiteJapanMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_YuanGeneMember" xlink:href="abvcd-20210331.xsd#abvcd_YuanGeneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvcd_YuanGeneMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_JIANGSMember" xlink:href="abvcd-20210331.xsd#abvcd_JIANGSMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvcd_JIANGSMember" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_NTMember" xlink:href="abvcd-20210331.xsd#abvcd_NTMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_TypeOfCurrencyDomain" xlink:to="abvcd_NTMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_RelatedPartiesTransactionsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateTerms" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateTerms"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_RelatedPartiesTransactionsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateTerms" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShorttermDebtAverageOutstandingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShorttermDebtAverageOutstandingAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_RelatedPartiesTransactionsDetailsLineItems" xlink:to="us-gaap_ShorttermDebtAverageOutstandingAmount" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_AccruedInterest" xlink:href="abvcd-20210331.xsd#abvcd_AccruedInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_RelatedPartiesTransactionsDetailsLineItems" xlink:to="abvcd_AccruedInterest" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_StockPurchaseAgreementDescription" xlink:href="abvcd-20210331.xsd#abvcd_StockPurchaseAgreementDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_RelatedPartiesTransactionsDetailsLineItems" xlink:to="abvcd_StockPurchaseAgreementDescription" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_AggregateWorkingcapital" xlink:href="abvcd-20210331.xsd#abvcd_AggregateWorkingcapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_RelatedPartiesTransactionsDetailsLineItems" xlink:to="abvcd_AggregateWorkingcapital" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_AdvancesBearInterestDescription" xlink:href="abvcd-20210331.xsd#abvcd_AdvancesBearInterestDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_RelatedPartiesTransactionsDetailsLineItems" xlink:to="abvcd_AdvancesBearInterestDescription" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_RelatedPartiesTransactionsDetailsLineItems" xlink:to="us-gaap_RelatedPartyTransactionRate" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_RelatedPartiesTransactionsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueFromOtherRelatedParties" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromOtherRelatedParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_RelatedPartiesTransactionsDetailsLineItems" xlink:to="us-gaap_DueFromOtherRelatedParties" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfLoanCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfLoanCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_RelatedPartiesTransactionsDetailsLineItems" xlink:to="us-gaap_PaymentsOfLoanCosts" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_RelatedPartiesTransactionsDetailsLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrent" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_RelatedPartiesTransactionsDetailsLineItems" xlink:to="us-gaap_InterestExpense" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_NumberOfEmployees" xlink:href="abvcd-20210331.xsd#abvcd_NumberOfEmployees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_RelatedPartiesTransactionsDetailsLineItems" xlink:to="abvcd_NumberOfEmployees" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_RelatedPartiesTransactionsDetailsLineItems" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="15" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/EquityDetails">
    <loc xlink:type="locator" xlink:label="abvcd_EquityDetailsLineItems" xlink:href="abvcd-20210331.xsd#abvcd_EquityDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="abvcd_EquityDetailsTable" xlink:href="abvcd-20210331.xsd#abvcd_EquityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abvcd_EquityDetailsLineItems" xlink:to="abvcd_EquityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvcd_EquityDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvcd_EquityDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvcd_EquityDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvcd_EquityDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvcd_EquityDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvcd_EquityDetailsTable" xlink:to="srt_RangeAxis" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_TwoThousandSixteenEquityIncentivePlanMember" xlink:href="abvcd-20210331.xsd#abvcd_TwoThousandSixteenEquityIncentivePlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="abvcd_TwoThousandSixteenEquityIncentivePlanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_ShareExchangeAgreementMember" xlink:href="abvcd-20210331.xsd#abvcd_ShareExchangeAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abvcd_ShareExchangeAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_ShareExchangeAgreementOneMember" xlink:href="abvcd-20210331.xsd#abvcd_ShareExchangeAgreementOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abvcd_ShareExchangeAgreementOneMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_ShareExchangeAgreementTwoMember" xlink:href="abvcd-20210331.xsd#abvcd_ShareExchangeAgreementTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abvcd_ShareExchangeAgreementTwoMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_ShareExchangeAgreementThreeMember" xlink:href="abvcd-20210331.xsd#abvcd_ShareExchangeAgreementThreeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abvcd_ShareExchangeAgreementThreeMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_ShareExchangeAgreementFourMember" xlink:href="abvcd-20210331.xsd#abvcd_ShareExchangeAgreementFourMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abvcd_ShareExchangeAgreementFourMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_EuroAsiaInvestmentAndFinanceCorpLtdMember" xlink:href="abvcd-20210331.xsd#abvcd_EuroAsiaInvestmentAndFinanceCorpLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abvcd_EuroAsiaInvestmentAndFinanceCorpLtdMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_CodevelopmentagreementMember" xlink:href="abvcd-20210331.xsd#abvcd_CodevelopmentagreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abvcd_CodevelopmentagreementMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_ConsultingAgreementMember" xlink:href="abvcd-20210331.xsd#abvcd_ConsultingAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abvcd_ConsultingAgreementMember" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_KameyamaMember" xlink:href="abvcd-20210331.xsd#abvcd_KameyamaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvcd_KameyamaMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_ArticlesOfIncorporationMember" xlink:href="abvcd-20210331.xsd#abvcd_ArticlesOfIncorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvcd_ArticlesOfIncorporationMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_ViewTradeSecuritiesIncMember" xlink:href="abvcd-20210331.xsd#abvcd_ViewTradeSecuritiesIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvcd_ViewTradeSecuritiesIncMember" order="2" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvcd_ConsultingAgreementMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_NonRelatedPartiesMember" xlink:href="abvcd-20210331.xsd#abvcd_NonRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvcd_NonRelatedPartiesMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_BioLiteMember" xlink:href="abvcd-20210331.xsd#abvcd_BioLiteMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="abvcd_BioLiteMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_BioKeyMember" xlink:href="abvcd-20210331.xsd#abvcd_BioKeyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="abvcd_BioKeyMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_CommonStockIssuedAfterStockSplit" xlink:href="abvcd-20210331.xsd#abvcd_CommonStockIssuedAfterStockSplit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_EquityDetailsLineItems" xlink:to="abvcd_CommonStockIssuedAfterStockSplit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_CommonStockIssuedBeforeStockSplit" xlink:href="abvcd-20210331.xsd#abvcd_CommonStockIssuedBeforeStockSplit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_EquityDetailsLineItems" xlink:to="abvcd_CommonStockIssuedBeforeStockSplit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_EquityDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_PercentageOfIssuedShareCapital" xlink:href="abvcd-20210331.xsd#abvcd_PercentageOfIssuedShareCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_EquityDetailsLineItems" xlink:to="abvcd_PercentageOfIssuedShareCapital" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_StockholderEquityReverseStockSplit" xlink:href="abvcd-20210331.xsd#abvcd_StockholderEquityReverseStockSplit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_EquityDetailsLineItems" xlink:to="abvcd_StockholderEquityReverseStockSplit" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_EquityDetailsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_EquityDetailsLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_AgreementDescription" xlink:href="abvcd-20210331.xsd#abvcd_AgreementDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_EquityDetailsLineItems" xlink:to="abvcd_AgreementDescription" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_EquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_FinancialAmendmentDescription" xlink:href="abvcd-20210331.xsd#abvcd_FinancialAmendmentDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_EquityDetailsLineItems" xlink:to="abvcd_FinancialAmendmentDescription" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_Consultingagreementdescription" xlink:href="abvcd-20210331.xsd#abvcd_Consultingagreementdescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_EquityDetailsLineItems" xlink:to="abvcd_Consultingagreementdescription" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_UnpaidConsultingFees" xlink:href="abvcd-20210331.xsd#abvcd_UnpaidConsultingFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_EquityDetailsLineItems" xlink:to="abvcd_UnpaidConsultingFees" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_EquityDetailsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalFees" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfessionalFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_EquityDetailsLineItems" xlink:to="us-gaap_ProfessionalFees" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_StockSubscriptionReceivable" xlink:href="abvcd-20210331.xsd#abvcd_StockSubscriptionReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_EquityDetailsLineItems" xlink:to="abvcd_StockSubscriptionReceivable" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_EquityDetailsLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_StockIssuedValue" xlink:href="abvcd-20210331.xsd#abvcd_StockIssuedValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_EquityDetailsLineItems" xlink:to="abvcd_StockIssuedValue" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_EquityDetailsLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_EquityDetailsLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_PlacementAgentAgreementDescription" xlink:href="abvcd-20210331.xsd#abvcd_PlacementAgentAgreementDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_EquityDetailsLineItems" xlink:to="abvcd_PlacementAgentAgreementDescription" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_RestrictedCommonShares" xlink:href="abvcd-20210331.xsd#abvcd_RestrictedCommonShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_EquityDetailsLineItems" xlink:to="abvcd_RestrictedCommonShares" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_WarrantIssued" xlink:href="abvcd-20210331.xsd#abvcd_WarrantIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_EquityDetailsLineItems" xlink:to="abvcd_WarrantIssued" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_EquityDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_WarrantTerm" xlink:href="abvcd-20210331.xsd#abvcd_WarrantTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_EquityDetailsLineItems" xlink:to="abvcd_WarrantTerm" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_UnrestrictedCommonShares" xlink:href="abvcd-20210331.xsd#abvcd_UnrestrictedCommonShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_EquityDetailsLineItems" xlink:to="abvcd_UnrestrictedCommonShares" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromContributionsFromAffiliates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromContributionsFromAffiliates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_EquityDetailsLineItems" xlink:to="us-gaap_ProceedsFromContributionsFromAffiliates" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_NumberOfInvestors" xlink:href="abvcd-20210331.xsd#abvcd_NumberOfInvestors"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_EquityDetailsLineItems" xlink:to="abvcd_NumberOfInvestors" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_EquityDetailsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_IssuanceOfCommonStock" xlink:href="abvcd-20210331.xsd#abvcd_IssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_EquityDetailsLineItems" xlink:to="abvcd_IssuanceOfCommonStock" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_EquityDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_EquityDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_StockIssuedDuringPeriodShareBasedCompensationServicesforShares" xlink:href="abvcd-20210331.xsd#abvcd_StockIssuedDuringPeriodShareBasedCompensationServicesforShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_EquityDetailsLineItems" xlink:to="abvcd_StockIssuedDuringPeriodShareBasedCompensationServicesforShares" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_AggregateCommonStockShares" xlink:href="abvcd-20210331.xsd#abvcd_AggregateCommonStockShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_EquityDetailsLineItems" xlink:to="abvcd_AggregateCommonStockShares" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_EquityDetailsLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature" order="34" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/StockOptionsDetails">
    <loc xlink:type="locator" xlink:label="abvcd_StockOptionsDetailsLineItems" xlink:href="abvcd-20210331.xsd#abvcd_StockOptionsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="abvcd_StockOptionsDetailsTable" xlink:href="abvcd-20210331.xsd#abvcd_StockOptionsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abvcd_StockOptionsDetailsLineItems" xlink:to="abvcd_StockOptionsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvcd_StockOptionsDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_TwoThousandSixteenEquityIncentivePlanMember" xlink:href="abvcd-20210331.xsd#abvcd_TwoThousandSixteenEquityIncentivePlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="abvcd_TwoThousandSixteenEquityIncentivePlanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_StockOptionsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_StockOptionsDetailsLineItems" xlink:to="us-gaap_SharePrice" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_ConsultingFees" xlink:href="abvcd-20210331.xsd#abvcd_ConsultingFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_StockOptionsDetailsLineItems" xlink:to="abvcd_ConsultingFees" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_StockOptionsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_StockOptionsDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_StockOptionsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_StockOptionsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants" xlink:href="abvcd-20210331.xsd#abvcd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_StockOptionsDetailsLineItems" xlink:to="abvcd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/BusinessCombinationDetails">
    <loc xlink:type="locator" xlink:label="abvcd_BusinessCombinationDetailsLineItems" xlink:href="abvcd-20210331.xsd#abvcd_BusinessCombinationDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="abvcd_BusinessCombinationDetailsTable" xlink:href="abvcd-20210331.xsd#abvcd_BusinessCombinationDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abvcd_BusinessCombinationDetailsLineItems" xlink:to="abvcd_BusinessCombinationDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvcd_BusinessCombinationDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_BioKeyMember" xlink:href="abvcd-20210331.xsd#abvcd_BioKeyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="abvcd_BioKeyMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_BusinessCombinationDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_CommonStockIssuedAfterStockSplit" xlink:href="abvcd-20210331.xsd#abvcd_CommonStockIssuedAfterStockSplit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_BusinessCombinationDetailsLineItems" xlink:to="abvcd_CommonStockIssuedAfterStockSplit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_BusinessCombinationDetailsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvcd_PercentageOfGoodwill" xlink:href="abvcd-20210331.xsd#abvcd_PercentageOfGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_BusinessCombinationDetailsLineItems" xlink:to="abvcd_PercentageOfGoodwill" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvcd_BusinessCombinationDetailsLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="17" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>abvcd-20210331_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon May 10 19:51:10 UTC 2021 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Stockholders&#8217; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Stockholders&#8217; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Total Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl1" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GrossProfit_lbl0" xml:lang="en-US">Gross profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income (expenses)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss before provision income tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl1" xml:lang="en-US">Net loss for the period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl1"/>
    <loc xlink:type="locator" xlink:label="abvcd_NetLossAttributableToAbvcAndSubsidiaries" xlink:href="abvcd-20210331.xsd#abvcd_NetLossAttributableToAbvcAndSubsidiaries"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="abvcd_NetLossAttributableToAbvcAndSubsidiaries_lbl" xml:lang="en-US">Net loss attributed to ABVC and subsidiaries</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_NetLossAttributableToAbvcAndSubsidiaries" xlink:to="abvcd_NetLossAttributableToAbvcAndSubsidiaries_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents and restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">Ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl0" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_ScheduleOfPropertyAndEquipmentAbstract" xlink:href="abvcd-20210331.xsd#abvcd_ScheduleOfPropertyAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_ScheduleOfPropertyAndEquipmentAbstract_lbl" xml:lang="en-US">Schedule of property and equipment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ScheduleOfPropertyAndEquipmentAbstract" xlink:to="abvcd_ScheduleOfPropertyAndEquipmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">Inventory Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_ScheduleOfInventoryAbstract" xlink:href="abvcd-20210331.xsd#abvcd_ScheduleOfInventoryAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_ScheduleOfInventoryAbstract_lbl" xml:lang="en-US">Schedule of inventory [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ScheduleOfInventoryAbstract" xlink:to="abvcd_ScheduleOfInventoryAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_LongTermInvestmentAbstract" xlink:href="abvcd-20210331.xsd#abvcd_LongTermInvestmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_LongTermInvestmentAbstract_lbl" xml:lang="en-US">Long Term Investment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_LongTermInvestmentAbstract" xlink:to="abvcd_LongTermInvestmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_ScheduleOfOwnershipPercentagesOfInvesteeAbstract" xlink:href="abvcd-20210331.xsd#abvcd_ScheduleOfOwnershipPercentagesOfInvesteeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_ScheduleOfOwnershipPercentagesOfInvesteeAbstract_lbl" xml:lang="en-US">Schedule of ownership percentages of investee [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ScheduleOfOwnershipPercentagesOfInvesteeAbstract" xlink:to="abvcd_ScheduleOfOwnershipPercentagesOfInvesteeAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_ScheduleOfExtentTheInvesteeReliesAbstract" xlink:href="abvcd-20210331.xsd#abvcd_ScheduleOfExtentTheInvesteeReliesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_ScheduleOfExtentTheInvesteeReliesAbstract_lbl" xml:lang="en-US">Schedule of extent the investee relies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ScheduleOfExtentTheInvesteeReliesAbstract" xlink:to="abvcd_ScheduleOfExtentTheInvesteeReliesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_ScheduleOfLongTermInvestmentAbstract" xlink:href="abvcd-20210331.xsd#abvcd_ScheduleOfLongTermInvestmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_ScheduleOfLongTermInvestmentAbstract_lbl" xml:lang="en-US">Schedule of long-term investment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ScheduleOfLongTermInvestmentAbstract" xlink:to="abvcd_ScheduleOfLongTermInvestmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_ScheduleOfBalanceSheetsAbstract" xlink:href="abvcd-20210331.xsd#abvcd_ScheduleOfBalanceSheetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_ScheduleOfBalanceSheetsAbstract_lbl" xml:lang="en-US">Schedule of balance sheets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ScheduleOfBalanceSheetsAbstract" xlink:to="abvcd_ScheduleOfBalanceSheetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_ScheduleOfStatementsOfOperationAbstract" xlink:href="abvcd-20210331.xsd#abvcd_ScheduleOfStatementsOfOperationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_ScheduleOfStatementsOfOperationAbstract_lbl" xml:lang="en-US">Schedule of statements of operation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ScheduleOfStatementsOfOperationAbstract" xlink:to="abvcd_ScheduleOfStatementsOfOperationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_ScheduleOfEquityInvestmentsAbstract" xlink:href="abvcd-20210331.xsd#abvcd_ScheduleOfEquityInvestmentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_ScheduleOfEquityInvestmentsAbstract_lbl" xml:lang="en-US">Schedule of equity investments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ScheduleOfEquityInvestmentsAbstract" xlink:to="abvcd_ScheduleOfEquityInvestmentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_ConvertibleNotesPayableDisclosureAbstract" xlink:href="abvcd-20210331.xsd#abvcd_ConvertibleNotesPayableDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_ConvertibleNotesPayableDisclosureAbstract_lbl" xml:lang="en-US">Convertible Notes Payable Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ConvertibleNotesPayableDisclosureAbstract" xlink:to="abvcd_ConvertibleNotesPayableDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_BankLoansAbstractAbstract" xlink:href="abvcd-20210331.xsd#abvcd_BankLoansAbstractAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_BankLoansAbstractAbstract_lbl" xml:lang="en-US">Bank Loans Abstract [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_BankLoansAbstractAbstract" xlink:to="abvcd_BankLoansAbstractAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_ScheduleOfShortTermBankLoanAbstract" xlink:href="abvcd-20210331.xsd#abvcd_ScheduleOfShortTermBankLoanAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_ScheduleOfShortTermBankLoanAbstract_lbl" xml:lang="en-US">Schedule of short-term bank loan [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ScheduleOfShortTermBankLoanAbstract" xlink:to="abvcd_ScheduleOfShortTermBankLoanAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xml:lang="en-US">Short-term Debt, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_PaycheckProtectionProgramLoanPayableAbstract" xlink:href="abvcd-20210331.xsd#abvcd_PaycheckProtectionProgramLoanPayableAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_PaycheckProtectionProgramLoanPayableAbstract_lbl" xml:lang="en-US">Paycheck Protection Program Loan Payable [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_PaycheckProtectionProgramLoanPayableAbstract" xlink:to="abvcd_PaycheckProtectionProgramLoanPayableAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract_lbl" xml:lang="en-US">Disclosure Text Block Supplement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_DisclosureTextBlockSupplementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_ScheduleOfRelatedPartyTransactionsAbstract" xlink:href="abvcd-20210331.xsd#abvcd_ScheduleOfRelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_ScheduleOfRelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Schedule of related party transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ScheduleOfRelatedPartyTransactionsAbstract" xlink:to="abvcd_ScheduleOfRelatedPartyTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_ScheduleOfAccountsReceivableDueFromRelatedPartiesAbstract" xlink:href="abvcd-20210331.xsd#abvcd_ScheduleOfAccountsReceivableDueFromRelatedPartiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_ScheduleOfAccountsReceivableDueFromRelatedPartiesAbstract_lbl" xml:lang="en-US">Schedule of accounts receivable due from related parties [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ScheduleOfAccountsReceivableDueFromRelatedPartiesAbstract" xlink:to="abvcd_ScheduleOfAccountsReceivableDueFromRelatedPartiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_ScheduleOfAmountDueFromRelatedPartiesAbstract" xlink:href="abvcd-20210331.xsd#abvcd_ScheduleOfAmountDueFromRelatedPartiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_ScheduleOfAmountDueFromRelatedPartiesAbstract_lbl" xml:lang="en-US">Schedule of amount due from related parties [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ScheduleOfAmountDueFromRelatedPartiesAbstract" xlink:to="abvcd_ScheduleOfAmountDueFromRelatedPartiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_ScheduleOfAmountDueToRelatedPartiesAbstract" xlink:href="abvcd-20210331.xsd#abvcd_ScheduleOfAmountDueToRelatedPartiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_ScheduleOfAmountDueToRelatedPartiesAbstract_lbl" xml:lang="en-US">Schedule of amount due to related parties [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ScheduleOfAmountDueToRelatedPartiesAbstract" xlink:to="abvcd_ScheduleOfAmountDueToRelatedPartiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Stockholders&apos; Equity Note [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_ScheduleOfConvertedAmountOfDebtAndSharesAbstract" xlink:href="abvcd-20210331.xsd#abvcd_ScheduleOfConvertedAmountOfDebtAndSharesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_ScheduleOfConvertedAmountOfDebtAndSharesAbstract_lbl" xml:lang="en-US">Schedule of converted amount of debt and shares [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ScheduleOfConvertedAmountOfDebtAndSharesAbstract" xlink:to="abvcd_ScheduleOfConvertedAmountOfDebtAndSharesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_StockOptionsAbstract" xlink:href="abvcd-20210331.xsd#abvcd_StockOptionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_StockOptionsAbstract_lbl" xml:lang="en-US">Stock Options [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_StockOptionsAbstract" xlink:to="abvcd_StockOptionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_ScheduleOfOptionsIssuedAndOutstandingAbstract" xlink:href="abvcd-20210331.xsd#abvcd_ScheduleOfOptionsIssuedAndOutstandingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_ScheduleOfOptionsIssuedAndOutstandingAbstract_lbl" xml:lang="en-US">Schedule of options issued and outstanding [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ScheduleOfOptionsIssuedAndOutstandingAbstract" xlink:to="abvcd_ScheduleOfOptionsIssuedAndOutstandingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of Underlying Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0" xml:lang="en-US">Number of Underlying Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xml:lang="en-US">Company granted stock option</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-Average Exercise Price Per Share, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted-Average Exercise Price Per Share, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_lbl" xml:lang="en-US">Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_ScheduleOfFairValueOfStockOptionsGrantedAbstract" xlink:href="abvcd-20210331.xsd#abvcd_ScheduleOfFairValueOfStockOptionsGrantedAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_ScheduleOfFairValueOfStockOptionsGrantedAbstract_lbl" xml:lang="en-US">Schedule of fair value of stock options granted [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ScheduleOfFairValueOfStockOptionsGrantedAbstract" xlink:to="abvcd_ScheduleOfFairValueOfStockOptionsGrantedAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Earnings Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_ScheduleOfLossPerShareAbstract" xlink:href="abvcd-20210331.xsd#abvcd_ScheduleOfLossPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_ScheduleOfLossPerShareAbstract_lbl" xml:lang="en-US">Schedule of loss per share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ScheduleOfLossPerShareAbstract" xlink:to="abvcd_ScheduleOfLossPerShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ASU201602TransitionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ASU201602TransitionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ASU201602TransitionAbstract_lbl" xml:lang="en-US">ASU 2016-02 Transition [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ASU201602TransitionAbstract" xlink:to="us-gaap_ASU201602TransitionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_ScheduleOfOperatingLeaseArrangementsAbstract" xlink:href="abvcd-20210331.xsd#abvcd_ScheduleOfOperatingLeaseArrangementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_ScheduleOfOperatingLeaseArrangementsAbstract_lbl" xml:lang="en-US">Schedule of operating lease arrangements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ScheduleOfOperatingLeaseArrangementsAbstract" xlink:to="abvcd_ScheduleOfOperatingLeaseArrangementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_ScheduleOfSupplementalInformationRelatedToOperatingLeasesAbstract" xlink:href="abvcd-20210331.xsd#abvcd_ScheduleOfSupplementalInformationRelatedToOperatingLeasesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_ScheduleOfSupplementalInformationRelatedToOperatingLeasesAbstract_lbl" xml:lang="en-US">Schedule of supplemental information related to operating leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ScheduleOfSupplementalInformationRelatedToOperatingLeasesAbstract" xlink:to="abvcd_ScheduleOfSupplementalInformationRelatedToOperatingLeasesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_ScheduleOfMinimumFutureAnnualPaymentsUnderNonCancellableLeasesAbstract" xlink:href="abvcd-20210331.xsd#abvcd_ScheduleOfMinimumFutureAnnualPaymentsUnderNonCancellableLeasesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_ScheduleOfMinimumFutureAnnualPaymentsUnderNonCancellableLeasesAbstract_lbl" xml:lang="en-US">Schedule of minimum future annual payments under non-cancellable leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ScheduleOfMinimumFutureAnnualPaymentsUnderNonCancellableLeasesAbstract" xlink:to="abvcd_ScheduleOfMinimumFutureAnnualPaymentsUnderNonCancellableLeasesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationsAbstract_lbl" xml:lang="en-US">Business Combinations [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_ScheduleOfAssetsAcquiredAndLiabilitiesAssumedBasedOnFairValueAbstract" xlink:href="abvcd-20210331.xsd#abvcd_ScheduleOfAssetsAcquiredAndLiabilitiesAssumedBasedOnFairValueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_ScheduleOfAssetsAcquiredAndLiabilitiesAssumedBasedOnFairValueAbstract_lbl" xml:lang="en-US">Schedule of assets acquired and liabilities assumed based on fair value [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ScheduleOfAssetsAcquiredAndLiabilitiesAssumedBasedOnFairValueAbstract" xlink:to="abvcd_ScheduleOfAssetsAcquiredAndLiabilitiesAssumedBasedOnFairValueAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Restricted cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableRelatedPartiesCurrent_lbl" xml:lang="en-US">Accounts receivable - related parties, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:to="us-gaap_AccountsReceivableRelatedPartiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueFromOtherRelatedPartiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromOtherRelatedPartiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DueFromOtherRelatedPartiesCurrent_lbl" xml:lang="en-US">Due from related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromOtherRelatedPartiesCurrent" xlink:to="us-gaap_DueFromOtherRelatedPartiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expense and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US">Goodwill, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermInvestments_lbl" xml:lang="en-US">Long-term investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermInvestments" xlink:to="us-gaap_LongTermInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xml:lang="en-US">Deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseNoncurrent_lbl" xml:lang="en-US">Prepaid expenses &#8211; noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseNoncurrent" xlink:to="us-gaap_PrepaidExpenseNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDeposit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US">Security deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermBankLoansAndNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable_lbl" xml:lang="en-US">Short-term bank loans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBankLoansAndNotesPayable" xlink:to="us-gaap_ShortTermBankLoansAndNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherShortTermBorrowings" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherShortTermBorrowings"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherShortTermBorrowings_lbl" xml:lang="en-US">Short-term loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherShortTermBorrowings" xlink:to="us-gaap_OtherShortTermBorrowings_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableToBankCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableToBankCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesPayableToBankCurrent_lbl" xml:lang="en-US">Notes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableToBankCurrent" xlink:to="us-gaap_NotesPayableToBankCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerAdvancesForConstruction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerAdvancesForConstruction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CustomerAdvancesForConstruction_lbl" xml:lang="en-US">Advance from customers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerAdvancesForConstruction" xlink:to="us-gaap_CustomerAdvancesForConstruction_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liabilities &#8211; current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl0" xml:lang="en-US">Operating lease liabilities (current)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xml:lang="en-US">Due to related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl0" xml:lang="en-US">Outstanding advance balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNotesPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNotesPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNotesPayableCurrent_lbl" xml:lang="en-US">Convertible notes payable - related parties, current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNotesPayableCurrent" xlink:to="us-gaap_OtherNotesPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LoansPayable_lbl" xml:lang="en-US">Paycheck Protection Program loan payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayable" xlink:to="us-gaap_LoansPayable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LoansPayable_lbl0" xml:lang="en-US">Outstanding loan balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayable" xlink:to="us-gaap_LoansPayable_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SecurityDepositLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDepositLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SecurityDepositLiability_lbl" xml:lang="en-US">Tenant security deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDepositLiability" xlink:to="us-gaap_SecurityDepositLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liability &#8211; noncurrent portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0" xml:lang="en-US">Operating lease liabilities (noncurrent)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleLongTermNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleLongTermNotesPayable_lbl" xml:lang="en-US">Convertible notes payable &#8211; noncurrent portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleLongTermNotesPayable" xlink:to="us-gaap_ConvertibleLongTermNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, $0.001 par value, 20,000,000 authorized, nil shares issued and outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.001 par value, 100,000,000 authorized, 24,420,526 and 24,420,526 shares issued and outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Common stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Common stock, authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinorityInterest_lbl" xml:lang="en-US">Noncontrolling interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterest" xlink:to="us-gaap_MinorityInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_lbl0" xml:lang="en-US">Net sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, general and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RentalIncomeNonoperating" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RentalIncomeNonoperating"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RentalIncomeNonoperating_lbl" xml:lang="en-US">Rental income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RentalIncomeNonoperating" xlink:to="us-gaap_RentalIncomeNonoperating_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_RentalIncomeRelatedParties" xlink:href="abvcd-20210331.xsd#abvcd_RentalIncomeRelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_RentalIncomeRelatedParties_lbl" xml:lang="en-US">Rental income &#8211; related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_RentalIncomeRelatedParties" xlink:to="abvcd_RentalIncomeRelatedParties_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US">Gain/Loss on foreign exchange changes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedGainLoss_lbl" xml:lang="en-US">Gain/Loss on investment in equity securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:to="us-gaap_EquitySecuritiesFvNiRealizedGainLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other income (expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_GovernmentGrantIncome" xlink:href="abvcd-20210331.xsd#abvcd_GovernmentGrantIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_GovernmentGrantIncome_lbl" xml:lang="en-US">Government grant income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_GovernmentGrantIncome" xlink:to="abvcd_GovernmentGrantIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Provision for income tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_lbl" xml:lang="en-US">Net loss attributable to noncontrolling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:to="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US">Foreign currency translation adjustment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xml:lang="en-US">Net loss per share:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl0" xml:lang="en-US">Loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Basic and diluted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_lbl" xml:lang="en-US">Weighted average number of common shares outstanding:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Basic and diluted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl0" xml:lang="en-US">Weighted-average shares outstanding - Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl1" xml:lang="en-US">Weighted-average shares outstanding - Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_lbl0" xml:lang="en-US">Depreciation expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Stock based compensation for nonemployees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xml:lang="en-US">Increase (decrease) in accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xml:lang="en-US">Increase (decrease) in accrued expenses and other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl" xml:lang="en-US">Increase (decrease) in due to related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Issuance of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_NetProceedsFromShortTermBorrowingsFromThirdParties" xlink:href="abvcd-20210331.xsd#abvcd_NetProceedsFromShortTermBorrowingsFromThirdParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_NetProceedsFromShortTermBorrowingsFromThirdParties_lbl" xml:lang="en-US">Proceeds from short-term borrowing from third parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_NetProceedsFromShortTermBorrowingsFromThirdParties" xlink:to="abvcd_NetProceedsFromShortTermBorrowingsFromThirdParties_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_lbl" xml:lang="en-US">Proceeds from long-term loans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xml:lang="en-US">Borrowings from related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents and restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xml:lang="en-US">Cash and cash equivalents and restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure of cash flows</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_CashPaidDuringTheYearForAbstract" xlink:href="abvcd-20210331.xsd#abvcd_CashPaidDuringTheYearForAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_CashPaidDuringTheYearForAbstract_lbl" xml:lang="en-US">Cash paid during the year for:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_CashPaidDuringTheYearForAbstract" xlink:to="abvcd_CashPaidDuringTheYearForAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest expense paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US">Income taxes paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of common shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of common shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0" xml:lang="en-US">Issuance of common shares, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1" xml:lang="en-US">Common stock issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US">Stock based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_CumulativeTransactionAdjustments" xlink:href="abvcd-20210331.xsd#abvcd_CumulativeTransactionAdjustments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_CumulativeTransactionAdjustments_lbl" xml:lang="en-US">Cumulative transaction adjustments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_CumulativeTransactionAdjustments" xlink:to="abvcd_CumulativeTransactionAdjustments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteSubscriptionsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockholdersEquityNoteSubscriptionsReceivable_lbl" xml:lang="en-US">Stock subscription receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:to="us-gaap_StockholdersEquityNoteSubscriptionsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_TreasuryStockValue_lbl" xml:lang="en-US">Treasury stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpense_lbl0" xml:lang="en-US">Interest expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrealizedGainLossOnInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xml:lang="en-US">Gain/Loss on investment in equity securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnInvestments" xlink:to="us-gaap_UnrealizedGainLossOnInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_IncreaseDecreaseInGovernmentGrantIncome" xlink:href="abvcd-20210331.xsd#abvcd_IncreaseDecreaseInGovernmentGrantIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="abvcd_IncreaseDecreaseInGovernmentGrantIncome_lbl" xml:lang="en-US">Government grant income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_IncreaseDecreaseInGovernmentGrantIncome" xlink:to="abvcd_IncreaseDecreaseInGovernmentGrantIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xml:lang="en-US">Other non-cash income and expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Decrease (increase) in accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets_lbl" xml:lang="en-US">Decrease (increase) in prepaid expenses and deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseDueFromOtherRelatedParties" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseDueFromOtherRelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseDueFromOtherRelatedParties_lbl" xml:lang="en-US">Decrease (increase) in due from related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseDueFromOtherRelatedParties" xlink:to="us-gaap_IncreaseDecreaseDueFromOtherRelatedParties_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireOtherInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireOtherInvestments_lbl" xml:lang="en-US">Prepayment for equity investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireOtherInvestments" xlink:to="us-gaap_PaymentsToAcquireOtherInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Repayment of convertible notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xml:lang="en-US">Repayment of long-term bank loans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermDebt" xlink:to="us-gaap_RepaymentsOfLongTermDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_StockSubscriptionReceivableMember" xlink:href="abvcd-20210331.xsd#abvcd_StockSubscriptionReceivableMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_StockSubscriptionReceivableMember_lbl" xml:lang="en-US">Stock Subscription Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_StockSubscriptionReceivableMember" xlink:to="abvcd_StockSubscriptionReceivableMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomeMember_lbl" xml:lang="en-US">Comprehensive Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeMember" xlink:to="us-gaap_ComprehensiveIncomeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TreasuryStockMember_lbl" xml:lang="en-US">Treasury Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockMember" xlink:to="us-gaap_TreasuryStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xml:lang="en-US">Non controlling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestMember" xlink:to="us-gaap_NoncontrollingInterestMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">ORGANIZATION AND DESCRIPTION OF BUSINESS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:href="abvcd-20210331.xsd#abvcd_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl" xml:lang="en-US">Schedule of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:to="abvcd_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xml:lang="en-US">Estimated Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US">COLLABORATIVE AGREEMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">INVENTORY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US">Finished goods</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcess" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xml:lang="en-US">Work-in-process</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryRawMaterials_lbl" xml:lang="en-US">Raw materials</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_AllowanceForInventoryValuationAndObsolescenceLoss" xlink:href="abvcd-20210331.xsd#abvcd_AllowanceForInventoryValuationAndObsolescenceLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_AllowanceForInventoryValuationAndObsolescenceLoss_lbl" xml:lang="en-US">Allowance for inventory valuation and obsolescence loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_AllowanceForInventoryValuationAndObsolescenceLoss" xlink:to="abvcd_AllowanceForInventoryValuationAndObsolescenceLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property and equipment, gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_LongTermInvestmentTextBlock" xlink:href="abvcd-20210331.xsd#abvcd_LongTermInvestmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_LongTermInvestmentTextBlock_lbl" xml:lang="en-US">LONG-TERM INVESTMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_LongTermInvestmentTextBlock" xlink:to="abvcd_LongTermInvestmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_ScheduleOfOwnershipPercentagesOfInvesteeTableTextBlocks" xlink:href="abvcd-20210331.xsd#abvcd_ScheduleOfOwnershipPercentagesOfInvesteeTableTextBlocks"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_ScheduleOfOwnershipPercentagesOfInvesteeTableTextBlocks_lbl" xml:lang="en-US">Schedule of ownership percentages of investee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ScheduleOfOwnershipPercentagesOfInvesteeTableTextBlocks" xlink:to="abvcd_ScheduleOfOwnershipPercentagesOfInvesteeTableTextBlocks_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US">Ownership percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl0" xml:lang="en-US">Percentage of common shares issued and outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl0"/>
    <loc xlink:type="locator" xlink:label="abvcd_AccountingTreatmentDescription" xlink:href="abvcd-20210331.xsd#abvcd_AccountingTreatmentDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_AccountingTreatmentDescription_lbl" xml:lang="en-US">Accounting treatments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_AccountingTreatmentDescription" xlink:to="abvcd_AccountingTreatmentDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_ScheduleOfExtentInvesteeReliesTableTextBlock" xlink:href="abvcd-20210331.xsd#abvcd_ScheduleOfExtentInvesteeReliesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_ScheduleOfExtentInvesteeReliesTableTextBlock_lbl" xml:lang="en-US">Schedule of extent the investee relies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ScheduleOfExtentInvesteeReliesTableTextBlock" xlink:to="abvcd_ScheduleOfExtentInvesteeReliesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_RelatedPartyTransactionDescriptionOfTransactions" xlink:href="abvcd-20210331.xsd#abvcd_RelatedPartyTransactionDescriptionOfTransactions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_RelatedPartyTransactionDescriptionOfTransactions_lbl" xml:lang="en-US">Relationship with the Company and its subsidiaries, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_RelatedPartyTransactionDescriptionOfTransactions" xlink:to="abvcd_RelatedPartyTransactionDescriptionOfTransactions_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_ScheduleOfLongTermInvestmentTableTextBlock" xlink:href="abvcd-20210331.xsd#abvcd_ScheduleOfLongTermInvestmentTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_ScheduleOfLongTermInvestmentTableTextBlock_lbl" xml:lang="en-US">Schedule of long-term investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ScheduleOfLongTermInvestmentTableTextBlock" xlink:to="abvcd_ScheduleOfLongTermInvestmentTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_NonMarketableCostMethodInvestmentsNetAbstract" xlink:href="abvcd-20210331.xsd#abvcd_NonMarketableCostMethodInvestmentsNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_NonMarketableCostMethodInvestmentsNetAbstract_lbl" xml:lang="en-US">Non-marketable Cost Method Investments, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_NonMarketableCostMethodInvestmentsNetAbstract" xlink:to="abvcd_NonMarketableCostMethodInvestmentsNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_NonmarketableCostMethodInvestmentsNet" xlink:href="abvcd-20210331.xsd#abvcd_NonmarketableCostMethodInvestmentsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_NonmarketableCostMethodInvestmentsNet_lbl" xml:lang="en-US">Sub total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_NonmarketableCostMethodInvestmentsNet" xlink:to="abvcd_NonmarketableCostMethodInvestmentsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_EquityMethodInvestmentsNetAbstract" xlink:href="abvcd-20210331.xsd#abvcd_EquityMethodInvestmentsNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_EquityMethodInvestmentsNetAbstract_lbl" xml:lang="en-US">Equity Method Investments, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_EquityMethodInvestmentsNetAbstract" xlink:to="abvcd_EquityMethodInvestmentsNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestments_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestments" xlink:to="us-gaap_EquityMethodInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfCondensedBalanceSheetTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock_lbl" xml:lang="en-US">Schedule of balance sheets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:to="srt_ScheduleOfCondensedBalanceSheetTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">Non-current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Non-current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedIncomeStatementTableTextBlock" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfCondensedIncomeStatementTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScheduleOfCondensedIncomeStatementTableTextBlock_lbl" xml:lang="en-US">Schedule of statements of operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedIncomeStatementTableTextBlock" xlink:to="srt_ScheduleOfCondensedIncomeStatementTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_LongTermInvestmentNetLoss" xlink:href="abvcd-20210331.xsd#abvcd_LongTermInvestmentNetLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_LongTermInvestmentNetLoss_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_LongTermInvestmentNetLoss" xlink:to="abvcd_LongTermInvestmentNetLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainLossOnInvestments_lbl" xml:lang="en-US">Share of losses from investments accounted for using the equity method</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnInvestments" xlink:to="us-gaap_GainLossOnInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentsTextBlock_lbl" xml:lang="en-US">Schedule of equity investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsTextBlock" xlink:to="us-gaap_EquityMethodInvestmentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_ShareOfEquityMethodInvesteeLosses" xlink:href="abvcd-20210331.xsd#abvcd_ShareOfEquityMethodInvesteeLosses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_ShareOfEquityMethodInvesteeLosses_lbl" xml:lang="en-US">Share of equity method investee losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ShareOfEquityMethodInvesteeLosses" xlink:to="abvcd_ShareOfEquityMethodInvesteeLosses_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_ConvertibleNotesPayableDisclosureTextBlock" xlink:href="abvcd-20210331.xsd#abvcd_ConvertibleNotesPayableDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_ConvertibleNotesPayableDisclosureTextBlock_lbl" xml:lang="en-US">CONVERTIBLE NOTES PAYABLE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ConvertibleNotesPayableDisclosureTextBlock" xlink:to="abvcd_ConvertibleNotesPayableDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_BankLoansAbstract" xlink:href="abvcd-20210331.xsd#abvcd_BankLoansAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_BankLoansAbstract_lbl" xml:lang="en-US">BANK LOANS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_BankLoansAbstract" xlink:to="abvcd_BankLoansAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShortTermDebtTextBlock_lbl" xml:lang="en-US">Schedule of short-term bank loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:to="us-gaap_ScheduleOfShortTermDebtTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowings" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermBorrowings"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermBorrowings_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowings" xlink:to="us-gaap_ShortTermBorrowings_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_PaycheckProtectionProgramLoanPayableTextBlock" xlink:href="abvcd-20210331.xsd#abvcd_PaycheckProtectionProgramLoanPayableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_PaycheckProtectionProgramLoanPayableTextBlock_lbl" xml:lang="en-US">PAYCHECK PROTECTION PROGRAM LOAN PAYABLE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_PaycheckProtectionProgramLoanPayableTextBlock" xlink:to="abvcd_PaycheckProtectionProgramLoanPayableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MembersEquityNotesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MembersEquityNotesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MembersEquityNotesDisclosureTextBlock_lbl" xml:lang="en-US">NOTES PAYABLE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MembersEquityNotesDisclosureTextBlock" xlink:to="us-gaap_MembersEquityNotesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermDebtTextBlock_lbl" xml:lang="en-US">SHORT-TERM LOAN</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTextBlock" xlink:to="us-gaap_ShortTermDebtTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTIES TRANSACTIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xml:lang="en-US">Schedule of related party transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_ScheduleOfAccountReceivableDueFromRelatedPartiesTableTextBlock" xlink:href="abvcd-20210331.xsd#abvcd_ScheduleOfAccountReceivableDueFromRelatedPartiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_ScheduleOfAccountReceivableDueFromRelatedPartiesTableTextBlock_lbl" xml:lang="en-US">Schedule of amount due to related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ScheduleOfAccountReceivableDueFromRelatedPartiesTableTextBlock" xlink:to="abvcd_ScheduleOfAccountReceivableDueFromRelatedPartiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableRelatedParties" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableRelatedParties_lbl" xml:lang="en-US">Accounts receivable due from related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableRelatedParties" xlink:to="us-gaap_AccountsReceivableRelatedParties_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl" xml:lang="en-US">Schedule of amount due from related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueFromRelatedPartiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DueFromRelatedPartiesCurrent_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromRelatedPartiesCurrent" xlink:to="us-gaap_DueFromRelatedPartiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_ScheduleOfRelatedPartyTransactionsAmountDueToRelatedParty" xlink:href="abvcd-20210331.xsd#abvcd_ScheduleOfRelatedPartyTransactionsAmountDueToRelatedParty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_ScheduleOfRelatedPartyTransactionsAmountDueToRelatedParty_lbl" xml:lang="en-US">Schedule of amount due to related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ScheduleOfRelatedPartyTransactionsAmountDueToRelatedParty" xlink:to="abvcd_ScheduleOfRelatedPartyTransactionsAmountDueToRelatedParty_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_lbl0" xml:lang="en-US">Due to related parties (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDebtConversionsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtConversionsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDebtConversionsTextBlock_lbl" xml:lang="en-US">Schedule of converted amount of debt and shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtConversionsTextBlock" xlink:to="us-gaap_ScheduleOfDebtConversionsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US">Amount of Debt Converted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl0" xml:lang="en-US">Due to related parties consideration (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US">Number of Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_StockOptionsTextBlock" xlink:href="abvcd-20210331.xsd#abvcd_StockOptionsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_StockOptionsTextBlock_lbl" xml:lang="en-US">STOCK OPTIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_StockOptionsTextBlock" xlink:to="abvcd_StockOptionsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of options issued and outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of Underlying Shares, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl0" xml:lang="en-US">Stock options aggregate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-Average Exercise Price Per Share, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm" xlink:href="abvcd-20210331.xsd#abvcd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Weighted-Average Contractual Life Remaining in Years, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm" xlink:to="abvcd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue" xlink:href="abvcd-20210331.xsd#abvcd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue" xlink:to="abvcd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of Underlying Shares, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-Average Exercise Price Per Share, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted-Average Contractual Life Remaining in Years, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of Underlying Shares, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-Average Exercise Price Per Share, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted-Average Contractual Life Remaining in Years, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Number of Underlying Shares, Vested and expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-Average Exercise Price Per Share, Vested and expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted-Average Contractual Life Remaining in Years, Vested and expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Vested and expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of fair value of stock options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term (in years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">LOSS PER SHARE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_NumeratorAbstract" xlink:href="abvcd-20210331.xsd#abvcd_NumeratorAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_NumeratorAbstract_lbl" xml:lang="en-US">Numerator:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_NumeratorAbstract" xlink:to="abvcd_NumeratorAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_NetLoss" xlink:href="abvcd-20210331.xsd#abvcd_NetLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_NetLoss_lbl" xml:lang="en-US">Net loss attributable to ABVC&#8217;s common stockholders (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_NetLoss" xlink:to="abvcd_NetLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_DenominatorAbstract" xlink:href="abvcd-20210331.xsd#abvcd_DenominatorAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_DenominatorAbstract_lbl" xml:lang="en-US">Denominator:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_DenominatorAbstract" xlink:to="abvcd_DenominatorAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">Weighted-average shares outstanding:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_StockOptions" xlink:href="abvcd-20210331.xsd#abvcd_StockOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_StockOptions_lbl" xml:lang="en-US">Stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_StockOptions" xlink:to="abvcd_StockOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">-Basic (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">-Diluted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_lbl" xml:lang="en-US">LEASE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:to="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_ScheduleOfOperatingLeaseArrangementsTableTextBlock" xlink:href="abvcd-20210331.xsd#abvcd_ScheduleOfOperatingLeaseArrangementsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_ScheduleOfOperatingLeaseArrangementsTableTextBlock_lbl" xml:lang="en-US">Schedule of operating lease arrangements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ScheduleOfOperatingLeaseArrangementsTableTextBlock" xlink:to="abvcd_ScheduleOfOperatingLeaseArrangementsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xml:lang="en-US">LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl" xml:lang="en-US">Schedule of supplemental information related to operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating lease expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLeaseIncomeLeasePayments_lbl" xml:lang="en-US">Cash paid for amounts included in the measurement of operating lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:to="us-gaap_OperatingLeaseLeaseIncomeLeasePayments_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_WeightedAverageRemainingLeaseTermAbstract" xlink:href="abvcd-20210331.xsd#abvcd_WeightedAverageRemainingLeaseTermAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_WeightedAverageRemainingLeaseTermAbstract_lbl" xml:lang="en-US">Weighted Average Remaining Lease Term:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_WeightedAverageRemainingLeaseTermAbstract" xlink:to="abvcd_WeightedAverageRemainingLeaseTermAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_WeightedAverageDiscountRateAbstract" xlink:href="abvcd-20210331.xsd#abvcd_WeightedAverageDiscountRateAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_WeightedAverageDiscountRateAbstract_lbl" xml:lang="en-US">Weighted Average Discount Rate:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_WeightedAverageDiscountRateAbstract" xlink:to="abvcd_WeightedAverageDiscountRateAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US">Schedule of minimum future annual payments under non-cancellable leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US">2021(excluding three months ended March 31, 2021)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US">2022</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US">2023</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xml:lang="en-US">2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xml:lang="en-US">2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" xml:lang="en-US">Thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US">Total future minimum lease payments, undiscounted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPortionOfMinimumLeasePaymentsSaleLeasebackTransactions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPortionOfMinimumLeasePaymentsSaleLeasebackTransactions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPortionOfMinimumLeasePaymentsSaleLeasebackTransactions_lbl" xml:lang="en-US">Less: Imputed interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPortionOfMinimumLeasePaymentsSaleLeasebackTransactions" xlink:to="us-gaap_InterestPortionOfMinimumLeasePaymentsSaleLeasebackTransactions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PresentValueOfFutureMinimumLeasePaymentsSaleLeasebackTransactions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PresentValueOfFutureMinimumLeasePaymentsSaleLeasebackTransactions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PresentValueOfFutureMinimumLeasePaymentsSaleLeasebackTransactions_lbl" xml:lang="en-US">Present value of future minimum lease payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PresentValueOfFutureMinimumLeasePaymentsSaleLeasebackTransactions" xlink:to="us-gaap_PresentValueOfFutureMinimumLeasePaymentsSaleLeasebackTransactions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xml:lang="en-US">BUSINESS COMBINATION</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xml:lang="en-US">Schedule of assets acquired and liabilities assumed based on fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_PurchaseConsiderationAbstract" xlink:href="abvcd-20210331.xsd#abvcd_PurchaseConsiderationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_PurchaseConsiderationAbstract_lbl" xml:lang="en-US">Purchase consideration:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_PurchaseConsiderationAbstract" xlink:to="abvcd_PurchaseConsiderationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredOther1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredOther1_lbl" xml:lang="en-US">Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredOther1_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_AllocationOfThePurchasePriceAbstract" xlink:href="abvcd-20210331.xsd#abvcd_AllocationOfThePurchasePriceAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_AllocationOfThePurchasePriceAbstract_lbl" xml:lang="en-US">Allocation of the purchase price:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_AllocationOfThePurchasePriceAbstract" xlink:to="abvcd_AllocationOfThePurchasePriceAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_lbl" xml:lang="en-US">Accounts receivable, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:href="abvcd-20210331.xsd#abvcd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Operating lease right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:to="abvcd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_lbl" xml:lang="en-US">Security deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl" xml:lang="en-US">Total assets acquired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability" xlink:href="abvcd-20210331.xsd#abvcd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability" xlink:to="abvcd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" xml:lang="en-US">Total net assets acquired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_lbl" xml:lang="en-US">Goodwill as a result of the Merger</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: accumulated depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_lbl" xml:lang="en-US">Tenant security deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_lbl" xml:lang="en-US">Total liabilities assumed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_BuildingsAndLeaseholdImprovementsMember" xlink:href="abvcd-20210331.xsd#abvcd_BuildingsAndLeaseholdImprovementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_BuildingsAndLeaseholdImprovementsMember_lbl" xml:lang="en-US">Buildings and leasehold improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_BuildingsAndLeaseholdImprovementsMember" xlink:to="abvcd_BuildingsAndLeaseholdImprovementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl" xml:lang="en-US">Machinery and equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_MachineryAndEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US">Office equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LandMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LandMember_lbl" xml:lang="en-US">Land [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandMember" xlink:to="us-gaap_LandMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_BraingenesisBiotechnologyCoLtdMember" xlink:href="abvcd-20210331.xsd#abvcd_BraingenesisBiotechnologyCoLtdMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_BraingenesisBiotechnologyCoLtdMember_lbl" xml:lang="en-US">Braingenesis Biotechnology Co., Ltd. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_BraingenesisBiotechnologyCoLtdMember" xlink:to="abvcd_BraingenesisBiotechnologyCoLtdMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_GenepharmBiotechCorporationMember" xlink:href="abvcd-20210331.xsd#abvcd_GenepharmBiotechCorporationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_GenepharmBiotechCorporationMember_lbl" xml:lang="en-US">Genepharm Biotech Corporation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_GenepharmBiotechCorporationMember" xlink:to="abvcd_GenepharmBiotechCorporationMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_BioHopeKingCorporationMember" xlink:href="abvcd-20210331.xsd#abvcd_BioHopeKingCorporationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_BioHopeKingCorporationMember_lbl" xml:lang="en-US">BioHopeKing Corporation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_BioHopeKingCorporationMember" xlink:to="abvcd_BioHopeKingCorporationMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_BioFirstCorporationMember" xlink:href="abvcd-20210331.xsd#abvcd_BioFirstCorporationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_BioFirstCorporationMember_lbl" xml:lang="en-US">BioFirst Corporation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_BioFirstCorporationMember" xlink:to="abvcd_BioFirstCorporationMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="abvcd_BioFirstCorporationMember_lbl0" xml:lang="en-US">BioFirst [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_BioFirstCorporationMember" xlink:to="abvcd_BioFirstCorporationMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="abvcd_RgeneCorporationMember" xlink:href="abvcd-20210331.xsd#abvcd_RgeneCorporationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_RgeneCorporationMember_lbl" xml:lang="en-US">Rgene Corporation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_RgeneCorporationMember" xlink:to="abvcd_RgeneCorporationMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="abvcd_RgeneCorporationMember_lbl0" xml:lang="en-US">Rgene [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_RgeneCorporationMember" xlink:to="abvcd_RgeneCorporationMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="abvcd_BioFirstMember" xlink:href="abvcd-20210331.xsd#abvcd_BioFirstMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_BioFirstMember_lbl" xml:lang="en-US">BioFirst [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_BioFirstMember" xlink:to="abvcd_BioFirstMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_RgeneMember" xlink:href="abvcd-20210331.xsd#abvcd_RgeneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_RgeneMember_lbl" xml:lang="en-US">Rgene [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_RgeneMember" xlink:to="abvcd_RgeneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_CathayUnitedBankMember" xlink:href="abvcd-20210331.xsd#abvcd_CathayUnitedBankMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_CathayUnitedBankMember_lbl" xml:lang="en-US">Cathay United Bank [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_CathayUnitedBankMember" xlink:to="abvcd_CathayUnitedBankMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_CTBCBankMember" xlink:href="abvcd-20210331.xsd#abvcd_CTBCBankMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_CTBCBankMember_lbl" xml:lang="en-US">CTBC Bank [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_CTBCBankMember" xlink:to="abvcd_CTBCBankMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_CathayBnakMember" xlink:href="abvcd-20210331.xsd#abvcd_CathayBnakMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_CathayBnakMember_lbl" xml:lang="en-US">Cathay Bnak [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_CathayBnakMember" xlink:to="abvcd_CathayBnakMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="abvcd_CathayBnakMember_lbl0" xml:lang="en-US">Cathay Bank [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_CathayBnakMember" xlink:to="abvcd_CathayBnakMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="abvcd_BioFirstCorporationtheBioFirstMember" xlink:href="abvcd-20210331.xsd#abvcd_BioFirstCorporationtheBioFirstMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_BioFirstCorporationtheBioFirstMember_lbl" xml:lang="en-US">BioFirst Corporation (the &quot;BioFirst&quot;) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_BioFirstCorporationtheBioFirstMember" xlink:to="abvcd_BioFirstCorporationtheBioFirstMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember" xlink:href="abvcd-20210331.xsd#abvcd_BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember_lbl" xml:lang="en-US">BioFirst (Australia) Pty Ltd. (the &#8220;BioFirst (Australia)&#8221;) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember" xlink:to="abvcd_BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_RgeneCorporationtheRgeneMember" xlink:href="abvcd-20210331.xsd#abvcd_RgeneCorporationtheRgeneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_RgeneCorporationtheRgeneMember_lbl" xml:lang="en-US">Rgene Corporation (the &#8220;Rgene&#8221;) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_RgeneCorporationtheRgeneMember" xlink:to="abvcd_RgeneCorporationtheRgeneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_YuanGeneCorporationtheYuanGeneMember" xlink:href="abvcd-20210331.xsd#abvcd_YuanGeneCorporationtheYuanGeneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_YuanGeneCorporationtheYuanGeneMember_lbl" xml:lang="en-US">YuanGene Corporation (the &#8220;YuanGene&#8221;) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_YuanGeneCorporationtheYuanGeneMember" xlink:to="abvcd_YuanGeneCorporationtheYuanGeneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_AsiaGeneCorporationtheAsiaGeneMember" xlink:href="abvcd-20210331.xsd#abvcd_AsiaGeneCorporationtheAsiaGeneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_AsiaGeneCorporationtheAsiaGeneMember_lbl" xml:lang="en-US">AsiaGene Corporation (the &#8220;AsiaGene&#8221;)	[Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_AsiaGeneCorporationtheAsiaGeneMember" xlink:to="abvcd_AsiaGeneCorporationtheAsiaGeneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_EugeneJiangMember" xlink:href="abvcd-20210331.xsd#abvcd_EugeneJiangMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_EugeneJiangMember_lbl" xml:lang="en-US">Eugene Jiang [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_EugeneJiangMember" xlink:to="abvcd_EugeneJiangMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_KeypointTechnologyLtdtheKeypointMember" xlink:href="abvcd-20210331.xsd#abvcd_KeypointTechnologyLtdtheKeypointMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_KeypointTechnologyLtdtheKeypointMember_lbl" xml:lang="en-US">Keypoint Technology Ltd. (the &#8220;Keypoint&#8217;) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_KeypointTechnologyLtdtheKeypointMember" xlink:to="abvcd_KeypointTechnologyLtdtheKeypointMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_LionArtsPromotionInctheLionArtsMember" xlink:href="abvcd-20210331.xsd#abvcd_LionArtsPromotionInctheLionArtsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_LionArtsPromotionInctheLionArtsMember_lbl" xml:lang="en-US">Lion Arts Promotion Inc. (the &#8220;Lion Arts&#8221;) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_LionArtsPromotionInctheLionArtsMember" xlink:to="abvcd_LionArtsPromotionInctheLionArtsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_YoshinobuOdairatheOdairaMember" xlink:href="abvcd-20210331.xsd#abvcd_YoshinobuOdairatheOdairaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_YoshinobuOdairatheOdairaMember_lbl" xml:lang="en-US">Yoshinobu Odaira (the &#8220;Odaira&#8221;) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_YoshinobuOdairatheOdairaMember" xlink:to="abvcd_YoshinobuOdairatheOdairaMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_GenePharmInctheGenePharmMember" xlink:href="abvcd-20210331.xsd#abvcd_GenePharmInctheGenePharmMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_GenePharmInctheGenePharmMember_lbl" xml:lang="en-US">GenePharm Inc. (the &#8220;GenePharm&#8221;) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_GenePharmInctheGenePharmMember" xlink:to="abvcd_GenePharmInctheGenePharmMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_EuroAsiaInvestmentFinanceCorpLtdtheEuroAsiaMember" xlink:href="abvcd-20210331.xsd#abvcd_EuroAsiaInvestmentFinanceCorpLtdtheEuroAsiaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_EuroAsiaInvestmentFinanceCorpLtdtheEuroAsiaMember_lbl" xml:lang="en-US">Euro-Asia Investment &amp; Finance Corp Ltd. (the &#8220;Euro-Asia&#8221;)	[Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_EuroAsiaInvestmentFinanceCorpLtdtheEuroAsiaMember" xlink:to="abvcd_EuroAsiaInvestmentFinanceCorpLtdtheEuroAsiaMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_LBGUSAInctheLBGUSAMember" xlink:href="abvcd-20210331.xsd#abvcd_LBGUSAInctheLBGUSAMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_LBGUSAInctheLBGUSAMember_lbl" xml:lang="en-US">LBG USA, Inc. (the &#8220;LBG USA&#8221;) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_LBGUSAInctheLBGUSAMember" xlink:to="abvcd_LBGUSAInctheLBGUSAMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_LionGeneCorporationtheLionGeneMember" xlink:href="abvcd-20210331.xsd#abvcd_LionGeneCorporationtheLionGeneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_LionGeneCorporationtheLionGeneMember_lbl" xml:lang="en-US">LionGene Corporation (the &#8220;LionGene&#8221;)	[Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_LionGeneCorporationtheLionGeneMember" xlink:to="abvcd_LionGeneCorporationtheLionGeneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_KimhoConsultantsCoLtdtheKimhoMember" xlink:href="abvcd-20210331.xsd#abvcd_KimhoConsultantsCoLtdtheKimhoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_KimhoConsultantsCoLtdtheKimhoMember_lbl" xml:lang="en-US">Kimho Consultants Co., Ltd. (the &#8220;Kimho&#8221;) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_KimhoConsultantsCoLtdtheKimhoMember" xlink:to="abvcd_KimhoConsultantsCoLtdtheKimhoMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_MrTsungShannJiangMsShuLingJiangMrChangJenJiangMsMeiLingJiangAndMrEugeneJiangcollectivelyTheJiangsMember" xlink:href="abvcd-20210331.xsd#abvcd_MrTsungShannJiangMsShuLingJiangMrChangJenJiangMsMeiLingJiangAndMrEugeneJiangcollectivelyTheJiangsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_MrTsungShannJiangMsShuLingJiangMrChangJenJiangMsMeiLingJiangAndMrEugeneJiangcollectivelyTheJiangsMember_lbl" xml:lang="en-US">Mr. Tsung-Shann Jiang, Ms. Shu-Ling Jiang, Mr. Chang-Jen Jiang, Ms. Mei-Ling Jiang, and Mr. Eugene Jiang (collectively the &quot;Jiangs&quot;) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_MrTsungShannJiangMsShuLingJiangMrChangJenJiangMsMeiLingJiangAndMrEugeneJiangcollectivelyTheJiangsMember" xlink:to="abvcd_MrTsungShannJiangMsShuLingJiangMrChangJenJiangMsMeiLingJiangAndMrEugeneJiangcollectivelyTheJiangsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_AmkeyVenturesLLCAmkeyMember" xlink:href="abvcd-20210331.xsd#abvcd_AmkeyVenturesLLCAmkeyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_AmkeyVenturesLLCAmkeyMember_lbl" xml:lang="en-US">Amkey Ventures, LLC (&#8220;Amkey&#8221;) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_AmkeyVenturesLLCAmkeyMember" xlink:to="abvcd_AmkeyVenturesLLCAmkeyMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_BioLiteJapanMember" xlink:href="abvcd-20210331.xsd#abvcd_BioLiteJapanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_BioLiteJapanMember_lbl" xml:lang="en-US">BioLite Japan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_BioLiteJapanMember" xlink:to="abvcd_BioLiteJapanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_GenePharmIncMember" xlink:href="abvcd-20210331.xsd#abvcd_GenePharmIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_GenePharmIncMember_lbl" xml:lang="en-US">GenePharm Inc. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_GenePharmIncMember" xlink:to="abvcd_GenePharmIncMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_AmkeyMember" xlink:href="abvcd-20210331.xsd#abvcd_AmkeyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_AmkeyMember_lbl" xml:lang="en-US">Amkey [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_AmkeyMember" xlink:to="abvcd_AmkeyMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_AsiaGeneMember" xlink:href="abvcd-20210331.xsd#abvcd_AsiaGeneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_AsiaGeneMember_lbl" xml:lang="en-US">AsiaGene [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_AsiaGeneMember" xlink:to="abvcd_AsiaGeneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_BioFirstAustraliaMember" xlink:href="abvcd-20210331.xsd#abvcd_BioFirstAustraliaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_BioFirstAustraliaMember_lbl" xml:lang="en-US">BioFirst (Australia) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_BioFirstAustraliaMember" xlink:to="abvcd_BioFirstAustraliaMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_LBGUSAMember" xlink:href="abvcd-20210331.xsd#abvcd_LBGUSAMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_LBGUSAMember_lbl" xml:lang="en-US">LBG USA [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_LBGUSAMember" xlink:to="abvcd_LBGUSAMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_KeypointMember" xlink:href="abvcd-20210331.xsd#abvcd_KeypointMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_KeypointMember_lbl" xml:lang="en-US">Keypoint [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_KeypointMember" xlink:to="abvcd_KeypointMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_TheJiangsMember" xlink:href="abvcd-20210331.xsd#abvcd_TheJiangsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_TheJiangsMember_lbl" xml:lang="en-US">The Jiangs [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_TheJiangsMember" xlink:to="abvcd_TheJiangsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_YuanGeneMember" xlink:href="abvcd-20210331.xsd#abvcd_YuanGeneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_YuanGeneMember_lbl" xml:lang="en-US">YuanGene [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_YuanGeneMember" xlink:to="abvcd_YuanGeneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_DueToshareholdersMember" xlink:href="abvcd-20210331.xsd#abvcd_DueToshareholdersMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_DueToshareholdersMember_lbl" xml:lang="en-US">Due to shareholders [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_DueToshareholdersMember" xlink:to="abvcd_DueToshareholdersMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_DueToEmployeesMember" xlink:href="abvcd-20210331.xsd#abvcd_DueToEmployeesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_DueToEmployeesMember_lbl" xml:lang="en-US">Due to employees [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_DueToEmployeesMember" xlink:to="abvcd_DueToEmployeesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_LionArtsPromotionInctheLIONMember" xlink:href="abvcd-20210331.xsd#abvcd_LionArtsPromotionInctheLIONMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_LionArtsPromotionInctheLIONMember_lbl" xml:lang="en-US">Lion Arts Promotion Inc [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_LionArtsPromotionInctheLIONMember" xlink:to="abvcd_LionArtsPromotionInctheLIONMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_LionGeneCorporationMember" xlink:href="abvcd-20210331.xsd#abvcd_LionGeneCorporationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_LionGeneCorporationMember_lbl" xml:lang="en-US">LionGene Corporation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_LionGeneCorporationMember" xlink:to="abvcd_LionGeneCorporationMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_AsiangeneCorporationMember" xlink:href="abvcd-20210331.xsd#abvcd_AsiangeneCorporationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_AsiangeneCorporationMember_lbl" xml:lang="en-US">AsiaGene Corporation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_AsiangeneCorporationMember" xlink:to="abvcd_AsiangeneCorporationMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="abvcd_AsiangeneCorporationMember_lbl0" xml:lang="en-US">Asiangene Corporation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_AsiangeneCorporationMember" xlink:to="abvcd_AsiangeneCorporationMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="abvcd_YuangeneCorporationMember" xlink:href="abvcd-20210331.xsd#abvcd_YuangeneCorporationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_YuangeneCorporationMember_lbl" xml:lang="en-US">YuanGene Corporation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_YuangeneCorporationMember" xlink:to="abvcd_YuangeneCorporationMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Stock Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_TypeOfCurrencyAxis" xlink:href="abvcd-20210331.xsd#abvcd_TypeOfCurrencyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_TypeOfCurrencyAxis_lbl" xml:lang="en-US">Type Of Currency [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_TypeOfCurrencyAxis" xlink:to="abvcd_TypeOfCurrencyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_AgreemnetAxis" xlink:href="abvcd-20210331.xsd#abvcd_AgreemnetAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_AgreemnetAxis_lbl" xml:lang="en-US">Agreemnet [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_AgreemnetAxis" xlink:to="abvcd_AgreemnetAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_CommonStockIssuedAfterStockSplit" xlink:href="abvcd-20210331.xsd#abvcd_CommonStockIssuedAfterStockSplit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_CommonStockIssuedAfterStockSplit_lbl" xml:lang="en-US">Common stock issued post-stock split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_CommonStockIssuedAfterStockSplit" xlink:to="abvcd_CommonStockIssuedAfterStockSplit_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="abvcd_CommonStockIssuedAfterStockSplit_lbl0" xml:lang="en-US">Reverse stock split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_CommonStockIssuedAfterStockSplit" xlink:to="abvcd_CommonStockIssuedAfterStockSplit_lbl0"/>
    <loc xlink:type="locator" xlink:label="abvcd_CommonStockIssuedBeforeStockSplit" xlink:href="abvcd-20210331.xsd#abvcd_CommonStockIssuedBeforeStockSplit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_CommonStockIssuedBeforeStockSplit_lbl" xml:lang="en-US">Common stock issued pre-stock split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_CommonStockIssuedBeforeStockSplit" xlink:to="abvcd_CommonStockIssuedBeforeStockSplit_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_PercentageOfCommonSharesIssuedAndOutstanding" xlink:href="abvcd-20210331.xsd#abvcd_PercentageOfCommonSharesIssuedAndOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_PercentageOfCommonSharesIssuedAndOutstanding_lbl" xml:lang="en-US">Percentage of common shares issued and outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_PercentageOfCommonSharesIssuedAndOutstanding" xlink:to="abvcd_PercentageOfCommonSharesIssuedAndOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_PercentageOfIssuedShareCapital" xlink:href="abvcd-20210331.xsd#abvcd_PercentageOfIssuedShareCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_PercentageOfIssuedShareCapital_lbl" xml:lang="en-US">Percentage of issued share capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_PercentageOfIssuedShareCapital" xlink:to="abvcd_PercentageOfIssuedShareCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xml:lang="en-US">Restricted cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_MarketableSecuritiesRealizedGainLossOtherThanTemporaryImpairmentsAmounts" xlink:href="abvcd-20210331.xsd#abvcd_MarketableSecuritiesRealizedGainLossOtherThanTemporaryImpairmentsAmounts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_MarketableSecuritiesRealizedGainLossOtherThanTemporaryImpairmentsAmounts_lbl" xml:lang="en-US">Impairments of equity investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_MarketableSecuritiesRealizedGainLossOtherThanTemporaryImpairmentsAmounts" xlink:to="abvcd_MarketableSecuritiesRealizedGainLossOtherThanTemporaryImpairmentsAmounts_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_PercentageOfMonthlyContribution" xlink:href="abvcd-20210331.xsd#abvcd_PercentageOfMonthlyContribution"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_PercentageOfMonthlyContribution_lbl" xml:lang="en-US">Percentage of monthly contribution</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_PercentageOfMonthlyContribution" xlink:to="abvcd_PercentageOfMonthlyContribution_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash_lbl" xml:lang="en-US">Employee benefits amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xml:lang="en-US">Employee stock-based compensation expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_StockBasedCompensationForNonemployees" xlink:href="abvcd-20210331.xsd#abvcd_StockBasedCompensationForNonemployees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_StockBasedCompensationForNonemployees_lbl" xml:lang="en-US">Non-employee stock-based compensation expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_StockBasedCompensationForNonemployees" xlink:to="abvcd_StockBasedCompensationForNonemployees_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_MilestonePayments" xlink:href="abvcd-20210331.xsd#abvcd_MilestonePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_MilestonePayments_lbl" xml:lang="en-US">Milestone payments to BioLite in cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_MilestonePayments" xlink:to="abvcd_MilestonePayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement_lbl" xml:lang="en-US">Description of payment settlement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement" xlink:to="us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_UpfrontCashPayment" xlink:href="abvcd-20210331.xsd#abvcd_UpfrontCashPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_UpfrontCashPayment_lbl" xml:lang="en-US">Upfront cash payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_UpfrontCashPayment" xlink:to="abvcd_UpfrontCashPayment_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_PercentageOfPaymentsUnderCodevelopmentAgreement" xlink:href="abvcd-20210331.xsd#abvcd_PercentageOfPaymentsUnderCodevelopmentAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_PercentageOfPaymentsUnderCodevelopmentAgreement_lbl" xml:lang="en-US">Percentage of payments under co-development agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_PercentageOfPaymentsUnderCodevelopmentAgreement" xlink:to="abvcd_PercentageOfPaymentsUnderCodevelopmentAgreement_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_IssuanceOfStockValue" xlink:href="abvcd-20210331.xsd#abvcd_IssuanceOfStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_IssuanceOfStockValue_lbl" xml:lang="en-US">Common stock newly issued, value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_IssuanceOfStockValue" xlink:to="abvcd_IssuanceOfStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_MilestonePaymentsRoyaltyPercentage" xlink:href="abvcd-20210331.xsd#abvcd_MilestonePaymentsRoyaltyPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_MilestonePaymentsRoyaltyPercentage_lbl" xml:lang="en-US">Milestone payments royalty percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_MilestonePaymentsRoyaltyPercentage" xlink:to="abvcd_MilestonePaymentsRoyaltyPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_CollaborativeAgreementsDescription" xlink:href="abvcd-20210331.xsd#abvcd_CollaborativeAgreementsDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_CollaborativeAgreementsDescription_lbl" xml:lang="en-US">Collaborative agreements, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_CollaborativeAgreementsDescription" xlink:to="abvcd_CollaborativeAgreementsDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForParticipationLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForParticipationLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForParticipationLiabilities_lbl" xml:lang="en-US">Company cash payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForParticipationLiabilities" xlink:to="us-gaap_PaymentsForParticipationLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_AdditionCashPayment" xlink:href="abvcd-20210331.xsd#abvcd_AdditionCashPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_AdditionCashPayment_lbl" xml:lang="en-US">Addition cash payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_AdditionCashPayment" xlink:to="abvcd_AdditionCashPayment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Amount received from BriVision</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent" xlink:to="us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_CoDevAgreementDescription" xlink:href="abvcd-20210331.xsd#abvcd_CoDevAgreementDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_CoDevAgreementDescription_lbl" xml:lang="en-US">Co-Dev agreement, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_CoDevAgreementDescription" xlink:to="abvcd_CoDevAgreementDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US">Licensing rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Shares issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssued_lbl0" xml:lang="en-US">Shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_lbl" xml:lang="en-US">Percentage of common stock shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements_lbl" xml:lang="en-US">Purchase additional shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements" xlink:to="us-gaap_IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_AggregateAmount" xlink:href="abvcd-20210331.xsd#abvcd_AggregateAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_AggregateAmount_lbl" xml:lang="en-US">Aggregate amount (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_AggregateAmount" xlink:to="abvcd_AggregateAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockDescriptionOfTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockDescriptionOfTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockDescriptionOfTransaction_lbl" xml:lang="en-US">Sale of common stock, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockDescriptionOfTransaction" xlink:to="us-gaap_SaleOfStockDescriptionOfTransaction_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockDescriptionOfTransaction_lbl0" xml:lang="en-US">Equity offering, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockDescriptionOfTransaction" xlink:to="us-gaap_SaleOfStockDescriptionOfTransaction_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Principal amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl0" xml:lang="en-US">Principal amount (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireNotesReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireNotesReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsToAcquireNotesReceivable_lbl" xml:lang="en-US">Convertible promissory note received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireNotesReceivable" xlink:to="us-gaap_PaymentsToAcquireNotesReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xml:lang="en-US">Bears interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockDescription_lbl" xml:lang="en-US">Conversion price, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockDescription" xlink:to="us-gaap_ConversionOfStockDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebt_lbl" xml:lang="en-US">Convertible debenture</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebt" xlink:to="us-gaap_ConvertibleDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl" xml:lang="en-US">Accrued convertible interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl0" xml:lang="en-US">Accrued interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl0"/>
    <loc xlink:type="locator" xlink:label="abvcd_TotalInterestExpenses" xlink:href="abvcd-20210331.xsd#abvcd_TotalInterestExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_TotalInterestExpenses_lbl" xml:lang="en-US">Total interest expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_TotalInterestExpenses" xlink:to="abvcd_TotalInterestExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US">Maturity date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl0" xml:lang="en-US">Loan maturity date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US">Bears interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US">Debt instrument term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestAndDebtExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestAndDebtExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestAndDebtExpense_lbl" xml:lang="en-US">Interest expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndDebtExpense" xlink:to="us-gaap_InterestAndDebtExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_ReceivedLoanAmount" xlink:href="abvcd-20210331.xsd#abvcd_ReceivedLoanAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_ReceivedLoanAmount_lbl" xml:lang="en-US">Received loan amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ReceivedLoanAmount" xlink:to="abvcd_ReceivedLoanAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_RegularInterestRateDescription" xlink:href="abvcd-20210331.xsd#abvcd_RegularInterestRateDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_RegularInterestRateDescription_lbl" xml:lang="en-US">Regular interest rate, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_RegularInterestRateDescription" xlink:to="abvcd_RegularInterestRateDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_ExceedingAmount" xlink:href="abvcd-20210331.xsd#abvcd_ExceedingAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_ExceedingAmount_lbl" xml:lang="en-US">Exceeding amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ExceedingAmount" xlink:to="abvcd_ExceedingAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_PaycheckProtectionProgramDescription" xlink:href="abvcd-20210331.xsd#abvcd_PaycheckProtectionProgramDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_PaycheckProtectionProgramDescription_lbl" xml:lang="en-US">Paycheck protection program, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_PaycheckProtectionProgramDescription" xlink:to="abvcd_PaycheckProtectionProgramDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_PercentageOfForgivenAmount" xlink:href="abvcd-20210331.xsd#abvcd_PercentageOfForgivenAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_PercentageOfForgivenAmount_lbl" xml:lang="en-US">Percentage of forgiven amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_PercentageOfForgivenAmount" xlink:to="abvcd_PercentageOfForgivenAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_InterestRate" xlink:href="abvcd-20210331.xsd#abvcd_InterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_InterestRate_lbl" xml:lang="en-US">Interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_InterestRate" xlink:to="abvcd_InterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_PromissoryNoteTerm" xlink:href="abvcd-20210331.xsd#abvcd_PromissoryNoteTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_PromissoryNoteTerm_lbl" xml:lang="en-US">Promissory note term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_PromissoryNoteTerm" xlink:to="abvcd_PromissoryNoteTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_LoanAmout" xlink:href="abvcd-20210331.xsd#abvcd_LoanAmout"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_LoanAmout_lbl" xml:lang="en-US">Loan amout (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_LoanAmout" xlink:to="abvcd_LoanAmout_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_UnsecuredLoanAgreementsDescription" xlink:href="abvcd-20210331.xsd#abvcd_UnsecuredLoanAgreementsDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_UnsecuredLoanAgreementsDescription_lbl" xml:lang="en-US">Unsecured loan agreement, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_UnsecuredLoanAgreementsDescription" xlink:to="abvcd_UnsecuredLoanAgreementsDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNotesPayable_lbl" xml:lang="en-US">Balance due amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNotesPayable" xlink:to="us-gaap_OtherNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseOther_lbl" xml:lang="en-US">Interest expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseOther" xlink:to="us-gaap_InterestExpenseOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnsecuredDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnsecuredDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnsecuredDebt_lbl" xml:lang="en-US">Unsecured loan amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnsecuredDebt" xlink:to="us-gaap_UnsecuredDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtInterestRateIncrease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtInterestRateIncrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermDebtInterestRateIncrease_lbl" xml:lang="en-US">Interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtInterestRateIncrease" xlink:to="us-gaap_ShortTermDebtInterestRateIncrease_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateTerms" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateTerms"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateTerms_lbl" xml:lang="en-US">Loan agreement, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateTerms" xlink:to="us-gaap_DebtInstrumentInterestRateTerms_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShorttermDebtAverageOutstandingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShorttermDebtAverageOutstandingAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShorttermDebtAverageOutstandingAmount_lbl" xml:lang="en-US">Outstanding advance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShorttermDebtAverageOutstandingAmount" xlink:to="us-gaap_ShorttermDebtAverageOutstandingAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_AccruedInterest" xlink:href="abvcd-20210331.xsd#abvcd_AccruedInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_AccruedInterest_lbl" xml:lang="en-US">Accrued interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_AccruedInterest" xlink:to="abvcd_AccruedInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_StockPurchaseAgreementDescription" xlink:href="abvcd-20210331.xsd#abvcd_StockPurchaseAgreementDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_StockPurchaseAgreementDescription_lbl" xml:lang="en-US">Stock purchase agreement, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_StockPurchaseAgreementDescription" xlink:to="abvcd_StockPurchaseAgreementDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_AggregateWorkingcapital" xlink:href="abvcd-20210331.xsd#abvcd_AggregateWorkingcapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_AggregateWorkingcapital_lbl" xml:lang="en-US">Aggregate working capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_AggregateWorkingcapital" xlink:to="abvcd_AggregateWorkingcapital_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_AdvancesBearInterestDescription" xlink:href="abvcd-20210331.xsd#abvcd_AdvancesBearInterestDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_AdvancesBearInterestDescription_lbl" xml:lang="en-US">Advances bear interest, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_AdvancesBearInterestDescription" xlink:to="abvcd_AdvancesBearInterestDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionRate_lbl" xml:lang="en-US">Interest rate percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionRate" xlink:to="us-gaap_RelatedPartyTransactionRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueFromOtherRelatedParties" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromOtherRelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DueFromOtherRelatedParties_lbl" xml:lang="en-US">Due from BHK</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromOtherRelatedParties" xlink:to="us-gaap_DueFromOtherRelatedParties_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfLoanCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfLoanCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsOfLoanCosts_lbl" xml:lang="en-US">Outstanding loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfLoanCosts" xlink:to="us-gaap_PaymentsOfLoanCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_NumberOfEmployees" xlink:href="abvcd-20210331.xsd#abvcd_NumberOfEmployees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_NumberOfEmployees_lbl" xml:lang="en-US">Number of employees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_NumberOfEmployees" xlink:to="abvcd_NumberOfEmployees_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xml:lang="en-US">Accrued employee amounted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_StockholderEquityReverseStockSplit" xlink:href="abvcd-20210331.xsd#abvcd_StockholderEquityReverseStockSplit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_StockholderEquityReverseStockSplit_lbl" xml:lang="en-US">Forward split ratio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_StockholderEquityReverseStockSplit" xlink:to="abvcd_StockholderEquityReverseStockSplit_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_AgreementDescription" xlink:href="abvcd-20210331.xsd#abvcd_AgreementDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_AgreementDescription_lbl" xml:lang="en-US">Agreement, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_AgreementDescription" xlink:to="abvcd_AgreementDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_FinancialAmendmentDescription" xlink:href="abvcd-20210331.xsd#abvcd_FinancialAmendmentDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_FinancialAmendmentDescription_lbl" xml:lang="en-US">Financial amendment, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_FinancialAmendmentDescription" xlink:to="abvcd_FinancialAmendmentDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_Consultingagreementdescription" xlink:href="abvcd-20210331.xsd#abvcd_Consultingagreementdescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_Consultingagreementdescription_lbl" xml:lang="en-US">Consulting agreement, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_Consultingagreementdescription" xlink:to="abvcd_Consultingagreementdescription_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_UnpaidConsultingFees" xlink:href="abvcd-20210331.xsd#abvcd_UnpaidConsultingFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_UnpaidConsultingFees_lbl" xml:lang="en-US">Unpaid consulting fees (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_UnpaidConsultingFees" xlink:to="abvcd_UnpaidConsultingFees_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalFees" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfessionalFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfessionalFees_lbl" xml:lang="en-US">Consulting fees (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_StockSubscriptionReceivable" xlink:href="abvcd-20210331.xsd#abvcd_StockSubscriptionReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_StockSubscriptionReceivable_lbl" xml:lang="en-US">Stock subscription receivable (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_StockSubscriptionReceivable" xlink:to="abvcd_StockSubscriptionReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_StockIssuedValue" xlink:href="abvcd-20210331.xsd#abvcd_StockIssuedValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_StockIssuedValue_lbl" xml:lang="en-US">Issuance of common shares (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_StockIssuedValue" xlink:to="abvcd_StockIssuedValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US">Common stock price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_PlacementAgentAgreementDescription" xlink:href="abvcd-20210331.xsd#abvcd_PlacementAgentAgreementDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_PlacementAgentAgreementDescription_lbl" xml:lang="en-US">Placement agent agreement, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_PlacementAgentAgreementDescription" xlink:to="abvcd_PlacementAgentAgreementDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_RestrictedCommonShares" xlink:href="abvcd-20210331.xsd#abvcd_RestrictedCommonShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_RestrictedCommonShares_lbl" xml:lang="en-US">Restricted common shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_RestrictedCommonShares" xlink:to="abvcd_RestrictedCommonShares_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_WarrantIssued" xlink:href="abvcd-20210331.xsd#abvcd_WarrantIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_WarrantIssued_lbl" xml:lang="en-US">Warrant issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_WarrantIssued" xlink:to="abvcd_WarrantIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_WarrantTerm" xlink:href="abvcd-20210331.xsd#abvcd_WarrantTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_WarrantTerm_lbl" xml:lang="en-US">Warrant term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_WarrantTerm" xlink:to="abvcd_WarrantTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_UnrestrictedCommonShares" xlink:href="abvcd-20210331.xsd#abvcd_UnrestrictedCommonShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_UnrestrictedCommonShares_lbl" xml:lang="en-US">Unrestricted common shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_UnrestrictedCommonShares" xlink:to="abvcd_UnrestrictedCommonShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromContributionsFromAffiliates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromContributionsFromAffiliates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromContributionsFromAffiliates_lbl" xml:lang="en-US">Aggregated capital contributions (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromContributionsFromAffiliates" xlink:to="us-gaap_ProceedsFromContributionsFromAffiliates_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_NumberOfInvestors" xlink:href="abvcd-20210331.xsd#abvcd_NumberOfInvestors"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_NumberOfInvestors_lbl" xml:lang="en-US">Number of investors</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_NumberOfInvestors" xlink:to="abvcd_NumberOfInvestors_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Number of investors (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl0" xml:lang="en-US">Common stock per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="abvcd_IssuanceOfCommonStock" xlink:href="abvcd-20210331.xsd#abvcd_IssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_IssuanceOfCommonStock_lbl" xml:lang="en-US">Issuance of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_IssuanceOfCommonStock" xlink:to="abvcd_IssuanceOfCommonStock_lbl"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb+OcBO0cz/DPQtq8WT+vHGytpy5eqldqmljvYMs+ffK0hVJun/LoadZRO6MVQWNprQnn57cflcp0+RqqLVbNVtuKFz5+pgq1gL8cjM8xFnzOUdEjZ0sDSJzg18XsOaa9RO4cDdhaiGpwVK1skYTQsz6wjLPW7PJKd/ex+Rw6OhX8y162iyhal6DMxBXk9JmBQom/TGRvzYEg==] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">PRice per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_StockIssuedDuringPeriodShareBasedCompensationServicesforShares" xlink:href="abvcd-20210331.xsd#abvcd_StockIssuedDuringPeriodShareBasedCompensationServicesforShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_StockIssuedDuringPeriodShareBasedCompensationServicesforShares_lbl" xml:lang="en-US">SaleOfStockPricePerShare</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_StockIssuedDuringPeriodShareBasedCompensationServicesforShares" xlink:to="abvcd_StockIssuedDuringPeriodShareBasedCompensationServicesforShares_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_AggregateCommonStockShares" xlink:href="abvcd-20210331.xsd#abvcd_AggregateCommonStockShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_AggregateCommonStockShares_lbl" xml:lang="en-US">Aggregate common stock shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_AggregateCommonStockShares" xlink:to="abvcd_AggregateCommonStockShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature_lbl" xml:lang="en-US">Debt conversion, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature" xlink:to="us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Conversion price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_ConsultingFees" xlink:href="abvcd-20210331.xsd#abvcd_ConsultingFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_ConsultingFees_lbl" xml:lang="en-US">Consulting fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ConsultingFees" xlink:to="abvcd_ConsultingFees_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Options vested grant date exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Options available for grant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants" xlink:href="abvcd-20210331.xsd#abvcd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants_lbl" xml:lang="en-US">Stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants" xlink:to="abvcd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_PercentageOfGoodwill" xlink:href="abvcd-20210331.xsd#abvcd_PercentageOfGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_PercentageOfGoodwill_lbl" xml:lang="en-US">Percentage of goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_PercentageOfGoodwill" xlink:to="abvcd_PercentageOfGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl" xml:lang="en-US">Goodwill write-down value (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiscalPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiscalPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiscalPeriod_lbl" xml:lang="en-US">Fiscal Year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiscalPeriod" xlink:to="us-gaap_FiscalPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xml:lang="en-US">Reclassifications</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_ForwardStockSplitsPolicyTextBlock" xlink:href="abvcd-20210331.xsd#abvcd_ForwardStockSplitsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_ForwardStockSplitsPolicyTextBlock_lbl" xml:lang="en-US">Forward Stock Split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ForwardStockSplitsPolicyTextBlock" xlink:to="abvcd_ForwardStockSplitsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_StockReverseSplitPolicyTextBlock" xlink:href="abvcd-20210331.xsd#abvcd_StockReverseSplitPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_StockReverseSplitPolicyTextBlock_lbl" xml:lang="en-US">Stock Reverse Split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_StockReverseSplitPolicyTextBlock" xlink:to="abvcd_StockReverseSplitPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US">Restricted Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of Credit Risk</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of Long-Lived Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_LongTermEquityInvestmentPolicy" xlink:href="abvcd-20210331.xsd#abvcd_LongTermEquityInvestmentPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_LongTermEquityInvestmentPolicy_lbl" xml:lang="en-US">Long-term Equity Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_LongTermEquityInvestmentPolicy" xlink:to="abvcd_LongTermEquityInvestmentPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_OtherThanTemporaryImpairmentPolicyTextBlock" xlink:href="abvcd-20210331.xsd#abvcd_OtherThanTemporaryImpairmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_OtherThanTemporaryImpairmentPolicyTextBlock_lbl" xml:lang="en-US">Other-Than-Temporary Impairment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_OtherThanTemporaryImpairmentPolicyTextBlock" xlink:to="abvcd_OtherThanTemporaryImpairmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xml:lang="en-US">Goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy_lbl" xml:lang="en-US">Post-retirement and post-employment benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy" xlink:to="us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US">Stock-based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_BeneficialConversionFeature" xlink:href="abvcd-20210331.xsd#abvcd_BeneficialConversionFeature"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_BeneficialConversionFeature_lbl" xml:lang="en-US">Beneficial Conversion Feature</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_BeneficialConversionFeature" xlink:to="abvcd_BeneficialConversionFeature_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_ValuationOfDeferredTaxAssetsPolicyTextBlock" xlink:href="abvcd-20210331.xsd#abvcd_ValuationOfDeferredTaxAssetsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_ValuationOfDeferredTaxAssetsPolicyTextBlock_lbl" xml:lang="en-US">Valuation of Deferred Tax Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ValuationOfDeferredTaxAssetsPolicyTextBlock" xlink:to="abvcd_ValuationOfDeferredTaxAssetsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Loss Per Share of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Foreign-currency Transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_TranslationAdjustmentPolicyTextBlock" xlink:href="abvcd-20210331.xsd#abvcd_TranslationAdjustmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_TranslationAdjustmentPolicyTextBlock_lbl" xml:lang="en-US">Translation Adjustment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_TranslationAdjustmentPolicyTextBlock" xlink:to="abvcd_TranslationAdjustmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_ShareExchangeAgreementMember" xlink:href="abvcd-20210331.xsd#abvcd_ShareExchangeAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_ShareExchangeAgreementMember_lbl" xml:lang="en-US">Share Exchange Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ShareExchangeAgreementMember" xlink:to="abvcd_ShareExchangeAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_ShareExchangeAgreementOneMember" xlink:href="abvcd-20210331.xsd#abvcd_ShareExchangeAgreementOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_ShareExchangeAgreementOneMember_lbl" xml:lang="en-US">Share Exchange Agreement One [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ShareExchangeAgreementOneMember" xlink:to="abvcd_ShareExchangeAgreementOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_ShareExchangeAgreementTwoMember" xlink:href="abvcd-20210331.xsd#abvcd_ShareExchangeAgreementTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_ShareExchangeAgreementTwoMember_lbl" xml:lang="en-US">Share Exchange Agreement Two [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ShareExchangeAgreementTwoMember" xlink:to="abvcd_ShareExchangeAgreementTwoMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_ShareExchangeAgreementThreeMember" xlink:href="abvcd-20210331.xsd#abvcd_ShareExchangeAgreementThreeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_ShareExchangeAgreementThreeMember_lbl" xml:lang="en-US">Share Exchange Agreement Three [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ShareExchangeAgreementThreeMember" xlink:to="abvcd_ShareExchangeAgreementThreeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_ShareExchangeAgreementFourMember" xlink:href="abvcd-20210331.xsd#abvcd_ShareExchangeAgreementFourMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_ShareExchangeAgreementFourMember_lbl" xml:lang="en-US">Share Exchange Agreement Four [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ShareExchangeAgreementFourMember" xlink:to="abvcd_ShareExchangeAgreementFourMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_MergerAgreementMember" xlink:href="abvcd-20210331.xsd#abvcd_MergerAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_MergerAgreementMember_lbl" xml:lang="en-US">Merger Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_MergerAgreementMember" xlink:to="abvcd_MergerAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_BHKCoDevelopmentAgreementMember" xlink:href="abvcd-20210331.xsd#abvcd_BHKCoDevelopmentAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_BHKCoDevelopmentAgreementMember_lbl" xml:lang="en-US">BHK Co-Development Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_BHKCoDevelopmentAgreementMember" xlink:to="abvcd_BHKCoDevelopmentAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_CodevelopmentagreementMember" xlink:href="abvcd-20210331.xsd#abvcd_CodevelopmentagreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_CodevelopmentagreementMember_lbl" xml:lang="en-US">Co-Dev Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_CodevelopmentagreementMember" xlink:to="abvcd_CodevelopmentagreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xml:lang="en-US">Collaborative Arrangement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="us-gaap_CollaborativeArrangementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_BioFirstStockPurchaseAgreementMember" xlink:href="abvcd-20210331.xsd#abvcd_BioFirstStockPurchaseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_BioFirstStockPurchaseAgreementMember_lbl" xml:lang="en-US">BioFirst Stock Purchase Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_BioFirstStockPurchaseAgreementMember" xlink:to="abvcd_BioFirstStockPurchaseAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_UnsecuredConvertiblePromissoryNoteMember" xlink:href="abvcd-20210331.xsd#abvcd_UnsecuredConvertiblePromissoryNoteMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_UnsecuredConvertiblePromissoryNoteMember_lbl" xml:lang="en-US">Unsecured convertible promissory note [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_UnsecuredConvertiblePromissoryNoteMember" xlink:to="abvcd_UnsecuredConvertiblePromissoryNoteMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_SecuritiesPurchaseAgreementMember" xlink:href="abvcd-20210331.xsd#abvcd_SecuritiesPurchaseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_SecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US">Securities Purchase Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_SecuritiesPurchaseAgreementMember" xlink:to="abvcd_SecuritiesPurchaseAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_NTMember" xlink:href="abvcd-20210331.xsd#abvcd_NTMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_NTMember_lbl" xml:lang="en-US">NT [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_NTMember" xlink:to="abvcd_NTMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_CathayUnitedLoanAgreementMember" xlink:href="abvcd-20210331.xsd#abvcd_CathayUnitedLoanAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_CathayUnitedLoanAgreementMember_lbl" xml:lang="en-US">Cathay United Loan Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_CathayUnitedLoanAgreementMember" xlink:to="abvcd_CathayUnitedLoanAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_LoanAgreementMember" xlink:href="abvcd-20210331.xsd#abvcd_LoanAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_LoanAgreementMember_lbl" xml:lang="en-US">Loan Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_LoanAgreementMember" xlink:to="abvcd_LoanAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_PAYCHECKPROTECTIONPROGRAMMember" xlink:href="abvcd-20210331.xsd#abvcd_PAYCHECKPROTECTIONPROGRAMMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_PAYCHECKPROTECTIONPROGRAMMember_lbl" xml:lang="en-US">Paycheck protection program [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_PAYCHECKPROTECTIONPROGRAMMember" xlink:to="abvcd_PAYCHECKPROTECTIONPROGRAMMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_ConversionAgreementsOneMember" xlink:href="abvcd-20210331.xsd#abvcd_ConversionAgreementsOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_ConversionAgreementsOneMember_lbl" xml:lang="en-US">Conversion Agreements One [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ConversionAgreementsOneMember" xlink:to="abvcd_ConversionAgreementsOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_BioLiteTaiwanMember" xlink:href="abvcd-20210331.xsd#abvcd_BioLiteTaiwanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_BioLiteTaiwanMember_lbl" xml:lang="en-US">BioLite Taiwan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_BioLiteTaiwanMember" xlink:to="abvcd_BioLiteTaiwanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_LbgUsaIncMember" xlink:href="abvcd-20210331.xsd#abvcd_LbgUsaIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_LbgUsaIncMember_lbl" xml:lang="en-US">LBG USA, Inc.[Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_LbgUsaIncMember" xlink:to="abvcd_LbgUsaIncMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_JIANGSMember" xlink:href="abvcd-20210331.xsd#abvcd_JIANGSMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_JIANGSMember_lbl" xml:lang="en-US">Jiangs [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_JIANGSMember" xlink:to="abvcd_JIANGSMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="abvcd_JIANGSMember_lbl0" xml:lang="en-US">JIANGS [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_JIANGSMember" xlink:to="abvcd_JIANGSMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="abvcd_TwoThousandSixteenEquityIncentivePlanMember" xlink:href="abvcd-20210331.xsd#abvcd_TwoThousandSixteenEquityIncentivePlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_TwoThousandSixteenEquityIncentivePlanMember_lbl" xml:lang="en-US">2016 Equity Incentive Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_TwoThousandSixteenEquityIncentivePlanMember" xlink:to="abvcd_TwoThousandSixteenEquityIncentivePlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_BioLiteMember" xlink:href="abvcd-20210331.xsd#abvcd_BioLiteMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_BioLiteMember_lbl" xml:lang="en-US">BioLite [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_BioLiteMember" xlink:to="abvcd_BioLiteMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_BioKeyMember" xlink:href="abvcd-20210331.xsd#abvcd_BioKeyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_BioKeyMember_lbl" xml:lang="en-US">BioKey [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_BioKeyMember" xlink:to="abvcd_BioKeyMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_KameyamaMember" xlink:href="abvcd-20210331.xsd#abvcd_KameyamaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_KameyamaMember_lbl" xml:lang="en-US">Kameyama [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_KameyamaMember" xlink:to="abvcd_KameyamaMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_EuroAsiaInvestmentAndFinanceCorpLtdMember" xlink:href="abvcd-20210331.xsd#abvcd_EuroAsiaInvestmentAndFinanceCorpLtdMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_EuroAsiaInvestmentAndFinanceCorpLtdMember_lbl" xml:lang="en-US">Euro-Asia Investment &amp; Finance Corp Ltd. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_EuroAsiaInvestmentAndFinanceCorpLtdMember" xlink:to="abvcd_EuroAsiaInvestmentAndFinanceCorpLtdMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_ArticlesOfIncorporationMember" xlink:href="abvcd-20210331.xsd#abvcd_ArticlesOfIncorporationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_ArticlesOfIncorporationMember_lbl" xml:lang="en-US">Articles of Incorporation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ArticlesOfIncorporationMember" xlink:to="abvcd_ArticlesOfIncorporationMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_ViewTradeSecuritiesIncMember" xlink:href="abvcd-20210331.xsd#abvcd_ViewTradeSecuritiesIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_ViewTradeSecuritiesIncMember_lbl" xml:lang="en-US">View Trade Securities Inc [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ViewTradeSecuritiesIncMember" xlink:to="abvcd_ViewTradeSecuritiesIncMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_ConsultingAgreementMember" xlink:href="abvcd-20210331.xsd#abvcd_ConsultingAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_ConsultingAgreementMember_lbl" xml:lang="en-US">Consulting Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ConsultingAgreementMember" xlink:to="abvcd_ConsultingAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_NonRelatedPartiesMember" xlink:href="abvcd-20210331.xsd#abvcd_NonRelatedPartiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvcd_NonRelatedPartiesMember_lbl" xml:lang="en-US">Non Related Parties [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_NonRelatedPartiesMember" xlink:to="abvcd_NonRelatedPartiesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_CollaborativeAgreementsTable" xlink:href="abvcd-20210331.xsd#abvcd_CollaborativeAgreementsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_CollaborativeAgreementsTable_lbl" xml:lang="en-US">Collaborative Agreements [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_CollaborativeAgreementsTable" xlink:to="abvcd_CollaborativeAgreementsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_CollaborativeAgreementsLineItems" xlink:href="abvcd-20210331.xsd#abvcd_CollaborativeAgreementsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_CollaborativeAgreementsLineItems_lbl" xml:lang="en-US">Collaborative Agreements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_CollaborativeAgreementsLineItems" xlink:to="abvcd_CollaborativeAgreementsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_NotesPayableTable" xlink:href="abvcd-20210331.xsd#abvcd_NotesPayableTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_NotesPayableTable_lbl" xml:lang="en-US">Notes Payable [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_NotesPayableTable" xlink:to="abvcd_NotesPayableTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_NotesPayableLineItems" xlink:href="abvcd-20210331.xsd#abvcd_NotesPayableLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_NotesPayableLineItems_lbl" xml:lang="en-US">Notes Payable [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_NotesPayableLineItems" xlink:to="abvcd_NotesPayableLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentTable" xlink:href="abvcd-20210331.xsd#abvcd_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentTable_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) - Schedule of property and equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentTable" xlink:to="abvcd_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems" xlink:href="abvcd-20210331.xsd#abvcd_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) - Schedule of property and equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems" xlink:to="abvcd_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related Party [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeTable" xlink:href="abvcd-20210331.xsd#abvcd_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeTable_lbl" xml:lang="en-US">Long-Term Investments (Details) - Schedule of ownership percentages of investee [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeTable" xlink:to="abvcd_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeLineItems" xlink:href="abvcd-20210331.xsd#abvcd_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeLineItems_lbl" xml:lang="en-US">Long-Term Investments (Details) - Schedule of ownership percentages of investee [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeLineItems" xlink:to="abvcd_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesTable" xlink:href="abvcd-20210331.xsd#abvcd_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesTable_lbl" xml:lang="en-US">Long-Term Investments (Details) - Schedule of extent the investee relies [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesTable" xlink:to="abvcd_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesLineItems" xlink:href="abvcd-20210331.xsd#abvcd_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesLineItems_lbl" xml:lang="en-US">Long-Term Investments (Details) - Schedule of extent the investee relies [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesLineItems" xlink:to="abvcd_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US">Related Party Transaction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_LongTermInvestmentsDetailsScheduleoflongterminvestmentTable" xlink:href="abvcd-20210331.xsd#abvcd_LongTermInvestmentsDetailsScheduleoflongterminvestmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_LongTermInvestmentsDetailsScheduleoflongterminvestmentTable_lbl" xml:lang="en-US">Long-Term Investments (Details) - Schedule of long-term investment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_LongTermInvestmentsDetailsScheduleoflongterminvestmentTable" xlink:to="abvcd_LongTermInvestmentsDetailsScheduleoflongterminvestmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_LongTermInvestmentsDetailsScheduleoflongterminvestmentLineItems" xlink:href="abvcd-20210331.xsd#abvcd_LongTermInvestmentsDetailsScheduleoflongterminvestmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_LongTermInvestmentsDetailsScheduleoflongterminvestmentLineItems_lbl" xml:lang="en-US">Long-Term Investments (Details) - Schedule of long-term investment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_LongTermInvestmentsDetailsScheduleoflongterminvestmentLineItems" xlink:to="abvcd_LongTermInvestmentsDetailsScheduleoflongterminvestmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedBalanceSheetStatementTable" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CondensedBalanceSheetStatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedBalanceSheetStatementTable_lbl" xml:lang="en-US">Condensed Balance Sheet Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedBalanceSheetStatementTable" xlink:to="srt_CondensedBalanceSheetStatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CondensedBalanceSheetStatementsCaptionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedBalanceSheetStatementsCaptionsLineItems_lbl" xml:lang="en-US">Condensed Balance Sheet Statements, Captions [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="srt_CondensedBalanceSheetStatementsCaptionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedIncomeStatementTable" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CondensedIncomeStatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedIncomeStatementTable_lbl" xml:lang="en-US">Condensed Income Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedIncomeStatementTable" xlink:to="srt_CondensedIncomeStatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CondensedIncomeStatementsCaptionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedIncomeStatementsCaptionsLineItems_lbl" xml:lang="en-US">Condensed Income Statements, Captions [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="srt_CondensedIncomeStatementsCaptionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xml:lang="en-US">Short-term Debt, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ShortTermDebtTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_lbl" xml:lang="en-US">Schedule of Short-term Debt [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US">Short-term Debt [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesTable" xlink:href="abvcd-20210331.xsd#abvcd_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesTable_lbl" xml:lang="en-US">Related Parties Transactions (Details) - Schedule of accounts receivable due from related parties [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesTable" xlink:to="abvcd_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesLineItems" xlink:href="abvcd-20210331.xsd#abvcd_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesLineItems_lbl" xml:lang="en-US">Related Parties Transactions (Details) - Schedule of accounts receivable due from related parties [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesLineItems" xlink:to="abvcd_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_lbl" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems_lbl" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_AccountsNotesAndLoansReceivableLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesTable" xlink:href="abvcd-20210331.xsd#abvcd_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesTable_lbl" xml:lang="en-US">Related Parties Transactions (Details) - Schedule of amount due to related parties [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesTable" xlink:to="abvcd_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesLineItems" xlink:href="abvcd-20210331.xsd#abvcd_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesLineItems_lbl" xml:lang="en-US">Related Parties Transactions (Details) - Schedule of amount due to related parties [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesLineItems" xlink:to="abvcd_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionTable_lbl" xml:lang="en-US">Debt Conversion [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionTable" xlink:to="us-gaap_DebtConversionTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionLineItems_lbl" xml:lang="en-US">Debt Conversion [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DebtConversionLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_lbl" xml:lang="en-US">Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:to="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_StockOptionsDetailsScheduleofoptionsissuedandoutstandingTable" xlink:href="abvcd-20210331.xsd#abvcd_StockOptionsDetailsScheduleofoptionsissuedandoutstandingTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_StockOptionsDetailsScheduleofoptionsissuedandoutstandingTable_lbl" xml:lang="en-US">Stock Options (Details) - Schedule of options issued and outstanding [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_StockOptionsDetailsScheduleofoptionsissuedandoutstandingTable" xlink:to="abvcd_StockOptionsDetailsScheduleofoptionsissuedandoutstandingTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:href="abvcd-20210331.xsd#abvcd_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems_lbl" xml:lang="en-US">Stock Options (Details) - Schedule of options issued and outstanding [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="abvcd_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_OrganizationandDescriptionofBusinessDetailsTable" xlink:href="abvcd-20210331.xsd#abvcd_OrganizationandDescriptionofBusinessDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_OrganizationandDescriptionofBusinessDetailsTable_lbl" xml:lang="en-US">Organization and Description of Business (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_OrganizationandDescriptionofBusinessDetailsTable" xlink:to="abvcd_OrganizationandDescriptionofBusinessDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_OrganizationandDescriptionofBusinessDetailsLineItems" xlink:href="abvcd-20210331.xsd#abvcd_OrganizationandDescriptionofBusinessDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_OrganizationandDescriptionofBusinessDetailsLineItems_lbl" xml:lang="en-US">Organization and Description of Business (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_OrganizationandDescriptionofBusinessDetailsLineItems" xlink:to="abvcd_OrganizationandDescriptionofBusinessDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_CollaborativeAgreementsDetailsTable" xlink:href="abvcd-20210331.xsd#abvcd_CollaborativeAgreementsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_CollaborativeAgreementsDetailsTable_lbl" xml:lang="en-US">Collaborative Agreements (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_CollaborativeAgreementsDetailsTable" xlink:to="abvcd_CollaborativeAgreementsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_CollaborativeAgreementsDetailsLineItems" xlink:href="abvcd-20210331.xsd#abvcd_CollaborativeAgreementsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_CollaborativeAgreementsDetailsLineItems_lbl" xml:lang="en-US">Collaborative Agreements (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_CollaborativeAgreementsDetailsLineItems" xlink:to="abvcd_CollaborativeAgreementsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_LongTermInvestmentsDetailsTable" xlink:href="abvcd-20210331.xsd#abvcd_LongTermInvestmentsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_LongTermInvestmentsDetailsTable_lbl" xml:lang="en-US">Long-Term Investments (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_LongTermInvestmentsDetailsTable" xlink:to="abvcd_LongTermInvestmentsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_LongTermInvestmentsDetailsLineItems" xlink:href="abvcd-20210331.xsd#abvcd_LongTermInvestmentsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_LongTermInvestmentsDetailsLineItems_lbl" xml:lang="en-US">Long-Term Investments (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_LongTermInvestmentsDetailsLineItems" xlink:to="abvcd_LongTermInvestmentsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_ConvertibleNotesPayableDetailsTable" xlink:href="abvcd-20210331.xsd#abvcd_ConvertibleNotesPayableDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_ConvertibleNotesPayableDetailsTable_lbl" xml:lang="en-US">Convertible Notes Payable (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ConvertibleNotesPayableDetailsTable" xlink:to="abvcd_ConvertibleNotesPayableDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_ConvertibleNotesPayableDetailsLineItems" xlink:href="abvcd-20210331.xsd#abvcd_ConvertibleNotesPayableDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_ConvertibleNotesPayableDetailsLineItems_lbl" xml:lang="en-US">Convertible Notes Payable (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ConvertibleNotesPayableDetailsLineItems" xlink:to="abvcd_ConvertibleNotesPayableDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_TypeOfCurrencyDomain" xlink:href="abvcd-20210331.xsd#abvcd_TypeOfCurrencyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_TypeOfCurrencyDomain_lbl" xml:lang="en-US">TypeOfCurrency [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_TypeOfCurrencyDomain" xlink:to="abvcd_TypeOfCurrencyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_BankLoansDetailsTable" xlink:href="abvcd-20210331.xsd#abvcd_BankLoansDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_BankLoansDetailsTable_lbl" xml:lang="en-US">Bank Loans (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_BankLoansDetailsTable" xlink:to="abvcd_BankLoansDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_BankLoansDetailsLineItems" xlink:href="abvcd-20210331.xsd#abvcd_BankLoansDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_BankLoansDetailsLineItems_lbl" xml:lang="en-US">Bank Loans (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_BankLoansDetailsLineItems" xlink:to="abvcd_BankLoansDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_PaycheckProtectionProgramLoanPayableDetailsTable" xlink:href="abvcd-20210331.xsd#abvcd_PaycheckProtectionProgramLoanPayableDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_PaycheckProtectionProgramLoanPayableDetailsTable_lbl" xml:lang="en-US">Paycheck Protection Program Loan Payable (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_PaycheckProtectionProgramLoanPayableDetailsTable" xlink:to="abvcd_PaycheckProtectionProgramLoanPayableDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_PaycheckProtectionProgramLoanPayableDetailsLineItems" xlink:href="abvcd-20210331.xsd#abvcd_PaycheckProtectionProgramLoanPayableDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_PaycheckProtectionProgramLoanPayableDetailsLineItems_lbl" xml:lang="en-US">Paycheck Protection Program Loan Payable (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_PaycheckProtectionProgramLoanPayableDetailsLineItems" xlink:to="abvcd_PaycheckProtectionProgramLoanPayableDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_AgreemnetDomain" xlink:href="abvcd-20210331.xsd#abvcd_AgreemnetDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_AgreemnetDomain_lbl" xml:lang="en-US">Agreemnet [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_AgreemnetDomain" xlink:to="abvcd_AgreemnetDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_RelatedPartiesTransactionsDetailsTable" xlink:href="abvcd-20210331.xsd#abvcd_RelatedPartiesTransactionsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_RelatedPartiesTransactionsDetailsTable_lbl" xml:lang="en-US">Related Parties Transactions (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_RelatedPartiesTransactionsDetailsTable" xlink:to="abvcd_RelatedPartiesTransactionsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_RelatedPartiesTransactionsDetailsLineItems" xlink:href="abvcd-20210331.xsd#abvcd_RelatedPartiesTransactionsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_RelatedPartiesTransactionsDetailsLineItems_lbl" xml:lang="en-US">Related Parties Transactions (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_RelatedPartiesTransactionsDetailsLineItems" xlink:to="abvcd_RelatedPartiesTransactionsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Title of Individual [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_EquityDetailsTable" xlink:href="abvcd-20210331.xsd#abvcd_EquityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_EquityDetailsTable_lbl" xml:lang="en-US">Equity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_EquityDetailsTable" xlink:to="abvcd_EquityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_EquityDetailsLineItems" xlink:href="abvcd-20210331.xsd#abvcd_EquityDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_EquityDetailsLineItems_lbl" xml:lang="en-US">Equity (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_EquityDetailsLineItems" xlink:to="abvcd_EquityDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_StockOptionsDetailsTable" xlink:href="abvcd-20210331.xsd#abvcd_StockOptionsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_StockOptionsDetailsTable_lbl" xml:lang="en-US">Stock Options (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_StockOptionsDetailsTable" xlink:to="abvcd_StockOptionsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_StockOptionsDetailsLineItems" xlink:href="abvcd-20210331.xsd#abvcd_StockOptionsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_StockOptionsDetailsLineItems_lbl" xml:lang="en-US">Stock Options (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_StockOptionsDetailsLineItems" xlink:to="abvcd_StockOptionsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_BusinessCombinationDetailsTable" xlink:href="abvcd-20210331.xsd#abvcd_BusinessCombinationDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_BusinessCombinationDetailsTable_lbl" xml:lang="en-US">Business Combination (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_BusinessCombinationDetailsTable" xlink:to="abvcd_BusinessCombinationDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abvcd_BusinessCombinationDetailsLineItems" xlink:href="abvcd-20210331.xsd#abvcd_BusinessCombinationDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_BusinessCombinationDetailsLineItems_lbl" xml:lang="en-US">Business Combination (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_BusinessCombinationDetailsLineItems" xlink:to="abvcd_BusinessCombinationDetailsLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvcd_AccruedInterest_lbl0" xml:lang="en-US">Accrued interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_AccruedInterest" xlink:to="abvcd_AccruedInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvcd_AdvancesBearInterestDescription_lbl0" xml:lang="en-US">Advances bear interest description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_AdvancesBearInterestDescription" xlink:to="abvcd_AdvancesBearInterestDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvcd_AggregateAmount_lbl0" xml:lang="en-US">The amount of income taxes from which a reporting entity is exempt or for which it will receive a reduction in income taxes as a result of the income tax holiday granted by the taxing jurisdiction.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_AggregateAmount" xlink:to="abvcd_AggregateAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvcd_AggregateCommonStockShares_lbl0" xml:lang="en-US">Aggregate Common Stock Shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_AggregateCommonStockShares" xlink:to="abvcd_AggregateCommonStockShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvcd_AggregateWorkingcapital_lbl0" xml:lang="en-US">Aggregate working capital.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_AggregateWorkingcapital" xlink:to="abvcd_AggregateWorkingcapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvcd_AgreementDescription_lbl0" xml:lang="en-US">Agreement related description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_AgreementDescription" xlink:to="abvcd_AgreementDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvcd_AllowanceForInventoryValuationAndObsolescenceLoss_lbl0" xml:lang="en-US">Allowance for inventory valuation and obsolescence loss.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_AllowanceForInventoryValuationAndObsolescenceLoss" xlink:to="abvcd_AllowanceForInventoryValuationAndObsolescenceLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvcd_BeneficialConversionFeature_lbl0" xml:lang="en-US">Disclosure of accounting policy for beneficial conversion feature.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_BeneficialConversionFeature" xlink:to="abvcd_BeneficialConversionFeature_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvcd_CoDevAgreementDescription_lbl0" xml:lang="en-US">Co-Dev agreement description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_CoDevAgreementDescription" xlink:to="abvcd_CoDevAgreementDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvcd_CollaborativeAgreementsDescription_lbl0" xml:lang="en-US">Collaborative Agreements, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_CollaborativeAgreementsDescription" xlink:to="abvcd_CollaborativeAgreementsDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvcd_CommonStockIssuedAfterStockSplit_lbl1" xml:lang="en-US">Common stock issued after stock split.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_CommonStockIssuedAfterStockSplit" xlink:to="abvcd_CommonStockIssuedAfterStockSplit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvcd_CommonStockIssuedBeforeStockSplit_lbl0" xml:lang="en-US">Common stock issued before stock split.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_CommonStockIssuedBeforeStockSplit" xlink:to="abvcd_CommonStockIssuedBeforeStockSplit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvcd_Consultingagreementdescription_lbl0" xml:lang="en-US">Consulting agreement description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_Consultingagreementdescription" xlink:to="abvcd_Consultingagreementdescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvcd_ConvertibleNotesPayableDisclosureTextBlock_lbl0" xml:lang="en-US">Disclosure of convertible notes payable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ConvertibleNotesPayableDisclosureTextBlock" xlink:to="abvcd_ConvertibleNotesPayableDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvcd_ExceedingAmount_lbl0" xml:lang="en-US">Exceeding amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ExceedingAmount" xlink:to="abvcd_ExceedingAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvcd_ForwardStockSplitsPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for forward stock splits.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ForwardStockSplitsPolicyTextBlock" xlink:to="abvcd_ForwardStockSplitsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvcd_GovernmentGrantIncome_lbl0" xml:lang="en-US">Amount of government grant income.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_GovernmentGrantIncome" xlink:to="abvcd_GovernmentGrantIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvcd_IncreaseDecreaseInGovernmentGrantIncome_lbl0" xml:lang="en-US">Increase Decrease in Government Grant Income.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_IncreaseDecreaseInGovernmentGrantIncome" xlink:to="abvcd_IncreaseDecreaseInGovernmentGrantIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvcd_IssuanceOfCommonStock_lbl0" xml:lang="en-US">Issuance of Common Stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_IssuanceOfCommonStock" xlink:to="abvcd_IssuanceOfCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvcd_LongTermEquityInvestmentPolicy_lbl0" xml:lang="en-US">Disclosure of accounting policy for long-term equity investment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_LongTermEquityInvestmentPolicy" xlink:to="abvcd_LongTermEquityInvestmentPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvcd_MarketableSecuritiesRealizedGainLossOtherThanTemporaryImpairmentsAmounts_lbl0" xml:lang="en-US">This element represents the amount of loss recognized for other than temporary impairments (OTTI) of investments in debt and equity securities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_MarketableSecuritiesRealizedGainLossOtherThanTemporaryImpairmentsAmounts" xlink:to="abvcd_MarketableSecuritiesRealizedGainLossOtherThanTemporaryImpairmentsAmounts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvcd_MilestonePayments_lbl0" xml:lang="en-US">Milestone payments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_MilestonePayments" xlink:to="abvcd_MilestonePayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvcd_MilestonePaymentsRoyaltyPercentage_lbl0" xml:lang="en-US">Milestone payments royalty percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_MilestonePaymentsRoyaltyPercentage" xlink:to="abvcd_MilestonePaymentsRoyaltyPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvcd_NetLossAttributableToAbvcAndSubsidiaries_lbl0" xml:lang="en-US">Net loss attributable to ABVC and subsidiaries.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_NetLossAttributableToAbvcAndSubsidiaries" xlink:to="abvcd_NetLossAttributableToAbvcAndSubsidiaries_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvcd_NetProceedsFromShortTermBorrowingsFromThirdParties_lbl0" xml:lang="en-US">Net proceeds from short term borrowings from third parties.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_NetProceedsFromShortTermBorrowingsFromThirdParties" xlink:to="abvcd_NetProceedsFromShortTermBorrowingsFromThirdParties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvcd_NumberOfEmployees_lbl0" xml:lang="en-US">Number of employees.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_NumberOfEmployees" xlink:to="abvcd_NumberOfEmployees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvcd_OtherThanTemporaryImpairmentPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for other than temporary impairment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_OtherThanTemporaryImpairmentPolicyTextBlock" xlink:to="abvcd_OtherThanTemporaryImpairmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvcd_PercentageOfCommonSharesIssuedAndOutstanding_lbl0" xml:lang="en-US">Percentage of common shares issued and outstanding.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_PercentageOfCommonSharesIssuedAndOutstanding" xlink:to="abvcd_PercentageOfCommonSharesIssuedAndOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvcd_PercentageOfIssuedShareCapital_lbl0" xml:lang="en-US">Percentage of issued share capital.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_PercentageOfIssuedShareCapital" xlink:to="abvcd_PercentageOfIssuedShareCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvcd_PercentageOfMonthlyContribution_lbl0" xml:lang="en-US">Percentage of monthly contribution.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_PercentageOfMonthlyContribution" xlink:to="abvcd_PercentageOfMonthlyContribution_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvcd_PercentageOfPaymentsUnderCodevelopmentAgreement_lbl0" xml:lang="en-US">Percentage of payments under co-development agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_PercentageOfPaymentsUnderCodevelopmentAgreement" xlink:to="abvcd_PercentageOfPaymentsUnderCodevelopmentAgreement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvcd_ReceivedLoanAmount_lbl0" xml:lang="en-US">Received loan amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ReceivedLoanAmount" xlink:to="abvcd_ReceivedLoanAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvcd_RegularInterestRateDescription_lbl0" xml:lang="en-US">Regular interest rate description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_RegularInterestRateDescription" xlink:to="abvcd_RegularInterestRateDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvcd_RelatedPartyTransactionDescriptionOfTransactions_lbl0" xml:lang="en-US">It represents related party descriptions.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_RelatedPartyTransactionDescriptionOfTransactions" xlink:to="abvcd_RelatedPartyTransactionDescriptionOfTransactions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvcd_RestrictedCommonShares_lbl0" xml:lang="en-US">Restricted Common Shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_RestrictedCommonShares" xlink:to="abvcd_RestrictedCommonShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvcd_ScheduleOfExtentInvesteeReliesTableTextBlock_lbl0" xml:lang="en-US">Schedule of extent the investee relies.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ScheduleOfExtentInvesteeReliesTableTextBlock" xlink:to="abvcd_ScheduleOfExtentInvesteeReliesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvcd_ScheduleOfOperatingLeaseArrangementsTableTextBlock_lbl0" xml:lang="en-US">Schedule of operating lease arrangements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ScheduleOfOperatingLeaseArrangementsTableTextBlock" xlink:to="abvcd_ScheduleOfOperatingLeaseArrangementsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvcd_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of property and equipment estimated useful life.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:to="abvcd_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvcd_ScheduleOfRelatedPartyTransactionsAmountDueToRelatedParty_lbl0" xml:lang="en-US">Tabular disclosure of related party transactions. Amount due to related party.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ScheduleOfRelatedPartyTransactionsAmountDueToRelatedParty" xlink:to="abvcd_ScheduleOfRelatedPartyTransactionsAmountDueToRelatedParty_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvcd_StockBasedCompensationForNonemployees_lbl0" xml:lang="en-US">Stock based compensation for nonemployees.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_StockBasedCompensationForNonemployees" xlink:to="abvcd_StockBasedCompensationForNonemployees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvcd_StockPurchaseAgreementDescription_lbl0" xml:lang="en-US">Stock purchase agreement description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_StockPurchaseAgreementDescription" xlink:to="abvcd_StockPurchaseAgreementDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvcd_StockReverseSplitPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for Stock Reverse Split.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_StockReverseSplitPolicyTextBlock" xlink:to="abvcd_StockReverseSplitPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvcd_StockSubscriptionReceivable_lbl0" xml:lang="en-US">The amount of stock subscription receivable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_StockSubscriptionReceivable" xlink:to="abvcd_StockSubscriptionReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvcd_StockholderEquityReverseStockSplit_lbl0" xml:lang="en-US">Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_StockholderEquityReverseStockSplit" xlink:to="abvcd_StockholderEquityReverseStockSplit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvcd_TotalInterestExpenses_lbl0" xml:lang="en-US">Total interest expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_TotalInterestExpenses" xlink:to="abvcd_TotalInterestExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvcd_TranslationAdjustmentPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for translation adjustment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_TranslationAdjustmentPolicyTextBlock" xlink:to="abvcd_TranslationAdjustmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvcd_UnsecuredLoanAgreementsDescription_lbl0" xml:lang="en-US">Description of unsecured loan agreements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_UnsecuredLoanAgreementsDescription" xlink:to="abvcd_UnsecuredLoanAgreementsDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvcd_UpfrontCashPayment_lbl0" xml:lang="en-US">The amount of upfront payments which are paid during the term of agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_UpfrontCashPayment" xlink:to="abvcd_UpfrontCashPayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvcd_ValuationOfDeferredTaxAssetsPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for valuation of deferred tax assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ValuationOfDeferredTaxAssetsPolicyTextBlock" xlink:to="abvcd_ValuationOfDeferredTaxAssetsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvcd_WarrantIssued_lbl0" xml:lang="en-US">Warrant issued.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_WarrantIssued" xlink:to="abvcd_WarrantIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvcd_WarrantTerm_lbl0" xml:lang="en-US">Warrant term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_WarrantTerm" xlink:to="abvcd_WarrantTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvcd_ShareExchangeAgreementMember_lbl0" xml:lang="en-US">Information by category of arrangement, including but not limited to collaborative arrangements and non-collaborative arrangements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ShareExchangeAgreementMember" xlink:to="abvcd_ShareExchangeAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_BioFirstStockPurchaseAgreementMember_lbl0" xml:lang="en-US">BioFirstStockPurchaseAgreementMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_BioFirstStockPurchaseAgreementMember" xlink:to="abvcd_BioFirstStockPurchaseAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_StockSubscriptionReceivable_lbl1" xml:lang="en-US">StockSubscriptionReceivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_StockSubscriptionReceivable" xlink:to="abvcd_StockSubscriptionReceivable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_LongTermInvestmentTextBlock_lbl0" xml:lang="en-US">LongTermInvestmentTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_LongTermInvestmentTextBlock" xlink:to="abvcd_LongTermInvestmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_LongTermInvestmentNetLoss_lbl0" xml:lang="en-US">LongTermInvestmentNetLoss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_LongTermInvestmentNetLoss" xlink:to="abvcd_LongTermInvestmentNetLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_AmkeyVenturesLLCAmkeyMember_lbl0" xml:lang="en-US">AmkeyVenturesLLCAmkeyMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_AmkeyVenturesLLCAmkeyMember" xlink:to="abvcd_AmkeyVenturesLLCAmkeyMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_BioFirstMember_lbl0" xml:lang="en-US">BioFirstMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_BioFirstMember" xlink:to="abvcd_BioFirstMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_ShareExchangeAgreementThreeMember_lbl0" xml:lang="en-US">ShareExchangeAgreementThreeMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ShareExchangeAgreementThreeMember" xlink:to="abvcd_ShareExchangeAgreementThreeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_BankLoansAbstract_lbl0" xml:lang="en-US">BankLoansAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_BankLoansAbstract" xlink:to="abvcd_BankLoansAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_LoanAmout_lbl0" xml:lang="en-US">LoanAmout</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_LoanAmout" xlink:to="abvcd_LoanAmout_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_ExceedingAmount_lbl1" xml:lang="en-US">ExceedingAmount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ExceedingAmount" xlink:to="abvcd_ExceedingAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_PercentageOfForgivenAmount_lbl0" xml:lang="en-US">PercentageOfForgivenAmount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_PercentageOfForgivenAmount" xlink:to="abvcd_PercentageOfForgivenAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_WeightedAverageDiscountRateAbstract_lbl0" xml:lang="en-US">WeightedAverageDiscountRateAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_WeightedAverageDiscountRateAbstract" xlink:to="abvcd_WeightedAverageDiscountRateAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_EugeneJiangMember_lbl0" xml:lang="en-US">EugeneJiangMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_EugeneJiangMember" xlink:to="abvcd_EugeneJiangMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_KeypointTechnologyLtdtheKeypointMember_lbl0" xml:lang="en-US">KeypointTechnologyLtdtheKeypointMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_KeypointTechnologyLtdtheKeypointMember" xlink:to="abvcd_KeypointTechnologyLtdtheKeypointMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_UnrestrictedCommonShares_lbl0" xml:lang="en-US">UnrestrictedCommonShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_UnrestrictedCommonShares" xlink:to="abvcd_UnrestrictedCommonShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_StockOptionsTextBlock_lbl0" xml:lang="en-US">StockOptionsTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_StockOptionsTextBlock" xlink:to="abvcd_StockOptionsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_BHKCoDevelopmentAgreementMember_lbl0" xml:lang="en-US">BHKCoDevelopmentAgreementMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_BHKCoDevelopmentAgreementMember" xlink:to="abvcd_BHKCoDevelopmentAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_LbgUsaIncMember_lbl0" xml:lang="en-US">LbgUsaIncMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_LbgUsaIncMember" xlink:to="abvcd_LbgUsaIncMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_MarketableSecuritiesRealizedGainLossOtherThanTemporaryImpairmentsAmounts_lbl1" xml:lang="en-US">MarketableSecuritiesRealizedGainLossOtherThanTemporaryImpairmentsAmounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_MarketableSecuritiesRealizedGainLossOtherThanTemporaryImpairmentsAmounts" xlink:to="abvcd_MarketableSecuritiesRealizedGainLossOtherThanTemporaryImpairmentsAmounts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_MilestonePayments_lbl1" xml:lang="en-US">MilestonePayments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_MilestonePayments" xlink:to="abvcd_MilestonePayments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_TotalInterestExpenses_lbl1" xml:lang="en-US">TotalInterestExpenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_TotalInterestExpenses" xlink:to="abvcd_TotalInterestExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_WarrantTerm_lbl1" xml:lang="en-US">WarrantTerm</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_WarrantTerm" xlink:to="abvcd_WarrantTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_AmkeyMember_lbl0" xml:lang="en-US">AmkeyMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_AmkeyMember" xlink:to="abvcd_AmkeyMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue_lbl0" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue" xlink:to="abvcd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_IssuanceOfCommonStock_lbl1" xml:lang="en-US">IssuanceOfCommonStock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_IssuanceOfCommonStock" xlink:to="abvcd_IssuanceOfCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_EquityMethodInvestmentsNetAbstract_lbl0" xml:lang="en-US">EquityMethodInvestmentsNetAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_EquityMethodInvestmentsNetAbstract" xlink:to="abvcd_EquityMethodInvestmentsNetAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_WeightedAverageRemainingLeaseTermAbstract_lbl0" xml:lang="en-US">WeightedAverageRemainingLeaseTermAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_WeightedAverageRemainingLeaseTermAbstract" xlink:to="abvcd_WeightedAverageRemainingLeaseTermAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_BioFirstCorporationtheBioFirstMember_lbl0" xml:lang="en-US">BioFirstCorporationtheBioFirstMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_BioFirstCorporationtheBioFirstMember" xlink:to="abvcd_BioFirstCorporationtheBioFirstMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_RegularInterestRateDescription_lbl1" xml:lang="en-US">RegularInterestRateDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_RegularInterestRateDescription" xlink:to="abvcd_RegularInterestRateDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_BuildingsAndLeaseholdImprovementsMember_lbl0" xml:lang="en-US">BuildingsAndLeaseholdImprovementsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_BuildingsAndLeaseholdImprovementsMember" xlink:to="abvcd_BuildingsAndLeaseholdImprovementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_BioLiteJapanMember_lbl0" xml:lang="en-US">BioLiteJapanMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_BioLiteJapanMember" xlink:to="abvcd_BioLiteJapanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_YuanGeneMember_lbl0" xml:lang="en-US">YuanGeneMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_YuanGeneMember" xlink:to="abvcd_YuanGeneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_ArticlesOfIncorporationMember_lbl0" xml:lang="en-US">ArticlesOfIncorporationMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ArticlesOfIncorporationMember" xlink:to="abvcd_ArticlesOfIncorporationMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_PercentageOfIssuedShareCapital_lbl1" xml:lang="en-US">PercentageOfIssuedShareCapital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_PercentageOfIssuedShareCapital" xlink:to="abvcd_PercentageOfIssuedShareCapital_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_StockBasedCompensationForNonemployees_lbl1" xml:lang="en-US">StockBasedCompensationForNonemployees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_StockBasedCompensationForNonemployees" xlink:to="abvcd_StockBasedCompensationForNonemployees_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_ViewTradeSecuritiesIncMember_lbl0" xml:lang="en-US">ViewTradeSecuritiesIncMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ViewTradeSecuritiesIncMember" xlink:to="abvcd_ViewTradeSecuritiesIncMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_UpfrontCashPayment_lbl1" xml:lang="en-US">UpfrontCashPayment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_UpfrontCashPayment" xlink:to="abvcd_UpfrontCashPayment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_IncreaseDecreaseInGovernmentGrantIncome_lbl1" xml:lang="en-US">IncreaseDecreaseInGovernmentGrantIncome</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_IncreaseDecreaseInGovernmentGrantIncome" xlink:to="abvcd_IncreaseDecreaseInGovernmentGrantIncome_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_ConvertibleNotesPayableDisclosureTextBlock_lbl1" xml:lang="en-US">ConvertibleNotesPayableDisclosureTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ConvertibleNotesPayableDisclosureTextBlock" xlink:to="abvcd_ConvertibleNotesPayableDisclosureTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_LBGUSAInctheLBGUSAMember_lbl0" xml:lang="en-US">LBGUSAInctheLBGUSAMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_LBGUSAInctheLBGUSAMember" xlink:to="abvcd_LBGUSAInctheLBGUSAMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_AsiangeneCorporationMember_lbl1" xml:lang="en-US">AsiangeneCorporationMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_AsiangeneCorporationMember" xlink:to="abvcd_AsiangeneCorporationMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_ScheduleOfAccountReceivableDueFromRelatedPartiesTableTextBlock_lbl0" xml:lang="en-US">ScheduleOfAccountReceivableDueFromRelatedPartiesTableTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ScheduleOfAccountReceivableDueFromRelatedPartiesTableTextBlock" xlink:to="abvcd_ScheduleOfAccountReceivableDueFromRelatedPartiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_LoanAgreementMember_lbl0" xml:lang="en-US">LoanAgreementMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_LoanAgreementMember" xlink:to="abvcd_LoanAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_FinancialAmendmentDescription_lbl0" xml:lang="en-US">FinancialAmendmentDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_FinancialAmendmentDescription" xlink:to="abvcd_FinancialAmendmentDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_DueToEmployeesMember_lbl0" xml:lang="en-US">DueToEmployeesMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_DueToEmployeesMember" xlink:to="abvcd_DueToEmployeesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl1" xml:lang="en-US">ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:to="abvcd_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_NetProceedsFromShortTermBorrowingsFromThirdParties_lbl1" xml:lang="en-US">NetProceedsFromShortTermBorrowingsFromThirdParties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_NetProceedsFromShortTermBorrowingsFromThirdParties" xlink:to="abvcd_NetProceedsFromShortTermBorrowingsFromThirdParties_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_StockholderEquityReverseStockSplit_lbl1" xml:lang="en-US">StockholderEquityReverseStockSplit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_StockholderEquityReverseStockSplit" xlink:to="abvcd_StockholderEquityReverseStockSplit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_CommonStockIssuedBeforeStockSplit_lbl1" xml:lang="en-US">CommonStockIssuedBeforeStockSplit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_CommonStockIssuedBeforeStockSplit" xlink:to="abvcd_CommonStockIssuedBeforeStockSplit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_BioKeyMember_lbl0" xml:lang="en-US">BioKeyMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_BioKeyMember" xlink:to="abvcd_BioKeyMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_YuanGeneCorporationtheYuanGeneMember_lbl0" xml:lang="en-US">YuanGeneCorporationtheYuanGeneMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_YuanGeneCorporationtheYuanGeneMember" xlink:to="abvcd_YuanGeneCorporationtheYuanGeneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_UnsecuredLoanAgreementsDescription_lbl1" xml:lang="en-US">UnsecuredLoanAgreementsDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_UnsecuredLoanAgreementsDescription" xlink:to="abvcd_UnsecuredLoanAgreementsDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_PercentageOfPaymentsUnderCodevelopmentAgreement_lbl1" xml:lang="en-US">PercentageOfPaymentsUnderCodevelopmentAgreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_PercentageOfPaymentsUnderCodevelopmentAgreement" xlink:to="abvcd_PercentageOfPaymentsUnderCodevelopmentAgreement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_IssuanceOfStockValue_lbl0" xml:lang="en-US">IssuanceOfStockValue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_IssuanceOfStockValue" xlink:to="abvcd_IssuanceOfStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_SecuritiesPurchaseAgreementMember_lbl0" xml:lang="en-US">SecuritiesPurchaseAgreementMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_SecuritiesPurchaseAgreementMember" xlink:to="abvcd_SecuritiesPurchaseAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_GenePharmIncMember_lbl0" xml:lang="en-US">GenePharmIncMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_GenePharmIncMember" xlink:to="abvcd_GenePharmIncMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_AccountingTreatmentDescription_lbl0" xml:lang="en-US">AccountingTreatmentDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_AccountingTreatmentDescription" xlink:to="abvcd_AccountingTreatmentDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_WarrantIssued_lbl1" xml:lang="en-US">WarrantIssued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_WarrantIssued" xlink:to="abvcd_WarrantIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_CashPaidDuringTheYearForAbstract_lbl0" xml:lang="en-US">CashPaidDuringTheYearForAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_CashPaidDuringTheYearForAbstract" xlink:to="abvcd_CashPaidDuringTheYearForAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_EuroAsiaInvestmentFinanceCorpLtdtheEuroAsiaMember_lbl0" xml:lang="en-US">EuroAsiaInvestmentFinanceCorpLtdtheEuroAsiaMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_EuroAsiaInvestmentFinanceCorpLtdtheEuroAsiaMember" xlink:to="abvcd_EuroAsiaInvestmentFinanceCorpLtdtheEuroAsiaMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_NumeratorAbstract_lbl0" xml:lang="en-US">NumeratorAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_NumeratorAbstract" xlink:to="abvcd_NumeratorAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_BraingenesisBiotechnologyCoLtdMember_lbl0" xml:lang="en-US">BraingenesisBiotechnologyCoLtdMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_BraingenesisBiotechnologyCoLtdMember" xlink:to="abvcd_BraingenesisBiotechnologyCoLtdMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_StockReverseSplitPolicyTextBlock_lbl1" xml:lang="en-US">StockReverseSplitPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_StockReverseSplitPolicyTextBlock" xlink:to="abvcd_StockReverseSplitPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_RelatedPartyTransactionDescriptionOfTransactions_lbl1" xml:lang="en-US">RelatedPartyTransactionDescriptionOfTransactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_RelatedPartyTransactionDescriptionOfTransactions" xlink:to="abvcd_RelatedPartyTransactionDescriptionOfTransactions_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_NonMarketableCostMethodInvestmentsNetAbstract_lbl0" xml:lang="en-US">NonMarketableCostMethodInvestmentsNetAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_NonMarketableCostMethodInvestmentsNetAbstract" xlink:to="abvcd_NonMarketableCostMethodInvestmentsNetAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_PAYCHECKPROTECTIONPROGRAMMember_lbl0" xml:lang="en-US">PAYCHECKPROTECTIONPROGRAMMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_PAYCHECKPROTECTIONPROGRAMMember" xlink:to="abvcd_PAYCHECKPROTECTIONPROGRAMMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_CTBCBankMember_lbl0" xml:lang="en-US">CTBCBankMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_CTBCBankMember" xlink:to="abvcd_CTBCBankMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_GovernmentGrantIncome_lbl1" xml:lang="en-US">GovernmentGrantIncome</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_GovernmentGrantIncome" xlink:to="abvcd_GovernmentGrantIncome_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_NonmarketableCostMethodInvestmentsNet_lbl0" xml:lang="en-US">NonmarketableCostMethodInvestmentsNet</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_NonmarketableCostMethodInvestmentsNet" xlink:to="abvcd_NonmarketableCostMethodInvestmentsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_LionArtsPromotionInctheLionArtsMember_lbl0" xml:lang="en-US">LionArtsPromotionInctheLionArtsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_LionArtsPromotionInctheLionArtsMember" xlink:to="abvcd_LionArtsPromotionInctheLionArtsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_StockSubscriptionReceivableMember_lbl0" xml:lang="en-US">StockSubscriptionReceivableMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_StockSubscriptionReceivableMember" xlink:to="abvcd_StockSubscriptionReceivableMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_ShareExchangeAgreementMember_lbl1" xml:lang="en-US">ShareExchangeAgreementMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ShareExchangeAgreementMember" xlink:to="abvcd_ShareExchangeAgreementMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_StockIssuedValue_lbl0" xml:lang="en-US">StockIssuedValue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_StockIssuedValue" xlink:to="abvcd_StockIssuedValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_AggregateAmount_lbl1" xml:lang="en-US">AggregateAmount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_AggregateAmount" xlink:to="abvcd_AggregateAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_AdditionCashPayment_lbl0" xml:lang="en-US">AdditionCashPayment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_AdditionCashPayment" xlink:to="abvcd_AdditionCashPayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_LongTermEquityInvestmentPolicy_lbl1" xml:lang="en-US">LongTermEquityInvestmentPolicy</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_LongTermEquityInvestmentPolicy" xlink:to="abvcd_LongTermEquityInvestmentPolicy_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_DenominatorAbstract_lbl0" xml:lang="en-US">DenominatorAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_DenominatorAbstract" xlink:to="abvcd_DenominatorAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_CumulativeTransactionAdjustments_lbl0" xml:lang="en-US">CumulativeTransactionAdjustments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_CumulativeTransactionAdjustments" xlink:to="abvcd_CumulativeTransactionAdjustments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_UnpaidConsultingFees_lbl0" xml:lang="en-US">UnpaidConsultingFees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_UnpaidConsultingFees" xlink:to="abvcd_UnpaidConsultingFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants_lbl0" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants" xlink:to="abvcd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_StockOptions_lbl0" xml:lang="en-US">StockOptions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_StockOptions" xlink:to="abvcd_StockOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_ScheduleOfOwnershipPercentagesOfInvesteeTableTextBlocks_lbl0" xml:lang="en-US">ScheduleOfOwnershipPercentagesOfInvesteeTableTextBlocks</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ScheduleOfOwnershipPercentagesOfInvesteeTableTextBlocks" xlink:to="abvcd_ScheduleOfOwnershipPercentagesOfInvesteeTableTextBlocks_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_NonRelatedPartiesMember_lbl0" xml:lang="en-US">NonRelatedPartiesMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_NonRelatedPartiesMember" xlink:to="abvcd_NonRelatedPartiesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_StockPurchaseAgreementDescription_lbl1" xml:lang="en-US">StockPurchaseAgreementDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_StockPurchaseAgreementDescription" xlink:to="abvcd_StockPurchaseAgreementDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_AsiaGeneMember_lbl0" xml:lang="en-US">AsiaGeneMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_AsiaGeneMember" xlink:to="abvcd_AsiaGeneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_PurchaseConsiderationAbstract_lbl0" xml:lang="en-US">PurchaseConsiderationAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_PurchaseConsiderationAbstract" xlink:to="abvcd_PurchaseConsiderationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_PaycheckProtectionProgramDescription_lbl0" xml:lang="en-US">PaycheckProtectionProgramDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_PaycheckProtectionProgramDescription" xlink:to="abvcd_PaycheckProtectionProgramDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_BioFirstAustraliaMember_lbl0" xml:lang="en-US">BioFirstAustraliaMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_BioFirstAustraliaMember" xlink:to="abvcd_BioFirstAustraliaMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_CoDevAgreementDescription_lbl1" xml:lang="en-US">CoDevAgreementDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_CoDevAgreementDescription" xlink:to="abvcd_CoDevAgreementDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember_lbl0" xml:lang="en-US">BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember" xlink:to="abvcd_BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_InterestRate_lbl0" xml:lang="en-US">InterestRate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_InterestRate" xlink:to="abvcd_InterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_BioHopeKingCorporationMember_lbl0" xml:lang="en-US">BioHopeKingCorporationMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_BioHopeKingCorporationMember" xlink:to="abvcd_BioHopeKingCorporationMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_BioLiteMember_lbl0" xml:lang="en-US">BioLiteMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_BioLiteMember" xlink:to="abvcd_BioLiteMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_PercentageOfMonthlyContribution_lbl1" xml:lang="en-US">PercentageOfMonthlyContribution</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_PercentageOfMonthlyContribution" xlink:to="abvcd_PercentageOfMonthlyContribution_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_LionGeneCorporationMember_lbl0" xml:lang="en-US">LionGeneCorporationMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_LionGeneCorporationMember" xlink:to="abvcd_LionGeneCorporationMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_NetLoss_lbl0" xml:lang="en-US">NetLoss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_NetLoss" xlink:to="abvcd_NetLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_BioFirstCorporationMember_lbl1" xml:lang="en-US">BioFirstCorporationMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_BioFirstCorporationMember" xlink:to="abvcd_BioFirstCorporationMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_NumberOfEmployees_lbl1" xml:lang="en-US">NumberOfEmployees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_NumberOfEmployees" xlink:to="abvcd_NumberOfEmployees_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_AllowanceForInventoryValuationAndObsolescenceLoss_lbl1" xml:lang="en-US">AllowanceForInventoryValuationAndObsolescenceLoss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_AllowanceForInventoryValuationAndObsolescenceLoss" xlink:to="abvcd_AllowanceForInventoryValuationAndObsolescenceLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_ScheduleOfRelatedPartyTransactionsAmountDueToRelatedParty_lbl1" xml:lang="en-US">ScheduleOfRelatedPartyTransactionsAmountDueToRelatedParty</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ScheduleOfRelatedPartyTransactionsAmountDueToRelatedParty" xlink:to="abvcd_ScheduleOfRelatedPartyTransactionsAmountDueToRelatedParty_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_AggregateWorkingcapital_lbl1" xml:lang="en-US">AggregateWorkingcapital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_AggregateWorkingcapital" xlink:to="abvcd_AggregateWorkingcapital_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_KimhoConsultantsCoLtdtheKimhoMember_lbl0" xml:lang="en-US">KimhoConsultantsCoLtdtheKimhoMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_KimhoConsultantsCoLtdtheKimhoMember" xlink:to="abvcd_KimhoConsultantsCoLtdtheKimhoMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_CathayUnitedBankMember_lbl0" xml:lang="en-US">CathayUnitedBankMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_CathayUnitedBankMember" xlink:to="abvcd_CathayUnitedBankMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_CollaborativeAgreementsDescription_lbl1" xml:lang="en-US">CollaborativeAgreementsDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_CollaborativeAgreementsDescription" xlink:to="abvcd_CollaborativeAgreementsDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_AdvancesBearInterestDescription_lbl1" xml:lang="en-US">AdvancesBearInterestDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_AdvancesBearInterestDescription" xlink:to="abvcd_AdvancesBearInterestDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_NTMember_lbl0" xml:lang="en-US">NTMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_NTMember" xlink:to="abvcd_NTMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_MrTsungShannJiangMsShuLingJiangMrChangJenJiangMsMeiLingJiangAndMrEugeneJiangcollectivelyTheJiangsMember_lbl0" xml:lang="en-US">MrTsungShannJiangMsShuLingJiangMrChangJenJiangMsMeiLingJiangAndMrEugeneJiangcollectivelyTheJiangsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_MrTsungShannJiangMsShuLingJiangMrChangJenJiangMsMeiLingJiangAndMrEugeneJiangcollectivelyTheJiangsMember" xlink:to="abvcd_MrTsungShannJiangMsShuLingJiangMrChangJenJiangMsMeiLingJiangAndMrEugeneJiangcollectivelyTheJiangsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_BioLiteTaiwanMember_lbl0" xml:lang="en-US">BioLiteTaiwanMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_BioLiteTaiwanMember" xlink:to="abvcd_BioLiteTaiwanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_TwoThousandSixteenEquityIncentivePlanMember_lbl0" xml:lang="en-US">TwoThousandSixteenEquityIncentivePlanMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_TwoThousandSixteenEquityIncentivePlanMember" xlink:to="abvcd_TwoThousandSixteenEquityIncentivePlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_EuroAsiaInvestmentAndFinanceCorpLtdMember_lbl0" xml:lang="en-US">EuroAsiaInvestmentAndFinanceCorpLtdMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_EuroAsiaInvestmentAndFinanceCorpLtdMember" xlink:to="abvcd_EuroAsiaInvestmentAndFinanceCorpLtdMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_ValuationOfDeferredTaxAssetsPolicyTextBlock_lbl1" xml:lang="en-US">ValuationOfDeferredTaxAssetsPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ValuationOfDeferredTaxAssetsPolicyTextBlock" xlink:to="abvcd_ValuationOfDeferredTaxAssetsPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_LionArtsPromotionInctheLIONMember_lbl0" xml:lang="en-US">LionArtsPromotionInctheLIONMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_LionArtsPromotionInctheLIONMember" xlink:to="abvcd_LionArtsPromotionInctheLIONMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_ConsultingAgreementMember_lbl0" xml:lang="en-US">ConsultingAgreementMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ConsultingAgreementMember" xlink:to="abvcd_ConsultingAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_AllocationOfThePurchasePriceAbstract_lbl0" xml:lang="en-US">AllocationOfThePurchasePriceAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_AllocationOfThePurchasePriceAbstract" xlink:to="abvcd_AllocationOfThePurchasePriceAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_KeypointMember_lbl0" xml:lang="en-US">KeypointMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_KeypointMember" xlink:to="abvcd_KeypointMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_RentalIncomeRelatedParties_lbl0" xml:lang="en-US">RentalIncomeRelatedParties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_RentalIncomeRelatedParties" xlink:to="abvcd_RentalIncomeRelatedParties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_MilestonePaymentsRoyaltyPercentage_lbl1" xml:lang="en-US">MilestonePaymentsRoyaltyPercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_MilestonePaymentsRoyaltyPercentage" xlink:to="abvcd_MilestonePaymentsRoyaltyPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_ScheduleOfLongTermInvestmentTableTextBlock_lbl0" xml:lang="en-US">ScheduleOfLongTermInvestmentTableTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ScheduleOfLongTermInvestmentTableTextBlock" xlink:to="abvcd_ScheduleOfLongTermInvestmentTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_OtherThanTemporaryImpairmentPolicyTextBlock_lbl1" xml:lang="en-US">OtherThanTemporaryImpairmentPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_OtherThanTemporaryImpairmentPolicyTextBlock" xlink:to="abvcd_OtherThanTemporaryImpairmentPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_AgreemnetAxis_lbl0" xml:lang="en-US">AgreemnetAxis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_AgreemnetAxis" xlink:to="abvcd_AgreemnetAxis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_NetLossAttributableToAbvcAndSubsidiaries_lbl1" xml:lang="en-US">NetLossAttributableToAbvcAndSubsidiaries</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_NetLossAttributableToAbvcAndSubsidiaries" xlink:to="abvcd_NetLossAttributableToAbvcAndSubsidiaries_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_YuangeneCorporationMember_lbl0" xml:lang="en-US">YuangeneCorporationMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_YuangeneCorporationMember" xlink:to="abvcd_YuangeneCorporationMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_PaycheckProtectionProgramLoanPayableTextBlock_lbl0" xml:lang="en-US">PaycheckProtectionProgramLoanPayableTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_PaycheckProtectionProgramLoanPayableTextBlock" xlink:to="abvcd_PaycheckProtectionProgramLoanPayableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability_lbl0" xml:lang="en-US">BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability" xlink:to="abvcd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_RgeneMember_lbl0" xml:lang="en-US">RgeneMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_RgeneMember" xlink:to="abvcd_RgeneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_LionGeneCorporationtheLionGeneMember_lbl0" xml:lang="en-US">LionGeneCorporationtheLionGeneMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_LionGeneCorporationtheLionGeneMember" xlink:to="abvcd_LionGeneCorporationtheLionGeneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_ScheduleOfExtentInvesteeReliesTableTextBlock_lbl1" xml:lang="en-US">ScheduleOfExtentInvesteeReliesTableTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ScheduleOfExtentInvesteeReliesTableTextBlock" xlink:to="abvcd_ScheduleOfExtentInvesteeReliesTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_Consultingagreementdescription_lbl1" xml:lang="en-US">Consultingagreementdescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_Consultingagreementdescription" xlink:to="abvcd_Consultingagreementdescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_CodevelopmentagreementMember_lbl0" xml:lang="en-US">CodevelopmentagreementMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_CodevelopmentagreementMember" xlink:to="abvcd_CodevelopmentagreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_ConversionAgreementsOneMember_lbl0" xml:lang="en-US">ConversionAgreementsOneMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ConversionAgreementsOneMember" xlink:to="abvcd_ConversionAgreementsOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_ReceivedLoanAmount_lbl1" xml:lang="en-US">ReceivedLoanAmount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ReceivedLoanAmount" xlink:to="abvcd_ReceivedLoanAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_ForwardStockSplitsPolicyTextBlock_lbl1" xml:lang="en-US">ForwardStockSplitsPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ForwardStockSplitsPolicyTextBlock" xlink:to="abvcd_ForwardStockSplitsPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_ScheduleOfOperatingLeaseArrangementsTableTextBlock_lbl1" xml:lang="en-US">ScheduleOfOperatingLeaseArrangementsTableTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ScheduleOfOperatingLeaseArrangementsTableTextBlock" xlink:to="abvcd_ScheduleOfOperatingLeaseArrangementsTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_AccruedInterest_lbl1" xml:lang="en-US">AccruedInterest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_AccruedInterest" xlink:to="abvcd_AccruedInterest_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_BeneficialConversionFeature_lbl1" xml:lang="en-US">BeneficialConversionFeature</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_BeneficialConversionFeature" xlink:to="abvcd_BeneficialConversionFeature_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_DueToshareholdersMember_lbl0" xml:lang="en-US">DueToshareholdersMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_DueToshareholdersMember" xlink:to="abvcd_DueToshareholdersMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_PlacementAgentAgreementDescription_lbl0" xml:lang="en-US">PlacementAgentAgreementDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_PlacementAgentAgreementDescription" xlink:to="abvcd_PlacementAgentAgreementDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_TheJiangsMember_lbl0" xml:lang="en-US">TheJiangsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_TheJiangsMember" xlink:to="abvcd_TheJiangsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_PercentageOfGoodwill_lbl0" xml:lang="en-US">PercentageOfGoodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_PercentageOfGoodwill" xlink:to="abvcd_PercentageOfGoodwill_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_ShareOfEquityMethodInvesteeLosses_lbl0" xml:lang="en-US">ShareOfEquityMethodInvesteeLosses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ShareOfEquityMethodInvesteeLosses" xlink:to="abvcd_ShareOfEquityMethodInvesteeLosses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm_lbl0" xml:lang="en-US">SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm" xlink:to="abvcd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_TypeOfCurrencyAxis_lbl0" xml:lang="en-US">TypeOfCurrencyAxis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_TypeOfCurrencyAxis" xlink:to="abvcd_TypeOfCurrencyAxis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_CathayUnitedLoanAgreementMember_lbl0" xml:lang="en-US">CathayUnitedLoanAgreementMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_CathayUnitedLoanAgreementMember" xlink:to="abvcd_CathayUnitedLoanAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_TranslationAdjustmentPolicyTextBlock_lbl1" xml:lang="en-US">TranslationAdjustmentPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_TranslationAdjustmentPolicyTextBlock" xlink:to="abvcd_TranslationAdjustmentPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_JIANGSMember_lbl1" xml:lang="en-US">JIANGSMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_JIANGSMember" xlink:to="abvcd_JIANGSMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_KameyamaMember_lbl0" xml:lang="en-US">KameyamaMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_KameyamaMember" xlink:to="abvcd_KameyamaMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_CommonStockIssuedAfterStockSplit_lbl2" xml:lang="en-US">CommonStockIssuedAfterStockSplit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_CommonStockIssuedAfterStockSplit" xlink:to="abvcd_CommonStockIssuedAfterStockSplit_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_ShareExchangeAgreementOneMember_lbl0" xml:lang="en-US">ShareExchangeAgreementOneMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ShareExchangeAgreementOneMember" xlink:to="abvcd_ShareExchangeAgreementOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_CathayBnakMember_lbl1" xml:lang="en-US">CathayBnakMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_CathayBnakMember" xlink:to="abvcd_CathayBnakMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_GenePharmInctheGenePharmMember_lbl0" xml:lang="en-US">GenePharmInctheGenePharmMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_GenePharmInctheGenePharmMember" xlink:to="abvcd_GenePharmInctheGenePharmMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_LBGUSAMember_lbl0" xml:lang="en-US">LBGUSAMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_LBGUSAMember" xlink:to="abvcd_LBGUSAMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_PercentageOfCommonSharesIssuedAndOutstanding_lbl1" xml:lang="en-US">PercentageOfCommonSharesIssuedAndOutstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_PercentageOfCommonSharesIssuedAndOutstanding" xlink:to="abvcd_PercentageOfCommonSharesIssuedAndOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_RgeneCorporationMember_lbl1" xml:lang="en-US">RgeneCorporationMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_RgeneCorporationMember" xlink:to="abvcd_RgeneCorporationMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_MergerAgreementMember_lbl0" xml:lang="en-US">MergerAgreementMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_MergerAgreementMember" xlink:to="abvcd_MergerAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_YoshinobuOdairatheOdairaMember_lbl0" xml:lang="en-US">YoshinobuOdairatheOdairaMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_YoshinobuOdairatheOdairaMember" xlink:to="abvcd_YoshinobuOdairatheOdairaMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_lbl0" xml:lang="en-US">BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:to="abvcd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_NumberOfInvestors_lbl0" xml:lang="en-US">NumberOfInvestors</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_NumberOfInvestors" xlink:to="abvcd_NumberOfInvestors_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_ConsultingFees_lbl0" xml:lang="en-US">ConsultingFees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ConsultingFees" xlink:to="abvcd_ConsultingFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_AgreementDescription_lbl1" xml:lang="en-US">AgreementDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_AgreementDescription" xlink:to="abvcd_AgreementDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_RgeneCorporationtheRgeneMember_lbl0" xml:lang="en-US">RgeneCorporationtheRgeneMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_RgeneCorporationtheRgeneMember" xlink:to="abvcd_RgeneCorporationtheRgeneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_UnsecuredConvertiblePromissoryNoteMember_lbl0" xml:lang="en-US">UnsecuredConvertiblePromissoryNoteMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_UnsecuredConvertiblePromissoryNoteMember" xlink:to="abvcd_UnsecuredConvertiblePromissoryNoteMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_StockIssuedDuringPeriodShareBasedCompensationServicesforShares_lbl0" xml:lang="en-US">StockIssuedDuringPeriodShareBasedCompensationServicesforShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_StockIssuedDuringPeriodShareBasedCompensationServicesforShares" xlink:to="abvcd_StockIssuedDuringPeriodShareBasedCompensationServicesforShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_PromissoryNoteTerm_lbl0" xml:lang="en-US">PromissoryNoteTerm</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_PromissoryNoteTerm" xlink:to="abvcd_PromissoryNoteTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_RestrictedCommonShares_lbl1" xml:lang="en-US">RestrictedCommonShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_RestrictedCommonShares" xlink:to="abvcd_RestrictedCommonShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_AggregateCommonStockShares_lbl1" xml:lang="en-US">AggregateCommonStockShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_AggregateCommonStockShares" xlink:to="abvcd_AggregateCommonStockShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_GenepharmBiotechCorporationMember_lbl0" xml:lang="en-US">GenepharmBiotechCorporationMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_GenepharmBiotechCorporationMember" xlink:to="abvcd_GenepharmBiotechCorporationMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_ShareExchangeAgreementTwoMember_lbl0" xml:lang="en-US">ShareExchangeAgreementTwoMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ShareExchangeAgreementTwoMember" xlink:to="abvcd_ShareExchangeAgreementTwoMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_AsiaGeneCorporationtheAsiaGeneMember_lbl0" xml:lang="en-US">AsiaGeneCorporationtheAsiaGeneMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_AsiaGeneCorporationtheAsiaGeneMember" xlink:to="abvcd_AsiaGeneCorporationtheAsiaGeneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvcd_ShareExchangeAgreementFourMember_lbl0" xml:lang="en-US">ShareExchangeAgreementFourMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvcd_ShareExchangeAgreementFourMember" xlink:to="abvcd_ShareExchangeAgreementFourMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableRelatedParties_lbl0" xml:lang="en-US">Accounts Receivable, Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableRelatedParties" xlink:to="us-gaap_AccountsReceivableRelatedParties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl0" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShorttermDebtAverageOutstandingAmount_lbl0" xml:lang="en-US">Short-term Debt, Average Outstanding Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShorttermDebtAverageOutstandingAmount" xlink:to="us-gaap_ShorttermDebtAverageOutstandingAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueFromOtherRelatedPartiesCurrent_lbl0" xml:lang="en-US">Due from Other Related Parties, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromOtherRelatedPartiesCurrent" xlink:to="us-gaap_DueFromOtherRelatedPartiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RentalIncomeNonoperating_lbl0" xml:lang="en-US">Rental Income, Nonoperating</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RentalIncomeNonoperating" xlink:to="us-gaap_RentalIncomeNonoperating_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl0" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockMember_lbl0" xml:lang="en-US">Treasury Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockMember" xlink:to="us-gaap_TreasuryStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAbstract_lbl0" xml:lang="en-US">Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNotesPayable_lbl0" xml:lang="en-US">Other Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNotesPayable" xlink:to="us-gaap_OtherNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl0" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl0" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy_lbl0" xml:lang="en-US">Pension and Other Postretirement Plans, Nonpension Benefits, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy" xlink:to="us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl0" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebt_lbl0" xml:lang="en-US">Convertible Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebt" xlink:to="us-gaap_ConvertibleDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentsTextBlock_lbl0" xml:lang="en-US">Equity Method Investments [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsTextBlock" xlink:to="us-gaap_EquityMethodInvestmentsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedGainLoss_lbl0" xml:lang="en-US">Equity Securities, FV-NI, Realized Gain (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:to="us-gaap_EquitySecuritiesFvNiRealizedGainLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">Selling, General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl0" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl0" xml:lang="en-US">Share Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl2" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl0" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShortTermDebtTextBlock_lbl0" xml:lang="en-US">Schedule of Short-term Debt [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:to="us-gaap_ScheduleOfShortTermDebtTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl0" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl1" xml:lang="en-US">Interest Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl0" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_lbl0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl0" xml:lang="en-US">Office Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl0" xml:lang="en-US">Proceeds from Related Party Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLeaseIncomeLeasePayments_lbl0" xml:lang="en-US">Operating Lease, Lease Income, Lease Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:to="us-gaap_OperatingLeaseLeaseIncomeLeasePayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnsecuredDebt_lbl0" xml:lang="en-US">Unsecured Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnsecuredDebt" xlink:to="us-gaap_UnsecuredDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0" xml:lang="en-US">Revenue [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl1" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl0" xml:lang="en-US">Accrued Employee Benefits, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcess_lbl0" xml:lang="en-US">Inventory, Work in Process, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl0" xml:lang="en-US">Inventory Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable_lbl0" xml:lang="en-US">Short-term Bank Loans and Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBankLoansAndNotesPayable" xlink:to="us-gaap_ShortTermBankLoansAndNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl0" xml:lang="en-US">Operating Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl0" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl0" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableToBankCurrent_lbl0" xml:lang="en-US">Notes Payable to Bank, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableToBankCurrent" xlink:to="us-gaap_NotesPayableToBankCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl0" xml:lang="en-US">Earnings Per Share [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US">Stockholders&apos; Equity Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_lbl1" xml:lang="en-US">Gross Profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl1" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherShortTermBorrowings_lbl0" xml:lang="en-US">Other Short-term Borrowings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherShortTermBorrowings" xlink:to="us-gaap_OtherShortTermBorrowings_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerAdvancesForConstruction_lbl0" xml:lang="en-US">Customer Advances for Construction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerAdvancesForConstruction" xlink:to="us-gaap_CustomerAdvancesForConstruction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnInvestments_lbl0" xml:lang="en-US">Gain (Loss) on Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnInvestments" xlink:to="us-gaap_GainLossOnInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl1" xml:lang="en-US">Due to Related Parties, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPortionOfMinimumLeasePaymentsSaleLeasebackTransactions_lbl0" xml:lang="en-US">Interest Portion of Minimum Lease Payments, Sale Leaseback Transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPortionOfMinimumLeasePaymentsSaleLeasebackTransactions" xlink:to="us-gaap_InterestPortionOfMinimumLeasePaymentsSaleLeasebackTransactions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl1" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl0" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseDueFromOtherRelatedParties_lbl0" xml:lang="en-US">Increase (Decrease) Due from Other Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseDueFromOtherRelatedParties" xlink:to="us-gaap_IncreaseDecreaseDueFromOtherRelatedParties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl0" xml:lang="en-US">Restricted Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl0" xml:lang="en-US">Inventory, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl1" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfLoanCosts_lbl0" xml:lang="en-US">Payments of Loan Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfLoanCosts" xlink:to="us-gaap_PaymentsOfLoanCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl2" xml:lang="en-US">Stockholders&apos; Equity, Including Portion Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterest_lbl0" xml:lang="en-US">Stockholders&apos; Equity Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterest" xlink:to="us-gaap_MinorityInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl0" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Five Years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LandMember_lbl0" xml:lang="en-US">Land [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandMember" xlink:to="us-gaap_LandMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl1" xml:lang="en-US">Debt Instrument, Face Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl0" xml:lang="en-US">Increase (Decrease) in Due to Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl0" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl0" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl0" xml:lang="en-US">Debt Instrument, Interest Rate During Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestments_lbl0" xml:lang="en-US">Equity Method Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestments" xlink:to="us-gaap_EquityMethodInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl0" xml:lang="en-US">Private Placement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl1" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_lbl0" xml:lang="en-US">Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl0" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl0" xml:lang="en-US">Cost of Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl0" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Related Party Transactions [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl0" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl0" xml:lang="en-US">Additional Paid in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl0" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl1" xml:lang="en-US">Debt Instrument, Increase, Accrued Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_lbl0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl0" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueFromOtherRelatedParties_lbl0" xml:lang="en-US">Due from Other Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromOtherRelatedParties" xlink:to="us-gaap_DueFromOtherRelatedParties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash_lbl0" xml:lang="en-US">Employee Benefit and Share-based Payment Arrangement, Noncash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl0" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForParticipationLiabilities_lbl0" xml:lang="en-US">Payments for Participation Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForParticipationLiabilities" xlink:to="us-gaap_PaymentsForParticipationLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Receivable and Other Operating Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl0" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due Thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionRate_lbl0" xml:lang="en-US">Related Party Transaction, Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionRate" xlink:to="us-gaap_RelatedPartyTransactionRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl0" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl0" xml:lang="en-US">Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MembersEquityNotesDisclosureTextBlock_lbl0" xml:lang="en-US">Members&apos; Equity Notes Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MembersEquityNotesDisclosureTextBlock" xlink:to="us-gaap_MembersEquityNotesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermBorrowings_lbl0" xml:lang="en-US">Short-term Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowings" xlink:to="us-gaap_ShortTermBorrowings_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl0" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl2" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl0" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl1" xml:lang="en-US">Debt Instrument, Maturity Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleLongTermNotesPayable_lbl0" xml:lang="en-US">Convertible Notes Payable, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleLongTermNotesPayable" xlink:to="us-gaap_ConvertibleLongTermNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockDescriptionOfTransaction_lbl1" xml:lang="en-US">Sale of Stock, Description of Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockDescriptionOfTransaction" xlink:to="us-gaap_SaleOfStockDescriptionOfTransaction_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl0" xml:lang="en-US">Preferred Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaid_lbl0" xml:lang="en-US">Income Taxes Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Lease, Disclosure [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:to="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl0" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_lbl0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl0" xml:lang="en-US">Repayments of Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncontrollingInterestMember_lbl0" xml:lang="en-US">Noncontrolling Interest [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestMember" xlink:to="us-gaap_NoncontrollingInterestMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl0" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl0" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl0" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl0" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateTerms_lbl0" xml:lang="en-US">Debt Instrument, Interest Rate Terms</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateTerms" xlink:to="us-gaap_DebtInstrumentInterestRateTerms_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl0" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl1" xml:lang="en-US">Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl0" xml:lang="en-US">Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_lbl0" xml:lang="en-US">Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl0" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTerm_lbl0" xml:lang="en-US">Debt Instrument, Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableRelatedPartiesCurrent_lbl0" xml:lang="en-US">Accounts Receivable, Related Parties, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:to="us-gaap_AccountsReceivableRelatedPartiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl1" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl0" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansPayable_lbl1" xml:lang="en-US">Loans Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayable" xlink:to="us-gaap_LoansPayable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl0" xml:lang="en-US">Earnings Per Share, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtInterestRateIncrease_lbl0" xml:lang="en-US">Short-term Debt, Interest Rate Increase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtInterestRateIncrease" xlink:to="us-gaap_ShortTermDebtInterestRateIncrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl0" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromContributionsFromAffiliates_lbl0" xml:lang="en-US">Proceeds from Contributions from Affiliates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromContributionsFromAffiliates" xlink:to="us-gaap_ProceedsFromContributionsFromAffiliates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl0" xml:lang="en-US">Other Noncash Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireNotesReceivable_lbl0" xml:lang="en-US">Payments to Acquire Notes Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireNotesReceivable" xlink:to="us-gaap_PaymentsToAcquireNotesReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl0" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl0" xml:lang="en-US">Business Combination Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl0" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNotesPayableCurrent_lbl0" xml:lang="en-US">Other Notes Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNotesPayableCurrent" xlink:to="us-gaap_OtherNotesPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl0" xml:lang="en-US">Other Nonoperating Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent_lbl0" xml:lang="en-US">Due to Other Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent" xlink:to="us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl0" xml:lang="en-US">Investment Income, Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiscalPeriod_lbl0" xml:lang="en-US">Fiscal Period, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiscalPeriod" xlink:to="us-gaap_FiscalPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl0" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredOther1_lbl0" xml:lang="en-US">Business Combination, Consideration Transferred, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredOther1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterials_lbl0" xml:lang="en-US">Inventory, Raw Materials, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl1" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestAndDebtExpense_lbl0" xml:lang="en-US">Interest and Debt Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndDebtExpense" xlink:to="us-gaap_InterestAndDebtExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecurityDepositLiability_lbl0" xml:lang="en-US">Security Deposit Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDepositLiability" xlink:to="us-gaap_SecurityDepositLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock_lbl0" xml:lang="en-US">Condensed Balance Sheet [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:to="srt_ScheduleOfCondensedBalanceSheetTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl1" xml:lang="en-US">Shares Issued, Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl0" xml:lang="en-US">Common Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl0" xml:lang="en-US">Cost of Goods and Services Sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTextBlock_lbl0" xml:lang="en-US">Short-term Debt [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTextBlock" xlink:to="us-gaap_ShortTermDebtTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_lbl0" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:to="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Other Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl0" xml:lang="en-US">Deferred Income Tax Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl0" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl0" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueFromRelatedPartiesCurrent_lbl0" xml:lang="en-US">Due from Related Parties, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromRelatedPartiesCurrent" xlink:to="us-gaap_DueFromRelatedPartiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl0" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecurityDeposit_lbl0" xml:lang="en-US">Security Deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl0" xml:lang="en-US">Liabilities, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockValue_lbl0" xml:lang="en-US">Treasury Stock, Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0" xml:lang="en-US">Stockholders&apos; Equity Note Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireOtherInvestments_lbl0" xml:lang="en-US">Payments to Acquire Other Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireOtherInvestments" xlink:to="us-gaap_PaymentsToAcquireOtherInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl0" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_lbl1" xml:lang="en-US">Due to Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl0" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfCondensedIncomeStatementTableTextBlock_lbl0" xml:lang="en-US">Condensed Income Statement [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedIncomeStatementTableTextBlock" xlink:to="srt_ScheduleOfCondensedIncomeStatementTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl0" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_lbl0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl0" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl0" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl0" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl0" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl2" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl0" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl0" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeMember_lbl0" xml:lang="en-US">Comprehensive Income [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeMember" xlink:to="us-gaap_ComprehensiveIncomeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermInvestments_lbl0" xml:lang="en-US">Long-term Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermInvestments" xlink:to="us-gaap_LongTermInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl1" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_lbl0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl0" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl0" xml:lang="en-US">Machinery and Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_MachineryAndEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl0" xml:lang="en-US">Repayments of Long-term Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermDebt" xlink:to="us-gaap_RepaymentsOfLongTermDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteSubscriptionsReceivable_lbl0" xml:lang="en-US">Stockholders&apos; Equity Note, Subscriptions Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:to="us-gaap_StockholdersEquityNoteSubscriptionsReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Trade</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl0" xml:lang="en-US">Property, Plant and Equipment, Estimated Useful Lives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseNoncurrent_lbl0" xml:lang="en-US">Prepaid Expense, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseNoncurrent" xlink:to="us-gaap_PrepaidExpenseNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl0" xml:lang="en-US">Accounts Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl0" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PresentValueOfFutureMinimumLeasePaymentsSaleLeasebackTransactions_lbl0" xml:lang="en-US">Present Value of Future Minimum Lease Payments, Sale Leaseback Transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PresentValueOfFutureMinimumLeasePaymentsSaleLeasebackTransactions" xlink:to="us-gaap_PresentValueOfFutureMinimumLeasePaymentsSaleLeasebackTransactions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement_lbl0" xml:lang="en-US">Related Party Transaction, Terms and Manner of Settlement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement" xlink:to="us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl0" xml:lang="en-US">Unrealized Gain (Loss) on Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnInvestments" xlink:to="us-gaap_UnrealizedGainLossOnInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl0" xml:lang="en-US">Inventory, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoods_lbl0" xml:lang="en-US">Inventory, Finished Goods, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl0" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl0" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl0" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfessionalFees_lbl0" xml:lang="en-US">Professional Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature_lbl0" xml:lang="en-US">Debt Instrument, Convertible, Terms of Conversion Feature</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature" xlink:to="us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl1" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDebtConversionsTextBlock_lbl0" xml:lang="en-US">Schedule of Debt Conversions [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtConversionsTextBlock" xlink:to="us-gaap_ScheduleOfDebtConversionsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl0" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseOther_lbl0" xml:lang="en-US">Interest Expense, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseOther" xlink:to="us-gaap_InterestExpenseOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl0" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Goodwill_lbl0" xml:lang="en-US">Goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl0" xml:lang="en-US">Sale of Stock, Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl0" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl0" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockDescription_lbl0" xml:lang="en-US">Conversion of Stock, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockDescription" xlink:to="us-gaap_ConversionOfStockDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementMember_lbl0" xml:lang="en-US">Collaborative Arrangement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="us-gaap_CollaborativeArrangementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl0" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl0" xml:lang="en-US">Employee Benefits and Share-based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_lbl0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl0" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_lbl0" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl1" xml:lang="en-US">Equity Method Investment, Ownership Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl0" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements_lbl0" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Equity Unit Purchase Agreements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements" xlink:to="us-gaap_IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_lbl0" xml:lang="en-US">Proceeds from Issuance of Other Long-term Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl0" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl1" xml:lang="en-US">Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>abvcd-20210331_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon May 10 19:51:10 UTC 2021 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_ConsolidatedBalanceSheet" roleURI="http://metuboutique.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://metuboutique.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_ConsolidatedIncomeStatement" roleURI="http://metuboutique.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_ConsolidatedCashFlow" roleURI="http://metuboutique.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_ShareholdersEquityType2or3" roleURI="http://metuboutique.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_OrganizationandDescriptionofBusiness" roleURI="http://metuboutique.com/role/OrganizationandDescriptionofBusiness"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_SummaryofSignificantAccountingPolicies" roleURI="http://metuboutique.com/role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_CollaborativeAgreements" roleURI="http://metuboutique.com/role/CollaborativeAgreements"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_Inventory" roleURI="http://metuboutique.com/role/Inventory"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_PropertyandEquipment" roleURI="http://metuboutique.com/role/PropertyandEquipment"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_LongTermInvestments" roleURI="http://metuboutique.com/role/LongTermInvestments"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_ConvertibleNotesPayable" roleURI="http://metuboutique.com/role/ConvertibleNotesPayable"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_BankLoans" roleURI="http://metuboutique.com/role/BankLoans"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_PaycheckProtectionProgramLoanPayable" roleURI="http://metuboutique.com/role/PaycheckProtectionProgramLoanPayable"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_NotesPayable" roleURI="http://metuboutique.com/role/NotesPayable"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_ShorttermLoan" roleURI="http://metuboutique.com/role/ShorttermLoan"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_RelatedPartiesTransactions" roleURI="http://metuboutique.com/role/RelatedPartiesTransactions"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_Equity" roleURI="http://metuboutique.com/role/Equity"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_StockOptions" roleURI="http://metuboutique.com/role/StockOptions"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_LossperShare" roleURI="http://metuboutique.com/role/LossperShare"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_Lease" roleURI="http://metuboutique.com/role/Lease"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_BusinessCombination" roleURI="http://metuboutique.com/role/BusinessCombination"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_SubsequentEvents" roleURI="http://metuboutique.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_AccountingPoliciesByPolicy" roleURI="http://metuboutique.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_SummaryofSignificantAccountingPoliciesTables" roleURI="http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_InventoryTables" roleURI="http://metuboutique.com/role/InventoryTables"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_PropertyandEquipmentTables" roleURI="http://metuboutique.com/role/PropertyandEquipmentTables"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_LongTermInvestmentsTables" roleURI="http://metuboutique.com/role/LongTermInvestmentsTables"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_BankLoansTables" roleURI="http://metuboutique.com/role/BankLoansTables"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_RelatedPartiesTransactionsTables" roleURI="http://metuboutique.com/role/RelatedPartiesTransactionsTables"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_EquityTables" roleURI="http://metuboutique.com/role/EquityTables"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_StockOptionsTables" roleURI="http://metuboutique.com/role/StockOptionsTables"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_LossperShareTables" roleURI="http://metuboutique.com/role/LossperShareTables"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_LeaseTables" roleURI="http://metuboutique.com/role/LeaseTables"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_BusinessCombinationTables" roleURI="http://metuboutique.com/role/BusinessCombinationTables"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_ScheduleofpropertyandequipmentTable" roleURI="http://metuboutique.com/role/ScheduleofpropertyandequipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_ScheduleofinventoryTable" roleURI="http://metuboutique.com/role/ScheduleofinventoryTable"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_ScheduleofpropertyandequipmentTable0" roleURI="http://metuboutique.com/role/ScheduleofpropertyandequipmentTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_ScheduleofownershippercentagesofinvesteeTable" roleURI="http://metuboutique.com/role/ScheduleofownershippercentagesofinvesteeTable"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_ScheduleofextenttheinvesteereliesTable" roleURI="http://metuboutique.com/role/ScheduleofextenttheinvesteereliesTable"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_ScheduleoflongterminvestmentTable" roleURI="http://metuboutique.com/role/ScheduleoflongterminvestmentTable"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_ScheduleofbalancesheetsTable" roleURI="http://metuboutique.com/role/ScheduleofbalancesheetsTable"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_ScheduleofstatementsofoperationTable" roleURI="http://metuboutique.com/role/ScheduleofstatementsofoperationTable"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_ScheduleofequityinvestmentsTable" roleURI="http://metuboutique.com/role/ScheduleofequityinvestmentsTable"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_ScheduleofshorttermbankloanTable" roleURI="http://metuboutique.com/role/ScheduleofshorttermbankloanTable"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_ScheduleofrelatedpartytransactionsTable" roleURI="http://metuboutique.com/role/ScheduleofrelatedpartytransactionsTable"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_ScheduleofaccountsreceivableduefromrelatedpartiesTable" roleURI="http://metuboutique.com/role/ScheduleofaccountsreceivableduefromrelatedpartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_ScheduleofamountduefromrelatedpartiesTable" roleURI="http://metuboutique.com/role/ScheduleofamountduefromrelatedpartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_ScheduleofamountduetorelatedpartiesTable" roleURI="http://metuboutique.com/role/ScheduleofamountduetorelatedpartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_ScheduleofconvertedamountofdebtandsharesTable" roleURI="http://metuboutique.com/role/ScheduleofconvertedamountofdebtandsharesTable"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_ScheduleofoptionsissuedandoutstandingTable" roleURI="http://metuboutique.com/role/ScheduleofoptionsissuedandoutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_ScheduleoffairvalueofstockoptionsgrantedTable" roleURI="http://metuboutique.com/role/ScheduleoffairvalueofstockoptionsgrantedTable"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_ScheduleoflosspershareTable" roleURI="http://metuboutique.com/role/ScheduleoflosspershareTable"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_ScheduleofoperatingleasearrangementsTable" roleURI="http://metuboutique.com/role/ScheduleofoperatingleasearrangementsTable"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_ScheduleofsupplementalinformationrelatedtooperatingleasesTable" roleURI="http://metuboutique.com/role/ScheduleofsupplementalinformationrelatedtooperatingleasesTable"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_ScheduleofminimumfutureannualpaymentsundernoncancellableleasesTable" roleURI="http://metuboutique.com/role/ScheduleofminimumfutureannualpaymentsundernoncancellableleasesTable"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_ScheduleofassetsacquiredandliabilitiesassumedbasedonfairvalueTable" roleURI="http://metuboutique.com/role/ScheduleofassetsacquiredandliabilitiesassumedbasedonfairvalueTable"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_OrganizationandDescriptionofBusinessDetails" roleURI="http://metuboutique.com/role/OrganizationandDescriptionofBusinessDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_CollaborativeAgreementsDetails" roleURI="http://metuboutique.com/role/CollaborativeAgreementsDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_PropertyandEquipmentDetails" roleURI="http://metuboutique.com/role/PropertyandEquipmentDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_LongTermInvestmentsDetails" roleURI="http://metuboutique.com/role/LongTermInvestmentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_ConvertibleNotesPayableDetails" roleURI="http://metuboutique.com/role/ConvertibleNotesPayableDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_BankLoansDetails" roleURI="http://metuboutique.com/role/BankLoansDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_PaycheckProtectionProgramLoanPayableDetails" roleURI="http://metuboutique.com/role/PaycheckProtectionProgramLoanPayableDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_NotesPayableDetails" roleURI="http://metuboutique.com/role/NotesPayableDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_ShorttermLoanDetails" roleURI="http://metuboutique.com/role/ShorttermLoanDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_RelatedPartiesTransactionsDetails" roleURI="http://metuboutique.com/role/RelatedPartiesTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_EquityDetails" roleURI="http://metuboutique.com/role/EquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_StockOptionsDetails" roleURI="http://metuboutique.com/role/StockOptionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#abvcd_r_BusinessCombinationDetails" roleURI="http://metuboutique.com/role/BusinessCombinationDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvcd-20210331.xsd#DocumentAndEntityInformation" roleURI="http://metuboutique.com/role/DocumentAndEntityInformation"/>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableRelatedPartiesCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueFromOtherRelatedPartiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromOtherRelatedPartiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DueFromOtherRelatedPartiesCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_AssetsCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Goodwill" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_LongTermInvestments" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseNoncurrent" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDeposit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_SecurityDeposit" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_Assets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermBankLoansAndNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ShortTermBankLoansAndNotesPayable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherShortTermBorrowings" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherShortTermBorrowings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherShortTermBorrowings" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableToBankCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableToBankCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_NotesPayableToBankCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerAdvancesForConstruction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerAdvancesForConstruction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_CustomerAdvancesForConstruction" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DueToRelatedPartiesCurrent" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNotesPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNotesPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherNotesPayableCurrent" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNotesPayableCurrent" xlink:to="us-gaap_LiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LoansPayable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SecurityDepositLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDepositLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_SecurityDepositLiability" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleLongTermNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_ConvertibleLongTermNotesPayable" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConvertibleLongTermNotesPayable" xlink:to="us-gaap_Liabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_EquityAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteSubscriptionsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_TreasuryStockValue" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_MinorityInterest" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MinorityInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostOfRevenue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GrossProfit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_OperatingExpenses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RentalIncomeNonoperating" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RentalIncomeNonoperating"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_RentalIncomeNonoperating" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RentalIncomeRelatedParties" xlink:href="abvcd-20210331.xsd#abvcd_RentalIncomeRelatedParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="RentalIncomeRelatedParties" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_EquitySecuritiesFvNiRealizedGainLoss" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GovernmentGrantIncome" xlink:href="abvcd-20210331.xsd#abvcd_GovernmentGrantIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="GovernmentGrantIncome" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GovernmentGrantIncome" xlink:to="us-gaap_NonoperatingIncomeExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetLossAttributableToAbvcAndSubsidiaries" xlink:href="abvcd-20210331.xsd#abvcd_NetLossAttributableToAbvcAndSubsidiaries"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLoss" xlink:to="NetLossAttributableToAbvcAndSubsidiaries" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrealizedGainLossOnInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseDecreaseInGovernmentGrantIncome" xlink:href="abvcd-20210331.xsd#abvcd_IncreaseDecreaseInGovernmentGrantIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="IncreaseDecreaseInGovernmentGrantIncome" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseDueFromOtherRelatedParties" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseDueFromOtherRelatedParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseDueFromOtherRelatedParties" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireOtherInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireOtherInvestments" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetProceedsFromShortTermBorrowingsFromThirdParties" xlink:href="abvcd-20210331.xsd#abvcd_NetProceedsFromShortTermBorrowingsFromThirdParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="NetProceedsFromShortTermBorrowingsFromThirdParties" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfNotesPayable" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfLongTermDebt" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockSubscriptionReceivableMember" xlink:href="abvcd-20210331.xsd#abvcd_StockSubscriptionReceivableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="StockSubscriptionReceivableMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_ComprehensiveIncomeMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_TreasuryStockMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_NoncontrollingInterestMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="7.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="CumulativeTransactionAdjustments" xlink:href="abvcd-20210331.xsd#abvcd_CumulativeTransactionAdjustments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="CumulativeTransactionAdjustments" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_0" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/OrganizationandDescriptionofBusiness">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/SummaryofSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/CollaborativeAgreements">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="CollaborativeAgreementsTable" xlink:href="abvcd-20210331.xsd#abvcd_CollaborativeAgreementsTable"/>
    <loc xlink:type="locator" xlink:label="CollaborativeAgreementsLineItems" xlink:href="abvcd-20210331.xsd#abvcd_CollaborativeAgreementsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="CollaborativeAgreementsTable" order="1.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeAgreementsTable" xlink:to="CollaborativeAgreementsLineItems" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeAgreementsLineItems" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/Inventory">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/PropertyandEquipment">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/LongTermInvestments">
    <loc xlink:type="locator" xlink:label="LongTermInvestmentAbstract" xlink:href="abvcd-20210331.xsd#abvcd_LongTermInvestmentAbstract"/>
    <loc xlink:type="locator" xlink:label="LongTermInvestmentTextBlock" xlink:href="abvcd-20210331.xsd#abvcd_LongTermInvestmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentAbstract" xlink:to="LongTermInvestmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ConvertibleNotesPayable">
    <loc xlink:type="locator" xlink:label="ConvertibleNotesPayableDisclosureAbstract" xlink:href="abvcd-20210331.xsd#abvcd_ConvertibleNotesPayableDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="ConvertibleNotesPayableDisclosureTextBlock" xlink:href="abvcd-20210331.xsd#abvcd_ConvertibleNotesPayableDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableDisclosureAbstract" xlink:to="ConvertibleNotesPayableDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/BankLoans">
    <loc xlink:type="locator" xlink:label="BankLoansAbstractAbstract" xlink:href="abvcd-20210331.xsd#abvcd_BankLoansAbstractAbstract"/>
    <loc xlink:type="locator" xlink:label="BankLoansAbstract" xlink:href="abvcd-20210331.xsd#abvcd_BankLoansAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BankLoansAbstractAbstract" xlink:to="BankLoansAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/PaycheckProtectionProgramLoanPayable">
    <loc xlink:type="locator" xlink:label="PaycheckProtectionProgramLoanPayableAbstract" xlink:href="abvcd-20210331.xsd#abvcd_PaycheckProtectionProgramLoanPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="PaycheckProtectionProgramLoanPayableTextBlock" xlink:href="abvcd-20210331.xsd#abvcd_PaycheckProtectionProgramLoanPayableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PaycheckProtectionProgramLoanPayableAbstract" xlink:to="PaycheckProtectionProgramLoanPayableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/NotesPayable">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <loc xlink:type="locator" xlink:label="NotesPayableTable" xlink:href="abvcd-20210331.xsd#abvcd_NotesPayableTable"/>
    <loc xlink:type="locator" xlink:label="NotesPayableLineItems" xlink:href="abvcd-20210331.xsd#abvcd_NotesPayableLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="NotesPayableTable" order="1.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableTable" xlink:to="NotesPayableLineItems" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MembersEquityNotesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MembersEquityNotesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableLineItems" xlink:to="us-gaap_MembersEquityNotesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ShorttermLoan">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ShortTermDebtTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/RelatedPartiesTransactions">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/Equity">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/StockOptions">
    <loc xlink:type="locator" xlink:label="StockOptionsAbstract" xlink:href="abvcd-20210331.xsd#abvcd_StockOptionsAbstract"/>
    <loc xlink:type="locator" xlink:label="StockOptionsTextBlock" xlink:href="abvcd-20210331.xsd#abvcd_StockOptionsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsAbstract" xlink:to="StockOptionsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/LossperShare">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/Lease">
    <loc xlink:type="locator" xlink:label="us-gaap_ASU201602TransitionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ASU201602TransitionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ASU201602TransitionAbstract" xlink:to="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/BusinessCombination">
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiscalPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiscalPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FiscalPeriod" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ForwardStockSplitsPolicyTextBlock" xlink:href="abvcd-20210331.xsd#abvcd_ForwardStockSplitsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ForwardStockSplitsPolicyTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockReverseSplitPolicyTextBlock" xlink:href="abvcd-20210331.xsd#abvcd_StockReverseSplitPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="StockReverseSplitPolicyTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LongTermEquityInvestmentPolicy" xlink:href="abvcd-20210331.xsd#abvcd_LongTermEquityInvestmentPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="LongTermEquityInvestmentPolicy" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherThanTemporaryImpairmentPolicyTextBlock" xlink:href="abvcd-20210331.xsd#abvcd_OtherThanTemporaryImpairmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="OtherThanTemporaryImpairmentPolicyTextBlock" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BeneficialConversionFeature" xlink:href="abvcd-20210331.xsd#abvcd_BeneficialConversionFeature"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="BeneficialConversionFeature" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ValuationOfDeferredTaxAssetsPolicyTextBlock" xlink:href="abvcd-20210331.xsd#abvcd_ValuationOfDeferredTaxAssetsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ValuationOfDeferredTaxAssetsPolicyTextBlock" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TranslationAdjustmentPolicyTextBlock" xlink:href="abvcd-20210331.xsd#abvcd_TranslationAdjustmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="TranslationAdjustmentPolicyTextBlock" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:href="abvcd-20210331.xsd#abvcd_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/InventoryTables">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/PropertyandEquipmentTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/LongTermInvestmentsTables">
    <loc xlink:type="locator" xlink:label="LongTermInvestmentAbstract" xlink:href="abvcd-20210331.xsd#abvcd_LongTermInvestmentAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfOwnershipPercentagesOfInvesteeTableTextBlocks" xlink:href="abvcd-20210331.xsd#abvcd_ScheduleOfOwnershipPercentagesOfInvesteeTableTextBlocks"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentAbstract" xlink:to="ScheduleOfOwnershipPercentagesOfInvesteeTableTextBlocks" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfExtentInvesteeReliesTableTextBlock" xlink:href="abvcd-20210331.xsd#abvcd_ScheduleOfExtentInvesteeReliesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentAbstract" xlink:to="ScheduleOfExtentInvesteeReliesTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfLongTermInvestmentTableTextBlock" xlink:href="abvcd-20210331.xsd#abvcd_ScheduleOfLongTermInvestmentTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentAbstract" xlink:to="ScheduleOfLongTermInvestmentTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfCondensedBalanceSheetTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentAbstract" xlink:to="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedIncomeStatementTableTextBlock" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfCondensedIncomeStatementTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentAbstract" xlink:to="srt_ScheduleOfCondensedIncomeStatementTableTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentAbstract" xlink:to="us-gaap_EquityMethodInvestmentsTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/BankLoansTables">
    <loc xlink:type="locator" xlink:label="BankLoansAbstractAbstract" xlink:href="abvcd-20210331.xsd#abvcd_BankLoansAbstractAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BankLoansAbstractAbstract" xlink:to="us-gaap_ScheduleOfShortTermDebtTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/RelatedPartiesTransactionsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfAccountReceivableDueFromRelatedPartiesTableTextBlock" xlink:href="abvcd-20210331.xsd#abvcd_ScheduleOfAccountReceivableDueFromRelatedPartiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="ScheduleOfAccountReceivableDueFromRelatedPartiesTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfRelatedPartyTransactionsAmountDueToRelatedParty" xlink:href="abvcd-20210331.xsd#abvcd_ScheduleOfRelatedPartyTransactionsAmountDueToRelatedParty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="ScheduleOfRelatedPartyTransactionsAmountDueToRelatedParty" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/EquityTables">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDebtConversionsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtConversionsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfDebtConversionsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/StockOptionsTables">
    <loc xlink:type="locator" xlink:label="StockOptionsAbstract" xlink:href="abvcd-20210331.xsd#abvcd_StockOptionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/LossperShareTables">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/LeaseTables">
    <loc xlink:type="locator" xlink:label="us-gaap_ASU201602TransitionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ASU201602TransitionAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfOperatingLeaseArrangementsTableTextBlock" xlink:href="abvcd-20210331.xsd#abvcd_ScheduleOfOperatingLeaseArrangementsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ASU201602TransitionAbstract" xlink:to="ScheduleOfOperatingLeaseArrangementsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ASU201602TransitionAbstract" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ASU201602TransitionAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/BusinessCombinationTables">
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofpropertyandequipmentTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyAndEquipmentAbstract" xlink:href="abvcd-20210331.xsd#abvcd_ScheduleOfPropertyAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentTable" xlink:href="abvcd-20210331.xsd#abvcd_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentTable"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems" xlink:href="abvcd-20210331.xsd#abvcd_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentAbstract" xlink:to="SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="BuildingsAndLeaseholdImprovementsMember" xlink:href="abvcd-20210331.xsd#abvcd_BuildingsAndLeaseholdImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="BuildingsAndLeaseholdImprovementsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_MachineryAndEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_OfficeEquipmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentTable" xlink:to="srt_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentTable" xlink:to="SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofinventoryTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfInventoryAbstract" xlink:href="abvcd-20210331.xsd#abvcd_ScheduleOfInventoryAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInventoryAbstract" xlink:to="us-gaap_InventoryFinishedGoods" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcess" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInventoryAbstract" xlink:to="us-gaap_InventoryWorkInProcess" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInventoryAbstract" xlink:to="us-gaap_InventoryRawMaterials" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AllowanceForInventoryValuationAndObsolescenceLoss" xlink:href="abvcd-20210331.xsd#abvcd_AllowanceForInventoryValuationAndObsolescenceLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInventoryAbstract" xlink:to="AllowanceForInventoryValuationAndObsolescenceLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInventoryAbstract" xlink:to="us-gaap_InventoryNet" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofpropertyandequipmentTable0">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyAndEquipmentAbstract" xlink:href="abvcd-20210331.xsd#abvcd_ScheduleOfPropertyAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LandMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LandMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BuildingsAndLeaseholdImprovementsMember" xlink:href="abvcd-20210331.xsd#abvcd_BuildingsAndLeaseholdImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="BuildingsAndLeaseholdImprovementsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_MachineryAndEquipmentMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_OfficeEquipmentMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofownershippercentagesofinvesteeTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfOwnershipPercentagesOfInvesteeAbstract" xlink:href="abvcd-20210331.xsd#abvcd_ScheduleOfOwnershipPercentagesOfInvesteeAbstract"/>
    <loc xlink:type="locator" xlink:label="LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeTable" xlink:href="abvcd-20210331.xsd#abvcd_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeTable"/>
    <loc xlink:type="locator" xlink:label="LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeLineItems" xlink:href="abvcd-20210331.xsd#abvcd_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOwnershipPercentagesOfInvesteeAbstract" xlink:to="LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="BraingenesisBiotechnologyCoLtdMember" xlink:href="abvcd-20210331.xsd#abvcd_BraingenesisBiotechnologyCoLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="BraingenesisBiotechnologyCoLtdMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GenepharmBiotechCorporationMember" xlink:href="abvcd-20210331.xsd#abvcd_GenepharmBiotechCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="GenepharmBiotechCorporationMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioHopeKingCorporationMember" xlink:href="abvcd-20210331.xsd#abvcd_BioHopeKingCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="BioHopeKingCorporationMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioFirstCorporationMember" xlink:href="abvcd-20210331.xsd#abvcd_BioFirstCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="BioFirstCorporationMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RgeneCorporationMember" xlink:href="abvcd-20210331.xsd#abvcd_RgeneCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RgeneCorporationMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeTable" xlink:to="LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccountingTreatmentDescription" xlink:href="abvcd-20210331.xsd#abvcd_AccountingTreatmentDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeLineItems" xlink:to="AccountingTreatmentDescription" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofextenttheinvesteereliesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfExtentTheInvesteeReliesAbstract" xlink:href="abvcd-20210331.xsd#abvcd_ScheduleOfExtentTheInvesteeReliesAbstract"/>
    <loc xlink:type="locator" xlink:label="LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesTable" xlink:href="abvcd-20210331.xsd#abvcd_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesTable"/>
    <loc xlink:type="locator" xlink:label="LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesLineItems" xlink:href="abvcd-20210331.xsd#abvcd_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfExtentTheInvesteeReliesAbstract" xlink:to="LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="BraingenesisBiotechnologyCoLtdMember" xlink:href="abvcd-20210331.xsd#abvcd_BraingenesisBiotechnologyCoLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="BraingenesisBiotechnologyCoLtdMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GenepharmBiotechCorporationMember" xlink:href="abvcd-20210331.xsd#abvcd_GenepharmBiotechCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="GenepharmBiotechCorporationMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioHopeKingCorporationMember" xlink:href="abvcd-20210331.xsd#abvcd_BioHopeKingCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="BioHopeKingCorporationMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioFirstCorporationMember" xlink:href="abvcd-20210331.xsd#abvcd_BioFirstCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="BioFirstCorporationMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RgeneCorporationMember" xlink:href="abvcd-20210331.xsd#abvcd_RgeneCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RgeneCorporationMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesTable" xlink:to="LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyTransactionDescriptionOfTransactions" xlink:href="abvcd-20210331.xsd#abvcd_RelatedPartyTransactionDescriptionOfTransactions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesLineItems" xlink:to="RelatedPartyTransactionDescriptionOfTransactions" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleoflongterminvestmentTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfLongTermInvestmentAbstract" xlink:href="abvcd-20210331.xsd#abvcd_ScheduleOfLongTermInvestmentAbstract"/>
    <loc xlink:type="locator" xlink:label="LongTermInvestmentsDetailsScheduleoflongterminvestmentTable" xlink:href="abvcd-20210331.xsd#abvcd_LongTermInvestmentsDetailsScheduleoflongterminvestmentTable"/>
    <loc xlink:type="locator" xlink:label="LongTermInvestmentsDetailsScheduleoflongterminvestmentLineItems" xlink:href="abvcd-20210331.xsd#abvcd_LongTermInvestmentsDetailsScheduleoflongterminvestmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLongTermInvestmentAbstract" xlink:to="LongTermInvestmentsDetailsScheduleoflongterminvestmentTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentsDetailsScheduleoflongterminvestmentTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="BraingenesisBiotechnologyCoLtdMember" xlink:href="abvcd-20210331.xsd#abvcd_BraingenesisBiotechnologyCoLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="BraingenesisBiotechnologyCoLtdMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GenepharmBiotechCorporationMember" xlink:href="abvcd-20210331.xsd#abvcd_GenepharmBiotechCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="GenepharmBiotechCorporationMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioHopeKingCorporationMember" xlink:href="abvcd-20210331.xsd#abvcd_BioHopeKingCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="BioHopeKingCorporationMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioFirstCorporationMember" xlink:href="abvcd-20210331.xsd#abvcd_BioFirstCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="BioFirstCorporationMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RgeneCorporationMember" xlink:href="abvcd-20210331.xsd#abvcd_RgeneCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="RgeneCorporationMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentsDetailsScheduleoflongterminvestmentTable" xlink:to="LongTermInvestmentsDetailsScheduleoflongterminvestmentLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="NonMarketableCostMethodInvestmentsNetAbstract" xlink:href="abvcd-20210331.xsd#abvcd_NonMarketableCostMethodInvestmentsNetAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentsDetailsScheduleoflongterminvestmentLineItems" xlink:to="NonMarketableCostMethodInvestmentsNetAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NonmarketableCostMethodInvestmentsNet" xlink:href="abvcd-20210331.xsd#abvcd_NonmarketableCostMethodInvestmentsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonMarketableCostMethodInvestmentsNetAbstract" xlink:to="NonmarketableCostMethodInvestmentsNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EquityMethodInvestmentsNetAbstract" xlink:href="abvcd-20210331.xsd#abvcd_EquityMethodInvestmentsNetAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentsDetailsScheduleoflongterminvestmentLineItems" xlink:to="EquityMethodInvestmentsNetAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityMethodInvestmentsNetAbstract" xlink:to="us-gaap_EquityMethodInvestments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofbalancesheetsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfBalanceSheetsAbstract" xlink:href="abvcd-20210331.xsd#abvcd_ScheduleOfBalanceSheetsAbstract"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedBalanceSheetStatementTable" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CondensedBalanceSheetStatementTable"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CondensedBalanceSheetStatementsCaptionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBalanceSheetsAbstract" xlink:to="srt_CondensedBalanceSheetStatementTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="BioFirstMember" xlink:href="abvcd-20210331.xsd#abvcd_BioFirstMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="BioFirstMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RgeneMember" xlink:href="abvcd-20210331.xsd#abvcd_RgeneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="RgeneMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementTable" xlink:to="srt_CondensedBalanceSheetStatementsCaptionsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_AssetsCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_AssetsNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_LiabilitiesCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_LiabilitiesNoncurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_StockholdersEquity" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofstatementsofoperationTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfStatementsOfOperationAbstract" xlink:href="abvcd-20210331.xsd#abvcd_ScheduleOfStatementsOfOperationAbstract"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedIncomeStatementTable" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CondensedIncomeStatementTable"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CondensedIncomeStatementsCaptionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStatementsOfOperationAbstract" xlink:to="srt_CondensedIncomeStatementTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="BioFirstMember" xlink:href="abvcd-20210331.xsd#abvcd_BioFirstMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="BioFirstMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RgeneMember" xlink:href="abvcd-20210331.xsd#abvcd_RgeneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="RgeneMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementTable" xlink:to="srt_CondensedIncomeStatementsCaptionsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="us-gaap_GrossProfit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LongTermInvestmentNetLoss" xlink:href="abvcd-20210331.xsd#abvcd_LongTermInvestmentNetLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="LongTermInvestmentNetLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="us-gaap_GainLossOnInvestments" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofequityinvestmentsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfEquityInvestmentsAbstract" xlink:href="abvcd-20210331.xsd#abvcd_ScheduleOfEquityInvestmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareOfEquityMethodInvesteeLosses" xlink:href="abvcd-20210331.xsd#abvcd_ShareOfEquityMethodInvesteeLosses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEquityInvestmentsAbstract" xlink:to="ShareOfEquityMethodInvesteeLosses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofshorttermbankloanTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfShortTermBankLoanAbstract" xlink:href="abvcd-20210331.xsd#abvcd_ScheduleOfShortTermBankLoanAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShortTermBankLoanAbstract" xlink:to="us-gaap_ScheduleOfShortTermDebtTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CathayUnitedBankMember" xlink:href="abvcd-20210331.xsd#abvcd_CathayUnitedBankMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="CathayUnitedBankMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CTBCBankMember" xlink:href="abvcd-20210331.xsd#abvcd_CTBCBankMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="CTBCBankMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CathayBnakMember" xlink:href="abvcd-20210331.xsd#abvcd_CathayBnakMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="CathayBnakMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ShortTermDebtLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowings" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermBorrowings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermBorrowings" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofrelatedpartytransactionsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfRelatedPartyTransactionsAbstract" xlink:href="abvcd-20210331.xsd#abvcd_ScheduleOfRelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="BioFirstCorporationtheBioFirstMember" xlink:href="abvcd-20210331.xsd#abvcd_BioFirstCorporationtheBioFirstMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="BioFirstCorporationtheBioFirstMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember" xlink:href="abvcd-20210331.xsd#abvcd_BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RgeneCorporationtheRgeneMember" xlink:href="abvcd-20210331.xsd#abvcd_RgeneCorporationtheRgeneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="RgeneCorporationtheRgeneMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="YuanGeneCorporationtheYuanGeneMember" xlink:href="abvcd-20210331.xsd#abvcd_YuanGeneCorporationtheYuanGeneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="YuanGeneCorporationtheYuanGeneMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AsiaGeneCorporationtheAsiaGeneMember" xlink:href="abvcd-20210331.xsd#abvcd_AsiaGeneCorporationtheAsiaGeneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="AsiaGeneCorporationtheAsiaGeneMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EugeneJiangMember" xlink:href="abvcd-20210331.xsd#abvcd_EugeneJiangMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="EugeneJiangMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="KeypointTechnologyLtdtheKeypointMember" xlink:href="abvcd-20210331.xsd#abvcd_KeypointTechnologyLtdtheKeypointMember"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb+OcBO0cz/DPQtq8WT+vHGytpy5eqldqmljvYMs+ffK0hVJun/LoadZRO6MVQWNprQnn57cflcp0+RqqLVbNVtuKFz5+pgq1gL8cjM8xFnzOUdEjZ0sDSJzg18XsOaa9RO4cDdhaiGpwVK1skYTQsz6wjLPW7PJKd/ex+Rw6OhX8y162iyhal6OmPilaahf9Vq7ytD9vFlrA==] CSR-->
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="KeypointTechnologyLtdtheKeypointMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LionArtsPromotionInctheLionArtsMember" xlink:href="abvcd-20210331.xsd#abvcd_LionArtsPromotionInctheLionArtsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="LionArtsPromotionInctheLionArtsMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="YoshinobuOdairatheOdairaMember" xlink:href="abvcd-20210331.xsd#abvcd_YoshinobuOdairatheOdairaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="YoshinobuOdairatheOdairaMember" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GenePharmInctheGenePharmMember" xlink:href="abvcd-20210331.xsd#abvcd_GenePharmInctheGenePharmMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="GenePharmInctheGenePharmMember" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EuroAsiaInvestmentFinanceCorpLtdtheEuroAsiaMember" xlink:href="abvcd-20210331.xsd#abvcd_EuroAsiaInvestmentFinanceCorpLtdtheEuroAsiaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="EuroAsiaInvestmentFinanceCorpLtdtheEuroAsiaMember" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LBGUSAInctheLBGUSAMember" xlink:href="abvcd-20210331.xsd#abvcd_LBGUSAInctheLBGUSAMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="LBGUSAInctheLBGUSAMember" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LionGeneCorporationtheLionGeneMember" xlink:href="abvcd-20210331.xsd#abvcd_LionGeneCorporationtheLionGeneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="LionGeneCorporationtheLionGeneMember" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="KimhoConsultantsCoLtdtheKimhoMember" xlink:href="abvcd-20210331.xsd#abvcd_KimhoConsultantsCoLtdtheKimhoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="KimhoConsultantsCoLtdtheKimhoMember" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MrTsungShannJiangMsShuLingJiangMrChangJenJiangMsMeiLingJiangAndMrEugeneJiangcollectivelyTheJiangsMember" xlink:href="abvcd-20210331.xsd#abvcd_MrTsungShannJiangMsShuLingJiangMrChangJenJiangMsMeiLingJiangAndMrEugeneJiangcollectivelyTheJiangsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="MrTsungShannJiangMsShuLingJiangMrChangJenJiangMsMeiLingJiangAndMrEugeneJiangcollectivelyTheJiangsMember" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AmkeyVenturesLLCAmkeyMember" xlink:href="abvcd-20210331.xsd#abvcd_AmkeyVenturesLLCAmkeyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="AmkeyVenturesLLCAmkeyMember" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioLiteJapanMember" xlink:href="abvcd-20210331.xsd#abvcd_BioLiteJapanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="BioLiteJapanMember" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyTransactionDescriptionOfTransactions" xlink:href="abvcd-20210331.xsd#abvcd_RelatedPartyTransactionDescriptionOfTransactions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="RelatedPartyTransactionDescriptionOfTransactions" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofaccountsreceivableduefromrelatedpartiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfAccountsReceivableDueFromRelatedPartiesAbstract" xlink:href="abvcd-20210331.xsd#abvcd_ScheduleOfAccountsReceivableDueFromRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesTable" xlink:href="abvcd-20210331.xsd#abvcd_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesTable"/>
    <loc xlink:type="locator" xlink:label="RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesLineItems" xlink:href="abvcd-20210331.xsd#abvcd_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccountsReceivableDueFromRelatedPartiesAbstract" xlink:to="RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="GenePharmIncMember" xlink:href="abvcd-20210331.xsd#abvcd_GenePharmIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="GenePharmIncMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AmkeyMember" xlink:href="abvcd-20210331.xsd#abvcd_AmkeyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="AmkeyMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesTable" xlink:to="RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableRelatedParties" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesLineItems" xlink:to="us-gaap_AccountsReceivableRelatedParties" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofamountduefromrelatedpartiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfAmountDueFromRelatedPartiesAbstract" xlink:href="abvcd-20210331.xsd#abvcd_ScheduleOfAmountDueFromRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAmountDueFromRelatedPartiesAbstract" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="RgeneMember" xlink:href="abvcd-20210331.xsd#abvcd_RgeneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="RgeneMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AsiaGeneMember" xlink:href="abvcd-20210331.xsd#abvcd_AsiaGeneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="AsiaGeneMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioFirstAustraliaMember" xlink:href="abvcd-20210331.xsd#abvcd_BioFirstAustraliaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="BioFirstAustraliaMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioHopeKingCorporationMember" xlink:href="abvcd-20210331.xsd#abvcd_BioHopeKingCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="BioHopeKingCorporationMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LBGUSAMember" xlink:href="abvcd-20210331.xsd#abvcd_LBGUSAMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="LBGUSAMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioLiteJapanMember" xlink:href="abvcd-20210331.xsd#abvcd_BioLiteJapanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="BioLiteJapanMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="KeypointMember" xlink:href="abvcd-20210331.xsd#abvcd_KeypointMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="KeypointMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TheJiangsMember" xlink:href="abvcd-20210331.xsd#abvcd_TheJiangsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="TheJiangsMember" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="us-gaap_AccountsNotesAndLoansReceivableLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueFromRelatedPartiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_DueFromRelatedPartiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofamountduetorelatedpartiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfAmountDueToRelatedPartiesAbstract" xlink:href="abvcd-20210331.xsd#abvcd_ScheduleOfAmountDueToRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesTable" xlink:href="abvcd-20210331.xsd#abvcd_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesTable"/>
    <loc xlink:type="locator" xlink:label="RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesLineItems" xlink:href="abvcd-20210331.xsd#abvcd_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAmountDueToRelatedPartiesAbstract" xlink:to="RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="BioFirstCorporationMember" xlink:href="abvcd-20210331.xsd#abvcd_BioFirstCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="BioFirstCorporationMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AsiaGeneMember" xlink:href="abvcd-20210331.xsd#abvcd_AsiaGeneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="AsiaGeneMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="YuanGeneMember" xlink:href="abvcd-20210331.xsd#abvcd_YuanGeneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="YuanGeneMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TheJiangsMember" xlink:href="abvcd-20210331.xsd#abvcd_TheJiangsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="TheJiangsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DueToshareholdersMember" xlink:href="abvcd-20210331.xsd#abvcd_DueToshareholdersMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="DueToshareholdersMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DueToEmployeesMember" xlink:href="abvcd-20210331.xsd#abvcd_DueToEmployeesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="DueToEmployeesMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesTable" xlink:to="RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofconvertedamountofdebtandsharesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfConvertedAmountOfDebtAndSharesAbstract" xlink:href="abvcd-20210331.xsd#abvcd_ScheduleOfConvertedAmountOfDebtAndSharesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfConvertedAmountOfDebtAndSharesAbstract" xlink:to="us-gaap_DebtConversionTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="LionArtsPromotionInctheLIONMember" xlink:href="abvcd-20210331.xsd#abvcd_LionArtsPromotionInctheLIONMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="LionArtsPromotionInctheLIONMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LionGeneCorporationMember" xlink:href="abvcd-20210331.xsd#abvcd_LionGeneCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="LionGeneCorporationMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioFirstCorporationMember" xlink:href="abvcd-20210331.xsd#abvcd_BioFirstCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="BioFirstCorporationMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AsiangeneCorporationMember" xlink:href="abvcd-20210331.xsd#abvcd_AsiangeneCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="AsiangeneCorporationMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="YuangeneCorporationMember" xlink:href="abvcd-20210331.xsd#abvcd_YuangeneCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="YuangeneCorporationMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TheJiangsMember" xlink:href="abvcd-20210331.xsd#abvcd_TheJiangsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="TheJiangsMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionTable" xlink:to="us-gaap_DebtConversionLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofoptionsissuedandoutstandingTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfOptionsIssuedAndOutstandingAbstract" xlink:href="abvcd-20210331.xsd#abvcd_ScheduleOfOptionsIssuedAndOutstandingAbstract"/>
    <loc xlink:type="locator" xlink:label="StockOptionsDetailsScheduleofoptionsissuedandoutstandingTable" xlink:href="abvcd-20210331.xsd#abvcd_StockOptionsDetailsScheduleofoptionsissuedandoutstandingTable"/>
    <loc xlink:type="locator" xlink:label="StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:href="abvcd-20210331.xsd#abvcd_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOptionsIssuedAndOutstandingAbstract" xlink:to="StockOptionsDetailsScheduleofoptionsissuedandoutstandingTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsScheduleofoptionsissuedandoutstandingTable" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:to="us-gaap_EmployeeStockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsScheduleofoptionsissuedandoutstandingTable" xlink:to="StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm" xlink:href="abvcd-20210331.xsd#abvcd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue" xlink:href="abvcd-20210331.xsd#abvcd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleoffairvalueofstockoptionsgrantedTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFairValueOfStockOptionsGrantedAbstract" xlink:href="abvcd-20210331.xsd#abvcd_ScheduleOfFairValueOfStockOptionsGrantedAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueOfStockOptionsGrantedAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueOfStockOptionsGrantedAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueOfStockOptionsGrantedAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueOfStockOptionsGrantedAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleoflosspershareTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfLossPerShareAbstract" xlink:href="abvcd-20210331.xsd#abvcd_ScheduleOfLossPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="NumeratorAbstract" xlink:href="abvcd-20210331.xsd#abvcd_NumeratorAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLossPerShareAbstract" xlink:to="NumeratorAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetLoss" xlink:href="abvcd-20210331.xsd#abvcd_NetLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NumeratorAbstract" xlink:to="NetLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLossPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="StockOptions" xlink:href="abvcd-20210331.xsd#abvcd_StockOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="StockOptions" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_0" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLossPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofoperatingleasearrangementsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfOperatingLeaseArrangementsAbstract" xlink:href="abvcd-20210331.xsd#abvcd_ScheduleOfOperatingLeaseArrangementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOperatingLeaseArrangementsAbstract" xlink:to="us-gaap_AssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOperatingLeaseArrangementsAbstract" xlink:to="us-gaap_LiabilitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofsupplementalinformationrelatedtooperatingleasesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfSupplementalInformationRelatedToOperatingLeasesAbstract" xlink:href="abvcd-20210331.xsd#abvcd_ScheduleOfSupplementalInformationRelatedToOperatingLeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSupplementalInformationRelatedToOperatingLeasesAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSupplementalInformationRelatedToOperatingLeasesAbstract" xlink:to="us-gaap_OperatingLeaseLeaseIncomeLeasePayments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSupplementalInformationRelatedToOperatingLeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSupplementalInformationRelatedToOperatingLeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofminimumfutureannualpaymentsundernoncancellableleasesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfMinimumFutureAnnualPaymentsUnderNonCancellableLeasesAbstract" xlink:href="abvcd-20210331.xsd#abvcd_ScheduleOfMinimumFutureAnnualPaymentsUnderNonCancellableLeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMinimumFutureAnnualPaymentsUnderNonCancellableLeasesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMinimumFutureAnnualPaymentsUnderNonCancellableLeasesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMinimumFutureAnnualPaymentsUnderNonCancellableLeasesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMinimumFutureAnnualPaymentsUnderNonCancellableLeasesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMinimumFutureAnnualPaymentsUnderNonCancellableLeasesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPortionOfMinimumLeasePaymentsSaleLeasebackTransactions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPortionOfMinimumLeasePaymentsSaleLeasebackTransactions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="us-gaap_InterestPortionOfMinimumLeasePaymentsSaleLeasebackTransactions" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PresentValueOfFutureMinimumLeasePaymentsSaleLeasebackTransactions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PresentValueOfFutureMinimumLeasePaymentsSaleLeasebackTransactions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="us-gaap_PresentValueOfFutureMinimumLeasePaymentsSaleLeasebackTransactions" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofassetsacquiredandliabilitiesassumedbasedonfairvalueTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfAssetsAcquiredAndLiabilitiesAssumedBasedOnFairValueAbstract" xlink:href="abvcd-20210331.xsd#abvcd_ScheduleOfAssetsAcquiredAndLiabilitiesAssumedBasedOnFairValueAbstract"/>
    <loc xlink:type="locator" xlink:label="PurchaseConsiderationAbstract" xlink:href="abvcd-20210331.xsd#abvcd_PurchaseConsiderationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAssetsAcquiredAndLiabilitiesAssumedBasedOnFairValueAbstract" xlink:to="PurchaseConsiderationAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredOther1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PurchaseConsiderationAbstract" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredOther1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AllocationOfThePurchasePriceAbstract" xlink:href="abvcd-20210331.xsd#abvcd_AllocationOfThePurchasePriceAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAssetsAcquiredAndLiabilitiesAssumedBasedOnFairValueAbstract" xlink:to="AllocationOfThePurchasePriceAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AllocationOfThePurchasePriceAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AllocationOfThePurchasePriceAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AllocationOfThePurchasePriceAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:href="abvcd-20210331.xsd#abvcd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AllocationOfThePurchasePriceAbstract" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AllocationOfThePurchasePriceAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AllocationOfThePurchasePriceAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AllocationOfThePurchasePriceAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AllocationOfThePurchasePriceAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability" xlink:href="abvcd-20210331.xsd#abvcd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AllocationOfThePurchasePriceAbstract" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AllocationOfThePurchasePriceAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AllocationOfThePurchasePriceAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" order="10.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AllocationOfThePurchasePriceAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AllocationOfThePurchasePriceAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/OrganizationandDescriptionofBusinessDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="OrganizationandDescriptionofBusinessDetailsTable" xlink:href="abvcd-20210331.xsd#abvcd_OrganizationandDescriptionofBusinessDetailsTable"/>
    <loc xlink:type="locator" xlink:label="OrganizationandDescriptionofBusinessDetailsLineItems" xlink:href="abvcd-20210331.xsd#abvcd_OrganizationandDescriptionofBusinessDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="OrganizationandDescriptionofBusinessDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandDescriptionofBusinessDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ShareExchangeAgreementMember" xlink:href="abvcd-20210331.xsd#abvcd_ShareExchangeAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="ShareExchangeAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareExchangeAgreementOneMember" xlink:href="abvcd-20210331.xsd#abvcd_ShareExchangeAgreementOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="ShareExchangeAgreementOneMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareExchangeAgreementTwoMember" xlink:href="abvcd-20210331.xsd#abvcd_ShareExchangeAgreementTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="ShareExchangeAgreementTwoMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareExchangeAgreementThreeMember" xlink:href="abvcd-20210331.xsd#abvcd_ShareExchangeAgreementThreeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="ShareExchangeAgreementThreeMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareExchangeAgreementFourMember" xlink:href="abvcd-20210331.xsd#abvcd_ShareExchangeAgreementFourMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="ShareExchangeAgreementFourMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MergerAgreementMember" xlink:href="abvcd-20210331.xsd#abvcd_MergerAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="MergerAgreementMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandDescriptionofBusinessDetailsTable" xlink:to="OrganizationandDescriptionofBusinessDetailsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="CommonStockIssuedAfterStockSplit" xlink:href="abvcd-20210331.xsd#abvcd_CommonStockIssuedAfterStockSplit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandDescriptionofBusinessDetailsLineItems" xlink:to="CommonStockIssuedAfterStockSplit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockIssuedBeforeStockSplit" xlink:href="abvcd-20210331.xsd#abvcd_CommonStockIssuedBeforeStockSplit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandDescriptionofBusinessDetailsLineItems" xlink:to="CommonStockIssuedBeforeStockSplit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfCommonSharesIssuedAndOutstanding" xlink:href="abvcd-20210331.xsd#abvcd_PercentageOfCommonSharesIssuedAndOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandDescriptionofBusinessDetailsLineItems" xlink:to="PercentageOfCommonSharesIssuedAndOutstanding" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfIssuedShareCapital" xlink:href="abvcd-20210331.xsd#abvcd_PercentageOfIssuedShareCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandDescriptionofBusinessDetailsLineItems" xlink:to="PercentageOfIssuedShareCapital" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_Cash" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalents" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MarketableSecuritiesRealizedGainLossOtherThanTemporaryImpairmentsAmounts" xlink:href="abvcd-20210331.xsd#abvcd_MarketableSecuritiesRealizedGainLossOtherThanTemporaryImpairmentsAmounts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="MarketableSecuritiesRealizedGainLossOtherThanTemporaryImpairmentsAmounts" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfMonthlyContribution" xlink:href="abvcd-20210331.xsd#abvcd_PercentageOfMonthlyContribution"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="PercentageOfMonthlyContribution" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationForNonemployees" xlink:href="abvcd-20210331.xsd#abvcd_StockBasedCompensationForNonemployees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="StockBasedCompensationForNonemployees" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/CollaborativeAgreementsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="CollaborativeAgreementsDetailsTable" xlink:href="abvcd-20210331.xsd#abvcd_CollaborativeAgreementsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="CollaborativeAgreementsDetailsLineItems" xlink:href="abvcd-20210331.xsd#abvcd_CollaborativeAgreementsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="CollaborativeAgreementsDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeAgreementsDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="BHKCoDevelopmentAgreementMember" xlink:href="abvcd-20210331.xsd#abvcd_BHKCoDevelopmentAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="BHKCoDevelopmentAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CodevelopmentagreementMember" xlink:href="abvcd-20210331.xsd#abvcd_CodevelopmentagreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="CodevelopmentagreementMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_CollaborativeArrangementMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioFirstStockPurchaseAgreementMember" xlink:href="abvcd-20210331.xsd#abvcd_BioFirstStockPurchaseAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="BioFirstStockPurchaseAgreementMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeAgreementsDetailsTable" xlink:to="CollaborativeAgreementsDetailsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="MilestonePayments" xlink:href="abvcd-20210331.xsd#abvcd_MilestonePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeAgreementsDetailsLineItems" xlink:to="MilestonePayments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeAgreementsDetailsLineItems" xlink:to="us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UpfrontCashPayment" xlink:href="abvcd-20210331.xsd#abvcd_UpfrontCashPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeAgreementsDetailsLineItems" xlink:to="UpfrontCashPayment" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfPaymentsUnderCodevelopmentAgreement" xlink:href="abvcd-20210331.xsd#abvcd_PercentageOfPaymentsUnderCodevelopmentAgreement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeAgreementsDetailsLineItems" xlink:to="PercentageOfPaymentsUnderCodevelopmentAgreement" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfStockValue" xlink:href="abvcd-20210331.xsd#abvcd_IssuanceOfStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeAgreementsDetailsLineItems" xlink:to="IssuanceOfStockValue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MilestonePaymentsRoyaltyPercentage" xlink:href="abvcd-20210331.xsd#abvcd_MilestonePaymentsRoyaltyPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeAgreementsDetailsLineItems" xlink:to="MilestonePaymentsRoyaltyPercentage" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CollaborativeAgreementsDescription" xlink:href="abvcd-20210331.xsd#abvcd_CollaborativeAgreementsDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeAgreementsDetailsLineItems" xlink:to="CollaborativeAgreementsDescription" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForParticipationLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForParticipationLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeAgreementsDetailsLineItems" xlink:to="us-gaap_PaymentsForParticipationLiabilities" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdditionCashPayment" xlink:href="abvcd-20210331.xsd#abvcd_AdditionCashPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeAgreementsDetailsLineItems" xlink:to="AdditionCashPayment" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeAgreementsDetailsLineItems" xlink:to="us-gaap_AdditionalPaidInCapital" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeAgreementsDetailsLineItems" xlink:to="us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CoDevAgreementDescription" xlink:href="abvcd-20210331.xsd#abvcd_CoDevAgreementDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeAgreementsDetailsLineItems" xlink:to="CoDevAgreementDescription" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeAgreementsDetailsLineItems" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeAgreementsDetailsLineItems" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeAgreementsDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/PropertyandEquipmentDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_Depreciation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/LongTermInvestmentsDetails">
    <loc xlink:type="locator" xlink:label="LongTermInvestmentAbstract" xlink:href="abvcd-20210331.xsd#abvcd_LongTermInvestmentAbstract"/>
    <loc xlink:type="locator" xlink:label="LongTermInvestmentsDetailsTable" xlink:href="abvcd-20210331.xsd#abvcd_LongTermInvestmentsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="LongTermInvestmentsDetailsLineItems" xlink:href="abvcd-20210331.xsd#abvcd_LongTermInvestmentsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentAbstract" xlink:to="LongTermInvestmentsDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="BioFirstCorporationMember" xlink:href="abvcd-20210331.xsd#abvcd_BioFirstCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="BioFirstCorporationMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="RgeneCorporationMember" xlink:href="abvcd-20210331.xsd#abvcd_RgeneCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RgeneCorporationMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentsDetailsTable" xlink:to="LongTermInvestmentsDetailsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentsDetailsLineItems" xlink:to="us-gaap_IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateAmount" xlink:href="abvcd-20210331.xsd#abvcd_AggregateAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentsDetailsLineItems" xlink:to="AggregateAmount" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockDescriptionOfTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockDescriptionOfTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentsDetailsLineItems" xlink:to="us-gaap_SaleOfStockDescriptionOfTransaction" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ConvertibleNotesPayableDetails">
    <loc xlink:type="locator" xlink:label="ConvertibleNotesPayableDisclosureAbstract" xlink:href="abvcd-20210331.xsd#abvcd_ConvertibleNotesPayableDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="ConvertibleNotesPayableDetailsTable" xlink:href="abvcd-20210331.xsd#abvcd_ConvertibleNotesPayableDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ConvertibleNotesPayableDetailsLineItems" xlink:href="abvcd-20210331.xsd#abvcd_ConvertibleNotesPayableDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableDisclosureAbstract" xlink:to="ConvertibleNotesPayableDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableDetailsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="UnsecuredConvertiblePromissoryNoteMember" xlink:href="abvcd-20210331.xsd#abvcd_UnsecuredConvertiblePromissoryNoteMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="UnsecuredConvertiblePromissoryNoteMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SecuritiesPurchaseAgreementMember" xlink:href="abvcd-20210331.xsd#abvcd_SecuritiesPurchaseAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="SecuritiesPurchaseAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableDetailsTable" xlink:to="ConvertibleNotesPayableDetailsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireNotesReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireNotesReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableDetailsLineItems" xlink:to="us-gaap_PaymentsToAcquireNotesReceivable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockDescriptionOfTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockDescriptionOfTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableDetailsLineItems" xlink:to="us-gaap_SaleOfStockDescriptionOfTransaction" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableDetailsLineItems" xlink:to="us-gaap_ConversionOfStockDescription" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableDetailsLineItems" xlink:to="us-gaap_ConvertibleDebt" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TotalInterestExpenses" xlink:href="abvcd-20210331.xsd#abvcd_TotalInterestExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableDetailsLineItems" xlink:to="TotalInterestExpenses" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/BankLoansDetails">
    <loc xlink:type="locator" xlink:label="BankLoansAbstractAbstract" xlink:href="abvcd-20210331.xsd#abvcd_BankLoansAbstractAbstract"/>
    <loc xlink:type="locator" xlink:label="BankLoansDetailsTable" xlink:href="abvcd-20210331.xsd#abvcd_BankLoansDetailsTable"/>
    <loc xlink:type="locator" xlink:label="BankLoansDetailsLineItems" xlink:href="abvcd-20210331.xsd#abvcd_BankLoansDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BankLoansAbstractAbstract" xlink:to="BankLoansDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BankLoansDetailsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CathayUnitedLoanAgreementMember" xlink:href="abvcd-20210331.xsd#abvcd_CathayUnitedLoanAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="CathayUnitedLoanAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CTBCBankMember" xlink:href="abvcd-20210331.xsd#abvcd_CTBCBankMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="CTBCBankMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LoanAgreementMember" xlink:href="abvcd-20210331.xsd#abvcd_LoanAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="LoanAgreementMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CathayBnakMember" xlink:href="abvcd-20210331.xsd#abvcd_CathayBnakMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="CathayBnakMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="TypeOfCurrencyAxis" xlink:href="abvcd-20210331.xsd#abvcd_TypeOfCurrencyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BankLoansDetailsTable" xlink:to="TypeOfCurrencyAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TypeOfCurrencyDomain" xlink:href="abvcd-20210331.xsd#abvcd_TypeOfCurrencyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypeOfCurrencyAxis" xlink:to="TypeOfCurrencyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="NTMember" xlink:href="abvcd-20210331.xsd#abvcd_NTMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypeOfCurrencyAxis" xlink:to="NTMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BankLoansDetailsTable" xlink:to="BankLoansDetailsLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BankLoansDetailsLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BankLoansDetailsLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BankLoansDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BankLoansDetailsLineItems" xlink:to="us-gaap_DebtInstrumentTerm" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestAndDebtExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestAndDebtExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BankLoansDetailsLineItems" xlink:to="us-gaap_InterestAndDebtExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReceivedLoanAmount" xlink:href="abvcd-20210331.xsd#abvcd_ReceivedLoanAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BankLoansDetailsLineItems" xlink:to="ReceivedLoanAmount" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RegularInterestRateDescription" xlink:href="abvcd-20210331.xsd#abvcd_RegularInterestRateDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BankLoansDetailsLineItems" xlink:to="RegularInterestRateDescription" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExceedingAmount" xlink:href="abvcd-20210331.xsd#abvcd_ExceedingAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BankLoansDetailsLineItems" xlink:to="ExceedingAmount" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BankLoansDetailsLineItems" xlink:to="us-gaap_LoansPayable" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/PaycheckProtectionProgramLoanPayableDetails">
    <loc xlink:type="locator" xlink:label="PaycheckProtectionProgramLoanPayableAbstract" xlink:href="abvcd-20210331.xsd#abvcd_PaycheckProtectionProgramLoanPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="PaycheckProtectionProgramLoanPayableDetailsTable" xlink:href="abvcd-20210331.xsd#abvcd_PaycheckProtectionProgramLoanPayableDetailsTable"/>
    <loc xlink:type="locator" xlink:label="PaycheckProtectionProgramLoanPayableDetailsLineItems" xlink:href="abvcd-20210331.xsd#abvcd_PaycheckProtectionProgramLoanPayableDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PaycheckProtectionProgramLoanPayableAbstract" xlink:to="PaycheckProtectionProgramLoanPayableDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PaycheckProtectionProgramLoanPayableDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PAYCHECKPROTECTIONPROGRAMMember" xlink:href="abvcd-20210331.xsd#abvcd_PAYCHECKPROTECTIONPROGRAMMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="PAYCHECKPROTECTIONPROGRAMMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PaycheckProtectionProgramLoanPayableDetailsTable" xlink:to="PaycheckProtectionProgramLoanPayableDetailsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="PaycheckProtectionProgramDescription" xlink:href="abvcd-20210331.xsd#abvcd_PaycheckProtectionProgramDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PaycheckProtectionProgramLoanPayableDetailsLineItems" xlink:to="PaycheckProtectionProgramDescription" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PaycheckProtectionProgramLoanPayableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfForgivenAmount" xlink:href="abvcd-20210331.xsd#abvcd_PercentageOfForgivenAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PaycheckProtectionProgramLoanPayableDetailsLineItems" xlink:to="PercentageOfForgivenAmount" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InterestRate" xlink:href="abvcd-20210331.xsd#abvcd_InterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PaycheckProtectionProgramLoanPayableDetailsLineItems" xlink:to="InterestRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PromissoryNoteTerm" xlink:href="abvcd-20210331.xsd#abvcd_PromissoryNoteTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PaycheckProtectionProgramLoanPayableDetailsLineItems" xlink:to="PromissoryNoteTerm" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LoanAmout" xlink:href="abvcd-20210331.xsd#abvcd_LoanAmout"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PaycheckProtectionProgramLoanPayableDetailsLineItems" xlink:to="LoanAmout" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/NotesPayableDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <loc xlink:type="locator" xlink:label="UnsecuredLoanAgreementsDescription" xlink:href="abvcd-20210331.xsd#abvcd_UnsecuredLoanAgreementsDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="UnsecuredLoanAgreementsDescription" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_OtherNotesPayable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_InterestExpenseOther" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ShorttermLoanDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnsecuredDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnsecuredDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_UnsecuredDebt" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtInterestRateIncrease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtInterestRateIncrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ShortTermDebtInterestRateIncrease" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/RelatedPartiesTransactionsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedPartiesTransactionsDetailsTable" xlink:href="abvcd-20210331.xsd#abvcd_RelatedPartiesTransactionsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="RelatedPartiesTransactionsDetailsLineItems" xlink:href="abvcd-20210331.xsd#abvcd_RelatedPartiesTransactionsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="RelatedPartiesTransactionsDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="RgeneCorporationMember" xlink:href="abvcd-20210331.xsd#abvcd_RgeneCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="RgeneCorporationMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioFirstMember" xlink:href="abvcd-20210331.xsd#abvcd_BioFirstMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="BioFirstMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AsiangeneCorporationMember" xlink:href="abvcd-20210331.xsd#abvcd_AsiangeneCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="AsiangeneCorporationMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="BioFirstAustraliaMember" xlink:href="abvcd-20210331.xsd#abvcd_BioFirstAustraliaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="BioFirstAustraliaMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioLiteTaiwanMember" xlink:href="abvcd-20210331.xsd#abvcd_BioLiteTaiwanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="BioLiteTaiwanMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LbgUsaIncMember" xlink:href="abvcd-20210331.xsd#abvcd_LbgUsaIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="LbgUsaIncMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioLiteJapanMember" xlink:href="abvcd-20210331.xsd#abvcd_BioLiteJapanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="BioLiteJapanMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="YuanGeneMember" xlink:href="abvcd-20210331.xsd#abvcd_YuanGeneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="YuanGeneMember" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="JIANGSMember" xlink:href="abvcd-20210331.xsd#abvcd_JIANGSMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="JIANGSMember" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="AgreemnetAxis" xlink:href="abvcd-20210331.xsd#abvcd_AgreemnetAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsDetailsTable" xlink:to="AgreemnetAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AgreemnetDomain" xlink:href="abvcd-20210331.xsd#abvcd_AgreemnetDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AgreemnetAxis" xlink:to="AgreemnetDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ConversionAgreementsOneMember" xlink:href="abvcd-20210331.xsd#abvcd_ConversionAgreementsOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AgreemnetAxis" xlink:to="ConversionAgreementsOneMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TypeOfCurrencyAxis" xlink:href="abvcd-20210331.xsd#abvcd_TypeOfCurrencyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsDetailsTable" xlink:to="TypeOfCurrencyAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TypeOfCurrencyDomain" xlink:href="abvcd-20210331.xsd#abvcd_TypeOfCurrencyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypeOfCurrencyAxis" xlink:to="TypeOfCurrencyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="NTMember" xlink:href="abvcd-20210331.xsd#abvcd_NTMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypeOfCurrencyAxis" xlink:to="NTMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsDetailsTable" xlink:to="RelatedPartiesTransactionsDetailsLineItems" order="4.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateTerms" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateTerms"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateTerms" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShorttermDebtAverageOutstandingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShorttermDebtAverageOutstandingAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsDetailsLineItems" xlink:to="us-gaap_ShorttermDebtAverageOutstandingAmount" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccruedInterest" xlink:href="abvcd-20210331.xsd#abvcd_AccruedInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsDetailsLineItems" xlink:to="AccruedInterest" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockPurchaseAgreementDescription" xlink:href="abvcd-20210331.xsd#abvcd_StockPurchaseAgreementDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsDetailsLineItems" xlink:to="StockPurchaseAgreementDescription" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateWorkingcapital" xlink:href="abvcd-20210331.xsd#abvcd_AggregateWorkingcapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsDetailsLineItems" xlink:to="AggregateWorkingcapital" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdvancesBearInterestDescription" xlink:href="abvcd-20210331.xsd#abvcd_AdvancesBearInterestDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsDetailsLineItems" xlink:to="AdvancesBearInterestDescription" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsDetailsLineItems" xlink:to="us-gaap_RelatedPartyTransactionRate" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueFromOtherRelatedParties" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromOtherRelatedParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsDetailsLineItems" xlink:to="us-gaap_DueFromOtherRelatedParties" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfLoanCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfLoanCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsDetailsLineItems" xlink:to="us-gaap_PaymentsOfLoanCosts" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsDetailsLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrent" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsDetailsLineItems" xlink:to="us-gaap_InterestExpense" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfEmployees" xlink:href="abvcd-20210331.xsd#abvcd_NumberOfEmployees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsDetailsLineItems" xlink:to="NumberOfEmployees" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsDetailsLineItems" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/EquityDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="EquityDetailsTable" xlink:href="abvcd-20210331.xsd#abvcd_EquityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="EquityDetailsLineItems" xlink:href="abvcd-20210331.xsd#abvcd_EquityDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="EquityDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="BioLiteMember" xlink:href="abvcd-20210331.xsd#abvcd_BioLiteMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="BioLiteMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioKeyMember" xlink:href="abvcd-20210331.xsd#abvcd_BioKeyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="BioKeyMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="KameyamaMember" xlink:href="abvcd-20210331.xsd#abvcd_KameyamaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="KameyamaMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ArticlesOfIncorporationMember" xlink:href="abvcd-20210331.xsd#abvcd_ArticlesOfIncorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="ArticlesOfIncorporationMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ViewTradeSecuritiesIncMember" xlink:href="abvcd-20210331.xsd#abvcd_ViewTradeSecuritiesIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="ViewTradeSecuritiesIncMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConsultingAgreementMember" xlink:href="abvcd-20210331.xsd#abvcd_ConsultingAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="ConsultingAgreementMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NonRelatedPartiesMember" xlink:href="abvcd-20210331.xsd#abvcd_NonRelatedPartiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="NonRelatedPartiesMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ShareExchangeAgreementMember" xlink:href="abvcd-20210331.xsd#abvcd_ShareExchangeAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="ShareExchangeAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareExchangeAgreementOneMember" xlink:href="abvcd-20210331.xsd#abvcd_ShareExchangeAgreementOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="ShareExchangeAgreementOneMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareExchangeAgreementTwoMember" xlink:href="abvcd-20210331.xsd#abvcd_ShareExchangeAgreementTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="ShareExchangeAgreementTwoMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareExchangeAgreementThreeMember" xlink:href="abvcd-20210331.xsd#abvcd_ShareExchangeAgreementThreeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="ShareExchangeAgreementThreeMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareExchangeAgreementFourMember" xlink:href="abvcd-20210331.xsd#abvcd_ShareExchangeAgreementFourMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="ShareExchangeAgreementFourMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_CollaborativeArrangementMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EuroAsiaInvestmentAndFinanceCorpLtdMember" xlink:href="abvcd-20210331.xsd#abvcd_EuroAsiaInvestmentAndFinanceCorpLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="EuroAsiaInvestmentAndFinanceCorpLtdMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CodevelopmentagreementMember" xlink:href="abvcd-20210331.xsd#abvcd_CodevelopmentagreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="CodevelopmentagreementMember" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConsultingAgreementMember_0" xlink:href="abvcd-20210331.xsd#abvcd_ConsultingAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="ConsultingAgreementMember_0" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="TwoThousandSixteenEquityIncentivePlanMember" xlink:href="abvcd-20210331.xsd#abvcd_TwoThousandSixteenEquityIncentivePlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="TwoThousandSixteenEquityIncentivePlanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="srt_RangeAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="EquityDetailsLineItems" order="7.0"/>
    <loc xlink:type="locator" xlink:label="CommonStockIssuedAfterStockSplit" xlink:href="abvcd-20210331.xsd#abvcd_CommonStockIssuedAfterStockSplit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="CommonStockIssuedAfterStockSplit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockIssuedBeforeStockSplit" xlink:href="abvcd-20210331.xsd#abvcd_CommonStockIssuedBeforeStockSplit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="CommonStockIssuedBeforeStockSplit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfIssuedShareCapital" xlink:href="abvcd-20210331.xsd#abvcd_PercentageOfIssuedShareCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="PercentageOfIssuedShareCapital" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockholderEquityReverseStockSplit" xlink:href="abvcd-20210331.xsd#abvcd_StockholderEquityReverseStockSplit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="StockholderEquityReverseStockSplit" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="AgreementDescription" xlink:href="abvcd-20210331.xsd#abvcd_AgreementDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="AgreementDescription" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="FinancialAmendmentDescription" xlink:href="abvcd-20210331.xsd#abvcd_FinancialAmendmentDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="FinancialAmendmentDescription" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="Consultingagreementdescription" xlink:href="abvcd-20210331.xsd#abvcd_Consultingagreementdescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="Consultingagreementdescription" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UnpaidConsultingFees" xlink:href="abvcd-20210331.xsd#abvcd_UnpaidConsultingFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="UnpaidConsultingFees" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalFees" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfessionalFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_ProfessionalFees" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockSubscriptionReceivable" xlink:href="abvcd-20210331.xsd#abvcd_StockSubscriptionReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="StockSubscriptionReceivable" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedValue" xlink:href="abvcd-20210331.xsd#abvcd_StockIssuedValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="StockIssuedValue" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PlacementAgentAgreementDescription" xlink:href="abvcd-20210331.xsd#abvcd_PlacementAgentAgreementDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="PlacementAgentAgreementDescription" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RestrictedCommonShares" xlink:href="abvcd-20210331.xsd#abvcd_RestrictedCommonShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="RestrictedCommonShares" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantIssued" xlink:href="abvcd-20210331.xsd#abvcd_WarrantIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="WarrantIssued" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantTerm" xlink:href="abvcd-20210331.xsd#abvcd_WarrantTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="WarrantTerm" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UnrestrictedCommonShares" xlink:href="abvcd-20210331.xsd#abvcd_UnrestrictedCommonShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="UnrestrictedCommonShares" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromContributionsFromAffiliates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromContributionsFromAffiliates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_ProceedsFromContributionsFromAffiliates" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfInvestors" xlink:href="abvcd-20210331.xsd#abvcd_NumberOfInvestors"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="NumberOfInvestors" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfCommonStock" xlink:href="abvcd-20210331.xsd#abvcd_IssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="IssuanceOfCommonStock" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodShareBasedCompensationServicesforShares" xlink:href="abvcd-20210331.xsd#abvcd_StockIssuedDuringPeriodShareBasedCompensationServicesforShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="StockIssuedDuringPeriodShareBasedCompensationServicesforShares" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateCommonStockShares" xlink:href="abvcd-20210331.xsd#abvcd_AggregateCommonStockShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="AggregateCommonStockShares" order="32.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature" order="33.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/StockOptionsDetails">
    <loc xlink:type="locator" xlink:label="StockOptionsAbstract" xlink:href="abvcd-20210331.xsd#abvcd_StockOptionsAbstract"/>
    <loc xlink:type="locator" xlink:label="StockOptionsDetailsTable" xlink:href="abvcd-20210331.xsd#abvcd_StockOptionsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="StockOptionsDetailsLineItems" xlink:href="abvcd-20210331.xsd#abvcd_StockOptionsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsAbstract" xlink:to="StockOptionsDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="TwoThousandSixteenEquityIncentivePlanMember" xlink:href="abvcd-20210331.xsd#abvcd_TwoThousandSixteenEquityIncentivePlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="TwoThousandSixteenEquityIncentivePlanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsTable" xlink:to="StockOptionsDetailsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsLineItems" xlink:to="us-gaap_SharePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConsultingFees" xlink:href="abvcd-20210331.xsd#abvcd_ConsultingFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsLineItems" xlink:to="ConsultingFees" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants" xlink:href="abvcd-20210331.xsd#abvcd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/BusinessCombinationDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <loc xlink:type="locator" xlink:label="BusinessCombinationDetailsTable" xlink:href="abvcd-20210331.xsd#abvcd_BusinessCombinationDetailsTable"/>
    <loc xlink:type="locator" xlink:label="BusinessCombinationDetailsLineItems" xlink:href="abvcd-20210331.xsd#abvcd_BusinessCombinationDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="BusinessCombinationDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="BioKeyMember" xlink:href="abvcd-20210331.xsd#abvcd_BioKeyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="BioKeyMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDetailsTable" xlink:to="BusinessCombinationDetailsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockIssuedAfterStockSplit" xlink:href="abvcd-20210331.xsd#abvcd_CommonStockIssuedAfterStockSplit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDetailsLineItems" xlink:to="CommonStockIssuedAfterStockSplit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDetailsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfGoodwill" xlink:href="abvcd-20210331.xsd#abvcd_PercentageOfGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDetailsLineItems" xlink:to="PercentageOfGoodwill" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDetailsLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract" xlink:href="abvcd-20210331.xsd#abvcd_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable" order="1.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140266618814440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>May 10, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ABVC BioPharma, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,420,526<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001173313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">333-91436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140266625001384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 2,615,073<span></span>
</td>
<td class="nump">$ 4,273,208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash and cash equivalents</a></td>
<td class="nump">718,163<span></span>
</td>
<td class="nump">728,163<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">392,532<span></span>
</td>
<td class="nump">159,712<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedPartiesCurrent', window );">Accounts receivable - related parties, net</a></td>
<td class="nump">145,075<span></span>
</td>
<td class="nump">143,435<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromOtherRelatedPartiesCurrent', window );">Due from related parties</a></td>
<td class="nump">702,889<span></span>
</td>
<td class="nump">696,255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expense and other current assets</a></td>
<td class="nump">631,721<span></span>
</td>
<td class="nump">172,193<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">5,205,453<span></span>
</td>
<td class="nump">6,172,966<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">504,952<span></span>
</td>
<td class="nump">514,834<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">1,714,740<span></span>
</td>
<td class="nump">1,772,747<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">1,126,884<span></span>
</td>
<td class="nump">1,190,727<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets</a></td>
<td class="nump">1,815,755<span></span>
</td>
<td class="nump">1,790,597<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseNoncurrent', window );">Prepaid expenses &#8211; noncurrent</a></td>
<td class="nump">117,639<span></span>
</td>
<td class="nump">119,315<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposits</a></td>
<td class="nump">40,639<span></span>
</td>
<td class="nump">45,519<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">10,526,062<span></span>
</td>
<td class="nump">11,606,705<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">10,334<span></span>
</td>
<td class="nump">23,044<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBankLoansAndNotesPayable', window );">Short-term bank loans</a></td>
<td class="nump">1,615,250<span></span>
</td>
<td class="nump">1,629,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherShortTermBorrowings', window );">Short-term loan</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableToBankCurrent', window );">Notes payable</a></td>
<td class="nump">105,300<span></span>
</td>
<td class="nump">106,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">2,135,912<span></span>
</td>
<td class="nump">2,118,854<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CustomerAdvancesForConstruction', window );">Advance from customers</a></td>
<td class="nump">12,070<span></span>
</td>
<td class="nump">12,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities &#8211; current portion</a></td>
<td class="nump">331,179<span></span>
</td>
<td class="nump">316,178<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Other payable</a></td>
<td class="nump">44,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Due to related parties</a></td>
<td class="nump">312,152<span></span>
</td>
<td class="nump">288,445<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNotesPayableCurrent', window );">Convertible notes payable - related parties, current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">4,666,300<span></span>
</td>
<td class="nump">4,844,391<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansPayable', window );">Paycheck Protection Program loan payable</a></td>
<td class="nump">236,498<span></span>
</td>
<td class="nump">124,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDepositLiability', window );">Tenant security deposit</a></td>
<td class="nump">11,080<span></span>
</td>
<td class="nump">19,280<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability &#8211; noncurrent portion</a></td>
<td class="nump">1,383,560<span></span>
</td>
<td class="nump">1,456,567<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible notes payable &#8211; noncurrent portion</a></td>
<td class="nump">2,500,000<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">8,797,438<span></span>
</td>
<td class="nump">8,944,638<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value, 20,000,000 authorized, nil shares issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, 100,000,000 authorized, 24,420,526 and 24,420,526 shares issued and outstanding</a></td>
<td class="nump">24,420<span></span>
</td>
<td class="nump">24,420<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">40,751,807<span></span>
</td>
<td class="nump">40,751,807<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteSubscriptionsReceivable', window );">Stock subscription receivable</a></td>
<td class="num">(2,934,620)<span></span>
</td>
<td class="num">(3,160,360)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(26,770,892)<span></span>
</td>
<td class="num">(25,642,387)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">601,000<span></span>
</td>
<td class="nump">564,860<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock</a></td>
<td class="num">(9,100,000)<span></span>
</td>
<td class="num">(9,100,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders&#8217; Equity</a></td>
<td class="nump">2,571,715<span></span>
</td>
<td class="nump">3,438,340<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
<td class="num">(843,091)<span></span>
</td>
<td class="num">(776,273)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total Equity</a></td>
<td class="nump">1,728,624<span></span>
</td>
<td class="nump">2,662,067<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Equity</a></td>
<td class="nump">$ 10,526,062<span></span>
</td>
<td class="nump">$ 11,606,705<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CustomerAdvancesForConstruction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For utilities only, represents the carrying amount of the liability as of the balance sheet date for payments received by a utility from its customers in advance of performing its obligations under terms of its construction agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CustomerAdvancesForConstruction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromOtherRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount receivable from related parties classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromOtherRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableToBankCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current portion of the total carrying amount as of the balance sheet date due within one year or the operating cycle, if longer, on all notes payable to banks paid on an installment with long term maturities. This can include the amount of any loans from the applicant firm. This does not, however, include any mortgage balances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a)(1),20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableToBankCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term notes classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowings classified as other, maturing within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a)(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDepositLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents money paid in advance to protect the provider of a product or service, such as a lessor, against damage or nonpayment by the buyer or tenant (lessee) during the term of the agreement. Such damages may include physical damage to the property, theft of property, and other contractual breaches. Security deposits held may be interest or noninterest bearing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDepositLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBankLoansAndNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowings from a bank classified as other, maturing within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBankLoansAndNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteSubscriptionsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Note received instead of cash as contribution to equity. The transaction may be a sale of capital stock or a contribution to paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteSubscriptionsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140266619944024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">24,420,526<span></span>
</td>
<td class="nump">24,420,526<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">24,420,526<span></span>
</td>
<td class="nump">24,420,526<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140266619846264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 263,150<span></span>
</td>
<td class="nump">$ 78,786<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenues</a></td>
<td class="nump">1,245<span></span>
</td>
<td class="nump">3,959<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">261,905<span></span>
</td>
<td class="nump">74,827<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="nump">1,167,595<span></span>
</td>
<td class="nump">1,152,889<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">121,315<span></span>
</td>
<td class="nump">92,790<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">225,740<span></span>
</td>
<td class="nump">525<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">1,514,650<span></span>
</td>
<td class="nump">1,246,204<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(1,252,745)<span></span>
</td>
<td class="num">(1,171,377)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">52,529<span></span>
</td>
<td class="nump">10,720<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(130,229)<span></span>
</td>
<td class="num">(131,517)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RentalIncomeNonoperating', window );">Rental income</a></td>
<td class="nump">4,867<span></span>
</td>
<td class="nump">5,231<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_RentalIncomeRelatedParties', window );">Rental income &#8211; related parties</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Gain/Loss on foreign exchange changes</a></td>
<td class="nump">951<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">Gain/Loss on investment in equity securities</a></td>
<td class="num">(47,791)<span></span>
</td>
<td class="num">(70,411)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense)</a></td>
<td class="nump">71<span></span>
</td>
<td class="nump">6,322<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_GovernmentGrantIncome', window );">Government grant income</a></td>
<td class="nump">124,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expenses)</a></td>
<td class="nump">6,398<span></span>
</td>
<td class="num">(178,453)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before provision income tax</a></td>
<td class="num">(1,246,347)<span></span>
</td>
<td class="num">(1,349,830)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income tax</a></td>
<td class="num">(51,024)<span></span>
</td>
<td class="num">(40,568)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(1,195,323)<span></span>
</td>
<td class="num">(1,309,262)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity', window );">Net loss attributable to noncontrolling interests</a></td>
<td class="num">(66,818)<span></span>
</td>
<td class="num">(61,724)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_NetLossAttributableToAbvcAndSubsidiaries', window );">Net loss attributed to ABVC and subsidiaries</a></td>
<td class="num">(1,128,505)<span></span>
</td>
<td class="num">(1,247,538)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">36,140<span></span>
</td>
<td class="num">(6,451)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (1,092,365)<span></span>
</td>
<td class="num">$ (1,253,989)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted (in Dollars per share)</a></td>
<td class="num">$ (0.05)<span></span>
</td>
<td class="num">$ (0.06)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Weighted average number of common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted (in Shares)</a></td>
<td class="nump">24,420,526<span></span>
</td>
<td class="nump">19,484,542<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_GovernmentGrantIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of government grant income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_GovernmentGrantIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_NetLossAttributableToAbvcAndSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net loss attributable to ABVC and subsidiaries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_NetLossAttributableToAbvcAndSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_RentalIncomeRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_RentalIncomeRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117546-209714<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121605123&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RentalIncomeNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income earned by providing the use of assets to an outside party in exchange for a payment or series of payments that is nonoperating in nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RentalIncomeNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140266619701800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (1,195,323)<span></span>
</td>
<td class="num">$ (1,309,262)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">2,928<span></span>
</td>
<td class="nump">11,174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation for nonemployees</a></td>
<td class="nump">225,740<span></span>
</td>
<td class="nump">525<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Gain/Loss on investment in equity securities</a></td>
<td class="nump">47,791<span></span>
</td>
<td class="nump">70,411<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_IncreaseDecreaseInGovernmentGrantIncome', window );">Government grant income</a></td>
<td class="num">(124,400)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other non-cash income and expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(2,333)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred tax</a></td>
<td class="num">(51,024)<span></span>
</td>
<td class="num">(40,568)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Decrease (increase) in accounts receivable</a></td>
<td class="num">(238,484)<span></span>
</td>
<td class="nump">52,950<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets', window );">Decrease (increase) in prepaid expenses and deposits</a></td>
<td class="num">(187,723)<span></span>
</td>
<td class="nump">27,834<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseDueFromOtherRelatedParties', window );">Decrease (increase) in due from related parties</a></td>
<td class="num">(18,229)<span></span>
</td>
<td class="num">(7,536)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Increase (decrease) in accounts payable</a></td>
<td class="num">(12,710)<span></span>
</td>
<td class="num">(3,632)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Increase (decrease) in accrued expenses and other current liabilities</a></td>
<td class="nump">136,519<span></span>
</td>
<td class="nump">500,743<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueToRelatedParties', window );">Increase (decrease) in due to related parties</a></td>
<td class="nump">1,841<span></span>
</td>
<td class="nump">68,750<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(1,413,074)<span></span>
</td>
<td class="num">(630,944)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherInvestments', window );">Prepayment for equity investment</a></td>
<td class="num">(281,952)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(281,952)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of common stock</a></td>
<td class="nump">40,448<span></span>
</td>
<td class="nump">267,740<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_NetProceedsFromShortTermBorrowingsFromThirdParties', window );">Proceeds from short-term borrowing from third parties</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">280,940<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayment of convertible notes</a></td>
<td class="num">(250,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt', window );">Proceeds from long-term loans</a></td>
<td class="nump">236,498<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Borrowings from related parties</a></td>
<td class="nump">15,280<span></span>
</td>
<td class="nump">71,688<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of long-term bank loans</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(9,981)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">42,226<span></span>
</td>
<td class="nump">610,387<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents and restricted cash</a></td>
<td class="num">(15,335)<span></span>
</td>
<td class="num">(93)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents and restricted cash</a></td>
<td class="num">(1,668,135)<span></span>
</td>
<td class="num">(20,650)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and cash equivalents and restricted cash</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Beginning</a></td>
<td class="nump">5,001,371<span></span>
</td>
<td class="nump">160,443<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Ending</a></td>
<td class="nump">3,333,236<span></span>
</td>
<td class="nump">139,793<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flows</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest expense paid</a></td>
<td class="nump">21,666<span></span>
</td>
<td class="nump">10,446<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes paid</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_IncreaseDecreaseInGovernmentGrantIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase Decrease in Government Grant Income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_IncreaseDecreaseInGovernmentGrantIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_NetProceedsFromShortTermBorrowingsFromThirdParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net proceeds from short term borrowings from third parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_NetProceedsFromShortTermBorrowingsFromThirdParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseDueFromOtherRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables due from related parties classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseDueFromOtherRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables, and operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of long-term debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140266618870696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Stock Subscription Receivable</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Comprehensive Income</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Non controlling Interest</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 19,478<span></span>
</td>
<td class="num">$ (4,063,320)<span></span>
</td>
<td class="nump">$ 28,180,348<span></span>
</td>
<td class="num">$ (15,851,223)<span></span>
</td>
<td class="nump">$ 663,753<span></span>
</td>
<td class="num">$ (9,100,000)<span></span>
</td>
<td class="nump">$ 26,147<span></span>
</td>
<td class="num">$ (124,817)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2019</a></td>
<td class="nump">19,478,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(275,347)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">225,740<span></span>
</td>
<td class="nump">41,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">267,739<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares (in Shares)</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">525<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,247,538)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(61,724)<span></span>
</td>
<td class="num">(1,309,262)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_CumulativeTransactionAdjustments', window );">Cumulative transaction adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,451)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,451)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2020</a></td>
<td class="nump">$ 19,488<span></span>
</td>
<td class="num">(3,837,580)<span></span>
</td>
<td class="nump">28,222,862<span></span>
</td>
<td class="num">(17,098,761)<span></span>
</td>
<td class="nump">657,302<span></span>
</td>
<td class="num">$ (9,100,000)<span></span>
</td>
<td class="num">(35,577)<span></span>
</td>
<td class="num">(1,172,266)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2020</a></td>
<td class="nump">19,488,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(275,347)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 24,420<span></span>
</td>
<td class="num">(3,160,360)<span></span>
</td>
<td class="nump">40,751,807<span></span>
</td>
<td class="num">(25,642,387)<span></span>
</td>
<td class="nump">564,860<span></span>
</td>
<td class="num">$ (9,100,000)<span></span>
</td>
<td class="num">(776,273)<span></span>
</td>
<td class="nump">2,662,067<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2020</a></td>
<td class="nump">24,420,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(275,347)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225,740<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,128,505)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(66,818)<span></span>
</td>
<td class="num">(1,195,323)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_CumulativeTransactionAdjustments', window );">Cumulative transaction adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,140<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2021</a></td>
<td class="nump">$ 24,420<span></span>
</td>
<td class="num">$ (2,934,620)<span></span>
</td>
<td class="nump">$ 40,751,807<span></span>
</td>
<td class="num">$ (26,770,892)<span></span>
</td>
<td class="nump">$ 601,000<span></span>
</td>
<td class="num">$ (9,100,000)<span></span>
</td>
<td class="num">$ (843,091)<span></span>
</td>
<td class="nump">$ 1,728,624<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2021</a></td>
<td class="nump">24,420,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(275,347)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_CumulativeTransactionAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_CumulativeTransactionAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140266622183848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">ORGANIZATION AND DESCRIPTION OF BUSINESS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>1. ORGANIZATION AND DESCRIPTION OF BUSINESS</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ABVC BioPharma, Inc. (the
&#x201c;Company&#x201d;), formerly known as American BriVision (Holding) Corporation, a Nevada corporation, through the Company&#x2019;s operating entity, American BriVision Corporation
(&#x201c;BriVision&#x201d;), which was incorporated in July 2015 in the State of Delaware, engages in biotechnology to fulfill unmet
medical needs and focuses on the development of new drugs and medical devices derived from plants. &#xa0;BriVision develops its
pipeline by carefully tracking new medical discoveries or medical device technologies in research institutions in the Asia-Pacific
region. Pre-clinical, disease animal model and Phase I safety studies are examined closely by the Company to identify drugs that
BriVision believes demonstrate efficacy and safety. Once a drug appears to be a good candidate for development and ultimately
commercialization, BriVision licenses the drug or medical device from the original researchers and begins to introduce the drugs
clinical plan to highly respected principal investigators in the United States, Australia and Taiwan to conduct a Phase II clinical
trial. At present, clinical trials for the Company&#x2019;s drugs and medical devices are being conducted at such world-famous
institutions as Memorial Sloan Kettering Cancer Center (&#x201c;MSKCC&#x201d;) and MD Anderson Cancer Center. BriVision had no
predecessor operations prior to its formation on July 21, 2015.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="text-decoration:underline">Name Change</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#x2019;s shareholders approved an amendment to the Company&#x2019;s
Articles of Incorporation to change the Company&#x2019;s corporate name from American BriVision (Holding) Corporation to ABVC BioPharma,
Inc. and approved and adopted the Certificate of Amendment to affect same at the 2020 annual meeting of shareholders (the &#x201c;Annual
Meeting&#x201d;). The name change amendment to the Company&#x2019;s Articles of Incorporation was filed with Nevada&#x2019;s Secretary of
State and became effective on March 8, 2021 and FINRA processed our request to change our name on April 30, 2021, which became effective
as of May 3, 2021.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#x2019;s stock symbol remains ABVC.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="text-decoration:underline">Reverse Merger</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 8, 2016, a Share Exchange
Agreement (the &#x201c;Share Exchange Agreement&#x201d;) was entered into by and among the Company, BriVision, and Euro-Asia Investment
&amp; Finance Corp. Limited, a company incorporated under the laws of Hong Kong Special Administrative Region of the People&#x2019;s
Republic of China (&#x201c;Euro-Asia&#x201d;), being the owners of record of 164,387,376 (52,336,000 pre-stock split) shares of Common
Stock of the Company, and the owners of record of all of the issued share capital of BriVision (the &#x201c;BriVision
Stock&#x201d;).</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Share Exchange Agreement, upon
surrender by the BriVision Shareholders and the cancellation by BriVision of the certificates evidencing the BriVision Stock as registered
in the name of each BriVision Shareholder, and pursuant to the registration of the Company in the register of members maintained by BriVision
as the new holder of the BriVision Stock and the issuance of the certificates evidencing the aforementioned registration of the BriVision
Stock in the name of the Company, the Company issued 166,273,921 (52,936,583 pre-stock split) shares (the &#x201c;Acquisition Stock&#x201d;)
(subject to adjustment for fractionalized shares as set forth below) of the Company&#x2019;s Common Stock to the BriVision Shareholders
(or their designees), and 163,159,952 (51,945,225 pre-stock split) shares of the Company&#x2019;s Common Stock owned by Euro-Asia were
cancelled and retired to treasury. The Acquisition Stock collectively represented 79.70% of the issued and outstanding Common Stock of
the Company immediately after the Closing, in exchange for the BriVision Stock, representing 100% of the issued share capital of BriVision
in a reverse merger (the &#x201c;Merger&#x201d;).</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Merger, all of the issued and
outstanding common shares of BriVision were converted, at an exchange ratio of 0.2536-for-1, into an aggregate of 166,273,921 (52,936,583pre-stock
split) common shares of the Company and BriVision had become a wholly owned subsidiary of the Company. The holders of Company&#x2019;s
Common Stock as of immediately prior to the Merger held an aggregate of 205,519,223(65,431,144 pre-stock split) shares of Company&#x2019;s
Common Stock. Because of the exchange of the BriVision Stock for the Acquisition Stock (the &#x201c;Share Exchange&#x201d;), BriVision
had become a wholly owned subsidiary (the &#x201c;Subsidiary&#x201d;) of the Company and there was a change of control of the Company following
the closing. There were no warrants, options or other equity instruments issued in connection with the share exchange agreement.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon the consummation of the Share Exchange,
BriVision became a wholly owned subsidiary of the Company.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Following the Share Exchange, the Company has
abandoned prior business plan and is now pursuing BriVision&#x2019;s historically proposed businesses, which focus on the development
of new drugs and innovative medical devices to fulfill unmet medical needs. The business model of the Company is to integrate research
achievements from world-famous institutions, conduct clinical trials of translational medicine for Proof of Concept (&#x201c;POC&#x201d;),
out-license to international pharmaceutical companies, and explore global markets.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="text-decoration:underline">Accounting Treatment of the Reverse Merger</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For financial reporting purposes, the Share Exchange
represents a &#x201c;reverse merger&#x201d;&#xa0;rather than a business combination and&#xa0;BriVision&#xa0;is deemed the accounting acquirer
in the transaction. The&#xa0;Share Exchange is being accounted for as a reverse-merger and recapitalization. BriVision&#xa0;is the acquirer
for financial reporting purposes and the&#xa0;Company&#xa0;is the acquired company. Consequently, the assets and liabilities and the
operations reflected in the historical financial statements prior to the Share Exchange will be those of&#xa0;BriVision&#xa0;and recorded
at the historical cost basis of&#xa0;BriVision. In addition, the consolidated financial statements after completion of the Share Exchange
will include the assets and liabilities of the Company and BriVision, and the historical operations of&#xa0;BriVision&#xa0;and operations
of the Combined Company from the closing date of the Share Exchange.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="text-decoration:underline">Merger</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 8, 2019, the Company, BioLite Holding,
Inc. (&#x201c;BioLite&#x201d;), BioKey, Inc. (&#x201c;BioKey&#x201d;), BioLite Acquisition Corp., a direct wholly-owned subsidiary of Parent
(&#x201c;Merger Sub 1&#x201d;), and BioKey Acquisition Corp., a direct wholly-owned subsidiary of Parent (&#x201c;Merger Sub 2&#x201d;) (collectively
referred to as the &#x201c;Parties&#x201d;) completed the business combination pursuant to the Agreement and Plan of Merger (the &#x201c;Merger
Agreement&#x201d;) dated as of January 31, 2018 where ABVC acquired BioLite and BioKey via issuing additional Common Stock of ABVC to
the shareholders of BioLite and BioKey.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the terms of the Merger Agreement,
BioLite and BioKey became two wholly-owned subsidiaries of the Company on February 8, 2019. ABVC issued an aggregate of 104,558,777 shares
(prior to the reverse stock split in 2019) to the shareholders of both BioLite and BioKey under a registration statement on Form S-4
(file number 333-226285), which became effective by operation of law on or about February 5, 2019.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BioLite Holding, Inc. (the &#x201c;BioLite Holding&#x201d;)
was incorporated under the laws of the State of Nevada on July 27, 2016. BioLite BVI, Inc. (the &#x201c;BioLite BVI&#x201d;), a wholly
owned subsidiary of BioLite Holding, was incorporated in the British Virgin Islands on September 13, 2016. BioLite Holding and BioLite
BVI are holding companies and have not carried out substantive business operations of their own.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BioLite, Inc., (the &#x201c;BioLite Taiwan&#x201d;)
was incorporated on February 13, 2006 under the laws of Taiwan. BioLite is in the business of developing and commercialization of new
botanical drugs with application in central nervous system, autoimmunity, inflammation, hematology, and oncology. In addition, BioLite
Taiwan distributes dietary supplements made from extracts of Chinese herbs and Maitake mushroom.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In January 2017, BioLite Holding, BioLite BVI,
BioLite Taiwan, and certain shareholders of BioLite Taiwan entered into a share purchase / exchange agreement (the &#x201c;BioLite Share
Purchase / Exchange Agreement&#x201d;). Pursuant to the BioLite Share Purchase / Exchange Agreement, the shareholder participants to the
BioLite Share Purchase / Exchange Agreement have sold their equity in BioLite Taiwan and were using the proceeds from such sales to purchase
shares of Common Stock of BioLite Holding at the same price per share, resulting in their owning the same number of shares of Common
Stock as they owned in the BioLite Taiwan. Upon closing of the Share Purchase/ Exchange Agreement in August 2017, BioLite Holding ultimately
owns via BioLite BVI approximately 73% of BioLite Taiwan. The other shareholders who did not enter this Share Purchase/ Exchange Agreement
retain their equity ownership in BioLite Taiwan.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BioKey, Inc. was incorporated on August 9, 2000
in the State of California. BioKey provides a wide range of services, including, API characterization, pre-formulation studies, formulation
development, analytical method development, stability studies, IND/NDA/ANDA/510K submissions, and manufacturing clinical trial materials
(Phase I through phase III) and commercial manufacturing. It also licenses out its technologies and initiates joint research and development
processes with other biotechnology, pharmaceutical, and nutraceutical companies.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="text-decoration:underline">Accounting Treatment of the Merger</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company adopted ASC 805, &#x201c;Business
Combination&#x201d; to record the merger transactions of BioKey. Since the Company and BioLite Holding are the entities under Dr. Tsung-Shann
Jiang&#x2019;s common control, the transaction is accounted for as a restructuring transaction.&#xa0;All the assets and liabilities of
BioLite Holding, BioLite BVI, and BioLite Taiwan were transferred to the Company at their respective carrying amounts on the closing
date of the Merger. The Company has recast prior period financial statements to reflect the conveyance of BioLite Holding&#x2019;s common
shares as if the restructuring transaction had occurred as of the earliest date of the financial statements. All material intercompany
accounts, transactions, and profits have been eliminated in consolidation. The nature of and effects on earnings per share (EPS) of nonrecurring
intra-entity transactions involving long-term assets and liabilities is not required to be eliminated and EPS amounts have been recast
to include the earnings (or losses) of the transferred net assets.</p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140266622529048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="text-decoration:underline">Basis of Presentation</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
have been prepared in accordance with the generally accepted accounting principles in the United States of America (the &#x201c;U.S. GAAP&#x201d;).
All significant intercompany transactions and account balances have been eliminated.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This basis of accounting involves the application
of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred.
The Company&#x2019;s financial statements are expressed in U.S. dollars.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="text-decoration:underline">Fiscal Year</font>&#xa0;</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company changed its fiscal year from the
period beginning on October 1st and ending on September 30th to the period beginning on January 1st and ending on December 31st, beginning
January 1, 2018. All references herein to a fiscal year prior to December 31, 2017 refer to the twelve months ended September 30th of
such year.&#xa0;</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="text-decoration:underline">Use of Estimates</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity
with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated
financial statements and the amount of revenues and expenses during the reporting periods. Actual results could differ materially from
those results.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="text-decoration:underline">Inventory</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inventory consists of raw materials, work-in-process,
finished goods, and merchandise. Inventories are stated at the lower of cost or market and valued on a moving weighted average cost basis.
Market is determined based on net realizable value. The Company periodically reviews the age and turnover of its inventory to determine
whether any inventory has become obsolete or has declined in value, and incurs a charge to operations for known and anticipated inventory
obsolescence.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="text-decoration:underline">Reclassifications</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain classifications have been made to the
prior year financial statements to conform to the current year presentation. The reclassification had no impact on previously reported
net loss or accumulated deficit.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="text-decoration:underline">Forward Stock Split</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 21, 2016, the Board of Directors of
the Company approved an amendment to Articles of Incorporation to effect a forward split at a ratio of 1 to 3.141 and increase the number
of our authorized shares of Common Stock, par value $0.001 per share, to 360,000,000, which was effective on April 8, 2016.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="text-decoration:underline">Stock Reverse Split</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 12, 2019, the Board of Directors of
the Company by unanimous written consent in lieu of a meeting approved to i) effect a stock reverse split at the ratio of 1-for-18 (the
&#x201c;Reverse Split&#x201d;) of both the authorized common stock of the Company (the &#x201c;Common Stock&#x201d;) and the issued and outstanding
Common Stock and ii) to amend the articles of incorporation of the Company to reflect the Reverse Split. The Board approved and authorized
the Reverse Split without obtaining approval of the Company&#x2019;s shareholders pursuant to Section 78.207 of Nevada Revised Statutes.
On May 3, 2019, the Company filed a certificate of amendment to the Company&#x2019;s articles of incorporation (the &#x201c;Amendment&#x201d;)
to effect the Reverse Split with the Secretary of State of Nevada. The Financial Industry Regulatory Authority (&#x201c;FINRA&#x201d;)
informed the Company that the Reverse Split was effective on May 8, 2019. All shares and related financial information in this Form 10-K
reflect this 1-for-18 reverse stock split.&#xa0;</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="text-decoration:underline">Fair Value Measurements</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FASB ASC 820, &#x201c;Fair Value Measurements&#x201d;
defines fair value for certain financial and nonfinancial assets and liabilities that are recorded at fair value, establishes a framework
for measuring fair value and expands disclosures about fair value measurements. It requires that an entity measure its financial instruments
to base fair value on exit price, maximize the use of observable units and minimize the use of unobservable inputs to determine the exit
price. It establishes a hierarchy which prioritizes the inputs to valuation techniques used to measure fair value. This hierarchy increases
the consistency and comparability of fair value measurements and related disclosures by maximizing the use of observable inputs and minimizing
the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that reflect
the assumptions market participants would use in pricing the assets or liabilities based on market data obtained from sources independent
of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s own assumptions about the assumptions market participants
would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy prioritizes
the inputs into three broad levels based on the reliability of the inputs as follows:</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#xa0;</td>
    <td style="width: 0.25in; text-align: justify"><font style="font-size: 10pt">&#x25cf;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">Level 1 - Inputs are quoted prices in active markets for identical
    assets or liabilities that the Company has the ability to access at the measurement date. Valuation of these instruments does not
    require a high degree of judgment as the valuations are based on quoted prices in active markets that are readily and regularly available.</font></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#xa0;</td>
    <td style="text-align: justify">&#xa0;</td>
    <td style="text-align: justify">&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#xa0;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">&#x25cf;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">Level 2 - Inputs other than quoted prices in active markets that are
    either directly or indirectly observable as of the measurement date, such as quoted prices for similar assets or liabilities; quoted
    prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially
    the full term of the assets or liabilities.</font></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#xa0;</td>
    <td style="text-align: justify">&#xa0;</td>
    <td style="text-align: justify">&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#xa0;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">&#x25cf;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">Level 3 - Valuations based on inputs that are unobservable and not
    corroborated by market data. The fair value for such assets and liabilities is generally determined using pricing models, discounted
    cash flow methodologies, or similar techniques that incorporate the assumptions a market participant would use in pricing the asset
    or liability.</font></td></tr>
  </table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The carrying values of certain assets and liabilities
of the Company, such as cash and cash equivalents, restricted cash, accounts receivable, due from related parties, inventory, prepaid
expenses and other current assets, accounts payable, accrued liabilities, and due to related parties approximate fair value due to their
relatively short maturities. The carrying value of the Company&#x2019;s short-term bank loan, convertible notes payable, and accrued interest
approximates their fair value as the terms of the borrowing are consistent with current market rates and the duration to maturity is
short. The carrying value of the Company&#x2019;s long-term bank loan approximates fair value because the interest rates approximate market
rates that the Company could obtain for debt with similar terms and maturities.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="text-decoration:underline">Cash and Cash Equivalents</font>&#xa0;</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers highly liquid investments
with maturities of three months or less, when purchased, to be cash equivalents. As of March 31, 2021 and December 31, 2020, the Company&#x2019;s
cash and cash equivalents amounted $2,615,073 and $4,273,208, respectively. Some&#xa0;of the Company&#x2019;s cash deposits are held in
financial institutions located in Taiwan where there is currently regulation mandated on obligatory insurance of bank accounts. The Company
believes this financial institution is of high credit quality.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="text-decoration:underline">Restricted Cash Equivalents</font>&#xa0;</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Restricted cash equivalents primarily consist
of cash held in a reserve bank account in Taiwan. As of March 31, 2021 and December 31, 2020, the Company&#x2019;s restricted cash equivalents
amounted $718,163 and $728,163, respectively.&#xa0;</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="text-decoration:underline">Concentration of Credit Risk</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#x2019;s financial instruments that
are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash and temporary
cash investments in high quality credit institutions, but these investments may be in excess of Taiwan Central Deposit Insurance Corporation
and the U.S. Federal Deposit Insurance Corporation&#x2019;s insurance limits. The Company does not enter into financial instruments for
hedging, trading or speculative purposes.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="text-decoration:underline">Revenue Recognition</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the fiscal year 2018, the Company adopted
Accounting Standards Codification (&#x201c;ASC&#x201d;), Topic 606 (ASC 606), Revenue from Contracts with Customers, using the modified
retrospective method to all contracts that were not completed as of January 1, 2018, and applying the new revenue standard as an adjustment
to the opening balance of accumulated deficit at the beginning of 2018 for the cumulative effect. The results for the Company&#x2019;s
reporting periods beginning on and after January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and
continue to be reported under the accounting standards in effect for the prior period. Based on the Company&#x2019;s review of existing
collaborative agreements as of January 1, 2018, the Company concluded that the adoption of the new guidance did not have a significant
change on the Company&#x2019;s revenue during all periods presented.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to ASC 606, the Company recognizes revenue
when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the Company expects
to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines is
within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify
the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance
obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only
applies the five-step model to contracts when it is probable that the Company will collect the consideration the Company is entitled
to in exchange for the goods or services the Company transfers to the customers. At inception of the contract, once the contract is determined
to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are
performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount
of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following are examples of when the Company
recognizes revenue based on the types of payments the Company receives.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Collaborative Revenues &#x2014; </b>The Company
recognizes collaborative revenues generated through collaborative research, development and/or commercialization agreements. The terms
of these agreements typically include payment to the Company related to one or more of the following: non-refundable upfront license
fees, development and commercial milestones, partial or complete reimbursement of research and development costs, and royalties on net
sales of licensed products. Each type of payments results in collaborative revenues except for revenues from royalties on net sales of
licensed products, which are classified as royalty revenues. To date, the Company has not received any royalty revenues. Revenue is recognized
upon satisfaction of a performance obligation by transferring control of a good or service to the collaboration partners.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As part of the accounting for these arrangements,
the Company applies judgment to determine whether the performance obligations are distinct, and develop assumptions in determining the
stand-alone selling price for each distinct performance obligation identified in the collaboration agreements. To determine the stand-alone
selling price, the Company relies on assumptions which may include forecasted revenues, development timelines, reimbursement rates for
R&amp;D personnel costs, discount rates and probabilities of technical and regulatory success.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company had multiple deliverables under the
collaborative agreements, including deliverables relating to grants of technology licenses, regulatory and clinical development, and
marketing activities. Estimation of the performance periods of the Company&#x2019;s deliverables requires the use of management&#x2019;s
judgment. Significant factors considered in management&#x2019;s evaluation of the estimated performance periods include, but are not limited
to, the Company&#x2019;s experience in conducting clinical development, regulatory and manufacturing activities. The Company reviews the
estimated duration of its performance periods under its collaborative agreements on an annually basis, and makes any appropriate adjustments
on a prospective basis. Future changes in estimates of the performance period under its collaborative agreements could impact the timing
of future revenue recognition.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(i) Non-refundable upfront payments</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If a license to the Company&#x2019;s intellectual
property is determined to be distinct from the other performance obligations identified in an arrangement, the Company recognizes revenue
from the related non-refundable upfront payments based on the relative standalone selling price prescribed to the license compared to
the total selling price of the arrangement. The revenue is recognized when the license is transferred to the collaboration partners and
the collaboration partners are able to use and benefit from the license. To date, the receipt of non-refundable upfront fees was solely
for the compensation of past research efforts and contributions made by the Company before the collaborative agreements entered into
and it does not relate to any future obligations and commitments made between the Company and the collaboration partners in the collaborative
agreements.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(ii) Milestone payments</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is eligible to receive milestone
payments under the collaborative agreement with collaboration partners based on achievement of specified development, regulatory and
commercial events. Management evaluated the nature of the events triggering these contingent payments, and concluded that these events
fall into two categories: (a) events which involve the performance of the Company&#x2019;s obligations under the collaborative agreement
with collaboration partners, and (b) events which do not involve the performance of the Company&#x2019;s obligations under the collaborative
agreement with collaboration partners.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The former category of milestone payments consists
of those triggered by development and regulatory activities in the territories specified in the collaborative agreements. Management
concluded that each of these payments constitute substantive milestone payments. This conclusion was based primarily on the facts that
(i) each triggering event represents a specific outcome that can be achieved only through successful performance by the Company of one
or more of its deliverables, (ii) achievement of each triggering event was subject to inherent risk and uncertainty and would result
in additional payments becoming due to the Company, (iii) each of the milestone payments is non-refundable, (iv) substantial effort is
required to complete each milestone, (v) the amount of each milestone payment is reasonable in relation to the value created in achieving
the milestone, (vi) a substantial amount of time is expected to pass between the upfront payment and the potential milestone payments,
and (vii) the milestone payments relate solely to past performance. Based on the foregoing, the Company recognizes any revenue from these
milestone payments in the period in which the underlying triggering event occurs.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(iii) Multiple Element Arrangements</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company evaluates multiple element arrangements
to determine (1) the deliverables included in the arrangement and (2) whether the individual deliverables represent separate units of
accounting or whether they must be accounted for as a combined unit of accounting. This evaluation involves subjective determinations
and requires management to make judgments about the individual deliverables and whether such deliverables are separate from other aspects
of the contractual relationship. Deliverables are considered separate units of accounting provided that: (i) the delivered item(s) has
value to the customer on a standalone basis and (ii) if the arrangement includes a general right of return relative to the delivered
item(s), delivery or performance of the undelivered item(s) is considered probable and substantially within its control. In assessing
whether an item under a collaboration has standalone value, the Company considers factors such as the research, manufacturing, and commercialization
capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. The Company also
considers whether its collaboration partners can use the other deliverable(s) for their intended purpose without the receipt of the remaining
element(s), whether the value of the deliverable is dependent on the undelivered item(s), and whether there are other vendors that can
provide the undelivered element(s).</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognizes arrangement consideration
allocated to each unit of accounting when all of the revenue recognition criteria in ASC 606 are satisfied for that particular unit of
accounting. In the event that a deliverable does not represent a separate unit of accounting, the Company recognizes revenue from the
combined unit of accounting over the Company&#x2019;s contractual or estimated performance period for the undelivered elements, which
is typically the term of the Company&#x2019;s research and development obligations. If there is no discernible pattern of performance
or objectively measurable performance measures do not exist, then the Company recognizes revenue under the arrangement on a straight-line
basis over the period the Company is expected to complete its performance obligations. Conversely, if the pattern of performance in which
the service is provided to the customer can be determined and objectively measurable performance measures exist, then the Company recognizes
revenue under the arrangement using the proportional performance method. Revenue recognized is limited to the lesser of the cumulative
amount of payments received or the cumulative amount of revenue earned, as determined using the straight-line method or proportional
performance method, as applicable, as of the period ending date.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the inception of an arrangement that includes
milestone payments, the Company evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent
nature of the milestone. This evaluation includes an assessment of whether: (1) the consideration is commensurate with either the Company&#x2019;s
performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting
from its performance to achieve the milestone, (2) the consideration relates solely to past performance and (3) the consideration is
reasonable relative to all of the deliverables and payment terms within the arrangement. The Company evaluates factors such as the scientific,
clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone and the level of effort and
investment required to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining
whether a milestone satisfies all of the criteria required to conclude that a milestone is substantive. Milestones that are not considered
substantive are recognized as earned if there are no remaining performance obligations or over the remaining period of performance, assuming
all other revenue recognition criteria are met.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(iv) Royalties and Profit Sharing Payments</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the collaborative agreement with the collaboration
partners, the Company is entitled to receive royalties on sales of products, which is at certain percentage of the net sales. The Company
recognizes revenue from these events based on the revenue recognition criteria set forth in ASC 606. Based on those criteria, the Company
considers these payments to be contingent revenues, and recognizes them as revenue in the period in which the applicable contingency
is resolved.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenues Derived from Research and Development
Activities Services &#x2014; Revenues related to research and development and regulatory activities are recognized when the related services
or activities are performed, in accordance with the contract terms. The Company typically has only one performance obligation at the
inception of a contract, which is to perform research and development services. The Company may also provide its customers with an option
to request that the Company provides additional goods or services in the future, such as active pharmaceutical ingredient, API, or IND/NDA/ANDA/510K
submissions. The Company evaluates whether these options are material rights at the inception of the contract. If the Company determines
an option is a material right, the Company will consider the option a separate performance obligation.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the Company is entitled to reimbursement from
its customers for specified research and development expenses, the Company accounts for the related services that it provides as separate
performance obligations if it determines that these services represent a material right. The Company also determines whether the reimbursement
of research and development expenses should be accounted for as revenues or an offset to research and development expenses in accordance
with provisions of gross or net revenue presentation. The Company recognizes the corresponding revenues or records the corresponding
offset to research and development expenses as it satisfies the related performance obligations.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company then determines the transaction price
by reviewing the amount of consideration the Company is eligible to earn under the contracts, including any variable consideration. Under
the outstanding contracts, consideration typically includes fixed consideration and variable consideration in the form of potential milestone
payments. At the start of an agreement, the Company&#x2019;s transaction price usually consists of the payments made to or by the Company
based on the number of full-time equivalent researchers assigned to the project and the related research and development expenses incurred.
The Company does not typically include any payments that the Company may receive in the future in its initial transaction price because
the payments are not probable. The Company would reassess the total transaction price at each reporting period to determine if the Company
should include additional payments in the transaction price.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company receives payments from its customers
based on billing schedules established in each contract. Upfront payments and fees may be recorded as advance from customers upon receipt
or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under these
arrangements. Amounts are recorded as accounts receivable when the right of the Company to consideration is unconditional. The Company
does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period
between payment by the customers and the transfer of the promised goods or services to the customers will be one year or less.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="text-decoration:underline">Property and Equipment</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property and equipment is carried at cost net
of accumulated depreciation. Repairs and maintenance are expensed as incurred. Expenditures that improve the functionality of the related
asset or extend the useful life are capitalized. When property and equipment is retired or otherwise disposed of, the related gain or
loss is included in operating income. Leasehold improvements are depreciated on the straight-line method over the shorter of the remaining
lease term or estimated useful life of the asset. Depreciation is calculated on the straight-line method, including property and equipment
under capital leases, generally based on the following useful lives:</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom; ">
    <td style="width: 91%; text-align: justify">&#xa0;</td>
    <td style="width: 1%">&#xa0;</td>
    <td style="border-bottom: black 1.5pt solid; width: 8%; text-align: center"><font style="font-size: 10pt"><b>Estimated&#xa0;Life<br/>
    in Years</b></font></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify"><font style="font-size: 10pt">Buildings and leasehold improvements</font></td>
    <td>&#xa0;</td>
    <td style="text-align: center"><font style="font-size: 10pt">5 ~ 50</font></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><font style="font-size: 10pt">Machinery and equipment</font></td>
    <td>&#xa0;</td>
    <td style="text-align: center"><font style="font-size: 10pt">5 ~ 10</font></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify"><font style="font-size: 10pt">Office equipment</font></td>
    <td>&#xa0;</td>
    <td style="text-align: center"><font style="font-size: 10pt">3 ~ 6</font></td></tr>
  </table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="text-decoration:underline">Impairment of Long-Lived Assets</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has adopted Accounting Standards
Codification subtopic 360-10, Property, Plant and Equipment (&#x201c;ASC 360-10&#x201d;). ASC 360-10 requires that long-lived assets and
certain identifiable intangibles held and used by the Company be reviewed for impairment whenever events or changes in circumstances
indicate that the carrying amount of an asset may not be recoverable. The Company evaluates its long-lived assets for impairment annually
or more often if events and circumstances warrant. Events relating to recoverability may include significant unfavorable changes in business
conditions, recurring losses, or a forecasted inability to achieve break-even operating results over an extended period. Should impairment
in value be indicated, the carrying value of intangible assets will be adjusted, based on estimates of future discounted cash flows resulting
from the use and ultimate disposition of the asset. ASC 360-10 also requires assets to be disposed of be reported at the lower of the
carrying amount or the fair value less costs to sell.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="text-decoration:underline">Long-term Equity Investment</font>&#xa0;</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company acquires the equity investments to
promote business and strategic objectives. The Company accounts for non-marketable equity and other equity investments for which the
Company does not have control over the investees as:</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#xa0;</td>
    <td style="width: 0.25in"><font style="font-size: 10pt">&#x25cf;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">Equity method investments when the Company has the ability to exercise
    significant influence, but not control, over the investee. Its proportionate share of the income or loss is recognized monthly and
    is recorded in gains (losses) on equity investments.</font></td></tr>
  </table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#xa0;</td>
    <td style="width: 0.25in"><font style="font-size: 10pt">&#x25cf;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">Non-marketable cost method investments when the equity method does
    not apply.</font></td></tr>
  </table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Significant judgment is required to identify
whether an impairment exists in the valuation of the Company&#x2019;s non-marketable equity investments, and therefore the Company considers
this a critical accounting estimate. Its yearly analysis considers both qualitative and quantitative factors that may have a significant
impact on the investee&#x2019;s fair value. Qualitative analysis of its investments involves understanding the financial performance and
near-term prospects of the investee, changes in general market conditions in the investee&#x2019;s industry or geographic area, and the
management and governance structure of the investee. Quantitative assessments of the fair value of its investments are developed using
the market and income approaches. The market approach includes the use of comparable financial metrics of private and public companies
and recent financing rounds. The income approach includes the use of a discounted cash flow model, which requires significant estimates
regarding the investees&#x2019; revenue, costs, and discount rates. The Company&#x2019;s assessment of these factors in determining whether
an impairment exists could change in the future due to new developments or changes in applied assumptions.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="text-decoration:underline">Other-Than-Temporary Impairment</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#x2019;s long-term equity investments
are subject to a periodic impairment review. Impairments affect earnings as follows:</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#xa0;</td>
    <td style="width: 0.25in"><font style="font-size: 10pt">&#x25cf;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">Marketable equity securities include the consideration of general market
    conditions, the duration and extent to which the fair value is below cost, and our ability and intent to hold the investment for
    a sufficient period of time to allow for recovery of value in the foreseeable future. The Company also considers specific adverse
    conditions related to the financial health of, and the business outlook for, the investee, which may include industry and sector
    performance, changes in technology, operational and financing cash flow factors, and changes in the investee&#x2019;s credit rating.
    The Company records other-than-temporary impairments on marketable equity securities and marketable equity method investments in
    gains (losses) on equity investments.</font></td></tr>
  </table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#xa0;</td>
    <td style="width: 0.25in"><font style="font-size: 10pt">&#x25cf;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">Non-marketable equity investments based on the Company&#x2019;s assessment
    of the severity and duration of the impairment, and qualitative and quantitative analysis of the operating performance of the investee;
    adverse changes in market conditions and the regulatory or economic environment; changes in operating structure or management of
    the investee; additional funding requirements; and the investee&#x2019;s ability to remain in business. A series of operating losses
    of an investee or other factors may indicate that a decrease in value of the investment has occurred that is other than temporary
    and that shall be recognized even though the decrease in value is in excess of what would otherwise be recognized by application
    of the equity method. A loss in value of an investment that is other than a temporary decline shall be recognized. Evidence of a
    loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the
    investment or inability of the investee to sustain an earnings capacity that would justify the carrying amount of the investment.
    The Company records other-than-temporary impairments for non-marketable cost method investments and equity method investments in
    gains (losses) on equity investments. Other-than-temporary impairments of equity investments were $0 and $0 for the three months
    ended March 31, 2021 and 2020, respectively.</font></td></tr>
  </table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="text-decoration:underline">Goodwill</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company evaluates goodwill for impairment
annually or more frequently when an event occurs or circumstances change that indicate the carrying value may not be recoverable. In
testing goodwill for impairment, the Company may elect to utilize a qualitative assessment to evaluate whether it is more likely than
not that the fair value of a reporting unit is less than its carrying amount. If the qualitative assessment indicates that goodwill impairment
is more likely than not, the Company performs a two-step impairment test. The Company tests goodwill for impairment under the two-step
impairment test by first comparing the book value of net assets to the fair value of the reporting units. If the fair value is determined
to be less than the book value or qualitative factors indicate that it is more likely than not that goodwill is impaired, a second step
is performed to compute the amount of impairment as the difference between the estimated fair value of goodwill and the carrying value.
The Company estimates the fair value of the reporting units using discounted cash flows. Forecasts of future cash flows are based on
our best estimate of future net sales and operating expenses, based primarily on expected category expansion, pricing, market segment
share, and general economic conditions.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company completed the required testing of
goodwill for impairment as of March 31, 2021, and determined that goodwill was impaired because of the current financial condition of
the Company and the Company&#x2019;s inability to generate future operating income without substantial sales volume increases, which are
highly uncertain. Furthermore, the Company anticipates future cash flows indicate that the recoverability of goodwill is not reasonably
assured.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="text-decoration:underline">Research and Development Expenses</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for the cost of using licensing
rights in research and development cost according to ASC Topic 730-10-25-1. This guidance provides that absent alternative future uses
the acquisition of product rights to be used in research and development activities must be charged to research and development expenses
when incurred.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For CDMO business unit, the Company accounts
for R&amp;D costs in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) 730, Research and Development (&#x201c;ASC
730&#x201d;). Research and development expenses are charged to expense as incurred unless there is an alternative future use in other
research and development projects or otherwise. Research and development expenses are comprised of costs incurred in performing research
and development activities, including personnel-related costs, facilities-related overhead, and outside contracted services including
clinical trial costs, manufacturing and process development costs for both clinical and preclinical materials, research costs, and other
consulting services. Non-refundable advance payment for goods and services that will be used in future research and development activities
are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. In instances
where the Company enters into agreements with third parties to provide research and development services, costs are expensed as services
are performed.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="text-decoration:underline">Post-retirement and post-employment benefits</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#x2019;s subsidiaries in Taiwan adopted
the government mandated defined contribution plan pursuant to the Labor Pension Act (the &#x201c;Act&#x201d;) in Taiwan. Such labor regulations
require that the rate of contribution made by an employer to the Labor Pension Fund per month shall not be less than 6% of the worker&#x2019;s
monthly salaries. Pursuant to the Act, the Company makes monthly contribution equal to 6% of employees&#x2019; salaries to the employees&#x2019;
pension fund. The Company has no legal obligation for the benefits beyond the contributions made. The total amounts for such employee
benefits, which were expensed as incurred, were $2,503 and $3,598 for the three months ended March 31, 2021 and 2020, respectively. Other
than the above, the Company does not provide any other post-retirement or post-employment benefits.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="text-decoration:underline">Stock-based Compensation</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company measures expense associated with
all employee stock-based compensation awards using a fair value method and recognizes such expense in the consolidated financial statements
on a straight-line basis over the requisite service period in accordance with FASB ASC Topic 718 &#x201c;Compensation-Stock Compensation&#x201d;.
Total employee stock-based compensation expenses were $0 and $0 for the three months ended March 31, 2021 and 2020, respectively.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounted for stock-based compensation
to non-employees in accordance with FASB ASC Topic 718 &#x201c;Compensation-Stock Compensation&#x201d; and FASB ASC Topic 505-50 &#x201c;Equity-Based
Payments to Non-Employees&#x201d; which requires that the cost of services received from non-employees is measured at fair value at the
earlier of the performance commitment date or the date service is completed and recognized over the period the service is provided. Total
non-employee stock-based compensation expenses were $225,740 and $525 for the three months ended March 31, 2021 and 2020, respectively.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="text-decoration:underline">Beneficial Conversion Feature</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, the Company may issue convertible
notes that may contain an imbedded beneficial conversion feature. A beneficial conversion feature exists on the date a convertible note
is issued when the fair value of the underlying common stock to which the note is convertible into is in excess of the remaining unallocated
proceeds of the note after first considering the allocation of a portion of the note proceeds to the fair value of the warrants, if related
warrants have been granted. The intrinsic value of the beneficial conversion feature is recorded as a debt discount with a corresponding
amount to additional paid in capital. The debt discount is amortized to interest expense over the life of the note using the effective
interest method.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="text-decoration:underline">Income Taxes</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for income taxes using the
asset and liability approach which allows the recognition and measurement of deferred tax assets to be based upon the likelihood of realization
of tax benefits in future years. Under the asset and liability approach, deferred taxes are provided for the net tax effects of temporary
differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax
purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not these items will expire before the
Company is able to realize their benefits, or future deductibility is uncertain.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under ASC 740, a tax position is recognized as
a benefit only if it is&#xa0;&#x201c;more likely than not&#x201d;&#xa0;that the tax position would be sustained in a tax examination, with
a tax examination being presumed to occur. The evaluation of a tax position is a two-step process. The first step is to determine whether
it is more-likely-than-not that a tax position will be sustained upon examination, including the resolution of any related appeals or
litigations based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not
threshold to determine the amount of benefits recognized in the financial statements. A tax position is measured at the largest amount
of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. Tax positions that previously failed to
meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which the threshold is met.
Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent
financial reporting period in which the threshold is no longer satisfied. Penalties and interest incurred related to underpayment of income
tax are classified as income tax expense in the year incurred. No significant penalty or interest relating to income taxes has been incurred
for the three months ended March 31, 2021 and 2020. GAAP also provides guidance on de-recognition, classification, interest and penalties,
accounting in interim periods, disclosures and transition.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 22, 2017, the SEC issued Staff Accounting
Bulletin (&#x201c;SAB 118&#x201d;), which provides guidance on accounting for tax effects of the Tax Act. SAB 118 provides a measurement
period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740.
In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the Act for which the accounting under
ASC 740 is complete. To the extent that a company&#x2019;s accounting for certain income tax effects of the Tax Act is incomplete but
it is able to determine a reasonable estimate, it must record a provisional estimate to be included in the financial statements. If a
company cannot determine a provisional estimate to be included in the financial statements, it should continue to apply ASC 740 on the
basis of the provision of the tax laws that were in effect immediately before the enactment of the Tax Act. While the Company is able
to make reasonable estimates of the impact of the reduction in corporate rate and the deemed repatriation transition tax, the final impact
of the Tax Act may differ from these estimates, due to, among other things, changes in our interpretations and assumptions, additional
guidance that may be issued by the I.R.S., and actions the Company may take. The Company is continuing to gather additional information
to determine the final impact.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="text-decoration:underline">Valuation of Deferred Tax Assets</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A valuation allowance is recorded to reduce the
Company&#x2019;s deferred tax assets to the amount that is more likely than not to be realized. In assessing the need for the valuation
allowance, management considers, among other things, projections of future taxable income and ongoing prudent and feasible tax planning
strategies. If the Company determines that sufficient negative evidence exists, then it will consider recording a valuation allowance
against a portion or all of the deferred tax assets in that jurisdiction. If, after recording a valuation allowance, the Company&#x2019;s
projections of future taxable income and other positive evidence considered in evaluating the need for a valuation allowance prove, with
the benefit of hindsight, to be inaccurate, it could prove to be more difficult to support the realization of its deferred tax assets.
As a result, an additional valuation allowance could be required, which would have an adverse impact on its effective income tax rate
and results. Conversely, if, after recording a valuation allowance, the Company determines that sufficient positive evidence exists in
the jurisdiction in which the valuation allowance was recorded, it may reverse a portion or all of the valuation allowance in that jurisdiction.
In such situations, the adjustment made to the deferred tax asset would have a favorable impact on its effective income tax rate and
results in the period such determination was made.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="text-decoration:underline">Loss Per Share of Common Stock</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company calculates net loss per share in
accordance with ASC Topic 260, &#x201c;Earnings per Share&#x201d;. Basic loss per share is computed by dividing the net loss by the weighted
average number of common shares outstanding during the period. Diluted loss per share is computed similar to basic loss per share except
that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential
common stock equivalents had been issued and if the additional common shares were dilutive. Diluted earnings per share excludes all dilutive
potential shares if their effect is anti-dilutive.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="text-decoration:underline">Commitments and Contingencies</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has adopted ASC Topic 450 &#x201c;Contingencies&#x201d;
subtopic 20, in determining its accruals and disclosures with respect to loss contingencies. Accordingly, estimated losses from loss
contingencies are accrued by a charge to income when information available before financial statements are issued or are available to
be issued indicates that it is probable that an assets had been impaired or a liability had been incurred at the date of the financial
statements and the amount of the loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred.
If a loss contingency is not probable or reasonably estimable, disclosure of the loss contingency is made in the financial statements
when it is at least reasonably possible that a material loss could be incurred.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="text-decoration:underline">Foreign-currency Transactions</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the Company&#x2019;s subsidiaries in Taiwan,
the foreign-currency transactions are recorded in New Taiwan dollars (&#x201c;NTD&#x201d;) at the rates of exchange in effect when the
transactions occur. Gains or losses resulting from the application of different foreign exchange rates when cash in foreign currency
is converted into New Taiwan dollars, or when foreign-currency receivables or payables are settled, are credited or charged to income
in the year of conversion or settlement. On the balance sheet dates, the balances of foreign-currency assets and liabilities are restated
at the prevailing exchange rates and the resulting differences are charged to current income except for those foreign currencies denominated
investments in shares of stock where such differences are accounted for as translation adjustments under the Statements of Stockholders&#x2019;
Equity (Deficit).</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="text-decoration:underline">Translation Adjustment</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accounts of the Company&#x2019;s subsidiaries
in Taiwan were maintained, and their financial statements were expressed, in New Taiwan Dollar (&#x201c;NT$&#x201d;). Such financial statements
were translated into U.S. Dollars (&#x201c;$&#x201d; or &#x201c;USD&#x201d;) in accordance ASC 830, &#x201c;Foreign Currency Matters&#x201d;,
with the NT$ as the functional currency. According to the Statement, all assets and liabilities are translated at the current exchange
rate, stockholder&#x2019;s deficit are translated at the historical rates and income statement items are translated at an average exchange
rate for the period. The resulting translation adjustments are reported under other comprehensive income (loss) as a component of stockholders&#x2019;
equity (deficit).</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="text-decoration:underline">Recent Accounting Pronouncements</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2019, the FASB issued ASU 2019-12,&#xa0;<i>Income
Taxes (Topic 740): Simplifying the Accounting for Income Taxes</i>, as part of its overall simplification initiative to reduce costs
and complexity of applying accounting standards while maintaining or improving the usefulness of the information provided to users of
financial statements. The FASB&#x2019;s amendments primarily impact ASC 740,&#xa0;<i>Income Taxes</i>, and may impact both interim and
annual reporting periods. ASU 2019-12 will be effective for fiscal years beginning after December 15, 2020, and interim periods within
those fiscal years and early adoption is permitted. The Company is currently evaluating the impact of adopting ASU 2019-12.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">In August 2020, the
FASB issued ASU 2020-06,&#xa0;<i>Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging- Contracts in Entity&#x2019;s
Own Equity (Subtopic 815-40)</i>, to reduce the complexity associated with applying U.S. GAAP principles for certain financial instruments
with characteristics of liabilities and equity. The amendments in this ASU reduce the number of accounting models for convertible instruments
and expand the existing disclosure requirements over earnings per share as it relates to convertible instruments. This ASU will be effective
for the fiscal year beginning January 1, 2022 and interim periods therein. Early adoption is permitted, but no earlier than fiscal years
beginning after December 15, 2020. The amendments may be adopted through either a modified retrospective method, or a fully retrospective
method. The Company is currently evaluating the impact of adopting ASU 2020-06.</p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140266622107448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_CollaborativeAgreementsLineItems', window );"><strong>Collaborative Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">COLLABORATIVE AGREEMENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>3. COLLABORATIVE AGREEMENTS</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><font style="text-decoration:underline">Collaborative agreements with BHK</font></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(i) On February 24, 2015, BioLite Taiwan and
BioHopeKing Corporation (the &#x201c;BHK&#x201d;) entered into a co-development agreement, (the &#x201c;BHK Co-Development Agreement&#x201d;),
pursuant to which it is collaborative with BHK to develop and commercialize BLI-1401-2 (Botanical Drug) Triple Negative Breast Cancer
(TNBC) Combination Therapy (BLI-1401-2 Products) in Asian countries excluding Japan for all related intellectual property rights, and
has developed it for medicinal use in collaboration with outside researchers. The development costs shall be shared 50/50 between BHK
and the Company. The BHK Co-Development Agreement will remain in effect for fifteen years from the date of first commercial sale of the
Product in in Asia excluding Japan.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 27, 2016, BioLite Taiwan and BHK agreed
to amend the payment terms of the milestone payment in an aggregate amount of $10 million based on the following schedule:</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#xa0;</td>
    <td style="width: 0.25in"><font style="font-size: 10pt">&#x25cf;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">Upon the signing of the BHK Co-Development Agreement: $1 million, or
    10% of total payment</font></td></tr>
  </table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#xa0;</td>
    <td style="width: 0.25in"><font style="font-size: 10pt">&#x25cf;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">Upon the first Investigational New Drug (IND) submission and BioLite
    Taiwan will deliver all data to BHK according to FDA Reviewing requirement: $1 million, or 10% of total payment</font></td></tr>
  </table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#xa0;</td>
    <td style="width: 0.25in"><font style="font-size: 10pt">&#x25cf;</font></td>
    <td><font style="font-size: 10pt">At the completion of first phase II clinical trial: $1 million, or 10% of total payment</font></td></tr>
  </table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#xa0;</td>
    <td style="width: 0.25in"><font style="font-size: 10pt">&#x25cf;</font></td>
    <td><font style="font-size: 10pt">At the initiation of phase III of clinical trial research: $3 million, or 30% of total payment</font></td></tr>
  </table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#xa0;</td>
    <td style="width: 0.25in"><font style="font-size: 10pt">&#x25cf;</font></td>
    <td><font style="font-size: 10pt">Upon the New Drug Application (NDA) submission: $4 million, or 40% of total payment</font></td></tr>
  </table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2015, BHK has paid a non-refundable
upfront cash payment of $1 million, or 10% of $10,000,000, upon the signing of BHK Co-Development Agreement. The Company concluded that
the deliverables are considered separate units of accounting as the delivered items have value to the customer on a standalone basis
and recognized this cash receipt as collaboration revenue when all research, technical, and development data was delivered to BHK in
2015. The receipt is for the compensation of past research efforts and contributions made by BioLite Taiwan before this collaborative
agreement was signed and it does not relate to any future commitments made by BioLite Taiwan and BHK in this collaborative agreement.
In August 2016, the Company has received the second milestone payment of NT$31,649,000, approximately equivalent to $1 million, and recognized
collaboration revenue for the year ended December 31, 2016. As of the date of this report, the Company has not completed the first phase
II clinical trial.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to the milestone payments, BioLite
Taiwan is entitled to receive royalty on 12% of BHK&#x2019;s net sales related to BLI-1401-2 Products. As of March 31, 2021 and December
31, 2020, the Company has not earned the royalty under the BHK Co-Development Agreement.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(ii) On December 9, 2015, BioLite Taiwan entered
into another two collaborative agreements (the &#x201c;BHK Collaborative Agreements&#x201d;), pursuant to which it is collaborative with
BHK to co-develop and commercialize BLI-1005 for &#x201c;Targeting Major Depressive Disorder&#x201d; (BLI-1005 Products) and BLI-1006 for
&#x201c;Targeting Inflammatory Bowel Disease&#x201d; (BLI-1006 Products) in Asia excluding Japan for all related intellectual property
rights, and has developed it for medicinal use in collaboration with outside researchers. The development costs shall be shared 50/50
between BHK and the Company. The BHK Co-Development Agreement will remain in effect for fifteen years from the date of first commercial
sale of the Product in in Asia excluding Japan.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In 2015, the Company recognized the cash receipt
in a total of NT$50 million, approximately equivalent to $1.6 million, as collaboration revenue when all research, technical, and development
data was delivered to BHK. The Company concluded that the deliverables are considered separate units of accounting as the delivered items
have value to the customer on a standalone basis and recognized this payment as collaboration revenue when all research, technical, data
and development data was delivered to BHK. The cash receipt is for the compensation of past research efforts and contributions made by
BioLite Taiwan before this BHK Collaborative Agreements was signed and it does not relate to any future commitments made by BioLite Taiwan
and BHK in this BHK Collaborative Agreements.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to the total of NT$50 million, approximately
equivalent to $1.60 million, BioLite Taiwan is entitled to receive 50% of the future net licensing income or net sales profit. As of
March 31, 2021 and December 31, 2020, the Company has not earned the royalty under the BHK Collaborative Agreements.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><font style="text-decoration:underline">Co-Development agreement with Rgene Corporation,
a related party</font></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 26, 2017, BriVision entered into a
co-development agreement (the &#x201c;Co-Dev Agreement&#x201d;) with Rgene Corporation (the &#x201c;Rgene&#x201d;), a related party
under common control by controlling beneficiary shareholder of YuanGene Corporation and the Company (See Note 12). Pursuant to
Co-Dev Agreement, BriVision and Rgene agreed to co-develop and commercialize ABV-1507 HER2/neu Positive Breast Cancer Combination
Therapy, ABV-1511 Pancreatic Cancer Combination Therapy and ABV-1527 Ovary Cancer Combination Therapy. Under the terms of the Co-Dev
Agreement, Rgene is required to&#xa0;pay the Company $3,000,000 in cash or stock of Rgene with equivalent value by August 15, 2017.
The payment is for the compensation of BriVision&#x2019;s past research efforts and contributions made by BriVision before the Co-Dev
Agreement was signed and it does not relate to any future commitments made by BriVision and Rgene in this Co-Dev Agreement. In
addition to $3,000,000, the Company is entitled to receive 50% of the future net licensing income or net sales profit earned by
Rgene, if any, and any development costs shall be equally shared by both BriVision and Rgene.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 1, 2017, the Company has delivered all
research, technical, data and development data to Rgene. Since both Rgene and the Company are related parties and under common control
by a controlling beneficiary shareholder of YuanGene Corporation and the Company, the Company has recorded the full amount of $3,000,000
in connection with the Co-Dev Agreement as additional paid-in capital during the year ended December 31, 2017. During the year ended
December 31, 2017, the Company has received $450,000 in cash. On December 24, 2018, the Company received the remaining balance of $2,550,000
in the form of newly issued shares of Rgene&#x2019;s Common Stock, at the price of NT$50 (approximately equivalent to $1.60 per share),
for an aggregate number of 1,530,000 shares, which accounted for equity method long-term investment as of December 31, 2018. During the
year ended December 31, 2018, the Company has recognized investment loss of $549. On December 31, 2018, the Company determined to fully
write off this investment based on the Company&#x2019;s assessment of the severity and duration of the impairment, and qualitative and
quantitative analysis of the operating performance of the investee, adverse changes in market conditions and the regulatory or economic
environment, changes in operating structure of Rgene, additional funding requirements, and Rgene&#x2019;s ability to remain in business.
All projects that have been initiated will be managed and supported by the Company and Rgene.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company and Rgene signed an amendment to
the Co-Dev Agreement on November 10, 2020, pursuant to which both parties agreed to delete AB-1507 HER2/neu Positive Breast Cancer Combination
Therapy and AB 1527 Ovary Cancer Combination Therapy and add ABV-1519 EGFR Positive Non-Small Cell Lung Cancer Combination Therapy and
ABV-1526 Large Intestine / Colon / Rectal Cancer Combination Therapy to the products to be co-developed and commercialized. Other provisions
of the Co-Dev Agreement remain in full force and effect.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><font style="text-decoration:underline">Collaborative agreement with BioFirst Corporation,
a related party</font></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 24, 2017, BriVision entered into a
collaborative agreement (the &#x201c;BioFirst Collaborative Agreement&#x201d;) with BioFirst Corporation (&#x201c;BioFirst&#x201d;),
pursuant to which BioFirst granted the Company the global licensing right for medical use of the product (the
&#x201c;Product&#x201d;): BFC-1401 Vitreous Substitute for Vitrectomy. BioFirst is a related party to the Company because a
controlling beneficiary shareholder of YuanGene Corporation and the Company is one of the directors and Common Stock shareholders of
BioFirst (See Note 12).</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the BioFirst Collaborative Agreement,
the Company will co-develop and commercialize the Product with BioFirst and pay BioFirst in a total amount of $3,000,000 in cash or stock
of the Company before December 31, 2018. The amount of $3,000,000 is in connection with the compensation for BioFirst&#x2019;s past research
efforts and contributions made by BioFirst before the BioFirst Collaborative Agreement was signed and it does not relate to any future
commitments made by BioFirst and BriVision in this BioFirst Collaborative Agreement. In addition, the Company is entitled to receive
50% of the future net licensing income or net sales profit, if any, and any development cost shall be equally shared by both BriVision
and BioFirst.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 25, 2017, BioFirst has delivered
all research, technical, data and development data to BriVision. The Company determined to fully expense the entire amount of $3,000,000
since currently the related licensing rights do not have alternative future uses. According to ASC 730-10-25-1, absent alternative future
uses the acquisition of product rights to be used in research and development activities must be charged to research and development
expenses immediately. Hence, the entire amount of $3,000,000 is fully expensed as research and development expense during the year ended
December 31, 2017.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 30, 2019, BriVision entered into a Stock
Purchase Agreement (the &#x201c;Purchase Agreement&#x201d;) with BioFirst Corporation (&#x201c;BioFirst&#x201d;). Pursuant to the Purchase
Agreement, the Company issued 428,571 shares of the Company&#x2019;s common stock (the &#x201c;Shares&#x201d;) to BioFirst in consideration
for $3,000,000 owed by the Company to BioFirst (the &#x201c;Total Payment&#x201d;) in connection with a certain collaborative agreement
between the Company and BioFirst dated July 24, 2017 (the &#x201c;Collaborative Agreement&#x201d;). Pursuant to the Collaborative Agreement,
BioFirst granted the Company the global licensing right to co-develop BFC-1401 or ABV-1701 Vitreous Substitute for Vitrectomy for medical
purposes in consideration for the Total Payment.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 5, 2019, BriVision entered into a second
Stock Purchase Agreement (&#x201c;Purchase Agreement 2&#x201d;) with BioFirst Corporation (&#x201c;BioFirst&#x201d;). Pursuant to Purchase
Agreement 2, the Company issued 414,702 shares of the Company&#x2019;s common stock (the &#x201c;Shares&#x201d;) to BioFirst in consideration
for $2,902,911 owed by the Company to BioFirst (the &#x201c;Total Payment&#x201d;) in connection with a loan provided to BriVision from
BioFirst.</p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_CollaborativeAgreementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_CollaborativeAgreementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140266624390264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>4. INVENTORY</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Inventory consists of the following:</p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Finished goods</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">99,549</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">100,967</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Work-in-process</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">21,729</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">22,038</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Raw materials</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">60,851</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">61,718</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Allowance for inventory valuation and obsolescence loss</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(182,129</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(184,723</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Inventory, net</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
  </table><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140266622256456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>5. PROPERTY AND EQUIPMENT</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-align: justify; text-indent: -23.75pt">Property and
equipment as of March 31, 2021 and December 31, 2020 are summarized as follows:</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#xa0;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">March 31,<br/>
    2021</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">December&#xa0;31,<br/>
    2020</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">(Unaudited)</td><td style="font-weight: bold">&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Land</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">390,088</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">395,645</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Buildings and leasehold improvements</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">2,231,712</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">2,233,573</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Machinery and equipment</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">992,882</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">994,544</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Office equipment</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">187,181</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">189,760</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">3,801,863</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">3,813,522</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,296,911</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,298,688</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Property and equipment, net</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">504,952</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">514,834</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
  </table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Depreciation expenses were $2,928 and $11,174
for three months ended March 31, 2021 and 2020, respectively.</p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140266717865128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Investments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_LongTermInvestmentAbstract', window );"><strong>Long Term Investment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_LongTermInvestmentTextBlock', window );">LONG-TERM INVESTMENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-indent: -23.75pt"><b>6. LONG-TERM INVESTMENTS</b></p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><font style="font-size: 10pt">(1)</font></td>
    <td><font style="font-size: 10pt">The ownership percentages of each investee are listed as follows:</font></td></tr>
  </table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Ownership percentage</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="text-align: center">&#xa0;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#xa0;</td><td style="white-space: nowrap; font-weight: bold">&#xa0;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">March 31,</td><td style="white-space: nowrap; font-weight: bold">&#xa0;</td><td style="white-space: nowrap; font-weight: bold">&#xa0;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">December&#xa0;31,</td><td style="white-space: nowrap; font-weight: bold">&#xa0;</td><td style="white-space: nowrap; font-weight: bold">&#xa0;</td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center">Accounting</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Name of related party</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">treatments</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Braingenesis Biotechnology Co., Ltd.</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">0.17</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">0.17</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 11%; text-align: center">Cost Method</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Genepharm Biotech Corporation</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">0.70</td><td style="text-align: left">%</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">0.70</td><td style="text-align: left">%</td><td>&#xa0;</td>
    <td style="text-align: center">Cost Method</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">BioHopeKing Corporation</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5.90</td><td style="text-align: left">%</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5.90</td><td style="text-align: left">%</td><td>&#xa0;</td>
    <td style="text-align: center">Cost Method</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">BioFirst Corporation</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">15.99</td><td style="text-align: left">%</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">15.99</td><td style="text-align: left">%</td><td>&#xa0;</td>
    <td style="text-align: center">Equity Method</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Rgene Corporation</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">31.62</td><td style="text-align: left">%</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">31.62</td><td style="text-align: left">%</td><td>&#xa0;</td>
    <td style="text-align: center">Equity Method</td></tr>
  </table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><font style="font-size: 10pt">(2)</font></td>
    <td><font style="font-size: 10pt">The extent the investee relies on the company for its business are summarized as follows:</font></td></tr>
  </table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom; ">
    <td style="border-bottom: black 1.5pt solid; width: 30%"><font style="font-size: 10pt"><b>Name of related party</b></font></td>
    <td style="width: 1%">&#xa0;</td>
    <td style="border-bottom: black 1.5pt solid; width: 69%"><font style="font-size: 10pt"><b>The extent the investee relies on the Company
    for its business &#xa0;</b></font></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td><font style="font-size: 10pt">Braingenesis Biotechnology Co., Ltd.</font></td>
    <td>&#xa0;</td>
    <td><font style="font-size: 10pt">No specific business relationship</font></td></tr>
  <tr>
    <td><font style="font-size: 10pt">Genepharm Biotech Corporation</font></td>
    <td>&#xa0;</td>
    <td><font style="font-size: 10pt">No specific business relationship</font></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td><font style="font-size: 10pt">BioHopeKing Corporation</font></td>
    <td>&#xa0;</td>
    <td><font style="font-size: 10pt">Collaborating with the Company to develop and commercialize drugs</font></td></tr>
  <tr>
    <td><font style="font-size: 10pt">BioFirst Corporation</font></td>
    <td>&#xa0;</td>
    <td><font style="font-size: 10pt">Loaned from the investee and provides research and development support service</font></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td><font style="font-size: 10pt">Rgene Corporation</font></td>
    <td>&#xa0;</td>
    <td><font style="font-size: 10pt">Collaborating with the Company to develop and commercialize drugs</font></td></tr>
  </table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><font style="font-size: 10pt">(3)</font></td>
    <td><font style="font-size: 10pt">Long-term investment mainly consists of the following:</font></td></tr>
  </table><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March&#xa0;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#xa0;31,<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2">&#xa0;</td><td>&#xa0;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Non-marketable Cost Method Investments, net</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: center">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2">&#xa0;</td><td>&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 9pt">Braingenesis Biotechnology Co., Ltd.</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,742</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,853</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Genepharm Biotech Corporation</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">23,638</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">23,974</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">BioHopeKing Corporation</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">878,056</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">890,564</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25in">Sub total</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">909,436</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">922,391</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Equity Method Investments, net</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">BioFirst Corporation</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">217,448</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">268,336</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Rgene Corporation</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; padding-left: 0.25in">Total</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,126,884</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,190,727</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
  </table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><font style="font-size: 10pt">(a)</font></td><td style="text-align: justify"><font style="font-size: 10pt">BioFirst
                                            Corporation (the &#x201c;BioFirst&#x201d;):</font></td>
</tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company holds an equity interest
in BioFirst Corporation, accounting for its equity interest using the equity method to accounts for its equity investment as prescribed
in ASC 323, Investments&#x2014;Equity Method and Joint Ventures (&#x201c;ASC 323&#x201d;). Equity method adjustments include the Company&#x2019;s
proportionate share of investee&#x2019;s income or loss and other adjustments required by the equity method. As of March 31, 2021 and December
31, 2020, the Company owns 15.99% and 15.99% common stock shares of BioFirst, respectively. During the three months ended March 31, 2021,
the Company made prepayment for equity investment in BioFirst to purchase additional 132,000 shares issued by BioFirst in the aggregate
amount of $281,952.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Summarized financial information for the Company&#x2019;s
equity method investee, BioFirst, is as follows:&#xa0;</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Balance Sheet</i></p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#xa0;31,<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Current Assets</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,216,963</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,299,822</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Non-current Assets</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">2,633,925</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">2,540,041</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current Liabilities</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,959,919</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,986,340</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Non-current Liabilities</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">76,082</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">73,197</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stockholders&#x2019; Equity</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,814,887</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,780,326</td><td style="text-align: left">&#xa0;</td></tr>
  </table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Statement of operation</i></p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended<br/> March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="6">&#xa0;</td><td>&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Net sales</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">12,239</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">12,110</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Gross profit</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">7,080</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,578</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(220,855</td><td style="text-align: left">)</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(325,652</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share of losses from investments accounted for using the equity method</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(47,791</td><td style="text-align: left">)</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(70,411</td><td style="text-align: left">)</td></tr>
  </table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><font style="font-size: 10pt">(b)</font></td><td style="text-align: justify"><font style="font-size: 10pt">Rgene
                                            Corporation (the &#x201c;Rgene&#x201d;)</font></td>
</tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Both Rgene and the Company are under
common control by Dr. Tsung-Shann Jiang, the CEO and chairman of the BioLite Inc. Since Dr. Tsung-Shann Jiang is able to exercise significant
influence, but not control, over the Rgene, the Company determined to use the equity method to accounts for its equity investment as
prescribed in ASC 323, Investments&#x2014;Equity Method and Joint Ventures (&#x201c;ASC 323&#x201d;). Equity method adjustments include
the Company&#x2019;s proportionate share of investee&#x2019;s income or loss and other adjustments required by the equity method. As of
March 31, 2021 and December 31, 2020, the Company owns 31.62% and 31.62% Common Stock shares of Rgene, respectively.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Summarized financial information for the Company&#x2019;s
equity method investee, Rgene, is as follows:</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Balance Sheets</i></p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#xa0;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">March 31,<br/>
    2021</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">December&#xa0;31,<br/>
    2020</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Current Assets</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">107,682</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">123,958</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Noncurrent Assets</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">395,665</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">412,342</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current Liabilities</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,451,387</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,392,756</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Noncurrent Liabilities</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">28,877</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">38,953</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Shareholders&#x2019; Deficit</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(976,917</td><td style="text-align: left">)</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(895,409</td><td style="text-align: left">)</td></tr>
  </table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Statement of operations</i></p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Three Months Ended<br/>
    March 31,</b></font></td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2021</b></font></td>
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2020</b></font></td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td colspan="6">&#xa0;</td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 76.98%"><font style="font-size: 10pt">Net sales</font></td>
    <td style="width: 0.98%">&#xa0;</td>
    <td style="width: 1.06%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 8.98%; text-align: right">-</td>
    <td style="width: 0.98%">&#xa0;</td>
    <td style="width: 0.98%">&#xa0;</td>
    <td style="width: 1.06%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 7.98%; text-align: right">-</td>
    <td style="width: 0.98%">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><font style="font-size: 10pt">Gross Profit</font></td>
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td style="text-align: right">-</td>
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td style="text-align: right">-</td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Net loss</font></td>
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(95,395</font></td>
    <td><font style="font-size: 10pt">)</font></td>
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(21,889</font></td>
    <td><font style="font-size: 10pt">)</font></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><font style="font-size: 10pt">Share of loss from investments accounted for using the equity method</font></td>
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td style="text-align: right"><font style="font-size: 10pt">-</font></td>
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td style="text-align: right"><font style="font-size: 10pt">-</font></td>
    <td>&#xa0;</td></tr>
  </table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><font style="font-size: 10pt">(4)</font></td><td style="text-align: justify"><font style="font-size: 10pt">Disposition
                                            of long-term investment</font></td>
</tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">During the year ended December 31,
2020, the Company sold 218,000 shares of common stock of BioHopeKing Corporation at price of NT$24, equivalent $0.85, to several individuals,
and the percentage of ownership decreased to 5.90% as of December 31, 2020. As a result of the transactions, the Company recognized investment
loss of $40,589 and impairment loss of $961,217 for the same period. As of March 31. 2021, there is no disposition of long-term investment.</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><font style="font-size: 10pt">(5)</font></td><td style="text-align: justify"><font style="font-size: 10pt">Losses
                                            on Equity Investments</font></td>
</tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The components of losses on equity investments
for each period were as follows:</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended<br/> March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#xa0;</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#xa0;</td><td style="font-weight: bold">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Share of equity method investee losses</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(47,791</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(70,411</td><td style="width: 1%; text-align: left">)</td></tr>
  </table><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_LongTermInvestmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_LongTermInvestmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_LongTermInvestmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_LongTermInvestmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140266622651112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes Payable<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_ConvertibleNotesPayableDisclosureAbstract', window );"><strong>Convertible Notes Payable Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_ConvertibleNotesPayableDisclosureTextBlock', window );">CONVERTIBLE NOTES PAYABLE</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>7. CONVERTIBLE NOTES PAYABLE</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 9, 2018, the Company issued an eighteen-month
term unsecured convertible promissory note (the &#x201c;Yu and Wei Note&#x201d;) in an aggregate principal amount of $300,000 to Guoliang
Yu and Yingfei Wei Family Trust (the &#x201c;Yu and Wei&#x201d;), pursuant to which the Company received $300,000. The Yu and Wei Note bears
interest at 8% per annum. The Company shall pay to the Yu and Wei an amount in cash representing all outstanding principal and accrued
and unpaid interest on the Eighteenth (18) month anniversary of the issuance date of the Yu and Wei Note, which is on November 8, 2019.
In the event that the Company raises gross proceeds from the sale of its common stock of at least $5,000,000 (an &#x201c;Equity Offering&#x201d;)
then within five days of the closing for such offering, the Company must repay the outstanding amount of this Yu and Wei Note. At any
time from the date hereof until this Yu and Wei Note has been satisfied, the Yu and Wei may convert the unpaid and outstanding principal
plus any accrued and unpaid interest and or default interest, if any, into shares of the Company&#x2019;s common stock at a conversion
price (the &#x201c;Conversion Price&#x201d;) equal to the lower of (i) $2.00 per share (the &#x201c;Fixed Conversion Price&#x201d;), subject
to adjustment or (ii) 80% of the per share offering price (the &#x201c;Alternative Conversion Price&#x201d;) of any completed equity offering
of the Company in an amount exceeding $500,000 that occurs when any part of the Yu and Wei Note is outstanding, subject to adjustments
set forth in the Yu and Wei Note. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial
conversion feature present in the Yu and Wei Note. On January 21, 2020, Yu and Wei entered into a new agreement that the new Note bears
interest at 20% per annum. The Company shall pay to the Yu and Wei an amount in cash representing all outstanding principal and accrued
and unpaid interest on the Twelve (12) month anniversary of the issuance date of the new &#x201c;Yu and Wei&#x201d; Note, which is on January
20, 2021. On April 5, 2020, the Company entered into an exchange agreement with &#x201c;Yu and Wei&#x201d;. The aggregate principal amount
plus accrued interest expenses were $354,722, and the Company agreed to issue to the Holders an aggregate of 192,784 shares of the Company&#x2019;s
common stock, and warrants to purchase 192,784 shares of the Company&#x2019;s common stock. As of March 31, 2021, these common shares have
been issued.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 27, 2018, the Company issued an eighteen-month
term unsecured convertible promissory note (the &#x201c;Keypoint Note&#x201d;) in the aggregate principal amount of $250,000 to Keypoint
Technology Ltd. (&#x201c;Keypoint&#x201d;), a related party, pursuant to which the Company received $250,000. The Keypoint Note bears interest
at 8% per annum. The Company shall pay to the Keypoint an amount in cash representing all outstanding principal and accrued and unpaid
interest on the Eighteenth (18) month anniversary of the issuance date of the Keypoint Note, which is on December 26, 2019. In the event
that the Company raises gross proceeds from the sale of its common stock of at least $5,000,000 (an &#x201c;Equity Offering&#x201d;) then
within five days of the closing for such offering, the Company must repay the outstanding amount of this Keypoint Note. At any time from
the date hereof until this Keypoint Note has been satisfied, Keypoint may convert the unpaid and outstanding principal plus any accrued
and unpaid interest and or default interest, if any, into shares of the Company&#x2019;s common stock at a conversion price (the &#x201c;Conversion
Price&#x201d;) equal to the lower of (i) $2.00 per share (the &#x201c;Fixed Conversion Price&#x201d;), subject to adjustment or (ii) 80%
of the per share offering price (the &#x201c;Alternative Conversion Price&#x201d;) of any completed equity offering of the Company in an
amount exceeding $500,000 that occurs when any part of the Keypoint Note is outstanding, subject to adjustments set forth in the Keypoint
Note. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature
present in the Keypoint Note. On January 21, 2020, Keypoint entered into a new agreement that the new Note bears interest at 20% per annum.
The Company shall pay to the Keypoint an amount in cash representing all outstanding principal and accrued and unpaid interest on the
Twelve (12) month anniversary of the issuance date of the new &#x201c;Keypoint&#x201d; Note, which is on January 20, 2021. On April 5, 2020,
the Company entered into an exchange agreement with &#x201c;Keypoint&#x201d;. The aggregate principal amount plus accrued interest expenses
were $292,826, and the Company agreed to issue to the Holders an aggregate of 159,145 shares of the Company&#x2019;s common stock, and
warrants to purchase 159,145 shares of the Company&#x2019;s common stock. As of March 31, 2021, these common shares have been issued.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 25, 2018, the Company issued an eighteen-month
term unsecured convertible promissory notes (the &#x201c;Odaira Note&#x201d;) in the aggregate principal amount of $250,000 to Yoshinobu
Odaira. (&#x201c;Odaira&#x201d;), pursuant to which the Company received $250,000. The Odaira Note bears interest at 8% per annum. The Company
shall pay to the Odaira an amount in cash representing all outstanding principal and accrued and unpaid interest on the Eighteenth (18)
month anniversary of the issuance date of the Odaira Note, which is on February 24, 2020. In the event that the Company raises gross proceeds
from the sale of its common stock of at least $5,000,000 (an &#x201c;Equity Offering&#x201d;) then within five days of the closing for such
offering, the Company must repay the outstanding amount of this Odaira Note. At any time from the date hereof until this Odaira Note has
been satisfied, Odaira may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default interest,
if any, into shares of the Company&#x2019;s common stock at a conversion price (the &#x201c;Conversion Price&#x201d;) equal to the lower
of (i) $2.00 per share (the &#x201c;Fixed Conversion Price&#x201d;), subject to adjustment or (ii) 80% of the per share offering price (the
&#x201c;Alternative Conversion Price&#x201d;) of any completed equity offering of the Company in an amount exceeding $500,000 that occurs
when any part of the Odaira Note is outstanding, subject to adjustments set forth in the Odaira Note. In accordance with FASB ASC 470-20,
the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the Odaira Note. On January 21,
2020, Odaira entered into a new agreement that the new Note bears interest at 20% per annum. The Company shall pay to the Odaira an amount
in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date
of the new &#x201c;Odaira&#x201d; Note, which is on January 20, 2021. On April 5, 2020, the Company entered into an exchange agreement with
&#x201c;Odaira&#x201d;. The aggregate principal amount plus accrued interest expenses were $284,036, and the Company agreed to issue to
the Holders an aggregate of 154,368 shares of the Company&#x2019;s common stock, and warrants to purchase 154,368 shares of the Company&#x2019;s
common stock. As of March 31, 2021, these common shares have been issued.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 30 and July 10, 2019, the Company issued
two (2) twelve-month term unsecured convertible promissory notes (the &#x201c;KSL Note&#x201d;) in an aggregate principal amount of $250,000
to Kuo Sheng Lung (the &#x201c;KSL&#x201d;), pursuant to which the Company received $160,000 and $90,000, respectively. The KSL Note bears
interest at 20% per annum. The Company shall pay to KSL an amount in cash representing all outstanding principal and accrued and unpaid
interest on the Twelve (12) month anniversary of the issuance date of the KSL Note, which is on May 29, 2020 and July 9, 2020. At any
time from the issuance date until the KSL Note has been satisfied, the KSL may convert the unpaid and outstanding principal plus any accrued
and unpaid interest and or default interest, if any, into shares of the Company&#x2019;s common stock at a conversion price (the &#x201c;Conversion
Price&#x201d;) equal to the lower of (i) $0.50 per share (the &#x201c;Fixed Conversion Price&#x201d;), subject to adjustment, or (ii) 70%
of the per share offering price (the &#x201c;Alternative Conversion Price&#x201d;) of the completed public equity offering of the Company
in an amount exceeding $10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission
on November 14, 2018 (the &#x201c;Public Offering&#x201d;), as amended from time to time. In accordance with FASB ASC 470-20, the Company
recognized none of the intrinsic value of the embedded beneficial conversion feature present in the KSL Note. On May 13, 2020, the Company
received an acknowledgement letter from KSL that they will not claim the repayment of loan for 12 months. On November 9, 2020, the Company
entered into an agreement with &#x201c;KSL&#x201d;. The aggregate principal amount plus accrued interest expenses are $270,272, and KSL
agreed to use the full amount to purchase certain securities pursuant to a securities purchase agreement; KSL agreed to purchase and the
Company agreed to issue 120,121 shares of the Company&#x2019;s common stock and warrants for a purchase price of $270,272.&#xa0;As of March
31, 2021, the Company issued to the Holders an aggregate of 120,121 shares of the Company&#x2019;s common stock.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 10, 2019, the Company issued a twelve-month
term unsecured convertible promissory note (the &#x201c;NEA Note&#x201d;) in an aggregate principal amount of $250,000 to New Eastern Asia
(the &#x201c;NEA&#x201d;), a related party, pursuant to which the Company received $250,000 on July 10, 2019. The NEA Note bears interest
at 20% per annum. The Company shall pay to the NEA an amount in cash representing all outstanding principal and accrued and unpaid interest
on the Twelve (12) month anniversary of the issuance date of the NEA Note, which is on July 9, 2020. At any time from the date hereof
until this NEA Note has been satisfied, the NEA may convert the unpaid and outstanding principal plus any accrued and unpaid interest
and or default interest, if any, into shares of the Company&#x2019;s common stock at a conversion price (the &#x201c;Conversion Price&#x201d;)
equal to the lower of (i) $.50 per share (the &#x201c;Fixed Conversion Price&#x201d;), subject to adjustment, or (ii) 70% of the per share
offering price (the &#x201c;Alternative Conversion Price&#x201d;) of the completed public equity offering of the Company in an amount exceeding
$10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018
(the &#x201c;Public Offering&#x201d;), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of
the intrinsic value of embedded beneficial conversion feature present in the NEA Note. As of March 31, 2021, the Company paid off the convertible
promissory note of $306,667, including principal and accrued and unpaid interest expense.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 28, 2019, the Company issued a twelve-month
term unsecured convertible promissory note (the &#x201c;KLS Note&#x201d;) in an aggregate principal amount of $200,000 to Kuo Li Shen (the
&#x201c;KLS&#x201d;), pursuant to which the Company received $200,000 on August 28, 2019. The KLS Note bears interest at 20% per annum.
The Company shall pay to the KLS an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve
(12) month anniversary of the issuance date of the KLS Note, which is on August 27, 2020. At any time from the date hereof until this
KLS Note has been satisfied, the KLS may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default
interest, if any, into shares of the Company&#x2019;s common stock at a conversion price (the &#x201c;Conversion Price&#x201d;) equal to
the lower of (i) $.50 per share (the &#x201c;Fixed Conversion Price&#x201d;), subject to adjustment, or (ii) 70% of the per share offering
price (the &#x201c;Alternative Conversion Price&#x201d;) of the completed public equity offering of the Company in an amount exceeding $10,000,000
as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the &#x201c;Public
Offering&#x201d;), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value
of embedded beneficial conversion feature present in the KLS Note. On April 20, 2020, the Company entered into an exchange agreement with
KLS. The aggregate principal amount plus accrued interest expenses were $225,222, and the Company agreed to issue to the Holders an aggregate
of 126,530 shares of the Company&#x2019;s common stock, and warrants to purchase 126,530 shares of common stock. As of March 31, 2021,
these common shares have been issued.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 4, 2019, the Company issued 3 twelve-month
term unsecured convertible promissory note (the &#x201c;C.L.L. Note&#x201d;) in an aggregate principal amount of $257,500 to Chang Ping
Shan, Lin Shan Tyan, and Liu Ching Hsuan (together the &#x201c;C.L.L.&#x201d;), pursuant to which the Company received $257,500 on September
4, 2019. Chang Ping Shan and Liu Ching Hsuan are related parties to the Company. The C.L.L. Note bears interest at 20% per annum. The
Company shall pay to the C.L.L. an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve
(12) month anniversary of the issuance date of the C.L.L. Note, which is on September 3, 2020. At any time from the date hereof until
this C.L.L. Note has been satisfied, the C.L.L. may convert the unpaid and outstanding principal plus any accrued and unpaid interest
and or default interest, if any, into shares of the Company&#x2019;s common stock at a conversion price (the &#x201c;Conversion Price&#x201d;)
equal to the lower of (i) $.50 per share (the &#x201c;Fixed Conversion Price&#x201d;), subject to adjustment, or (ii) 70% of the per share
offering price (the &#x201c;Alternative Conversion Price&#x201d;) of the completed public equity offering of the Company in an amount exceeding
$10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018
(the &#x201c;Public Offering&#x201d;), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of
the intrinsic value of embedded beneficial conversion feature present in the C.L.L. Note. On April 20, 2020, the Company entered into
an exchange agreement with C.L.L.. The aggregate principal amount plus accrued interest expenses were $289,974, and the Company agreed
to issue to the Holders an aggregate of 162,908 shares of the Company&#x2019;s common stock, and warrants to purchase 162,908 shares of
common stock. As of March 31, 2021, these common shares have been issued.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 29, 2019, the Company issued a twelve-month
term unsecured convertible promissory note (the &#x201c;Lee Note&#x201d;) in an aggregate principal amount of $250,000 to Hwalin Lee (the
&#x201c;Lee&#x201d;), a related party, pursuant to which the Company received $250,000 on October 29, 2019. The Lee Note bears interest
at 20% per annum. The Company shall pay to the Lee an amount in cash representing all outstanding principal and accrued and unpaid interest
on the Twelve (12) month anniversary of the issuance date of the Lee Note, which is on October 28, 2020. At any time from the date hereof
until this Lee Note has been satisfied, the Lee may convert the unpaid and outstanding principal plus any accrued and unpaid interest
and or default interest, if any, into shares of the Company&#x2019;s common stock at a conversion price (the &#x201c;Conversion Price&#x201d;)
equal to the lower of (i) $.50 per share (the &#x201c;Fixed Conversion Price&#x201d;), subject to adjustment, or (ii) 70% of the per share
offering price (the &#x201c;Alternative Conversion Price&#x201d;) of the completed public equity offering of the Company in an amount exceeding
$10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018
(the &#x201c;Public Offering&#x201d;), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of
the intrinsic value of embedded beneficial conversion feature present in the Lee Note. As of March 31, 2021, the Company paid off the
convertible promissory note of $311,233, including principal and accrued and unpaid interest expense.&#xa0;</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 23, 2020, the Company entered
into a Securities Purchase Agreement (the &#x201c;October SPA&#x201d;) with one accredited investor. Pursuant to the October SPA, the Company
sold and issued a convertible promissory note (the &#x201c;October Note&#x201d;) in the principal amount of $2,500,000 to the investor and
received the payment from such investor on October 30, 2020. The October Note was issued on October 23, 2020 and the maturity date of
the October Note is the twenty-four (24) month anniversary from the issuance date (the &#x201c;Maturity Date&#x201d;). Upon the Maturity
Date, the Company shall pay to the holder, in cash, an amount representing all outstanding principal amount and accrued and unpaid interest
under the October Note. The October Note bears an interest rate of ten percent (10%) per annum and may be convertible into shares of the
Company&#x2019;s common stock at a fixed conversion price of $2.25 per share. The holder of the October Note may elect to convert part
or all of the outstanding balance of the October Note from the issuance date until the Maturity Date. The Company may prepay the outstanding
amount at any time, in whole or in part, without any penalty.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2021 and December 31, 2020, the
aggregate carrying values of the convertible debentures were $2,500,000 and $2,750,000, respectively; and accrued convertible interest
was $110,215 and $104,551, respectively.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Total interest expenses in connection with the above convertible note
payable were $66,897 and $95,214 for the three months ended March 31, 2021 and 2020, respectively.</p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_ConvertibleNotesPayableDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_ConvertibleNotesPayableDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_ConvertibleNotesPayableDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of convertible notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_ConvertibleNotesPayableDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140266718855992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Bank Loans<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_BankLoansAbstractAbstract', window );"><strong>Bank Loans Abstract [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_BankLoansAbstract', window );">BANK LOANS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>8. BANK LOANS</b></p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt"><font style="font-size: 10pt">(1)</font></td>
    <td style="font-size: 10pt"><font style="font-size: 10pt">Short-term bank loan consists of the following:</font></td></tr>
  </table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; white-space: nowrap; text-align: center">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center">&#xa0;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap">March 31,</td><td style="vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center">&#xa0;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap">December&#xa0;31,</td><td style="vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center">&#xa0;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; white-space: nowrap; text-align: center">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap; text-align: center">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap">2021</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap; text-align: center">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap; text-align: center">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap">2020</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap; text-align: center">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Cathay United Bank</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">263,250</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">267,000</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">CTBC Bank</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">702,000</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">712,000</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Cathay Bank</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">650,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">650,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,615,250</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,629,000</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
  </table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="text-decoration:underline">Cathay United Bank</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 28, 2016, BioLite Taiwan and Cathay United
Bank entered into a one-year bank loan agreement (the &#x201c;Cathay United Loan Agreement&#x201d;) in an amount of NT$7,500,000, equivalent
to $263,250. The term started June 28, 2016 with maturity date at June 28, 2017. The loan balance bears interest at a floating rate of
prime rate plus 1.15%. The prime rate is based on term deposit saving interest rate of Cathay United Bank. On September 6, 2017, BioLite
Taiwan extended the Cathay United Loan Agreement for one year, which was due on September 6, 2018, with the principal amount of NT$7,500,000,
equivalent to $263,250. On October 1, 2018, BioLite Taiwan extended the Cathay United Loan Agreement with the same principal amount of
NT$7,500,000, equivalent to $263,250 for one year, which was due on September 6, 2019. On September 6, 2019, BioLite Taiwan extended the
Cathay United Loan Agreement with the same principal amount of NT$7,500,000, equivalent to $263,250 for one year, which is due on September
6, 2020. On September 6, 2020, BioLite Taiwan extended the Cathay United Loan Agreement with the same principal amount of NT$7,500,000,
equivalent to $263,250 for one year, which is due on September 6, 2021. As of March 31, 2021 and December 31, 2020, the effective interest
rates per annum was 2.1%. The loan is collateralized by the building and improvement of BioLite Taiwan, and is also personal guaranteed
by the Company&#x2019;s chairman.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Interest expenses were $1,383 and $1,378 for the
three months ended March 31, 2021 and 2020, respectively.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="text-decoration:underline">CTBC Bank</font>&#xa0;</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 12, 2017 and July 19, 2017, BioLite Taiwan
and CTBC Bank entered into short-term saving secured bank loan agreements (the &#x201c;CTBC Loan Agreements&#x201d;) in an amount of NT$10,000,000,
equivalent to $351,000, and NT$10,000,000, equivalent to $351,000, respectively. Both two loans with the same maturity date at January
19, 2018. In February 2018, BioLite Taiwan combined two loans and extended the loan contract with CTBC for one year. On January 18, 2019,
BioLite Taiwan and CTBC Bank agreed to extend the loan with a new maturity date, which was July 18, 2019. On July 18, 2019, BioLite Taiwan
extended the CTBC Loan Agreement with the same principal amount of NT$20,000,000, equivalent to $702,000 for six months, which is due
on January 17, 2020. On January 19, 2020, BioLite Taiwan extended the CTBC Loan Agreement with the same principal amount of NT$20,000,000,
equivalent to $702,000 for six months, which is due on July 19, 2020. On July 17, 2020, BioLite Taiwan extended the CTBC Loan Agreement
with the same principal amount of NT$20,000,000, equivalent to $702,000 for six months, which is due on January 15, 2021. On January 15,
2021, BioLite Taiwan extended the CTBC Loan Agreement with the same principal amount of NT$20,000,000, equivalent to $702,000 for six
months, which is due on July 15, 2021. The loan balances bear interest at a fixed rate of 1.68% per annum. The loan is secured by the
money deposited in a savings account with the CTBC Bank. This loan was also personal guaranteed by the Company&#x2019;s chairman and BioFirst.
During the year ended December 31, 2020, BioLite Taiwan has opened a TCD account with CTBC bank to guarantee the loan going forward.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Interest expenses were $2,949 and $2,755 for the
three months ended March 31, 2021 and 2020, respectively.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="text-decoration:underline">Cathay Bank</font>&#xa0;</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 21, 2019, the Company received a loan
in the amount of $500,000 from Cathay Bank (the &#x201c;Bank&#x201d;) pursuant to a business loan agreement (the &#x201c;Loan Agreement&#x201d;)
entered by and between the Company and Bank on January 8, 2019 and a promissory note (the &#x201c;Note&#x201d;) executed by the Company
on the same day. The Loan Agreement provides for a revolving line of credit in the principal amount of $1,000,000 with a maturity date
(the &#x201c;Maturity Date&#x201d;) of January 1, 2020. The Note executed in connection with the Loan Agreement bears an interest rate (the
&#x201c;Regular Interest Rate&#x201d;) equal to the sum of one percent (1%) and the prime rate as published in the Wall Street Journal (the
&#x201c;Index&#x201d;) and the accrued interest shall become payable each month from February 1, 2019. Pursuant to the Note, the Company
shall pay the entire outstanding principal plus accrued unpaid interest on the Maturity Date and may prepay portion or all of the Note
before the Maturity Date without penalty. If the Company defaults on the Note, the default interest rate shall become five percent (5%)
plus the Regular Interest Rate.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Note and Loan Agreement,
on January 8, 2019, each of Dr. Tsung Shann Jiang and Dr. George Lee, executed a commercial guaranty (the &#x201c;Guaranty&#x201d;) to guaranty
the loans for the Company pursuant to the Loan Agreement and Note, severally and individually, in the amount not exceeding $500,000 each
until the entire Note plus interest are fully paid and satisfied. Dr. Tsung Shann Jiang is the Chairman and Chief Executive Officer of
BioLite Holding, Inc. and Dr. George Lee serves as the Chairman of the board of directors of BioKey, Inc, which became a wholly-owned
subsidiary of the Company effective by operation of law on or about February 5, 2019. On December 29, 2020, the Company entered into a
new loan extension agreement and assignment of deposit account with the Bank, which allowed Dr. Tsung Shann Jiang and Dr. George Lee to
be removed as guarantees from the list of Guaranty.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, on January 8, 2019, each of the
Company and BioKey, a wholly-owned subsidiary of the Company, signed a commercial security agreement (the &#x201c;Security Agreement&#x201d;)
to secure the loans under the Loan Agreement and the Note. Pursuant to the Security Agreements, each of the Company and BioKey (each,
a &#x201c;Grantor&#x201d;, and collectively, the &#x201c;Grantors&#x201d;) granted security interest in the collaterals as defined therein,
comprised of almost all of the assets of each Grantor, to secure such loans for the benefit of the Bank. On March 31, 2020, the Company
extended the Loan Agreement with the same term for seven months, which is due on October 31, 2020. On April 8, 2020 and October 3, 2020,
the Company repaid an aggregated principal amount of $350,000. On December 3, 2020, The Company renewed the Loan Agreement with the principal
amount of $650,000 for ten months, which is due on October 31, 2021. The outstanding loan balance was $650,000 as of March 31, 2021.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Interest expenses were $3,927 and $13,740 for
the three months ended March 31, 2021 and 2020, respectively.</p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_BankLoansAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_BankLoansAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_BankLoansAbstractAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_BankLoansAbstractAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140266718855992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Paycheck Protection Program Loan Payable<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_PaycheckProtectionProgramLoanPayableAbstract', window );"><strong>Paycheck Protection Program Loan Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_PaycheckProtectionProgramLoanPayableTextBlock', window );">PAYCHECK PROTECTION PROGRAM LOAN PAYABLE</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>9. PAYCHECK PROTECTION PROGRAM LOAN PAYABLE</b>&#xa0;</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 14, 2020, the Company received a loan
in the amount of $124,400 under the Paycheck Protection Program (&#x201c;PPP&#x201d;) administered by the United States Small Business
Administration (the &#x201c;SBA&#x201d;) from East West Bank. According to the Coronavirus Aid, Relief, and Economic Security Act (the
&#x201c;Cares Act&#x201d;), PPP loan provides for forgiveness of up to the full principal amount and accrued interest if the funds are
used for payroll costs, interest on mortgages, rent, and utilities. However, at least 60% of the forgiven amount must have been used
for payroll.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The loan was granted pursuant to a promissory
note dated April 14, 2020 issued by the Company, which matures on April 13, 2022 and bears interest at a rate of 1.00% per annum. The
Company will pay the principal in one payment of all outstanding principal plus all accrued unpaid interest on that date that is two years
after the date of the promissory note. In addition, the Company will pay regular monthly payments in an amount equal to one month&#x2019;s
accrued interest commencing on the date that is seven months after the date of the promissory note, with all subsequent interest payments
to be due on the same day of each month after that. No collateral or personal guarantees are required.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 29, 2021, the entity of BioKey received
a loan in the amount of $132,331 under the Paycheck Protection Program administered by the United States Small Business Administration
from East West Bank. According to the Coronavirus Aid, Relief, and Economic Security Act (the &#x201c;Cares Act&#x201d;), PPP loan provides
for forgiveness of up to the full principal amount and accrued interest if the funds are used for payroll costs, interest on mortgages,
rent, and utilities. However, at least 60% of the forgiven amount must have been used for payroll. The loan was granted pursuant to a
promissory note dated January 27, 2021 issued by the Company, which matures on January 28, 2026 and bears interest at a rate of 1.00%
per annum. The Company will pay the principal in one payment of all outstanding principal plus all accrued unpaid interest on that date
that is five years after the date of the promissory note. In addition, the Company will start the application with the US Government regarding
the loan forgiveness program as soon as the US Government allows. No collateral or personal guarantees are required.&#xa0;</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 7, 2021, the entity of ABVC received
a loan in the amount of $104,167 under the Paycheck Protection Program administered by the United States Small Business Administration
from Cathay Bank. According to the Coronavirus Aid, Relief, and Economic Security Act (the &#x201c;Cares Act&#x201d;), PPP loan provides
for forgiveness of up to the full principal amount and accrued interest if the funds are used for payroll costs, interest on mortgages,
rent, and utilities. However, at least 60% of the forgiven amount must have been used for payroll. The loan was granted pursuant to a
promissory note dated February 7, 2021 issued by the Company, which matures on February 6, 2026 and bears interest at a rate of 1.00%
per annum. The Company will pay the principal in one payment of all outstanding principal plus all accrued unpaid interest on that date
that is five years after the date of the promissory note. In addition, the Company will start the application with the US Government regarding
the loan forgiveness program as soon as the US Government allows. No collateral or personal guarantees are required.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>PPP loan Forgiveness&#xa0;</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 27, 2021, the Company submitted all
required to East West Bank for the application of forgiveness. During 2021, the PPP loan from East West Bank of $124,400 was waived by
the SBA as a gesture of supporting the operation of the Company. The Company recorded the forgiveness of the PPP loan as government grant
income during the three months ended March 31, 2021.</p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_PaycheckProtectionProgramLoanPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_PaycheckProtectionProgramLoanPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_PaycheckProtectionProgramLoanPayableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_PaycheckProtectionProgramLoanPayableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140266619912888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_NotesPayableLineItems', window );"><strong>Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MembersEquityNotesDisclosureTextBlock', window );">NOTES PAYABLE</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>10. NOTES PAYABLE</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In January, 2019, BioLite Taiwan entered an unsecured
loan agreement with one individual bearing interest at fixed rates at 12% per annum of NT$3,000,000, equivalent to $105,300, for working
capital purpose. As of the date of this report, BioLite Taiwan is still in discussion with the individual with respect to the terms of
the unsecured loans.&#xa0;As of March 31, 2021 and 2020, the balance due to this individual amounted to $105,300 and $106,800, respectively.&#xa0;Interest
expense was $3,204 and $2,988 for the three months ended March 31, 2021 and 2020, respectively.</p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_NotesPayableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_NotesPayableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MembersEquityNotesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the formation, structure, control and ownership of a limited liability company (LLC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 272<br> -URI http://asc.fasb.org/topic&amp;trid=2124037<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 272<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 272<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MembersEquityNotesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140266618783384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Loan<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTextBlock', window );">SHORT-TERM LOAN</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>11. SHORT-TERM LOAN</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 18, 2020, the Company entered an unsecured
loan agreement with a third-party in the amount of $100,000. This loan bears the interest rate of 1.5% per annum and will be matured on
August 17, 2020. On August 18, 2020, the Company extended the contract for six months under the same term. Accrued interest expense was
$375 and $1,302 as of March 31, 2021 and December 31, 2020, respectively.</p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for short-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140266709751368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties Transactions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTIES TRANSACTIONS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>12. RELATED PARTIES TRANSACTIONS</b>&#xa0;</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The related parties of the company with whom transactions
are reported in these financial statements are as follows:</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; width: 36%"><font style="font-size: 10pt"><b>Name of entity or Individual</b></font></td>
    <td style="vertical-align: bottom; width: 2%">&#xa0;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 62%; text-align: justify"><font style="font-size: 10pt"><b>Relationship with the Company and its subsidiaries</b></font></td></tr>
  <tr>
    <td style="vertical-align: top"><font style="font-size: 10pt">BioFirst Corporation (the &#x201c;BioFirst&#x201d;)</font></td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom; text-align: justify"><font style="font-size: 10pt">Entity controlled by controlling beneficiary shareholder of YuanGene</font></td></tr>
  <tr>
    <td style="vertical-align: top"><font style="font-size: 10pt">BioFirst (Australia) Pty Ltd. (the &#x201c;BioFirst (Australia)&#x201d;)</font></td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom; text-align: justify"><font style="font-size: 10pt">100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene</font></td></tr>
  <tr>
    <td style="vertical-align: top"><font style="font-size: 10pt">Rgene Corporation (the &#x201c;Rgene&#x201d;)</font></td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom; text-align: justify"><font style="font-size: 10pt">Shareholder of the Company; entity controlled by controlling beneficiary shareholder of YuanGene</font></td></tr>
  <tr>
    <td style="vertical-align: top"><font style="font-size: 10pt">YuanGene Corporation (the &#x201c;YuanGene&#x201d;)</font></td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom; text-align: justify"><font style="font-size: 10pt">Controlling beneficiary shareholder of the Company</font></td></tr>
  <tr>
    <td style="vertical-align: top"><font style="font-size: 10pt">AsiaGene Corporation (the &#x201c;AsiaGene&#x201d;)</font></td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom; text-align: justify"><font style="font-size: 10pt">Shareholder; entity controlled by controlling beneficiary shareholder of YuanGene</font></td></tr>
  <tr>
    <td style="vertical-align: top"><font style="font-size: 10pt">Eugene Jiang</font></td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom; text-align: justify"><font style="font-size: 10pt">Former President and Chairman</font></td></tr>
  <tr>
    <td style="vertical-align: top"><font style="font-size: 10pt">Keypoint Technology Ltd. (the &#x201c;Keypoint&#x2019;)</font></td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom; text-align: justify"><font style="font-size: 10pt">The Chairman of Keypoint is Eugene Jiang&#x2019;s mother.</font></td></tr>
  <tr>
    <td style="vertical-align: top"><font style="font-size: 10pt">Lion Arts Promotion Inc. (the &#x201c;Lion Arts&#x201d;)</font></td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom; text-align: justify"><font style="font-size: 10pt">Shareholder of the Company</font></td></tr>
  <tr>
    <td style="vertical-align: top"><font style="font-size: 10pt">Yoshinobu Odaira (the &#x201c;Odaira&#x201d;)</font></td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom; text-align: justify"><font style="font-size: 10pt">Director of the Company</font></td></tr>
  <tr>
    <td style="vertical-align: top"><font style="font-size: 10pt">GenePharm Inc. (the &#x201c;GenePharm&#x201d;)</font></td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom; text-align: justify"><font style="font-size: 10pt">Dr. George Lee, Board Director of Biokey, is the Chairman of GenePharm.</font></td></tr>
  <tr>
    <td style="vertical-align: top"><font style="font-size: 10pt">Euro-Asia Investment &amp; Finance Corp Ltd. (the &#x201c;Euro-Asia&#x201d;)</font></td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom; text-align: justify"><font style="font-size: 10pt">Shareholder of the Company</font></td></tr>
  <tr>
    <td style="vertical-align: top"><font style="font-size: 10pt">LBG USA, Inc. (the &#x201c;LBG USA&#x201d;)</font></td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom; text-align: justify"><font style="font-size: 10pt">100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene</font></td></tr>
  <tr>
    <td style="vertical-align: top"><font style="font-size: 10pt">LionGene Corporation (the &#x201c;LionGene&#x201d;)</font></td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom; text-align: justify"><font style="font-size: 10pt">Shareholder of the Company; Entity controlled by controlling beneficiary shareholder of YuanGene</font></td></tr>
  <tr>
    <td style="vertical-align: top"><font style="font-size: 10pt">Kimho Consultants Co., Ltd. (the &#x201c;Kimho&#x201d;)</font></td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom; text-align: justify"><font style="font-size: 10pt">Shareholder of the Company</font></td></tr>
  <tr>
    <td style="vertical-align: top"><font style="font-size: 10pt"></font></td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom; text-align: justify"><font style="font-size: 10pt">Mr. Tsung-Shann Jiang, the controlling beneficiary shareholder of the Company and Rgene, the Chairman and CEO of the BioLite Holding Inc. and BioLite Inc. and the President and a member of board of directors of BioFirst<br/>
&#xa0;<br/>
Ms. Shu-Ling Jiang, Mr. Tsung-Shann Jiang&#x2019;s wife, is the Chairman of Keypoint; and a member of board of directors of BioLite Inc.<br/>
&#xa0;<br/>
Mr. Eugene Jiang is Mr. and Ms. Jiang&#x2019;s son. Mr. Eugene Jiang is the chairman, and majority shareholder of the Company and a member of board of directors of BioLite Inc.<br/>
&#xa0;<br/>
Mr. Chang-Jen Jiang is Mr. Tsung-Shann Jiang&#x2019;s sibling and the director of the Company.<br/>
&#xa0;<br/>
Ms. Mei-Ling Jiang is Ms. Shu-Ling Jiang&#x2019;s sibling.</font></td></tr>
  <tr>
    <td style="vertical-align: top"><font style="font-size: 10pt">Amkey Ventures, LLC (&#x201c;Amkey&#x201d;)</font></td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom; text-align: justify"><font style="font-size: 10pt">An entity controlled by Dr. George Lee, who serves as one of the board directors of BioKey, Inc</font></td></tr>
  <tr>
    <td style="vertical-align: top"><font style="font-size: 10pt">BioLite Japan</font></td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom; text-align: justify"><font style="font-size: 10pt">Entity controlled by controlling beneficiary shareholder of ABVC</font></td></tr>
  </table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="text-decoration:underline">Accounts receivable - related parties</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounts receivable due from related parties consisted
of the following as of the periods indicated:</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; text-align: center; white-space: nowrap">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center">&#xa0;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap">March 31,</td><td style="vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center">&#xa0;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap">December 31,</td><td style="vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center">&#xa0;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; text-align: center; white-space: nowrap">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap; text-align: center">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap">2021</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap; text-align: center">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap; text-align: center">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap">2020</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap; text-align: center">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">GenePharm Inc.</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">142,225</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">142,225</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Amkey</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,850</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,210</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; padding-left: 9pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">145,075</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#xa0;</td><td style="font-weight: bold; padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">143,435</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#xa0;</td></tr>
  </table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="text-decoration:underline">Due from related parties</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Amount due from related parties consisted of the
following as of the periods indicated:</p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#xa0;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Rgene</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">43,266</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">42,911</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>AsiaGene</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">4,287</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">4,241</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">BioFirst (Australia)</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">379,110</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">373,235</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">BioHopeKing Corporation</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">121,848</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">123,583</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">LBG USA</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">675</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">675</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">BioLite Japan</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">150,000</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">150,000</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Keypoint</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,610</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,610</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">The Jiangs</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,093</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; padding-left: 9pt">Total</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">702,889</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">696,255</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
  </table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</font></td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">As of March 31, 2021, and December 31, 2020,
    the Company has advanced an aggregate amount of $43,266 and $42,911 to Rgene for working capital purpose. Under the terms of the
    loan agreement, the loan bears interest at 1% per month (or equivalent to 12% per annum) and the maturity date was December 31, 2020.
    As of March 31, 2021, and December 31, 2020, the outstanding loan balance was $31,239 and $31,684; and accrued interest was $12,027
    and $11,227, respectively.</font></td></tr>
  </table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</font></td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">On May 27, 2019, the Company entered into
    loan agreements with AsiaGene for NT $100,000, equivalent to $3,510, to meet its working capital needs.&#xa0;&#xa0;Under the terms
    of the loan agreement, the loan bears interest at 1% per month (or equivalent to 12% per annum) and the loan maturity date was December
    31, 2020. As of March 31, 2021, and December 31, 2020, the outstanding loan balance was $3,510 and $3,560, and accrued interest was
    $777 and $681, respectively.</font></td></tr>
  </table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</font></td>
    <td style="text-align: justify; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 11, 2018, the Company and BioFirst (Australia) entered into a loan agreement for a total amount of $40,000 to meet its working capital needs. The advances bear 0% interest rate and are due on demand prior to June 30, 2020. Afterwards, all outstanding load will bear interest rate at 12% per annum. On July 1, 2020, the Company entered into a loan agreement with BioFirst (Australia) for $321,487 to properly record R&amp;D cost and tax refund allocation based on co-development contract executed on July 24, 2017. The loan will be matured on June 30, 2021 with an interest rate of 12% per annum. As of March 31, 2021 and December 31, 2020, the aggregate amount of outstanding loan and accrued interest was $379,110 and $373,235, respectively.</font></td></tr>
  </table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</font></td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">On February 24, 2015, BioLite Taiwan and
    BioHopeKing Corporation (the &#x201c;BHK&#x201d;) entered into a co-development agreement, (the &#x201c;BHK Co-Development Agreement&#x201d;,
    see Note 3). The development costs shall be shared 50/50 between BHK and the Company. Under the term of the agreement, BioLite issued
    relevant development cost to BHK. As of March 31, 2021 and 2020, due from BHK was $121,848 and $123,583, respectively.&#xa0;</font></td></tr>
  </table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</font></td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 27, 2019, the
    Company has advanced funds to LBG USA for working capital purpose. The advances bear 0% interest rate and are due on demand. As of
    March 31, 2021 and 2020, the outstanding advance balances was $675 and $675, respectively.</font></td></tr>
  </table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</font></td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">On May 8, 2020, the Company and Lucidaim
    entered into a Letter of Intent (LOI) in regard to a potential joint venture of BioLite Japan. Based on the LOI, each party will
    advance an aggregated amount of $150,000 to meet BioLite Japan&#x2019;s working capital needs, which the Company advanced an amount
    of $150,000 and the advance bear 0% interest rate. As of March 31, 2021 and December 31, 2020, the outstanding advance balances was
    $150,000 and $150,000, respectively.</font></td></tr>
  <tr style="vertical-align: top">
    <td><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td></tr>
  <tr style="vertical-align: top">
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</font></td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 31, 2020, the
    Company has advanced an aggregate amount of $1,610 to Keypoint for working capital purpose. Under the terms of the loan agreement,
    the loan bears interest at 6.5% per annum and the loan will be matured on October 30, 2021. As of March 31, 2021 and December 31, 2020, the outstanding
    loan balance was $1,610.</font></td></tr>
  </table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8) </font></td>
    <td style="text-align: justify; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2021, the Company has advanced funds to the Jiangs. The advances bear 0% interest rate and are due on demand. As of March 31, 2021 and December 31, 2020, the outstanding advance balances was $2,093 and $0, respectively</font></td></tr>
  </table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="text-decoration:underline">Due to related parties</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Amount due to related parties consisted of the
following as of the periods indicated:</p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">March&#xa0;31,</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#xa0;31,</td><td style="font-weight: bold">&#xa0;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">BioFirst Corporation</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">23,647</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">23,647</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>AsiaGene</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">24,017</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>YuanGene</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">9,205</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">9,205</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">The Jiangs</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">18,750</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">16,627</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Due to shareholders</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">163,566</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">166,261</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Due to employee</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">72,967</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">72,704</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; padding-left: 9pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">312,152</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#xa0;</td><td style="font-weight: bold; padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">288,445</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#xa0;</td></tr>
  </table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><font style="font-size: 10pt">(1)</font></td>
    <td style="text-align: justify">
    Since 2019, BioFirst has advanced funds to the Company for working
capital purpose. The advances bear interest 1% per month (or equivalent to 12% per annum). As of March 31, 2021 and December 31, 2020,
the aggregate amount of outstanding balance and accrued interest is $23,647 and $23,647, respectively.</td></tr>
  </table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><font style="font-size: 10pt">(2)</font></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2021, and December 31, 2020, AsiaGene
    has advanced the Company an aggregate amount of $24,017 and $0, respectively for working capital purpose. This advance bears 0% interest
    rate and is due on demand.</p></td></tr>
  </table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><font style="font-size: 10pt">(3)</font></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2021, and December 31, 2020, YuanGene
    has advanced the Company an aggregate amount of $9,205 for working capital purpose. This advance bears 0% interest rate and is due on
    demand.</p></td></tr>
  </table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><font style="font-size: 10pt">(4)</font></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since 2019, the Jiangs advanced funds to the Company
    for working capital purpose. As of March 31, 2021, and December 31, 2020, the outstanding balance due to the Jiangs amounted to $18,750
    and $16,627, respectively. These loans bear interest rate of 0% to 1% per month, and are due on demand.</p></td></tr>
  </table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</font></td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">Since 2018, the Company&#x2019;s shareholders
    have advanced funds to the Company for working capital purpose. The advances bear interest rate from 12% to 13.6224% per annum. As
    of March 31, 2021 and December 31, 2020, the outstanding principal and accrued interest was $163,566 and $166,261, respectively.
    Interest expenses in connection with these loans were $5,298 and $5,269 for the three months ended March 31, 2021 and 2020, respectively.&#xa0;</font></td></tr>
  </table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</font></td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">Commencing January, 2020, the Company had
    advances from one employee for working capital purpose. The outstanding balance including accrued interest due to this employee amounted
    to $72,967 and $72,704 as of March 31, 2021 and December 31, 2020, respectively. This loan bears interest rate of 1.5% per annum,
    and is due on demand.</font></td></tr>
  </table><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140266709855160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">EQUITY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>13. EQUITY</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 8, 2016, a Share Exchange
Agreement (&#x201c;Share Exchange Agreement&#x201d;) was entered into by and among the&#xa0;Company, BriVision, Euro-Asia Investment
&amp; Finance Corp. Limited, a company incorporated under the laws of Hong Kong Special Administrative Region of People&#x2019;s
Republic of China (&#x201c;Euro-Asia&#x201d;), being the owners of record of 164,387,376 (52,336,000 pre-stock split) shares of Common
Stock of the Company, and the owners of record of all of the issued share capital of BriVision (the&#xa0;&#x201c;BriVision
Stock&#x201d;). Pursuant to the Share Exchange Agreement, upon surrender by the BriVision Shareholders and the cancellation by
BriVision of the certificates evidencing the BriVision Stock as registered in the name of each BriVision Shareholder, and pursuant
to the registration of the Company in the register of members maintained by BriVision as the new holder of the BriVision Stock and
the issuance of the certificates evidencing the aforementioned registration of the BriVision Stock in the name of the Company, the
Company should issue 166,273,921(52,936,583 pre-stock split) shares (the&#xa0;&#x201c;Acquisition Stock&#x201d;) (subject to
adjustment for fractionalized shares as set forth below) of the Company&#x2019;s Common Stock to the BriVision Shareholders (or their
designees), and 163,159,952 (51,945,225 pre-stock split) shares of the Company&#x2019;s Common Stock owned by Euro-Asia should be
cancelled and retired to treasury. The Acquisition Stock collectively should represent 79.70% of the issued and outstanding Common
Stock of the Company immediately after the Closing, in exchange for the BriVision Stock, representing 100% of the issued share
capital of BriVision in a reverse merger, or the Merger. Pursuant to the Merger, all of the issued and outstanding shares of
BriVision&#x2019;s Common Stock were converted, at an exchange ratio of 0.2536-for-1, into an aggregate of 166,273,921(52,936,583
pre-stock split) shares of Company&#x2019;s Common Stock and BriVision became a wholly owned subsidiary, of the Company. The holders
of Company&#x2019;s Common Stock as of immediately prior to the Merger held an aggregate of 205,519,223 (65,431,144 pre-stock split)
shares of Company&#x2019;s Common Stock,&#xa0;Because of the exchange of the BriVision Stock for the Acquisition Stock
(the&#xa0;&#x201c;Share Exchange&#x201d;), BriVision became a wholly owned subsidiary (the &#x201c;Subsidiary&#x201d;) of the Company
and there was a change of control of the Company following the closing.&#xa0;&#xa0;There were no warrants, options or other equity
instruments issued in connection with the share exchange agreement.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 17, 2016, pursuant to the 2016 Equity
Incentive Plan (the &#x201c;2016 Plan&#x201d;), 157,050 (50,000 pre-stock split) shares were granted to the employees.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 21, 2016, the Board of Directors of the
Company approved an amendment to Articles of Incorporation to effect a forward split at a ratio of 1 to 3:141 (the &#x201c;Forward&#xa0;Stock&#xa0;Split&#x201d;)
and increase the number of our authorized shares of Common Stock, par value $0.001 per share, to 360,000,000, which was effective on April
8, 2016.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 6, 2016, the Company and BioLite Taiwan
agreed to amend the BioLite Collaborative Agreement, through entry into the Milestone Payment Agreement, whereby the Company has agreed
to issue shares of Common Stock of the Company, at the price of $1.60 per share, for an aggregate number of 562,500 shares, as part of
the Company&#x2019;s first installation of payment pursuant to the Milestone Payment. The shares issuance was completed in June 2016. On
August 26, 2016, the Company issued 1,468,750 shares (&#x201c;Shares&#x201d;) of the Company&#x2019;s Common Stock, par value $0.001 (the
&#x201c;Offering&#x201d;) to BioLite Taiwan pursuant to a certain Stock Purchase Agreement dated August 26, 2016 (the &#x201c;SPA&#x201d;).
The Shares are exempt from the registration requirements of the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;),
pursuant to Regulation S of the Securities Act promulgated thereunder. The purchase price per share of the Offering is $1.60. The net
proceeds to the Company from the Offering are approximately $2,350,000. Pursuant to the BioLite Collaborative Agreement, BriVision should
pay a total of $100,000,000 in cash or stock of the Company with equivalent value according to the milestone achieved. The agreement requires
that 6.5% of total payment, $6,500,000 shall be made upon the first IND submission which was submitted in March 2016. In February 2017,
the Company remitted this amount to BioLite with $650,000 in cash and $5,850,000 in the form of newly issued shares of the Company&#x2019;s
Common Stock, at the price of $2.0 per share, for an aggregate number of 2,925,000 shares. Upon the consummation of the restructuring
transaction between the Company and BioLite on February 8, 2019, the Company&#x2019;s Common Stock held by BioLite Taiwan was accounted
for treasury stocks in the statement of equity (deficit). On February 8, 2019, after the Merger, the Company issued 74,997,546 shares
to the shareholders of BioLite and 29,561,231 shares to the shareholders of BioKey.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 3, 2019, the Company filed a Certificate
of Amendment with the Secretary of State of Nevada, which was effective May 8, 2019 upon its receipt of the written notice from Financial
Industry Regulatory Authority (&#x201c;FINRA&#x201d;). Pursuant to the Certificate of Amendment, the Company effectuated a 1-for-18 reverse
stock split of its issued and outstanding shares of common stock, $0.001 par value, whereby 318,485,252 outstanding shares of the Company&#x2019;s
common stock were exchanged for 17,693,625 shares of the Company&#x2019;s Common Stock. All shares and related financial information in
this Form 10-K reflect this 1-for-18 reverse stock split.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 1, 2016, the Company entered into a
consulting agreement with Kazunori Kameyama (&#x201c;Kameyama&#x201d;) for the provision of services related to the clinical trials and
other administrative work, public relation work, capital raising, trip coordination, In consideration for providing such services, the
Company agreed to indemnify the consultant in an amount of $150 per hour in cash up to $3,000 per month, and issue to Kameyama the Company&#x2019;s
Common Stock at $1.00 per share for any amount exceeding $3,000. The Company&#x2019;s stocks shall be calculated and issued in December
every year. On November 21, 2020, the Company entered into an agreement with Kameyama, pursuant to which the Company granted and issued
24,694 stock options to Kameyama related to unpaid consulting fees of $49,388 (see Note 14).</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2019, the Company
entered into service agreements with Euro-Asia Investment &amp; Finance Corp Ltd. (a related party), Ever Adventure inv. (Formosa) Consultant
Co., Ltd., New Eastern Asia (a related party), and Kimho Consultants Co., Ltd. (a related party) for the maintenance of the listing in
the U.S. stock exchange market, investor relations, and business development. Pursuant to the agreements, the Company issued 644,972 shares
of the Company&#x2019;s common stock for the consulting service from July 2019 to July 2024 for the service fee of $4,514,800 in aggregate,
and recorded as stock subscription receivable. As of March 31, 2021 and December 31, 2020, stock subscription receivable was $2,934,620
and $3,160,360, respectively.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 24, 2017, BriVision entered into a collaborative agreement
(the &#x201c;BioFirst Collaborative Agreement&#x201d;) with BioFirst (See Note 3). On September 25, 2017, BioFirst has delivered all research,
technical, data and development data to BriVision, and the Company has recorded the full amount of $3,000,000 due to BioFirst. On June
30, 2019, the Company entered into a Stock Purchase Agreement with BioFirst, pursuant to which the Company agreed to issue 428,571 shares
of the Company&#x2019;s common stock to BioFirst in consideration for $3,000,000 owed by the Company to BioFirst. These common shares were
issued during the year ended December 31, 2019.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August, 2019, the Company entered into several
Conversion Agreements to all creditors that are listed under below table of &#x201c;due to related parties&#x201d; in consideration for
a total of $4,872,340 owed by the Company to various creditors based on outstanding loan agreements. Under the Conversion Agreements,
creditor agrees to convert the amount of debt into the Company&#x2019;s common stock at a price of $7.00 per share.</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: bottom; text-align: center">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Amount of<br/> Debt<br/> Converted</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Number of<br/> Shares<br/> Issued</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#xa0;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left">Lion Arts Promotion Inc</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">97,864</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">13,981</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">LionGene Corporation</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">428,099</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">61,157</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">BioFirst Corporation</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">2,902,911</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">414,702</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">AsiaGene Corporation</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">160,000</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">22,858</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">YuanGene Corporation</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">92,690</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">13,242</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">The Jiangs</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,190,776</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">170,111</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-bottom: 4pt; padding-left: 0.25in">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">4,872,340</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#xa0;</td><td style="font-weight: bold; padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">696,051</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#xa0;</td></tr>
  </table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 12, 2020, the board of directors of the
Company approved and adopted an amendment to the Company&#x2019;s Articles of Incorporation, to increase the authorized shares of its common
stock, par value $0.001 per share, from 20,000,000 to 100,000,000 shares.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 8, 2020, the Company entered an agreement
with View Trade Securities Inc. (&#x201c;ViewTrade&#x201d;) to engage ViewTrade as the placement agent&#xa0;and the Company&#x2019;s advisor
with respect to its ongoing capital events. Pursuant to the agreement, the Company agreed to pay View Trade 60,000 restricted common shares
of the Company and 60,000 warrants to purchase common shares of the Company at an exercise price of $6 per share for a period of 5 years
with cashless exercise provision. As of December 31, 2020, the Company has issued 60,000 shares of common stock to ViewTrade for the consulting
fee with an estimated value of $135,000. The warrants were never issued and the parties mutually agreed to terminate the agreement on
November 19, 2020. As a termination fee, the Company agreed to issue ViewTrade 50,000 restricted common shares of the Company.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">Also on November 19,
2020, the Company and ViewTrade agreed to a new Advisory agreement under which ViewTrade was engaged to provide advisory services only.
In addition to a retainer fee, the Company agreed to issue 200,000 warrants, with an exercise price of $2.25, an industry standard cashless
exercise provision, and a term of 5 years from November 19, 2020.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year&#xa0;ended December 31, 2020,
the Company entered into a consulting agreement with a service provider for consulting and advisory services, pursuant to which the Company
agreed to pay the service fee by issuing 50,000 shares of unrestricted common shares, valued at the closing price of $2.9 per share on
the grant date. As of December 31, 2020, these shares have been issued.&#xa0;&#xa0;&#xa0;</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2020, the Company
received aggregated capital contributions of $7,615,331 in cash from 45 investors through private placements of the sale of the Company&#x2019;s
common stock for the purchase price of&#xa0;$2.25 per share and a free warrant attached with each common stock purchased. As of March
31, 2021, 3,384,615 shares of the Company&#x2019;s common stock have been issued.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2020, the Company
entered into consulting agreements with four service providers for consulting and advisory services, pursuant to which the Company agreed
to pay the service fee by issuing 521,887 shares of unrestricted common shares, valued at the closing price from $2 to $3.68 per share
on the grant date. As of March 31, 2021, these shares have been issued.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2021, the Company issued aggregated
common shares of 915,856 &#xa0;to six previous note holders, who had converted their outstanding principals and accrued and unpaid interests,
including the debt conversion to the following:</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#xa0;</td>
    <td style="width: 0.25in"><font style="font-size: 10pt">a.</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">Keypoint converted the aggregated amount of $292,826 at the conversion price of $1.84 on April 5, 2020, in exchange for 159,145 shares of the Company&#x2019;s common stock, and warrants to purchase 159,145 shares of the Company&#x2019;s common stock.</font></td></tr>
  </table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#xa0;</td>
    <td style="width: 0.25in"><font style="font-size: 10pt">b.</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">Odaira converted the aggregated amount of $284,036 at the conversion price of $1.84 on April 5, 2020, in exchange for 154,368 shares of the Company&#x2019;s common stock, and warrants to purchase 154,368 shares of the Company&#x2019;s common stock.</font></td></tr>
  </table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#xa0;</td>
    <td style="width: 0.25in"><font style="font-size: 10pt">c.</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">C.L.L. converted the aggregated amount of $289,974 at the conversion price of $1.78 on April 20, 2020, in exchange for 162,908 shares of the Company&#x2019;s common stock, and warrants to purchase 162,908 shares of the Company&#x2019;s common stock.</font></td></tr>
  </table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#xa0;</td>
    <td style="width: 0.25in"><font style="font-size: 10pt">d.</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">KLS converted the aggregated amount of $225,222 at the conversion price of $1.78 on April 20, 2020, in exchange for 126,530 shares of the Company&#x2019;s common stock, and warrants to purchase 126,530 shares of the Company&#x2019;s common stock.</font></td></tr>
  </table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#xa0;</td>
    <td style="width: 0.25in"><font style="font-size: 10pt">e.</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">Yu and Wei converted the aggregated amount of $354,722 at the conversion price of $1.84 on April 5, 2020, in exchange for 192,784 shares of the Company&#x2019;s common stock, and warrants to purchase 192,784 shares of the Company&#x2019;s common stock.</font></td></tr>
  </table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#xa0;</td>
    <td style="width: 0.25in"><font style="font-size: 10pt">f.</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">KSL converted the aggregated amount of $270,272 at the conversion price of $2.25 on November 9, 2020, in exchange for 120,121 shares of the Company&#x2019;s common stock, and warrants to purchase 120,121 shares of the Company&#x2019;s common stock.</font></td></tr>
  </table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">See Note 7 for more details in connection with the above debt conversion.&#xa0;&#xa0;</p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140266624401128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Options<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_StockOptionsAbstract', window );"><strong>Stock Options [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_StockOptionsTextBlock', window );">STOCK OPTIONS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>14. STOCK OPTIONS</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 30, 2020, the Company issued an aggregate
of 545,182 shares of common stock in lieu of unpaid salaries of certain employees and unpaid consulting fees under the 2016 Equity Incentive
Plan, as amended, at a conversion price of $2 per share; the total amount of converted salaries and consulting fees was $1,090,361. On
November 21, 2020, the Company has entered&#xa0;into&#xa0;acknowledgement&#xa0;agreements and stock option purchase agreements with these
employees and consultant; pursuant to which the Company granted stock options to purchase 545,182 shares of the Company&#x2019;s common
stock in lieu of common stock. The options were vested at the grant date and become exercisable for 10 years from the grant date.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Options issued and outstanding as of December
31, 2020, and their activities during the year then ended are as follows:</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; text-align: center">&#xa0;</td><td style="vertical-align: bottom; text-align: center">&#xa0;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: center">&#xa0;</td><td style="vertical-align: bottom; text-align: center">&#xa0;</td><td style="vertical-align: bottom; text-align: center">&#xa0;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: center">&#xa0;</td><td style="vertical-align: bottom; text-align: center">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; text-align: center">&#xa0;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Weighted-</td><td style="vertical-align: bottom; font-weight: bold; text-align: center">&#xa0;</td><td style="vertical-align: bottom; text-align: center">&#xa0;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: center">&#xa0;</td><td style="vertical-align: bottom; text-align: center">&#xa0;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; text-align: center">&#xa0;</td><td style="vertical-align: bottom; text-align: center">&#xa0;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: center">&#xa0;</td><td style="vertical-align: bottom; text-align: center">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; text-align: center">&#xa0;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Weighted-</td><td style="vertical-align: bottom; font-weight: bold; text-align: center">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; text-align: center">&#xa0;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Average</td><td style="vertical-align: bottom; font-weight: bold; text-align: center">&#xa0;</td><td style="vertical-align: bottom; text-align: center">&#xa0;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: center">&#xa0;</td><td style="vertical-align: bottom; text-align: center">&#xa0;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; text-align: center">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; text-align: center">&#xa0;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"></td><td style="vertical-align: bottom; font-weight: bold; text-align: center">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; text-align: center">&#xa0;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Average</td><td style="vertical-align: bottom; font-weight: bold; text-align: center">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; text-align: center">&#xa0;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Contractual</td><td style="vertical-align: bottom; font-weight: bold; text-align: center">&#xa0;</td><td style="vertical-align: bottom; text-align: center">&#xa0;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: center">&#xa0;</td><td style="vertical-align: bottom; text-align: center">&#xa0;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; text-align: center">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; text-align: center">&#xa0;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Number&#xa0;of</td><td style="vertical-align: bottom; font-weight: bold; text-align: center">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; text-align: center">&#xa0;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Exercise </td><td style="vertical-align: bottom; font-weight: bold; text-align: center">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; text-align: center">&#xa0;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Life </td><td style="vertical-align: bottom; font-weight: bold; text-align: center">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; text-align: center">&#xa0;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Aggregate</td><td style="vertical-align: bottom; font-weight: bold; text-align: center">&#xa0;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; text-align: center">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Underlying<br/>
Shares</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Price<br/>
Per&#xa0;Share</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Remaining<br/>
in Years</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Intrinsic<br/>
 Value</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding as of January 1, 2020</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<font style="font-size: 10pt">-</font></td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#x202f;</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 52%">Granted</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">545,182</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">2.00</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">9.89</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">616,056</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt; text-align: right">&#xa0;</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt; text-align: right">&#xa0;</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Outstanding as of December 31, 2020</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">545,182</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt; text-align: right">2.00</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt; text-align: right">9.89</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">616,056</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Exercisable as of December 31, 2020</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">545,182</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt; text-align: right">2.00</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt; text-align: right">9.89</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">616,056</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Vested and expected to vest</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">545,182</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">2.00</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt; text-align: right">9.89</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">616,056</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
  </table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of stock options granted for the
year ended December 31, 2020 was calculated using the Black-Scholes option-pricing model applying the following assumptions:</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 0pt; vertical-align: bottom; text-align: center">&#xa0;</td><td style="padding-bottom: 0pt; vertical-align: bottom; font-weight: bold; text-align: center">&#xa0;</td>
    <td colspan="2" style="padding-bottom: 0pt; vertical-align: bottom; font-weight: bold; text-align: center">Year ended</td><td style="padding-bottom: 0pt; vertical-align: bottom; font-weight: bold; text-align: center">&#xa0;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; padding-bottom: 0pt; vertical-align: bottom; text-align: center">&#xa0;</td><td style="white-space: nowrap; vertical-align: bottom; font-weight: bold; padding-bottom: 0pt; text-align: center">&#xa0;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; padding-bottom: 0pt; vertical-align: bottom; font-weight: bold; text-align: center">December&#xa0;31,<br/>
2020</td><td style="white-space: nowrap; vertical-align: bottom; padding-bottom: 0pt; font-weight: bold; text-align: center">&#xa0;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 0pt">&#xa0;</td><td style="padding-bottom: 0pt">&#xa0;</td>
    <td colspan="2" style="padding-bottom: 0pt">&#xa0;</td><td style="padding-bottom: 0pt">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 0pt; width: 88%; text-align: left">Risk free interest rate</td><td style="padding-bottom: 0pt; width: 1%">&#xa0;</td>
    <td style="padding-bottom: 0pt; width: 1%; text-align: left">&#xa0;</td><td style="padding-bottom: 0pt; width: 9%; text-align: right">0.38</td><td style="padding-bottom: 0pt; width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 0pt; text-align: left">Expected term (in years)</td><td style="padding-bottom: 0pt">&#xa0;</td>
    <td style="padding-bottom: 0pt; text-align: left">&#xa0;</td><td style="padding-bottom: 0pt; text-align: right">5.00</td><td style="padding-bottom: 0pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 0pt; text-align: left">Dividend yield</td><td style="padding-bottom: 0pt">&#xa0;</td>
    <td style="padding-bottom: 0pt; text-align: left">&#xa0;</td><td style="padding-bottom: 0pt; text-align: right">0</td><td style="padding-bottom: 0pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 0pt; text-align: left">Expected volatility</td><td style="padding-bottom: 0pt">&#xa0;</td>
    <td style="padding-bottom: 0pt; text-align: left">&#xa0;</td><td style="padding-bottom: 0pt; text-align: right">89.01</td><td style="padding-bottom: 0pt; text-align: left">%</td></tr>
  </table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The weighted average grant date fair value of
options granted during 2020 was $3.13. There are 2,812,949 options available for grant under the 2016 Equity Incentive Plan as of December
31, 2020. Compensation costs associated with the Company&#x2019;s stock options are recognized, based on the grant-date fair values of
these options over vesting period. Accordingly, the Company recognized stock-based compensation expense of $0 and $0 for the three months
ended March 31, 2021 and 2020, respectively. As of March 31, 2021, there were no unvested options.</p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_StockOptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_StockOptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_StockOptionsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_StockOptionsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140266709850728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">LOSS PER SHARE</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>15. LOSS PER SHARE</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic loss per share is computed by dividing net
loss by the weighted-average number of common shares outstanding during the year. Diluted loss per share is computed by dividing net loss
by the weighted-average number of common shares and dilutive potential common shares outstanding during the three months ended March 31,
2021 and 2020.</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; text-align: center">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center">&#xa0;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">For the Three Months Ended</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#xa0;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; text-align: center">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">March&#xa0;31,<br/> 2021</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">March&#xa0;31,<br/> 2020</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#xa0;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Numerator:</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: center">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: center">&#xa0;</td><td>&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Net loss attributable to ABVC&#x2019;s common stockholders</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(1,128,505</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(1,247,538</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Denominator:</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Weighted-average shares outstanding:</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Weighted-average shares outstanding - Basic</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">24,420,526</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">19,484,542</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Stock options</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">&#xa0;</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">&#x2013;</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Weighted-average shares outstanding - Diluted</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">24,420,526</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">19,484,542</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Loss per share</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">-Basic</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(0.05</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(0.06</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">-Diluted</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(0.05</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(0.06</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  </table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Diluted loss per share takes into account the
potential dilution that could occur if securities or other contracts to issue Common Stock were exercised and converted into Common Stock.</p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140266624406760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ASU201602TransitionAbstract', window );"><strong>ASU 2016-02 Transition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock', window );">LEASE</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>16. LEASE</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company adopted FASB Accounting Standards
Codification, Topic 842, Leases (&#x201c;ASC 842&#x201d;) using the modified retrospective approach, electing the practical expedient that
allows the Company not to restate its comparative periods prior to the adoption of the standard on January 1, 2019. </p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company applied the following practical expedients in the transition
to the new standard and allowed under ASC 842:</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#xa0;</td>
    <td style="width: 0.25in"><font style="font-size: 10pt">&#x25cf;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">Reassessment of expired or existing contracts: The Company elected not to reassess, at the application date, whether any expired or existing contracts contained leases, the lease classification for any expired or existing leases, and the accounting for initial direct costs for any existing leases.</font></td></tr>
  </table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#xa0;</td>
    <td style="width: 0.25in"><font style="font-size: 10pt">&#x25cf;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">Use of hindsight: The Company elected to use hindsight in determining the lease term (that is, when considering options to extend or terminate the lease and to purchase the underlying asset) and in assessing impairment of right-to-use assets.</font></td></tr>
  </table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#xa0;</td>
    <td style="width: 0.25in"><font style="font-size: 10pt">&#x25cf;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">Reassessment of existing or expired land easements: The Company elected not to evaluate existing or expired land easements that were not previously accounted for as leases under ASC 840, as allowed under the transition practical expedient. Going forward, new or modified land easements will be evaluated under ASU No. 2016-02.</font></td></tr>
  </table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#xa0;</td>
    <td style="width: 0.25in"><font style="font-size: 10pt">&#x25cf;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">Separation of lease and non- lease components: Lease agreements that contain both lease and non-lease components are generally accounted for separately.</font></td></tr>
  </table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#xa0;</td>
    <td style="width: 0.25in"><font style="font-size: 10pt">&#x25cf;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">Short-term lease recognition exemption: The Company also elected the short-term lease recognition exemption and will not recognize ROU assets or lease liabilities for leases with a term less than 12 months.</font></td></tr>
  </table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The new leasing standard requires recognition
of leases on the consolidated balance sheets as right-of-use (&#x201c;ROU&#x201d;) assets and lease liabilities. ROU assets represent the
Company&#x2019;s right to use underlying assets for the lease terms and lease liabilities represent the Company&#x2019;s obligation to make
lease payments arising from the leases. Operating lease ROU assets and operating lease liabilities are recognized based on the present
value and future minimum lease payments over the lease term at commencement date. The Company&#x2019;s future minimum based payments used
to determine the Company&#x2019;s lease liabilities mainly include minimum based rent payments. As most of Company&#x2019;s leases do not
provide an implicit rate, the Company uses its estimated incremental borrowing rate based on the information available at commencement
date in determining the present value of lease payments.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognized lease liabilities, with
corresponding ROU assets, based on the present value of unpaid lease payments for existing operating leases longer than twelve months.
The ROU assets were adjusted per ASC 842 transition guidance for existing lease-related balances of accrued and prepaid rent, unamortized
lease incentives provided by lessors, and restructuring liabilities. Operating lease cost is recognized as a single lease cost on a straight-line
basis over the lease term and is recorded in Selling, general and administrative expenses. Variable lease payments for common area maintenance,
property taxes and other operating expenses are recognized as expense in the period when the changes in facts and circumstances on which
the variable lease payments are based occur.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has no finance leases. The Company&#x2019;s
leases primarily include various office and laboratory spaces, copy machine, and vehicles under various operating lease arrangements.
The Company&#x2019;s operating leases have remaining lease terms of up to approximately five years.</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; text-align: center">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">March&#xa0;31, <br/> 2021</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">December&#xa0;31, <br/> 2020</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#xa0;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">ASSETS</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Operating lease right-of-use assets</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,714,740</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,772,747</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold">LIABILITIES</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating lease liabilities (current)</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">331,179</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">316,178</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Operating lease liabilities (noncurrent)</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,383,560</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,456,567</td><td style="text-align: left">&#xa0;</td></tr>
  </table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Supplemental Information</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following provides details of the Company&#x2019;s
lease expenses:</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; text-align: center">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center">&#xa0;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Three Months Ended<br/> March 31,</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#xa0;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; text-align: center">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2021</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2020</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Operating lease expenses</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">78,847</p></td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">77,527</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
  </table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other information related to leases is presented
below:</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; text-align: center">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center">&#xa0;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Three Months Ended <br/> March&#xa0;31,</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#xa0;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; text-align: center">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2021</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2020</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Cash paid for amounts included in the measurement of operating lease liabilities</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">78,847</p></td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">77,527</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
  </table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; text-align: center">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">March&#xa0;31, <br/> 2021</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">December&#xa0;31, <br/> 2020</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#xa0;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Weighted Average Remaining Lease Term:</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Operating leases</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right"><font style="font-size: 10pt">&#xa0;3.58 years </font></td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right"><font style="font-size: 10pt">&#xa0;3.08 years</font></td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Weighted Average Discount Rate:</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Operating leases</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1.45</td><td style="text-align: left">%</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">0.55</td><td style="text-align: left">%</td></tr>
  </table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The minimum future annual payments under non-cancellable
leases during the next five years and thereafter, at rates now in force, are as follows:</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#xa0;</td>
    <td style="text-align: center">&#xa0;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Operating leases</b></font></td>
    <td style="text-align: center">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 90%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021(excluding three months ended March 31, 2021)</font></td>
    <td style="width: 1%">&#xa0;</td>
    <td style="width: 1%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</font></td>
    <td style="width: 7%; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">253,618</font></td>
    <td style="width: 1%">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</font></td>
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">352,248</font></td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</font></td>
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">359,591</font></td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</font></td>
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">374,584</font></td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</font></td>
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">338,676</font></td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thereafter</font></td>
    <td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">56,916</font></td>
    <td style="padding-bottom: 1.5pt">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total future minimum lease payments, undiscounted</font></td>
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,735,633</font></td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less: Imputed interest</font></td>
    <td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20,893</font></td>
    <td style="padding-bottom: 1.5pt">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Present value of future minimum lease payments</font></td>
    <td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</font></td>
    <td style="border-bottom: Black 4pt double; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,714,740</font></td>
    <td style="padding-bottom: 4pt">&#xa0;</td></tr>
  </table><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ASU201602TransitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ASU201602TransitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for lessee's operating leases. Includes, but is not limited to, description of lessee's operating lease, existence and terms of renewal or purchase options and escalation clauses, restrictions imposed by lease, such as those concerning dividends, additional debt, and further leasing, rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 1,3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41499-112717<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121555522&amp;loc=d3e12069-110248<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121549808&amp;loc=d3e36991-112694<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140266628178712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combination<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">BUSINESS COMBINATION</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>17. BUSINESS COMBINATION</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 8, 2019, the Company consummated the
Merger transactions of BioLite and BioKey (See Note 1). Pursuant to the terms of the Merger Agreement, BioLite and BioKey became two wholly-owned
subsidiaries of the Company on February 8, 2019. The Company adopted ASC 805, &#x201c;Business Combination&#x201d; to record the merger
transactions of BioKey. The acquisition was accounted for as a business combination under the purchase method of accounting. BioKey&#x2019;s
results of operations were included in the Company&#x2019;s results beginning February 8, 2019. The purchase price has been allocated to
the assets acquired and the liabilities assumed based on their fair value at the acquisition date as summarized in the following:</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>Purchase consideration:</td><td>&#xa0;</td>
    <td colspan="2">&#xa0;</td><td>&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Common Stock (*)</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">44,341,847</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Allocation of the purchase price:</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash and cash equivalents</td><td>&#xa0;</td>
    <td style="text-align: left">$</td><td style="text-align: right">531,147</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accounts receivable, net</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">188,550</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Property and equipment, net</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">56,075</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Operating lease right-of-use assets</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">485,684</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Security deposits</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,440</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Total assets acquired</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,271,896</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accounts payable</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(56,204</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accrued expenses and other current liabilities</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(251,335</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating lease liability</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(267,256</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Tenant security deposit</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,880</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total liabilities assumed</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(577,675</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Total net assets acquired</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">694,221</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Goodwill as a result of the Merger</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">43,647,626</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
  </table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px">&#xa0;</td>
    <td style="width: 24px"><font style="font-size: 10pt">*</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">29,561,231 shares (1,642,291 after stock reverse split) of common stock of the Company was issued to BioKey in connection with the Merger. Those shares were valued at $1.50 per share, based on the bid-and-ask share price of common stock of the Company on the final day of trading, February 8, 2019.</font></td></tr>
  </table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 8, 2019, the Company has recorded
a 100% goodwill write-down of $43,647,626. Goodwill was determined to have been impaired because of the current financial condition of
the Company and the Company&#x2019;s inability to generate future operating income without substantial sales volume increases, which are
highly uncertain. Furthermore, the Company&#x2019;s anticipated future cash flows indicate that the recoverability of goodwill is not reasonably
assured. The goodwill write-down was reflected as a decrease in additional paid-in capital in the statement of equity upon the consummation
of the Merger.</p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140266709855160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>18. SUBSEQUENT EVENTS</b>&#xa0;&#xa0;</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has evaluated subsequent events through the date which
the financial statements were available to be issued. All subsequent events requiring recognition as of March 31, 2021 have been incorporated
into these financial statements and there are no subsequent events that require disclosure in accordance with FASB ASC Topic 855, &#x201c;Subsequent
Events.&#x201d;&#xa0;&#xa0;</p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140266625111336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="text-decoration:underline">Basis of Presentation</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
have been prepared in accordance with the generally accepted accounting principles in the United States of America (the &#x201c;U.S. GAAP&#x201d;).
All significant intercompany transactions and account balances have been eliminated.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This basis of accounting involves the application
of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred.
The Company&#x2019;s financial statements are expressed in U.S. dollars.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiscalPeriod', window );">Fiscal Year</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="text-decoration:underline">Fiscal Year</font>&#xa0;</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company changed its fiscal year from the
period beginning on October 1st and ending on September 30th to the period beginning on January 1st and ending on December 31st, beginning
January 1, 2018. All references herein to a fiscal year prior to December 31, 2017 refer to the twelve months ended September 30th of
such year.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="text-decoration:underline">Use of Estimates</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity
with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated
financial statements and the amount of revenues and expenses during the reporting periods. Actual results could differ materially from
those results.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="text-decoration:underline">Inventory</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inventory consists of raw materials, work-in-process,
finished goods, and merchandise. Inventories are stated at the lower of cost or market and valued on a moving weighted average cost basis.
Market is determined based on net realizable value. The Company periodically reviews the age and turnover of its inventory to determine
whether any inventory has become obsolete or has declined in value, and incurs a charge to operations for known and anticipated inventory
obsolescence.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="text-decoration:underline">Reclassifications</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain classifications have been made to the
prior year financial statements to conform to the current year presentation. The reclassification had no impact on previously reported
net loss or accumulated deficit.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_ForwardStockSplitsPolicyTextBlock', window );">Forward Stock Split</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="text-decoration:underline">Forward Stock Split</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 21, 2016, the Board of Directors of
the Company approved an amendment to Articles of Incorporation to effect a forward split at a ratio of 1 to 3.141 and increase the number
of our authorized shares of Common Stock, par value $0.001 per share, to 360,000,000, which was effective on April 8, 2016.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_StockReverseSplitPolicyTextBlock', window );">Stock Reverse Split</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="text-decoration:underline">Stock Reverse Split</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 12, 2019, the Board of Directors of
the Company by unanimous written consent in lieu of a meeting approved to i) effect a stock reverse split at the ratio of 1-for-18 (the
&#x201c;Reverse Split&#x201d;) of both the authorized common stock of the Company (the &#x201c;Common Stock&#x201d;) and the issued and outstanding
Common Stock and ii) to amend the articles of incorporation of the Company to reflect the Reverse Split. The Board approved and authorized
the Reverse Split without obtaining approval of the Company&#x2019;s shareholders pursuant to Section 78.207 of Nevada Revised Statutes.
On May 3, 2019, the Company filed a certificate of amendment to the Company&#x2019;s articles of incorporation (the &#x201c;Amendment&#x201d;)
to effect the Reverse Split with the Secretary of State of Nevada. The Financial Industry Regulatory Authority (&#x201c;FINRA&#x201d;)
informed the Company that the Reverse Split was effective on May 8, 2019. All shares and related financial information in this Form 10-K
reflect this 1-for-18 reverse stock split.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="text-decoration:underline">Fair Value Measurements</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FASB ASC 820, &#x201c;Fair Value Measurements&#x201d;
defines fair value for certain financial and nonfinancial assets and liabilities that are recorded at fair value, establishes a framework
for measuring fair value and expands disclosures about fair value measurements. It requires that an entity measure its financial instruments
to base fair value on exit price, maximize the use of observable units and minimize the use of unobservable inputs to determine the exit
price. It establishes a hierarchy which prioritizes the inputs to valuation techniques used to measure fair value. This hierarchy increases
the consistency and comparability of fair value measurements and related disclosures by maximizing the use of observable inputs and minimizing
the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that reflect
the assumptions market participants would use in pricing the assets or liabilities based on market data obtained from sources independent
of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s own assumptions about the assumptions market participants
would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy prioritizes
the inputs into three broad levels based on the reliability of the inputs as follows:</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#xa0;</td>
    <td style="width: 0.25in; text-align: justify"><font style="font-size: 10pt">&#x25cf;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">Level 1 - Inputs are quoted prices in active markets for identical
    assets or liabilities that the Company has the ability to access at the measurement date. Valuation of these instruments does not
    require a high degree of judgment as the valuations are based on quoted prices in active markets that are readily and regularly available.</font></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#xa0;</td>
    <td style="text-align: justify">&#xa0;</td>
    <td style="text-align: justify">&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#xa0;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">&#x25cf;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">Level 2 - Inputs other than quoted prices in active markets that are
    either directly or indirectly observable as of the measurement date, such as quoted prices for similar assets or liabilities; quoted
    prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially
    the full term of the assets or liabilities.</font></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#xa0;</td>
    <td style="text-align: justify">&#xa0;</td>
    <td style="text-align: justify">&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#xa0;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">&#x25cf;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">Level 3 - Valuations based on inputs that are unobservable and not
    corroborated by market data. The fair value for such assets and liabilities is generally determined using pricing models, discounted
    cash flow methodologies, or similar techniques that incorporate the assumptions a market participant would use in pricing the asset
    or liability.</font></td></tr>
  </table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The carrying values of certain assets and liabilities
of the Company, such as cash and cash equivalents, restricted cash, accounts receivable, due from related parties, inventory, prepaid
expenses and other current assets, accounts payable, accrued liabilities, and due to related parties approximate fair value due to their
relatively short maturities. The carrying value of the Company&#x2019;s short-term bank loan, convertible notes payable, and accrued interest
approximates their fair value as the terms of the borrowing are consistent with current market rates and the duration to maturity is
short. The carrying value of the Company&#x2019;s long-term bank loan approximates fair value because the interest rates approximate market
rates that the Company could obtain for debt with similar terms and maturities.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="text-decoration:underline">Cash and Cash Equivalents</font>&#xa0;</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers highly liquid investments
with maturities of three months or less, when purchased, to be cash equivalents. As of March 31, 2021 and December 31, 2020, the Company&#x2019;s
cash and cash equivalents amounted $2,615,073 and $4,273,208, respectively. Some&#xa0;of the Company&#x2019;s cash deposits are held in
financial institutions located in Taiwan where there is currently regulation mandated on obligatory insurance of bank accounts. The Company
believes this financial institution is of high credit quality.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash Equivalents</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="text-decoration:underline">Restricted Cash Equivalents</font>&#xa0;</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Restricted cash equivalents primarily consist
of cash held in a reserve bank account in Taiwan. As of March 31, 2021 and December 31, 2020, the Company&#x2019;s restricted cash equivalents
amounted $718,163 and $728,163, respectively.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="text-decoration:underline">Concentration of Credit Risk</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#x2019;s financial instruments that
are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash and temporary
cash investments in high quality credit institutions, but these investments may be in excess of Taiwan Central Deposit Insurance Corporation
and the U.S. Federal Deposit Insurance Corporation&#x2019;s insurance limits. The Company does not enter into financial instruments for
hedging, trading or speculative purposes.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="text-decoration:underline">Revenue Recognition</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the fiscal year 2018, the Company adopted
Accounting Standards Codification (&#x201c;ASC&#x201d;), Topic 606 (ASC 606), Revenue from Contracts with Customers, using the modified
retrospective method to all contracts that were not completed as of January 1, 2018, and applying the new revenue standard as an adjustment
to the opening balance of accumulated deficit at the beginning of 2018 for the cumulative effect. The results for the Company&#x2019;s
reporting periods beginning on and after January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and
continue to be reported under the accounting standards in effect for the prior period. Based on the Company&#x2019;s review of existing
collaborative agreements as of January 1, 2018, the Company concluded that the adoption of the new guidance did not have a significant
change on the Company&#x2019;s revenue during all periods presented.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to ASC 606, the Company recognizes revenue
when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the Company expects
to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines is
within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify
the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance
obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only
applies the five-step model to contracts when it is probable that the Company will collect the consideration the Company is entitled
to in exchange for the goods or services the Company transfers to the customers. At inception of the contract, once the contract is determined
to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are
performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount
of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following are examples of when the Company
recognizes revenue based on the types of payments the Company receives.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Collaborative Revenues &#x2014; </b>The Company
recognizes collaborative revenues generated through collaborative research, development and/or commercialization agreements. The terms
of these agreements typically include payment to the Company related to one or more of the following: non-refundable upfront license
fees, development and commercial milestones, partial or complete reimbursement of research and development costs, and royalties on net
sales of licensed products. Each type of payments results in collaborative revenues except for revenues from royalties on net sales of
licensed products, which are classified as royalty revenues. To date, the Company has not received any royalty revenues. Revenue is recognized
upon satisfaction of a performance obligation by transferring control of a good or service to the collaboration partners.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As part of the accounting for these arrangements,
the Company applies judgment to determine whether the performance obligations are distinct, and develop assumptions in determining the
stand-alone selling price for each distinct performance obligation identified in the collaboration agreements. To determine the stand-alone
selling price, the Company relies on assumptions which may include forecasted revenues, development timelines, reimbursement rates for
R&amp;D personnel costs, discount rates and probabilities of technical and regulatory success.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company had multiple deliverables under the
collaborative agreements, including deliverables relating to grants of technology licenses, regulatory and clinical development, and
marketing activities. Estimation of the performance periods of the Company&#x2019;s deliverables requires the use of management&#x2019;s
judgment. Significant factors considered in management&#x2019;s evaluation of the estimated performance periods include, but are not limited
to, the Company&#x2019;s experience in conducting clinical development, regulatory and manufacturing activities. The Company reviews the
estimated duration of its performance periods under its collaborative agreements on an annually basis, and makes any appropriate adjustments
on a prospective basis. Future changes in estimates of the performance period under its collaborative agreements could impact the timing
of future revenue recognition.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(i) Non-refundable upfront payments</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If a license to the Company&#x2019;s intellectual
property is determined to be distinct from the other performance obligations identified in an arrangement, the Company recognizes revenue
from the related non-refundable upfront payments based on the relative standalone selling price prescribed to the license compared to
the total selling price of the arrangement. The revenue is recognized when the license is transferred to the collaboration partners and
the collaboration partners are able to use and benefit from the license. To date, the receipt of non-refundable upfront fees was solely
for the compensation of past research efforts and contributions made by the Company before the collaborative agreements entered into
and it does not relate to any future obligations and commitments made between the Company and the collaboration partners in the collaborative
agreements.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(ii) Milestone payments</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is eligible to receive milestone
payments under the collaborative agreement with collaboration partners based on achievement of specified development, regulatory and
commercial events. Management evaluated the nature of the events triggering these contingent payments, and concluded that these events
fall into two categories: (a) events which involve the performance of the Company&#x2019;s obligations under the collaborative agreement
with collaboration partners, and (b) events which do not involve the performance of the Company&#x2019;s obligations under the collaborative
agreement with collaboration partners.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The former category of milestone payments consists
of those triggered by development and regulatory activities in the territories specified in the collaborative agreements. Management
concluded that each of these payments constitute substantive milestone payments. This conclusion was based primarily on the facts that
(i) each triggering event represents a specific outcome that can be achieved only through successful performance by the Company of one
or more of its deliverables, (ii) achievement of each triggering event was subject to inherent risk and uncertainty and would result
in additional payments becoming due to the Company, (iii) each of the milestone payments is non-refundable, (iv) substantial effort is
required to complete each milestone, (v) the amount of each milestone payment is reasonable in relation to the value created in achieving
the milestone, (vi) a substantial amount of time is expected to pass between the upfront payment and the potential milestone payments,
and (vii) the milestone payments relate solely to past performance. Based on the foregoing, the Company recognizes any revenue from these
milestone payments in the period in which the underlying triggering event occurs.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(iii) Multiple Element Arrangements</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company evaluates multiple element arrangements
to determine (1) the deliverables included in the arrangement and (2) whether the individual deliverables represent separate units of
accounting or whether they must be accounted for as a combined unit of accounting. This evaluation involves subjective determinations
and requires management to make judgments about the individual deliverables and whether such deliverables are separate from other aspects
of the contractual relationship. Deliverables are considered separate units of accounting provided that: (i) the delivered item(s) has
value to the customer on a standalone basis and (ii) if the arrangement includes a general right of return relative to the delivered
item(s), delivery or performance of the undelivered item(s) is considered probable and substantially within its control. In assessing
whether an item under a collaboration has standalone value, the Company considers factors such as the research, manufacturing, and commercialization
capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. The Company also
considers whether its collaboration partners can use the other deliverable(s) for their intended purpose without the receipt of the remaining
element(s), whether the value of the deliverable is dependent on the undelivered item(s), and whether there are other vendors that can
provide the undelivered element(s).</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognizes arrangement consideration
allocated to each unit of accounting when all of the revenue recognition criteria in ASC 606 are satisfied for that particular unit of
accounting. In the event that a deliverable does not represent a separate unit of accounting, the Company recognizes revenue from the
combined unit of accounting over the Company&#x2019;s contractual or estimated performance period for the undelivered elements, which
is typically the term of the Company&#x2019;s research and development obligations. If there is no discernible pattern of performance
or objectively measurable performance measures do not exist, then the Company recognizes revenue under the arrangement on a straight-line
basis over the period the Company is expected to complete its performance obligations. Conversely, if the pattern of performance in which
the service is provided to the customer can be determined and objectively measurable performance measures exist, then the Company recognizes
revenue under the arrangement using the proportional performance method. Revenue recognized is limited to the lesser of the cumulative
amount of payments received or the cumulative amount of revenue earned, as determined using the straight-line method or proportional
performance method, as applicable, as of the period ending date.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the inception of an arrangement that includes
milestone payments, the Company evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent
nature of the milestone. This evaluation includes an assessment of whether: (1) the consideration is commensurate with either the Company&#x2019;s
performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting
from its performance to achieve the milestone, (2) the consideration relates solely to past performance and (3) the consideration is
reasonable relative to all of the deliverables and payment terms within the arrangement. The Company evaluates factors such as the scientific,
clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone and the level of effort and
investment required to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining
whether a milestone satisfies all of the criteria required to conclude that a milestone is substantive. Milestones that are not considered
substantive are recognized as earned if there are no remaining performance obligations or over the remaining period of performance, assuming
all other revenue recognition criteria are met.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(iv) Royalties and Profit Sharing Payments</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the collaborative agreement with the collaboration
partners, the Company is entitled to receive royalties on sales of products, which is at certain percentage of the net sales. The Company
recognizes revenue from these events based on the revenue recognition criteria set forth in ASC 606. Based on those criteria, the Company
considers these payments to be contingent revenues, and recognizes them as revenue in the period in which the applicable contingency
is resolved.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenues Derived from Research and Development
Activities Services &#x2014; Revenues related to research and development and regulatory activities are recognized when the related services
or activities are performed, in accordance with the contract terms. The Company typically has only one performance obligation at the
inception of a contract, which is to perform research and development services. The Company may also provide its customers with an option
to request that the Company provides additional goods or services in the future, such as active pharmaceutical ingredient, API, or IND/NDA/ANDA/510K
submissions. The Company evaluates whether these options are material rights at the inception of the contract. If the Company determines
an option is a material right, the Company will consider the option a separate performance obligation.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the Company is entitled to reimbursement from
its customers for specified research and development expenses, the Company accounts for the related services that it provides as separate
performance obligations if it determines that these services represent a material right. The Company also determines whether the reimbursement
of research and development expenses should be accounted for as revenues or an offset to research and development expenses in accordance
with provisions of gross or net revenue presentation. The Company recognizes the corresponding revenues or records the corresponding
offset to research and development expenses as it satisfies the related performance obligations.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company then determines the transaction price
by reviewing the amount of consideration the Company is eligible to earn under the contracts, including any variable consideration. Under
the outstanding contracts, consideration typically includes fixed consideration and variable consideration in the form of potential milestone
payments. At the start of an agreement, the Company&#x2019;s transaction price usually consists of the payments made to or by the Company
based on the number of full-time equivalent researchers assigned to the project and the related research and development expenses incurred.
The Company does not typically include any payments that the Company may receive in the future in its initial transaction price because
the payments are not probable. The Company would reassess the total transaction price at each reporting period to determine if the Company
should include additional payments in the transaction price.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company receives payments from its customers
based on billing schedules established in each contract. Upfront payments and fees may be recorded as advance from customers upon receipt
or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under these
arrangements. Amounts are recorded as accounts receivable when the right of the Company to consideration is unconditional. The Company
does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period
between payment by the customers and the transfer of the promised goods or services to the customers will be one year or less.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="text-decoration:underline">Property and Equipment</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property and equipment is carried at cost net
of accumulated depreciation. Repairs and maintenance are expensed as incurred. Expenditures that improve the functionality of the related
asset or extend the useful life are capitalized. When property and equipment is retired or otherwise disposed of, the related gain or
loss is included in operating income. Leasehold improvements are depreciated on the straight-line method over the shorter of the remaining
lease term or estimated useful life of the asset. Depreciation is calculated on the straight-line method, including property and equipment
under capital leases, generally based on the following useful lives:</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom; ">
    <td style="width: 91%; text-align: justify">&#xa0;</td>
    <td style="width: 1%">&#xa0;</td>
    <td style="border-bottom: black 1.5pt solid; width: 8%; text-align: center"><font style="font-size: 10pt"><b>Estimated&#xa0;Life<br/>
    in Years</b></font></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify"><font style="font-size: 10pt">Buildings and leasehold improvements</font></td>
    <td>&#xa0;</td>
    <td style="text-align: center"><font style="font-size: 10pt">5 ~ 50</font></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><font style="font-size: 10pt">Machinery and equipment</font></td>
    <td>&#xa0;</td>
    <td style="text-align: center"><font style="font-size: 10pt">5 ~ 10</font></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify"><font style="font-size: 10pt">Office equipment</font></td>
    <td>&#xa0;</td>
    <td style="text-align: center"><font style="font-size: 10pt">3 ~ 6</font></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="text-decoration:underline">Impairment of Long-Lived Assets</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has adopted Accounting Standards
Codification subtopic 360-10, Property, Plant and Equipment (&#x201c;ASC 360-10&#x201d;). ASC 360-10 requires that long-lived assets and
certain identifiable intangibles held and used by the Company be reviewed for impairment whenever events or changes in circumstances
indicate that the carrying amount of an asset may not be recoverable. The Company evaluates its long-lived assets for impairment annually
or more often if events and circumstances warrant. Events relating to recoverability may include significant unfavorable changes in business
conditions, recurring losses, or a forecasted inability to achieve break-even operating results over an extended period. Should impairment
in value be indicated, the carrying value of intangible assets will be adjusted, based on estimates of future discounted cash flows resulting
from the use and ultimate disposition of the asset. ASC 360-10 also requires assets to be disposed of be reported at the lower of the
carrying amount or the fair value less costs to sell.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_LongTermEquityInvestmentPolicy', window );">Long-term Equity Investment</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="text-decoration:underline">Long-term Equity Investment</font>&#xa0;</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company acquires the equity investments to
promote business and strategic objectives. The Company accounts for non-marketable equity and other equity investments for which the
Company does not have control over the investees as:</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#xa0;</td>
    <td style="width: 0.25in"><font style="font-size: 10pt">&#x25cf;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">Equity method investments when the Company has the ability to exercise
    significant influence, but not control, over the investee. Its proportionate share of the income or loss is recognized monthly and
    is recorded in gains (losses) on equity investments.</font></td></tr>
  </table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#xa0;</td>
    <td style="width: 0.25in"><font style="font-size: 10pt">&#x25cf;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">Non-marketable cost method investments when the equity method does
    not apply.</font></td></tr>
  </table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Significant judgment is required to identify
whether an impairment exists in the valuation of the Company&#x2019;s non-marketable equity investments, and therefore the Company considers
this a critical accounting estimate. Its yearly analysis considers both qualitative and quantitative factors that may have a significant
impact on the investee&#x2019;s fair value. Qualitative analysis of its investments involves understanding the financial performance and
near-term prospects of the investee, changes in general market conditions in the investee&#x2019;s industry or geographic area, and the
management and governance structure of the investee. Quantitative assessments of the fair value of its investments are developed using
the market and income approaches. The market approach includes the use of comparable financial metrics of private and public companies
and recent financing rounds. The income approach includes the use of a discounted cash flow model, which requires significant estimates
regarding the investees&#x2019; revenue, costs, and discount rates. The Company&#x2019;s assessment of these factors in determining whether
an impairment exists could change in the future due to new developments or changes in applied assumptions.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_OtherThanTemporaryImpairmentPolicyTextBlock', window );">Other-Than-Temporary Impairment</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="text-decoration:underline">Other-Than-Temporary Impairment</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#x2019;s long-term equity investments
are subject to a periodic impairment review. Impairments affect earnings as follows:</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#xa0;</td>
    <td style="width: 0.25in"><font style="font-size: 10pt">&#x25cf;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">Marketable equity securities include the consideration of general market
    conditions, the duration and extent to which the fair value is below cost, and our ability and intent to hold the investment for
    a sufficient period of time to allow for recovery of value in the foreseeable future. The Company also considers specific adverse
    conditions related to the financial health of, and the business outlook for, the investee, which may include industry and sector
    performance, changes in technology, operational and financing cash flow factors, and changes in the investee&#x2019;s credit rating.
    The Company records other-than-temporary impairments on marketable equity securities and marketable equity method investments in
    gains (losses) on equity investments.</font></td></tr>
  </table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#xa0;</td>
    <td style="width: 0.25in"><font style="font-size: 10pt">&#x25cf;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">Non-marketable equity investments based on the Company&#x2019;s assessment
    of the severity and duration of the impairment, and qualitative and quantitative analysis of the operating performance of the investee;
    adverse changes in market conditions and the regulatory or economic environment; changes in operating structure or management of
    the investee; additional funding requirements; and the investee&#x2019;s ability to remain in business. A series of operating losses
    of an investee or other factors may indicate that a decrease in value of the investment has occurred that is other than temporary
    and that shall be recognized even though the decrease in value is in excess of what would otherwise be recognized by application
    of the equity method. A loss in value of an investment that is other than a temporary decline shall be recognized. Evidence of a
    loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the
    investment or inability of the investee to sustain an earnings capacity that would justify the carrying amount of the investment.
    The Company records other-than-temporary impairments for non-marketable cost method investments and equity method investments in
    gains (losses) on equity investments. Other-than-temporary impairments of equity investments were $0 and $0 for the three months
    ended March 31, 2021 and 2020, respectively.</font></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="text-decoration:underline">Goodwill</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company evaluates goodwill for impairment
annually or more frequently when an event occurs or circumstances change that indicate the carrying value may not be recoverable. In
testing goodwill for impairment, the Company may elect to utilize a qualitative assessment to evaluate whether it is more likely than
not that the fair value of a reporting unit is less than its carrying amount. If the qualitative assessment indicates that goodwill impairment
is more likely than not, the Company performs a two-step impairment test. The Company tests goodwill for impairment under the two-step
impairment test by first comparing the book value of net assets to the fair value of the reporting units. If the fair value is determined
to be less than the book value or qualitative factors indicate that it is more likely than not that goodwill is impaired, a second step
is performed to compute the amount of impairment as the difference between the estimated fair value of goodwill and the carrying value.
The Company estimates the fair value of the reporting units using discounted cash flows. Forecasts of future cash flows are based on
our best estimate of future net sales and operating expenses, based primarily on expected category expansion, pricing, market segment
share, and general economic conditions.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company completed the required testing of
goodwill for impairment as of March 31, 2021, and determined that goodwill was impaired because of the current financial condition of
the Company and the Company&#x2019;s inability to generate future operating income without substantial sales volume increases, which are
highly uncertain. Furthermore, the Company anticipates future cash flows indicate that the recoverability of goodwill is not reasonably
assured.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="text-decoration:underline">Research and Development Expenses</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for the cost of using licensing
rights in research and development cost according to ASC Topic 730-10-25-1. This guidance provides that absent alternative future uses
the acquisition of product rights to be used in research and development activities must be charged to research and development expenses
when incurred.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For CDMO business unit, the Company accounts
for R&amp;D costs in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) 730, Research and Development (&#x201c;ASC
730&#x201d;). Research and development expenses are charged to expense as incurred unless there is an alternative future use in other
research and development projects or otherwise. Research and development expenses are comprised of costs incurred in performing research
and development activities, including personnel-related costs, facilities-related overhead, and outside contracted services including
clinical trial costs, manufacturing and process development costs for both clinical and preclinical materials, research costs, and other
consulting services. Non-refundable advance payment for goods and services that will be used in future research and development activities
are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. In instances
where the Company enters into agreements with third parties to provide research and development services, costs are expensed as services
are performed.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy', window );">Post-retirement and post-employment benefits</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="text-decoration:underline">Post-retirement and post-employment benefits</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#x2019;s subsidiaries in Taiwan adopted
the government mandated defined contribution plan pursuant to the Labor Pension Act (the &#x201c;Act&#x201d;) in Taiwan. Such labor regulations
require that the rate of contribution made by an employer to the Labor Pension Fund per month shall not be less than 6% of the worker&#x2019;s
monthly salaries. Pursuant to the Act, the Company makes monthly contribution equal to 6% of employees&#x2019; salaries to the employees&#x2019;
pension fund. The Company has no legal obligation for the benefits beyond the contributions made. The total amounts for such employee
benefits, which were expensed as incurred, were $2,503 and $3,598 for the three months ended March 31, 2021 and 2020, respectively. Other
than the above, the Company does not provide any other post-retirement or post-employment benefits.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-based Compensation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="text-decoration:underline">Stock-based Compensation</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company measures expense associated with
all employee stock-based compensation awards using a fair value method and recognizes such expense in the consolidated financial statements
on a straight-line basis over the requisite service period in accordance with FASB ASC Topic 718 &#x201c;Compensation-Stock Compensation&#x201d;.
Total employee stock-based compensation expenses were $0 and $0 for the three months ended March 31, 2021 and 2020, respectively.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounted for stock-based compensation
to non-employees in accordance with FASB ASC Topic 718 &#x201c;Compensation-Stock Compensation&#x201d; and FASB ASC Topic 505-50 &#x201c;Equity-Based
Payments to Non-Employees&#x201d; which requires that the cost of services received from non-employees is measured at fair value at the
earlier of the performance commitment date or the date service is completed and recognized over the period the service is provided. Total
non-employee stock-based compensation expenses were $225,740 and $525 for the three months ended March 31, 2021 and 2020, respectively.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_BeneficialConversionFeature', window );">Beneficial Conversion Feature</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="text-decoration:underline">Beneficial Conversion Feature</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, the Company may issue convertible
notes that may contain an imbedded beneficial conversion feature. A beneficial conversion feature exists on the date a convertible note
is issued when the fair value of the underlying common stock to which the note is convertible into is in excess of the remaining unallocated
proceeds of the note after first considering the allocation of a portion of the note proceeds to the fair value of the warrants, if related
warrants have been granted. The intrinsic value of the beneficial conversion feature is recorded as a debt discount with a corresponding
amount to additional paid in capital. The debt discount is amortized to interest expense over the life of the note using the effective
interest method.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="text-decoration:underline">Income Taxes</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for income taxes using the
asset and liability approach which allows the recognition and measurement of deferred tax assets to be based upon the likelihood of realization
of tax benefits in future years. Under the asset and liability approach, deferred taxes are provided for the net tax effects of temporary
differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax
purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not these items will expire before the
Company is able to realize their benefits, or future deductibility is uncertain.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under ASC 740, a tax position is recognized as
a benefit only if it is&#xa0;&#x201c;more likely than not&#x201d;&#xa0;that the tax position would be sustained in a tax examination, with
a tax examination being presumed to occur. The evaluation of a tax position is a two-step process. The first step is to determine whether
it is more-likely-than-not that a tax position will be sustained upon examination, including the resolution of any related appeals or
litigations based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not
threshold to determine the amount of benefits recognized in the financial statements. A tax position is measured at the largest amount
of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. Tax positions that previously failed to
meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which the threshold is met.
Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent
financial reporting period in which the threshold is no longer satisfied. Penalties and interest incurred related to underpayment of income
tax are classified as income tax expense in the year incurred. No significant penalty or interest relating to income taxes has been incurred
for the three months ended March 31, 2021 and 2020. GAAP also provides guidance on de-recognition, classification, interest and penalties,
accounting in interim periods, disclosures and transition.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 22, 2017, the SEC issued Staff Accounting
Bulletin (&#x201c;SAB 118&#x201d;), which provides guidance on accounting for tax effects of the Tax Act. SAB 118 provides a measurement
period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740.
In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the Act for which the accounting under
ASC 740 is complete. To the extent that a company&#x2019;s accounting for certain income tax effects of the Tax Act is incomplete but
it is able to determine a reasonable estimate, it must record a provisional estimate to be included in the financial statements. If a
company cannot determine a provisional estimate to be included in the financial statements, it should continue to apply ASC 740 on the
basis of the provision of the tax laws that were in effect immediately before the enactment of the Tax Act. While the Company is able
to make reasonable estimates of the impact of the reduction in corporate rate and the deemed repatriation transition tax, the final impact
of the Tax Act may differ from these estimates, due to, among other things, changes in our interpretations and assumptions, additional
guidance that may be issued by the I.R.S., and actions the Company may take. The Company is continuing to gather additional information
to determine the final impact.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_ValuationOfDeferredTaxAssetsPolicyTextBlock', window );">Valuation of Deferred Tax Assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="text-decoration:underline">Valuation of Deferred Tax Assets</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A valuation allowance is recorded to reduce the
Company&#x2019;s deferred tax assets to the amount that is more likely than not to be realized. In assessing the need for the valuation
allowance, management considers, among other things, projections of future taxable income and ongoing prudent and feasible tax planning
strategies. If the Company determines that sufficient negative evidence exists, then it will consider recording a valuation allowance
against a portion or all of the deferred tax assets in that jurisdiction. If, after recording a valuation allowance, the Company&#x2019;s
projections of future taxable income and other positive evidence considered in evaluating the need for a valuation allowance prove, with
the benefit of hindsight, to be inaccurate, it could prove to be more difficult to support the realization of its deferred tax assets.
As a result, an additional valuation allowance could be required, which would have an adverse impact on its effective income tax rate
and results. Conversely, if, after recording a valuation allowance, the Company determines that sufficient positive evidence exists in
the jurisdiction in which the valuation allowance was recorded, it may reverse a portion or all of the valuation allowance in that jurisdiction.
In such situations, the adjustment made to the deferred tax asset would have a favorable impact on its effective income tax rate and
results in the period such determination was made.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss Per Share of Common Stock</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="text-decoration:underline">Loss Per Share of Common Stock</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company calculates net loss per share in
accordance with ASC Topic 260, &#x201c;Earnings per Share&#x201d;. Basic loss per share is computed by dividing the net loss by the weighted
average number of common shares outstanding during the period. Diluted loss per share is computed similar to basic loss per share except
that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential
common stock equivalents had been issued and if the additional common shares were dilutive. Diluted earnings per share excludes all dilutive
potential shares if their effect is anti-dilutive.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="text-decoration:underline">Commitments and Contingencies</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has adopted ASC Topic 450 &#x201c;Contingencies&#x201d;
subtopic 20, in determining its accruals and disclosures with respect to loss contingencies. Accordingly, estimated losses from loss
contingencies are accrued by a charge to income when information available before financial statements are issued or are available to
be issued indicates that it is probable that an assets had been impaired or a liability had been incurred at the date of the financial
statements and the amount of the loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred.
If a loss contingency is not probable or reasonably estimable, disclosure of the loss contingency is made in the financial statements
when it is at least reasonably possible that a material loss could be incurred.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign-currency Transactions</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="text-decoration:underline">Foreign-currency Transactions</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the Company&#x2019;s subsidiaries in Taiwan,
the foreign-currency transactions are recorded in New Taiwan dollars (&#x201c;NTD&#x201d;) at the rates of exchange in effect when the
transactions occur. Gains or losses resulting from the application of different foreign exchange rates when cash in foreign currency
is converted into New Taiwan dollars, or when foreign-currency receivables or payables are settled, are credited or charged to income
in the year of conversion or settlement. On the balance sheet dates, the balances of foreign-currency assets and liabilities are restated
at the prevailing exchange rates and the resulting differences are charged to current income except for those foreign currencies denominated
investments in shares of stock where such differences are accounted for as translation adjustments under the Statements of Stockholders&#x2019;
Equity (Deficit).</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_TranslationAdjustmentPolicyTextBlock', window );">Translation Adjustment</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="text-decoration:underline">Translation Adjustment</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accounts of the Company&#x2019;s subsidiaries
in Taiwan were maintained, and their financial statements were expressed, in New Taiwan Dollar (&#x201c;NT$&#x201d;). Such financial statements
were translated into U.S. Dollars (&#x201c;$&#x201d; or &#x201c;USD&#x201d;) in accordance ASC 830, &#x201c;Foreign Currency Matters&#x201d;,
with the NT$ as the functional currency. According to the Statement, all assets and liabilities are translated at the current exchange
rate, stockholder&#x2019;s deficit are translated at the historical rates and income statement items are translated at an average exchange
rate for the period. The resulting translation adjustments are reported under other comprehensive income (loss) as a component of stockholders&#x2019;
equity (deficit).</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="text-decoration:underline">Recent Accounting Pronouncements</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2019, the FASB issued ASU 2019-12,&#xa0;<i>Income
Taxes (Topic 740): Simplifying the Accounting for Income Taxes</i>, as part of its overall simplification initiative to reduce costs
and complexity of applying accounting standards while maintaining or improving the usefulness of the information provided to users of
financial statements. The FASB&#x2019;s amendments primarily impact ASC 740,&#xa0;<i>Income Taxes</i>, and may impact both interim and
annual reporting periods. ASU 2019-12 will be effective for fiscal years beginning after December 15, 2020, and interim periods within
those fiscal years and early adoption is permitted. The Company is currently evaluating the impact of adopting ASU 2019-12.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">In August 2020, the
FASB issued ASU 2020-06,&#xa0;<i>Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging- Contracts in Entity&#x2019;s
Own Equity (Subtopic 815-40)</i>, to reduce the complexity associated with applying U.S. GAAP principles for certain financial instruments
with characteristics of liabilities and equity. The amendments in this ASU reduce the number of accounting models for convertible instruments
and expand the existing disclosure requirements over earnings per share as it relates to convertible instruments. This ASU will be effective
for the fiscal year beginning January 1, 2022 and interim periods therein. Early adoption is permitted, but no earlier than fiscal years
beginning after December 15, 2020. The amendments may be adopted through either a modified retrospective method, or a fully retrospective
method. The Company is currently evaluating the impact of adopting ASU 2020-06.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_BeneficialConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for beneficial conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_BeneficialConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_ForwardStockSplitsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for forward stock splits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_ForwardStockSplitsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_LongTermEquityInvestmentPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-term equity investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_LongTermEquityInvestmentPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_OtherThanTemporaryImpairmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for other than temporary impairment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_OtherThanTemporaryImpairmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_StockReverseSplitPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for Stock Reverse Split.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_StockReverseSplitPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_TranslationAdjustmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for translation adjustment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_TranslationAdjustmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_ValuationOfDeferredTaxAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for valuation of deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_ValuationOfDeferredTaxAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6052-115624<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6049-115624<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiscalPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining an entity's fiscal year or other fiscal period. This disclosure may include identification of the fiscal period end-date, the length of the fiscal period, any reporting period lag between the entity and its subsidiaries, or equity investees. If a reporting lag exists, the closing date of the entity having a different period end is generally noted, along with an explanation of the necessity for using different closing dates. Any intervening events that materially affect the entity's financial position or results of operations are generally also disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=d3e5291-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiscalPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for plans, other than pension plans, that provide postretirement benefits (including both defined benefit and defined contribution plans). This accounting policy may address (1) the types of plans sponsored by the entity, and the benefits provided by each plan (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 80<br> -URI http://asc.fasb.org/subtopic&amp;trid=2235144<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -URI http://asc.fasb.org/subtopic&amp;trid=2235172<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -URI http://asc.fasb.org/subtopic&amp;trid=2235116<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140266624417032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock', window );">Schedule of property and equipment</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom; ">
    <td style="width: 91%; text-align: justify">&#xa0;</td>
    <td style="width: 1%">&#xa0;</td>
    <td style="border-bottom: black 1.5pt solid; width: 8%; text-align: center"><font style="font-size: 10pt"><b>Estimated&#xa0;Life<br/>
    in Years</b></font></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify"><font style="font-size: 10pt">Buildings and leasehold improvements</font></td>
    <td>&#xa0;</td>
    <td style="text-align: center"><font style="font-size: 10pt">5 ~ 50</font></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><font style="font-size: 10pt">Machinery and equipment</font></td>
    <td>&#xa0;</td>
    <td style="text-align: center"><font style="font-size: 10pt">5 ~ 10</font></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify"><font style="font-size: 10pt">Office equipment</font></td>
    <td>&#xa0;</td>
    <td style="text-align: center"><font style="font-size: 10pt">3 ~ 6</font></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of property and equipment estimated useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140266623259160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of inventory</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Finished goods</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">99,549</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">100,967</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Work-in-process</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">21,729</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">22,038</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Raw materials</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">60,851</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">61,718</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Allowance for inventory valuation and obsolescence loss</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(182,129</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(184,723</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Inventory, net</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140266624166856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#xa0;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">March 31,<br/>
    2021</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">December&#xa0;31,<br/>
    2020</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">(Unaudited)</td><td style="font-weight: bold">&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Land</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">390,088</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">395,645</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Buildings and leasehold improvements</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">2,231,712</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">2,233,573</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Machinery and equipment</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">992,882</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">994,544</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Office equipment</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">187,181</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">189,760</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">3,801,863</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">3,813,522</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,296,911</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,298,688</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Property and equipment, net</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">504,952</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">514,834</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140266622697400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_LongTermInvestmentAbstract', window );"><strong>Long Term Investment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_ScheduleOfOwnershipPercentagesOfInvesteeTableTextBlocks', window );">Schedule of ownership percentages of investee</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Ownership percentage</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="text-align: center">&#xa0;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#xa0;</td><td style="white-space: nowrap; font-weight: bold">&#xa0;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">March 31,</td><td style="white-space: nowrap; font-weight: bold">&#xa0;</td><td style="white-space: nowrap; font-weight: bold">&#xa0;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">December&#xa0;31,</td><td style="white-space: nowrap; font-weight: bold">&#xa0;</td><td style="white-space: nowrap; font-weight: bold">&#xa0;</td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center">Accounting</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Name of related party</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">treatments</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Braingenesis Biotechnology Co., Ltd.</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">0.17</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">0.17</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 11%; text-align: center">Cost Method</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Genepharm Biotech Corporation</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">0.70</td><td style="text-align: left">%</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">0.70</td><td style="text-align: left">%</td><td>&#xa0;</td>
    <td style="text-align: center">Cost Method</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">BioHopeKing Corporation</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5.90</td><td style="text-align: left">%</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5.90</td><td style="text-align: left">%</td><td>&#xa0;</td>
    <td style="text-align: center">Cost Method</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">BioFirst Corporation</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">15.99</td><td style="text-align: left">%</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">15.99</td><td style="text-align: left">%</td><td>&#xa0;</td>
    <td style="text-align: center">Equity Method</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Rgene Corporation</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">31.62</td><td style="text-align: left">%</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">31.62</td><td style="text-align: left">%</td><td>&#xa0;</td>
    <td style="text-align: center">Equity Method</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_ScheduleOfExtentInvesteeReliesTableTextBlock', window );">Schedule of extent the investee relies</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom; ">
    <td style="border-bottom: black 1.5pt solid; width: 30%"><font style="font-size: 10pt"><b>Name of related party</b></font></td>
    <td style="width: 1%">&#xa0;</td>
    <td style="border-bottom: black 1.5pt solid; width: 69%"><font style="font-size: 10pt"><b>The extent the investee relies on the Company
    for its business &#xa0;</b></font></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td><font style="font-size: 10pt">Braingenesis Biotechnology Co., Ltd.</font></td>
    <td>&#xa0;</td>
    <td><font style="font-size: 10pt">No specific business relationship</font></td></tr>
  <tr>
    <td><font style="font-size: 10pt">Genepharm Biotech Corporation</font></td>
    <td>&#xa0;</td>
    <td><font style="font-size: 10pt">No specific business relationship</font></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td><font style="font-size: 10pt">BioHopeKing Corporation</font></td>
    <td>&#xa0;</td>
    <td><font style="font-size: 10pt">Collaborating with the Company to develop and commercialize drugs</font></td></tr>
  <tr>
    <td><font style="font-size: 10pt">BioFirst Corporation</font></td>
    <td>&#xa0;</td>
    <td><font style="font-size: 10pt">Loaned from the investee and provides research and development support service</font></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td><font style="font-size: 10pt">Rgene Corporation</font></td>
    <td>&#xa0;</td>
    <td><font style="font-size: 10pt">Collaborating with the Company to develop and commercialize drugs</font></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_ScheduleOfLongTermInvestmentTableTextBlock', window );">Schedule of long-term investment</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March&#xa0;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#xa0;31,<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2">&#xa0;</td><td>&#xa0;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Non-marketable Cost Method Investments, net</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: center">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2">&#xa0;</td><td>&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 9pt">Braingenesis Biotechnology Co., Ltd.</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,742</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,853</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Genepharm Biotech Corporation</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">23,638</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">23,974</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">BioHopeKing Corporation</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">878,056</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">890,564</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25in">Sub total</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">909,436</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">922,391</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Equity Method Investments, net</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">BioFirst Corporation</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">217,448</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">268,336</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Rgene Corporation</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; padding-left: 0.25in">Total</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,126,884</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,190,727</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfCondensedBalanceSheetTableTextBlock', window );">Schedule of balance sheets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#xa0;31,<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Current Assets</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,216,963</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,299,822</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Non-current Assets</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">2,633,925</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">2,540,041</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current Liabilities</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,959,919</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,986,340</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Non-current Liabilities</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">76,082</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">73,197</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stockholders&#x2019; Equity</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,814,887</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,780,326</td><td style="text-align: left">&#xa0;</td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#xa0;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">March 31,<br/>
    2021</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">December&#xa0;31,<br/>
    2020</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Current Assets</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">107,682</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">123,958</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Noncurrent Assets</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">395,665</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">412,342</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current Liabilities</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,451,387</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,392,756</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Noncurrent Liabilities</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">28,877</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">38,953</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Shareholders&#x2019; Deficit</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(976,917</td><td style="text-align: left">)</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(895,409</td><td style="text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfCondensedIncomeStatementTableTextBlock', window );">Schedule of statements of operation</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended<br/> March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="6">&#xa0;</td><td>&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Net sales</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">12,239</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">12,110</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Gross profit</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">7,080</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,578</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(220,855</td><td style="text-align: left">)</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(325,652</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share of losses from investments accounted for using the equity method</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(47,791</td><td style="text-align: left">)</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(70,411</td><td style="text-align: left">)</td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Three Months Ended<br/>
    March 31,</b></font></td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2021</b></font></td>
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2020</b></font></td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td colspan="6">&#xa0;</td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 76.98%"><font style="font-size: 10pt">Net sales</font></td>
    <td style="width: 0.98%">&#xa0;</td>
    <td style="width: 1.06%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 8.98%; text-align: right">-</td>
    <td style="width: 0.98%">&#xa0;</td>
    <td style="width: 0.98%">&#xa0;</td>
    <td style="width: 1.06%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 7.98%; text-align: right">-</td>
    <td style="width: 0.98%">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><font style="font-size: 10pt">Gross Profit</font></td>
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td style="text-align: right">-</td>
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td style="text-align: right">-</td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Net loss</font></td>
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(95,395</font></td>
    <td><font style="font-size: 10pt">)</font></td>
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(21,889</font></td>
    <td><font style="font-size: 10pt">)</font></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><font style="font-size: 10pt">Share of loss from investments accounted for using the equity method</font></td>
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td style="text-align: right"><font style="font-size: 10pt">-</font></td>
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td style="text-align: right"><font style="font-size: 10pt">-</font></td>
    <td>&#xa0;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsTextBlock', window );">Schedule of equity investments</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended<br/> March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#xa0;</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#xa0;</td><td style="font-weight: bold">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Share of equity method investee losses</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(47,791</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(70,411</td><td style="width: 1%; text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_LongTermInvestmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_LongTermInvestmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_ScheduleOfExtentInvesteeReliesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of extent the investee relies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_ScheduleOfExtentInvesteeReliesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_ScheduleOfLongTermInvestmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_ScheduleOfLongTermInvestmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_ScheduleOfOwnershipPercentagesOfInvesteeTableTextBlocks">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_ScheduleOfOwnershipPercentagesOfInvesteeTableTextBlocks</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfCondensedBalanceSheetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 3<br> -Paragraph i<br> -Subsection 10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfCondensedBalanceSheetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfCondensedIncomeStatementTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed income statement, including, but not limited to, income statements of consolidated entities and consolidation eliminations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 3<br> -Paragraph i<br> -Subsection 10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfCondensedIncomeStatementTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140266624445048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Bank Loans (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_BankLoansAbstractAbstract', window );"><strong>Bank Loans Abstract [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShortTermDebtTextBlock', window );">Schedule of short-term bank loan</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; white-space: nowrap; text-align: center">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center">&#xa0;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap">March 31,</td><td style="vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center">&#xa0;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap">December&#xa0;31,</td><td style="vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center">&#xa0;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; white-space: nowrap; text-align: center">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap; text-align: center">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap">2021</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap; text-align: center">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap; text-align: center">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap">2020</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap; text-align: center">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Cathay United Bank</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">263,250</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">267,000</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">CTBC Bank</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">702,000</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">712,000</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Cathay Bank</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">650,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">650,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,615,250</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,629,000</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_BankLoansAbstractAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_BankLoansAbstractAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShortTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of short-term debt arrangements (having initial terms of repayment within one year or the normal operating cycle, if longer) including: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShortTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140266622303176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of related party transactions</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; width: 36%"><font style="font-size: 10pt"><b>Name of entity or Individual</b></font></td>
    <td style="vertical-align: bottom; width: 2%">&#xa0;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 62%; text-align: justify"><font style="font-size: 10pt"><b>Relationship with the Company and its subsidiaries</b></font></td></tr>
  <tr>
    <td style="vertical-align: top"><font style="font-size: 10pt">BioFirst Corporation (the &#x201c;BioFirst&#x201d;)</font></td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom; text-align: justify"><font style="font-size: 10pt">Entity controlled by controlling beneficiary shareholder of YuanGene</font></td></tr>
  <tr>
    <td style="vertical-align: top"><font style="font-size: 10pt">BioFirst (Australia) Pty Ltd. (the &#x201c;BioFirst (Australia)&#x201d;)</font></td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom; text-align: justify"><font style="font-size: 10pt">100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene</font></td></tr>
  <tr>
    <td style="vertical-align: top"><font style="font-size: 10pt">Rgene Corporation (the &#x201c;Rgene&#x201d;)</font></td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom; text-align: justify"><font style="font-size: 10pt">Shareholder of the Company; entity controlled by controlling beneficiary shareholder of YuanGene</font></td></tr>
  <tr>
    <td style="vertical-align: top"><font style="font-size: 10pt">YuanGene Corporation (the &#x201c;YuanGene&#x201d;)</font></td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom; text-align: justify"><font style="font-size: 10pt">Controlling beneficiary shareholder of the Company</font></td></tr>
  <tr>
    <td style="vertical-align: top"><font style="font-size: 10pt">AsiaGene Corporation (the &#x201c;AsiaGene&#x201d;)</font></td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom; text-align: justify"><font style="font-size: 10pt">Shareholder; entity controlled by controlling beneficiary shareholder of YuanGene</font></td></tr>
  <tr>
    <td style="vertical-align: top"><font style="font-size: 10pt">Eugene Jiang</font></td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom; text-align: justify"><font style="font-size: 10pt">Former President and Chairman</font></td></tr>
  <tr>
    <td style="vertical-align: top"><font style="font-size: 10pt">Keypoint Technology Ltd. (the &#x201c;Keypoint&#x2019;)</font></td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom; text-align: justify"><font style="font-size: 10pt">The Chairman of Keypoint is Eugene Jiang&#x2019;s mother.</font></td></tr>
  <tr>
    <td style="vertical-align: top"><font style="font-size: 10pt">Lion Arts Promotion Inc. (the &#x201c;Lion Arts&#x201d;)</font></td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom; text-align: justify"><font style="font-size: 10pt">Shareholder of the Company</font></td></tr>
  <tr>
    <td style="vertical-align: top"><font style="font-size: 10pt">Yoshinobu Odaira (the &#x201c;Odaira&#x201d;)</font></td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom; text-align: justify"><font style="font-size: 10pt">Director of the Company</font></td></tr>
  <tr>
    <td style="vertical-align: top"><font style="font-size: 10pt">GenePharm Inc. (the &#x201c;GenePharm&#x201d;)</font></td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom; text-align: justify"><font style="font-size: 10pt">Dr. George Lee, Board Director of Biokey, is the Chairman of GenePharm.</font></td></tr>
  <tr>
    <td style="vertical-align: top"><font style="font-size: 10pt">Euro-Asia Investment &amp; Finance Corp Ltd. (the &#x201c;Euro-Asia&#x201d;)</font></td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom; text-align: justify"><font style="font-size: 10pt">Shareholder of the Company</font></td></tr>
  <tr>
    <td style="vertical-align: top"><font style="font-size: 10pt">LBG USA, Inc. (the &#x201c;LBG USA&#x201d;)</font></td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom; text-align: justify"><font style="font-size: 10pt">100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene</font></td></tr>
  <tr>
    <td style="vertical-align: top"><font style="font-size: 10pt">LionGene Corporation (the &#x201c;LionGene&#x201d;)</font></td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom; text-align: justify"><font style="font-size: 10pt">Shareholder of the Company; Entity controlled by controlling beneficiary shareholder of YuanGene</font></td></tr>
  <tr>
    <td style="vertical-align: top"><font style="font-size: 10pt">Kimho Consultants Co., Ltd. (the &#x201c;Kimho&#x201d;)</font></td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom; text-align: justify"><font style="font-size: 10pt">Shareholder of the Company</font></td></tr>
  <tr>
    <td style="vertical-align: top"><font style="font-size: 10pt"></font></td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom; text-align: justify"><font style="font-size: 10pt">Mr. Tsung-Shann Jiang, the controlling beneficiary shareholder of the Company and Rgene, the Chairman and CEO of the BioLite Holding Inc. and BioLite Inc. and the President and a member of board of directors of BioFirst<br/>
&#xa0;<br/>
Ms. Shu-Ling Jiang, Mr. Tsung-Shann Jiang&#x2019;s wife, is the Chairman of Keypoint; and a member of board of directors of BioLite Inc.<br/>
&#xa0;<br/>
Mr. Eugene Jiang is Mr. and Ms. Jiang&#x2019;s son. Mr. Eugene Jiang is the chairman, and majority shareholder of the Company and a member of board of directors of BioLite Inc.<br/>
&#xa0;<br/>
Mr. Chang-Jen Jiang is Mr. Tsung-Shann Jiang&#x2019;s sibling and the director of the Company.<br/>
&#xa0;<br/>
Ms. Mei-Ling Jiang is Ms. Shu-Ling Jiang&#x2019;s sibling.</font></td></tr>
  <tr>
    <td style="vertical-align: top"><font style="font-size: 10pt">Amkey Ventures, LLC (&#x201c;Amkey&#x201d;)</font></td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom; text-align: justify"><font style="font-size: 10pt">An entity controlled by Dr. George Lee, who serves as one of the board directors of BioKey, Inc</font></td></tr>
  <tr>
    <td style="vertical-align: top"><font style="font-size: 10pt">BioLite Japan</font></td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom; text-align: justify"><font style="font-size: 10pt">Entity controlled by controlling beneficiary shareholder of ABVC</font></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_ScheduleOfAccountReceivableDueFromRelatedPartiesTableTextBlock', window );">Schedule of amount due to related parties</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; text-align: center; white-space: nowrap">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center">&#xa0;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap">March 31,</td><td style="vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center">&#xa0;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap">December 31,</td><td style="vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center">&#xa0;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; text-align: center; white-space: nowrap">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap; text-align: center">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap">2021</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap; text-align: center">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap; text-align: center">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap">2020</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap; text-align: center">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">GenePharm Inc.</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">142,225</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">142,225</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Amkey</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,850</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,210</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; padding-left: 9pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">145,075</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#xa0;</td><td style="font-weight: bold; padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">143,435</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#xa0;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of amount due from related parties</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#xa0;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Rgene</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">43,266</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">42,911</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>AsiaGene</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">4,287</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">4,241</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">BioFirst (Australia)</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">379,110</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">373,235</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">BioHopeKing Corporation</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">121,848</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">123,583</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">LBG USA</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">675</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">675</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">BioLite Japan</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">150,000</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">150,000</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Keypoint</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,610</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,610</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">The Jiangs</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,093</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; padding-left: 9pt">Total</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">702,889</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">696,255</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_ScheduleOfRelatedPartyTransactionsAmountDueToRelatedParty', window );">Schedule of amount due to related parties</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">March&#xa0;31,</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#xa0;31,</td><td style="font-weight: bold">&#xa0;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">BioFirst Corporation</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">23,647</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">23,647</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>AsiaGene</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">24,017</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>YuanGene</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">9,205</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">9,205</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">The Jiangs</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">18,750</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">16,627</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Due to shareholders</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">163,566</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">166,261</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Due to employee</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">72,967</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">72,704</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; padding-left: 9pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">312,152</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#xa0;</td><td style="font-weight: bold; padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">288,445</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#xa0;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_ScheduleOfAccountReceivableDueFromRelatedPartiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_ScheduleOfAccountReceivableDueFromRelatedPartiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_ScheduleOfRelatedPartyTransactionsAmountDueToRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Amount due to related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_ScheduleOfRelatedPartyTransactionsAmountDueToRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140266624482392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtConversionsTextBlock', window );">Schedule of converted amount of debt and shares</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: bottom; text-align: center">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Amount of<br/> Debt<br/> Converted</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Number of<br/> Shares<br/> Issued</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#xa0;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left">Lion Arts Promotion Inc</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">97,864</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">13,981</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">LionGene Corporation</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">428,099</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">61,157</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">BioFirst Corporation</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">2,902,911</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">414,702</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">AsiaGene Corporation</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">160,000</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">22,858</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">YuanGene Corporation</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">92,690</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">13,242</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">The Jiangs</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,190,776</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">170,111</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-bottom: 4pt; padding-left: 0.25in">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">4,872,340</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#xa0;</td><td style="font-weight: bold; padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">696,051</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#xa0;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtConversionsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information on an original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. The information may be presented entirely or partially in this block of text or in the associated elements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtConversionsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140266622194168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Options (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_StockOptionsAbstract', window );"><strong>Stock Options [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of options issued and outstanding</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; text-align: center">&#xa0;</td><td style="vertical-align: bottom; text-align: center">&#xa0;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: center">&#xa0;</td><td style="vertical-align: bottom; text-align: center">&#xa0;</td><td style="vertical-align: bottom; text-align: center">&#xa0;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: center">&#xa0;</td><td style="vertical-align: bottom; text-align: center">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; text-align: center">&#xa0;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Weighted-</td><td style="vertical-align: bottom; font-weight: bold; text-align: center">&#xa0;</td><td style="vertical-align: bottom; text-align: center">&#xa0;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: center">&#xa0;</td><td style="vertical-align: bottom; text-align: center">&#xa0;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; text-align: center">&#xa0;</td><td style="vertical-align: bottom; text-align: center">&#xa0;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: center">&#xa0;</td><td style="vertical-align: bottom; text-align: center">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; text-align: center">&#xa0;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Weighted-</td><td style="vertical-align: bottom; font-weight: bold; text-align: center">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; text-align: center">&#xa0;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Average</td><td style="vertical-align: bottom; font-weight: bold; text-align: center">&#xa0;</td><td style="vertical-align: bottom; text-align: center">&#xa0;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: center">&#xa0;</td><td style="vertical-align: bottom; text-align: center">&#xa0;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; text-align: center">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; text-align: center">&#xa0;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"></td><td style="vertical-align: bottom; font-weight: bold; text-align: center">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; text-align: center">&#xa0;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Average</td><td style="vertical-align: bottom; font-weight: bold; text-align: center">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; text-align: center">&#xa0;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Contractual</td><td style="vertical-align: bottom; font-weight: bold; text-align: center">&#xa0;</td><td style="vertical-align: bottom; text-align: center">&#xa0;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: center">&#xa0;</td><td style="vertical-align: bottom; text-align: center">&#xa0;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; text-align: center">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; text-align: center">&#xa0;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Number&#xa0;of</td><td style="vertical-align: bottom; font-weight: bold; text-align: center">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; text-align: center">&#xa0;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Exercise </td><td style="vertical-align: bottom; font-weight: bold; text-align: center">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; text-align: center">&#xa0;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Life </td><td style="vertical-align: bottom; font-weight: bold; text-align: center">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; text-align: center">&#xa0;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Aggregate</td><td style="vertical-align: bottom; font-weight: bold; text-align: center">&#xa0;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; text-align: center">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Underlying<br/>
Shares</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Price<br/>
Per&#xa0;Share</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Remaining<br/>
in Years</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Intrinsic<br/>
 Value</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding as of January 1, 2020</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<font style="font-size: 10pt">-</font></td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#x202f;</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 52%">Granted</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">545,182</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">2.00</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">9.89</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">616,056</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt; text-align: right">&#xa0;</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt; text-align: right">&#xa0;</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Outstanding as of December 31, 2020</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">545,182</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt; text-align: right">2.00</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt; text-align: right">9.89</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">616,056</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Exercisable as of December 31, 2020</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">545,182</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt; text-align: right">2.00</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt; text-align: right">9.89</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">616,056</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Vested and expected to vest</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">545,182</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">2.00</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt; text-align: right">9.89</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">616,056</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of fair value of stock options granted</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 0pt; vertical-align: bottom; text-align: center">&#xa0;</td><td style="padding-bottom: 0pt; vertical-align: bottom; font-weight: bold; text-align: center">&#xa0;</td>
    <td colspan="2" style="padding-bottom: 0pt; vertical-align: bottom; font-weight: bold; text-align: center">Year ended</td><td style="padding-bottom: 0pt; vertical-align: bottom; font-weight: bold; text-align: center">&#xa0;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; padding-bottom: 0pt; vertical-align: bottom; text-align: center">&#xa0;</td><td style="white-space: nowrap; vertical-align: bottom; font-weight: bold; padding-bottom: 0pt; text-align: center">&#xa0;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; padding-bottom: 0pt; vertical-align: bottom; font-weight: bold; text-align: center">December&#xa0;31,<br/>
2020</td><td style="white-space: nowrap; vertical-align: bottom; padding-bottom: 0pt; font-weight: bold; text-align: center">&#xa0;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 0pt">&#xa0;</td><td style="padding-bottom: 0pt">&#xa0;</td>
    <td colspan="2" style="padding-bottom: 0pt">&#xa0;</td><td style="padding-bottom: 0pt">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 0pt; width: 88%; text-align: left">Risk free interest rate</td><td style="padding-bottom: 0pt; width: 1%">&#xa0;</td>
    <td style="padding-bottom: 0pt; width: 1%; text-align: left">&#xa0;</td><td style="padding-bottom: 0pt; width: 9%; text-align: right">0.38</td><td style="padding-bottom: 0pt; width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 0pt; text-align: left">Expected term (in years)</td><td style="padding-bottom: 0pt">&#xa0;</td>
    <td style="padding-bottom: 0pt; text-align: left">&#xa0;</td><td style="padding-bottom: 0pt; text-align: right">5.00</td><td style="padding-bottom: 0pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 0pt; text-align: left">Dividend yield</td><td style="padding-bottom: 0pt">&#xa0;</td>
    <td style="padding-bottom: 0pt; text-align: left">&#xa0;</td><td style="padding-bottom: 0pt; text-align: right">0</td><td style="padding-bottom: 0pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 0pt; text-align: left">Expected volatility</td><td style="padding-bottom: 0pt">&#xa0;</td>
    <td style="padding-bottom: 0pt; text-align: left">&#xa0;</td><td style="padding-bottom: 0pt; text-align: right">89.01</td><td style="padding-bottom: 0pt; text-align: left">%</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_StockOptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_StockOptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140266624214472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of loss per share</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; text-align: center">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center">&#xa0;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">For the Three Months Ended</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#xa0;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; text-align: center">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">March&#xa0;31,<br/> 2021</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">March&#xa0;31,<br/> 2020</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#xa0;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Numerator:</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: center">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: center">&#xa0;</td><td>&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Net loss attributable to ABVC&#x2019;s common stockholders</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(1,128,505</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(1,247,538</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Denominator:</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Weighted-average shares outstanding:</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Weighted-average shares outstanding - Basic</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">24,420,526</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">19,484,542</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Stock options</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">&#xa0;</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">&#x2013;</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Weighted-average shares outstanding - Diluted</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">24,420,526</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">19,484,542</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Loss per share</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">-Basic</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(0.05</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(0.06</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">-Diluted</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(0.05</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(0.06</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140266624228904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ASU201602TransitionAbstract', window );"><strong>ASU 2016-02 Transition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_ScheduleOfOperatingLeaseArrangementsTableTextBlock', window );">Schedule of operating lease arrangements</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; text-align: center">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">March&#xa0;31, <br/> 2021</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">December&#xa0;31, <br/> 2020</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#xa0;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">ASSETS</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Operating lease right-of-use assets</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,714,740</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,772,747</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold">LIABILITIES</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating lease liabilities (current)</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">331,179</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">316,178</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Operating lease liabilities (noncurrent)</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,383,560</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,456,567</td><td style="text-align: left">&#xa0;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Schedule of supplemental information related to operating leases</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; text-align: center">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center">&#xa0;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Three Months Ended<br/> March 31,</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#xa0;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; text-align: center">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2021</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2020</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Operating lease expenses</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">78,847</p></td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">77,527</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; text-align: center">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center">&#xa0;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Three Months Ended <br/> March&#xa0;31,</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#xa0;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; text-align: center">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2021</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2020</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Cash paid for amounts included in the measurement of operating lease liabilities</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">78,847</p></td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">77,527</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; text-align: center">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">March&#xa0;31, <br/> 2021</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#xa0;</td><td style="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; text-align: center">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">December&#xa0;31, <br/> 2020</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#xa0;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Weighted Average Remaining Lease Term:</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Operating leases</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right"><font style="font-size: 10pt">&#xa0;3.58 years </font></td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right"><font style="font-size: 10pt">&#xa0;3.08 years</font></td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Weighted Average Discount Rate:</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Operating leases</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1.45</td><td style="text-align: left">%</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">0.55</td><td style="text-align: left">%</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of minimum future annual payments under non-cancellable leases</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#xa0;</td>
    <td style="text-align: center">&#xa0;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Operating leases</b></font></td>
    <td style="text-align: center">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 90%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021(excluding three months ended March 31, 2021)</font></td>
    <td style="width: 1%">&#xa0;</td>
    <td style="width: 1%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</font></td>
    <td style="width: 7%; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">253,618</font></td>
    <td style="width: 1%">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</font></td>
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">352,248</font></td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</font></td>
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">359,591</font></td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</font></td>
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">374,584</font></td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</font></td>
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">338,676</font></td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thereafter</font></td>
    <td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">56,916</font></td>
    <td style="padding-bottom: 1.5pt">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total future minimum lease payments, undiscounted</font></td>
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,735,633</font></td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less: Imputed interest</font></td>
    <td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20,893</font></td>
    <td style="padding-bottom: 1.5pt">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Present value of future minimum lease payments</font></td>
    <td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</font></td>
    <td style="border-bottom: Black 4pt double; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,714,740</font></td>
    <td style="padding-bottom: 4pt">&#xa0;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_ScheduleOfOperatingLeaseArrangementsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of operating lease arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_ScheduleOfOperatingLeaseArrangementsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ASU201602TransitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ASU201602TransitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140266624442456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combination (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of assets acquired and liabilities assumed based on fair value</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>Purchase consideration:</td><td>&#xa0;</td>
    <td colspan="2">&#xa0;</td><td>&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Common Stock (*)</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">44,341,847</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Allocation of the purchase price:</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash and cash equivalents</td><td>&#xa0;</td>
    <td style="text-align: left">$</td><td style="text-align: right">531,147</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accounts receivable, net</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">188,550</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Property and equipment, net</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">56,075</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Operating lease right-of-use assets</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">485,684</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Security deposits</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,440</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Total assets acquired</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,271,896</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accounts payable</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(56,204</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accrued expenses and other current liabilities</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(251,335</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating lease liability</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(267,256</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Tenant security deposit</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,880</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total liabilities assumed</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(577,675</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Total net assets acquired</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">694,221</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Goodwill as a result of the Merger</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">43,647,626</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px">&#xa0;</td>
    <td style="width: 24px"><font style="font-size: 10pt">*</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">29,561,231 shares (1,642,291 after stock reverse split) of common stock of the Company was issued to BioKey in connection with the Merger. Those shares were valued at $1.50 per share, based on the bid-and-ask share price of common stock of the Company on the final day of trading, February 8, 2019.</font></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140266616302648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Description of Business (Details) - shares<br></strong></div></th>
<th class="th"><div>Feb. 08, 2019</div></th>
<th class="th"><div>Feb. 08, 2016</div></th>
<th class="th"><div>Feb. 08, 2016</div></th>
<th class="th"><div>Aug. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_OrganizationandDescriptionofBusinessDetailsLineItems', window );"><strong>Organization and Description of Business (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_PercentageOfCommonSharesIssuedAndOutstanding', window );">Percentage of common shares issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abvcd_ShareExchangeAgreementMember', window );">Share Exchange Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_OrganizationandDescriptionofBusinessDetailsLineItems', window );"><strong>Organization and Description of Business (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_CommonStockIssuedAfterStockSplit', window );">Common stock issued post-stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,387,376<span></span>
</td>
<td class="nump">164,387,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_CommonStockIssuedBeforeStockSplit', window );">Common stock issued pre-stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,336,000<span></span>
</td>
<td class="nump">52,336,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abvcd_ShareExchangeAgreementOneMember', window );">Share Exchange Agreement One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_OrganizationandDescriptionofBusinessDetailsLineItems', window );"><strong>Organization and Description of Business (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_CommonStockIssuedAfterStockSplit', window );">Common stock issued post-stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,273,921<span></span>
</td>
<td class="nump">166,273,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_CommonStockIssuedBeforeStockSplit', window );">Common stock issued pre-stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,936,583<span></span>
</td>
<td class="nump">52,936,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abvcd_ShareExchangeAgreementTwoMember', window );">Share Exchange Agreement Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_OrganizationandDescriptionofBusinessDetailsLineItems', window );"><strong>Organization and Description of Business (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_CommonStockIssuedAfterStockSplit', window );">Common stock issued post-stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">163,159,952<span></span>
</td>
<td class="nump">163,159,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_CommonStockIssuedBeforeStockSplit', window );">Common stock issued pre-stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,945,225<span></span>
</td>
<td class="nump">51,945,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_PercentageOfCommonSharesIssuedAndOutstanding', window );">Percentage of common shares issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79.70%<span></span>
</td>
<td class="nump">79.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_PercentageOfIssuedShareCapital', window );">Percentage of issued share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abvcd_ShareExchangeAgreementThreeMember', window );">Share Exchange Agreement Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_OrganizationandDescriptionofBusinessDetailsLineItems', window );"><strong>Organization and Description of Business (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_CommonStockIssuedAfterStockSplit', window );">Common stock issued post-stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,273,921<span></span>
</td>
<td class="nump">166,273,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_CommonStockIssuedBeforeStockSplit', window );">Common stock issued pre-stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,936<span></span>
</td>
<td class="nump">52,936,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abvcd_ShareExchangeAgreementFourMember', window );">Share Exchange Agreement Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_OrganizationandDescriptionofBusinessDetailsLineItems', window );"><strong>Organization and Description of Business (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_CommonStockIssuedAfterStockSplit', window );">Common stock issued post-stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">205,519,223<span></span>
</td>
<td class="nump">205,519,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_CommonStockIssuedBeforeStockSplit', window );">Common stock issued pre-stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,431,144<span></span>
</td>
<td class="nump">65,431,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abvcd_MergerAgreementMember', window );">Merger Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_OrganizationandDescriptionofBusinessDetailsLineItems', window );"><strong>Organization and Description of Business (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_CommonStockIssuedBeforeStockSplit', window );">Common stock issued pre-stock split</a></td>
<td class="nump">104,558,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_CommonStockIssuedAfterStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock issued after stock split.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_CommonStockIssuedAfterStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_CommonStockIssuedBeforeStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock issued before stock split.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_CommonStockIssuedBeforeStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_OrganizationandDescriptionofBusinessDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_OrganizationandDescriptionofBusinessDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_PercentageOfCommonSharesIssuedAndOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of common shares issued and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_PercentageOfCommonSharesIssuedAndOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_PercentageOfIssuedShareCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of issued share capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_PercentageOfIssuedShareCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abvcd_ShareExchangeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abvcd_ShareExchangeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abvcd_ShareExchangeAgreementOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abvcd_ShareExchangeAgreementOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abvcd_ShareExchangeAgreementTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abvcd_ShareExchangeAgreementTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abvcd_ShareExchangeAgreementThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abvcd_ShareExchangeAgreementThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abvcd_ShareExchangeAgreementFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abvcd_ShareExchangeAgreementFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abvcd_MergerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abvcd_MergerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140266621290536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 2,615,073<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,273,208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash equivalents</a></td>
<td class="nump">718,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 728,163<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_MarketableSecuritiesRealizedGainLossOtherThanTemporaryImpairmentsAmounts', window );">Impairments of equity investments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_PercentageOfMonthlyContribution', window );">Percentage of monthly contribution</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash', window );">Employee benefits amount</a></td>
<td class="nump">$ 2,503<span></span>
</td>
<td class="nump">3,598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Employee stock-based compensation expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_StockBasedCompensationForNonemployees', window );">Non-employee stock-based compensation expenses</a></td>
<td class="nump">$ 225,740<span></span>
</td>
<td class="nump">$ 525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_MarketableSecuritiesRealizedGainLossOtherThanTemporaryImpairmentsAmounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of loss recognized for other than temporary impairments (OTTI) of investments in debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_MarketableSecuritiesRealizedGainLossOtherThanTemporaryImpairmentsAmounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_PercentageOfMonthlyContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of monthly contribution.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_PercentageOfMonthlyContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_StockBasedCompensationForNonemployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock based compensation for nonemployees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_StockBasedCompensationForNonemployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for employee benefit and equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense (reversal of expense) for employee benefits and share-based payment arrangement. Includes, but is not limited to, pension, other postretirement, postemployment and termination benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140266619717144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - Schedule of property and equipment<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=abvcd_BuildingsAndLeaseholdImprovementsMember', window );">Buildings and leasehold improvements [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of property and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Estimated Life</a></td>
<td class="text">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=abvcd_BuildingsAndLeaseholdImprovementsMember', window );">Buildings and leasehold improvements [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of property and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Estimated Life</a></td>
<td class="text">50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of property and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Estimated Life</a></td>
<td class="text">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of property and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Estimated Life</a></td>
<td class="text">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of property and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Estimated Life</a></td>
<td class="text">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of property and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Estimated Life</a></td>
<td class="text">6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68071081&amp;loc=d3e1205-110223<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=abvcd_BuildingsAndLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=abvcd_BuildingsAndLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140266616256232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Agreements (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="7">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 15, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 24, 2018</div></th>
<th class="th">
<div>Sep. 25, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 26, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 27, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2016 </div>
<div>TWD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 05, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_CollaborativeAgreementsDetailsLineItems', window );"><strong>Collaborative Agreements (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_MilestonePaymentsRoyaltyPercentage', window );">Milestone payments royalty percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,751,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,751,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_CoDevAgreementDescription', window );">Co-Dev agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company received the remaining balance of $2,550,000 in the form of newly issued shares of Rgene&#x2019;s Common Stock, at the price of NT$50 (approximately equivalent to $1.60 per share), for an aggregate number of 1,530,000 shares, which accounted for equity method long-term investment as of December 31, 2018. During the year ended December 31, 2018, the Company has recognized investment loss of $549.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abvcd_BHKCoDevelopmentAgreementMember', window );">BHK Co-Development Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_CollaborativeAgreementsDetailsLineItems', window );"><strong>Collaborative Agreements (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_MilestonePayments', window );">Milestone payments to BioLite in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,649,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement', window );">Description of payment settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#x25cf; Upon the signing of the BHK Co-Development Agreement: $1 million, or 10% of total payment &#x25cf; Upon the first Investigational New Drug (IND) submission and BioLite Taiwan will deliver all data to BHK according to FDA Reviewing requirement: $1 million, or 10% of total payment &#x25cf; At the completion of first phase II clinical trial: $1 million, or 10% of total payment &#x25cf; At the initiation of phase III of clinical trial research: $3 million, or 30% of total payment &#x25cf; Upon the New Drug Application (NDA) submission: $4 million, or 40% of total payment<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_UpfrontCashPayment', window );">Upfront cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_PercentageOfPaymentsUnderCodevelopmentAgreement', window );">Percentage of payments under co-development agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_IssuanceOfStockValue', window );">Common stock newly issued, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_CollaborativeAgreementsDescription', window );">Collaborative agreements, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In addition to the total of NT$50 million, approximately equivalent to $1.60 million, BioLite Taiwan is entitled to receive 50% of the future net licensing income or net sales profit. As of March 31, 2021 and December 31, 2020, the Company has not earned the royalty under the BHK Collaborative Agreements.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In 2015, the Company recognized the cash receipt in a total of NT$50 million, approximately equivalent to $1.6 million, as collaboration revenue when all research, technical, and development data was delivered to BHK.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abvcd_CodevelopmentagreementMember', window );">Co-Dev Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_CollaborativeAgreementsDetailsLineItems', window );"><strong>Collaborative Agreements (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_PercentageOfPaymentsUnderCodevelopmentAgreement', window );">Percentage of payments under co-development agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForParticipationLiabilities', window );">Company cash payments</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_AdditionCashPayment', window );">Addition cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent', window );">Amount received from BriVision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_CollaborativeAgreementsDetailsLineItems', window );"><strong>Collaborative Agreements (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_PercentageOfPaymentsUnderCodevelopmentAgreement', window );">Percentage of payments under co-development agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_IssuanceOfStockValue', window );">Common stock newly issued, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForParticipationLiabilities', window );">Company cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Licensing rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abvcd_BioFirstStockPurchaseAgreementMember', window );">BioFirst Stock Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_CollaborativeAgreementsDetailsLineItems', window );"><strong>Collaborative Agreements (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent', window );">Amount received from BriVision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,902,911<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">414,702<span></span>
</td>
<td class="nump">428,571<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_AdditionCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_AdditionCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_CoDevAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Co-Dev agreement description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_CoDevAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_CollaborativeAgreementsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreements, description</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_CollaborativeAgreementsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_CollaborativeAgreementsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_CollaborativeAgreementsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_IssuanceOfStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_IssuanceOfStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_MilestonePaymentsRoyaltyPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments royalty percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_MilestonePaymentsRoyaltyPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_PercentageOfPaymentsUnderCodevelopmentAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of payments under co-development agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_PercentageOfPaymentsUnderCodevelopmentAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_UpfrontCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of upfront payments which are paid during the term of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_UpfrontCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount payable to related parties classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForParticipationLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash payments related to participation costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473203&amp;loc=d3e55336-107963<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForParticipationLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the terms and manner of settlement of the related party transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abvcd_BHKCoDevelopmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abvcd_BHKCoDevelopmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abvcd_CodevelopmentagreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abvcd_CodevelopmentagreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abvcd_BioFirstStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abvcd_BioFirstStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140266622736504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory (Details) - Schedule of inventory - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_ScheduleOfInventoryAbstract', window );"><strong>Schedule of inventory [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">$ 99,549<span></span>
</td>
<td class="nump">$ 100,967<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work-in-process</a></td>
<td class="nump">21,729<span></span>
</td>
<td class="nump">22,038<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">60,851<span></span>
</td>
<td class="nump">61,718<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_AllowanceForInventoryValuationAndObsolescenceLoss', window );">Allowance for inventory valuation and obsolescence loss</a></td>
<td class="num">(182,129)<span></span>
</td>
<td class="num">(184,723)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_AllowanceForInventoryValuationAndObsolescenceLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Allowance for inventory valuation and obsolescence loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_AllowanceForInventoryValuationAndObsolescenceLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_ScheduleOfInventoryAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_ScheduleOfInventoryAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140266625267416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expenses</a></td>
<td class="nump">$ 2,928<span></span>
</td>
<td class="nump">$ 11,174<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140266619732328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment (Details) - Schedule of property and equipment - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 3,801,863<span></span>
</td>
<td class="nump">$ 3,813,522<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(3,296,911)<span></span>
</td>
<td class="num">(3,298,688)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">504,952<span></span>
</td>
<td class="nump">514,834<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">390,088<span></span>
</td>
<td class="nump">395,645<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=abvcd_BuildingsAndLeaseholdImprovementsMember', window );">Buildings and leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">2,231,712<span></span>
</td>
<td class="nump">2,233,573<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">992,882<span></span>
</td>
<td class="nump">994,544<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 187,181<span></span>
</td>
<td class="nump">$ 189,760<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=abvcd_BuildingsAndLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=abvcd_BuildingsAndLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140266625010184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Investments (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_LongTermInvestmentsDetailsLineItems', window );"><strong>Long-Term Investments (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements', window );">Purchase additional shares (in Shares)</a></td>
<td class="nump">132,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_AggregateAmount', window );">Aggregate amount (in Dollars)</a></td>
<td class="nump">$ 281,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvcd_BioFirstCorporationMember', window );">BioFirst [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_LongTermInvestmentsDetailsLineItems', window );"><strong>Long-Term Investments (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Percentage of common stock shares</a></td>
<td class="nump">15.99%<span></span>
</td>
<td class="nump">15.99%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockDescriptionOfTransaction', window );">Sale of common stock, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company sold 218,000 shares of common stock of BioHopeKing Corporation at price of NT$24, equivalent $0.85, to several individuals, and the percentage of ownership decreased to 5.90% as of December 31, 2020. As a result of the transactions, the Company recognized investment loss of $40,589 and impairment loss of $961,217 for the same period.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvcd_RgeneCorporationMember', window );">Rgene [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_LongTermInvestmentsDetailsLineItems', window );"><strong>Long-Term Investments (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Percentage of common stock shares</a></td>
<td class="nump">31.62%<span></span>
</td>
<td class="nump">31.62%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_AggregateAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income taxes from which a reporting entity is exempt or for which it will receive a reduction in income taxes as a result of the income tax holiday granted by the taxing jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_AggregateAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_LongTermInvestmentsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_LongTermInvestmentsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of equity unit purchase agreements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1757-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1707-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockDescriptionOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569655-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockDescriptionOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvcd_BioFirstCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvcd_BioFirstCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvcd_RgeneCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvcd_RgeneCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140266616235928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Investments (Details) - Schedule of ownership percentages of investee<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvcd_BraingenesisBiotechnologyCoLtdMember', window );">Braingenesis Biotechnology Co., Ltd. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeLineItems', window );"><strong>Long-Term Investments (Details) - Schedule of ownership percentages of investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">0.17%<span></span>
</td>
<td class="nump">0.17%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_AccountingTreatmentDescription', window );">Accounting treatments</a></td>
<td class="text">Cost Method<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvcd_GenepharmBiotechCorporationMember', window );">Genepharm Biotech Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeLineItems', window );"><strong>Long-Term Investments (Details) - Schedule of ownership percentages of investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_AccountingTreatmentDescription', window );">Accounting treatments</a></td>
<td class="text">Cost Method<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvcd_BioHopeKingCorporationMember', window );">BioHopeKing Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeLineItems', window );"><strong>Long-Term Investments (Details) - Schedule of ownership percentages of investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">5.90%<span></span>
</td>
<td class="nump">5.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_AccountingTreatmentDescription', window );">Accounting treatments</a></td>
<td class="text">Cost Method<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvcd_BioFirstCorporationMember', window );">BioFirst Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeLineItems', window );"><strong>Long-Term Investments (Details) - Schedule of ownership percentages of investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">15.99%<span></span>
</td>
<td class="nump">15.99%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_AccountingTreatmentDescription', window );">Accounting treatments</a></td>
<td class="text">Equity Method<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvcd_RgeneCorporationMember', window );">Rgene Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeLineItems', window );"><strong>Long-Term Investments (Details) - Schedule of ownership percentages of investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">31.62%<span></span>
</td>
<td class="nump">31.62%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_AccountingTreatmentDescription', window );">Accounting treatments</a></td>
<td class="text">Equity Method<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_AccountingTreatmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_AccountingTreatmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvcd_BraingenesisBiotechnologyCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvcd_BraingenesisBiotechnologyCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvcd_GenepharmBiotechCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvcd_GenepharmBiotechCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvcd_BioHopeKingCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvcd_BioHopeKingCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvcd_BioFirstCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvcd_BioFirstCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvcd_RgeneCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvcd_RgeneCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140266619734232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Investments (Details) - Schedule of extent the investee relies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvcd_BraingenesisBiotechnologyCoLtdMember', window );">Braingenesis Biotechnology Co., Ltd. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesLineItems', window );"><strong>Long-Term Investments (Details) - Schedule of extent the investee relies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_RelatedPartyTransactionDescriptionOfTransactions', window );">Relationship with the Company and its subsidiaries, description</a></td>
<td class="text">No specific business relationship<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvcd_GenepharmBiotechCorporationMember', window );">Genepharm Biotech Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesLineItems', window );"><strong>Long-Term Investments (Details) - Schedule of extent the investee relies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_RelatedPartyTransactionDescriptionOfTransactions', window );">Relationship with the Company and its subsidiaries, description</a></td>
<td class="text">No specific business relationship<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvcd_BioHopeKingCorporationMember', window );">BioHopeKing Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesLineItems', window );"><strong>Long-Term Investments (Details) - Schedule of extent the investee relies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_RelatedPartyTransactionDescriptionOfTransactions', window );">Relationship with the Company and its subsidiaries, description</a></td>
<td class="text">Collaborating with the Company to develop and commercialize drugs<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvcd_BioFirstCorporationMember', window );">BioFirst Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesLineItems', window );"><strong>Long-Term Investments (Details) - Schedule of extent the investee relies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_RelatedPartyTransactionDescriptionOfTransactions', window );">Relationship with the Company and its subsidiaries, description</a></td>
<td class="text">Loaned from the investee and provides research and development support service<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvcd_RgeneCorporationMember', window );">Rgene Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesLineItems', window );"><strong>Long-Term Investments (Details) - Schedule of extent the investee relies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_RelatedPartyTransactionDescriptionOfTransactions', window );">Relationship with the Company and its subsidiaries, description</a></td>
<td class="text">Collaborating with the Company to develop and commercialize drugs<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_RelatedPartyTransactionDescriptionOfTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents related party descriptions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_RelatedPartyTransactionDescriptionOfTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvcd_BraingenesisBiotechnologyCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvcd_BraingenesisBiotechnologyCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvcd_GenepharmBiotechCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvcd_GenepharmBiotechCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvcd_BioHopeKingCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvcd_BioHopeKingCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvcd_BioFirstCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvcd_BioFirstCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvcd_RgeneCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvcd_RgeneCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140266622400120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-Term Investments (Details) - Schedule of long-term investment - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_NonMarketableCostMethodInvestmentsNetAbstract', window );"><strong>Non-marketable Cost Method Investments, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_NonmarketableCostMethodInvestmentsNet', window );">Sub total</a></td>
<td class="nump">$ 909,436<span></span>
</td>
<td class="nump">$ 922,391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_EquityMethodInvestmentsNetAbstract', window );"><strong>Equity Method Investments, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Total</a></td>
<td class="nump">1,126,884<span></span>
</td>
<td class="nump">1,190,727<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvcd_BraingenesisBiotechnologyCoLtdMember', window );">Braingenesis Biotechnology Co., Ltd. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_NonMarketableCostMethodInvestmentsNetAbstract', window );"><strong>Non-marketable Cost Method Investments, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_NonmarketableCostMethodInvestmentsNet', window );">Sub total</a></td>
<td class="nump">7,742<span></span>
</td>
<td class="nump">7,853<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvcd_GenepharmBiotechCorporationMember', window );">Genepharm Biotech Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_NonMarketableCostMethodInvestmentsNetAbstract', window );"><strong>Non-marketable Cost Method Investments, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_NonmarketableCostMethodInvestmentsNet', window );">Sub total</a></td>
<td class="nump">23,638<span></span>
</td>
<td class="nump">23,974<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvcd_BioHopeKingCorporationMember', window );">BioHopeKing Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_NonMarketableCostMethodInvestmentsNetAbstract', window );"><strong>Non-marketable Cost Method Investments, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_NonmarketableCostMethodInvestmentsNet', window );">Sub total</a></td>
<td class="nump">878,056<span></span>
</td>
<td class="nump">890,564<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvcd_BioFirstCorporationMember', window );">BioFirst Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_EquityMethodInvestmentsNetAbstract', window );"><strong>Equity Method Investments, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Total</a></td>
<td class="nump">217,448<span></span>
</td>
<td class="nump">268,336<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvcd_RgeneCorporationMember', window );">Rgene Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_EquityMethodInvestmentsNetAbstract', window );"><strong>Equity Method Investments, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_EquityMethodInvestmentsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_EquityMethodInvestmentsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_NonMarketableCostMethodInvestmentsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_NonMarketableCostMethodInvestmentsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_NonmarketableCostMethodInvestmentsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_NonmarketableCostMethodInvestmentsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvcd_BraingenesisBiotechnologyCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvcd_BraingenesisBiotechnologyCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvcd_GenepharmBiotechCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvcd_GenepharmBiotechCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvcd_BioHopeKingCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvcd_BioHopeKingCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvcd_BioFirstCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvcd_BioFirstCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvcd_RgeneCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvcd_RgeneCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140266625199768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-Term Investments (Details) - Schedule of balance sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvcd_BioFirstMember', window );">BioFirst [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedBalanceSheetStatementsCaptionsLineItems', window );"><strong>Condensed Balance Sheet Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Current Assets</a></td>
<td class="nump">$ 1,216,963<span></span>
</td>
<td class="nump">$ 1,299,822<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Non-current Assets</a></td>
<td class="nump">2,633,925<span></span>
</td>
<td class="nump">2,540,041<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current Liabilities</a></td>
<td class="nump">1,959,919<span></span>
</td>
<td class="nump">1,986,340<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Non-current Liabilities</a></td>
<td class="nump">76,082<span></span>
</td>
<td class="nump">73,197<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders&#8217; Equity</a></td>
<td class="nump">1,814,887<span></span>
</td>
<td class="nump">1,780,326<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvcd_RgeneMember', window );">Rgene [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedBalanceSheetStatementsCaptionsLineItems', window );"><strong>Condensed Balance Sheet Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Current Assets</a></td>
<td class="nump">107,682<span></span>
</td>
<td class="nump">123,958<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Non-current Assets</a></td>
<td class="nump">395,665<span></span>
</td>
<td class="nump">412,342<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current Liabilities</a></td>
<td class="nump">1,451,387<span></span>
</td>
<td class="nump">1,392,756<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Non-current Liabilities</a></td>
<td class="nump">28,877<span></span>
</td>
<td class="nump">38,953<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders&#8217; Equity</a></td>
<td class="num">$ (976,917)<span></span>
</td>
<td class="num">$ (895,409)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedBalanceSheetStatementsCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedBalanceSheetStatementsCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvcd_BioFirstMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvcd_BioFirstMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvcd_RgeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvcd_RgeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140266616213880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Investments (Details) - Schedule of statements of operation - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvcd_BioFirstMember', window );">BioFirst [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedIncomeStatementsCaptionsLineItems', window );"><strong>Condensed Income Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net sales</a></td>
<td class="nump">$ 12,239<span></span>
</td>
<td class="nump">$ 12,110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">7,080<span></span>
</td>
<td class="nump">1,578<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_LongTermInvestmentNetLoss', window );">Net loss</a></td>
<td class="num">(220,855)<span></span>
</td>
<td class="num">(325,652)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Share of losses from investments accounted for using the equity method</a></td>
<td class="num">(47,791)<span></span>
</td>
<td class="num">(70,411)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvcd_RgeneMember', window );">Rgene [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedIncomeStatementsCaptionsLineItems', window );"><strong>Condensed Income Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net sales</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_LongTermInvestmentNetLoss', window );">Net loss</a></td>
<td class="num">(95,395)<span></span>
</td>
<td class="num">(21,889)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Share of losses from investments accounted for using the equity method</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_LongTermInvestmentNetLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_LongTermInvestmentNetLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedIncomeStatementsCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedIncomeStatementsCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27405-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvcd_BioFirstMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvcd_BioFirstMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvcd_RgeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvcd_RgeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140266618850312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Investments (Details) - Schedule of equity investments - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_ScheduleOfEquityInvestmentsAbstract', window );"><strong>Schedule of equity investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_ShareOfEquityMethodInvesteeLosses', window );">Share of equity method investee losses</a></td>
<td class="num">$ (47,791)<span></span>
</td>
<td class="num">$ (70,411)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_ScheduleOfEquityInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_ScheduleOfEquityInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_ShareOfEquityMethodInvesteeLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_ShareOfEquityMethodInvesteeLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140266616587304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes Payable (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="9">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 23, 2020</div></th>
<th class="th"><div>Oct. 29, 2019</div></th>
<th class="th"><div>Sep. 04, 2019</div></th>
<th class="th"><div>Aug. 28, 2019</div></th>
<th class="th"><div>Jul. 10, 2019</div></th>
<th class="th"><div>Aug. 25, 2018</div></th>
<th class="th"><div>Jun. 27, 2018</div></th>
<th class="th"><div>May 30, 2018</div></th>
<th class="th"><div>May 09, 2018</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=abvcd_UnsecuredConvertiblePromissoryNoteMember', window );">Unsecured convertible promissory note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_ConvertibleNotesPayableDetailsLineItems', window );"><strong>Convertible Notes Payable (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="nump">$ 257,500<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireNotesReceivable', window );">Convertible promissory note received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="nump">$ 257,500<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="nump">$ 160,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Bears interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockDescriptionOfTransaction', window );">Equity offering, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The KSL Note bears interest at 20% per annum. The Company shall pay to KSL an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the KSL Note, which is on May 29, 2020 and July 9, 2020.<span></span>
</td>
<td class="text">In the event that the Company raises gross proceeds from the sale of its common stock of at least $5,000,000 (an &#x201c;Equity Offering&#x201d;) then within five days of the closing for such offering, the Company must repay the outstanding amount of this Yu and Wei Note.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockDescription', window );">Conversion price, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(i) $.50 per share (the &#x201c;Fixed Conversion Price&#x201d;), subject to adjustment, or (ii) 70% of the per share offering price (the &#x201c;Alternative Conversion Price&#x201d;) of the completed public equity offering of the Company in an amount exceeding $10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the &#x201c;Public Offering&#x201d;), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the Lee Note. As of March 31, 2021, the Company paid off the convertible promissory note of $311,233, including principal and accrued and unpaid interest expense.<span></span>
</td>
<td class="text">(i) $.50 per share (the &#x201c;Fixed Conversion Price&#x201d;), subject to adjustment, or (ii) 70% of the per share offering price (the &#x201c;Alternative Conversion Price&#x201d;) of the completed public equity offering of the Company in an amount exceeding $10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the &#x201c;Public Offering&#x201d;), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the C.L.L. Note. On April 20, 2020, the Company entered into an exchange agreement with C.L.L.. The aggregate principal amount plus accrued interest expenses were $289,974, and the Company agreed to issue to the Holders an aggregate of 162,908 shares of the Company&#x2019;s common stock, and warrants to purchase 162,908 shares of common stock. As of March 31, 2021, these common shares have been issued.<span></span>
</td>
<td class="text">(i) $.50 per share (the &#x201c;Fixed Conversion Price&#x201d;), subject to adjustment, or (ii) 70% of the per share offering price (the &#x201c;Alternative Conversion Price&#x201d;) of the completed public equity offering of the Company in an amount exceeding $10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the &#x201c;Public Offering&#x201d;), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the KLS Note. On April 20, 2020, the Company entered into an exchange agreement with KLS. The aggregate principal amount plus accrued interest expenses were $225,222, and the Company agreed to issue to the Holders an aggregate of 126,530 shares of the Company&#x2019;s common stock, and warrants to purchase 126,530 shares of common stock. As of March 31, 2021, these common shares have been issued.<span></span>
</td>
<td class="text">(i) $.50 per share (the &#x201c;Fixed Conversion Price&#x201d;), subject to adjustment, or (ii) 70% of the per share offering price (the &#x201c;Alternative Conversion Price&#x201d;) of the completed public equity offering of the Company in an amount exceeding $10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the &#x201c;Public Offering&#x201d;), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the NEA Note. As of March 31, 2021, the Company paid off the convertible promissory note of $306,667, including principal and accrued and unpaid interest expense.<span></span>
</td>
<td class="text">In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the Odaira Note. On January 21, 2020, Odaira entered into a new agreement that the new Note bears interest at 20% per annum. The Company shall pay to the Odaira an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the new &#x201c;Odaira&#x201d; Note, which is on January 20, 2021. On April 5, 2020, the Company entered into an exchange agreement with &#x201c;Odaira&#x201d;. The aggregate principal amount plus accrued interest expenses were $284,036, and the Company agreed to issue to the Holders an aggregate of 154,368 shares of the Company&#x2019;s common stock, and warrants to purchase 154,368 shares of the Company&#x2019;s common stock. As of March 31, 2021, these common shares have been issued.<span></span>
</td>
<td class="text">In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the Keypoint Note. On January 21, 2020, Keypoint entered into a new agreement that the new Note bears interest at 20% per annum. The Company shall pay to the Keypoint an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the new &#x201c;Keypoint&#x201d; Note, which is on January 20, 2021. On April 5, 2020, the Company entered into an exchange agreement with &#x201c;Keypoint&#x201d;. The aggregate principal amount plus accrued interest expenses were $292,826, and the Company agreed to issue to the Holders an aggregate of 159,145 shares of the Company&#x2019;s common stock, and warrants to purchase 159,145 shares of the Company&#x2019;s common stock. As of March 31, 2021, these common shares have been issued.<span></span>
</td>
<td class="text">In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of the embedded beneficial conversion feature present in the KSL Note. On May 13, 2020, the Company received an acknowledgement letter from KSL that they will not claim the repayment of loan for 12 months. On November 9, 2020, the Company entered into an agreement with &#x201c;KSL&#x201d;. The aggregate principal amount plus accrued interest expenses are $270,272, and KSL agreed to use the full amount to purchase certain securities pursuant to a securities purchase agreement; KSL agreed to purchase and the Company agreed to issue 120,121 shares of the Company&#x2019;s common stock and warrants for a purchase price of $270,272. As of March 31, 2021, the Company issued to the Holders an aggregate of 120,121 shares of the Company&#x2019;s common stock.<span></span>
</td>
<td class="text">(i) $2.00 per share (the &#x201c;Fixed Conversion Price&#x201d;), subject to adjustment or (ii) 80% of the per share offering price (the &#x201c;Alternative Conversion Price&#x201d;) of any completed equity offering of the Company in an amount exceeding $500,000 that occurs when any part of the Yu and Wei Note is outstanding, subject to adjustments set forth in the Yu and Wei Note. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the Yu and Wei Note. On January 21, 2020, Yu and Wei entered into a new agreement that the new Note bears interest at 20% per annum. The Company shall pay to the Yu and Wei an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the new &#x201c;Yu and Wei&#x201d; Note, which is on January 20, 2021. On April 5, 2020, the Company entered into an exchange agreement with &#x201c;Yu and Wei&#x201d;. The aggregate principal amount plus accrued interest expenses were $354,722, and the Company agreed to issue to the Holders an aggregate of 192,784 shares of the Company&#x2019;s common stock, and warrants to purchase 192,784 shares of the Company&#x2019;s common stock. As of March 31, 2021, these common shares have been issued.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible debenture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="nump">$ 2,750,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseAccruedInterest', window );">Accrued convertible interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,215<span></span>
</td>
<td class="nump">104,551<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_TotalInterestExpenses', window );">Total interest expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66,897<span></span>
</td>
<td class="nump">$ 95,214<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=abvcd_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_ConvertibleNotesPayableDetailsLineItems', window );"><strong>Convertible Notes Payable (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockDescription', window );">Conversion price, description</a></td>
<td class="text">Pursuant to the October SPA, the Company sold and issued a convertible promissory note (the &#x201c;October Note&#x201d;) in the principal amount of $2,500,000 to the investor and received the payment from such investor on October 30, 2020. The October Note was issued on October 23, 2020 and the maturity date of the October Note is the twenty-four (24) month anniversary from the issuance date (the &#x201c;Maturity Date&#x201d;). Upon the Maturity Date, the Company shall pay to the holder, in cash, an amount representing all outstanding principal amount and accrued and unpaid interest under the October Note. The October Note bears an interest rate of ten percent (10%) per annum and may be convertible into shares of the Company&#x2019;s common stock at a fixed conversion price of $2.25 per share.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_ConvertibleNotesPayableDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_ConvertibleNotesPayableDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_TotalInterestExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total interest expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_TotalInterestExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique description of a noncash or part noncash stock conversion. The description would be expected to include sufficient information to provide an understanding of the nature and purpose of the conversion. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIncreaseAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase for accrued, but unpaid interest on the debt instrument for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIncreaseAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireNotesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire an agreement for an unconditional promise by the maker to pay the entity (holder) a definite sum of money at a future date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireNotesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockDescriptionOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569655-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockDescriptionOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=abvcd_UnsecuredConvertiblePromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=abvcd_UnsecuredConvertiblePromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=abvcd_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=abvcd_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140266614327016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Bank Loans (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="7">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 15, 2021</div></th>
<th class="th"><div>Dec. 03, 2020</div></th>
<th class="th"><div>Sep. 06, 2020</div></th>
<th class="th"><div>Sep. 06, 2019</div></th>
<th class="th"><div>Jan. 08, 2019</div></th>
<th class="th"><div>Oct. 01, 2018</div></th>
<th class="th"><div>Sep. 06, 2017</div></th>
<th class="th"><div>Jun. 12, 2017</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Jul. 17, 2020</div></th>
<th class="th"><div>Jan. 19, 2020</div></th>
<th class="th"><div>Jul. 18, 2019</div></th>
<th class="th"><div>Jan. 21, 2019</div></th>
<th class="th"><div>Jun. 19, 2017</div></th>
<th class="th"><div>Jun. 28, 2016</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Feb. 07, 2021</div></th>
<th class="th"><div>Jan. 29, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Oct. 03, 2020</div></th>
<th class="th"><div>Apr. 08, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_BankLoansDetailsLineItems', window );"><strong>Bank Loans (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104,167<span></span>
</td>
<td class="nump">$ 132,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 17,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Bears interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansPayable', window );">Outstanding loan balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 236,498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 124,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=abvcd_CathayUnitedLoanAgreementMember', window );">Cathay United Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_BankLoansDetailsLineItems', window );"><strong>Bank Loans (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 263,250<span></span>
</td>
<td class="nump">$ 263,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 263,250<span></span>
</td>
<td class="nump">$ 263,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 263,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 28,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Bears interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndDebtExpense', window );">Interest expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,383<span></span>
</td>
<td class="nump">$ 1,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=abvcd_CathayUnitedLoanAgreementMember', window );">Cathay United Loan Agreement [Member] | NT [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_BankLoansDetailsLineItems', window );"><strong>Bank Loans (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=abvcd_CTBCBankMember', window );">CTBC Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_BankLoansDetailsLineItems', window );"><strong>Bank Loans (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 702,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 351,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 702,000<span></span>
</td>
<td class="nump">$ 702,000<span></span>
</td>
<td class="nump">$ 702,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 351,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 19,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Bears interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.68%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument term</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndDebtExpense', window );">Interest expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,949<span></span>
</td>
<td class="nump">$ 2,755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=abvcd_CTBCBankMember', window );">CTBC Bank [Member] | NT [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_BankLoansDetailsLineItems', window );"><strong>Bank Loans (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=abvcd_LoanAgreementMember', window );">Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_BankLoansDetailsLineItems', window );"><strong>Bank Loans (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_ReceivedLoanAmount', window );">Received loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_RegularInterestRateDescription', window );">Regular interest rate, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Note executed in connection with the Loan Agreement bears an interest rate (the &#x201c;Regular Interest Rate&#x201d;) equal to the sum of one percent (1%) and the prime rate as published in the Wall Street Journal (the &#x201c;Index&#x201d;) and the accrued interest shall become payable each month from February 1, 2019. Pursuant to the Note, the Company shall pay the entire outstanding principal plus accrued unpaid interest on the Maturity Date and may prepay portion or all of the Note before the Maturity Date without penalty. If the Company defaults on the Note, the default interest rate shall become five percent (5%) plus the Regular Interest Rate.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On March 31, 2020, the Company extended the Loan Agreement with the same term for seven months, which is due on October 31, 2020.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_ExceedingAmount', window );">Exceeding amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=abvcd_CathayBnakMember', window );">Cathay Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_BankLoansDetailsLineItems', window );"><strong>Bank Loans (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndDebtExpense', window );">Interest expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,927<span></span>
</td>
<td class="nump">$ 13,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_ReceivedLoanAmount', window );">Received loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000<span></span>
</td>
<td class="nump">$ 350,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansPayable', window );">Outstanding loan balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_BankLoansDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_BankLoansDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_ExceedingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exceeding amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_ExceedingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_ReceivedLoanAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Received loan amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_ReceivedLoanAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_RegularInterestRateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Regular interest rate description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_RegularInterestRateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndDebtExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest and debt related expenses associated with nonoperating financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndDebtExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=abvcd_CathayUnitedLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=abvcd_CathayUnitedLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_TypeOfCurrencyAxis=abvcd_NTMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_TypeOfCurrencyAxis=abvcd_NTMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=abvcd_CTBCBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=abvcd_CTBCBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=abvcd_LoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=abvcd_LoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=abvcd_CathayBnakMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=abvcd_CathayBnakMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140266616544824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Bank Loans (Details) - Schedule of short-term bank loan - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Total</a></td>
<td class="nump">$ 1,615,250<span></span>
</td>
<td class="nump">$ 1,629,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=abvcd_CathayUnitedBankMember', window );">Cathay United Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Total</a></td>
<td class="nump">263,250<span></span>
</td>
<td class="nump">267,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=abvcd_CTBCBankMember', window );">CTBC Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Total</a></td>
<td class="nump">702,000<span></span>
</td>
<td class="nump">712,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=abvcd_CathayBnakMember', window );">Cathay Bnak [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Total</a></td>
<td class="nump">$ 650,000<span></span>
</td>
<td class="nump">$ 650,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=abvcd_CathayUnitedBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=abvcd_CathayUnitedBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=abvcd_CTBCBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=abvcd_CTBCBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=abvcd_CathayBnakMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=abvcd_CathayBnakMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140266616513592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Paycheck Protection Program Loan Payable (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 07, 2021</div></th>
<th class="th"><div>Apr. 14, 2020</div></th>
<th class="th"><div>Jan. 29, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jan. 21, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_PaycheckProtectionProgramLoanPayableDetailsLineItems', window );"><strong>Paycheck Protection Program Loan Payable (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount (in Dollars)</a></td>
<td class="nump">$ 104,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 132,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_PercentageOfForgivenAmount', window );">Percentage of forgiven amount</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_InterestRate', window );">Interest rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_PromissoryNoteTerm', window );">Promissory note term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvcd_PAYCHECKPROTECTIONPROGRAMMember', window );">Paycheck protection program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_PaycheckProtectionProgramLoanPayableDetailsLineItems', window );"><strong>Paycheck Protection Program Loan Payable (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_PaycheckProtectionProgramDescription', window );">Paycheck protection program, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company received a loan in the amount of $124,400 under the Paycheck Protection Program (&#x201c;PPP&#x201d;) administered by the United States Small Business Administration (the &#x201c;SBA&#x201d;) from East West Bank. According to the Coronavirus Aid, Relief, and Economic Security Act (the &#x201c;Cares Act&#x201d;), PPP loan provides for forgiveness of up to the full principal amount and accrued interest if the funds are used for payroll costs, interest on mortgages, rent, and utilities. However, at least 60% of the forgiven amount must have been used for payroll. The loan was granted pursuant to a promissory note dated April 14, 2020 issued by the Company, which matures on April 13, 2022 and bears interest at a rate of 1.00% per annum. The Company will pay the principal in one payment of all outstanding principal plus all accrued unpaid interest on that date that is two years after the date of the promissory note. In addition, the Company will pay regular monthly payments in an amount equal to one month&#x2019;s accrued interest commencing on the date that is seven months after the date of the promissory note, with all subsequent interest payments to be due on the same day of each month after that. No collateral or personal guarantees are required. On January 29, 2021, the entity of BioKey received a loan in the amount of $132,331 under the Paycheck Protection Program administered by the United States Small Business Administration from East West Bank. According to the Coronavirus Aid, Relief, and Economic Security Act (the &#x201c;Cares Act&#x201d;), PPP loan provides for forgiveness of up to the full principal amount and accrued interest if the funds are used for payroll costs, interest on mortgages, rent, and utilities. However, at least 60% of the forgiven amount must have been used for payroll. The loan was granted pursuant to a promissory note dated January 27, 2021 issued by the Company, which matures on January 28, 2026 and bears interest at a rate of 1.00% per annum. The Company will pay the principal in one payment of all outstanding principal plus all accrued unpaid interest on that date that is five years after the date of the promissory note. In addition, the Company will start the application with the US Government regarding the loan forgiveness program as soon as the US Government allows. No collateral or personal guarantees are required. On February 7, 2021, the entity of ABVC received a loan in the amount of $104,167 under the Paycheck Protection Program administered by the United States Small Business Administration from Cathay Bank. According to the Coronavirus Aid, Relief, and Economic Security Act (the &#x201c;Cares Act&#x201d;), PPP loan provides for forgiveness of up to the full principal amount and accrued interest if the funds are used for payroll costs, interest on mortgages, rent, and utilities. However, at least 60% of the forgiven amount must have been used for payroll. The loan was granted pursuant to a promissory note dated February 7, 2021 issued by the Company, which matures on February 6, 2026 and bears interest at a rate of 1.00% per annum. The Company will pay the principal in one payment of all outstanding principal plus all accrued unpaid interest on that date that is five years after the date of the promissory note. In addition, the Company will start the application with the US Government regarding the loan forgiveness program as soon as the US Government allows. No collateral or personal guarantees are required.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_LoanAmout', window );">Loan amout (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 124,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_InterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_InterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_LoanAmout">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_LoanAmout</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_PaycheckProtectionProgramDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_PaycheckProtectionProgramDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_PaycheckProtectionProgramLoanPayableDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_PaycheckProtectionProgramLoanPayableDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_PercentageOfForgivenAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_PercentageOfForgivenAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_PromissoryNoteTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_PromissoryNoteTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvcd_PAYCHECKPROTECTIONPROGRAMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvcd_PAYCHECKPROTECTIONPROGRAMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140266622175656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockSupplementAbstract', window );"><strong>Disclosure Text Block Supplement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_UnsecuredLoanAgreementsDescription', window );">Unsecured loan agreement, description</a></td>
<td class="text">In January, 2019, BioLite Taiwan entered an unsecured loan agreement with one individual bearing interest at fixed rates at 12% per annum of NT$3,000,000, equivalent to $105,300, for working capital purpose.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNotesPayable', window );">Balance due amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105,300<span></span>
</td>
<td class="nump">$ 106,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseOther', window );">Interest expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,204<span></span>
</td>
<td class="nump">$ 2,988<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_UnsecuredLoanAgreementsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of unsecured loan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_UnsecuredLoanAgreementsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term notes payable classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140266619937992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Loan (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Feb. 18, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnsecuredDebt', window );">Unsecured loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtInterestRateIncrease', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseAccruedInterest', window );">Accrued interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 375<span></span>
</td>
<td class="nump">$ 1,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">Oct. 30,  2021<span></span>
</td>
<td class="text">Aug. 17,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIncreaseAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase for accrued, but unpaid interest on the debt instrument for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIncreaseAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtInterestRateIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage increase in the stated interest rate on a short-term debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtInterestRateIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnsecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of uncollateralized debt obligations (with maturities initially due after one year or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnsecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140266614488328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties Transactions (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 08, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Feb. 03, 2019</div></th>
<th class="th">
<div>May 11, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 27, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th">
<div>Feb. 07, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 29, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 01, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 21, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_RelatedPartiesTransactionsDetailsLineItems', window );"><strong>Related Parties Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104,167<span></span>
</td>
<td class="nump">$ 132,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateTerms', window );">Loan agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The advances bear interest rate from 12% to 13.6224% per annum.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShorttermDebtAverageOutstandingAmount', window );">Outstanding advance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_AccruedInterest', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 163,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_AggregateWorkingcapital', window );">Aggregate working capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_AdvancesBearInterestDescription', window );">Advances bear interest, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">0%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionRate', window );">Interest rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Loan maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 17,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfLoanCosts', window );">Outstanding loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Outstanding advance balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">312,152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 288,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,229<span></span>
</td>
<td class="nump">$ 131,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_NumberOfEmployees', window );">Number of employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Accrued employee amounted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvcd_RgeneCorporationMember', window );">Rgene Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_RelatedPartiesTransactionsDetailsLineItems', window );"><strong>Related Parties Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateTerms', window );">Loan agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the loan bears interest at 1% per month (or equivalent to 12% per annum) and the maturity date was December 31, 2020.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShorttermDebtAverageOutstandingAmount', window );">Outstanding advance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_AccruedInterest', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvcd_BioFirstMember', window );">BioFirst [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_RelatedPartiesTransactionsDetailsLineItems', window );"><strong>Related Parties Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateTerms', window );">Loan agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The advances bear interest 1% per month (or equivalent to 12% per annum).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Loan maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Outstanding advance balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvcd_BioFirstMember', window );">BioFirst [Member] | Conversion Agreements One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_RelatedPartiesTransactionsDetailsLineItems', window );"><strong>Related Parties Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_StockPurchaseAgreementDescription', window );">Stock purchase agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On May 27, 2019, the Company entered into loan agreements with AsiaGene for NT $100,000, equivalent to $3,510, to meet its working capital needs. Under the terms of the loan agreement, the loan bears interest at 1% per month (or equivalent to 12% per annum) and the loan maturity date was December 31, 2020.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvcd_AsiangeneCorporationMember', window );">Asiangene Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_RelatedPartiesTransactionsDetailsLineItems', window );"><strong>Related Parties Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShorttermDebtAverageOutstandingAmount', window );">Outstanding advance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_AccruedInterest', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_AggregateWorkingcapital', window );">Aggregate working capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,510<span></span>
</td>
<td class="nump">$ 24,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionRate', window );">Interest rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvcd_AsiangeneCorporationMember', window );">Asiangene Corporation [Member] | NT [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_RelatedPartiesTransactionsDetailsLineItems', window );"><strong>Related Parties Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_AggregateWorkingcapital', window );">Aggregate working capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvcd_BioFirstAustraliaMember', window );">BioFirst (Australia) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_RelatedPartiesTransactionsDetailsLineItems', window );"><strong>Related Parties Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 321,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShorttermDebtAverageOutstandingAmount', window );">Outstanding advance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 379,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">373,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_AdvancesBearInterestDescription', window );">Advances bear interest, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The advances bear 0% interest rate and are due on demand prior to June 30, 2020.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionRate', window );">Interest rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvcd_BioLiteTaiwanMember', window );">BioLite Taiwan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_RelatedPartiesTransactionsDetailsLineItems', window );"><strong>Related Parties Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateTerms', window );">Loan agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The development costs shall be shared 50/50 between BHK and the Company. Under the term of the agreement, BioLite issued relevant development cost to BHK.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromOtherRelatedParties', window );">Due from BHK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 121,848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvcd_LbgUsaIncMember', window );">LBG USA, Inc.[Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_RelatedPartiesTransactionsDetailsLineItems', window );"><strong>Related Parties Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShorttermDebtAverageOutstandingAmount', window );">Outstanding advance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">675<span></span>
</td>
<td class="nump">675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvcd_BioLiteJapanMember', window );">BioLite Japan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_RelatedPartiesTransactionsDetailsLineItems', window );"><strong>Related Parties Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateTerms', window );">Loan agreement, description</a></td>
<td class="text">the Company advanced an amount of $150,000 and the advance bear 0% interest rate.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShorttermDebtAverageOutstandingAmount', window );">Outstanding advance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_AggregateWorkingcapital', window );">Aggregate working capital</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvcd_YuanGeneMember', window );">YuanGene [Member] | Conversion Agreements One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_RelatedPartiesTransactionsDetailsLineItems', window );"><strong>Related Parties Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_AggregateWorkingcapital', window );">Aggregate working capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionRate', window );">Interest rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvcd_JIANGSMember', window );">JIANGS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_RelatedPartiesTransactionsDetailsLineItems', window );"><strong>Related Parties Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_AggregateWorkingcapital', window );">Aggregate working capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionRate', window );">Interest rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,298<span></span>
</td>
<td class="nump">$ 5,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_AccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_AccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_AdvancesBearInterestDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Advances bear interest description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_AdvancesBearInterestDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_AggregateWorkingcapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate working capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_AggregateWorkingcapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_NumberOfEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_NumberOfEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_RelatedPartiesTransactionsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_RelatedPartiesTransactionsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_StockPurchaseAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock purchase agreement description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_StockPurchaseAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromOtherRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount receivable from related parties classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromOtherRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfLoanCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan origination associated cost which is usually collected through escrow.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfLoanCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Identify the stated interest rate per the agreement, for example, leasing and debt arrangements between related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShorttermDebtAverageOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the form of debt having an initial term of less than one year or less than the normal operating cycle, if longer, average borrowings during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShorttermDebtAverageOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvcd_RgeneCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvcd_RgeneCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvcd_BioFirstMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvcd_BioFirstMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_AgreemnetAxis=abvcd_ConversionAgreementsOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_AgreemnetAxis=abvcd_ConversionAgreementsOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvcd_AsiangeneCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvcd_AsiangeneCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_TypeOfCurrencyAxis=abvcd_NTMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_TypeOfCurrencyAxis=abvcd_NTMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvcd_BioFirstAustraliaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvcd_BioFirstAustraliaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvcd_BioLiteTaiwanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvcd_BioLiteTaiwanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvcd_LbgUsaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvcd_LbgUsaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvcd_BioLiteJapanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvcd_BioLiteJapanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvcd_YuanGeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvcd_YuanGeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvcd_JIANGSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvcd_JIANGSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140266616618056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties Transactions (Details) - Schedule of related party transactions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvcd_BioFirstCorporationtheBioFirstMember', window );">BioFirst Corporation (the "BioFirst") [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_RelatedPartyTransactionDescriptionOfTransactions', window );">Relationship with the Company and its subsidiaries, description</a></td>
<td class="text">Entity controlled by controlling beneficiary shareholder of YuanGene<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvcd_BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember', window );">BioFirst (Australia) Pty Ltd. (the &#8220;BioFirst (Australia)&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_RelatedPartyTransactionDescriptionOfTransactions', window );">Relationship with the Company and its subsidiaries, description</a></td>
<td class="text">100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvcd_RgeneCorporationtheRgeneMember', window );">Rgene Corporation (the &#8220;Rgene&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_RelatedPartyTransactionDescriptionOfTransactions', window );">Relationship with the Company and its subsidiaries, description</a></td>
<td class="text">Shareholder of the Company; entity controlled by controlling beneficiary shareholder of YuanGene<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvcd_YuanGeneCorporationtheYuanGeneMember', window );">YuanGene Corporation (the &#8220;YuanGene&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_RelatedPartyTransactionDescriptionOfTransactions', window );">Relationship with the Company and its subsidiaries, description</a></td>
<td class="text">Controlling beneficiary shareholder of the Company<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvcd_AsiaGeneCorporationtheAsiaGeneMember', window );">AsiaGene Corporation (the &#8220;AsiaGene&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_RelatedPartyTransactionDescriptionOfTransactions', window );">Relationship with the Company and its subsidiaries, description</a></td>
<td class="text">Shareholder; entity controlled by controlling beneficiary shareholder of YuanGene<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvcd_EugeneJiangMember', window );">Eugene Jiang [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_RelatedPartyTransactionDescriptionOfTransactions', window );">Relationship with the Company and its subsidiaries, description</a></td>
<td class="text">Former President and Chairman<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvcd_KeypointTechnologyLtdtheKeypointMember', window );">Keypoint Technology Ltd. (the &#8220;Keypoint&#8217;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_RelatedPartyTransactionDescriptionOfTransactions', window );">Relationship with the Company and its subsidiaries, description</a></td>
<td class="text">The Chairman of Keypoint is Eugene Jiang's mother.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvcd_LionArtsPromotionInctheLionArtsMember', window );">Lion Arts Promotion Inc. (the &#8220;Lion Arts&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_RelatedPartyTransactionDescriptionOfTransactions', window );">Relationship with the Company and its subsidiaries, description</a></td>
<td class="text">Shareholder of the Company<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvcd_YoshinobuOdairatheOdairaMember', window );">Yoshinobu Odaira (the &#8220;Odaira&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_RelatedPartyTransactionDescriptionOfTransactions', window );">Relationship with the Company and its subsidiaries, description</a></td>
<td class="text">Director of the Company<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvcd_GenePharmInctheGenePharmMember', window );">GenePharm Inc. (the &#8220;GenePharm&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_RelatedPartyTransactionDescriptionOfTransactions', window );">Relationship with the Company and its subsidiaries, description</a></td>
<td class="text">Dr. George Lee, Board Director of Biokey, is the Chairman of GenePharm.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvcd_EuroAsiaInvestmentFinanceCorpLtdtheEuroAsiaMember', window );">Euro-Asia Investment &amp; Finance Corp Ltd. (the &#8220;Euro-Asia&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_RelatedPartyTransactionDescriptionOfTransactions', window );">Relationship with the Company and its subsidiaries, description</a></td>
<td class="text">Shareholder of the Company<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvcd_LBGUSAInctheLBGUSAMember', window );">LBG USA, Inc. (the &#8220;LBG USA&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_RelatedPartyTransactionDescriptionOfTransactions', window );">Relationship with the Company and its subsidiaries, description</a></td>
<td class="text">100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvcd_LionGeneCorporationtheLionGeneMember', window );">LionGene Corporation (the &#8220;LionGene&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_RelatedPartyTransactionDescriptionOfTransactions', window );">Relationship with the Company and its subsidiaries, description</a></td>
<td class="text">Shareholder of the Company; Entity controlled by controlling beneficiary shareholder of YuanGene<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvcd_KimhoConsultantsCoLtdtheKimhoMember', window );">Kimho Consultants Co., Ltd. (the &#8220;Kimho&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_RelatedPartyTransactionDescriptionOfTransactions', window );">Relationship with the Company and its subsidiaries, description</a></td>
<td class="text">Shareholder of the Company<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvcd_MrTsungShannJiangMsShuLingJiangMrChangJenJiangMsMeiLingJiangAndMrEugeneJiangcollectivelyTheJiangsMember', window );">Mr. Tsung-Shann Jiang, Ms. Shu-Ling Jiang, Mr. Chang-Jen Jiang, Ms. Mei-Ling Jiang, and Mr. Eugene Jiang (collectively the "Jiangs") [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_RelatedPartyTransactionDescriptionOfTransactions', window );">Relationship with the Company and its subsidiaries, description</a></td>
<td class="text">Mr. Tsung-Shann Jiang, the controlling beneficiary shareholder of the Company and Rgene, the Chairman and CEO of the BioLite Holding Inc. and BioLite Inc. and the President and a member of board of directors of BioFirst Ms. Shu-Ling Jiang, Mr. Tsung-Shann Jiang's wife, is the Chairman of Keypoint; and a member of board of directors of BioLite Inc. Mr. Eugene Jiang is Mr. and Ms. Jiang's son. Mr. Eugene Jiang is the chairman, and majority shareholder of the Company and a member of board of directors of BioLite Inc. Mr. Chang-Jen Jiang is Mr. Tsung-Shann Jiang's sibling and the director of the Company. Ms. Mei-Ling Jiang is Ms. Shu-Ling Jiang's sibling.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvcd_AmkeyVenturesLLCAmkeyMember', window );">Amkey Ventures, LLC (&#8220;Amkey&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_RelatedPartyTransactionDescriptionOfTransactions', window );">Relationship with the Company and its subsidiaries, description</a></td>
<td class="text">An entity controlled by Dr. George Lee, who serves as one of the board directors of BioKey, Inc<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvcd_BioLiteJapanMember', window );">BioLite Japan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_RelatedPartyTransactionDescriptionOfTransactions', window );">Relationship with the Company and its subsidiaries, description</a></td>
<td class="text">Entity controlled by controlling beneficiary shareholder of ABVC<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_RelatedPartyTransactionDescriptionOfTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents related party descriptions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_RelatedPartyTransactionDescriptionOfTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvcd_BioFirstCorporationtheBioFirstMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvcd_BioFirstCorporationtheBioFirstMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvcd_BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvcd_BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvcd_RgeneCorporationtheRgeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvcd_RgeneCorporationtheRgeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvcd_YuanGeneCorporationtheYuanGeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvcd_YuanGeneCorporationtheYuanGeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvcd_AsiaGeneCorporationtheAsiaGeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvcd_AsiaGeneCorporationtheAsiaGeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvcd_EugeneJiangMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvcd_EugeneJiangMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvcd_KeypointTechnologyLtdtheKeypointMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvcd_KeypointTechnologyLtdtheKeypointMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvcd_LionArtsPromotionInctheLionArtsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvcd_LionArtsPromotionInctheLionArtsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvcd_YoshinobuOdairatheOdairaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvcd_YoshinobuOdairatheOdairaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvcd_GenePharmInctheGenePharmMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvcd_GenePharmInctheGenePharmMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvcd_EuroAsiaInvestmentFinanceCorpLtdtheEuroAsiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvcd_EuroAsiaInvestmentFinanceCorpLtdtheEuroAsiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvcd_LBGUSAInctheLBGUSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvcd_LBGUSAInctheLBGUSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvcd_LionGeneCorporationtheLionGeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvcd_LionGeneCorporationtheLionGeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvcd_KimhoConsultantsCoLtdtheKimhoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvcd_KimhoConsultantsCoLtdtheKimhoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvcd_MrTsungShannJiangMsShuLingJiangMrChangJenJiangMsMeiLingJiangAndMrEugeneJiangcollectivelyTheJiangsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvcd_MrTsungShannJiangMsShuLingJiangMrChangJenJiangMsMeiLingJiangAndMrEugeneJiangcollectivelyTheJiangsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvcd_AmkeyVenturesLLCAmkeyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvcd_AmkeyVenturesLLCAmkeyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvcd_BioLiteJapanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvcd_BioLiteJapanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140266717547224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Related Parties Transactions (Details) - Schedule of accounts receivable due from related parties - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesLineItems', window );"><strong>Related Parties Transactions (Details) - Schedule of accounts receivable due from related parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedParties', window );">Accounts receivable due from related parties</a></td>
<td class="nump">$ 145,075<span></span>
</td>
<td class="nump">$ 143,435<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvcd_GenePharmIncMember', window );">GenePharm Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesLineItems', window );"><strong>Related Parties Transactions (Details) - Schedule of accounts receivable due from related parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedParties', window );">Accounts receivable due from related parties</a></td>
<td class="nump">142,225<span></span>
</td>
<td class="nump">142,225<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvcd_AmkeyMember', window );">Amkey [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesLineItems', window );"><strong>Related Parties Transactions (Details) - Schedule of accounts receivable due from related parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedParties', window );">Accounts receivable due from related parties</a></td>
<td class="nump">$ 2,850<span></span>
</td>
<td class="nump">$ 1,210<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amount of receivables arising from transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvcd_GenePharmIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvcd_GenePharmIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvcd_AmkeyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvcd_AmkeyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140266614425544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Related Parties Transactions (Details) - Schedule of amount due from related parties - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Total</a></td>
<td class="nump">$ 702,889<span></span>
</td>
<td class="nump">$ 696,255<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvcd_RgeneMember', window );">Rgene [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Total</a></td>
<td class="nump">43,266<span></span>
</td>
<td class="nump">42,911<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvcd_AsiaGeneMember', window );">AsiaGene [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Total</a></td>
<td class="nump">4,287<span></span>
</td>
<td class="nump">4,241<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvcd_BioFirstAustraliaMember', window );">BioFirst (Australia) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Total</a></td>
<td class="nump">379,110<span></span>
</td>
<td class="nump">373,235<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvcd_BioHopeKingCorporationMember', window );">BioHopeKing Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Total</a></td>
<td class="nump">121,848<span></span>
</td>
<td class="nump">123,583<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvcd_LBGUSAMember', window );">LBG USA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Total</a></td>
<td class="nump">675<span></span>
</td>
<td class="nump">675<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvcd_BioLiteJapanMember', window );">BioLite Japan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Total</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvcd_KeypointMember', window );">Keypoint [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Total</a></td>
<td class="nump">1,610<span></span>
</td>
<td class="nump">1,610<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvcd_TheJiangsMember', window );">The Jiangs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Total</a></td>
<td class="nump">$ 2,093<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvcd_RgeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvcd_RgeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvcd_AsiaGeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvcd_AsiaGeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvcd_BioFirstAustraliaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvcd_BioFirstAustraliaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvcd_BioHopeKingCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvcd_BioHopeKingCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvcd_LBGUSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvcd_LBGUSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvcd_BioLiteJapanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvcd_BioLiteJapanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvcd_KeypointMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvcd_KeypointMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvcd_TheJiangsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvcd_TheJiangsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140266622363752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Related Parties Transactions (Details) - Schedule of amount due to related parties - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesLineItems', window );"><strong>Related Parties Transactions (Details) - Schedule of amount due to related parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Total</a></td>
<td class="nump">$ 312,152<span></span>
</td>
<td class="nump">$ 288,445<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvcd_BioFirstCorporationMember', window );">BioFirst Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesLineItems', window );"><strong>Related Parties Transactions (Details) - Schedule of amount due to related parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Total</a></td>
<td class="nump">23,647<span></span>
</td>
<td class="nump">23,647<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvcd_AsiaGeneMember', window );">AsiaGene [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesLineItems', window );"><strong>Related Parties Transactions (Details) - Schedule of amount due to related parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Total</a></td>
<td class="nump">24,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvcd_YuanGeneMember', window );">YuanGene [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesLineItems', window );"><strong>Related Parties Transactions (Details) - Schedule of amount due to related parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Total</a></td>
<td class="nump">9,205<span></span>
</td>
<td class="nump">9,205<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvcd_TheJiangsMember', window );">The Jiangs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesLineItems', window );"><strong>Related Parties Transactions (Details) - Schedule of amount due to related parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Total</a></td>
<td class="nump">18,750<span></span>
</td>
<td class="nump">16,627<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvcd_DueToshareholdersMember', window );">Due to shareholders [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesLineItems', window );"><strong>Related Parties Transactions (Details) - Schedule of amount due to related parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Total</a></td>
<td class="nump">163,566<span></span>
</td>
<td class="nump">166,261<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvcd_DueToEmployeesMember', window );">Due to employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesLineItems', window );"><strong>Related Parties Transactions (Details) - Schedule of amount due to related parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Total</a></td>
<td class="nump">$ 72,967<span></span>
</td>
<td class="nump">$ 72,704<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvcd_BioFirstCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvcd_BioFirstCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvcd_AsiaGeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvcd_AsiaGeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvcd_YuanGeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvcd_YuanGeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvcd_TheJiangsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvcd_TheJiangsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvcd_DueToshareholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvcd_DueToshareholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvcd_DueToEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvcd_DueToEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140266608310008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="8">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 08, 2020</div></th>
<th class="th"><div>May 03, 2019</div></th>
<th class="th">
<div>Feb. 08, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Oct. 01, 2016</div></th>
<th class="th"><div>May 06, 2016</div></th>
<th class="th">
<div>Feb. 08, 2016 </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 08, 2016 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 21, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 19, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th"><div>Feb. 28, 2017</div></th>
<th class="th"><div>Aug. 26, 2016</div></th>
<th class="th">
<div>Mar. 21, 2016 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 17, 2016 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 12, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 24, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_StockholderEquityReverseStockSplit', window );">Forward split ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On March 21, 2016, the Board of Directors of the Company approved an amendment to Articles of Incorporation to effect a forward split at a ratio of 1 to 3:141 (the &#x201c;Forward Stock Split&#x201d;) and increase the number of our authorized shares of Common Stock, par value $0.001 per share, to 360,000,000, which was effective on April 8, 2016.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_AgreementDescription', window );">Agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company and BioLite Taiwan agreed to amend the BioLite Collaborative Agreement, through entry into the Milestone Payment Agreement, whereby the Company has agreed to issue shares of Common Stock of the Company, at the price of $1.60 per share, for an aggregate number of 562,500 shares, as part of the Company&#x2019;s first installation of payment pursuant to the Milestone Payment. The shares issuance was completed in June 2016.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company remitted this amount to BioLite with $650,000 in cash and $5,850,000 in the form of newly issued shares of the Company&#x2019;s Common Stock, at the price of $2.0 per share, for an aggregate number of 2,925,000 shares. Upon the consummation of the restructuring transaction between the Company and BioLite on February 8, 2019, the Company&#x2019;s Common Stock held by BioLite Taiwan was accounted for treasury stocks in the statement of equity (deficit).<span></span>
</td>
<td class="text">the Company issued 1,468,750 shares (&#x201c;Shares&#x201d;) of the Company&#x2019;s Common Stock, par value $0.001 (the &#x201c;Offering&#x201d;) to BioLite Taiwan pursuant to a certain Stock Purchase Agreement dated August 26, 2016 (the &#x201c;SPA&#x201d;). The Shares are exempt from the registration requirements of the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;), pursuant to Regulation S of the Securities Act promulgated thereunder. The purchase price per share of the Offering is $1.60. The net proceeds to the Company from the Offering are approximately $2,350,000. Pursuant to the BioLite Collaborative Agreement, BriVision should pay a total of $100,000,000 in cash or stock of the Company with equivalent value according to the milestone achieved. The agreement requires that 6.5% of total payment, $6,500,000 shall be made upon the first IND submission which was submitted in March 2016.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_FinancialAmendmentDescription', window );">Financial amendment, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company filed a Certificate of Amendment with the Secretary of State of Nevada, which was effective May 8, 2019 upon its receipt of the written notice from Financial Industry Regulatory Authority (&#x201c;FINRA&#x201d;). Pursuant to the Certificate of Amendment, the Company effectuated a 1-for-18 reverse stock split of its issued and outstanding shares of common stock, $0.001 par value, whereby 318,485,252 outstanding shares of the Company&#x2019;s common stock were exchanged for 17,693,625 shares of the Company&#x2019;s Common Stock. All shares and related financial information in this Form 10-K reflect this 1-for-18 reverse stock split.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,420,526<span></span>
</td>
<td class="nump">24,420,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Consulting fees (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,514,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_StockSubscriptionReceivable', window );">Stock subscription receivable (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,934,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,160,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due to related parties (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 312,152<span></span>
</td>
<td class="nump">$ 288,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Due to related parties consideration (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,872,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Common stock price per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_WarrantIssued', window );">Warrant issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_WarrantTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_IssuanceOfCommonStock', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,384,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_AggregateCommonStockShares', window );">Aggregate common stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">915,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=abvcd_TwoThousandSixteenEquityIncentivePlanMember', window );">2016 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_CommonStockIssuedAfterStockSplit', window );">Common stock issued post-stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_CommonStockIssuedBeforeStockSplit', window );">Common stock issued pre-stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abvcd_ShareExchangeAgreementMember', window );">Share Exchange Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_CommonStockIssuedAfterStockSplit', window );">Common stock issued post-stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,387,376<span></span>
</td>
<td class="nump">164,387,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_CommonStockIssuedBeforeStockSplit', window );">Common stock issued pre-stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,336,000<span></span>
</td>
<td class="nump">52,336,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abvcd_ShareExchangeAgreementOneMember', window );">Share Exchange Agreement One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_CommonStockIssuedAfterStockSplit', window );">Common stock issued post-stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,273,921<span></span>
</td>
<td class="nump">166,273,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_CommonStockIssuedBeforeStockSplit', window );">Common stock issued pre-stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,936,583<span></span>
</td>
<td class="nump">52,936,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abvcd_ShareExchangeAgreementTwoMember', window );">Share Exchange Agreement Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_CommonStockIssuedAfterStockSplit', window );">Common stock issued post-stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">163,159,952<span></span>
</td>
<td class="nump">163,159,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_CommonStockIssuedBeforeStockSplit', window );">Common stock issued pre-stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,945,225<span></span>
</td>
<td class="nump">51,945,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of common shares issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79.70%<span></span>
</td>
<td class="nump">79.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_PercentageOfIssuedShareCapital', window );">Percentage of issued share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abvcd_ShareExchangeAgreementThreeMember', window );">Share Exchange Agreement Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_CommonStockIssuedAfterStockSplit', window );">Common stock issued post-stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,273,921<span></span>
</td>
<td class="nump">166,273,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_CommonStockIssuedBeforeStockSplit', window );">Common stock issued pre-stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,936,583<span></span>
</td>
<td class="nump">52,936<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abvcd_ShareExchangeAgreementFourMember', window );">Share Exchange Agreement Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_CommonStockIssuedAfterStockSplit', window );">Common stock issued post-stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">205,519,223<span></span>
</td>
<td class="nump">205,519,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_CommonStockIssuedBeforeStockSplit', window );">Common stock issued pre-stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,431,144<span></span>
</td>
<td class="nump">65,431,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">428,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_Consultingagreementdescription', window );">Consulting agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On October 1, 2016, the Company entered into a consulting agreement with Kazunori Kameyama (&#x201c;Kameyama&#x201d;) for the provision of services related to the clinical trials and other administrative work, public relation work, capital raising, trip coordination, In consideration for providing such services, the Company agreed to indemnify the consultant in an amount of $150 per hour in cash up to $3,000 per month, and issue to Kameyama the Company&#x2019;s Common Stock at $1.00 per share for any amount exceeding $3,000.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_StockIssuedValue', window );">Issuance of common shares (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abvcd_EuroAsiaInvestmentAndFinanceCorpLtdMember', window );">Euro-Asia Investment &amp; Finance Corp Ltd. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">644,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abvcd_CodevelopmentagreementMember', window );">Co-Dev Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due to related parties (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abvcd_ConsultingAgreementMember', window );">Consulting Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">521,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abvcd_ConsultingAgreementMember', window );">Consulting Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">PRice per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abvcd_ConsultingAgreementMember', window );">Consulting Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_StockIssuedDuringPeriodShareBasedCompensationServicesforShares', window );">SaleOfStockPricePerShare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvcd_KameyamaMember', window );">Kameyama [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_UnpaidConsultingFees', window );">Unpaid consulting fees (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvcd_ArticlesOfIncorporationMember', window );">Articles of Incorporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvcd_ArticlesOfIncorporationMember', window );">Articles of Incorporation [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvcd_ArticlesOfIncorporationMember', window );">Articles of Incorporation [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvcd_ViewTradeSecuritiesIncMember', window );">View Trade Securities Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Consulting fees (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 135,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_PlacementAgentAgreementDescription', window );">Placement agent agreement, description</a></td>
<td class="text">Pursuant to the agreement, the Company agreed to pay View Trade 60,000 restricted common shares of the Company and 60,000 warrants to purchase common shares of the Company at an exercise price of $6 per share for a period of 5 years with cashless exercise provision.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_RestrictedCommonShares', window );">Restricted common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvcd_ConsultingAgreementMember', window );">Consulting Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Common stock price per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_UnrestrictedCommonShares', window );">Unrestricted common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvcd_NonRelatedPartiesMember', window );">Non Related Parties [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature', window );">Debt conversion, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">a. Keypoint converted the aggregated amount of $292,826 at the conversion price of $1.84 on April 5, 2020, in exchange for 159,145 shares of the Company&#x2019;s common stock, and warrants to purchase 159,145 shares of the Company&#x2019;s common stock. b. Odaira converted the aggregated amount of $284,036 at the conversion price of $1.84 on April 5, 2020, in exchange for 154,368 shares of the Company&#x2019;s common stock, and warrants to purchase 154,368 shares of the Company&#x2019;s common stock. c. C.L.L. converted the aggregated amount of $289,974 at the conversion price of $1.78 on April 20, 2020, in exchange for 162,908 shares of the Company&#x2019;s common stock, and warrants to purchase 162,908 shares of the Company&#x2019;s common stock. d. KLS converted the aggregated amount of $225,222 at the conversion price of $1.78 on April 20, 2020, in exchange for 126,530 shares of the Company&#x2019;s common stock, and warrants to purchase 126,530 shares of the Company&#x2019;s common stock. e. Yu and Wei converted the aggregated amount of $354,722 at the conversion price of $1.84 on April 5, 2020, in exchange for 192,784 shares of the Company&#x2019;s common stock, and warrants to purchase 192,784 shares of the Company&#x2019;s common stock. f. KSL converted the aggregated amount of $270,272 at the conversion price of $2.25 on November 9, 2020, in exchange for 120,121 shares of the Company&#x2019;s common stock, and warrants to purchase 120,121 shares of the Company&#x2019;s common stock.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromContributionsFromAffiliates', window );">Aggregated capital contributions (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,615,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_NumberOfInvestors', window );">Number of investors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Number of investors (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=abvcd_BioLiteMember', window );">BioLite [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,997,546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=abvcd_BioKeyMember', window );">BioKey [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_CommonStockIssuedAfterStockSplit', window );">Common stock issued post-stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,642,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,561,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Number of investors (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_AggregateCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate Common Stock Shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_AggregateCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_AgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreement related description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_AgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_CommonStockIssuedAfterStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock issued after stock split.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_CommonStockIssuedAfterStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_CommonStockIssuedBeforeStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock issued before stock split.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_CommonStockIssuedBeforeStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_Consultingagreementdescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consulting agreement description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_Consultingagreementdescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_EquityDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_EquityDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_FinancialAmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_FinancialAmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_IssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of Common Stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_IssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_NumberOfInvestors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_NumberOfInvestors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_PercentageOfIssuedShareCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of issued share capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_PercentageOfIssuedShareCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_PlacementAgentAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_PlacementAgentAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_RestrictedCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restricted Common Shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_RestrictedCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_StockIssuedDuringPeriodShareBasedCompensationServicesforShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_StockIssuedDuringPeriodShareBasedCompensationServicesforShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_StockIssuedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_StockIssuedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_StockSubscriptionReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of stock subscription receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_StockSubscriptionReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_StockholderEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_StockholderEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_UnpaidConsultingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_UnpaidConsultingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_UnrestrictedCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_UnrestrictedCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_WarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_WarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_WarrantTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_WarrantTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the conversion terms of a debt instrument which may include the conversion ratio (including all potential conversion ratios if contingently adjustable), type of debt or equity security into which the debt is convertible, the dollars of debt or the number of shares into which the instrument is convertible (or potentially convertible into), the conversion period, any contingencies associated with the conversion terms, and the existence and amount of a beneficial conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromContributionsFromAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from an entity that is affiliated with the entity by means of direct or indirect ownership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromContributionsFromAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.2(a),(b),(c),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=118262090&amp;loc=SL114874205-224268<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=abvcd_TwoThousandSixteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=abvcd_TwoThousandSixteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abvcd_ShareExchangeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abvcd_ShareExchangeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abvcd_ShareExchangeAgreementOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abvcd_ShareExchangeAgreementOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abvcd_ShareExchangeAgreementTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abvcd_ShareExchangeAgreementTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abvcd_ShareExchangeAgreementThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abvcd_ShareExchangeAgreementThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abvcd_ShareExchangeAgreementFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abvcd_ShareExchangeAgreementFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abvcd_EuroAsiaInvestmentAndFinanceCorpLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abvcd_EuroAsiaInvestmentAndFinanceCorpLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abvcd_CodevelopmentagreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abvcd_CodevelopmentagreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abvcd_ConsultingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abvcd_ConsultingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvcd_KameyamaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvcd_KameyamaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvcd_ArticlesOfIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvcd_ArticlesOfIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvcd_ViewTradeSecuritiesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvcd_ViewTradeSecuritiesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvcd_ConsultingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvcd_ConsultingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvcd_NonRelatedPartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvcd_NonRelatedPartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=abvcd_BioLiteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=abvcd_BioLiteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=abvcd_BioKeyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=abvcd_BioKeyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140266614449048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Details) - Schedule of converted amount of debt and shares<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Aug. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Debt Conversion [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Amount of Debt Converted | $</a></td>
<td class="nump">$ 4,872,340<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Number of Shares Issued | shares</a></td>
<td class="nump">696,051<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abvcd_LionArtsPromotionInctheLIONMember', window );">Lion Arts Promotion Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Debt Conversion [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Amount of Debt Converted | $</a></td>
<td class="nump">$ 97,864<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Number of Shares Issued | shares</a></td>
<td class="nump">13,981<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abvcd_LionGeneCorporationMember', window );">LionGene Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Debt Conversion [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Amount of Debt Converted | $</a></td>
<td class="nump">$ 428,099<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Number of Shares Issued | shares</a></td>
<td class="nump">61,157<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abvcd_BioFirstCorporationMember', window );">BioFirst Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Debt Conversion [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Amount of Debt Converted | $</a></td>
<td class="nump">$ 2,902,911<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Number of Shares Issued | shares</a></td>
<td class="nump">414,702<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abvcd_AsiangeneCorporationMember', window );">AsiaGene Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Debt Conversion [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Amount of Debt Converted | $</a></td>
<td class="nump">$ 160,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Number of Shares Issued | shares</a></td>
<td class="nump">22,858<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abvcd_YuangeneCorporationMember', window );">YuanGene Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Debt Conversion [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Amount of Debt Converted | $</a></td>
<td class="nump">$ 92,690<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Number of Shares Issued | shares</a></td>
<td class="nump">13,242<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abvcd_TheJiangsMember', window );">The Jiangs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Debt Conversion [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Amount of Debt Converted | $</a></td>
<td class="nump">$ 1,190,776<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Number of Shares Issued | shares</a></td>
<td class="nump">170,111<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abvcd_LionArtsPromotionInctheLIONMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abvcd_LionArtsPromotionInctheLIONMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abvcd_LionGeneCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abvcd_LionGeneCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abvcd_BioFirstCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abvcd_BioFirstCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abvcd_AsiangeneCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abvcd_AsiangeneCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abvcd_YuangeneCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abvcd_YuangeneCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abvcd_TheJiangsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abvcd_TheJiangsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140266621296552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Options (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Nov. 21, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_StockOptionsDetailsLineItems', window );"><strong>Stock Options (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Stock options aggregate</a></td>
<td class="nump">545,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Conversion price</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_ConsultingFees', window );">Consulting fees</a></td>
<td class="nump">$ 1,090,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Company granted stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">545,182<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Options vested grant date exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=abvcd_TwoThousandSixteenEquityIncentivePlanMember', window );">2016 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_StockOptionsDetailsLineItems', window );"><strong>Stock Options (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Options available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,812,949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_ConsultingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_ConsultingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_StockOptionsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_StockOptionsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=abvcd_TwoThousandSixteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=abvcd_TwoThousandSixteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140266616176632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Options (Details) - Schedule of options issued and outstanding - Stock Options [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems', window );"><strong>Stock Options (Details) - Schedule of options issued and outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Underlying Shares, Outstanding | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Outstanding | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Number of Underlying Shares, Granted | shares</a></td>
<td class="nump">545,182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Granted | $ / shares</a></td>
<td class="nump">$ 2.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm', window );">Weighted-Average Contractual Life Remaining in Years, Granted</a></td>
<td class="text">9 years 324 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue', window );">Aggregate Intrinsic Value, Granted | $</a></td>
<td class="nump">$ 616,056<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Underlying Shares, Forfeited | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Forfeited | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Underlying Shares, Outstanding | shares</a></td>
<td class="nump">545,182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Outstanding | $ / shares</a></td>
<td class="nump">$ 2.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Contractual Life Remaining in Years, Outstanding</a></td>
<td class="text">9 years 324 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding | $</a></td>
<td class="nump">$ 616,056<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Underlying Shares, Exercisable | shares</a></td>
<td class="nump">545,182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Exercisable | $ / shares</a></td>
<td class="nump">$ 2.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Contractual Life Remaining in Years, Exercisable</a></td>
<td class="text">9 years 324 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable | $</a></td>
<td class="nump">$ 616,056<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Underlying Shares, Vested and expected to vest | shares</a></td>
<td class="nump">545,182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Vested and expected to vest | $ / shares</a></td>
<td class="nump">$ 2.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Contractual Life Remaining in Years, Vested and expected to vest</a></td>
<td class="text">9 years 324 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and expected to vest | $</a></td>
<td class="nump">$ 616,056<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140266624321848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Options (Details) - Schedule of fair value of stock options granted<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_ScheduleOfFairValueOfStockOptionsGrantedAbstract', window );"><strong>Schedule of fair value of stock options granted [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">0.38%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">89.01%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_ScheduleOfFairValueOfStockOptionsGrantedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_ScheduleOfFairValueOfStockOptionsGrantedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140266619701880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss per Share (Details) - Schedule of loss per share - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_NumeratorAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_NetLoss', window );">Net loss attributable to ABVC&#8217;s common stockholders (in Dollars)</a></td>
<td class="num">$ (1,128,505)<span></span>
</td>
<td class="num">$ (1,247,538)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average shares outstanding - Basic</a></td>
<td class="nump">24,420,526<span></span>
</td>
<td class="nump">19,484,542<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_StockOptions', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average shares outstanding - Diluted</a></td>
<td class="nump">24,420,526<span></span>
</td>
<td class="nump">19,484,542<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">-Basic (in Dollars per share)</a></td>
<td class="num">$ (0.05)<span></span>
</td>
<td class="num">$ (0.06)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">-Diluted (in Dollars per share)</a></td>
<td class="num">$ (0.05)<span></span>
</td>
<td class="num">$ (0.06)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_NetLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_NetLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_NumeratorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_NumeratorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_StockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_StockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140266622271240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Lease (Details) - Schedule of operating lease arrangements - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 1,714,740<span></span>
</td>
<td class="nump">$ 1,772,747<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities (current)</a></td>
<td class="nump">331,179<span></span>
</td>
<td class="nump">316,178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities (noncurrent)</a></td>
<td class="nump">$ 1,383,560<span></span>
</td>
<td class="nump">$ 1,456,567<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140266619911608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease (Details) - Schedule of supplemental information related to operating leases - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_ScheduleOfSupplementalInformationRelatedToOperatingLeasesAbstract', window );"><strong>Schedule of supplemental information related to operating leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease expenses</a></td>
<td class="nump">$ 78,847<span></span>
</td>
<td class="nump">$ 77,527<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncomeLeasePayments', window );">Cash paid for amounts included in the measurement of operating lease liabilities</a></td>
<td class="nump">$ 78,847<span></span>
</td>
<td class="nump">$ 77,527<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating leases</a></td>
<td class="text">3 years 211 days<span></span>
</td>
<td class="text">3 years 29 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating leases</a></td>
<td class="nump">1.45%<span></span>
</td>
<td class="nump">0.55%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_ScheduleOfSupplementalInformationRelatedToOperatingLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_ScheduleOfSupplementalInformationRelatedToOperatingLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLeaseIncomeLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease income from lease payments paid and payable to lessor. Excludes variable lease payments not included in measurement of lease receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6A<br> -URI http://asc.fasb.org/extlink&amp;oid=121640914&amp;loc=SL77927221-108306<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121576215&amp;loc=SL77919372-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLeaseIncomeLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140266712005816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Lease (Details) - Schedule of minimum future annual payments under non-cancellable leases<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_ScheduleOfMinimumFutureAnnualPaymentsUnderNonCancellableLeasesAbstract', window );"><strong>Schedule of minimum future annual payments under non-cancellable leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2021(excluding three months ended March 31, 2021)</a></td>
<td class="nump">$ 253,618<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2022</a></td>
<td class="nump">352,248<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2023</a></td>
<td class="nump">359,591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2024</a></td>
<td class="nump">374,584<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2025</a></td>
<td class="nump">338,676<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">Thereafter</a></td>
<td class="nump">56,916<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total future minimum lease payments, undiscounted</a></td>
<td class="nump">1,735,633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPortionOfMinimumLeasePaymentsSaleLeasebackTransactions', window );">Less: Imputed interest</a></td>
<td class="nump">20,893<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PresentValueOfFutureMinimumLeasePaymentsSaleLeasebackTransactions', window );">Present value of future minimum lease payments</a></td>
<td class="nump">$ 1,714,740<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_ScheduleOfMinimumFutureAnnualPaymentsUnderNonCancellableLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_ScheduleOfMinimumFutureAnnualPaymentsUnderNonCancellableLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPortionOfMinimumLeasePaymentsSaleLeasebackTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount necessary to reduce minimum lease payments to present value for sale-leaseback transactions accounted for using the deposit method or as a financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121616839&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPortionOfMinimumLeasePaymentsSaleLeasebackTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PresentValueOfFutureMinimumLeasePaymentsSaleLeasebackTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of minimum lease payments for sale-leaseback transactions accounted for using the deposit method or as a financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121616839&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PresentValueOfFutureMinimumLeasePaymentsSaleLeasebackTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140266709872824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business Combination (Details)<br></strong></div></th>
<th class="th">
<div>Feb. 08, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_BusinessCombinationDetailsLineItems', window );"><strong>Business Combination (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_PercentageOfGoodwill', window );">Percentage of goodwill</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Goodwill write-down value (in Dollars) | $</a></td>
<td class="nump">$ 43,647,626<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=abvcd_BioKeyMember', window );">BioKey [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_BusinessCombinationDetailsLineItems', window );"><strong>Business Combination (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued</a></td>
<td class="nump">29,561,231<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_CommonStockIssuedAfterStockSplit', window );">Reverse stock split</a></td>
<td class="nump">1,642,291<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock per share (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.50<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_BusinessCombinationDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_BusinessCombinationDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_CommonStockIssuedAfterStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock issued after stock split.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_CommonStockIssuedAfterStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_PercentageOfGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_PercentageOfGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=abvcd_BioKeyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=abvcd_BioKeyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140266731523464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business Combination (Details) - Schedule of assets acquired and liabilities assumed based on fair value<br></strong></div></th>
<th class="th" colspan="2">
<div>Feb. 08, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_PurchaseConsiderationAbstract', window );"><strong>Purchase consideration:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredOther1', window );">Common Stock</a></td>
<td class="nump">$ 44,341,847<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_AllocationOfThePurchasePriceAbstract', window );"><strong>Allocation of the purchase price:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">531,147<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts receivable, net</a></td>
<td class="nump">188,550<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment, net</a></td>
<td class="nump">56,075<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets', window );">Operating lease right-of-use assets</a></td>
<td class="nump">485,684<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets', window );">Security deposits</a></td>
<td class="nump">10,440<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total assets acquired</a></td>
<td class="nump">1,271,896<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(56,204)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(251,335)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvcd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="num">(267,256)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther', window );">Tenant security deposit</a></td>
<td class="num">(2,880)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Total liabilities assumed</a></td>
<td class="num">(577,675)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total net assets acquired</a></td>
<td class="nump">694,221<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Goodwill as a result of the Merger</a></td>
<td class="nump">$ 43,647,626<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">29,561,231 shares (1,642,291 after stock reverse split) of common stock of the Company was issued to BioKey in connection with the Merger. Those shares were valued at $1.50 per share, based on the bid-and-ask share price of common stock of the Company on the final day of trading, February 8, 2019.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_AllocationOfThePurchasePriceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_AllocationOfThePurchasePriceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvcd_PurchaseConsiderationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvcd_PurchaseConsiderationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvcd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredOther1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tangible or intangible assets, including a business or subsidiary of the acquirer transferred by the entity to the former owners of the acquiree. Excludes cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredOther1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>87
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MTA=&[<BG82WO5%5 &38@-OD1N8@P"7?1,B$)61[Z.0P90(UQG^P9JSR,U=^
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M]&G/!&VYEH@V!5KR&@IEUZ[@D:$_N)3H['-##T4)KJ_0''V^?XO.?GYUL5"
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ML]7*P::+13K16M.>2ZF_(>VX8"?%H<C! ZN'$Y)FHQT=MY,A(20>>,0A%N.
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M 'Y?2*D^;O0+I^UKV.DO4$L#!!0    ( /&&JE+UN8G%&1$  !4O   8
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M#@X[8&62;Z+<KN>&4A.U B7;>""^("U:I(('99>(D<^Y^*#FMB9!68+1)2&
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M:,>3#IO1X[5:STDPBL%*,E3JBD,1S=P ];E= \T](;QFR'X< #^@"(DJQE8
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M"_@YEEAFGL1I$696!@GO)2SHF6L]M$!C. 8CE6F0..&RZ,':A"'2]QUM.U2
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MG\65CJ+GNV44=MO>*CZHO;(-VC?E%].M>WO4O;U=7BW??1^Y5[ZKY>[%^0^
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M:R+ ][G"J;1YH0TV5^'G?P!02P,$%     @ \8:J4E&HZUG$#0  &DT  !D
M  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL[5QM;]LX$O[.7T'DNH<44!U)
MMF-G^P*D:7KM-FV#3787Q>$^T#)M:ZL75Z+B^G[]S9 4+<F2X]>DP!4%&ELB
MAS/#X3P/1[1>S.+D:SKA7-#O81"E+X\F0DQ_/3E)O0D/6=J*ISR".Z,X"9F
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MX(#34?O5DA^NE475?8*%&C)0 5F)"GQ< CBI\'?CPA59GPO)W=)6?"A??@8
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MCZ^=#5B[/'@>O6"W*U6:ET:4.00:(,\ .5LH2 !M-%,I,RO!4I5!(LEB^2H
M<RU69*\;L1#Y7)3X$*#QT(*CX)J;%=^R7PMI1,+(&L<L/AV'\61$OZ;A: 33
M[JZN[>AT%.,;-HUB.V(%T-CI9$1C[G]PIPS/0$H4GD83)Q%^QV<TJV?KSP5[
M7Q6"Q3-T<'0:LBNI/L XN^-R ZKR(O'7!;1.%& 2$"(+HQAGJA OMX*7'1OQ
M92D$,(5AS]%$__AA%L>CUSX$# -V64^D*='K%R"4H8!<5; :3/SI[G@:3D:D
M8LC$[Y6\YQDL"&#O8V>Z ;N#7<A/VO 2I7N*00J;%22IJ4IIMBSAH"(WWIRI
ME4'HYSSCQ4*P.2BE44O05AM<P5D*,PPXFY4H1*7!N@1*M$_KK-(L&D239U98
M9TAJHJH$C&5Q)F*MM#1,\WN4UFSBQ/:X:X#^NA5K8P/KU,)N?!8XGXD'(S#[
M*38?LS@$;HF^8^B[D&U6$F)WPS5+*H$P=[<".Y$9C=6L6,@UA-L!1P6MHYCG
M*-#A\\(H%!O58G>B[ND:-'@TSWM!!8>BIPOJCQKBK-<39X_J$?QO>AS,@N_J
M(??5" AP/.I3(Q[]G>YX4HP\50T'.!JP2^+BEGR);Y&[NBSLE$-X(DT%]1Y-
MV@68=IJM82HOBBHG]\>#Z%F'%0 "U/8,)I8\D_\!]>=;$C>O9)9@$N.6,E^7
MZM[: T#YM@SM%,UXIA7NIE4!]EE6O.2 !/C5B;Q6^9H76R3%:/H:-EYQ"1U/
M,6#O:J(0#] &:@"]@6=V'(7CV9C$X\_IC*R(@6=6X!Z6V[[ .K+'4M8X('AM
M+9-M!ZRM0G6A@")$I$-+WE?9EF'8>S3D- VH=#0"O(JAVZKJV$^+187#/05$
M^Q4$)?I1IQ^K')&-M+YH&T\BFTR(U)^ZFU_-5-\^5PK#?:,(L=Z)_OUBPPMP
M\S9P%INA*]E;,2_Q;3\1+E0^AQXEZ6R"8+V$K%L2VTL1!C)2-XDHT=W^+)HY
MN@KZBGWC,7) @NK;[=K-: _."NCO/26[S&EC8]:A2^_-7K3X'+/OY*=12WS8
MA74?A6;1\L'E@\\N@>I8:=KAR.;EV9,H\B^ OQNL3X&/Y-C)R1H[O9G^2>#!
M_\/NK&OW24WJG[V7U$/__7;_#OS@<;LWV'<[24VMY&XG*1\ >=WO18/3V;.V
M /EUI^%'J@Z(0FSK#I)8%<19*@6&6"Q(MT;U)J=1)@BS2<P/%R'VG2)$3 &>
M>"M+;0;!#5  <#BNH%. ]4A/Z=UQW@H@X%4&3.;L[OK&1TZHJ1Z 'QIL+0LM
M%6X*?MGP,CE<%N/P[.3,EL4XG$XF?T59[!S!.D$:1S6W=6P'2Q<"UJ&*"#L
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MPY0S?%30 =Q?*H1^/2$#[=W?Z9]02P,$%     @ \8:J4F\=##H% P  >P8
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M^8;_XP]^S5?&:KH)OX]0CSKJD:<>':+^^G!Y#\OYS_GB^O*MU!V'Q]$ 7E'
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MX ,U,MVTNB:PJO3M9:4L-2L_S.GK@-IMH/6UHA)L W= ][V9_0%02P,$%
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M*/_=N(]=XANKWS,E$0Y%' 48QPD!SM8V57X8CALXM=K9&I#J,"0K(@W\IZR
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M50?ZU(Y(&B[U^ 6(U> :5,=HH8]% J63$+AZ*[))+&H_Z""T+)/CL5^/SR6
MAZ*4FWV?=?,6HP#',:6M+52&$YW6M]B$V)K2U4CD,M9M&WQ;X-V.'JQIY U?
M._T^5$RPE@ L"0;UPY2/O>4$G!4X1_'TH;IN'_JFR<.N*(,UTDX;R7%&-?<M
MI!6L1AYZVI[M!=XE@8=]AG:0JI1N):/@/A\KCSU+"SSND76N&Y*QK6S/DQ=-
M(?RF%MR8GGZHPX&S=67-9<8&'KX1.EXOITL_7BS8E1)"7UV%4TAQ;ZER$@LH
M*=,8U>K W*$=I'IO)*MQIUY@I24^=<O#CF]YV*<6D-95+P5V2/MG/GL'ZF>K
M[ ZV=6!T6=[!,DP/E>+/8*MU2W"7B4]4?*@A._:.XX0>VE4\^@1=U.Q'66RK
M 0U,78;(\187ZC3I%^5P1I]#Z!)X+@F-_3ZYF1A#N:%)P9L_18OS0-0"D+)A
MK30OZPZB62C%,G"XO*IU*W=8>GKMGBS_LRG4_WED:_^9_#Q*]%:J@:]84U+M
M_*7+][KB @OF331UV]Q:H2'>U$_"J;_0*-(A.]_3J1_!-GJULHF[6ZL4TI=I
MI*"0W_%U+J!HD+-JW&LO<$E-!RZ)X7<O*4(0ESABA?") N(#\D,X"WP<=B!R
MK.WDG.);BSCU-;@>]"#CR*:1>]^U.+N,1HF E]X3S#_3XO07J!@I;O75C8W-
M6(/!&U&W)NDDCC&[&H<:F<B!,'*':0WG[*@Y: U$NJ6*XV,'S$F# __2'V)[
MT-_*V@NZX<S$&8[:@@Z.&&3_V+5@F4[JEC.CSE)X<7 **1XH]&SO/E+.0XES
M4+^HR$RCA9_,PQ^)B($(9B!Z4$@'(E<[?9LS9&&D JA!2CCZ_;#2,Q&;/2[Q
M4M^GQQ</JE)AQ0*L^X:N*LAW5WU21EV# 0%Z9Y(FGM3&8CW%).9NT^EZC;44
M0J TX]#&PL/$*-WDYZ2RO&&_#HEA'OGQ]*S>[G@CJTX-N,.G8S+LTH8X-J^&
ME16;0_<$P$FA?<\2U+M("^8F1Z=5Y\Z96+?]A/%>/Z%Q;M_<SD?H9.*M',W/
MMJWU/A%?#9CA"^36BI3TH4S9)8.F;3&;LC#VEXN0UOVO*'5IM(-E=.5@N630
MJH7)W!LDEWX-)+H _L*032$-SX/(P_IW1"K4<UX61=#T+[P_()Z.UBPCP!L!
M<A1-(YJ(_2*AD@$(]\-EX,_G,^@( C\,0^\;6?B2]?:=+6=^D(3]X#V,AFAI
M;0?OV2,&[_"7 =XY,80_9:*S@WE?@]K!]/SDO!P;,6UF3ST\,Z<2&?53*#AB
M.)2RPPM;5Q;W0<:A3WN4].@)M&\-SHT&HSZ0:N(:$EQ"*X:S4E'><H <[CO[
M$$*=\U3G5/@:_QWG>J=#GD$O [%+3)@*2=K#"6=Y6V$,VC9$W.D0/(M4_#/Y
M&8=Y P&-1](D1Z9H[5'2/,C<Q+K98F^ZB*@M'^.,>[C9W-R*)I5J.*":';87
M^%Y6Y*H))6BEE8(M3HYH;4#$-( 6O)Q *H=UU:*VH;,<]ODH56_(8[3F(?(B
MGE D@*$%I6;ML-2=Q4G?#CE=Z6M"K!3#L0,YB4[JK.C:CN/U9F\R\-,">TPQ
MMC#XA.?:(BQ-*"VI@;LM5 Z$..<,NECW<B;W>\/1#?8J5Q56B2$;WK'24<9!
M5/1W4?1\SDJ[_7X@F2Z&&F;T&_7S;AACVI.IL18V;/9]_U^5@"H]*-T\RZ2]
M'<3&@IX4:A[62!2,?=SO37WLO=$$X2''*8J9<E'%Q%1K_=4[]E<-^;2E!GZN
M4]L)LSZJ503%>V<!"F?G1R_<=11&JPWY_' #%80#33\ "[UQVCEL7-:Z@4+J
MR6$L=N4Y)_1UD&5VSFTNXD<&60YO6G1S2*T]74C=GRF4N\3;<F@:UCC%UJ'Z
M>!N,=*";(N37MF69R^+TI(%<=^9) 80S_BQ,_#@.W42''&*:N Y6N7M9D/@.
MLX*K+RY %<\/'S,[/6]T<[3Q/95UZX$:M;=N&N&R&1B@Y>D6Q-&7//C WXBX
M)9J-&DO/-I8^B_UX,46!'YALCJ@^D5E&H7$J,,P@98/3M</@4$\1'8,[\8>B
M Y2U6,R?(#S(F2XC/2.<S!:]@3USSW,<)^-QP(-!<G;3X=2DCP?OJ,HL0[P7
MFR&?2G['YT_NJ$,IL3TW5R,X>*^ @:Q_.@R/D<VH:0&YRU369NZ+]T2-+;MF
M7"?)$Q3V*[ T[S+K3-24I'UG8R"6>P[HA<<G[*/8UX#,VC$3PV ?-.T1H/M%
M-'.VZ6D/GW!83-T#'RRQOGOXM!\^(1E.?R1R=,4Y"=M^G-C$6P.^SKAL^.,D
MAT /XB>2?.K'X+I/)/F/$IMXT >\F7R"_QXI^=)?SJ</2#Y?]))'P5G19]AI
M/I7H/TQLXD%\?_QT\SBY(WQL-WH:N:.9G\3!$\G]P\0F'B3#/SHB^0\A'R5^
M#(XU?U#\QSD\9(TYK'P:Z7^8V,3;@-5O/CW.ZO/ C^;WBTW(8M@U+,_;/?##
M*'PJN_\HL0ES(^$Y\5-4#98%:"-R=>ZI3;X&L0YKQX2=^H'2]>#'7O2 -?ZD
M#5D ;>K??;E/W:_F5OK'8OUR_9,[J+>W$C!D+C:P-9C,DPO6Z)^QZ3=M5=-/
MQ]95VU8%O=P*Z*H:7 #?;RH0T[S! ]QO"5__/U!+ P04    " #QAJI28<N
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M$S\8OEGR"XW&!?#\1O-2[3LN0?_FS_\!4$L#!!0    ( /&&JE+1S$I-.0D
M $D7   9    >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;(U8VW+;1A)]QU=,
M,=F47053O).2)551LI-5REF[3#EYV-J'(3 D9PU@D!F E/;K<[H' ,&+E'TA
M<9GIZ^G3/;C>&?O=;90JQ%.:9.ZFLRF*_.KBPD4;E4K7-;G*\&9E;"H+W-KU
MA<NMDC%O2I.+0:\WN4BESCJWU_SLB[V]-F61Z$Q]L<*5:2KM\YU*S.ZFT^_4
M#[[J]::@!Q>WU[E<JX4JON5?+.XN&BFQ3E7FM,F$5:N;SKQ_=3>B];S@=ZUV
MKG4MR).E,=_IYB&^Z?3(()6HJ" )$G];=:^2A 3!C#\KF9U&)6UL7]?2?V;?
MX<M2.G5ODC]T7&QN.K..B-5*EDGQU>S^J2I_QB0O,HGC7['S:X>CCHA*5YBT
MV@P+4IWY?_E4Q:&U8=9[8<.@VC!@N[TBMO*#+.3MM34[86DUI-$%N\J[89S.
M*"F+PN*MQK[B]I."2]<7!431@XNHVG;GMPU>V#84OYFLV#CQ,8M5?+C_ B8T
M=@QJ.^X&KPK\3=JN&/9#,>@-^J_(&S9^#5G>\ 5Y\\4WB.I/WO4&XM%*@(A!
M\._YTA464/C/*SI&C8X1ZQB]%+N/\\7'<[%[=1N5V97+9:1N.J@CI^Q6=6[[
MDZY@>>)QH\2]27.9/0L9F[Q0L?AYOK@3\R@R95;H;"T6A<QB:6,7W)M8KW0D
MR;M0/)I<1V(V&H2"$^O$FY]^F T&O??SQ3T]Y[O^^[>B="2G@*Z4)4")584U
M+E=<)T+FN34RVH3"5U"U.J?@05\BU%.N8JVR L]E$<@$]>UX36U]9O#.0*XK
M9*&$+IR(Z)65K"%75IO80:0VEA;27O:8,F56?.\J3P4>_2JS$L0A&"7]R^YA
MJ/(\(2]HT\J0,63R&7.=T!FO*AI8!)7R#"32*,2?8*<@M 3*K:AB>!7\],/E
M9'KY7GQ%C!%DEU(48#!T:(OE<$<]:<=!BU G9(2[.C"7@XJE38R\I%#(PL>!
MW/%I%3&B%XK=1N&%%;S[-45\!3K&^X1!$+)$OA91 D4-8A"IEP76FRD0;-(>
M?[1-9X@= AMC8U1 J8/JO;P#(=TF9-]@ R*UT5GLB##/1P41*;&P644IBU6A
M+!BP1J+WAYZ)-X1 H1T'*2/_G4;":*5'DR.)ZJE0&;OH!1$F]X+82R/RTD8;
M%HPWG/;DF>10>HJWO JV^&31<PW#M:T!8,G8=X5Y1];SEI;KIVBI8L1!]_%/
M2 '90XM>AXS:RJ0D'_Y>#E>HV"FK>#-89ZM-Z9+G.J?8P9ES5;X. -\+Z<5A
M*1S6S[DRZXI?3 65'<HIY.*"CH9NCDS<Z2012]6XM2^Z;^)?IEN3^3Z<"^69
MQ'/%/HF9R=[58$?D3.8C^<DO6%O5CDE5*F)IBLV1C&,10B)\:Y4IBU <1\YY
M8U3RW#)P8RS 0 #ULE G9IWYB*DGE3(T#W,L$V?V54#\]W\)8:,Y@I3?:LG_
ME/CZ^5L%0PJ]%Y!HN=0)!"A?KE7&=QH1D*+2Y#@^F>@/D#!J])YL*8>TGA+;
M$*55?Y8 G6N;%M0I<43<Y @5I4ETS*E=2F0_(N\4V09X^<HQ*ZZ<NFG!_*9A
M56Z0HR=^=-N.6L5=E?N2"JK DIC^]'VEI^:7X_KV 3DDEQ=4'JH1QVK,,M%K
M#T[H2N5W%7@1N7Q.*S1I#N/*FG2O$JY\1E^4>^YLNT:6F*/7;9L(H4WR8YY6
MXSK^E;4!E9<'^:HL2FP@2DW+&EZ-?6:KCD,AN&!2O(^XAK@Q'73AQO\CV=Z2
M1C9B'U//K2E=G8WAJ7]TR$#IZ2Q*ROA8NB6+:A5=,<=RM"3BAK."G8@-54N
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MP[K 1(=:%RO-'C54>X:Y@@JZ.)2DT-1B&U*,H0G PO3L&125;!  @S,)'^B
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MJ0KW$M4-SU-&UY%%5Y-+ U(P[%'E:%F2TS0*QL?])1/PAQ9>AH'.-V#Z!$R
MQ^Z0?:@US5>AJ)S[8)'M1%:.9#LPCH56(#T"G4HB8*AVI$FI1X]N8T%^^N1+
MPTIE&<%2"#;?>#1>R&9+\ON*U+ABKNCY2RU(\Y2*-C!J9)ZV.4;PJ$MZ1+W-
M*TD#VK$SDF/=)4](B/6 J:ZZGNM?&S#A/1O0X;ZWU&CGA>KN87J'TQT*.FL?
MJ_UN_]2_:%^X3^+M[P0\#7'C&;#5"JK!<!8/6K;=?EA5N??N4EF\GMTRP\\5
MH4D YRN%IT[W00[Z'T#G_P%02P,$%     @ \8:J4A'W+J>V @  W@4  !D
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M:F">NNF=\$EB*YMKV),-H@C>^>>PVFS95T13!%["ZPQXNV_!1B@4J[*Z$VZ
M.D.+?X63-\+K/.*U(7< #/3PV9POZ:45J>XP#Z*]CG_%XU%TNM5C).89.3;A
M@716W,(..!$L8/H8OY(77 1S#QN >X']%;[-2[3G$Q\R8*)@AO4OD VW;;-
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MY,W_6':?)S?FZX>S)#F1=V&U>PX;<_9%(^;^T@[-J@:/W>+8LI]FAW5GI[C
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M5E=]$W55=Q&]W%>:$:59,V$H#5/2_AY0>@][SZ=Z+/8F^*F96(XZ)"6OR>%
M+>5 >\R0(D;\>I0[%51Y-.7)3TUJPW2>#(=G7*J(F$2P0+$HA7B(P]@PF9H&
M($R%01M;]=<D^502ND%#X"Q:S@O%(LT^VTODDP$ZZ[O>3VT34N*H82RAE$KB
M'7"&;;'T U5HP\,;K$^@@-G%A[=4,/KVMS=/?WMS\?0"__?L[/0_D4MNRZYC
M17Y:"AJC&C-%M(X4696TAV.'4:CI/I@*J-;31,ZJ"W@B)C(:.F51DO7()Y5=
M%?RF,5T/)62. -CC=C9'B5KVI5NZEGH'#A4=)!<M,QTE+FIEJ9JNXQ,CFG%O
MR*$+2SJ4GX@R#"/,-J\QA";#R-:^3W&[[S*R8UD?38(=1Y;'/>O'^E2,S4RY
MB$.OQ88<=\UZC7S[&$L*HR:\@^.=A+%."X0VK71HX]Y_S(CW.\!-V-1,KBVF
M4S9LUE@XN3W,Q%/NSX!?8,F148LL*1PTLA-&B"PWV?")7%&WT,2E4,P=3,;C
M:<(FXH]J4A+<E?1DFPV'K]V 4J)R+(X\8^6$K'W3<<L.,X(D</A@8:W++WXU
M>HQ[1$[-&%ADPWZ>B9B4B]%6L54!+LXE+4SVY'2VV7Y&[M!QWI9MG<D*]YU)
MX, .CNTH;.H2C89[W5$SFJ&J3B@2%PO7 E51%DV'U1;1HP"T3\%2-1&4EAYR
MD"9:(T>GX-YVT%Z;U-V1%$-Y:$H?HJS*Q'U?HJH&F[&/1BG0=@GJ5*O7V$!Z
M"C3LRV8+'P)*?]H?76/SXVJA-/.W3&2#$]X5ECX15=9$@O&$>^R%TIKC>\&8
M#I(E$L.BY.0MO"9@-:"B'9LHD?Z8)+3#$1LGE^%N4RZ4%!W&GE:H7MP0:R$
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M&9\/1<[<T+Z7E/L8PS9G'N\&Q,M(B3PE]P7O;1'IS@=<1R![-U(Y!]P:(#Q
M$IJT&+@T:17D#^=4'YA@+;$8SCA?Z_RQ,*3SGED!4>=$B"N*EY#S5*PHB]&@
MP ;*4ZY^[8N*KI +'#5J;'A#:]-\1CCR$5_?[Z 0F#7I>719BTM22,SIB3T%
M\G@?E+0^,!['P'GDB$N"NAEG2FIH3STR<-)X@$:]2'L\P6[6)Z%+GB'>+K9_
M/T"([$L;/S"A%96U^R9M:T+#71SKI149I%9W=&AY*]7:2G]"7EASKLK(8>7$
M:A <JU8K<J).0K?EE1-JM/NVKP+$B$](U$!W&3S1;(&B?7U3MDV-@+ZR T40
MC+!O;56-7!<4P+'1#ZQ_8R.89!FA]U4 98^PC'+/_CUKH8-5B<YH*9&(</&V
M.W9:Z)"QW;@*+SY)UO6!Z>UR@U2PN!/<TO(H?V3)CMM,>^J89NVQ"20O"QX
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MN%4PM7>H_ 9SG6-5F:HF@4 6_JX)G1C'[2-Y3,Y*UPLDPDV!"HW3L<*=]/Y
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MVP+@G.L;+K:FE %YPK(-BGE'V<,G88YC1R=V/ID?[U5R:>X6Q65>AL;3Y8&
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M%-Z,C__TXPY.P3N0<*BH5'X-KY[.7CQ[Q#6'^@< @T-B_57?;.DC%H#Y%A^
MW]<-F)_R!TZ =1H$WD__#U!+ P04    " #QAJI2)>YWA$8"  #D!   &0
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M&.*I",N*GR&TWH'/"V-HO_$"_<,V_P-02P,$%     @ \8:J4@(<3BB2 @
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M'&IG0/=KI>Q><0&ZI3G_"U!+ P04    " #QAJI2@%O[SL8"  "Z!0  &0
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M!>T"\/M:*;MW7('#NI[_ 5!+ P04    " #QAJI2^P^RB:(%  # #P  &0
M 'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6RE5TMOXS80ONM7$&Y:) !C2]1[
MFQA(LJ^BV338I.VAZ(&6:(N()&I).M[TUW=(V5HYD+5&>[!)BO.>CS/DQ4;(
M)U4PIM'7JJS5Y:30NGDSFZFL8!554]&P&G:60E94PU*N9JJ1C.:6J2IGQ'6C
M645Y/9E?V&_W<GXAUKKD-;N72*VKBLJ7:U:*S>7$F^P^?.:K0IL/L_E%0U?L
M@>G?FWL)JUDG)><5JQ47-9)L>3FY\MY<IX;>$OS!V4;UYLAXLA#BR2Q^R2\G
MKC&(E2S31@*%X9G=L+(T@L",+UN9DTZE8>S/=]+?6]_!EP55[$:4?_)<%Y>3
M9()RMJ3K4G\6FX]LZT]HY&6B5/8?;5K:()J@;*VTJ+;,8$'%ZW:D7[=QZ#$D
M[@$&LF4@UNY6D;7R+=5T?B'%!DE##=+,Q+IJN<$X7IND/&@)NQSX]/Q6U*OS
M1R8K]$O]S)2&>&N%3A_IHF3J[&*F08>AG&5;>=>M/') GH\^B5H7"KVK<Y;O
M\\_ MLY LC/PFHP*_$3E%/D>1L0EWH@\OW/8M_+\$8?1*X?17U<+I24@Y.\1
M#4&G(; :@@,:'N#@Y.N2(;%$8E,SJ0K>H(;)#%0!T)79X%8Y8T,1'A?_VX!(
M!Z*4%39,;UG&J@63=G&596)=:UZOG#M:68LD*ZEF.6JHU"\VJ.;/11J.=)M]
MYUK"85ZQFBFNT#47FF5%+4JQ>D$W8HK1K<ZGR)UZ,?IQ-]P(I=$GI@N1.Q^
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M@_!*X@2[8822U,5A%#@/ZP7D1M,2I6Z* S]"*2'83SUGKT@,>#"$,N+%. C
MB"C!OA\-P.0<G3N/5M\)\K!'(IPD03L'BV(2HQ$<Q!T.XJ-QL* EK3.&[/UA
ML :-RSJ0[)NUE.9@7"D%8JT#Q(MP&OGM/$UQ0HC%1+9/2B!-D",2PBP,7.P&
M7B?MEM,%+[DV=<S#:9CBU$O-+(FP'[A[XOJT<83=A*#8ARC&SH,6V5,ARAR:
MZ$\_))"4GW<EW\.)%T#(8YC%B8M]$AUHK ,>NC&.$@-'SX L3(PYKYSSTQ!'
M48@"#T 4D ..!:&'?6N#GQ(<AU%?4I^4)#B)8^0GH,YW'@#[[)5?;QF46*[1
M:0HQ2*%1GZ'3!(P(W!2=C4 IZ:"4' TEI:$+M;='<^^!NXG%]!"F1H4.5Y7'
M0D(Y[E\MG>[JXMS!VT51N*_:Z&/BI^W$\USG@Q307*"&+R$.,0#!A<"&<6*9
M2K-W2H@+%20TP?$)9"@DZ*P-9ULJ(7FJ[0V\=T6F[=7*M UHHJ:+K6Q-9RV6
MJK8RG 90I5+/R(Y=''@P<X[VY=S\MA[<MQZ8"O'-<D@E8,H()X#=)'UM]W^U
M&K2,59JT@T=Z_,VG5="S90@9X_)& ]<YON]*U\JW>3SII>3D6U*&O)WU7E70
MCU?V[:B0#6#[P.J^=L_3J_95]HV\?=M"%5GQ6J&2+8$5[KYPM9/M>[%=:-'8
M-]I":'CQV6D!3VPF#0'L+P7TM.W"*.@>[?-_ 5!+ P04    " #QAJI2#Y=X
MIE@"   #!0  &0   'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6R%5$MOVS ,
MOO=7",(.&Y#5MIQ'5R0!FG3#"JQ T<=V&'90;"8VJH<G,4W[[T?)CI<!;7:Q
M2)'?QX=)37?6/?H* -FS5L;/>(78G">)+RK0TI_:!@Q9UM9IB:2Z3>(;![*,
M(*T2D:;C1,O:\/DTWMVX^=1N4=4&;ASS6ZVE>UF LKL9S_C^XK;>5!@NDOFT
MD1NX WQH;AQI2<]2UAJ,KZUA#M8S?I&=+X;!/SI\KV'G#V06*EE9^QB4JW+&
MTY 0*"@P,$@ZGF )2@4B2N-WQ\G[D %X*._9O\3:J9:5]+"TZD==8C7C9YR5
ML)9;A;=V]Q6Z>D:!K[#*QR_;M;YYSEFQ]6AU!Z8,=&W:4SYW?3@ G*5O $0'
M$#'O-E#,\E*BG$^=W3$7O(DM"+'4B*;D:A-^RATZLM:$P_E"FD?VS4KCV?M[
MN5+@/TP3).)@3HJ.9-&2B#=(<G9M#5:>?38EE/_B$TJHSTKLLUJ(HX37TIVR
M/!LPD8KL"%_>5YE'OOS_55ZL/#J:!?9S+_TZ$F#8!QC& ,,W MS1LI1;!<RN
MF:^LPX\(3M.\4%Q%<5_KZ5'&L(SGOI$%S#AMFP?W!#STI:AB8RZA +T"%Y23
MT*70JO1D*;&2+^S!U @EBV6_8V*<#\0HC=)DD*;D=K]8MM9)*L(-FV2BM;0$
MT38>I='6G2?W%J4BEFPPSD8=(\GB4_1ZK8O)P6!J<)NX?IX5=FNPG='^MM_P
MBW:P_[JWSP.5OJGI_RE8$S0]G8PX<^W*M0K:)H[YRB(M310K>J7 !0>RKZW%
MO1("]._>_ ]02P,$%     @ \8:J4HHF9;28!0  ]A   !D   !X;"]W;W)K
M<VAE971S+W-H965T,S$N>&ULO5A;C]HX%'[G5UALMYI*+L2Y,IV+!$RO,]VB
MF6E7U6H?##'$:F)G;:>4?[_'#@DP91!JN_M XLLYW[GZY)CSI51?=,:80=^*
M7.B+;F9,^:+?U[.,%53W9,D$[,RE*JB!J5KT=:D831U3D?=]SXO[!>6B>WGN
MUB;J\EQ6)N>"313255%0M1JQ7"XONJ3;+-SR16;L0O_RO*0+=L?,QW*B8-9O
M45)>,*&Y%$BQ^45W2%Z,$DOO"#YQMM1;8V0MF4KYQ4[>IA==SRK$<C8S%H'"
MZRL;LSRW0*#&/VO,;BO2,FZ/&_17SG:P94HU&\O\3YZ:[*([Z**4S6F5FUNY
M?,/6]D06;R9S[9YH6=.&81?-*FUDL68&#0HNZC?]MO;#%L/ >X3!7S/X3N]:
MD-/RBAIZ>:[D$BE+#6AVX$QUW* <%S8H=T;!+@<^<WG+<FI8BB94&<XTNE=4
M:.H\IM')/9WF3#\[[QL091GZLS7LJ(;U'X$-T'LI3*;12Y&R=)>_#RJV>OJ-
MGB/_(.![JGHH(!CYGD\.X 6MW8'#"XZP>[5K]5_#J38*9G\?D!.V<D(G)WQ$
MSAV<HK3*&9)SR.%:9NEDFBV9^QQ\&/</6CA,)@P',*G06Y'RKSRM:(Z<<18W
MXR7DD\F0R1@:RZ*D8H6H2!$W&L[A5/.44P5Q[XRX?,65-D"E2JD<.SJQ;$]_
M&_B^=]80N"DY>P:1=9)G$&<E\QSLFFYF7"S0E DVYS,0L$(ZHXIE,D^9LEI_
MKJAX#=L;L2?#RCH]Y_09F@#LC4E[>^5O4[:Z$,_['<FEJ)5H2,]^C8ZW"W@^
MZA>WVRIRMXNQY?:S)E0_ITPS>%2?AJ!5:7R<A"U5.T/-Z4$A#<$^NW^1H2\K
MY_9WG *#+<"P/U$,,A;@70Z/,\JA+HO.-5N5DL/J/9ME0N9RL2=_&B([)0FH
M?&\-7D-8R2T*AZJU)7S-H%$A 4[U.C?6&T,%)VBB)"S:Z5LQVQ77$AV1&IW/
M$DZJD-,*?4A!(;J#5"^U,%=<P0=-?H=AG38!$<7WNK1;&Q HIJ\9?,H9NF$,
MHY&D*MV!AC/TA:VP=89YX*@6K@=!4O*Y3080^I5I4]C8/*5%>89><4'%K$ZA
M[Z/1,A[CGIO1:_3Q;HCW>+G>^7_J@ WIP5/1$!Q5#7Z)2M>\R*0]X1J:$"H@
M)<>RA_<DOZ4[QM7O(3'N=246SX%(B/H$8$=RI&X/OS2N/N+=)'*G]^6'AASB
M=,,-0V\ Q**[,%N:9J-=L-2[18"B@A736O3493$,TG4BZW4FNRSH# O(:/0)
M."N  "_=C-%)4]#L7NN@H=A?PQX>FR4X7S,%F8\HR!*LL:C6Y*$:U_9 @2V=
MQJYW%-ST4YDP''T:'^A2HK9+B8[N4F@A*W!N6C%DY$[/ GW"OD;E(+2]5+S0
M)9VQBR[<&IRWNK:;FV6NG;MBLSI^,.G8WLXV>-[#:O8$D=#'OA]M1NMP^G@0
M>8A@GWB=>VF@^;$4$?:2FC; 81"A RZ*6Q?%/^*B.7P"CG'20? ?=%+=F#Q!
M8*0?QW;@XU-"-I_O$/N#Q#Y#LK_3"I)33(@';X ((DOT!NY[US;KMJL<\0D>
MA -X!S@:!$U%1C%X&7X/$II$'O8\KWEOOL\$Q\2KGQW[^77514,,O=, /6_C
MEW@0U<$IC.+3&/O1P?@E;?R2_R[%#T+_8/3V=MQ/$'@X#I-VL FF'V*/)."F
MM@4\Q;X7U<]M=Y(!3NR9B''L)YVKVLBMN@$4,801,H;$X-Z8-#2L*'.Y8@PE
MD$=Q8E^)%[9A"8B/2>1;U08#'(;[P]+?NHM"S[9P-VX-]0P\7E]+V]7V4C^L
M[[(;\OH? 7#A@L.%+&=S8/5Z"50:5=^RZXF1I;O93J6!>[(;9HR"B98 ]N=2
MFF9B!;1_=5S^"U!+ P04    " #QAJI2;OAJJ;4"  !]!0  &0   'AL+W=O
M<FMS:&5E=',O<VAE970S,BYX;6Q]5%%OVC 0?N=7G*))VZ2HL4T@I (DZ-JM
MTUJAMMLT37LPR4&B)C:SG=+^^]D.S:A:>(#<V?=]]YU]Y_%6JGM=(!IXK"NA
M)T%AS.8TBG168,WUB=R@L#LKJ6INK*O6D=XHY+D'U57$"!E&-2]%,!W[M86:
MCF5CJE+@0H%NZIJKISE6<CL):/"\<%.N"^,6HNEXP]=XB^;[9J&L%W4L>5FC
MT*44H' U"6;T=!Z[>!_PH\2MWK/!5;*4\MXYE_DD($X05I@9Q\#MYP'/L*H<
MD97Q=\<9="D=<-]^9K_PM=M:EESCF:Q^EKDI)L$H@!Q7O*G,C=Q^P5T] \>7
MR4K[?]BVL;$-SAIM9+T#6P5U*=HO?]R=PQY@1 X V [ O.XVD5?YB1L^'2NY
M!>6B+9LS?*D>;<65PEW*K5%VM[0X,SW_VY3F"3[<\66%^N,X,I;4;479CF#>
M$K #!'VXDL(4&LY%COE+?&3%=(K8LZ(Y.TIXQ=4)]&D(C#!ZA*_?5=CW?/T#
M?+=&9O>%K')4^CWLZKV6!N'W;*F-LGWQYTB:N$L3^S3QH31V7/*F0I KR*1X
M0&4P!U[+1ABWEN/2 !<YZ((KU&\=]-$$;CI/]89G. GL^&E4#QA,9QW_=5,O
M45FK]\UU^TP9#0LE:^F;_U)D\ [2)!P-8Z#],!U1'_<9!<*95!NIN ^,V2@D
M:0I#&M)!TIN7\J)4VKR(86%*[(]2B&D<)H3U9KKDKZCHD(2$$& L' U&O5\-
M?YTN9>$P)4X1BUGOKD#X6G*QUF#3IR1,DB'0A(24TMZ=-+RR1<3A*&%A/R8P
M3(<A&5!XZ_:BO9&H4:W]X&M[,_:XVNGH5KNW9=:.U/_P]F&R#;DNA88*5Q9*
M3I)! *H=]M8Q<N,';"F-'5=O%O9]1.4"[/Y*VF[;.2Y!]^)._P%02P,$%
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MA32T)IR8TUY&90WH?BFEV2HV0+OI)_\ 4$L#!!0    ( /&&JE+;-0OYYP,
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MEHCB$VU+6\\Q4+@1DJ456#%(XZS\ID]5(G8 ^"4 J0!D*,"N /90@%,!G*$
MMP(4H9ME[$7BKJBDLPEG6\2UM?*F!T7V"[3*5YSI0KF77#V-%4[./O*(9O%_
MM#RU;(FN0(0\SHLY6Z'+C5 ((=";*Y T3L2?Z"T2:\I!3$RI"&@W9EAM=EEN
M1E[8[ 86(V2-_T+$PL$!^'PXW#L O_I_\.M^^,4F&B$;%W"_#3=5TNO,DSKS
MI/!G_[[,?_^@5M![":GXT</ KAG8!0/G!09WP$/(I.H'>K^0I:G:N3Q;% NQ
M@67!2[47(=4@SJ)#6>O?P[='EO5'#UFG)NOT.KK7O-#U4[BFF2)\$7$ U; D
M^GX+Z0)X7T+<>@_W3$?BU0R\WBCGU2%(%CX\GT'.A'Q;KH@\B>6A%Z?TZA9>
MM38\SK#GV&/?]E6E/^Z^(T,L6]3]FKK_>NH<?L7<W^/C$MOV+,OJ$!]@V.(]
MKGF/CRNLC^I@!Q174.\3G*FXL-4T>^LDY56Y;5>-1WP[(+AS3(-,V_1WM J?
MHL0JK^W2"6S/'=M=\@,LV]R;;H_)<67V><N&E!ENNCJVSU5H3;/&_=WZZ$)S
M#E2/C=T@<$GWK(:8MNDW.H#=DQ2:NU\^.'!<0MPN^0&6;>Z-@N!^"?DMJC[_
MQ29^,/*[LEY%]GI@.]!&;W"_X+0#K4(K D4AS6-)DX.!]3O%EK7_@Z6*[ AD
M.[1&DO"1FO1YK4:#VD4C2_A<ND0:72*GT24R7)<&F;;I-[I$3J)+Y 6UZ3)_
MK2B1G;\@1XK2#=OP(65&&E4BYU(ETJ@2.8TJD7VI(9:K&C8AW5\0@TS;]!M5
M(B=1);*O-9[KV!@[3I?\ ,LV]T:52'_?OP4> 7_=WS;22 'QSU5<3<\F_3W[
MN-.YK+RV^I+EN.[8]_U.TLV=:QY]BW=+>11G B6P4EAKY"LGO+P8*R>2Y<7-
MSX))R=)BN :Z!*X-U/,58_)YHB^3ZNO)V4]02P,$%     @ \8:J4I%WQI\O
M P  DPD  !D   !X;"]W;W)K<VAE971S+W-H965T,S@N>&ULI99=;]HP%(;_
MBA5M4BNMY(LD4 $2'YW6BTZHJ-O%M L3#F UMJEMH/S[V4Y("82HTFZ(;<[[
MGN?8B>W>GHM7N090Z)UF3/:=M5*;>]>5Z1HHEBV^ :;_67)!L=)=L7+E1@!>
M6!'-W,#S8I=BPIQ!SXY-Q:#'MRHC#*8"R2VE6!Q&D/%]W_&=X\ S6:V5&7 '
MO0U>P0S4RV8J=,\M71:$ I.$,R1@V7>&_OW$]XS 1OPBL)<G;61*F7/^:CJ/
MB[[C&2+((%7& NO'#L:09<9)<[P5IDZ9TPA/VT?W[[9X7<P<2QCS[#=9J'7?
MZ3AH 4N\S=0SW_^ HJ#(^*4\D_87[?/8.'10NI6*TT*L"2AA^1._%Q-Q(M ^
M]8*@$ 3G@O8505@(PL\*VH6@;6<F+\7.PP0K/.@)OD?"1&LWT["3:=6Z?,+,
MNL^4T/\2K5.#6;[>B"_1C*P869(4,X6&:<JW3!&V0E.>D92 1#<34)AD\A;=
MH9?9!-U\N>VY2C,8)S<M\HWR?,&5?"%ZXDRM)7I@"UA4]:YF+PL(C@6,@D;#
M)RQ:*/2_H< +_!J>\>?E7HU\TBR?0'I-7JDF+)<CM'[A%;^Z>?\SG$LE] ?R
MMR%!NTS0M@G:5Q*,L5PCS!8H-0UXVY(=SH I6;>4N55LK<P&LAL$L1]Y2=AS
M=Z=S=!G7#I(P\#IE7(4U*EFC1M9GT'635,'G:'.SZ(0B\3M^? X;7< F026L
MPAJ7K'$CZR/=8"*H83/?DD%5!T383M= KQ''%RA>%7;<%%'A3$K.I)%S"B+5
M.'I+-YC4?(O9 :7Z*<A\:[;B.M!FS[CE>5\;WLU.R=9I]'F@FXP? - <&"R)
MGDE,S==01]2Y?#4C[VRIQYV+-R*,NE=>RFX)V?T<I-Z:T]<[<^;HUY-3?1!+
M;(\R>#=MJ%WQ[@71^8HW152 ?>]CB_<:D7]R=@?_A5TDJ$QW$"7M<_B:N"B(
MSOC=D].*@EC94U\BN_'E^WXY6MXLAO8\/1L?^??C_'[P89-?5_2NOB),H@R6
MVM)K)7H^17X#R#N*;^R9..=*G["VN=:W)A F0/^_Y%P=.R9!>0\;_ -02P,$
M%     @ \8:J4C @P)?N @  G0T  !D   !X;"]W;W)K<VAE971S+W-H965T
M,SDN>&ULS5==;]L@%/TKR$^;M-7&^6JK)%+3=EJE18L:;7NH]D#LZQB5CQ1P
MTTK[\0.<V)G6TFZ9IKPD@#F'<SG<*QBNI;K5)8!!#YP)/8I*8U:G<:RS$CC1
M1W(%PGXII.+$V*Y:QGJE@.0>Q%F<)DD_YH2*:#ST8S,U'LK*,"I@II"N."?J
M<0),KD<1CK8#UW19&C<0CX<KLH0YF"^KF;*]N&')*0>AJ11(03&*SO#I)$T<
MP,_X2F&M=]K(A;*0\M9UKO)1E#A%P" SCH+8OWLX!\8<D]5QMR&-FC4=<+>]
M9?_@@[?!+(B&<\F^T=R4H^@X0CD4I&+F6JX_PB:@GN/+)-/^%ZTW<Y,(994V
MDF_ 5@&GHOXG#YN-V %8GJ<!Z0:0>MWU0E[E!3%D/%1RC92;;=E<PX?JT58<
M%<Z5N5'V*[4X,Y[7;B!9H#E="EK0C B#SK),5L)0L40SR6A&0:,W%V (9?HM
M>H_F]G3D%0.'6RE[1I1Y1$3D".XJNK*NF6%LK#RW2)QMI$QJ*>DS4CIH*H4I
M-;H4.>2_XF,;5A-;NHUMD@8)IT0=H0Y^A](DQ0&^3K-7'<_7?89O4E&6VRW1
M/E(&]C"4DN6(<KL%]^"BUNAF"GP!ZCOZ@:944%[Q9B@@H=M(Z'H)G?]M%[KY
M9)="5P:X#@GM-4)[P;VZU(;:G($<?:(%/'48POA>0$._T=#_MWZ1A]?Z-6@D
M# [;K^-&Z/&>?H7QO20@XJ01<1(DF9*LM$/JMUC_*J=PTM; Y+!=PCOE&N_I
MTPL$H<3":2LCW=NIUV<3;BLP[ARX4VVEQMU]G0H3X%!*X;80XW E_5S838+]
MLZFMNKA_X!ZUU1D/]O4H3- )R6AK+PX7SZ!%?Y!&;9W%)X=M4=K6YC39TZ(7
M"/I/R8AW;LP<U-*_"S3RX=>7YV:T>7N<U3?N=GK]<+&WS"45VMXO"@M-C@8V
M'57]%J@[1J[\_7LAC;W-^V9IWT^@W 3[O9#2;#MN@>9%-OX)4$L#!!0    (
M /&&JE+Y;NN"NP<  - ?   9    >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM
M;+U976_;N!+]*X1O]B(%7%ND+7^T20 GWFS=M&F0M+L/B_O R+1-5!*U)!4G
M%_?'WR$E2W(B4TI1M ^-)'/.#,F9,X?2R5;([VK#F$:/41BKT\Y&Z^1=OZ^"
M#8NHZHF$Q?#+2LB(:KB5Z[Y*)*-+:Q2%?>)YHWY$>=PY.['/;N39B4AUR&-V
M(Y%*HXC*IW,6BNUI!W=V#V[Y>J/-@_[924+7[([I;\F-A+M^@;+D$8L5%S&2
M;'7:F>%W7P;6P([XD[.MJEPC,Y5[(;Z;F\7RM..9B%C( FT@*/QY8!<L# T2
MQ/%/#MHI?!K#ZO4._=).'B9S3Q6[$.%??*DWIYU)!RW9BJ:AOA7;#RR?D&_P
M A$J^S_:9F/]80<%J=(BRHTA@HC'V5_ZF"]$Q8#@ P8D-R!M#0:YP>"9P<0[
M8##,#89M/?BY@?_<X)"'46XP:AO2.#<8MPUIDAM,VAI,<X-IVY"PM]LYKZT/
M7&SV\]T^[&6WW;CU?N/=AN/G.T[&ATQV6XY?[/E!D]VF9PG?SS+>ELN<:GIV
M(L4623,>\,R%K3EK#U7"8T,/=UK"KQSL]!F454COA:2F2M%L+1F#XM<*'<^9
MICQ4;T[Z&OR8T?T@QSS/,,D!S%FZ[B'L=Q'Q\/C;W1P=']6A7+A1YBSHH0&V
M*)/#*/,6*&28H=28_^XVOV,)F#=.Y=*-\ID^(3)J OG##?(Q#2&4L449'4;Y
MT+ WB815]9I0%J] ^?K7(92/3<LB=SM,\.%8KMKGB6-U/[5'\6O,/[<V)][A
M(*Y;%(Z79=LT1U$;*IFJP?K2E"YQL44NK#X01L$:I& -8L$'/\P:Z.]/8(,6
MFD7J/PZ/@\+CP'H<'LH5'C*@0X!,Z%/F2XHG&NHGE# 9P ,0,W4IZ(;%I.=Y
MOSGB&Q;Q#9U L^62&[U#0PB0+]_R& 4TX9J&=4%E6".+903<P]G0&_MXXHU/
M^@_5K&LQ<"]<OPC7=X9[(=[.V0.BNYWK@J12@>2)F4,=R[KA](:A"Q$E-'X"
MS1@PR(HE,@\E,Q*5QVO0<"&- X;$"AV1KN][7<_S$"R3&69DKODE9MOP"7&E
M4K#/LM4\OEVSF/V;1LG[?SV:='ZOC+<(U.6=%L'W+J+:PB229QZNOQ[Y'CJF
M22+%(P<1R0"6_9/R!QK";)$6Z CW1I[)G<S/FZX) E$0K&M8E#68H#B-[N%W
MP,-=?Y %G 751=L-#S8@;@.1QAJ"-<;& >1CQ/1&+%$HXO5;S6!B/'Z W#7+
MC*B=#[ %L]"[]M9#\U2:53*S>&(4L.(EH+X8V$75I=X '"RW6,?\OS"ZXB<4
MRGHZ\H?3GB.]1T6^C)P;?/[A"F4Y P>*Q+HHJA[]_=D&Z2KS<>%G_(N(95)X
MG+R66" [SKGXQ"$%;!FK35VWGKPH3>QE__9K>/%RX "/AM/JP+W(IT7D4V?D
M\[)BS5;GX2/%M [MJM5%[8;<U9@?K-ZC;XG(JE/QM2UA<&)N7;GP#NH*A&H8
M0E!=!#6!O=^LG="6&;,0Z]VLN%0:+6P2<RC C$VOX80YE^D:'2^NYV_@&'L?
M 3_8DV6\+/;I*^5;J-TM> 8F"R%YH);--6ABNY\0LRE6N;15)M#E?(9NV0.<
M-LT#:4I7_N@,9AG[!%"5(=MM1S:;!$H4DG6! EAJ'@""EIR&/^X$4#2GQ9[G
M\ MSL^\"YJ2 2((-^!KL^1JTWY)B\6=)$@*V]7M\/9]5-P(<#/<<#&L<."H5
M>^59Q7.FY[=D)04$:TJR'C@7TMZAVJRO.%PY+6%G!#>%UJB4G$(IL+6$!'B[
MK!1%T5QK0W3[P5Z#+L&E5,.DH=7;3JE,I]QKL%T$W3"M$TU_Y)#-Y/;A\,@#
M2UT*/NR69ONMH%A,U215/C;@+H Y<K%FB,"D>9:IA6XH<KE9/Q1#GQ$15]#!
M-0<B7IK!N29"?EX9ANU2G4K0& R:-:B66!D>XC&0"#,U9)XK<*9 U(@5USTT
MLPW]LRGIXM!D.?"92"#>2Y$0"XV #.*=*LN5<Y:V):?7]]Y>[6FJ<9'-06H_
MDHI4L7QIJMBN3*)-HZ4_O ^5D0JJL)B&?8/YP.*4@5YCL>T(.UJ$T%BPL839
MM<M8+5W;-K8 EO>2;!=AD5Q:"I=G!>P^+.3J^U4*"I?2'ON_2$/A4AYBMS[\
M6;QXV>#';^3%4FGB<1,OVJRL-I.Z<_9YCK,GX)P45TI/[-:>NT-C4T.[Q#4:
MTAE"J2&Q6_&]ZMQZE8.UCH.4K9VX6_LL,@>I\O (C3Y"YY+_R54]S5_E@'[U
M;.P[0BE[/''WWF?U(R6-UZW+E%1>H?RJ=RBD[*G$3<L_JTPO&OPTEBDIN9(T
M<>6KY<L%>?G:Q)VF);>2IO<F[4CC(L=I'T))M<1-@9\*M2#-IZ\Z[[_G$.V]
MEZQ)W*QYF[?/%RV3/2805MUV7)%7$B@I"92X"114UZ4]9]GW0.@FA<C,B>A5
MG9649$FFO^JU9TF,@Y],C->#EZ<?,O7(%.-][?ZE9J!S7P8EA0[<%'J7O;K+
M7^0=0U/)GKQ!_T,'7VA?YZ![C(Z'8X\\C[MF')GX8_PL['[ELYCYU@W:><UC
MA4*V D.O-P8$F7T^SFZT2.R7LGNAM8CLY891X$8S 'Y?":%W-^;C6_$1_^S_
M4$L#!!0    ( /&&JE)O)#@OH@(  $@'   9    >&PO=V]R:W-H965T<R]S
M:&5E=#0Q+GAM;*5536^C,!#]*Q;:0RLUY2M 4A&D-E&U/:Q4->KVL-J# Y/$
MJK%9VPGMOU\;J$4;@E;:"]AFWIOW!GN<UER\RCV 0F\E97+A[)6J;EQ7YGLH
ML;SF%3#]9<M%B96>BITK*P&X:$ E=0//B]T2$^9D:;/V*+*4'Q0E#!X%DH>R
MQ.+]#BBO%X[O?"P\D=U>F04W2RN\@S6HY^I1Z)EK60I2 I.$,R1@NW!N_9ME
M8N*;@)\$:MD;(^-DP_FKF3P4"\<S@H!"K@P#UJ\C+(%20Z1E_.DX'9O2 /OC
M#_;[QKOVLL$2EIR^D$+M%\[,005L\8&J)UY_A\Y/9/AR3F7S1'4;&\4.R@]2
M\;(#:P4E8>T;OW5UZ '\Z1E T &"?P6$'2!LC+;*&ELKK'"6"EXC8:(UFQDT
MM6G0V@UAYB^NE=!?B<:I[($=@2DNWM'%"A0F5%ZB"5KKS5(<*""^1<1&3-#S
M>H4NOEVFKM*I#8&;=VGNVC3!F30_L+A&H7^% B_P!^#+<?@*<@OW/L-=;=BZ
M#JSKH.$+S_ -^_MUNY%*Z(WU>R1%:%.$38KIF13WA!']6PJTX[R00Q5K\7&#
M-X?MF,WGT72>NL=^84ZC?,^;QXD-^Z1N:M5-1]6]Z+,U(6Q2"9Z#')37$D2]
MQ(&?!%_E#40%7C@;5A=9==&HNB=<ZSVN0!!,![5%)UEC;Q;Y7[0-1/F)?T9;
M;+7%H]INJ6Y\F.6 = OM;9XCI@?<=B96(+Z1G(+,P012/ESA^$3?Q)\%_DF-
M!^.F21 ..TFLDV34B3WZ5XB!&A(XBC?WRXVL< X+1U\@$L01G P-'>[_YVD-
MNKT^9^X8W55VA$E$8:N9O>M$UTBT?;N=*%XUK6_#E6ZDS7"OKSH0)D!_WW*N
M/B:FF]K+,_L+4$L#!!0    ( /&&JE*9@;>R, (   D%   9    >&PO=V]R
M:W-H965T<R]S:&5E=#0R+GAM;(U4R6[;,!#]%4+H(0%2:VV2!K( +RG:0P C
M1MI#T0,MC2TB%*F0E.7\?8>4K#JI[?8B<8;SWNQ,6ZF>=0E@R*[B0H^]TICZ
MSO=U7D)%]4C6(/!F+55%#8IJX^M: 2T<J.)^% 37?D69\++4Z18J2V5C.!.P
M4$0W5475ZQ2X;,=>Z.T5CVQ3&JOPL[2F&UB">:H7"B5_8"E8!4(S*8B"]=B;
MA'>SQ-H[@^\,6GUP)C:3E93/5OA6C+W !@0<<F,9*/ZV, /.+1&&\=)S>H-+
M"SP\[]F_N-PQEQ75,)/\!RM,.?9N/5+ FC;</,KV*_3Y?+)\N>3:?4G;V2:Q
M1_)&&UGU8(R@8J+[TUU?AP, \AP'1#T@>@](3@#B'A"[1+O(7%IS:FB6*MD2
M9:V1S1Y<;1P:LV'"=G%I%-XRQ)ELH7 @E'DE5!3D_J5A-;;(D(LY&,JXOB0?
MR=-R3BX^7*:^07\6Y><]][3CCDYPQ^1!"E-J<B\**-[B?8QS"#;:!SN-SA(^
M4#4B<7A%HB *C\0S^W]X<":<>*A=[/CB?]3NBBPXQ:*]+>'/R4H;A6/ZZXRK
M9'"5.%?)"5=SP!W-&76C#SO<80WZ6$<ZFFM'8S=XFT6?H]O4WQZ6Z6^C, QO
MDL&J"]$_F*H*U,8MFR:Y;(3I>C9HAWV>N#%^IY_BGG=K^8>F>R2P(QLF-.&P
M1LI@=(-;HKK%ZP0C:S>[*VEP$]RQQ+<*E#7 ^[649B]8!\/KE_T&4$L#!!0
M   ( /&&JE+QYFH(-P,  /P+   9    >&PO=V]R:W-H965T<R]S:&5E=#0S
M+GAM;+U6WT_;,!#^5ZQH#R !B?,[J*TTRJ8A@5:!V![0'DQR;2V<N-@.A?]^
M=AK2T(:L3,!+:SOWG;_[SC[?8,G%G9P#*/28LT(.K;E2BV/;END<<B*/^ (*
M_67*14Z4GHJ9+1<"2%:!<F:[CA/:.:&%-1I4:Q,Q&O!2,5K 1"!9YCD13R?
M^')H8>MYX9+.YLHLV*/!@LS@"M3U8B+TS&Z\9#2'0E)>( '3H?45'X]Q9 "5
MQ2\*2]D:(Q/*+>=W9G*6#2W', (&J3(NB/Y[@#$P9CQI'O>U4ZO9TP#;XV?O
MWZO@=3"W1,*8L]\T4_.A%5LH@RDIF;KDRQ]0!Q08?REGLOI%R]K6L5!:2L7S
M&JP9Y+18_9/'6H@6 /NO -P:X.X*\&J 5P6Z8E:%=4H4&0T$7R)AK+4W,ZBT
MJ= Z&EJ8-%XIH;]2C5.CB= G0J@G1(H,?;LOZ4+G2*&]4U"$,KF/#M&5/CI9
MR0#Q*5JTS:$Q/T375Z=H[\O^P%::E'%MIS6!DQ4!]Q4"%T0<(0\?(-=Q<0=\
MW \_A;2!.R_AMI:BT<-M]' K?]X_]#A $T9T9"]EN3G7YNA,02[_]&SF-9MY
MU6;^+N(W:AZ@F>!2=DFY<A=6[LP%?1AYL8/CT!O8#VW-NNRP%[AN8_>"K]_P
M]7OYGH.4Q_KFI65>,J(@TQ=&%X^4$G,ENPBO_ 4M(H>>FX0)QAN,NPWC,(Z[
M*0<-Y>"_)"Y =?$-MF@$CI\$[@;;#C/LQY[?S35LN(;]\AJ.-Q>0WX+H.UY1
MXR_Z^+,<-YO%[WN6XRT-O<1Q6OE>2=UE%H1^T"UUTK!->MF>E)1EM)C)BBX#
M_1#,.<L0S76%>P!#7>Z2"NRLZZSS\<G K;*.WS<=M;^VT*[KX0AOGOUN0R^(
MO.Z4X'7IQ6XOYPN2SO62V'Q==LG#NN1B[Q/RL*Z8N+]DOCT/VY4P2=PXWDI#
MEYT?^*_4(+PNF+B_8OZ<3FD*;Y1_7>)P^ GRKRL@CMY9_FCKZ<1QA./-]ZK3
M+HE"9T-^N]6:F;Y8MSLS6DA=<J8:Z!Q%.AEBU6JN)HHOJF[MEBO=^U7#N6[/
M01@#_7W*N7J>F :P:?A'?P%02P,$%     @ \8:J4H8ADB&B P  S@H  !D
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MM>P\EP,C2]>\W4N#K:"[S;!;!V4GX/NIQ&^]:F #U/W_Z ]02P,$%     @
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MKL-C29\S:/P&6I]KZ@>:@0=H/Y FOP!02P,$%     @ \8:J4A"F'FYC P
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MSN+MA,> ],QNU=Z8GSM;WAW7G/<ITWE.5[S7(E_#=!M>(EJ)W2HZF*G]1,L
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M+M;A+='%LU:.LE:.E#[[=UKYCS,A!<:<^-&_&AMV9L-6-MH5-B;,#1PWQ![
M/HT#7K99EAJZ2H,\-3SL0TO]VVT]K*Z,,KDV[/:*8C<E8C:R;9B)%0)I9X&T
MM8&<8QXSES^#&>:DK-WIX<MV9^W\\>%#Q=*[U"OX$M^KAK=4H"M_)XNHH]5X
M0#"+@!MPPDC$ 2N/ZU:O!#6A]5'C3#=SIJO5,R)3+GR).(O%&8\#X91?UI?U
M6KK@60:E\:>7^=/3UROF$<?!S WN@2>VB#CJ>3APRC)TV=M8<,CNM@?]XKJ\
MW12#J-U>6>4%1_N9HWVMHT/,%_@9W 8N)S.UF\&7>T:(RN*/<^)/"=-MY$%F
M9_!NS0):^7!IO;9=C!(5A7QW;=19:Q>'AG+'AG(GAG*3>KEB<E8F;_BJ%C2I
MP:?$KUK(^N10]"FG$(C>H(E,:K3 )NSHN@C,Z0;J^<:PCXQJU$#52$H/!"\$
M'K\4>/("8#%Y.<5!/<>,TS*2IY $$8E*I\-V";_V[>(FN"J5ZO4KMD!.65!/
M-T;=#OP'OMV8]#Z8LQ/LOE_WRSD'ZDG'J/MMTDBO4S(M'9H*'IL*GI@*3@P$
MBQG*R0[6L-W-P1"H8IB4-^<V^'[DAG)R0Z\FMP.T21X],>ZMIWA<(F=WX(;<
MJ:&^,T.Y<T.YBWK_BDG,21"]C@3'-?CTY+\DP;ZNL"OGJ+<@P<L:+;#9[>M(
M$.4DB-Z$! ]JU)1.TTF27TAFIR\V>?9BY,4+G"TF/B=0] 8$BC:I$0W:@S4"
M+9/J=3H5VR<G4%1#H!L-U)@M4<Z6Z/W8$N5LB5[-E@>HY&QFE3U<&)=(PE+)
M4V.=9\:2Y\:2%R9^%A.:DRO2D^OO'QY1SK#H_1C6SAG6UC/L%7&(^R F0W5D
MUSQQVF0GW7QBY^QDZ]GEBMS''F9%+M@!,Q(YS WE[\ZE[NB5WBP(^$8Y$5V%
M.+$<?-T .#0(DE^R'UV^ %P(K15PJFA)?%7P!FQ)T;^Q'W[^\TE0H/,Y=3KK
M7E="+!>8?=X&Y%<L]AFGRDP4^X#. 16U"PESI*DM^'%;6)JI^R%S?;*TA2,0
MQE//C19+K^7M.^QY0,0GWS'X2F,6",T;/HV#&7DJ^I"JQX[#8J4N<3=:2(U3
MXE!A-L3/>.J)7&%G 7P:B-3,&?7!$9FR&+-GD#QV;X))S*(82WI<AB53O*.N
MAM0/<?"<*!8:U;<B3I<10%>>#(59"PJ].,H\BX,0NRL.TF7@V>@R4JD1X?A"
M=<B(M!!2IHI)&9!&17Y3GT1D<RH,;ZJ0A1?NB"J('/+G)AC/"_XG;R-$J0-Y
MA,F=M9512.1<;*2\OAU17Q6C1)<NF&;9;P$U*_LB$!$Q4:CTF7HQ_^2)$[$.
M9F6+.UOT$1;.R@D'B"R!B#R08%GW: <\+ERAW(W +"8R"1<.IZ*E9>::NJZ3
MCW^V?G [?'((4>NALN,<)2J,.\[*\W7]])*<B$W/1'8^R]CM]^O8^3QBZ^<1
M Q(?)BI6<]?M:'*7SRGVFSQT'M:H@5;M8V<[GVIL_51C-$(F.CJKIZL!6OLA
MY,HN&17L7KLJ;?F<8.OG!$.6_9ZH*9X!-T>:NWJYHJ/YT&$/WNPA?J*J=I&U
M5EZ=D.^IB?YU+Y80\,A< *UF3Q2%+5_]6G[@-%1O4TPIY]17EPN"9X1) 7%_
M3D573C[(%S2R%_#V_P=02P,$%     @ \8:J4I%F]HR3 @  5P@  !D   !X
M;"]W;W)K<VAE971S+W-H965T-3,N>&ULM59=;]HP%/TK5K2'5EI)[)!0*H@T
M0-,JM5)5VNVAVH,A%Q+5B9EM2OOO=^VD(5V!H4I](?XXY_C>D_A>!ANI'G4&
M8,AS(4H]]#)C5A>^K^<9%%QWY I*W%E(57"#4[7T]4H!3QVI$#X+@M@O>%YZ
MR<"MW:AD(-=&Y"7<**+71<'5RPB$W P]ZKTNW.;+S-@%/QFL^!*F8.Y7-PIG
M?J.2Y@64.I<E4; 8>M_HQ9@R2W"(GSEL=&M,;"HS*1_MY#(=>H&-" 3,C97@
M^'B",0AAE3"./[6HUYQIB>WQJ_IWESPF,^,:QE+\RE.3#;USCZ2PX&MA;N7F
M!]0)159O+H5VOV138>/8(_.U-K*HR1A!D9?5DS_71K0(M+N'P&H".Y80UH30
M)5I%YM*:<,.3@9(;HBP:U>S >>/8F$U>VM<X-0IW<^299,3+1W(E>:G)R00,
MSX4^)6=DBI]+NA9 Y(+H3"IS9D 5:!BB!:(1<C^=D),OIP/?8!A6S)_71XZJ
M(]F>(Z^YZI"0?B4L8'0'?7R8/H%Y0P_>TGU,OG& -0XPIQ?NT9MNTYO S)"'
M*P202P.%_GU /FSD0R??W2-_)PT7NTRJ:+&CV<OVE-"81BS"G)[:;NS"L7X0
M;'%OXNHV<74/QC7F)N,OY+[,#:3$?08/UU#,0!W*.FK4H\\P-6[DXX^96M&B
MEEDL#M][N@O6VVMIKXFJ=]C2N]'X:"?/&]'SSW"RW\CW/^9D_YU%/;QOP;].
M[H!1MM=)&FS+4G#,YSDJ^5%NTE:]HY_A)]V6$\H^YFC-:]_D. K>6_I_7!69
MWZKZMN5B75WF6,<%+) 8='KX5E35Q:J)D2O7"&;28%MQPPP[/R@+P/V%E.9U
M8GM+\U\B^0M02P,$%     @ \8:J4B>:&]T!!@  8Q@  !D   !X;"]W;W)K
M<VAE971S+W-H965T-30N>&UL[5EM<]I&$/XK.S3IV#,4)/%B.\;,&&PW;I.6
M"4WR(=,/AW3 C:4[Y>X$X=]W]R0$.*"0--..9Y(/B5[NV=UG7QY.E]Y2Z0<S
MY]S"IR26YJHVMS9]T6R:<,X39AHJY1+?3)5.F,5;/6N:5',6.5 2-P//ZS83
M)F2MWW//1KK?4YF-A>0C#29+$J97 QZKY57-KZT?O!&SN:4'S7XO93,^YO9M
M.M)XURRM1"+AT@@E0?/I5>W:?W'G>P1P*]X)OC1;UT!4)DH]T,U]=%7S*"(>
M\]"2"8;_+/B0QS%9PC@^%D9KI4\";E^OK=\Y\DAFP@P?JOB]B.S\JG9>@XA/
M61;;-VKYDA>$.F0O5+%Q?\,R7]MMUR#,C%5) <8($B'S?]FG(A%; /\0("@
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M(N<0"DRM8V#T6.$%"N&(R(VGFC-H)!UP>_W"_LW'3K',F,$+)7[SS"Y'P2"
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M26\PT04BZ^923U!L[>VY$JCO8CO,=3\&:3;H]VLA<#\Q!MH.'_\%4$L#!!0
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MWCLTYELD/JSCM2+N')%J@?=\NRR^4\F"V8OH%P1[.8#-*EY0L0/8?.*%!W<
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M"YH^V8N%LIN62]*1\8L"HVCSZ:VQ83L;ML^0L3Q=YX'05E:AN\[II'#P0%_
M:S*A=TF_WT-'10=;C^V5.6SU$E;<\6S;2J5]\([G%HD=MKEI_?0<.(?\+8F
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M[$1V6."W D@3@/NY$/IA8MI1]_61_ 902P,$%     @ \8:J4A\ZS:6] P
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MPN :E,-Z^/ RRAM9L(6OX[,PW(-\)(IU*3W..*IKBEIK&FK!/YR).:YSQM?
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M2"W2E,J7"^!B.7"P\WKCFLT37=QPA_V<SN$&]%T^D6;FUEEBED*FF,B0A-G
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M7)1LR 8V5U2>(A]_1L0C> U\M!T^AFD-]]["7:-++0ZIQ2$VG___Q+G_8=9
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M_T9:T+Z2G?FB,[XH?'@G1OKF]*$+/D:M;O:UZHW7;<?K/F&\RFAC@Y&<W(X
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M%RSG#>#]?9:5S1?^@X?M;\V^^P]02P,$%     @ \8:J4OCB9)>L P  "A
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M1$X0"DS),3 [[/ )A7!$5L:OAC-H0SK@^?S$_M'G;G-9,8-/2GSG&173X"Z
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M"851K3 R@5:>F;"66.)HRMD><2VMT/3"<&.T530DU]>XDEQ])4I/1C=,"%0
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M"K3AE&*A^_ =G0VI;+ CBVU.[3&93:/9/ JBV#T.J H[5>&HJC7A'^$9/=P
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M)]&$)+!E5::_BOV?T";D&W^QR%3]2_;MN_:$Q)72(F^-$4'.B^:?O;9$?,3
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MVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA])
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M [MD"S]R49<"5H@)9I2$V"BG"IR?S! 3,TQ";!@4LW.G)YAJ$G+5]-9AAPL
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MYS9_'#\^R\XV_5L^&_^^>?X"4$L! A0#%     @ \8:J4@=!36*!    L0
M !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M" #QAJI2P#-OINX    K @  $0              @ &O    9&]C4')O<',O
M8V]R92YX;6Q02P$"% ,4    " #QAJI2F5R<(Q &  "<)P  $P
M    @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( /&&JE+6
MJM59X ,  $@.   8              " @0T(  !X;"]W;W)K<VAE971S+W-H
M965T,2YX;6Q02P$"% ,4    " #QAJI2NRZ+S>@'  #V(@  &
M    @($C#   >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @
M\8:J4M L<N7? @  # H  !@              ("!010  'AL+W=O<FMS:&5E
M=',O<VAE970S+GAM;%!+ 0(4 Q0    ( /&&JE(!^*0C*@8  )T7   8
M          " @587  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4
M    " #QAJI2X+_MU.8&   K'0  &               @(&V'0  >&PO=V]R
M:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ \8:J4M*+/D$W!0  DA4
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M965T,3 N>&UL4$L! A0#%     @ \8:J4J&ZHND8 P  <@8  !D
M     ("!9G<  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( /&&JE)O'0PZ!0,  'L&   9              "
M@?FA  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ \8:J
M4D)97\'1 @  W04  !D              ("!-:4  'AL+W=O<FMS:&5E=',O
M<VAE970Q-RYX;6Q02P$"% ,4    " #QAJI2?SGAO0H+   V)0  &0
M        @($]J   >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0
M   ( /&&JE+@PA3951(  %<X   9              " @7ZS  !X;"]W;W)K
M<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ \8:J4F'+@!YU!0  >0P
M !D              ("!"L8  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q0
M2P$"% ,4    " #QAJI2*7+=F&H#  #_!P  &0              @(&VRP
M>&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( /&&JE+1S$I-
M.0D  $D7   9              " @5?/  !X;"]W;W)K<VAE971S+W-H965T
M,C(N>&UL4$L! A0#%     @ \8:J4FL\:[7W!0  # T  !D
M ("!Q]@  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " #Q
MAJI2$?<NI[8"  #>!0  &0              @('UW@  >&PO=V]R:W-H965T
M<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( /&&JE*4 R_PZS<  +B^   9
M          " @>+A  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#
M%     @ \8:J4B7N=X1& @  Y 0  !D              ("!!!H! 'AL+W=O
M<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " #QAJI2 AQ.*)("  !
M!0  &0              @(&!' $ >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM
M;%!+ 0(4 Q0    ( /&&JE* 6_O.Q@(  +H%   9              " @4H?
M 0!X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ \8:J4OL/
MLHFB!0  P \  !D              ("!1R(! 'AL+W=O<FMS:&5E=',O<VAE
M970R.2YX;6Q02P$"% ,4    " #QAJI2#Y=XIE@"   #!0  &0
M    @($@* $ >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    (
M /&&JE**)F6TF 4  /80   9              " @:\J 0!X;"]W;W)K<VAE
M971S+W-H965T,S$N>&UL4$L! A0#%     @ \8:J4F[X:JFU @  ?04  !D
M             ("!?C ! 'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"
M% ,4    " #QAJI27_(!H"0#   H!P  &0              @(%J,P$ >&PO
M=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( /&&JE*:PL0SM (
M /4%   9              " @<4V 0!X;"]W;W)K<VAE971S+W-H965T,S0N
M>&UL4$L! A0#%     @ \8:J4MLU"_GG P  7PD  !D              ("!
ML#D! 'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " #QAJI2
MF1+WA]0#  #H!P  &0              @('./0$ >&PO=V]R:W-H965T<R]S
M:&5E=#,V+GAM;%!+ 0(4 Q0    ( /&&JE($QOG2\ ,  *H4   9
M      " @=E! 0!X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%
M  @ \8:J4I%WQI\O P  DPD  !D              ("! $8! 'AL+W=O<FMS
M:&5E=',O<VAE970S."YX;6Q02P$"% ,4    " #QAJI2,"# E^X"  "=#0
M&0              @(%F20$ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+
M 0(4 Q0    ( /&&JE+Y;NN"NP<  - ?   9              " @8M, 0!X
M;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ \8:J4F\D."^B
M @  2 <  !D              ("!?50! 'AL+W=O<FMS:&5E=',O<VAE970T
M,2YX;6Q02P$"% ,4    " #QAJI2F8&WLC "   )!0  &0
M@(%65P$ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( /&&
MJE+QYFH(-P,  /P+   9              " @;U9 0!X;"]W;W)K<VAE971S
M+W-H965T-#,N>&UL4$L! A0#%     @ \8:J4H8ADB&B P  S@H  !D
M         ("!*UT! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4
M    " #QAJI2=_O+N60#   +$   &0              @($$80$ >&PO=V]R
M:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( /&&JE(RUHN+00,  "P-
M   9              " @9]D 0!X;"]W;W)K<VAE971S+W-H965T-#8N>&UL
M4$L! A0#%     @ \8:J4A"F'FYC P  U P  !D              ("!%V@!
M 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4    " #QAJI2_:A*
M?6L#  "A"P  &0              @(&Q:P$ >&PO=V]R:W-H965T<R]S:&5E
M=#0X+GAM;%!+ 0(4 Q0    ( /&&JE+S8LLB90,  -(+   9
M  " @5-O 0!X;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @
M\8:J4A'[T>!  @  /@4  !D              ("![W(! 'AL+W=O<FMS:&5E
M=',O<VAE970U,"YX;6Q02P$"% ,4    " #QAJI2XFJH>V<*  #9.   &0
M            @(%F=0$ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4
M Q0    ( /&&JE(7:#7?I <  (PG   9              " @02  0!X;"]W
M;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ \8:J4I%F]HR3 @
M5P@  !D              ("!WX<! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX
M;6Q02P$"% ,4    " #QAJI2)YH;W0$&  !C&   &0              @(&I
MB@$ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( /&&JE)N
MVH!0#P,  .,'   9              " @>&0 0!X;"]W;W)K<VAE971S+W-H
M965T-34N>&UL4$L! A0#%     @ \8:J4GNNB9BX @  [0<  !D
M     ("!)Y0! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"% ,4
M" #QAJI2./J5N1()  "',   &0              @($6EP$ >&PO=V]R:W-H
M965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( /&&JE(R_K.7BP8  +XE   9
M              " @5^@ 0!X;"]W;W)K<VAE971S+W-H965T-3@N>&UL4$L!
M A0#%     @ \8:J4FZR4&=] @  B0@  !D              ("!(:<! 'AL
M+W=O<FMS:&5E=',O<VAE970U.2YX;6Q02P$"% ,4    " #QAJI2'SK-I;T#
M  !&$   &0              @('5J0$ >&PO=V]R:W-H965T<R]S:&5E=#8P
M+GAM;%!+ 0(4 Q0    ( /&&JE(G1HTR*@,  !D.   9              "
M@<FM 0!X;"]W;W)K<VAE971S+W-H965T-C$N>&UL4$L! A0#%     @ \8:J
M4D..L:@-$0  =U8  !D              ("!*K$! 'AL+W=O<FMS:&5E=',O
M<VAE970V,BYX;6Q02P$"% ,4    " #QAJI2^.)DEZP#   *$   &0
M        @(%NP@$ >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0
M   ( /&&JE+%#5NW7 ,  !4+   9              " @5'& 0!X;"]W;W)K
M<VAE971S+W-H965T-C0N>&UL4$L! A0#%     @ \8:J4I?W,4[U P  ,1(
M !D              ("!Y,D! 'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6Q0
M2P$"% ,4    " #QAJI2\C0\>64"  !+!@  &0              @($0S@$
M>&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4 Q0    ( /&&JE(9)KY
M( ,  &T)   9              " @:S0 0!X;"]W;W)K<VAE971S+W-H965T
M-C<N>&UL4$L! A0#%     @ \8:J4CT;RP]E @  +P8  !D
M ("! ]0! 'AL+W=O<FMS:&5E=',O<VAE970V."YX;6Q02P$"% ,4    " #Q
MAJI2HS1&L+<"  #8!P  &0              @(&?U@$ >&PO=V]R:W-H965T
M<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0    ( /&&JE(?RRRSX (  #,(   9
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M 0!X;"]S='EL97,N>&UL4$L! A0#%     @ \8:J4I>*NQS     $P(   L
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64$L%!@    !0 %  YQ4  &GR 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>323</ContextCount>
  <ElementCount>446</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>94</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="abvcd-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="abvcd-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="abvcd-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="abvcd-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="abvcd-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="abvcd-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Consolidated Statements of Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="abvcd-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Disclosure - Organization and Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/OrganizationandDescriptionofBusiness</Role>
      <ShortName>Organization and Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="abvcd-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="abvcd-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Collaborative Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/CollaborativeAgreements</Role>
      <ShortName>Collaborative Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="abvcd-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="abvcd-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/PropertyandEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="abvcd-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Long-Term Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/LongTermInvestments</Role>
      <ShortName>Long-Term Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="abvcd-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Convertible Notes Payable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://metuboutique.com/role/ConvertibleNotesPayable</Role>
      <ShortName>Convertible Notes Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="abvcd-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Bank Loans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/BankLoans</Role>
      <ShortName>Bank Loans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="abvcd-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Paycheck Protection Program Loan Payable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/PaycheckProtectionProgramLoanPayable</Role>
      <ShortName>Paycheck Protection Program Loan Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="abvcd-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Notes Payable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://metuboutique.com/role/NotesPayable</Role>
      <ShortName>Notes Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="abvcd-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Short-term Loan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ShorttermLoan</Role>
      <ShortName>Short-term Loan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="abvcd-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Related Parties Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/RelatedPartiesTransactions</Role>
      <ShortName>Related Parties Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="abvcd-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="abvcd-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Stock Options</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/StockOptions</Role>
      <ShortName>Stock Options</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="abvcd-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/LossperShare</Role>
      <ShortName>Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="abvcd-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Lease</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/Lease</Role>
      <ShortName>Lease</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="abvcd-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Business Combination</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/BusinessCombination</Role>
      <ShortName>Business Combination</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="abvcd-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="abvcd-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://metuboutique.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="abvcd-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://metuboutique.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="abvcd-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://metuboutique.com/role/Inventory</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="abvcd-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://metuboutique.com/role/PropertyandEquipment</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="abvcd-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - Long-Term Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/LongTermInvestmentsTables</Role>
      <ShortName>Long-Term Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://metuboutique.com/role/LongTermInvestments</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="abvcd-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Disclosure - Bank Loans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/BankLoansTables</Role>
      <ShortName>Bank Loans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://metuboutique.com/role/BankLoans</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="abvcd-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030 - Disclosure - Related Parties Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/RelatedPartiesTransactionsTables</Role>
      <ShortName>Related Parties Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://metuboutique.com/role/RelatedPartiesTransactions</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="abvcd-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>031 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/EquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://metuboutique.com/role/Equity</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="abvcd-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>032 - Disclosure - Stock Options (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/StockOptionsTables</Role>
      <ShortName>Stock Options (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://metuboutique.com/role/StockOptions</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="abvcd-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>033 - Disclosure - Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/LossperShareTables</Role>
      <ShortName>Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://metuboutique.com/role/LossperShare</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="abvcd-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>034 - Disclosure - Lease (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/LeaseTables</Role>
      <ShortName>Lease (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://metuboutique.com/role/Lease</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="abvcd-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>035 - Disclosure - Business Combination (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/BusinessCombinationTables</Role>
      <ShortName>Business Combination (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://metuboutique.com/role/BusinessCombination</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="abvcd-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>036 - Disclosure - Organization and Description of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/OrganizationandDescriptionofBusinessDetails</Role>
      <ShortName>Organization and Description of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/OrganizationandDescriptionofBusiness</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="abvcd-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>037 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="abvcd-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>038 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of property and equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofpropertyandequipmentTable</Role>
      <ShortName>Summary of Significant Accounting Policies (Details) - Schedule of property and equipment</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="abvcd-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>039 - Disclosure - Collaborative Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/CollaborativeAgreementsDetails</Role>
      <ShortName>Collaborative Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/CollaborativeAgreements</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="abvcd-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>040 - Disclosure - Inventory (Details) - Schedule of inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofinventoryTable</Role>
      <ShortName>Inventory (Details) - Schedule of inventory</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/InventoryTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="abvcd-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>041 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/PropertyandEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="abvcd-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>042 - Disclosure - Property and Equipment (Details) - Schedule of property and equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofpropertyandequipmentTable0</Role>
      <ShortName>Property and Equipment (Details) - Schedule of property and equipment</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="abvcd-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>043 - Disclosure - Long-Term Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/LongTermInvestmentsDetails</Role>
      <ShortName>Long-Term Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/LongTermInvestmentsTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="abvcd-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>044 - Disclosure - Long-Term Investments (Details) - Schedule of ownership percentages of investee</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofownershippercentagesofinvesteeTable</Role>
      <ShortName>Long-Term Investments (Details) - Schedule of ownership percentages of investee</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/LongTermInvestmentsTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="abvcd-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>045 - Disclosure - Long-Term Investments (Details) - Schedule of extent the investee relies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofextenttheinvesteereliesTable</Role>
      <ShortName>Long-Term Investments (Details) - Schedule of extent the investee relies</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/LongTermInvestmentsTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="abvcd-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>046 - Disclosure - Long-Term Investments (Details) - Schedule of long-term investment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleoflongterminvestmentTable</Role>
      <ShortName>Long-Term Investments (Details) - Schedule of long-term investment</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/LongTermInvestmentsTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="abvcd-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>047 - Disclosure - Long-Term Investments (Details) - Schedule of balance sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofbalancesheetsTable</Role>
      <ShortName>Long-Term Investments (Details) - Schedule of balance sheets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/LongTermInvestmentsTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="abvcd-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>048 - Disclosure - Long-Term Investments (Details) - Schedule of statements of operation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofstatementsofoperationTable</Role>
      <ShortName>Long-Term Investments (Details) - Schedule of statements of operation</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/LongTermInvestmentsTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="abvcd-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>049 - Disclosure - Long-Term Investments (Details) - Schedule of equity investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofequityinvestmentsTable</Role>
      <ShortName>Long-Term Investments (Details) - Schedule of equity investments</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/LongTermInvestmentsTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="abvcd-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>050 - Disclosure - Convertible Notes Payable (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://metuboutique.com/role/ConvertibleNotesPayableDetails</Role>
      <ShortName>Convertible Notes Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/ConvertibleNotesPayable</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="abvcd-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>051 - Disclosure - Bank Loans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/BankLoansDetails</Role>
      <ShortName>Bank Loans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/BankLoansTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="abvcd-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>052 - Disclosure - Bank Loans (Details) - Schedule of short-term bank loan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofshorttermbankloanTable</Role>
      <ShortName>Bank Loans (Details) - Schedule of short-term bank loan</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/BankLoansTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="abvcd-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>053 - Disclosure - Paycheck Protection Program Loan Payable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/PaycheckProtectionProgramLoanPayableDetails</Role>
      <ShortName>Paycheck Protection Program Loan Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/PaycheckProtectionProgramLoanPayable</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="abvcd-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>054 - Disclosure - Notes Payable (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://metuboutique.com/role/NotesPayableDetails</Role>
      <ShortName>Notes Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/NotesPayable</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="abvcd-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>055 - Disclosure - Short-term Loan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ShorttermLoanDetails</Role>
      <ShortName>Short-term Loan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/ShorttermLoan</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="abvcd-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>056 - Disclosure - Related Parties Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/RelatedPartiesTransactionsDetails</Role>
      <ShortName>Related Parties Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/RelatedPartiesTransactionsTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="abvcd-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>057 - Disclosure - Related Parties Transactions (Details) - Schedule of related party transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofrelatedpartytransactionsTable</Role>
      <ShortName>Related Parties Transactions (Details) - Schedule of related party transactions</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/RelatedPartiesTransactionsTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="abvcd-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>058 - Disclosure - Related Parties Transactions (Details) - Schedule of accounts receivable due from related parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofaccountsreceivableduefromrelatedpartiesTable</Role>
      <ShortName>Related Parties Transactions (Details) - Schedule of accounts receivable due from related parties</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/RelatedPartiesTransactionsTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="abvcd-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>059 - Disclosure - Related Parties Transactions (Details) - Schedule of amount due from related parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofamountduefromrelatedpartiesTable</Role>
      <ShortName>Related Parties Transactions (Details) - Schedule of amount due from related parties</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/RelatedPartiesTransactionsTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="abvcd-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>060 - Disclosure - Related Parties Transactions (Details) - Schedule of amount due to related parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofamountduetorelatedpartiesTable</Role>
      <ShortName>Related Parties Transactions (Details) - Schedule of amount due to related parties</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/RelatedPartiesTransactionsTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="abvcd-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>061 - Disclosure - Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/EquityDetails</Role>
      <ShortName>Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/EquityTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="abvcd-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>062 - Disclosure - Equity (Details) - Schedule of converted amount of debt and shares</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofconvertedamountofdebtandsharesTable</Role>
      <ShortName>Equity (Details) - Schedule of converted amount of debt and shares</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/EquityTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="abvcd-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>063 - Disclosure - Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/StockOptionsDetails</Role>
      <ShortName>Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/StockOptionsTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="abvcd-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>064 - Disclosure - Stock Options (Details) - Schedule of options issued and outstanding</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofoptionsissuedandoutstandingTable</Role>
      <ShortName>Stock Options (Details) - Schedule of options issued and outstanding</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/StockOptionsTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="abvcd-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>065 - Disclosure - Stock Options (Details) - Schedule of fair value of stock options granted</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleoffairvalueofstockoptionsgrantedTable</Role>
      <ShortName>Stock Options (Details) - Schedule of fair value of stock options granted</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/StockOptionsTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="abvcd-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>066 - Disclosure - Loss per Share (Details) - Schedule of loss per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleoflosspershareTable</Role>
      <ShortName>Loss per Share (Details) - Schedule of loss per share</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/LossperShareTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="abvcd-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>067 - Disclosure - Lease (Details) - Schedule of operating lease arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofoperatingleasearrangementsTable</Role>
      <ShortName>Lease (Details) - Schedule of operating lease arrangements</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/LeaseTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="abvcd-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>068 - Disclosure - Lease (Details) - Schedule of supplemental information related to operating leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofsupplementalinformationrelatedtooperatingleasesTable</Role>
      <ShortName>Lease (Details) - Schedule of supplemental information related to operating leases</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/LeaseTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="abvcd-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>069 - Disclosure - Lease (Details) - Schedule of minimum future annual payments under non-cancellable leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofminimumfutureannualpaymentsundernoncancellableleasesTable</Role>
      <ShortName>Lease (Details) - Schedule of minimum future annual payments under non-cancellable leases</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/LeaseTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="abvcd-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>070 - Disclosure - Business Combination (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/BusinessCombinationDetails</Role>
      <ShortName>Business Combination (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/BusinessCombinationTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="abvcd-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>071 - Disclosure - Business Combination (Details) - Schedule of assets acquired and liabilities assumed based on fair value</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofassetsacquiredandliabilitiesassumedbasedonfairvalueTable</Role>
      <ShortName>Business Combination (Details) - Schedule of assets acquired and liabilities assumed based on fair value</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/BusinessCombinationTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>abvcd-20210331.xml</File>
    <File>abvcd-20210331.xsd</File>
    <File>abvcd-20210331_cal.xml</File>
    <File>abvcd-20210331_def.xml</File>
    <File>abvcd-20210331_lab.xml</File>
    <File>abvcd-20210331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>92
<FILENAME>0001213900-21-025389-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-21-025389-xbrl.zip
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MF]8G)X*/<F;VAALD7O+X1OS-OO%&\-W8<R,#87*U-8G3<''YZW=O3+8RJ\N
M:/[M5?J:,OJK='C^S9SA-QRI\['=B))WC%^\ =A@0TWK;Z_2;PU#>=@-1LJC
M3;;W, =])^9,I\ ]><4WA<^I[Y'UY3R^&ELF8U*[MS-$*0E?;/O4,O_V2GSW
ME,7:N-@=)0-]L83931;;Y(M]YP[AH.[L8LU3R]YXL2WUJ)OI4=^Q96M'W:Q^
MU,TZCGI;)0BKOUL[DQ($4S!J((B.=M1WC PTZJ_AJ'=US'YA2NPL#&Z3</CU
MDSL;N-%W;[:R>*!P=S)SY3+P*])37KO?YKXW]!*"R!AY[#E2T;FF^/HV8:0-
M;[__<\& !%4\#-B?\?DW+_[NC7@LM[J_O2J<0L+ 3IB Z@4ILI=!$B[@=C&(
MAY$W3]A&W+A#U[MW!KZ;(FW_L8;*VNN5BRW%H0KF3N"QG\'C^6CDP8H<_]KQ
M1I?!A3/W$L=7<+C_2!2/+5WK$A3N% (M,X/!&S=QO, =O7>BP LF\2$=/_%8
M\1KW@W-:5EZ^S2-W"EMQ[UX&S-1.6>;!8*QTD<M8Y6[AS<[@[2YRG7@1/68T
MDT,Z9P5+W!N^V,R@ZW,8P -1Z/N,95RR1R,W3@Y2L"U;:CG^=@M]I39PL3UP
M.,C;DD'PHL:[U2[%;C5#8O_1_>*6Q,L20*>4 "I8(/N/_1<U05X6\]U2S!\M
MET-B\;U2/!\UL>?4Q%X6Z_UE:MO1S*W?S'U1=-NF?C%QU,UK=CG5<Z-B6QDT
M'97LK;OK:\*DG<'D45O>GL.^)A0V,R@\JKT[SCU;>2%WU&2>TV%?$][:&;P=
M'?8[S1<S02Y',W%+#ON:T-?5(_2.ID#]PJR&>Q6[ET'3T11X"5.@#DSV,Y@\
MF@);-05J0&'3S*#P: KL-O=L6GDA=S0%GMD4J -O=@9O1U-@I_EB)MOC: IL
MSQ2H WVMLE2UH[;Y(M$=VT[#:[9+">"HX3SC'?_6\=PIQ?.18V_MCG_K6.^6
M8OVH#C__'?_6T=W3\XR/CKVZ3=-Z$J3[&30=5:WM._9JP63+S&#RZ-C;HF.O
M'A1:&10>U=[=YIXM.R_DCIK,LSKVZL%;,X.WHV-OI_EB*X.NHYFX)<=>/>@C
MOX[]P1W8IM6Y"WO\TY?;J1.Y[[\-ITXP<<\GD8L;LE=2[NYQ[EZ-SZ,(E@"C
M:.KEDO5MP<:W.J>FS?Y7P>CCC_8V,_I:G?4P?17LDWA\ JKE K?CLMT^PKOK
M(?SN(3QLA,L%'BK"R:US1/.SHUE)C9>8VT@*]]<\JE/VX=!%L;+(0Y3';7,]
MG'\(%U&*\H/$>+K$Y[]9VSZ^+17??8GO_I=/;C1QH[R*O><X+ES6ED1OOSIR
M^[4@5SB;SA<3-F9W>PZ*=>55EZUU8ZNQW2R]+_SD!=YL,2.T?GF[\'RH:QZ?
M!Z./KA.[T] ?7<[F47B/1*%Z37>8WN,H>7V#K KI&_[4UEG!N;;.L;J.0H:-
MY/':9PAB.P=>B#D _?813IQZR"IN\"%>6K?+8Y(^.=_^-8A07>>1"%^"",OC
MHG1.^,D93KW C1[5K=P'?6X7>9]X>,FF'B2QE0=GZ1SOH(CMI7G<ORJQE<>$
MZ9SM:CSVAFZ>S/:+RG:%I17NY@$&FK9[%7G989#7KC"Q?QGRXA[57Q8^>=?L
M+O_XY>U__7H1OG/O73_$/2BXV]Q=VJKD>5FQPNU=?W2K.]BZIW9W,Y1W*,CN
MB.@M(%J_ "'<;=0-A3M'S^<1'=>FR3\>L;B]X]JJ?EQ;ITUSP^-J*PJ U08%
M@.IZMX\HWQ+*VY6%,GN49Q%NA/)RM_$1Y8>9-]AI<<9.]R)WH=7F'[]<A*-T
M-YR" +-]Q_BR!6[C1ANO>JIQ='S4:F^(:QY+B*T: ==VAW\\XGH+N&Y7QW7[
MU.YLB.N.UHOCB.%G[L#1K:7G((\())SUV %M\8\[=E^MD78/EEZ-M/%1N[4A
M:?<RNR2(O,>(W/>=01@YB7?O*G2R!TZI%32>YH\L6^$6PG+6Q?;&"@IW%-VZ
M<RZTVOSC$=O/CVTFB_K5Q5;_U-Y01>FJ+;<!VZH .V+[^;%=U=[LUG&VNSQG
MT_QE$6"DW5LO_.!%<8)Y5M>+:#AUXJ+<EKU%-3<U*RQS2_U,S0XZBC9J'DRQ
M==QNK(S$(PYKPR&S(ML;XC";U/G1"49[A*JU[MC2M>U/A8)N*U.?[8B@VA!4
M2P6V;CMS@M:*:CP4#.Y"O&'M1Z^3.7I'S+X\9NLYL]W,F5T1EW<HN'RYB+G:
MSV:VMOH1@]O#8#UG,%M$JRR>[-!0M\5(K[I/72];1/V(LYVOH]ZSRN_VN2E[
M$49S]#Z%P1Y9%C>N[R3NZ-IA2+QCIGKL#&$%\=M']9<BTSVWW@.]X^_9N0ZA
M4I4]HGZKJ%^K6V@-'M9>>43/S<0-W"*\[P/77A_SQ<L]Q,207JOTN!]QOB6<
M;_V<Y[Q/D</,=+;\V(L9TTO<X30(_7#R>!%^3$;[I* ]@<E76/N>*-HYU],1
MK2^+UGIT\?+4O2."7P+!+RNOL]7>?V9;,)\ZT8QO0K' /D@26+GT?2F[VLNV
M"CPB]4616@O?[INE?/N(WNVC]T6Y=C];;YZM_K_"N?LK$V'_0LA?MNI]X=7]
M;*O"(RKWED,OR6 [(O5?@B]GZ]T?7=S/[N*NG2&W\PSYB,/]BH?K=[+]>(Z^
MY[T)J^EW,P?PB+S]B:CI9_U)!^]3W TG8NV',.M".N)Q+[W]EIGM+EC16708
MB-P%[U\MY]$RK:?Y=(]XW+'SF.T\N-HU<!@H/ 1GG64VU_;6';&W.V=O'??,
MP>!MWQTREKF.1^:(MITY;6LX80X#:WOM=K',-?PN1WSMP/G*N5HXT]A_[W01
M*US-_W;L..4\*$?T[-#IL;)^$60&A^!:SG&X??([6E;6SW'$RVZ<%WME"M^1
ML>U;O()E-7/I.H35H[BJ#ZMKY>/4@M7RYG=';KJ'A[1=>DB/Z-S#TTE^D3Z5
MO^Y]^2U@^[^(W-%%&-R[4>(-?/>:X=N+XS!Z_!PF[AZQX-MI&"5W;C1[YPZ2
M; &?JBO=@A5A]; F=G]3K8@736Y30Y+>7?@4M![Q6J.X!<RVL!9LE2+!G @V
M.] ]V5LH.*+^18]T9^-F0Y8EFX,%O [Z$:\[<*0[E>M^<R+8Z$C;O%T8KRM[
M1/W+'>D>\O*-CK1MJ7UFX$@?\;H#1[IJ_QE)!)L=:1YX8QX5M)<^TNV-RWY;
M-G=<<61"3\ C7E_^2+<K5O"71+#9D:9X'LNDII[](^I?YDCWH<NGM?&1YAW"
M.KPAPUWX-,0>,5OGH<8N#= 0;/6AEF2PV:$F]YC=$RT=CH?ZI0XUT[IZFQYJ
M7FV((Y.IWD>\[L"1[E64TY((-CO2Y"!K4>^LM3!_1'R=!YK]K[7I@>;N,5.>
MZ*>@]8C7V@^T;58\T$0$&QWH)G>/]:^&R1'U+WFD+?/4WO02J\FK<W-D,AE]
MQ.O+'VG+K"RC.1%L=J1MA0@@R,!N\H]?;F%?O,1SXR5=\8R])X"5R]Q.[=ZJ
M>*='[>:F>,\V7SL>^9=@Y35%SS:SG=J.V'P1;-83<]MLE\;Q'?'Z,H)Y^]%_
MS4YI1?TC$;P0$6R[PK[5['*G*/G&.U\^W]'"OEPXR=1Y_"WP$G?T,72"O6I8
M3+BE5K<7BRAR@Z%6"DFL<J7F51N=K=C.K335[:#+?5//:[.7(9D*E++#I/*O
MAKT^Y_J$//";'_'X_'C4;'#$9#4;7")](R[?XB6^R:':O0L[_--^<_D]0GD7
MW:.54$Z/=C9%.:4[2D2O(==W%^%'L5XD&"3!;"086K9.,$?.L$>X(U\;=[3W
MCH?]< ][3_AQ-R.8EDXPQ\.^1[CCX6QMXM2]NW =-![Q6%-$:K]R*AA'^F;J
M7$>5SOTCAS]<#M^O1R7HZ@1SY/![A+N>:J[WI;E^Q.*V^'N_NKG>K\=<[RO'
MU3:/_/U@^3O<\=3 (]JF3C!'SK!'N+,4_@XWKT<L;I>_<SQ6K<U2 W]OEU<Y
M.QIM6T+ZUB,LVN5%T(Y(W]Y)WVX5IC9WK?$Z'^K-R]W;B[=.\'5/8EMW4'O3
M-O#YNP. =[YS:MF;BOMVAB)RA+"[1'#0>"&?FM4_GM0#H8A-$U;:W0Q%'$_J
M;N"EIP8M=>_"(R^MT=G5K1Z.)!GO9BI2/XO.XX%[071NFN'5(5>4U1-%-8YR
M=+_()U=Q9=,@TXZ5H8CCL=X-O @O%*&%,5Z!H>V@Y$D7,=WJ%S&T19LQLZ90
M <EI<V1F>WMHR/>SL?+9:64HXLC,=@,OV>KU1PS5IT6NZ3>U:M BN3>FBQ+I
MR'CWCGST \Y$\:8%LSO=#$4<C_5NX*6G:)'(>(\8JI7Q5M1X4W1NQG@I],AJ
M\[OI(^/=,_+1BWTP4;QI6?.NF:&(X['>#;Q8F2"2(X9J9+SKA8<0.C=BO%T[
M4R'IB,2=J'74;9;':ATQM'=16-U6>136$9U[%U_5I6@:F_!I];_L6U1\)4RN
M%S!7$_\$%[IU:F_,/SLZAG;H;J'^M785YH(E3H]T^1R7VOW*;"9%[&9LII=!
M;&\Y7M.5'''[S+@U-[WCZ_9+-8+CH=UGW:!'CHL>-DV54?9O T=Q8>TY+K-+
MVE;:4PN/W4:RLD=1(;+\\Q$[=6$'*@PT-\4.]T:(&J!'[-2&';L&['"?!,<.
M$UE'/-6 IVR)='N=XJOFIB72>ZVL [  ET=D/N'0U>,([)67R3YBJK9CMW6'
M8"]?^%I/RSRB=2^5_VXA-Z4$U.PU]D'@-+NT4LSN&%OM97I)'!%5-Z+J:1/1
MZV<1=;POV06\],W" W046[N"'QZGP=U0=Z'5$AZIZ_,_+O[K_<6OUS=7=^\O
M[BZO/K-//]^<?]HKQ-VX/A/3HVLFV!_O(B>(G6'"'E#1MV*AS\,!LPI(J[H"
MTCJU-FU>V+=Y\T)N+^SDO1>IVQNW]NN3/\*6IM$NKKK S+ KA_=LW/BN3]9]
M]X,[X/N2POKR>Z-3A'UJ;AH5W.=E:;N2))25[\JJ\Q1A=RM2!&W19A31R5@H
M1VFP5X9+/WO9W]S!$(>-KE8W-L+[NFVW2V=?(X=:U+Q^SCVX>ZM^NJNMAO9B
MMBE* Y H,'=H8_3K37OCY&IVA$J]Q3<3-W OPF@>1@ZPQOUR<%3@[\4+W$9?
MVVU[C]DXI6T3CVA^-C1ONS&B;7(#IYT*>^1A4,P".T7"YLF@FO@JX'TBO[SU
MP@]>%.]#\! AE181N(GF?5FVQM6.LIKI3M_3;35*!^N@4HN'/EH'&]X&VR:/
M4__D//)0TB[_F&;DG<>>$Y1RF5VGM"VGYE4@K/+]?'X'%9!-N[IRWD93=3,*
M:Y=2V'+"VF'*.B*[#-GE[9V/R'Y^U_.6M95NJ>UQ1/8S(WO[%D@OXT8\HGCW
MG8>VF;U,/V)M]T,@;(L[L+C.U)/FW?DB3B+']YP]RP!:P]K*+'$+^8<]T'RL
MC7%FJ6HN]$<\8F\[F5R]ZDJN1/5&HM"B*W=1BF@Y?H_HW;QXU*;=2VVKO+C"
M\7 >5.$%V\H77A"ZSQ'5NY-X68?]:95G2K!]^.@E[IWC/3BI?GLH*,XN;2N^
MZ1<XRMG(E2-6:\%J[5:FU<U8F4=$U8VHF@S+7BG'_#B8_!8[E\%P'VYVUL!7
M9ET'FEYF6TNJ2QPQ^U):3AV891A,'0N V1[_)+CL+\[<.;RHC_SBMJ7$5G0F
M\$<W+ MCV^4!7&7X/2)XGSBS71ZZ=43P(9BA-G<N\0HS@&#^<8<"3[,U)\SJ
M6V36L$6E3IG=W:)M4U'>F;$7N4W52Q=OOD6=\LH82Z,C_U@XP<^N^'.G+=&]
MB8[4]_1 /5!VMU1V'RGN7X'BMB\&RCTTOUR>?_[Y]N ,/759!YF[8>==,X*)
M'%&ZGZ>T::HYF3V)4JNWH\H:1#Y4S<GLU;-%5JE#\DCUVZ?Z.AA9TUX91:%$
MW"53-Y>5=""8KK+:0XP!;JX11G.=/'Y,1LJVY*,N#HH6*B_\0$VE9JMR(C+;
M&_SJP.ZCEB_S4"\>F^5!.,)@T_<D9QH?"/JKK/8@A4*Y5PX"\?-;(KX]- *H
MLMJ#)(#R-+#W"V" OT ZQL&I^[FU':3SHEGNC_K5?9R'7I#<N<-I$/KAA.L]
MXOO#N]&LMN+#O,9NYNL.R= QV*8HB:_9[R'LV64P9+LBOCZXDU]IO0?)#5IF
MN;(7QE,O" >+JY'C,>DW=>G#@2GYRY=YJ$I^JSQ("72;ZZD3S>@0R#\/#._+
MEWFP>"_W^+U?1"'HMI?!O1LGL*X/7N $0U1_22R*1P[+X;/VP@_4X=,J=P9^
M?/OS;[?G7"KBY\,B@;+U'2JFRUU[H//D;5[Q[:%9^%56>X@6?JO<Q_>K-YN&
M%V$0+WQ(2XDO0FX2P?<'I@-46.O!*@+E3KY/T5V\"":W4R<(R!L2WTX7'[U@
M0G]%%^R7R2^N^/&3Z\D?SX/1ITAQI Q#WW?9OM^[_N/=E+Z+#\^/L*4M.TQ'
M1&M)U:G95_?Q=[:"1>3&'S]>X-\'YWY8LLK#=#ID*T^IMMCA,8?\ZK909J.>
M/.!6MMK4$5.U8ZJ>1."VF:WFEF&5!X&@*IQQMTY0V\K6:SOB92?.BUU0_7!/
M OR?<(7]S.Z,^H]-LZ#,X1$].W-ZLBVGCY68=EZ7:[?S-5V..-MQK2Y;,"GC
M?#\4/%7SN>_8><K62#KB9G?.3=;#<"S,L*M2*>MA.&)J1V51)^MAR(4%'@2&
M*H?^[=A!ZF0=#4?T[-3IR?H;"F[##@)!U:^L=NX$97T.1Q3MW"G*^AWVJ"S'
M[A7&J/\$95T,1_3LU.G)>A/>+=R[,)XZD3L-_9$;'6!D1LD2]\8^ZF2]#$><
M[;ZEE/4^X(+>S^9^^.BZAZ9-%"UNG[2^K /BB*S=U?^Z/%V)>BAW[L(>__3E
M%MC%^V]#B+-S97&S_7+&4F/;\RB"-< H*N:6+7 +46)6![L35ZHW1(]N6D>Y
M:ZV'ZZO]JC_Q!&17J=2WWRBWUT/YW<->1:0_ >5RA0>+\N::*)^R#P?/UI55
M'B9O;ZV']0_A(MJKF+DGX#Q=XQ;ZB&\?X^T,QJVN0#GC<7?3<!$[P>C6^Y:X
M;O#^SP5;S64PA&7=N]?^WET% LB?G9FKN5VKKW,K;3;7I0%KTU[RW8YH?!(1
M#=CBXZX6V>R B5EYBYJG]J:I$5UR]^SBQB@-=N5:-S/F>FJ#748.'?YI>Z?\
M2111M3<M/=K9E")XF9;SQ80?F@[_N$.TD=VB7O4MZIW:FVY13_,*=-D6<76B
MNZM;U*W.>O%1>U/QV].,Z;Y4N/HBWF8_5.HX2E[?>8G/=*O+8.3=>Z.%XQ?$
MUVQ1BO:KH[)?BR;5LY>@\M<]R2VI@LA?MY@$^0)H;*K2CZ&QR3_MLO3K5Y=^
M]&ASTUTB0]%NW;IS;C=@*R9F-ER$ON\,L&K#O:M86@?@$1(_+U_B=LS$_JG=
MJB;*>0NJS?#-S<3/X3T5F;?%QR^_,G/JT9D=6/$A?57;ZH%BK=%=P=K<JNEU
MU#LV)JGR)9?.@Y%>=6DOQ%@E=T_EQ6[C(H[QY3HNXGIJS0:47@*WNZIR]ZOW
MR^C7TB^C1U$ =NN7!>Q1EPFLD7OO^N$<T.<475'N.Z4O6^&SIXZ I=1!8;49
M98NRJ M!V2;_>-0XMJ!Q] &)E37,SFG3W/"8]DW5OX*<C'_<84Y6U;^"CV[,
MR?HBM6#W-D83;'RM&QW_/L7I6[;H;70>)=[0=V,P5(=IF;C#TD*7+G([ :YF
MDTG=39'7S"#ODQ=XLP6OZ;H2E2FLNXA.<)G<X(TA(@[^U)97 4U'JBFDFE:6
M:IQO!TTUZO*.5/-4JA$E-!<^>2IZ_-.7WSWW@:U]Y-ZZPT7D)9X;9ZIE[2ZY
MK(''9<O<5E_X;O5V>=W-7;;]3B94>#6FCZBNY<#6X;+HE[=^/N)Q>T=VNWU=
M^[V,/]GJ\X\[9,1LY)RU^IMN$25 [.+&Z#R UKH)#VB:IK[6+[SXLQ=,"G(&
M#N+,EZYP6VD?=: MWWI8L.[KR+MG6W#M.\,]S/BX70QB;^0YT>.M W?AMTDX
M_*I[Y(H7N'/MB&M@UDW3SNA71^3N<I6EIIDMF+#GW'3%W<83^.B.X:N5P9?N
M'EN&O=U%WI;=8@=/(^U24:N[Q0Z'6I[1';9CU/+"XKV\Y<CG,%!46<\]P*(&
M)4L\R)8>3;-;=JE:VEOT\NKSGB%]Z>%>N<PM!;5N]::X:?:6XCW3:NM@=,/2
MM6V%D[\ FONE:!85EP\1S:5K.U T6Z6A,5B./YB4'>=]1W3YZK:4AK]]5%NE
MJ(9J9Z68WG-$EZ[M4$^T78KFO2QVN12Y:Y2YW&>4\CPB3(M!@]WD'W?H(B=[
MPV56-SS-C4,\FQ;W>^W@QNC^&UKK1OX;J\T3R'?_-F_3!/*FE8W'.%:2V%HE
MB=H=CU8WFR/$J]3AM<G5?-_TCG?NV(TB=W01SN;L-]0M%$'U#R^9IIFO6!'F
MK1.#<^@1?H[?/I)L*QQ&NT,JW:?]22=J6KU2K_.1#':6#%[6G6QE"W<>*65G
M*:5V:6%3(,^Q]$$-#)Q7,]@,'V7U17:\FL%6:SXT;5NCVAW;FQJ(8A%XM%:L
MWAU+XV/F.O$B<M\ ,7NOZ<>_O1+?TE#PKMR0=*1%/%(.M'C%B\.6;75?_W;[
M3AE'@E4^UK4;2=CXF'@&774GX(7/BYD;.4FHG+4J\\MCF1U#&_R=&X0S+Q _
M%4Q0LE.Y*;(C"42EBUJZ(W,VJAI/I4\/O^:65SI6\K ,4W?_J( IWPN^OAZ'
M81*$B?N1_6%\PZ\2)MI^^HX1&CM^[N@[_FT4^OJ9 *C/PFCRRC;-YBOX^14\
MF*(:7_/#H38L^QNV3XSJ.P/7_^F[+V\7L1>X<<P$Z0 VF#%ON+%GNTJ.0KSG
M)5E[E4S=R#I=P@:_ !GS"::1._[IN__]#!.\>J.N4^RCMEA&3N$B&KKK[*$8
M*+-#XR1(OICLRYG/O@HF#$'!Z6^WW[VQ^XUVQVK83<L@ C:^MQJ=EMVP^Y;A
MC!-@:*![&)%[SXZC:\1,MB4_&.'8&(:S61CPG]G?;-T&:#).\&@\.+'AQ?'"
M'1E):)"4-+R O1,$+MZW&P],2<)W/KG1Q(W.#&8FP_@$Q8,;N<:]X\,(3F+\
MFW76-HTY0 ._-XP!Z%,&&P9&&'BC4V9?GSKQ5_K=F$?>T%T%)'][S!#J&R/G
M$7^/G)$73!H&PU6T<*)'H]<P &EG?WNE8:H0?>>13JY.-!2(8!]7X(\_\6KL
M#)/3+!['C)*>D]"3,"62,&+#_?2=!33*CW[NL(M?1J[W^ISI-"/0:S[XSL3@
M8N8&#L[0+ LC^>[-V/%CQK%R [Q)![Y8L(6P;[UXZ/A_N$[TGB1ZY3E.A0*[
M;+0W<KYWX7 QDX]<H_S\P+Z+*T_X=SY7Z4CJOND/ 43K30;_%DTG1\JOC"!9
M=QO56)/2T8I6!F9.Y5DL\_3O^OCPNA1E\,-[U(PNV$^1XS.-W/T&?*7J!*KF
M53K:F_QT1#<W[CR,( +L-G&2-;#T!R@%JT9+Q6KZY'NFD$S8$S]'X4,R%4SK
M"<=KR7!%\W[P?)=I0V *59VLV6R>]JU6LZ-.F([SIFB*Z((1S22,JB_I<QB<
M.L.AZP.S8]P?1\G.*(<M6IJ6Q0H[[UZ$"X;^1ZB&4AV.W]5)EXZ9IZ9+-D<$
M(6?W+CLU#B>'IU)3\6A%2[]Q)QXTU@X2\%!7GN_\[>\7(+^OF5B=.0V#K?9,
M!4 ?]DUFTMNIZ_L;4ZXZ2HZ4;F>.[PNQ6'F.)%KH4ZBC%+  U"+0"8/>G/AJ
MD8"Q!:J" 6HQ3LB-%1T(JL=AF5@QD$UMC-RAQV:+?_KN\O,'QEM;+=MLV]K)
M63:=Y(>R#(P33\^#$?P?W"PPG0E<3.?)A1-%C^R%WT&)2H%$F:]!F.EVJ4)H
M,O@Z5MOL,HZYUGQO:H8QD[V0@;%E=YLVF,";P'CC,CKVAHRQ//..=JV>U5$V
M=,V)WSP7U,OWN&O7"/7Y< @\,KYQARY[8< $A9L(5OCDC6WV[7;33D%<-LN;
MS"EZ*D3+-\UJ][M6;1#I,<D;;Y?58@>[O0RXP@D5;T)]D*[8QE:SU:P#TG<+
M%T0"FD8U[V;7M'N]?@KCRJFR^-X(MN7[U^EW['9[ ]B@'&*0,*6*D>M:6_0M
M?AUX_D_?@;PE<_))X^:6MV+<Z\B=.][H_3>X5G$9<\*EGL>QFVR.Z4[3ZH+A
MM<9D;VH%;\5A8<#UFYN 5],^M9E>TVHKD&3G?.*L*VB=K;_?Z52=]3H*YVZ4
M/$(4!M3Z! F&)1'7I71]Z6:KW[95')3/DCUK3X5H^;:TK5:OV7H:1%=S]"X%
MDX^N$[LWWF2:7(U_8[0$.[N!_.E:K6[+3&%:.L^;>D!:=7:Z=K?5?1)(/X?A
MZ,'S_4WYX]J#5F&.VJ ?PV!RYT:SM,AMO $6+;O3ZRF453#ZFTVF7X$QJV\R
MG*TQO;AT![M]YMXYWXA!;'3>F4;?[FH2MG22 J7D20"M(N2^R73/IP&D2XS/
M83#<6-6TNIUFOTPFI3/4 \M*BFE:[:? PBOQ/+YSYV'L;; =+5/;C<RX;YXZ
MZ0HCN=VVJDY*Q+$!OL&C87;LK!1>=Y95F&1S=,WVBEFXL7#M/(*EL+G99#95
M05H\?+F15!V,Y8NWFV;K"6#<3L,H ?[XU@F^?@R=(&;"_W.8N.+-#3:F8[7M
MMB+/5\Z5T\8V@FX%L73LOFEN!!TJSNEK812%#TPUV.B<F!I,93/D\?@46%9L
MT)-A43?M+H3MK.&0M9LJ,*53O*D!E%7[TND]!11V(IG^-?KH.0//]VKQ,=A6
ML]W/^).*YRAP)JT/S H&9%F]7KOU!& N%G'"E)#H?'0/?17B#V$$E]A,7:7(
M@*=3C6UV%4RMF*=&L%90T$9@Z2:(V-W'C8FIV61:6;_,U,G.\Z8NH)9O59,)
MD6[OB4!E9*!T==1_$%LMRVR6"M^5$[_)>?[NPIK=D4W+ME0/1/D<.3'W-'!6
M, MF(K;:3P('MU)ENIL#TRZ0= 4S%%C.==)0I]/19%PQX]Q@_A7V ,-(LV^M
M-S^H21LKBG:ST^KW5),]'37K*J@VWRK^VVII&UTZ7\8HDOQF$\O7[)FE5I><
M(*\)/P&2%;O0MY\$20D+KL4MT.PUVYU2#V#!7/5"M^K6J=UI=TJ=@56@8W+]
MWF7<C1&:\$O58VL1"U.5BN4SY5G9!J!5X:Z;@*8PHJ?O4*_;[[::O4+V]N0I
MEZ^\UV^U.I6GO(ZX2P[C/-:/*<AZ>3<8>Z4'N7QL)KRO(HQZ&N$TUV S0@2N
M.ET:R%\9@\WOWIAGIJE?LU68]]E@78+ZYX"5XG[.%PDSP+V_W-&***,E.TE1
M1J:9.97+IRNZ47TZ=$OV[OF@NZ3P\S7WK3KEKS'+!N=KW7"SC1=4?:JU5J6$
MM&T:D 8!<ZITT0?.6?5K3+Q"L#UYXNTQR0J3%JD"]4"Z%HO<%-*:&:1EYGC0
MDLD*%+VG K:*-]8-V-/88FG0ZHIY*J#P:1ST&0':@-FN#U4VLK<NT&K8L*6@
MG8]&'G@K'?_:\4:7P84S]Q)GO>"'S)UHMVWU3,7<*IFB%EA6N$:>#@ONWS3T
M1XQ'4J$7L'6@O/PP\C!_7XE:W$ (]INMCBJ-UIHW*ZIJ WJE<]=L=NH"^L9-
M'"]P1^^=*(![J?/A<#%;H$?QG3N&_/NG;^^IW>EVS5Y?<:"NGJY> )=OY:G=
M[K3L9J^["8#*$^@"A12+R)U"\8-[EP)%/H8QQ(A<C>^<;QM$3)J6)L#6G#AW
MGU\7U"M"YCJM7J<NJ.\B3*=^K$,#[F>O:O.#Y_2 ]>9?OC%/F3]_U#=Q?G6M
MKAK"DQ]\P_E7\+%6L]=L+>5CN?D_>4$8B80M-]Z$-_5:35/UVV>'S@NE=29?
MP7>ZW8ZM9@.MGCR_.>RL^ M0*ZXA!3(,SI,D\@:+A&[4P9W* (I"WV>/;+Y?
M5M?N=>S6,FP]!:#5,K3N9:ZP3CM,'U"]U<^S3,6E>1Z,ZCS5^9BQ57/5"=NZ
MD6;KPG;CWKO!8KEWN3Q?,8OJIJ7&68FQGS)G*U?,C7?6S::W]+J]3N&4NL$2
M,^''?ZQCJ9:MWAIKPV?]2Q5GKKK@9K_=KS3SSQ$3^M=1.%ZNSU5'KM57"4T9
M/B=4*DY=&<>MGAI)G9E9OYU$)@%U]"/'9P?@?#3S DP$AE1D'DM;"P%8G6Z[
MK\KZ2E,7W*=N"G'57;2LMIX)]D2(;]S8=:(AI%:^8W3GAYB>4>?6VI86"+UT
MPKQ<?S)\53>R;W?[YCK@Z9&DHNB>6EROE@/*U$]-^2N<Z<V&T%3=I+;=7@U*
MR94YW[M:9)+5MEJ==M%5OIBE+(*L"A25SYX-7I'6$Z!([;<Z=N/4LMMV5Q5=
M!1-M!DK5+3FUF*W4[!:%,92"DN;.T"-5M-.J6\,(UE:88]E4A:FBZ\)4F6S,
MKNI+6P,F^J%.IMPT;7U_M"ERB*H,0.6]8#+!ZE8%X(9M$M3.@6UB!D0H2*N.
MK6CU.II[JWBFO-*[/D35F6W3J@X150A5G](#'FLAEP[X85;-5 =$U5GP.A")
MO?P01JXW"2CN<*CV9?O9\0)@46_=,7MFA4.OZK;UVPH>UY@[KP75!'C5W;6?
M#+8*-)FH:6/Y#_>?O1O7\>$&4;Q<BQAL=;NJIZK*O#DFNRFPE05EUVQ9FP++
M0XE39D#$7Z. Z"H@+I\MI_<]&;:J6]AIVO8ZT*E<Z>?PWHT"$+H_0S4I>K8F
M%T(K94F%TQ2E-#TC"CM--?JYP@YM!%5U1;';T\HU5":L5(^$F2[8Y%ZP8"]Q
M13,,.">2N<=N_/X;LW[#:.0%3O1XF;BS>'U_Z!K*>*O3;&DZS;,!_&87=J8Z
MRINM?J]IOMC.L $X3;UU [<F#]IIVS)5?W_)5,54O!9$E?>Y9;8[O;4A^NPF
M=9NE5K_=M-4SKDY1P'"J0K &Q9E]6W7RKX!@-4$NN\6@<GJU;%VGT[-R*-P,
MKO7YZ&9KK8PDJ*&3.T#UK)4W6'83&$Y_[9S]!'<IBT'LC3PGJLE$8D1O]]K@
M4E]O[JR"4@?,U8^)W>JV(97@J3!K2EA)I$*Y!<&&Q;]\:DDR^N>"_"%5@BJJ
MXJ79L5K9)+S: 2W4@;>Z'=4/7:N=5>V??3L*)J@3Q:<68_;-CG:#5SIA3;"M
M<<3:3 _O/PDV$6,E(I7?.K$'9_&=YR\2-9AU2;1TI4VT&:#FF7H?N&+J-_4#
M6FE'.:"=IP+Z#Q=J:[FC<V:>.1->-_IJC&\J@:BE\#]]BTO"89\&T#9650D?
M%#O>;S&3KF77O*IW+CLG0Z^^&[6^K6A6ZNCYW/2*4U>_K+6ZK25SZY&'/K8?
M<4?%]VPU>@BR=XS59L[%=VX,[Y-N(:L#JX/[6Q!EW&M70<4:<4]U2*Z8,D=^
M&X#X5#=D51!)461B"V(QW7<N_?]EL"6_6L6)W]0+ZY)-75$A5C@GATX\K</!
MEYMNX\DJ7PDTF\V\TS4W586Z@\_OBEDQ90&[?S*(3_7-K MBGHKSU:EK$0G-
M7JNG&^4KYZT=V,J;VK;[;7,+P(I2.S*F875-P<K\K=?MJJZR#< I=&L]Q]HJ
MX\?N:M6 GW5MY=7&ZT%3)EZBZN3/!7CE:,MVL_-DN*O1DJA2%SFC6G@0LYF[
M5J5CK<Y<X.;<$-[*9-[LJ/T@*H.[$MI,6:_<T:A83J1Z4%!'J]VZ*4P5^5%-
MJZQL1)AFM[6*X=:\RH(Z9/4PI9:U;"$%TU8XUFL"6_G6OM==+JO+H,U>%4$'
MF.LHA&:FH[>/O\6@1*72 II4U78B3JV6U315T[WZ_ 77;#5 7MW/VS3[K:<"
MKE7OX-W$[\+SX9\++W+Q)-1L,=L]2^]DL&K2[.YN!.5Z]ET5K-+$]=-C=I^J
M3Y^M8%L+W$\WC-G$0]<=X54?E$R $J578Z4X0"VAG6:KI=A<*^?,4OXF,%:V
MJSM=S0=7!4C]NE!]HZ"0,GQ]-_6B#05/V4%X#C J[UV/\3A3N;U<$X9\4.^<
MLY&K<=4J=94Y7*8::-E<11DPZT.UQL%<3?'(2D5-O7?NH)X$M$QUSHI3%Q6X
MVQCF&G9+T5L>Z]HBR/ JX0S9Z99PKG4@JVQ46IU>">Y60*82<PTDM0P]3YFJ
M<M)8OV<5G^4LL580NA^\@!%M[<I"R[;5F\;JDU?6<M8$O+*E8)E:R9%U(-=N
MI<=C=YA<C=]_&TZ=8.+>,,*\"HK[2-9C+;2;:O_ =>;/[WE=T%>V&-1N;FN"
MK@54L%\S3^2:>.I?*$]2J^^\;<@K"JC@$(CUX VB[E3,;7<-^6IJ.[.%U3V]
MII:6N?4-K&W[-BCD8YI64\V;V B.@C)MS[6LMKHLJY_/_6JUFG6N:BN+6M65
MHMFT5<?XON"JHRTKGU79[_:?#5<BQ!YJTZUH&U?9"F"L5[N>T&;(QO)7GKYZ
M1FZK57UZF8L OS_'!?X:4ZSC><F5"%BCP&-7YPU?%$?$)Q>BNHJBP;H]2[WK
M+JCSN-V21FLMPN1+>(X21UM>=R^S;JJZJ=0]3*]="_?A%#H(-I?7?]R/HE;]
MS$Z4%-HLW 6[9_7,9NL0",(R,_N0K>983 96N]>V;#5*87]WP,KS@FPX=N$F
M=#K-;GL+.[ F?[;LS'JT(HDE+/K49DM1,Q4+*_%N&3%K+@0MUFR%R!J1LNWE
M-S/++QZBF$%UK-8S5.3;[@8L-T(@4ZEG/7O901R5*GB_6T0P%IJB=#P^NP_X
M4[SJ2);J9E6TIP*"7@E0 :[R[V#!U((U%-#B$Q> "O5*V'4XZ@:]70KZNLI/
MK@#72RRG4[J<=328EJ5E(+W$2M:Y#FT^'ZSK5TBK"05Z ;6U(2P12;6M\FEU
MX)ZVC"=E?EO=4C14U&%%JFOAU!L UBL%; T1GLV%S@&77K5?4'5PIJVJ&9DR
M!W,YL/UEG+V2'LP32*O!4A_D:^:W5@5O$]7;-G5?7#7?2&^E;V3+BM=ZRS#Y
M(@Y!Y[:MS,K7]H\T>\PH[#V/ ;+EO; S>[&>A\2VH?KY01!%,[,1%<5+U^SW
MNAWK$$BAE6<(U5PD[6[3?!XBV(A/MS/KV5<7R;H+.3 7B9VY^UI+OVJVV]WG
M<!]L=PN6W_Y!#5[;5N_3=N4$=O6+\PJ:4KY2P@YH2FLMP\RU<MSCH]?+K'Q]
M36EU4ZY]$8_]S%ZLY8G)M7S;7Z)HFIF-J*8IY5N*[2TI-*T\0ZBD*65[?NT(
MGV[:F?7LJZ:T[D(.3%-J9@+5UM*4LJVWMGK3\D3W9;-5%G'SK&[_4B?G\ZWT
MR>U#-EU&98=HLUV*BXJFM"BD6+.GMMDI!6PM3ZU>H?.9/+7-;BFP584,KWRX
M;4_MFH49M^&I;?;T8- ]M3_66\8AV1_-?F;E:]L?%3H9[XG2V3(S>_&O:G^T
MK,Q&5+0_<CV7]Y<4[#Q#J.:IS71*WA'[H]7,K&=?[8]U%W)@]D>KE5G^.OI5
MMN]PC?;'W_[7Z:GQ?__QZ??V__N__SV<+[[]$;3[H[^Z]Y,_'H/?WBT>?NY&
M_>ZO]C]_NWN,_>[]\"_3_R5YE=RZO_S5;7[]9@T_)N;_?/A@W_[ZZO[;VXL_
MS/O1;33XSZOAVRMS^->K=]=_3_[L_>/N/^__Z^?'9/[8=O_T1W_._'_>__$I
M_L_Q^%=S^OLOB^#5Q] 9_<_-5>?3[W__Q^=Y]/<@:'>'8W\X-__SYL\_/_X^
M^/Q[LOCUPU_M_YQ/_K0F'WO#?W[J??L0_'7UV^C]/__'C-_=_O+7Q.K]=WSE
M./V;J];PW6CJ>#_/'W[_U8J__G'W]_BOSL,_/U[_HWO]RZ^C5^ZW_[QYZ%Q-
M_[OW:'5L[W'J^)W.__P\"H-WX1]-?_*7/W_WOG\UFI__]-/_,RYN;TY/=87K
M*IHX@?<7V@4781"'OC=R>"7H:[:]T( )_KP:\Z1,Q[]EW[BHN[WSXJ$?,NIW
M[QB%O/6A<$)%C?'-?_C)CW,C3AY]]Z?_^',1)C^.V9NO#<N<)\:=-W-CX[/[
M8-R$,R=HT!<-XY:9-N,?C9D33;S@M0&/FO3R?TS8?VS( 7RPSHRKFY_//U_^
MS_G=Y=5GX_SS.^/=^]N+F\MK_/OJ@_'VM]O+S^]O;^&=5P/Q]JNY'"=Z)3[6
M N6/!NS*J>-[$_85:+_>^#$%_?SM[Q?&6R^\9AQNYC0,=A#.C.^3J0O$_1_.
M;/[C__YFF];P1Y #3O"8?C7Z\8>&,0ZCF1OYC\;7('P(#"<VSMG?WM )C+>1
M][L7@^WY_7^QH\8.S@_&11C-0ZJ\WS <MH)[9^0PS"G?)M,H7$RF!H"0F[/_
M8VRD?=%<K,_?*)I2F0@6\KVZ$OE49BT/4V\X-1[8&KQ @.2.V!_&+PNV0O98
M&_X P) 2C7!LO'-]YX')A@8#9N),7'C7&'AAX@ZG0>B'DT<C"8WQPA][OL_X
MV\Q-C).9.V+@^D8 ">X&$RAL&X<+:"09TO"CM$LH3!(P1(^BQ82>%6^SA[PA
M>X<Q,2:9V1B,X(VY[[#C<6;PI3EFNEHQ*@.165O&R=R;NXR=N<;@T1BR)3 @
MV2J3R!E^A<V%2>54[+A!@5-(Q@ZC# 2&7*M'RX]XNU/VF1%;LL ^"V+GSF//
M.;UVAM[8&QHGD3MA/YX9[,"?#ADP,&P#IH/L3+9:X.'&+!RY/BZ=$2G[^M*(
MG;&;/++3P5@VFY,!;[C?G!DH:@;P!9<MA*U*(2' @C<"@AD_\KU,IDZ"<BS=
MH0';$+9)L*?,",(VMVSD,0/5&3XB!#0S.^4!6[B#(QG.?,[6&\,4 _AR$H8,
M#- 31O ^.R(:0F&8A9^PI24 YPG3J!C] G_CW+"AT+'/-AA;C")9P&SY_4?$
MP^]AY+%SSWX0&&#B#:<;L&T.$$ /I-AH 5CC \:X!V+SD8#@P:DWF3+HV$AS
M%Q+YC'G$3H4W9X]X5-!GXB1A)/'Z&Q/=["D\&(P3G2]@]WS/P?GO'.^!AF5,
MFLW.-D'@\M*04QLG3.8Z_IEQGK#94 (TTE_QMQAWLY0UE!\2()&!"W3-(6"P
M,O3'"SCQ8>2/3L?.+%S$QHE&M(P7,(TBA*F-6S]D:_C539CTAX$NH"I(9%RX
MH X8&H?Y=/OKQ87&71"H3^\,)MP84H!!J6^?*1B?.B,C"$G#8KO %!DWCMFB
M0]FR!% !NQ#B008.3'PN%(S*:B"S.GM1P0+SP,C:5/@&6Q)GS:\7L!W A-+W
M/CLSAEW,QD;X88P7EY)W912'-@?7)($11"&P8D8G;!7!",\[PU,IP9Z<,VUS
MZ -;'8/H5:06'!;<A?*WI9 R M@TY -5Q2^,GY7])RC\@5*5E;#_1N$<S@O"
MX3* @1^2^#M75^E0ZG\,L+"S!8_#30$;(U@ &W==E-KL-6W74-E03\\Y/7_R
MB5[0SM&9 :C Y?+=J;;1Y?L,\IX)9[:^!R^9<I5$?_D6R@4D3O0(;^/!)/E/
MK'4(P+BX=B:'X11^0NG7@U-H6_C4A\O/-^?LW(9PF-E4X2)BK/7/!1@]*:+A
M6UP:&^.<'7+?:)HTB%!.<K,9)PZNZ9/S:#3IV9<]]N4G!:N;Q8^S00@":N:
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M$Y#!AF%3%P&OP"+H/+-%&LUKZR7"MCJ=AMUM-OI,ZL+)ZK.3U>XU2T]67O.
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MV0_R=!;D7>V[E^.#XT4&=GTR/F&-)]+1=H>%?SB_?4OAEK:IAUN6@:[&6YZ
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M0[+$BQVHME>$F,CVD_#)O*<>L,:YXDM\<4XO;]FYJA"G/B27PZM=C>,%8NH
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M)UHQT7@Q2+!@:+-CGEIFPQ#Z.?OD._Q"2YH1N=JC_#6M!.F9D?Y@Z!U#L:>
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M3\%=,+P0CF3=N=""L@"02TI8=JD5:@FL>F8I#.7ZW$.P2#R((&><3)/GJ8(
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M$R6TND( _Z%MV&G((/#.7D (@1E-:GG #[.]8K )F>U/C3LW4]/*H1--68)
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MR4:%P8$\#M_!;]7VFYMF:M$]-KCD\VPRI)TIP!CZU 5#H;L[J2'JCIOJ7 ,
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MI@9&&QM"T>;M#;%&<A, %X'$?#?0CD3@H;)Q%2(9'DG:7.>&N<SU\$1<)"]
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MOW=]5V=#,(WU)297#O=H[D/OXT1M+KL5-N&/-3MJD6D/<JG7GFQ4T&65JG;
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M0.'+\%.O-^D+5-QL^+UFQ0)<2X#5=]UVQ]GTZZW^QL>Y9]M9+O&7X)L'<4Y
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MGM<R/D3'[N ]_M86/7Z GAZI"]P];SS<5/?*!1@_ /14.0$SA 3"BB!G7LW
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M[N#G5"EKFL2 K5/Z"6:AE]X!O#^^,0@]]^/J>3%@QQ-O#.2((&ZLGITX+TU
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MXY(<;;W>Z-E$W-*29;.Q&QI2EX=D$K-[&!)C#DPL]4I'341J,B-VKQR$L\P
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M_16O5.WM;+7GJF)U:^TU*UA@-J7B5>I#J]+N;KGAIWABTSJ0U<G"]U/H@[J
M67F0+=U;M72R_MU)K]<VG,M+";3I,62+]=890[_3VN<8&O7Z8VHH@?NZU6WU
M5QW"1D?0>$S-)(Y@T&OO=03--8L/E?#]7K_>Z>YW";76+#<$\0=*^I65OTGQ
M,[K/R#>H#]JME=6[0?$RNLV*UU2+M[&.>(NKK]+%$[Y6P2/LM$9/W72K2K^6
MHA^HD'"M6D:0L-MOP7QO7\)E*P#_3'^:1.._?S=+YN%W/RY;D%CQ\F4+][;P
M\L7[K:%\4.6"+C$!CY=D\=9J*%=->6K+2Y(F,^%/G<6343A)P]&;8!Q,AN'E
M71CN'\GXTKGP\5#&C?.<.H3;SPK!N&_-OD 8GQR$<0/IC(U/PLX;R)W-DP1*
M#$[3-,RQ'^^%"'<CB"_HK=+U!]VMHKZ>M'H& [_?W"I@<(<X!OL5@ $/%Z_I
M \R8-OUNJ^4/FIW=IN;V-MI.N^[7VUN$,!Q,@BYO:3]$P74TCF9105_.U6W&
M5B>JX0\Z W_06)N7\TDM2S7:?M=OM=>FTCT(>'"Q*5QOT>UM*GI=O]Y?FRCS
MZ:" >RV_,:A(T3Q]%+#]&C:R@X:&89*R],UZ8_"S1Q&/E9;FGFQ$O]'V^_W-
MS]EA6L1>O^ZWFEO$T11D#/$-AQZ#VLC-VG6V=]<*;NT@R^;#+!MO(Z?C+2QJ
M=7"K4(+M1;RV.T.'.#V5H3%/3%:%\[7MR5H++O02.7N)G#V?T%"]YW>K?.\]
M59(>0BUI RKW.A48ZLT$SG9[5WQ,U&POWFEKT/&[W1V'S/8RTG:CZ;>JJKN?
M 9K]B0?+VIV&W_K+7 U;@Z;?JZI!?4K!LD?'RO833._[_=YNU]Q^K'U?';L5
MZ;QG%2J["Y*P*%3V-KR)AM&*)#9[F;)7@U[7'U0U(BT7X?53&&-?>2'M^MH9
MDNP8%P7&_O;CRL"O''B-O#M]O"Y$[N5P\PQL+$0S-IJ-[J#;LA@VYT4GZ\J0
MP[TOEF$PZ#>;*\@@K/[F5-'LMM39V,F*8=]U4C0ERXJRDD::G7:]WFXL+8HX
M^K:P1 :=P: ANG?DWW;R*&E66RR#?K?5KJ\ES5:63:];[S<+Q7&FRRN=L:VL
MH%ZK,>BM+)7,\W#Q_@;74;_1[O>%4/FWG3Q*FM764:]?;S6[RTNSO/5K9 MF
M$#M=+$6]U^V76[YU!<C6NRP0H*FNX_U5!%ARN:Z@!"5!M[O8[CY"CN5UH:[K
MK79N,LKE6-'.K;(LU)6TU2_>OV>;$6:%):).Q5ZGNZ8PFU\N365$EC!MCY1G
M>?VTE"O96DV>%2W;"LHY4K[[H%%A9!\GS/*:.5*:43[V,L*4>,CGDV%\'U[.
M@EEX$#S/AYZ97N5VM/W:B.Y:N<L5TY17=TD8>A_5E^Y2[YU:-]@#5^<HG1SS
M3C'\+]4NZ\[HLRALV;\.=U^V<L#I]^[FLMNK1[AWG.&&>N$T&!>$P9]L<KNI
M-%41J]M7;OL@M*-<Q&UJ9Z?T;?8KOR1QFD*?E9LG$3?O^?7^YD'H!PGT;OB=
MWN;YZ [ PBZVJF.U'I_"]+QJ-NM^O[,VQN))9'!:S8[?[:R-KJC.X.S"Q&&Z
M$#K)PM)2]TEL-14)=H* ^@E#%ZHX\:"WV"TV8 KIIGZ/9 /K^DB[FZQVS^^M
MSWV[VGK<SPA[=;_=V-@(<R[U?G'V*W=XWNY%8.4/K1Z8*&B>O.B^!:]9JXGR
MHN %C< -8:S07WJYL_:P9VJ)R_)N9LH$)19/P%]-)_4-Z>0)+<FJ4,*V-V&1
MM_M?9V?OWKU_OX0K8D((QX/^VDW@W0A#Q9P7O;Z>>?MJKHH^C8[KW;6'\'VY
M#:UX;1]D7YHEM_)Q&U'%4]9G;_?Z+/2P'N7NKZXP"FY\ML&-S;6U7AO]N5#O
MVY%EWP+OS@RO9V9-R&%]=V]KZEYM-*\&';\UZ*PPF)4>_WK'/MEV=-1L^/W^
M8.<Z>L0NV-1B=R(ACXF#//F-<K3CX^#I#K5HV2Z!NUZ(*LE =;Z$7\/)/%S,
MEMIH5G:7+T'?-5L"'J/?E4-_+R>$T]R];H6HA%\W&O4EA$"'A?R5K2BC5^\+
M,<3;UI=D78UT>OW%DA";<IX17YW8'\!\;4,_1\UFO=_I:"KGTI>?/%["-?5V
MU&IVNIWFDA(:_0;1!'Y[,5F6G'AM#;9[O8% U1>^^='"K:N\7KW=6$VXY<Q"
MNU19#G*O@,AY]7=U2L>^RKN6WM_K#FVMEZT[MD?OQB5'F<&!=I2OO<1.?+QX
M2^HE8\L:RLU=5KQ';,:-K)#57_N8M5+!)OY,X:\KQF%6#_L6N+$O"-AG  =\
M0<"^(&#_8@C8Q?.U4GIJB9E94>_;DOLO/O1]<[XL!STV03PG+,>!/'5($<II
ML796X94Z /3M4M"FI<3)HYR>M%Z6 42MI9=%$;]EG6=;^\QM#F'A7MSDOQ:&
M'PB9M\#?+_>]B^,/2[[R9(,BMLLN)"51B/5$/(LG:(C4='R*9V'Z.7B J7D;
MI4.U\^?)FK5[TS4O(?=!<ANIY00?K;LK[#_S=!;=/+AQ:X2Q](Z]LXM/O[W[
M<G7^YL,[[]/%U;M+[_/IOT_5OW"U6;#+U'R1?.U=R7HQ45[]@S?PO6:]T?<Q
M#W(6WZNS[,&+TG0>CKQ@XN'Y$H:3HWNX&7@U=53=JR62AD,U$7#ZF;D"B/V]
M^F*</'@3-6_>*WBB9:\9_OSON7KBR/N?,/)@8NV?1C^_5M8=7A?<WB;A;3"#
MIT63830-QEYP#SD;. ^^;]7K?KU>]V:Q]\M<.73!Y-:K\6/_K;RP&_5H>/S[
MX#X:/WA7B1KT(CD<$7QO.D_2>:#>I9[_[2Y2-QZIE"0<AM%7-6@MQK%WI?Z<
M&95W'09)BBLZ@H-=K7,OF'G]'[QIF*A/3N;W]#W]V/0N&(^5=_P ;YVY#P2-
MT.B5>H9!>J>$F*I'*BL$J2OX8CR?I3/U>?BWT)EZ0# <)O^?O7?M;=Q(%H:_
M^U<0P028 +16I.[).08TMV029^QW[.PBGP:T1-L\D4D]I&2/]]>_5=7=9/-^
M$252-G>11);([NJZ=W5U%5*18,$OMO;:L-".<K <F^;[R$D,Y'VK37]2&*4!
M4EBLZQE 3D ]/HA<@:5FE"42B'\96;[*$6=Y./P7YY&"%,J4N&S64TX^LTDQ
M$ AXOC<V81P;%NJ@.W%G8V&:2WZ.AX]ANA!.;&T\8+T'@!0$!14!? <CK4P#
MEO5FA,0A/GD+")0ISV\F7]S>@KS8=V$.1#3!)+;R9&WN =^WL'Y8ZK,GEHKJ
M!]&,9X?>%A;I\''"PO. 3 =T0HK"US*! E:&&;PH[GK*''@%1B!(0+"#A1/&
M[X%L\"J,8*T2!U#N#0_X#Y;@&1O+N[7,I1HET@. Q:66?N),@3\GLY)RLEYM
M/8)+<%02,]$ +MB!6V.[VOC?JXIUB^^J^(V#S [?"H1RC,D5KB)T!:(:'%S/
M@F\1,P#:(D&[O ^>NL0GPL0%5Q+6PB5LY3P!3P(0;ZV?E#=Z#S@%A9. BP_\
MR?H.:\X<7@5^N/D_<[%!PCF*L41MB[X"HN2M!;-,^S^*50=3"?Y14I8T7P$2
M;2#EHYD]/_&_C81]6*],/-_FKK,_ V$NC':A<AE/FM]1UO#1-R.A95$ZG05H
M>@^DVK1IBK7A;E)DGX0^X*$ *2&4> P6S]R@((&FL>RDP7H*: H\KW>7I'-0
M*)5/\ZMWROSJO3*<]$_UOAK5S\Z=;?T75F\[MJ^@@.\  YZU4!Z-U9;M*T G
M+9?PW(UI4T$U9'. 26*T6]/8@(53N+9-!1*L*#@<6]22NJ92$6M5?HHV=^:2
M<;^AV&"Y#3!Q=&0<J#_\6C(>(<NA]YLS'5EFX_K)7 %?OM7TLB8#5YMOCQ/,
MB< T$0L1C=X=T6 .\*^4D2" S!9A"MC(Z/?@-Y@2'8BW\B%BR,]P482JY-CS
M,69^7V/* $@1_ WNPVBH3G1=I3ED4 FB)1*3'#!!U=]8K8NP?P2XU+ (YW18
M1*DB;P=JE<W\9+BN@?((TX#G UCQS#)CRB."Z:*'_3@QD88( 8.*)]F8]P:P
M#4!$AHIYFKVF/>'?MZ P]$DI7W@W9_@/\WGM (<DN\*;;$9#7U@?^;ZP/Q8)
MQK7?#UXYWRQ[RMND:2/FRP#ML#+0<*!^?R[N"G,HF&B$UL1UF2\$)^6\8'^L
M6A29I,?"KGDM/G!HW6&5)?H?*/I8N, A#QA=SA;YP.3_GAS, 0XASG=_ ]>7
M'/(TYS?,;4FNK_]$::<WYO(F6L+#^+SY_NY)@PYONKLK>9R-N+R)WB[;#%=W
M><-,5]#AC?FZDL(^:<+937!T^=8JY.U&Q#/1U_6?J>3I9CBZS)8U8B*BUH$@
MJ<W=33+!&<YNEI_+0Q8[^;I)X.1ZNCE^+H#%7%T=W,DIFKY=7=W13-6&H[*Z
ME,U+X"0ZN]5&+>WLMLG3G6_OT#SKHW*^;BEOUXOK]8NE8;E&'<[NWXX'SHES
MLV4:@@T<\7+9EQ6CNR&75H([066E^[,G,6W%1]JWKHIZLB?EE)6TWK Z^F3>
MN$P?#9GVB3BR!=U8Y>2 CFQA/Y8\E=U<60EQ"8YLAALK<Q@ZL7QC++FQ_(G=
MG=A2/BQMDP[KQQ9S8[E?>4A7MI ;"V =TI,MYL2>)'JQ,L]5]6%##%_$?8WX
M*K5[L!'G-01?Q'4]8>X3?Z1NSS73:8V9 1:.V(<IJ."R^CNVJ-,:MZ@57=8J
M[FI$LN*P[.JO<F=U.E3[@V+.JN#F=(=UJ [&TVH.:XJS6GC$2+CWJ/U5S%$8
M] DMOV]7SS %BZ,E.JXGFR='>0OLOB'6Y\[K3H[K'U?G5;,5A-.JL%/!/[:.
M<@7:^$XYW\*_DF:JZ+%J8S81(NG-C#ZK\+.W!CT.3ZR>>7B6+T6D*%0Z9L)!
MZO9A8^'8ZIMML<:P8D(FTF=,!06L-!..;.JQ>W@*X;1)F$P[<,<'NJ"C''3L
M]T9[\M14WU6;L*CCOL..M(7PG;7U]F8%WDJ.SW:2YK1I?7^# [SD;>@0AHL!
M*!?+V[@ %M&)WS3&7PWEDP-*[>I4@]W-"MX@.XGO7*&6H\8!Q"D?A4D%0%#3
MB20*.3E'&[)80!PMEVQMB5LL%>$U "#TS)C$H.P@\>&_Y2.:)\4=0MIU5G(*
MA>"29X):01LD.2:((5^](MD6_]C.$^#YCE$ * _\PE:-0PHG\1G6"<H/3 GL
M,0WK@5,15"<C'-8E@.%PWZGI3+-Y!(I/BUD:.%%?*2NB%S8DNSI'!OE&D[ZJ
M3_B9-2Z9XNB^7[0%1P(AOMVN_&%EYV4!2M  &G@!=\K&S8C\P%[RE_@+LSK^
M;,$3W%%33M)<-0UPJ>E:>7THNV%(+R.8E>D0LO ,*[T@A5KVM "LD+,5]5;R
M8I[50&_<8\MWTXRP?[;C2?J7C_-=/32@!*[^H^&A&0!WV3( J*29:CXWIUV3
MC"\FK&))26?H93:;.,[> H["CNSFL(FE1G:22?Y9>C@-(9%":C[ZTMPS?& _
MX321:]L&#RW!>V&F)-U+.Y"3%O//@OAK8QY:BH.FG#3AHB6Z9PD:Z9 .6H)_
M)J(@M07MA.1FA"Q\>$CP@)J<VH'%.(F:#'9U8*R.QQ,4OL5J6U+5<5^H<=,J
M#N^F!S.N?YQ?53:NP64-#'V<6Q3]X+'RD\@D5<_J^KX9C>"&ASPX^(72#7*R
M#6"H?1_><3-Z4B7PP5<:MJ,"*9/"IE0RHX@2'X&ID0YXX" G4U*\J@V6U#>B
M0@>VPY &"?]I]R2:,J2R&65N4I.V-,V24DI!0]8TR9**<%;%< >77ND@AI_-
M5#^)@3%K.F[11ZJ^:QH\(4?3Q^IHT*_SL"4V8I$#%:X*VG^H<F6N-TP@AAF>
MQ*!63^)][QS^7WVG/E%'S)EXCYRI7/);32=7]XB.<Q@%/RG7S_@G$O;<VL*S
M^-AO:"\!(N?.!*A<)1FTRNE"##)'1BL"-A2.B 0P@9@$'.IN.92 "HWS/9^2
M;_4#+!8[B%:DX%C,I^&C'<BM(5@JN#;2FL/>38#O04G_ADDJC"+C,\W%X<]T
M 8,N8- %#%H6,)#DMYR3P^0NU=%AX]:55S)39Y-AJJ,C$@2*94*/=776KS6Q
M)#:B\J(R2"X6&X=N8,T.%C4Y-\T:CB1^>X)5V0H.1C.<1*;8PUE$%%=, ,1R
MHAX'R5"Y$PD<JN4G$F*U85_#Q\RTQ*F$?"CA(S'-S< '.A^C\S$Z'Z-E/H:0
MW-*'$HI?4R+9;M"YA*:I^F"PX[F$GW_0&F.;F%<C/# *Y6+:A\1UE\(?F?N>
M6/P6$1_]ZC)\$,\8!>F/V (9V9BB7J#C]G!HWQ#BD-(PL40;Y<0#SXNP[;L&
MI6R_&#SUJE.RV5='P7$)XUX&/;O!%F0CT0@\GXCDARZP^$]+EFK0%Y;J6EHS
MF: G$$*^.B=.,]]/?4!Q0/4DS*,0K=!@8-OP._"?[,WSZ:VS!9VJ#Y.L;DI>
M90R%?XIY/Q@1'/:4O]9<R?D/$53X9)B6,=?CGCQJ53@=JJ19B_H?[.E";L@6
M-)RK1)&50 OF4P$L_ONN<$; 1P!KM"!1T/H__A1X630O.@LWX://!"/NAW_R
MS/@MV=&8,2?N[.FCP#"R13!T^C=*Y"4A8.:*FUOASM#]$W+07(9B]J*,Z1MC
M15R1-&9N3FZ(:<)>*,*S3K[%)>Z"&X$S1QSR!,LST3V SPBY2BH&WF1W:4S;
M6&V>F]W:)!DCX@N_YL1 DY4PR]@3FX\%; 6?$0-D'(.K<1(S+4TPDV@0_8VL
MKZ0HTUQ7)Z.$9/-?0@(2X4Y)0E )O=' C]&U$1M0ZP_5T4B+Y*XWBN1K9P."
M']_9HQ)Q;!N!=.S BS)NP$$*K9F,!*UWS>I8<ER.Q^IT-N$I^R/ P9#2#$F3
M4BEVEAVJ,$\I@<J,L/F8$F4XBY?5#/<'^6#>;#[;X$YNT>9\,A;FG(E,9N^"
M\;>Y=W$[^]-X1B_QVU]B'RU!<>E;4H0GL</#H(__"PJRIL$2:7IPR>RC=^W,
M%^!?NVS!7\F$$@DR09]0'5%]-%^["/NU4_<J\L"+M3()+_LS9\:O(,8?MNAA
M7P)?.\M@5;#Q-_>\+/V'LWZO/TTC31J,0<5<\=Z5@5VUKM ,?3"]A6NM4:(N
M;J]=P_8,)E[UK^2LO64H-XV6H P(6H P$;$+=L#Q]_9!P];= &[?]=\ZRS:V
MK6)C6ZHUMJ588SMK-;:P3&-;BS2VK$2C?(83F(4L)1^W[M6<QRDYC_KD]ZV]
MB]^ECPI[CS6ZCS-FV3CLUT[MRVC&?:QW6;6YCV5\CAJ6<-8V$]=HB;9,\W:P
MZFRMK,RVJVG;1U6V%I5D:TTYMA*&;6>[IO>971O-MW='9]=TC6E/#CMHS[J7
MT8A=JWE93=BU.I;0.KN65;VI1<6;VF[1&BW;U+::3=G6K,%Z3<=IS72R9H/^
MCM'Q9JP9[Z_.8;]V=EZ&-M[1FI4/A->QB#,4PDAAJ+:4A6JV*E392'C]KDF]
M/$JNB9XJ:/MQ3>K@T/VY)G0"M,\Z0BVJ(=2V^D&MJ1W4;.6@ BF%^ZT6=-#(
MKCXDGT'K@Z9%8([+9QBQ?=:810UGUT[MZRCD--1O:&I>6&5+4]7*U '_63NN
M[;<LT;PU:>9M2S*O-=A12]6;O16]*6PA=C</+&M,G[+X576U6CQMK$;SP%):
M- [[M5/[,IH)D-:[K$9V(34LH3,/G7EH[(RW[BHN[2KATJ("+O4&67>WARP1
M9GAEKG?;94Q&A\ZBUGFR1=]7NG6OHAEK6.^R&K&&-2RALX:=-6S*&E:N^-&2
M:A]M*O31P,'CSD9QP+-H9A>+S='%$ <L5T/CL,-6I.YE-&(6:UY6$V:QCB5T
M9K$SBTV9Q<I%*@Y2H**H?:@JO+HDO'H?A'? /WX+F$44F/#K2PBI+5P>HH65
M(=I1%V(3':CIFA!M*@?1FDH0M=>!J"[5!"-:]6QO:<!2S#109JC%=O.1^E%P
M?2!V@'#((?Q@+DC=5(5P,BH!8=0=6K@FZC7&@Y\#OLN FQV9:K\;-B+VVMD9
MQYH&+X_27;9$&'.=T0HK&\LKZ^/*=J2-UA^.1EK5E;'B"U1&0OSV46P8#TNA
M\7@ZFXAJ$(D G>T(<NVHGXUT;5@<Y'>&_<^Y8]C>_ 9]2O"?0P#VTS#ZP]FA
MRHE070[\,.TI[^9?_E#.+^9?KJANQXWX/;'6R8:VE@MSM5H;2[1#',P^^P_]
MXJV-1?R7:HMZLI:;>WRT_V, />&:H'%#PQ)%%\9*+'OCK*673E 4Z*UEZ"T^
MA3Y<?_]%0<A./7"/&7AAC.&/L74D/OU6^XE0B _X^-PL&?!,(A-AJ6GZJWO'
MW9Q2Y= ;X$66J0<\Z,$>QS?#M\YJY3P!H7Y. Y5]=$,H_Q=Q0 LXXP;V/*9[
MNH!5&&L/4" ^[<@T-\YFXSS([Z63*_G=7S"[=V.>XFH!+MMY<HUU6" 7%!&4
MR!LNG!>@O^"$Q E/IG5WO\$O5\NZ8(AQ*V 9QK0Y/'H""4O & <G$>X 1G\W
MV3(TM0&&-M%)E/X* &TGS7SM]LJ4 U?1I^P14)6]T7I3H\XHQXE<E0M@WJT,
MV ,22!CJL #>??(J>E[5$)N"Q99JF3W3_,A(WC\>DE=34N A 4[O7&=K+]%+
M<MR?%??NYJW>'ZKZ8*KJH]%/8466YR%/QC_F;"O>&YM[XUGYRZ;"M[@-RL:R
M<-1^+*=1$H<(@[8R;R5_^$TA,&:1,5PDI\0TXP$@+8=O"H%35+A+H*<5^)E@
M>'B?^!&24$X."NP!L[GZ^MW[9&:N1)'=^2*#").^GD^$2A 45/V'6ZFVGY5&
M-[R'5K8)K)AB=F)Z-U_AYHQ3FI?SS?CN/%!NC@B7C%EEX I8J0/TBNCNL%U2
M5 ]B$.)2.)2)26'A<BL?UB][,*2R=+8W*W,'>U]JY @+:.I8&^7[20FHV(?
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M61 ]G9P\6,FZB%C?N;J)V!"%]5+U$3:1S*'_Y:R0-:QC"4K<<RJT#,>695;
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MY'@$WW_NG>.ZU(0QNZ7I=))XGL"V&NDY$)&+"0FSU@#:--)ZN"!HD]"!QUY
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MSLLMQIM'!!5>^_U8A5>$1 CGDR4ES06L 0)*&8/&LR@217EN&=ET\'-F1AV
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MM*0"7KK,?]R2&?C=,NR[#&O_DJC[R7$?@#R7K@E.O<GSLM[?&Y8+6\E"E&J
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MF;RG#,.1QQ9_FI;$%@1)C%D2P2BXAVGB&. !-F#*OT&:\.(EV*CS]^%B*O3
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M4:(^Q^7F&1QY"1NQ>CK[W [O@JXZ$39,15BT(A]@BKX2V-EW<D5;,)1>>$1
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M"$FVK<EA-VH(ZV/PQER@9C"P3^8*R,B8$:32LY;8*5*-]1I%5A,"HYP4FY)
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M9H:53(P%3++![L^7QC,QC_3.$ZHOOI,10-VCCF0 X$Z!><7)](KOYS;T-U"
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MHGV+('0^X<*]A27&N#3<"Y?JBB__C:"!Q6.-J>2>L9=H#1.YF#5(#L@N\>,
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MN+B5C%*>DDS?U+.<E\%T"%05R$J<(AUAN2(_B&"GA,CKVG0Z2492S%&X,E8
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M7P&;; WW6=%4!1/*>LI^B99"G_5ZA?A"X&X=7#0B)P$Q> V$U2=W#=NS:%&
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M,%;/MHX=^(V 2^SXG86"#G]UF=> V>G-5VZD<AO%6X,[VBGT]O43;R2X?V*
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M*>S%VPZCD?H3. 5"_OX?4$L#!!0    ( /&&JE+59><A!PT  !&>   6
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MTP9*\G%$4+GO;^E4(61*Y@6 -K2!B:!Q#@CB,8N:KCL#QSWFGL&>J:N)I:=
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M!%2_BBS0@ K@S:.8K*Z<#HQYJ1*8#/)'N$"=0-_A*(YO<;2$N8JO#F_OI*(
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M84*7[>N?N6W74;BBFG2.'D&V3UG2DY>I-,;B$&9?$5>B)OLAY-J@][GMF4U
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MW2 RBA(MW5)K @/D"3+]H+F8R#M/,=4*=H'_BQ.DZ 8]L7\!"M3)$)Z J.0
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MC&QA2 ,SJL2Z!XET]Y%MT6) "CQK'2)/ 6PI,4.%J4]1ZE.4^A2E'FV4.H^
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MF$ZP1YFB@QBNR7BW"#/ M/WKUD'T<O]OT@W"]%\5F6E^9^U$*H5MF3'?,F.
M\K(W**'LR**9_[8M#+E:4(&MF!!0Q9BCV%1V-4%L%15F->^K74_-; 7*/%B-
M04KKO3[$4'YK%R<51LB.XKNSD#@O09H@D*<=FIQ8K.RINU!D-:$+?Z &<U6'
M1'8SK'YBKXQC'V&TS1VD+.>%@VF4_V CCL0*:5%E28_ 09:UHM)HRM18,"?/
MP:1G<;4I*K)0:G#E[XZH 6Y@/%)V.T,:E-3QYB/L*6NCM"WUG@G3 2)GX$JA
M[6H'L%['QD5!X9I2J!7WUCU$2@S9PT:1(S_B,6>H?TV=P@AV$'DAU9K5'"$%
MU72HSMT=]5L6RX\Q8O0A!-1-T&9M_%;=K,I$@!7(/=*U[SS2@)B/0)=-&YG)
MKIU6S* .K746"]+[.5Q_4 %%JZ4=.]25OY*:H,$4:N10A>WF*B9JUR?K)S&U
M9JRV/+$XW6ZSJNL.^7@9X0V[K,@[TB91W5.+343T[RLDKTJ2>5/;AZB.I[Z_
MIDO'S!J:1_$ BX91&4=0M:=8^2LJ0W(8+X_]YRHD"R7[8U%T>0#SQZ/\F4N7
MC_@P;@DOQ9?](UA6D3(/G[D6R$@!J@1K)R?G?NS2#E#TTOT687<05TB"AR]+
M'UJE(%DH=7B?:D-&W:2;94HK'3EAF#K!-K=J*1D4A\0S=$(7!0'UILPY5A\R
MNI>,[HS1+:SI1TJ7>*3SDFY/[ZH7,3,N5IP1SSDIJ)^G:+ 3II #^SD>)I2"
MOT[%(ACBO,KEXBI\>(I^0PX>P(&386($<2-+^E"5A.QI&% KB!J@$>A%R<87
M:RCJPI!JQ0BG%Y=1BNVK1<G%*%X(6%.,BC2$OAZL6OB[$5B+DHLO7"U*:0B+
MS0.JQ<,:$>]^F<"4 %%GPN+]H/Y"TE" *NY6G4N+8O]BA W5*ZIXYG@;80K=
MP9K50I#W3FZW'AWW4[4%/(3D>W)DXP6768WH*Q*P[,%;PA6AG;\%JLW.GKKT
M9\KJ9;@9E3$@F;$^HW)8RHWC_I'ZF)6&",K+:(>^#D,>>U<;A8>Z!Z92Y_)L
MGYST+/2J]^ 9:?9R;1&6[]5THXA]:&EGS]^FV%VSB\4P]CVFB$3QU:;0/<8X
MHO,&!%FFW0M @_'$SM+8#U$<SZ/-HQ\RDC7Z;"UG'5 7"?$+0>[JU)FP%N:3
MTNRJ!=4 V/1%?,;Y+&#_RC9^XN$7$V&UQQ27IM10HSA"&UV@<@A"7:JW*-(=
M<J-5Z/^)O"N/[,+^TF>%A<1SGCOQFM8F(K]"-C:H] M@CJW9 )65)# %1B4(
MD@-LE.GLRBK[33(*(KR3+\>O?#R^+=JX42@A5YXP,063O-]BFGB9[&\#A\P@
M6TG;#="=]C",V[KA&H,J=HA3(FRA[DV9Y+WS:8?LZ^,!&9J0U1M>6"#W:$8G
M0$\99>I\FY*-S^BU,VVOJ-883!Y'D!+MH:WKX#24[J1E%5&)NSS;5ZO<'ZW^
M@\NR6N-;9\]BMR/7./$$ONQ#KUB^PK;0X]-19L>GIYD9VR=];).EL$?TF X<
MA_>4UD\:)2<VKW?&=L:HR$>B6[-U U=ZI%.S<1V<?]D^8)=(A9V61Z"2E9^,
M70>KK'[92E<3FKB5\ACT[ :F:HUI%K]HG^VF4BVGJUGR@+KT+HJ\)S\()J!3
M0E:_&)LE%IIT<^.A<M\6>.606;$I.J%WCF(7^ZS,9[0L4,@;*+W4JMRM0.#Z
MN/F2X-"A-;3604N!TD,SIF1B @^'2 _(2G*"H&W]]!%>>0Q21Z^9M1"%"='N
MB^S9^T\O8[3*[V7-170>R.\LEI6:7K-G'\0W;"<$=%.[)E]B-WU$K\A/41B3
M87M*NJ;A5:O) 1 D!:56>BVDIY%*/<MJLO&'VN9@M+*C(@MPVV AV%?9AMB>
M_-VIWK5*CZK00A4)4F3D]S>CD3*XG-'228-D6$%3?,WF\.29F;1\[L4S\<P(
MZ=D*(T:_;=WR4]N[AK#Y2$?33%7JKG>" ] 1I)W@(D0&!%*.8O49#)!0*AB9
MSO?M(OOP%!D033G*YRB:"D:FZUEUDJ4U%DP(IS+.9VC-:C 9S97JHDKK'!B0
M3648>QT'@ 13A4@FA4A#-A\07B&LM^NW?SMM^\7!PW2F349L'FTV4<A:NURQ
M9M@S^L"?_?U^&_BR3W^$P]A*0C83OA"C)+'=&Q#.&5I&&/673F,<>_%9( $U
MD8+9]?.BB,Z*G+=R)EA'I5Q-0J_26DE26DI#VLR(,",Z-01E:D_V%&-&F#$Q
M=[9^X@0:@FL9Q-K]FGDYM4$D4Q)HL.?\Z6;CX'VTO/=7H;_T7?KZ(\L))%IT
M&P6^ZZ/JI89F=*HQ)&@;&3XUS0@J?2T(P2D;UV;;%*%<JC&P# 6@_EIWB!#V
M:1_A_&DF_1_P ULA3:L'2"79B.$SVH<P=\ =_(F8AL< W2,WQ>P&]PXY ;WY
M?4?F1_OOL32G!W)6>D";;82)L;G:;!T?9V[_AF4?RYYA3)&S>/B4$JII=.$]
MN@]1F*R#_9S\#_N/:5*Y.5/P!=I&L7M$51"7$ ZY0C[JC0DWVR#:(W2&0@(/
M.TJWMW>G68A ^Y@R#W;;YJB95G6 Q?$?4$%;E?#HC:L&G#(1)9U8*SUT-\A=
M1O11(LJY4VJ>+!QK[+)1PD7X5.G%H-EA\XC6D8WHPX-=&1;6/SL5\9JN41NG
M4&%\2VXT;97N)J"2[R4S$M3)B9/AI2B+:M!- I7>>5RZA_,O.I=+06%-I&\-
MDMPSFM2>4P(7F(Q/"5S33. Z^_O[>72.=BB(6'D=O=M<T2C3OM<58@13X'$>
M>25-1TLNG4-,.ANE&QRCL<5#N+FV-9?LPFUR HI3756R@!JO3YXO9S^Z]'&<
ML&-=\:Q(T^[)##55,:F@)=E94#6>[P<H3L@AN[VI+#\PW_C.5A:+]A&M9>I@
M3<#RYI.W#D[V%96@342ISGQPPA#AQ?(>)4EV]H.Y^U)EPMJUO(90>T -<UGR
M<4MF%";T5B[7,,FUU?*AO1PD[>75-GV [-7J'4RMU5/-?3DPKG%%)3/JY(R?
M,FQ ":XT6X8VY"(+DNY^K)RXI(Q:/YV2Q>I"0.+^P<!F?Q?MG2#9E\J@N_LW
M![*9?&?.)6@!2'P'83"&?LA&ZQM"+P>:I&!D !)6$--KM)1KPF6$J4OAN_[6
MR>Z/0 ODR)"U6%2XAW\F!:A,U2Z=AAZ>QS!2]\G:OISD2FJ%0%R12BN^G9.B
M/3A][RILS1@V%,7FD)J8B(3(215UTI$5[6$9L=2RROF)+,6B7T%8J6@&(4 E
M^E-R\O0 EJBVI!GP/D>[ ^,Z_@7O^RG)1(B%5!TBO0!WG"R6M! 22SY">.>[
M*+Z/ @]B4750F]"!50:[0F =T5$=<>7K-49D?C3#NG)#=?%,TY1@^NV*J4YI
MM:F 6<C17)BAH%Y]. 4AM-KXDPK7M2-42$(0@1@JU:YH5N-4^M24>79:!SM>
M^QO(=TIBHCU4_!QM,7)]L(3@VO@VK[:E15=SP&KHR*5M#:7=UU&XHA<45^$.
MQ4DSB53#T^,/V3 " I]/9B2]L!=_9)6T4=$H<&$23M*H O2E-RK$HG^RJ,&+
MR_AL7_T7J/11!>I@]D@RJU12ER5N*ENQE<E_ZBW@\UIZ)90@<RK#)!)V)(RJ
MJS9/> 5N(*4<FX1@$D$Y(K*8Z&E:0'()GGWRG>81WD99DVJM)*?F]Q9?BO,M
M0S-UJ67B,!F;=RL4(EV8.1_;>R(E S%OQB )F.?H,;D*B1.=TAUL'I'-#"<^
MV;]H$;)X'05>-7$@2UBCU<(?L+]:P61H]F7)YA6 HB=H3 I0#=6O0A<S;],)
MJN5H9DGVYIDZ.@\1/8TE^X\$YD8N(XB3V)\IBQ>IFAIB0!#"I#>-Z]45&7]%
M+%I6AD#V:O7H*VNQ3:US6V/.IO-T#^$Y)R@6>^6N8K&L>$8@<4T)LM-;/U)@
MCJEJ4V43N(D25'1O[/W4N&M4U4"1[&@];B^["*@]-1:/-/A38R595.\Q)5"Q
M]M3X?AWAA*Y0ZM30IWM0L:)V0K:?&DLK;/TFIA4SH*?&#6IP82 >*>NQH$XM
M[12-=.S'V *"# )U"<AB)*BO>"0C/QIO/,*8%NJB94L.*_V6L.['<83W=,TK
M!2BDA[,8%A*8B\H#$&EL8$)%90FU?B\0Q>/8O N5%H<$'&9?O[=',RX=M_5X
M"!$LJM"RF#"C[-:)@8.*[Q2YV0]1WK./L7R'7.3OFMZUV4QW+DV;R33:LA,C
M*7YTV'^Q71$?'Y-S\9V3H'.R^L/5+<)^!)( )4G9;D:VH;7(QQ6HXN,I^&-8
MGF8"0+IV-F,\9A2/>8"08R>]B:[(;@P-OY^L$V7\4HL )ZN2Q#375P,HF=*-
M1G8\%R/JV[HN&=<K#/40&UX[X4EZ+Y*8FGUQF7']$"5.4)#(\\)E ]#MWTYK
M 76B(/,L<L!+B3,G_'0=D0VS;[+J\4"J-P_\[S5+MAV-IW*UT/[MX$FH0D@K
M23SML[63</I%WQ=TZIV9&X+3%<'IBN!T13#@%0$EL5AFSWS=EDQYOC?3_-!V
MDKO0/O&G#)-X6Z?49I4DX1U.B5M,C$A1>,B"&18^L6.;H@ZO%2O1#V$PVS!W
MDK7#,O201]>5W@65:!2KU3&E[Z>$6 !I^?SA;$[MFAKD]8_L]K:1A_AHJB Z
MK:_'?-T=/;)="MM51$+79)R%CJ+"'G\V):-0G2U0D].;!R4X#[]N+[S7Y?J4
M );S$IO/T^6^J@RD@BQFKO,-2.>#D] ,D/VYDX#<Y'=0LU5NIH> ZF@-?5M_
ML5PBE];PX-7FA+ZT;V/ 8B2]AR"%L!JM2MS. ]WKX.7'J-B\SNTAI0PAF1MW
MO8=KF0ZPLD./D,6;.)3L^0E*,N'A!%*..,N&RD][*B_&6CX<.;[\"4.4$[Y#
MJS1P<"U+2;G4GV"0<?M<<CB([Z]UT+]X=A'R_'"EI-/'7TT!W\9,)>^GE<TW
MXR>_/(<PVK7Q1VY*VC$15_ =M%J;LW?7B+Y*CQ+$DNG(GU;8V5"FFT\7U=>8
M H$&B*+6#SI#Z[6ND*>DDH"@/"R8PG-2$_H(K]+!0AF]W@D-!@MH#5PQ:Q2W
MA[KZ+E$S2S;]P: $ARF6U21HYXI209TEQ"5_<6E<8/#%L]I%-L9*6EI2DZVB
MI;,ASGZ;__UB_O[V;O%P,7^X6MR0/[V[FWU0BLV+1K%Z\R%E3"J;G @1HR7G
M!&9:_0PI-93%J"*P)]):4_YT_S(>^4E?S1B*^^=<5XIW79)Y^SND%O_J&&#Z
MBZD#'/'=K[HPJL$A2?AKG]BZV3*#=GWV$M%W#6VO/?EO7H3PM;SYH;W0C"'E
M;L%"(K2NFX5#EHVL22E_W^;]D1F4*W.7?74V5&",5[M+:^OW8SJ;%!-%>D[.
MR"]_ND^WVRR8 =G$0(YPWXHJM90JC5:($@/932Y3DE]+694.@&#.U:R!2U6#
M(92K2<1F=15E&75@!7, .'HDR.A"WFO7Z%@]2FO+IATRF2;@0VX5+$>2,,KV
M/NTZC]433@D8Z.[03DG[R?W!WD$]N*\3L+PG=(JIJL1'L Q1&[!Z6"C>A$,(
M1$QT*D*2@,]P#OZI*H)!\:F500#-#?VB<G?[2JHU=;<SO7.H3;W>^[7:U*17
M.H1PV,9I69C\)3V@UAV#<'R5A ?)P89.<U 72C5S30Z?4TH#D$PE4QK4]/B4
MR'!*9#@E,GP!B0Q96"Y$B4*YA_HWTS-LK3,WVJ3JB()2M8?CKVP6>FC5CA8(
M@<L['-&1KNS0!J7%H@YJ:)[*O  N_HZZ+_S#\:GHRZGH"Z1]&%_1ET/AVO+V
M;A&J-8KH'L/F%3YG>SYN5\2=ON% =F[0/MNNH1(YI((&HH;.+/D+IKP?K%;W
MVU&4?%$$]WC",&7.9K'OA'UTN&. *:5#=^$ X&@4PIVE-/(<^(Z66A]_;?/N
M0U.[&P 8;G-PH';M)^C!\9\<Y?[9C2^G9D::4S==#"'/CGM<?8R=J]!5J\UU
M])6%E&]-:!OSE4FXU-?>GYVMGO)6/YR6B6A,6R+K4AW?WU(G?(<4_>2CCR9E
M$XXG#%.MX.>KV<V[>R50:Y],Q@VN3U1<J>!40ZXYKU,-.?,RT+LF-E%4SFS%
M,IKF!'+_*R)IZP6.2<&U "F3CZJ=TI?D.6FS'<+TJ56:Q(D3\HK6&$SK$Q*V
M9PS[R5,25J#RI9V)??RH0$M6WH2@YTQ=>&Q2AY?U%VNT355_DR(>9VKJ+XT/
MS#.WV8H06Q&^?XWP)[+,7&?K)TX@J_^<KZ<I!"X6,H_@-*#W=D[HHO@,E176
MU%>$:!2+[YE[R4($CMG6:8(C4?-M,VBR4/$N>E)RDX)0IK[=*=G;MC/=FO[=
M51E/3V0INB038*_'ZMR#B(Q/;:(BZX"O.+J:[Y15M.5>+.FKNGD4)R#2:B,S
M,>>Z$[%"0,9?+:7H(:KSFP6G8&)!?&J375-<^ J1"=^W]GV!#"&I8Q*3\PJY
M6!5BZ0P(:(2B4\K_8GFQV0;1'DEWT&U^-ZV5P)U]@;/QRO)Y^*$@=89"@E,"
M:;8$%">[-D1(%B(4A1"&>LMW\4=*G<P^[_9J0S3 $54,;_]8*\!5&TOE[5W+
MAT._L^L&L5*MO&6.@[Z?BW'R^X.?!&BQO H]?^=[J1-(OIHCWU8L!/G;L77@
M#PYXZ2V93\[7+BJ=#EC,WC>V$OK53];,;E$SM?:W#]%%F%!N95_%Z4E&0-9.
M2KI00;GB$J%HM$RI!@=2C^7 )&DE^QU*F++/YK3N)M/'V/=\!^_O'<H3NU<
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MCY5:DLLQ@2F&K/5LH.7!P-@1;9\M2.NSOLMMD29Q0HPYX3*[LQFC.6PR:2N
M-K0U;!$/6+UEQLBCF-='#J^_H#A!WBST+IZWB-Z+/T3T1WF"!SW!_(IH3@?Y
MG1W"S@K=(8HVF1J[BG7<)'4"&OP 2:P9T>RF8,)&")M$$0'[WN31;-@_GCL)
MNG1\W))_/P[[JCJ%+\7Z*HM6I@[WL$I:)&+D%0-V!#.ZZ"XCS/@?E3:*>)V<
MW001F+C2@V8CC-X+138L;H:8M2L>Q5BZ(6C%U<P'O/DY2V,RXS@F4WKT0S:C
MZ@605M5#[I"J-T$R(VE69N2.K'(M)!H%+F3 N1Q2@+Y2KE&$1?^K(M62KXT2
ME";;>[8/#K@E2=X62>ID41^6@Y%,!=[^\I K"6I<4@*R=FZ;A K+E9@(1:.]
M_S0X,->>5$>2UIJ80@A3]HKK5&2XTZ((B@P;S@L]E?7B^\Z*KH9FC2_#:^5S
M+QRMY?])5Y'FWR&='GL,N82$+S],=M:LEN5]%T7>DQ_H5"0^?&KML*^U-MIG
M+W-QH[,DKC9;Q\>L^#39&1,G7-$LTED<HR2^>':#E-X>M0O!S#)18V!Z2T<1
M8.$UQ8"!FO/(3?/.D9EC=!4N([QA4W^I>,3VD/][,5YE&$YXAK(5%]**D?O7
M5;0CD_:)6KW]@?[A%?U#19N$PZNO$,Z0+<$:4]P^0)83:X1O9"5"E;D;"P-Y
MO<J2R13R#JW\.*%!3IIV9D JK</:2*E3E4X['H9[<529>B"_9W 9L.$L;-2Z
MJR";ODRFDS+">8&W2S]VG> WY."+T*-7A0;0Y@X]_.E!%7@^*N(&&7K&I?%0
MJI)/8\S4=!(9OU1DD!*[KJKR.=2*O@P<$Z*HCV?%QU0%_@@"&;=19PD@FD83
M7!''\?D]VIO3^J-Q[425-)7]&!/3_=,KI#*;=X>V$::IH+2_1FK"5>X<?A+Z
MWPV0T0[J);E+/T!X3C:=583-+8;ZJ%.Q^4=82&48:#F:6;36G _4/NXT+! '
M$V%WBAY^?NEP79*?F#RG'X\\";O#A47<J:*G"#*9PPBA.O843KL=R$@TKM#=
MCN\W3A 484!CYK\^ZE3,_Q$6$BTM-$&_V""\HB%2'#TE:YH&YX3F]M[VT2<0
MA^@$1]S'0G,!K%$0F!9!;=!)[ %M8$BTKM#W.7F/JWHXG.53J,D 7D5"JFV%
M)N)7H1MA<J#(ZA,EK&1.2LY\^WGDF8LQ=U.9PB8LA99,7PIM.26(OO'Q=XBX
MP<Z<UU!$6T"MPT_(0O$ DFALP;]E_-MK2HF^V**_]O\!4$L#!!0    ( /&&
MJE)]SC5>![<  #&7"0 6    86)V8V0M,C R,3 S,S%?;&%B+GAM;.R]?7/D
MMK$O_/>]GP(WN96R*RM;NSEYL9.<6Z.WC6RM1I%FU\<G=2I%#3$SS'+(,<F1
M-/[T#P"20Y!$@P!( I2?_)%8*P&-!OK'1G>CT?C+_WO9AN@))VD01W_]U=NO
M3G^%<+2,_2!:__57'Q].9@_GU]>_^G__B=#__LO_.3E![W&$$R_#/GH\H/-X
MNWM8!FB1>%&ZBI,M^B+;?HE.T";+=M]^_?7S\_-72](F708)3N-]LL0I_04Z
M.2$$2Y+G":8$OT4?X@A]\ [H[2EZ^\VWOW_[+?GAX^(<O3M]]S;O\K__$@;1
MYT<OQ8CP':5__14WTLMC$GX5)^NOWYV>_N[KLN&O\I;?OM!?U-H__XZU?OO-
M-]]\S?YZ;)H&HH:$[-NO_^O#S<-R@[?>21"EF1<MZ0!I\&W*?GD3+[V,K60G
M7PAL0?]U4C8[H;\Z>?ONY'=OOWI)_5_EZX;07Y(XQ/=XA1CGWV:''?[KK])@
MNPLI0^QWFP2OQ(R$2?(U[?]UA-=TZ>D@W]!!WOZ!#O+KXM<WWB,.?X5HRX_W
MU^"<OJG1RCM]/32?69O'3)>_K.*-<A;2?]T0#FJ\X9<,1S[V2^YH7XDX&6D&
MGG+&E'*\K-$,*2SBI"3)!O[KK_;IR=KS=O]\R,BZ;7&4S5=7040@%7CA79P&
M%$BSQS1+O&4F7"O&R<I+'QD[!3G"UKO3KW&8I>5O3NAO3D[?%A#ZM=:X9+&*
M.5&F:[,J/VFME<I%9KP._PP?0_:9DLY40^'HY./#K_[SV!7%*W3LC,K>Z!]E
M___Y2\["?U:RHO^<)76!><FR9)+\V#&QHL77RYAH@UUV4IOC*HFW9J+.8H.E
M^=H8A;,TQ5EZOD\2,LP8<*L/D#,Z*+:R.//"&PG :AP 2%I0(JAH@_(>;C$C
M% P/CO:TOO[/H9>6& A8:VE/!6O[NE?UM/?'-=Y7-;2:5OR4I-_0=*0,B[>G
MSKP)O,<@)%H8CZDX!:.XT)YM-I14*-?-+19@8?&X &9I7Z.*&9&IU5_$2O?1
MLAS%D;]#Z_J6&UOZU4T1 QW"[ZF#'[)X^7D3AS[YH"Y_V@?981Q?J36*"QW<
M9D.*!K[Y;W[]IW=O__AGE'?CP.'($8*D5G=[A-.UKXS%C(B4\2]SR?MHY3;%
MZV@9[FF$\2Y.F >;94GPN,^\QQ OXELRE3C*R+0(M?5U1(2#TY$"((-P5EL:
M5WK A'.I[FB"=A*([8,<.<J-U^_K_QQ6]CN<!+'_D'E)9@<!(BUVYH4TM,VK
MK'_+'UB]P7>C' &7D6]'_F]5Y/]OZ0-KQTO?U%F91;X=*[9SS.$M*PW'1LB2
MJK>#O,B?B*&E*EG 'X*7H7(ZM9!&P!UO\?$(8<PC)6BH$7PEV4D2P : I;PU
MJLZ0A*=%3J#4(3H>0;(Y&RNI]TF<IG=)O I&@0M/WG9$A1L;P 5K@7:LB=M@
MBD ,O.B;4QG!(>ERD!LLB&Q*8#FGOYZG#?6E]07-=S1=AI@-ER\['*7C1";;
M@]C?R%L\2'?NN&R-<-'\" D'> "%Q*-"/$'#/?E(+%?;-P1PHP*#&V9HAU4=
M&143 #;HGQ 538F/.$H=JPJ)H(3@:,RQA^8@7D=<IUH ;PR@P(,YB&Z!S,A5
M2K;!"0IR8^Z+4JU\Z1@_G5+D422?./?A&MC_%))7A+5SXLD&T9Z,,#]^8V=X
M%2<X;[?P7G!Z^4*,QS@A'K&7'*Z)19G:B\J.R:YM(W/$N<A4Z",C2FVMIX F
M]I9?1>:]N#5D+4"Q[1.-M_SFAR*W.!MWYZ\/X.*LLL8!@%;2!H7DSRZ-/Z$H
M:EJY-1'[!Y M'D0>5FLU7\=RGHY@8SSAY#'67%)1(+Q<4D34!"(&!LJ#\ZZ-
M"NTU?FN@J[S'IZ5/25$B]8CXC/R)QBGWCVG@!U[2RKAA?:EN>GOZNT(S:9*S
MYJ;H\=6AR)!7$, ^RF(T._MTSB+3*4?"R>=I)DR**8/U,8XWT@M%"=X0DS=X
M*G9E,O!\1;;F,39)V7#V(R@2;@#4U7HT5+\;S:0@0%Y/=4W9,+K"79<X]]+-
M51@_IY9NTK3'LWSV(>-%Y?8,[818+^$YB-M+,Z T@<LRXA4P5D\$FY3B'?6K
M?.R?'3ZFV+^.CL&?V3(+GD;+/]48W;[R4F=.LH,N*?;VI"-Q6+D0L7?LZ][N
MTI1_PRC362)#W0>,<AT]$:_5%49%HT\&HP+F5#$:E%TGCU&)_!4P"BW1L!@M
MKC8ZPJAH],E@5,!<%T9W!0EZ47]5=A?C=#HPE4!  :;0*AG"E Y!_T=3<)Z\
MD%@4Z3WY#))@2=P[^@?B^]1_P;6\8X$"8M,FV$OQ!<[_>TPTNWQ9;HC8\#VQ
M52Y7*SR.86IY!@[.BNS.4/+-!045](5?T/F2[A#L4Z01 /8#KL9FOTR.G+&_
M.S6SW:"]Y@W:EZ7IF5HO5B?WI0]]+J:8P]Z+9^!3/,/K((J(P%T>*0R"CL&^
MC)%RPI32U'LS+CKG(&/R OZWA'MGJ7$ADW;NL:7(F63@P<UPQ0 :S))*)*UV
M%=#;Q6EY$U 46',;5^L6.A!@ZU@AT_CMQB-2G>\S6F&+?NNC0*\UR$@W>;KO
M<C4Y@?:V_%8.^H+8E7F?+]T&9B$QU< BG-PH!D?7E2D1)Y+;;\)U?E7+?&IL
MWQX_\?RCIN<T<42WFME+,(K]*A]PZ,-@)?TOX@3X,@N]7K4E*IZTGDJU,9D0
MA8H=G'H/&V.V7,9[FH&UOHO#8$EO.HUH6$A&LUC2#N8" %+5 94])F(M=(NO
M5EY)/G'39!1:>M/?AWB^NDOH^1 Q-R*?@G4'WVP#4U$4B5DQ/G4X@FS/HC,U
M/7=%=Q9DPB4!QT@R$6&5@**Q-N9IF27I.[*R&4__[+ @W<?:_%2&'=Z!ERDN
M!8[ !.1H?7(3/&$?+<CO@T>"2%9LK;4E.E!B&O+EM9GJ:NA:6VF2_?.>1B45
M@47:<Z B_VH"JD[0PD97&U#B% =I%BR]$'W 7KI/RFNV#1/)*B2$:T^%WIZ2
MJ1$]3]9>%/S,,LW/XR@E.Z'/_D$@=$<D0!:!_9,KZGJTP$8UCH9AS*91/@C'
M #YYVF]0C3K;/WGZ]?K"U1"3J3 \*.9J-]P&DT /'X+F(43DSX>+(%V&,54E
MXY8S@(>S&I.4, (6-2AZH*K+9$"J(,;Z-1[Y[#6CC$U[\DC>V']H4["P]78R
MH> G!$>4.,[U5):)R"$0S]QTUP:-O3$U3?>@EM.(.QD"T%7V>X-8SV-9'M !
MG98?(%-#:DNBG5R<HYFZ30N<;/-,.X-HAH2 '=>QBPV)OXAH#U1UF4 %'E6I
M5/JH8^8&5D]3S\V?(YRDFV!WAXF\B+VUQFFN_=(, X:0PNZE2-9)'$R--X6=
M+BX)T1M\):5R"Z2TIK8#Z@E;M"UJK)UYQ.P>A_35GSN/*$;V#!1-,*47JP_\
M7\8*G&F,;M5>5^<+@&[1#+%V4XB<Z<N9WSHUUZ.G07])GW#*%AM<8IT, AXW
M*2C(+GHV]U=EKA1T(GOJ*F/7FH]:,&%$G!MJAB(5J4&5=1I@<^YMP"F1<@,U
M;:..1UE(#P0R:N %<@//(;QT[#SE9>D1YP+TI>5M=#+[IO)&R?41'"],9]O4
MW">'VAB+Q*:'#<;0 8.">A)3<:.9A+PH**7'(L4K91TG=C N%9-($<&K,,#&
M5D7QB4M1%DXR!H^<FJ4@EQ93"FA*JW,@ZFJ6%"9G12F)4@2P[@7J:[(79=C+
MC;2'L0Y2LG%>J<R-BGF>)Q565A-@ECNUR[OD)K3(I8MB&$ ]CPF])*/Y)K=Q
MAM,[[T"+U'0=%(*(4J=G<^=3Y@JL&'/LCQ@!5%#H.":T#C%M<59 TULCXQWR
MS(L^W\3$1BO):0(,[F]/48$\@#<0HL^(=4!ERXEL<IW2J/ AG[2A^N'VRDV<
M9-0M+,<QMY5 2BZV,I ;%0.)]LV# (\40B'I/@DUHR$VH5TD71/C.D-'LA?X
M,1LS\50\D,TWWT4,0("J0$1;OT&T_33<?*G ZM=TH/F:IL23W8W <?GY+B%[
M'8L6D)_6B;>E<"RV/DT-I$72JLNFPQF4H%"00!4-5!!A.]O1()K&OF8BWDI3
M::^7X87-RK9:X)?LC#3^_+#?[<+1'QQ2&]AJ#%.))0"<G!%..R/6&U7=)Y 8
M821R7@6JKX\I&(EJM9,?"HQD%VY"'B!\D<933 B5BZR&'GBZAG"!SJ;'!$[G
MF%,X=>F*58%'+Q.(4^D*5R598<AXIQ[H%'Q%%439]A@-<<4[CDF!L1W#6#8I
MC)G*5.1(JF*N%^B*2[GI/5[BX(G%Q/:8OHS!C=XG3T:7O@-(:K*H@%"OH$B@
M6I)$_A[GSUCQ\(72:APBUA 0(@";+&QO/&_ID -C6(&FB^B; E\J8&547@\^
MU04LQ*3BFO4.^1X'6L1#PQ"DZ"0=NY,M/0QFL1(")P'!+M%* 2A=+O/DZW;U
M+7K@-:;CTC&BW2(%<F; V^A053;:>2+%5M0$*W_3OK46?;?;XEP5^SFLYROJ
MB]/G7UCI*6-5ITC6B;Y3XTU!Z2U+0J7Z([_S:3"&/0[$J$W/H=$3N$@!:JR?
MN1:DQRA$UR8)+=K @H@CG9:)![)X6B9D ,ST"$GOF*9J/6'$]6&0X_\]9P^G
M9ALO0O5.DSA:DTJ7UX#PXAA7FZ(Z=;XS"LR(NEKT&P3#R_9#5+2=B ,@67=.
MRT!S[&W.%T2OTW1/-%?D<U45S2]9*M!TX5<J\*5RN[* 3\#(, T35X0FENFA
M(5[AM4K%%>N1_4$VQS,OQ3XMP(BC-,^VK13;V:%J<N<=F*Y[]A*_X(QCZ':_
M?<3)&'OA\$RZJ4$_^#R@)R+8'^FW\C$B-GIXH-]%;@:]01P1]P5]QT!>JU+M
MX"ONJ+[]*),1ONVKBY]_PT=KQ<=X(;OK4>=1IB)ZQ9B2]Z(#6A/*U =-F<V7
M;]JN\TA>+VC>-D#C:I/_ 0?K#?6QB:OMK?'E"TZ608KODJ#"ZT2W?BGK(WR2
M]HT"V0P!4Z'L<E+T064GQ'JA.[(/L.$!P^&5?\4J<![IV^X4UD@O1-@S,KIF
M*#(]^N+QWW <35CF0=,+O,)) C+Y0Y!MK@D33X&_]\(6PVE>^)C&<P5D1@J_
MCLVRW<.KD6<C?:CBA)'B@\#$B:A&HS5P61PC+>Y8$*^C' ?Q SDNX6P9R_4T
MU/&EU_>\[LH+DD]>N,?%,TV%@GF?.P'&D4Q%LD[.Z]1X4PAHK@@A]$0IY??[
M*W\I/7I1DSNOTQ.X*+:IL7[F6\^EE] '&NF+G>S+&#-? 1S+9O%RB E(1Q?-
M*\/*>5:,JNAX%2F=]2 %M](.""F5VA(0<7$.(V)$J;A6FM**EGD.P02N!^E(
M25Q3"U@'X^.4V</'=Z=O_W#ZCN55!W#UFH$>GI(,9_56AX01Z/&IAX^(=CDY
M?8>J3A, E88H:X]0=:Q SSL<12&<:'U#7YKFC>D>I\2=)!V52.KF3.F8N"""
M0O94NL>1<;['F8M7?$JLM%X](5A=G/3"ZV@5)UOF0A3)IHNXSH4Y+DW'<5*G
MPHQ7E2H6'&445*2/2<Q9W(3X]&#=$S+"*A@]5KQWLLZ'( JV^^W5/J/W0:.(
M^-NEE\U.2F_CZ)P6QZ.);2'N^1WT&LS%Q]"'884O8IN31RM&'WEL +0K1D![
M.@2*XNAD60TB_3"<?AI#0$GT??06@K'M>[9/@PBGZ7F\?0PB;_1[S=+Q++]@
M(N,%*F]5=$%\GPD 54><O '<N03];S[1EQW3V?*G?9"P;+B;P'L,PH!=<DG3
M_1;[+/ YCXZA)?,[43W&<F0U]V!9Y285HXZ\@CQ+NPRK >C?Z0CHD47[B9W"
M134G%[P< $G"*U@])6!85.)A_YCBG_9$Q5\^P1[A0/D8T%A67TT'F(!@?&R.
M\O:N,\]5!5<[ZI7-V2#"Z>/@GS-B%OC4-+@*O74;+6D)EQ0OOUK'3U^3/F2.
M;[^A/YS0'SB M.D-?\0))KFU!H>"3F4;1!NY\9' A:?2%D_$4+SG^R2A9()T
MZ84_8B^YC/P+XB4-(&F0],")U5*)0TQ EY3RYBAOCV@'1'H@VL4=%+J$5*)"
M.EG=TUM*\")>[K='BG<L-^B*_$Z03J$-#YCVX%%I*4) /J"2547[$B-Y#\2Z
M.#)=E$15@D0^7_U3U#9-BKQQ4%)1MKQQ &PH0H2ID19 W"*D)20Q/NI3-=QD
M2I)W97+A0#N,F*[-S'F0BRYD%%JCM;<XPH10,DU$M">HZ8SPQ&B^T8 08.2&
M]B^4Q$Y'[I(V;>-:Q/R"-R5[G(-V_(52N8RR(#N<8YJC%UY'/G[Y'A\&D*V8
MKNW/6\@%E"G#VJ*B,6*M$6GN2O92R90@@"=H\'D7Q.+M-HY8QE9^)8Q+(AX.
M&+)!;/H8W>QTP(7U1*SKF^(.'7"3PA& %,390%/78IAX(P7IW,FYQ[LXH6=X
M]"F@04Q-*7G+]J:,EPXP%1[LL1/*>[FT/%4$U\ //'-#&S2G>[G%R9K0>Y_$
MS]FFN(8X&';$U*U:)1)&Y+@INZ"\#RHZN0MZ* BLCAEXTCVLFJL@Q%#1 D.4
M<"3=V#(5 W)(T'8H;^A>>[0%49=^8U+&I@NEDYP3!V<=)\-IACI5^\9);?QN
MJ2>H;.O6<A4*HRWW^LS,38OK:!DGNSA_39 ],7A.JX0EQ)SQAW!654:Q&_Q4
MX$B.EEK7-\S6P"@F^,D)($K!N?VJ)-<ZK+J7Q"Q26E(G4J$5M9_PA9=YA;4S
M(,*$Y)W8L&)>ND!U[$.C8UYIU+K?A>2":T((G'DO&_8>KP-ZKAMEM]YV.+74
M(.M"#]59D&.D:HMH8]=VJE@H=4 (IM='B3QL<!@.[<+4B#I1&#P'<@BPE@)'
MQ0T"1.*HR[\ULUYJX&'KA6&94#><_&M4[1NJM?$[Q$^;HK*M6T-5*(R&]%LS
MTS54C]>(\A2R,>^,U4>P%L$0CP_>#GNX7#RX3H$5"Z-VZZL]F1YUFG)JA3$Q
M/@:: ]G2"%(N.I)W\C[3  8@J#8^1%,TO])^[J6;6>33_] *&T]>R/(!LW,O
M26BE/I97.@9JU :V9UQJ\07ABG1BN<Q+^@.NNCM-#-42,8\W]:4P?L".8#A8
M9MAW!D-=%NP#4I-#\,F[DDH.3CE*7<#4$ SU]^_TE\H0NNU7HVYQ!H9G!MAD
M9>.Y* $J8PBRP]H/CKU!$<Z<:D<50=8VX:YYFY=[:%&N/[UC%5WBH>W;]VJ,
MJ0,.G30?;JI#<!((E,I=#D9X>7JX$L5#9.RY#6N8[![4A=KKY K*\ ,>KG.J
M^Y3E6BL@I[0"QEKP.J(WDN+D0-3J&+"JT;=OS?'# U Y-G&NF42RX*'0FHRA
M,767X)T7^)<OM)0@IB]34'#5W-TQH* RK,7(M@9; '**G@CG7?/73-@;2<LB
MXN%-(N*A(6\>;JH+8QHNO4MH#93L<$<6E;[U13V''<UZ'DD52<=SL;G)& (A
MEW=A6,-E^X99[PIEW>*LPZMC]L9[6KV,S#VMC3Q??200IM = UGR :U;\5)V
M &#-&Q6W$MKK)%Z=[*EB:ZDQ!_A2DBH/L.YEZ&&COX]C_SD(PS'@=*3M0BF5
M@P,X*?_LW%AJ"H"7?&T.QFKD)H[6"YQLJ=F59JP*SQC2%@UC764(F   0%N>
M$'I;%%1M7>\]$E'QN(!FV<=7+PIST[RT+5YX+[E]-)()(QG-]@$@S KDDI>%
MX3/O92*&<;?P1*7<@1F;'PK6#>U;PK<M)XP;R[K*@3A1<[92])M?_^G=V[=_
MIE7CENTT1.=N5EN,L&_5F'R?UZ(P(11DAPN\B]-@G"I"C2$<N.P-%J#2044K
MY.?-W ;_ ,G4R@0)IF7J7//5JR*__>C[F!DJRF,[@(XJ;Y#U<ST[N[ZY7EQ?
M/J#9[06Z_/O'Z\6/3H&E*^F:0:2S&@- T4)ZE&0TVR82S$I'HA37T;6)U"T\
M $_#YDV5)V]WWH$>NUDXFVV,9/_H0LQ(U]'K+F_M-K=$+BW1B:I@DJ8%%3=Q
MDE$G[\R+/M_$7D0UVVV<X7*,46RBSD'=/!O;P15D.-%^N8__2'JBD'9U;%PK
MB[7^Q)[* IC'F>EY2#5&G"3Q,WW(9I00,S26_>@RP$DWF"B.7 >1.T16BQ_+
M)MK#1^,!N(@I-$?<SN#!'!C?(#, =EC[:6QIG4+CD2.?I_'UDN4RV6._;6.-
M9 8!@SG #<@,; W1]E6LJ'TR'PI,;#>6DERF#6-)L@RFL#K?IUF\Q<G,?Z)O
M"Z17<7(>1\1JWR_I'>LQP-4UI&U'K8,?"&5YZSS/;%F0<)S5K2C,VK4#A<F;
M.V[U0]@2NH<1-5?'B [4EYPCQ0-YOEY_&?HNE1DKQA1'+A69FISAXWGAJ@QM
MVS[AY#'N*RO1R^<R87U12.E+UZ&<,41TVC__OK"3COEEEJT</1Y<7OU091)2
M*,S^:1K3[J-#RH*7Q(W4UL08JA=[8L;;S,2'1K-^R ^R(LF[SV(XZ]Y1VGV'
M]!KY]K(I#V\^*&Q*<IZ$&U)5UA-YA9WZZ(7TORX__2%%<=HG!L.T!>^FCVF0
M0F.Y"=T).(&.H^*(@#,+Z#VNB _%B&YU0;:HPSB?1+ZM.!^T*CTPQ@+.(QXZ
MU.C;/Y_BAX=R=KS#<H.7G]%=0I:7N9/TQW7BY<'@=FC/2>Y@6TSUI,'&/ ?>
MA!7T?Y.%+HW/UK:I[AV='VNN[JEQ'*N1/7/T5D8Y[X/&LJ[2(4Z +W*!(UJ9
M+6VD1DTI,ZHE.$F*5'VZ?>P!L:<[;BYF]Z NW,U.KC0#5@=!IJ;(2IA02$2>
MNZFV0(-OR.;!JSIGVO&K2FQ?3C#".("L3GO$MSD;N;Q=,':R2=>0UD]/Y/QH
M.Q=*ZL+%V8J:J&MG*PI+8XZ]\3-Y!?FZ5J&EE).;-W*]E70GVP(IM8;"OTN*
MZR@L:W>T@EVB85Q<%6DR =\2*6X9I?FK/?_W]*O3T[<T3)&_9_T&O3M]<WK*
M_H>\?;:)D^!G[+]!41"B-'_B)TC3??%*=BQ^[<?1]1)(X(V;)<*U&@QJ=UXR
M3UCE=9]1OZ-)4F3=QD<?.+*;R_LJK*G!M((G^B*(T$4<AEY"-D2<Y)!T:G?I
M21^&HG2)C(]FZF/D;UK-CI_U^)ALC>BF@HF$(U5-62B_2B>ZOTZG(%D8;\)U
M,*]5TB9]S;8)6Q K1K-MW,.L:.(JWU2GH\A$,NP"$S?Q7K=]6X2ESS".@R<7
MCS(J\J.)+)&--A%X >\QZJQ#G]#$\:W'\<I*-\>P'WRH,P!&&]A3GJ!3\/94
M[!6\^X\W_T$<AM^_^P-S![A_*OH*3N(48KG7 Q."91L$:C;= Y5A'=AC"FPI
MP%3=*7!DH&D('8!>ITM@.7ZNR)HH@EY7,#JB^\5)KD=.:.MYXG%=.=EP#IY"
M@+E1VM5D#IQ;D*DX;UVSMY]UT<%1MQ:8C"L]K"C,4S1:A,=SH:&A7(0* 5YT
M/NJ&]SP5','NLVS.PVT/(_O-TO$F@:1NKUD(IPD=:ZC(5 HLH<-L="'%]P-Z
MRNR%=U[@7T?GWB[(O%$J?$)#.;E>(N8%O/18MD:T@-D),6^7>0?'>UR']&J7
M1R0S-D;//<Z\(,+^I9=$M$K ;+G<;_<L2?H"KX+E.,78%$:U?EK;S1-\;;ML
MB/R\I>LWDE1E6G\626G^?=X:K"BRY'7Z=FF"-SA*@R><EZ>\B5-:F7*^6G@O
MHV@P31:<U$_2X5 !DT4% 9X."A@AUYNH(2 :-^JTE\NP1-.'((J3\B%NG(ZB
M&%MCV Y,-QD 2YR0I8TR0C.DZ9=!T=KQ9@I)B >,<(+F(>1[_(2C/1ZE>-*1
MM@O[JAP<?"DP_[/+HZOFVM=W,XY]%TG-/ .BF O12"CU0O>E$E57L5^Z<4KT
M;T%M')>7'\"-C\MQ #JU:8;B%4J:'X\K'U8@E;K3VIQ3_\=-BMK1H[XW#@_F
MLHQ*DYG."REE'2BWWD2GY(07%X23-;\CQ\R,]S@BU,-9Y,_\;1 %E')&S+QB
MK#&0I#BRDS*92JR!1<99YS=HG7=GF0!>C8  ?DYNV>F(OG[G3GE]>D1/4DPF
M0Q\1OB!:,HS92U CXE$^H(.8B80=^(UIUH=!SJ]Z30-O2A)MO";=L01]WD6@
MH>(S+\4^]6L)16^LVG; 2/;C'V)&(#5&X^DGC[0U"W"4S5UZ)7*9U>O\@E,U
M#%$0MSPN=^ \^%$^@SBBM=4]J(OML9,K:;VI/#Z&OBATDO.D)67!UNNYJBQ!
MKS=X\^>H<N)CQL7 L:QO>1 GX#.]^9\%$5<',.H26?/97G"B/?:T>T+1"W.:
M/$+',9> L1Q82F).0".)-F^!QHE!)!=7W1:23-( ,M[CT]*O4:V7U:I#AK6F
M2'A[^KL"!YT$+,8#NGA10<+QDCE4J<XB0%2%0P&B-/<>.N4J3G"PCO(*6,O#
M(O&(,<4*-[WW@H@> )WA%6DSTJFBSO N;"$-_J#W4TF[KVE#%$=HE9,C#MMR
M0QIAE/_'>23;  6\]M)=)6/#*;]17]0$(NB_>KH-[K$7TDS%<J@Q8*HTKNT#
M1Q6F5$!9/>M*?F1OC&>'LF#4!!ZDTI%YN_J"PO+TJ'6>%Q($?(51XO/R$5T$
MZ:4<&;J*[@I(=LA24$92-G/=L'V^V[^/GW 2T0_R/=&DA1.A:+&)^UHWUH1L
M@"^,EVW1FC9V:;LK"*"RRN!)]C#(CH\-%S@ZPQ%>C9-+" WEPM "> %O!L=/
M01KD%E6I1S+OQ:D&Z9!</4( S[9'5*G,V;HB?)W'$=%)>Z*6BI/%.$IG698$
MC_LL?Z:HGHET29J/4SMS$+[<8;(?XU 6&,Y02.TOCZ- "ZE'XO0PMT<[0R*K
M_1D,L,#]7O0#,A]AKV86^>Q?(6-RYO]KG]O/8^;?CL2I;:=EG&D 7UE!L"A5
MOCR@K"*"O",5UQ[.N"!LF:SCK'Z/JH9%VGQYI?C,2X,E/10.PGV&_5'+'2H.
M;;\.HAIC7;O+\0+ZMVXSH31%7'/C-59B!"-!(5]5@T-1.NM-35 NS]_M2.G4
M](B^8PP'^L%^R$_.#Z .6*L\:2AO-\&B@XK"U<#<N+L2VTDO@G1)].P^&3<I
MUY05!]% 0U8!X/Y #)(-Q:M'U+"WQBC:;Q\)7.,5S5EBMYQ;UYNGO=-UP48#
MW]*U-,T7+E=\EB_X+5OO^8J-S]V[MJ!Z#3FQ;JF9\:FEJ?-K[U^Z!78_9/"X
M[K%B;@P\<X9%]EY)[:14:FT=ADX0(^;:,9V"S$\',[*^R04>X6P<8;\U%G9!
MY-\?^%OC]%V<G7OIAIT+^-@_.WQ,L7\='2_5S)99\,2.@4?-Y]7GPH&-IL\E
M="F/4$&K,'Y.\R?1CP>AR#N2<.E3F(.BE@MLMERF%E@57DOI6YATFD&("1-5
MI&X13P#KH_!IW7H;8Q9@(9WC4/F+N<5@*"JC=?3XA_R\I)_5GE[,(+:?Z)OZ
MUGGEG?$@6B_;,Y)P>AS/7^ =D5PPVFVB&GW[=XCXX:$7G[DFCH$H$D;M/>'F
M;.S7E&RR(/((^#;MNWRO8%W-"T3.0O9W[(MO=(V82:<XLI,";4JLR2[VH?;%
M/I8I$\41WN["^("=EU#0DWQM6U!?'N.\@(NB3K_%;*RN(6V?-73P ^X.Q9,-
MM6PL-TI,281UO=8]9?,3!4(UH8]27N#\OYR=4A0D'-->UQC=OMFASASDBN;W
M*!H6<YIB8FS3<"KWONFW+G=6?0PT\J5TELDPEM(>9;9<QGMBA1>O6"X2SQ]E
M3U8<V5$NH )KX%76O!/ZPB^Z?TF1ZA44RH=07>?X:4A=CDIP:?KDMK;'2/;8
MOZD^[%F4GXE53P!7?[.&5AV>'-S [L>Q-KPI[:-'D[^9DY?4+)[YY=2R6V-A
M*'QU?A>ZJ]WO)D%C_(L]IH$4^"+P6!^&:. I6!D"OO0P[N]Q'LP37RJ>!I0E
M8I?C%5J>80]I\G()K@]I9%Q,YY!&PJ7B(4U04ICV(8T"*!0.:;J6RS1L!0QW
M%41>M'2-9!D7TT&RA$M%)*]*"M-&L@(H%)#<M5SF[]S&2XQ]=@&'OMA"!L'S
M%??FQAC [1[4S0/?'5Q!ID'1ED]+I,V=6@'*<JT_3ZJR MI.7'Y;E@";I_^P
MB9-L@9/M69PD\3--=*2_7FR"1+-(C0%A:YZ7*8?PO5=&)5> *:5S0L;>HL>2
M4OZ7C))R7^+&7.35)6O#M>OQOKSH&V!.VDT<K>G0%_AQE/U<=6CK<0-%QI1
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M1T$&.RTE."+TAG1AH24?[Y/K,KP%'+TZ5U9W#J_0G]6<8G^GMOU53S0L-1+
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MEF8+S(/SW(YN\?2/],TG\PLQB+IGJA_[^/^?[Z0.?@NFCZ)(AZB-)V:/+W]
MQ\NGE:;[;5$GQ$FICAX<NGT/9H@I*)3Q6'E!@IXH/-ACI;5;YNMV(8*I5//H
M#[RNRAX]5]W^1GU%),F^<XZQ^R#]?)5@J@@PP6MV3Y3"I#9D9:8GF'[?=T[0
MVV.D*5J1ML1ZSQNCI%'IX57MH;JX'&2OU)*![:QY$7/'S7QR;GTWMZ_IT*]S
M-E %Y:-)2U_RIB4G#[A></)U.<_*&!S$&59;=>OG?#*V+H*GP,>1_RJV3"'3
MKWS+%,T)^#C+)N@0X/!U7BG5A>)HNR2X['UVR:&9^Q2'A$P89(=7]7DVV'X]
M1^_JD^K:/I^.K2>0(&,'EJ-_J@()]#A$O_02&GY.[W#"6!DU9 ,/YL"H!)D!
M0'TS?WA =Y?WZ.%OL_M+QY9@I]AX&,IG:FR''<,H3?H$SL%R%I%-)=Q3D\]B
M*%"/%1>NC!FK"K&],$Y3M,-)_M3&-%[:,$*&.%:GOURZP,YKZ-SNM_2I@3B9
M/:;L1*X.6+"Z4[N?W0?S6N/#&7%YNV]=Q9@ZUKDJ9R2>DJ%8<79#/A!581:M
M+8LP'Q42',[R;]S+LB1XW&?L2>(L1K.S3^>_^?6?WKW]XY_I8QG;;1SEH?WB
M"27@R0PG0J]+@1,U-W4S 5_@*-X&D<&7*^II\S0(Y +R?ZN6WSHR0SJ7O)(L
M-"]#![.1/Y%GDA8G.?R-:S$&AC$WM'EP<;:HRV17_I%7Y!\QZR+EJ_^[ F%?
M2/!VAM%JF3[QRYTO*JJH6A?+#_%R0T-6*'^.[,;1AU=6_(Q)+\]':(K:\)?S
M@6QG)0FY *!PPO[(6QR52^+,]E"2F\QAKF9LGE#3I%GX+39@4P[E8AL">('@
M4_Q9 4 3P$]#A#($\=,V3A:9[]@C>-'Z!GLIV996-SA-L:WW<C5&MW\6I<X<
M%-V[G#U<.JW2H"]='G":"V!6'?\8C*F/QI<YE 7[8/-&G[#M.M?:'"H]JE60
M0B&EA3R.F%,SREC.G+%EMF#&NO$F\![IH4B TS%=/]$PU@_V!$Q 6NUZ=G9]
M<[VXOGQP;7Q)!,3K,6AN@[PT>.ZEFZLP?G[8[W8APZ 75AK2:LZR'BM.#RJT
M6%50>RE'!P71*DZV[%ST^/!O%C=58^HZ\:H?A,0G&OKK:NJPUE7P>9R.HAL%
MH[CP.-IL )B<-[9?>H\EJF'-N17(BPJV]HYS',BS8/]W'2WC;?YCD9F0C@\:
M<&3W0()8 \!%/VZT\P(?$?V&//:<=TJTW3+<^T3%$?<VVV"T)93(MTX)B0S"
ML-H,W>;/Z.$#1JIT$0W#J="-2C8 33?5/ Y2IV?]C6EEUCJ"^:B\3%S='68D
M$*7QK1/]9RC+RN'06YL>YF0=T9W#CI+>K\V#>_W9S:3:-NW:%#05/ZP4%5=F
M&/5(#4RZ%]'<P7Z*44C)<EA&@25555CV1;2SVW-U#9&!^@]<BH%L1,EP=Y@(
M.;+@8BCP,#F])V#R%Z#W).)7UGO0RIC?K3UZVE=[^K#.!Z)5M_OM/7.T2\OS
M*DX:H7.;4: ^C-F_3S $VPKQH6U.%ZW8*,B+(EKK9E<,@/:TD!^*XNADZ1'4
MAB'+@VM_(V[C1 - 3APUZKOV@UF^:8V3DH>+/3[?)XD5_=_)@>U,"3WV@$^!
M6EY?X!<:**#*/]O0R^';.,HV*<(1#1Y\((C<H-^]?8-H6^=I%6:PD!Q>JJR;
M>2*&XF#7T>(Y9N6T' *98\*ZNM=F$<;SNRE%KS0D;H#1QG*,KVW)@%1#3 "I
M%1L3U;L\CS!8?_=*]*E(\&: K2^*!<UZ12#@'K 5%PZ.5_6YA!'['Y-R#77D
M;H37^HH,<R8J&RYXFH!VK;B8-%A++F&P_O[5@+4I=S.PUE9D9+ N-CC!WBH;
MYY$"?2:F:K-6+ (XK1J\#K2V!6\ UL:JC&^Z.@3I9*$) 3*FR5)%1*P,D.5)
M F5@[ V-C!4QU%H9Q^G"M@=8^T*T+ MW%R<T]VR^*H:HI24\>&&>I_#H+3\O
M$B]*O:7@VM8PR.W)D?V<^WX,0QFK.$V_1=?;';L&4M9$=*R%AP$+C_(!UL[P
M NT=&9809]5E&M%D=]COSY0#J[@WT\ G4-"MZO1*U;[+0A^#88G_-(995E-+
M^VR?!A'10>?Q]I'>6B<$+=VO4AS9Q8FV&FL G,\^/ES?7CX\H//YA[/KV]GB
M>G[KUCK1DS&/38V%&.#8^AXOXW44_(S]:Y\@/E@%V)^E*<[2V?*G?9"PNO#\
MA0E:+,QNO:5A6'1XE#W(!!0.M3U&$WD%4?9P I?>2_].Z2)63!7%$5>JW74\
M>B1 BH^WAY.'@7.09U+=$;AM6%I]E 8^\T;B2#-73D[#?G49*3^0'5+T04N^
MD^.R44K"J;+BNN=M:$8+=H+:&,P@6>&$ ':>;7 R2AJP/A/6-:TVB]!]BKRN
M%:OAX=+D-99[AQFAL"C&"FT6LK\R/W.QP>4WP1['T]1K2J2LWXM0X0IZXNC8
ME>[2]$[.KE1[.]K=Y6T(';E5*D]Y,7I$SP0 ;F_<['&B[JV;WI2B[QN1)L3<
M&>N>V<@<3T&O#C@?V:4V:KDNZ0^X:N\X/F<'CAT:?.CEG\KGF2?=Y2T)%4R8
M)#VG_Y%"?#N(%-J8%[2_+9?YU=/DV/0-BK#KB+I-A([VW<HD,6#\T9C!NX1>
M*,X.=P016:%A=MN14K/M,&X[L]#*K,!S@+Q]_LAFV;CY];[RC[<3HV-]O7)I
MZ"=!YL;WD!S63\+OZ66I^>IC6G15=-@L,F3=[;,W-\4*(@GM=A*O3O:TFA?K
MZ?0BJ7TT5FZH9>%,Q%IFX9I;(A?>-ICZ=BMFVGY"R>AS@LYI,&D5D(W6Q[LX
M#7Y1[JP4D&/MK?#B#Q=M-V;N=7R3OXB/4/K5Y2F-C7/17XYA:^=+,_^TQMZE
MR[\?G!NJ%2?VSUTMS$K1-BV3#0X.#S0LHLV&(5H7P02VMEL\^= .9?%5'Y:0
M"4@WM AGDDWMM>]J',+&VM+*!;;OT;V/8_\Y",-7\&UULOIJ#,>NF0 ?6]F-
M?&O(0V1"^S K3_ _X&3-W=QZ/9^<*@ '^/24EMWT$>C]8XI_VI.A+Y_H<>:X
MN:C@8"Z*9D/,0)&'CV</EW__>'F[0)>?R/\_.*T]W"FW6LJF=*JFQU^SY7*_
MW;,RX!=XE^!ED"=9XUV(6>I>Y,^V],[,S^SW5D^X!N-M.-W\38[+"*\I5S)D
M#L6\]-J65PU"8VG'41P;0$.#BO\,!EW7";@0Q:$V_X<B@^#..U :$S*"#"<P
MF/NA_O59G6!7)L@N;^9TJW$"V9$303HD,I$3JC:S+%K_^C[KG.U?W,?,I@5_
MPLF>[*WE2Q4L,R2F'5!QU")^,N 7]X'7(&OOLZYD,Y&/N3IC>VW?LX1S%^:Q
MG:E!@4,<$6L0I8UCZ%_,]]N-TM%BB7)13,#>YGXS]4^69_6U?Z/<;Z31?,$5
MW5]0-%\ OK&^Q.:"&YY6!R$MBIS2(>@)W"8._>OM+HF?\A<E/V#Z;KORB;,:
M-1>GQDJ<0047RM[Y)?.R/PHX N@?.8G_<7H:K"5-_D17?7D,5?P';[DAV$\.
M?(Q&A*YAU+1L./LG.1)N ,@=>]1SU04H<Z(S%:3)Z[VN^1MB:KY:!4ML 4WB
M@:P7919Q 26KL+8RX+@H8B>35ZUD'3A3_6L$:9+]LZAVI P0TH<#!_E7$QAM
MHA;/QEJ#0SJD*&\ETADVQ0]*@(I</!F#:  CY+V,(.<:4=MRY@<']XJ7Z<A9
M)(&CG%N3Z1'UN2$;XW@:GZ/NX-2[&ATZ':16@4#>#I1Z6PZUU\?K,]$]Q2[,
MT\0CQBDFGE.0G@5QAI>;* [C]>$\OLF$((!=%!52]N]=*7 %^29<5U3KB\[C
MK]X@TO\KUU:COA0YUT1U:8R+N;PGQ'<;+]D6Y,_C9!?G96.TH-5-QY[CH<@1
ME I6]BL!A;B>TP"3LM J)*FMAO$]U2#^6[S#WQ.PF@)(2L(V=F3,0*JHZM(%
M&/O*1T$\G-+IFGP/E%P%29KU@ C0W_([L2 C,#98^PY@N,"%7" U4$BF//CW
M^823Q]A8!*<R&4SD@QQDX4^-O\5[:E68?HA 9ULA(1D3P!?(&LL_/^L@D(N@
M0H!DHD/KO<[/#N9%],WEJSX!1==_J4]-'TPOOU^CG<[=D5&-@:YM;1)&L7BA
MVXK4//+.841?7;KRKKG!I;IQ"MNB8&D;W^80+N^YEVV\P\<HR+!_YD6?M60)
M=+:[]8F9 *LLTL8H;XUH\REH9+D0*JE+IFH63CM?G)WK2[W>R;X^KC, 29HT
M@@3LXG,6+S4GV_:DC#1RCI&SR#/YE+ENUG5SDP/Y%TS;36.KA1:\^=DV9C;"
M9]-IL(H8$9FJY1I/2CWJKO"I81Y4V\7,-KB7X2HE9?^$08$KG=#-%_1:\&]^
MVL?9G\N_Y__Z<B*:5T>BTE"#>)F,3:^2UFQ/"X>'@7>7'6XRGQOE^!<CV*G3
M=>=2*?/8A<@OCNV_1(16?MB50_/7?WKW[O3/HI;L3V]%0'4&4FTPM!&KMZ;F
M;E_]RS#T!&$BEL/8<FZ4(VD\Y-A?88PY489JDH.#0()E,8P%_;CWHO<MXN5O
MM9"D1,KZ1JO"%8"KLA$(K;*!!%W6H:4CT I@RJMD_D1+&GCM$<K?:@%-B93]
M)UH4N()N/1:-0*"5#4J@_:\) $U'H-S;+:JK9 RTRSW5C-\%9(&U4-7N9S>"
MUAH? $O>#K&&$S"9P.6N9"Z>F5FL['M\V,5!E"V.>4>Y<57^7DODBL1LIWJH
ML07 HVR$JMYM,[QL1/_Y]H]BL\@ZDO1$6\%+8[E,CZ9O:)V3)$OO"+LQU5G7
MT9*,4/Y:"W1JM.SJ'B6>H-17NEG15NC8&Y'N=< =&\D,<>N(TQ)K!3CUU3+3
M<3_&Z2:(XL?]W/<"LD=N</Z#GC4N)V+9KY-S ]G?92>4-ZXA*O_5Q/PZ-<EQ
M9G?WLACZ==2:NJ/)E3DVC__4SJ"5$+&,(3DWDM19UJJMDXY_FE  2DUL]1S:
MCC4Q!-#E/HFI67X=/>$TH[>^KH+((^Q3RSW?8,LFFF:V+EW[<5%M'D%3/8E/
M:"M444*_\;:[/Z."(//XVO;9L:/$X7.AWXQ!P3L#)FMK%!^].7O_\6%6;,[L
M9SU##>IN'Y 0*Y!)=O8>D39O!'98_I<I!:RZI,397;)5,$,(,=G:T8CRM]IF
M?2<IZT$I%:XD=KTT*%4VF%)02D>@=8->:96,@U+?!]M-3%_ WH>9%V4INRQ%
M?53Z>[V8A0(ERX:9 DM0L(*V0%Q7[HY<+5Y!VTW,UM<0*1>K4%PJ0Z/M0[)(
M]]'Z8>-%41YO2Q\V^YL@6N?_2L[)7];?X?*/'W!P_.,L\C\D7*AN&8<A7F;!
M$PX/BTW^.[U(ARUN;,?G+,T+NEV>?(78^">,@3P0_ 9]2+]"A(L3.M+Q=Z0I
MX^6$,,,W)!S5&M+;R[1Q+;;\!<\;JO)+<A[A[!+K7Z)EU%=?LTT@F(8N9]O/
M^/")F-E[\B7<W)RS?^L=MTDHV U32CB!3M9H"U1V(3O+S3GZHCQ4HW^;V*:B
M("WN+*UC.0PO]P?Q39#A[[R=IWT7LMG1P279!@MPQA)MB%C+2<2BX66OY1:)
MIF>J&OC@D7%<T)&DVRRH!0 GD:P,+[PXLC?4-J"O]ITE4RAJ]BE\N=TZ>LC\
M&:-,&6>!*[WTETE\G*H9+'UC3P.G%[O;<?LF"D_#\C)/\!TBO\ T.NTF6T Y
M CV!$S65D/)@64E&V4?.E+->/M$DE+-J+E!?Y6P6\!(%IBS*4RU^1%KE 9Y)
ME$CNC+& L1#S7'>CK'9G7ZE>JOHDOE+5;/.^7^G%'B_BE#A)K#XV648MR4*]
M;9M0 !^ I$EKE,6(;S\-H7<(HY*^;+ZF!A2C>;G=A?$!8P,8-+M:UMPB'N3R
MQV7C2;C LN5O"%XT2T-]#N5A7L]O!\G(K>C85@F='.GEXDX"(\K2ZDZTK2]#
MGZ3NQJE_WXP/-]H#9$0GLV,"MF"G0*09&_WU"8WL1'V*T$D(.+F.)N9%YQ+:
M%!1'MUCJP3G)K%V4^Y"S)"K\<>PQM0]T.$D8E@6ACD.?#Q3N;_L^!,2(SE7D
M"2"B4R!UIZ_CR]0!1%G0OK0G'[)X^7F^@R QS"L$\& .'B4 F0$PQ-JAO*'C
MV(^R\/BG"^3S-0O<+DB+^2I_!W5YF+T$J:(F$72T[22T68 B?J0AFJ]0V13]
M@S9V&RV %YX+_8DG:'P$ODXPWD8XTQ!SO8]M"==&A\RVLDU+JO;- ]$"<Q9!
M:S;ZDBQUP1U9@UMOB]NB'$;1U^@/+O90HM7YD0&1TR:(MFE_R YTN$@4O-IN
M34C3\J,/%2V"+"2JX#KR@Z? WWNAHMR5WI,2$Q_!51")'60 TN6T+8I7J&KM
M% 6=TBG?FH(G:?C8X,/^,0W\P$L.#QZES,R"L?0!/-CPAI],.X!\0#:?EZ,E
MM_W:^[X+A=$I.%Y[R"=L6&\WWF[CB%&Z3M,]]F<KLA&S?S_LPB!3M TZR5BN
MP-S!#E3)E75#*0-(P#JB79QF)_EO4MK57?:&JJBX(J0JRV#]D0(5KH3/%> G
M*G4D$L8O11K&[QBTB)_A59S@_A]RBXYMP[^3(YV/.<$3_98A<4G@(UP'4X?P
M#A.I19FWIEYF/A(]E4X+I$;^?)^EF1?1E[@5H:1%TGXNB0Y[D/-Q)$'MBF4!
M.$:E1!R]3197A!PJ+!,)5^C37BVCF#8_2DZ9C7+N[8+,"PUP)R!B.;HMYT8)
M6 64&+#0,N\X$2#!0A)#!U@!XXCWN9=NQO!Q&%UK2.%'!1\92#=,F2SI#_3I
M]"?B T19ZBAR*1( [ZL<I]+C%>5[G&9)L,RP3ZD1'4/_<UE-?0S!=XYIS_Q1
M90FJ!'WL-C7,J,J5QY/2(ACM.1^\Y#/.O,<0/^#E/@FR *?WV N#G['_W@NB
MFSA-Y]D&)XN-%RWPEA[8)8?K[<X+$EJR)YUMXWT+C>#N--AP=CWJH=@&P,HU
MI#L>Q6IV0,&Q+E+J,NEB:(1PE^:'7%6S !"_.W^@M5["PSGY3Q(\[NFIHH'-
M):)B/>6G@R$ENVN;]R.&?=71)0X5126VO*!%Z+$_EX?09SC"JX" ,<HMNS,O
M)6HZWNYPE++<AELRLY$,-6T>;#J:IDQ")?0*,NBQH(,\]OE/(FU!%P2B; :M
M]>F=)=,YFE.\6MO?M3GK0B<+L)T\TFXT)G+LA_ +_1D[VLN-Q6^$U%[!.!;3
M:Y&\BA."_^-E!\6=68V676-2B2< 9J3)"=:'FO7-6DN&U9:MOC1FYMZ'("0F
M-:%UYQVV;2<:=EM:_2S['\WQH8I@93NT*QK2&T)EB9L@8KZPR_I<T/IS3H%P
MJKKBKASGT"->\YV79(=%XA% +2FB%CC94NWUP8LBG,Q7#SC+0DR'&R>JHLN$
M]=B;-HO0G32<+I. 9612'Z) (4J/_9Q::\9HJ,=B3);*N-K+QQV90Y31@$_Q
M12CJ+$%'VX>7;18 V!0-\U!= 1IWFQ>\Y)6: J8VQ %DJ?@^1CY.SF,?/^$P
MWM%?Y7F3ZA#0I6IW4]/D3BEH<=SV]I00L8I..%+(*VE-)8ZA(6IQ7$-UW<S,
M)7I>10NR%\E6G[QPCQ6A)^QJ^?!1Q(-*ND2$G\-#<>[X!CW1;FXK$LGD4.$"
MG*YI">&F)78?'[PP.U3X,[6>VX3L)T!T,Z5N8R=Y5[0[]G5ZHT)=<!*S6[P<
M1F=,YW%(_LUN>CWAHUY*.5M1.3VKDY!]('4S!>H<KF.U-Z5OD%_U=0HD=<'Q
MB5I*RV&8ZEVB\RI.J $>+(,="Q'<!-YC$+(3I#$\.)5A'=S[4V +WN]V7G2H
M&=Q.PD4&@JU=*5%< 3/[9^;[ :6F[WR)>CJHN=GF KH[5K04>V N;I#!2\_=
M(P/F9ZA<6%4:=N#,^?@$0?F]PXPX]_0$)O_'&%I&:WSK(2(=[L!*O?3 #B5X
MB<GFX",J<'26!)^"U-U6UT?ZO"K27A_CD-!Y?(&?CENKB1D%];?LH(&,@+O6
M">E0F4J I>3 3NH0"&\>R:9LG@D:I]E\]3Z.?78HAY.G8(G3ASCTQU!4DM%L
MG]O"K( ECX@_D](73Y)@O>%3JUSDCW:*K995*I^K^1WJ0FNEF+!.LPLOJC#2
M97Z4. :*%$:UOLEU\P3GF[(^+$N9CSD69[$N;6MU\?)H4UR*'AE4_!V*,0!6
MHV\_<YD?'KJ46[LM\T40H?PW7SK52B*YU&[B-B<VL-*7W*&$6!#=F*PMKMNL
M&]T5/34^\+[ C]EUE&;)GGZHYW%$%C,+'D.\(%]62LNL\L<'+%!\EY!M9$%V
MP_4XI9+ZLN0B9[$GSUHWYO(;F0P!+G>)@9!3<XD&6$5CD_@Z6B;,R/9"_LK>
M+,LS@&G:^2*^9*GV'Z,@NR,8VG@I%[(<XUOHSY2#,&-OIJ'/H6B(O"*.XX7E
M_5'A5NCBJQ@,1?QW,<R"&L8TUX3*VLMP'HQ1C6<V>ED.%#2&!PM@%:V*S'"&
MH@MZ'I$XLJBD2\[7PVI/SUCO<=51N/#"?,7E*HUB;"L,ZT!W*;#543"'WZ:A
MHSD7)J6ZF&N6IN)Z6*R+HLF:R-3/=261U@HG 7W&5B2F7YR0#,JEB"VS*V\I
MW [&L/^YL>P?80"<0/8)P1(]4 Q;-XT<G5!T" TVO1M3M5O\6H4ET4?=7'[Q
M=OZ*Y:!=^KIYZKV(9TNB^1)\&V?TZBP]5J/&XY@I$."8]@-L72R!ITA'/Q3M
MB&"#-(V3 XI(Y^/1I.-"FHKR%65"2!?#]&"\!N+KB$@&I]D],5@O]G2_)5Y\
M$(\2PE4<V7V("&(->OX2$R6&@J(32D@OIR%?/0G#"DZZ##U.-^D7FS(;J&D5
MC7.^*1G/!=9D#$FU'.U"E%RPQ.[/RG6D63_V[)A\3URQG8#">#PH54,X<($;
M+"CLBCY^)-_R/G%Z:@D(IXV,^LR&.3AA$3H:<ELNDSWV2[5F8XL3#VS?NE+B
M"XK$Y:UH[9 CJ,K-;EI>5(>@93L=O"#VST.5>1.^,E1(ZVB.-',6?JF"TC]F
M+9ZCB#,O+ D5R1#*SX4(^UJO$"1D ZHT3]NVT.$F<TI! -RS(> D>V2MU-'U
MP<MHY:K#!3%XQ]\=:J/93K6#68%N2A5-D%]S;R:@3$12@S5(:ZK#?ZW:*K[)
MDTBOW\1>A+9B(;QR$9P.]P7S+NOE:H67].(2=,=Q[*B&B $'+H,6@R8AC@D
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MX" ?I\JJFQ:R'41AJ(;;AQG,\CWJ8;B67:8\878:C9(>R9<OCKC-/1\6'5Q
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M@Y,\KAGA3,N(;O:RMYTV1H:N^Y6M)F U RM<25PT)<,=LO,:QJ 7[:9WBVZ
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MD)>&PNGY;+R.Z,!,[G'U:E)6CHN":F#TQ7RQN/XR/R.N"IX15>O31TYHN+T
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MT2FIZM$(C74P'J]JBE"/2=G+)"5 WL0WV^D%]M7INIUOR\^*>TA8+C74;?M
M]0%@>IW9KKK7/OK'_NWAIT3[+>XXR^-(+,U/?OA<D"IOZLU45IK<G@34')\<
MVQ"=>X:)'W.)32$N"6JGBX/MB%GC]318>_O)NLF?%<&)-7TP/TEOVV^])2O1
M#AL!R^1&RSQ,.NC>/9+,Z5&*GF35O$"!F ;0*UKDI,2\K+;_2M??:;HR"D]F
M.2PU)3N5;?36GB4RTG,X5O1A7B$,[HT:XR9BG@U(@/)YD(YOF#_+8^-$0ASY
M.\*);"7P"F/M1(ZT&U#MGG#4.+3 :J"R;+".6G0KC7@A%22@]ESJV!5=72M;
MR[X .NKQ!6#NOH/:&JK+N!P\C[O7PPGJ[ UR3?@JG-J*$3_T'$.L.HQPI_RR
M;+ HGRGFUX" 2&N P(5W6==[N3G;5_!NU*;_W[+=7N)Z:5#3KX49:R7T""L\
M3LK5_[.M>O>(B[+:RAP.:/[H]%G2\+[*#Y I4TW7<=;#J*;&_-JM&-32I%+)
MDHLBS))(^&UW@' 9K\W6" &./7?I^F9]<HEV<3G:$6N&L#[<)5VJ/C[C5VQ8
M0K0F;T]]16^:EJ_6)/.^\["!S4608UKA?S@B]+=I0@SG;AIR/O..+T)LS;S5
M1%%J:==5_JP.G.N=4O#CB.RVM>B:+^7YB+.!F\S\#'."38ZN;Q>: 7MD)FI"
M"X&G2&06/9CGR(FRK+R#*0\:.:2Y7&T=/-,T8/VV*VBW+K(KK\\XQIO'%ITB
M$ YP%_#@12 /;4Q$WY+;XCRFW!\:,>9N*6Z;&?FW0=?-,A%'YK ]RW43RL'E
M]-JZ"5*N!Q&,#R:Q"C09\[OY+_M UIO^F%.0H/V><#X8?O,OQ+-[N 13O;RO
MG2-J-+H)_+=34"V""(7"H#O=^4&B0LRY$SI''*06'(@"N]K:7'8_4%2M*\S:
M9NSP\P[)V*Y!>"*&RNRV;1<J:F,;YQ^:3EQL!TBWX!B7,,/A,RY%6$Q6;A^8
MQOSY#,"0!.:5=4[3F _/[1P!$C\?UFOP>3I%\S[+)HZ>KOLX50Q;7]3);E=^
MTZ\]#>]0R4W>"$AL7A*PNI=A] 42%1#QA&TVNK1+MKO.\LUE<9H]Y4VV\\Y5
MUUQ >W -VQ[L$X$S@LY!B.=%YH)>%K??RB/'%ZD11^%%/!,W6P2O"C :RI$4
M8G2DJAJOM%]+G&KK*^O1YTVGQ/G 5<< R[3[["++*^WT_Z36AUH:?<AG8JPL
M#& "*80S1%J0+,,L)?.+S=M,85%G5>^RNK[:_IY!Z$IS5=T T,P 7Z;[8VW_
M6GOK&>G!0).T/0"=77=9C4"!G#9UUX@W4>D@0:#[]'")TN[BL?_?A&_92C5N
MUD92E&';'Q(>3/V>2:;* J(C4!Y3@B,"PJ%TVQW3Y]L;[IV_Z:QI8H=]3X@8
M@*%H6ICU*1J!O[5[/S;5I%D U7VF>- , 2B?N@0WQCA<;*[5QQ21F8'XN5!L
M%^L\V^F:&$;K3'?JN-]9B<&7]%)TOP7W4?<UT7]NF;Z?8TL0?0*\R2S11@#.
MQLU(Q<C@@4J; 8F1 H%!.!/CLG>0CX2&"\,YE=4/7M_+J"*@WL?10&P[*+=)
M9:X0T&B4@P1)JU9^EM^L60YB2*NR4#^:6*=ZUAM1C2/Z@<1PI*76NIO+/#;)
MAPF0=I*A9-6C!-LQG#-0MSTO]HI<:SE2%\8'N2TK:=K=9M]E??Z]J;*RVJCK
MHGJY5#=%[4_:]^32J*%:(%%]3/??%?V'Q9W^LK#M];=7B\RB?T,A8NOJS>?L
MG0$J.][M&+XN6IWBB(#*#BE_=4#E1*FC+CO*":<]3T\#6L_I2'EA0OU#;5VN
MCL$>\??*.+^EQ7#%^9P5V,<7SM>ZC"[*2K]"UOF3WKF.+2**: 4>ZT%GUU3$
M'?T?YP^=J52QT :6O/*0_:@-VY>%R1X;G;/ZCV?J.=HY12C*%1B2=-%R311R
MQ>HF B@3O6_JG=^T,V?B+6[<@Q8#.8[[.']]&E6BSE%M2^D<X^'$-D_:/Q*:
MHZ\@8VWJ8PY&"6P\J^\58O$\/EXG9<+[*C'\X5:1*G5DU9'"2/H!WP.:>$_M
M*T)(QC(DG&5/V!_D/\^NT[;2:>'L@+Q>AK 9BO)/"L/[^*0N 5@5$&NK'FGW
M>>?9.O]ND1\_EN7F6[[SAM/U@YCHY':8UA/Y0S>2:(?ZD1ET90[;Z+$Z7VZT
M,?RO 6OW65Z.A,'/7#+Z-9+QO<5?*>JE&?#JUZB71ZN*5A_QG?&^3'G'D_]!
MCXMC3S\+UN'Y=V#-;^'H=<2VY2( "EMB@KK=D#=*\1K8!(MDJ6N,SX@,L9V'
ML,NFWOHBXSV2F,4F:H:4:$$_Y%96E30YHDH!O:IT[(@!$FN1%OQ&7-N[#>=6
M T ,J1G"1A5WL!3<7O\T7G%#;KJ4B',(TZO[.G5](:*2>S82Z_DNH93O\ &M
MPX2OME]KH]LG&AQ6)K#ZIW+[D^IIGD'<4Q#D*VY)0 5!."V?9=/[T7VU'E0C
M,0Q7&(/ZJ^TLV6N?#'C!(U$FS!*'F?3/VTI=7>J^SG90(D0MAORY1:U*C"=R
MK0.5:$<SI5**^Y_T@*(%8DE":V>V&"1+)&(XF"E92DUA&(7_*6OV4%'BS)JH
MDO(2VD[:N<,;PNEE!IN@&.O4>4)EH=Y5#5B78)' Y:@52O4L@S/-GWC7=;,:
MMNW@PSIBR<$+LH;:6E*D06U-R308"RB+9[)>5_F3B<]V;+O>4*;,HN 8A=KI
M#K]U!N#%,(XSB"ISJ7)9@)O]X&(S-MZWM2&P@C.DPTE'(*-YWJ/!L(3)X].B
M@8]3B9?PV/1Z];W\TL+JMT&F !L0"?K5[31& CM(ODNUQ]$]98S^:+F+!VW<
MS0Z3O)&/60YPF! \#+"7^VP'=]_?**)XPC&R'6G"H4T <<Q ;/23X3UJ.=8$
MZ<H?!1VH]XQ4[Q@YPS1L.JS$Q) R, S[XT39#2HAIA/B-*(BXWO].3JW^;%6
M"U-[=[QX!)/'H#-&^P\89>*-8W\=!IB-/Q:CDEI@A-WK0^FX#3,)3'KTA43A
M$,_:@?GG;; )GH?N-UV_"EM@U07TK (P Y+;TO!&(L66U9O.'FE-\<T_][8:
M!A25 BGG&N:MMTS?EA#-<EV5S_E&;CZ\?*T!HJ./(C4U1H$/!ZT=QV/KOF7J
M<]FOB:E!7_U9QQ.U7P4M]@?XL#J=?G1C>;N/XVCX/.!NQQ<IM@;?;NI(PT2?
MNMKD*1;/OCW8S@8V3U8UT<<'-G%AGBF];6BV:;A(B"?3=UHJA,/C%N '=<!%
M^>>%C.I+1IUOMQ(V*P0FK $<Y-Z[0\*UM5:B&TKT8RU)-X^P'=?/D^1&\G#N
ML;\OX&3>A_:5:2<N]'VH6W+L)(QB5^)^CBB4EO[K7QZSW:Y5PB(BU6U%VYCE
MEO 0CDL6X8W4S&-1V!P%-8Z)K!'I!NAB".0Q#^(QS@NJ4(499P(@;]^K6E/X
MM<P*@*6QJ%#%??^*G85%W@ZZ,BK42NB!]>.N&]K-HUM:\O8KQ(/:;U\K;<KJ
M+:^-Z^YKYBXGMM^AZ7]1@/_,F4AW\K[U:N S4[O*'?A!_&!SX1*SNN]2U5Y-
MW#Q%UY$%L2'S1M92<0WY3V?R6>Y*#8=A(R5,B)O_,6^ZFJJ&?><VSF*I,&0)
M+./O_D1),3Q.JE.UB.[+RCM7SOND$FUC9F5Z0+C_F3+BC3Y:8%SIR8MW-?3#
M\X:#A8I:1;@CK;2JLV]BIF>;A839B#FP*@<T8X+%N"+4,2-E636,1._#CAK^
MD\K96D!J)Q3 8]/GF+##Y('.[&M$2WIT'>CC(O5,)KLCWY$_DL /&?4_+@P+
MYM4(,   P[T<$GE-"",*BXEP^H;O$7B#)#_'1K&#"WB! 47Q1U?/)'>QNB'R
M^"%UZT8([ NN4X?RZK'AIHN)[:!K#]\7AQSL43")D^PZ3N>*_40;,Q4_R' Q
MD"/HJ-MPA-<24V@[_)LQZ,U27AAAMK"921$$Z<QHX[L3&8'M#^.U&,=_,,C;
M)1:3[I09RC<R5.T\3@@71&H=)3"+)Q_["%%7A\J2UNH$F4<F:>IL7T&= VW8
MU[E(G^4W_1<_J 1TMBE7PG3O'#(V'PN*1YA!F-V *7RBAJMT 5%NU-X/.5#Q
M;R!R9>< &H_> _-K48^>2>8#_6L)X*#';ZNE)68<159A9_"K)X';9#?;(,=K
M%L582+:A,17)L% VYI'8^^/:O(-$Y)ZQ>[+MSIU=%^$.]PDDB8084VG_]+33
M_O!L!]?WQ:[\=EFH8^[1^,LC:H_;W>@_,(!P1O"$G[/,6AJOZ-S-$1-M38JU
ME)NNLHX&^]'1"^H7)]NM>D2J!>8O<V"[]V6-N@',K_HAV&M2I/")3=TL$5$:
M/L"A8?$33&*"=7A[;;K:"]0B+K1I(;;3CZSF#A\KJ*4CS#?I<Z!56FY+ZP#0
MT6WQ[,!.'VS*UN-B4RX6DQ<88PW=*DGB8($S#=OW+XO;ATK*?\BL2@ \30+%
MSPNAQQ1Z4.;"J_.E\ IGR528_!F@,U+I,;?I,O%5T_A,]&Z&:]_2&2?CM97P
M DH<MLEPG22\'A*]8\M:1]LJ)8=D(1@/EQW(J?VR[ 2%6=R'?%[S)$@-:ONZ
M4D>_J4>DCEL +0H0]F]+^)6-3=9LW]]7\EZ_,Y7R6]3YFJP"EB'.U+NSY('*
M!+]>"8?$E>B(%!V5TV)8BXQE?ZOYP4T(K(N%^ "T+X4^#SART+4/I '<X_0T
MXWL@33@)O(\\7#,\4,M6;9SW2NVZ+?*IBC,5>J^&Q$#Z: U&RQ^:4<",$1#@
M")N3!!%0!GOMY6VIEPD:4J.([#%GO6%@>XW/;7;/*/R(.1MG!G?87,V7#BD<
MY+,T4"%F5\>+P;?M[:FV6DI)=YP/;$+"/--BVF,1 UU2Z=&B+_K,W?<3?1&0
MPHSHBZ@L26^NB[Q>9SL34>";2M.FBZM8+""^RPLV(5->J8 @SLJU#L@UWSY7
M5V2@M&3;V I<G(-ZP(58[Z7>%7"$14KK]#&3#&R8X:@V'F%>2!>ZB98J7(9Y
M](C2332K'GT^EP2(X+,6=(6Q-2_&='"3UW]>5%*Z@0MO:$+JJZ$+AP@H+%3_
M*8".85P(?T;H6\KYJ*:@>9/+?)R>*N*4/E/I?^C*"09!7K\GO/B[^ DY&$LX
M@]D$R^6!=(:Y3SS!4D1(_.(JFK)ZN<F^?5++K,JS7:"@O6T,A:Z_B:X]U#PM
M:^:',<J)[\'E89G8H@J19STTL\5KAG="F\1U\@@.DY^#58[Z 3I@:U ZG!0V
M,PJGF2^54=1@,4M(I ^H]GS6=J^[F,VONR&-S>\.,?;Q[!N,"7SC^-DEC3Z7
M:U,%2SZ5==YTV5E>_<>V%[9#GYW&6B#'PP6J700Y)K@NZJIQXLW5)MS U&\^
M9$K0:_GE0<HF+;B_ZRIL7Z$[AX';**=G-J?N?!THIJ457)^CJ[:NR[,<+%W%
MANDATOFS6SJ&[Y#W_@S!I/SFSQ#_U)(BOYO'?0RSW=A5%I+6.J09C85!N.)/
M\QZZ?N9F>F.E'-G#,Q'>4+=RFD 8@I%JD_ZG40W=<M]^<"Z;$[DRX)-($70V
MF"Z$%>\IYN>;-O&^?'PLBWA)0-,N6@^0(\=^Q $F<9Q+Z@C+G5*)P"6-WV*1
MYU6T..;TM<5R-20QB5X9,\1#>T[AF PWZJFH-F_3&=]'?P]C;GJA*\"WT@XL
M JU27)6+0;Q(DQ6Z<U\M>^+CM&ZNME!?" "KO\CJ61WO]9=RY_5 0P](!==]
M]%RWO01TXS6>^-G!3]DP\YQ)P?&T_&$F,)ZXP9W\&TZ8#_!+^:+IZQZU29!Y
ML5>JI]5!U<OKI#%YD=I64 [+OQB\V$"A/*<\59=':CX@^B]HX$%=UCO[OA+N
M]R#NS5,\ASFFZO52PZV:QYH-ZE3QNUK^UQX"+9]UEF!T W<=A.FQG"WL8P7=
MQ6&^::%'LSJONV(, ,^B[U7SWWAJ'/1VJESHDL;+1!)/8Q1U@<X0$>T&LD&P
M!T1OMV'!J3'<;)'ULR.Y4V5"BMUI'.1=175C.@L@];8]1%\VWL9=C>%V65RA
M/G9PYV>8>6*-T0.^UYQF5?6B]G;80N)_JV40+VR&&*>9+>:)-N(R_2V&BH=2
MW[RN["K2]AUC7#O9-TH;AD Z/QA)NXVL3<L:%_N>W+F 8;ZP"4J1!$L$P766
MA[#'N] !: >6K/5N#V4,U*YYRIML9^),;:,5"F^XC" #RV<HNF @"OH:&'=Q
MY]F=)YW3R=L<E2:ZD8]9#E!@&O$F6S?[; </46_(W#&S?@>)O9-*51UIPJ%M
MC'K-Y3"@G0RO*X)C39"N_+.]A,?O+*1N2)'3]H4X.C=/FIR7(U31BDJ YG'B
MIE.8G!4 ?KE0O_%7$&MS1FRN#G00N@=7958/ Z[<HWQ2!N8/HZM2P\AX@]R'
M-*-'%\86+31VGX813[D=@)Y@H00\]Q#* R;N +/4?E3]1@Q'RO!>[H8&?UP,
MB]AN ?5S7[W$??UMRX&WGWNA3LG'Y.MCDMAV#5]_*'<;6=6FA!@@;,Q %7,'
M^)=,G6__+FSI-!@HBB_&!0&>PC)ZE,^3%_'&F> 4:BMBG]?NQSM%<!N-;=7I
MS#EI4<Y0(T.:.+CT29.D.TNCM,G(0YV2^)@+,A+6+"<<DU>>;=1+3VY:./!/
M\O%.5GYH&--:=.#G?Y@.W"GV.!O8#@@Q3%J2&;!.TF!.T/0J P+CA7_A0G]Y
M!?!+JC!(,;.G-ED3-SG7,CV.MER(2=J0E6J.=EDG.J<\62O&Y_2E40M&%Y2;
MF=]CG6]=_TB*SP)R?((,N_-WN,"(:QX&\R;=]>8U1">FF'IV(%NUQ'3&<:_K
M?-&1IPZ/',/6/?]!%G+KMV%AKG';4_Q@^_[(/G]!UI+<Y)@T^&&S#T<O,7>S
M^X<AEBXU.(VA9PA4/ 8V7AZ P]O)'UN4# N \'HY)G==#0JKCP;MEV^TI/MR
M'G9M+\%.^N9"?NMU&YA9*OPU$Z%[_BBK>_46_5B5WYH'\.5FA3>(VG01;1]A
M.@G;B^E<B_ R-H%$V::S/QE2[!%V(Y_*"F)30$_VFZ#L%+073==+F&Y<GLT0
M*_@,A-@F.*Y=:]BM&CEJ\H-&[&B#0(3/IM=S0>NSF*EIIRG8;'D426IU@CI-
M)?VOM7IIG]=-_A@JH*9:03Q]UV[!@*5#AC#I8RR3(H.9,HAGTOS_LI@6ZFA+
M>/39\_%Z,^VXXH=VY!^ANA-2^\2IC.+ #J#E:I@VTJL$Y-EQ1Q Z)6BT#XD_
MBA$=*DG@J5+) 0<=XP^;Q42A4&M@.L(V@XA@>98U622^SVI@3B= (LXFT7TL
M&AC."JZ!A=BFC#+#2WD;4^*@EO??? $/GF+G9@A/M?,EU3L?\>J-=$B4$JT&
M,B[F?);O]HW?2865KK9=.",:/%Q@4Q%DF%;VD#+_+=_MU-6G=K,2<]Z9'Q)S
M+=L1M$[1C]'EA2TS[3*=;VP"YTJ-TC7O*9!@HF0&!1(.+#+1C83GP"RHM 3"
M,ZI4S)08Y6R"8:F2#TK%49>LT7C"02Z##JWZA\6Y, $FX=Q@TQ)AG3;>NBSN
M(84D(?0.FAHPCX6$VB&T8^+VLDBIR>7W1;[-UUG1C-+:U>:+AZ[VO9W$?]'V
M7U!!W#0^42UNAH3>5WU/)Y_K\SYTPKU9!I_Y[/NLL. 3(KJ&WF:FJ#/F>V"]
MZZRZJG1TT$8'WL? '(>(@JJW*"L33K6Q"+A39$>V"S/&I.?J3),-+:;+$=V?
M2EE[DE7S<KW+=)@EQ.YK, UBYW9+A_H)*%EUA84T,7^A0 VOP-_:T1V9Z;]4
M[)&V/B\AXFA<)^:=+UZ/I.ECBYP))E2KX3K(C4H/("H:B.U>%J R)AIYG!$,
MT(P[1JHOD.L"36/==X_.$1RQ9:"]XZ,6@4[;64K&RX3XB!;#E>?BO7QT629_
M&L5 *1CJ!).23BS)%"&VL+E($02I,ODI6S^H@[IZ<8D);X2NRW!"%F,="["$
M34E4 LNT.K^RQ#%F?5YZB>. %%YGCV8L<7PCGVPV[M6V-1U"=H<_^;)M#W%$
MO9$4^O!.FH\3;&K"7%/[O"=YZX#@NJYR6^M2KF7^',IA".?ZK\1@.-&/QVLB
MF\.YUQ$^3W3$R'5(I)*;D7!;99M +3Q?$-@@A60E]"C<5UX:K\GQ7!XIT1K"
MO:I2&W&X4>?Y=K_[-7_V^V C*F0WE#!C"3T8LU(_B_%92J9?<J0[\[I2QW^^
ML2%G<> EV[X-4UY,'2<?'_B<A'@FO/%&VSL28S<][R;8>2SP3"@3F-Q#[%(E
M^-B/]BARY\7F+%"%L#4ENG!YYP#A/2A<3I[[X&/#%7N<7=*3YF2SR4$3R78
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M#WEL./!C1@&#MK8I="#*D&UHV?9HW]-F,AA[693EN&XS3EPKR[1':C<K>\1
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M#=.+'%XQ08>(P;O5:U].6B<<[ 9-7;SG"JW #<!W'(P0U28(8YZ%=^_XG[W
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M%8\PVI9BTY?3$4[CNJ&:\AF]3V0$\6G!='GI-Z:. [U#2%!-R%SLY)I!JSK
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MK2)79"F@TZ3G-;4EI,F]IGHVV43$(LL<@S!#M1@O1HG5AM7J%XITPYG0':C
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M$.9-.*>R25G&HFP$/ZFC4<8BN.E,\HR#O[WF!/%:4_Y?_Q]02P$"% ,4
M" #QAJI2]CJ%LZEM 0 .J@T $@              @ $     86)V8V0M,C R
M,3 S,S$N>&UL4$L! A0#%     @ \8:J4CI5Y--Z'   *6 ! !(
M     ( !V6T! &%B=F-D+3(P,C$P,S,Q+GAS9%!+ 0(4 Q0    ( /&&JE+5
M9><A!PT  !&>   6              "  8.* 0!A8G9C9"TR,#(Q,#,S,5]C
M86PN>&UL4$L! A0#%     @ \8:J4M/K26<(40  1CP% !8
M ( !OI<! &%B=F-D+3(P,C$P,S,Q7V1E9BYX;6Q02P$"% ,4    " #QAJI2
M?<XU7@>W   QEPD %@              @ 'ZZ $ 86)V8V0M,C R,3 S,S%?
M;&%B+GAM;%!+ 0(4 Q0    ( /&&JE(Z-@ ^ 5(  #)P!0 6
M  "  36@ @!A8G9C9"TR,#(Q,#,S,5]P<F4N>&UL4$L%!@     &  8 D $
' &KR @    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
